PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Lionti, S; Bonetti, LR; Bettelli, S; Spallanzani, A; Gelsomino, F; Barresi, V				Lionti, Simona; Bonetti, Luca Reggiani; Bettelli, Stefania; Spallanzani, Andrea; Gelsomino, Fabio; Barresi, Valeria			Histopathological variables in liver metastases of patients with stage IV colorectal cancer: potential prognostic relevance of poorly differentiated clusters	HUMAN PATHOLOGY			English	Article						PDC; Liver metastases; Colorectal cancer; Prognosis; Synchronous; Stage IV	HEPATIC RESECTION; RECURRENCE; SURVIVAL; CHEMOTHERAPY; MANAGEMENT; SYSTEM; COLON; SCORE	The prognosis of patients with colorectal liver metastases (LMs) is mostly established on clinical variables or on the anatomic extent of colorectal cancer (CRC). Histopathological factors of LMs which may actually reflect the biological aggressiveness of the tumor are not routinely considered to define the risk of worse clinical outcome in those patients. The number of poorly differentiated clusters (PDCs) of neoplastic cells in primary CRC is associated with metastatic risk and bad prognosis, but PDC presence in LMs has been barely analyzed thus far. We assessed PDC presence in the histological slides of surgically resected and synchronous LMs in 63 patients with CRC who had been not submitted to any neoadjuvant treatments. Then, we analyzed its association with patients' cancer-specific survival (CSS) or progression-free survival. The presence of PDCs (P=.016) and PDC localization at tumor edge of LMs (P=.0004) were significantly associated with shorter CSS. PDC presence at the periphery of LMs and positive resection margin were independent prognostic variables for CSS. PDC localization at the tumor edge of LMs was a significant (P=.0079) and independent prognosticator of shorter progression-free survival. Our data suggest that PDC presence and peripheral localization in LMs may be relevant to predict outcome and useful for clinical decision making in patients with colorectal synchronous LMs. (C) 2018 Elsevier Inc. All rights reserved.	[Lionti, Simona; Barresi, Valeria] Univ Messina, Dept Pathol Evolut Age & Adulthood Gaetano Barres, I-98125 Messina, Italy; [Bonetti, Luca Reggiani] Univ Modena & Reggio Emilia, Dept Lab Integrated Act Anat Pathol & Legal Med, I-41125 Modena, Italy; [Bettelli, Stefania; Spallanzani, Andrea; Gelsomino, Fabio] Univ Hosp Modena, Dept Oncol & Hematol, Div Oncol, I-41124 Modena, Italy	Barresi, V (reprint author), AOU Polyclin G Martino, Dept Pathol Evolut Age & Adulthood, Pad D,Via Consolare Valeria, I-98125 Messina, Italy.	vbarresi@unime.it	Reggiani Bonetti, Luca/Q-3946-2017	Reggiani Bonetti, Luca/0000-0002-9917-4080; Spallanzani, Andrea/0000-0001-6955-7139			Adam R, 2010, ANN SURG, V252, P774, DOI 10.1097/SLA.0b013e3181fcf3e3; Barresi V, 2017, CLIN COLORECTAL CANC, V16, P9, DOI 10.1016/j.clcc.2016.06.002; Barresi V, 2015, HISTOL HISTOPATHOL, V30, P1059, DOI 10.14670/HH-11-633; Barresi V, 2014, AM J CLIN PATHOL, V142, P375, DOI 10.1309/AJCPFEA7KA0SBBNA; Barresi V, 2012, VIRCHOWS ARCH, V461, P621, DOI 10.1007/s00428-012-1326-8; Bird NC, 2006, J SURG ONCOL, V94, P68, DOI 10.1002/jso.20558; Blazer DG, 2008, J CLIN ONCOL, V26, P5344, DOI 10.1200/JCO.2008.17.5299; Bonetti LR, 2017, HISTOPATHOLOGY, V71, P393, DOI 10.1111/his.13242; Bonetti LR, 2017, HUM PATHOL, V62, P91, DOI 10.1016/j.humpath.2016.12.011; Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004; Fonseca GM, 2018, J SURG ONCOL, V117, P1364, DOI 10.1002/jso.25017; Fonseca GM, 2018, HISTOPATHOLOGY, V72, P377, DOI 10.1111/his.13378; Hamilton S. R., 2010, WHO CLASSIFICATION T, P110; Hayashi M, 2010, BMC SURG, V10, DOI 10.1186/1471-2482-10-27; House MG, 2010, J AM COLL SURGEONS, V210, P744, DOI 10.1016/j.jamcollsurg.2009.12.040; JASS JR, 1987, LANCET, V1, P1303; Kinoshita O, 2016, INT J COLORECTAL DIS, V31, P283, DOI 10.1007/s00384-015-2393-5; Lee WS, 2008, LANGENBECK ARCH SURG, V393, P13, DOI 10.1007/s00423-007-0231-0; Malik HZ, 2007, EJSO-EUR J SURG ONC, V33, P468, DOI 10.1016/j.ejso.2006.09.030; Minagawa M, 2007, ARCH SURG-CHICAGO, V142, P269, DOI 10.1001/archsurg.142.3.269; Mutsaerts ELAR, 2005, J GASTROINTEST SURG, V9, P178, DOI 10.1016/j.gassur.2004.06.005; Nakai T, 2015, WORLD J SURG, V39, P1527, DOI 10.1007/s00268-015-2980-1; Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R; Park MS, 2014, ANN SURG TREAT RES, V87, P14, DOI 10.4174/astr.2014.87.1.14; Rees M, 2008, ANN SURG, V247, P125, DOI 10.1097/SLA.0b013e31815aa2c2; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Slesser AAP, 2013, SURG ONCOL, V22, P36, DOI 10.1016/j.suronc.2012.11.002; Smith MD, 2009, BRIT J SURG, V96, P1101, DOI 10.1002/bjs.6735; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Ueno H, 2015, SURGERY, V157, P899, DOI 10.1016/j.surg.2014.12.025; Ueno H, 2012, AM J SURG PATHOL, V36, P193, DOI 10.1097/PAS.0b013e318235edee; Vigano L, 2008, ANN SURG ONCOL, V15, P2458, DOI 10.1245/s10434-008-9935-9; Wang Y, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0244-1	34	6	6	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						115	124		10.1016/j.humpath.2018.04.019			10	Pathology	Pathology	GR0GG	WOS:000442191800014	29715463				2019-10-28	
J	Chi, ZK; Bhalla, A; Saeed, O; Cheng, L; Curless, K; Wang, HLL; Patil, DT; Lin, JM				Chi, Zhikai; Bhalla, Amarpreet; Saeed, Omer; Cheng, Liang; Curless, Kendra; Wang, Hanlin L.; Patil, Deepa T.; Lin, Jingmei			Mucinous intrahepatic cholangiocarcinoma: a distinct variant	HUMAN PATHOLOGY			English	Article						Mucinous intrahepatic cholangiocarcinoma; Immunohistochemistry; Intrahepatic cholangiocarcinoma; Mucinous adenocarcinoma; Cholangiocarcinoma	CARCINOMA; DIAGNOSIS; BREAST; PATHOGENESIS; GUIDELINES; PREDICTORS; RECURRENCE; EXPRESSION; MUTATIONS; PANCREAS	Mucinous variant of intrahepatic cholangiocarcinoma (iCC) is rare, and its clinicopathological features and prognosis are far less clear. Six patients who had iCCs with more than 50% of mucinous and 79 conventional iCCs were included in the study. The mean size of mucinous and conventional iCCs was 6.2 and 6.0 cm, respectively. Most patients (83%) with mucinous iCC presented at T3 stage or above compared with 28% of the conventional group (P<.01). Three patients with mucinous iCC (50%) died within 1 year. The average survival time of patients with mucinous iCCs was significantly reduced compared with that of the conventional group (9 months versus 2 years; P<.001). Immunohistochemistry was performed on 6 mucinous and 12 conventional iCCs with matched age, sex, and stage, which revealed positive immunoreactivity in MUC1 (83% versus 58%), MUC2 (33% versus 17%), MUC5AC (100% versus 42%), MUC6 (50% versus 0), CK7 (83% versus 83%), CK20 (0 versus 17%), CDX2 (17% versus 0), p53 (67% versus 67%), Smad4 (67% versus 58%), and EGFR (83% versus 42%) in mucinous and conventional iCCs, respectively. Molecular studies showed one mucinous iCC with KRAS G 12C mutation and no or IDI/1/2 mutations. Mucinous iCC is a unique variant that constitutes 7% of iCCs. It is more immunoreactive for MUC1, MUC2, MUC5AC, and MUC6. Unlike adenocarcinomas of colorectal primary, mucinous iCCs are often CK7+/CK20 /CDX2 and microsatellite stable. Patients with mucinous iCC likely present at advanced stage upon diagnosis with shorter survival time compared with the conventional counterparts. (C) 2018 Elsevier Inc. All rights reserved.	[Chi, Zhikai; Bhalla, Amarpreet; Saeed, Omer; Cheng, Liang; Curless, Kendra; Lin, Jingmei] Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St, Indianapolis, IN 46202 USA; [Wang, Hanlin L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Patil, Deepa T.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Cleveland, OH 44195 USA	Lin, JM (reprint author), Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St, Indianapolis, IN 46202 USA.	jinglin@iupui.edu					Adsay NV, 2005, VIRCHOWS ARCH, V447, P111, DOI 10.1007/s00428-005-1234-2; Adsay NV, 2003, AM J SURG PATHOL, V27, P571, DOI 10.1097/00000478-200305000-00002; Adsay NV, 2001, AM J SURG PATHOL, V25, P26, DOI 10.1097/00000478-200101000-00003; Blechacz B, 2011, NAT REV GASTRO HEPAT, V8, P512, DOI 10.1038/nrgastro.2011.131; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021; Dursun N, 2012, ARCH PATHOL LAB MED, V136, P1347, DOI 10.5858/arpa.2011-0447-OA; Haga H, 2015, J HEPATO-BIL-PAN SCI, V22, P114, DOI 10.1002/jhbp.156; Hayashi A, 2016, AM J SURG PATHOL, V40, P1021, DOI 10.1097/PAS.0000000000000670; Keum YS, 2015, BMB REP, V48, P266, DOI 10.5483/BMBRep.2015.48.5.021; Khan SA, 2012, GUT, V61, P1657, DOI 10.1136/gutjnl-2011-301748; Lee MJ, 2003, MODERN PATHOL, V16, P403, DOI 10.1097/01.MP.0000067683.84284.66; Liau JY, 2014, MODERN PATHOL, V27, P1163, DOI 10.1038/modpathol.2013.241; Maemura K, 2014, J HEPATO-BIL-PAN SCI, V21, P754, DOI 10.1002/jhbp.126; Marks EI, 2016, WORLD J GASTROENTERO, V22, P1335, DOI 10.3748/wjg.v22.i4.1335; Nakanuma Y, WHO CLASSIFICATION T; Nakanuma Yasuni, 2012, Nihon Shokakibyo Gakkai Zasshi, V109, P1865; Okuda K, 2002, J GASTROEN HEPATOL, V17, P1049, DOI 10.1046/j.1440-1746.2002.02781.x; Park SY, 2009, ONCOL REP, V22, P649, DOI 10.3892/or_00000485; Patel T, 2014, J GASTROENTEROL, V49, P165, DOI 10.1007/s00535-013-0894-y; Robertson S, 2013, HUM PATHOL, V44, P2768, DOI 10.1016/j.humpath.2013.07.026; ROSEN PP, 1981, ANN SURG, V193, P15, DOI 10.1097/00000658-198101000-00003; ROSES DF, 1982, AM J CLIN PATHOL, V78, P817, DOI 10.1093/ajcp/78.6.817; Ruzzenente A, 2016, ANN SURG ONCOL, V23, P1699, DOI 10.1245/s10434-015-5046-6; Seeree P, 2015, INT J GENOMICS, DOI 10.1155/2015/179528; Tavadia H B, 1970, Scott Med J, V15, P149; Wei MY, 2016, CANCER LETT, V379, P253, DOI 10.1016/j.canlet.2016.02.038; Xiao HD, 2011, J PATHOL, V224, P508, DOI 10.1002/path.2875; Yamagiwa H, 1985, Rinsho Byori, V33, P1061; Yamasaki Susumu, 2003, J Hepatobiliary Pancreat Surg, V10, P288, DOI 10.1007/s00534-002-0732-8	30	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						131	137		10.1016/j.humpath.2018.04.010			7	Pathology	Pathology	GR0GG	WOS:000442191800016	29698701				2019-10-28	
J	Toth, LN; de Abreu, FB; Tafe, LJ				Toth, Laura N.; de Abreu, Francine B.; Tafe, Laura J.			Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations	HUMAN PATHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Molecular-Pathology	NOV 10-12, 2016	Charlotte, NC	Assoc Mol Pathol		Isocitrate dehydrogenase mutations; Non-small cell lung cancer; KRAS mutations; Clear cell change; Next generation sequencing	ACUTE MYELOID-LEUKEMIA; IDH2 MUTATIONS; ADENOCARCINOMA; PERSPECTIVES; GLIOMAS; GROWTH; DRIVER; GENES; KRAS	Isocitrate dehydrogenases 1 and 2 (IDH1/2) are important metabolic enzymes that convert isocitrate to alpha-ketoglutarate. IDH1/2 mutations are associated with the development of multiple malignancies. In this study, we examine the prevalence and features of non small cell lung cancers (NSCLC) with IDH1/2 mutations. From May 2013 to March 2017, 800 lung cancer samples were successfully sequenced for somatic mutations on the Ion Torrent PGM with the 50-gene AmpliSeq Cancer Hotspot Panel v2 on the Ion Torrent PGM (318 chip). Variants were identified using the Ion Torrent Variant Caller Plugin and reference genome hg19. Golden Helix's SVS software was used for variant annotation and prediction of significance. Nine samples (1.1%) from 8 patients harbored an IDH1 (3 p.R132C and 2 p.R132L) or IDH2 mutation (p.R140W, p.R172S, and p.R172T). All patients' tumors had adenocarcinoma histology, and all patients had a smoking history. Eighty-eight percent of patients' tumors had a coexisting KRAS mutation and 6 of 8 were diagnosed at greater than 70 years of age. Five patients presented with stage IV disease and 3 with stage I. After comparison to a cohort of KRAS-mutated NSCLC with a history of smoking, IDH-mutated cases were significantly older but presented with similar rates of advanced-stage disease and sex distribution. Additional studies are needed to understand the role of IDH1/2 mutations in the development of NSCLC, but such patients who have poor prognostic indicators (KRAS mutation and advanced stage at presentation) may benefit from IDH1/2-directed therapies. (C) 2018 Elsevier Inc. All rights reserved.	[Toth, Laura N.; de Abreu, Francine B.; Tafe, Laura J.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03756 USA; [Tafe, Laura J.] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA; [Tafe, Laura J.] Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	Tafe, LJ (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One Med Ctr Dr, Lebanon, NH 03756 USA.	Laura.J.Tafe@hitchcock.org					Bhatt A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e13071; Chen RH, 2014, P NATL ACAD SCI USA, V111, P14217, DOI 10.1073/pnas.1409653111; DiNardo CD, 2015, AM J HEMATOL, V90, P732, DOI 10.1002/ajh.24072; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; Gutman DA, 2013, J AM MED INFORM ASSN, V20, P1091, DOI 10.1136/amiajnl-2012-001469; Hirsch FR, 2004, SEMIN ONCOL, V31, P75, DOI 10.1053/j.seminoncol.2003.12.018; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Marks JL, 2008, J THORAC ONCOL, V3, P111, DOI 10.1097/JTO.0b013e318160c607; Memorial Sloan Kettering Cancer Center, 2017, NAT MED, V2017; Molenaar RJ, 2015, LEUKEMIA, V29, P2134, DOI 10.1038/leu.2015.91; Molenaar RJ, 2018, CLIN CANCER RES, V24, P1705, DOI 10.1158/1078-0432.CCR-17-2796; Molenaar RJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014961; Molenaar RJ, 2014, BBA-REV CANCER, V1846, P326, DOI 10.1016/j.bbcan.2014.05.004; Mondesir J, 2016, J BLOOD MED, V7, P171, DOI 10.2147/JBM.S70716; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Saha SK, 2016, CANCER DISCOV, V6, P727, DOI 10.1158/2159-8290.CD-15-1442; Schaap FG, 2013, ADV ANAT PATHOL, V20, P32, DOI 10.1097/PAP.0b013e31827b654d; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Tafe LJ, 2016, NEOPLASIA, V18, P577, DOI 10.1016/j.neo.2016.07.010; Travis WD, 2009, J THORAC ONCOL, V4, pS86; Tsongalis GJ, 2014, CLIN CHEM LAB MED, V52, P707, DOI 10.1515/cclm-2013-0883; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang H, 2012, CLIN CANCER RES, V18, P5562, DOI 10.1158/1078-0432.CCR-12-1773; Yen KE, 2010, ONCOGENE, V29, P6409, DOI 10.1038/onc.2010.444; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	27	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						138	143		10.1016/j.humpath.2018.04.014			6	Pathology	Pathology	GR0GG	WOS:000442191800017	29723602				2019-10-28	
J	Vosoughi, A; Smith, PT; Zeitouni, JA; Sodeman, GM; Jorda, M; Gomez-Fernandez, C; Garcia-Buitrago, M; Ordobazari, A; Petito, CK; Chapman, JR; Campuzano-Zuluaga, G; Rosenberg, AE; Kryvenko, ON				Vosoughi, Aram; Smith, Paul Taylor; Zeitouni, Joseph A.; Sodeman, Gregori M.; Jorda, Merce; Gomez-Fernandez, Carmen; Garcia-Buitrago, Monica; Ordobazari, Atousa; Petito, Carol K.; Chapman, Jennifer R.; Campuzano-Zuluaga, German; Rosenberg, Andrew E.; Kryvenko, Oleksandr N.			Frozen section evaluation via dynamic real-time nonrobotic telepathology system in a university cancer center by resident/faculty cooperation team	HUMAN PATHOLOGY			English	Article						Telepathology; Frozen section; Discrepancy; Efficiency; Pathology resident	PATHOLOGISTS Q-PROBES; INTRAOPERATIVE CONSULTATION; EXPERIENCE; DIAGNOSIS; IMPLEMENTATION; CHALLENGES; MICROSCOPY; ACCURACY; PROJECT; SERVICE	Frozen section telepathology interpretation experience has been largely limited to practices with locations significantly distant from one another with sporadic need for frozen section diagnosis. In 2010, we established a real-time nonrobotic telepathology system in a very active cancer center for daily frozen section service. Herein, we evaluate its accuracy compared to direct microscopic interpretation performed in the main hospital by the same faculty and its cost-efficiency over a 1-year period. From 643 (1,416 parts) cases requiring intraoperative consultation, 333 cases (690 parts) were examined by telepathology and 310 cases (726 parts) by direct microscopy. Corresponding discrepancy rates were 2.6% (18 cases: 6 [0.9%] sampling and 12 [1.7%] diagnostic errors) and 3.2% (23 cases: 8 [1.1%] sampling and 15 [2.1%] diagnostic errors), PO-A.63. The sensitivity and specificity of intraoperative frozen diagnosis were 0.92 and 0.99, respectively, in telepathology and 0.90 and 0.99, respectively, in direct microscopy. There was no correlation of error incidence with postgraduate year level of residents involved in the telepathology service. Cost analysis indicated that the time saved by telepathology was $19,691.00 over 1 year of the study period, whereas the capital cost for establishing the system was $8,924.00. Thus, real-time nonrobotic telepathology is a reliable and easy-to-use tool for frozen section evaluation in busy clinical settings, especially when frozen section service involves more than one hospital, and it is cost-efficient when travel is a component of the service. (C) 2018 Elsevier Inc. All rights reserved.	[Vosoughi, Aram; Smith, Paul Taylor; Zeitouni, Joseph A.; Sodeman, Gregori M.; Jorda, Merce; Gomez-Fernandez, Carmen; Garcia-Buitrago, Monica; Ordobazari, Atousa; Petito, Carol K.; Chapman, Jennifer R.; Campuzano-Zuluaga, German; Rosenberg, Andrew E.; Kryvenko, Oleksandr N.] Univ Miami, Dept Pathol & Lab Med, Miller Sch Med, Miami, FL 33136 USA; [Jorda, Merce; Kryvenko, Oleksandr N.] Univ Miami, Dept Urol, Miller Sch Med, Miami, FL 33136 USA; [Jorda, Merce; Gomez-Fernandez, Carmen; Garcia-Buitrago, Monica; Chapman, Jennifer R.; Rosenberg, Andrew E.; Kryvenko, Oleksandr N.] Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA	Kryvenko, ON (reprint author), Univ Miami, Dept Pathol, Miller Sch Med, 1400 NW 12th Ave,Room 4076, Miami, FL 33136 USA.	o.kryvenko@med.miami.edu					BECKER RL, 1993, HUM PATHOL, V24, P909, DOI 10.1016/0046-8177(93)90142-4; Chorneyko K, 2002, AM J CLIN PATHOL, V117, P783; Evans AJ, 2009, HUM PATHOL, V40, P1070, DOI 10.1016/j.humpath.2009.04.012; FERREIRO JA, 1995, MAYO CLIN PROC, V70, P1137, DOI 10.4065/70.12.1137; Gephardt GN, 1996, ARCH PATHOL LAB MED, V120, P804; Ghadiali MT, 2007, OTOLARYNG HEAD NECK, V136, P714, DOI 10.1016/j.otohns.2007.01.002; Gomez-Gelvez JC, 2015, AM J CLIN PATHOL, V144, P68, DOI 10.1309/AJCP25ALMXQFJCQA; Kaplan KJ, 2002, MODERN PATHOL, V15, P1197, DOI 10.1097/01.MP.0000033928.11585.42; KAYSER K, 1995, ANAL CELL PATHOL, V9, P53; Meyer J, 2015, ARCH PATHOL LAB MED, V139, P1550, DOI 10.5858/arpa.2014-0606-RA; Mizushima H, 2001, INT J MED INFORM, V61, P207, DOI 10.1016/S1386-5056(01)00142-3; Moser PL, 2003, J TELEMED TELECARE, V9, P130, DOI 10.1258/135763303767149915; NORDRUM I, 1991, HUM PATHOL, V22, P514, DOI 10.1016/0046-8177(91)90226-F; Novis DA, 1996, ARCH PATHOL LAB MED, V120, P1087; Pantanowitz Liron, 2011, J Pathol Inform, V2, P36, DOI 10.4103/2153-3539.83746; Perron E, 2014, ARCH PATHOL LAB MED, V138, P1223, DOI 10.5858/arpa.2013-0466-OA; Ribback S, 2014, PATHOL RES PRACT, V210, P377, DOI 10.1016/j.prp.2014.02.007; Tetu B, 2012, ANAL CELL PATHOL, V35, P11, DOI 10.3233/ACP-2011-0023; The Association of American Medical Colleges, FAC SAL REP; Wellnitz U, 2000, ANAL CELL PATHOL, V21, P213, DOI 10.1155/2000/904578; Winokur TS, 2000, HUM PATHOL, V31, P781, DOI 10.1053/hupa.2000.8452	21	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						144	150		10.1016/j.humpath.2018.04.012			7	Pathology	Pathology	GR0GG	WOS:000442191800018	29723604				2019-10-28	
J	Chang, CC; Chang, YS; Huang, HY; Yeh, KT; Liu, TC; Chang, JG				Chang, Chun-Chi; Chang, Ya-Sian; Huang, Hsi-Yuan; Yeh, Kun-Tu; Liu, Ta-Chih; Chang, Jan-Gowth			Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing	HUMAN PATHOLOGY			English	Article						Papillary thyroid cancer; Whole-exome sequencing; LRRC8D mutation; NDRG1 mutation; The Cancer Genome Atlas	LABORATORY STANDARDS; CARCINOMA; FRAMEWORK; VARIANTS; PATHWAYS; CAFFEINE	Among women in Taiwan, thyroid cancer is the fifth most common malignant neoplasia. However, genomic profiling of papillary thyroid cancer (PTC) cases from Taiwan has not been attempted previously. We used whole-exome sequencing to identify mutations in a cohort of 19 PTC patients. Sequencing was performed using the Illumina system; Sanger sequencing was used to validate all identified mutations. We identified new somatic mutations in APC, DICER1, LRRC8D and NDRG1. We also found somatic mutations in ARID5A, CREB3L2, MDM4, PPP2R5A and TFPT; mutations in these genes had been found previously in other tumors, but had not been described previously in PTC. We also investigated the pathway deregulation in BRAF-mutated PTC compared with wild-type BRAF PTC. In checking our gene mutations against The Cancer Genome Atlas (TCGA) database, we identified aberrations in one pathway that are specific to BRAF-mutated PTC: maturity-onset diabetes of the young. In addition, the caffeine metabolism pathway showed aberrations that are specific to wild-type BRAF PTC. For this study, we performed a comprehensive exome-wide analysis of the mutational spectra of Taiwanese patients with PTC. We identified novel genes that are potentially associated with PTC tumorigenesis, as well as aberrations in pathways that led to the distinct pathogeneses of BRAF-mutated PTC and wild-type BRAF PTC, which may provide a new target for PTC therapy. (C) 2018 Elsevier Inc. All rights reserved.	[Chang, Chun-Chi; Liu, Ta-Chih] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, 100 Shih Chun 1st Rd, Kaohsiung 807, Taiwan; [Chang, Chun-Chi] Changhua Christian Hosp, Dept Internal Med, Div Chest Med, Changhua, Taiwan; [Chang, Ya-Sian; Huang, Hsi-Yuan; Chang, Jan-Gowth] China Med Univ Hosp, Epigenome Res Ctr, 2 Yuh Der Rd, Taichung 404, Taiwan; [Chang, Ya-Sian; Huang, Hsi-Yuan; Chang, Jan-Gowth] China Med Univ Hosp, Dept Lab Med, Taichung, Taiwan; [Chang, Ya-Sian; Huang, Hsi-Yuan; Chang, Jan-Gowth] China Med Univ Hosp, Ctr Precis Med, Taichung, Taiwan; [Chang, Ya-Sian] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan; [Yeh, Kun-Tu] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan; [Chang, Jan-Gowth] China Med Univ, Sch Med, Taichung, Taiwan; [Chang, Jan-Gowth] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan	Liu, TC (reprint author), Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, 100 Shih Chun 1st Rd, Kaohsiung 807, Taiwan.; Chang, JG (reprint author), China Med Univ Hosp, Epigenome Res Ctr, 2 Yuh Der Rd, Taichung 404, Taiwan.	d730093@kmu.edu.tw; d6781@mail.cmuh.org.tw			China Medical University Hospital grant [DMR106-105]; Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 103-2320-B-039 -050- MY3]; Taiwan Ministry of Health and Welfare Clinical Trial [MOHW107-TDU-B-212-123004]	This work has been support in part by China Medical University Hospital grant (DMR106-105), Ministry of Science and Technology of Taiwan (MOST 103-2320-B-039 -050- MY3) and Taiwan Ministry of Health and Welfare Clinical Trial (MOHW107-TDU-B-212-123004).	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Ai RN, 2016, CANCER BIOL THER, V17, P943, DOI 10.1080/15384047.2016.1210734; Anik A, 2015, J PEDIATR ENDOCR MET, V28, P251, DOI 10.1515/jpem-2014-0384; Aschebrook-Kilfoy B, 1992, THYROID CANC INCIDEN; Ashcroft FM, 2005, J CLIN INVEST, V115, P2047, DOI 10.1172/JCI25495; Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP; Costa V, 2015, ONCOTARGET, V6, P11242, DOI 10.18632/oncotarget.3593; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Han MA, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14020129; Hua X, 2013, AM J HUM GENET, V93, P439, DOI 10.1016/j.ajhg.2013.07.003; Kalaydjieva L, 1996, NAT GENET, V14, P214, DOI 10.1038/ng1096-214; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Lee CC, 2014, J BIOL CHEM, V289, P17124, DOI 10.1074/jbc.M114.571257; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/mpath.2008.10; Pan WT, 2016, HUM MOL GENET, V25, P1875, DOI 10.1093/hmg/ddw056; Planells-Cases R, 2015, EMBO J, V34, P2993, DOI 10.15252/embj.201592409; Porta M, 2003, EUR J EPIDEMIOL, V18, P289, DOI 10.1023/A:1023700216945; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Siraj AK, 2016, AM J HUM GENET, V98, P1170, DOI 10.1016/j.ajhg.2016.04.014; Smith LK, 2016, PHARMACOL RES, V107, P42, DOI 10.1016/j.phrs.2016.02.009; Thorn CF, 2012, PHARMACOGENET GENOM, V22, P389, DOI 10.1097/FPC.0b013e3283505d5e; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wu WX, 2015, SCI REP-UK, V5, DOI 10.1038/srep09051; Zulli A, 2016, EUR J NUTR, V55, P1331, DOI 10.1007/s00394-016-1179-z	35	0	0	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						151	158		10.1016/j.humpath.2018.04.023			8	Pathology	Pathology	GR0GG	WOS:000442191800019	29753010				2019-10-28	
J	Walcott-Sapp, S; Tang, E; Kakar, S; Shen, J; Hansen, P				Walcott-Sapp, Sarah; Tang, Ephraim; Kakar, Sanjay; Shen, Jian; Hansen, Paul			Resection of the largest reported hepatic small vessel neoplasm	HUMAN PATHOLOGY			English	Article						Hepatic small vessel neoplasm; Hemangioma; Angiosarcoma; Hepatic vascular neoplasm; Liver	ADULT CAPILLARY HEMANGIOMA; ANASTOMOSING HEMANGIOMA; MIMICKING-ANGIOSARCOMA; LIVER	Hepatic small vessel neoplasm (HSVN) is a recently described vascular neoplasm of the adult liver. The neoplastic cells are positive for markers of vascular lineage (CD31, CD34, FLI-1). The distinctive morphology and infiltrative borders separate HSVN from benign vascular tumors such as cavernous hemangioma, while lack of atypical morphologic features, low to absent mitotic activity and low proliferation index distinguish it from malignant vascular tumors such as epithelioid hemangioendothelioma and angiosarcoma. Due to its infiltrative nature and lack of adequate follow-up information, the benign versus low-grade nature of this tumor is currently uncertain. We present a patient with resected HSVN involving all but the right posterior section of the liver, making this case the largest reported in the current literature. (C) 2018 Elsevier Inc. All rights reserved.	[Walcott-Sapp, Sarah; Tang, Ephraim; Hansen, Paul] Oregon Clin, Gastrointestinal & Minimally Invas Surg, Portland, OR 97213 USA; [Walcott-Sapp, Sarah; Hansen, Paul] Oregon Hlth & Sci Univ, Sch Med, Dept Surg, Portland, OR 97239 USA; [Kakar, Sanjay] Univ Calif San Francisco, Dept Pathol & Lab Med, Liver GI Serv, San Francisco, CA 94143 USA; [Shen, Jian] Providence Portland Med Ctr, Dept Pathol, Portland, OR 97213 USA	Walcott-Sapp, S (reprint author), 3181 SW Sam Jackson Pk Rd,Mail Code L223, Portland, OR 97239 USA.	walcotts@ohsu.edu					Benevento A, 2003, J AM COLL SURGEONS, V197, P860, DOI 10.1016/S1072-7515(03)00653-7; Bioulac-Sage P, 2008, SEMIN LIVER DIS, V28, P302, DOI 10.1055/s-0028-1085098; Chaudhary P, 2015, EJSO-EUR J SURG ONC, V41, P1137, DOI 10.1016/j.ejso.2015.04.022; Flucke U, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-131; Gill R, 2013, MODERN PATHOL, V26, p402A; Gill RM, 2012, MOD PATHOL S2, V25, P412; Gill RM, 2016, HUM PATHOL, V54, P143, DOI 10.1016/j.humpath.2016.03.018; Jhuang JY, 2011, KAOHSIUNG J MED SCI, V27, P344, DOI 10.1016/j.kjms.2011.03.003; Kameda R, 2011, KANZO, V52, P244; Lewis S, 2015, CLIN IMAG, V39, P702, DOI 10.1016/j.clinimag.2015.02.007; Lin JM, 2013, AM J SURG PATHOL, V37, P1761, DOI 10.1097/PAS.0b013e3182967e6c; Montgomery E, 2009, AM J SURG PATHOL, V33, P1364, DOI 10.1097/PAS.0b013e3181ad30a7; Noda T, 2005, SURG TODAY, V35, P796, DOI 10.1007/s00595-005-3007-6; Riener MO, 2008, GENE CHROMOSOME CANC, V47, P363, DOI 10.1002/gcc.20540	14	7	7	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						159	162		10.1016/j.humpath.2018.01.013			4	Pathology	Pathology	GR0GG	WOS:000442191800020	29366622				2019-10-28	
J	Singh, K; Paquette, C; Kalife, ET; Wang, YH; Mangray, S; Quddus, MR; Steinhoff, MM				Singh, Kamaljeet; Paquette, Cherie; Kalife, Elizabeth T.; Wang, Yihong; Mangray, Shamlal; Quddus, M. Ruhul; Steinhoff, Margaret M.			Evaluating agreement, histological features, and relevance of separating pleomorphic and florid lobular carcinoma in situ subtypes	HUMAN PATHOLOGY			English	Article						Breast cancer; Pleomorphic; Lobular carcinoma; Agreement; Interobserver variability; Florid; Apocrine	INTRAEPITHELIAL NEOPLASIA; CLINICAL-IMPLICATIONS; BREAST; DIAGNOSIS; MANAGEMENT; PATHOLOGY; LESIONS; PLCIS; RISK	Morphological variants of lobular carcinoma in situ (LCIS) include classical (CLCIS), pleomorphic (PLCIS) and florid type (FLCIS). Treatment guidelines suggest managing PLCIS and FLCIS like ductal carcinoma in situ (DCIS); therefore accurate identification of LCIS subtypes is critical. However, the significance of separating PLCIS from FLCIS is not clear. Also, interobserver agreement in identifying LCIS subtypes, using contemporary criteria, is not known. We aimed to evaluate interobserver agreement amongst breast pathologists in diagnosing LCIS subtypes and use the agreement data to justify LCIS classification for management purposes. Six breast pathologists independently reviewed 50 hematoxylin and eosin stained slides comprised of a mix of LCIS subtypes. After reviewing published criteria, participants diagnosed PLCIS, CLCIS and apocrine change in a marked region of interest and FLCIS based on entire section. PLCIS was identified in 8 to 37 slides with overall moderate agreement (Fleiss' kappa = 0.565) and pair wise kappa (Cohen's) ranging from-.008 to 0.492. FLCIS was diagnosed in 15-26 slides with overall substantial agreement (Fleiss' kappa = 0.687) and pairwise kappa ranging from-.068 to 0.706. Both FLCIS and PLCIS coexisted in 45% of slides with consensus on non-classical LCIS. Comedo-type necrosis (odds ratio = 5.5) and apoptosis (odds ratio = 1.8) predicted FLCIS. We found moderate and substantial agreement in diagnosing PLCIS and FLCIS respectively. Objective histological features linked with aggressive behavior were more frequent with FLCIS. PLCIS and FLCIS patterns frequently coexist, contain similar molecular aberrations, and are managed similarly (like DCIS); therefore, combining FLCIS and PLCIS into one category (non-classical LCIS) should be considered. Published by Elsevier Inc.	[Singh, Kamaljeet; Paquette, Cherie; Kalife, Elizabeth T.; Quddus, M. Ruhul; Steinhoff, Margaret M.] Women & Infants Hosp Rhode Isl, Dept Pathol, 101 Dudley St, Providence, RI 02905 USA; [Wang, Yihong; Mangray, Shamlal] Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA	Singh, K (reprint author), Women & Infants Hosp Rhode Isl, Dept Pathol, 101 Dudley St, Providence, RI 02905 USA.	KSingh@wihri.org					Amin MB, 2017, AJCC CANC STAGING MA; Andrade VP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3222; [Anonymous], 2018, NCCN GUIDELINES TREA; Bagaria SP, 2011, ANN SURG ONCOL, V18, P1845, DOI 10.1245/s10434-011-1563-0; Blanco LZ, 2015, AM J CLIN PATHOL, V144, P722, DOI 10.1309/AJCPZHZ2TUE2UYNV; Bratthauer GL, 2002, VIRCHOWS ARCH, V440, P134, DOI 10.1007/s00428-001-0541-5; Carder PJ, 2010, HISTOPATHOLOGY, V57, P472, DOI 10.1111/j.1365-2559.2010.03634.x; Chen YY, 2009, AM J SURG PATHOL, V33, P1683, DOI 10.1097/PAS.0b013e3181b18a89; Chester R, 2015, ANN ROY COLL SURG, V97, P574, DOI 10.1308/rcsann.2015.0037; Chivukula M, 2008, AM J SURG PATHOL, V32, P1721, DOI 10.1097/PAS.0b013e31817dc3a6; Cutuli B, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0379-7; DIXON JM, 1982, HISTOPATHOLOGY, V6, P149, DOI 10.1111/j.1365-2559.1982.tb02712.x; Downs-Kelly E, 2011, ARCH PATHOL LAB MED, V135, P737, DOI 10.1043/2010-0204-OA.1; EUSEBI V, 1992, HUM PATHOL, V23, P655, DOI 10.1016/0046-8177(92)90321-S; Fadare O, 2006, AM J SURG PATHOL, V30, P1445, DOI 10.1097/01.pas.0000213290.58283.82; Flanagan MR, 2015, ANN SURG ONCOL, V22, P4263, DOI 10.1245/s10434-015-4552-x; Frost AR, 1996, PATHOL CASE REV, V1, P27, DOI DOI 10.1097/00132583-199605000-00009; Gao FY, 2010, AM J CLIN PATHOL, V133, P767, DOI 10.1309/AJCP04ZJQTJHQYVY; Gomes DS, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-121; HAAGENSEN CD, 1972, SURG CLIN N AM, V52, P497; HAAGENSEN CD, 1978, CANCER, V42, P737, DOI 10.1002/1097-0142(197808)42:2<737::AID-CNCR2820420247>3.0.CO;2-T; Hwang ES, 2004, CANCER, V100, P2562, DOI 10.1002/cncr.20273; Jacobs TW, 2001, AM J SURG PATHOL, V25, P229, DOI 10.1097/00000478-200102000-00011; Khoury T, 2014, HISTOPATHOLOGY, V64, P981, DOI 10.1111/his.12353; King TA, 2015, J CLIN ONCOL, V33, P3945, DOI 10.1200/JCO.2015.61.4743; Lakhani SREI, 2012, WHO CLASSIFICATION T; Nayar R, 1997, HUM PATHOL, V28, P277, DOI 10.1016/S0046-8177(97)90124-6; Pieri A, 2014, WORLD J CLIN ONCOL, V5, P546, DOI 10.5306/wjco.v5.i3.546; Rakha EA, 2013, MODERN PATHOL, V26, P496, DOI 10.1038/modpathol.2012.197; Reis JS, 2005, J PATHOL, V207, P1, DOI 10.1002/path.1806; Shin SJ, 2013, HUM PATHOL, V44, P1998, DOI 10.1016/j.humpath.2013.04.004; Sneige N, 2002, MODERN PATHOL, V15, P1044, DOI 10.1097/01.MP.0000030450.20581.E3; Sneige N, 1999, HUM PATHOL, V30, P257, DOI 10.1016/S0046-8177(99)90002-3; Sullivan ME, 2010, ARCH PATHOL LAB MED, V134, P1024, DOI 10.1043/2009-0300-OA.1	34	0	0	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						163	170		10.1016/j.humpath.2018.04.026			8	Pathology	Pathology	GR0GG	WOS:000442191800021	29753007				2019-10-28	
J	Zhang, Y; Tao, L; Yin, C; Wang, WW; Zou, H; Ren, Y; Liang, WH; Jiang, JF; Zhang, WJ; Jia, W; Li, F				Zhang, Ying; Tao, Lin; Yin, Can; Wang, Weiwei; Zou, Hong; Ren, Yan; Liang, Weihua; Jiang, Jinfang; Zhang, Wenjie; Jia, Wei; Li, Feng			Ovarian microcystic stromal tumor with undetermined potential: case study with molecular analysis and literature review	HUMAN PATHOLOGY			English	Review						Microcystic stromal tumor of the ovary; Immunohistochemistry; Mutation; beta-Catenin gene; APC gene	FAMILIAL ADENOMATOUS POLYPOSIS; SOLID PSEUDOPAPILLARY NEOPLASM; BETA-CATENIN CTNNB1; MUTATION	Ovarian microcystic stromal tumor is a relatively rare tumor type. This tumor is characterized by a unique microcyst structure, and essentially all tumors show benign biological behavior. Here, we report a case with a primary ovarian microcystic stromal tumor that experienced recurrence. Pathological findings showed that the original tumor, relapsed tumor in the ovary, and the recurrent tumor in the iliac fossa presented similar histologic features. The tumor mainly consisted of microcysts, solid cellular regions, and a fibrous stroma. Immunohistochemically, the tumor cells were positive for beta-catenin, CD10, vimentin, and WT-1. Mutational analysis revealed a missense mutation (c.1590C>T; pG530E) in exon 15 of the APC gene and another missense mutation (c.740G>A; pA247V) in exon 1 of the KRAS gene. We also reviewed other published cases to evaluate the prognosis and treatment. This is the first report to describe a microcystic stromal tumor of the ovary presenting with undetermined biological potential. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Ying; Tao, Lin; Yin, Can; Zou, Hong; Ren, Yan; Liang, Weihua; Jiang, Jinfang; Zhang, Wenjie; Jia, Wei; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol, Xining 832002, Qinghai, Peoples R China; [Li, Feng] Capital Med Univ, Beijing ChaoYang Hosp, Dept Pathol, Beijing 100020, Peoples R China; [Wang, Weiwei] Zhucheng Maternal & Child Care Serv Ctr, Dept Pathol, Weifang 262200, Peoples R China	Jia, W (reprint author), Shihezi Univ, Sch Med, Dept Pathol, Xining 832002, Qinghai, Peoples R China.; Li, F (reprint author), Capital Med Univ, Beijing ChaoYang Hosp, Dept Pathol, Beijing 100020, Peoples R China.	jiaweipatho@sina.com; lifeng7855@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81660431]; Ministry of Human Resources and Social Security Foundation [2016LX008]	This work was funded by the National Natural Science Foundation of China (No. 81660431) and the Ministry of Human Resources and Social Security Foundation (No. 2016LX008). No funding or other benefits related to the subject of this article were received from any commercial entity.	Agaimy A, 2016, ADV ANAT PATHOL, V23, P1, DOI 10.1097/PAP.0000000000000104; Bi R, 2015, HISTOPATHOLOGY, V67, P872, DOI 10.1111/his.12722; Caso R, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.50; Chen Q, 2015, INT J CLIN EXP PATHO, V8, P11792; Deshpande V, 2010, AM J SURG PATHOL, V34, P1514, DOI 10.1097/PAS.0b013e3181f133e9; Irving JA, 2015, AM J SURG PATHOL, V39, P1420, DOI 10.1097/PAS.0000000000000482; Irving JA, 2009, AM J SURG PATHOL, V33, P367, DOI 10.1097/PAS.0b013e31818479c3; Kang YN, 2015, INT J GYNECOL PATHOL, V34, P121, DOI 10.1097/PGP.0000000000000122; Lee SH, 2015, GENE CHROMOSOME CANC, V54, P353, DOI 10.1002/gcc.22233; Liu C, 2016, INT J GYNECOL PATHOL, V35, P561, DOI 10.1097/PGP.0000000000000289; Maeda D, 2011, AM J SURG PATHOL, V35, P1429, DOI 10.1097/PAS.0b013e31822d6c71; Na K, 2017, ANTICANCER RES, V37, P3249, DOI 10.21873/anticanres.11688; Yang M, 2014, ULTRASTRUCT PATHOL, V38, P261, DOI 10.3109/01913123.2014.893045	13	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						171	176		10.1016/j.humpath.2018.02.012			6	Pathology	Pathology	GR0GG	WOS:000442191800022	29458068				2019-10-28	
J	Hayashi, T; Takamochi, K; Yanai, Y; Mitani, K; Tomita, H; Mogushi, K; Suehara, Y; Takahashi, F; Suzuki, K; Saito, T; Yao, T				Hayashi, Takuo; Takamochi, Kazuya; Yanai, Yuka; Mitani, Keiko; Tomita, Hisashi; Mogushi, Kaoru; Suehara, Yoshiyuki; Takahashi, Fumiyuki; Suzuki, Kenji; Saito, Tsuyoshi; Yao, Takashi			Non-small cell lung carcinoma with diffuse coexpression of thyroid transcription factor-1 and Delta Np63/p40	HUMAN PATHOLOGY			English	Article						TTF-1; p40; Lung adenocarcinoma; Lung squamous cell carcinoma; Next-generation sequencing	ADENOCARCINOMAS; DIAGNOSIS	Here, we present a case of non small cell lung carcinoma (NSCLC) with widespread and strong nuclear immunopositivity for both thyroid transcription factor-1 (TTF-1) and Delta Np63/p40 (p40). Double immunofluorescence for TTF-1 and p40 showed coexpression of both markers in the tumor cells. Furthermore, PTEN (pHis123Asp) and TP53 (pVal272Leu) mutations were identified as possible mitogenic driver mutations by next-generation sequencing. To the best of our knowledge, this is the first case of NSCLC harboring concurrent PTEN and TP53 mutations with widespread and strong coexpression of TTF-1 and p40, which has been confirmed in the resected specimen, and only the second documented case of NSCLC with TTF-1 and p40 diffuse coexpression in the carcinoma cells from the same individual. Our case illustrates the possibility that poorly differentiated NSCLCs with widespread and strong nuclear positivity for TTF-1 and p40 may be an underrecognized and new entity. (C) 2018 Elsevier Inc. All rights reserved.	[Hayashi, Takuo; Yanai, Yuka; Mitani, Keiko; Saito, Tsuyoshi; Yao, Takashi] Juntendo Univ, Dept Human Pathol, Sch Med, Tokyo 1138421, Japan; [Takamochi, Kazuya; Tomita, Hisashi; Suzuki, Kenji] Juntendo Univ, Dept Gen Thorac Surg, Sch Med, Tokyo 1138421, Japan; [Mogushi, Kaoru] Juntendo Univ, Ctr Genom & Regenerat Med, Sch Med, Tokyo 1138421, Japan; [Suehara, Yoshiyuki] Juntendo Univ, Dept Orthoped Surg, Sch Med, Tokyo 1138421, Japan; [Takahashi, Fumiyuki] Juntendo Univ, Dept Resp Med, Sch Med, Tokyo 1138421, Japan; [Mogushi, Kaoru] Juntendo Univ, Diagnost & Therapeut Intractable Dis, Grad Sch Med, Tokyo 1138421, Japan	Hayashi, T (reprint author), Juntendo Univ, Dept Human Pathol, Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	tkhyz@juntendo.ac.jp			Japan Agency for Medical Research and Development, Tokyo, JapanJapan Agency for Medical Research and Development (AMED) [16K08674]	This study was supported by the Grant-in-Aid for Japan Society for the Promotion of Science KAKENHI (grant 16K08674 to T. H.) Tokyo, Japan and Leading Advanced Projects for Medical Innovation from the Japan Agency for Medical Research and Development, Tokyo, Japan.	Aviel-Ronen S, 2008, MODERN PATHOL, V21, P817, DOI 10.1038/modpathol.2008.37; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Pelosi G, 2015, J THORAC ONCOL, V10, P1500, DOI 10.1097/JTO.0000000000000553; Rodriguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337; Suehara Y, 2012, CLIN CANCER RES, V18, P6599, DOI 10.1158/1078-0432.CCR-12-0838; Takamochi K, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2792-1; Travis WD, 2015, WHO CLASSIFICATION T; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	13	1	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						177	181		10.1016/j.humpath.2018.01.023			5	Pathology	Pathology	GR0GG	WOS:000442191800023	29410129				2019-10-28	
J	Shen, J; Shrestha, S; Rao, PN; Asatrian, G; Scott, MA; Nguyen, V; Giacomelli, P; Soo, C; Ting, K; Eilber, FC; Peault, B; Dry, SM; James, AW				Shen, Jia; Shrestha, Swati; Rao, P. Nagesh; Asatrian, Greg; Scott, Michelle A.; Vi Nguyen; Giacomelli, Paulina; Soo, Chia; Ting, Kang; Eilber, Fritz C.; Peault, Bruno; Dry, Sarah M.; James, Aaron W.			Pericytic mimicry in well-differentiated liposarcoma/atypical lipomatous tumor (vol 54, pg 92, 2016)	HUMAN PATHOLOGY			English	Correction									[Shen, Jia; Asatrian, Greg; Ting, Kang; James, Aaron W.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; [Shrestha, Swati; Rao, P. Nagesh; Asatrian, Greg; Vi Nguyen; Giacomelli, Paulina; Dry, Sarah M.; James, Aaron W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Scott, Michelle A.] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Soo, Chia; Peault, Bruno; James, Aaron W.] Univ Calif Los Angeles, Orthoped Hosp Res Ctr, Los Angeles, CA 90095 USA; [Soo, Chia; Eilber, Fritz C.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90095 USA; [Peault, Bruno] Univ Edinburgh, Ctr Regenerat Med, Edinburgh, Midlothian, Scotland	James, AW (reprint author), Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.; James, AW (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.; James, AW (reprint author), Univ Calif Los Angeles, Orthoped Hosp Res Ctr, Los Angeles, CA 90095 USA.						Shen J, 2016, HUM PATHOL, V54, P92, DOI 10.1016/j.humpath.2016.03.008	1	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	AUG	2018	78						188	188		10.1016/j.humpath.2018.04.021			1	Pathology	Pathology	GR0GG	WOS:000442191800025	29958690				2019-10-28	
J	Rovira, ARI; Bennet, BM; Bolon, B; Braendli-Baiocco, A; Chandra, S; Fleurance, R; Garman, R; Hutto, D; Lane, J; Romeike, A; Sargeant, A; Zimmerman, B				Rovira, Armando R. Irizarry; Bennet, Bindu M.; Bolon, Brad; Braendli-Baiocco, Annamaria; Chandra, Sundeep; Fleurance, Renaud; Garman, Robert; Hutto, David; Lane, Joan; Romeike, Annette; Sargeant, Aaron; Zimmerman, Bevin			Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products	TOXICOLOGIC PATHOLOGY			English	Article						PEG; pegylation; vacuolation; histology; immunohistochemistry; polyethylene glycol	NONACOG BETA PEGOL; TISSUE DISTRIBUTION; VACUOLE FORMATION; PROTEINS; RATS; PHARMACOKINETICS; METABOLISM; PATHOLOGY; TOXICITY; BIOPHARMACEUTICALS	Colorless, intracytoplasmic vacuoles occur in multiple tissues in animals following repeated administration of polyethylene glycol (PEG)-conjugated molecules. The extent of vacuolation depends on physical characteristics and molecular backbone of the PEG and the dose, product, drug target/pharmacology, and duration of exposure. The collective experience gathered from multiple nonclinical toxicology studies of PEGylated biopharmaceuticals indicates that in general, PEG-related vacuolation is not associated with demonstrable cell and tissue damage or dysfunction and is reversible with sufficient duration of drug-free periods. Existing data are insufficient to predict whether nonclinical animal species differ in their sensitivity to develop PEG-associated vacuoles; however, recent data suggest that there may be species differences. Recent comprehensive reviews have addressed the basic challenges in developing PEGylated pharmaceutical products, including general reference to and description of PEG-associated tissue findings. These manuscripts have identified gaps in our current understanding of PEG-associated vacuolation, including the lack of a widely accepted standardized histological terminology and criteria to record and grade the severity of vacuolation as well as insufficient knowledge regarding the nature of the contents of these vacuoles. The goal of this article is to help address some of the gaps identified above by providing points to consider, including a pictorial review of PEG-associated microscopic findings, when evaluating and reporting the extent, severity, and significance (adversity or lack of adversity) of PEG-associated cytoplasmic vacuolation in safety assessment studies.	[Rovira, Armando R. Irizarry] Eli Lilly & Co, Indianapolis, IN 46265 USA; [Bennet, Bindu M.] Janssen Pharmaceut, Spring House, PA USA; [Bolon, Brad] GEMpath Inc, Longmont, CO USA; [Braendli-Baiocco, Annamaria] Roche Innovat Ctr, Roche Pharma Res & Early Dev, Pharmaceut Sci, Basel, Switzerland; [Chandra, Sundeep] BioMarin Pharmaceut Inc, San Rafael, CA USA; [Fleurance, Renaud] UCB Biopharma, Braine Lalleud, Belgium; [Garman, Robert] Vet Pathol, Murrysville, PA USA; [Hutto, David] Shire Pharmaceut, Cambridge, MA USA; [Lane, Joan] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA; [Romeike, Annette] Covance Inc, Rueil Malmaison, France; [Sargeant, Aaron] Charles River Labs, Spencerville, OH USA; [Zimmerman, Bevin] Charles River Labs, Ashland, OH USA	Rovira, ARI (reprint author), Eli Lilly & Co, Dept Pathol, Lilly Res Labs, Lilly Corp Ctr, Indianapolis, IN 46265 USA.	irizarryar@lilly.com		Fleurance, Renaud/0000-0003-2274-3393			Baumann A, 2014, DRUG DISCOV TODAY, V19, P1623, DOI 10.1016/j.drudis.2014.06.002; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; Bendele A, 1998, TOXICOL SCI, V42, P152, DOI 10.1006/toxs.1997.2396; Bjornsdottir I, 2016, EUR J PHARM SCI, V87, P58, DOI 10.1016/j.ejps.2015.10.020; Bolon B., 2001, TOXICOLOGIST, V60, P376; Byrd RA, 2017, TOXICOL PATHOL, V45, P402, DOI 10.1177/0192623317696283; Conover C, 1996, ARTIF CELL BLOOD SUB, V24, P599, DOI 10.3109/10731199609118885; Crissman JW, 2004, TOXICOL PATHOL, V32, P126, DOI 10.1080/01926230490268756; EMA (European Medicines Agency), 2012, EMACHMPSWP6472582012; EMA (European Medicines Agency), 2009, EPAR CIMZ CERT PEG; EMA (European Medicines Agency), 2007, EPAR MAC PEG; EMA (European Medicines Agency), 2012, CHMP ASS REP KRYST P; EMA (European Medicines Agency), 2005, EPAR SOM PEGV; EMA (European Medicines Agency), 2013, WITHDR ASS REP OM PE; FDA (Food and Drug Administration), 2008, 125160 FDA BLA; FDA (Food and Drug Administration), 2017, 125611 FDA BLA; FDA (Food and Drug Administration), 2010, 125293 FDA BLA; FDA (Food and Drug Administration), 2004, 21756 FDA NDA; FDA (Food and Drug Administration), 2003, 021106 FDA NDA; FDA (Food and Drug Administration), 2012, 202799 FDA NDA; Forest T, 2017, TOXICOL PATHOL, V45, P604, DOI 10.1177/0192623317714068; Fruijtier-Polloth C, 2005, TOXICOLOGY, V214, P1, DOI 10.1016/j.tox.2005.06.001; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Ivens IA, 2013, HAEMOPHILIA, V19, P11, DOI 10.1111/j.1365-2516.2012.02931.x; Ivens IA, 2015, TOXICOL PATHOL, V43, P959, DOI 10.1177/0192623315591171; Jain A, 2008, CRIT REV THER DRUG, V25, P403, DOI 10.1615/CritRevTherDrugCarrierSyst.v25.i5.10; Kaufman LS, 2014, OCCURRENCE MICROSCOP; Kerlin R, 2016, TOXICOL PATHOL, V44, P147, DOI 10.1177/0192623315623265; Kronenberg S, 2013, DRUG DISCOV TODAY, V18, P1138, DOI 10.1016/j.drudis.2013.08.003; Li XT, 2003, TOXICOL PATHOL, V31, P682, DOI 10.1080/01926230390241981; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; Markovsky E, 2012, J CONTROL RELEASE, V161, P446, DOI 10.1016/j.jconrel.2011.12.021; McDuffie E., 2016, 35 ANN S SOC TOX PAT; Morton D, 2006, TOXICOL PATHOL, V34, P806, DOI 10.1080/01926230601034624; Naas D, 2015, INT J TOXICOL, V34, P318, DOI 10.1177/1091581815585854; Peyvandi F., 2015, WORKSH HAEM REG JUL; Rasmussen CE, 2016, TOXICOL PATHOL, V44, P726, DOI 10.1177/0192623316633311; Rudmann DG, 2013, TOXICOL PATHOL, V41, P970, DOI 10.1177/0192623312474726; Schafer KA, 2018, TOXICOL PATHOL, V46, P256, DOI 10.1177/0192623318761348; Sternebring O, 2016, EUR J PHARM SCI, V92, P163, DOI 10.1016/j.ejps.2016.06.025; Stidl R, 2016, HAEMOPHILIA, V22, P54, DOI 10.1111/hae.12762; Ton NC, 2007, CLIN CANCER RES, V13, P7113, DOI 10.1158/1078-0432.CCR-07-1550; Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015; Veronese FM, 2008, BIODRUGS, V22, P315, DOI 10.2165/00063030-200822050-00004; Wang HJ, 2012, J VIROL, V86, P6286, DOI 10.1128/JVI.00205-12; Webster R, 2007, DRUG METAB DISPOS, V35, P9, DOI 10.1124/dmd.106.012419; Webster R, 2009, MILESTONES DRUG THER, P127, DOI 10.1007/978-3-7643-8679-5_8; White CA, 2007, P NATL ACAD SCI USA, V104, P19357, DOI 10.1073/pnas.0710110104; Xu J, 2013, BIOCONJUGATE CHEM, V24, P915, DOI 10.1021/bc300603k; Young MA, 2007, TRANSL RES, V149, P333, DOI 10.1016/j.trsl.2006.09.007; Yu D., 2004, P AM ASSOC CANC RES, V45, pa644	51	4	4	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					616	635		10.1177/0192623318791801			20	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300001	30092727				2019-10-28	
J	Ennulat, D; Ringenberg, M; Frazier, KS				Ennulat, Daniela; Ringenberg, Michael; Frazier, Kendall S.			Toxicologic Pathology Forum Opinion Paper*: Recommendations for a Tiered Approach to Nonclinical Mechanistic Nephrotoxicity Evaluation	TOXICOLOGIC PATHOLOGY			English	Article						toxicity; kidney; pharmaceutical; mechanism; nephrotoxicity	ACUTE KIDNEY INJURY; GLOMERULAR-FILTRATION-RATE; GELATINASE-ASSOCIATED LIPOCALIN; RENAL-FUNCTION; CYSTATIN-C; ANTISENSE OLIGONUCLEOTIDE; BIOMARKER QUALIFICATION; GENTAMICIN; TOXICITY; ANIMALS	Nephrotoxicity is one of the more common causes of attrition in nonclinical drug development. Like most tissues, the kidney has a limited number of ways of responding to toxicological insults from diverse mechanistic pathways, which can limit the ability to determine mechanisms of renal injury using the assays routinely performed in preclinical toxicologic studies. In situations where the renal injury is unusual in morphology or if a therapeutic margin is low, additional investigative techniques may be needed to identify a potential mechanism of toxicity in order to inform clinical risk assessment or establish human relevance and translatability of the toxicity. While routine microscopic evaluation can suggest a specific pathogenesis, understanding the mechanism of renal injury often requires additional hypothesis-driven investigations and specialized techniques to obtain the data necessary to identify a nephrotoxic mechanism. Nonclinical mechanistic investigations can be resource-intensive and often yield limited new information. Although there are multiple avenues to investigate renal toxicity, no single mechanistic study or prescriptive battery of tests will identify the pathophysiologic basis for every potential mechanism of renal injury. To aid the nonclinical investigator, we outline a tiered approach for prioritizing investigations to provide a rational and linear road map for the exploration of mechanisms of drug-induced kidney injury. Note: This is an opinion article submitted to the Toxicologic Pathology Forum. It represents the views of the authors. It does not constitute an official position of the Society of Toxicologic Pathology, British Society of Toxicological Pathology or European Society of Toxicologic Pathology, and the views expressed might not reflect the best practices recommended by these Societies. This article should not be construed to represent the policies, positions, or opinions of their respective organizations, employers, or regulatory agencies.	[Ennulat, Daniela; Ringenberg, Michael; Frazier, Kendall S.] GlaxoSmithKline, 709 Swedeland Rd,UEO462,POB 1539, King Of Prussia, PA 19406 USA	Ennulat, D (reprint author), GlaxoSmithKline, 709 Swedeland Rd,UEO462,POB 1539, King Of Prussia, PA 19406 USA.	daniela.2.ennulat@gsk.com					Almy FS, 2002, J VET INTERN MED, V16, P45, DOI 10.1892/0891-6640(2002)016<0045:EOCCAA>2.3.CO;2; Bonventre JV, 2010, NAT BIOTECHNOL, V28, P436, DOI 10.1038/nbt0510-436; Brott DA, 2015, DRUG DES DEV THER, V9, P3191, DOI 10.2147/DDDT.S78792; Brott DA, 2014, DRUG DES DEV THER, V8, P227, DOI 10.2147/DDDT.S54956; Capati A, 2017, MAGN RESON INSIGHTS, V10, DOI 10.1177/1178623X17694346; Cappuccilli M, 2018, ARTIF ORGANS, V42, P8, DOI 10.1111/aor.13039; Cardenas-Gonzales M., 2016, COMPREHENSIVE TOXICO, V14, P147; Charlton JR, 2014, NEPHROL DIAL TRANSPL, V29, P1301, DOI 10.1093/ndt/gft510; Dieterle F, 2010, NAT BIOTECHNOL, V28, P463, DOI 10.1038/nbt.1622; Dieterle F, 2010, NAT BIOTECHNOL, V28, P455, DOI 10.1038/nbt.1625; Emwas AH, 2015, METABOLOMICS, V11, P872, DOI 10.1007/s11306-014-0746-7; FDA, 2018, LIST QUAL BIOM; FDA (Food and Drug Administration), 2018, FDA ISS LETT SUPP; Feingold S, 2010, INVEST RADIOL, V45, P669, DOI 10.1097/RLI.0b013e3181ef0a78; Ferguson MA, 2008, TOXICOLOGY, V245, P182, DOI 10.1016/j.tox.2007.12.024; Ferguson MA, 2012, CLIN CHEM, V58, P680, DOI 10.1373/clinchem.2011.167494; Frazier KS, 2015, TOXICOL PATHOL, V43, P915, DOI 10.1177/0192623315570340; Frazier KS, 2014, TOXICOL PATHOL, V42, P923, DOI 10.1177/0192623313505781; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Frazier KS, 2013, TOXICOL PATHOL, P421; Friedemann J, 2016, KIDNEY INT, V90, P1377, DOI 10.1016/j.kint.2016.07.024; Gautier JC, 2016, TOXICOL APPL PHARM, V303, P1, DOI 10.1016/j.taap.2016.04.012; Geary RS, 2009, EXPERT OPIN DRUG MET, V5, P381, DOI [10.1517/17425250902877680 , 10.1517/17425250902877680]; Granata A, 2015, CLIN EXP NEPHROL, V19, P606, DOI 10.1007/s10157-014-1040-8; Groseclose MR, 2015, J AM SOC MASS SPECTR, V26, P887, DOI 10.1007/s13361-015-1103-4; Guha M, 2011, TOXICOL SCI, V120, P269, DOI 10.1093/toxsci/kfr013; Hall RL, 2013, TOXICOL PATHOL, P133; Hamdam J, 2013, TOXICOL APPL PHARM, V273, P229, DOI 10.1016/j.taap.2013.04.039; Harpur E, 2011, TOXICOL SCI, V122, P235, DOI 10.1093/toxsci/kfr112; HASEGAWA T, 1994, BIOL PHARM BULL, V17, P1651; Houbois C, 2018, EUR J RADIOL, V103, P105, DOI 10.1016/j.ejrad.2018.04.016; Humphreys BD, 2013, J CLIN INVEST, V123, P4023, DOI 10.1172/JCI45361; Issa N, 2013, AM J NEPHROL, V37, P602, DOI 10.1159/000351648; Jochmans I, 2011, TRANSPL P, V43, P3486, DOI 10.1016/j.transproceed.2011.09.035; Keevil BG, 1998, CLIN CHEM, V44, P1535; Lefebvre HP, 2008, VET CLIN PATH, V37, P4, DOI 10.1111/j.1939-165X.2008.00010.x; Lentini P, 2017, MOL MED REP, V15, P3413, DOI 10.3892/mmr.2017.6389; Mariager CO, 2018, MAGN RESON MED, V80, P696, DOI 10.1002/mrm.27050; Martensson J, 2012, BRIT J ANAESTH, V109, P843, DOI 10.1093/bja/aes357; Morgan WA, 1998, TOXICOL LETT, V94, P209, DOI 10.1016/S0378-4274(98)00024-1; Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786; Phillips JA, 2016, TOXICOL SCI, V151, P214, DOI 10.1093/toxsci/kfw038; Pressler BM, 2013, VET CLIN N AM-SMALL, V43, P1193, DOI 10.1016/j.cvsm.2013.07.011; Prinzen FW, 2000, CARDIOVASC RES, V45, P13, DOI 10.1016/S0008-6363(99)00252-7; Quiros Y, 2011, TOXICOL SCI, V119, P245, DOI 10.1093/toxsci/kfq267; Reasor MJ, 2006, EXPERT OPIN DRUG SAF, V5, P567, DOI 10.1517/14740338.5.4.567; Robertson DG, 2011, TOXICOL SCI, V120, pS146, DOI 10.1093/toxsci/kfq358; Rojko JL, 2014, TOXICOL PATHOL, V42, P725, DOI 10.1177/0192623314526475; Schock-Kusch D, 2011, KIDNEY INT, V79, P1254, DOI 10.1038/ki.2011.31; Seely JC, 2015, TOXICOL PATHOL, V43, P457, DOI 10.1177/0192623315573044; Sharkey J, 2016, EUR J PHARMACOL, V790, P74, DOI 10.1016/j.ejphar.2016.06.056; Soo JYC, 2018, NAT REV NEPHROL, V14, P378, DOI 10.1038/s41581-018-0003-9; Stoynev A. G., 1983, ACTA PHYSL PHARM BUL, V11, P55; Uchino H, 2017, J TOXICOL SCI, V42, P629, DOI 10.2131/jts.42.629; Vaidya VS, 2008, ANNU REV PHARMACOL, V48, P463, DOI 10.1146/annurev.pharmtox.48.113006.094615; Vaidya VS, 2010, NAT BIOTECHNOL, V28, P478, DOI 10.1038/nbt.1623; Wagoner MP, 2017, CURR TOP MED CHEM, V17, P2767, DOI 10.2174/1568026617666170713172331; Wang E, 2012, KIDNEY INT, V81, P112, DOI 10.1038/ki.2011.294; Warrack BM, 2009, J CHROMATOGR B, V877, P547, DOI 10.1016/j.jchromb.2009.01.007; Westhuyzen J, 2003, NEPHROL DIAL TRANSPL, V18, P543, DOI 10.1093/ndt/18.3.543; Xia JG, 2013, METABOLOMICS, V9, P280, DOI 10.1007/s11306-012-0482-9	61	3	3	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					636	646		10.1177/0192623318788302			11	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300002	30049250				2019-10-28	
J	Shockley, KR; Kissling, GE				Shockley, Keith R.; Kissling, Grace E.			Statistical Guidance for Reviewers of Toxicologic Pathology	TOXICOLOGIC PATHOLOGY			English	Review						biostatistics; manuscript peer review; statistical analysis; study design	GUIDELINES; HISTOPATHOLOGY; ARTICLES; JOURNALS	Study design, statistical analysis, interpretation of results, and conclusions should be a part of all research papers. Statistics are integral to each of these components and are therefore necessary to evaluate during manuscript peer review. Research published in Toxicological Pathology is often focused on animal studies that may seek to compare defined treatment groups in randomized controlled experiments or focus on the reliability of measurements and diagnostic accuracy of observed lesions from preexisting studies. Reviewers should distinguish scientific research goals that aim to test sufficient effect size differences (i.e., minimizing false positive rates) from common toxicologic goals of detecting a harmful effect (i.e., minimizing false negative rates). This journal comprises a wide range of study designs that require different kinds of statistical assessments. Therefore, statistical methods should be described in enough detail so that the experiment can be repeated by other research groups. The misuse of statistics will impede reproducibility.	[Shockley, Keith R.; Kissling, Grace E.] NIEHS, Biostat & Computat Biol Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA	Shockley, KR (reprint author), NIEHS, Biostat & Computat Biol Branch, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	shockleykr@niehs.nih.gov			Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported (in part) by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS).	ALTMAN DG, 1983, BRIT MED J, V286, P1489, DOI 10.1136/bmj.286.6376.1489; American Statistical Association, 2018, ETH GUID STAT PRACT; [Anonymous], 2013, NAT METHODS, V10, P367, DOI 10.1038/nmeth.2471; Armbruster David A, 2008, Clin Biochem Rev, V29 Suppl 1, pS49; Bland JM, 1998, BRIT MED J, V317, P1151; Crissman JW, 2004, TOXICOL PATHOL, V32, P126, DOI 10.1080/01926230490268756; Festing Michael F W, 2002, ILAR J, V43, P244; Fisher R.A., 1971, DESIGN EXPT; Hickey GL, 2015, EUR J CARDIO-THORAC, V48, P180, DOI 10.1093/ejcts/ezv168; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hills RK, 2017, BRIT J HAEMATOL, V176, P345, DOI 10.1111/bjh.14426; Hofner B, 2016, BIOMETRICAL J, V58, P416, DOI 10.1002/bimj.201500156; Hothorn LA, 2014, TOXICOL RES-UK, V3, P418, DOI 10.1039/c4tx00047a; Hutton B, 2017, EVID-BASED MENT HEAL, V20, P46, DOI 10.1136/eb-2017-102666; Iatropoulos M J, 1984, Toxicol Pathol, V12, P305; Khan AM, 2017, J THORAC DIS, V9, P2697, DOI 10.21037/jtd.2017.07.30; Lang TA, 2015, INT J NURS STUD, V52, P5, DOI 10.1016/j.ijnurstu.2014.09.006; Levesque RJR, 2015, J YOUTH ADOLESCENCE, V44, P2391, DOI 10.1007/s10964-015-0375-0; Moore D. S., 2001, INTRO PRACTICE STAT; Mullane K, 2015, BIOCHEM PHARMACOL, V97, P225, DOI 10.1016/j.bcp.2015.06.023; Neef N, 2012, TOXICOL PATHOL, V40, P697, DOI 10.1177/0192623312438737; Newberne P M, 1985, Toxicol Pathol, V13, P255; Rousseaux CG, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P893, DOI 10.1016/B978-0-12-415759-0.00030-3; Stephens R, 2015, HEALTH INFO LIBR J, V32, P81, DOI 10.1111/hir.12106; Wade A, 2000, J CLIN PATHOL, V53, P16, DOI 10.1136/jcp.53.1.16; Williams R, 2015, CIRC RES, V117, P667, DOI 10.1161/CIRCRESAHA.115.307532	26	0	0	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					647	652		10.1177/0192623318785097			6	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300003	29966505	Green Accepted			2019-10-28	
J	Clayton, NP; Burwell, A; Jensen, H; Williams, BF; Brown, QD; Ovwigho, P; Ramaiahgari, S; Hermon, T; Dixon, D				Clayton, Natasha P.; Burwell, Alanna; Jensen, Heather; Williams, Barbara F.; Brown, Quashana D.; Ovwigho, Pamela; Ramaiahgari, Sreenivasa; Hermon, Tonia; Dixon, Darlene			Preparation of Three-dimensional (3-D) Human Liver (HepaRG) Cultures for Histochemical and Immunohistochemical Staining and Light Microscopic Evaluation	TOXICOLOGIC PATHOLOGY			English	Article						3-D cultures; HepaRG spheroids; in vitro; histochemistry; immunohistochemistry; light microscopy; liver spheroids	SYSTEMS	The use of three-dimensional (3-D) in vitro culture systems (spheroids, organoids) in biomolecular and drug discovery research has become increasingly popular. The popularity is due, in part, to a diminished reliance on animal bioassays and a desire to develop physiologically relevant cell culture systems that simulate the in vivo tissue microenvironment. Most evaluations of 3-D cultures are by confocal microscopy and high-content imaging; however, these technologies do not allow for detailed cellular morphologic assessments or permit basic hematoxylin and eosin histologic evaluations. There are few studies that have reported detailed processes for preparing 3-D cultures for paraffin embedding and subsequent use for histochemical or immunohistochemical staining. In an attempt to do so, we have developed a protocol to paraffin-embed human liver spheroids that can be sectioned with a microtome and mounted onto glass slides for routine histochemical and immunohistochemical staining and light microscopic evaluations.	[Clayton, Natasha P.; Jensen, Heather; Williams, Barbara F.; Brown, Quashana D.; Ovwigho, Pamela] NIEHS, Pathol Support Cellular & Mol Pathol Branch, NTP, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Burwell, Alanna; Hermon, Tonia; Dixon, Darlene] NIEHS, Mol Pathogenesis Grp, NTPL, NTP,NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Ramaiahgari, Sreenivasa] NIEHS, Mol Toxicol & Genom Grp, Biomol Screening Branch, NTP,NIH, POB 12233, Res Triangle Pk, NC 27709 USA	Dixon, D (reprint author), NIEHS, Natl Toxicol Program, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	dixon@niehs.nih.gov			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [ZIA ES021196-23]		Alturkistani Hani A, 2015, Glob J Health Sci, V8, P72, DOI 10.5539/gjhs.v8n3p72; Canene-Adams K, 2013, METHOD ENZYMOL, V533, P225, DOI 10.1016/B978-0-12-420067-8.00015-5; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Costa EC, 2016, BIOTECHNOL ADV, V34, P1427, DOI 10.1016/j.biotechadv.2016.11.002; de Hoogt R, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.170; Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573; Hoffman AF, 2017, ASSAY DRUG DEV TECHN, V15, P1, DOI 10.1089/adt.2016.29054.afh; Lovitt Carrie J, 2014, Biology (Basel), V3, P345, DOI 10.3390/biology3020345; MacArthur Clark Judy, 2018, Br J Nutr, V120, pS1, DOI 10.1017/S0007114517002227; Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013; Pinto Mauricio P, 2011, Front Endocrinol (Lausanne), V2, P15, DOI 10.3389/fendo.2011.00015; Ramaiahgari SC, 2017, TOXICOL SCI, V160, P189, DOI 10.1093/toxsci/kfx194; Stock K, 2016, SCI REP-UK, V6, DOI 10.1038/srep28951; Tox21 collaboration, TOX 21 CENT TOX21; Ware MJ, 2016, BIOMATERIALS, V108, P129, DOI 10.1016/j.biomaterials.2016.08.041; Zhang P, 2017, INT J GENOMICS, DOI 10.1155/2017/1926304	16	1	1	3	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					653	659		10.1177/0192623318789069			7	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300004	30089414	Green Accepted			2019-10-28	
J	Kato, Y; Masago, Y; Kondo, C; Yogo, E; Torii, M; Hishikawa, A; Izawa, T; Kuwamura, M; Yamate, J				Kato, Yuki; Masago, Yusaku; Kondo, Chiaki; Yogo, Erika; Torii, Mikinori; Hishikawa, Atsuko; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji			Comparison of Acute Gene Expression Profiles of Islet Cells Obtained via Laser Capture Microdissection between Alloxan- and Streptozotocin-treated Rats	TOXICOLOGIC PATHOLOGY			English	Article						apoptosis; cell cycle arrest; ER stress; insulin secretion; microarray; p53	PANCREATIC BETA-CELLS; DIABETES-MELLITUS; TYPE-1; MECHANISMS; APOPTOSIS; DAMAGE; DNA; ETIOLOGY; PATHWAY; STRESS	To identify the molecular profiles of islets from alloxan (ALX)- and streptozotocin (STZ)-treated rats, a microarray-based global gene expression analysis was performed on frozen islets isolated via laser capture microdissection. At 6 weeks old, rats were injected with ALX (40 mg/kg) or STZ (50 or 100 mg/kg) and then euthanized 24 hr later. Histopathological analysis showed -cell necrosis, macrophage infiltration, and islet atrophy. The extent of these changes was more notable in the STZ groups than in the ALX group. Transcriptome analysis demonstrated a significant up- or downregulation of cell cycle arrest-related genes in the p53 signaling pathway. Cyclin D2 and cyclin-dependent kinase inhibitor 1A, mediators of G1 arrest, were remarkably altered in STZ-treated rats. In contrast, cyclin-B1 and cyclin-dependent kinase 1, mediators of G2 arrest, were remarkably changed in ALX-treated rats. Genes involved in the intrinsic mitochondria-mediated apoptotic pathway were upregulated in the ALX and STZ groups. Moreover, heat-shock 70 kDA protein 1A (Hspa1a), Hsp90ab1, and Hsph1 were upregulated in ALX-treated rats, suggesting that ALX treatment injures cells via endoplasmic reticulum stress. These results contribute to a better understanding of gene expression in the pathogenesis of islet toxicity.	[Kato, Yuki; Kondo, Chiaki; Torii, Mikinori; Hishikawa, Atsuko] Shionogi & Co Ltd, Res Lab Dev, Osaka, Japan; [Kato, Yuki; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji] Osaka Prefecture Univ, Lab Vet Pathol Life & Environm Sci, Osaka, Japan; [Masago, Yusaku; Yogo, Erika] Shionogi & Co Ltd, Discovery Res Lab, Osaka, Japan	Kato, Y (reprint author), Shionogi & Co Ltd, Drug Safety Evaluat, Res Lab Dev, 3-1-1 Futaba Cho, Toyonaka, Osaka 5610825, Japan.	yuuki.katou@shionogi.co.jp					Aida K, 2011, DIABETES, V60, P884, DOI 10.2337/db10-0795; Akerblom HK, 2002, AM J MED GENET, V115, P18, DOI 10.1002/ajmg.10340; Atkinson MA, 2014, LANCET, V383, P69, DOI 10.1016/S0140-6736(13)60591-7; Bhattacharya S, 2011, TOXICOL APPL PHARM, V257, P272, DOI 10.1016/j.taap.2011.09.013; Boone DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127287; Butler AE, 2016, J HISTOTECHNOL, V39, P59, DOI 10.1080/01478885.2015.1106073; BYNUM JW, 1976, ANAL BIOCHEM, V73, P209, DOI 10.1016/0003-2697(76)90156-1; Catlin NR, 2014, TOXICOL PATHOL, V42, P1221, DOI 10.1177/0192623314526319; Christen U, 2011, CELL MOL IMMUNOL, V8, P193, DOI 10.1038/cmi.2010.71; Dotta F, 2007, P NATL ACAD SCI USA, V104, P5115, DOI 10.1073/pnas.0700442104; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Erickson HS, 2009, NAT PROTOC, V4, P902, DOI 10.1038/nprot.2009.61; GORUS FK, 1982, BIOCHEM J, V208, P513, DOI 10.1042/bj2080513; Hoyer P.B., 2013, CASARETT DOULLS TOXI, P907; KARUNANAYAKE EH, 1976, DIABETOLOGIA, V12, P123, DOI 10.1007/BF00428976; Kato Y, 2013, J COMP PATHOL, V148, P188, DOI 10.1016/j.jcpa.2012.06.009; Kumar V, 2015, PROCEEDING OF THE THIRD INTERNATIONAL SYMPOSIUM ON WOMEN IN COMPUTING AND INFORMATICS (WCI-2015), P31, DOI 10.1145/2791405.2791443; LEDOUX SP, 1986, DIABETES, V35, P866, DOI 10.2337/diabetes.35.8.866; Lee D, 2017, J PHARM PHARMACOL, V69, P875, DOI 10.1111/jphp.12719; Lenzen S, 2008, DIABETOLOGIA, V51, P216, DOI 10.1007/s00125-007-0886-7; Marre ML, 2017, FRONT ENDOCRINOL, V8, DOI [10.3339/fendo.2017.00262, 10.3389/fendo.2017.00262]; Richardson SJ, 2009, DIABETOLOGIA, V52, P1143, DOI 10.1007/s00125-009-1276-0; Rieusset J, 2017, ADV EXP MED BIOL, V997, P171, DOI 10.1007/978-981-10-4567-7_13; Rosol TJ, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P2391, DOI 10.1016/B978-0-12-415759-0.00058-3; Szulawski R, 2016, BIOTECHNIQUES, V60, P293, DOI 10.2144/000114426; TAKASU N, 1991, J BIOL CHEM, V266, P2112; Tanaka H, 2000, NATURE, V404, P42; Todd JA, 2010, IMMUNITY, V32, P457, DOI 10.1016/j.immuni.2010.04.001; Tonne JM, 2013, DIS MODEL MECH, V6, P1236, DOI 10.1242/dmm.012591; Mena JET, 2014, ANAL BIOCHEM, V447, P126, DOI 10.1016/j.ab.2013.11.015; Vehik K, 2011, DIABETES-METAB RES, V27, P3, DOI 10.1002/dmrr.1141; WINTERBOURN CC, 1989, BIOCHEM PHARMACOL, V38, P611, DOI 10.1016/0006-2952(89)90206-2; WINTERBOURN CC, 1989, BIOCHEM PHARMACOL, V38, P271, DOI 10.1016/0006-2952(89)90037-3; Wu W, 2018, FOOD CHEM TOXICOL, V111, P19, DOI 10.1016/j.fct.2017.10.043; Zheng SJ, 2005, DIABETES, V54, P1423, DOI 10.2337/diabetes.54.5.1423	35	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					660	670		10.1177/0192623318783957			11	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300005	29929439				2019-10-28	
J	Knight, B; Yuan, J; Koegler, S; Pande, P; Hall, J; Hill, JD; Hart, SE; Phillips, JA; Ku, WW				Knight, Brian; Yuan, Jing; Koegler, Sally; Pande, Parimal; Hall, Jennifer; Hill, Jon D.; Hart, Susan Emeigh; Phillips, Jonathan A.; Ku, Warren W.			Pathogenesis of Renal Injury and Gene Expression Changes in the Male CD-1 Mouse Associated with Exposure to Empagliflozin	TOXICOLOGIC PATHOLOGY			English	Article						genomics; histopathology; renal; preclinical safety assessment; risk management; toxicogenomics; toxicologic pathology	COTRANSPORTER 2 INHIBITOR; GLUCOSE TRANSPORTERS; KIDNEY; RATS; SEX; DIFFERENTIATION; CARCINOGENICITY; NEPHROTOXICITY; TESTOSTERONE; METABOLISM	An increased incidence of renal tubular adenomas and carcinomas was identified in the 2-year CD-1 mouse carcinogenicity study with empagliflozin (sodium-glucose transporter 2 inhibitor) in high dose (1,000 mg/kg/day) male mice. A 13-week mouse renal investigative pathogenesis study was conducted with empagliflozin to evaluate dose dependency and temporal onset of nonneoplastic degenerative/regenerative renal tubular and molecular (genes, pathways) changes which precede neoplasia. Male and female CD-1 mice were given daily oral doses of 0, 100, 300, or 1,000 mg/kg/day (corresponding carcinogenicity study dose levels) for 1, 2, 4, 8, or 13 weeks. The maximum expected pharmacology with secondary osmotic diuresis was observed by week 1 at 100 mg/kg/day in both genders. Histopathologic kidney changes were first detected after 4 weeks of dosing in the male 1,000 mg/kg/day dose group, with progressive increases in the incidence and/or number of findings in this dose group so that they were more readily detected during weeks 8 and 13. Changes detected starting on week 4 consisted of minimal single-cell necrosis and minimal increases in mitotic figures. These changes persisted at an increased incidence at weeks 8 and 13 and were accompanied by minimal to mild tubular epithelial karyomegaly, minimal proximal convoluted tubular epithelial cell hyperplasia, and a corresponding increase in Ki-67-positive nuclei in epithelial cells of the proximal convoluted tubules. There were no corresponding changes in serum chemistry or urinalysis parameters indicative of any physiologically meaningful effect on renal function and thus these findings were not considered to be adverse. Similar changes were not identified in lower-dose groups in males nor were they present in females of any dose group. RNA-sequencing analysis revealed male mouse-specific changes in kidney over 13 weeks of dosing at 1,000 mg/kg/day. Treatment-related changes included genes and pathways related to p53-regulated cell cycle and proliferation, transforming growth factor , oxidative stress, and renal injury and the number of genes with significant expression change dramatically increased at week 13. These treatment-related changes in genes and pathways were predominant in high-dose males and complemented the observed temporal renal tubular changes. Overall, these mouse investigative study results support the role of early empagliflozin-related degenerative/regenerative changes only observed in high-dose male CD-1 mice as a key contributing feature to a nongenotoxic mode of renal tumor pathogenesis.	[Knight, Brian; Yuan, Jing; Koegler, Sally; Pande, Parimal; Hall, Jennifer; Hill, Jon D.; Hart, Susan Emeigh; Phillips, Jonathan A.; Ku, Warren W.] Boehringer Ingelheim Pharmaceut Inc, Nonclin Drug Safety, 900 Ridgebury Rd, Ridgefield, CT 06877 USA; [Yuan, Jing] Amgen Inc, Cambridge, MA USA; [Koegler, Sally] Portland Gastroenterol Ctr, Portland, ME USA; [Phillips, Jonathan A.] Vertex Pharmaceut, Boston, MA USA	Knight, B (reprint author), Boehringer Ingelheim Pharmaceut Inc, Nonclin Drug Safety, 900 Ridgebury Rd, Ridgefield, CT 06877 USA.	brian.knight@boehringer-ingelheim.com	Phillips, Jonathan/X-2958-2019	Phillips, Jonathan/0000-0001-7290-754X			ABRASS CK, 1984, AM J NEPHROL, V4, P337, DOI 10.1159/000166849; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289; Bogdanffy MS, 2014, INT J TOXICOL, V33, P436, DOI 10.1177/1091581814551648; Bumpus NN, 2011, J PHARMACOL EXP THER, V339, P886, DOI 10.1124/jpet.111.184242; Dieterich C, 2009, TOXICOL SCI, V107, P258, DOI 10.1093/toxsci/kfn203; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Ford P, 2005, BIOL CELL, V97, P687, DOI 10.1042/BC20040116; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; Frazier KS, 2013, TOXICOL PATHOL, P421; Grempler R, 2012, DIABETES OBES METAB, V14, P83, DOI 10.1111/j.1463-1326.2011.01517.x; Handler JS, 1996, KIDNEY INT, V49, P1682, DOI 10.1038/ki.1996.246; Hard GC, 2000, TOXICOL SCI, V53, P237, DOI 10.1093/toxsci/53.2.237; HENDERSON CJ, 1990, BIOCHEM J, V266, P675, DOI 10.1042/bj2660675; HENDERSON CJ, 1991, BIOCHEM J, V278, P499, DOI 10.1042/bj2780499; Kempson SA, 2004, PFLUG ARCH EUR J PHY, V449, P227, DOI 10.1007/s00424-004-1338-6; Kharasch ED, 2006, TOXICOL SCI, V90, P419, DOI 10.1093/toxsci/kfj088; Kim J, 2006, J BIOL CHEM, V281, P20349, DOI 10.1074/jbc.M512740200; Kutina AV, 2008, B EXP BIOL MED+, V146, P671, DOI 10.1007/s10517-009-0366-9; Lina BAR, 1996, REGUL TOXICOL PHARM, V24, pS264, DOI 10.1006/rtph.1996.0108; Lock EA, 2004, CRIT REV TOXICOL, V34, P211, DOI 10.1080/10408440490265210; Lohr JW, 1998, PHARMACOL REV, V50, P107; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; National Research Council(US), 2011, GUIDE CARE USE LAB A, P963, DOI [DOI 10.17226/12910, 10.17226/12910.]; Park KM, 2004, J BIOL CHEM, V279, P52282, DOI 10.1074/jbc.M407629200; Reeves WB, 2000, P NATL ACAD SCI USA, V97, P7667, DOI 10.1073/pnas.97.14.7667; Sabolic I, 2012, AM J PHYSIOL-CELL PH, V302, pC1174, DOI 10.1152/ajpcell.00450.2011; Smith JD, 2017, INT J TOXICOL, V36, P440, DOI 10.1177/1091581817735090; Taub ME, 2015, CHEM RES TOXICOL, V28, P103, DOI 10.1021/tx500380t; Tirmenstein M, 2013, INT J TOXICOL, V32, P336, DOI 10.1177/1091581813505331; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Wright EM, 2011, PHYSIOL REV, V91, P733, DOI 10.1152/physrev.00055.2009; Yanes LL, 2008, HYPERTENSION, V51, P976, DOI 10.1161/HYPERTENSIONAHA.107.105767; Zhao FQ, 2007, CURR GENOMICS, V8, P113, DOI 10.2174/138920207780368187	34	1	2	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					671	682		10.1177/0192623318784514			12	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300006	29945496				2019-10-28	
J	Teo, S; Paranjpe, M; Mckeon, M; Mann, P; Lee, S; LaRock, R; Brown, T				Teo, Steve; Paranjpe, Madhav; Mckeon, Marie; Mann, Peter; Lee, Sophie; LaRock, Richard; Brown, Tom			The Antitussive Benzonatate Is Not Tumorigenic in Rodent Carcinogenicity Studies	TOXICOLOGIC PATHOLOGY			English	Article						benzonatate; 4-(butylamino) benzoic acid; carcinogenicity; rodent; Tg; rasH2 mouse; Wistar Han rat	TG.RASH2 MICE	Benzonatate is a peripheral oral antitussive that dampens the activity of cough stretch receptors. Rodent carcinogenicity studies were performed in Tg.rasH2 mice and Wistar Han rats. Mice were orally gavaged benzonatate at 10, 30, 75, and 100 mg/kg/day for males and 5, 15, and 50 mg/kg/day for females. Rats were gavaged at 10, 30, and 90 mg/kg/day for males and 5, 15, and 50 mg/kg/day for females. Higher doses in males were due to differences in maximum tolerated doses in dose-ranging studies. In both species, benzonatate was not detected in plasma because of rapid ester hydrolysis producing 4-(butylamino) benzoic acid (BBA) and methylated polyethylene glycol polymer. This metabolism was similar in human plasma; therefore, plasma BBA was used to show systemic exposure. Both species had no evidence of a benzonatate-related increase in any neoplasm. A slight increase in nasal cavity exudative inflammation was present in benzonatate-dosed male mice. Retinal atrophy was observed in male rats at 30 mg/kg/day, but the incidence was within historical control data range and not related to benzonatate. In conclusion, benzonatate and its 2 major metabolites were not carcinogenic in rodent carcinogenicity studies at BBA exposures of 32 and 70 times a 200 mg human benzonatate dose, respectively.	[Teo, Steve] Pfizer Inc, 1 Giralda Farms, Madison, NJ 07940 USA; [Paranjpe, Madhav; Mckeon, Marie] MilliporeSigma BioReliance, Toxicol Serv, Rockville, MD USA; [Mann, Peter] Expt Pathol Labs, Seattle, WA USA; [Lee, Sophie; LaRock, Richard] Covance Labs, Madison, WI USA; [Lee, Sophie] TaiGen Biotechnol, Taipei, Taiwan; [Brown, Tom] Pfizer Inc, Drug Safety Res & Dev, Groton, CT 06340 USA; [Brown, Tom] Clemson Vet Diagnost Lab, Columbia, SC USA	Teo, S (reprint author), Pfizer Inc, 1 Giralda Farms, Madison, NJ 07940 USA.	steve.teo@pfizer.com			Pfizer Inc.Pfizer	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: These studies were funded by Pfizer Inc.	[Anonymous], 1997, TEST CARC PHARM; [Anonymous], 2017, TESSALON US PRODUCT; [Anonymous], 2008, DOS SEL CARC STUD PH; Berry Loren M, 2009, Drug Metab Lett, V3, P70; BRODIE BB, 1948, J PHARMACOL EXP THER, V94, P359; BUCHER K, 1956, Schweiz Med Wochenschr, V86, P94; CHMP Safety Working Party, 2005, CHMP SWP CONCL REC U; Dicpinigaitis PV, 2014, PHARMACOL REV, V66, P468, DOI 10.1124/pr.111.005116; FDA Guidance, 2001, STAT ASP DES AN INT; Guffanti E., 1989, COUGH; LANGREHR D, 1963, N-S ARCH EX PATH PH, V245, P427; Leung HW, 2000, INT J TOXICOL, V19, P305, DOI 10.1080/10915810050178752; Lin Wen-Jen, 1996, Chinese Pharmaceutical Journal, V48, P53; McInnes E., 2012, BACKGROUND LESIONS L, P35; McInnes EF, 2012, BACKGROUND LESIONS L, P17; Paranjpe MG, 2017, INT J TOXICOL, V36, P21, DOI 10.1177/1091581816673583; Paranjpe MG, 2013, INT J TOXICOL, V32, P48, DOI 10.1177/1091581812471565; Peto R., 1980, GUIDELINES SIMPLE S2, P311; Shah SA, 2012, INT J TOXICOL, V31, P423, DOI 10.1177/1091581812458957; Teo S, 2018, MUTAT RES-GEN TOX EN, V829, P19, DOI 10.1016/j.mrgentox.2018.03.007	20	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					683	692		10.1177/0192623318789130			10	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300007	30033829				2019-10-28	
J	Ramot, Y; Hazan, Z; Lucassen, A; Adamsky, K; Ross, V; Young, N; Saunders, M; Ehall, H; Nyska, A				Ramot, Yuval; Hazan, Zadik; Lucassen, Andre; Adamsky, Konstantin; Ross, Vanessa; Young, Nigel; Saunders, Matt; Ehall, Helmut; Nyska, Abraham			Toxicity and Toxicokinetic Study of Subcutaneously Administered RPh201 in Minipigs	TOXICOLOGIC PATHOLOGY			English	Article						Pistacia lentiscus; mastic gum; RPh201; toxicity; safety; minipigs; toxicokinetics	CHIOS MASTIC GUM; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITIES; HELICOBACTER-PYLORI; PISTACIA-ATLANTICA; CROHNS-DISEASE; CANCER CELLS; VAR. CHIA; IN-VITRO; OIL	Mastic gum extracts are widely used as herbal remedies and are being tested for several clinical indications. Nevertheless, information on their safety is limited. RPh201 is an extract of the mastic gum, formulated and stabilized in a proprietary method, which is being developed as a novel drug candidate for neurological indications. The aim of this study was to assess the systemic toxic potential of RPh201, administered twice weekly by subcutaneous injections to minipigs, after 39 weeks of administration followed by a recovery period of 6 weeks. No clinical or dose-related signs were observed, but treatment-related findings were seen at the injection sites of the high-dose animals, composed of abscesses, chronic inflammation, and subcutaneous fibrosis. Abscesses >30 mm in size, graded as marked severity, were confined to the high-dose group and were considered as adverse. Minimal-slight subcutaneous and lymph nodes abscesses seen in control, low, and intermediate doses, related to the vehicle (cottonseed oil), were not considered as adverse. Additionally, minimal-to-slight cystic spaces or vacuolation related to the vehicle were observed in the skin, lymph nodes, kidney, and lungs. These findings were considered not to be adverse. The no-observed-adverse-effect level was considered to be 12.5 mg/kg/occasion.	[Ramot, Yuval] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel; [Hazan, Zadik; Lucassen, Andre; Adamsky, Konstantin] Regenera Pharma, Ness Ziona, Israel; [Ross, Vanessa; Young, Nigel; Saunders, Matt; Ehall, Helmut] Envigo Ltd, Alconbury, Cambs, England; [Nyska, Abraham] Toxicol Pathol, Timrat, Israel; [Nyska, Abraham] Tel Aviv Univ, Tel Aviv, Israel	Nyska, A (reprint author), Haharuv 18,POB 184, IL-36576 Timrat, Israel.	anyska@bezeqint.net			Regenera Pharma, Nes-Ziona, Israel	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by Regenera Pharma, Nes-Ziona, Israel.	Ahmad NS, 2010, J ETHNOPHARMACOL, V129, P250, DOI 10.1016/j.jep.2010.03.017; ALHABBAL MJ, 1984, CLIN EXP PHARMACOL P, V11, P541, DOI 10.1111/j.1440-1681.1984.tb00864.x; [Anonymous], 2001, INT J TOXICOL, V20, P21; Balan KV, 2007, PHYTOMEDICINE, V14, P263, DOI 10.1016/j.phymed.2006.03.009; Balan KV, 2005, IN VIVO, V19, P93; Clark ER, 1917, AM J ANAT, V21, P421, DOI 10.1002/aja.1000210305; CORDES VC, 1949, AM J DIS CHILD, V78, P387, DOI 10.1001/archpedi.1949.02030050400011; Dimas K, 2009, IN VIVO, V23, P63; Ezz Eldin Hayam Mohamed, 2015, J Parasit Dis, V39, P465, DOI 10.1007/s12639-013-0374-6; Gholami M, 2016, PATHOL RES PRACT, V212, P500, DOI 10.1016/j.prp.2016.02.024; Giaginis C, 2011, NUTR CANCER, V63, P1174, DOI 10.1080/01635581.2011.607546; Hatamnia AA, 2016, NAT PROD RES, V30, P1445, DOI 10.1080/14786419.2015.1060593; Hazan Z., 2016, ISOPT CLIN C ROM DEC; He ML, 2006, CANCER-AM CANCER SOC, V106, P2547, DOI 10.1002/cncr.21935; HUWEZ F U, 1986, Gastroenterologia Japonica, V21, P273; Huwez FU, 1998, NEW ENGL J MED, V339, P1946, DOI 10.1056/NEJM199812243392618; Jin Y, 2017, ARCH PHARM RES, V40, P49, DOI 10.1007/s12272-016-0853-2; Jones DPG, 1996, NEW ZEAL MED J, V109, P363; Kaliora AC, 2007, WORLD J GASTROENTERO, V13, P6031, DOI 10.3748/wjg.13.6031; Kaliora AC, 2007, WORLD J GASTROENTERO, V13, P748, DOI 10.3748/wjg.v13.i5.748; Karygianni L, 2014, BIOMED RES INT, DOI 10.1155/2014/839019; Kerlin R, 2016, TOXICOL PATHOL, V44, P147, DOI 10.1177/0192623315623265; Koychev S, 2017, J PERIODONTOL, V88, P511, DOI 10.1902/jop.2017.150691; Loget O, 2000, J TOXICOL-CUTAN OCUL, V19, P69, DOI 10.3109/15569520009051479; LOGET O, 1995, OCULAR TOXICOLOGY, P351; Loizzo MR, 2008, CHEM BIODIVERS, V5, P461, DOI 10.1002/cbdv.200890045; Loutrari H, 2006, NUTR CANCER, V55, P86, DOI 10.1207/s15327914nc5501_11; Magkouta S, 2009, NUTR CANCER, V61, P640, DOI 10.1080/01635580902825647; Manno RA, 2016, J APPL TOXICOL, V36, P1060, DOI 10.1002/jat.3266; Miyamoto T, 2014, NAT PRODUCT BIOPROSP, V4, P227, DOI 10.1007/s13659-014-0033-3; Moulos P, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-68; Ozcelik B, 2005, MICROBIOL RES, V160, P159, DOI 10.1016/j.micres.2004.11.002; Peyre M, 2004, VACCINE, V22, P2430, DOI 10.1016/j.vaccine.2003.11.068; Ramot Y, 2018, FOOD CHEM TOXICOL, V112, P168, DOI 10.1016/j.fct.2017.12.036; Ramot Y, 2015, TOXICOL PATHOL, V43, P267, DOI 10.1177/0192623314534995; Ramot Y, 2009, TOXICOL PATHOL, V37, P882, DOI 10.1177/0192623309347911; Saez Jose Miguel, 2005, J Hist Dent, V53, P109; Sakagami H, 2009, IN VIVO, V23, P215; Spyridopoulou K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03971-8; STARMARK JE, 1980, ACTA PSYCHIAT SCAND, V62, P154, DOI 10.1111/j.1600-0447.1980.tb00602.x; Strickley RG, 2004, PHARM RES, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23; Suzuki R, 2017, IN VIVO, V31, P591, DOI 10.21873/invivo.11099; Takahashi K, 2003, J PERIODONTOL, V74, P501, DOI 10.1902/jop.2003.74.4.501; Tolooei Mohsen, 2015, Glob J Health Sci, V7, P32, DOI 10.5539/gjhs.v7n7p32; Toul F, 2017, NAT PROD RES, V31, P718, DOI 10.1080/14786419.2016.1217205; Vezzali E, 2011, TOXICOL PATHOL, V39, P700, DOI 10.1177/0192623311406930; Vlastos D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130498	47	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					693	705		10.1177/0192623318786428			13	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300008	30009686				2019-10-28	
J	Auerbach, SS; Xu, MF; Merrick, BA; Hoenerhoff, MJ; Phadke, D; Taxman, DJ; Shah, R; Hong, HHL; Ton, TV; Kovi, RC; Sills, RC; Pandiri, AR				Auerbach, Scott S.; Xu, Miaofei; Merrick, B. Alex; Hoenerhoff, Mark J.; Phadke, Dhiral; Taxman, Debra J.; Shah, Ruchir; Hong, Hue-Hua L.; Thai-Vu Ton; Kovi, Ramesh C.; Sills, Robert C.; Pandiri, Arun R.			Exome Sequencing of Fresh-frozen or Formalin-fixed Paraffin-embedded B6C3F1/N Mouse Hepatocellular Carcinomas Arising Either Spontaneously or due to Chronic Chemical Exposure	TOXICOLOGIC PATHOLOGY			English	Article						exome sequencing; Sanger sequencing; methyleugenol (MEG); gingko biloba extract (GBE); mutational spectra; formalin-fixed paraffin-embedded tissues	GINKGO-BILOBA EXTRACT; CONSTITUTIVE ANDROSTANE RECEPTOR; HUMAN CANCERS; MUTATIONAL SIGNATURES; GENE-MUTATIONS; ANIMAL-MODELS; AFLATOXIN B-1; LIVER-TUMORS; CARCINOGENESIS; GENOTOXICITY	Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide; however, the mutational properties of HCC-associated carcinogens remain largely uncharacterized. We hypothesized that mechanisms underlying chemical-induced HCC can be characterized by evaluating the mutational spectra of these tumors. To test this hypothesis, we performed exome sequencing of B6C3F1/N HCCs that arose either spontaneously in vehicle controls (n = 3) or due to chronic exposure to gingko biloba extract (GBE; n = 4) or methyleugenol (MEG; n = 3). Most archived tumor samples are available as formalin-fixed paraffin-embedded (FFPE) blocks, rather than fresh-frozen (FF) samples; hence, exome sequencing from paired FF and FFPE samples was compared. FF and FFPE samples showed 63% to 70% mutation concordance. Multiple known (e.g., Ctnnb1T41A, BrafV637E) and novel (e.g., Erbb4C559S, Card10A700V, and Klf11P358L) mutations in cancer-related genes were identified. The overall mutational burden was greater for MEG than for GBE or spontaneous HCC samples. To characterize the mutagenic mechanisms, we analyzed the mutational spectra in the HCCs according to their trinucleotide motifs. The MEG tumors clustered closest to Catalogue of Somatic Mutations in Cancer signatures 4 and 24, which are, respectively, associated with benzo(a)pyrene- and aflatoxin-induced HCCs in humans. These results establish a novel approach for classifying liver carcinogens and understanding the mechanisms of hepatocellular carcinogenesis.	[Auerbach, Scott S.; Xu, Miaofei; Merrick, B. Alex; Hoenerhoff, Mark J.; Hong, Hue-Hua L.; Thai-Vu Ton; Kovi, Ramesh C.; Sills, Robert C.; Pandiri, Arun R.] NIEHS, Div Natl Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA; [Hoenerhoff, Mark J.] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA; [Phadke, Dhiral; Taxman, Debra J.; Shah, Ruchir] Sciome LLC, Res Triangle Pk, NC USA; [Kovi, Ramesh C.] Expt Pathol Labs Inc, Res Triangle Pk, NC USA	Pandiri, AR (reprint author), 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	arun.pandiri@nih.gov			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z99 ES999999]		Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI 10.2147/JHC.S61146; Bode AM, 2015, CANCER PREV RES, V8, P1, DOI 10.1158/1940-6207.CAPR-14-0160; Burkey JL, 2000, MUTAT RES-FUND MOL M, V453, P25, DOI 10.1016/S0027-5107(00)00070-1; Chawanthayatham S, 2017, P NATL ACAD SCI USA, V114, pE3101, DOI 10.1073/pnas.1700759114; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; Do HD, 2015, CLIN CHEM, V61, P64, DOI 10.1373/clinchem.2014.223040; Feng YF, 2013, EXP CELL RES, V319, P1124, DOI 10.1016/j.yexcr.2013.02.009; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Fluhr S, 2017, EPIGENETICS-US, V12, P715, DOI 10.1080/15592294.2017.1356959; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gonzalez-Perez A, 2013, NAT METHODS, V10, P1081, DOI [10.1038/NMETH.2642, 10.1038/nmeth.2642]; Grimm S., 2018, COMMUNICATION; Gross-Steinmeyer K, 2012, TOXICOLOGY, V299, P69, DOI 10.1016/j.tox.2012.05.016; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Hoenerhoff MJ, 2013, TOXICOL PATHOL, V41, P826, DOI 10.1177/0192623312467520; Jackson MA, 2006, TOXICOL SCI, V90, P400, DOI 10.1093/toxsci/kfj101; Jiang JR, 2011, EXP THER MED, V2, P505, DOI 10.3892/etm.2011.229; King-Herbert A, 2006, TOXICOL PATHOL, V34, P802, DOI 10.1080/01926230600935938; King-Herbert AP, 2010, TOXICOL PATHOL, V38, P180, DOI 10.1177/0192623309356450; Lea IA, 2007, CARCINOGENESIS, V28, P1851, DOI 10.1093/carcin/bgm176; Lee YJ, 2015, INT J MOL SCI, V16, P26629, DOI 10.3390/ijms161125984; Li LH, 2009, PHARM RES-DORDR, V26, P872, DOI 10.1007/s11095-008-9788-8; Lin DC, 2017, CANCER RES, V77, P2255, DOI 10.1158/0008-5472.CAN-16-2822; Maeda J, 2015, FOOD CHEM TOXICOL, V83, P201, DOI 10.1016/j.fct.2015.06.010; Maeda J, 2014, TOXICOL SCI, V140, P298, DOI 10.1093/toxsci/kfu090; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; MILLER EC, 1983, CANCER RES, V43, P1124; Mu WB, 2016, J MOL DIAGN, V18, P923, DOI 10.1016/j.jmoldx.2016.07.006; Nash KM, 2015, INTEGR MED INSIGHTS, V10, P1, DOI 10.4137/IMI.S25054; National Toxicology Program, 2013, Natl Toxicol Program Tech Rep Ser, P1; National Toxicology Program, 2000, NATL TOXICOL PROGRAM, V491, P1; Nault JC, 2012, J HEPATOL, V56, P184, DOI 10.1016/j.jhep.2011.07.018; Nik-Zainal S, 2015, MUTAGENESIS, V30, P763, DOI 10.1093/mutage/gev073; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Prentice LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196434; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Shi JJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep31898; Shiraha H, 2013, INT J ONCOL, V42, P1133, DOI 10.3892/ijo.2013.1829; Smith MT, 2016, ENVIRON HEALTH PERSP, V124, P713, DOI 10.1289/ehp.1509912; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Umegaki K, 2007, J PHARM PHARMACOL, V59, P871, DOI 10.1211/jpp.59.6.0014; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; Weng MW, 2017, ONCOTARGET, V8, P18213, DOI 10.18632/oncotarget.15313; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Xu HT, 2013, INT J CLIN EXP PATHO, V6, P711; Zhou SF, 2007, CURR DRUG METAB, V8, P526	52	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					706	718		10.1177/0192623318789398			13	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300009	30045675	Green Accepted			2019-10-28	
J	Schuh, JCL				Schuh, JoAnn C. L.			Letter to the Editor Regarding "Spontaneous Findings in the Eyes of Cynomolgus Monkeys (Macaca fascicularis) of Mauritian Origin" by Woicke et al. (Toxicol Pathol 46, 273-282, 2018)	TOXICOLOGIC PATHOLOGY			English	Letter						immune system; inflammation; immunopathology; special senses; eye; microanatomy; mucosa-associated lymphoid tissue	LYMPHOID-TISSUE; CONJUNCTIVA		[Schuh, JoAnn C. L.] JCL Schuh PLLC, Bainbridge Isl, WA 98110 USA	Schuh, JCL (reprint author), JCL Schuh PLLC, Bainbridge Isl, WA 98110 USA.			Schuh, JoAnn C. L./0000-0002-2399-8518			Cain C, 2008, INVEST OPHTH VIS SCI, V49, P644, DOI 10.1167/iovs.07-0856; Cesta MF, 2006, TOXICOL PATHOL, V34, P599, DOI 10.1080/01926230600865531; Chodosh J, 1998, DEV COMP IMMUNOL, V22, P621, DOI 10.1016/S0145-305X(98)00022-6; DUA HS, 1994, CURR EYE RES, V13, P87, DOI 10.3109/02713689409042401; Elmore SA, 2006, TOXICOL PATHOL, V34, P687, DOI 10.1080/01926230600939989; Greaves P., 2011, HISTOPATHOLOGY PRECL, P832; Knop N, 2000, INVEST OPHTH VIS SCI, V41, P1270; McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49; Miyasaka M, 2004, NAT REV IMMUNOL, V4, P360, DOI 10.1038/nri1354; Siebelmann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082355; Sinha DP, 2006, TOXICOL PATHOL, V34, P148, DOI 10.1080/01926230500531779; Steven P, 2009, OPHTHAL RES, V42, P2, DOI 10.1159/000219678; Streilein JW, 2003, J LEUKOCYTE BIOL, V74, P179, DOI 10.1189/jlb.1102574	13	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					719	720		10.1177/0192623318791524			2	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300010	30092740				2019-10-28	
J	Woicke, J; Haile, S; Mysore, J; Peden, M; Lejeune, T; Sanderson, TP; Brodie, T				Woicke, Jochen; Haile, Solomon; Mysore, Jagannatha; Peden, Michael; Lejeune, Typhaine; Sanderson, Thomas P.; Brodie, Thomas			"Spontaneous Findings in the Eyes of Cynomolgus Monkeys (Macaca fascicularis) of Mauritian Origin" Response	TOXICOLOGIC PATHOLOGY			English	Letter							LYMPHOID-TISSUE		[Woicke, Jochen; Peden, Michael; Sanderson, Thomas P.] Bristol Myers Squibb Co, Mt Vernon, IN 47620 USA; [Haile, Solomon; Lejeune, Typhaine] Charles River Labs, Senneville, PQ, Canada; [Mysore, Jagannatha; Brodie, Thomas] Bristol Myers Squibb Co, New Brunswick, NJ USA; [Peden, Michael] Expt Pathol Labs, Evansville, IN USA	Woicke, J (reprint author), Bristol Myers Squibb Co, Mt Vernon, IN 47620 USA.						Cain C, 2008, INVEST OPHTH VIS SCI, V49, P644, DOI 10.1167/iovs.07-0856; Klintworth G. K., 2012, HISTOLOGY PATHOLOGIS, P375; Knop N, 2000, INVEST OPHTH VIS SCI, V41, P1270; Steven P, 2009, OPHTHAL RES, V42, P2, DOI 10.1159/000219678	4	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					721	721		10.1177/0192623318794180			1	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300011	30160207				2019-10-28	
J	Kozlowski, C; Brumm, J; Cain, G				Kozlowski, C.; Brumm, J.; Cain, G.			An Automated Image Analysis Method to Quantify Veterinary Bone Marrow Cellularity on H&E Sections (vol 46, pg 324, 2018)	TOXICOLOGIC PATHOLOGY			English	Correction								Kozlowski, C., Brumm, J., and Cain, G. (2018). An Automated Image Analysis Method to Quantify Veterinary Bone Marrow Cellularity on H&E Sections. Tox Path46, 324-335. (Original DOI: 10.1177/0192623318766457). Kozlowski, C., Fullerton, A., Cain, G., Katavolos, P., Bravo, J., and Tarrant, J. M. (2018). Proof of Concept for an Automated Image Analysis Method to Quantify Rat Bone Marrow Hematopoietic Lineages on H&E Sections. Tox Path46, 336-347. (Oringinal DOI: 10.1177/0192623318766458). In the print issue and initial version of the online issue, the figures for Kozlowski, Brumm, and Cain were mistakenly placed into Kozlowski, Fullerton, et al., and vice versa. The online versions of both articles have been updated to display the appropriate figures.								Kozlowski C, 2018, TOXICOL PATHOL, V46, P324, DOI 10.1177/0192623318766457	1	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	AUG	2018	46	6					722	722		10.1177/0192623318794946			1	Pathology; Toxicology	Pathology; Toxicology	GS1OD	WOS:000443297300012		Bronze			2019-10-28	
J	Cameselle-Teijeiro, JM; Peteiro-Gonzalez, D; Caneiro-Gomez, J; Sanchez-Ares, M; Abdulkader, I; Eloy, C; Melo, M; Amendoeira, I; Soares, P; Sobrinho-Simoes, M				Manuel Cameselle-Teijeiro, Jose; Peteiro-Gonzalez, Diego; Caneiro-Gomez, Javier; Sanchez-Ares, Maria; Abdulkader, Ihab; Eloy, Catarina; Melo, Miguel; Amendoeira, Isabel; Soares, Paula; Sobrinho-Simoes, Manuel			Cribriform-morular variant of thyroid carcinoma: a neoplasm with distinctive phenotype associated with the activation of the WNT/beta-catenin pathway	MODERN PATHOLOGY			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; OF-THE-LITERATURE; TERT PROMOTER MUTATIONS; PAPILLARY CARCINOMA; BETA-CATENIN; APC GENE; SPORADIC COUNTERPART; MOLECULAR ANALYSIS; COLI GENE; CANCER	Cribriform-morular variant of thyroid carcinoma is classically associated with familial adenomatous polyposis but, it can also occur as a sporadic neoplasm. This neoplasm is much more frequently observed in women than in men (ratio of 61: 1). In familial adenomatous polyposis patients, tumors are generally multifocal and/or bilateral (multinodular appearance), whereas in the sporadic cases tumors tend to occur as single nodules. The tumors are well delimited, and characteristically show a blending of follicular, cribriform, papillary, trabecular, solid, and morular patterns. Neoplastic cells are tall or cuboidal with the occasional nuclear features of classic papillary thyroid carcinoma. The morules include cells with peculiar nuclear clearing and show positivity for CDX2 and CD10. Angioinvasion and capsular invasion have been described in about 30 and 40% of cases, respectively, with lymph node metastases in less than 10% of patients and distant metastases in 6%. Although this tumor has good prognosis, neuroendocrine and/or poor differentiation have been associated with aggressive behavior. Tumor cells can be focally positive or negative for thyroglobulin, but are always positive for TTF-1, estrogen and progesterone receptors, and negative for calcitonin and cytokeratin 20. Nuclear and cytoplasmic staining for beta-catenin is the hallmark of this tumor type; this feature plays a role in fine needle aspiration biopsy. Cribriform-morular variant of thyroid carcinoma has a peculiar endodermal (intestinal-like) type phenotype, activation of the WNT/beta-catenin signaling pathway, and belongs to the non-BRAF-non-RAS subtype of the molecular classification of thyroid tumors. Elevated expression of estrogen and progesterone receptors and activation of the WNT/beta-catenin pathway may prove useful as putative therapeutic targets in cases that do not respond to conventional therapy. Clinicians should be alerted to the possibility of familial adenomatous polyposis when a diagnosis of cribriform-morular variant of thyroid carcinoma is made. Instead of being considered as a variant of papillary thyroid carcinoma its designation as cribriform-morular thyroid carcinoma seems more appropriate.	[Manuel Cameselle-Teijeiro, Jose; Caneiro-Gomez, Javier; Sanchez-Ares, Maria; Abdulkader, Ihab] Clin Univ Hosp, Galician Healthcare Serv SERGAS, Dept Pathol, Santiago De Compostela, Spain; [Manuel Cameselle-Teijeiro, Jose; Caneiro-Gomez, Javier; Abdulkader, Ihab] Univ Santiago de Compostela, Fac Med, Santiago De Compostela, Spain; [Peteiro-Gonzalez, Diego] Hosp El Bierzo, Dept Endocrinol, Ponferrada, Spain; [Eloy, Catarina; Melo, Miguel; Soares, Paula; Sobrinho-Simoes, Manuel] I3S, Porto, Portugal; [Eloy, Catarina; Melo, Miguel; Amendoeira, Isabel; Soares, Paula; Sobrinho-Simoes, Manuel] Univ Porto, Inst Mol Pathol & Immunol, Porto, Portugal; [Eloy, Catarina; Amendoeira, Isabel; Soares, Paula; Sobrinho-Simoes, Manuel] Univ Porto, Fac Med, Porto, Portugal; [Melo, Miguel] Ctr Hosp Coimbra, Dept Endocrinol Diabet & Metab, Coimbra, Portugal; [Melo, Miguel] Univ Coimbra, Dept Endocrinol Diabet & Metab, Coimbra, Portugal; [Melo, Miguel] Univ Coimbra, Unit Endocrinol, Fac Med, Coimbra, Portugal; [Amendoeira, Isabel; Sobrinho-Simoes, Manuel] Ctr Hosp S Joao, Dept Pathol, Porto, Portugal	Cameselle-Teijeiro, JM (reprint author), Clin Univ Hosp, Galician Healthcare Serv SERGAS, Dept Pathol, Santiago De Compostela, Spain.; Cameselle-Teijeiro, JM (reprint author), Univ Santiago de Compostela, Fac Med, Santiago De Compostela, Spain.	josemanuel.cameselle@usc.es	Sobrinho-Simoes, Manuel/J-8290-2013; Soares, Paula/B-6054-2008	Soares, Paula/0000-0001-9607-6998	Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain [PI15/01501-FEDER]; FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020-Operacional Program for Competitiveness and Internationalization (POCI), Portugal 2020; Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao [POCI-01-0145-FEDER-007274]; Norte 2020-Programa Operacional Regional do Norte [NORTE-01-0145-FEDER-000029]; European Regional Development Fund (ERDF) through the Operational Program for Competitiveness and Internationalization-COMPETE 2020; Portuguese national funds via FCT-Fundacao para a Ciencia e a Tecnologia [POCI-01-0145-FEDER-016390: CANCEL STEM"]	This work was supported by Grant PI15/01501-FEDER from the Instituto de Salud Carlos III, Ministry of Economy and Competitiveness, Spain. This work was also financed by FEDER - Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020-Operacional Program for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao in the framework of the project "Institute for Research and Innovation in Health Sciences" (POCI-01-0145-FEDER-007274). Further funding was obtained from the project "Advancing cancer research: from basic knowledgment to application"; NORTE-01-0145-FEDER-000029; "Projetos Estruturados de I&D&I", funded by Norte 2020-Programa Operacional Regional do Norte. Further funded by the European Regional Development Fund (ERDF) through the Operational Program for Competitiveness and Internationalization-COMPETE 2020, and Portuguese national funds via FCT-Fundacao para a Ciencia e a Tecnologia, under project POCI-01-0145-FEDER-016390: CANCEL STEM".	Abbosh PH, 2005, THYROID, V15, P551, DOI 10.1089/thy.2005.15.551; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Alikhan M, 2015, CLIN CHIM ACTA, V438, P181, DOI 10.1016/j.cca.2014.08.026; Baloch ZW, 2011, ENDOCR PATHOL, V22, P200, DOI 10.1007/s12022-011-9174-7; Boonyaarunnate T, 2013, ACTA CYTOL, V57, P127, DOI 10.1159/000345879; Bulow C, 1997, INT J COLORECTAL DIS, V12, P240, DOI 10.1007/s003840050097; Camacho Gonzalez D., 2016, THESIS; Teiieiro JC, 2016, VIRCHOWS ARCH, V469, pS72; Cameselle-Teijeiro J, 2008, HISTOPATHOLOGY, V52, P389, DOI 10.1111/j.1365-2559.2007.02911.x; Cameselle-Teijeiro J, 1999, MODERN PATHOL, V12, P400; Cameselle-Teijeiro J, 2001, AM J CLIN PATHOL, V115, P486; Cameselle-Teijeiro JM, 2018, RARE TUMORS THYROID, P57; Cameselle-Teijeiro J, 2012, AM J CLIN PATHOL, V138, P907, DOI 10.1309/AJCP1BGCA6MFCNKH; Cameselle-Teijeiro J, 2009, AM J CLIN PATHOL, V131, P134, DOI 10.1309/AJCP7ULS0VSISBEB; CameselleTeijeiro J, 1995, PATHOL RES PRACT, V191, P1214, DOI 10.1016/S0344-0338(11)81129-5; CAMIEL MR, 1968, NEW ENGL J MED, V278, P1056, DOI 10.1056/NEJM196805092781908; Casellas-Cabrera N, 2016, FAM CANCER, V15, P267, DOI 10.1007/s10689-015-9862-4; Cetta F, 2012, ACTA CYTOL, V56, P107, DOI 10.1159/000332380; Cetta F, 2000, J CLIN ENDOCR METAB, V85, P286, DOI 10.1210/jc.85.1.286; Cetta F, 1997, HISTOPATHOLOGY, V31, P231, DOI 10.1046/j.1365-2559.1997.2390858.x; Cetta F, 1998, WORLD J SURG, V22, P1231, DOI 10.1007/s002689900550; Cetta F, 2001, J CLIN ENDOCR METAB, V86, P427, DOI 10.1210/jc.86.1.427; CHAN JKC, 1990, ARCH PATHOL LAB MED, V114, P622; Chen CS, 2006, FAM CANCER, V5, P397, DOI 10.1007/s10689-006-0011-y; Chikkamuniyappa Shylashree, 2004, Int J Med Sci, V1, P43; 심영란, 2005, The Korean Journal of Pathology, V39, P48; Chong Y, 2013, THYROID, V23, P45, DOI 10.1089/thy.2011.0534; Chuah KL, 2005, ACTA CYTOL, V49, P75, DOI 10.1159/000326100; Chung DC, 2006, NEW ENGL J MED, V355, P2349, DOI 10.1056/NEJMcpc069028; COLLETTA G, 1994, BRIT J CANCER, V70, P1085, DOI 10.1038/bjc.1994.452; CRAIL H W, 1949, U S Nav Med Bull, V49, P123; Crippa Stefano, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr-2012-007046; CURTIS L, 1994, EUR J CANCER, V30A, P984, DOI 10.1016/0959-8049(94)90129-5; Dalal KM, 2006, HEAD NECK-J SCI SPEC, V28, P471, DOI 10.1002/hed.20383; Devic A, 1912, ARCH FR MAL APPL DIG, V6, P278; Dong YC, 2009, PATHOLOGY, V41, P509, DOI 10.1080/00313020903041101; Donnellan KA, 2009, AM J OTOLARYNG, V30, P58, DOI 10.1016/j.amjoto.2008.01.001; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fenton PA, 2001, THYROID, V11, P193, DOI 10.1089/105072501300042965; Fujimoto T, 2015, J MED ULTRASON, V42, P83, DOI 10.1007/s10396-014-0555-7; Gamachi A, 2003, MODERN PATHOL, V16, P1124, DOI 10.1097/01.MP.0000092953.20717.48; Giannelli SM, 2014, THYROID, V24, P1184, DOI 10.1089/thy.2013.0589; GIARDIELLO FM, 1993, GUT, V34, P1394, DOI 10.1136/gut.34.10.1394; Gronnier C, 2012, ANN ENDOCRINOL-PARIS, V73, P213, DOI 10.1016/j.ando.2012.01.003; HARACH HR, 1994, HISTOPATHOLOGY, V25, P549, DOI 10.1111/j.1365-2559.1994.tb01374.x; Herraiz M, 2007, CLIN GASTROENTEROL H, V5, P367, DOI 10.1016/j.cgh.2006.10.019; Hirokawa M, 2004, APMIS, V112, P275, DOI 10.1111/j.1600-0463.2004.apm11204-0508.x; Hirokawa M, 2010, DIAGN CYTOPATHOL, V38, P890, DOI 10.1002/dc.21309; Hizawa K, 1996, J CLIN PATHOL, V49, P611, DOI 10.1136/jcp.49.7.611; Ito Y, 2011, ENDOCR J, V58, P685, DOI 10.1507/endocrj.EJ11-0022; IWAMA T, 1993, ANN SURG, V217, P101, DOI 10.1097/00000658-199302000-00002; Jarrar AM, 2011, ANN SURG, V253, P515, DOI 10.1097/SLA.0b013e3181fcba8a; Jung CK, 2009, THYROID, V19, P905, DOI 10.1089/thy.2008.0332; Kameyama K, 2004, ULTRASTRUCT PATHOL, V28, P97, DOI 10.1080/01913120490431435; Koo JS, 2011, ACTA CYTOL, V55, P13, DOI 10.1159/000320856; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Kuma S, 2004, ACTA CYTOL, V48, P431, DOI 10.1159/000326399; Kumamoto K, 2015, ONCOL LETT, V10, P2239, DOI 10.3892/ol.2015.3578; Kurihara K, 2000, JPN J CANCER RES, V91, P1100, DOI 10.1111/j.1349-7006.2000.tb00891.x; Kwon MJ, 2015, HUM PATHOL, V46, P1180, DOI 10.1016/j.humpath.2015.04.010; Lam AKY, 2018, HUM PATHOL, V74, P170, DOI 10.1016/j.humpath.2018.01.006; Lee JH, 2015, J ULTRAS MED, V34, P1, DOI 10.7863/ultra.34.1.1; Lee S, 2004, ENDOCR J, V51, P317, DOI 10.1507/endocrj.51.317; Levy RA, 2014, FAM CANCER, V13, P547, DOI 10.1007/s10689-014-9732-5; Liyanapathirana Nishantha, 2015, BMC Res Notes, V8, P795, DOI 10.1186/s13104-015-1736-1; Melo M, 2014, J CLIN ENDOCR METAB, V99, pE754, DOI 10.1210/jc.2013-3734; Miyaki M, 2000, AM J PATHOL, V157, P1825, DOI 10.1016/S0002-9440(10)64821-3; Mizukami Y, 1996, PATHOL RES PRACT, V192, P67, DOI 10.1016/S0344-0338(96)80134-8; Mogos V, 2012, MED-SURG J, V116, P1048; Mohindra S, 2018, HEAD NECK PATHOL, V12, P455, DOI 10.1007/s12105-017-0873-3; Monappa V, 2017, J CYTOL, V34, P183, DOI 10.4103/JOC.JOC_164_16; Nakatani Y, 2004, HUM PATHOL, V35, P869, DOI 10.1016/j.humpath.2004.03.018; Nakazawa T, 2013, INT J SURG PATHOL, V21, P379, DOI 10.1177/1066896912473355; Nesland JM, 2004, ULTRASTRUCT PATHOL, V28, P53, DOI 10.1080/01913120490434847; Ng SB, 2003, PATHOLOGY, V35, P42, DOI 10.1080/003130202201476; Nikiel B, 2009, THYROID RES, V2, DOI 10.1186/1756-6614-2-5; Oh EJ, 2017, ENDOCR PATHOL, V28, P49, DOI 10.1007/s12022-016-9454-3; OKAMOTO Y, 1995, PATHOL INT, V45, P573, DOI 10.1111/j.1440-1827.1995.tb03505.x; Onder S, 2016, ENDOCR PATHOL, V27, P153, DOI 10.1007/s12022-016-9420-0; del Pozo EP, 2015, INT J SURG CASE REP, V16, P192, DOI 10.1016/j.ijscr.2015.08.013; Perrier ND, 1998, WORLD J SURG, V22, P738, DOI 10.1007/s002689900462; PLAIL RO, 1987, BRIT J SURG, V74, P377, DOI 10.1002/bjs.1800740517; Priyani AAH, 2016, J CYTOL, V33, P235, DOI 10.4103/0970-9371.190450; Rosai JASJ, 2017, WHO CLASSIFICATION T, P81; Rosen EJ, 2003, ARCH OTOLARYNGOL, V129, P679, DOI 10.1001/archotol.129.6.679; Rossi ED, 2012, INT J SURG PATHOL, V20, P629, DOI 10.1177/1066896912441830; Schaeffer DF, 2011, CASE REP MED, DOI 10.1155/2011/767610; Schuetze D, 2009, ARCH PATHOL LAB MED, V133, P803, DOI 10.1043/1543-2165-133.5.803; Soravia C, 1999, AM J PATHOL, V154, P127, DOI 10.1016/S0002-9440(10)65259-5; Subramaniam MM, 2007, AM J CLIN PATHOL, V128, P994, DOI 10.1309/YXR3PKK4TV3DJC56; Suhaimi SNA, 2015, MALAYS J MED SCI, V22, P69; Tomoda C, 2004, WORLD J SURG, V28, P886, DOI 10.1007/s00268-004-7475-4; Truta Brindusa, 2003, Fam Cancer, V2, P95, DOI 10.1023/A:1025762706854; Uchino S, 2006, WORLD J SURG, V30, P775, DOI 10.1007/s00268-005-0368-3; Uchino S, 2016, J CLIN ENDOCR METAB, V101, P4611, DOI 10.1210/jc.2016-2043; van der Linde K, 1998, EUR J GASTROEN HEPAT, V10, P777, DOI 10.1097/00042737-199809000-00009; Wang YY, 2010, ONCOTARGET, V1, P674; Xu B, 2003, J PATHOL, V199, P58, DOI 10.1002/path.1225; YAMASHITA T, 1992, CANCER, V70, P2923, DOI 10.1002/1097-0142(19921215)70:12<2923::AID-CNCR2820701232>3.0.CO;2-G; Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144; Yeoh ECK, 2014, ENDOCR PATHOL, V25, P302, DOI 10.1007/s12022-013-9274-7; Yoo SK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006239	102	5	5	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1168	1179		10.1038/s41379-018-0070-2			12	Pathology	Pathology	GR8SZ	WOS:000443000300001	29785019				2019-10-28	
J	Chiu, K; Riddell, RH; Schaeffer, DF				Chiu, Kenrry; Riddell, Robert H.; Schaeffer, David F.			DALM, rest in peace: a pathologist's perspective on dysplasia in inflammatory bowel disease in the post-DALM era	MODERN PATHOLOGY			English	Review							LOW-GRADE DYSPLASIA; CHRONIC ULCERATIVE-COLITIS; WHITE-LIGHT ENDOSCOPY; COLORECTAL-CANCER; SURVEILLANCE COLONOSCOPY; CROHNS COLITIS; INTRAEPITHELIAL NEOPLASIA; DETECTING DYSPLASIA; CONSENSUS STATEMENT; POLYPOID DYSPLASIA	There are few abbreviations in surgical pathology that are associated with as much immediate recognition, frustration, and confusion as DALM (dysplasia-associated lesion or mass). DALM is used to describe endoscopically visible dysplastic lesions in the surveillance of patients with inflammatory bowel disease. However, the diagnosis of DALM has been complicated by the inconsistent criteria and use of terminology for describing dysplasia in inflammatory bowel disease, and a tendency to relate DALM with the need for colectomy. Fortunately, advancements in both endoscopic visualization and local excision capability have allowed for a more defined management of dysplasia in inflammatory bowel disease. In 2015, the Surveillance for Colorectal Endoscopic Neoplasia Detection and Management in Inflammatory Bowel Disease Patients International Consensus Recommendations (SCENIC) Development Panel, a panel of predominantly expert gastroenterologists and endoscopists in surveillance of inflammatory bowel disease, published a consensus statement. One recommendation was to abandon DALM-related terminology in favor of endoscopic descriptors modified from the Paris endoscopic classification. Recommendations on surveillance and management of dysplastic lesions were also provided. Nevertheless, interval carcinomas and metachronous neoplasia remain persistent issues. This review aims to provide an update on the post-DALM terminology and management recommendations for inflammatory bowel disease-associated dysplasia necessary for a meaningful communication between pathologists and clinicians.	[Chiu, Kenrry; Schaeffer, David F.] Univ British Columbia, Vancouver Gen Hosp, Div Anat Pathol, Vancouver, BC, Canada; [Riddell, Robert H.] Univ Toronto, Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada	Schaeffer, DF (reprint author), Univ British Columbia, Vancouver Gen Hosp, Div Anat Pathol, Vancouver, BC, Canada.	david.schaeffer@vch.ca					Annese V, 2013, J CROHNS COLITIS, V7, P982, DOI 10.1016/j.crohns.2013.09.016; [Anonymous], 2003, GASTROINTEST ENDOSC, V58, pS3; BERNSTEIN CN, 1994, LANCET, V343, P71; Bernstein CN, 2001, CANCER, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z; BLACKSTONE MO, 1981, GASTROENTEROLOGY, V80, P366; Blonski W, 2008, SCAND J GASTROENTERO, V43, P698, DOI 10.1080/00365520701866150; BUTT JH, 1983, DIGEST DIS SCI, V28, P18, DOI 10.1007/BF01393356; Carballal S, 2018, GUT, V67, P70, DOI 10.1136/gutjnl-2016-312332; Choi CHR, 2015, AM J GASTROENTEROL, V110, P1461, DOI 10.1038/ajg.2015.248; Choi CHR, 2015, AM J GASTROENTEROL, V110, P1022, DOI 10.1038/ajg.2015.65; Cleveland NK, 2016, INFLAMM BOWEL DIS, V22, P631, DOI 10.1097/MIB.0000000000000634; CONNELL WR, 1994, GASTROENTEROLOGY, V107, P934, DOI 10.1016/0016-5085(94)90216-X; Crohn UB, 1925, AM J MED SCI, V170, P220; Deepak P, 2016, GASTROINTEST ENDOSC, V83, P1005, DOI 10.1016/j.gie.2015.09.021; Dekker E, 2007, ENDOSCOPY, V39, P216, DOI 10.1055/s-2007-966214; DIXON MF, 1988, HISTOPATHOLOGY, V13, P385, DOI 10.1111/j.1365-2559.1988.tb02055.x; Eaden J, 2001, J PATHOL, V194, P152, DOI 10.1002/path.876; East James E, 2014, Gastrointest Endosc Clin N Am, V24, P435, DOI 10.1016/j.giec.2014.03.003; Efthymiou M, 2013, INFLAMM BOWEL DIS, V19, P2132, DOI 10.1097/MIB.0b013e31829637b9; Eluri S, 2017, DIGEST DIS SCI, V62, P3586, DOI 10.1007/s10620-017-4652-5; Engelsgjerd M, 1999, GASTROENTEROLOGY, V117, P1288, DOI 10.1016/S0016-5085(99)70278-7; Farraye FA, 2010, GASTROENTEROLOGY, V138, P746, DOI [10.1053/j.gastro.2009.12.035, 10.1053/j.gastro.2009.12.037]; Friedman S, 2001, GASTROENTEROLOGY, V120, P820, DOI 10.1053/gast.2001.22449; Fumery M, 2017, CLIN GASTROENTEROL H, V15, P665, DOI 10.1016/j.cgh.2016.11.025; Geboes K., 2014, LEWIN WEINSTEIN RIDD, V2, P983; Goldstone R, 2011, GASTROINTEST ENDOSC, V74, P1087, DOI 10.1016/j.gie.2011.06.028; Gordon IO, 2017, FENOGLIO PREISERS GA, P547; Gunther U, 2011, INT J COLORECTAL DIS, V26, P667, DOI 10.1007/s00384-011-1130-y; Hata K, 2003, BRIT J CANCER, V89, P1232, DOI 10.1038/sj.bjc.6601247; Higgins PDR, 2015, AM J GASTROENTEROL, V110, P1035, DOI 10.1038/ajg.2015.179; Hlavaty T, 2011, EUR J GASTROEN HEPAT, V23, P680, DOI 10.1097/MEG.0b013e32834791b4; Ignjatovic A, 2012, AM J GASTROENTEROL, V107, P885, DOI 10.1038/ajg.2012.67; Itzkowitz SH, 2004, GASTROENTEROLOGY, V126, P1634, DOI 10.1053/j.gastro.2004.03.025; Jaramillo E, 1996, GASTROINTEST ENDOSC, V44, P15, DOI 10.1016/S0016-5107(96)70223-7; Kiesslich R, 2003, GASTROENTEROLOGY, V124, P880, DOI 10.1053/gast.2003.50146; Kiesslich R, 2007, GASTROENTEROLOGY, V132, P874, DOI 10.1053/j.gastro.2007.01.048; Kisiel JB, 2012, INFLAMM BOWEL DIS, V18, P226, DOI 10.1002/ibd.21687; Laine L, 2015, GASTROENTEROLOGY, V148, P639, DOI 10.1053/j.gastro.2015.01.031; Leong RW, 2017, GASTROENTEROLOGY, V152, P1337, DOI 10.1053/j.gastro.2017.01.008; Levi GS, 2006, AM J SURG PATHOL, V30, P1022, DOI 10.1097/00000478-200608000-00014; Magro F, 2017, J CROHNS COLITIS, V11, P649, DOI 10.1093/ecco-jcc/jjx008; Marion JF, 2008, AM J GASTROENTEROL, V103, P2342, DOI 10.1111/j.1572-0241.2008.01934.x; Marion JF, 2016, CLIN GASTROENTEROL H, V14, P713, DOI 10.1016/j.cgh.2015.11.011; Marion JF, 2015, GASTROENTEROLOGY, V148, P462, DOI 10.1053/j.gastro.2015.01.029; Maser EA, 2013, INFLAMM BOWEL DIS, V19, P1827, DOI 10.1097/MIB.0b013e318289c166; Matsumoto T, 2003, AM J GASTROENTEROL, V98, P1827, DOI 10.1016/S0002-9270(03)00429-5; Mooiweer E, 2015, CLIN GASTROENTEROL H, V13, P1656, DOI 10.1016/j.cgh.2015.04.183; Mueller E, 1999, HUM PATHOL, V30, P898, DOI 10.1016/S0046-8177(99)90242-3; Mummery P L, 1907, Med Chir Trans, V90, P589; Navaneethan U, 2013, J CROHNS COLITIS, V7, P974, DOI [10.1016/j.crohns.2013.06.006, 10.1016/j.crohns.2012.04.006, 10.1016/j.crohns.2013.02.009]; Odze RD, 1999, AM J GASTROENTEROL, V94, P1746, DOI 10.1111/j.1572-0241.1999.01201.x; Odze RD, 2002, MODERN PATHOL, V15, P379, DOI 10.1038/modpathol.3880534; Odze RD, 2006, GASTROENTEROL CLIN N, V35, P533, DOI 10.1016/j.gtc.2006.07.007; Odze RD, 2004, CLIN GASTROENTEROL H, V2, P534, DOI 10.1016/S1542-3565(04)00237-X; Odze RD, 2010, ARCH PATHOL LAB MED, V134, P896, DOI 10.1043/1543-2165-134.6.896; Patil DT, 2015, ODZE GOLDBLUM SURG P, P436; Pekow JR, 2010, INFLAMM BOWEL DIS, V16, P1352, DOI 10.1002/ibd.21184; Picco MF, 2013, INFLAMM BOWEL DIS, V19, P1913, DOI 10.1097/MIB.0b013e3182902aba; RIDDELL RH, 1983, HUM PATHOL, V14, P931, DOI 10.1016/S0046-8177(83)80175-0; Riddell RH, 1996, AM J GASTROENTEROL, V91, P864; ROSENSTOCK E, 1985, GASTROENTEROLOGY, V89, P1342, DOI 10.1016/0016-5085(85)90653-5; Rubin DT, 2007, GASTROINTEST ENDOSC, V65, P998, DOI 10.1016/j.gie.2006.09.025; Rubin PH, 1999, GASTROENTEROLOGY, V117, P1295, DOI 10.1016/S0016-5085(99)70279-9; Rutter MD, 2004, GUT, V53, P256, DOI 10.1136/gut.2003.016386; Rutter MD, 2004, GASTROINTEST ENDOSC, V60, P334, DOI 10.1016/S0016-5107(04)01710-9; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Shergill AK, 2015, GASTROINTEST ENDOSC, V81, P1101, DOI 10.1016/j.gie.2014.10.030; Soetikno R, 2013, GASTROENTEROLOGY, V144, P1349, DOI 10.1053/j.gastro.2013.04.008; Subramanian V, 2013, INFLAMM BOWEL DIS, V19, P350, DOI 10.1002/ibd.23002; ten Hove JR, 2017, CLIN GASTROENTEROL H, V15, P222, DOI 10.1016/j.cgh.2016.08.035; Thomas T, 2007, ALIMENT PHARM THERAP, V25, P657, DOI 10.1111/j.1365-2036.2007.03241.x; Torres C, 1998, AM J SURG PATHOL, V22, P275, DOI 10.1097/00000478-199803000-00001; TYTGAT GNJ, 1995, EUR J CANCER, V31A, P1174, DOI 10.1016/0959-8049(95)00133-4; Ullman T, 2003, GASTROENTEROLOGY, V125, P1311, DOI 10.1053/S0016-5085(03)01361-1; van den Broek FJC, 2008, GUT, V57, P1083, DOI 10.1136/gut.2007.144097; van den Broek FJC, 2011, ENDOSCOPY, V43, P108, DOI 10.1055/s-0030-1255956; van den Broek FJC, 2014, AM J GASTROENTEROL, V109, P715, DOI 10.1038/ajg.2011.93; van Schaik FDM, 2013, INFLAMM BOWEL DIS, V19, P342, DOI 10.1097/MIB.0b013e318286f771; Velayos F, 2017, GASTROENTEROLOGY, V152, P440, DOI 10.1053/j.gastro.2016.10.006; Wanders LK, 2014, CLIN GASTROENTEROL H, V12, P756, DOI 10.1016/j.cgh.2013.07.024	80	2	2	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1180	1190		10.1038/s41379-018-0068-9			11	Pathology	Pathology	GR8SZ	WOS:000443000300002	29789648				2019-10-28	
J	Theise, ND; Jia, JD; Sun, YM; Wee, A; You, H				Theise, Neil D.; Jia, Jidong; Sun, Yameng; Wee, Aileen; You, Hong			Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification	MODERN PATHOLOGY			English	Review							LIVER-BIOPSY ASSESSMENT; HEPATOCELLULAR-CARCINOMA; HUMAN CIRRHOSIS; SCORING SYSTEM; B PATIENTS; DISEASE; ENTECAVIR; PATHOLOGY; FEATURES; THERAPY	In this new era of successful long term suppression of hepatitis B viral replication and consistent eradication of hepatitis C virus the necessity for routine pre-treatment biopsies has often been eliminated. Thus, whether there is utility to perform liver biopsy in chronic viral hepatitis is undergoing re-examination. In response to these changing needs, we have developed a new staging system, the Beijing Classification, for assessment of biopsy specimens from patients with chronic viral hepatitis. The most important novelty of the Beijing Classification is that it includes not only extent (stage) of fibrosis, but the quality of fibrosis, namely if the specimen shows predominantly regressive vs. progressive features (or is indeterminantly balanced between the two), the P-I-R score. This histologic distinction between regressive and progressive fibrosis, while invoked in this particular setting of chronic viral hepatitis, may have applicability to all forms of chronic liver disease. Thus, the review contains a description of the concepts of regression and progression with the aim of empowering pathologists to apply them in histopathologic-clinical correlation research as well as in the specific clinical setting for which it was developed. Also, in light of changing clinical needs, grading of necroinflammatory activity and staging of fibrosis are simplified into three point scales. These simplifications should aid the general diagnostic pathologist in being comfortable and confident in assessing biopsy specimens as the criteria for their distinction are far more precise, with significantly reduced " gray zones" of prior grading/staging systems.	[Theise, Neil D.] Mt Sinai Beth Israel Med Ctr, Dept Pathol, New York, NY 10003 USA; [Theise, Neil D.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; [Jia, Jidong; Sun, Yameng; You, Hong] Capital Med Univ, Beijing Friendship Hosp, Beijing Key Lab Translat Med Liver Cirrhosis, Liver Res Ctr,Natl Clin Res Ctr Digest Dis, Beijing, Peoples R China; [Wee, Aileen] Natl Univ Singapore, Natl Univ Hosp, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore	Theise, ND (reprint author), Mt Sinai Beth Israel Med Ctr, Dept Pathol, New York, NY 10003 USA.; Theise, ND (reprint author), NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.	neil.theise@nyumc.org					[Anonymous], 1977, Lancet, V2, P914; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; BEDOSSA P, 1994, HEPATOLOGY, V20, P15; Bedossa P, 2015, LIVER INT, V35, P78, DOI 10.1111/liv.12710; Bruden DJT, 2017, HEPATOLOGY, V66, P37, DOI 10.1002/hep.29115; Burt AD, 2012, ACUTE CHRONIC VIRAL, P361; Chang TT, 2010, HEPATOLOGY, V52, P886, DOI 10.1002/hep.23785; Chedid A, 2000, ARCH PATHOL LAB MED, V124, P1591; Chejfec G, 2000, ARCH PATHOL LAB MED, V124, P1585; Crawford JM, MACSWEENS PATHOLOGY; Crawford JM, SURG PATHOLOGY GI TR; DEGROOTE J, 1968, LANCET, V2, P626; European Ass Study Liver, 2017, J HEPATOL, V66, P153, DOI 10.1016/j.jhep.2016.09.001; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Garcia-Tsao G, 2010, HEPATOLOGY, V51, P1445, DOI 10.1002/hep.23478; Geller SA, 2000, ARCH PATHOL LAB MED, V124, P1587; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Hudacko R, 2011, ARCH PATHOL LAB MED, V135, P1320, DOI 10.5858/arpa.2011-0021-RA; Hytiroglou P, 2012, AM J CLIN PATHOL, V137, P5, DOI 10.1309/AJCP2T2OHTAPBTMP; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Kim JH, 2017, HEPATOLOGY, V66, P335, DOI 10.1002/hep.28916; Kim MY, 2011, J HEPATOL, V55, P1004, DOI 10.1016/j.jhep.2011.02.012; Kim SU, 2012, J HEPATOL, V57, P556, DOI 10.1016/j.jhep.2012.04.029; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; Lim YS, 2014, GASTROENTEROLOGY, V147, P152, DOI 10.1053/j.gastro.2014.02.033; Manne V, 2014, J CLIN GASTROENTEROL, V48, pE76, DOI 10.1097/MCG.0000000000000162; Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1; Papatheodoridis GV, 2015, J HEPATOL, V62, P956, DOI 10.1016/j.jhep.2015.01.002; Persico M, 2002, AM J GASTROENTEROL, V97, P491; Pockros PJ, 2010, HEPATOLOGY, V52, P1193, DOI 10.1002/hep.23809; Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023; Quaglia A, 2016, HISTOPATHOLOGY, V68, P953, DOI 10.1111/his.12957; Ray MB, 2000, ARCH PATHOL LAB MED, V124, P1589; Regev A, 2002, AM J GASTROENTEROL, V97, P2614; Sempoux C, PRACTICAL HEPATIC PA; Sun YM, 2017, HEPATOLOGY, V65, P1438, DOI 10.1002/hep.29009; Theise ND, ROBBINS COTRAN PATHO; Theise ND, 2007, MODERN PATHOL, V20, pS3, DOI 10.1038/modpathol.3800693; Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38; Wang Y, 2017, HEPATOLOGY, V65, P1891, DOI 10.1002/hep.29090; Wanless IR, 2000, ARCH PATHOL LAB MED, V124, P1599; Xu SY, 2014, J HEPATOL, V61, P260, DOI [10.1016/j.jhep.2014.02.015, 10.1016/j.jhep.2014.03.006]	44	1	2	1	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1191	1200		10.1038/s41379-018-0048-0			10	Pathology	Pathology	GR8SZ	WOS:000443000300003	29700417				2019-10-28	
J	Zoroquiain, P; Esposito, E; Logan, P; Aldrees, S; Dias, AB; Mansure, JJ; Santapau, D; Garcia, C; Saornil, MA; Neto, RB; Burnier, MN				Zoroquiain, Pablo; Esposito, Evangelina; Logan, Patrick; Aldrees, Sultan; Dias, Ana Beatriz; Mansure, Jose Joao; Santapau, Daniela; Garcia, Ciro; Saornil, Maria Antonia; Neto, Rubens Belfort; Burnier, Miguel N.			Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma	MODERN PATHOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) - Imaging in the Eye	MAY 07-11, 2017	Baltimore, MD	Assoc Res Vis & Ophthalmol			PD-L1 EXPRESSION; LUNG-CANCER; IMMUNOHISTOCHEMISTRY ASSAYS; PROGNOSTIC-SIGNIFICANCE; PREDICTIVE BIOMARKERS; MALIGNANT-MELANOMA; CLINICAL-OUTCOMES; UNITED-STATES; IMMUNOTHERAPY; BLOCKADE	Programmed cell death-1/ligand (PD-1/PD-L1) interaction negatively regulates T cell activity. PD-L1 expression in tumor cells, antigen-presenting cells, and lymphocytes of the tumor microenvironment is associated with response to treatment with PD-1/PD-L1 inhibitors, but there is still debate on the cutoff value that correlates with responders. In uveal melanoma (UM), 40% of patients will develop liver metastases and, amongst them, 90% will succumb to their disease. The aim of this study was to analyze PD-L1 expression as a prognostic marker and as a possible therapeutic target for UM. Sixty-seven enucleated eyes from UM patients with relevant clinical information were analyzed. Univariate and multivariate analysis were used to evaluate association of PD-L1 with survival. PD-L1 expression was positive relatively to tumor cells, immune cells, and the tumor and tumor-infiltrating immune cell group scoring in 46, 34 and 55% of the cases, respectively. On univariate analysis, tumor cells and the tumor and tumor-infiltrating immune cell group PD-L1 expression was associated with a longer metastasis-free survival (P = 0.04 and P = 0.007). However, on multivariate analysis, only the tumor and tumor-infiltrating immune cell group positivity was associated with longer metastasis-free survival (P = 0.01). Furthermore, tumor cells and the tumor and tumor-infiltrating immune cell group PD-L1 expression was associated with decreased tumor-infiltrating lymphocytes (P = 0.02). PD-L1, when expressed in uveal melanoma, is associated with better patient outcome and decreased tumor-infiltrating lymphocytes. These results support the consideration of anti-PD-1/PD-L1 therapy in uveal melanoma. To determine the best cutoff value, further studies from patients enrolled in clinical trials treated with PD-1/PD-L1 inhibitors are necessary.	[Zoroquiain, Pablo; Esposito, Evangelina; Logan, Patrick; Aldrees, Sultan; Dias, Ana Beatriz; Mansure, Jose Joao; Santapau, Daniela; Garcia, Ciro; Saornil, Maria Antonia; Neto, Rubens Belfort; Burnier, Miguel N.] McGill Univ, Ctr Hlth, McGill Ocular Pathol Lab, Montreal, PQ, Canada; [Zoroquiain, Pablo] Pontificia Univ Catolica Chile, Dept Pathol, Sch Med, Santiago, Chile; [Zoroquiain, Pablo; Neto, Rubens Belfort; Burnier, Miguel N.] Univ Fed Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil	Zoroquiain, P (reprint author), McGill Univ, Ctr Hlth, McGill Ocular Pathol Lab, Montreal, PQ, Canada.; Zoroquiain, P (reprint author), Pontificia Univ Catolica Chile, Dept Pathol, Sch Med, Santiago, Chile.; Zoroquiain, P (reprint author), Univ Fed Sao Paulo, Sch Med, Dept Ophthalmol, Sao Paulo, Brazil.	zoroquiain@gmail.com			Henry Shibata Fellowship from Cedars Cancer foundation; MITACS	This work was funded by Henry Shibata Fellowship from Cedars Cancer foundation and MITACS.	Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250; Algazi AP, 2016, CANCER-AM CANCER SOC, V122, P3344, DOI 10.1002/cncr.30258; Ameratunga M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153954; Angi M, 2011, ACTA OPHTHALMOL, V89, pE155, DOI 10.1111/j.1755-3768.2009.01769.x; Bu X, 2016, TRENDS MOL MED, V22, P448, DOI 10.1016/j.molmed.2016.04.008; Butte MJ, 2008, MOL IMMUNOL, V45, P3567, DOI 10.1016/j.molimm.2008.05.014; Callejo SA, 2007, EYE, V21, P752, DOI 10.1038/sj.eye.6702322; Collaborative Ocular Melanoma Grp, 2006, ARCH OPHTHALMOL-CHIC, V124, P1684; Correa ZM, 2014, GRAEF ARCH CLIN EXP, V252, P131, DOI 10.1007/s00417-013-2515-0; DELACRUZ PO, 1990, CANCER-AM CANCER SOC, V65, P112; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Driver BR, 2017, ARCH PATHOL LAB MED, V141, P1529, DOI 10.5858/arpa.2017-0028-OA; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fernandes Bruno F., 2007, Arq. Bras. Oftalmol., V70, P593, DOI 10.1590/S0004-27492007000400007; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Guan J, 2017, ARCH PATHOL LAB MED, V141, P851, DOI 10.5858/arpa.2016-0361-RA; Hawkins BS, 2004, AM J OPHTHALMOL, V138, P936, DOI DOI 10.1016/J.AJ0.2004.07.006; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Ilie M, 2016, VIRCHOWS ARCH, V468, P511, DOI 10.1007/s00428-016-1910-4; Jia RB, 2011, MOL MED REP, V4, P163, DOI 10.3892/mmr.2010.397; Kang J, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0156-7; Kerr KM, 2016, ARCH PATHOL LAB MED, V140, P249, DOI 10.5858/arpa.2015-0303-SA; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P394, DOI 10.1038/nrclinonc.2016.65; Khalil DN, 2016, NAT REV CLIN ONCOL, V13, P273, DOI 10.1038/nrclinonc.2016.25; Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Logan PT, 2008, CLIN EXP METASTAS, V25, P509, DOI 10.1007/s10585-008-9158-2; Ma J, 2012, EXP EYE RES, V96, P98, DOI 10.1016/j.exer.2011.12.014; Madore J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12340; Makitie T, 2001, INVEST OPHTH VIS SCI, V42, P1414; MCLEAN IW, 1983, AM J OPHTHALMOL, V96, P502, DOI 10.1016/S0002-9394(14)77914-0; McLean IW, 1994, TUMORS UVEAL TRACT; Meng XJ, 2015, CANCER TREAT REV, V41, P868, DOI 10.1016/j.ctrv.2015.11.001; Nguyen LT, 2015, NAT REV IMMUNOL, V15, P45, DOI 10.1038/nri3790; Niederkorn JY, 2009, PROG RETIN EYE RES, V28, P329, DOI 10.1016/j.preteyeres.2009.06.002; Ott PA, 2013, CLIN CANCER RES, V19, P5300, DOI 10.1158/1078-0432.CCR-13-0143; Ribas A, 2014, CLIN CANCER RES, V20, P4982, DOI 10.1158/1078-0432.CCR-14-0933; Santarpia M, 2015, CANCER BIOL MED, V12, P74, DOI 10.7497/j.issn.2095-3941.2015.0022; Schats KA, 2017, HISTOPATHOLOGY, V70, P253, DOI 10.1111/his.13056; Sholl LM, 2016, ARCH PATHOL LAB MED, V140, P341, DOI 10.5858/arpa.2015-0506-SA; Singh AD, 2003, OPHTHALMOLOGY, V110, P956, DOI 10.1016/S0161-6420(03)00078-2; Singh AD, 2003, OPHTHALMOLOGY, V110, P962, DOI 10.1016/S0161-6420(03)00077-0; Sun WY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0925-6; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130; Wang QQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006369; Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862; WHELCHEL JC, 1993, INVEST OPHTH VIS SCI, V34, P2603; Wimberly H, 2015, CANCER IMMUNOL RES, V3, P326, DOI 10.1158/2326-6066.CIR-14-0133; Yang WH, 2008, INVEST OPHTH VIS SCI, V49, P2518, DOI 10.1167/iovs.07-1606; Yang WH, 2009, INVEST OPHTH VIS SCI, V50, P273, DOI 10.1167/iovs.08-2397	53	3	3	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1201	1210		10.1038/s41379-018-0043-5			10	Pathology	Pathology	GR8SZ	WOS:000443000300004	29581543				2019-10-28	
J	Andreasen, S; Tan, QH; Agander, TK; Steiner, P; Bjorndal, K; Hogdall, E; Larsen, SR; Erentaite, D; Olsen, CH; Ulhoi, BP; von Holstein, SL; Wessel, I; Heegaard, S; Homoe, P				Andreasen, Simon; Tan, Qihua; Agander, Tina Klitmoller; Steiner, Petr; Bjorndal, Kristine; Hogdall, Estrid; Larsen, Stine Rosenkilde; Erentaite, Daiva; Olsen, Caroline Holkmann; Ulhoi, Benedicte Parm; von Holstein, Sarah Linea; Wessel, Irene; Heegaard, Steffen; Homoe, Preben			Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles	MODERN PATHOLOGY			English	Article							HISTOLOGICAL SPECIAL TYPES; TRANSCRIPTION FACTOR NFIB; MOLECULAR CHARACTERIZATION; PROGNOSTIC-FACTORS; GENOMIC LANDSCAPE; CANCER; MYB; TUMORS; HEAD; NECK	Adenoid cystic carcinoma is among the most frequent malignancies in the salivary and lacrimal glands and has a grave prognosis characterized by frequent local recurrences, distant metastases, and tumor-related mortality. Conversely, adenoid cystic carcinoma of the breast is a rare type of triple-negative (estrogen and progesterone receptor, HER2) and basal-like carcinoma, which in contrast to other triple-negative and basal-like breast carcinomas has a very favorable prognosis. Irrespective of site, adenoid cystic carcinoma is characterized by gene fusions involving MYB, MYBL1, and NFIB, and the reason for the different clinical outcomes is unknown. In order to identify the molecular mechanisms underlying the discrepancy in clinical outcome, we characterized the phenotypic profiles, pattern of gene rearrangements, and global microRNA expression profiles of 64 salivary gland, 9 lacrimal gland, and 11 breast adenoid cystic carcinomas. All breast and lacrimal gland adenoid cystic carcinomas had triple-negative and basal-like phenotypes, while salivary gland tumors were indeterminate in 13% of cases. Aberrations in MYB and/or NFIB were found in the majority of cases in all three locations, whereas MYBL1 involvement was restricted to tumors in the salivary gland. Global microRNA expression profiling separated salivary and lacrimal gland adenoid cystic carcinoma from their respective normal glands but could not distinguish normal breast adenoid cystic carcinoma from normal breast tissue. Hierarchical clustering separated adenoid cystic carcinomas of salivary gland origin from those of the breast and placed lacrimal gland carcinomas in between these. Functional annotation of the microRNAs differentially expressed between salivary gland and breast adenoid cystic carcinoma showed these as regulating genes involved in metabolism, signal transduction, and genes involved in other cancers. In conclusion, microRNA dysregulation is the first class of molecules separating adenoid cystic carcinoma according to the site of origin. This highlights a novel venue for exploring the biology of adenoid cystic carcinoma.	[Andreasen, Simon; Homoe, Preben] Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark; [Andreasen, Simon; Wessel, Irene] Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Copenhagen, Denmark; [Tan, Qihua] Univ Southern Denmark, Dept Clin Res, Human Genet Unit, Odense, Denmark; [Agander, Tina Klitmoller] Rigshosp, Dept Pathol, Copenhagen, Denmark; [Steiner, Petr] Charles Univ Prague, Fac Med, Dept Pathol, Plzen, Czech Republic; [Steiner, Petr] Biopt Lab Ltd, Mol Pathol Lab, Plzen, Czech Republic; [Bjorndal, Kristine] Odense Univ Hosp, Dept ORL Head & Neck Surg, Odense, Denmark; [Hogdall, Estrid] Univ Copenhagen, Herlev Hosp, Dept Pathol, Herlev, Denmark; [Larsen, Stine Rosenkilde] Odense Univ Hosp, Dept Pathol, Odense, Denmark; [Erentaite, Daiva] Aalborg Univ Hosp, Dept Pathol, Aalborg, Denmark; [Olsen, Caroline Holkmann] Zealand Univ Hosp, Dept Pathol, Roskilde, Denmark; [Ulhoi, Benedicte Parm] Aarhus Univ Hosp, Dept Pathol, Aarhus, Denmark; [von Holstein, Sarah Linea; Heegaard, Steffen] Rigshosp Glostrup, Dept Ophthalmol, Copenhagen, Denmark; [von Holstein, Sarah Linea] Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark	Andreasen, S (reprint author), Zealand Univ Hosp, Dept Otorhinolaryngol & Maxillofacial Surg, Koge, Denmark.; Andreasen, S (reprint author), Rigshosp, Dept Otorhinolaryngol Head & Neck Surg & Audiol, Copenhagen, Denmark.	Simon@Andreasen.pm	; Tan, Qihua/F-1349-2015	Homoe, Preben/0000-0003-2877-3518; Hogdall, Estrid/0000-0003-4689-5658; Andreasen, Simon/0000-0002-1528-4988; Tan, Qihua/0000-0003-3194-0030	Einar Willumsen Foundation; Merchant Kristjan Kjaer and wife Margrethe Kjaer's Foundation; Danielsen Foundation; Resino A/S; Else and Mogens Wedell-Wedellsborg's Foundation; Region Zealand's Research Fund; Hans Skouby and wife Emma Skouby's Foundation; A.P. Moller Foundation for the Advancement of Medical Research	We thank Sanni Pedersen, Heidi Ugleholdt, and Pernille Frederiksen for brilliant technical assistance. The study was funded by Einar Willumsen Foundation, Merchant Kristjan Kjaer and wife Margrethe Kjaer's Foundation, The Danielsen Foundation, Resino A/S, Else and Mogens Wedell-Wedellsborg's Foundation, Region Zealand's Research Fund, Hans Skouby and wife Emma Skouby's Foundation, and the A.P. Moller Foundation for the Advancement of Medical Research.	Amin MB, 2017, AJCC CANC STAGING MA; Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006; Andreasen S, 2018, CANCER CYTOPATHOL, V126, P275, DOI 10.1002/cncy.21959; Andreasen S, 2017, ASIA-PAC J OPHTHALMO, V6, P159, DOI 10.22608/APO.201707; Andreasen S, 2017, ACTA OPHTHALMOL, V95, P299, DOI 10.1111/aos.13310; Andreasen S, 2017, HISTOPATHOLOGY, V70, P880, DOI 10.1111/his.13162; Andreasen S, 2016, EUR ARCH OTO-RHINO-L, V273, P3847, DOI 10.1007/s00405-016-4000-y; Andreasen S, 2016, ONCOL REP, V35, P2177, DOI 10.3892/or.2016.4621; Andreasen S, 2015, APMIS, V123, P706, DOI 10.1111/apm.12407; Andreoli MT, 2015, OTOLARYNG HEAD NECK, V152, P279, DOI 10.1177/0194599814556624; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Becker-Santos DD, 2016, J PATHOL, V240, P161, DOI 10.1002/path.4765; Bjorndal K, 2015, ORAL ONCOL, V51, P1138, DOI 10.1016/j.oraloncology.2015.10.002; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brill LB, 2011, MODERN PATHOL, V24, P1169, DOI 10.1038/modpathol.2011.86; Chen TY, 2017, EYE, V31, P720, DOI 10.1038/eye.2016.307; Cheng CM, 2016, J PATHOL, V240, P38, DOI 10.1002/path.4752; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Dalin MG, 2016, CLIN CANCER RES, V22, P4623, DOI 10.1158/1078-0432.CCR-16-0637; Di Palma S, 2012, HISTOPATHOLOGY, V61, P629, DOI 10.1111/j.1365-2559.2012.04252.x; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Erichsen Rune, 2010, Clin Epidemiol, V2, P51; Fane ME, 2017, EBIOMEDICINE, V16, P63, DOI 10.1016/j.ebiom.2017.01.013; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fujii K, 2017, HISTOPATHOLOGY, V71, P823, DOI 10.1111/his.13281; Gao RL, 2014, ONCOTARGET, V5, P12528, DOI 10.18632/oncotarget.2985; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Horlings HM, 2013, BREAST CANCER RES TR, V142, P257, DOI 10.1007/s10549-013-2740-6; Howe K, 2017, METHODS MOL BIOL, V1509, P17, DOI 10.1007/978-1-4939-6524-3_3; Hudson JB, 2014, ARCH PATHOL LAB MED, V138, P403, DOI 10.5858/arpa.2012-0736-OA; Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140; Kato S, 2015, ONCOTARGET, V6, P25631, DOI 10.18632/oncotarget.4554; Kiss O, 2015, PATHOL ONCOL RES, V21, P29, DOI 10.1007/s12253-014-9770-1; Krings G, 2017, MODERN PATHOL, V30, P1086, DOI 10.1038/modpathol.2017.32; Li N, 2012, CANCER-AM CANCER SOC, V118, P3945, DOI 10.1002/cncr.26740; Liu B, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx033; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marchio C, 2010, J CLIN PATHOL, V63, P220, DOI 10.1136/jcp.2009.073908; Martelotto LG, 2015, J PATHOL, V237, P179, DOI 10.1002/path.4573; Mellas RE, 2015, J DENT RES, V94, P312, DOI 10.1177/0022034514559129; Mitani Y, 2016, CLIN CANCER RES, V22, P725, DOI 10.1158/1078-0432.CCR-15-2867-T; Mitani Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066778; Miyai Kosuke, 2014, World J Clin Cases, V2, P732, DOI 10.12998/wjcc.v2.i12.732; Moore HM, 2011, J PROTEOME RES, V10, P3429, DOI 10.1021/pr200021n; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Persson M, 2012, GENE CHROMOSOME CANC, V51, P805, DOI 10.1002/gcc.21965; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Pia-Foschini M, 2003, J CLIN PATHOL, V56, P497, DOI 10.1136/jcp.56.7.497; Poling JS, 2017, AM J SURG PATHOL, V41, P973, DOI 10.1097/PAS.0000000000000878; Rettig EM, 2016, CANCER PREV RES, V9, P265, DOI 10.1158/1940-6207.CAPR-15-0316; RO JY, 1987, HUM PATHOL, V18, P1276, DOI 10.1016/S0046-8177(87)80413-6; Ross JS, 2014, AM J SURG PATHOL, V38, P235, DOI 10.1097/PAS.0000000000000102; Semenova EA, 2016, CELL REP, V16, P631, DOI 10.1016/j.celrep.2016.06.020; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; Stringer BW, 2016, ONCOTARGET, V7, P29306, DOI 10.18632/oncotarget.8720; Tan DSP, 2008, BREAST CANCER RES TR, V111, P27, DOI 10.1007/s10549-007-9756-8; Ul Hussain M, 2012, CELL TISSUE RES, V349, P405, DOI 10.1007/s00441-012-1438-0; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; von Holstein SL, 2013, OPHTHALMOLOGY, V120, P2130, DOI 10.1016/j.ophtha.2013.03.030; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Wetterskog D, 2012, J PATHOL, V226, P84, DOI 10.1002/path.2974; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Wong N, 2016, CANCER MED-US, V5, P1619, DOI 10.1002/cam4.718; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Zhang L, 2013, AM J PATHOL, V182, P2048, DOI 10.1016/j.ajpath.2013.02.020	72	4	4	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1211	1225		10.1038/s41379-018-0005-y			15	Pathology	Pathology	GR8SZ	WOS:000443000300005	29467480				2019-10-28	
J	Shih, AR; Cote, GM; Chebib, I; Choy, E; DeLaney, T; Deshpande, V; Hornicek, FJ; Miao, RY; Schwab, JH; Nielsen, GP; Chen, YL				Shih, Angela R.; Cote, Gregory M.; Chebib, Ivan; Choy, Edwin; DeLaney, Thomas; Deshpande, Vikram; Hornicek, Francis J.; Miao, Ruoyu; Schwab, Joseph H.; Nielsen, G. Petur; Chen, Yen-Lin			Clinicopathologic characteristics of poorly differentiated chordoma	MODERN PATHOLOGY			English	Article							DOSE PHOTON/PROTON RADIOTHERAPY; MALIGNANT RHABDOID TUMORS; MOBILE SPINE; PHASE-II; PROGNOSTIC-FACTORS; SACRAL CHORDOMAS; EXPRESSION; CHILDREN; BRACHYURY; EZH2	Chordoma is a rare malignant tumor of bone with high morbidity and mortality. Recently, aggressive pediatric poorly differentiated chordoma with SMARCB1 loss has been described. This study summarizes the clinicopathologic features of poorly differentiated chordoma with SMARCB1 loss in the largest series to date. A search of records between 1990-2017 at MGH identified 19 patients with poorly differentiated chordoma. Immunohistochemical stains were evaluated. Kaplan-Meier survival statistics and log-rank (Mantel Cox) tests compared survival with other subtypes. The patients (n = 19) were diagnosed at a median age of 11 years (range: 1-29). Tumors arose in the skull base and clivus (n = 10/19; 53%); cervical spine (n = 6/19; 32%); and sacrum or coccyx (n = 3/19; 16%). The clinical stage of these patients (AJCC 7e) was stage 2A (n = 7/16; 44%); stage 2B (n = 6/16; 38%); stage 4A (n = 1/16; 6%); and stage 4B (n = 2/16; 13%). The tumors were composed of sheets of epithelioid cells with nuclear pleomorphism, abundant eosinophilic cytoplasm, and increased mitoses. Tumors were positive for cytokeratin (n = 18/18; 100%) and brachyury (n = 18/18; 100%). Patients were treated with a combination of excision, radiation therapy, and chemotherapy. No difference in overall survival, progression free survival, local control time, and metastasis free survival was identified between poorly differentiated chordoma of the skull base and of the spine. Compared to other chordoma subtypes, poorly differentiated chordoma has a significantly decreased mean overall survival after stratification by site (p = 0.037). Pediatric poorly differentiated chordoma has a distinct clinical and immunohistochemical profile, with characteristic SMARCB1 loss and decreased survival compared to conventional/chondroid chordoma. Recognition of this subtype is important because these malignancies should be treated aggressively with multimodality therapy.	[Shih, Angela R.; Chebib, Ivan; Deshpande, Vikram; Nielsen, G. Petur] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Cote, Gregory M.; Choy, Edwin] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA; [DeLaney, Thomas; Miao, Ruoyu; Chen, Yen-Lin] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Hornicek, Francis J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthoped Surg, Los Angeles, CA 90095 USA; [Schwab, Joseph H.] Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA	Nielsen, GP (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.; Chen, YL (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.	gnielsen@mgh.harvard.edu; ychen9@mgh.harvard.edu					Al-Rahawan MM, 2012, PEDIATR BLOOD CANCER, V59, P323, DOI 10.1002/pbc.23297; Alimova I, 2013, NEURO-ONCOLOGY, V15, P149, DOI 10.1093/neuonc/nos285; Antonelli M, 2017, AM J SURG PATHOL, V41, P56, DOI 10.1097/PAS.0000000000000741; AZZARELLI A, 1988, J SURG ONCOL, V37, P185, DOI 10.1002/jso.2930370311; Bergh P, 2000, CANCER-AM CANCER SOC, V88, P2122, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2122::AID-CNCR19>3.0.CO;2-1; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; BJORNSSON J, 1993, CANCER-AM CANCER SOC, V71, P735, DOI 10.1002/1097-0142(19930201)71:3<735::AID-CNCR2820710314>3.0.CO;2-8; Boriani S, 1996, SPINE, V21, P1569, DOI 10.1097/00007632-199607010-00017; Cha YJ, NEUROPATHOLOGY; CHAMBERS PW, 1979, AM J CLIN PATHOL, V72, P765; Chen YL, 2013, SPINE, V38, pE930, DOI 10.1097/BRS.0b013e318296e7d7; DAHLIN DC, 1952, CANCER, V5, P1170, DOI 10.1002/1097-0142(195211)5:6<1170::AID-CNCR2820050613>3.0.CO;2-C; Delaney TF, 2014, J SURG ONCOL, V110, P115, DOI 10.1002/jso.23617; Fletcher C, 2013, WHO CLASSIFICATION T; Gleason BC, 2007, AM J SURG PATHOL, V31, P1813, DOI 10.1097/PAS.0b013e31805f6775; Gounder MM, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11058; Hamamoto Shinichi, 2014, BMC Res Notes, V7, P765, DOI 10.1186/1756-0500-7-765; Hasselblatt M, 2016, ACTA NEUROPATHOL, V132, P149, DOI 10.1007/s00401-016-1574-9; HEALEY JH, 1989, ORTHOP CLIN N AM, V20, P417; Hoch BL, 2006, AM J SURG PATHOL, V30, P811, DOI 10.1097/01.pas.0000209828.39477.ab; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; HORTEN BC, 1976, ACTA NEUROPATHOL, V35, P13, DOI 10.1007/BF00688940; Kayani B, 2014, NEUROSURGERY, V75, P269, DOI 10.1227/NEU.0000000000000423; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Kurmasheva RT, PEDIAT BLOOD CANC; LASKIN WB, 1991, AM J SURG PATHOL, V15, P1136, DOI 10.1097/00000478-199112000-00004; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735; Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462; Mobley BC, 2010, ACTA NEUROPATHOL, V120, P745, DOI 10.1007/s00401-010-0767-x; Patel SS, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0543-8; Renard C, 2014, CANCER GENET-NY, V207, P384, DOI 10.1016/j.cancergen.2014.05.005; Scimeca PG, 1996, J PEDIAT HEMATOL ONC, V18, P237, DOI 10.1097/00043426-199605000-00032; Shen J, 2011, J CLIN NEUROSCI, V18, P96, DOI 10.1016/j.jocn.2010.03.066; Stacchiotti S, 2013, ANN ONCOL, V24, P1931, DOI 10.1093/annonc/mdt117; Stacchiotti S, 2012, J CLIN ONCOL, V30, P914, DOI 10.1200/JCO.2011.35.3656; Stacchiotti S, 2011, CURR ONCOL REP, V13, P323, DOI 10.1007/s11912-011-0176-x; Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; WOLD LE, 1983, J NEUROSURG, V59, P1043, DOI 10.3171/jns.1983.59.6.1043; Yadav R, 2014, NEURO-ONCOLOGY, V16, P372, DOI 10.1093/neuonc/not228	41	7	7	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1237	1245		10.1038/s41379-018-0002-1			9	Pathology	Pathology	GR8SZ	WOS:000443000300007	29483606				2019-10-28	
J	Niskakoski, A; Pasanen, A; Lassus, H; Renkonen-Sinisalo, L; Kaur, S; Mecklin, JP; Butzow, R; Peltomaki, P				Niskakoski, Anni; Pasanen, Annukka; Lassus, Heini; Renkonen-Sinisalo, Laura; Kaur, Sippy; Mecklin, Jukka-Pekka; Butzow, Ralf; Peltomaki, Paivi			Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance	MODERN PATHOLOGY			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; HYPERPLASIA; CARCINOMA; REPRODUCIBILITY; EXPRESSION; MANAGEMENT; DIAGNOSIS; PROFILES; PATTERNS; SURVIVAL	Molecular alterations preceding endometrial and ovarian cancer and the sequence of events are unknown. Consecutive specimens from lifelong surveillance for Lynch syndrome provides a natural setting to address such questions. To molecularly define the multistep gynecological tumorigenesis, DNA mismatch repair gene mutation carriers with endometrial or ovarian carcinoma or endometrial hyperplasia were identified from a nation-wide registry and endometrial biopsy specimens taken from these individuals during 20 years of screening were collected. A total of 213 endometrial and ovarian specimens from Lynch syndrome individuals and 197 histology-matched (non-serous) samples from sporadic cases were available for this investigation. The specimens were profiled for markers linked to endometrial and ovarian tumorigenesis, including ARID1A protein expression, mismatch repair status, and tumor suppressor gene promoter methylation. In Lynch syndrome-associated endometrial and ovarian carcinomas, ARID1A protein was lost in 61-100% and mismatch repair was deficient in 97-100%, compared to 0-17% and 14-44% in sporadic cases (P = 0.000). ARID1A loss appeared in complex hyperplasia and deficient mismatch repair and tumor suppressor gene promoter methylation in histologically normal endometrium. Despite quantitative differences between Lynch syndrome and sporadic cases, ARID1A expression, mismatch repair, and tumor suppressor gene promoter methylation divided endometrial samples from both patient groups into three categories of increasing abnormality, comprising normal endometrium and simple hyperplasia (I), complex hyperplasia with or without atypia (II), and endometrial cancer (III). Complex hyperplasias without vs. with atypia were molecularly indistinguishable. In conclusion, surveillance specimens from Lynch syndrome identify mismatch repair deficiency, tumor suppressor gene promoter methylation, and ARID1A loss as early changes in tumor development. Our findings are clinically relevant for the classification of endometrial hyperplasias and have potential implications in cancer prevention in Lynch syndrome and beyond.	[Niskakoski, Anni; Kaur, Sippy; Peltomaki, Paivi] Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland; [Pasanen, Annukka; Butzow, Ralf] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Pasanen, Annukka; Butzow, Ralf] Helsinki Univ Hosp, HUSLAB, Helsinki, Finland; [Lassus, Heini; Butzow, Ralf] Univ Helsinki, Helsinki Univ Hosp, Dept Obstet & Gynecol, Helsinki, Finland; [Renkonen-Sinisalo, Laura] Univ Helsinki, Cent Hosp, Dept Surg 2, Helsinki, Finland; [Kaur, Sippy] Univ Helsinki, Dept Oral & Maxillofacial Dis, Helsinki, Finland; [Kaur, Sippy] Helsinki Univ Hosp, Helsinki, Finland; [Mecklin, Jukka-Pekka] Cent Finland Hlth Care Dist, Dept Surg & Educ & Sci, Helsinki, Finland; [Mecklin, Jukka-Pekka] Jyvaskyla Univ, Dept Sport & Hlth Sci, Jyvaskyla, Finland	Niskakoski, A (reprint author), Univ Helsinki, Dept Med & Clin Genet, Helsinki, Finland.	anni.niskakoski@helsinki.fi		Peltomaki, Paivi/0000-0001-8819-2980; Pasanen, Annukka/0000-0002-0079-9807	Jane and Aatos Erkko Foundation; Academy of FinlandAcademy of Finland [294643]; Finnish Cancer Organizations; Sigrid Juselius FoundationSigrid Juselius Foundation; HiLIFE; K Albin Johanssons Stiftelse; Integrative Life Science Doctoral Program ILS	We thank the patients and responsible clinical experts for participation. Saila Saarinen is thanked for expert technical assistance. This work was supported by Jane and Aatos Erkko Foundation (to P.P. and J.-P.M.), the Academy of Finland (Grant No. 294643, to P.P.), the Finnish Cancer Organizations (to P.P. and J.-P.M), the Sigrid Juselius Foundation (to P.P.), the HiLIFE Fellows 2017-2020 (to P.P.), K Albin Johanssons Stiftelse (to A.N.), and the Integrative Life Science Doctoral Program ILS (to A.N.).	Baldwin LA, 2012, OBSTET GYNECOL, V120, P612, DOI 10.1097/AOG.0b013e318264f794; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bergeron C, 1999, AM J SURG PATHOL, V23, P1102, DOI 10.1097/00000478-199909000-00014; Bonadona V, 2011, JAMA-J AM MED ASSOC, V305, P2304, DOI 10.1001/jama.2011.743; Bosse T, 2013, MODERN PATHOL, V26, P1525, DOI 10.1038/modpathol.2013.96; Burn J, 2013, FAM CANCER, V12, P707, DOI 10.1007/s10689-013-9650-y; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Grindedal EM, 2010, J MED GENET, V47, P99, DOI 10.1136/jmg.2009.068130; Gylling AHS, 2008, CARCINOGENESIS, V29, P1351, DOI 10.1093/carcin/bgn133; ISOLA J, 1994, AM J PATHOL, V145, P1301; Joensuu EI, 2008, CANCER RES, V68, P4597, DOI 10.1158/0008-5472.CAN-07-6645; Karnezis AN, 2017, NAT REV CANCER, V17, P65, DOI 10.1038/nrc.2016.113; Kendall BS, 1998, AM J SURG PATHOL, V22, P1012, DOI 10.1097/00000478-199808000-00012; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Kurman RJ, 2008, INT J GYNECOL PATHOL, V27, P151, DOI 10.1097/PGP.0b013e318161e4f5; Loukola A, 2001, CANCER RES, V61, P4545; Lu KH, 2013, FAM CANCER, V12, P273, DOI 10.1007/s10689-013-9664-5; Moller P, 2017, GUT, V66, P464, DOI 10.1136/gutjnl-2015-309675; Ng A, 2015, NAT REV MOL CELL BIO, V16, P625, DOI 10.1038/nrm4056; Nieminen TT, 2009, CLIN CANCER RES, V15, P5772, DOI 10.1158/1078-0432.CCR-09-0506; Niskakoski A, 2014, EPIGENETICS-US, V9, P1577, DOI 10.4161/15592294.2014.983374; Niskakoski A, 2013, INT J CANCER, V133, P2596, DOI 10.1002/ijc.28287; Ollikainen M, 2005, J CLIN ONCOL, V23, P4609, DOI 10.1200/JCO.2005.06.055; Pasanen A, 2016, INT J GYNECOL CANCER, V26, P1465, DOI 10.1097/IGC.0000000000000801; Porkka N, 2017, ONCOTARGET, V8, P108020, DOI 10.18632/oncotarget.22445; Prat J, 2007, PATHOLOGY, V39, P72, DOI 10.1080/00313020601136153; Prat J, 2012, VIRCHOWS ARCH, V460, P237, DOI 10.1007/s00428-012-1203-5; Renkonen-Sinisalo L, 2007, INT J CANCER, V120, P821, DOI 10.1002/ijc.22446; Rossi L, 2017, INT J GYNECOL CANCER, V27, P953, DOI 10.1097/IGC.0000000000000985; Scully RE, 1994, HIST TYPING FEMALE G; Silverberg SG, 2003, WHO CLASSIFICATION T, P221; Soovares P, 2017, GYNECOL ONCOL, V146, P615, DOI 10.1016/j.ygyno.2017.06.010; Sorosky JI, 2012, OBSTET GYNECOL, V120, P383, DOI 10.1097/AOG.0b013e3182605bf1; Takeda T, 2016, ONCOL REP, V35, P607, DOI [10.3892/or.20154421, 10.3892/or.2015.4421]; Trimble CL, 2012, OBSTET GYNECOL, V120, P1160, DOI [http://10.1097/AOG.0b013e31826bb121, 10.1097/AOG.0b013e31826bb121]; van der Putten LJM, 2017, CARCINOGENESIS, V38, P329, DOI 10.1093/carcin/bgx008; Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356; Zaino RJ, 2006, CANCER-AM CANCER SOC, V106, P804, DOI 10.1002/cncr.21649; Zaino RJ, 2014, WHO CLASSIFICATION T, P125; Zhang XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053931	42	5	5	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1291	1301		10.1038/s41379-018-0044-4			11	Pathology	Pathology	GR8SZ	WOS:000443000300012	29588532				2019-10-28	
J	Arvidsson, Y; Rehammar, A; Bergstrom, A; Andersson, E; Altiparmak, G; Sward, C; Wangberg, B; Kristiansson, E; Nilsson, O				Arvidsson, Yvonne; Rehammar, Anna; Bergstrom, Anders; Andersson, Ellinor; Altiparmak, Gulay; Sward, Christina; Wangberg, Bo; Kristiansson, Erik; Nilsson, Ola			miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival	MODERN PATHOLOGY			English	Article							CONSENSUS GUIDELINES UPDATE; WNT/BETA-CATENIN ACTIVATION; CELL-LIKE PHENOTYPE; COLON-CANCER CELLS; MICRORNA EXPRESSION; LUNG-CANCER; COLORECTAL-CANCER; GASTRIC-CANCER; LIVER METASTASES; DOWN-REGULATION	The aim of this study was to define the miRNA profile of small intestinal neuroendocrine tumors and to search for novel molecular subgroups and prognostic biomarkers. miRNA profiling was conducted on 42 tumors from 37 patients who underwent surgery for small intestinal neuroendocrine tumors. Unsupervised hierarchical clustering analysis of miRNA profiles identified two groups of tumor metastases, denoted cluster M1 and M2. The smaller cluster M1 was associated with shorter overall survival and contained tumors with higher grade (WHO grade G2/3) and multiple chromosomal gains including gain of chromosome 14. Tumors of cluster M1 had elevated expression of miR-1246 and miR-663a, and reduced levels of miR-488-3p. Pathway analysis predicted Wnt signaling to be the most significantly altered signaling pathway between clusters M1 and M2. Analysis of miRNA expression in relation to tumor proliferation rate showed significant alterations including downregulation of miR-137 and miR-204-5p in tumors with Ki67 index above 3%. Similarly, tumor progression was associated with significant alterations in miRNA expression, e. g. higher expression of miR-95 and miR-210, and lower expression of miR-378a-3p in metastases. Pathway analysis predicted Wnt signaling to be altered during tumor progression, which was supported by decreased nuclear translocation of beta-catenin in metastases. Survival analysis revealed that downregulation of miR-375 was associated with shorter overall survival. We performed in situ hybridization on biopsies from an independent cohort of small intestinal neuroendocrine tumors using tissue microarrays. Expression of miR-375 was found in 578/635 (91%) biopsies and survival analysis confirmed that there was a correlation between downregulation of miR-375 in tumor metastases and shorter patient survival. We conclude that miRNA profiling defines novel molecular subgroups of metastatic small intestinal neuroendocrine tumors and identifies miRNAs associated with tumor proliferation rate and progression. miR-375 is highly expressed in small intestinal neuroendocrine tumors and may be used as a prognostic biomarker.	[Arvidsson, Yvonne; Bergstrom, Anders; Andersson, Ellinor; Altiparmak, Gulay; Nilsson, Ola] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Sahlgrenska Canc Ctr,Dept Pathol & Genet, Gothenburg, Sweden; [Rehammar, Anna; Kristiansson, Erik] Chalmers Univ Technol, Dept Math Sci, Gothenburg, Sweden; [Sward, Christina; Wangberg, Bo] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Surg, Gothenburg, Sweden	Arvidsson, Y (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Sahlgrenska Canc Ctr,Dept Pathol & Genet, Gothenburg, Sweden.	yvonne.arvidsson@gu.se			Swedish Cancer Society, Sahlgrenska Academy (the government ALF agreement); BioCARE- a National Strategic Research program at University of Gothenburg; Chalmers University of Technology; Sahlgrenska University Funds; Assar Gabrielsson Research Foundation	The expert technical assistance of Pauline Brattberg and Linda Inge is greatly appreciated. This study was supported by the Swedish Cancer Society, Sahlgrenska Academy (the government ALF agreement), BioCARE- a National Strategic Research program at University of Gothenburg, Chalmers University of Technology, The Sahlgrenska University Funds, and the Assar Gabrielsson Research Foundation.	Ahmed A, 2009, ENDOCR-RELAT CANCER, V16, P885, DOI 10.1677/ERC-09-0042; Andersson E, 2016, MODERN PATHOL, V29, P616, DOI 10.1038/modpathol.2016.48; Andersson E, 2009, ENDOCR-RELAT CANCER, V16, P953, DOI 10.1677/ERC-09-0052; Anton R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026257; Avnit-Sagi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005033; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bosman TFCF, 2010, WHO CLASSIFICATION T, P102; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chai S, 2016, HEPATOLOGY, V64, P2062, DOI 10.1002/hep.28821; Crona J, 2015, ANN SURG ONCOL, V22, pS1428, DOI 10.1245/s10434-014-4351-9; Dai J, 2016, ONCOTARGET, V7, P87147, DOI 10.18632/oncotarget.13515; Fan DM, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0432-x; Fotouhi O, 2014, EPIGENETICS-US, V9, P987, DOI 10.4161/epi.28936; Francis JM, 2013, NAT GENET, V45, P1483, DOI 10.1038/ng.2821; Hashemi J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-505; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He J, 2015, CLIN ENDOCRINOL, V83, P581, DOI 10.1111/cen.12814; Hu Y, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0407-9; Hua HW, 2015, ONCOTARGET, V6, P3840, DOI 10.18632/oncotarget.2927; Huang WH, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0366-1; Jeon Min Kyung, 2013, World J Gastrointest Pathophysiol, V4, P94, DOI 10.4291/wjgp.v4.i4.94; Jiang JX, 2015, ONCOTARGET, V6, P2767, DOI 10.18632/oncotarget.3089; Karpahakis A, 2017, ENDOCR-RELAT CANCER, V24, pL21, DOI 10.1530/ERC-16-0419; Karpathakis A, 2016, CLIN CANCER RES, V22, P250, DOI 10.1158/1078-0432.CCR-15-0373; Keller DM, 2007, J BIOL CHEM, V282, P32084, DOI 10.1074/jbc.M700899200; Kim G, 2016, LUNG CANCER, V91, P15, DOI 10.1016/j.lungcan.2015.11.013; Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018; Knudsen LA, 2015, ENDOCRINOLOGY, V156, P3971, DOI 10.1210/en.2015-1088; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Li SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125553; Li SC, 2013, MODERN PATHOL, V26, P685, DOI 10.1038/modpathol.2012.216; Lin MX, 2016, GENE, V582, P137, DOI 10.1016/j.gene.2016.02.001; Liu ZY, 2011, ASIAN PAC J CANCER P, V12, P2819; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116; Vinas JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060937; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Miao CG, 2015, IMMUNOL LETT, V166, P45, DOI 10.1016/j.imlet.2015.05.011; Miller HC, 2016, ENDOCR-RELAT CANCER, V23, P711, DOI 10.1530/ERC-16-0044; Modlin IM, 2008, J NATL CANCER I, V100, P1282, DOI 10.1093/jnci/djn275; Neerincx M, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.29; Niederle B, 2016, NEUROENDOCRINOLOGY, V103, P125, DOI 10.1159/000443170; Pavel M, 2016, NEUROENDOCRINOLOGY, V103, P172, DOI [10.1159/000446025, 10.1159/000443167]; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Ruebel K, 2010, MODERN PATHOL, V23, P367, DOI 10.1038/modpathol.2009.161; Shen H, 2016, ONCOTARGET, V7, P20728, DOI 10.18632/oncotarget.8011; Smyth GK, 2004, STAT APPL GENET MOL, V3, P1, DOI DOI 10.2202/1544-6115.1027; Sobin LH, 2010, TNM CLASSIFICATION M, p310xx; Song GS, 2010, HEPATOLOGY, V51, P1735, DOI 10.1002/hep.23547; Song QC, 2014, CANCER RES, V74, P3031, DOI 10.1158/0008-5472.CAN-13-2193; Sorbye H, 2013, ANN ONCOL, V24, P152, DOI 10.1093/annonc/mds276; Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359; Tang LH, 2012, AM J SURG PATHOL, V36, P1761, DOI 10.1097/PAS.0b013e318263207c; Ullmann P, 2016, ONCOTARGET, V7, P65454, DOI 10.18632/oncotarget.11772; Vishnubalaji R, 2016, ONCOTARGET, V7, P35789, DOI 10.18632/oncotarget.8937; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wan LY, 2015, BIOCHEM BIOPH RES CO, V457, P125, DOI 10.1016/j.bbrc.2014.11.039; Wang ZP, 2015, BIOCHEM BIOPH RES CO, V464, P1228, DOI 10.1016/j.bbrc.2015.07.110; Wu J, 2013, CANCER LETT, V329, P155, DOI 10.1016/j.canlet.2012.10.038; Xu LL, 2016, ONCOTARGET, V7, P40644, DOI 10.18632/oncotarget.9811; Yan JW, 2014, INT J CANCER, V135, P1011, DOI 10.1002/ijc.28563; Yi C, 2012, ONCOGENE, V31, P4421, DOI 10.1038/onc.2011.629; Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030; Zhang GJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-109; Zhao Y, 2016, TUMOR BIOL, V37, P8691, DOI 10.1007/s13277-015-4645-y	68	7	7	2	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1302	1317		10.1038/s41379-018-0010-1			16	Pathology	Pathology	GR8SZ	WOS:000443000300013	29487354				2019-10-28	
J	Matarraz, S; Leoz, P; Fernandez, C; Colado, E; Chillon, MC; Vidriales, MB; Gonzalez, M; Rivera, D; Osuna, CS; Caballero-Velazquez, T; Van der Velden, V; Jongen-Lavrencic, M; Gutierrez, O; Bermejo, AY; Alonso, LG; Garcia, MB; Sanchez, CD; Garcia-Donas, G; Mateo, AG; Recio, I; Sanchez-Real, J; Mayado, A; Gutierrez, ML; Barcena, P; Barrena, S; Lopez, A; Van Dongen, J; Orfao, A				Matarraz, Sergio; Leoz, Pilar; Fernandez, Carlos; Colado, Enrique; Carmen Chillon, Maria; Belen Vidriales, Maria; Gonzalez, Marcos; Rivera, Daniel; Salvador Osuna, Carlos; Caballero-Velazquez, Teresa; Van der Velden, Vincent; Jongen-Lavrencic, Mojca; Gutierrez, Oliver; Yeguas Bermejo, Ana; Garcia Alonso, Luis; Bourgeois Garcia, Monique; De Ramon Sanchez, Cristina; Garcia-Donas, Gloria; Garcia Mateo, Aranzazu; Recio, Isabel; Sanchez-Real, Javier; Mayado, Andrea; Laura Gutierrez, Maria; Barcena, Paloma; Barrena, Susana; Lopez, Antonio; Van Dongen, Jacques; Orfao, Alberto			Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy	MODERN PATHOLOGY			English	Article							TRANS-RETINOIC ACID; MULTIPARAMETER FLOW-CYTOMETRY; EARLY DEATH RATE; REMISSION INDUCTION; FLT3-ACTIVATING MUTATIONS; PROGNOSTIC-FACTORS; MAST-CELLS; DIFFERENTIATION; PATHOGENESIS; IDENTIFICATION	Severe hemorrhagic events occur in a significant fraction of acute promyelocytic leukemia patients, either at presentation and/or early after starting therapy, leading to treatment failure and early deaths. However, identification of independent predictors for high-risk of severe bleeding at diagnosis, remains a challenge. Here, we investigated the immunophenotype of bone marrow leukemic cells from 109 newly diagnosed acute promyelocytic leukemia patients, particularly focusing on the identification of basophil-related features, and their potential association with severe bleeding episodes and patient overall survival. From all phenotypes investigated on leukemic cells, expression of the CD203c and/or CD22 basophil-associated markers showed the strongest association with the occurrence and severity of bleeding (p <= 0.007); moreover, aberrant expression of CD7, coexpression of CD34(+)/CD7(+) and lack of CD71 was also more frequently found among patients with (mild and severe) bleeding at baseline and/or after starting treatment (p <= 0.009). Multivariate analysis showed that CD203c expression (hazard ratio: 26.4; p = 0.003) and older age (hazard ratio: 5.4; p = 0.03) were the best independent predictors for cumulative incidence of severe bleeding after starting therapy. In addition, CD203c expression on leukemic cells (hazard ratio: 4.4; p = 0.01), low fibrinogen levels (hazard ratio: 8.8; p = 0.001), older age (hazard ratio: 9.0; p = 0.002), and high leukocyte count (hazard ratio: 5.6; p = 0.02) were the most informative independent predictors for overall survival. In summary, our results show that the presence of basophil-associated phenotypic characteristics on leukemic cells from acute promyelocytic leukemia patients at diagnosis is a powerful independent predictor for severe bleeding and overall survival, which might contribute in the future to (early) risk-adapted therapy decisions.	[Matarraz, Sergio; Leoz, Pilar; Fernandez, Carlos; Mayado, Andrea; Laura Gutierrez, Maria; Barcena, Paloma; Barrena, Susana; Lopez, Antonio; Orfao, Alberto] Univ Salamanca, Cytometry Serv NUCLEUS, Dept Med, IBSAL,IBMCC,CSIC, Salamanca, Spain; [Matarraz, Sergio; Leoz, Pilar; Fernandez, Carlos; Mayado, Andrea; Laura Gutierrez, Maria; Barcena, Paloma; Barrena, Susana; Lopez, Antonio; Orfao, Alberto] Univ Salamanca, CIBERONC, Canc Res Ctr, IBMCC,CSIC, Salamanca, Spain; [Matarraz, Sergio; Leoz, Pilar; Fernandez, Carlos; Carmen Chillon, Maria; Belen Vidriales, Maria; Gonzalez, Marcos; Rivera, Daniel; Caballero-Velazquez, Teresa; Mayado, Andrea; Laura Gutierrez, Maria; Barcena, Paloma; Barrena, Susana; Lopez, Antonio; Orfao, Alberto] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Colado, Enrique] Cent Univ Hosp Asturias, Hematol & Lab Med Dept, Oviedo, Spain; [Colado, Enrique] Cent Univ Hosp Asturias, IUOPA, Oviedo, Spain; [Carmen Chillon, Maria; Belen Vidriales, Maria; Gonzalez, Marcos; Rivera, Daniel] Univ Hosp Salamanca, IBSAL, Hematol Serv, Salamanca, Spain; [Carmen Chillon, Maria; Belen Vidriales, Maria; Gonzalez, Marcos; Rivera, Daniel] CIBERONC, Salamanca, Spain; [Salvador Osuna, Carlos] Miguel Servet Hosp, Hematol Serv, Zaragoza, Spain; [Caballero-Velazquez, Teresa] Virgen del Rocio Hosp, Hematol Serv, Seville, Spain; [Van der Velden, Vincent] Univ Med Ctr Rotterdam, Dept Immunol, Erasmus MC, Rotterdam, Netherlands; [Jongen-Lavrencic, Mojca] Univ Med Ctr Rotterdam, Dept Hematol, Erasmus MC, Rotterdam, Netherlands; [Gutierrez, Oliver] Rio Hortega Hosp, Hematol Serv, Valladolid, Spain; [Yeguas Bermejo, Ana; Garcia Alonso, Luis] Univ Hosp Getafe, Hematol Serv, Madrid, Spain; [Bourgeois Garcia, Monique; De Ramon Sanchez, Cristina] Univ Hosp, Hematol Serv, Valladolid, Spain; [Garcia-Donas, Gloria] Juan Ramon Jimenez Hosp, Hematol Serv, Huelva, Spain; [Garcia Mateo, Aranzazu] Segovia Gen Hosp, Hematol Serv, Segovia, Spain; [Recio, Isabel] Nuestra Senora Sonsoles Hosp, Hematol Serv, Avila, Spain; [Sanchez-Real, Javier] Leon Hosp, Hematol Serv, Leon, Spain; [Van Dongen, Jacques] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, Leiden, Netherlands	Orfao, A (reprint author), Univ Salamanca, Cytometry Serv NUCLEUS, Dept Med, IBSAL,IBMCC,CSIC, Salamanca, Spain.; Orfao, A (reprint author), Univ Salamanca, CIBERONC, Canc Res Ctr, IBMCC,CSIC, Salamanca, Spain.; Orfao, A (reprint author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	orfao@usal.es	Orfao, Alberto/B-5801-2017; Chillon, M. Carmen MCC/E-1339-2018; Colado, Enrique/Z-6326-2019; Gutierrez, Maria Laura ML/J-4313-2016	Chillon, M. Carmen MCC/0000-0003-1624-6059; Colado, Enrique/0000-0001-8675-8207; Gutierrez, Maria Laura ML/0000-0003-2997-6317; Van Dongen, Jacques/0000-0002-3650-7087	Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC, Madrid, Spain); Fundacion Rafael del Pino (Madrid, Spain); CIBERONC from Instituto de Salud Carlos III (Ministerio de Economia y Competitividad, Madrid, Spain) [CB16/12/00400, CB16/12/00233, CB16/12/00480]; Instituto de Salud Carlos III (Ministerio de Economia y Competitividad, Madrid, Spain) [PI16/00787]	This work was supported by the Fundacion Cientifica de la Asociacion Espanola Contra el Cancer (AECC, Madrid, Spain) and the Fundacion Rafael del Pino (Madrid, Spain) and both CIBERONC (CB16/12/00400, CB16/12/00233, CB16/12/00480) and grant PI16/00787 from Instituto de Salud Carlos III (Ministerio de Economia y Competitividad, Madrid, Spain).	Abla O, 2017, ANN HEMATOL, V96, P1449, DOI 10.1007/s00277-017-3042-6; Altman JK, 2013, LEUKEMIA RES, V37, P1004, DOI 10.1016/j.leukres.2013.05.007; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Breccia M, 2014, THROMB RES, V133, pS112, DOI 10.1016/S0049-3848(14)50019-9; Breen KA, 2012, BRIT J HAEMATOL, V156, P24, DOI 10.1111/j.1365-2141.2011.08922.x; CASTOLDI GL, 1994, LEUKEMIA, V8, P1441; Chang H, 2012, EUR J HAEMATOL, V88, P321, DOI 10.1111/j.1600-0609.2011.01747.x; Chen ZG, 2016, INT J HEMATOL, V103, P306, DOI 10.1007/s12185-015-1923-9; Chillon MC, 2004, HEMATOL J, V5, P239, DOI 10.1038/sj.thj.6200382; Choudhry A, 2012, AM J HEMATOL, V87, P596, DOI 10.1002/ajh.23158; Cicconi L, 2016, ANN ONCOL, V27, P1474, DOI 10.1093/annonc/mdw171; Dally N, 2005, THROMB RES, V116, P109, DOI 10.1016/j.thromres.2004.11.001; de la Serna J, 2008, BLOOD, V111, P3395, DOI 10.1182/blood-2007-07-100669; Deissler H, 1999, FASEB J, V13, P657; Di Bona E, 2000, BRIT J HAEMATOL, V108, P689, DOI 10.1046/j.1365-2141.2000.01936.x; Dong HY, 2011, AM J CLIN PATHOL, V135, P76, DOI 10.1309/AJCPW9TSLQNCZAVT; Falanga A, 2003, BEST PRACT RES CL HA, V16, P463, DOI 10.1053/ybeha.2003.270; Falcone FH, 2000, BLOOD, V96, P4028; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Han XH, 2008, ARCH PATHOL LAB MED, V132, P813, DOI 10.1043/1543-2165(2008)132[813:ISOBBM]2.0.CO;2; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P28; IWAKIRI R, 1994, BRIT J HAEMATOL, V86, P870, DOI 10.1111/j.1365-2141.1994.tb04845.x; Kettenhofen R, 1998, J MOL BIOL, V279, P323, DOI 10.1006/jmbi.1998.1768; Kim DY, 2011, LEUKEMIA RES, V35, P152, DOI 10.1016/j.leukres.2010.05.022; KOIKE T, 1992, NEW ENGL J MED, V327, P385, DOI 10.1056/NEJM199208063270604; KUBONISHI I, 1985, ACTA HAEMATOL JAPON, V48, P1390; Kwaan HC, 2014, BEST PRACT RES CL HA, V27, P11, DOI 10.1016/j.beha.2014.04.005; Lehmann S, 2011, LEUKEMIA, V25, P1128, DOI 10.1038/leu.2011.78; Lo-Coco F, 2016, NEW ENGL J MED, V374, P1197, DOI 10.1056/NEJMc1513710; Lo-Coco F, 2014, BEST PRACT RES CL HA, V27, P3, DOI 10.1016/j.beha.2014.04.006; Lo-Coco F, 2014, CURR HEMATOL MALIG R, V9, P138, DOI 10.1007/s11899-014-0206-5; Mantha S, 2016, CURR OPIN HEMATOL, V23, P121, DOI 10.1097/MOH.0000000000000221; Masamoto Y, 2009, BRIT J HAEMATOL, V144, P798, DOI 10.1111/j.1365-2141.2008.07507.x; Montesinos P, 2011, BLOOD, V117, P1799, DOI 10.1182/blood-2010-04-277434; Orfao A, 1999, HAEMATOLOGICA, V84, P405; Park JH, 2011, BLOOD, V118, P1248, DOI 10.1182/blood-2011-04-346437; Rahme R, 2014, LEUKEMIA, V28, P2422, DOI 10.1038/leu.2014.240; Sanz MA, 2000, BLOOD, V96, P1247; Sanz MA, 2014, BLOOD, V123, P2777, DOI 10.1182/blood-2013-10-512640; SHIMAMOTO Y, 1994, ACTA HAEMATOL-BASEL, V92, P109; Siracusa MC, 2010, IMMUNOL CELL BIOL, V88, P275, DOI 10.1038/icb.2010.1; Tallman Martin S, 2011, Clin Adv Hematol Oncol, V9, P1; TALLMAN MS, 1993, LEUKEMIA, V7, P521; Teodosio C, 2015, J LEUKOCYTE BIOL, V97, P49, DOI 10.1189/jlb.5RU0614-296R; Testa U, 2016, ANN HEMATOL, V95, P673, DOI 10.1007/s00277-016-2622-1; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; van Dongen JJM, 2012, LEUKEMIA, V26, P1908, DOI 10.1038/leu.2012.120; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Watts JM, 2014, BLOOD REV, V28, P205, DOI 10.1016/j.blre.2014.07.001; Yanada M, 2007, EUR J HAEMATOL, V78, P213, DOI 10.1111/j.1600-0609.2006.00803.x; Yano Y, 2004, CANCER LETT, V207, P139, DOI 10.1016/j.canlet.2003.11.002; Yano Y, 2003, INT J MOL MED, V12, P763	52	2	2	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	AUG	2018	31	8					1318	1331		10.1038/s41379-018-0038-2			14	Pathology	Pathology	GR8SZ	WOS:000443000300014	29572500				2019-10-28	
J	Bhattacharya, R; Panda, CK; Nandi, S; Mukhopadhyay, A				Bhattacharya, Rittwika; Panda, Chinmay Kumar; Nandi, Sourav; Mukhopadhyay, Ashis			An insight into metastasis: Random or evolving paradigms?	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Metastasis; ECM; FAC; Microenvironment; Anoikis; Organ torpism	BREAST-CANCER; STEM-CELLS; APC GENE; TUMOR; MECHANISMS; EXPRESSION; MIGRATION; PROMOTER; MIMICRY; GROWTH	Mechanical or fostered molecular events define metastatic cascade. Three distinct sets of molecular events characterize metastasis, viz invasion of extracellular matrix; angiogenesis, vascular dissemination and anoikis resistance; tumor homing and relocation of tumor cells to selective organ. Invasion of extracellular matrix requires epithelial to mesenchymal transition through disrupted lamellopodia formation and contraction of actin cytoskeleton; aberration of Focal adhesion complex formation involving integrins and the extracellular matrix; degradation of extracellular matrix by matrix metalloproteases; faulty immune surveillance in tumor micro environment and an upregulated proton efflux pump NHE1 in tumors. Vascular dissemination and anoikis resistance depend upon upregulation of integrins, phosphorylation of CDCP1, attenuated apoptotic pathways and upregulation of angiogenesis. Tumor homing depends on recruitment of mesenchymal stem cells, expression on chemokines and growth factors, upregulated stem cell renewal pathways. Despite of many potential challenges in curbing metastasis, future targeted therapies involving immunotherapy, stem cell engineered and oncolytic virus based therapy, pharmacological activation of circadian clock are held promising. To sum up, metastasis is a complex cascade of events and warrants detailed molecular understanding for development of therapeutic strategies.	[Bhattacharya, Rittwika; Nandi, Sourav] Netaji Subhas Chandra Bose Canc Res Inst, Dept Mol Biol, 16A Pk Lane, Kolkata 700016, India; [Panda, Chinmay Kumar] Chittaranjan Natl Canc Inst, Dept Oncogene Regulat, 37 SP Mukherjee Rd, Kolkata 700026, India; [Mukhopadhyay, Ashis] Netaji Subhas Chandra Bose Canc Res Inst, Dept Haematooncol, 16A Pk Lane, Kolkata 700016, India; [Bhattacharya, Rittwika; Nandi, Sourav; Mukhopadhyay, Ashis] Netaji Subhas Chandra Bose Canc Res Inst, 3081 Nayabad, Kolkata 700094, India	Mukhopadhyay, A (reprint author), Netaji Subhas Chandra Bose Canc Res Inst, Dept Haematooncol, 16A Pk Lane, Kolkata 700016, India.; Mukhopadhyay, A (reprint author), Netaji Subhas Chandra Bose Canc Res Inst, 3081 Nayabad, Kolkata 700094, India.	rittwikab@gmail.com; ckpanda.cnci@gmail.com; souravkmandi@gmail.com; amukhopadhyay.ncri@gmail.com			institutional Research and Development Department	The authors acknowledge institutional Research and Development Department for necessary fund to support this study.	Amith SR, 2015, ONCOTARGET, V6, P1262, DOI 10.18632/oncotarget.2860; Arvelo F, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.701; Barar J, 2013, BIOIMPACTS, V3, P149, DOI 10.5681/bi.2013.036; Beaty BT, 2014, J CELL BIOL, V205, P737, DOI 10.1083/jcb.201312046; Beauchamp A, 2012, SEMIN CELL DEV BIOL, V23, P109, DOI 10.1016/j.semcdb.2011.10.019; Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Butuner B. D., 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0109868, DOI 10.1371/JOURNAL.PONE.0109868]; Chu JE, 2012, INT J BREAST CANCER, DOI 10.1155/2012/209748; Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796; Fidler IJ, 2002, DIFFERENTIATION, V70, P498, DOI 10.1046/j.1432-0436.2002.700904.x; Fisher DT, 2014, SEMIN IMMUNOL, V26, P38, DOI 10.1016/j.smim.2014.01.008; Fregni G, 2018, EBIOMEDICINE, V29, P128, DOI 10.1016/j.ebiom.2018.02.017; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Gwak HS, 2015, J KOREAN NEUROSURG S, V58, P1, DOI 10.3340/jkns.2015.58.1.1; Hanna A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0509-3; Hill BS, 2017, ONCOTARGET, V8, P73296, DOI 10.18632/oncotarget.20265; Hu JCC, 2006, CLIN CANCER RES, V12, P6737, DOI 10.1158/1078-0432.CCR-06-0759; Jadeski L, 2008, J BIOL CHEM, V283, P1008, DOI 10.1074/jbc.M708466200; Jiang WG, 2015, SEMIN CANCER BIOL, V35, pS244, DOI 10.1016/j.semcancer.2015.03.008; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kim JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081604; Kim Yong-Nyun, 2012, Int J Cell Biol, V2012, P306879, DOI 10.1155/2012/306879; Klein-Goldberg A, 2014, CANCER LETT, V352, P54, DOI 10.1016/j.canlet.2013.08.029; Krakhmal NV, 2015, ACTA NATURAE, V7, P17, DOI 10.32607/20758251-2015-7-2-17-28; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lin F, 2004, DIAGN CYTOPATHOL, V30, P92, DOI 10.1002/dc.10419; Maccauro G, 2011, INT J SURG ONCOL, DOI 10.1155/2011/107969; Mahauad-Fernandez WD, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0493-8; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; MORGANPARKES JH, 1995, AM J ROENTGENOL, V164, P1075, DOI 10.2214/ajr.164.5.7717206; Motta JM, 2016, J IMMUNOL RES, DOI 10.1155/2016/4753607; Munguti J, 2013, OA ANATOMY, V1, P23, DOI DOI 10.13172/2052-7829-3-847; NICHOLSON GL, 1987, CHEST, V91, pS27, DOI 10.1378/chest.91.3_Supplement.27S; Novitskiy SV, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0425-7; Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Park GT, 2016, ONCOTARGET, V7, P58684, DOI 10.18632/oncotarget.11017; Qian CN, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0206-7; Qiao LL, 2015, J CELL MOL MED, V19, P315, DOI 10.1111/jcmm.12496; Ramakrishna Rohan, 2013, Surg Neurol Int, V4, pS256, DOI 10.4103/2152-7806.111303; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sak Katrin, 2012, Chemother Res Pract, V2012, P282570, DOI 10.1155/2012/282570; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; Shi XD, 2016, ONCOTARGET, V7, P70378, DOI 10.18632/oncotarget.11859; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Song Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074464; Sulli G, 2018, NATURE, V553, P351, DOI 10.1038/nature25170; Sun JY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02494-6; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thyavihally Yuvaraja B, 2005, World J Surg Oncol, V3, P48, DOI 10.1186/1477-7819-3-48; Timar J, 2005, ONCOLOGY-BASEL, V69, P185, DOI 10.1159/000088069; Turcotte Simon, 2011, Adv Surg, V45, P341; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van der Auwera I, 2008, BRIT J CANCER, V99, P1735, DOI 10.1038/sj.bjc.6604705; Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voorzanger-Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Weidle UH, 2015, CANCER GENOM PROTEOM, V12, P167; Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Xie Y., 2015, ONCOLOGY, V4, P86; Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015	69	0	0	0	5	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1064	1073		10.1016/j.prp.2018.06.017			10	Pathology	Pathology	GR9QG	WOS:000443104700002	30078401				2019-10-28	
J	Liu, KK; Zhao, K; Wang, LN; Sun, EL				Liu, Kangkang; Zhao, Kun; Wang, Lining; Sun, Erlin			The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Tumor-infiltrating neutrophils; Tumor-infiltrating lymphocytes; Neutrophil/lymphocyte rates; Prognosis; Bladder cancer	CLASSIFICATION; SURVIVAL	Tumor-infiltrating neutrophils (TINs) and lymphocytes (TILs) are found to play essential roles in many tumors and associate with the prognosis of patients. But, the prognostic values of TINs, TILs and NLR (neutrophils-lymphocytes ratio) in bladder cancer (BC) are still undefined. The object of our study was to systematically interrogate the associations of these immune cells with clinical outcomes of BC patients. In our study, a total of 102 patients pathologically diagnosed with BC were included. CD66b(+) and CD8(+) antibodies were used to mark neutrophils and CD8(+) lymphocytes by immunohistochemistry. The results found that TINs and NLR were significantly associated with pathological T-stages of tumors (P < 0.01), but TILs were not. And TINS were also related to pathological tumor grades (P = 0.012). Regarding the prognostic values, TINs was related to the high risk of recurrence in non-muscle invasive BC (NMIBC) patients. Elevated TINs and NLR were associated with poor overall survivals of BC patients, whereas higher TILs were related to longer survivals (P < 0.01). Multivariate analysis showed that both of TINs (HR 2.427, 1.024-5.752, P = 0.044) and NLR (HR 3.529, 1.147-10.864, P = 0.028) were independent unfavorable prognosis markers. In conclusion, Tumor infiltrating immune cells, including TINs, TILs and NLR were important markers in predicting the prognosis of bladder cancer patients. TINs and NLR were more likely to be negative predictors, but TILs were favorable in patients with BC.	[Liu, Kangkang; Zhao, Kun; Wang, Lining; Sun, Erlin] Tianjin Med Univ, Tianjin Inst Urol, Dept Urol, Hosp 2, Tianjin 300211, Peoples R China	Sun, EL (reprint author), Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, 23 PingJiang Rd, Tianjin, Peoples R China.	drelsun@163.com					Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Cavallo F, 2011, CANCER IMMUNOL IMMUN, V60, P319, DOI 10.1007/s00262-010-0968-0; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Horn T, 2016, WORLD J UROL, V34, P181, DOI 10.1007/s00345-015-1615-3; Jensen HK, 2009, J CLIN ONCOL, V27, P4709, DOI 10.1200/JCO.2008.18.9498; Kang BW, 2016, ANN ONCOL, V27, P494, DOI 10.1093/annonc/mdv610; Kawahara T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2219-z; Kinoshita T, 2016, ANN ONCOL, V27, P2117, DOI 10.1093/annonc/mdw319; Krpina K, 2015, VIRCHOWS ARCH, V467, P443, DOI 10.1007/s00428-015-1808-6; Liakou Chrysoula I, 2007, Cancer Immun, V7, P10; Lokeshwar SD, 2015, WORLD J UROL, V33, P1929, DOI 10.1007/s00345-015-1548-x; Mao ZY, 2015, WORLD J GASTROENTERO, V21, P4961, DOI 10.3748/wjg.v21.i16.4961; McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211; Mosmann TR, 2005, J IMMUNOL, V175, P5; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Rakaee M, 2016, ONCOTARGET, V7, P72184, DOI 10.18632/oncotarget.12360; Reid MD, 2011, MODERN PATHOL, V24, P1612, DOI 10.1038/modpathol.2011.113; Sawanobori Y, 2008, BLOOD, V111, P5457, DOI 10.1182/blood-2008-01-136895; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shariat SF, 2006, CLIN CANCER RES, V12, P6663, DOI 10.1158/1078-0432.CCR-06-0372; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Shen MX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098259; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; van Kempen PMW, 2016, CANCER IMMUNOL IMMUN, V65, P575, DOI 10.1007/s00262-016-1819-4; Wang JB, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-7; Webber C, 2014, INT J CANCER, V135, P371, DOI 10.1002/ijc.28683; Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020; Zhang S, 2017, 2017 CHINESE AUTOMATION CONGRESS (CAC), P3921; Zhou L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1293211; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	33	3	3	0	1	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1074	1080		10.1016/j.prp.2018.05.010			7	Pathology	Pathology	GR9QG	WOS:000443104700003	29803657				2019-10-28	
J	Yang, L; Tang, XF; Peng, X; Qian, D; Guo, QN; Guo, H				Yang, Li; Tang, Xuefeng; Peng, Xue; Qian, Dan; Guo, Qiaonan; Guo, Hong			Clinical characteristics of primary intestinal NK/T cell lymphoma, nasal type: Case series and review of the literature	PATHOLOGY RESEARCH AND PRACTICE			English	Review						NK/T lymphoma; Primary; Intestinal neoplasm; Clinicopathologic	HEALTH-ORGANIZATION CLASSIFICATION; GASTROINTESTINAL-TRACT; NEOPLASMS; FEATURES	Bacicgrotard: Primary intestinal NK/T cell lymphoma is rare but aggressive and exhibits a poor prognosis. Little is known about its clinical characteristics because few studies with small sample sizes have been reported. Aims: To provide clinicopathological features and endoscopic findings and to summarize the treatment outcomes of primary intestinal NK/T cell lymphoma to improve our understanding of this disease. Methods: Between January 2011 to December 2016, 13 patients with confirmed primary gastrointestinal NK/T cell lymphoma at our center were described, and an updated literature review was provided. Results: In this series of 13 cases, 69.23% were men, the median age was 39 years, and the median survival was 6 months. The common clinical manifestations included abdominal pain (76.92%) and gastrointestinal bleeding (46.15%). Lymphomas were common in the large intestine (69.23%). In 76.92% of patients, the clinical staging was stage I, and all 13 patients manifested ulcerative lesions and no tumor mass on endoscopy. The clinical characteristics of primary intestinal NK/T cell lymphomas were similar to results in existing literature. Conclusion: Intestinal NK/T cell lymphoma shows nonspecific clinical features and poor prognosis, which is mainly expressed as ulcers on endoscopy. Emergency surgery may be an adverse prognostic factor of lymphoma, since it is prone to progress toward gastrointestinal perforation.	[Yang, Li; Peng, Xue; Guo, Hong] Third Mil Med Univ, Dept Gastroenterol, Xinqiao Hosp, Chongqing 400037, Peoples R China; [Tang, Xuefeng; Guo, Qiaonan] Third Mil Med Univ, Dept Pathol, Xinqiao Hosp, Chongqing 400037, Peoples R China; [Qian, Dan] Third Mil Med Univ, Dept Clin Lab, Xinqiao Hosp, Chongqing 400037, Peoples R China	Guo, H (reprint author), Third Mil Med Univ, Dept Gastroenterol, Xinqiao Hosp, Chongqing 400037, Peoples R China.; Guo, QN (reprint author), Third Mil Med Univ, Dept Pathol, Xinqiao Hosp, Chongqing 400037, Peoples R China.	qiaonan85@263.net; hguoxqyy@163.com		Yang, Li/0000-0003-1146-9528			Au WY, 2009, BLOOD, V113, P3931, DOI 10.1182/blood-2008-10-185256; CARBONE PP, 1971, CANCER RES, V31, P1860; Chihara D, 2014, BRIT J HAEMATOL, V164, P536, DOI 10.1111/bjh.12659; DAMORE F, 1994, J CLIN ONCOL, V12, P1673, DOI 10.1200/JCO.1994.12.8.1673; Ding WS, 2016, ACTA HAEMATOL-BASEL, V135, P21, DOI 10.1159/000437130; Fang JC, 2015, INT J SURG PATHOL, V23, P609, DOI 10.1177/1066896915595863; Gualco G, 2011, AM J SURG PATHOL, V35, P1195, DOI 10.1097/PAS.0b013e31821ec4b5; Jiang M, 2013, J CLIN GASTROENTEROL, V47, pE74, DOI 10.1097/MCG.0b013e31829e444f; Kim JH, 2007, ENDOSCOPY, V39, P156, DOI 10.1055/s-2006-945114; Kim SJ, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-86; Lee J, 2006, J CLIN ONCOL, V24, P612, DOI 10.1200/JCO.2005.04.1384; Li SY, 2013, AM J SURG PATHOL, V37, P14, DOI 10.1097/PAS.0b013e31826731b5; Pongpruttipan T, 2012, AM J SURG PATHOL, V36, P481, DOI 10.1097/PAS.0b013e31824433d8; Sun J, 2012, AM J CLIN PATHOL, V138, P429, DOI 10.1309/AJCP7YLTQPUSDQ5C; Suzuki R, 2010, ANN ONCOL, V21, P1032, DOI 10.1093/annonc/mdp418; Suzuki R, 2014, SEMIN HEMATOL, V51, P42, DOI 10.1053/j.seminhematol.2013.11.007; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Wang W. Y., 2008, CLIN ONCOL, V20, P619; William BM, 2013, BEST PRACT RES CL HA, V26, P23, DOI 10.1016/j.beha.2013.04.003; Yong WB, 2016, HEMATOL ONCOL, V34, P61, DOI 10.1002/hon.2207; Yu BH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161831; Zheng SM, 2012, ARCH IRAN MED, V15, P36, DOI 012151/AIM.0011	22	1	2	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1081	1086		10.1016/j.prp.2018.05.013			6	Pathology	Pathology	GR9QG	WOS:000443104700004	29853314				2019-10-28	
J	Lu, LH; Wang, SN; Zhu, Q; Qu, YQ; Gu, WY; Ning, Y; Chen, XC; Wang, YQ				Lu, Linghui; Wang, Shunni; Zhu, Qin; Qu, Yuqing; Gu, Weiyong; Ning, Yan; Chen, Xiaochen; Wang, Yiqin			The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes	PATHOLOGY RESEARCH AND PRACTICE			English	Article						IMP3; Napsin-A; HNF-1 beta; Ovarian clear cell carcinoma; Immunocytochemistry	HISTOLOGIC SUBTYPE; IGF2BP3 IMP3; CANCER; ADENOCARCINOMA; NAPSIN; TUMORS; PROGNOSIS; MARKER	The clear cell (CCC), high grade serous (HGSC) and endometrioid (EC) ovarian carcinomas share overlapping histological features. The oncogene IMP3 is implicated in CCC with an elusive utility in differential diagnosis. We collected 366 cases with ovarian primary carcinomas to detect IMP3, Napsin-A and HNF-1 beta by immunochemistry. In 351 cases, the positive expression rate of IMP3 in CCC was significantly higher than that either in EC or HGSC (p < 0.01). The sensitivity of IMP3 in CCC was higher than Napsin-A but lower than HNF-1 beta (p < 0.01). The specificity of IMP3 in CCC was lower than Napsin-A but higher than HNF-1 beta (p < 0.01). The composite markers Napsin-A+/IMP3+ and the IMP3+HNF-1 beta+/Napsin-A+ offered the highest odds ratio (p < 0.001), the highest specificity, the highest positive predictive value and the highest positive likelihood ratio. The ROC analysis showed that the combination of Napsin-A, HNF-1 beta and IMP3 offered the biggest AUC compared with either the singular marker performances or the other binary combinations (p < 0.001). In 15 cases of EC mixed with CCC, IMP3 showed a better discrimination value than the other two markers. Consequently, adding IMP3 to the diagnostic panel might provide some help with the pathological diagnosis of ovarian CCC.	[Lu, Linghui; Wang, Shunni; Zhu, Qin; Qu, Yuqing; Gu, Weiyong; Ning, Yan; Chen, Xiaochen; Wang, Yiqin] Fudan Univ, Dept Pathol, Obstet & Gynecol Hosp, 128 Shenyang Rd, Shanghai 200090, Peoples R China	Lu, LH; Wang, SN (reprint author), Fudan Univ, Dept Pathol, Obstet & Gynecol Hosp, 128 Shenyang Rd, Shanghai 200090, Peoples R China.; Wang, YQ (reprint author), Fudan Univ, Dept Pathol, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200011, Peoples R China.	474842034@qq.com; wangsn@126.com; zhuq1215@163.com; quyuqing0707@126.com; gwyljf@163.com; yanningkxy@163.com; happychen917@163.com; yiqinwang11@icloud.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602269]	This study was supported by a grant from the National Natural Science Foundation of China (81602269).	Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552; Bhargava S, 2017, ONCOTARGET, V8, P40469, DOI 10.18632/oncotarget.17118; Bi R, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0467-5; Chen LY, 2017, ONCOTARGETS THER, V10, P2849, DOI 10.2147/OTT.S128810; Chiste M, 2014, APPL IMMUNOHISTO M M, V22, P658, DOI 10.1097/PAI.0000000000000021; Coburn SB, 2017, INT J CANCER, V140, P2451, DOI 10.1002/ijc.30676; Denel-Bobrowska M, 2016, Asian Pac J Cancer Prev, V17, P4223; El-Balat A, 2017, ANTICANCER RES, V37, P583, DOI 10.21873/anticanres.11351; Fadare O, 2015, PATHOLOGY, V47, P105, DOI 10.1097/PAT.0000000000000223; Fadare O, 2013, HUM PATHOL, V44, P1508, DOI 10.1016/j.humpath.2012.12.003; Han G, 2008, AM J SURG PATHOL, V32, P955, DOI 10.1097/PAS.0b013e318164edf7; Hsu KF, 2015, BRIT J CANCER, V113, P414, DOI 10.1038/bjc.2015.254; Kobel M, 2014, AM J CLIN PATHOL, V142, P735, DOI 10.1309/AJCPAVGZKA1A1HVC; Kobel M, 2009, MODERN PATHOL, V22, P469, DOI 10.1038/modpathol.2008.206; Li Q, 2015, INT J CLIN EXP PATHO, V8, P8305; Liao B., 2008, J BIOL CHEM, V280, P18517; McCluggage WG, 2008, J CLIN PATHOL, V61, P152, DOI 10.1136/jcp.2007.049478; McCluggage WG, 2011, PATHOLOGY, V43, P420, DOI 10.1097/PAT.0b013e328348a6e7; Mhawech-Fauceglia P, 2013, HISTOPATHOLOGY, V62, P976, DOI 10.1111/his.12096; Mhawech-Fauceglia P, 2010, AM J CLIN PATHOL, V133, P899, DOI 10.1309/AJCPQDQXJ4FNRFQB; Ohler Aleksandra, 2015, Ginekol Pol, V86, P574; Pei XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124338; Samanta S, 2016, ONCOGENE, V35, P1111, DOI 10.1038/onc.2015.164; Schmiedel D, 2016, ELIFE, V5, DOI 10.7554/eLife.13426; Silva EG, 2007, AM J SURG PATHOL, V31, P1203, DOI 10.1097/PAS.0b013e3180339ed7; Soslow RA, 2008, INT J GYNECOL PATHOL, V27, P161, DOI 10.1097/PGP.0b013e31815ea812; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wang YY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0060-2; Wentzensen N, 2016, J CLIN ONCOL, V34, P2888, DOI 10.1200/JCO.2016.66.8178; Wu R, 2013, AM J PATHOL, V182, P1391, DOI 10.1016/j.ajpath.2012.12.031; Yamashita Y, 2015, MODERN PATHOL, V28, P111, DOI 10.1038/modpathol.2014.61; Yan JH, 2016, LUNG, V194, P137, DOI 10.1007/s00408-015-9829-0; Zheng WX, 2008, AM J SURG PATHOL, V32, P304, DOI 10.1097/PAS.0b013e3181483ff8	33	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1087	1094		10.1016/j.prp.2018.05.026			8	Pathology	Pathology	GR9QG	WOS:000443104700005	29866423	Other Gold			2019-10-28	
J	Pei, XF; Cao, LL; Huang, F; Qiao, X; Yu, J; Ye, H; Xi, CL; Zhou, QC; Zhang, GF; Gong, ZL				Pei, Xu-Feng; Cao, Long-Lei; Huang, Fang; Qiao, Xu; Yu, Jie; Ye, Hui; Xi, Chang-Lei; Zhou, Qi-Chang; Zhang, Guo-Fei; Gong, Zhi-Lin			Role of miR-22 in intestinal mucosa tissues and peripheral blood CD4+T cells of inflammatory bowel disease	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MiR-22; Inflammatory bowel disease; Intestinal mucosa tissue; CD4+T cells; Th17	T-CELLS; TH17 CELLS; UP-REGULATION; EXPRESSION; CYTOKINES; HDAC4; DIFFERENTIATION; HYPERTROPHY; MICRORNA-21; ARTHRITIS	Objective: miR-22 is known to be involved in the pathogenesis of several autoimmune diseases, but it remains unclear whether miR-22 is associated with inflammatory intestinal disease (IBD). Methods: The patients with ulcerative colitis (UC) and Crohn's disease (CD) were enrolled in this study. After the CD4+ T cells from healthy controls and active IBD patients were isolated and then transfected with miR-22 mimics/inhibitors, Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to measure expressions of miR-22, HDAC4, specific transcription factors in intestinal mucosa tissue and CD4+ T cells, while enzyme-linked immuno sorbent assay (ELISA) to detect expressions of inflammatory cytokines in PB. Antisense miR-22 was administered into mice during trinitrobenzene sulphoni cacid (TNBS)-induced colitis to determine its role in IBD. Results: A significant elevation of miR-22 but an evident decrease of HDAC4 was found in CD4+ T cells in PB and intestinal mucosa tissues from IBD patients. In addition, there was a great reduction in HDAC4 and a dramatic enhancement in Th17 cell specific transcription factor (RORC) and inflammatory cytokines (IL-17A, IL-6 and TNF-alpha) after overexpression miR-22, which was opposite to the effect of inhibition of miR-22. Furthermore, administration of antisense miR-22 in TNBS-induced mouse colitis model significantly decreased numbers of interleukin (IL)-17A+ CD4+ T cells and the expressions of IL-17A, RORC, IL-6 and TNF-alpha. Conclusion: MiR-22 was up-regulated in CD4+ T cells in PB and intestinal mucosa tissues of IBD patients, which could promote Th17 cell differentiation via targeting HDAC4 to be involved in IBD progression.	[Pei, Xu-Feng] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Emergency Surg, Jingzhou 434020, Peoples R China; [Cao, Long-Lei; Yu, Jie; Ye, Hui; Xi, Chang-Lei; Zhou, Qi-Chang; Gong, Zhi-Lin] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Anal Colorectal Surg, Renmin Rd 1, Jingzhou 434020, Peoples R China; [Huang, Fang] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Gynaecol & Obstet, Renmin Rd 1, Jingzhou 434020, Peoples R China; [Qiao, Xu] Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Gastroenterol, Renmin Rd 1, Jingzhou 434020, Peoples R China; [Zhang, Guo-Fei] Gongan Cty Peoples Hosp Hubei Prov, Dept Gastrointestinal Surg, Wuhan 434020, Hubei, Peoples R China	Gong, ZL (reprint author), Yangtze Univ, Clin Med Coll 2, Jingzhou Cent Hosp, Dept Anal Colorectal Surg, Renmin Rd 1, Jingzhou 434020, Peoples R China.	gong_zhilin@sina.com					Abraham C, 2009, INFLAMM BOWEL DIS, V15, P1090, DOI 10.1002/ibd.20894; Brustle A, 2012, J CLIN INVEST, V122, P4698, DOI 10.1172/JCI63528; Caruso R, 2007, GASTROENTEROLOGY, V132, P166, DOI 10.1053/j.gastro.2006.09.053; Chen Z, 2008, IMMUNOL RES, V41, P87, DOI 10.1007/s12026-007-8014-9; Crome SQ, 2010, CLIN EXP IMMUNOL, V159, P109, DOI 10.1111/j.1365-2249.2009.04037.x; D'Inca R, 2008, AM J GASTROENTEROL, V103, P2007, DOI 10.1111/j.1572-0241.2008.01870.x; da Silva JC, 2013, CLINICS, V68, P766, DOI 10.6061/clinics/2013(06)07; De Simone V, 2015, ONCOGENE, V34, P3493, DOI 10.1038/onc.2014.286; Fan H, 2012, CHIN J INTEGR MED, V18, P514, DOI 10.1007/s11655-012-1146-3; Fasseu M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013160; Feuerstein JD, 2017, DIGEST DIS SCI, V62, P352, DOI 10.1007/s10620-016-4394-9; Ghosh Subrata, 2010, Therap Adv Gastroenterol, V3, P239, DOI 10.1177/1756283X10373176; Gurha P, 2012, CIRCULATION, V125, P2751, DOI 10.1161/CIRCULATIONAHA.111.044354; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; He C, 2016, GUT, V65, P1938, DOI 10.1136/gutjnl-2015-309389; Himmel ME, 2008, IMMUNOLOGY, V125, P145, DOI 10.1111/j.1365-2567.2008.02939.x; Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014; Huang ZP, 2014, TRENDS CARDIOVAS MED, V24, P267, DOI 10.1016/j.tcm.2014.07.005; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Liu YH, 2014, NEUROCHEM RES, V39, P2105, DOI 10.1007/s11064-014-1401-4; Lu W, 2015, NAT IMMUNOL, V16, P1185, DOI 10.1038/ni.3292; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Mondal A, 2010, J IMMUNOL, V184, P4123, DOI 10.4049/jimmunol.0901242; Muthuswamy Vasantha, 2014, Indian J Med Ethics, V11, P2; Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060; Paraskevi A, 2012, J CROHNS COLITIS, V6, P900, DOI 10.1016/j.crohns.2012.02.006; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Rocchi A, 2012, CAN J GASTROENTEROL, V26, P811, DOI 10.1155/2012/984575; Sanders VM, 2002, BRAIN BEHAV IMMUN, V16, P290, DOI 10.1006/brbi.2001.0639; Serre K, 2010, MOL IMMUNOL, V47, P1914, DOI 10.1016/j.molimm.2010.03.010; Sethi Apoorva, 2013, Frontiers in Genetics, V4, P8, DOI 10.3389/fgene.2013.00008; Soboslay PT, 1999, IMMUNOLOGY, V97, P219, DOI 10.1046/j.1365-2567.1999.00018.x; Tu YF, 2014, EUR J NUCL MED MOL I, V41, P972, DOI 10.1007/s00259-013-2596-3; Usui T, 2012, AM J PHYSIOL-HEART C, V302, pH1894, DOI 10.1152/ajpheart.01039.2011; Wu F, 2014, INFLAMM BOWEL DIS, V20, P1972, DOI 10.1097/MIB.0000000000000201; Wu F, 2010, INFLAMM BOWEL DIS, V16, P1729, DOI 10.1002/ibd.21267; Xu XD, 2012, J CELL PHYSIOL, V227, P1391, DOI 10.1002/jcp.22852; Yoshiga Y, 2008, INT J MOL MED, V22, P369, DOI 10.3892/ijmm_00000032; Zenewicz LA, 2009, TRENDS MOL MED, V15, P199, DOI 10.1016/j.molmed.2009.03.002	39	2	2	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1095	1104		10.1016/j.prp.2018.04.009			10	Pathology	Pathology	GR9QG	WOS:000443104700006	29880327				2019-10-28	
J	Zhang, XW; Zhou, TT; Li, WB; Zhang, TT; Che, NW; Zu, G				Zhang, Xiangwen; Zhou, Tingting; Li, Wenbin; Zhang, Taotao; Che, Ninwei; Zu, Guo			Clinicopathological and prognostic significance of C/EBP homologous protein (CHOP) in advanced gastric cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Clinicopathological parameters; Prognosis; C/EBP homologous protein; Gastric cancer	ENDOPLASMIC-RETICULUM STRESS; DOWN-REGULATION; DEATH RECEPTOR; ER STRESS; APOPTOSIS; CELLS; EXPRESSION; SURVIVAL; DISEASE; MARKER	Background: Few studies have reported the clinical and prognostic significance of C/EBP homologous protein (CHOP) in advanced gastric cancer (GC). Therefore, the present study investigated the expression of CHOP in advanced GC patients to determine its potential prognostic role. Methods: The levels of CHOP in 95 patients with advanced GC and adjacent non-cancerous tissues were evaluated by qRT-PCR, western blot and immunohistochemistry. Furthermore, the association of CHOP expression with clinicopathological parameters and prognosis of advanced GC patients was analyzed. Results: The levels of CHOP were down-regulated in advanced GC compared with non-cancerous tissues (P < 0.01). In addition, high CHOP expression more frequently occurred in advanced GC tissues with depth of invasion of T1-2 (P < 0.01), lower clinical stage (TNM I-II stage) (P < 0.05) and without lymph node metastasis (P < 0.05). No significant difference was observed between the expression of CHOP and age, gender, tumor size, lesion site and differentiation (P > 0.05). The Kaplan-Meier survival analyses showed that the overall survival rate of advanced GC patients with positive CHOP expression was significantly higher than that of patients with negative CHOP expression (P < 0.01). Univariate and multivariate Cox proportional hazards models revealed that low CHOP expression (OR = 0.314, 95%CI: 0.176 similar to 0.794, P = 0.003) was an independent factor for poor overall survival in advanced GC patients. Conclusion: Low expression of CHOP predicts the poor prognosis of advanced GC patients, and CHOP may be a prognostic biomarker for patients with advanced GC.	[Zhang, Xiangwen; Li, Wenbin; Zhang, Taotao; Zu, Guo] Dalian Med Univ, Dalian Municipal Cent Hosp, Dept Gastroenterol Surg, Dalian 116044, Peoples R China; [Zhou, Tingting] Dalian Med Univ, Affiliated Hosp 1, Dept Neurol, Dalian 116011, Peoples R China; [Che, Ninwei] Dalian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Dalian 116027, Peoples R China	Zu, G (reprint author), Dalian Med Univ, Dalian Municipal Cent Hosp, Dept Gastroenterol Surg, 826 Southwest Rd Shahekou Dist, Dalian 116033, Peoples R China.	zushanghai@163.com			Medical Scientific Research Projects of Dalian [1811017]	This work was supported by the Medical Scientific Research Projects of Dalian (grant number 1811017).	Dai CS, 2014, ANTIMICROB AGENTS CH, V58, P4075, DOI 10.1128/AAC.00070-14; Dalton LE, 2013, BRIT J CANCER, V108, P1340, DOI 10.1038/bjc.2013.66; Gu YH, 2017, ENVIRON TOXICOL PHAR, V49, P194, DOI 10.1016/j.etap.2017.01.003; Guo FJ, 2012, HISTOCHEM CELL BIOL, V138, P447, DOI 10.1007/s00418-012-0967-7; Guo J, 2015, CLIN TRANSL ONCOL, V17, P788, DOI 10.1007/s12094-015-1305-z; Huang ZL, 2017, ONCOL REP, V37, P3093, DOI 10.3892/or.2017.5568; Jakobsen CH, 2008, J LIPID RES, V49, P2089, DOI 10.1194/jlr.M700389-JLR200; Jung KJ, 2015, ONCOTARGET, V6, P1556, DOI 10.18632/oncotarget.2727; Kang JH, 2012, J BIOL CHEM, V287, P15661, DOI 10.1074/jbc.M112.358473; Kumara MHSR, 2016, ONCOL REP, V36, P2268, DOI 10.3892/or.2016.5038; Lee YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081540; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Matsuo K, 2013, GYNECOL ONCOL, V128, P552, DOI 10.1016/j.ygyno.2012.11.024; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Russo A., 2015, ONCOTARGET, V7, P79670; Russo A, 2016, SCI REP-UK, V6, DOI 10.1038/srep38369; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Xu YY, 2012, HEPATO-GASTROENTEROL, V59, P2377, DOI 10.5754/hge12369; Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219; Yuan SB, 2016, ONCOTARGET, V7, P65295, DOI 10.18632/oncotarget.11321; Zhang R, 2012, INT J BIOCHEM CELL B, V44, P224, DOI 10.1016/j.biocel.2011.10.019; Zheng YZ, 2014, BREAST CANCER RES TR, V145, P349, DOI 10.1007/s10549-014-2967-x; Zhu XJ, 2015, CLIN RES HEPATOL GAS, V39, P391, DOI 10.1016/j.clinre.2014.11.010	26	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1105	1109		10.1016/j.prp.2018.06.005			5	Pathology	Pathology	GR9QG	WOS:000443104700007	29910063				2019-10-28	
J	Ma, RQ; Tang, ZJ; Sun, KK; Ye, X; Cheng, HY; Chang, XH; Cui, H				Ma, Ruiqiong; Tang, Zhijian; Sun, Kunkun; Ye, Xue; Cheng, Hongyan; Chang, Xiaohong; Cui, Heng			Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Epithelial ovarian cancer; ADAM23; Survival; Prognostic marker	PROMOTER HYPERMETHYLATION; CELL PROLIFERATION; CARCINOMA-CELLS; LUNG-CARCINOMA; METHYLATION; TUMOR; METASTASIS; METALLOPROTEINASES; DISINTEGRIN; PROTEINS	Background: ADAM23, a member of the disintegrin and metalloprotease (ADAM) family, has been reported to be expressed in several types of tumours. Nevertheless, the exact role of ADAM23 in epithelial ovarian cancer (EOC) remains unclear. The aim of this study was to investigate ADAM23 expression in EOC and evaluate its clinicopathological and prognostic significance. Methods: Immunohistochemistry (IHC), western blot and real-time PCR (RT-PCR) were used to analyse ADAM23 expression in 133 EOC, 42 benign ovarian tumour and 35 healthy control samples. Moreover, we evaluated the expression of ADAM23 in both public database (Oncomine and Kaplan-Meier plotter). The association between ADAM23 expression and various clinicopathological parameters was analysed. Results: The levels of ADAM23 mRNA and protein expression were significantly lower in EOC tissues than in corresponding control tissues and benign ovarian tumours, verifying results from the Oncomine databases. The loss of ADAM23 expression was significantly correlated with an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis. The IHC data in the EOC samples correlated with the RT-PCR data. Furthermore, patients with low ADAM23 expression had shorter progression-free survival (PFS) and overall survival (OS) than patients with high ADAM23 expression. The multivariate analysis indicated that ADAM23 was an independent predictor in patients with EOC. Conclusions: Our results demonstrate that ADAM23 expression is likely involved in the progression of EOC and may provide potential diagnostic and prognostic information regarding EOC.	[Ma, Ruiqiong; Tang, Zhijian; Ye, Xue; Cheng, Hongyan; Chang, Xiaohong; Cui, Heng] Peking Univ, Gynaecol Oncol Ctr, Peoples Hosp, 11 Xizhimen Nan Rd, Beijing 100044, Peoples R China; [Sun, Kunkun] Peking Univ, Peoples Hosp, Dept Pathol, 11 Xizhimen Nan Rd, Beijing 100044, Peoples R China	Chang, XH; Cui, H (reprint author), Peking Univ, Gynaecol Oncol Ctr, Peoples Hosp, 11 Xizhimen Nan Rd, Beijing 100044, Peoples R China.	changxiaohong@pkuph.edu.cn; cuih2014@126.com			National Key Research and Development Programme of China [2016YFA0201400]; National Key Technology RD ProgramNational Key Technology R&D Program [2015BAI13B06]	This work was financially supported by the National Key Research and Development Programme of China (Grant No. 2016YFA0201400) and the National Key Technology R&D Program (Grant No. 2015BAI13B06).	Benarroch EE, 2012, NEUROLOGY, V78, P914, DOI 10.1212/WNL.0b013e31824c4728; Bret C, 2011, EXP HEMATOL, V39, P546, DOI 10.1016/j.exphem.2011.02.002; Cabral J, 2016, J LEUKOCYTE BIOL, V100, P838, DOI 10.1189/jlb.2CE0616-266R; Calmon MF, 2007, CANCER GENET CYTOGEN, V173, P31, DOI 10.1016/j.cancergencyto.2006.09.008; Choi JS, 2009, INT J CANCER, V124, P1258, DOI 10.1002/ijc.24023; Costa ET, 2015, ONCOGENE, V34, P1270, DOI 10.1038/onc.2014.70; Costa FF, 2005, NEUROSCI LETT, V380, P260, DOI 10.1016/j.neulet.2005.01.050; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Costa MDM, 2009, NEUROSCI LETT, V461, P16, DOI 10.1016/j.neulet.2009.05.049; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Elizondo DM, 2016, J LEUKOCYTE BIOL, V100, P855, DOI 10.1189/jlb.2HI1115-525R; Fridrichova I, 2015, TRANSL RES, V165, P717, DOI 10.1016/j.trsl.2014.12.006; Conceicao ALG, 2015, J CANCER, V6, P593, DOI 10.7150/jca.11238; Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783; Hu CY, 2011, INT J EXP PATHOL, V92, P333, DOI 10.1111/j.1365-2613.2011.00766.x; Lin JT, 2013, DEV GROWTH DIFFER, V55, P368, DOI 10.1111/dgd.12051; Lin JT, 2011, DEV DYNAM, V240, P2142, DOI 10.1002/dvdy.22703; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Ota M, 2016, CANCER SCI, V107, P433, DOI 10.1111/cas.12895; Pan QH, 2010, BIOCHEM BIOPH RES CO, V401, P306, DOI 10.1016/j.bbrc.2010.09.058; Prisco MG, 2012, HUM PATHOL, V43, P282, DOI 10.1016/j.humpath.2011.05.002; Sagane K, 1998, BIOCHEM J, V334, P93, DOI 10.1042/bj3340093; Shiomi T, 2010, PATHOL INT, V60, P477, DOI 10.1111/j.1440-1827.2010.02547.x; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Verbisck NV, 2009, CANCER RES, V69, P5546, DOI 10.1158/0008-5472.CAN-08-2976; Wang YM, 2012, CELL BIOL INT, V36, P1275, DOI 10.1042/CBI20120154; Yamanoi K, 2015, CARCINOGENESIS, V36, P509, DOI 10.1093/carcin/bgv013; Zhou SY, 2013, GYNECOL ONCOL, V131, P69, DOI 10.1016/j.ygyno.2013.06.031	29	2	2	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1115	1122		10.1016/j.prp.2018.06.007			8	Pathology	Pathology	GR9QG	WOS:000443104700009	29921495				2019-10-28	
J	Peng, XL; Liu, Y; Peng, X; Wang, ZM; Zhang, Z; Qiu, YL; Jin, MH; Wang, R; Kong, DX				Peng, Xiaolin; Liu, Yao; Peng, Xin; Wang, Zhengming; Zhang, Zhe; Qiu, Yuling; Jin, Meihua; Wang, Ran; Kong, Dexin			Clinical features and the molecular biomarkers of olfactory neuroblastoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Olfactory neuroblastoma; Clinical feature; Akt; Erk; Stat3	SIGNALING PATHWAY; CANCER; ESTHESIONEUROBLASTOMA; EXPERIENCE; EXPRESSION; PROGNOSIS	Olfactory neuroblastoma (ONB) is a kind of rare and complex head and neck tumor. The reports on this field are very scarce due to the low morbidity. Here, we summarized the clinical features and prognosis of ONB through analysis of 10 cases, and determined the phosphorylation status of some molecules known to be involved in carcinogesis such as Akt, Erk, Stat3 and Stat5 in ONB tissue. Ten ONB patients were recruited in this study, 6 male and 4 female, ranging from 26 to 66 years old. In the 10 cases, 6 were diagnosed as late T stage (T-3/T-4), 6 were at late Kadish stage (C/D) and 3 were at high Hyams grade (III), which indicated a poorer prognosis. Patient characteristics gender and tumor features were evaluated with respect to the overall survival (OS) through univariate analysis. The result indicated that the OS of male is obviously higher than that of female after a series of combined treatment. The OS of ONB patients in the late stage or high grade is lower than those in early stages or low grade. Moreover, p-Akt, p-Erk, p-Stat3 and p-Stat5 was detected in 5 (50%), 9 (90%), 7 (70%) and 0 patients (0%), respectively, suggesting the former 3 molecules might be potential biomarkers for diagnosis of ONB.	[Peng, Xiaolin; Liu, Yao; Peng, Xin; Wang, Zhengming; Zhang, Zhe; Qiu, Yuling; Jin, Meihua; Wang, Ran; Kong, Dexin] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China; [Kong, Dexin] Tianjin Med Univ, Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China; [Peng, Xiaolin] Tianjin First Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tianjin 300192, Peoples R China	Wang, R; Kong, DX (reprint author), Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.	wangran@tmu.edu.cn; kongdexin@tmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81373441, 81673464, 81402901]	This work was supported by grants from National Natural Science Foundation of China (81373441, 81673464 and 81402901).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Alvarez JV, 2006, CANCER RES, V66, P3162, DOI 10.1158/0008-5472.CAN-05-3757; Berger L., 1924, FRANC ETUDE CANCER, V13, P410; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Constantinidis J, 2004, OTOLARYNG HEAD NECK, V130, P567, DOI 10.1016/j.otohns.2003.10.010; Diaz EM, 2005, HEAD NECK-J SCI SPEC, V27, P138, DOI 10.1002/hed.20127; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DULGUEROV P, 1992, LARYNGOSCOPE, V102, P843, DOI 10.1288/00005537-199208000-00001; FOOTE RL, 1993, INT J RADIAT ONCOL, V27, P835, DOI 10.1016/0360-3016(93)90457-7; Fujimori Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-30; Hyams VJ, 1988, ATLAS TUMOR PATHOL, P240; Jethanamest D, 2007, ARCH OTOLARYNGOL, V133, P276, DOI 10.1001/archotol.133.3.276; Jiang GY, 2011, OTOLARYNG HEAD NECK, V145, P951, DOI 10.1177/0194599811416752; KADISH S, 1976, CANCER, V37, P1571, DOI 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008; Li M, 2012, ONCOL LETT, V4, P1213, DOI 10.3892/ol.2012.930; Liu ZF, 2012, J CELL BIOCHEM, V113, P1080, DOI 10.1002/jcb.23440; Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2; McCain Jack, 2013, P T, V38, P96; Resto VA, 2000, HEAD NECK-J SCI SPEC, V22, P550, DOI 10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0; Sangawa A, 2014, INT J CLIN EXP PATHO, V7, P3312; Sebolt-Leopold JS, 2008, CLIN CANCER RES, V14, P3651, DOI 10.1158/1078-0432.CCR-08-0333; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005; Sukawa Y, 2012, WORLD J GASTROENTERO, V18, P6577, DOI 10.3748/wjg.v18.i45.6577; Thompson LDR, 2009, HEAD NECK PATHOL, V3, P252, DOI 10.1007/s12105-009-0125-2; Wang YC, 2016, ONCOTARGET, V7, P19897, DOI 10.18632/oncotarget.7658; Wu M, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-36; Yu GZ, 2009, CLIN CANCER RES, V15, P1821, DOI 10.1158/1078-0432.CCR-08-2138; Yumusakhuylu AC, 2013, J CRANIOFAC SURG, V24, P2189, DOI 10.1097/SCS.0b013e3182a41c52; Zafereo ME, 2008, OTOLARYNG HEAD NECK, V138, P452, DOI 10.1016/j.otohns.2007.12.038; Zhang LY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166046	35	2	2	1	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1123	1129		10.1016/j.prp.2018.06.002			7	Pathology	Pathology	GR9QG	WOS:000443104700010	29921494				2019-10-28	
J	Dai, HY; Ma, Y; Zhao, D; Hou, XM				Dai, Huan-yu; Ma, Yan; Zhao, Da; Hou, Xiao-ming			Knockdown of TRIM66 inhibits malignant behavior and epithelial-mesenchymal transition in non-small cell lung cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						NSCLC; TRIM66; EMT; Malignant phenotype	CARCINOGENESIS; TRANSCRIPTION; STATISTICS; EXPRESSION; INVASION	Objective: The tripartite motif 66(TRIM66) is an important member of the TRIM protein superfamily, which can participate in the expression of multiple proteins, and is closely associated with the behaviors of non-small cell lung cancer (NSCLC). In this study, we aimed to explore the effect of TRIM66 in this process in vitro using NSCLC cell lines, and the role of TRIM66 in regulating epithelial-mesenchymal transition(EMT) in NSCLC. Methods: Western blotting was used to detect the TRIM66 protein expression levels in NSCLC cell lines and normal lung epithelial cells BEAS-2B. We silenced its expression in A549 cells by transient siRNA transfection to ascertain the function of TRIM66 in NSCLC cells. Western blotting was used to detect the expression of EMT related proteins. Results: TRIM66 protein content was highest in NSCLC cell line A549, compared with BEAS-2B, it showed that the TRIM66-siRNA group lung cancer cell proliferation was significantly reduced after knockdown of TRIM66, and knockdown of TRIM66 also suppressed invasion, migration and clonogenic ability of A549 cells. Finally, we found that siRNA-mediated TRIM66 silencing suppressed EMT by downregulating expression of N-cadherin and vimentin and upregulating that of E-cadherin in NSCLC cells, which could effectively reduce the invasive, migratory, and proliferative capacities of lung cancer cells. Conclusion: Silence TRIM66 expression suppressed NSCLC cell proliferation, invasion, and migration. The siRNA-mediated TRIM66 silencing could block the occurrence of EMT. TRIM66 could be a promising novel target for future NSCLC treatments.	[Dai, Huan-yu; Zhao, Da; Hou, Xiao-ming] Lanzhou Univ, Dept Oncol, Hosp 1, Lanzhou, Gansu, Peoples R China; [Ma, Yan; Zhao, Da; Hou, Xiao-ming] Lanzhou Univ, Hosp 1, Dept Radiat Oncol, Lanzhou, Gansu, Peoples R China	Hou, XM (reprint author), 1 Donggang West Rd, Lanzhou, Gansu, Peoples R China.	houxiaoming19@163.com					Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77; Chambon M, 2011, AM J PATHOL, V178, P1461, DOI 10.1016/j.ajpath.2010.12.026; Chen Y, 2015, ONCOTARGET, V6, P23708, DOI 10.18632/oncotarget.4291; Esposito D, 2017, BIOCHEM SOC T, V45, P183, DOI 10.1042/BST20160325; Jiang SM, 2015, J HEPATOL, V62, P371, DOI 10.1016/j.jhep.2014.09.026; Liu CX, 2015, THORAC CANCER, V6, P31, DOI 10.1111/1759-7714.12130; Ma Y, 2017, CANCER BIOMARK, V20, P309, DOI 10.3233/CBM-170207; Miyajima N, 2008, CANCER RES, V68, P3486, DOI 10.1158/0008-5472.CAN-07-6059; Nakashima H, 2012, MOL CARCINOGEN, V51, P400, DOI 10.1002/mc.20802; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Qin Y, 2016, TECHNOL CANCER RES T, V15, P707, DOI 10.1177/1533034615595903; Selek U, 2014, BALK MED J, V31, P286, DOI 10.5152/balkanmedj.2014.14529; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Song XM, 2015, ONCOL LETT, V10, P2283, DOI 10.3892/ol.2015.3623; Thomson S, 2011, CLIN EXP METASTAS, V28, P137, DOI 10.1007/s10585-010-9367-3; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zaman MMU, 2013, MOL CELL BIOL, V33, P4971, DOI 10.1128/MCB.00465-13; Zhan WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142596	21	4	4	1	5	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1130	1135		10.1016/j.prp.2018.06.008			6	Pathology	Pathology	GR9QG	WOS:000443104700011	29929749				2019-10-28	
J	Bosmuller, H; Pfefferle, V; Bittar, Z; Scheble, V; Horger, M; Sipos, B; Fend, F				Boesmueller, Hans; Pfefferle, Vanessa; Bittar, Zeid; Scheble, Veit; Horger, Marius; Sipos, Bence; Fend, Falko			Microvessel density and angiogenesis in primary hepatic malignancies: hock for Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Microvessel density; Hepatocellular carcinoma; Intrahepatic cholangiocellular carcinoma; VEGFR-2; CD31; Hypovascular; Hypervascular	CIRRHOSIS; NODULES; CT	Background: Microvessel density is an indicator of tumor-driven neoangiogenesis. Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have distinct vascular patterns, which are also reflected in their imaging characteristics. Since a significant proportion of HCC are treated without biopsy confirmation, it is essential to discriminate HCC and ICC radiologically. The aim of our study was therefore to compare microvessel density and expression of VEGFR-2 in HCC and ICC, since these data may ultimately help us to better understand their imaging characteristics. Whereas CD31 documents vessel density, VEGFR-2 expression is an indicator of tumor-related neoangiogenesis. Methods: CD31 and VEGFR-2 expressing microvessels were quantified on tissue microarrays of 95 resection specimens of HCC and 47 cases of ICC. Microvessel density was evaluated by counting immuno-reactive vascular structures both within the tumor and adjacent liver control tissue, respectively. Further 16 cases of ICC were immunostained for CD31 and VEGFR-2 on full sections. Results: The frequency of VEGFR-2 (46.2/HPF; range 0-150) and CD31 (61.2/HPF; range 2.6-140) expressing vascular structures was significantly increased in HCC compared to adjacent liver parenchyma (VEGFR-2 33.3/ HPF, range 0-87, CD31 21.4/HPF, range 0-78, both p < 0,001). ICC revealed significantly less VEGFR2-positive microvessels (15.4/HPF; range 2-77) compared to matched control tissue (42.3/HPF; range 4.6-109), whereas microvessel density with CD31 was comparable between ICC and adjacent liver (32.1/HPF; range 5.3-78 versus 28.0/HPF; range 5.3-57; p = 0.89). In ICC, the tumor-to-normal microvessel density ratio was 0.38 for VEGFR-2 and 1.24 for CD31. These ratios were nearly identical (VEGFR: 0.38; CD31: 0,97) for the 16 cases of ICC studied on whole sections, confirming the validity of the TMA approach. In contrast, ratios of VEGFR-2 and CD31 in HCC vs. adjacent liver were significantly higher (VEGFR: 2.23; CD31: 6.57). Expression of VEGFR-2 by tumor cells was not observed in any of the cases. Conclusions: HCC and ICC differ significantly in their microvessel density, confirming the hypovascular nature of ICC as compared to the hypervascularity of HCC. Of note, inverse tumor-to-normal ratios of microvascular VEGFR-2 expression between the two neoplasms indicate distinct features of neoangiogenesis. Whether these differences can be exploited for improvements in imaging of hepatic tumors and may play a role for antiangiogenic treatment strategies requires further studies.	[Boesmueller, Hans; Pfefferle, Vanessa; Sipos, Bence; Fend, Falko] Univ Hosp Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany; [Boesmueller, Hans; Pfefferle, Vanessa; Sipos, Bence; Fend, Falko] Univ Hosp Tubingen, Comprehens Canc Ctr, Liebermeisterstr 8, D-72076 Tubingen, Germany; [Horger, Marius] Univ Hosp Tubingen, Dept Radiol, Tubingen, Germany; [Bittar, Zeid] Katharinenhosp Stuttgart, Dept Pathol, Stuttgart, Germany; [Scheble, Veit] Univ Hosp Tubingen, Dept Internal Med 1, Tubingen, Germany	Bosmuller, H (reprint author), Univ Hosp Tubingen, Inst Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany.; Bosmuller, H (reprint author), Univ Hosp Tubingen, Comprehens Canc Ctr, Liebermeisterstr 8, D-72076 Tubingen, Germany.	hans.boesmueller@med.uni-tuebingen.de; vanessa.pfefferle@student.uni-tuebingen.de; z.bittar@klinikum-stuttgart.de; veit.scheble@med.uni-tuebingen.de; marius.horger@med.uni-tuebingen.de; bence.sipos@med.uni-tuebingen.de; falko.fend@med.uni-tuebingen.de					Agni RM, 2017, SEMIN DIAGN PATHOL, V34, P126, DOI 10.1053/j.semdp.2016.12.008; Aishima S, 2009, HISTOPATHOLOGY, V54, P452, DOI 10.1111/j.1365-2559.2009.03240.x; Bunsiripaiboon Paisit, 2010, Journal of the Medical Association of Thailand, V93, P66; Fujita N, 2017, EUR RADIOL, V27, P498, DOI 10.1007/s00330-016-4386-3; Hanna RF, 2008, RADIOGRAPHICS, V28, P747, DOI 10.1148/rg.283055108; Huang JF, 2011, J CLIN PATHOL, V64, P343, DOI 10.1136/jcp.2010.085142; Mar WA, 2016, ABDOM RADIOL, V41, P553, DOI 10.1007/s00261-015-0583-9; Mobius C, 2007, EJSO-EUR J SURG ONC, V33, P1025, DOI 10.1016/j.ejso.2007.02.020; Ning SL, 2013, J GASTROINTEST SURG, V17, P360, DOI 10.1007/s11605-012-2105-1; Peng S, 2014, HEPATOLOGY, V60, P1264, DOI 10.1002/hep.27236; Rimola J, 2009, HEPATOLOGY, V50, P791, DOI 10.1002/hep.23071; Shimizu D, 2017, ONCOL REP, V37, P2527, DOI 10.3892/or.2017.5541; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Thaiss WM, 2016, EUR J RADIOL, V85, P2036, DOI 10.1016/j.ejrad.2016.09.012; Thelen A, 2008, J GASTROENTEROL, V43, P959, DOI 10.1007/s00535-008-2255-9; Xu J, 2012, LIVER INT, V32, P1156, DOI 10.1111/j.1478-3231.2012.02783.x; Yang ZF, 2008, ANAT REC, V291, P721, DOI 10.1002/ar.20668	17	3	3	3	10	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1136	1141		10.1016/j.prp.2018.06.011			6	Pathology	Pathology	GR9QG	WOS:000443104700012	29935812				2019-10-28	
J	Shi, XQ; Li, BJ; Yuan, YY; Chen, LYH; Zhang, YD; Yang, M; Wang, JJ; Qin, DC				Shi, Xiaoqing; Li, Bingjie; Yuan, Yingying; Chen, Liyinghui; Zhang, Yadi; Yang, Meng; Wang, Junjie; Qin, Dongchun			The possible association between the presence of an MPO-463 G > A (rs2333227) polymorphism and cervical cancer risk	PATHOLOGY RESEARCH AND PRACTICE			English	Article						MPO; Polymorphism; Cervical cancer risk; Susceptibility; Meta-analysis	MYELOPEROXIDASE GENE; HUMAN-PAPILLOMAVIRUS; MPO; DNA; METAANALYSIS; CONTAINS; WOMEN	Purpose: The association between myeloperoxidase (MPO) polymorphism and the risk of cervical cancer is inconclusive. We performed a meta-analysis to clarify if a correlation exists between MPO polymorphism and the risk for developing cervical cancer. Methods: All case-control research studies that determined a relationship between MPO and cervical cancer reported up until March 1, 2018 in PubMed, Web of Science, VIP, WanFang, and the CNKI Database were accessed and included. The strength of association was evaluated with pooled odds ratios (Oils) and their corresponding 95% confidence intervals (95% CIs). We used sensitivity analysis to detect the stability of our results, conducted Q-test to evaluate heterogeneity and applied Begg's funnel plot and Egger's test to investigate any publication bias among selected studies. Results: In this meta-analysis, we included 5 eligible studies in the final evaluation, which included 1125 patients with cervical cancer and 1150 cancer-free control patients. A potential association between the MPO -463 G > A polymorphism and cervical cancer risk was observed (recessive model: OR = 0.65, 95%, CI: 0.43-0.98, P = 0.038; homozygous model: OR = 0.65, 95%, CI: 0.43-0.99, P = 0.045), which indicates that genotype AA reduces the risk of cervical cancer by 35% compared to GG/GA or GG genotypes in our results. A stratified analysis by ethnicity identified a significant correlation among Caucasian patients (recessive model: OR = 0.57, 95%, CI: 0.34-0.95, P = 0.029; homozygous model: OR = 0.60, 95%, CI: 0.36-0.99, P = 0.048) and a stratified analysis by source of control identified a significant correlation among population-based studies. Conclusions: Our results suggest that the presence of polymorphism, -463 G > A in patients might offer them protection against cervical cancer. By implementing randomized case-control or cohort studies with larger sample sizes, the clinical significance of our results can be further strengthened and verified.	[Shi, Xiaoqing; Li, Bingjie; Yuan, Yingying; Qin, Dongchun] Zhengzhou Univ, Dept Clin Lab, Key Lab Lab Med Henan Prov, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China; [Chen, Liyinghui] Zhengzhou Univ, Dept Blood Transfus, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China; [Zhang, Yadi; Yang, Meng] Zhengzhou Univ, Clin Pharmacol Base, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China; [Wang, Junjie] Xinyang Huaibin Peoples Hosp, Dept Cardiovasc Med, Xinyang, Henan, Peoples R China	Qin, DC (reprint author), Zhengzhou Univ, Dept Clin Lab, Key Lab Lab Med Henan Prov, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.	qindongchunyfy@outlook.com			Scientific and Technological Project of Henan Province [172102310077]; Funds for Creative Research Team of Henan Province	This study was funded by grants from the Scientific and Technological Project of Henan Province (172102310077), Funds for Creative Research Team of Henan Province.	Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; Castelao C, 2015, MOL CELL BIOCHEM, V404, P1, DOI 10.1007/s11010-015-2359-5; Castellsague X, 2002, VIRUS RES, V89, P191, DOI 10.1016/S0168-1702(02)00188-0; CLARK RA, 1975, J EXP MED, V141, P1442, DOI 10.1084/jem.141.6.1442; CLARK RA, 1975, BLOOD, V45, P161; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dongol S, 2014, MOL CLIN ONCOL, V2, P71, DOI 10.3892/mco.2013.193; Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149; Hansson M, 2006, ARCH BIOCHEM BIOPHYS, V445, P214, DOI 10.1016/j.abb.2005.08.009; He CY, 2009, BREAST CANCER RES TR, V113, P585, DOI 10.1007/s10549-008-9962-z; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Khan MJ, 2005, JNCI-J NATL CANCER I, V97, P1072, DOI 10.1093/jnci/dji187; Klebanoff S. J., 2005, J LEUKOC BIOL, V77; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; MANTEL N, 1959, J NATL CANCER I, V22, P719; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; Mika Denish, 2011, J Exp Ther Oncol, V9, P93; Mustea A, 2007, ANTICANCER RES, V27, P1531; Natter C, 2016, ARCH GYNECOL OBSTET, V293, P865, DOI 10.1007/s00404-015-3869-9; NAUSEEF WM, 1989, BLOOD, V73, P290; Nishino K, 2008, J OBSTET GYNAECOL RE, V34, P994, DOI 10.1111/j.1447-0756.2008.00798.x; Ohnishi S, 2002, CANCER LETT, V178, P37, DOI 10.1016/S0304-3835(01)00812-6; Pero RW, 1996, CARCINOGENESIS, V17, P13, DOI 10.1093/carcin/17.1.13; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Reynolds WF, 2000, NEUROLOGY, V55, P1284, DOI 10.1212/WNL.55.9.1284; Reynolds WF, 1997, BLOOD, V90, P2730, DOI 10.1182/blood.V90.7.2730.2730_2730_2737; Roszak A, 2016, INT J BIOL MARKER, V31, pE440, DOI 10.5301/jbm.5000212; Rudolph V, 2009, FREE RADICAL BIO MED, V47, P1584, DOI 10.1016/j.freeradbiomed.2009.09.001; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; WHITEHEAD A, 1991, STAT MED, V10, P1665, DOI 10.1002/sim.4780101105; Whitlock EP, 2011, ANN INTERN MED, V155, P687, DOI 10.7326/0003-4819-155-10-201111150-00376; Winterbourn CC, 2000, FREE RADICAL BIO MED, V29, P403, DOI 10.1016/S0891-5849(00)00204-5; Wright Thomas C Jr, 2007, J Low Genit Tract Dis, V11, P223; Wu D, 2017, EUR J GYNAECOL ONCOL, V38, P756, DOI 10.12892/ejgo3662.2017; YAMADA M, 1984, J BIOL CHEM, V259, P3021; Yang WJ, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1183-7; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	39	0	0	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1142	1148		10.1016/j.prp.2018.05.018			7	Pathology	Pathology	GR9QG	WOS:000443104700013	29937309				2019-10-28	
J	Sabzevary-Ghahfarokhi, M; Shohan, M; Shirzad, H; Rahimian, G; Soltani, A; Ghatreh-Samani, M; Deris, F; Bagheri, N; Shafigh, M; Tahmasbi, K				Sabzevary-Ghahfarokhi, Milad; Shohan, Mojtaba; Shirzad, Hedayatollah; Rahimian, Ghorbanali; Soltani, Amin; Ghatreh-Samani, Mandi; Deris, Fatemeh; Bagheri, Nader; Shafigh, Mohammedhadi; Tahmasbi, Kamran			The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Oxidative stress; Ulcerative colitis; Nrf2; GST-A4; PRDX1	OXIDATIVE STRESS; INTESTINAL INFLAMMATION; ACTIVATOR PROTEIN-1; TH17 CELLS; MECHANISMS; PATHOGENESIS; INDUCE	Background: Reactive oxygen species (ROS) is one of the pathogenic factors responsible for intestinal injury in Ulcerative colitis (UC). Nuclear factor erythroid-2 related factor 2 (Nrf2) plays a critical role against ROS factors to conserve epithelial integrity. This study aimed to localize Nrf2 and IL-17A protein in the inflamed mucosa of patients with ulcerative colitis. The gene expression of Nrf2 was also correlated with GST-A4 and PRDX1. Materials and methods: A total of 20 patients and 20 healthy controls with definite UC based on the clinical criteria were enrolled for this study. The expression pattern of Nrf2 and IL-17A protein was compared in inflamed and non-inflamed colonic biopsies by immunohistochemical staining. Nrf2, GST-A4 and PRDX1 gene expression were determined by real-time polymerase chain reaction (RT-PCR). Results: In inflamed colonic biopsies, an increased level of Nrf2 protein factor was detected in epithelial cells. Conversely, IL-17A protein was presented more in mononuclear cells in mucosa and lamina propria regions. A significant increase of Nrf2, GST-A4 gene expression was observed in both mild and severe patients with ulcerative colitis. GST-A4 gene expression indicated a high exponential rate in logistic regression. Conclusion; Oxidative stress in inflamed colonic tissue can induce Nrf2 gene expression. The performance of Nrf2 transcription factor may lead to the induction of GST-A4 and PRDX1. IL-17A is less detected in intestinal inflammation, presenting Nrf2 factor. The present findings suggest that Nrf2 function in the gut plays a role in arresting both inflammatory response and oxidative damages of UC.	[Sabzevary-Ghahfarokhi, Milad; Shohan, Mojtaba; Ghatreh-Samani, Mandi; Bagheri, Nader] Shahrekord Univ Med Sci, Fac Med, Dept Microbiol & Immunol, Shahrekord, Iran; [Shirzad, Hedayatollah] Shahrekord Univ Med Sci, Basic Hlth Sci Inst, Cellular & Mol Res Ctr, Shahrekord, Iran; [Rahimian, Ghorbanali; Shafigh, Mohammedhadi] Shahrekord Univ Med Sci, Dept Internal Med, Shahrekord, Iran; [Soltani, Amin] Shahrekord Univ Med Sci, Basic Hlth Sci Inst, Med Plants Res Ctr, Shahrekord, Iran; [Deris, Fatemeh] Shahrekord Univ Med Sci, Sch Hlth, Dept Epidemiol & Biostat, Shahrekord, Iran; [Tahmasbi, Kamran] Shahrekord Univ Med Sci, Dept Pathol, Shahrekord, Iran	Shirzad, H (reprint author), Shahrekord Univ Med Sci, Basic Hlth Sci Inst, Cellular & Mol Res Ctr, Shahrekord, Iran.	shirzad1951@yahoo.com	Bagheri, Nader/V-1546-2017	Bagheri, Nader/0000-0001-5196-5513	Shahrekord University of Medical Sciences [1395-01-74-3214, 2337]	This study was financially supported by research deputy of Shahrekord University of Medical Sciences with research number: 1395-01-74-3214 and with grant-funded number 2337.	Ananthakrishnan AN, 2018, NAT REV GASTRO HEPAT, V15, P39, DOI 10.1038/nrgastro.2017.136; Awasthi YC, 2017, FREE RADICAL BIO MED, V111, P235, DOI 10.1016/j.freeradbiomed.2016.10.493; Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Cuadrado A, 2015, FREE RADICAL BIO MED, V88, P147, DOI 10.1016/j.freeradbiomed.2015.04.029; D'Ambrosio A, 2016, J CROHNS COLITIS, V10, P346, DOI 10.1093/ecco-jcc/jjv216; Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821; Foresti R, 2015, PHARMACOL RES, V99, P296, DOI 10.1016/j.phrs.2015.07.006; Gerstgrasser A, 2017, J CROHNS COLITIS, V11, P485, DOI 10.1093/ecco-jcc/jjw172; Hindryckx P, 2016, NAT REV GASTRO HEPAT, V13, P654, DOI 10.1038/nrgastro.2016.116; Hsieh SY, 2006, PROTEOMICS, V6, P5322, DOI 10.1002/pmic.200500541; Hundorfean G, 2012, INFLAMM BOWEL DIS, V18, P180, DOI 10.1002/ibd.21677; Jena G, 2012, FREE RADICAL RES, V46, P1339, DOI 10.3109/10715762.2012.717692; Keshavarzian A, 2003, GUT, V52, P720, DOI 10.1136/gut.52.5.720; Kim YJ, 2007, CANCER RES, V67, P546, DOI 10.1158/0008-5472.CAN-06-2401; Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624; Kruse ML, 2016, INFLAMM BOWEL DIS, V22, P2593, DOI 10.1097/MIB.0000000000000925; Leppkes M, 2009, GASTROENTEROLOGY, V136, P257, DOI 10.1053/j.gastro.2008.10.018; Lu MC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26585; Matsuura A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20538-3; Mercado N, 2011, BIOCHEM BIOPH RES CO, V406, P292, DOI 10.1016/j.bbrc.2011.02.035; Moriyama I, 2008, LAB INVEST, V88, P652, DOI 10.1038/labinvest.2008.38; Nassour H, 2016, SCI REP-UK, V6, DOI 10.1038/srep29389; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Pareek TK, 2011, SCI REP-UK, V1, DOI 10.1038/srep00201; Rhee S. G., 2011, REDOX SIGNAL, V15, P781, DOI [10.1089/ars.2010.3393, DOI 10.1089/ARS.2010.3393]; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; SCHROEDER KW, 1987, NEW ENGL J MED, V317, P1625, DOI 10.1056/NEJM198712243172603; Turner JR, 2006, AM J PATHOL, V169, P1901, DOI 10.2353/ajpath.2006.060681; Wang ZQ, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/9875298; Wu YZ, 2014, CANCER LETT, V345, P164, DOI 10.1016/j.canlet.2013.08.014; Yang Y, 2016, ONCOGENE, V35, P5795, DOI 10.1038/onc.2016.113; Zhang Z, 2006, INFLAMM BOWEL DIS, V12, P382, DOI 10.1097/01.MIB.0000218764.06959.91; Zhong WW, 2010, J PEDIATR GASTR NUTR, V50, P132, DOI 10.1097/MPG.0b013e3181c61591	35	3	3	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1149	1155		10.1016/j.prp.2018.06.001			7	Pathology	Pathology	GR9QG	WOS:000443104700014	29941222				2019-10-28	
J	Muscarella, LA; Bisceglia, M; Galliani, CA; Zidar, N; Ben-Dor, DJ; Pasquinelli, G; la Torre, A; Sparaneo, A; Fanburg-Smith, JC; Lamovec, J; Michal, M; Bacchi, CE				Muscarella, Lucia Anna; Bisceglia, Michele; Galliani, Carlos A.; Zidar, Nina; Ben-Dor, David Jonathan; Pasquinelli, Gianandrea; la Torre, Annamaria; Sparaneo, Angelo; Fanburg-Smith, Julie C.; Lamovec, Janez; Michal, Michal; Bacchi, Carlos E.			Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hemangioblastoma; Extraneuraxial hemangioblastoma; von Hippel-Lindau disease; VHL-type tumor; VHL gene; Molecular analysis	HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR GENE; CENTRAL-NERVOUS-SYSTEM; SPORADIC CEREBELLAR HEMANGIOBLASTOMAS; CAPILLARY HEMANGIOBLASTOMA; GERMLINE MUTATIONS; SOMATIC MUTATIONS; POLYCYTHEMIA; EXPRESSION; KIDNEY	Less than 250 extraneuraxial hemangioblastomas occurring in paraneuraxial or peripheral sites have been reported to date, sporadically or in the setting of von Hippel-Lindau disease. Seventeen such cases underwent molecular genetic analysis, using either the patient's peripheral blood in 9 cases or paraffin embedded tumor tissue in the rest. VHL gene mutations were documented in 3/9 cases in which DNA from peripheral blood lymphocytes was used, all with clinically manifest von Hippel-Lindau disease; instead, no VHL gene alterations were found in all of the 8 cases with sporadic extraneuraxial hemangioblastoma in which DNA from tumor tissue was analyzed. Our aim is to investigate the molecular genetic profile of the VHL gene in extraneuraxial hemangioblastoma using paraffin embedded tumor tissues. The clinical features, histopathology, and molecular investigations of 10 extraneuraxial hemangioblastomas (7 females, 3 males; median age: 47 years) are presented herein. The histopathologic diagnosis was supported by immunohistochemistry (10/10) and electron microscopy (4/10). Molecular genetic analysis was conducted (10/10) for VHL gene mutations, LOH, and gene promoter methylation. Two of the present cases were already published with only limited or no molecular investigations. Four tumors of the present series were paraneuraxial, and 6 peripheral (2 involved soft tissues, and 4 the kidney). One tumor was von Hippel-Lindau disease-associated, 1 was classified as "hemangioblastoma-only VHLD", 7 were sporadic, and one was unknown. All were histopathologically analogous to their counterpart located inside the central nervous system. Immunophenotypically, all tumors expressed vimentin, S-100, NSE, and alpha-inhibin (10/10). Ultrastructurally, unbound lipid droplets filled the cytoplasms of the stromal cells. Molecular analysis revealed 3 inactivating mutations (1 germline, two somatic) in the coding sequence of the VHL gene in 2 different extraneuraxial hemangioblastomas, and LOH in 4 (two as a double hit), all non-renal extraneuraxial hemangioblastomas. Methylation analysis failed to disclose promoter methylation in any case. In conclusion, we report eight new cases from the wide category of extraneuraxial hemangioblastomas (4 paraneuraxial, and 4 renal), one of which was von Hippel-Lindau disease-associated and 7 sporadic. VHL gene alterations were found not only in the von Hippel-Lindau disease-associated tumor, but for the first time also in 3 sporadic ones, two of which with novel mutations.	[Muscarella, Lucia Anna; la Torre, Annamaria; Sparaneo, Angelo] IRCCS Casa Sollievo della Sofferenza Hosp, Lab Oncol, San Giovanni Rotondo, FG, Italy; [Bisceglia, Michele] Etromapmax Pole, Anat Pathol, Sch Biomed Sci, Lesina, FG, Italy; [Galliani, Carlos A.] Childrens Minnesota, Dept Pathol, Minneapolis, MN USA; [Galliani, Carlos A.] Childrens Minnesota, Dept Pathol, St Paul, MN USA; [Zidar, Nina] Univ Ljubljana, Med Fac, Inst Pathol, Ljubljana, Slovenia; [Ben-Dor, David Jonathan] Barzilai Govt Hosp, Dept Pathol, Ashqelon, Israel; [Pasquinelli, Gianandrea] Univ Bologna, Dept Hemathol Oncol & Clin Pathol, S Orsola Polyclin, Bologna, Italy; [Fanburg-Smith, Julie C.] Penn State Hlth Milton S Hershey Med Ctr, Dept Pathol, Hershey, PA USA; [Lamovec, Janez] Inst Oncol, Dept Pathol, Ljubljana, Slovenia; [Michal, Michal] Charles Univ Prague, Dept Pathol, Med Fac Hosp, Plzen, Czech Republic; [Bacchi, Carlos E.] Lab Bacchi, Botucatu, SP, Brazil	Bisceglia, M (reprint author), Via Santa Chiara 9, I-71043 Manfredonia, FG, Italy.	l.muscarella@operapadrepio.it; bismich@alice.it; Carlos.Galliani@childrensmn.org; nina.zidar@mf.uni-lj.si; ben_dordavid@hotmail.com; gianandrea.pasquinelli@gmail.com; latorreannamaria@gmail.com; a.sparaneo@operapadrepio.it; jcfsmd@gmail.com; jlamovec@onko-i.si; michal@medima.cz; bacchi@labbacchi.com.br	la Torre, Annamaria/B-2717-2017; Pasquinelli, Gianandrea/I-7088-2012	la Torre, Annamaria/0000-0003-4199-1077; Pasquinelli, Gianandrea/0000-0003-1506-1829; Sparaneo, Angelo/0000-0002-3211-3072			Bader HL, 2012, FEBS LETT, V586, P1562, DOI 10.1016/j.febslet.2012.04.032; Bisceglia M., 2017, ADV ANAT PATHOL, DOI [1097/PAP.0000000000000176, DOI 1097/PAP.0000000000000176]; Butman JA, 2008, JAMA-J AM MED ASSOC, V300, P1334, DOI 10.1001/jama.300.11.1334; Catapano D, 2005, NEUROSURGERY, V56, P1215, DOI 10.1227/01.NEU.0000159646.15026.D6; Chan CC, 2007, RETINA-J RET VIT DIS, V27, P1, DOI 10.1097/01.iae.0000244659.62202.ee; Chew Emily Ying, 2005, Trans Am Ophthalmol Soc, V103, P495; Cho H, 2011, J KOREAN NEUROSURG S, V49, P381, DOI 10.3340/jkns.2011.49.6.381; Conway JE, 2001, NEUROSURGERY, V48, P55, DOI 10.1097/00006123-200101000-00009; Delanghe SE, 2015, CLIN CHIM ACTA, V438, P304, DOI 10.1016/j.cca.2014.09.013; Ding ZY, 2014, CANCER RES, V74, P3127, DOI 10.1158/0008-5472.CAN-13-3213; Doyle LA, 2014, AM J SURG PATHOL, V38, P119, DOI 10.1097/PAS.0b013e3182a266c1; Fanburg-Smith J C, 2000, Ann Diagn Pathol, V4, P81, DOI 10.1016/S1092-9134(00)90016-9; Frantzen C., HIPPEL LINDAU SYNDRO; Glasker S, 2005, NEUROSURGERY, V56, P503, DOI 10.1227/01.NEU.0000153909.70381.C8; Glasker S, 2001, J NEUROL NEUROSUR PS, V70, P644, DOI 10.1136/jnnp.70.5.644; HARDWIG P, 1984, OPHTHALMOLOGY, V91, P263; Hes FJ, 2000, J MED GENET, V37, P939, DOI 10.1136/jmg.37.12.939; HORTON WA, 1976, ARCH INTERN MED, V136, P769, DOI 10.1001/archinte.136.7.769; Hussein MR, 2007, INT J EXP PATHOL, V88, P311, DOI 10.1111/j.1365-2613.2007.00535.x; Ip YT, 2010, AM J SURG PATHOL, V34, P1695, DOI 10.1097/PAS.0b013e3181f2d9b8; Jiang JG, 2013, INT J CLIN EXP PATHO, V6, P1953; KANNO H, 1994, CANCER RES, V54, P4845; KNUDSON AG, 1991, MUTAT RES, V247, P185, DOI 10.1016/0027-5107(91)90013-E; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Kruizinga RC, 2016, FAM CANCER, V15, P607, DOI 10.1007/s10689-016-9879-3; Kuroda N, 2015, INT J CLIN EXP PATHO, V8, P2131; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; LINDSTEDT G, 1994, CLIN CHEM, V40, P2093; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Lonser RR, 2014, J NEUROSURG, V120, P1055, DOI 10.3171/2014.1.JNS131431; Maher E. R., 2003, PATHOLOGY GENETICS T, P230; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; Mehrian-Shai R, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2370-6; MELMON KL, 1964, AM J MED, V36, P595, DOI 10.1016/0002-9343(64)90107-X; Michal M, 2004, AM J SURG PATHOL, V28, P962, DOI 10.1097/00000478-200407000-00018; Muscarella LA, 2014, J NEUROPATH EXP NEUR, V73, P50, DOI [10.1097/NEN.0000000000000024, 10.1097/NEN.0000000000000026]; Oberstrass J, 1996, J PATHOL, V179, P151, DOI 10.1002/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0; Olschwang S, 1998, HUM MUTAT, V12, P424, DOI 10.1002/(SICI)1098-1004(1998)12:6<424::AID-HUMU9>3.0.CO;2-H; Parrella P, 1999, CANCER RES, V59, P3032; Perrotta S, 2006, BLOOD, V107, P514, DOI 10.1182/blood-2005-06-2422; Plate K. H., 2016, WHO CLASSIFICATION T, P254; Plate K. H., 2016, WHO CLASSIFICATION T, P304; Prowse AH, 1997, AM J HUM GENET, V60, P765; Raghavan R, 2000, NEUROSURGERY, V47, P1443, DOI 10.1097/00006123-200012000-00038; Shankar GM, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0167-x; Skotheim RI, 2001, CANCER GENET CYTOGEN, V127, P64, DOI 10.1016/S0165-4608(00)00433-7; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.3.CO;2-B; Tse JYM, 1997, AM J CLIN PATHOL, V107, P459; Vortmeyer AO, 1997, HUM PATHOL, V28, P540, DOI 10.1016/S0046-8177(97)90075-7; Wang CC, 2012, INT J SURG PATHOL, V20, P519, DOI 10.1177/1066896911434548; Wei Jianguo, 2015, Zhonghua Bing Li Xue Za Zhi, V44, P749; Woodward ER, 2007, BRAIN, V130, P836, DOI 10.1093/brain/awl362; Wu Y, 2015, J CLIN PATHOL, V68, P1020, DOI 10.1136/jclinpath-2015-202900; Zhang Xueping, 2015, Zhonghua Bing Li Xue Za Zhi, V44, P377	56	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1156	1165		10.1016/j.prp.2018.05.007			10	Pathology	Pathology	GR9QG	WOS:000443104700015	29941223				2019-10-28	
J	Li, F; Ma, L; Geng, CZ; Liu, C; Deng, HY; Yue, M; Ding, Y; Wang, XL; Liu, YP				Li, Fang; Ma, Li; Geng, Cuizhi; Liu, Chang; Deng, Huiyan; Yue, Meng; Ding, Yan; Wang, Xiaolin; Liu, Yueping			Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Breast cancer; Molecular subtypes; Neoadjuvant chemotherapy; Efficacy; Prognostic	PATHOLOGICAL COMPLETE RESPONSE; TUMORS	Background: Accurate pathological assessment of breast specimens after NACT is crucial. It is beneficial to determine the treatment efficacy and predict prognosis. So we should explore the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors, which about survival analysis and disease free survival involved, which was one part of contributing for evaluating in terms of global survival and disease free survival. Methods: Medical records of 264 patients with breast cancer who received neoadjuvant chemotherapy in Breast Center, the Fourth Hospital of Hebei Medical University, between January 2008 and May 2013. The relationship between molecular subtypes and neoadjuvant chemotherapy, and clinical pathological features were analyzed. Results: The total pCR rate was 12.50% (33/264). The rate of pCR were 3.03% (1/33), 9.40% (14/149), 17.39%(8/46), 27.78% (10/36) in Luminal A type, Luminal B type, HER2 overexpression type, and Triple negative type, respectively. Which was predicted that The pCR rate associated with breast cancer molecular subtypes (P < 0.05). The pCR rate in Triple negative type was highest, HER2 overexpression type was showed higher pCR rate than Luminal A and Luminal B type. Multiple factors analysis results showed that: the independent impact factors of 5-year overall survival rate in neoadjuvant chemotherapy breast cancer patients were clinical stage, tumor size, chemotherapy regimens, lymph node metastasis, estrogen receptor status and pathological remission; the independent impact factors of 5-year disease free survival rate were tumor size, chemotherapy regimens, estrogen receptor status, progesterone receptor status and pathological remission (P < 0.05). Triple negative type of breast cancer had shorter overall survival and disease-free survival (P < 0.05). Conclusions: The pCR was more frequently observed in HER2 overexpression type and Triple negative type of breast cancer. That could achieve a higher rate of pCR on paclitaxel class joint anthracycline-based chemotherapy. But Triple negative type showed worse prognosis, due to residual tumor after neoadjuvant chemotherapy, which could be in combination or sequential, at the neoadjuvant / adjuvant setting (NCCN 2016 Breast cancer, chemotherapy regimens), So how to choose a more appropriate neoadjuvant chemotherapy regimens, we should need further research.	[Li, Fang; Liu, Chang; Deng, Huiyan; Yue, Meng; Ding, Yan; Wang, Xiaolin; Liu, Yueping] Hebei Med Univ, Hosp 4, Dept Pathol, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China; [Ma, Li; Geng, Cuizhi; Wang, Xiaolin] Hebei Med Univ, Hosp 4, Dept Surg, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China	Liu, YP (reprint author), Hebei Med Univ, Hosp 4, 12 Jiankang Rd, Shijiazhuang 050011, Hebei, Peoples R China.	annama@163.com			Department of Finance in Hebei Province of China	Tissue samples were provided by Breast center of Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital in China, and the approval of the ethics committee of Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital. The experiment was supported by Yueping Liu's Funding from Department of Finance, which was in Hebei Province of China (2016).	Bu Hong, 2015, CHINESE J PATHOL, V44, P232; Chen W.Q., 2015, CHINA CANC, V24, P1; Ferlay J., 2015, IJC, V1, pE359; Gianni L, 2010, LANCET, V375, P377, DOI 10.1016/S0140-6736(09)61964-4; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Loibl S, 2015, CURR OPIN OBSTET GYN, V27, P85, DOI 10.1097/GCO.0000000000000147; Luangdilok S, 2014, J BREAST CANCER, V17, P376, DOI 10.4048/jbc.2014.17.4.376; Niu H F, 2016, Zhonghua Zhong Liu Za Zhi, V38, P190, DOI 10.3760/cma.j.issn.0253-3766.2016.03.006; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Salim DK, 2014, ASIAN PAC J CANCER P, V15, P9379, DOI 10.7314/APJCP.2014.15.21.9379; Wang Xing, 2015, Zhonghua Yi Xue Za Zhi, V95, P256; [王玉洁(综述) Wang Yujie], 2015, [中国癌症杂志, China Oncology], V25, P629; Zhou Yi-jun, 2013, Zhonghua Yi Xue Za Zhi, V93, P1711	13	1	1	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1166	1172		10.1016/j.prp.2018.06.010			7	Pathology	Pathology	GR9QG	WOS:000443104700016	29945816				2019-10-28	
J	Singh, V; Singh, M; Schurman, JV; Friesen, CA				Singh, Vivekanand; Singh, Meenal; Schurman, Jennifer, V; Friesen, Craig A.			Histopathological changes in the gastroduodenal mucosa of children with functional dyspepsia	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Functional dyspepsia; Mast cells; Eosinophil; Inflammation; Tryptase	IRRITABLE-BOWEL-SYNDROME; MAST-CELLS; ABDOMINAL-PAIN; DUODENAL EOSINOPHILIA; QUANTITATIVE-EVALUATION; GASTROINTESTINAL-TRACT; NONULCER DYSPEPSIA; DEGRANULATION; ASSOCIATION; COHORT	Introduction and Objective: Functional dyspepsia (FD) is a functional gastrointestinal disorder that affects a significant number of children presenting with chronic abdominal pain. A high proportion of these children undergo endoscopy to obtain mucosa] biopsies which, by standard criteria, generally do not identify a clear explanation for symptoms. We undertook this study of children diagnosed with FD to elucidate the histopathological changes of gastroduodenal mucosa and to describe mast cell and eosinophil densities. Methods: In this retrospective study, we evaluated 114 FD subjects and 10 control subjects from whom gastric antral and duodenal biopsies were available as formalin-fixed paraffin embedded tissue. We reviewed the H&E stained slides and performed immunohistochemistry for tryptase, to determine eosinophil and mast cell densities, respectively. Results: We found that the duodenal mucosa showed no evidence of inflammation in 86% of subjects, a median peak eosinophil count of 24 and a median peak mast cell count of 22. The histopathological features of the gastric antral mucosa comprised no evidence of inflammation in 52% of subjects, mild chronic inflammation in 41% of subjects, a median peak eosinophil count of 11.5 and a median peak mast cell count of 18. Conclusions: A significant proportion of children with FD do not show chronic or active inflammation, but have increased mast cell density and eosinophil density in the stomach and duodenum mucosa. Our study adds functional dyspepsia to the list of various abnormalities that have increased gastroduodenal mucosal elevations of eosinophils and/or mast cells.	[Singh, Vivekanand] Childrens Mercy Hosp, Dept Pathol & Lab Med, 2401 Gillham Rd, Kansas City, MO 64108 USA; [Singh, Meenal; Friesen, Craig A.] Childrens Mercy Hosp, Div Gastroenterol, Kansas City, MO 64108 USA; [Schurman, Jennifer, V] Childrens Mercy Hosp, Div Dev & Behav Sci, Kansas City, MO 64108 USA	Singh, V (reprint author), Childrens Mercy Hosp, Dept Pathol & Lab Med, 2401 Gillham Rd, Kansas City, MO 64108 USA.	vsingh@cmh.edu			Children's Mercy Departmental Funding for the Division of Gastroenterology	The study was funded by Children's Mercy Departmental Funding for the Division of Gastroenterology. The sponsor had no role in the study design.	Barbara G, 2004, GASTROENTEROLOGY, V126, P693, DOI 10.1053/j.gastro.2003.11.055; Chaudhari AA, 2017, J CLIN DIAGN RES, V11, pEC01, DOI 10.7860/JCDR/2017/25297.9985; Chernetsova E, 2016, HUM PATHOL, V54, P55, DOI 10.1016/j.humpath.2016.03.004; Chitkara DK, 2005, AM J GASTROENTEROL, V100, P1868, DOI 10.1111/j.1572-0241.2005.41893.x; Choi M. G., 2004, NEUROGASTROENT MOTIL, V16, P669; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; Du LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34305; Friesen CA, 2002, J PEDIATR GASTR NUTR, V35, P329, DOI 10.1097/01.MPG.0000025354.04164.5E; Friesen CA, 2008, DIGEST DIS SCI, V53, P2634, DOI 10.1007/s10620-008-0207-0; Friesen Craig A, 2013, World J Gastrointest Pharmacol Ther, V4, P86, DOI 10.4292/wjgpt.v4.i4.86; Hall W, 2003, CLIN GASTROENTEROL H, V1, P363, DOI 10.1053/S1542-3565(03)00184-8; Hyams J. S., 2016, GASTROENTEROLOGY; Jakate S, 2006, ARCH PATHOL LAB MED, V130, P362; Kalach N, 2011, J PEDIATR GASTR NUTR, V52, P175, DOI 10.1097/MPG.0b013e3181e2ae00; Lee EH, 2016, J NEUROGASTROENTEROL, V22, P459, DOI 10.5056/jnm15174; Lowichik A, 1996, MODERN PATHOL, V9, P110; MATTER SE, 1990, DIGEST DIS SCI, V35, P1358, DOI 10.1007/BF01536741; O'Sullivan M, 2000, NEUROGASTROENT MOTIL, V12, P449; Schurman JV, 2010, J PEDIATR GASTR NUTR, V51, P298, DOI 10.1097/MPG.0b013e3181d1363c; Schurman JV, 2010, J PEDIATR GASTR NUTR, V50, P32, DOI 10.1097/MPG.0b013e3181ae3610; Talley NJ, 2007, CLIN GASTROENTEROL H, V5, P1175, DOI 10.1016/j.cgh.2007.05.015; Thakkar K, 2009, ALIMENT PHARM THER, V30, P662, DOI 10.1111/j.1365-2036.2009.04084.x; Walker MM, 2010, ALIMENT PHARM THER, V31, P1229, DOI 10.1111/j.1365-2036.2010.04282.x; Walker MM, 2009, ALIMENT PHARM THER, V29, P765, DOI 10.1111/j.1365-2036.2009.03937.x; Walker MM, 2014, J GASTROEN HEPATOL, V29, P474, DOI 10.1111/jgh.12419; Wang X, 2015, ANN DIAGN PATHOL, V19, P50, DOI 10.1016/j.anndiagpath.2015.02.001; Wauters L, 2017, ALIMENT PHARM THER, V45, P1358, DOI 10.1111/apt.14045; WESTON AP, 1993, DIGEST DIS SCI, V38, P1590, DOI 10.1007/BF01303164; Yuan HP, 2015, INT J CLIN EXP MED, V8, P8010	30	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1173	1178		10.1016/j.prp.2018.06.014			6	Pathology	Pathology	GR9QG	WOS:000443104700017	30078402				2019-10-28	
J	Jang, TJ; Kim, SA; Kim, MK				Jang, Tae Jung; Kim, Sun A.; Kim, Min Kyung			Increased number of arginase 1-positive cells in the stroma of carcinomas compared to precursor lesions and nonneoplastic tissues	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Arginase 1; Tumor-associated myeloid-derived cells; Polymorphonuclear neutrophils	TUMOR-BEARING MICE; SUPPRESSOR-CELLS; COLORECTAL-CANCER; MICROENVIRONMENT; DIFFERENTIATION; NEUTROPHILS; INHIBITION; RESPONSES; ARGININE	Arginase 1 (Arg1) is involved in dampening the response of antitumor T lymphocytes. Arg1 expression has been reported in a variety of cancer cell lines and tumor-associated myeloid-derived cells. However, its examination in situ in tumor microenvironment is poorly investigated. We examined the Arg1-positive cells in tumor micro environment of gastric carcinomas (GCs), colorectal carcinomas (CRCs) and prostate carcinomas (PCs), and analyzed their clinicopathological significance. Immunohistochemical staining for Arg1 was done in 60 GCs, 38 gastric adenomas, 40 CRCs, 10 colonic adenomas, 36 PCs, and 15 benign prostatic hyperplasia (BPH). Arg1 expression was predominantly localized in tumor microenvironment and the stroma of nonneoplastic tissues. Cells with Arg1 expression were mostly leukocytes, morphologically resembling polymorphonuclear neutrophils, and showed CD15 expression. Arg1 expression was focally expressed in cancer cells of 6 PCs, but not in those of GCs and CRCs. Arg1-positive cells were significantly more infiltrated in tumors than adenomas and nonneoplastic tissues, such as BPH, intestinal metaplasia and adjacent tissues. There were no significant findings between them and clinicopathological parameters, except for the relationship to gender and tumor differentiation in CRCs. These findings suggest that Arg1-positive cells in tumor microenvironment is involved in the occurrence of GCs, CRCs, and PCs. More expansive studies are necessary to better elucidate their dinicopathological significance in carcinomas.	[Jang, Tae Jung; Kim, Sun A.; Kim, Min Kyung] Dongguk Univ, Dept Pathol, Coll Med, Dongdaero 123, Gyeongju 38066, Gyeongbuk, South Korea	Jang, TJ (reprint author), Dongguk Univ, Dept Pathol, Coll Med, Dongdaero 123, Gyeongju 38066, Gyeongbuk, South Korea.	taejung@dongguk.ac.kr		Kim, Min-Kyung/0000-0001-8937-3492			Bronte V, 2005, J EXP MED, V201, P1257, DOI 10.1084/jem.20042028; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Compton CC, 2003, MODERN PATHOL, V16, P376, DOI 10.1097/01.MP.0000062859.46942.93; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Dumitru CA, 2012, CANCER IMMUNOL IMMUN, V61, P1155, DOI 10.1007/s00262-012-1294-5; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Haverkamp JM, 2014, IMMUNITY, V41, P947, DOI 10.1016/j.immuni.2014.10.020; Hossain D. M., 2015, CLIN CANC RES, V21; Hurt B, 2017, AM J SURG, V214, P938, DOI 10.1016/j.amjsurg.2017.08.003; Jang TJ, 2013, KOREAN J PATHOL, V47, P443, DOI 10.4132/KoreanJPathol.2013.47.5.443; Kim Y, 2009, CURR MOL MED, V9, P425, DOI 10.2174/156652409788167113; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Morris SM, 2009, BRIT J PHARMACOL, V157, P922, DOI 10.1111/j.1476-5381.2009.00278.x; Munder M, 2006, BLOOD, V108, P1627, DOI 10.1182/blood-2006-11-010389; Pileri A, 2017, VIRCHOWS ARCH, V470, P575, DOI 10.1007/s00428-017-2107-1; Rodriguez PC, 2002, J BIOL CHEM, V277, P21123, DOI 10.1074/jbc.M110675200; Rotondo R, 2009, INT J CANCER, V125, P887, DOI 10.1002/ijc.24448; Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Timosenko E, 2017, IMMUNOTHERAPY-UK, V9, P83, DOI 10.2217/imt-2016-0118; Toor SM, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00560; Tsukamoto H, 2013, CANCER IMMUNOL RES, V1, P64, DOI 10.1158/2326-6066.CIR-13-0030; Ueno H, 2012, AM J SURG PATHOL, V36, P193, DOI 10.1097/PAS.0b013e318235edee; Wu AA, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1016700; Wu C W, 1987, Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi, V20, P279; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Youn JI, 2013, NAT IMMUNOL, V14, P211, DOI 10.1038/ni.2526; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177	30	0	0	0	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1179	1184		10.1016/j.prp.2018.06.016			6	Pathology	Pathology	GR9QG	WOS:000443104700018	29970307				2019-10-28	
J	Lopes, NM; Xavier, FCA; Ortiz, RC; Amor, NG; Garlet, GP; Lara, VS; Batista, AC; Costa, NL; Rodini, CO				Lopes, Nathalia Martins; Aquino Xavier, Flavia Calo; Ortiz, Rafael Carneiro; Amor, Nadia Ghinelli; Garlet, Gustavo Pompermaier; Lara, Vanessa Soares; Batista, Aline Carvalho; Costa, Nadia Lago; Rodini, Camila Oliveira			Subcellular localization and expression of E-cadherin and SNAIL are relevant since early stages of oral carcinogenesis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Oral squamous cell carcinoma; Epithelial-To-Mesenchyrnal transition; Oral leukoplakia; Epithelial dysplasia; Oral carcinogenesis	SQUAMOUS-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITIONS; MALIGNANT-TRANSFORMATION; BETA-CATENIN; TUMOR PROGRESSION; GENE-EXPRESSION; DOWN-REGULATION; CANCER; TWIST; KERATINOCYTES	The biological process of epithelial-to-mesenchymal transition (EMT) has been studied in oral squamous cell carcinoma (OSCC) metastasis, but it is rarely evaluated at several stages of oral carcinogenesis. This study aimed to analyze the presence of SNAIL and E-cadherin proteins, markers of EMT, in the development and progression of OSCC, evaluating excised specimens of potentially malignant lesions (oral leukoplakia with and without dysplasia-OL and OLD, respectively), tumor tissues (OSCC), metastatic lymph nodes (LN), and normal oral mucosa (NOM) by immunohistochemistry, considering subcellular localization. Additionally, SNAIL and Ecadherin transcripts were evaluated in vitro by qPCR, using SCC-9 cell line in comparison to human keratinocytes (HPEC). There was a significant increase in nuclear expression of SNAIL from NOM to OLD followed by a noticeable decrease in nuclear expression accompanied by increased cytoplasmic expression in OSCC (p < 0.05). The E-cadherin cytoplasmic expression was remarkable and statistically significant higher in OSCC and LN, both compared to NOM (p < 0.0001), OL (p < 0.01) and OLD (p < 0.0001 and p < 0.001, respectively). In vitro, Ecadherin and SNAIL transcripts were lower in SCC-9 compared to HPEC cells, although only the decrease of Ecadherin was statistically significant (p < 0.05). Regarding the association of E-cadherin and SNAIL expression with the clinical findings, the analysis revealed an association between the cytoplasmic expression of SNAIL and the invasion pattern (p = 0.05) in OSCC. The increased nuclear SNAIL expression may be characteristic of OLD, and the presence of E-cadherin in cell cytoplasm a marker of transformation to malignancy of potentially malignant oral leukoplakias into OSCC.	[Lopes, Nathalia Martins; Ortiz, Rafael Carneiro; Amor, Nadia Ghinelli; Garlet, Gustavo Pompermaier; Rodini, Camila Oliveira] Univ Sao Paulo, Bauru Sch Dent, Dept Biol Sci, Alameda Dr Octavio Pinheiro Brisolla 9-75, BR-17012901 Bauru, SP, Brazil; [Aquino Xavier, Flavia Calo] Univ Fed Bahia, Lab Oral Surg Pathol, Sch Dent, Araujo Pinho Ave 62,9th Floor, BR-40110150 Salvador, BA, Brazil; [Lara, Vanessa Soares] Univ Sao Paulo, Dept Surg Stomatol Pathol & Radiol, Bauru Sch Dent, Alameda Dr Octavio Pinheiro Brisolla 9-75, BR-17012901 Bauru, SP, Brazil; [Batista, Aline Carvalho; Costa, Nadia Lago] Univ Fed Goias, Sch Dent, Dept Oral Med Oral Pathol Stomatol & Radiol, Praca Univ S-N Campus 1,2nd Floor, BR-74605220 Goiania, Go, Brazil	Rodini, CO (reprint author), Alameda Dr Octavio Pinheiro Brisolla 9-75, BR-17012901 Bauru, SP, Brazil.	carodini@usp.br	Garlet, Gustavo Pompermaier/E-6762-2012; Rodini, Camila/C-4437-2012	Garlet, Gustavo Pompermaier/0000-0002-5071-8382; Rodini, Camila/0000-0002-8763-4967; Batista, Aline Carvalho/0000-0002-2117-5593; COSTA, NADIA/0000-0003-0198-5828; Xavier, Flavia/0000-0002-0199-6503	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/01042-9]	The authors are grateful to Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) for the support by scholarship (#2013/01042-9).	[Anonymous], 2017, WHO CLASS HEAD NECK; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Chaw SY, 2012, ORAL ONCOL, V48, P997, DOI 10.1016/j.oraloncology.2012.05.011; Chi AC, 2015, CA-CANCER J CLIN, V65, P401, DOI 10.3322/caac.21293; Silva BSD, 2014, J ORAL PATHOL MED, V43, P125, DOI 10.1111/jop.12096; Fan CC, 2013, J CANCER RES CLIN, V139, P1735, DOI 10.1007/s00432-013-1499-9; Feller L, 2010, HEAD FACE MED, V6, DOI 10.1186/1746-160X-6-14; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Klingbeil MFG, 2009, CELL TISSUE BANK, V10, P197, DOI 10.1007/s10561-009-9122-7; Hoteiya T, 1999, J ORAL PATHOL MED, V28, P107; Huang Cheng-Hui, 2007, J Chin Med Assoc, V70, P164; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kaur Gurkiran, 2009, Indian J Dent Res, V20, P71; Krisanaprakornkit S., 2012, ISRN ONCOL; Kujan O, 2006, ORAL ONCOL, V42, P987, DOI 10.1016/j.oraloncology.2005.12.014; Malik UU, 2016, ARCH ORAL BIOL, V63, P53, DOI 10.1016/j.archoralbio.2015.11.017; Ng J.H., 2016, CHANGING EPIDEMIOLOG; Pannone G, 2014, CURR CANCER DRUG TAR, V14, P115, DOI 10.2174/1568009613666131126115012; Pereira CH, 2016, ARCH ORAL BIOL, V61, P8, DOI [10.1016/j.archoraibio.2015.10.003, 10.1016/j.archoralbio.2015.10.003]; Petersen PE, 2009, ORAL ONCOL, V45, P454, DOI 10.1016/j.oraloncology.2008.05.023; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Rhodus Nelson L, 2014, Dent Clin North Am, V58, P315, DOI 10.1016/j.cden.2013.12.004; Rivera C, 2015, INT J CLIN EXP PATHO, V8, P11884; Rodini CO, 2017, J APPL ORAL SCI, V25, P708, DOI 10.1590/1678-7757-2016-0665; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Scanlon CS, 2013, J DENT RES, V92, P114, DOI 10.1177/0022034512467352; Soares MQS, 2015, HISTOL HISTOPATHOL, V30, P1213, DOI 10.14670/HH-11-616; Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.E04-08-0658; Vered M, 2012, HISTOL HISTOPATHOL, V27, P141, DOI 10.14670/HH-27.141; von Zeidler SV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-972; Yao XF, 2017, ONCOTARGETS THER, V10, P781, DOI 10.2147/OTT.S111920; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2; Yuen HF, 2007, HISTOPATHOLOGY, V50, P648, DOI 10.1111/j.1365-2559.2007.02665.x; Zhang X, 2017, ORAL ONCOL, V73, P48, DOI 10.1016/j.oraloncology.2017.08.004; Zhao D, 2012, CLIN EXP METASTAS, V29, P957, DOI 10.1007/s10585-012-9485-1	40	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1185	1191		10.1016/j.prp.2018.06.004			7	Pathology	Pathology	GR9QG	WOS:000443104700019	29970306				2019-10-28	
J	Zuo, JJ; Hu, ZW; Liu, T; Chen, C; Tao, ZZ; Chen, SM; Li, F				Zuo, Jingjing; Hu, Zhangwei; Liu, Tao; Chen, Chen; Tao, Zezhang; Chen, Shiming; Li, Fen			Calpeptin attenuates cigarette smoke-induced pulmonary inflammation via suppressing calpain/I kappa B alpha signaling in mice and BEAS-2B cells	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Calpeptin; Cigarette smoke; Pulmonary; Inflammation; Calpain; I kappa B alpha	INHIBITOR CALPEPTIN; OXIDATIVE STRESS; EPITHELIAL-CELLS; TOBACCO-SMOKE; PEST DOMAIN; ACTIVATION; PROTEIN; COPD; DEGRADATION; MODEL	Exposure to cigarette smoke including secondhand smoking is the most important risk factor in the development of chronic obstructive pulmonary disease where incidence has substantially increased in recent decades. The mechanisms responsible for cigarette smoke-induced pulmonary inflammation remain unclear, and thus lack of effective treatment. The present study investigated the effect of calpeptin on attenuating cigarette smoke induced pulmonary inflammation and its potential mechanism and function. When BALB/c mice were exposed to cigarette smoke and received calpeptin intraperitoneally injection after 90 days, calpeptin histologically attenuated the accumulation of neutrophils (P < 0.001), eosinophils (P < 0.001), macrophages (P < 0.01), fibrinous exudation and proliferation within the interstitial and alveolar spaces. BEAS-2B cells were added with cigarette smoke extract in vitro and treated with calpeptin for 24h in the treatment group. The markedly up regulation of-calpain (P < 0.01), m-calpain (P < 0.001) and I kappa B alpha (P < 0.01) in cigarette smoke-induced lungs were simultaneously decreased by calpeptin treatment (P < 0.05). The increased expression of-calpain, m-calpain and I kappa B alpha (P < 0.05) in cigarette smoke extract-stimulated BEAS-2B cells were also decreased by calpeptin treatment (P < 0.05). These data indicated that calpeptin attenuated cigarette smoke-induced pulmonary inflammation by suppressing the pathway of p-calpain, m-calpain and I kappa B alpha in vivo and in vitro. Calpeptin might have a potential for prevention of the development of inflammatory pulmonary diseases and warrant further pharmaceutical investigation.	[Zuo, Jingjing; Hu, Zhangwei; Liu, Tao; Tao, Zezhang; Chen, Shiming] Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China; [Zuo, Jingjing; Hu, Zhangwei; Liu, Tao; Chen, Chen; Tao, Zezhang; Chen, Shiming; Li, Fen] Wuhan Univ, Renmin Hosp, Res Inst Otolaryngol Head & Neck Surg, Wuhan 430060, Hubei, Peoples R China; [Zuo, Jingjing; Hu, Zhangwei; Liu, Tao] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan 430060, Hubei, Peoples R China	Tao, ZZ (reprint author), Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.	taozezhang@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372880, 81670910]; Natural Science Foundation of Hubei Province of ChinaNatural Science Foundation of Hubei Province [2012FFA045]	This work was funded by the National Natural Science Foundation of China (NO. 81372880, NO. 81670910), and the Natural Science Foundation of Hubei Province of China (No. 2012FFA045).	Alexander LEC, 2015, CHEST, V148, P1307, DOI 10.1378/chest.15-0409; Awji EG, 2015, TOXICOL SCI, V147, P75, DOI 10.1093/toxsci/kfv108; Birrell MA, 2008, J CELL PHYSIOL, V214, P27, DOI 10.1002/jcp.21158; Boskabady MH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0574-y; Chen F., 1997, ARCH BIOCHEM BIOPHYS, V342, P244; Cox LA, 2011, RISK ANAL, V31, P38, DOI 10.1111/j.1539-6924.2010.01487.x; D'hulst AI, 2005, EUR RESPIR J, V26, P204, DOI 10.1183/09031936.05.00095204; Deng Y. Q., 2014, PLOS ONE, V10; Devaney J, 2013, CRIT CARE, V17, DOI 10.1186/cc12696; Ghorani V, 2017, TOB INDUC DIS, V15, DOI 10.1186/s12971-017-0130-2; Gobin K, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00083; Guyton MK, 2010, J NEUROSCI RES, V88, P2398, DOI 10.1002/jnr.22408; Gwozdz AM, 2010, THROMB HAEMOSTASIS, V103, P1218, DOI 10.1160/TH09-08-0557; Han Y., 1999, J BIOL CHEM, V274; Lee FYI, 2005, J BIOL CHEM, V280, P29929, DOI 10.1074/jbc.M414600200; Li M, 2015, MOL MED REP, V11, P4645, DOI 10.3892/mmr.2015.3287; Li XH, 2006, ACTA PHARMACOL SIN, V27, P971, DOI 10.1111/j.1745-7254.2006.00353.x; Libert S, 2016, MOL VIS, V22, P100; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; Nozaki K, 2011, J NEUROSCI RES, V89, P536, DOI 10.1002/jnr.22585; Nozaki K, 2010, EXP NEUROL, V225, P430, DOI 10.1016/j.expneurol.2010.07.021; Owen Caroline A, 2008, Int J Chron Obstruct Pulmon Dis, V3, P253; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Schaecher K, 2004, NEUROCHEM RES, V29, P1443, DOI 10.1023/B:NERE.0000026410.56000.dd; Schoenwaelder SM, 1999, J BIOL CHEM, V274, P14359, DOI 10.1074/jbc.274.20.14359; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; Shen N, 2011, AM J PATHOL, V178, P110, DOI 10.1016/j.ajpath.2010.11.016; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Siklos M, 2015, ACTA PHARM SIN B, V5, P506, DOI 10.1016/j.apsb.2015.08.001; Sinden NJ, 2010, THORAX, V65, P930, DOI 10.1136/thx.2009.130260; Smith LA, 2010, IMMUNOL RES, V46, P94, DOI 10.1007/s12026-009-8133-6; Tabata C, 2010, CLIN EXP IMMUNOL, V162, P560, DOI 10.1111/j.1365-2249.2010.04257.x; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; van der Vaart H, 2004, THORAX, V59, P713, DOI 10.1136/thx.2003.012468; Wei XC, 2009, AM J PHYSIOL-CELL PH, V297, pC310, DOI 10.1152/ajpcell.00597.2008; Zhou XM, 2017, MOL MED REP, V15, P2983, DOI 10.3892/mmr.2017.6416	38	1	1	0	5	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1199	1209		10.1016/j.prp.2018.06.019			11	Pathology	Pathology	GR9QG	WOS:000443104700021	30078403				2019-10-28	
J	Pu, Y; Liu, HY; Xu, H; Liu, HH; Cheng, Y; Chen, XP; Xu, WH; Xu, YP; Fan, JP				Pu, Yu; Liu, Hongyi; Xu, He; Liu, Huanhai; Cheng, Yin; Chen, Xiaoping; Xu, Weihua; Xu, Yaping; Fan, Jingping			IL-1 beta promotes the migration of olfactory epithelium neural stem cells through activating matrix metalloproteinase expressions	PATHOLOGY RESEARCH AND PRACTICE			English	Article						IL-1 beta; Olfactory epithelium neural stem cells; Migration; MMP	INDUCED HEARING-LOSS; GASTRIC-CARCINOMA; INVASION; MMP-9; TISSUE; VEGF; P38; JNK	Background: To investigate the effects of IL-1 beta on the migration of olfactory epithelium neural stem cells (OENSCs), and to assess the mechanisms. Methods: The effects of different concentrations of IL-1 beta on cell proliferation, apoptosis and migration were evaluated by cell counting assay, flow cytometry and transwell migration assay, respectively. Matrix metalloproteinase (MMP)-2 and MMP-9 expression in both protein and mRNA levels were detected. Small interfering RNA (siRNA) technique was employed to knockdown MMP-2 and MMP-9 expression. Additionally, c-Jun N-terminal kinase (JNK) and nuclear factor-kappa B (NF-kappa B) inhibitors were applied to assess the potential signaling pathways involved in the effects of IL-1 beta on cell migration. Results: IL-1 beta promoted cell migration of OENSCs in a concentration-dependent manner at the concentration range of 0-80 ng/ml, but did not affect cell proliferation and apoptosis. Mechanically, IL-1 beta promoted MMP-2 and MMP-9 expressions. Knockdown of MMP-2 or MMP-9 could significantly reduce IL-1 beta-induced cell migration. IL-1 beta activated JNK, NF-kappa B, Extracellular Signal-Regulated Kinase (ERK) and p-65 phosphorylation. Finally, we evidenced that inhibition of JNK or NF-kappa B significantly inhibited cell migration. Conclusion: Our study demonstrated that IL-1 beta promoted the migration of OENSCs through activating MMP expression. Moreover, JNK and NF-kappa beta signaling pathways were involved in the regulation. This study provides important experimental evidence for the application of OENSCs in the transplantation therapy.	[Pu, Yu; Liu, Hongyi; Xu, He; Liu, Huanhai; Cheng, Yin; Xu, Yaping; Fan, Jingping] Second Mil Med Univ, Changzheng Hosp, Dept Otolaryngol Head & Neck Surg, Shanghai 200003, Peoples R China; [Chen, Xiaoping; Xu, Weihua] Second Mil Med Univ, Gongli Hosp, Dept Otolaryngol Head & Neck Surg, Shanghai 200135, Peoples R China	Xu, YP; Fan, JP (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Otolaryngol Head & Neck Surg, Shanghai 200003, Peoples R China.	anjingp@163.com			Foundation for Military Medicine, China [BWS11C035]; Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai [PWZxq2017-09]	This work was funded by Foundation for Military Medicine, China (BWS11C035), and Funded by Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2017-09).	Akiyama Y, 2001, EXP NEUROL, V167, P27, DOI 10.1006/exnr.2000.7539; Arslan HH, 2012, OTOL NEUROTOL, V33, P1672, DOI 10.1097/MAO.0b013e31826bf3f6; Capuano R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01790-5; De Becker A, 2007, HAEMATOL-HEMATOL J, V92, P440, DOI 10.3324/haematol.10475; Gao ZL, 2007, HEPATO-GASTROENTEROL, V54, P1591; Jia H, 2016, NEUROSCIENCE, V316, P261, DOI 10.1016/j.neuroscience.2015.12.031; Liang KC, 2007, J CELL PHYSIOL, V211, P759, DOI 10.1002/jcp.20992; Lindsay SL, 2010, GLIA, V58, P125, DOI 10.1002/glia.20917; Lisboa RA, 2013, ARCH ORAL BIOL, V58, P731, DOI 10.1016/j.archoralbio.2012.12.009; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Makowski GS, 2005, CLIN CHIM ACTA, V358, P182, DOI 10.1016/j.cccn.2005.03.012; Nivet E, 2011, J CLIN INVEST, V121, P2808, DOI 10.1172/JCI44489; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Pan Q, 2017, PLACENTA, V53, P48, DOI 10.1016/j.placenta.2017.03.008; Ries C, 2007, BLOOD, V109, P4055, DOI 10.1182/blood-2006-10-051060; Shao Y, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0080-6; Tseng HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057955; Uusi-Rauva K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050955; Wang Jun, 2016, Zhongguo Zhong Xi Yi Jie He Za Zhi, V36, P718; Xu YP, 2016, NEUROSCI LETT, V616, P19, DOI 10.1016/j.neulet.2016.01.016; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zheng HC, 2006, ANTICANCER RES, V26, P3579	22	0	0	1	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1210	1217		10.1016/j.prp.2018.05.027			8	Pathology	Pathology	GR9QG	WOS:000443104700022	29983220				2019-10-28	
J	Lv, ZC; Zhang, Y; Yu, X; Lin, Y; Ge, YL				Lv, Zhongchuan; Zhang, Yong; Yu, Xiang; Lin, Yang; Ge, Yinlin			The function of long non-coding RNA MT1JP in the development and progression of gastric cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Gastric cancer; Long non-coding RNA; Prognosis; Molecular mechanisms	CELL LUNG-CANCER; METASTASIS; DIFFERENTIATION; EXPRESSION; METHYLATION; BIOMARKER; PATHWAY; GENE	Gastric cancer is one of the most common malignant tumors with the third mortality rate of cancer in world. A larger number of researches showed that genetic factors played an important role in the development of gastric cancer. More and more evidences have indicated that lncRNAs can regulate the gene expression through the transcription, post transcription and epigenetic levels including cancer invasion and metastasis, cell differentiation and apoptosis. However, the mechanisms of lncRNAs in the pathogenesis of gastric cancer remaining unclear. LncRNA MT1JP overexpression vector was constructed and then transfected into gastric cancer cells. Further CCK-8 and transwell detection showed that lncRNA MT1JP exerted an evident inhibition role on proliferation, migration and invasion. By combining molecular cell biology experiments of the reporter gene, cell over expression or interference and Western blot, we found that IncRNA MT1JP may regulate FBXW7 expression involved in the occurrence and development of gastric cancer. The results of this study not only explain the role of lncRNA MT1JP in the development of gastric cancer, but also provide important ideas and clues for the study of genetic regulation mechanism in gastric cancer.	[Lv, Zhongchuan; Yu, Xiang; Lin, Yang] Yantai Yuhuangding Hosp, Dept Gastrointestinal Surg, Yantai, Peoples R China; [Zhang, Yong] Penglai Peoples Hosp, Dept Gastrointestinal Surg, Penglai, Peoples R China; [Ge, Yinlin] Qingdao Univ, Sch Med, Dept Biochem & Mol Biol, Qingdao, Peoples R China	Lin, Y (reprint author), Yantai Yuhuangding Hosp, Dept Gastrointestinal Surg, Yantai, Peoples R China.; Ge, YL (reprint author), Qingdao Univ, Sch Med, Dept Biochem & Mol Biol, Qingdao, Peoples R China.	sxrdrc@126.com; iygpf1@163.com			Natural Science Foundation of Shandong ProvinceNatural Science Foundation of Shandong Province [ZR2014HM061]	Natural Science Foundation of Shandong Province, ZR2014HM061.	Abdel-Latif MMM, 2009, J CELL BIOCHEM, V108, P249, DOI 10.1002/jcb.22247; Carcas Lauren Peirce, 2014, J Carcinog, V13, P14, DOI 10.4103/1477-3163.146506; Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028; Fang J, 2016, BIOCHEM BIOPH RES CO, V478, P811, DOI 10.1016/j.bbrc.2016.08.030; Fang XY, 2015, CANCER LETT, V356, P357, DOI 10.1016/j.canlet.2014.11.005; Ge XS, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0588-6; Gu L, 2017, BIOMED PHARMACOTHER, V89, P1269, DOI 10.1016/j.biopha.2017.02.041; Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Heo JB, 2011, SCIENCE, V331, P76, DOI 10.1126/science.1197349; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Lai J, 2014, ONCOTARGET, V5, P6909, DOI 10.18632/oncotarget.2230; Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846; Luo JH, 2006, HEPATOLOGY, V44, P1012, DOI 10.1002/hep.21328; Milne AN, 2010, CELL ONCOL, V32, P347, DOI 10.3233/CLO-2010-523; Ren SC, 2013, EUR J CANCER, V49, P2949, DOI 10.1016/j.ejca.2013.04.026; Sun CC, 2016, ONCOTARGET, V7, P51784, DOI 10.18632/oncotarget.10108; Wang Guang-Yu, 2014, Bull Cancer, V101, pE27, DOI 10.1684/bdc.2014.2023; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang YF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0702-z; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wiestler B, 2014, NEURO-ONCOLOGY, V16, P1630, DOI 10.1093/neuonc/nou138; Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013; Yan TH, 2015, INT J CLIN EXP PATHO, V8, P4126; Yang Z, 2015, INT J CLIN EXP MED, V8, P19954; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067; Zhou H, 2016, AGING-US, V8, P2023, DOI 10.18632/aging.101048; Zhu FF, 2018, PATHOL ONCOL RES, V24, P419, DOI 10.1007/s12253-017-0258-7	30	2	2	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1218	1223		10.1016/j.prp.2018.07.001			6	Pathology	Pathology	GR9QG	WOS:000443104700023	30006025				2019-10-28	
J	Sakashita, S; Shiba-Ishii, A; Murata, Y; Sekimoto, R; Minami, Y; Sato, Y; Noguchi, M				Sakashita, Shingo; Shiba-Ishii, Aya; Murata, Yoshihiko; Sekimoto, Ryutaro; Minami, Yuko; Sato, Yukio; Noguchi, Masayuki			Case report of three EGFR TKI naive lung adenocarcinoma containing double EGFR mutations (L858R/T790M or Exon 19 Deletion/T790M); Comparing genetic information and histology	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Lung adenocarcinoma; EGFR T790M mutation; Heterogeneity; Stepwise progression; Droplet digital PCR	DNA COPY NUMBER; T790M MUTATION; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; CANCER; AMPLIFICATION; SENSITIVITY	EGFR T790M mutation is a crucial gene alteration causing EGFR TKI resistance. However, the implication of T790M mutation is still unknown for the stepwise progression of EGFR TKI naive lung adenocarcinoma. In this study, we studied site-related EGFR T790M mutation analysis in EGFR TM nave lung adenocarcinomas harboring double EGFR mutation (L858R and T790M or Exon 19 deletion (Del.19) and T790M) by droplet digital (dd) PCR method. We examined three resected lung adenocarcinoma cases harboring EGFR double mutation including T790M. These cases didn't receive EGFR TM treatment. We divided formalin-fixed and paraffin embedded (FFPE) unstained slide tissues into 11-18 areas in each tumor and extracted DNAs from each area separately. The DNAs were analyzed by ddPCR. T790M mutation ratio (T790M/L858R or 1790M/Del.19) were calculated. For three cases, we also performed EGFR FISH for analyzing EGFR copy number. In Case 2 and 3, T790M mutation ratio were 100% and 30% homogeneously and showed increased EGFR copy number also homogeneously. However, in case 1, it was different between invasive and non-invasive areas. EGFR copy number was also heterogeneous and showed increasing only in invasive area. We indicated a peculiar case harboring T790M heterogeneity and only invasive area had T790M mutation even though the case was not treated by EGFR TM. It suggests that T790M is possibly significant not only for EGFR TM resistance but also the progression in lung adenocarcinoma.	[Sakashita, Shingo; Shiba-Ishii, Aya; Noguchi, Masayuki] Univ Tsukuba, Fac Med, Diagnost Pathol, Tsukuba, Ibaraki, Japan; [Murata, Yoshihiko] Univ Tsukuba Hosp, Dept Pathol, Tsukuba, Ibaraki, Japan; [Sekimoto, Ryutaro] Univ Tsukuba, Sch Med, Tsukuba, Ibaraki, Japan; [Minami, Yuko] Natl Org Ibaraki Higashi Hosp, Dept Pathol, Tokai, Ibaraki, Japan; [Sato, Yukio] Univ Tsukuba, Fac Med, Dept Thorac Surg, Tsukuba, Ibaraki, Japan	Sakashita, S (reprint author), Univ Tsukuba, Fac Med, Dept Pathol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	sakashingo@hotmail.com			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K08715]; Tsukuba Human Tissue Diagnostic Center	This work was supported by JSPS KAKENHI Grant Number 17K08715 and Tsukuba Human Tissue Diagnostic Center.	Bai H, 2012, J CLIN ONCOL, V30, P3077, DOI 10.1200/JCO.2011.39.3744; Brierley J.D., 2016, TNM CLASSIFICATION M, P272; Cai YR, 2016, SCI REP-UK, V6, DOI 10.1038/srep23755; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gridelli C, 2011, LUNG CANCER, V71, P249, DOI 10.1016/j.lungcan.2010.12.008; Hidaka N, 2017, LUNG CANCER, V108, P75, DOI 10.1016/j.lungcan.2017.02.019; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jia XF, 2015, GENET MOL RES, V14, P11006, DOI 10.4238/2015.September.21.13; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Li H, 2014, ONCOTARGETS THER, V7, P513, DOI 10.2147/OTT.S60122; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Taniguchi K, 2008, CANCER SCI, V99, P929, DOI 10.1111/j.1349-7006.2008.00782.x; Travis WD, 2015, WHO CLASSIFICATION T, P412; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yatabe Y, 2011, J CLIN ONCOL, V29, P2972, DOI 10.1200/JCO.2010.33.3906; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105	26	0	0	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1224	1230		10.1016/j.prp.2018.05.016			7	Pathology	Pathology	GR9QG	WOS:000443104700024	29887244				2019-10-28	
J	Choi, YJ; Ho, J; Lee, A; Hur, SY; Park, HC; Park, JS; Chung, YJ; Lee, SH				Choi, Youn Jin; Ho, Jungyoon; Lee, Ahwon; Hur, Soo Young; Park, Hyeon-Chun; Park, Jong Sup; Chung, Yeun-Jun; Lee, Sug Hyung			Disparate genomic characteristics of concurrent endometrial adenocarcinoma and ovarian granulosa cell tumor, revealed by targeted next-generation sequencing	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Concurrent cancers; Endometrial adenocarcinoma; Mutation; Ovarian adult granulosa cell tumor; Targeted next-generation sequencing	HYPERPLASIA; CARCINOMA; MUTATION; FOXL2	Concurrence of both endometrial adenocarcinoma and ovarian adult granulosa cell tumor (aGCT) is believed to be related to high estrogen milieu, but genomic alterations of the concurrent endometrial adenocarcinoma and aGCT are not known. For this, we analyzed an uterine endometrial adenocarcinoma and an ovarian aGCT in a same patient by a targeted next generation sequencing (NGS). We found a germline mutation in STK11 (p.L113fs). The endometrial adenocarcinoma harbored FGFR2 and TP53 mutations and the aGCT harbored a FOXL2 (p.C134 W) mutation. These germline and somatic mutations have been reported in non-concurrent tumors. These two tumors harbored 20 CNAs but only one CNA was exactly overlapped in the tumors. Our findings indicate that the concurrent endometrial adenocarcinoma and aGCT in this patient might not be genetically related to each other at germline or somatic level and suggest that such concurrence might be originated from non-genetic backgrounds including stimulated estrogen milieu.	[Choi, Youn Jin; Ho, Jungyoon; Hur, Soo Young; Park, Jong Sup] Catholic Univ Korea, Dept Gynecol, Coll Med, Seoul, South Korea; [Lee, Ahwon] Catholic Univ Korea, Dept Obstet, Coll Med, Seoul, South Korea; [Lee, Ahwon] Catholic Univ Korea, Dept Hosp Pathol, Coll Med, Seoul, South Korea; [Park, Hyeon-Chun; Chung, Yeun-Jun] Catholic Univ Korea, Coll Med, Integrated Res Ctr Genome Polymorphism, Seoul, South Korea; [Park, Hyeon-Chun; Chung, Yeun-Jun] Catholic Univ Korea, Coll Med, Dept Microbiol, 222 Banpo Daero, Seoul 06591, South Korea; [Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Dept Pathol, 222 Banpo Daero, Seoul 06591, South Korea; [Lee, Sug Hyung] Catholic Univ Korea, Coll Med, Canc Evolut Res Ctr, Seoul, South Korea	Chung, YJ (reprint author), Catholic Univ Korea, Coll Med, Dept Microbiol, 222 Banpo Daero, Seoul 06591, South Korea.; Lee, SH (reprint author), Catholic Univ Korea, Coll Med, Dept Pathol, 222 Banpo Daero, Seoul 06591, South Korea.	yejun@catholic.ac.kr; suhulee@catholic.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2016R1D1A1B04932862]	This study was supported by grant from National Research Foundation of Korea (2016R1D1A1B04932862).	Al-Agha OM, 2011, AM J SURG PATHOL, V35, P484, DOI 10.1097/PAS.0b013e31820a406c; Bacalbasa N, 2015, ANTICANCER RES, V35, P5547; Banno K, 2013, ONCOL LETT, V6, P1184, DOI 10.3892/ol.2013.1527; Geiersbach KB, 2011, CANCER GENET-NY, V204, P596, DOI 10.1016/j.cancergen.2011.10.002; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Hong JH, 2017, PATHOLOGY, V49, P453, DOI 10.1016/j.pathol.2017.01.011; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Ottolina J, 2015, GYNECOL ONCOL, V136, P230, DOI 10.1016/j.ygyno.2014.12.016; Petrucelli N, 2010, GENET MED, V12, P245, DOI 10.1097/GIM.0b013e3181d38f2f; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Skov BG, 1997, INT J GYNECOL PATHOL, V16, P33, DOI 10.1097/00004347-199701000-00006; Ukah Cornelius O, 2011, J Med Case Rep, V5, P340, DOI 10.1186/1752-1947-5-340; Young RH, 2005, MODERN PATHOL, V18, pS81, DOI 10.1038/modpathol.3800311	14	1	1	0	0	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	AUG	2018	214	8					1231	1233		10.1016/j.prp.2018.06.009			3	Pathology	Pathology	GR9QG	WOS:000443104700025	29937308				2019-10-28	
J	McCarthy, AJ; Chetty, R				McCarthy, Aoife J.; Chetty, Runjan			Smad4/DPC4	JOURNAL OF CLINICAL PATHOLOGY			English	Article							HEREDITARY HEMORRHAGIC TELANGIECTASIA; TRANSFORMING GROWTH-FACTORS; HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; NEUROENDOCRINE TUMORS; PROGNOSTIC MARKER; PANCREATIC-CANCER; DPC4 INACTIVATION; PROSTATE-CANCER	Smad4 or DPC4 belongs to a family of signal transduction proteins that are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor beta (TGF-beta) signaling via several pathways. The gene acts as a tumour suppressor gene and inactivation of smad4/DPC4 is best recognised in pancreatic cancer. However, smad4/DPC4 is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers. Immunohistochemistry for smad4/DPC4 protein is most useful in separating benign/reactive conditions from pancreatic cancer in needle/core biopsies. In normal and reactive states, the protein is localised to the cytoplasm and nucleus, while the protein is lost in high-grade pancreatic intraepithelial neoplasia/carcinoma in situ and pancreatic cancer.	Univ Hlth Network, Dept Anat Pathol, Lab Med Program, Toronto, ON, Canada; Univ Toronto, Toronto, ON, Canada	Chetty, R (reprint author), Univ Hlth Network, Toronto Gen Hosp, Dept Anat Pathol, Lab Med Program, Toronto, ON M5G 2C4, Canada.	runjan.chetty@gmail.com		Chetty, Runjan/0000-0002-2124-515X			Ahn BK, 2011, HEPATO-GASTROENTEROL, V58, P1933, DOI 10.5754/hge11186; Aitchison AA, 2008, PROSTATE, V68, P661, DOI 10.1002/pros.20730; Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458; Alkhasawneh A, 2016, J GASTROINTEST ONCOL, V7, P974, DOI 10.21037/jgo.2016.06.14; Argani P, 2001, CANCER, V91, P1332; Banck MS, 2013, J CLIN INVEST, V123, P2502, DOI 10.1172/JCI67963; Barrett MT, 1996, CANCER RES, V56, P4351; CHAUDHRY A, 1994, ANTICANCER RES, V14, P2085; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chen H, 2015, EXP THER MED, V9, P227, DOI 10.3892/etm.2014.2065; Demagny H, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1025181; Demagny H, 2014, CELL REP, V9, P688, DOI 10.1016/j.celrep.2014.09.020; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Ding ZH, 2012, CELL, V148, P896, DOI 10.1016/j.cell.2012.01.039; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Furukawa T, 2006, CANCER SCI, V97, P1, DOI 10.1111/j.1349-7006.2005.00134.x; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hiwatashi K, 2009, ANN SURG ONCOL, V16, P3176, DOI 10.1245/s10434-009-0614-2; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; Iacobuzio-Donahue CA, 2000, AM J SURG PATHOL, V24, P1544, DOI 10.1097/00000478-200011000-00011; Kidd M, 2007, CANCER-AM CANCER SOC, V109, P2420, DOI 10.1002/cncr.22725; Kozak MM, 2015, J CLIN PATHOL, V68, P341, DOI 10.1136/jclinpath-2014-202660; Lee SH, 2017, ONCOTARGET, V8, P6579, DOI 10.18632/oncotarget.14172; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu NN, 2014, TUMOR BIOL, V35, P641, DOI 10.1007/s13277-013-1088-1; Liu NN, 2015, ONCOL LETT, V10, P1709, DOI 10.3892/ol.2015.3442; Lu Y, 2008, HEPATOB PANCREAT DIS, V7, P174; McCarthy DM, 2003, MODERN PATHOL, V16, P272, DOI 10.1097/01.MP.0000057246.03448.26; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; O'Malley M, 2012, DIS COLON RECTUM, V55, P886, DOI 10.1097/DCR.0b013e31825aad32; Roland CL, 2017, SURGERY, V161, P753, DOI 10.1016/j.surg.2016.09.002; Roth AD, 2012, JNCI-J NATL CANCER I, V104, P1635, DOI 10.1093/jnci/djs427; Saiki Y, 2014, PATHOL INT, V64, P10, DOI 10.1111/pin.12114; Schutte M, 1996, CANCER RES, V56, P2527; Shia J, 2017, MODERN PATHOL, V30, P599, DOI 10.1038/modpathol.2016.198; Stuhrmann M, 2007, SAUDI MED J, V28, P11; Tanaka T, 2008, J SURG ONCOL, V97, P69, DOI 10.1002/jso.20896; Torbenson M, 2002, HUM PATHOL, V33, P871, DOI 10.1053/hupa.2002.128061; Valkenburg KC, 2017, ONCOTARGET, V8, P80265, DOI 10.18632/oncotarget.17919; Voorham QJM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041963; Voorneveld PW, 2015, TRANSL ONCOL, V8, P18, DOI 10.1016/j.tranon.2014.11.003; Wilentz RE, 2000, CANCER RES, V60, P2002; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wrana JL, 2009, CELL, V136, P13, DOI 10.1016/j.cell.2008.12.028; Xia X, 2015, TUMOR BIOL, V36, P111, DOI 10.1007/s13277-014-2883-z; Xie W, 2003, CANCER J, V9, P302, DOI 10.1097/00130404-200307000-00013; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Yamazaki K, 2011, DIGEST DIS, V29, P284, DOI 10.1159/000327560	52	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					661	664		10.1136/jclinpath-2018-205095			4	Pathology	Pathology	GR3CW	WOS:000442467400001	29720405				2019-10-28	
J	Dessauvagie, BF; Lee, AHS; Meehan, K; Nijhawan, A; Tan, PH; Thomas, J; Tie, B; Treanor, D; Umar, S; Hanby, AM; Millican-Slater, R				Dessauvagie, Benjamin F.; Lee, Andrew H. S.; Meehan, Katie; Nijhawan, Anju; Tan, Puay Hoon; Thomas, Jeremy; Tie, Bibiana; Treanor, Darren; Umar, Seemeen; Hanby, Andrew M.; Millican-Slater, Rebecca			Interobserver variation in the diagnosis of fibroepithelial lesions of the breast: a multicentre audit by digital pathology	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CORE NEEDLE-BIOPSY; PHYLLODES TUMORS; FIBROADENOMA; FEATURES; DISTINCTION	Aim Fibroepithelial lesions (FELs) of the breast span a morphological continuum including lesions where distinction between cellular fibroadenoma (FA) and benign phyllodes tumour (PT) is difficult. The distinction is clinically important with FAs managed conservatively while equivocal lesions and PTs are managed with surgery. We sought to audit core biopsy diagnoses of equivocal FELs by digital pathology and to investigate whether digital point counting is useful in clarifying FEL diagnoses. Method Scanned slide images from cores and subsequent excisions of 69 equivocal FELs were examined in a multicentre audit by eight pathologists to determine the agreement and accuracy of core needle biopsy (CNB) diagnoses and by digital point counting of stromal cellularity and expansion to determine if classification could be improved. Results Interobserver variation was high on CNB with a unanimous diagnosis from all pathologists in only eight cases of FA, diagnoses of both FA and PT on the same CNB in 15 and a 'weak' mean kappa agreement between pathologists (k=0.36). 'Moderate' agreement was observed on CNBs among breast specialists (k=0.44) and on excision samples (k=0.49). Up to 23% of lesions confidently diagnosed as FA on CNB were PT on excision and up to 30% of lesions confidently diagnosed as PT on CNB were FA on excision. Digital point counting did not aid in the classification of FELs. Conclusion Accurate and reproducible diagnosis of equivocal FELs is difficult, particularly on CNB, resulting in poor interobserver agreement and suboptimal accuracy. Given the diagnostic difficulty, and surgical implications, equivocal FELs should be reported in consultation with experienced breast pathologists as a small number of benign FAs can be selected out from equivocal lesions.	[Dessauvagie, Benjamin F.; Nijhawan, Anju; Treanor, Darren; Umar, Seemeen; Hanby, Andrew M.; Millican-Slater, Rebecca] Leeds Teaching Hosp NHS Trust, St Jamess Univ Hosp, Dept Cellular Pathol, Leeds, W Yorkshire, England; [Dessauvagie, Benjamin F.; Treanor, Darren; Hanby, Andrew M.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England; [Dessauvagie, Benjamin F.; Tie, Bibiana] Fiona Stanley Hosp, Dept Anat Pathol, PathWest Lab Med, Murdoch, WA, Australia; [Dessauvagie, Benjamin F.; Meehan, Katie] Univ Western Australia, UWA Med Sch, Perth, WA, Australia; [Dessauvagie, Benjamin F.; Meehan, Katie] Univ Western Australia, Sch Biomed Sci, Perth, WA, Australia; [Lee, Andrew H. S.] Nottingham Univ Hosp NHS Trust, Dept Histopathol, Nottingham, England; [Tan, Puay Hoon] Singapore Gen Hosp, Div Pathol, Singapore, Singapore; [Thomas, Jeremy] Western Gen Hosp, Dept Pathol, Edinburgh, Midlothian, Scotland; [Treanor, Darren] Linkoping Univ, Linkoping, Sweden	Dessauvagie, BF (reprint author), Fiona Stanley Hosp, Dept Anat Pathol, PathWest Lab Med, Murdoch, WA, Australia.	ben.dessauvagie@health.wa.gov.au					Abdulcadir D, 2014, EJSO-EUR J SURG ONC, V40, P859, DOI 10.1016/j.ejso.2014.02.222; Bandyopadhyay S, 2016, HUM PATHOL, V47, P38, DOI 10.1016/j.humpath.2015.09.001; Bode MK, 2007, ACTA RADIOL, V48, P708, DOI 10.1080/02841850701367911; Chng TW, 2016, J CLIN PATHOL, V69, P1124, DOI 10.1136/jclinpath-2016-203951; Cserni G, 2006, PATHOL ONCOL RES, V12, P216, DOI 10.1007/BF02893415; Dillon MF, 2006, SURGERY, V140, P779, DOI 10.1016/j.surg.2006.03.022; Foxcroft LM, 2007, BREAST, V16, P27, DOI 10.1016/j.breast.2006.05.004; Hanby A.M., 2017, DIAGN HISTOPATHOL, V23, P149; Jacobs TW, 2005, AM J CLIN PATHOL, V124, P342, DOI 10.1309/5N2C4N5XCV8XW8JL; Jara-Lazaro AR, 2010, HISTOPATHOLOGY, V57, P220, DOI 10.1111/j.1365-2559.2010.03607.x; Komenaka IK, 2003, ARCH SURG-CHICAGO, V138, P987, DOI 10.1001/archsurg.138.9.987; Lawton TJ, 2014, INT J SURG PATHOL, V22, P695, DOI 10.1177/1066896914548763; Lee AHS, 2007, HISTOPATHOLOGY, V51, P336, DOI 10.1111/j.1365-2559.2007.02786.x; Lee AH, 2016, GUIDELINES NONOPERAT; McKenna AM, 2007, ARCH PATHOL LAB MED, V131, P1568; Tsang AKH, 2011, HISTOPATHOLOGY, V59, P600, DOI 10.1111/j.1365-2559.2011.03939.x; Wright Alexander I, 2015, J Pathol Inform, V6, P8, DOI 10.4103/2153-3539.151906; Yasir S, 2014, AM J CLIN PATHOL, V142, P362, DOI 10.1309/AJCPZUZ96RESGPUP	18	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					672	679		10.1136/jclinpath-2017-204977			8	Pathology	Pathology	GR3CW	WOS:000442467400003	29440134	Green Published			2019-10-28	
J	Haynes, HR; Killick-Cole, CL; Hares, KM; Redondo, J; Kemp, KC; Moutasim, KA; Faulkner, C; Wilkins, A; Kurian, KM				Haynes, Harry R.; Killick-Cole, Clare L.; Hares, Kelly M.; Redondo, Juliana; Kemp, Kevin C.; Moutasim, Karwan A.; Faulkner, Claire; Wilkins, Alastair; Kurian, Kathreena M.			Evaluation of the quality of RNA extracted from archival FFPE glioblastoma and epilepsy surgical samples for gene expression assays	JOURNAL OF CLINICAL PATHOLOGY			English	Article							PARAFFIN-EMBEDDED TISSUE; NEWLY-DIAGNOSED GLIOBLASTOMA; BREAST-CANCER; GLIOMAS; BRAIN; MICRODISSECTION; BEVACIZUMAB; FIXATION; RECOVERY; TUMORS	Aims Histopathological tissue samples are being increasingly used as sources of nucleic acids in molecular pathology translational research. This study investigated the suitability of glioblastoma and control central nervous system (CNS) formalin-fixed paraffin embedded (FFPE) tissue-derived RNA for gene expression analyses. Methods Total RNA was extracted from control (temporal lobe resection tissue) and glioblastoma FFPE tissue samples. RNA purity (260/280 ratios) was determined and RNA integrity number (RIN) analysis was performed. RNA was subsequently used for RT-qPCR for two reference genes, 185 and GAPDH. Results Reference gene expression was equivalent between control and glioblastoma tissue when using RNA extracted from FFPE tissue, which has key implications for biological normalisation for CNS gene expression studies. There was a significant difference between the mean RIN values of control and glioblastoma FFPE tissue. There was no significant correlation between 260/280 or RIN values versus total RNA yield. The age of the tissue blocks did not influence RNA yield, fragmentation or purity. There was no significant correlation between RIN or 260/280 ratios and mean qPCR cycle threshold for either reference gene. Conclusions This study showed that routinely available CNS FFPE tissue is suitable for RNA extraction and downstream gene expression studies, even after 60 months of storage. Substantial RNA fragmentation associated with glioblastoma and control FFPE tissue blocks did not preclude downstream RT-qPCR gene expression analyses. Cross validation with both archival and prospectively collated FFPE specimens is required to further demonstrate that CNS tissue blocks can be used in novel translational molecular biomarker studies.	[Haynes, Harry R.; Kurian, Kathreena M.] Univ Bristol, Inst Clin Neurosci, Brain Tumour Res Grp, Bristol, Avon, England; [Haynes, Harry R.] North Bristol NHS Trust, Dept Cellular Pathol, Bristol, Avon, England; [Killick-Cole, Clare L.] Univ Bristol, Inst Clin Neurosci, Funct Neurosurg Res Grp, Bristol, Avon, England; [Hares, Kelly M.; Redondo, Juliana; Kemp, Kevin C.; Wilkins, Alastair] Univ Bristol, Inst Clin Neurosci, MS & Stem Cell Res Grp, Bristol, Avon, England; [Moutasim, Karwan A.] Univ Hosp Southampton NHS Fdn Trust, Dept Cellular Pathol, Southampton, Hants, England; [Faulkner, Claire] North Bristol NHS Trust, Bristol Genet Lab, Bristol, Avon, England	Haynes, HR (reprint author), Univ Bristol, Southmead Hosp, Clin Neurosci, Bristol BS10 5NB, Avon, England.	harryrhaynes@doctors.org.uk	Kemp, Kevin/B-9755-2017	Kemp, Kevin/0000-0003-1465-1309	Pathological Society and Jean Shanks Foundation Pathological Research Training Fellowship (HRH); Brain Tumour Bank South West (BRASH) at North Bristol NHS Trust UK; Medical Research Council and Brainstrust	This work was supported by the Pathological Society and Jean Shanks Foundation Pathological Research Training Fellowship (HRH) and the Brain Tumour Bank South West (BRASH) at North Bristol NHS Trust UK. FFPE tissue samples were obtained from North Bristol NHS Trust as part of the UK Brain Archive Information Network (BRAIN UK), which is funded by the Medical Research Council and Brainstrust.	Abdueva D, 2010, J MOL DIAGN, V12, P409, DOI 10.2353/jmoldx.2010.090155; Appleby-Mallinder C, 2016, J NEUROSCI METH, V268, P125, DOI 10.1016/j.jneumeth.2016.05.007; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Chung JY, 2006, DIAGN MOL PATHOL, V15, P229, DOI 10.1097/01.pdm.0000213468.91139.2d; Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007; Conley BA, 2004, DIS MARKERS, V20, P35, DOI 10.1155/2004/202031; Dubbink HJ, 2014, MOL ONCOL, V8, P830, DOI 10.1016/j.molonc.2014.03.004; Dundas J, 2012, THEOR BIOSCI, V131, P215, DOI 10.1007/s12064-012-0152-5; Durrenberger PF, 2010, J NEUROPATH EXP NEUR, V69, P70, DOI 10.1097/NEN.0b013e3181c7e32f; Esteve-Codina A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170632; Fairley JA, 2012, CURR DRUG TARGETS, V13, P1475; Farragher SM, 2008, HISTOCHEM CELL BIOL, V130, P435, DOI 10.1007/s00418-008-0479-7; Fend F, 2000, J CLIN PATHOL, V53, P666, DOI 10.1136/jcp.53.9.666; Geffen DB, 2011, ANN ONCOL, V22, P2381, DOI 10.1093/annonc/mdq769; Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573; Gramatzki D, 2016, CANCER-AM CANCER SOC, V122, P2206, DOI 10.1002/cncr.30023; Gravendeel LAM, 2012, BRIT J CANCER, V106, P538, DOI 10.1038/bjc.2011.547; Greytak SR, 2015, CANCER RES, V75, P1541, DOI 10.1158/0008-5472.CAN-14-2378; Harris G, 2017, HISTOPATHOLOGY, V70, P123, DOI 10.1111/his.13067; Haynes HR, 2017, HISTOPATHOLOGY, V70, P1030, DOI 10.1111/his.13142; Haynes HR, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00047; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Johnson DR, 2013, CURR ONCOL REP, V15, P56, DOI 10.1007/s11912-012-0279-z; Kojima K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086961; Kristensen VN, 2014, NAT REV CANCER, V14, P299, DOI 10.1038/nrc3721; Kurian KM, 2013, BRIT J NEUROSURG, V27, P442, DOI 10.3109/02688697.2013.771139; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ludyga N, 2012, VIRCHOWS ARCH, V460, P131, DOI 10.1007/s00428-011-1184-9; Martelotto LG, 2017, NAT MED, V23, P376, DOI 10.1038/nm.4279; Mittempergher L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017163; Movassaghi M, 2017, EXP MOL PATHOL, V103, P87, DOI 10.1016/j.yexmp.2017.06.006; Ortiz MV, 2016, PEDIATR BLOOD CANCER, V63, P1368, DOI 10.1002/pbc.26002; Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207; Ribeiro-Silva A, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-118; ThermoScientific, 2006, TECHN B ASS NUCL AC; Turashvili G, 2012, EXP MOL PATHOL, V92, P33, DOI 10.1016/j.yexmp.2011.09.013; van Maldegem F, 2008, DIAGN MOL PATHOL, V17, P51, DOI 10.1097/PDM.0b013e31814b8866; von Ahlfen S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001261; Walter RFH, 2013, PATHOL RES PRACT, V209, P784, DOI 10.1016/j.prp.2013.09.007	39	2	2	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					695	701		10.1136/jclinpath-2017-204969			7	Pathology	Pathology	GR3CW	WOS:000442467400006	29463577				2019-10-28	
J	Lin, MX; Lee, PL; Chiu, L; Chua, C; Ban, KHK; Lin, AHF; Chan, ZL; Chung, TH; Yan, B; Chng, WJ				Lin, Mingxuan; Lee, Peak Ling; Chiu, Lily; Chua, Constance; Ban, Kenneth H. K.; Lin, Adeline H. F.; Chan, Zit Liang; Chung, Tae-Hoon; Yan, Benedict; Chng, Wee-Joo			Identification of novel fusion transcripts in multiple myeloma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							GENE; MYC	Aims Multiple myeloma (MM) is a heterogeneous disease characterised by genetically complex abnormalities. The classical mutational spectrum includes recurrent chromosomal aberrations and gene-level mutations. Recurrent translocations involving the IGH gene such as t(11;14), t(4;14) and t(14;16) are well known. However, the presence of complex genetic abnormalities raises the possibility that fusions other than the recurrent IGH translocations exist. We therefore employed a targeted RNA-sequencing panel to identify novel putative fusions in a local cohort of MM. Methods Targeted RNA-sequencing was performed on 21 patient samples using the Illumina TruSight RNA Pan-Cancer Panel (comprising 1385 genes). Fusion calls were generated from the Illumina RNA-Sequencing Alignment software (V.1.0.0). These samples had conventional cytogenetic and fluorescence in situ hybridisation data for the common recurrent chromosomal abnormalities (t(11;14), t(4;14), t(14;16) and 17p13 deletion). The MMRF CoMMpass dataset was analysed using the TopHat-fusion pipeline. Results A total of 10 novel fusions were identified by the TruSight RNA Pan-Cancer Panel. Two of these fusions, HGFICACNA2D1 and SMC31MX11, were validated by reverse transcription PCR and Sanger sequencing as they involve genes that may have biological relevance in MM genesis. Four of these (MAP2K41MAP2K4P1) are likely to be spurious secondary to misalignment of reads to a pseudogene. One record of the HGF/CACNA2D1 fusion was identified from the MMRF CoMMpass dataset. Conclusions The identification of novel fusions offers insights into the biology of MM and might have clinical relevance. Further functional studies are required to determine the biological and clinical relevance of these novel fusions.	[Lin, Mingxuan; Chiu, Lily; Yan, Benedict] Natl Univ Hlth Syst, Dept Lab Med, Mol Diag Ctr, Singapore 119074, Singapore; [Lee, Peak Ling; Chua, Constance] Natl Univ Hlth Syst, Dept Lab Med, Cytogenet Lab, Singapore, Singapore; [Ban, Kenneth H. K.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore, Singapore; [Lin, Adeline H. F.; Chng, Wee-Joo] Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119074, Singapore; [Chan, Zit Liang; Chung, Tae-Hoon; Chng, Wee-Joo] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Yan, Benedict] Natl Univ Hlth Syst, Translat Ctr Dev & Res, Singapore, Singapore; [Chng, Wee-Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore	Yan, B (reprint author), Natl Univ Hlth Syst, Dept Lab Med, Mol Diag Ctr, Singapore 119074, Singapore.; Chng, WJ (reprint author), Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol Oncol, Singapore 119074, Singapore.	benedict_yan@nuhs.edu.sg; mdccwj@nus.edu.sg			NUHS Clinician Research Grant from the NUHS Research Office award [NUHSRO/2016/026/CRG/05]	This study was partially supported by the NUHS Clinician Research Grant (grant number NUHSRO/2016/026/CRG/05) from the NUHS Research Office awarded to Benedict Yan.	Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; GOULD J, 1988, BLOOD, V71, P453; Jia YM, 2016, TRENDS CANCER, V2, P475, DOI 10.1016/j.trecan.2016.07.006; Kumar S, 2016, WIRES RNA, V7, P811, DOI 10.1002/wrna.1382; Liu JY, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.87, 10.1038/nmicrobiol.2016.87]; Mahtouk K, 2010, BBA-REV CANCER, V1806, P208, DOI 10.1016/j.bbcan.2010.07.006; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Nagoshi H, 2012, CANCER RES, V72, P4954, DOI 10.1158/0008-5472.CAN-12-0213; Pratt G, 2002, J CLIN PATHOL-MOL PA, V55, P273, DOI 10.1136/mp.55.5.273; Preudhomme C, 2000, ONCOGENE, V19, P2023, DOI 10.1038/sj.onc.1203521; Saez B, 2006, CANCER GENET CYTOGEN, V169, P143, DOI 10.1016/j.cancergencyto.2006.04.008; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tjin EPM, 2004, BLOOD, V104, P2172, DOI 10.1182/blood-2003-12-4386; Wong WJ, 2013, MOL CELL BIOL, V33, P3494, DOI 10.1128/MCB.00853-12; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406	16	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					708	712		10.1136/jclinpath-2017-204961			5	Pathology	Pathology	GR3CW	WOS:000442467400008	29453220				2019-10-28	
J	Susanti, S; Fadhil, W; Ebili, HO; Asiri, A; Nestarenkaite, A; Hadjimichael, E; Ham-Karim, HA; Field, J; Stafford, K; Matharoo-Ball, B; Hassall, JC; Sharif, A; Oniscu, A; Ilyas, M				Susanti, Susanti; Fadhil, Wakkas; Ebili, Henry Okuchukwu; Asiri, Abutaleb; Nestarenkaite, Ausrine; Hadjimichael, Efthymios; Ham-Karim, Hersh A.; Field, Joanne; Stafford, Katherine; Matharoo-Ball, Balwir; Hassall, James C.; Sharif, Abid; Oniscu, Anca; Ilyas, Mohammad			N_LyST: a simple and rapid screening test for Lynch syndrome	JOURNAL OF CLINICAL PATHOLOGY			English	Article							RESOLUTION MELTING ANALYSIS; HEREDITARY COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; COST-EFFECTIVENESS; COLON-CANCER; MUTATION DETECTION; GERMLINE MUTATION; BRAF MUTATION; KRAS; PCR	Aims We sought to use PCR followed by high-resolution melting analysis to develop a single closed-tube screening panel to screen for Lynch syndrome. This comprises tests for microsatellite instability (MSI), MLH1 methylation promoter and BRAF mutation. Methods For MSI testing, five mononucleotide markers (BAT25, BAT26, BCAT25, MYB, EWSR1) were developed. In addition, primers were designed to interrogate Region C of the MLH1 promoter for methylation (using bisulphite-modified DNA) and to test for mutations in codon 600 of BRAF. Two separate cohorts from Nottingham (n=99, 46 with MSI, 53 being microsatellite stable (MSS)) and Edinburgh (n=88, 45 MSI, 43 MSS) were tested. Results All the cases (n=187) were blind tested for MSI and all were correctly characterised by our panel. The MLH1 promoter and BRAF were tested only in the Nottingham cohort. Successful blinded analysis was performed on the MLH1 promoter in 97 cases. All MSS cases showed a pattern of non-methylation while 41/44 cases with MSI showed full methylation. The three cases with MSI and a non-methylated pattern had aberrations in MSH2 and MSH6 expression. BRAF mutation was detected in 61% of MSI cases and 11% of MSS cases. Finally, 12 cases were blind screened by using the whole panel as a single test. Of these, five were identified as MSS, four as MSI/non-LS and three as MSI/possible LS. These results were concordant with the previous data. Conclusion We describe the Nottingham Lynch Syndrome Test (N_LyST). This is a quick, simple and cheap method for screening for Lynch syndrome	[Susanti, Susanti; Fadhil, Wakkas; Ebili, Henry Okuchukwu; Asiri, Abutaleb; Hadjimichael, Efthymios; Ham-Karim, Hersh A.; Hassall, James C.; Ilyas, Mohammad] Univ Nottingham, Sch Med, Div Canc & Stem Cell, Mol Pathol Grp,Unit Acad Mol Pathol,Queens Med Ct, Nottingham, England; [Susanti, Susanti] Univ Muhammadiyah Purwokerto, Dept Pharmacol & Clin Pharm, Fac Pharm, Cent Java, Indonesia; [Susanti, Susanti; Fadhil, Wakkas; Ebili, Henry Okuchukwu; Asiri, Abutaleb; Hadjimichael, Efthymios; Ham-Karim, Hersh A.; Hassall, James C.; Ilyas, Mohammad] Univ Nottingham, Queens Med Ctr, Nottingham Mol Pathol Node, Nottingham, England; [Ebili, Henry Okuchukwu] Olabisi Onabanjo Univ, Dept Morbid Anat & Histopathol, Ago Iwoye, Nigeria; [Nestarenkaite, Ausrine] Vilnius Univ Hosp Santaros Klin, Natl Ctr Pathol, Vilnius, Lithuania; [Field, Joanne; Stafford, Katherine; Sharif, Abid] Nottingham Univ Hosp NHS Trust, East Midlands Reg Mol Genet Serv, Nottingham, England; [Matharoo-Ball, Balwir] Nottingham Univ Hosp NHS Trust, Nottingham Hlth Sci Biobank, Nottingham, England; [Oniscu, Anca] Royal Infirm Hosp, Mol Pathol, Edinburgh, Midlothian, Scotland	Ilyas, M (reprint author), Univ Nottingham, Div Pathol, Nottingham NG7 2UH, England.	mohammad.ilyas@nottingham.ac.uk		Hadjimichael, Efthymios/0000-0002-4622-1488	EC Marie Curie Actions, AIDPATH projectEuropean Union (EU) [612471]; Nottingham Molecular Pathology Node (NMPN)	This research received financial support from the EC Marie Curie Actions, AIDPATH project (Contract No. 612471) and Nottingham Molecular Pathology Node (NMPN).	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Bacher JW, 2004, DIS MARKERS, V20, P237, DOI 10.1155/2004/136734; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Boland CR, 1998, CANCER RES, V58, P5248; Bouzourene H, 2010, FAM CANCER, V9, P167, DOI 10.1007/s10689-009-9302-4; Chiaravalli AM, 2001, VIRCHOWS ARCH, V438, P39, DOI 10.1007/s004280000325; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Deng GR, 1999, CANCER RES, V59, P2029; Des Guetz G, 2009, EUR J CANCER, V45, P1890, DOI 10.1016/j.ejca.2009.04.018; Dietmaier W, 2001, LAB INVEST, V81, P1453, DOI 10.1038/labinvest.3780358; Ebili Henry O, 2017, J Biomol Tech, V28, P97, DOI 10.7171/jbt.17-2803-001; Fadhil W, 2014, INT J EXP PATHOL, V95, P16, DOI 10.1111/iep.12070; Fadhil W, 2012, HISTOPATHOLOGY, V61, P1117, DOI 10.1111/j.1365-2559.2012.04321.x; Fadhil W, 2010, J CLIN PATHOL, V63, P134, DOI 10.1136/jcp.2009.070508; Gausachs M, 2012, EUR J HUM GENET, V20, P762, DOI 10.1038/ejhg.2011.277; Grosse SD, 2015, GENET MED, V17, P510, DOI 10.1038/gim.2015.53; Gryfe Robert, 2009, Clin Colon Rectal Surg, V22, P198, DOI 10.1055/s-0029-1242459; Hampel H, 2009, SURG ONCOL CLIN N AM, V18, P687, DOI 10.1016/j.soc.2009.08.001; Ibrahem S, 2010, INT J EXP PATHOL, V91, P500, DOI 10.1111/j.1365-2613.2010.00733.x; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Janavicius R, 2010, CLIN CHEM, V56, P1750, DOI 10.1373/clinchem.2010.150680; Kastrinos F, 2011, CANCER J, V17, P405, DOI 10.1097/PPO.0b013e318237e408; Kishore S, 2014, CANCER RES, V74, P224, DOI 10.1158/0008-5472.CAN-13-2100; Klingbiel D, 2015, ANN ONCOL, V26, P126, DOI 10.1093/annonc/mdu499; Kondelin J, 2015, FAM CANCER, V14, P449, DOI 10.1007/s10689-015-9804-1; Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295; Leenen CHM, 2016, GENET MED, V18, P966, DOI 10.1038/gim.2015.206; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Montgomery J, 2007, NAT PROTOC, V2, P59, DOI 10.1038/nprot.2007.10; National Institute for Health and Care Excellence, MOL TEST STRAT LYNCH; Nowak JA, 2017, J MOL DIAGN, V19, P84, DOI 10.1016/j.jmoldx.2016.07.010; Peltomaki P, 2003, J CLIN ONCOL, V21, P1174, DOI 10.1200/JCO.2003.04.060; Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512; Seth R, 2009, GUT, V58, P1234, DOI 10.1136/gut.2008.159137; Shia J, 2005, AM J SURG PATHOL, V29, P96, DOI 10.1097/01.pas.0000146009.85309.3b; Simi L, 2008, AM J CLIN PATHOL, V130, P247, DOI 10.1309/LWDY1AXHXUULNVHQ; Snowsill T, 2017, HEALTH TECHNOL ASSES, V21, P1, DOI 10.3310/hta21510; Stewart S, 2011, BIOTECHNOL LETT, V33, P2217, DOI 10.1007/s10529-011-0682-9; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Thiel A, 2013, VIRCHOWS ARCH, V463, P613, DOI 10.1007/s00428-013-1470-9; Tomlinson I, 2015, ANN CLIN BIOCHEM, V52, P690, DOI 10.1177/0004563215597944; Woerner SM, 2010, NUCLEIC ACIDS RES, V38, pD682, DOI 10.1093/nar/gkp839; Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397; Zhang L., 2008, J MOL DIAGN, V10	46	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					713	720		10.1136/jclinpath-2018-205013			8	Pathology	Pathology	GR3CW	WOS:000442467400009	29472252	Green Accepted			2019-10-28	
J	Chen, L; Chen, MH; Han, ZL; Jiang, FX; Xu, CY; Qin, Y; Ding, N; Liu, Y; Zhang, TL; An, ZJ; Guo, CY				Chen, Ling; Chen, Meihui; Han, Zenglei; Jiang, Fengxing; Xu, Chunyuan; Qin, Yue; Ding, Ning; Liu, Yang; Zhang, Tenglong; An, Zhijie; Guo, Chengye			Clinical significance of FAP-alpha on microvessel and lymphatic vessel density in lung squamous cell carcinoma	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CANCER-ASSOCIATED FIBROBLASTS; POOR-PROGNOSIS; TUMOR MICROENVIRONMENT; ACTIVATION PROTEIN; ANGIOGENESIS; METASTASIS; STROMA; LYMPHANGIOGENESIS; VEGF; MYOFIBROBLASTS	Aims We aimed to determine whether cancer-associated fibroblasts (CAFs) are associated with microvessel density (MVD) and lymphatic vessel density (LVD) in lung squamous cell carcinoma, as well as their clinical significance in predicting survival. Methods 122 patients were enrolled in the study. Samples were obtained on resection at the Department of Thoracic Surgery of the Qingdao Municipal Hospital between January 2011 and December 2014. Immunohistochemistry was used to determine vessel and lymphatic vessel density, and CAF abundance (fibroblast activation protein alpha (FAP-alpha) positivity). Statistical analyses were performed on 85 patients to test for correlation of CAF density and other clinicopathological variables with 3-year overall survival (OS) and disease-free survival (DFS). Results High stromal CAF abundance significantly correlated with increased MVD and LVD in lung squamous cell carcinoma (p<0.05). chi(2) test revealed a significant association of CAF density with lymph node metastasis. Cox proportional hazards model showed that both higher CAF density and lymph node metastasis negatively correlate with survival. CAF density or lymph node status can be used as an independent prognostic factor to predict 3-year OS and DFS. Conclusions CAF density, identified by FAP-alpha staining pattern, should be considered as a novel biomarker for disease prognosis in patients with lung squamous cell carcinoma.	[Chen, Ling; Han, Zenglei; Xu, Chunyuan; Liu, Yang; Zhang, Tenglong; An, Zhijie; Guo, Chengye] Qingdao Municipal Hosp, Dept Oncol, Qingdao 266000, Peoples R China; [Chen, Meihui; Qin, Yue; Ding, Ning] Qingdao Univ, Inst Clin Med, Med Coll, Qingdao, Peoples R China; [Jiang, Fengxing] Qingdao Municipal Hosp, Div Hepatobiliary & Pancreat Surg, Qingdao, Peoples R China	An, ZJ (reprint author), Qingdao Municipal Hosp, Dept Oncol, Qingdao 266000, Peoples R China.; Guo, CY (reprint author), Qingdao Municipal Hosp, Dept Oncol, Qingdao 266012, Peoples R China.	18661628172@163.com; chengye_guo@126.com			Qingdao Municipal Hospital	This study was funded by Qingdao Municipal Hospital.	Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Bremnes RM, 2006, LUNG CANCER, V51, P143, DOI 10.1016/j.lungcan.2005.09.005; Bremnes RM, 2011, J THORAC ONCOL, V6, P209, DOI 10.1097/JTO.0b013e3181f8a1bd; Cheng YF, 2015, INT J CLIN EXP MED, V8, P1896; Cirri P, 2011, AM J CANCER RES, V1, P482; Derman BA, 2015, TRANSL LUNG CANCER R, V4, P524, DOI 10.3978/j.issn.2218-6751.2015.06.07; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Feng LH, 2017, ONCOTARGET, V8, P87329, DOI 10.18632/oncotarget.20607; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Giatromanolaki A, 2002, AM J CLIN ONCOL-CANC, V25, P38, DOI 10.1097/00000421-200202000-00007; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; Imamura M, 2007, MODERN PATHOL, V20, P529, DOI 10.1038/modpathol.3800767; Kellermann MG, 2007, HISTOPATHOLOGY, V51, P849, DOI 10.1111/j.1365-2559.2007.02873.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kilvaer TK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134965; Liao YD, 2013, J CANCER RES CLIN, V139, P1523, DOI 10.1007/s00432-013-1471-8; Matsuyama K, 1998, ANN THORAC SURG, V65, P1405, DOI 10.1016/S0003-4975(97)01416-1; Mori D, 2007, MODERN PATHOL, V20, P694, DOI 10.1038/modpathol.3800786; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Mumprecht V, 2009, J CELL MOL MED, V13, P1405, DOI 10.1111/j.1582-4934.2009.00834.x; Qu S, 2016, ONCOL TRANSL MED, V2, P7; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; Saigusa S, 2011, INT J ONCOL, V38, P655, DOI 10.3892/ijo.2011.906; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Takagi K, 2005, J GASTROENTEROL, V40, P402, DOI 10.1007/s00535-004-1556-x; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Vered M, 2010, CANCER SCI, V101, P274, DOI 10.1111/j.1349-7006.2009.01357.x; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Werynska B, 2009, FOLIA HISTOCHEM CYTO, V47, P333, DOI 10.2478/v10042-009-0090-3; Xing F, 2010, FRONT BIOSCI-LANDMRK, V15, P166, DOI 10.2741/3613; Yurugi Y, 2017, ANTICANCER RES, V37, P207, DOI 10.21873/anticanres.11308; Zhang B, 2016, ACS APPL MATER INTER, V8, P8918, DOI 10.1021/acsami.6b00036	34	1	1	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					721	728		10.1136/jclinpath-2017-204872			8	Pathology	Pathology	GR3CW	WOS:000442467400010	29559517				2019-10-28	
J	La Gioia, A; Fumi, M; Fiorini, F; Pezzati, P; Balboni, F; Bombara, M; Marini, A; Pancione, Y; Solarino, L; Marchese, E; Sale, S; Rocco, V; Fiorini, M				La Gioia, Antonio; Fumi, Maurizio; Fiorini, Fabiana; Pezzati, Paola; Balboni, Fiamma; Bombara, Maria; Marini, Alessandra; Pancione, Ylenia; Solarino, Leonardo; Marchese, Elisa; Sale, Silvia; Rocco, Vincenzo; Fiorini, Marcello			Short preheating at 41 degrees C leads to a red blood cells count comparable to that in RET channel of Sysmex analysers in samples showing cold agglutination	JOURNAL OF CLINICAL PATHOLOGY			English	Article							S COULTER-COUNTER; HEMATOLOGY ANALYZERS; SPURIOUS COUNTS; HEMOGLOBIN; INDEXES; PARAMETERS; PATIENT; VALUES	Aims The presence of cold agglutinin in blood samples can cause a spontaneous agglutination of red blood cells (RBCs) when low temperature occurs. This phenomenon causes a spurious lowering of RBC count on the automated haematological analysers that are detected by incongruous values (>= 370 g/L) of the mean cellular haemoglobi concentration (MCHC). A preheating at 37 degrees C can remove the RBC agglutination generally resulting in a reliable count. It has been reported that the same result can be reached by using the optical reticulocyte (RET) channel of Sysmex analysers where the RBC count is not influenced by the presence of cold agglutinin. This study aims to evaluate these data in a larger population, with regard to environmental conditions on Sysmex analysers. We have also evaluated the influence of different thermal pretreatments on the RBC count. Methods This study was performed on 96 remnants of peripheral blood samples (48 with MCHC in normal range and 48 with MCHC >= 370g/L) which have been analysed in different preanalytical conditions on the Sysmex analysers. Results A preheating of samples at 41 degrees C for 1 min leads to a reversibility of the cold agglutination comparable to the one observed in the RET channel and yields better results compared with 37 degrees C for 2 hours. Conclusions None of described procedures assure the complete cold agglutination reversibility in every case. Consequently, since the haematological analysers not yet provide reliable parameters to confirm the complete resolution of agglutination, further verification of RBC count accuracy needs to be performed.	[La Gioia, Antonio] Docemus Onlus Theoret & Pract Training Sch Improv, Torrevecchia Teatina, Italy; [Fumi, Maurizio; Pancione, Ylenia; Sale, Silvia; Rocco, Vincenzo] UO Patol Clin AORN G Rummo, Benevento, Italy; [Fiorini, Fabiana] UOC Med Lab Azienda USL Toscana Nord Ovest, Pontedera, Italy; [Pezzati, Paola] Ctr Reg Controllo Qualita AOU Careggi, Florence, Italy; [Balboni, Fiamma] Ist Fiorentino Cura & Assistenza, Lab Anal IFCA, Florence, Italy; [Bombara, Maria; Fiorini, Marcello] UOC Med Lab Azienda USL Toscana Nord Ovest, Livorno, Italy; [Marini, Alessandra] UOC Med Lab Azienda USL Toscana Nord Ovest, Versilia, Italy; [Solarino, Leonardo; Marchese, Elisa] Azienda Univ Osped, UOC Lab Anal 1, Policlin Vittorio Emanuele, Catania, Italy	La Gioia, A (reprint author), Docemus Onlus Theoret & Pract Training Sch Improv, Torrevecchia Teatina, Italy.	ant.lagioia@gmail.com					Bendix BJ, 2014, TRANSFUSION, V54, P1294, DOI 10.1111/trf.12453; Berda-Haddad Y, 2017, INT J LAB HEMATOL, V39, P32, DOI 10.1111/ijlh.12565; Berentsen S., 2018, BRIT J HAEMATOL, P126; Berentsen S, 2016, HEMATOL-AM SOC HEMAT, P226, DOI 10.1182/asheducation-2016.1.226; BESSMAN JD, 1980, AM J CLIN PATHOL, V74, P797; BRITTIN GM, 1969, AM J CLIN PATHOL, V52, P237; Cembrowski GS, 2015, CLIN LAB MED, V35, P59, DOI 10.1016/j.cll.2014.10.006; Choccalingam C, 2016, J CLIN DIAGN RES, V10, pED10, DOI 10.7860/JCDR/2016/21990.8852; *CLSI, 2008, C28A3 CLSI IFCC, V28, P1; Ercan S, 2014, BIOCHEM MEDICA, V24, P391, DOI 10.11613/BM.2014.042; Ferrero-Vacher C, 2015, ANN BIOL CLIN-PARIS, V73, P729, DOI 10.1684/abc.2015.1093; FINLAND M, 1945, J CLIN INVEST, V24, P451, DOI 10.1172/JCI101623; Godon A, 2012, ANN BIOL CLIN-PARIS, V70, P155, DOI 10.1684/abc.2012.0685; HATTERSL.PG, 1971, AM J CLIN PATHOL, V55, P442; Hill QA, 2017, BRIT J HAEMATOL, V176, P395, DOI 10.1111/bjh.14478; Johnson F, 2002, LAB MED, V33, P457; La Gioia A, 2018, J CLIN PATHOL, V71, P168, DOI 10.1136/jclinpath-2017-204580; LaGioia A, 2016, CLIN CHEM LAB MED, V54; Mauro FR, 2017, HAEMATOLOGICA, V102, P473, DOI 10.3324/haematol.2017.177675; PETRUCCI JV, 1971, AM J CLIN PATHOL, V56, P500; Sandhaus LM, 2002, AM J CLIN PATHOL, V118, P787; Schoorl M, 2017, INT J LAB HEMATOL, V39, P489, DOI 10.1111/ijlh.12674; Shelat SG, 2011, DIAGNOSTIC PEDIAT HE, P77; SOLANKI DL, 1985, AM J CLIN PATHOL, V83, P218, DOI 10.1093/ajcp/83.2.218; Stamminger G, 2000, SYSMEX J IN, V10, P3; Swiecicki PL, 2013, BLOOD, V122, P1114, DOI 10.1182/blood-2013-02-474437; Wang H, 2013, CLIN LAB, V59, P217, DOI 10.7754/Clin.Lab.2012.120718; Wintrobe MM, 1934, ARCH INTERN MED, V54, P256, DOI 10.1001/archinte.1934.00160140099006; Yael B, 2015, CLIN CHEM LAB MED S1, V53, pS156, DOI [10.1515/cclm-2015-5003, DOI 10.1515/CCLM-2015-5003]; Zandecki M, 2007, INT J LAB HEMATOL, V29, P21, DOI 10.1111/j.1365-2257.2006.00871.x	30	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					729	734		10.1136/jclinpath-2017-204954			6	Pathology	Pathology	GR3CW	WOS:000442467400011	29535214				2019-10-28	
J	Matejckova, N; Zajicova, A; Hermankova, B; Kossl, J; Bohacova, P; Holan, V; Javorkova, E				Matejckova, Nicole; Zajicova, Alena; Hermankova, Barbora; Kossl, Jan; Bohacova, Pavla; Holan, Vladimir; Javorkova, Eliska			Characterisation of mesenchymal stem cells from patients with amyotrophic lateral sclerosis	JOURNAL OF CLINICAL PATHOLOGY			English	Article							STROMAL CELLS; INTERFERON-GAMMA; DIFFERENTIATION; TRANSPLANTATION; INTERLEUKIN-6; EXPRESSION; CRITERIA	Aims Mesenchymal stem cells (MSCs) have recently been tested in clinical trials to treat severe diseases, including amyotrophic lateral sclerosis (ALS). Since autologous MSCs are frequently used for therapy, we aimed to evaluate the possible influence of the disease on characteristics and function of these cells. Methods MSCs were isolated from the bone marrow of patients with ALS and compared with MSCs from healthy controls (HC). The cells were tested for phenotype, growth properties, differentiation ability, metabolic activity, secretory potential, expression of genes for immunomodulatory molecules and for the ability to regulate proliferation of mitogen-stimulated peripheral blood leucocytes. MSCs from patients with ALS and HC were either unstimulated or treated with proinflammatory cytokines for 24 hours before testing. Results MSCs isolated from patients with ALS have a higher differentiation potential into adipocytes, express elevated levels of mRNA for interleukin-6, but produce less hepatocyte growth factor than MSCs from HC. On the other hand, there were no significant differences between MSCs from patients with ALS and HC in the expression of phenotypic markers, growth properties, metabolic activity, osteogenic differentiation potential and immunoregulatory properties. Conclusions The results suggest that, in spite of some differences in cytokine production, MSCs from patients with ALS can be useful as autologous cells in therapy of ALS.	[Matejckova, Nicole; Zajicova, Alena; Hermankova, Barbora; Kossl, Jan; Bohacova, Pavla; Holan, Vladimir; Javorkova, Eliska] Czech Acad Sci, Dept Transplantat Immunol, Inst Expt Med, Prague 4, Czech Republic; [Matejckova, Nicole; Hermankova, Barbora; Kossl, Jan; Bohacova, Pavla; Holan, Vladimir; Javorkova, Eliska] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague, Czech Republic	Javorkova, E (reprint author), Czech Acad Sci, Dept Transplantat Immunol, Inst Expt Med, Prague 4, Czech Republic.	javorkova@biomed.cas.cz	Kossl, Jan/N-7871-2019	Kossl, Jan/0000-0001-7503-4131	Ministry of Education, Youth and SportsMinistry of Education, Youth & Sports - Czech Republic [CZ.1.05/1.1.00/02.0109, CZ.2.16/3.1.00/21528, NPUI: LO1309, NPUI: LO1508, SVV 244-260435]; Charles University [UNCE204013]	This research was funded by Ministry of Education, Youth and Sports (CZ.1.05/1.1.00/02.0109, CZ.2.16/3.1.00/21528, NPUI: LO1309, NPUI: LO1508, SVV 244-260435) and Charles University (UNCE204013).	Abumaree M, 2012, STEM CELL REV REP, V8, P375, DOI 10.1007/s12015-011-9312-0; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x; Brooks BR, 2000, AMYOTROPH LATERAL SC, V1, P293, DOI 10.1080/146608200300079536; Cho GW, 2010, STEM CELLS DEV, V19, P1035, DOI 10.1089/scd.2009.0453; Cipriani P, 2013, CLIN EXP IMMUNOL, V173, P195, DOI 10.1111/cei.12111; de Oliveira GLV, 2015, CELL TRANSPLANT, V24, P151, DOI 10.3727/096368913X675142; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56; Ferrero I, 2008, CELL TRANSPLANT, V17, P255, DOI 10.3727/096368908784153940; Gao P, 2015, MOL MED REP, V12, P1971, DOI 10.3892/mmr.2015.3632; Geng L, 2014, J IMMUNOL RES, V2014, P1; Harkins JM, 2004, J NUTR, V134, P2673; Jacobs SA, 2013, IMMUNOL CELL BIOL, V91, P32, DOI 10.1038/icb.2012.64; Javorkova E, 2014, STEM CELLS DEV, V23, P2490, DOI 10.1089/scd.2013.0568; Joe IS, 2015, NEUROSCI LETT, V584, P97, DOI 10.1016/j.neulet.2014.10.024; Koh SH, 2012, EXP NEUROL, V233, P472, DOI 10.1016/j.expneurol.2011.11.021; Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008; Labovsky V, 2016, TUMOR BIOL, V37, P13377, DOI 10.1007/s13277-016-5268-7; Larghero J, 2008, ANN RHEUM DIS, V67, P443, DOI 10.1136/ard.2007.071233; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Petrou P, 2016, JAMA NEUROL, V73, P337, DOI 10.1001/jamaneurol.2015.4321; Sohni A, 2013, STEM CELLS INT, DOI 10.1155/2013/130763; Sun Y, 2015, J IMMUNOL RES, DOI 10.1155/2015/284215; Sykova E, 2017, CELL TRANSPLANT, V26, P647, DOI 10.3727/096368916X693716; Tang Y, 2013, STEM CELLS DEV, V22, P668, DOI 10.1089/scd.2012.0226; Yan ZD, 2014, IMMUNOL LETT, V162, P248, DOI 10.1016/j.imlet.2014.09.013; Zeng X, 2015, BIOMATERIALS, V53, P184, DOI 10.1016/j.biomaterials.2015.02.073	28	1	1	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					735	742		10.1136/jclinpath-2017-204681			8	Pathology	Pathology	GR3CW	WOS:000442467400012	29523587				2019-10-28	
J	Libbrecht, L; Baldin, P; Dekairelle, AF; Jouret-Mourin, A				Libbrecht, Louis; Baldin, Pamela; Dekairelle, Anne-France; Jouret-Mourin, Anne			Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MUTATIONS; TRIAL; CELLS	Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessment by a pathologist, which has been criticised for being inaccurate and suffering from interobserver variability. Based on the 'Big Bang theory' which states that KRAS mutation in colorectal cancer is mostly homogeneous, we investigated this issue by performing a critical analysis of the correlation of the KRAS mutant allele fraction with the TNP in 99 colorectal tumour samples with a positive KRAS mutation status as determined by next-generation sequencing. Our results yield indirect evidence that the KRAS zygosity status influences the correlation between these parameters and we show that a well-trained pathologist is indeed capable of accurately assessing TNP. Our findings indicate that tumour zygosity, a feature which has largely been neglected until now, should be taken into account in future studies on (colorectal) molecular tumour heterogeneity.	[Libbrecht, Louis; Baldin, Pamela; Jouret-Mourin, Anne] Univ Hosp St Luc, Dept Pathol, B-1200 Brussels, Belgium; [Dekairelle, Anne-France] Univ Hosp St Luc, Dept Genet, Brussels, Belgium	Libbrecht, L (reprint author), Univ Hosp St Luc, Dept Pathol, B-1200 Brussels, Belgium.	louis.libbrecht@uclouvain.be					Boleij A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2810-3; Haley L, 2015, MODERN PATHOL, V28, P1390, DOI 10.1038/modpathol.2015.86; Normanno N, 2015, ANN ONCOL, V26, P1710, DOI 10.1093/annonc/mdv176; Smits AJJ, 2014, MODERN PATHOL, V27, P168, DOI 10.1038/modpathol.2013.134; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Viray H, 2013, ARCH PATHOL LAB MED, V137, P1545, DOI 10.5858/arpa.2012-0561-CP	7	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					743	744		10.1136/jclinpath-2018-205085			2	Pathology	Pathology	GR3CW	WOS:000442467400013	29703759				2019-10-28	
J	De Luca, C; Rappa, AG; Gragnano, G; Malapelle, U; Troncone, G; Barberis, M				De Luca, Caterina; Rappa, Alessandra G.; Gragnano, Gianluca; Malapelle, Umberto; Troncone, Giancarlo; Barberis, Massimo			Idylla assay and next generation sequencing: an integrated EGFR mutational testing algorithm	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CELL LUNG-CANCER; MOLECULAR PATHOLOGY; KRAS MUTATIONS; SPECIMENS; PARADIGM; SAMPLES	Aims Any reference laboratory testing non-small cell lung cancer samples for predictive biomarkers needs to develop and validate a wide range of different molecular techniques, each with a specific time requirement and application. Updated international guidelines suggest that next generation sequencing (NGS) to be the initial procedure. However, in a non-negligible subset of cases, library generation may fail or amplicon coverage may be insufficient. In these NGS 'invalid' cases, the Idylla system may represent a viable option for rapid epidermal growth factor receptor (EGFR) genotyping. Methods This retrospective study included 68 archival DNA samples previously processed by Ion Torrent NGS assay. Out of these, 43 cases, including 24 EGFR mutant samples, had a valid NGS result, whereas 25/68 (37%) were invalid. All samples were retested by directly pipetting the DNA inside the EGFR Idylla assay cartridge. Results In all 43 cases with a valid NGS result, Idylla confirmed the EGFR mutational status. In particular, 24/24 (100%) of EGFR mutant samples as detected by NGS were confirmed by Idylla. Moreover, a large portion of cases (20/25; 80%) whose assessment by NGS was invalid were adequately processed by Idylla. Noteworthy, in 4/25 (16%) of cases, Idylla detected actionable EGFR mutations. Conclusions Idylla assay could be very useful to quickly process cases for which NGS does not allow genotyping.	[De Luca, Caterina; Gragnano, Gianluca; Malapelle, Umberto; Troncone, Giancarlo] Univ Naples Federico II, Dept Publ Hlth, I-80131 Naples, Italy; [Rappa, Alessandra G.; Barberis, Massimo] Ist Europeo Oncol, Div Pathol & Lab Med, Milan, Italy	Troncone, G (reprint author), Univ Naples Federico II, Dept Publ Hlth, I-80131 Naples, Italy.	giancarlo.troncone@unina.it		Malapelle, Umberto/0000-0003-3211-9957			de Biase D, 2016, J CLIN PATHOL, V69, P986, DOI 10.1136/jclinpath-2016-203696; De Luca C, 2017, J CLIN PATHOL, V70, P295, DOI 10.1136/jclinpath-2016-203989; Deans ZC, 2017, VIRCHOWS ARCH, V470, P5, DOI 10.1007/s00428-016-2025-7; Gandara DR, 2009, CLIN LUNG CANCER, V10, P148, DOI 10.3816/CLC.2009.n.020; Lambros L, 2017, J CLIN PATHOL, V70, P544, DOI 10.1136/jclinpath-2016-204202; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; Malapelle U, 2017, CANCER CYTOPATHOL, V125, P615, DOI 10.1002/cncy.21868; Malapelle U, 2017, BRIT J CANCER, V116, P802, DOI 10.1038/bjc.2017.8; Roy-Chowdhuri S, 2015, CANCER CYTOPATHOL, V123, P659, DOI 10.1002/cncy.21597; Salto-Tellez M, 2014, J PATHOL, V234, P5, DOI 10.1002/path.4365; Troncone G, 2018, CANCER CYTOPATHOL, V126, P155, DOI 10.1002/cncy.21962; Vigliar E, 2015, CYTOPATHOLOGY, V26, P312, DOI 10.1111/cyt.12221	12	4	4	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					745	750		10.1136/jclinpath-2018-205197			6	Pathology	Pathology	GR3CW	WOS:000442467400014	29798838				2019-10-28	
J	Regard, L; Martin, C; Zemoura, L; Geolier, V; Sage, E; Burgel, PR				Regard, Lucile; Martin, Clemence; Zemoura, Leila; Geolier, Virginie; Sage, Edouard; Burgel, Pierre-Regis			Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis	JOURNAL OF CLINICAL PATHOLOGY			English	Letter							DESENSITIZATION; DISEASES		[Regard, Lucile; Martin, Clemence; Geolier, Virginie; Burgel, Pierre-Regis] Paris Descartes Univ, Sorbonne Paris Cite, F-75014 Paris, France; [Regard, Lucile; Martin, Clemence; Burgel, Pierre-Regis] Cochin Hosp, Pulm Dept, Paris, France; [Regard, Lucile; Martin, Clemence; Burgel, Pierre-Regis] Cochin Hosp, Adult Cyst Fibrosis Ctr, Paris, France; [Zemoura, Leila] Foch Hosp, Pathol Dept, Suresnes, France; [Sage, Edouard] Foch Hosp, Dept Thorac Surg & Lung Transplantat, Suresnes, France	Burgel, PR (reprint author), Paris Descartes Univ, Sorbonne Paris Cite, F-75014 Paris, France.	pierre-regis.burgel@aphp.fr		Regard, Lucile/0000-0002-6530-4449; Burgel, Pierre Regis/0000-0003-0903-9828	Legs Poix-Chancellerie des Universites de Paris; Vaincre la Mucoviscidose, Paris, France	This work was funded by Legs Poix-Chancellerie des Universites de Paris and Vaincre la Mucoviscidose, Paris, France.	Engel P, 2011, PHARMACOL REV, V63, P127, DOI 10.1124/pr.109.002006; Frija-Masson J, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01873-2016; Genberg H, 2006, AM J TRANSPLANT, V6, P2418, DOI 10.1111/j.1600-6143.2006.01497.x; Maglione PJ, 2014, J ALLERGY CLIN IMMUN, V133, P535, DOI 10.1016/j.jaci.2013.08.022; Rosengren S, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2497; Snyder LD, 2014, AM J TRANSPLANT, V14, P849, DOI 10.1111/ajt.12636; Thaunat O, 2008, TRANSPLANTATION, V85, P1648, DOI 10.1097/TP.0b013e3181735723; Vo AA, 2008, NEW ENGL J MED, V359, P242, DOI 10.1056/NEJMoa0707894; Yadava K, 2013, THORAX, V68, P597, DOI 10.1136/thoraxjnl-2012-203008	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					752	753		10.1136/jclinpath-2018-205160			2	Pathology	Pathology	GR3CW	WOS:000442467400015	29703760				2019-10-28	
J	Sorber, L; Zwaenepoel, K; Wouters, A; Janssens, A; Hiddinga, B; Van Meerbeeck, J; Lardon, F; Pauwels, P; Rolfo, C				Sorber, Laure; Zwaenepoel, Karen; Wouters, An; Janssens, Annelies; Hiddinga, Birgitta; Van Meerbeeck, Jan; Lardon, Filip; Pauwels, Patrick; Rolfo, Christian			Monitoring EGFR TKI resistance in real time using ddPCR-based liquid biopsy: a case report	JOURNAL OF CLINICAL PATHOLOGY			English	Letter							CELL LUNG-CANCER; KINASE INHIBITORS		[Sorber, Laure; Zwaenepoel, Karen; Wouters, An; Van Meerbeeck, Jan; Lardon, Filip; Pauwels, Patrick] Univ Antwerp, CORE, Fac Med & Hlth Sci, Antwerp, Belgium; [Sorber, Laure; Zwaenepoel, Karen; Pauwels, Patrick] Antwerp Univ Hosp UZA, Dept Pathol, Edegem, Belgium; [Janssens, Annelies; Hiddinga, Birgitta; Van Meerbeeck, Jan] Antwerp Univ Hosp UZA, Thorac Oncol MOCA, Edegem, Belgium; [Pauwels, Patrick] Antwerp Univ Hosp UZA, Biobank UZA, Edegem, Belgium; [Rolfo, Christian] Antwerp Univ Hosp UZA, Oncol Dept, Phase Early Clin Trials Unit 1, Edegem, Belgium	Sorber, L (reprint author), Univ Antwerp, CORE, Fac Med & Hlth Sci, Antwerp, Belgium.	Laure.Sorber@uantwerpen.be	Wouters, An/B-5384-2017; Lardon, Filip/A-3559-2010	Wouters, An/0000-0001-7771-1239; Sorber, Laure/0000-0002-7172-700X; Lardon, Filip/0000-0001-7174-4144	PfizerPfizer; AstraZenecaAstraZeneca; Boehringer-IngelheimBoehringer Ingelheim; RocheRoche Holding; Belgian Foundation Against Cancer [FA/2014/237]; 'Kom op tegen Kanker' (Stand up to Cancer), the Flemish Cancer Society	The authors received research grants from Pfizer, AstraZeneca, Boehringer-Ingelheim and Roche. This work was supported by the Belgian Foundation Against Cancer (grant number: FA/2014/237). AW is funded by 'Kom op tegen Kanker' (Stand up to Cancer), the Flemish Cancer Society, as postdoctoral fellow.	Chmielecki J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002356; Gao H-F, 2016, ANN ONCOL, V27; Goethals S, 2018, OPEN J BIORESOUR, V5, P4, DOI [10.5334/ojb.30, DOI 10.5334/OJB.30]; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Minari R, 2016, TRANSL LUNG CANCER R, V5, P695, DOI 10.21037/tlcr.2016.12.02; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Sorber L, 2017, LUNG CANCER, V107, P100, DOI 10.1016/j.lungcan.2016.04.026; Suda K, 2010, CLIN CANCER RES, V16, P5489, DOI 10.1158/1078-0432.CCR-10-1371	9	0	0	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	AUG	2018	71	8					754	756		10.1136/jclinpath-2018-205210			3	Pathology	Pathology	GR3CW	WOS:000442467400016	29853531				2019-10-28	
J	Michalova, K; Steiner, P; Alaghehbandan, R; Trpkov, K; Martinek, P; Grossmann, P; Montiel, DP; Sperga, M; Straka, L; Prochazkova, K; Cempirkova, D; Horava, V; Bulimbasic, S; Pivovarcikova, K; Daum, O; Ondic, O; Rotterova, P; Michal, M; Hora, M; Hes, O				Michalova, Kvetoslava; Steiner, Petr; Alaghehbandan, Reza; Trpkov, Kiril; Martinek, Petr; Grossmann, Petr; Montiel, Delia Perez; Sperga, Maris; Straka, Lubomir; Prochazkova, Kristyna; Cempirkova, Dana; Horava, Vladimir; Bulimbasic, Stela; Pivovarcikova, Kristyna; Daum, Ondrej; Ondic, Ondrej; Rotterova, Pavla; Michal, Michal; Hora, Milan; Hes, Ondrej			Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Kidney; Papillary renal cell carcinoma; Oncocytic; Oncocytoma; High grade; FISH; Chromosomal aberration pattern	CYTOGENETIC FEATURES; TUMOR; EMPHASIS; SPECTRUM; SUBTYPE	Background: We present a series of papillary renal cell carcinomas (PRCC) reminiscent of so-called "oncocytic variant of papillary renal cell carcinoma" (OPRCC), included in the 2016 WHO classification as a potential type 3 PRCC. OPRCC is a poorly understood entity, cytologically characterized by oncocytic cells with non-overlapping low grade nuclei. OPRCC is not genotypically distinct and the studies concerning this variant have shown an inconsistent genetic profile. The tumors presented herein demonstrated predominantly papillary/tubulopapillary architecture and differed from OPRCC by pseudostratification and grade 2-3 nuclei (Fuhrman/ISUP). Because there is a morphologic overlap between renal oncocytoma (RO) and PRCC in the cases included in this study, the most frequently affected chromosomes in RO and PRCC were analyzed. Materials and methods: 147 PRCC composed of oncocytic cells were retrieved from our registry in order to select a group of morphologically uniform tumors. 10 cases with predominantly papillary, tubulopapillary or solid architectural patterns were identified. For immunohistochemical analysis, the following antibodies were used: vimentin, antimitochondrial antigene (MIA), AMACR, PAX8, CK7, CK20, AE1-3, CAM5.2, OSCAR, Cathepsin K, HMB45, SDHB, CD10, and CD117. Enumeration changes of locus 1p36, chromosomes 7, 14, 17, X, Y and rearrangement of CCND1 were examined by FISH. For further study, only tumors showing karyotype similar to that of RO were selected. The tumors exhibiting either trisomy of chromosomes 7, 17 or gain of Y, thus abnormalities characteristic for PRCC, were excluded. Results: There were 5 males and 5 females, with patient age ranging from 56 to 79 years (mean 66.8 years). The tumor size ranged from 2 to 10 cm (mean 5.1 cm). Follow-up was available for 8/10 patients (mean 5.2 years); one patient died of the disease, while 7 of 8 are alive and well. Immunohistochemically, all cases were reactive for AMACR, vimentin, PAX8, OSCAR, CAM5.2, and MIA. SDHB was retained in all cases. 9/10 cases were positive for CD10, 7/10 cases reacted with CK7, 4/10 with Cathepsin K, and 2/10 with AE1-3. None of the cases were positive for CD117, HMB45 and CK20. All 10 cases were analyzable by FISH and showed chromosomal abnormalities similar to that usually seen in RO (i.e. loss of 1p36 gene loci, loss of chromosome Y, rearrangement of CCND1 and numerical changes of chromosome 14). Conclusions: We analyzed a series of renal tumors combining the features of PRCC/OPRCC and RO, that included pseudostratification and mostly high grade oncocytic cells lining papillary/tubulopapillary structures, karyotype characterized by loss of 1p36, loss of chromosome Y, rearrangement of CCND1 gene and numerical changes of chromosome 14. Despite the chromosomal numerical abnormalities typical of RO, we classified these tumors as part of the spectrum of PRCC because of their predominant papillary/tubulopapillary architecture, immunoprofile that included reactivity for AMACR, vimentin and lack of reactivity for CD117, all of which is incompatible with the diagnosis of RO. This study expands the morphological spectrum of PRCC by adding a cohort of diagnostically challenging cases, which may be potentially aggressive.	[Michalova, Kvetoslava; Steiner, Petr; Martinek, Petr; Grossmann, Petr; Pivovarcikova, Kristyna; Daum, Ondrej; Ondic, Ondrej; Michal, Michal; Hes, Ondrej] Charles Univ Prague, Med Fac, Dept Pathol, Alej Svobody 80, Plzen 30460, Czech Republic; [Michalova, Kvetoslava; Steiner, Petr; Martinek, Petr; Grossmann, Petr; Prochazkova, Kristyna; Pivovarcikova, Kristyna; Daum, Ondrej; Ondic, Ondrej; Michal, Michal; Hora, Milan; Hes, Ondrej] Charles Univ Hosp Plzen, Alej Svobody 80, Plzen 30460, Czech Republic; [Alaghehbandan, Reza] Univ British Columbia, Royal Columbian Hosp, Fac Med, Dept Pathol, Vancouver, BC, Canada; [Trpkov, Kiril] Univ Calgary, Calgary Lab Serv, Dept Pathol & Lab Med, Calgary, AB, Canada; [Montiel, Delia Perez] Inst Nacl Cancerol, Dept Pathol, Mexico City, DF, Mexico; [Sperga, Maris] Rigas Stradins Univ, Dept Pathol, Riga, Latvia; [Straka, Lubomir] Alpha Med, Dept Pathol, Presov, Slovakia; [Prochazkova, Kristyna; Hora, Milan] Charles Univ Prague, Med Fac, Dept Urol, Plzen, Czech Republic; [Cempirkova, Dana] Reg Hosp Jindrichuv Hradec, Dept Pathol, Jindrichuv Hradec, Czech Republic; [Horava, Vladimir] Reg Hosp Fridek Mistek, Dept Pathol, Frydek Mystek, Czech Republic; [Bulimbasic, Stela] Clin Hosp Ctr Zagreb, Dept Pathol, Zagreb, Croatia; [Rotterova, Pavla] Biopt Lab, Plzen, Czech Republic	Hes, O (reprint author), Charles Univ Prague, Med Fac, Dept Pathol, Alej Svobody 80, Plzen 30460, Czech Republic.; Hes, O (reprint author), Charles Univ Hosp Plzen, Alej Svobody 80, Plzen 30460, Czech Republic.	hes@medima.cz	Pivovarcikova, Kristyna/Q-5634-2018; Steiner, Petr/J-4074-2017; Prochazkova, Kristyna/M-2059-2017	Pivovarcikova, Kristyna/0000-0002-9553-0105; Steiner, Petr/0000-0003-0320-8061; Prochazkova, Kristyna/0000-0002-4306-7075; Hora, Milan/0000-0002-5061-3687; Michalova, Kvetoslava/0000-0003-3231-6870; Ondic, Ondrej/0000-0002-4038-5641	Charles University Fund [SVV 2017-260391]	The study was supported by Charles University Fund SVV 2017-260391.	Argani P, 2008, AM J SURG PATHOL, V32, P1353, DOI 10.1097/PAS.0b013e31816a1c34; Arroyo MR, 2001, AM J SURG PATHOL, V25, P433, DOI 10.1097/00000478-200104000-00002; BAITHUN SI, 1983, HISTOPATHOLOGY, V7, P107, DOI 10.1111/j.1365-2559.1983.tb02220.x; Cacciamani G, 2019, APPL IMMUNOHISTO M M, V27, pE48, DOI 10.1097/PAI.0000000000000490; CAPLAN RH, 1984, JAMA-J AM MED ASSOC, V251, P3114, DOI 10.1001/jama.251.23.3114; Delahunt B, 1997, MODERN PATHOL, V10, P537; Hes Ondrej, 2006, Ann Diagn Pathol, V10, P133, DOI 10.1016/j.anndiagpath.2005.12.002; Hes O, 2016, AM J SURG PATHOL, V40, P664, DOI 10.1097/PAS.0000000000000639; Klatte T, 2011, J UROLOGY, V185, P30, DOI 10.1016/j.juro.2010.09.013; Kumar V, 2009, ROBBINS COTRAN PATHO; Kunju LP, 2008, HUM PATHOL, V39, P96, DOI 10.1016/j.humpath.2007.05.016; Lefevre M, 2005, AM J SURG PATHOL, V29, P1576; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Mai KT, 2008, PATHOL INT, V58, P164, DOI 10.1111/j.1440-1827.2007.02205.x; Masuzawa N, 2008, PATHOL INT, V58, P300, DOI 10.1111/j.1440-1827.2008.02227.x; Mearini L, 2013, UROL INT, V91, P125, DOI 10.1159/000345141; Moch H, 2016, WHO CLASSIFICATION T; Okada A, 2009, INT J UROL, V16, P765, DOI 10.1111/j.1442-2042.2009.02336.x; Park BH, 2009, PATHOL INT, V59, P137, DOI 10.1111/j.1440-1827.2009.02341.x; Pivovarcikova K, 2016, VIRCHOWS ARCH, V469, P71, DOI 10.1007/s00428-016-1936-7; Saleeb RM, 2017, AM J SURG PATHOL, V41, P1618, DOI 10.1097/PAS.0000000000000962; Srigley JR, 2009, MODERN PATHOL, V22, pS2, DOI 10.1038/modpathol.2009.70; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Trpkov K, 2010, HISTOPATHOLOGY, V57, P893, DOI 10.1111/j.1365-2559.2010.03726.x; Ulamec M, 2016, ANN DIAGN PATHOL, V23, P51, DOI 10.1016/j.anndiagpath.2016.04.008; Xia QY, 2013, INT J CLIN EXP PATHO, V6, P1392	26	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						1	6		10.1016/j.anndiagpath.2018.01.010			6	Pathology	Pathology	GP5ZJ	WOS:000440955900001	30072012				2019-10-28	
J	Prayson, RA				Prayson, Richard A.			Accuracy of frozen section in determining meningioma subtype and grade	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Review						Meningioma; Intraoperative consultation; Frozen section; Tumor grading	CENTRAL-NERVOUS-SYSTEM; INTRAOPERATIVE DIAGNOSIS; LESIONS; TUMORS; CONSULTATION; 10-YEAR; AUDIT	Frozen section intraoperative consultation is a well-established means of evaluating brain tumors at the time of surgery. Limitations to the procedure are also well recognized resulting in less than perfect specificity of diagnosis. This study retrospectively reviewed 424 consecutive meningioma cases (N = 310 females; mean age 57.3 years) to examine concordance between frozen section evaluation of meningioma subtype and grade as compared with the final diagnosis subtype and grade. A discrepancy between frozen section diagnosis and final diagnosis was observed in 114 (26.9%) of cases. Of the WHO grade I subtypes, the most common discrepancy involved transitional meningiomas (N = 31) which were most commonly diagnosed at frozen section as either fibrous (N = 18) or meningothelial (N = 13) meningiomas. None of the grade I tumors were diagnosed as higher grade lesions. Of the higher grade meningiomas (WHO grade II and III) (N = 145) reviewed, concordance between tumor type and grade was seen in only 26.2% of cases; most commonly, 73/98 atypical meningiomas were under-graded as some subtype of WHO grade I meningioma (71/73 cases). In conclusion, discrepancies at frozen section with respect to accurately identifying higher grade meningiomas and higher grade meningioma subtypes are common and are generally due to tumor sampling and heterogeneity.	[Prayson, Richard A.] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA	Prayson, RA (reprint author), Cleveland Clin, CCLCM, 9500 Euclid Ave, Cleveland, OH 44195 USA.	praysor@ccf.org					Al-Ajmi Radiya, 2016, Oman Med J, V31, P414, DOI 10.5001/omj.2016.84; Ali S, 2008, DIAGN CYTOPATHOL, V36, P827, DOI 10.1002/dc.20929; Brainard JA, 1997, ARCH PATHOL LAB MED, V121, P481; Di Stefano D, 1998, ACTA CYTOL, V42, P346, DOI 10.1159/000331614; Khoddami M, 2015, IRAN J CHILD NEUROL, V9, P25; Kleinschmidt-DeMasters BK, 2006, ARCH PATHOL LAB MED, V130, P1630; Louis DN, 2016, WHO CLASSIFICATION T; ONESON RH, 1989, AM J SURG PATHOL, V13, P237, DOI 10.1097/00000478-198903000-00009; Plesec TP, 2007, ARCH PATHOL LAB MED, V131, P1532; Prayson RA, 2011, FROZEN SECT LIBR, P1, DOI 10.1007/978-1-4419-7579-9_1; Regragui A, 2003, NEUROCHIRURGIE, V49, P67; Roessler K, 2002, ACTA CYTOL, V46, P667, DOI 10.1159/000326973; Savargaonkar P, 2001, ANN CLIN LAB SCI, V31, P133; Shah AB, 1998, ACTA CYTOL, V42, P1149, DOI 10.1159/000332104; Somerset HL, 2011, ADV ANAT PATHOL, V18, P446, DOI 10.1097/PAP.0b013e3182169934; TARATUTO AL, 1991, ARCH PATHOL LAB MED, V115, P596; Tofte Kathrine, 2014, Surg Neurol Int, V5, P170, DOI 10.4103/2152-7806.146153; Willis J, 2005, NEUROPATH APPL NEURO, V31, P141, DOI 10.1111/j.1365-2990.2004.00621.x; Yachnis AT, 2002, SEMIN DIAGN PATHOL, V19, P192, DOI 10.1053/sdia.2002.36035	19	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						7	10		10.1016/j.anndiagpath.2018.02.001			4	Pathology	Pathology	GP5ZJ	WOS:000440955900002	30072016				2019-10-28	
J	Hu, SM; Szymanski, J; Khairy, Z; Lo, YT; Wang, YH				Hu, Shaomin; Szymanski, James; Khairy, Zeina; Lo, Yungtai; Wang, Yanhua			Breast pathology and mammography BI-RADS category correlation study - A single institute experience	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Breast cancer; Mammography; BI-RADS; Pathology	SCREENING MAMMOGRAPHY; CANCER STATISTICS; WHITE WOMEN; PERFORMANCE; DENSITY; VARIABILITY; RACE	Although recent technological advances, there is still discordance between mammography findings and pathologic diagnoses, especially for certain racial/ethnic populations. In this study we correlated the mammography BI-RADS categories with pathologic diagnoses, aiming to evaluate the performance of mammography in breast cancer detection in a unique poor population consisting of mostly Hispanics and African Americans. A total of 3935 female patients with a breast mammography and a subsequent breast pathology report within 90 days were retrospectively analyzed. There were 875 (22.2%) patients with a negative or probably benign mammography (BI-RADS 1, 2 and 3), and 33 (3.8%) of them had a malignant pathologic diagnosis. Patients with malignant pathologic diagnoses were older, higher in socioeconomic status (SES), and more likely to be African American or White, compared to those with non-malignant pathologic findings. They mostly presented with related symptoms (e.g. breast pain, mass or discharge) and/or family history or past history of breast cancers, which triggered secondary imaging examination and subsequent breast biopsy/excision, and eventually resulted to the diagnosis of breast cancers. In conclusion, our studies indicated that the performance of mammography is comparable in detection of breast cancers among Hispanics, African American and White populations, if it was done in the same facility. Our results also suggested that for patients with presenting symptoms, past history of breast cancer or strong family history of breast cancer, a secondary breast imaging examination may be warranted following a negative to probably benign mammography (BI-RADS 1-3).	[Hu, Shaomin; Szymanski, James; Khairy, Zeina; Wang, Yanhua] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; [Lo, Yungtai] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA	Wang, YH (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, 111 E 210th St, Bronx, NY 10467 USA.	ywang@Montefiore.org					Boyer B, 2013, EUR J RADIOL, V82, P388, DOI 10.1016/j.ejrad.2012.02.005; Daly B, 2015, CA-CANCER J CLIN, V65, P221, DOI 10.3322/caac.21271; del Carmen MG, 2007, AM J ROENTGENOL, V188, P1147, DOI 10.2214/AJR.06.0619; DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320; Elmore JG, 2004, ARCH INTERN MED, V164, P1140, DOI 10.1001/archinte.164.10.1140; Euhus D, 2015, SURG CLIN N AM, V95, P991, DOI 10.1016/j.suc.2015.05.008; Idowu MO, 2012, ARCH PATHOL LAB MED, V136, P53, DOI 10.5858/arpa.2011-0217-CP; Kolb TM, 2002, RADIOLOGY, V225, P165, DOI 10.1148/radiol.2251011667; Merry GM, 2014, RADIOL CLIN N AM, V52, P527, DOI 10.1016/j.rcl.2013.12.003; Molins E, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-91; Rauscher GH, 2014, AM J ROENTGENOL, V202, P145, DOI 10.2214/AJR.13.10806; Rauscher GH, 2012, J WOMENS HEALTH, V21, P154, DOI 10.1089/jwh.2010.2415; Redondo A, 2012, BRIT J RADIOL, V85, P1465, DOI 10.1259/bjr/21256379; Sickles EA, 2013, ACR BL RADSE ATLAS B; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Society AC, 2015, BREAST CANC FACTS FI; Ursin G, 2003, CANCER EPIDEM BIOMAR, V12, P332; Yankaskas BC, 2005, CANCER, V104, P2671, DOI 10.1002/cncr.21550; Yankaskas BC, 2004, J MED SCREEN, V11, P187, DOI 10.1258/0969141042467430	19	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						11	15		10.1016/j.anndiagpath.2018.02.002			5	Pathology	Pathology	GP5ZJ	WOS:000440955900003	30072013				2019-10-28	
J	Erik, K; Jozef, V; Tomas, B; Anna, F; Payol, Z; Lukas, P; Jan, D				Erik, Kudela; Jozef, Visnovsky; Tomas, Balharek; Anna, Farkasova; Payol, Zubor; Lukas, Plank; Jan, Danko			Different amplification patterns of 3q26 and 5p15 regions in cervical intraepithelial neoplasia and cervical cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Cervical intraepithelial neoplasia; Telomerase; Amplification; Fluorescent in situ hybridization; TERC; TERT	TELOMERASE GENE TERC; GENOMIC AMPLIFICATION; PAP-SMEARS; DIAGNOSIS; LESIONS; WOMEN	Purpose: The aim of this study was to evaluate and correlate the amplification of chromosomal regions 3q26 and 5p15 in different cytological and histological subgroups of patients and to compare the sensitivity and specificity of amplification tests with cytology, colposcopy and HPV status. Methods: The work was conducted at the Department of Obstetrics and Gynaecology in cooperation with the Institute of Pathological Anatomy, JFM CU in Martin and UNM during years 2013-2016. Prospective longitudinal study included 131 patients. We focused on the FISH diagnosis of the amplification of regions encoding the components of telomerase enzyme (3q26, 5p15) in cytology specimens. We manually evaluated 100 atypical cells per slide and analysed the amplification patterns. Correlations between cytological, histological, HPV DNA results and amplification patterns of chromosomal regions 3q26 and 5p15 were analysed by chi-squared test and non-parametric Man - Whitney U test. Results: The results showed that the amplification of chromosomal regions increases with the degree of dysplasia toward the invasive disease (p < 0.001). Whereas the increase in the amplification of 3q26 is noticeable already at CIN 2 + lesions (p < 0.01), 5p15 amplification is shifted up toward CIN 3/CIS (p < 0.001) and cervical cancer. Amplification of selected regions correlated with each other and also with hrHPV-positive status (p < 0.01). Conclusion: The analysis of the amplification of 3q26 and 5p15 regions may serve in the future for the differential diagnosis of cervical lesions and to determine their malignant potential. High specificity of these tests can improve the excellent sensitivity of HPV DNA test.	[Erik, Kudela; Jozef, Visnovsky; Payol, Zubor; Jan, Danko] Comenius Univ, Jessenius Fac Med Martin, Dept Obstet & Gynaecol, Bratislava, Slovakia; [Tomas, Balharek; Anna, Farkasova; Lukas, Plank] Comenius Univ, Jessenius Fac Med Martin, Inst Pathol Anat, Bratislava, Slovakia	Erik, K (reprint author), Mala Hora 4A, Martin 03601, Slovakia.	kudela.erik@gmail.com	Zubor, Pavol/X-8191-2018		project "Molecular diagnostics of cervical cancer" [ITMS: 26220220113]	This work was supported by the project "Molecular diagnostics of cervical cancer" (ITMS: 26220220113).	Alameda F, 2009, HUM PATHOL, V40, P1474, DOI 10.1016/j.humpath.2009.03.013; Andersson S, 2006, AM J PATHOL, V95, P331; Andersson S, 2009, AM J PATHOL, V175, P1831, DOI 10.2353/ajpath.2009.090122; Caraway NP, 2008, GYNECOL ONCOL, V110, P37, DOI 10.1016/j.ygyno.2008.01.040; Earley A, 2014, J LOW GENIT TRACT DI, V18, P218, DOI 10.1097/LGT.0000000000000007; Heselmeyer-Haddad K, 2005, AM J PATHOL, V166, P1229, DOI 10.1016/S0002-9440(10)62341-3; Heselmeyer-Haddad K, 2003, AM J PATHOL, V163, P1405, DOI 10.1016/S0002-9440(10)63498-0; Jiang J, 2010, J MOL DIAGN, V12, P808, DOI 10.2353/jmoldx.2010.100021; Luhn P, 2013, GYNECOL ONCOL, V130, P595, DOI 10.1016/j.ygyno.2013.06.005; Policht FA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-432; Ramsaroop R, 2009, DIAGN CYTOPATHOL, V37, P411, DOI 10.1002/dc.21007; Ruden M, 2013, CANCER TREAT REV, V39, P444, DOI 10.1016/j.ctrv.2012.06.007; Tu Z, 2009, CANCER GENET CYTOGEN, V191, P10, DOI 10.1016/j.cancergencyto.2009.01.004; Xiang LB, 2012, DIAGN CYTOPATHOL, V40, P849, DOI 10.1002/dc.21635	14	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						16	20		10.1016/j.anndiagpath.2018.02.003			5	Pathology	Pathology	GP5ZJ	WOS:000440955900004	30072014				2019-10-28	
J	Calhoun, BC; Mosteller, B; Warren, D; Smith, M; Rowe, JJ; Lanigan, CP; Mrazeck, KC; Walker, E; Newell, AH; Jones, R				Calhoun, Benjamin C.; Mosteller, Brian; Warren, Daniel; Smith, Margie; Rowe, J. Jordi; Lanigan, Christopher P.; Mrazeck, Karen C.; Walker, Espen; Newell, Amy Hanlon; Jones, Raymond			Analytical and clinical performance of progesterone receptor antibodies in breast cancer	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Progesterone receptor; Hormone receptor; Breast cancer; Diagnosis; Pathology; Monoclonal antibody; Clone 1E2; Clone 636; Clone 1A6; Clone 16	ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; HORMONE-RECEPTORS; ADJUVANT TAMOXIFEN; KINETIC-ANALYSIS; IMMUNOHISTOCHEMISTRY; ASSOCIATION; CARCINOMAS; EXPRESSION; TRIAL	Objective: Comparison of analytical and immunohistochemical performance of progesterone receptor (PR) antibodies with correlation to recurrence of invasive breast cancer treated with endocrine therapy. Methods: The binding-affinity kinetics of PR clones 1E2, 1A6, 16 and 636 were compared using synthetic peptides derived from identified epitopes on a Biacore T200. A cohort of 351 cases (Hormone Receptor (HR) +/HER2-) were stained for PR expression with immunohistochemistry (IHC) and scored according to ASCO/CAP criteria. Results: The stability of the antigen/antibody complex was greater for the 1E2 clone compared to 1A6, 16 and 636 clones. PR IHC on archival tissue resulted in 94.3% (299/317) concordance with clones. Conclusion: Clones evaluated in this study had a high level of concordance with IHC despite PR (1E2) demonstrating higher analytical binding properties than other clones. In a minority of cases (1.3% for 1E2 and 2.5% for 636) IHC results could convert estrogen receptor (ER)-/PR- to ER-/PR+ tumors, making these patients potentially eligible for endocrine therapy.	[Calhoun, Benjamin C.; Rowe, J. Jordi; Lanigan, Christopher P.; Mrazeck, Karen C.] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Pathol, Cleveland, OH 44106 USA; [Mosteller, Brian; Warren, Daniel; Smith, Margie; Walker, Espen; Newell, Amy Hanlon; Jones, Raymond] Ventana Med Syst Inc, Tucson, AZ 85755 USA	Calhoun, BC (reprint author), Univ North Carolina Chapel Hill, Dept Pathol & Lab Med, 160 North Med Dr,Campus Box 7525, Chapel Hill, NC 27599 USA.; Jones, R (reprint author), Ventana Med Syst Inc, Syst Integrat, 1910 E Innovat Pk Dr, Tucson, AZ 85755 USA.	ben.calhoun@unchealth.unc.edu; raymond.jones.rj2@roche.com			Ventana Medical Systems, Inc.	Research funding by Ventana Medical Systems, Inc.	Abdel-Hafiz HA, 2014, J STEROID BIOCHEM, V140, P80, DOI 10.1016/j.jsbmb.2013.12.008; Ahmed SS, 2017, J CLIN PATHOL, V70, P320, DOI 10.1136/jclinpath-2016-203847; Allred DC, 2010, MODERN PATHOL, V23, pS52, DOI 10.1038/modpathol.2010.55; Allred DC, 2008, ONCOLOGIST, V13, P1134, DOI 10.1634/theoncologist.2008-0184; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Balaton AJ, 1996, ANN PATHOL, V16, P144; Banerjee M, 2004, J CLIN ONCOL, V22, P2567, DOI 10.1200/JCO.2004.11.141; Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099; Bartlett JMS, 2011, J CLIN ONCOL, V29, P1531, DOI 10.1200/JCO.2010.30.3677; Cancello G, 2013, ANN ONCOL, V24, P661, DOI 10.1093/annonc/mds430; Castagnetta LAM, 1999, ANAL QUANT CYTOL, V21, P59; Cui XJ, 2005, J CLIN ONCOL, V23, P7721, DOI 10.1200/JCO.2005.09.004; Daltoe RD, 2014, INT J CLIN EXP PATHO, V7, P331; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Dowsett M, 2015, AROMATASE INHIBITORS; Dunnwald LK, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1639; Fivash M, 1998, CURR OPIN BIOTECH, V9, P97, DOI 10.1016/S0958-1669(98)80091-8; Gianetti TL, 2011, J AM CHEM SOC, V133, P14904, DOI 10.1021/ja206016s; Grann VR, 2005, CANCER-AM CANCER SOC, V103, P2241, DOI 10.1002/cncr.21030; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Hede K., 2008, BREAST CANC TESTING; Hefti MM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3462; Huang HJ, 2005, J CLIN PATHOL, V58, P611, DOI 10.1136/jcp.2004.022772; Ibrahim M, 2008, AM J CLIN PATHOL, V129, P398, DOI 10.1309/2YXRLEQVPPNRWHGA; Jacobsen BM, 2012, MOL CELL ENDOCRINOL, V357, P18, DOI 10.1016/j.mce.2011.09.016; Jisa E, 2003, J STEROID BIOCHEM, V84, P141, DOI 10.1016/S0960-0760(03)00023-2; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Kornaga EN, 2016, MODERN PATHOL, V29, P1492, DOI 10.1038/modpathol.2016.151; Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9; Levenson RM, 2015, LAB INVEST, V95, P397, DOI 10.1038/labinvest.2015.2; Liu SZ, 2010, BREAST CANCER RES TR, V119, P53, DOI 10.1007/s10549-009-0318-0; Ma Y, 2007, CLIN CANCER RES, V13, P2014, DOI 10.1158/1078-0432.CCR-06-2222; MacGrogan G, 2005, J CLIN ONCOL, V23, P2870, DOI 10.1200/JCO.2005.05.241; MacGrogan G, 1996, APPL IMMUNOHISTO M M, V4, P219; Mc Cormack O, 2007, CRIT REV ONCOG, V13; Mitchell JS, 2010, METHODS MOL BIOL, V627, P113, DOI 10.1007/978-1-60761-670-2_7; Mote PA, 2001, J CLIN PATHOL, V54, P624, DOI 10.1136/jcp.54.8.624; Mote PA, 2015, BREAST CANCER RES TR, V151, P309, DOI 10.1007/s10549-015-3397-0; Nguyen AH, 2015, BIOSENS BIOELECTRON, V70, P358, DOI 10.1016/j.bios.2015.03.064; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Novis DA, 2004, CLIN LAB MED, V24, P965, DOI 10.1016/j.cll.2004.09.001; Olivotto IA, 2004, J CLIN ONCOL, V22, P1769, DOI 10.1200/JCO.2004.99.251; Prat A, 2013, J CLIN ONCOL, V31, P203, DOI 10.1200/JCO.2012.43.4134; Press M, 2002, STEROIDS, V67, P799, DOI 10.1016/S0039-128X(02)00039-9; Rakha EA, 2007, J CLIN ONCOL, V25, P4772, DOI 10.1200/JCO.2007.12.2747; Rakha EA, 2017, HISTOPATHOLOGY, V70, P622, DOI 10.1111/his.13108; Rhodes A, 2009, J CLIN PATHOL, V62, P95, DOI 10.1136/jcp.2008.060723; Rich RL, 2009, ANAL BIOCHEM, V386, P98, DOI 10.1016/j.ab.2008.12.011; Rich RL, 2002, P NATL ACAD SCI USA, V99, P8562, DOI 10.1073/pnas.142288199; Rocha R, 2008, PATHOL RES PRACT, V204, P655, DOI 10.1016/j.prp.2008.03.010; Stendahl M, 2006, CLIN CANCER RES, V12, P4614, DOI 10.1158/1078-0432.CCR-06-0248; Troxell ML, 2017, ARCH PATHOL LAB MED, V141, P1402, DOI 10.5858/arpa.2016-0497-OA; Viale G, 2007, J CLIN ONCOL, V25, P3846, DOI 10.1200/JCO.2007.11.9453; Yang LH, 2012, J BREAST CANCER, V15, P288, DOI 10.4048/jbc.2012.15.3.288; Yu KD, 2008, J CANCER RES CLIN, V134, P1347, DOI 10.1007/s00432-008-0414-2	55	1	1	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						21	26		10.1016/j.anndiagpath.2018.02.007			6	Pathology	Pathology	GP5ZJ	WOS:000440955900005	29758480				2019-10-28	
J	Abdelrahman, AE; Fathy, A; Elsebai, EA; Nawar, N; Etman, WM				Abdelrahman, Aziza E.; Fathy, Anan; Elsebai, Eman A.; Nawar, Nashwa; Etman, Waleed M.			Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Serous ovarian carcinoma; Apaf-1; Cyclin D1; AQP-5; Immunohistochemistry; Chemotherapy	COLORECTAL CARCINOGENESIS; CANCER STATISTICS; POOR-PROGNOSIS; CELL CARCINOMA; BETA-CATENIN; COLON-CANCER; EXPRESSION; APOPTOSIS; TUMORS; CHEMORESISTANCE	Chemoresistance is the major obstacle to effective treatment in patients with serous ovarian carcinoma (SOC), which frequently related to the failure of chemotherapeutic agents to induce apoptosis. In this study, the immunohistochemical expression of Apaf-1, Cyclin D1, and Aquaporin-5 (AQP-5) was studied in 50 paraffin blocks of SOC. Data on overall survival (OS), disease-free survival (DFS) and response to the first-line chemotherapy were collected and then statistically analyzed. Apaf-1 expression was observed in 84% of the SOC cases with a significant down-regulation with higher tumor grade, lymph node metastasis, and advanced FIGO stage. Cyclin D1 expression was found in 70% of the cases with a significant up-regulation with higher tumor grade, lymph node metastasis, and advanced FIGO stage. Positive AQP-5 expression was noted in 84% of the cases with a significant positive association with higher tumor grade, lymph node metastasis, and advanced FIGO stage. During the follow-up period, the Apaf-1 expression had a significant negative association with OS and DFS (p < 0.001 for each), while both Cyclin D1 and AQP-5 expression had a significant positive association with unfavorable OS and DFS. The cases of SOC treated with suboptimal surgery revealed a significant association of low Apaf-1, high Cyclin D1, and strong AQPs with the poor response to the first-line chemotherapy (p = 0.047, p < 0.001, and 0.006 respectively). Conclusions: Down-regulation of Apaf-1 protein and the overexpression of Cyclin D1 and AQP-5 proteins possibly contribute to an aggressive SOC with a high risk of recurrence and poor response to the first-line chemotherapy.	[Abdelrahman, Aziza E.; Fathy, Anan] Zagazig Univ, Fac Med, Pathol Dept, Zagazig 44519, Egypt; [Elsebai, Eman A.; Nawar, Nashwa] Zagazig Univ, Fac Med, Clin Oncol & Nucl Med Dept, Zagazig, Egypt; [Etman, Waleed M.] Zagazig Univ, Fac Med, Gynecol & Obstet Dept, Zagazig, Egypt	Abdelrahman, AE (reprint author), Zagazig Univ, Fac Med, Pathol Dept, Zagazig 44519, Egypt.	azaelsayed@gmail.com	Abdelrahman, Aziza E./I-3399-2019	Abdelrahman, Aziza E./0000-0003-4074-4779			Ahmad ST, 2012, TUMOR BIOL, V33, P395, DOI 10.1007/s13277-011-0235-9; Austin G. J., 2011, INT J GYNECOL CANCER, V21, P419, DOI DOI 10.1097/1GC.013013E318207007; Baldwin LA, 2012, OBSTET GYNECOL, V120, P612, DOI 10.1097/AOG.0b013e318264f794; Bali A, 2004, CLIN CANCER RES, V10, P5168, DOI 10.1158/1078-0432.CCR-03-0751; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Campioni M, 2005, EXP DERMATOL, V14, P811, DOI 10.1111/j.1600-0625.2005.00360.x; Chae YK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002594; Christoph F, 2006, BRIT J CANCER, V95, P1701, DOI 10.1038/sj.bjc.6603482; Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5; Denes L, 2013, ARS MED, V1, P26, DOI [10.2478/arsm-2013-0005, DOI 10.2478/ARSM-2013-0005]; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Ezzati Mohammad, 2014, Int Sch Res Notices, V2014, P953509, DOI 10.1155/2014/953509; Fu C, 2016, J CANCER RES CLIN, V363, P741; Gomes D, 2009, BBA-BIOMEMBRANES, V1788, P1213, DOI 10.1016/j.bbamem.2009.03.009; Guo XD, 2013, BIOMED RES INT, DOI 10.1155/2013/206525; Hajra KM, 2004, APOPTOSIS, V9, P691, DOI 10.1023/B:APPT.0000045786.98031.1d; Hashimoto T, 2011, EXP THER MED, V2, P213, DOI 10.3892/etm.2011.194; Huang YH, 2013, TUMOR BIOL, V34, P1743, DOI 10.1007/s13277-013-0712-4; Itami A, 1999, ONCOLOGY-BASEL, V57, P311, DOI 10.1159/000012067; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kang BW, 2015, ONCOLOGY-BASEL, V88, P369, DOI 10.1159/000369073; Kang SK, 2008, AM J PATHOL, V173, P518, DOI 10.2353/ajpath.2008.071198; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Kurman RJ, 2014, WHO CLASSIFICATION T; Leo C, 2005, GYNECOL ONCOL, V97, P602, DOI 10.1016/j.ygyno.2005.01.044; Li YJ, 2005, WORLD J GASTROENTERO, V11, P2117, DOI 10.3748/wjg.v11.i14.2117; Liu JR, 2002, CANCER RES, V62, P924; Meinhold-Heerlein I, 2015, GEBURTSH FRAUENHEILK, V75, P1021, DOI 10.1055/s-0035-1558079; Mobasheri A, 2005, INT J ONCOL, V26, P1149; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; Otterbach F, 2010, BREAST CANCER RES TR, V120, P67, DOI 10.1007/s10549-009-0370-9; Prat J, 2015, J GYNECOL ONCOL, V26, P87, DOI 10.3802/jgo.2015.26.2.87; Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001; Rajanbabu A, 2014, ECANCERMEDICALSCIENC, V8, DOI 10.3332/ecancer.2014.422; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Shi XM, 2014, TUMOR BIOL, V35, P7035, DOI 10.1007/s13277-014-1956-3; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sui L, 1999, GYNECOL ONCOL, V73, P202, DOI 10.1006/gyno.1999.5373; Takai N, 2004, CANCER-AM CANCER SOC, V101, P2760, DOI 10.1002/cncr.20709; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tan LJ, 2011, CANCER-AM CANCER SOC, V117, P784, DOI 10.1002/cncr.25649; Umekita Y, 2002, INT J CANCER, V98, P415, DOI 10.1002/ijc.10151; Wang H, 2014, INT J CLIN EXP PATHO, V7, P264; Wang J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0439-7; Willaert W, 2014, CANCER TREAT REV, V40, P405, DOI 10.1016/j.ctrv.2013.09.013; Wolf BB, 2001, J BIOL CHEM, V276, P34244, DOI 10.1074/jbc.M011778200; Xu JL, 2014, TUMOR BIOL, V35, P6191, DOI 10.1007/s13277-014-2169-5; Yan CX, 2012, ARCH GYNECOL OBSTET, V285, P459, DOI 10.1007/s00404-011-1942-6; Yang JH, 2006, GYNECOL ONCOL, V100, P294, DOI 10.1016/j.ygyno.2005.08.054; Yang JH, 2011, HISTOL HISTOPATHOL, V26, P1197, DOI 10.14670/HH-26.1197; Yang JH, 2012, ARCH GYNECOL OBSTET, V285, P239, DOI 10.1007/s00404-011-1908-8; Zhou XJ, 2009, INT J CANCER, V124, P483, DOI 10.1002/ijc.23964; Zlobec I, 2007, EUR J CANCER, V43, P1101, DOI 10.1016/j.ejca.2007.01.029	57	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						27	37		10.1016/j.anndiagpath.2018.02.005			11	Pathology	Pathology	GP5ZJ	WOS:000440955900006	30072015				2019-10-28	
J	Bekers, EM; van Broekhoven, DLM; van Dalen, T; Bonenkamp, JJ; van der Geest, ICM; de Rooy, JWJ; van Gorp, JM; Creytens, DH; de Leng, WWJ; Scheijen, B; Eijkelenboom, A; Flucke, U				Bekers, Elise M.; van Broekhoven, Danique L. M.; van Dalen, Thijs; Bonenkamp, Johan J.; van der Geest, Ingrid C. M.; de Rooy, Jacky W. J.; van Gorp, Joost M.; Creytens, David H.; de Leng, Wendy W. J.; Scheijen, Blanca; Eijkelenboom, Astrid; Flucke, Uta			Multifocal occurrence of extra-abdominal desmoid type fibromatosis - A rare manifestation. A clinicopathological study of 6 sporadic cases and 1 hereditary case	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Desmoid; Fibromatosis; Soft tissue tumors	AGGRESSIVE FIBROMATOSIS; BETA-CATENIN; LOCAL RECURRENCE; TUMORS; MUTATIONS; MANAGEMENT	Desmoid-type fibromatosis, also called desmoid tumor, is a locally aggressive myofibroblastic neoplasm that usually arises in deep soft tissue with significant potential for local recurrence. It displays an unpredictable clinical course. beta-Catenin, the genetic key player of desmoid tumors shows nuclear accumulation due to mutations that prevent its degradation leading to activation of Wnt signaling and myofibroblastic cell proliferation. The corresponding hot spot mutations are located in exon 3 of the CTNNB1 gene or alternatively, in the APC tumor suppressor gene, most often as a germline mutation. Multifocal desmoid tumors are very rare and clinical characteristics are poorly understood. Here we present six sporadic and one familial case of multifocal desmoid tumors. Four female and three male patients, aged between 7 and 30 years (mean 18.4 years) were identified in a cohort of 1392 cases. Tumors were located in (distal) extremities, thorax, breast, abdominal wall, shoulder, and neck. Four cases showed a CTNNB1 mutation and one an APC germline mutation. In two sporadic cases no CTNNB1 mutation was identified. Four patients showed (multiple) recurrences and one patient was lost to follow-up. In conclusion, multifocal desmoid tumors are a very rare disease and may occur in sporadic cases that are characterized by recurrent CTNNB1 mutations. However, the underlying pathogenesis of multifocal desmoid tumors remains poorly understood with often aggressive clinical behavior and challenging therapeutical management.	[Bekers, Elise M.; Scheijen, Blanca; Eijkelenboom, Astrid; Flucke, Uta] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, HP 824,POB 9101, NL-6500 HB Nijmegen, Netherlands; [Bekers, Elise M.] Jeroen Bosch Hosp, Dept Pathol DNA, Den Bosch, Netherlands; [van Broekhoven, Danique L. M.] Erasmus MC Canc Inst, Rotterdam, Netherlands; [van Dalen, Thijs] Univ Med Ctr Utrecht, Dept Surg, Diakonessenhuis Utrecht, Utrecht, Netherlands; [Bonenkamp, Johan J.] Radboud Univ Nijmegen, Med Ctr, Dept Surg Oncol, Nijmegen, Netherlands; [van der Geest, Ingrid C. M.] Radboud Univ Nijmegen, Med Ctr, Dept Orthoped, Nijmegen, Netherlands; [de Rooy, Jacky W. J.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands; [van Gorp, Joost M.] Diakonessenhuis Utrecht, Dept Pathol, Utrecht, Netherlands; [Creytens, David H.] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [de Leng, Wendy W. J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands	Flucke, U (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pathol, HP 824,POB 9101, NL-6500 HB Nijmegen, Netherlands.	uta.flucke@radboudumc.nl	Scheijen, Blanca GPH/E-3523-2016	Scheijen, Blanca GPH/0000-0001-8029-9230			Colombo C, 2013, CANCER-AM CANCER SOC, V119, P3696, DOI 10.1002/cncr.28271; Domont J, 2010, BRIT J CANCER, V102, P1032, DOI 10.1038/sj.bjc.6605557; Doyen J, 2016, VIRCHOWS ARCH, V468, P369, DOI 10.1007/s00428-015-1883-8; Eastley N, 2016, EJSO-EUR J SURG ONC, V42, P1071, DOI 10.1016/j.ejso.2016.02.012; Fletcher CD, 2013, WHO CLASSIFICATION T, P72; Garg Pankaj, 2014, J Clin Diagn Res, V8, P1, DOI 10.7860/JCDR/2014/7532.3990; Heinrich MC, 2006, J CLIN ONCOL, V24, P1195, DOI 10.1200/JCO.2005.04.0717; Janssen ML, 2017, BRIT J SURG, V104, P347, DOI 10.1002/bjs.10477; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Lips DJ, 2009, EJSO-EUR J SURG ONC, V35, P3, DOI 10.1016/j.ejso.2008.07.003; Mouravieva AAK, 2012, EUR J CANCER, V48, P1867, DOI 10.1016/j.ejca.2012.01.004; Mullen JT, 2013, ONCOLOGIST, V18, P1043, DOI 10.1634/theoncologist.2012-0449; Penel N, 2017, CURR OPIN ONCOL, V29, P268, DOI 10.1097/CCO.0000000000000374; Salas S, 2010, GENE CHROMOSOME CANC, V49, P560, DOI 10.1002/gcc.20766; Shimoyama T, 2010, RARE TUMORS, V2, P36, DOI 10.4081/rt.2010.e12; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; van Broekhoven DLM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2704-4; van Broekhoven DLM, 2015, ANN SURG ONCOL, V22, P1464, DOI 10.1245/s10434-014-4156-x; Wu C, 2010, CANCER RES, V70, P7690, DOI 10.1158/0008-5472.CAN-10-1656	19	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						38	41		10.1016/j.anndiagpath.2018.04.001			4	Pathology	Pathology	GP5ZJ	WOS:000440955900007	29705714	Other Gold, Green Published			2019-10-28	
J	Erlenbach-Wunscha, K; Bihl, M; Hartmann, A; Groisman, GM; Vieth, M; Agaimy, A				Erlenbach-Wuenscha, Katharina; Bihl, Michel; Hartmann, Arndt; Groisman, Gabriel M.; Vieth, Michael; Agaimy, Abbas			Serrated epithelial colorectal polyps (hyperplastic polyps, sessile serrated adenomas) with perineurial stroma: Clinicopathological and molecular analysis of a new series	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						BRAF mutations; Fibroblastic polyps; Hyperplastic polyp; Sessile serrated adenoma; SSA; Perineurioma	BENIGN FIBROBLASTIC POLYPS; COLONIC PERINEURIOMA; MUTATIONS; BRAF	Serrated colorectal fibroblastic polyps (FPs) are rare benign mucosal lesions composed of serrated epithelial crypts separated and distorted by intimately associated bland spindle cell proliferations with perineurial-like phenotype. We herein describe 21 new FPs affecting 10 females and 9 males aged 45 to 80 yrs. (mean, 62 yrs). Lesions originated in the sigmoid colon/rectosigmoid junction (n = 16), rectum (n = 2), and other parts of the colon (n = 3). Most patients had additional synchronous or metachronous polyps: classical adenomas (12 patients), sessile serrated adenoma/SSA (1 patient), hyperplastic polyps/HPs (7 patients), both HPs and adenomas (6 patients) and colorectal cancer (2 patients). Size of the lesions varied from 1 to 6 mm (mean: 3 mm). Histologically, all lesions were composed of serrated epithelial crypts that were separated and distorted by spindle cell stromal proliferations (consistently EMA +, claudin-1 + and GLUT-1 +). The epithelial component displayed features of HPs (n = 17) and SSA (n = 4). Laser-microdissection-guided molecular testing was successful for 13 epithelial and 9 stromal components (9 paired samples). The BRAF V600E mutation was detected in 54% of the epithelial but in none of the stromal components. In conclusion, colorectal FPs represent genuine serrated epithelial polyps corresponding either to HP or (less frequently) SSA and should be better classified as such with a note on the presence of the stromal component. A more concise terminology reflecting their epithelial nature is needed to fulfill the requirements for colorectal cancer risk assessment and hence adopt appropriate follow-up strategies.	[Erlenbach-Wuenscha, Katharina; Hartmann, Arndt; Agaimy, Abbas] Univ Hosp, Inst Pathol, Erlangen, Germany; [Bihl, Michel] Univ Basel, Inst Pathol, Basel, Switzerland; [Groisman, Gabriel M.] Hillel Yaffe Med Ctr, Inst Pathol, Hadera, Israel; [Vieth, Michael] Klinikum Bayreuth, Inst Pathol, Bayreuth, Germany	Agaimy, A (reprint author), Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Agaimy A, 2010, AM J SURG PATHOL, V34, P1663, DOI 10.1097/PAS.0b013e3181f4a458; Anderson JC, 2018, GASTROENTEROLOGY, V154, P117, DOI 10.1053/j.gastro.2017.09.011; Baretton GB, 2011, PATHOLOGE, V32, P76, DOI 10.1007/s00292-010-1365-3; Burks EJ, 2006, MODERN PATHOL, V19, p104A; Chung SM, 2008, AM J SURG PATHOL, V32, P407, DOI 10.1097/PAS.0b013e318158dde2; Eslami-Varzaneh F, 2004, AM J SURG PATHOL, V28, P374, DOI 10.1097/00000478-200403000-00010; Groisman G, 2010, INT J SURG PATHOL, V18, P292, DOI 10.1177/1066896909350883; Groisman GM, 2008, AM J SURG PATHOL, V32, P1088, DOI 10.1097/PAS.0b013e318160df3f; Groisman GM, 2013, AM J SURG PATHOL, V37, P745, DOI 10.1097/PAS.0b013e318277a1a9; Groisman GM, 2006, HISTOPATHOLOGY, V48, P431, DOI 10.1111/j.1365-2559.2006.02357.x; Hornick JL, 2005, AM J SURG PATHOL, V29, P859, DOI 10.1097/01.pas.0000154130.87219.2c; Langner C, 2015, DIGEST DIS, V33, P28, DOI 10.1159/000366032; MCCLYMONT K, 2006, PATHOL INT S, V56, pA5; Moutinho C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-10; Pai RK, 2011, AM J SURG PATHOL, V35, P1373, DOI 10.1097/PAS.0b013e318224d9df; Pettus JR, 2012, MODERN PATHOL, V25, p175A; Rau TT, 2014, VIRCHOWS ARCH, V464, P663, DOI 10.1007/s00428-014-1569-7; Sandmeier D, 2009, HISTOPATHOLOGY, V55, P206, DOI 10.1111/j.1365-2559.2009.03356.x; van Wyk AC, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0694-z	19	2	2	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						48	52		10.1016/j.anndiagpath.2018.05.002			5	Pathology	Pathology	GP5ZJ	WOS:000440955900009	29747061				2019-10-28	
J	Flucke, U; Shepard, SJ; Bekersa, EM; Tirabosco, R; van Diest, PJ; Creytens, D; van Gorp, JM				Flucke, Uta; Shepard, Sarah J.; Bekersa, Elise M.; Tirabosco, Roberto; van Diest, Paul J.; Creytens, David; van Gorp, Joost M.			Fibro-osseous pseudotumor of digits - Expanding the spectrum of clonal transient neoplasms harboring USP6 rearrangement	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						USP6 rearrangement; Fibro-osseous pseudotumor of digits; Soft tissue tumors	ANEURYSMAL BONE-CYST; PAROSTEAL OSTEOCHONDROMATOUS PROLIFERATION; NODULAR FASCIITIS; SOFT-TISSUE; MYOSITIS-OSSIFICANS; TRANSLOCATION; EXOSTOSIS; LESION; FUSION; TUMOR	Fibro-osseous pseudotumors of the digits (FOPD) is a rare self-limiting lesion composed of bland looking hypercellular fibrous tissue and bone. USP6 rearrangement is a consistent genetic finding in aneurysmal bone cyst, nodular fasciitis, myositis ossificans and giant cell lesions of small bones. We report herein the occurrence of USP6 rearrangement in fibro-osseous pseudotumors of the digits using fluorescence in situ hybridization analysis (FISH). Of the five patients included, three were female and two were male. The age ranged from 33 to 72 years (mean 48 years). Lesions arose in the palm (n = 2), thenar (n = 1), middle finger (n = 1) and great toe (n = 1). All patients underwent resection. Four cases (80%) harbored USP6 rearrangements showing that fibro-osseous pseudotumors of digits belongs to the spectrum of clonal transient neoplasms including aneurysmal bone cyst, nodular fasciitis, myositis ossificans and giant cell lesion of small bones.	[Flucke, Uta; Bekersa, Elise M.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands; [Shepard, Sarah J.; Tirabosco, Roberto] Royal Natl Orthoped Hosp NHS Trust, Stanmore, Middx, England; [Bekersa, Elise M.] Jeroen Bosch Hosp, Dept Pathol Pathol DNA, Den Bosch, Netherlands; [van Diest, Paul J.] Univ Utrecht Hosp, Dept Pathol, Utrecht, Netherlands; [Creytens, David] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [van Gorp, Joost M.] Diakonessenhuis Utrecht, Dept Pathol Pathol DNA, Utrecht, Netherlands	Flucke, U (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	uta.flucke@radboudumc.nl					Agaram NP, 2014, HUM PATHOL, V45, P1147, DOI 10.1016/j.humpath.2014.01.020; Amary MF, 2013, VIRCHOWS ARCH, V463, P97, DOI 10.1007/s00428-013-1418-0; Bekers EM, 2018, ANN DIAGN PATHOL, V34, P56, DOI 10.1016/j.anndiagpath.2018.01.006; Chaudhry IH, 2010, J CUTAN PATHOL, V37, P323, DOI 10.1111/j.1600-0560.2009.01385.x; de Silva MVC, 2003, INT J SURG PATHOL, V11, P187, DOI 10.1177/106689690301100305; DUPREE WB, 1986, CANCER, V58, P2103, DOI 10.1002/1097-0142(19861101)58:9<2103::AID-CNCR2820580923>3.0.CO;2-C; Endo M, 2005, VIRCHOWS ARCH, V447, P99, DOI 10.1007/s00428-005-1266-7; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Moosavi CA, 2008, ANN DIAGN PATHOL, V12, P21, DOI 10.1016/j.anndiagpath.2007.02.001; Nielsen GP, 2002, AM J SURG PATHOL, V26, P64, DOI 10.1097/00000478-200201000-00007; Nilsson M, 2004, HUM PATHOL, V35, P1063, DOI 10.1016/j.humpath.2004.02.008; Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Rosenberg AE, 2013, WHO CLASSIFICATION T, P50; Rosenberg AE, 2008, ARCH PATHOL LAB MED, V132, P579, DOI 10.1043/1543-2165(2008)132[579:POST]2.0.CO;2; Storlazzi CT, 2006, INT J CANCER, V118, P1972, DOI 10.1002/ijc.21586; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; Suurmeijer AJH, 2013, WHO CLASSIFICATION T, P213; Zambrano E, 2004, AM J SURG PATHOL, V28, P1033, DOI 10.1097/01.pas.0000126642.61690.d6	19	5	5	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						53	55		10.1016/j.anndiagpath.2018.05.003			3	Pathology	Pathology	GP5ZJ	WOS:000440955900010	29787930				2019-10-28	
J	Niranjan, KC; Sarathy, NA				Niranjan, Kochli Channappa; Sarathy, Niharika Abhay			Prognostic impact of tumor-stroma ratio in oral squamous cell carcinoma - A pilot study	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article							BREAST-CANCER; SURVIVAL; STAGE	Background: Several prognostic indicators have been used for many decades in an attempt to predict clinical behaviour of Oral Squamous Cell Carcinoma (OSCC). The prognostic value of TSR is yet to be explored in OSCC. Hence, the aim of the present study was to evaluate the prognostic value of TSR in OSCC patients. Methodology: A cohort of 60 histologically diagnosed cases of OSCC who underwent Radical Neck Dissection was included in the study. TSR was assessed and patients with > 50% intratumor stroma were quantified as the stroma-poor group and those with < 50% as the stroma-rich group. Results: The parametric tests were performed for the statistical evaluation of TSR with the clinico-pathological variables and the survival. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 95.23% and 69.04%, respectively, in stroma-poor group and 77% and 44%, respectively in the stroma-rich group. Conclusion: TSR may serve as a reliable histologic prognostic indicator in OSCC and could be used in routine diagnostic pathology.	[Niranjan, Kochli Channappa; Sarathy, Niharika Abhay] SDM Coll Dent Sci & Hosp, Dept Oral & Maxillofacial Pathol, Dharwad 580009, Karnataka, India	Niranjan, KC (reprint author), SDM Coll Dent Sci & Hosp, Dept Oral & Maxillofacial Pathol, Dharwad 580009, Karnataka, India.	niranjankc@sdmcds.edu					Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chen Y, 2015, CHEM ENG SCI, V132, P1, DOI 10.1016/j.ces.2015.04.006; Downey CL, 2014, BRIT J CANCER, V110, P1744, DOI 10.1038/bjc.2014.69; Huijbers A, 2013, ANN ONCOL, V24, P179, DOI 10.1093/annonc/mds246; Kruijf E, 2011, BREAST CANC RES TREA, V125, P687; Mao SY, 2017, INT J CLIN EXP PATHO, V10, P5850; Mesker WE, 2007, CELL ONCOL, V29, P387; Pongsuvareeyakul Tip, 2015, Asian Pac J Cancer Prev, V16, P4363; Wang K, 2012, J THORAC ONCOL, V7, P1457, DOI 10.1097/JTO.0b013e318260dfe8; Wu JY, 2016, ONCOTARGET, V7, P68954, DOI 10.18632/oncotarget.12135	10	1	1	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						56	61		10.1016/j.anndiagpath.2018.05.005			6	Pathology	Pathology	GP5ZJ	WOS:000440955900011	29787931				2019-10-28	
J	Zaleski, M; Chen, YA; Chetlen, AL; Mack, J; Xu, LY; Dodge, DG; Karamchandani, DM				Zaleski, Michael; Chen, Yun An; Chetlen, Alison L.; Mack, Julie; Xu, Liyan; Dodge, Daleela G.; Karamchandani, Dipti M.			Should we excise? Are there any clinical or histologic features that predict upgrade in in papillomas, incidental or non-incidental?	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Intraductal papilloma; Incidental; Non-incidental; Ductal carcinoma in situ; Atypical ductal hyperplasia; Upgrade	CORE-NEEDLE-BIOPSY; PAPILLARY BREAST-LESIONS; INTRADUCTAL PAPILLOMAS; MALIGNANCY; MANAGEMENT; CARCINOMA; RISK; ASSOCIATION; ATYPIA; CANCER	The clinical decision to excise intraductal papilloma (IDP) without atypia diagnosed on biopsy remains controversial. We sought to establish clinical and histologic predictors (if any) which may predict upgrade in IDP. 296 biopsies (in 278 women) with histologic diagnosis of IDP without atypia were retrospectively identified and placed into Incidental (no corresponding imaging correlate), or Non-incidental (positive imaging correlate) groups. 253/296 (85.5%) cases were non-incidental, and 43/296 (14.5%) were incidental. 73.1% (185/253) non-incidental and 48.8% (21/43) incidental cases underwent excision. 12.4% (23/185) non-incidental cases underwent an upgrade to cancer or high-risk lesion; namely 8-Ductal carcinoma in situ (DOS), 8-atypical ductal hyperplasia (ADH), 6-lobular neoplasia, and 1-flat epithelial atypia. There was no histopathologic feature on the biopsy in the non-incidental group which predicted upgrade; however a past history of atypia was significantly associated with upgrade. 2 of the 21 incidental cases upgraded (1 to ADH and 1 to lobular neoplasia); the former had a past history of ADH. Both incidental upgrades were > 1 mm in size, and were not completely excised on the biopsy. None of the incidental cases which appeared completely excised on biopsy upgraded, irrespective of the size on biopsy. These findings suggest that all non-incidental IDPs should be considered candidates for surgical excision, given the 12.4% upgrade rate and no definitive histologic predictors of upgrade. Patients with incidental IDPs (if < 1 mm, completely excised on biopsy and with no history of high risk breast lesion) can be spared excision.	[Zaleski, Michael; Karamchandani, Dipti M.] Penn State Hlth Milton S Hershey Med Ctr, Dept Pathol, Div Anat Pathol, 500 Univ Dr,H179, Hershey, PA 17033 USA; [Chen, Yun An] Penn State Coll Med, Hershey, PA USA; [Chetlen, Alison L.; Mack, Julie] Penn State Hlth Milton S Hershey Med Ctr, Dept Radiol, Div Breast Imaging, Hershey, PA USA; [Xu, Liyan] Duke Univ, Dept Pathol, Durham, NC 27706 USA; [Dodge, Daleela G.] Penn State Hlth Milton S Hershey Med Ctr, Dept Surg, Hershey, PA USA	Karamchandani, DM (reprint author), Penn State Hlth Milton S Hershey Med Ctr, Dept Pathol, Div Anat Pathol, 500 Univ Dr,H179, Hershey, PA 17033 USA.	dkaramchandani@pennstatehealth.psu.edu					Agoff SN, 2004, AM J CLIN PATHOL, V122, P440, DOI 10.1309/NAPJMB0GXKJC6PTH; Ashkenazi I, 2007, AM J SURG, V194, P183, DOI 10.1016/j.amjsurg.2006.11.028; Gendler LS, 2004, AM J SURG, V188, P365, DOI 10.1016/j.amjsurg.2004.06.026; Hong YR, 2016, J BREAST CANCER, V19, P410, DOI 10.4048/jbc.2016.19.4.410; Ivan D, 2004, MODERN PATHOL, V17, P165, DOI 10.1038/modpathol.3800014; Jaffer S, 2013, BREAST J, V19, P130, DOI 10.1111/tbj.12073; Jaffer S, 2009, CANCER, V115, P2837, DOI 10.1002/cncr.24321; Khan S, 2018, BREAST J, V24, P350, DOI 10.1111/tbj.12907; Ko D, 2017, CLIN BREAST CANCER, V17, P367, DOI 10.1016/j.clbc.2017.03.016; Lam WWM, 2006, AM J ROENTGENOL, V186, P1322, DOI 10.2214/AJR.04.1908; Page DL, 1996, CANCER, V78, P258, DOI 10.1002/(SICI)1097-0142(19960715)78:2<258::AID-CNCR11>3.0.CO;2-V; Pareja F, 2016, CANCER-AM CANCER SOC, V122, P2819, DOI 10.1002/cncr.30118; Renshaw AA, 2004, AM J CLIN PATHOL, V122, P217, DOI 10.1309/K1BNJXETEY3H06UL; Rizzo M, 2008, ANN SURG ONCOL, V15, P1040, DOI 10.1245/s10434-007-9780-2; Sakr R, 2008, EJSO-EUR J SURG ONC, V34, P1304, DOI 10.1016/j.ejso.2008.03.013; Shiino S, 2015, PATHOL INT, V65, P293, DOI 10.1111/pin.12285; Swapp RE, 2013, ANN SURG ONCOL, V20, P1900, DOI 10.1245/s10434-012-2846-9; Tatarian T, 2016, ANN SURG ONCOL, V23, P2501, DOI 10.1245/s10434-016-5182-7; Tran HT, 2017, AM SURGEON, V83, P1294	19	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						62	68		10.1016/j.anndiagpath.2018.05.004			7	Pathology	Pathology	GP5ZJ	WOS:000440955900012	29793212				2019-10-28	
J	Wang, MP; Liang, L; Lei, XD; Multani, A; Meric-Bernstam, F; Tripathy, D; Wu, Y; Chen, H; Zhang, H				Wang, Mopei; Liang, Li; Lei, Xiudong; Multani, Asha; Meric-Bernstam, Funda; Tripathy, Debasish; Wu, Yun; Chen, Hui; Zhang, Hong			Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Triple Negative; Breast Cancer; cMET; FISH; Immunohistochemistry	HEPATOCYTE GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; C-MET; TYROSINE KINASE; SCATTER FACTOR; COPY NUMBER; CLINICAL ONCOLOGY/COLLEGE; PROGNOSTIC-SIGNIFICANCE; AMERICAN SOCIETY; EXPRESSION	Purpose: To evaluate the incidence of cMET proto-oncogene aberration in a cohort of triple negative breast cancers using immunohistochemistry and fluorescence in situ hybridization (FISH) methods and correlated with patient outcome. Patients and methods: One hundred and six female patients with diagnosis of triple negative invasive breast carcinoma at The University of Texas-M D Anderson Cancer Center from 1983 to 2009 were included in the study. Expression of cMET was assessed by IHC using rabbit monoclonal anti-total cMET antibody (SP44 from Ventana). Staining intensity was scored on a scale of 0, 1 +, 2 + and 3 +. cMET overexpression was defined as at least moderate membranous/cytoplasmic staining in >= 50% of tumor cells (score >= 2 +). FISH analysis was performed using MET (7q31) specific probe (BAC clone RP11-95i20, Abbott Molecular Inc.) and the centromere probe (CEP7/D7Z1, Abbott Molecular Inc.) as internal control. cMET amplification was defined as gene copy numbers >= 4 per cell or cMET/CEP7 ratio >= 2. cMET status was tested for correlation using Fisher's exact test with other clinicopathological parameters. The Kaplan-Meier product limit method was used to estimate the survival outcomes. Cox proportional hazards models were fit to determine the association of cMET status by IHC, or by FISH, or by copy number with survival outcomes after adjustment for other patient and disease characteristics. Results: Medium follow up is 69.4 months (range 9-317 months). cMET was successfully evaluated by both IHC and FISH methods in ninety-six patients. There were 13 patients whose tumors overexpressed cMET was by IHC. Two patients had cMET amplification by FISH using definitive of cMET/CEP7 ratio of 2 and four patients had cMET copy number > 4. Only one patient showed cMET/CEP7 ratio of 2.53 and one was positive for cMET overexpression by IHC. No significant association between cMET overexpression by IHC and by FISH using cutoff of with either cMET/CEP7 ratio of >= 2 or cMET copy number of > 4 (P = 1.0). There was no significant correlation between the cMET overexpression and other clinicopathological characteristics, such as patient demographics, tumor grade, stage, or chemotherapy treatment history. cMET overexpression and gene amplification did not correlate with the prognosis of TNBC regarding OS or DFS. Conclusion: MET amplification is a rare incidence in TNBCs. cMET overexpression is infrequent in TNBCs and may not be driven by gene amplification. Neither have significant prognostic value nor do they correlate with other clinicopathological characteristics in this TNBC cohort.	[Wang, Mopei; Liang, Li; Wu, Yun; Chen, Hui; Zhang, Hong] Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1400 Pressler St, Houston, TX 77030 USA; [Wang, Mopei; Liang, Li] Peking Univ, Hosp 3, Dept Tumor Chemotherapy & Radiat Sickness, Beijing 100191, Peoples R China; [Lei, Xiudong] Univ Texas MD Anderson Canc Ctr, Dept Biostat, 1400 Pressler St, Houston, TX 77030 USA; [Multani, Asha] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1400 Pressler St, Houston, TX 77030 USA; [Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, 1400 Pressler St, Houston, TX 77030 USA; [Meric-Bernstam, Funda] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, 1400 Holcombe Blvd,Unit 455, Houston, TX 77030 USA; [Tripathy, Debasish] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1400 Pressler St, Houston, TX 77030 USA; [Zhang, Hong] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Zhang, H (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, 1400 Pressler St, Houston, TX 77030 USA.	fmeric@mdanderson.org; zhangh3@mskcc.org					BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Carracedo A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2239; Chen HHW, 2007, BREAST CANCER RES TR, V103, P167, DOI 10.1007/s10549-006-9360-3; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Fujita S, 1997, JPN J CLIN ONCOL, V27, P378, DOI 10.1093/jjco/27.6.378; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Gonzalez-Angulo AM, 2013, CANCER-AM CANCER SOC, V119, P7, DOI 10.1002/cncr.27608; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI 10.1043/1543-2165-134.6.907; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Ichimura E, 1996, JPN J CANCER RES, V87, P1063, DOI 10.1111/j.1349-7006.1996.tb03111.x; Inanc M, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0801-7; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kang JY, 2003, CANCER RES, V63, P1101; Kim YJ, 2014, INT J CANCER, V134, P2424, DOI 10.1002/ijc.28566; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Lo Muzio L, 2006, TUMOR BIOL, V27, P115, DOI 10.1159/000092716; Marshall DD, 1998, LARYNGOSCOPE, V108, P1413, DOI 10.1097/00005537-199809000-00031; Miyata Y, 2006, CLIN CANCER RES, V12, P4876, DOI 10.1158/1078-0432.CCR-06-0362; Nakopoulou L, 2000, HISTOPATHOLOGY, V36, P313; Ocal IT, 2003, CANCER, V97, P1841, DOI 10.1002/cncr.11335; Park S, 2012, HISTOL HISTOPATHOL, V27, P197, DOI 10.14670/HH-27.197; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Raghav KP, 2012, CLIN CANCER RES, V18, P2269, DOI 10.1158/1078-0432.CCR-11-2830; Sattler Martin, 2011, Ther Adv Med Oncol, V3, P171, DOI 10.1177/1758834011408636; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Sweeney P, 2002, J UROLOGY, V168, P51, DOI 10.1016/S0022-5347(05)64830-6; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yan SC, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0296-y; Zagouri F, 2013, BRIT J CANCER, V108, P1100, DOI 10.1038/bjc.2013.31; Zagouri F, 2014, ANTICANCER RES, V34, P1227; Zhao XX, 2017, ONCOTARGET, V8, P56758, DOI 10.18632/oncotarget.18142	39	2	2	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						69	76		10.1016/j.anndiagpath.2018.04.004			8	Pathology	Pathology	GP5ZJ	WOS:000440955900013	29843069	Other Gold			2019-10-28	
J	Tolonen, TT; Riikonen, J; Tammela, TLJ; Koivusalo, L; Haapasalo, H; Kujala, P; Kaipia, A				Tolonen, Teemu T.; Riikonen, Jarno; Tammela, Teuvo L. J.; Koivusalo, Laura; Haapasalo, Hannu; Kujala, Paula; Kaipia, Antti			Extraprostatic extension (pT3a) in prostate biopsy is an under-recognized feature indicating high risk disease	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Prostate cancer; Prostate biopsy; Prostatic needle biopsy; Extraprostatic extension; pT3a; Fat infiltration; Prognosis	RADICAL PROSTATECTOMY; PERINEURAL INVASION; NEEDLE-BIOPSY; PATHOLOGICAL STAGE; CORE BIOPSY; CANCER; ADENOCARCINOMA; PREDICTOR; CARCINOMA; SPECIMENS		[Tolonen, Teemu T.; Koivusalo, Laura; Haapasalo, Hannu; Kujala, Paula] Tampere Univ Hosp, Dept Pathol, Fimlab Labs, Tampere, Finland; [Riikonen, Jarno; Tammela, Teuvo L. J.] Tampere Univ Hosp, Dept Urol, Tampere, Finland; [Koivusalo, Laura] Tampere Univ Technol, Dept Mat Sci, Tampere, Finland; [Koivusalo, Laura; Kaipia, Antti] Satakunta Cent Hosp, Dept Urol, Pori, Finland	Tolonen, TT (reprint author), Fimlab Labs, Arvo Ylponkatu 4, FI-33520 Tampere, Finland.	teemu.tolonen@fimlab.fi			Pirkanmaa Hospital District; Satakunta Hospital District	Competitive funding of Pirkanmaa and Satakunta Hospital Districts.	Amin A., 2016, ANN CLIN PATHOL, V4, P1086; Billis AR, 2004, HUM PATHOL, V35, P525, DOI 10.1016/j.humpath.2003.12.005; Bismar TA, 2003, AM J SURG PATHOL, V27, P432, DOI 10.1097/00000478-200304000-00002; Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0; Cozzi G, 2013, SCAND J UROL, V47, P443, DOI 10.3109/21681805.2013.776106; de la Taille A, 1999, UROLOGY, V54, P1039, DOI 10.1016/S0090-4295(99)00350-7; Elharram M, 2012, CAN J UROL, V19, P6567; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Fleshner K, 2016, J UROLOGY, V196, P703, DOI 10.1016/j.juro.2016.03.152; Han M, 2003, J UROLOGY, V169, P517, DOI 10.1097/01.ju.0000045749.90353.c7; HASUI Y, 1989, PROSTATE, V14, P65, DOI 10.1002/pros.2990140108; Heidenreich A, 2011, EUR UROL, V59, P61, DOI 10.1016/j.eururo.2010.10.039; Lopez JI, 2006, HISTOPATHOLOGY, V48, P663, DOI 10.1111/j.1365-2559.2006.02399.x; Miller JS, 2010, BJU INT, V106, P330, DOI 10.1111/j.1464-410X.2009.09110.x; Nazeer T, 2009, HUM PATHOL, V40, P538, DOI 10.1016/j.humpath.2008.10.004; Sebo TJ, 2000, J UROLOGY, V163, P174, DOI 10.1016/S0022-5347(05)67998-0; Sung MT, 2006, PATHOLOGY, V38, P309, DOI 10.1080/00313020600820914; Ye HH, 2010, J UROLOGY, V184, P2308, DOI 10.1016/j.juro.2010.08.006; Yilmaz A, 2004, MOD PATHOL S1, V17, p186A; Zam NABM, 2008, PATHOLOGY, V40, P586, DOI 10.1080/00313020802320671	20	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						80	84		10.1016/j.anndiagpath.2018.06.001			5	Pathology	Pathology	GP5ZJ	WOS:000440955900015	29886397				2019-10-28	
J	Yasir, S; Nassar, A; Jimenez, RE; Jenkins, SM; Hartmann, LC; Degnim, AC; Frost, M; Visscher, DW				Yasir, Saba; Nassar, Aziza; Jimenez, Rafael E.; Jenkins, Sarah M.; Hartmann, Lynn C.; Degnim, Amy C.; Frost, Marlene; Visscher, Daniel W.			Cellular fibroepithelial lesions of the breast: A long term follow up study	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Article						Cellular fibroepithelial lesions; Cellular fibroadenoma; Benign phyllodes tumor; Follow-up	CYSTOSARCOMA-PHYLLODES; LOCAL RECURRENCE; TUMORS; FEATURES; THERAPY	Some fibroepithelial lesions (FEL) of the breast are difficult to classify as cellular fibroadenoma (CFA) or benign phyllodes tumor (BPT) due to overlapping histologic features. This indeterminate group is histologically characterized by prominent stromal cellularity, mild atypia, and mitotic activity. The local recurrence potential of cellular FEL (CFEL) has been insufficiently studied. The objective of this study was to evaluate the histologic features, characterize the long-term follow-up and recurrence rate of CFEL, and compare this data with the recurrence rate of definitive BPT. Ninety CFEL that were < 4 cm were recovered from the benign breast disease cohort. The control group comprised of 10 randomly selected patients with BPT. Cases were classified based on a combination of mitotic activity, intracanalicular growth, stromal atypia, stromal prominence, and fat infiltration. None of the CFEL was widely excised. Of the 90 CFEL cases, there were 22 BPT-like, 35 CFA, and 33 indeterminate. The mean age of the patients was 40.1 years. The mean tumor size was 2.4 cm. All patients had at least two years of follow-up (median 27). None of the patients with BPT-like CFEL showed ipsilateral recurrence. Five of the 35 patients with CFA had recurrent ipsilateral CFA. This occurred within 1 to 11 years after the initial diagnosis. One of 33 patients with indeterminate type had a recurrent ipsilateral lesion five years after the initial diagnosis with histologic features of CFA. None of the patients in control group had any recurrence. In conclusion, as a group, CFEL have a low proclivity for recurrence, even when enucleated with close or positive margins. The presence of histologic features of BPT did not correlate with an increased potential for recurrence.	[Yasir, Saba; Nassar, Aziza; Jimenez, Rafael E.; Visscher, Daniel W.] Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA; [Jenkins, Sarah M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Hartmann, Lynn C.; Frost, Marlene] Mayo Clin, Dept Med Oncol, Rochester, MN USA; [Degnim, Amy C.] Mayo Clin, Dept Surg, Rochester, MN USA	Visscher, DW (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA.	Visscher.daniel@mayo.edu	Nassar, Aziza/M-6254-2014	Nassar, Aziza/0000-0002-6678-9329			Barrio AV, 2007, ANN SURG ONCOL, V14, P2961, DOI 10.1245/s10434-007-9439-z; Barth RJ, 1999, BREAST CANCER RES TR, V57, P291, DOI 10.1023/A:1006260225618; Devilee P, 2003, PATHOLOGY GENETICS T, P99; FEKETE P, 1987, ARCH PATHOL LAB MED, V111, P427; HAAGENSEN CD, 1986, DISEASES BREAST, P284; HAJDU SI, 1976, CANCER, V38, P1402, DOI 10.1002/1097-0142(197609)38:3<1402::AID-CNCR2820380346>3.0.CO;2-9; Halverson J D, 1974, Am Surg, V40, P295; HART J, 1988, ARCH SURG-CHICAGO, V123, P1079; Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383; MOFFAT CJC, 1995, HISTOPATHOLOGY, V27, P205, DOI 10.1111/j.1365-2559.1995.tb00212.x; OBERMAN HA, 1965, CANCER, V18, P697, DOI 10.1002/1097-0142(196506)18:6<697::AID-CNCR2820180607>3.0.CO;2-L; PIETRUSZKA M, 1978, CANCER, V41, P1974, DOI 10.1002/1097-0142(197805)41:5<1974::AID-CNCR2820410543>3.0.CO;2-C; PIKE AM, 1985, AM J SURG PATHOL, V9, P730, DOI 10.1097/00000478-198510000-00004; REMADI S, 1994, ANN PATHOL, V14, P392; Taira N, 2007, JPN J CLIN ONCOL, V37, P730, DOI 10.1093/jjco/hym099; Tan PH, 2005, AM J CLIN PATHOL, V123, P529, DOI 10.1309/U6DVBFM81MLJC1FN; Tan PH, 2012, WHO CLASSIFICATION T, P142; Tteves N, 1951, CANCER, V4, P1286; ZURRIDA S, 1992, EUR J CANCER, V28A, P654, DOI 10.1016/S0959-8049(05)80119-4	19	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						85	91		10.1016/j.anndiagpath.2018.01.005			7	Pathology	Pathology	GP5ZJ	WOS:000440955900016	30029048				2019-10-28	
J	Lionti, S; Ieni, A; Cannavo, S; Barresi, V				Lionti, Simona; Ieni, Antonio; Cannavo, Salvatore; Barresi, Valeria			Immunohistochemical expression of glypican-3 in adrenocortical carcinoma: A potential cause of diagnostic pitfalls	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Letter						Adrenocortical carcinoma; Hepatocellular carcinoma; HSP-70; Glypican-3; Immunohistochemistry; Pitfall	HEPATOCELLULAR-CARCINOMA; NEOPLASMS; TUMORS; LIVER		[Lionti, Simona; Ieni, Antonio; Cannavo, Salvatore; Barresi, Valeria] Univ Messina, Dept Human Pathol, Messina, Italy	Barresi, V (reprint author), Polyclin G Martino, Dept Human Pathol, Pad D, Via Consolare Valeria, I-98125 Messina, Italy.	vbarresi@unime.it		Barresi, Valeria/0000-0001-7086-1920			Baumhoer D, 2008, AM J CLIN PATHOL, V129, P899, DOI 10.1309/HCQWPWD50XHD2DW6; Chivite A, 1998, APPL IMMUNOHISTO M M, V6, P42, DOI 10.1097/00022744-199803000-00008; Di Tommaso L, 2009, J HEPATOL, V50, P746, DOI 10.1016/j.jhep.2008.11.014; Ghorab Z, 2003, APPL IMMUNOHISTO M M, V11, P330; Ibrahim TR, 2015, PATHOL ONCOL RES, V21, P379, DOI 10.1007/s12253-014-9830-6; Park WY, 2017, ANN DIAGN PATHOL, V31, P9, DOI 10.1016/j.anndiagpath.2017.05.016	6	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						92	93		10.1016/j.anndiagpath.2018.05.001			2	Pathology	Pathology	GP5ZJ	WOS:000440955900017	29748062				2019-10-28	
J	Gutmann, EJ				Gutmann, Edward J.			GRAND(ER) ROUNDS: Expanding the universe of topics and speakers in a pathology department seminar series	ANNALS OF DIAGNOSTIC PATHOLOGY			English	Editorial Material						Pathology education; Grand Rounds; Continuing medical education; Medical humanities		This article reports on a unique pathology department seminar series that included talks on social science and humanities topics in addition to traditional biomedical subjects. The goals, achievements, and potential of such a series are addressed via review of selected speakers and topics.	[Gutmann, Edward J.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH 03756 USA; [Gutmann, Edward J.] Dartmouth Geisel Med Sch, Hanover, NH 03755 USA	Gutmann, EJ (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH 03756 USA.; Gutmann, EJ (reprint author), Dartmouth Geisel Med Sch, Hanover, NH 03755 USA.	Edward.J.Gutmann@Hitchcock.org					Dreifus C., 2007, NY TIMES, pF2; Grimes W., 2015, NY TIMES; Korbar Bruno, 2017, J Pathol Inform, V8, P30, DOI 10.4103/jpi.jpi_34_17	3	0	0	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1092-9134	1532-8198		ANN DIAGN PATHOL	Ann. Diagn. Pathol.	AUG	2018	35						94	96		10.1016/j.anndiagpath.2018.05.006			3	Pathology	Pathology	GP5ZJ	WOS:000440955900018	29970293				2019-10-28	
J	Steger, CM; Bonaros, N; Rieker, RJ; Bonatti, J; Schachner, T				Steger, Christina Maria; Bonaros, Nikolaos; Rieker, Ralf Joachim; Bonatti, Johannes; Schachner, Thomas			Gene therapy with antisense oligonucleotides silencing c-myc reduces neointima formation and vessel wall thickness in a mouse model of vein graft disease	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Coronary artery bypass grafting; Vein graft disease; Mouse model; Gene therapy; Antisense oligonucleotides; C-myc	SMOOTH-MUSCLE-CELLS; HUMAN SAPHENOUS-VEIN; MATRIX METALLOPROTEINASES; TNF-ALPHA; GROWTH-FACTOR; TGF-BETA; PROLIFERATION; EXPRESSION; ONCOPROTEIN; RESTENOSIS	Gene therapy for avoiding intimal hyperplasia of vein grafts after coronary artery bypass grafting is still discussed controversially. A promising application of gene therapy in vein grafts is the use of antisense oligonucleotides to block the expression of genes encoding cell cycle regulatory proteins in vascular smooth muscle cells. C-myc, either directly or by regulating the expression of other proteins, controls cell proliferation, apoptosis and cell survival, tissue remodeling, angiogenesis, cell metabolism, production of inflammatory and anti-in-flammatory cytokines, and also participates in cell transformation. Forty C57BL/6J mice underwent interposition of the inferior vena cava from isogenic donor mice into the common carotid artery using a previously described cuff technique. Twenty mice received periadventitial administration of antisense oligonucleotides directed against c-myc (treatment group), the other twenty mice received no treatment (control group). All vein grafts were harvested two weeks after surgery, dehydrated, wax embedded, cut into slides of 2 mu m thickness, stained and histologically and immunohistochemically examined under light microscope. In our study, we could show the promising effects of antisense oligonucleotide treatment in a mouse model of vein graft disease including the significant reduction of neointimal, media and total vessel wall thickness with a significantly lower percentage of SMA positive cells, elastic fibres and acid mucopolysaccharides in the neointima and media, a decreased vascularization, and a lower expression of PDGFR beta, MMP-9 and VEGF-A positive cells throughout the whole vein graft wall.	[Steger, Christina Maria] Acad Teaching Hosp Feldkirch, Dept Pathol, Carinagasse 47, A-6800 Feldkirch, Austria; [Bonaros, Nikolaos; Schachner, Thomas] Innsbruck Med Univ, Dept Cardiac Surg, Anichstr 35, A-6020 Innsbruck, Austria; [Rieker, Ralf Joachim] Univ Hosp Erlangen, Dept Pathol, Erlangen, Germany; [Bonatti, Johannes] Cleveland Clin Abu Dhabi, Inst Heart & Vasc, Abu Dhabi, U Arab Emirates	Steger, CM (reprint author), Acad Teaching Hosp Feldkirch, Dept Pathol, Carinagasse 47, A-6800 Feldkirch, Austria.	christina.steger@lkhf.at		Schachner, Thomas/0000-0002-5865-2787			AMENTO EP, 1991, ARTERIOSCLER THROMB, V11, P1223, DOI 10.1161/01.ATV.11.5.1223; BENNETT MR, 1994, BIOCHEM J, V302, P701, DOI 10.1042/bj3020701; Bennett MR, 1997, ARTERIOSCL THROM VAS, V17, P2326, DOI 10.1161/01.ATV.17.11.2326; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Cable D.G, 1997, CIRCULATION S1, V96; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; Di Micco G, 2002, EUR J CARDIO-THORAC, V22, P266, DOI 10.1016/S1010-7940(02)00274-9; EDELMAN ER, 1995, CIRC RES, V76, P176, DOI 10.1161/01.RES.76.2.176; Ehsan A, 2000, VASC MED, V5, P103, DOI 10.1191/135886300668426194; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Forte A, 2005, J VASC RES, V42, P214, DOI 10.1159/000085379; Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8; George SJ, 1996, ATHEROSCLEROSIS, V120, P227, DOI 10.1016/0021-9150(95)05717-X; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; George SJ, 1998, HUM GENE THER, V9, P867, DOI 10.1089/hum.1998.9.6-867; Golja AM, 1995, CELL MOL BIOL RES, V41, P487; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; HOLT CM, 1992, CARDIOVASC RES, V26, P1189, DOI 10.1093/cvr/26.12.1189; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kutryk MJB, 2002, J AM COLL CARDIOL, V39, P281, DOI 10.1016/S0735-1097(01)01741-7; LYTLE BW, 1992, J THORAC CARDIOV SUR, V103, P831; Mann MJ, 1997, J CLIN INVEST, V99, P1295, DOI 10.1172/JCI119288; Mannion JD, 1998, ANN THORAC SURG, V66, P1948, DOI 10.1016/S0003-4975(98)01168-0; Mannion JD, 1998, J THORAC CARDIOV SUR, V115, P152, DOI 10.1016/S0022-5223(98)70453-2; MARIN ML, 1993, J VASC SURG, V18, P170, DOI 10.1016/0741-5214(93)90596-E; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Newby AC, 2005, PHYSIOL REV, V85, P1, DOI 10.1152/physrev.00048.2003; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Ramirez JA, 1996, J SURG RES, V61, P323, DOI 10.1006/jsre.1996.0124; Regueira T, 2009, LIVER INT, V29, P1582, DOI 10.1111/j.1478-3231.2009.02109.x; ROALD HE, 1995, ARTERIOSCL THROM VAS, V15, P128, DOI 10.1161/01.ATV.15.1.128; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schreier B, 2016, BBA-MOL CELL RES, V1863, P1519, DOI 10.1016/j.bbamcr.2016.03.017; Sharony R, 2006, AM J PHYSIOL-HEART C, V290, pH1651, DOI 10.1152/ajpheart.00530.2005; Simionescu A, 2005, BIOCHEM BIOPH RES CO, V334, P524, DOI 10.1016/j.bbrc.2005.06.119; Song SS, 2014, INT IMMUNOPHARMACOL, V20, P117, DOI 10.1016/j.intimp.2014.02.027; Tanaka H, 1996, ARTERIOSCL THROM VAS, V16, P12, DOI 10.1161/01.ATV.16.1.12; Tu QM, 2016, EUR REV MED PHARMACO, V20, P2363; Vaday GG, 2000, J LEUKOCYTE BIOL, V68, P737; Wang J, 2011, J SURG RES, V169, pE85, DOI 10.1016/j.jss.2011.03.060; Wang X, 2017, IMMUNOL LETT, V184, P7, DOI 10.1016/j.imlet.2017.02.006; Wesley RB, 1998, ARTERIOSCL THROM VAS, V18, P432, DOI 10.1161/01.ATV.18.3.432; Zou YP, 1998, AM J PATHOL, V153, P1301, DOI 10.1016/S0002-9440(10)65675-1	51	0	1	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					1	9		10.1016/j.yexmp.2018.05.003			9	Pathology	Pathology	GP6AE	WOS:000440958500001	29775572				2019-10-28	
J	Dimitrijevic, M; Arsenovic-Ranin, N; Bufan, B; Nacka-Aleksic, M; Macanovic, ML; Milovanovic, P; Duric, M; Sopta, J; Leposavic, G				Dimitrijevic, Mirjana; Arsenovic-Ranin, Nevena; Bufan, Biljana; Nacka-Aleksic, Mirjana; Macanovic, Mirjana Lazarevic; Milovanovic, Petar; Duric, Marija; Sopta, Jelena; Leposavic, Gordana			Collagen-induced arthritis in Dark Agouti rats as a model for study of immunological sexual dimorphisms in the human disease	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						CIA; Sexual dimorphism; DA rat strain; IL-17+T cells; IFN-gamma plus T cells; T regulatory cells	REGULATORY T-CELLS; GM-CSF PRODUCTION; RHEUMATOID-ARTHRITIS; GENDER-DIFFERENCES; DENDRITIC CELLS; EFFECTOR PHASE; B-CELLS; INDUCTION; INTERLEUKIN-10; DISTINCT	Collagen-induced arthritis (CIA) is a frequently used animal model of rheumatoid arthritis, human autoimmune disease that exhibits clear sex bias in incidence and clinical course. Female Dark Agouti rats immunized for CIA showed also greater incidence and higher arthritic score than their male counterparts. The study investigated sex differences in mechanisms controlling the primary immune responses in draining lymph nodes (dLNs), as a factor contributing to this dimorphism. The higher frequencies of CD4 + CD25 + Foxp3- cells, presumably activated effector T (Teff) cells, and IL-17+, IFN-gamma + and IL-17 + IFN-gamma + T cells were found in female compared with male rat dLNs. However, the frequency of CD4 + CD25 + Foxp3 + T regulatory cells (Treg) did not differ between sexes. Thus, CD4 + Teff cells/Treg ratio, and IL-17 + T cells/Treg and IFN-gamma + T cells/Treg ratios were higher in female than in male rats, and among them was found lower frequency of PD-1+ cells. This suggested less efficient control of (auto)immune Th1/Th17 cell responses in female rat dLNs. On the contrary, the frequency of IL-4 + T cells was lower in female than in male rat dLNs. Consistently, the ratio of serum levels of collagen-specific IgG2a (IFN-gamma-dependent, with an important pathogenic role in CIA) and IgG1 (IL-4-dependent) was shifted towards IgG2a in female compared with male rats. As a whole, the study suggests that sexual dimorphism in the control of T cell activation/polarization could contribute to sex bias in the susceptibility to CIA. Moreover, the study advises the use of animals of both sexes in the preclinical testing of new drugs for rheumatoid arthritis.	[Dimitrijevic, Mirjana] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Bulevar Despots Stefana 142, Belgrade 11060, Serbia; [Arsenovic-Ranin, Nevena; Bufan, Biljana] Univ Belgrade, Fac Pharm, Dept Microbiol & Immunol, Vojvode Stepe 450, Belgrade, Serbia; [Nacka-Aleksic, Mirjana; Leposavic, Gordana] Univ Belgrade, Fac Pharm, Dept Physiol, Vojvode Stepe 450, Belgrade, Serbia; [Macanovic, Mirjana Lazarevic] Univ Belgrade, Fac Vet Med, Dept Radiol & Radiat Hyg, Bulevar Oslobodenja 18, Belgrade, Serbia; [Milovanovic, Petar; Duric, Marija] Univ Belgrade, Fac Med, Inst Anat, Lab Anthropol, Dr Subotica 4-2, Belgrade, Serbia; [Sopta, Jelena] Univ Belgrade, Fac Med, Dept Pathol, Dr Subotica 4-2, Belgrade, Serbia	Dimitrijevic, M (reprint author), Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Immunol, Bulevar Despots Stefana 142, Belgrade 11060, Serbia.	mirjana.dimitrijevic@ibiss.bg.ac.rs		Milovanovic, Petar/0000-0003-1461-8437	Ministry of Education, Science and Technological Development of Republic of Serbia [175050]	This work was supported by the grant No. 175050 from Ministry of Education, Science and Technological Development of Republic of Serbia.	Banko Z, 2017, J IMMUNOL, V198, P1512, DOI 10.4049/jimmunol.1600218; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Brenner M, 2013, PHYSIOL GENOMICS, V45, P552, DOI 10.1152/physiolgenomics.00029.2013; Brzustewicz E, 2015, CYTOKINE, V76, P527, DOI 10.1016/j.cyto.2015.08.260; Byng-Maddick R, 2015, RHEUMATOLOGY, V54, P768, DOI 10.1093/rheumatology/keu487; Campbell IK, 2011, J IMMUNOL, V186, P5468, DOI 10.4049/jimmunol.1002923; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Clavel C, 2008, ARTHRITIS RHEUM-US, V58, P678, DOI 10.1002/art.23284; Codarri L, 2011, NAT IMMUNOL, V12, P560, DOI 10.1038/ni.2027; Cook AD, 2001, ARTHRITIS RES, V3, P293, DOI 10.1186/ar318; De Leon-Nava MA, 2009, J STEROID BIOCHEM, V113, P57, DOI 10.1016/j.jsbmb.2008.11.003; Dinesh RK, 2010, AUTOIMMUN REV, V9, P583, DOI 10.1016/j.autrev.2010.04.003; Djikic J, 2014, EXP GERONTOL, V58, P179, DOI 10.1016/j.exger.2014.08.005; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031; Fairweather D, 2008, AM J PATHOL, V173, P600, DOI 10.2353/ajpath.2008.071008; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303; Flores-Borja F, 2008, P NATL ACAD SCI USA, V105, P19396, DOI 10.1073/pnas.0806855105; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Frey O, 2005, ARTHRITIS RES THER, V7, pR291, DOI 10.1186/ar1484; Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Herndler-Brandstetter D, 2014, CELL RES, V24, P1379, DOI 10.1038/cr.2014.155; HOLMDAHL R, 1995, SCAND J IMMUNOL, V42, P104, DOI 10.1111/j.1365-3083.1995.tb03632.x; Hou W, 2010, CLIN EXP RHEUMATOL, V28, P532; Iikuni N, 2009, J RHEUMATOL, V36, P508, DOI 10.3899/jrheum.080724; Kared H, 2008, BLOOD, V112, P2575, DOI 10.1182/blood-2008-02-140681; KLEINAU S, 1991, J AUTOIMMUN, V4, P871, DOI 10.1016/0896-8411(91)90050-M; Koenders MI, 2005, ARTHRITIS RHEUM-US, V52, P975, DOI 10.1002/art.20885; Kovacs WJ, 2011, NAT REV RHEUMATOL, V7, P307, DOI 10.1038/nrrheum.2010.231; Kugyelka R, 2016, MEDIAT INFLAMM, DOI 10.1155/2016/6145810; Lamacchia C, 2010, ARTHRITIS RHEUM-US, V62, P452, DOI 10.1002/art.27235; LARSSON P, 1990, ARTHRITIS RHEUM, V33, P693, DOI 10.1002/art.1780330512; Markle JG, 2014, TRENDS IMMUNOL, V35, P97, DOI 10.1016/j.it.2013.10.006; Mavropoulos A, 2017, CLIN IMMUNOL, V184, P26, DOI 10.1016/j.clim.2017.04.013; McWilliams IL, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0351-3; Menon B, 2014, ARTHRITIS RHEUMATOL, V66, P1272, DOI 10.1002/art.38376; Miller LR, 2017, FASEB J, V31, P29, DOI 10.1096/fj.201600781R; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morgan ME, 2005, ARTHRITIS RHEUM-US, V52, P2212, DOI 10.1002/art.21195; Morita Y, 2001, J CLIN INVEST, V107, P1275, DOI 10.1172/JCI11490; Moudgil KD, 2011, CURR RHEUMATOL REP, V13, P456, DOI 10.1007/s11926-011-0200-z; Mussener A, 1997, EUR J IMMUNOL, V27, P695, DOI 10.1002/eji.1830270318; Nacka-Aleksic M, 2015, BRAIN BEHAV IMMUN, V49, P101, DOI 10.1016/j.bbi.2015.04.017; Nadkarni S, 2007, J EXP MED, V204, P33, DOI 10.1084/jem.20061531; Nandakumar KS, 2007, ARTHRITIS RHEUM-US, V56, P3253, DOI 10.1002/art.22930; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; Noack M, 2017, SEMIN IMMUNOPATHOL, V39, P365, DOI 10.1007/s00281-017-0619-z; Nolte-'t Hoen ENM, 2008, J LEUKOCYTE BIOL, V83, P112, DOI 10.1189/jlb.0607436; Ortiz MA, 2015, CLIN IMMUNOL, V158, P174, DOI 10.1016/j.clim.2015.03.025; Ortona Elena, 2016, Ann Ist Super Sanita, V52, P205, DOI 10.4415/ANN_16_02_12; Pennell LM, 2012, J AUTOIMMUN, V38, pJ282, DOI 10.1016/j.jaut.2011.11.013; Persson S, 1996, SCAND J IMMUNOL, V44, P607, DOI 10.1046/j.1365-3083.1996.d01-355.x; Ponchel F, 2014, ANN RHEUM DIS, V73, P2047, DOI 10.1136/annrheumdis-2013-203566; Postigo J, 2011, ARTHRITIS RHEUM-US, V63, P971, DOI 10.1002/art.30220; Reddy J, 2005, J IMMUNOL, V175, P5591, DOI 10.4049/jimmunol.175.9.5591; Reynolds G, 2016, ANN RHEUM DIS, V75, P899, DOI 10.1136/annrheumdis-2014-206578; Sarkar S, 2010, CLIN EXP IMMUNOL, V159, P225, DOI 10.1111/j.1365-2249.2009.04016.x; Sheng W, 2014, CELL RES, V24, P1387, DOI 10.1038/cr.2014.154; Sokka T, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2591; Stojic-Vukanic Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166498; Trouw LA, 2009, ARTHRITIS RHEUM-US, V60, P1923, DOI 10.1002/art.24622; van den Berg WB, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2803; van Nieuwenhuijze AEM, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0683-5; van Roon JAG, 2001, ARTHRITIS RHEUM-US, V44, P3, DOI 10.1002/1529-0131(200101)44:1<3::AID-ANR2>3.0.CO;2-U; Wong AH, 2015, AUTOIMMUNITY, V48, P389, DOI 10.3109/08916934.2015.1030613; Yanaba K, 2007, J IMMUNOL, V179, P1369, DOI 10.4049/jimmunol.179.2.1369	67	1	1	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					10	22		10.1016/j.yexmp.2018.05.007			13	Pathology	Pathology	GP6AE	WOS:000440958500002	29792851				2019-10-28	
J	Daniel, PM; Filiz, G; Tymms, MJ; Ramsay, RG; Kaye, AH; Stylli, SS; Mantamadiotis, T				Daniel, Paul M.; Filiz, Gulay; Tymms, Martin J.; Ramsay, Robert G.; Kaye, Andrew H.; Stylli, Stanley S.; Mantamadiotis, Theo			Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Glioblastoma; Cell signaling; Heterogeneity; MAPK; PI3K; CREB	NEURAL STEM/PROGENITOR CELLS; PROTEIN-KINASE; POOR SURVIVAL; CANCER; ACTIVATION; SUBTYPES; INVASION; EGFR; AKT; TRANSCRIPTION	Limitations in discovering useful tumor biomarkers and drug targets is not only due to patient-to-patient differences but also due to intratumor heterogeneity. Heterogeneity arises due to the genetic and epigenetic variation of tumor cells in response to microenvironmental interactions and cytotoxic therapy. We explored specific signaling pathway activation in glioblastoma (GBM) by investigating the intratumor activation of the MAPK and PI3K pathways. We present data demonstrating a striking preponderance for mutual exclusivity of MAPK and PI3K activation in GBM tissue, where MAPK activation correlates with proliferation and transcription factor CREB activation and PI3K activation correlates with CD44 expression. Bioinformatic analysis of signaling and CREB-regulated target genes supports the immunohistochemical data, showing that the MAPK-CREB activation correlates with proliferative regions. In-silico analysis suggests that MAPK-CREB signaling activates a pro-inflammatory molecular signature and correlates with a mesenchymal GBM subtype profile, while PI3K-CREB activation correlates with the proneural GBM subtype and a tumor cell invasive gene signature. Overall, the data suggests the existence of intratumor subtype heterogeneity in GBM and that using combinations of both MAPK and PI3K drug inhibitors is necessary for effective targeted therapy.	[Daniel, Paul M.; Filiz, Gulay; Tymms, Martin J.; Ramsay, Robert G.; Mantamadiotis, Theo] Univ Melbourne, Sch Biomed Sci, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia; [Ramsay, Robert G.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia; [Kaye, Andrew H.; Stylli, Stanley S.; Mantamadiotis, Theo] Univ Melbourne, Dept Surg RMH, Parkville, Vic 3010, Australia; [Kaye, Andrew H.; Stylli, Stanley S.] Royal Melbourne Hosp, Dept Neurosurg, Parkville, Vic 3050, Australia; [Mantamadiotis, Theo] Univ Melbourne, Sch Biomed Sci, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia	Mantamadiotis, T (reprint author), Univ Melbourne, Sch Biomed Sci, Dept Microbiol & Immunol, Parkville, Vic 3010, Australia.	theom@unimelb.edu.au	Mantamadiotis, Theo/W-9010-2019; stylli, stanley/R-7540-2019	Mantamadiotis, Theo/0000-0003-3971-5380; stylli, stanley/0000-0002-3505-7387; Kaye, Andrew Henry/0000-0001-5049-8861	CASS Foundation Grant [7941]; Brain Foundation Award (Brain Tumours Award 2017)- Better drugs for Brain Cancer	Parts of this work were funded by a CASS Foundation Grant (7941) and Brain Foundation Award (Brain Tumours Award 2017)- Better drugs for Brain Cancer.	Albeck JG, 2013, MOL CELL, V49, P249, DOI 10.1016/j.molcel.2012.11.002; Anders S, 2010, GENOME BIOL, V11; Bozdag S, 2014, CANCER INFORM, V13, P33, DOI 10.4137/CIN.S14027; Bratton MR, 2010, INT J ONCOL, V37, P541, DOI 10.3892/ijo_00000703; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown DV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172791; Brown DV, 2015, ONCOTARGET, V6, P6267, DOI 10.18632/oncotarget.3365; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Failly M, 2007, MOL CANCER THER, V6, P773, DOI 10.1158/1535-7163.MCT-06-0566; Guo G, 2015, CANCER RES, V75, P3436, DOI 10.1158/0008-5472.CAN-15-0989; Kita D, 2007, ACTA NEUROPATHOL, V113, P295, DOI 10.1007/s00401-006-0186-1; Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003; Kondraganti S, 2000, CANCER RES, V60, P6851; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Mantamadiotis T, 2012, BIOESSAYS, V34, P293, DOI 10.1002/bies.201100133; Marziali G, 2016, SCI REP-UK, V6, DOI 10.1038/srep21557; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Mittal S, 2014, MOL CANCER THER, V13, P3198, DOI 10.1158/1535-7163.MCT-14-0280; Mizoguchi M, 2006, J NEUROPATH EXP NEUR, V65, P1181, DOI 10.1097/01.jnen.0000248549.14962.b2; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Patil CG, 2013, NEURO-ONCOLOGY, V15, P104, DOI 10.1093/neuonc/nos272; Pelloski CE, 2006, CLIN CANCER RES, V12, P3935, DOI 10.1158/1078-0432.CCR-05-2202; Penzvalto Z, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-837; Radotra B, 1997, J PATHOL, V181, P434; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Roberts E, 2016, TECHNOLOGY, V4, P174, DOI 10.1142/S2339547816500060; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sampurno S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.119; Santo EE, 2013, CANCER RES, V73, P2189, DOI 10.1158/0008-5472.CAN-12-3767; SASAKI A, 1992, ACTA NEUROCHIR, V117, P178, DOI 10.1007/BF01400617; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vitucci M, 2013, NEURO-ONCOLOGY, V15, P1317, DOI 10.1093/neuonc/not084; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	45	4	4	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					23	31		10.1016/j.yexmp.2018.05.009			9	Pathology	Pathology	GP6AE	WOS:000440958500003	29852183				2019-10-28	
J	Dennis, RP; David, JO; James, RR; Colin, TS				Dennis, Petersen R.; David, Orlicky J.; James, Roede R.; Colin, Shearn T.			Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Thioredoxins; Cholestasis; Oxidative stress; Cholangiocyte	PRIMARY BILIARY-CIRRHOSIS; S-TRANSFERASE-PI; LIVER-TRANSPLANTATION; 1-CYSTEINE PEROXIREDOXIN; LIPID-PEROXIDATION; OXIDATIVE STRESS; THIOREDOXIN; CHOLANGITIS; DAMAGE; RATS	Objective: Primary Sclerosing Cholangitis (PSC) is a severe cholestatic liver disease characterized by progressive peri-biliary tract inflammation, elevated oxidative stress and hepatocellular injury. A hallmark of PSC patients is the concurrent diagnosis of Inflammatory Bowel Disease occurring in approximately 70%-80% of PSC patients (PSC/IBD). We previously reported dysregulation of key anti-oxidant pathways in PSC/IBD. The objective of this study was to expand previous data by examining the abundance of thioredoxins (Trx) in PSC/IBD. Methods: Using hepatic tissue and whole cell extracts isolated from age-matched healthy humans and patients diagnosed with end stage PSC/IBD, the protein abundance of thioredoxin, thioredoxin reductase (TrxR1), and their downstream substrates peroxiredoxins was assessed. Results: Western blot analyses of thioredoxin and peroxiredoxin abundance revealed significant increases in abundance of Trx1 and TrxR1 whereas expression of thioredoxin-interacting protein was significantly decreased in PSC/IBD. Concurrently, abundance of cytosolic peroxiredoxins was not significantly impacted. The abundance of mitochondrial Trx2, along with peroxiredoxins 3, 5 and 6 were significantly decreased by concurrent PSC/IBD. Histological staining of Trx1/TrxR1 revealed elevated nuclear Trx1 and TrxR1 staining within cholangiocytes as well as an overall periportal increase in expression in PSC/IBD. An examination of additional anti-oxidant responses reveal suppression of gamma-glutamylcysteine synthetase and heme oxygenase (HO-1) whereas expression of the protein chaperone glucose regulated protein 78 increased suggesting elevated cellular stress in PSC/IBD. Conclusions: Results herein suggest that in addition to severe dysregulation of anti-oxidant responses, cholestasis impacts both cytosolic/nuclear (Trx1) as well as mitochondrial (Trx2) redox signaling and control pathways.	[Dennis, Petersen R.; James, Roede R.; Colin, Shearn T.] Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, La Jolla, CA USA; [David, Orlicky J.] Univ Colorado, Sch Med, Pathol, Anschutz Med Campus, Aurora, CO 80045 USA	Colin, TS (reprint author), Univ Colorado Denver, Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus,12850 East Montview Blvd Box, Denver, CO 80208 USA.	Colin.Shearn@ucdenver.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37AA009300-22 DRP]; NIH/NCRR Colorado CTSI Grant [UL1 RR025780]; University of Colorado Cancer Center Grant [P30 CA046934]	This research was supported by the following grants from the National Institutes of Health; R37AA009300-22 DRP. The authors wish to thank E. Erin Smith, HTL(ASCP)CMQIHC of the University of Colorado Denver Cancer Center Research Histology Core for assistance in preparing histology slides. The UCDCCRHC is supported in part by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780 and the University of Colorado Cancer Center Grant (P30 CA046934).	Aboutwerat A, 2003, BBA-MOL BASIS DIS, V1637, P142, DOI 10.1016/S0925-4439(02)00225-9; Cohen JI, 2009, HEPATOLOGY, V49, P1709, DOI 10.1002/hep.22837; De Morrow S, 2008, AM J PHYSIOL-GASTR L, V294, pG506, DOI 10.1152/ajpgi.00304.2007; Eaton JE, 2013, GASTROENTEROLOGY, V145, P521, DOI 10.1053/j.gastro.2013.06.052; Eismann T, 2009, AM J PHYSIOL-GASTR L, V296, pG266, DOI 10.1152/ajpgi.90583.2008; Fickert P, 2006, 24 NORURSODEOXYCHOLI; Go YM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018918; Grattagliano I, 2008, EUR J CLIN INVEST, V38, P523, DOI 10.1111/j.1365-2362.2008.01963.x; Grattagliano I, 2007, HEPATOLOGY, V45, P331, DOI 10.1002/hep.21519; Grattagliano I, 2014, WORLD J GASTROENTERO, V20, P5746, DOI 10.3748/wjg.v20.i19.5746; Heidari R, 2018, BIOMED PHARMACOTHER, V97, P1086, DOI 10.1016/j.biopha.2017.10.166; Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3; Jones DP, 2010, DIABETES OBES METAB, V12, P116, DOI 10.1111/j.1463-1326.2010.01266.x; Jones DP, 2008, AM J PHYSIOL-CELL PH, V295, pC849, DOI 10.1152/ajpcell.00283.2008; Kawata K, 2010, ANTIOXID REDOX SIGN, V13, P259, DOI 10.1089/ars.2009.2903; Kugelmas M, 2003, LIVER TRANSPLANT, V9, P727, DOI 10.1053/jlts.2003.50143; Lunder AK, 2016, GASTROENTEROLOGY, V151, P660, DOI 10.1053/j.gastro.2016.06.021; Manevich Y, 2013, FREE RADICAL BIO MED, V54, P62, DOI 10.1016/j.freeradbiomed.2012.10.556; Oka S, 2009, ENDOCRINOLOGY, V150, P1225, DOI 10.1210/en.2008-0646; Okuyama H, 2008, IUBMB LIFE, V60, P656, DOI 10.1002/iub.102; Oliveira Elze Maria Gomes, 2012, J Clin Med Res, V4, P429, DOI 10.4021/jocmr1060w; Parola M, 1996, FREE RADICAL BIO MED, V20, P351, DOI 10.1016/0891-5849(96)02055-2; Peres W, 2000, J HEPATOL, V33, P742, DOI 10.1016/S0168-8278(00)80305-0; Ralat LA, 2006, BIOCHEMISTRY-US, V45, P360, DOI 10.1021/bi0520737; Ralat LA, 2008, ARCH BIOCHEM BIOPHYS, V474, P109, DOI 10.1016/j.abb.2008.02.043; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Salem T A, 2003, Egypt J Immunol, V10, P37; Selvaggio G, 2018, REDOX BIOL, V15, P297, DOI 10.1016/j.redox.2017.12.008; Shearn CT, 2013, FREE RADICAL BIO MED, V65, P680, DOI 10.1016/j.freeradbiomed.2013.07.011; Shearn CT, 2011, BIOCHEMISTRY-US, V50, P3984, DOI 10.1021/bi200029w; Shearn Colin T, 2018, Exp Mol Pathol, V104, P1, DOI 10.1016/j.yexmp.2017.11.012; Shearn CT, 2014, J BIOL CHEM, V289, P15449, DOI 10.1074/jbc.M113.543942; Shearn CT, 2013, J NUTR BIOCHEM, V24, P1436, DOI 10.1016/j.jnutbio.2012.12.002; SOKOL RJ, 1995, GASTROENTEROLOGY, V109, P1249, DOI 10.1016/0016-5085(95)90585-5; Tamura S, 2007, LIVER INT, V27, P86, DOI 10.1111/j.1478-3231.2006.01395.x; Trevelin SC, 2016, SCI REP-UK, V6, DOI 10.1038/srep34581; Vendemiale G, 2002, J HEPATOL, V37, P601, DOI 10.1016/S0168-8278(02)00234-9; Weismuller TJ, 2017, GASTROENTEROLOGY, V152, P1975, DOI 10.1053/j.gastro.2017.02.038; Wu JD, 2010, J HEPATOL, V53, P73, DOI 10.1016/j.jhep.2010.01.032	39	0	1	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					32	36		10.1016/j.yexmp.2018.05.012			5	Pathology	Pathology	GP6AE	WOS:000440958500004	29852184				2019-10-28	
J	Bartels, S; Schipper, E; Hasemeier, B; Kreipe, H; Lehmann, U				Bartels, Stephan; Schipper, Elisa; Hasemeier, Britta; Kreipe, Hans; Lehmann, Ulrich			Hotspot mutations in cancer genes may be missed in routine diagnostics due to neighbouring sequence variants	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Molecular diagnostics; Sequence analysis; False-negative; Primer binding site	MYELOID NEOPLASMS; BRAF MUTATIONS; LEUKEMIA	The detection of hotspot mutations in key cancer genes is now an essential part of the diagnostic work-up in molecular pathology. Nearly all assays for mutation detection involve an amplification step. A second single nucleotide variant (SNV) on the same allele adjacent to a mutational hotspot can interfere with primer binding, leading to unnoticed allele-specific amplification of the wild type allele and thereby false-negative mutation testing. We present two diagnostic cases with false negative sequence results for JAK2 and SRSF2. In both cases mutations would have escaped detection if only one strand of DNA had been analysed. Because many commercially available diagnostic kits rely on the analysis of only one DNA strand they are prone to fail in cases like these. Detailed protocols and quality control measures to prevent corresponding pitfalls are presented.	[Bartels, Stephan; Schipper, Elisa; Hasemeier, Britta; Kreipe, Hans; Lehmann, Ulrich] Med Sch Hannover, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany	Lehmann, U (reprint author), Med Sch Hannover, Inst Pathol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Lehmann.Ulrich@MH-Hannover.de		Bartels, Stephan/0000-0002-8903-2345			Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bartels S, 2016, ONCOTARGET, V7, P30084, DOI 10.18632/oncotarget.8310; Bartels S, 2015, METHODS MOL BIOL, V1315, P103, DOI 10.1007/978-1-4939-2715-9_8; Gielen GH, 2013, AM J CLIN PATHOL, V139, P345, DOI 10.1309/AJCPABOHBC33FVMO; Heinzerling L, 2013, BRIT J CANCER, V109, P2833, DOI 10.1038/bjc.2013.622; Inokuchi S, 2017, INT J LEGAL MED, V131, P1531, DOI 10.1007/s00414-017-1571-0; Kline MC, 2011, FORENSIC SCI INT-GEN, V5, P329, DOI 10.1016/j.fsigen.2010.09.005; Levine RL, 2007, CURR OPIN HEMATOL, V14, P43, DOI 10.1097/00062752-200701000-00009; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209; Yoshida K, 2011, NATURE, V478, P64, DOI 10.1038/nature10496; Zhang L, 2015, LEUKEMIA RES, V39, P6, DOI 10.1016/j.leukres.2014.10.006	12	0	0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					37	40		10.1016/j.yexmp.2018.05.010			4	Pathology	Pathology	GP6AE	WOS:000440958500005	29847769				2019-10-28	
J	Janostiak, R; Vyas, M; Cicek, AF; Wajapeyee, N; Harigopal, M				Janostiak, Radoslav; Vyas, Monika; Cicek, Ali Fuat; Wajapeyee, Narendra; Harigopal, Malini			Loss of of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Breast Cancer; c-KIT; Epigenetics; DNA methylation; Immunohistochemistry	RECEPTOR TYROSINE KINASE; STEM-CELLS; LESIONS; BENIGN; IMMUNOHISTOCHEMISTRY; CARCINOMAS; MUTATIONS; PATHOLOGY; PATTERNS; MELANOMA	KIT Proto-Oncogene Receptor Tyrosine Kinase (KIT) is a transmembrane receptor tyrosine kinase which plays an important role in regulation of cell proliferation, survival and migration. Interestingly, the role of c-KIT in malignant transformation seems to be highly tissue-specific and it can act either as an oncogene or tumor suppressor gene. Here we analyzed the expression of c-KIT in normal breast tissues and tissues from different stages encompassing major steps of breast tumor development. Our study showed, that the c-KIT protein expression is gradually lost during the process of breast tissue transformation. The analysis of previously published datasets revealed that c-KIT expression in breast malignancies was downregulated at mRNA level. Because sequencing studies did not identify any recurrent mutations or copy number alterations, we proposed a potential epigenetic mechanism for the downregulation of c-KIT expression. In-silico analysis of the KIT promoter revealed the presence of CpG islands, therefore we performed bisulfite sequencing of normal breast epithelial tissues as well as breast tumor samples. We found, that KIT promoter is hypermethylated in breast tumors compared to normal breast tissues. Furthermore, treatment of breast cancer cell lines, that lack the expression of c-KIT, with methyltransferase inhibitor 5-Azacytidine (5Aza-2dC) resulted in increased expression of c-KIT mRNA. Collectively, our studies demonstrate that c-KIT expression is epigenetically downregulated during breast epithelium transformation and cancer development via KIT promoter hypermethylation.	[Janostiak, Radoslav; Vyas, Monika; Cicek, Ali Fuat; Wajapeyee, Narendra; Harigopal, Malini] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Janostiak, R (reprint author), 310 Cedar St, New Haven, CT 06520 USA.	radoslay.janostiak@yale.edu		Vyas, Monika/0000-0002-7020-9948; Janostiak, Radoslav/0000-0002-6602-9389	Chairman's challenge grant (Department of Pathology, Yale School of Medicine)	This work was supported by the Chairman's challenge grant (Department of Pathology, Yale School of Medicine).	Aoki H, 2015, J INVEST DERMATOL, V135, P1829, DOI 10.1038/jid.2015.83; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Bratthauer GL, 2002, HUM PATHOL, V33, P620, DOI 10.1053/hupa.2002.124789; Buza N, 2010, VIRCHOWS ARCH, V457, P337, DOI 10.1007/s00428-010-0950-4; Chui X, 1996, BRIT J CANCER, V73, P1233, DOI 10.1038/bjc.1996.236; Dahl C, 2015, J INVEST DERMATOL, V135, P516, DOI 10.1038/jid.2014.372; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Esserman LJ, 2012, BREAST CANCER RES TR, V132, P1049, DOI 10.1007/s10549-011-1895-2; Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/PREACCEPT-2333349012841587, 10.1186/s13059-014-0435-x]; Ghoncheh Mahshid, 2016, Asian Pac J Cancer Prev, V17, P43; Huang SY, 1996, ONCOGENE, V13, P2339; Kitamura Y, 2004, CELL MOL LIFE SCI, V61, P2924, DOI 10.1007/s00018-004-4273-y; Koenig C, 2000, INT J SURG PATHOL, V8, P303, DOI 10.1177/106689690000800409; Kohler BA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv048; Kondi-Pafiti A, 2010, TUMORI J, V96, P978; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Liu HY, 2014, ARCH PATHOL LAB MED, V138, P1629, DOI 10.5858/arpa.2014-0094-RA; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; Ohta H, 2000, DEVELOPMENT, V127, P2125; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polat A, 2007, PATHOL RES PRACT, V203, P765, DOI 10.1016/j.prp.2007.08.010; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Rojas-Sutterlin S, 2014, CURR OPIN HEMATOL, V21, P256, DOI 10.1097/MOH.0000000000000052; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Simon R, 2004, CLIN CANCER RES, V10, P178, DOI 10.1158/1078-0432.CCR-0597-3; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Talaiezadeh A, 2012, WSPOLCZESNA ONKOL, V16, P306, DOI 10.5114/wo.2012.30058; Tramm T, 2016, VIRCHOWS ARCH, V469, P285, DOI 10.1007/s00428-016-1966-1; Ulivi P, 2004, BREAST CANCER RES TR, V83, P33, DOI 10.1023/B:BREA.0000010694.35023.9e; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; Yared Marwan A, 2004, Breast J, V10, P323, DOI 10.1111/j.1075-122X.2004.21351.x; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786; Zhao L, 2014, ARCH PATHOL LAB MED, V138, P16, DOI 10.5858/arpa.2012-0440-RA	38	1	1	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					41	49		10.1016/j.yexmp.2018.05.011			9	Pathology	Pathology	GP6AE	WOS:000440958500006	29852185				2019-10-28	
J	Neubauer, E; Latif, M; Krause, J; Heumann, A; Armbrust, M; Luehr, C; Fraune, C; Hube-Magg, C; Kluth, M; Moller-Koop, C; Sauter, G; Simon, R; Beyer, B; Pompe, RS; Thederan, I; Schlomm, T; Buscheck, F				Neubauer, Emily; Latif, Morwari; Krause, Jenny; Heumann, Asmus; Armbrust, Moritz; Luehr, Clara; Fraune, Christoph; Hube-Magg, Claudia; Kluth, Martina; Moeller-Koop, Christina; Sauter, Guido; Simon, Ronald; Beyer, Burkhard; Pompe, Raisa S.; Thederan, Imke; Schlomm, Thorsten; Buescheck, Franziska			Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						HSD3B2; Prostate cancer; Prognosis; TMA	ANDROGEN-DEPRIVATION THERAPY; INTRATUMORAL ANDROGENS; GENOMIC DELETION; RECEPTOR; CHD1; SPECIMENS; PATHWAYS; BIOPSIES; ABSENCE; MAP3K7	HSD3B2 plays a crucial role in steroid hormone biosynthesis and is thus of particular interest in hormone dependent tumors such as prostate cancer. To clarify the clinical relevance of HSD3B2 expression in prostate cancer, we analyzed HSD3B2 protein expression by immunohistochemistry on our preexisting tissue microarray with 12.247 annotated cancers. Compared with normal tissue cytoplasmic HSD3B2 staining was stronger in prostate cancers. In 9371 interpretable cancers, HSD3B2 expression was found in 95.5% of cancers and was considered weak in 29.9%, moderate in 40.7% and strong in 24.9%. HSD3B2 up regulation was linked to advanced pathological tumor stage (pT), high Gleason grade, elevated preoperative PSA levels (p < 0.0001 each), lymph node metastasis (p = 0.0019), accelerated cell proliferation (p < 0.0001), androgen receptor (AR) expression (p < 0.0001), and early biochemical recurrence (p < 0.0001). HSD3B2 up regulation was only marginally more frequent in ERG positive (98%) than in ERG negative cancers (94%; p < 0.0001) and was strongly linked to deletions of 5q and 6q (p < 0.0001 each). Multivariate analyses showed that the prognostic impact of HSD3B2 expression was independent of established preoperative, but not of postoperative prognostic parameters. In summary, the results of our study demonstrate that HSD3B2 is strongly up regulated in a fraction of prostate cancers that are characterized by increased AR signaling, adverse tumor phenotype and early biochemical recurrence.	[Neubauer, Emily; Latif, Morwari; Armbrust, Moritz; Luehr, Clara; Fraune, Christoph; Hube-Magg, Claudia; Kluth, Martina; Moeller-Koop, Christina; Sauter, Guido; Simon, Ronald; Buescheck, Franziska] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Martinistr 52, D-20246 Hamburg, Germany; [Krause, Jenny] Univ Hosp Hamburg Eppendorf, Ctr Internal Med, Dept Internal Med, Hamburg, Germany; [Heumann, Asmus] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Beyer, Burkhard; Pompe, Raisa S.; Thederan, Imke; Schlomm, Thorsten] Univ Med Ctr Hamburg Eppendorf, Martini Clin, Prostate Canc Ctr, Hamburg, Germany; [Schlomm, Thorsten] Univ Med Ctr Hamburg Eppendorf, Sect Translat Prostate Canc Res, Dept Urol, Hamburg, Germany; [Schlomm, Thorsten] Charite, Dept Urol, Berlin, Germany	Simon, R (reprint author), Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Martinistr 52, D-20246 Hamburg, Germany.	r.simon@uke.de					Arai S, 2013, ANDROLOGY-US, V1, P169, DOI 10.1111/j.2047-2927.2012.00026.x; Burkhardt L, 2013, CANCER RES, V73, P2795, DOI 10.1158/0008-5472.CAN-12-1342; Chang BL, 2002, CANCER RES, V62, P1784; Chen HY, 2010, J BIOL CHEM, V285, P27776, DOI 10.1074/jbc.M110.156091; Erbersdobler A, 2002, EUR UROL, V41, P40, DOI 10.1016/S0302-2838(01)00021-5; Hamzeh M, 2011, J ENDOCRINOL, V209, P55, DOI 10.1530/JOE-10-0223; Hearn JWD, 2018, JAMA ONCOL, V4, P558, DOI 10.1001/jamaoncol.2017.3164; Hearn JWD, 2016, LANCET ONCOL, V17, P1435, DOI 10.1016/S1470-2045(16)30227-3; Kluth M, 2013, MODERN PATHOL, V26, P975, DOI 10.1038/modpathol.2012.236; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Krohn A, 2013, J PATHOL, V231, P130, DOI 10.1002/path.4223; Krohn A, 2012, AM J PATHOL, V181, P401, DOI 10.1016/j.ajpath.2012.04.026; Lapointe J, 2007, CANCER RES, V67, P8504, DOI 10.1158/0008-5472.CAN-07-0673; Metzger E, 2016, NAT STRUCT MOL BIOL, V23, P132, DOI 10.1038/nsmb.3153; Minner S, 2011, CLIN CANCER RES, V17, P5878, DOI 10.1158/1078-0432.CCR-11-1251; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2013, TRANSL ANDROL UROL, V2, P212, DOI 10.3978/j.issn.2223-4683.2013.09.16; Neslund-Dudas C, 2007, PROSTATE, V67, P1654, DOI 10.1002/pros.20625; Rodrigues LU, 2015, CANCER RES, V75, P1021, DOI 10.1158/0008-5472.CAN-14-1596; Sakai M, 2016, PROSTATE, V76, P575, DOI 10.1002/pros.23146; Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029; Schweizer MT, 2016, THER ADV MED ONCOL, V8, P388, DOI 10.1177/1758834016647962; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thompson IM, 2012, NEW ENGL J MED, V367, P270, DOI 10.1056/NEJMe1205012; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang L., 2007, FRONT BIOL CHINA, V2, P1, DOI DOI 10.1109/TVT.2016.2553121.[; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wilt TJ, 2012, NEW ENGL J MED, V367, P203, DOI 10.1056/NEJMoa1113162	28	0	0	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					50	56		10.1016/j.yexmp.2018.05.006			7	Pathology	Pathology	GP6AE	WOS:000440958500007	29803408				2019-10-28	
J	Song, Y; Lu, MY; Qiu, HS; Yin, J; Luo, K; Zhang, ZJ; Jia, XT; Zheng, GP; Liu, H; He, ZM				Song, Ying; Lu, Minying; Qiu, Huisi; Yin, Jiang; Luo, Kai; Zhang, Zhijie; Jia, Xiaoting; Zheng, Guopei; Liu, Hao; He, Zhimin			Activation of FOXO3a reverses 5-Fluorouracil resistance in human breast cancer cells	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Breast cancer; Drug resistance; Tic10; FOXO3a	PROMOTES TUMORIGENESIS; INDEPENDENT MECHANISMS; TRANSCRIPTION FACTORS; IN-VIVO; THERAPY; TIC10/ONC201; INHIBITION; EXPRESSION; PATHWAY; ONC201	Breast cancer is the most frequently diagnosed tumor type and the primary leading cause of cancer deaths in women worldwide. Drug resistance is the major obstacle for breast cancer treatment improvement. TRAIL-inducing compound 10 (Tic10), a novel activator of FOXO3, exhibits potent antitumor efficacy both in vitro and in vivo. In the present study, we investigated the resistance reversal effect of Tic10 on multidrug-resistant breast cancer cells T47D/5Fu derived from T47D breast cancer cells. We found that FOXO3a was significantly decreased in T47D/5-Fu cells, whereas treatment of Tic10 enhances FOXO3a expression and nuclear translocation. Moreover, treatment of Tic10 could reverses 5-Fluorouracil resistance of T47D/5-Fu cells via induction of G0/G1 cell cycle arrest and apoptosis. Furthermore, we found that Tic10 decreased the expression of CDK4 via FOXO3a-dependment mechanism. In addition, our data showed that Tic10 could sensitize drug resistant T47D/5-Fu cells to 5-Fu in vivo. Taken together, these data suggested Tic10 as capable of restoring sensitivity for drug-resistant breast cancer cells.	Guangzhou Med Univ, Affiliated Canc Hosp, Guangzhou 510095, Guangdong, Peoples R China; [Liu, Hao] Guangzhou Med Univ, Canc Res Inst, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China	Liu, H (reprint author), Guangzhou Med Univ, Canc Res Inst, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.; Liu, H (reprint author), Guangzhou Med Univ, Canc Hosp, 78 Hengzhigang Rd, Guangzhou 510095, Guangdong, Peoples R China.	haoliu2020@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402497, 81772825]; Guangdong Natural Science Funds [2017A030313500, 2017A030313867]; Science and Technology Program of Guangzhou [201707010381]; Innovation Project of Education Department in Guangdong [2016KTSCX117]; Youth Innovation Talent Project of Education Department in Guangdong [2016KQNCX140]; Scientific Research Project of Guangzhou Municipal Colleges and Universities [1201630143]	This study was supported by grants from the National Natural Science Foundation of China (Grant No. 81402497, No. 81772825), Guangdong Natural Science Funds (Grant No. 2017A030313500, No. 2017A030313867), the Science and Technology Program of Guangzhou (Grant No. 201707010381), the Innovation Project of Education Department in Guangdong (Grant No. 2016KTSCX117), the Youth Innovation Talent Project of Education Department in Guangdong (No. 2016KQNCX140), and the Scientific Research Project of Guangzhou Municipal Colleges and Universities (Grant No. 1201630143).	Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Karpel-Massler G, 2015, ONCOTARGET, V6, P36456, DOI 10.18632/oncotarget.5505; Levanon K, 2014, ONCOGENE, V33, P4424, DOI 10.1038/onc.2013.394; Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001; Liu H, 2012, FREE RADICAL BIO MED, V53, P2204, DOI 10.1016/j.freeradbiomed.2012.10.537; Lu MD, 2009, PATHOL ONCOL RES, V15, P679, DOI 10.1007/s12253-009-9171-z; Martin HL, 2014, BREAST CANCER-TARGET, V6, P1, DOI 10.2147/BCTT.S37638; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Prabhu VV, 2015, CANCER RES, V75, P1423, DOI 10.1158/0008-5472.CAN-13-3451; Ralff MD, 2017, MOL CANCER THER, V16, P1290, DOI 10.1158/1535-7163.MCT-17-0121; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Taylor S, 2015, CANC CELL INT, V15; Videira M, 2014, BBA-REV CANCER, V1846, P312, DOI 10.1016/j.bbcan.2014.07.011; Wagner J, 2014, ONCOTARGET, V5, P12728, DOI 10.18632/oncotarget.2890; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2011, CURR DRUG TARGETS, V12, P1284, DOI 10.2174/138945011796150299; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Yu S, 2015, INT J CLIN EXP PATHO, V8, P2963; Zhang QB, 2016, BIOCHEM BIOPH RES CO, V476, P260, DOI 10.1016/j.bbrc.2016.05.106	25	1	1	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					57	62		10.1016/j.yemp.2018.05.013			6	Pathology	Pathology	GP6AE	WOS:000440958500008	29856982				2019-10-28	
J	Muller, MF; Kendall, TJ; Adams, DJ; Zhou, Y; Arends, MJ				Muller, Mike Freya; Kendall, Timothy James; Adams, David James; Zhou, Ying; Arends, Mark Johan			The murine hepatic sequelae of long-term ethanol consumption are sex-specific and exacerbated by Aldh1b1 loss	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Hepatic steatosis; Non-alcoholic fatty lover disease; Alcoholic liver disease; Aldh; Acetaldehyde; EUCOMM	FATTY LIVER-DISEASE; HEPATOCELLULAR-CARCINOMA; SCORING SYSTEM; ALCOHOL; ACETALDEHYDE; INJURY; PROLIFERATION; PATHOGENESIS; STEATOSIS; CYP2E1	Disease progression in alcoholic and non-alcoholic fatty liver disease shows sex-specific differences and is influenced by mechanisms linked to oxidative stress. Acetaldehyde plays a critical pathogenic role but its effects are mitigated by the activity of aldehyde dehydrogenases. Aldehyde dehydrogenase 1b1 (Aldh1b1) is the aldehyde dehydrogenase isoform with the second highest affinity for acetaldehyde after Aldh2, and is highly expressed in the intestine and liver. We examined sex differences and the effect of Aldh1b1 depletion in a murine model of chronic alcohol-induced liver disease. Male and female wild-type and Aldh1b1-depleted mice received either ethanol (10-20% v/v) in drinking water or water alone for one year, and livers were examined histopathologically, histochemically and by immunohistochemistry. A significant increase in hepatic steatosis was observed in female mice after one year of ethanol consumption, and expression of ethanol-metabolising enzymes and up-regulation by ethanol was also sex-dependent. Ethanol-induced hyperproliferation of hepatocytes was observed in female and male wild-type mice, and Aldh1b1 depletion enhanced this effect in males. Further, one ethanol-treated, Aldh1b1-depleted male developed a steatohepatitic hepatocellular carcinoma. These sex-specific differences in susceptibility to hepatic steatosis and disease progression may be related to differences in expression of ethanol-metabolising enzymes, informing the clinically significant differences. Aldh1b1 plays a role in protection from ethanol-induced hepatocellular hyperproliferation and may protect from tumour development.	[Muller, Mike Freya; Kendall, Timothy James; Zhou, Ying; Arends, Mark Johan] Univ Edinburgh, Div Pathol, Ctr Comparat Pathol, Canc Res UK Edinburgh Ctr,Inst Genet & Mol Med,We, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland; [Kendall, Timothy James] Western Gen Hosp, Inst Genet & Mol Med, MRC Human Genet Unit, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland; [Adams, David James] Wellcome Trust Sanger Inst, Cambridge, England	Arends, MJ (reprint author), Univ Edinburgh, Div Pathol, Ctr Comparat Pathol, Canc Res UK Edinburgh Ctr,Inst Genet & Mol Med,We, Crewe Rd South, Edinburgh EH4 2XR, Midlothian, Scotland.	M.Arends@ed.ac.uk	Kendall, Tim/H-2698-2019	Kendall, Tim/0000-0002-4174-2786	Wellcome Trust Intermediate Clinical FellowshipWellcome Trust [095898/Z/11/Z]	We thank KJ Patel for providing mouse models and H Caldwell and E McLay for technical support and sample processing. TJK was supported by a Wellcome Trust Intermediate Clinical Fellowship [095898/Z/11/Z].	Arganda-Carreras I, 2017, BIOINFORMATICS, V33, P2424, DOI 10.1093/bioinformatics/btx180; Baffy G, 2012, J HEPATOL, V56, P1384, DOI 10.1016/j.jhep.2011.10.027; BARONI GS, 1994, J HEPATOL, V20, P508, DOI 10.1016/S0168-8278(05)80498-2; Becskei C, 2009, NEUROENDOCRINOLOGY, V90, P371, DOI 10.1159/000251723; Bedossa P, 2012, HEPATOLOGY, V56, P1751, DOI 10.1002/hep.25889; Bellentani S, 2004, EUR J GASTROEN HEPAT, V16, P1087, DOI 10.1097/00042737-200411000-00002; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Calvaruso V, 2009, HEPATOLOGY, V49, P1236, DOI 10.1002/hep.22745; Chung JG, 2001, CARCINOGENESIS, V22, P1213, DOI 10.1093/carcin/22.8.1213; Day CP, 2002, BEST PRACT RES CL GA, V16, P663, DOI 10.1053/bega.2002.0333; Eagon PK, 2010, WORLD J GASTROENTERO, V16, P1377, DOI 10.3748/wjg.v16.i11.1377; Hart CL, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1240; Iimuro Y, 1997, AM J PHYSIOL-GASTR L, V272, pG1186; Kinoshita Shinichi, 2008, Kobe J Med Sci, V54, pE200; Kiyoshi Ameno, 2009, Leg Med (Tokyo), V11 Suppl 1, pS413, DOI 10.1016/j.legalmed.2009.02.043; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kwon HJ, 2014, HEPATOLOGY, V60, P146, DOI 10.1002/hep.27036; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; Liu JY, 2014, WORLD J GASTROENTERO, V20, P14672, DOI 10.3748/wjg.v20.i40.14672; Liu WS, 2016, CELL MOL LIFE SCI, V73, P1969, DOI 10.1007/s00018-016-2161-x; Loomba R, 2013, AM J EPIDEMIOL, V177, P333, DOI 10.1093/aje/kws252; Lu Y, 2008, FREE RADICAL BIO MED, V44, P723, DOI 10.1016/j.freeradbiomed.2007.11.004; Lutz Thomas A, 2012, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0561s58; Mandrekar P, 2009, J HEPATOL, V50, P1258, DOI 10.1016/j.jhep.2009.03.007; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697 , 10.1517/17425250802102627]; Muller MF, 2017, J PATHOL, V241, P649, DOI 10.1002/path.4869; Nettschwander-Tetri BA, 2010, HEPATOLOGY, V52, P913, DOI 10.1002/hep.23784; NHS Blood and Transplant, 2016, ANN REP LIV TRANSPL; Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z; Salomao M, 2012, HUM PATHOL, V43, P737, DOI 10.1016/j.humpath.2011.07.005; Sato N, 2001, ALCOHOL CLIN EXP RES, V25, p40S, DOI 10.1097/00000374-200105051-00007; Schaffert CS, 2009, WORLD J GASTROENTERO, V15, P1209, DOI 10.3748/wjg.15.1209; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Seitz HK, 2010, GENES NUTR, V5, P121, DOI 10.1007/s12263-009-0154-1; Setshedi M, 2010, OXID MED CELL LONGEV, V3, P178, DOI 10.4161/oxim.3.3.12288; Singh S, 2015, PLOS ONE, V10, DOI [10.1371/journalpone.0121648, DOI 10.1371/JOURNALPONE.0121648.]; Stagos D, 2010, DRUG METAB DISPOS, V38, P1679, DOI 10.1124/dmd.110.034678; Szabo G, 2010, WORLD J GASTROENTERO, V16, P1321, DOI 10.3748/wjg.v16.i11.1321; Volzke H, 2012, WORLD J GASTROENTERO, V18, P3492, DOI 10.3748/wjg.v18.i27.3492; Wagnerberger S, 2013, ALCOHOL ALCOHOLISM, V48, P648, DOI 10.1093/alcalc/agt138; Wang Yuefei, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0103161, DOI 10.1371/JOURNAL.PONE.0103161.]; Younossi ZM, 2016, HEPATOLOGY, V64, P1577, DOI 10.1002/hep.28785; Younossi ZM, 2012, MEDICINE, V91, P319, DOI 10.1097/MD.0b013e3182779d49; Yu HS, 2009, TOXICOL MECH METHOD, V19, P535, DOI 10.3109/15376510903401708; Zhong W, 2015, J HEPATOL, V62, P1375, DOI [10.1016/j.jhep.2014.12.022, 10.1016/j.jhep.2015.02.011]	45	0	0	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					63	70		10.1016/j.yexmp.2018.05.008			8	Pathology	Pathology	GP6AE	WOS:000440958500009	29859945				2019-10-28	
J	Mubariz, F; Bryant, JL; Nimmagadda, VKC; Ray, J; Makar, TK				Mubariz, Fahad; Bryant, Joseph L.; Nimmagadda, Vamshi K. C.; Ray, Jayanta; Makar, Tapas K.			AQP4 and HIVAN	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Review							AQUAPORIN WATER CHANNELS; IMMUNOREACTIVE ENTERIC NEURONS; MEDULLARY COLLECTING DUCT; RENAL AQUAPORINS; ORTHOGONAL ARRAYS; MOLECULAR-MECHANISMS; EPITHELIAL-CELLS; KIDNEY-DISEASE; IN-SILICO; EXPRESSION		[Mubariz, Fahad; Nimmagadda, Vamshi K. C.; Makar, Tapas K.] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Makar, Tapas K.] VA Med Ctr, Baltimore, MD USA; [Bryant, Joseph L.] Univ Maryland, Inst Human Virol, Baltimore, MD 21201 USA; [Ray, Jayanta] Univ Maryland Baltimore Cty, Dept Chem & Biochem, Catonsville, MD USA	Makar, TK (reprint author), Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA.	tmakar@som.umaryland.edu			Institute of Virology, Baltimore, MD	This work was supported by the departmental grant, Institute of Virology, Baltimore, MD.	Agarwal S K, 2008, Indian J Nephrol, V18, P95, DOI 10.4103/0971-4065.43687; Ampawong S, 2012, J COMP PATHOL, V146, P332, DOI 10.1016/j.jcpa.2011.08.005; Arnspang E. C, 2013, PLOS ONE, V8; Atta MG, 2005, AM J MED, V118, DOI 10.1016/j.amjmed.2005.05.027; Bao Jun-qiang, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P1108; Bedford JJ, 2003, J AM SOC NEPHROL, V14, P2581, DOI 10.1097/01.ASN.0000089566.28106.F6; Brooks HL, 2003, AM J PHYSIOL-RENAL, V284, pF218, DOI 10.1152/ajprenal.00054.2002; Bryant JL, 2018, EXP MOL PATHOL, V104, P239, DOI 10.1016/j.yexmp.2018.03.005; Cadnapaphornchai MA, 2003, J AM SOC NEPHROL, V14, P566, DOI 10.1097/01.ASN.0000053417.33945.63; Calvanese L, 2013, PROTEIN SCI, V22, P455, DOI 10.1002/pro.2227; Chen YC, 2005, AM J PHYSIOL-RENAL, V289, pF672, DOI 10.1152/ajprenal.00384.2004; Cheng YS, 2013, EUR J PHARMACOL, V721, P249, DOI 10.1016/j.ejphar.2013.09.028; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549; Christensen BM, 2006, AM J PHYSIOL-RENAL, V291, pF39, DOI 10.1152/ajprenal.00383.2005; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; Dibas AI, 1998, P SOC EXP BIOL MED, V219, P183; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Eitner F, 2000, J AM SOC NEPHROL, V11, P856; Esteva-Font C, 2014, FASEB J, V28, P1446, DOI 10.1096/fj.13-245621; Fabian J, 2009, NAT REV NEPHROL, V5, P591, DOI 10.1038/nrneph.2009.141; Fang XH, 2002, J PHYSIOL-LONDON, V542, P63, DOI 10.1113/jphysiol.2001.013813; Fernandez-Llama P, 1998, KIDNEY INT, V53, P1244, DOI 10.1046/j.1523-1755.1998.00878.x; Fernandez-Llama P, 1999, J AM SOC NEPHROL, V10, P1950; Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; Goubau C, 2013, GENET MED, V15, P55, DOI 10.1038/gim.2012.90; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hibuse T, 2005, P NATL ACAD SCI USA, V102, P10993, DOI 10.1073/pnas.0503291102; Ho JD, 2009, P NATL ACAD SCI USA, V106, P7437, DOI 10.1073/pnas.0902725106; Ishibashi K, 2002, BBA-GENE STRUCT EXPR, V1576, P335, DOI 10.1016/S0167-4781(02)00393-7; Ishibashi K, 2009, CLIN EXP NEPHROL, V13, P107, DOI 10.1007/s10157-008-0118-6; Ishihara E, 2008, AUTON NEUROSCI-BASIC, V138, P31, DOI 10.1016/j.autneu.2007.09.002; Janosi L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059897; Jin BJ, 2011, BIOPHYS J, V100, P2936, DOI 10.1016/j.bpj.2011.05.012; Kasembeli Alex N, 2015, World J Nephrol, V4, P295, DOI 10.5527/wjn.v4.i2.295; Kwon TH, 2001, SEMIN NEPHROL, V21, P231, DOI 10.1053/snep.2001.21647; Lee J, 2006, KIDNEY BLOOD PRESS R, V29, P18, DOI 10.1159/000092483; Li CL, 2003, AM J PHYSIOL-RENAL, V284, pF1066, DOI 10.1152/ajprenal.00090.2002; Lu MQ, 1996, P NATL ACAD SCI USA, V93, P10908, DOI 10.1073/pnas.93.20.10908; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Maurel C, 2008, ANNU REV PLANT BIOL, V59, P595, DOI 10.1146/annurev.arplant.59.032607.092734; Mobasheri A, 2014, J MAMMARY GLAND BIOL, V19, P91, DOI 10.1007/s10911-013-9312-6; Nagahama M, 2006, NEUROSCI LETT, V395, P206, DOI 10.1016/j.neulet.2005.10.092; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Ohara M, 2002, BIOCHEM BIOPH RES CO, V299, P285, DOI 10.1016/S0006-291X(02)02634-7; Ozu M, 2011, EUR BIOPHYS J BIOPHY, V40, P737, DOI 10.1007/s00249-011-0687-2; Poulsen SB, 2013, NEPHROL DIAL TRANSPL, V28, P2058, DOI 10.1093/ndt/gft088; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; Procino G, 2011, AM J HYPERTENS, V24, P822, DOI 10.1038/ajh.2011.47; Rao TKS, 2001, INFECT DIS CLIN N AM, V15, P833; Ray PE, 2012, NEPHROL DIAL TRANSPL, V27, P3969, DOI 10.1093/ndt/gfs114; Ray PE, 1998, KIDNEY INT, V53, P1217, DOI 10.1046/j.1523-1755.1998.00900.x; Rossi A, 2012, J CELL SCI, V125, P4405, DOI 10.1242/jcs.109603; Seeliger D, 2013, ACS CHEM BIOL, V8, P249, DOI 10.1021/cb300153z; Smith AJ, 2014, J CELL BIOL, V204, P559, DOI 10.1083/jcb.201308118; Snyder A, 2010, AIDS, V24, P1107, DOI 10.1097/QAD.0b013e328337b0ab; Snyder A, 2009, J VIROL, V83, P11983, DOI 10.1128/JVI.00034-09; Tajima M, 2010, J BIOL CHEM, V285, P8163, DOI 10.1074/jbc.M109.093948; Takata K, 2004, J PHARMACOL SCI, V96, P255, DOI 10.1254/jphs.FMJ04004X3; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775; Tham DKL, 2011, AM J PHYSIOL-RENAL, V301, pF396, DOI 10.1152/ajprenal.00315.2010; Tornroth-Horsefield S, 2010, FEBS LETT, V584, P2580, DOI 10.1016/j.febslet.2010.04.037; Trepiccione F, 2013, AM J PHYSIOL-RENAL, V305, pF919, DOI 10.1152/ajprenal.00152.2012; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Verkman AS, 2013, BRAIN PATHOL, V23, P684, DOI 10.1111/bpa.12085; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Verkman AS, 2002, J PHYSIOL-LONDON, V542, P31, DOI 10.1113/jphysiol.2002.024398; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13; Wang Y, 2007, J NUTR, V137, p1509S, DOI 10.1093/jn/137.6.1509S; Wang Y, 2010, PROTEINS, V78, P661, DOI 10.1002/prot.22595; Wen JG, 2009, SCAND J UROL NEPHROL, V43, P486, DOI 10.3109/00365590903127446; Xu Mengmeng, 2017, Adv Exp Med Biol, V969, P81, DOI 10.1007/978-94-024-1057-0_5; Yang BX, 1996, J BIOL CHEM, V271, P4577; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zhang YB, 2013, BIOPHYS CHEM, V171, P24, DOI 10.1016/j.bpc.2012.09.004; Zuber AM, 2009, P NATL ACAD SCI USA, V106, P16523, DOI 10.1073/pnas.0904890106	77	1	1	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					71	75		10.1016/j.yexmp.2018.05.004			5	Pathology	Pathology	GP6AE	WOS:000440958500010	29778884				2019-10-28	
J	Paramita, D; Wisnubroto, JDP				Paramita, Dyah; Wisnubroto, J. D. P.			Effect of methylglyoxal on reactive oxygen species, KI-67, and caspase-3 expression in MCF-7 cells	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Breast cancer; Methylglyoxal; Oxidant; In vitro; Confocal laser scanning microscopy	BREAST-CANCER INCIDENCE; INDUCED APOPTOSIS; METHYL GLYOXAL; ACCUMULATION; ACTIVATION; INDUCTION; TOXICITY; KINASE	Background: Methylglyoxal (MG) is an extremely reactive alpha-ketoaldehyde endogenously produced by various metabolic pathways, including the dephosphorylation of glycolytic intermediates, metabolites of the polyol pathway, and aminoacetone metabolism. MG cytotoxicity occurs through the induction of apoptosis. There are multiple mechanisms by which MG can induce apoptosis, e.g., through the generation of reactive oxygen species (ROS), induction of oxidative DNA damage, or accumulation of a specific MG-derived advanced glycation end product (AGE). Objective: This study aimed to investigate the effect of MG on ROS production, KI-67 expression, and caspase-3 expression in MCF-7 cells. Methods: At confluency, MCF-7 cells were divided into five groups, including control (untreated); and MCF-7 cells exposed to MG (1 mM) for 0; 12; 24; and 48 h of incubation. Reactive oxygen species level, KI-67 expression, and caspase-3 expression were evaluated by laser scanning confocal microscopy. Results: The level of reactive oxygen species was significantly lower in 12 h of incubation compared to the control group (p < .05). The reactive oxygen species level was significantly higher in 48 h of incubation compared to the control group (p < .05). The expressions of KI-67 was significantly higher in all groups of MCF-7 cells treated with MG compared to the control group (p < .05). The maximal expression of KI-67 was achieved in 12 h of incubation. The expression of KI-67 was significantly lower in 48 h of incubation compared to 12 h of incubation (p < .05). The caspase-3 expressions were significantly greater in all groups of MCF-7 cells treated with MG groups compared to the control group (p < .05). The maximal expression of caspase-3 was achieved in 48 h of incubation. The increased expression of caspase-3 in 48 h of incubation was significantly higher compared to 0; 12; and 24 h of incubation (p < .05). Conclusion: Methylglyoxal at 48 h of incubation disturbs the defense mechanisms of MCF-7 cells to reactive oxygen species. This incubation time also induces apoptosis and inhibits the cells proliferation. Therefore, this may provide a novel approach for inhibiting the breast cancer cell growth.	[Paramita, Dyah] Brawijaya Univ, Saiful Anwar Gen Hosp, Dept Surg, Fac Med, Malang, East Java, Indonesia; [Wisnubroto, J. D. P.] Brawijaya Univ, Saiful Anwar Gen Hosp, Dept Surg, Div Surg Oncol,Fac Med, Malang, East Java, Indonesia	Paramita, D (reprint author), Brawijaya Univ, Saiful Anwar Gen Hosp, Dept Surg, Fac Med, Malang, East Java, Indonesia.	paramita1512@gmail.com					Ahmad S, 2011, BIOCHEM BIOPH RES CO, V407, P568, DOI 10.1016/j.bbrc.2011.03.064; Amicarelli F, 2003, FREE RADICAL BIO MED, V35, P856, DOI 10.1016/S0891-5849(03)00438-6; Amicarelli F, 2001, INT J BIOCHEM CELL B, V33, P1129, DOI 10.1016/S1357-2725(01)00010-3; Antognelli C, 2013, INT J BIOCHEM CELL B, V45, P836, DOI 10.1016/j.biocel.2013.01.003; Banerjee D, 2004, SPECTROCHIM ACTA A, V60, P1523, DOI 10.1016/j.saa.2003.08.022; Bronsveld HK, 2017, PRIM CARE DIABETES, V11, P373, DOI 10.1016/j.pcd.2017.02.001; Chan WH, 2007, J CELL BIOCHEM, V100, P1056, DOI 10.1002/jcb.21114; Chang TJ, 2011, FASEB J, V25, P1746, DOI 10.1096/fj.10-178053; Cignarelli A, 2018, DIABETES RES CLIN PR, V143, P378, DOI 10.1016/j.diabres.2018.04.002; Du J, 2001, FREE RADICAL BIO MED, V31, P469, DOI 10.1016/S0891-5849(01)00611-6; Ferlay J, 2013, GLOBOCAN 2012 1 0 IN; Ghosh A, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1164, DOI 10.1134/S0006297911100105; Ghosh A, 2011, BIOCHEMISTRY-MOSCOW+, V76, P1051, DOI 10.1134/S0006297911090100; GILLESPIE E, 1975, FED PROC, V34, P541; Gloire G, 2006, BIOCHEM PHARMACOL, V72, P1493, DOI 10.1016/j.bcp.2006.04.011; Huang FJ, 2013, ENVIRON TOXICOL, V28, P431, DOI 10.1002/tox.20734; Kang YB, 1996, LEUKEMIA RES, V20, P397, DOI 10.1016/0145-2126(95)00162-X; Kim J, 2012, EXP MOL MED, V44, P167, DOI 10.3858/emm.2012.44.2.012; Kim J, 2010, BIOCHEM BIOPH RES CO, V391, P346, DOI 10.1016/j.bbrc.2009.11.061; Li D, 2017, CHEM-BIOL INTERACT, V276, P203, DOI 10.1016/j.cbi.2017.02.020; Li D, 2015, CHEM-BIOL INTERACT, V234, P366, DOI 10.1016/j.cbi.2014.10.019; Li SY, 2007, LIFE SCI, V80, P1051, DOI 10.1016/j.lfs.2006.11.035; LO TWC, 1994, J BIOL CHEM, V269, P32299; Lyon RC, 2013, NEUROCHEM INT, V62, P113, DOI 10.1016/j.neuint.2012.10.007; Maskarinec G, 2018, CAN J DIABETES, V42, P100, DOI 10.1016/j.jcjd.2017.02.005; Oba T, 2012, ENVIRON TOXICOL PHAR, V34, P117, DOI 10.1016/j.etap.2012.03.007; Okado A, 1996, BIOCHEM BIOPH RES CO, V225, P219, DOI 10.1006/bbrc.1996.1157; Rabbani N, 2012, AMINO ACIDS, V42, P1133, DOI 10.1007/s00726-010-0783-0; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; SZENTGYORGYI A, 1968, SCIENCE, V161, P988, DOI 10.1126/science.161.3845.988; Vaca L. E, 1994, CARCINOGENESIS; Zhang X, 2018, BIOMED PHARMACOTHER, V99, P142, DOI 10.1016/j.biopha.2017.12.084	32	3	3	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					76	80		10.1016/j.yexmp.2018.05.005			5	Pathology	Pathology	GP6AE	WOS:000440958500011	29775571				2019-10-28	
J	Alam, MF; Safhi, MM; Anwer, T; Siddiqui, R; Khan, G; Moni, SS				Alam, Mohammad Firoz; Safhi, Mohammed M.; Anwer, Tarique; Siddiqui, Rahimullah; Khan, Gyas; Moni, Sivakumar Sivagurunathan			Therapeutic potential of Vanillylacetone against CCl4 induced hepatotoxicity by suppressing the serum marker, oxidative stress, inflammatory cytokines and apoptosis in Swiss albino mice	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Antioxidant enzyme; Apoptosis; Carbon tetrachloride; Free radicals; Hepatotoxicity; Inflammatory cytokines; Vanillylacetone	INDUCED LIVER FIBROSIS; GLUTATHIONE-REDUCTASE; MOLECULAR-MECHANISMS; ISCHEMIA-REPERFUSION; INJURY; NECROSIS; ALPHA; OXIDE; ACID	The aim of this research was to investigate the therapeutic potential of Vanillylacetone against carbon tetrachloride (CCl4) induced hepatotoxicity in mice through understanding the serum marker, oxidative stress mechanism and cytokine networks. Carbon tetrachloride is highly hepatotoxic used as research based on animal model. The mice were classified into five groups and each had eight mice. Group-I was controlled and the vehicle was given orally. Group-II was toxic and carbon tetrachloride (1.5 ml/kg) twice a week for 15 days was administered by intra-peritoneainjections. Group- III and IV were pre-treated with Vanillylacetone 50 & 100 mg kg(-1) body weight given every day p.o. while, Group-V received only Vanillylacetone (100 mg kg(-1) body weight) for 15 days orally. The finding indicates that the administration of CCl4 causes significant elevation of enzyme markers, oxidative stress, inflammatory cytokine and apoptotic markers in Group-II as compared to Group-I. The administration of Vanillylacetone (50 and100 mg kg(-1)) significantly suppresses the elevated serum enzymes, oxidative stress (TBARS), an inflammatory cytokine (IL2 and TNF alpha) and apoptotic markers (Caspase-3 and 9) in Group-III and IV as compared to Group-II. It was also noticed that the higher dose of Vanillylacetone (100 mg) is more effective than lower dose of Vanillylacetone (50 mg). There were no significant changes observed with higher dose of Vanillylacetone (100 mg kg(-1)) in Group-V as compared to Group-I. Histopathological analysis also supported the above findings. Overall, this results shows that Vanillylacetone has a good anti-oxidant and therapeutic properties which can help in preventing the chemically (CCl4) induced hepatotoxicity.	[Alam, Mohammad Firoz; Safhi, Mohammed M.; Anwer, Tarique; Siddiqui, Rahimullah] Jazan Univ, Pharm Coll, Pharmacol & Toxicol Dept, Neurosci & Toxicol Unit, Gizan, Saudi Arabia; [Khan, Gyas; Moni, Sivakumar Sivagurunathan] Jazan Univ, Pharm Coll, Pharmaceut Dept, Div Pharmaceut Biotechnol, Gizan, Saudi Arabia	Alam, MF (reprint author), Jazan Univ, Toxicol Coll Pharm, Dept Pharmacol, Post Box 114, Gizan, Saudi Arabia.	firozalam309@gmail.com	MONI, SIVAKUMAR SIVAGURUNATHAN/Y-1949-2019	MONI, SIVAKUMAR SIVAGURUNATHAN/0000-0002-4860-0166	Jazan University [1437/7/000148]	We are thankful to Deanship of Scientific Research, Jazan University for funding the project no 1437/7/000148 and financial support to complete it.	Aghel N, 2007, IRAN J PHARM RES, V6, P285; Ahmad A, 2002, J ETHNOPHARMACOL, V79, P35, DOI 10.1016/S0378-8741(01)00349-X; Alam M.F, 2018, THYMOQUINONE AMELIOR, V2018, P1, DOI 10.1155/2018/1483041; Alam M.F, 2017, J LIVER S, V6, DOI [10.4172/2167-0889-C1-011, DOI 10.4172/2167-0889-C1-011.]; Bianchi M, 2000, P NATL ACAD SCI USA, V97, P9573, DOI 10.1073/pnas.160099797; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; Chen JH, 2004, AM J CLIN NUTR, V80, P742; Clairborne A., 1985, CRC HDB METHODS OXYG, P283; David W. Chang, 2003, J BIOL CHEM, V278, P16466; El-mohsen Ali S. A., 2014, INT J PHARM SCI REV, V26, P62; Esposito E, 2009, CURR MED CHEM, V16, P3152, DOI 10.2174/092986709788803024; FREEMAN BA, 1982, LAB INVEST, V47, P412; Fursule RA, 2010, J ETHNOPHARMACOL, V129, P416, DOI 10.1016/j.jep.2010.04.021; Gao DK, 2006, LIFE SCI, V78, P2564, DOI 10.1016/j.lfs.2005.10.030; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Habib SHM, 2008, CLINICS, V63, P807, DOI 10.1590/S1807-59322008000600017; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Iman H, 2016, INT J PHARM PHARM SC, V8, P377; Janbaz KH, 2002, FITOTERAPIA, V73, P557, DOI 10.1016/S0367-326X(02)00217-4; JOLLOW DJ, 1974, PHARMACOLOGY, V11, P151, DOI 10.1159/000136485; Kim MK, 2010, EXP GERONTOL, V45, P419, DOI 10.1016/j.exger.2010.03.005; LIU KX, 1993, HEPATOLOGY, V17, P651, DOI 10.1002/hep.1840170420; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mohammed M. Safhi, 2018, MOL MECH OXIDATIVE M, V1-7, DOI [10.1155/2018/2474831, DOI 10.1155/2018/2474831.]; Mohammed M. Safhi, 2014, J ETHNOPHARMACOL, V156, P102; MOHANDAS J, 1984, CANCER RES, V44, P5086; MORON MS, 1979, BIOCHIM BIOPHYS ACTA, V582, P67, DOI 10.1016/0304-4165(79)90289-7; Motawi TK, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-40; MULLER C, 1989, HEPATOLOGY, V10, P928, DOI 10.1002/hep.1840100606; Nakagawa K, 1996, CANCER RES, V56, P507; National Research Council, 1996, GUIDE CARE USE LAB A; Noosheen Alaverdi, 2007, EBIOSCIENCE, V2008, P02; Nordic Council of Ministers Copenhagen, 2003, TEMANORD, V2003, P516; Peng QL, 2014, INFECT GENET EVOL, V27, P375, DOI 10.1016/j.meegid.2014.08.021; Qiao Y, 2011, INT IMMUNOPHARMACOL, V11, P121, DOI 10.1016/j.intimp.2010.10.016; Rajesh M. G., 2004, Indian Journal of Pharmacology, V36, P284; Ramappa V, 2013, J CLIN EXP HEPATOL, V3, P37, DOI 10.1016/j.jceh.2012.12.001; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Safhi MM, 2016, ACTA POL PHARM, V73, P675; Seidler S, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-38; SEIFERT WF, 1994, HEPATOLOGY, V19, P193, DOI 10.1016/0270-9139(94)90071-X; Shaker ME, 2011, TOXICOL APPL PHARM, V252, P165, DOI 10.1016/j.taap.2011.02.004; Shen XC, 2009, J ETHNOPHARMACOL, V122, P555, DOI 10.1016/j.jep.2009.01.027; Shim JY, 2010, TOXICOL APPL PHARM, V242, P318, DOI 10.1016/j.taap.2009.11.005; Stevens MJ, 2000, DIABETES, V49, P1006, DOI 10.2337/diabetes.49.6.1006; Teraoka R, 2012, BIOL PHARM BULL, V35, P171, DOI 10.1248/bpb.35.171; Tipoe GL, 2010, TOXICOLOGY, V273, P45, DOI 10.1016/j.tox.2010.04.014; Utley H.C., 1967, ARCH BIOCHEM BIOPHYS, V260, P521; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WILLIAMS AT, 1990, SEMIN LIVER DIS, V10, P279, DOI 10.1055/s-2008-1040483; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e	52	5	5	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					81	88		10.1016/j.yexmp.2018.06.001			8	Pathology	Pathology	GP6AE	WOS:000440958500012	29909158				2019-10-28	
J	Gajdosik, MS; Hixson, DC; Brilliant, KE; Yang, DQ; De Paepe, ME; Josic, D; Mills, DR				Gajdosik, Martina Srajer; Hixson, Douglas C.; Brilliant, Kate E.; Yang, DongQin; De Paepe, Monique E.; Josic, Djuro; Mills, David R.			Soft agar-based selection of spontaneously transformed rat prostate epithelial cells with highly tumorigenic characteristics	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Prostate epithelial cells; Neoplastic conversion; Tumorigenicity; Cancer stem cell	CANCER STEM-CELLS; ANCHORAGE-INDEPENDENT GROWTH; BREAST-CANCER; IN-VITRO; PROSPECTIVE IDENTIFICATION; MONOCLONAL-ANTIBODIES; STEM/PROGENITOR CELLS; CHOLANGIOCYTE MARKER; LIVER; EXPRESSION	The critical molecular and cellular mechanisms involved in the development and progression of prostate cancer remain elusive. In this report, we demonstrate that normal rat prostate epithelial cells (PEC) undergo spontaneous transformation at high passage (p > 85) evidenced by the acquisition of anchorage independent growth when plated on soft agar and tumorigenicity when injected into immunodeficient mice. In addition, we also report the discovery of a minor subpopulation of spontaneously transformed PEC derived from high passage PEC with the ability to migrate through a layer of 1% agar and form expanding colonies on the underlying plastic substratum. Comparison of these soft agar invasive (SAI) cells with low (p < 35), mid (p36-84) and high passage (p > 85) PEC identified marked differences in cell morphology, proliferation and motility. The SAI subpopulation was more tumorigenic than the high passage anchorage independent cultures from which they were isolated, as manifested by a decreased latency period and an increase in the size of tumors arising in immunodeficient mice. In contrast, low and mid passage cells were unable to grow on soft agar and failed to form tumors when injected into immunodeficient mice. Screening with antibody-based signaling arrays identified several differences in the altered expression levels of signaling proteins between SAI-derived cells and low or high passage PEC, including the up-regulation of EGFR and MAPK-related signaling pathways in SAI-selected cells. In summary, these studies suggest that the SAI assay selects for a novel, highly tumorigenic subpopulation of transformed cells that may represent an early step in the progression of slow growing prostatic carcinomas into more rapidly growing and aggressive tumors.	[Gajdosik, Martina Srajer] Univ JJ Strossmayer Osijek, Dept Chem, Cara Hadrijana 8-A, HR-31000 Osijek, Croatia; [Gajdosik, Martina Srajer; Hixson, Douglas C.; Brilliant, Kate E.; Yang, DongQin; Mills, David R.] Rhode Isl Hosp, Div Hematol & Oncol, 593 Eddy St, Providence, RI 02903 USA; [Hixson, Douglas C.; De Paepe, Monique E.; Josic, Djuro; Mills, David R.] Brown Univ, Warren Alpert Med Sch, 222 Richmond St, Providence, RI 02903 USA; [De Paepe, Monique E.] Women & Infants Hosp Rhode Isl, Dept Pathol, 101 Dudley St, Providence, RI 02905 USA; [Josic, Djuro] Univ Rijeka, Dept Biotechnol, Radmile Matejcic 2, HR-51000 Rijeka, Croatia	Mills, DR (reprint author), Brown Univ, Warren Alpert Med Sch, 222 Richmond St, Providence, RI 02903 USA.	msgajdosik@kemija.unios.hr; dmille15@providence.edu	Gajdosik, Martina Srajer/I-1436-2019	Gajdosik, Martina Srajer/0000-0002-8790-9465	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA42715, CA93840]; National Institute of General Medical Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103421]; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20GM103421, P20RR017695]	Research reported in this publication was supported by NIH grants CA42715 and CA93840 and by the National Institute of General Medical Sciences of the National Institutes of Health under award number P20GM103421. The previous segment of P20GM103421 was supported by the National Center for Research Resources (NCRR) under P20RR017695. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; American Cancer Society, 2018, CANC FACTS FIG 2018; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Britt DE, 2004, EXP CELL RES, V300, P134, DOI 10.1016/j.yexcr.2004.06.026; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; COLBURN NH, 1978, CANCER RES, V38, P624; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dasgupta Subhamoy, 2012, J Carcinog, V11, P4, DOI 10.4103/1477-3163.93001; DUNNING W. F., 1963, NATL CANCER INST MONOGR, V12, P351; Guille A, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-66; Halpert G., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P508; Han W, 2013, MOL CARCINOGEN, V52, P959, DOI 10.1002/mc.21936; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HIXSON DC, 1985, CANCER RES, V45, P3750; Hixson DC, 2000, EXP MOL PATHOL, V68, P152, DOI 10.1006/exmp.2000.2302; Karamboulas C, 2013, BBA-GEN SUBJECTS, V1830, P2481, DOI 10.1016/j.bbagen.2012.11.008; Kenneth CV, 2011, PROSTATE CANC, V2011, P1; Lai GH, 2005, GASTROENTEROLOGY, V129, P2047, DOI 10.1053/j.gastro.2005.10.010; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Makarovskiy AN, 1999, ONCOGENE, V18, P3252, DOI 10.1038/sj.onc.1202665; Marks JL, 2008, J THORAC ONCOL, V3, P111, DOI 10.1097/JTO.0b013e318160c607; Mills DR, 2012, EXP MOL PATHOL, V93, P250, DOI 10.1016/j.yexmp.2012.04.023; Mimeault M, 2012, J MOL BIOMARK DIAGN, V3; Nogalski MT, 2012, JOVE-J VIS EXP, DOI 10.3791/4165; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rozich RA, 2010, EXP MOL PATHOL, V89, P248, DOI 10.1016/j.yexmp.2010.07.005; Rutella S, 2009, CLIN CANCER RES, V15, P4299, DOI 10.1158/1078-0432.CCR-08-1883; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Simper-Ronan R, 2006, DEVELOPMENT, V133, P4269, DOI 10.1242/dev.02589; Singh SK, 2003, CANCER RES, V63, P5821; Yang JJ, 1997, J BIOL CHEM, V272, P3103, DOI 10.1074/jbc.272.5.3103; YANG L, 1993, GASTROENTEROLOGY, V104, P840, DOI 10.1016/0016-5085(93)91021-9; Zuo KQ, 2012, BIOCHEM BIOPH RES CO, V421, P396, DOI 10.1016/j.bbrc.2012.04.032	37	0	0	2	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					89	97		10.1016/j.yexmp.2018.05.014			9	Pathology	Pathology	GP6AE	WOS:000440958500013	29856983	Green Accepted			2019-10-28	
J	Kazmierska-Grebowska, P; Kobrzycka, A; Bocian, R; Kowalczyk, T; Krokosz, A; Grebowski, J				Kazmierska-Grebowska, Paulina; Kobrzycka, Anna; Bocian, Renata; Kowalczyk, Tomasz; Krokosz, Anita; Grebowski, Jacek			Fullerenol C-60(OH)(36) at relatively high concentrations impairs hippocampal theta oscillations (in vivo and in vitro) and triggers epilepsy (in vitro) - A dose response study	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Fullerenol; Hippocampal formation; Electrophysiology; Epilepsy; Theta rhythm	GLUTAMATERGIC SYNAPTIC-TRANSMISSION; INTRACEREBRAL MICROINJECTION; POLYHYDROXYLATED C-60; FORMATION SLICES; RHYTHM; RATS; INHIBITION; EXCITABILITY; SUPPRESSION; DYSFUNCTION	Since the first identification of fullerenes (C-60) and their synthesis in 1985, those compounds have been extensively studied in the biomedical field. In particular, their water-soluble derivatives, fullerenols (C-60(OH)(n), n = 2-48), have recently been the subject of numerous investigations concerning their antioxidant and prooxidant properties in biological systems. A small fraction of that research has focused on the possible use of C-50 and C-60(OH)(n) in neuroscience and the therapy of pathologies such as dementia, amyloid-beta (A beta) formation, and Parkinson's disease. However, only a few studies have focused on their direct effects on neuronal network viability and excitability, especially with the use of electrophysiological and electrochemical approaches. Therefore, we addressed the issue of the direct effect of hydroxylated fullerene nanoparticles C-60(OH)(36) on local field potentials at the hippocampal formation (HPC) level. With the use of in vitro hippocampal formation slices as a stable model of inducing theta oscillations, and an in vivo model of an anesthetized rat, herein we provide the first convergent electropharmacological evidence that C-60(OH)(36) at relatively high concentrations (60 mu M and 80 mu M in vitro; 0.2 mu g/mu l in vivo) is capable of attenuating the amplitude, power, and frequency of theta oscillations in the HPC neuronal network. At the same time, lower concentrations did not induce any apparent changes. Theta band oscillations constitute a key physiological phenotypic property, which served here as a sensitive assay enabling the study of neural network excitability. Moreover, we report that C-60(OH)(36) at the concentrations of 60 mu M and 80 mu M is capable of producing epilepsy in the HPC in vitro, which suggests that C-60(OH)(n) , when applied at higher doses, may have a deleterious effect on the functioning of neuronal networks.	[Kazmierska-Grebowska, Paulina; Kobrzycka, Anna; Bocian, Renata; Kowalczyk, Tomasz] Univ Lodz, Fac Biol & Environm Protect, Dept Neurobiol, Pomorska St 141-143, PL-90236 Lodz, Poland; [Krokosz, Anita; Grebowski, Jacek] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Biophys, Pomorska St 141-143, PL-90236 Lodz, Poland; [Grebowski, Jacek] Mil Med Training Ctr, 6 Sierpnia St 92, PL-90646 Lodz, Poland	Kazmierska-Grebowska, P (reprint author), Univ Lodz, Fac Biol & Environm Protect, Dept Neurobiol, Pomorska St 141-143, PL-90236 Lodz, Poland.	paulina.kazmierska@biol.uni.lodz.pl	; Krokosz, Anita/C-4356-2013	Grebowski, Jacek/0000-0001-5407-9533; Kazmierska-Grebowska, Paulina/0000-0002-3784-6718; Kowalczyk, Tomasz/0000-0003-1375-4250; Krokosz, Anita/0000-0002-1008-0548; Bocian, Renata/0000-0003-0335-4923	Ministry of Science and Higher EducationMinistry of Science and Higher Education, Poland [B1611000001204.02, B1711000001556.02, B1711000001505.02]	This research was partly supported by the specific purpose grants for young scientists from the Ministry of Science and Higher Education (Project codes: B1611000001204.02, B1711000001556.02, B1711000001505.02).	Bakry R, 2007, INT J NANOMED, V2, P639; Bland BH, 2001, BEHAV BRAIN RES, V127, P119, DOI 10.1016/S0166-4328(01)00358-8; BLAND BH, 1993, PROG NEUROBIOL, V41, P157, DOI 10.1016/0301-0082(93)90007-F; Bland BH, 2016, HIPPOCAMPUS, V26, P289, DOI 10.1002/hipo.22521; Bocian R, 2007, BRAIN RES BULL, V73, P289, DOI 10.1016/j.brainresbull.2007.04.003; Bocian R, 2015, HIPPOCAMPUS, V25, P1393, DOI 10.1002/hipo.22459; Bostanci MO, 2007, SEIZURE-EUR J EPILEP, V16, P166, DOI 10.1016/j.seizure.2006.11.007; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Cai XQ, 2008, J NEUROSCI RES, V86, P3622, DOI 10.1002/jnr.21805; Cappaert NLM, 2009, HIPPOCAMPUS, V19, P1065, DOI 10.1002/hipo.20570; Chen L, 2014, BIOMATERIALS, V35, P9269, DOI 10.1016/j.biomaterials.2014.07.030; Chen T, 2014, TOXICOL LETT, V229, P423, DOI 10.1016/j.toxlet.2014.06.036; Chen T, 2013, TOXICOL LETT, V217, P121, DOI 10.1016/j.toxlet.2012.12.013; Djordjevic A, 2015, J NANOMATER, DOI 10.1155/2015/567073; Ekstrom AD, 2005, HIPPOCAMPUS, V15, P881, DOI 10.1002/hipo.20109; Fluri F, 2015, EXP NEUROL, V265, P142, DOI 10.1016/j.expneurol.2015.01.005; Friedman A, 2007, EPILEPSIA, V48, P126, DOI 10.1111/j.1528-1167.2007.01300.x; Giust D, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/s12951-014-0027-7; Grebowski J, 2013, BIOMED RES INT, DOI 10.1155/2013/751913; Grebowski J, 2013, BBA-BIOMEMBRANES, V1828, P2007, DOI 10.1016/j.bbamem.2013.05.009; Grebowski J, 2013, BBA-BIOMEMBRANES, V1828, P241, DOI 10.1016/j.bbamem.2012.09.008; Guldi DM, 2000, ACCOUNTS CHEM RES, V33, P695, DOI 10.1021/ar990144m; Hajos M, 2003, J PHARMACOL EXP THER, V306, P605, DOI 10.1124/jpet.103.051169; Hilder TA, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-323; Huang YY, 2005, LEARN MEMORY, V12, P587, DOI 10.1101/lm.98905; Jin H, 2000, J NEUROSCI RES, V62, P600, DOI 10.1002/1097-4547(20001115)62:4<600::AID-JNR15>3.0.CO;2-F; Johnson-Lyles DN, 2010, TOXICOL APPL PHARM, V248, P249, DOI 10.1016/j.taap.2010.08.008; Jovanovic B, 2014, NANOTOXICOLOGY, V8, P755, DOI 10.3109/17435390.2013.828794; Kazmierska P, 2015, BRAIN RES, V1625, P142, DOI 10.1016/j.brainres.2015.08.041; Kazmierska P, 2013, BRAIN RES BULL, V98, P93, DOI 10.1016/j.brainresbull.2013.07.010; Kokubo K, 2011, NANO RES, V4, P204, DOI 10.1007/s12274-010-0071-z; Konopacki J, 2006, EUR J NEUROSCI, V23, P1811, DOI 10.1111/j.1460-9568.2006.04679.x; KONOPACKI J, 1988, BRAIN RES, V451, P33, DOI 10.1016/0006-8993(88)90746-9; Kowalczyk T, 2013, EUR J NEUROSCI, V37, P679, DOI 10.1111/ejn.12091; Kubota R, 2011, TOXICOL LETT, V206, P172, DOI 10.1016/j.toxlet.2011.07.010; Leung LS, 2010, CEREB CORTEX, V20, P1865, DOI 10.1093/cercor/bhp251; Leung LS, 2004, HIPPOCAMPUS, V14, P510, DOI 10.1002/hipo.10199; Liu YY, 2017, ACS APPL MATER INTER, V9, P18626, DOI 10.1021/acsami.7b05459; Liu ZW, 2012, NANOTOXICOLOGY, V6, P414, DOI 10.3109/17435390.2011.583996; Lopes da Silva F H, 1976, Prog Brain Res, V45, P281; MacIver M B, 1986, Proc West Pharmacol Soc, V29, P159; Makarova EG, 2012, J NANOSCI NANOTECHNO, V12, P119, DOI 10.1166/jnn.2012.5709; Markovic Z, 2008, BIOMATERIALS, V29, P3561, DOI 10.1016/j.biomaterials.2008.05.005; McNaughton N, 2007, BEHAV PHARMACOL, V18, P329, DOI 10.1097/FBP.0b013e3282ee82e3; Monaghan MM, 2008, NEUROSCIENCE, V156, P550, DOI 10.1016/j.neuroscience.2008.07.057; Nunes A, 2012, J CONTROL RELEASE, V161, P290, DOI 10.1016/j.jconrel.2012.03.026; Otalora LFP, 2011, BRAIN RES, V1368, P308, DOI 10.1016/j.brainres.2010.10.047; Pastorin G, 2006, ORG BIOMOL CHEM, V4, P2556, DOI 10.1039/b604361e; Paxinos G., 2014, RAT BRAIN STEREOTAXI; Podolski I. Ya, 2010, Biofizika, V55, P88; Quick KL, 2008, NEUROBIOL AGING, V29, P117, DOI 10.1016/j.neurobiolaging.2006.09.014; Rokitskaya TI, 2016, BBA-BIOMEMBRANES, V1858, P1165, DOI 10.1016/j.bbamem.2016.02.009; Schroder W, 2000, EPILEPSIA, V41, pS181, DOI 10.1111/j.1528-1157.2000.tb01578.x; Tsai MC, 1997, J PHARM PHARMACOL, V49, P438, DOI 10.1111/j.2042-7158.1997.tb06821.x; Wang S, 2005, SYNTHETIC COMMUN, V35, P1803, DOI 10.1081/SCC-200063958; Wang XX, 2016, INT J NANOMED, V11, P4947, DOI 10.2147/IJN.S104856; Wang ZY, 2009, CHEMOSPHERE, V77, P67, DOI 10.1016/j.chemosphere.2009.05.015; Xie LG, 2014, NANOSCALE, V6, P9752, DOI 10.1039/c4nr01005a; Yamada T, 2008, J NANOSCI NANOTECHNO, V8, P3973, DOI 10.1166/jnn.2008.414; Yamada T, 2010, J NANOSCI NANOTECHNO, V10, P604, DOI 10.1166/jnn.2010.1720; Yang B, 2012, THESIS; Yin JJ, 2009, BIOMATERIALS, V30, P611, DOI 10.1016/j.biomaterials.2008.09.061; Yoder RM, 2005, HIPPOCAMPUS, V15, P381, DOI 10.1002/hipo.20062; Zha YY, 2012, INT J NANOMED, V7, P3099, DOI 10.2147/IJN.S30934	64	1	1	2	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					98	109		10.1016/j.yexmp.2018.06.002			12	Pathology	Pathology	GP6AE	WOS:000440958500014	29909157				2019-10-28	
J	Ceolin, L; Goularte, APP; Ferreira, CV; Romitti, M; Maia, AL				Ceolin, Lucieli; Palauro Goularte, Ana Paula; Ferreira, Carla Vaz; Romitti, Mirian; Maia, Ana Luiza			Global DNA methylation profile in medullary thyroid cancer patients	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Global DNA methylation; Cancer methylation; Thyroid cancer	METHYLTRANSFERASES; EXPRESSION	Background: Changes in global DNA methylation have been suggested to cause genomic instability leading to increased risk of cancer. The accumulation of epigenetic changes is believed to contribute to tumorigenesis and dedifferentiation, but the effects of such changes in thyroid cancer are still yet defined. Objective: To evaluate the global DNA methylation levels in thyroid cancer patients. Methods: Total DNA was extracted from peripheral blood leukocytes of the medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) patients and the methylation pattern was evaluated using the Imprint Methylated DNA Quantification kit (Sigma-Aldrich). Results: A total of 42 patients were analyzed (24 MTC, 12 PTC, and 6 controls). For MTC, the mean age was 41 +/- 20 years, 54% were women and 12 cases were sporadic. The median calcitonin level at diagnosis was 1692 (637-8865), 65% of the MTC patients had local metastases and 23% distant metastases. For PTC, the median age was 43 +/- 15 years, 58% were women and 50% had local metastases. The percentage of overall methylation differed according to the tumor subtype. Patients with MTC had a higher level of DNA methylation when compared to individuals with PTC (35 (24-48) vs. 17 (6.5-20.5); P = 0.002, respectively). Interestingly, among patients with MTC, individuals with the sporadic form of the disease had a higher level of methylation when compared to the hereditary form (25 (16-37) vs. 43 (33-52); P = 0.025, respectively). No association was observed between global methylation levels and clinical and/or oncological characteristics of the disease. Conclusion: Global methylation levels were higher in MTC as compared to PTC patients. These results suggest the overall DNA methylation profile may be influenced by the histological subtype of thyroid cancer.	[Ceolin, Lucieli; Palauro Goularte, Ana Paula; Ferreira, Carla Vaz; Romitti, Mirian; Maia, Ana Luiza] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Thyroid Sect, Endocrine Div, Porto Alegre, RS, Brazil	Ceolin, L (reprint author), Hosp Clin Porto Alegre, Serv Endocrinol, Rua Ramiro Barcelos 2350, BR-90035003 Porto Alegre, RS, Brazil.	lu.ceolin@gmail.com		Ceolin, Lucieli/0000-0001-6794-6042	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), grant MCTI/CNPq/CT-Saude/MS/SCTIE/DECIT; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) scholarship; Fundacao de Amparo Pesquisa do Estado do Rio Grande do Sul (FAPERGS), grant PRONEX FAPERGS/CNPq; Fundo de Incentivo a Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE) [15-0160]	This work was supported by: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), grant MCTI/CNPq/CT-Saude/MS/SCTIE/DECIT; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) scholarship; Fundacao de Amparo Pesquisa do Estado do Rio Grande do Sul (FAPERGS), grant PRONEX FAPERGS/CNPq; and Fundo de Incentivo a Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE), project number 15-0160.	Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; Dhe-Paganon Sirano, 2011, Int J Biochem Mol Biol, V2, P58; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Johansson E, 2015, DEVELOPMENT, V142, P3519, DOI 10.1242/dev.126581; Joo LJS, 2018, MOL CELL ENDOCRINOL, V469, P48, DOI 10.1016/j.mce.2017.03.014; Kapiteijn E, 2012, ANN ONCOL, V23, P10, DOI 10.1093/annonc/mdr117; Khatami F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184892; Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]; Li L, 2012, J EPIDEMIOL, V22, P384, DOI 10.2188/jea.JE20120003; Maia AL, 2014, ARQ BRAS ENDOCRINOL, V58, P667, DOI 10.1590/0004-2730000003427; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; National Comprehensive Cancer Network, 2017, CLIN PRACT GUID ONC; Niiya M, 2004, ONCOLOGY-BASEL, V67, P310, DOI 10.1159/000081332; O'Sullivan Brian, 2003, Semin Surg Oncol, V21, P30, DOI 10.1002/ssu.10019; Pellegriti G, 2013, J CANCER EPIDEMIOL, DOI 10.1155/2013/965212; Punales MK, 2003, J CLIN ENDOCR METAB, V88, P2644, DOI 10.1210/jc.2002-021422; Rodriguez-Rodero S, 2013, J CLIN ENDOCR METAB, V98, P2811, DOI 10.1210/jc.2012-3566; Sponziello M, 2014, MOL CELL ENDOCRINOL, V392, P8, DOI 10.1016/j.mce.2014.04.016; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Vitale G, 2017, MOL ONCOL, V11, P1007, DOI 10.1002/1878-0261.12070; Wells SA, 2015, THYROID, V25, P567, DOI 10.1089/thy.2014.0335; Witte T, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0066-6; Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615	27	4	4	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					110	114		10.1016/j.yexmp.2018.06.003			5	Pathology	Pathology	GP6AE	WOS:000440958500015	29935954				2019-10-28	
J	Dragovic, G; Sumarac-Dumanovic, M; Khawla, A; Soldatovic, I; Andjic, M; Jevtovic, D; Nair, D				Dragovic, Gordana; Sumarac-Dumanovic, Mirjana; Khawla, Al Musalhi; Soldatovic, Ivan; Andjic, Mladen; Jevtovic, Djordje; Nair, Devaki			Correlation between PAI-1, leptin and ferritin with HOMA in HIV/AIDS patients	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						PAI-1; Leptin; Ferritin; HOMA; HIV/AIDS patients	PLASMINOGEN-ACTIVATOR INHIBITOR-1; HIV-INFECTED PATIENTS; BETA-CELL FUNCTION; INSULIN-RESISTANCE; ANTIRETROVIRAL THERAPY; GROWTH-FACTOR; INFLAMMATION; ADIPONECTIN; GENE; DISEASE	Background: Data about correlation of interleukins (IL-1 alpha, IL-1 beta, IFN gamma, IL-2, IL-4, IL-6, IL-8, IL-10), adipocytokines (leptin, adiponectin, monocyte chemoattractant protein-1 (MCP-1), resistin, plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor alpha (TNF alpha), ferritin, C reactive protein (CRP) and vascular endothelial growth factor (VEGF) with homeostasis model assessment (HOMA) in HIV/AIDS patients are still limited. Therefore the aim of this study was to evaluate the possible correlations of serum levels of PAI-1, leptin and ferritin with HOMA in HIV/AIDS patients treated with combined antiretroviral therapy (cART). Methods: This cross-sectional study included 64 HIV/AIDS patients, all Caucasians, receiving cART at the HIV/AIDS Centre, Belgrade, Serbia. PAI-1, leptin, ferritin and insulin levels were measured using the Metabolic Syndrome Array I (Randox Laboratories Ltd., London, UK), while adiponectin and resistin levels were measured using Metabolic Syndrome Array II (Randox Laboratories Ltd., London, UK), interleukins (IL-1 alpha , IL-1 beta, IFN gamma, IL-2, IL-4, IL-6, IL-8, IL-10), MCP-1, TNF-alpha as well as VEGF was measured using Cytokine Array I (Randox Laboratories Ltd., London, UK). Insulin resistance was determined using the homeostasis model assessment index (HOMA). Multicollinearity of independent variables in multivariate model was analyzed using Variance Inflation Factor. Results: Correlation analysis revealed significant correlations between HOMA and waist circumference, body mass index, patients' age, number of cART combinations and triglycerides (p = 0.001, p = 0.001, p = 0.050, p = 0.044, p = 0.002, respectively). HOMA negatively correlated with levels of high density lipoprotein (HDL) (Rho = -0.282; p = 0.025). PAI-1 (Rho = 0.334; p = 0.007) and leptin (Rho = 0.492; p = 0.001) together with ferritin (Rho = 0.396, p = 0.001) positively and significantly correlated with HOMA. Levels of IL-1 alpha, IL-1 beta, IFN gamma, IL-2, IL-4, IL-6, IL-8, IL-10, adiponectin, MCP-1, resistin, TNF-alpha, CRP and VEGF did not significantly correlate with HOMA. Further, multiple logistic regression showed that there is a statistically significant correlation between PAI, leptin and ferritin with HOMA levels (p = 0.042; p < 0.001, p = 0.009). Conclusions: We showed significant correlation between PAI-1, leptin and ferritin, independently of each other with HOMA, in HIV/AIDS patients on cART.	[Dragovic, Gordana; Andjic, Mladen] Univ Belgrade, Sch Med, Dept Pharmacol Clin Pharmacol & Toxicol, Dr Subotica 1-3, Belgrade 11129, Serbia; [Sumarac-Dumanovic, Mirjana] Univ Clin Ctr, Inst Endocrinol Diabet & Dis Metab, Belgrade, Serbia; [Khawla, Al Musalhi; Nair, Devaki] UCL, Royal Free Hosp, Dept Clin Biochem, London, England; [Soldatovic, Ivan] Univ Belgrade, Sch Med, Inst Biomed Stat, Belgrade, Serbia; [Jevtovic, Djordje] Univ Belgrade, Sch Med, Infect & Trop Dis Hosp, Belgrade, Serbia	Dragovic, G (reprint author), Univ Belgrade, Sch Med, Dept Pharmacol Clin Pharmacol & Toxicol, Dr Subotica 1-3, Belgrade 11129, Serbia.	gordana.dragovic@med.bg.ac.rs		Jevtovic, Dorde/0000-0003-1127-6072	Ministry of Science and Technological Development of Serbia [175024]	The work was part of the project (Grant No 175024) supported by Ministry of Science and Technological Development of Serbia.	Abrahams Z, 2015, AIDS RES THER, V12, DOI 10.1186/s12981-015-0065-8; Al-Fadhli M, 2013, MED PRIN PRACT, V22, P54, DOI 10.1159/000339201; Angelo LS, 2007, CLIN CANCER RES, V13, P2825, DOI 10.1158/1078-0432.CCR-06-2416; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Barbaro G, 2006, CURR HIV RES, V4, P79, DOI 10.2174/157016206775197664; Bastard JP, 2000, DIABETES METAB RES, V16, P192, DOI 10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.3.CO;2-7; Brazionis L, 2008, ARTERIOSCL THROM VAS, V28, P786, DOI 10.1161/ATVBAHA.107.160168; Cesari M, 2010, CARDIOVASC THER, V28, pe72, DOI 10.1111/j.1755-5922.2010.00171.x; Chaudhari Sameer. P, 2012, JIACM, V13, P286; Chung JO, 2012, KOREAN J INTERN MED, V27, P66, DOI 10.3904/kjim.2012.27.1.66; De Larranaga G, 2004, J THROMB HAEMOST, V2, P532, DOI 10.1111/j.1538-7836.2004.00602.x; Deray G, 2004, AM J NEPHROL, V24, P522, DOI 10.1159/000081058; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dimitrijevic-Sreckovic V, 2007, CLIN CHEM LAB MED, V45, P1140, DOI 10.1515/CCLM.2007.259; Emerit J, 2001, BIOMED PHARMACOTHER, V55, P333, DOI 10.1016/S0753-3322(01)00068-3; Espino A, 2011, ANN HEPATOL, V10, P493, DOI 10.1016/S1665-2681(19)31518-2; Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12; Forood Afsaneh, 2014, Addict Health, V6, P119; Gabrielsen JS, 2012, J CLIN INVEST, V122, P3529, DOI 10.1172/JCI44421; Galli-Tsinopoulou A, 2011, EUR J PEDIATR, V170, P879, DOI 10.1007/s00431-010-1370-9; Gijon-Conde T, 2015, REV ESP CARDIOL, V68, P672, DOI 10.1016/j.rec.2014.08.015; Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768; Guzman-Fulgencio M, 2011, J INFECTION, V63, P382, DOI 10.1016/j.jinf.2011.08.006; Halon-Golabek M, 2018, J CACHEXIA SARCOPENI, V9, P557, DOI 10.1002/jcsm.12283; Johnson AMF, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201700036; Kell DB, 2014, METALLOMICS, V6, P748, DOI 10.1039/c3mt00347g; Kim JW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002335; Krentz HB, 2005, HIV MED, V6, P99, DOI 10.1111/j.1468-1293.2005.00271.x; Lopez-Alemany R, 2003, EUR J BIOCHEM, V270, P814, DOI 10.1046/j.1432-1033.2003.03453.x; Malvoisin E, 2006, AIDS, V20, P457, DOI 10.1097/01.aids.0000199824.26618.62; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mente A, 2010, DIABETES CARE, V33, P1629, DOI 10.2337/dc09-1392; Messner DJ, 2013, DIGEST DIS SCI, V58, P1899, DOI 10.1007/s10620-013-2648-3; Niu XH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006622; Padilla S, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-40; Padwal MK, 2015, J CLIN DIAGN RES, V9, pBC11, DOI 10.7860/JCDR/2015/13480.6564; Samaras K, 2009, JAIDS-J ACQ IMM DEF, V50, P499, DOI 10.1097/QAI.0b013e31819c291b; Sanchez-Pozo C, 2003, CLIN EXP IMMUNOL, V134, P464, DOI 10.1046/j.1365-2249.2003.02321.x; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCHNEIDER DJ, 1991, P NATL ACAD SCI USA, V88, P9959, DOI 10.1073/pnas.88.22.9959; Simental-Mendia LE, 2015, EUR J PEDIATR, V174, P597, DOI 10.1007/s00431-014-2426-z; Skrypnik K, 2017, ACTA SCI POLON-TECHN, V16, P83, DOI 10.17306/J.AFS.2017.0442; Szulinska M, 2017, FOOD NUTR RES, V61, DOI [10.1080/16546628.2017, 10.1080/16546628.2017.1295525]; Taniguchi A, 2006, METABOLISM, V55, P258, DOI 10.1016/j.metabol.2005.08.020; Thomas MC, 2003, DIABETES CARE, V26, P1164, DOI 10.2337/diacare.26.4.1164; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Vermeire S, 2005, NAT CLIN PRACT GASTR, V2, P580, DOI 10.1038/ncpgasthep0359; Waldman B, 2013, HEART LUNG CIRC, V22, P68; Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487; Wang TN, 2013, KAOHSIUNG J MED SCI, V29, P436, DOI 10.1016/j.kjms.2012.08.041; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yadav A, 2011, INDIAN J CLIN BIOCHE, V26, P193, DOI 10.1007/s12291-011-0119-1; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	53	0	0	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					115	119		10.1016/j.yexmp.2018.06.004			5	Pathology	Pathology	GP6AE	WOS:000440958500016	29940157				2019-10-28	
J	Miyata, KN; Nast, CC; Dai, T; Dukkipati, R; LaPage, JA; Troost, JP; Schurgers, LJ; Kretzler, M; Adler, SG				Miyata, Kana N.; Nast, Cynthia C.; Dai, Tiane; Dukkipati, Ramanath; LaPage, Janine A.; Troost, Jonathan P.; Schurgers, Leon J.; Kretzler, Matthias; Adler, Sharon G.			Renal matrix Gla protein expression increases progressively with CKD and predicts renal outcome	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Matrix gla protein; Chronic kidney disease; Gene expression; Vitamin K; Renal outcome	K-DEPENDENT PROTECTION; NEPHROTIC SYNDROME; CALCIFICATION; NEPTUNE; DISEASE	Background: Matrix Gla Protein (MGP) is a potent inhibitor of ectopic calcification and modulates bone morphogenesis. Little is known about MGP expression or function in kidney. Methods: We investigated renal MGP expression in Sprague-Dawley rats after 5/6 nephrectomy (5/6 Nx) and in human kidney biopsies in the Nephrotic Syndrome Study Network (NEPTUNE) cohort. We analyzed associations between glomerular (n = 182) and tubulointerstitial (TI) (n = 219) MGP mRNA levels and the disease activity/histologic features in NEPTUNE patients. Additionally, uncarboxylated and carboxylated MGP (ucMGP and cMGP, respectively) were localized by immunohistochemistry and quantitated in kidney tissues of patients at different stages of CKD (n = 18). Results: Renal MGP expression was increased in rats after 5/6 Nx. In NEPTUNE data, baseline estimated glomerular filtration rate (eGFR) negatively correlated with glomerular and TI MGP expression (p < 0.001). TI MGP expression strongly correlated with interstitial fibrosis, tubular atrophy, acute tubular injury, and interstitial inflammation, independent of eGFR. Kaplan-Meier analysis and multivariable Cox regression showed that higher levels of TI MGP expression were associated with an increased risk for the composite of 40% decline in eGFR and end-stage renal disease (ESRD) (HR, 3.31; 95% CI, 1.31 to 6.32; p = 0.02). Glomerular and tubulointerstitial cells demonstrated nuclear and cytoplasmic cMGP and ucMGP staining, and eGFR inversely correlated with quantified glomerular cMGP staining (p < 0.05). Conclusions: Our data demonstrate that renal MGP expression is increased in human and experimental CKD, and is associated with renal outcome. Additional studies are needed to determine its mechanism of action.	[Miyata, Kana N.; Dai, Tiane; Dukkipati, Ramanath; LaPage, Janine A.; Adler, Sharon G.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Nephrol & Hypertens, 1124 W Carson St, Torrance, CA 90502 USA; [Nast, Cynthia C.] Cedars Sinai Med Ctr, Dept Pathol, 8700 Beverly Blvd, Los Angeles, CA 90048 USA; [Troost, Jonathan P.] Univ Michigan, CS Mott Childrens Hosp, Dept Pediat & Communicable Dis, Div Nephrol, 1540 E Hosp Dr SPC 4259, Ann Arbor, MI 48109 USA; [Schurgers, Leon J.] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Dept Biochem, POB 616, NL-6200 MD Maastricht, Netherlands; [Kretzler, Matthias] Univ Michigan, Dept Internal Med, Div Nephrol, 1560 MSRB 2,1150 West Med Ctr Dr,SPC5676, Ann Arbor, MI 48109 USA	Miyata, KN (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Nephrol & Hypertens, 1124 W Carson St, Torrance, CA 90502 USA.	kananoshiro@gmail.com	Miyata, 1qaz!QAZ/L-9286-2019	Miyata, 1qaz!QAZ/0000-0001-6486-4666	UCLA Clinical and Translational Science Institute [530693]; Cedars-Sinai CSRI Academic Pathology Award for Basic, Translational and Clinical ResearchNAST2017A	This study was supported in part by UCLA Clinical and Translational Science Institute seed grant 530693, and Cedars-Sinai CSRI Academic Pathology Award for Basic, Translational and Clinical ResearchNAST2017A. KNM was supported by a generous gift honoring the life and work of nephrologist Henry Shavelle, MD.	Barisoni L, 2016, MODERN PATHOL, V29, P671, DOI 10.1038/modpathol.2016.58; Cozzolino M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025782.24383.0D; Evenepoel P, 2015, NEPHROL DIAL TRANSPL, V30, P843, DOI 10.1093/ndt/gfu400; Gadegbeku CA, 2013, KIDNEY INT, V83, P749, DOI 10.1038/ki.2012.428; GIMENEZ LF, 1987, KIDNEY INT, V31, P93, DOI 10.1038/ki.1987.14; Gipson DS, 2016, CLIN J AM SOC NEPHRO, V11, P81, DOI 10.2215/CJN.02560315; Hogan MC, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0185-3; Holden Rachel M, 2015, Can J Kidney Health Dis, V2, P17, DOI 10.1186/s40697-015-0053-x; Hultstrom M, 2012, PHYSIOL GENOMICS, V44, P576, DOI 10.1152/physiolgenomics.00186.2011; IBELS LS, 1978, NEW ENGL J MED, V298, P122, DOI 10.1056/NEJM197801192980302; IBELS LS, 1981, AM J MED, V71, P33, DOI 10.1016/0002-9343(81)90255-2; Knapen MHJ, 2015, THROMB HAEMOSTASIS, V113, P1135, DOI 10.1160/TH14-08-0675; Krueger T, 2013, NEPHROL DIAL TRANSPL, V28, P33; Kurnatowska I, 2016, KIDNEY BLOOD PRESS R, V41, P231, DOI 10.1159/000443426; Lai JY, 2015, J AM SOC NEPHROL, V26, P805, DOI 10.1681/ASN.2013121274; LAU K, 1989, KIDNEY INT, V36, P918, DOI 10.1038/ki.1989.281; Levey AS, 2014, AM J KIDNEY DIS, V64, P821, DOI 10.1053/j.ajkd.2014.07.030; Luo GB, 1997, NATURE, V386, P78, DOI 10.1038/386078a0; Mariani L. H, 2017, NEPHROL DIAL TRANSPL, DOI [10.1093/ndt/gfw443, DOI 10.1093/NDT/GFW443.EPUBAHEADOFPRINT.]; O'Young J, 2011, J AM CHEM SOC, V133, P18406, DOI 10.1021/ja207628k; Proudfoot D, 1998, ARTERIOSCL THROM VAS, V18, P379, DOI 10.1161/01.ATV.18.3.379; Rennenberg RJMW, 2008, HYPERTENS RES, V31, P1745, DOI 10.1291/hypres.31.1745; Schmid H, 2006, DIABETES, V55, P2993, DOI 10.2337/db06-0477; Schurgers LJ, 2007, J THROMB HAEMOST, V5, P2503, DOI 10.1111/j.1538-7836.2007.02758.x; Schurgers L. J, 2015, ARTERIOSCLER THROMB, V25, P1629; Schurgers LJ, 2013, TRENDS MOL MED, V19, P217, DOI 10.1016/j.molmed.2012.12.008; Schurgers LJ, 2010, CLIN J AM SOC NEPHRO, V5, P568, DOI 10.2215/CJN.07081009; SHANAHAN CM, 1994, J CLIN INVEST, V93, P2393, DOI 10.1172/JCI117246; Viegas CSB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177829; Wei F. F, 2017, NEPHROL DIAL TRANSPL, DOI [10.1093/ndt/gfx258, DOI 10.1093/NDT/GFX258.EPUBAHEADOFPRINT.]; Wei FF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193967; Wei FF, 2016, PULSE, V4, P85, DOI 10.1159/000448008; Wei FF, 2016, EBIOMEDICINE, V4, P162, DOI 10.1016/j.ebiom.2016.01.011; Wei X, 2018, BIOMED RES INT, DOI 10.1155/2018/8371604; Woroniecka KI, 2011, DIABETES, V60, P2354, DOI 10.2337/db10-1181; Yang YL, 2009, ENDOCRINOLOGY, V150, P727, DOI 10.1210/en.2008-0090; Zebboudj AF, 2002, J BIOL CHEM, V277, P4388, DOI 10.1074/jbc.M109683200	37	1	3	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					120	129		10.1016/j.yexmp.2018.07.001			10	Pathology	Pathology	GP6AE	WOS:000440958500017	29981754	Green Accepted			2019-10-28	
J	Zani, BC; Sanches, BDA; Maldarine, JS; Biancardi, MF; Santos, FCA; Barquilha, CN; Zucao, MI; Baraldi, CMB; Felisbino, SL; Goes, RM; Vilamaior, PSL; Taboga, SR				Zani, Bruno C.; Sanches, Bruno D. A.; Maldarine, Juliana S.; Biancardi, Manoel F.; Santos, Fernanda C. A.; Barquilha, Caroline N.; Zucao, Mariele I.; Baraldi, Carolina M. B.; Felisbino, Sergio L.; Goes, Rejane M.; Vilamaior, Patricia S. L.; Taboga, Sebastido R.			Telocytes role during the postnatal development of the Mongolian gerbil jejunum	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Telocytes; CD34; Muscularis mucosae; C-kit; Differentiation; Weaning	CAJAL-LIKE CELLS; INTERSTITIAL-CELLS; SMALL-INTESTINE; MERIONES-UNGUICULATUS; LAMINA PROPRIA; STROMAL CELLS; PROSTATE; FEMALE; GLAND; IDENTIFICATION	Telocytes are recently categorised CD34-positive interstitial cells that comprise the cells which were previously called interstitial Cajal-like cells (ICLCs). These were detected in the stroma of various organs such as the prostate, lungs, mammary glands, liver, gallbladder, and jejunum, among others. Several functions have been proposed for telocytes, such as a supportive role in smooth muscle contraction and immune function in adult organs, and tissue organisation and paracrine signalling during development, as well as others. In the jejunum, little is known about the function of telocytes in the adult organ, or is there any information about when these cells develop or if they could have an auxiliary role in the development of the jejunum. The present study employed histological, immunohistochemical and immunofluorescence techniques on histological sections of the jejunum of Mongolian gerbil pups on two different days of postnatal development of the jejunum, covering the maturation period of the organ. By immunolabelling for CD34, it was observed that telocytes are already present in the jejunum during the first week of postnatal life and exist in close association with the developing muscularis mucosae, which are therefore TGF beta 1-positive. The telocytes are still present at the end of the first month of life, and a portion of them present co-localisation with c-Kit. Fibroblast-like cells, which are exclusively c-Kit-positive, are also observed, which may indicate the presence of interstitial Cajal cells (ICCs). Finally, it can be hypothesised that a portion of the telocytes may give rise to ICCs, which are c-Kit-positive but CD34 negative.	[Zani, Bruno C.; Zucao, Mariele I.; Baraldi, Carolina M. B.; Felisbino, Sergio L.; Goes, Rejane M.; Vilamaior, Patricia S. L.; Taboga, Sebastido R.] Univ Estadual Paulista UNESP, Dept Biol, Lab Microscopy & Microanal, Cristovao Colombo St 2265, Sao Jose Do Rio Preto, SP, Brazil; [Sanches, Bruno D. A.; Maldarine, Juliana S.; Goes, Rejane M.; Taboga, Sebastido R.] Univ Estadual Campinas, Dept Struct & Funct Biol, Bertrand Russel Av, Campinas, SP, Brazil; [Biancardi, Manoel F.; Santos, Fernanda C. A.] Univ Fed Goias, Dept Histol Embryol & Cell Biol, Samambaia 2, BR-74001970 Goiania, Go, Brazil; [Barquilha, Caroline N.; Felisbino, Sergio L.] Univ Estadual Paulista UNESP, Inst Biosci, Prof Dr Antonio Celso Wagner Zanin St 250, BR-18618689 Botucatu, SP, Brazil	Taboga, SR (reprint author), Sao Paulo State Univ, Lab Microscopy & Microanal, Dept Biol, 2265 Cristevao Colombo St, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.	taboga@ibilce.unesp.br	Santos, Fernanda Cristina Alcantara dos/L-8390-2019; Vilamaior, Patricia S L/E-7680-2012; Biancardi, Manoel/AAC-6071-2019	Santos, Fernanda Cristina Alcantara dos/0000-0002-4476-6046; Vilamaior, Patricia S L/0000-0001-9559-5497; Biancardi, Manoel/0000-0001-9995-3546; Nascimento Barquilha, Caroline/0000-0001-7221-4460	FAPESP (Sao Paulo Research Foundation)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/15939-0, 2013/16443-9]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financially supported by FAPESP (Sao Paulo Research Foundation); Number of contracts: 2013/15939-0, 2013/16443-9.	Aleksandrovych Veronika, 2017, Folia Med Cracov, V57, P5; Sanches BDA, 2014, MICROSC RES TECHNIQ, V77, P458, DOI 10.1002/jemt.22370; Bani D, 2016, ADV EXP MED BIOL, V913, P127, DOI 10.1007/978-981-10-1061-3_8; Bei YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115991; Carmona IC, 2011, J CELL MOL MED, V15, P26, DOI 10.1111/j.1582-4934.2010.01207.x; Corradi LS, 2013, J CELL MOL MED, V17, P398, DOI 10.1111/jcmm.12021; Cretoiu D, 2012, HISTOL HISTOPATHOL, V27, P1067, DOI 10.14670/HH-27.1067; Cretoiu SM, 2012, J CELL MOL MED, V16, P2844, DOI 10.1111/j.1582-4934.2012.01651.x; CUMMINS AG, 1988, GUT, V29, P1672, DOI 10.1136/gut.29.12.1672; de Lima RF, 2015, REPROD TOXICOL, V58, P238, DOI 10.1016/j.reprotox.2015.10.016; Diaz-Flores L, 2016, CURR STEM CELL RES T, V11, P395, DOI 10.2174/1574888X10666151001115111; Drumm BT, 2014, NAT REV UROL, V11, P555, DOI 10.1038/nrurol.2014.241; Esrefoglu M, 2017, BEZMIALEM SCI, V5, P36, DOI 10.14235/bs.2016.824; Faussone-Pellegrini MS, 2010, J CELL MOL MED, V14, P1061, DOI 10.1111/j.1582-4934.2010.01074.x; Fochi RA, 2013, INT J EXP PATHOL, V94, P373, DOI 10.1111/iep.12050; Guo Xia, 2012, World J Biol Chem, V3, P41, DOI 10.4331/wjbc.v3.i3.41; HAYASHI N, 1991, BIOL REPROD, V45, P308, DOI 10.1095/biolreprod45.2.308; Hong JH, 2004, J UROLOGY, V171, P1965, DOI 10.1097/01.ju.0000123064.78663.2c; Iino S, 2009, ARCH HISTOL CYTOL, V72, P107, DOI 10.1679/aohc.72.107; Kammeraad A, 1942, J MORPHOL, V70, P323, DOI 10.1002/jmor.1050700209; Kang YL, 2015, J CELL MOL MED, V19, P2530, DOI 10.1111/jcmm.12671; Komuro T, 1996, J AUTONOM NERV SYST, V61, P169, DOI 10.1016/S0165-1838(96)00078-1; KUEHN RE, 1968, J COMP PHYSIOL PSYCH, V66, P747, DOI 10.1037/h0026558; Li XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159420; Liang J, 2013, INT J BIOL SCI, V9, P435, DOI 10.7150/ijbs.6087; Lorincz A, 2008, GASTROENTEROLOGY, V134, P1083, DOI 10.1053/j.gastro.2008.01.036; LOSKOTA WJ, 1974, EPILEPSIA, V15, P109, DOI 10.1111/j.1528-1157.1974.tb04000.x; Matyja A, 2013, J CELL MOL MED, V17, P734, DOI 10.1111/jcmm.12057; Mou YC, 2013, J CELL MOL MED, V17, P65, DOI 10.1111/j.1582-4934.2012.01646.x; Nicolescu MI, 2011, ANAT REC HOBOKEN, V295, P378, DOI [10.1002/ar.21540, DOI 10.1002/AR.21540]; Nicolescu MI, 2012, PANCREAS, V41, P949, DOI 10.1097/MPA.0b013e31823fbded; NORRIS M L, 1972, Laboratory Animals (London), V6, P49, DOI 10.1258/002367772781082703; Pasternak A, 2016, FOLIA MORPHOL, V75, P281, DOI 10.5603/FM.a2016.0002; Pasternak A, 2012, FOLIA HISTOCHEM CYTO, V50, P581, DOI [10.5603/FHC.2012.0081, 10.5603/19673]; Popescu LM, 2010, J CELL MOL MED, V14, P729, DOI 10.1111/j.1582-4934.2010.01059.x; Qi GS, 2012, J CELL MOL MED, V16, P3116, DOI 10.1111/j.1582-4934.2012.01582.x; Rakoff-Nahoum S, 2015, P NATL ACAD SCI USA, V112, P1929, DOI 10.1073/pnas.1424886112; Ramon Y, 1911, HISTOLOGIC DU SYSTEM, V2; Salyards GW, 2013, COMPARATIVE MED, V63, P62; Sanches BDA, 2017, J CELL MOL MED, V21, P3309, DOI 10.1111/jcmm.13234; Sanches BDA, 2017, REPROD TOXICOL, V73, P30, DOI 10.1016/j.reprotox.2017.07.013; Sanches BDA, 2016, ADV EXP MED BIOL, V913, P193, DOI 10.1007/978-981-10-1061-3_13; Santos F. C. A., 2006, Animal Reproduction, V3, P3; Schaeffer C, 2000, GUT, V47, P192, DOI 10.1136/gut.47.2.192; Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624; Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661; SPITZER MW, 1995, J NEUROPHYSIOL, V73, P1668; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Sureda EA, 2017, WORLD J GASTROENTERO, V23, P7531, DOI 10.3748/wjg.v23.i42.7531; Taboga SR, 2009, ARQ BRAS ENDOCRINOL, V53, P946, DOI 10.1590/S0004-27302009000800007; THUNEBERG L, 1982, ADV ANAT EMBRYOL CEL, V71, P1; Wells JM, 2014, DEVELOPMENT, V141, P752, DOI 10.1242/dev.097386; Xiao JJ, 2013, J CELL MOL MED, V17, P1537, DOI 10.1111/jcmm.12195; Zheng YH, 2014, J CELL MOL MED, V18, P568, DOI 10.1111/jcmm.12290; Zheng YH, 2012, EXPERT REV RESP MED, V6, P45, DOI [10.1586/ers.11.91, 10.1586/ERS.11.91]	55	3	3	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					130	138		10.1016/j.yexmp.2018.07.003			9	Pathology	Pathology	GP6AE	WOS:000440958500018	30003874				2019-10-28	
J	Martin, I; Navarro, B; Villamon, E; Solano, C; Serrano, A; Calabuig, M; Amat, P; Domingo, F; Abelian, R; Garcia, F; Olivares, MD; Chaves, FJ; Tormo, M; Hernandez-Boluda, JC				Martin, Ivan; Navarro, Blanca; Villamon, Eva; Solano, Carlos; Serrano, Alicia; Calabuig, Marisa; Amat, Paula; Domingo, Fernando; Abelian, Rosario; Garcia, Francisca; Dolores Olivares, Maria; Javier Chaves, Francisco; Tormo, Mar; Carlos Hernandez-Boluda, Juan			Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Chemotherapy; Allogeneic transplantation; Therapy-related acute myeloid leukemia; DNMT3A mutation; Molecular monitoring	DNMT3A MUTATIONS; TP53 MUTATIONS; RISK; NEOPLASMS; PATTERNS	Background: Therapy-related acute myeloid leukemia (t-AML) develops in patients with prior exposure to cytotoxic therapies. Selection of a pre-existing TP53 mutated clone prone to acquire additional mutational events has been suggested as the main pathogenic mechanism of t-AML. Here, we report a unique case of t-AML which developed from a pre-existing DNMT3A mutated clone that persisted in the patient for more than 10 years despite treatment with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). Case presentation: A 42-year-old male was diagnosed with AML harboring a normal karyotype and mutations in the NPM1 (c.863_864ins, p.W288 fs*12), DNMT3A (c.2645G > A, p.R882H), and IDH1 (c.395G > A, p.R132H) genes. He achieved complete remission with intensive chemotherapy and was subsequently submitted to alloHSCT. Eleven years later, he was given chemotherapy and radiotherapy to treat a lung carcinoma. Three years later, t-AML was diagnosed; the disease had arisen from a pre-existing DNMT3A mutated patient-origin clone that had subsequently acquired a TP53 mutation and a complex karyotype. Although a second transplantation was intended, the disease was refractory to induction chemotherapy, and the patient eventually died from disease complications. We retrospectively demonstrated the persistence and post-transplantation latency of the R882H-DNMT3A mutation using a real-time PCR allele-specific analysis at different time-points during the observation period. Discussion and conclusion: The present case highlights the potential clinical implications of a R882H-DNMT3A mutated clone that persisted after conventional AML treatment, including alloHSCT. It also reinforces the notion of the importance of cell non-intrinsic factors, such as the hematopoietic-stress induced by chemotherapy and radiotherapy, as drivers of clonal expansion.	[Martin, Ivan; Navarro, Blanca; Villamon, Eva; Solano, Carlos; Serrano, Alicia; Calabuig, Marisa; Amat, Paula; Domingo, Fernando; Garcia, Francisca; Tormo, Mar; Carlos Hernandez-Boluda, Juan] Univ Valencia, INCLIVA Res Inst, Hematol Dept, Hosp Clin Univ, Valencia, Spain; [Solano, Carlos] Univ Valencia, Sch Med, Dept Med, Valencia, Spain; [Abelian, Rosario; Dolores Olivares, Maria; Javier Chaves, Francisco] Univ Valencia, Genom & Genotyping Unit, INCLIVA Res Inst, Valencia, Spain	Martin, I (reprint author), Hosp Clin Univ, Hematol Dept, Ave Blasco Ibanez 17, Valencia 46010, Spain.	marcasi@alumni.uv.es; nacublan@ext.uv.es; eva.villamon@uv.es; carlos.solano@uv.es; m.rosario.abellan@uv.es; felipe.chaves@uv.es; tormo_mar@gva.es; hernandez_ica@gva.es	, Marisa/E-7760-2015	, Marisa/0000-0002-3250-820X	Institute de Salud Carlos III, SpainInstituto de Salud Carlos III [PI13/00636]	This work was supported by the grant PI13/00636 from the Institute de Salud Carlos III, Spain.	Alpermann T, 2016, HAEMATOLOGICA, V101, pE55, DOI 10.3324/haematol.2015.133819; Bacher U, 2008, BONE MARROW TRANSPL, V42, P145, DOI 10.1038/bmt.2008.185; Berenstein R, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0173-2; Bullinger L, 2016, CETLAM AML M; Bullinger L, 2017, J CLIN ONCOL, V35, P934, DOI 10.1200/JCO.2016.71.2208; Fabiani E, 2017, ONCOTARGET, V8, P12031, DOI 10.18632/oncotarget.14509; Ganser A, 2017, CURR OPIN HEMATOL, V24, P152, DOI 10.1097/MOH.0000000000000316; Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405; Guryanova OA, 2016, NAT MED, V22, P1488, DOI 10.1038/nm.4210; Hahn CN, 2015, LEUKEMIA, V29, P2101, DOI 10.1038/leu.2015.67; Heuser M, 2016, HEMATOL-AM SOC HEMAT, P24, DOI 10.1182/asheducation-2016.1.24; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762; Patel JP, 2012, NEW ENGL J MED, V366, P1079, DOI 10.1056/NEJMoa1112304; Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038; Takahashi K, 2017, LANCET ONCOL, V18, P100, DOI 10.1016/S1470-2045(16)30626-X; Wong TN, 2015, NATURE, V518, P552, DOI 10.1038/nature13968; Yang LB, 2015, NAT REV CANCER, V15, P152, DOI 10.1038/nrc3895; Zeichner SB, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0355-3; Zhang WS, 2017, CANCER INFORM, V16, DOI 10.1177/1176935117691267	20	0	0	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					139	143		10.1016/j.yexmp.2018.07.002			5	Pathology	Pathology	GP6AE	WOS:000440958500019	30017658				2019-10-28	
J	Jia, Y; French, B; Tillman, B; French, S				Jia, Yue; French, Barbara; Tillman, Brittany; French, Samuel			Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH)	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article							MALLORY-DENK BODIES; NF-KAPPA-B; LIVER-DISEASE; SIGNALING PATHWAYS; NATURAL-HISTORY; FATTY LIVER; EXPRESSION; HEPATITIS; PROTEINS; CELLS	Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer related deaths worldwide. Among others, non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH) are the two major risk factors as both of them may develop cirrhosis and hepatocellular carcinoma (HCC) if left untreated. However, patients with NASH progress to HCC at a rate around 0.5% annually, while 3-10% ASH patients may progress to HCC annually. The present study is to demonstrate the molecular differences in oncogenesis pathway between NASH and ASH. By using immunofluorescence study and quantitating the fluorescence intensity morphometrically in liver biopsied specimens from NASH and ASH patients, the protein expression of candidate molecules within hepatocytes cytoplasm are studied, including two HCC-related molecules FAT10 and FOXO1, and one GPCR pathway related molecule ADRA2A. Compared with the control group patients, the expression levels of all the molecules were upregulated in the ASH group of patients (p < 0.001 in all molecules), while FAT10 and ADRA2A were upregulated, FOXO1 did not change in the NASH group of patients. The most important finding is that compared with the ASH group of patients, the expression levels of all three molecules were significantly lower than in the NASH group of patients (p < 0.001 in all molecules). These results confirmed our previous finding that there are significant differences of molecules change in ASH compared to NASH. Thus, we conclude that there are significantly different molecules and pathways involved during the pathogenesis of HCC development in ASH compared to NASH which could help explain why the tumorigenic rate is different in ASH and NASH.	[Jia, Yue; French, Barbara; Tillman, Brittany; French, Samuel] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90502 USA	Jia, Y (reprint author), Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90502 USA.	yjia@dhs.lacounty.gov			NIH/AAA [UO-21898-05]	This study was funded by NIH/AAA grant # UO-21898-05.	Afifiyan N, 2017, EXP MOL PATHOL, V103, P191, DOI 10.1016/j.yexmp.2017.09.001; Afifiyan N, 2017, EXP MOL PATHOL, V102, P106, DOI 10.1016/j.yexmp.2017.01.011; Ahles A, 2014, PHARMACOL REV, V66, P598, DOI 10.1124/pr.113.008219; Aichem A, 2016, INT J BIOCHEM CELL B, V79, P451, DOI 10.1016/j.biocel.2016.07.001; Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; Canaan A, 2006, MOL CELL BIOL, V26, P5180, DOI 10.1128/MCB.00966-05; Choi Y, 2014, MOL ONCOL, V8, P642, DOI 10.1016/j.molonc.2014.01.007; Dam-Larsen S, 2004, GUT, V53, P750, DOI 10.1136/gut.2003.019984; Fagerholm V, 2011, BASIC CLIN PHARMACOL, V108, P365, DOI 10.1111/j.1742-7843.2011.00699.x; Ferlay J, 2015, GLOBOCAN 2012 V1 0 C; French SW, 2012, EXP MOL PATHOL, V93, P309, DOI 10.1016/j.yexmp.2012.09.002; French SW, 2013, ALCOHOL RES-CURR REV, V35, P57; French SW, 2012, J GASTROINTEST ONCOL, V3, P174, DOI 10.3978/j.issn.2078-6891.2012.025; French SW, 2010, WORLD J HEPATOL, V2, P295, DOI 10.4254/wjh.v2.i8.295; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Gao Y, 2014, CARCINOGENESIS, V35, P923, DOI 10.1093/carcin/bgt407; Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005; Hornsveld M, 2018, SEMIN CANCER BIOL, V50, P90, DOI 10.1016/j.semcancer.2017.11.017; Huang HJ, 2011, BBA-MOL CELL RES, V1813, P1961, DOI 10.1016/j.bbamcr.2011.01.007; Jackson Brian C., 2010, Human Genomics, V4, P345; Kaestner KH, 2000, GENE DEV, V14, P142; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Leong J, 2010, LIFE SCI, V86, P740, DOI 10.1016/j.lfs.2010.03.009; Lindenmeyer CC, 2018, CLIN LIVER DIS, V22, P11, DOI 10.1016/j.cld.2017.08.003; Liu H, 2014, EXP MOL PATHOL, V97, P234, DOI 10.1016/j.yexmp.2014.07.001; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Lu JG, 2018, EXP MOL PATHOL, V104, P125, DOI 10.1016/j.yexmp.2018.02.001; Nguyen L, 2018, EXP MOL PATHOL, V104, P45, DOI 10.1016/j.yexmp.2017.12.007; Lukasiak S, 2008, ONCOGENE, V27, P6068, DOI 10.1038/onc.2008.201; Morgan TR, 2004, GASTROENTEROLOGY, V127, pS87, DOI 10.1053/j.gastro.2004.09.020; Nan L, 2006, EXP MOL PATHOL, V80, P109, DOI 10.1016/j.yexmp.2005.11.001; Nan L, 2005, EXP MOL PATHOL, V78, P198, DOI 10.1016/j.yexmp.2004.12.002; Oliva J, 2008, EXP MOL PATHOL, V84, P102, DOI 10.1016/j.yexmp.2007.12.003; Oliva J, 2010, EXP MOL PATHOL, V89, P1, DOI 10.1016/j.yexmp.2010.04.001; Qing X, 2011, EXP MOL PATHOL, V90, P51, DOI 10.1016/j.yexmp.2010.09.005; Ramadori P, 2017, CANCERS, V9, DOI 10.3390/cancers9100130; Rani N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1752; Ren JW, 2011, J CELL SCI, V124, P3665, DOI 10.1242/jcs.087403; Scaglioni F, 2011, DIGEST DIS, V29, P202, DOI 10.1159/000323886; Schmidtke G, 2014, BBA-MOL CELL RES, V1843, P97, DOI 10.1016/j.bbamcr.2013.01.009; Schmidtke G, 2009, FEBS LETT, V583, P591, DOI 10.1016/j.febslet.2009.01.006; Schwartz JM, 2012, CLIN LIVER DIS, V16, P659, DOI 10.1016/j.cld.2012.08.001; Shi FY, 2018, SEMIN CANCER BIOL, V50, P124, DOI 10.1016/j.semcancer.2017.09.009; Stickel F, 2002, GUT, V51, P132, DOI 10.1136/gut.51.1.132; Stickel F, 2015, ADV EXP MED BIOL, V815, P113, DOI 10.1007/978-3-319-09614-8_7; Testino G, 2014, WORLD J GASTROENTERO, V20, P15943, DOI 10.3748/wjg.v20.i43.15943; Theng SS, 2014, P NATL ACAD SCI USA, V111, pE5282, DOI 10.1073/pnas.1403383111; Wang YY, 2016, 2016 INTERNATIONAL CONFERENCE ON SUSTAINABLE ENERGY, ENVIRONMENT AND INFORMATION ENGINEERING (SEEIE 2016), P4; Wong RJ, 2015, GASTROENTEROLOGY, V148, P547, DOI 10.1053/j.gastro.2014.11.039; Wong RJ, 2014, HEPATOLOGY, V59, P2188, DOI 10.1002/hep.26986; Yadav RK, 2018, SEMIN CANCER BIOL, V50, P65, DOI 10.1016/j.semcancer.2018.01.004; Yan DW, 2010, BRIT J CANCER, V103, P961, DOI 10.1038/sj.bjc.6605870	52	1	1	2	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					144	149		10.1016/j.yexmp.2018.07.005			6	Pathology	Pathology	GP6AE	WOS:000440958500020	30009772	Green Accepted			2019-10-28	
J	French, SW; Lu, JJG				French, Samuel W.; Lu, Jiajie G.			Piecemeal necrosis is due to the immunologic synapse formation and internalization of intact TCR-MHC II complexes by CD4 T cells	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						Immunologic synapse; piecemeal necrosis; troxis necrosis; trogocytosis		The nature of the immunologic synapse in autoimmune hepatitis is defined. This process involves the T cell receptor (TCR) which binds to the hepatocyte antigen presenting major histocompatibility complex (MHC) on the plasma membrane. This complex is quickly removed from the liver cell and taken into the T cell cytoplasm to be digested by the lysosome. The liver cell is gradually diminished to the point of its total removal by the lymphocytes binding to it.	[French, Samuel W.; Lu, Jiajie G.] Harbor UCLA Med Ctr, 1000 W Carson St, Torrance, CA 90500 USA	French, SW (reprint author), Harbor UCLA Med Ctr, 1000 W Carson St, Torrance, CA 90500 USA.	sfrench@labiomed.org					Albano E., 1999, FRONT BIOSCI, V4, P533, DOI DOI 10.2741/ALBAN010369806; Chen GC, 2010, WORLD J HEPATOL, V2, P410, DOI 10.4254/wjh.v2.i11.410; Dustin ML, 2014, CANCER IMMUNOL RES, V2, P1023, DOI 10.1158/2326-6066.CIR-14-0161; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; Hwang I, 2001, J IMMUNOL, V166, P5099, DOI 10.4049/jimmunol.166.8.5099; Ingelman-Sundberg M, 1998, ALCOHOL CLIN EXP RES, V22, P739, DOI 10.1111/j.1530-0277.1998.tb04321.x; Lytton SD, 1999, MOL PHARMACOL, V55, P223; Martinez-Martin N, 2011, IMMUNITY, V35, P208, DOI 10.1016/j.immuni.2011.06.003; Popper H., 1962, 2 INT S IMM, P303; Sage PT, 2012, J IMMUNOL, V188, P3686, DOI 10.4049/jimmunol.1102594; Schwartz M, 2017, SCIENCE, V357, P254, DOI 10.1126/science.aai8231; Wang MX, 2001, EXP MOL PATHOL, V71, P137, DOI 10.1006/exmp.2001.2397; Wei CH, 2015, EXP MOL PATHOL, V99, P341, DOI 10.1016/j.yexmp.2015.08.006	14	0	0	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					150	152		10.1016/j.yexmp.2018.07.004			3	Pathology	Pathology	GP6AE	WOS:000440958500021	30009774				2019-10-28	
J	Zhang, XY; Wang, LL; Wang, JG; Zhao, H; Wu, J; Liu, SH; Zhang, L; Li, YJ; Xing, XM				Zhang, Xiangyan; Wang, Lili; Wang, Jigang; Zhao, Han; Wu, Jie; Liu, Shuhong; Zhang, Lu; Li, Yujun; Xing, Xiaoming			Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma	EXPERIMENTAL AND MOLECULAR PATHOLOGY			English	Article						BRAF V600E; Immunohistochemistry; VE1; Colorectal carcinoma; Papillary thyroid carcinoma	BRAF V600E MUTATION; DIAGNOSTIC-VALUE; LYNCH SYNDROME; ANTIBODY; CANCER; EXPRESSION; VE1	Aims: To investigate whether immunohistochemistry (IHC) could be used to screen BRAF mutation status in formalin-fixed paraffin-embedded (FFPE) colorectal carcinoma (CRC) and papillary thyroid carcinoma (PTC) samples. Methods: Eight surgical resected samples, including 2 CRCs with mutated BRAF V600E, 2 PTCs with mutated BRAF V600E, 2 CRCs with wild-type BRAF and 2 PTCs with wild-type BRAF, were selected to explore the optimized IHC conditions for BRAF V600E (VE1) immunostaining using BenchmarkXT automated immunostainer VENTANA Medical System. BRAF V600E status was tested by optimized IHC and ARMS-PCR methods in 255 samples (123 CRCs and 132 PTCs). Sanger sequencing was performed to validate the BRAF V600E status if discordant results were found between optimized IHC and ARMS-PCR methods. Results: Antigen retrieval time in 32 min and 64 min showed satisfactory intensity and homogeneity of BRAF V600E staining in CRC and PTC samples, respectively. The concordance between IHC and ARMS/Sanger sequencing was 99.2% (122/123) in CRCs and 96.2% (127/132) in PTCs. In CRCs, the sensitivity of IHC staining for BRAF V600E was 100% (3/3) and the specificity was 99.1% (119/120). In PTCs, the sensitivity was 100% (106/106) and specificity was 80.8% (21/26). The overall concordance across all cases was 97.6% (249/255). Conclusion: The appropriate antigen retrieval protocol is critical for accurate analysis of BRAF V600E status by Benchmark XT automated immunostainer. IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.	[Zhang, Xiangyan; Wang, Lili; Wang, Jigang; Zhao, Han; Wu, Jie; Li, Yujun; Xing, Xiaoming] Qingdao Univ, Affiliated Hosp, Dept Pathol, 16 Jiangsu Rd, Qingdao 266003, Peoples R China; [Liu, Shuhong] Qingdao Univ, Affiliated Hosp, Dept Pneumol, 16 Jiangsu Rd, Qingdao 266003, Peoples R China; [Zhang, Lu] Qingdao Univ, Affiliated Hosp, Prenatal Diag Ctr, 16 Jiangsu Rd, Qingdao 266003, Peoples R China	Xing, XM (reprint author), Qingdao Univ, Affiliated Hosp, Dept Pathol, 16 Jiangsu Rd, Qingdao 266003, Peoples R China.	edithxing@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81201947]; Natural Science Foundation of Shandong, ChinaNatural Science Foundation of Shandong Province [ZR2009CM014]; Excellent Young Scientist Foundation of Shandong Province, China [2006BSB14001]; Qingdao Minsheng Science and Technology Project [17-3-3-38-nsh]	The present study was supported by grants from the National Natural Science Foundation of China [grant number 81201947], the Natural Science Foundation of Shandong, China [grant number ZR2009CM014], and the Excellent Young Scientist Foundation of Shandong Province, China [grant number 2006BSB14001], Qingdao Minsheng Science and Technology Project [grant number 17-3-3-38-nsh].	Abd Elmageed ZY, 2017, SURGERY, V161, P1122, DOI 10.1016/j.surg.2016.06.081; Adackapara CA, 2013, HISTOPATHOLOGY, V63, P187, DOI 10.1111/his.12154; Bledsoe JR, 2014, AM J SURG PATHOL, V38, P1418, DOI 10.1097/PAS.0000000000000263; Boursault L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070826; Capper D, 2013, INT J CANCER, V133, P1624, DOI 10.1002/ijc.28183; Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z; Day F, 2015, TARGET ONCOL, V10, P99, DOI 10.1007/s11523-014-0319-8; de Biase D, 2014, J CLIN ENDOCR METAB, V99, pE1530, DOI 10.1210/jc.2013-4389; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Dong Y, 2016, ONCOL LETT, V11, P2371, DOI 10.3892/ol.2016.4235; Dvorak K, 2017, PATHOL ONCOL RES, P1; Emoto K, 2005, J HISTOCHEM CYTOCHEM, V53, P1311, DOI 10.1369/jhc.5C6627.2005; Fisher KE, 2014, APPL IMMUNOHISTO M M, V22, P562, DOI 10.1097/PAI.0b013e3182a2f75f; Gertz RJ, 2016, ARCH PATHOL LAB MED, V140, P134, DOI 10.5858/arpa.2014-0612-OA; Ilie MI, 2014, THYROID, V24, P858, DOI 10.1089/thy.2013.0302; Ioannou M, 2016, J BUON, V21, P618; Kuan SF, 2014, HUM PATHOL, V45, P464, DOI 10.1016/j.humpath.2013.10.026; Long GV, 2013, AM J SURG PATHOL, V37, P61, DOI 10.1097/PAS.0b013e31826485c0; Loughrey MB, 2007, FAM CANCER, V6, P301, DOI 10.1007/s10689-007-9124-1; Oh HS, 2018, ENDOCRINOL METAB, V33, P62, DOI 10.3803/EnM.2018.33.1.62; Sinicrope FA, 2013, CANCER-AM CANCER SOC, V119, P2765, DOI 10.1002/cncr.28133; Song L, 2014, ACTA HISTOCHEM, V116, P126, DOI 10.1016/j.acthis.2013.06.003; Szymonek M, 2017, ONCOTARGET, V8, P74897, DOI 10.18632/oncotarget.20451; Toon CW, 2013, AM J SURG PATHOL, V37, P1592, DOI 10.1097/PAS.0b013e31828f233d; Zagzag J, 2013, SURGERY, V154, P1199, DOI 10.1016/j.surg.2013.06.020; Zhu XL, 2016, EXP MOL PATHOL, V100, P236, DOI 10.1016/j.yexmp.2016.01.004	26	3	3	1	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4800	1096-0945		EXP MOL PATHOL	Exp. Mol. Pathol.	AUG	2018	105	1					153	159		10.1016/j.yexmp.2018.07.006			7	Pathology	Pathology	GP6AE	WOS:000440958500022	30009773				2019-10-28	
J	Mazor, R; King, EM; Pastan, I				Mazor, Ronit; King, Emily M.; Pastan, Ira			Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins	AMERICAN JOURNAL OF PATHOLOGY			English	Review							T-CELL EPITOPE; IN-SILICO PREDICTION; PSEUDOMONAS EXOTOXIN; HLA-DR; TOLEROGENIC NANOPARTICLES; DE-IMMUNIZATION; PHASE-I; IMMUNOLOGICAL-TOLERANCE; THERAPEUTIC PROTEINS; ANTITUMOR-ACTIVITY	Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen and a fragment of a bacterial toxin that kills tumor cells. Because the toxin is a foreign protein, it is immunogenic. The clinical success of RITs in patients with a normal immune system is limited by their immunogenicity. In this review, we discuss our progress in therapeutic protein deimmunization and the balancing act between immunogenicity and therapeutic potency. One approach is to prevent the activation of B cells by mapping and elimination of B cell epitopes. A second approach is to prevent helper T-cell activation by interfering with major histocompatibility complex II presentation or T-cell recognition. Immunizing mice with RITs that were deimmunized by elimination of the murine B- or T-cell epitopes showed that both approaches are effective. Another approach to control immunogenicity is to modify the host immune system. Nanoparticles containing synthetic vaccine particles encapsulating rapamycin can induce immune tolerance and prevent anti-drug antibody formation. This treatment restores RIT anti-tumor activity that is otherwise neutralized because of immunogenicity.	[Mazor, Ronit; King, Emily M.; Pastan, Ira] NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37, Bethesda, MD 20892 USA; [Mazor, Ronit] Medimmune Inc, Gaithersburg, MD 20878 USA	Pastan, I (reprint author), NCI, Mol Biol Lab, 37 Convent Dr,Room 5106, Bethesda, MD 20892 USA.	pastani@mail.nih.gov	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; King, Emily/0000-0001-6045-4803	Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)	Supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH.	Alewine C, 2015, ONCOLOGIST, V20, P176, DOI 10.1634/theoncologist.2014-0358; Alewine C, 2014, MOL CANCER THER, V13, P2653, DOI 10.1158/1535-7163.MCT-14-0132; Bauss F, 2016, MOL ONCOL, V10, P1317, DOI 10.1016/j.molonc.2016.07.003; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; Cantor JR, 2011, P NATL ACAD SCI USA, V108, P1272, DOI 10.1073/pnas.1014739108; Cizeau J, 2009, J IMMUNOTHER, V32, P574, DOI 10.1097/CJI.0b013e3181a6981c; De Groot AS, 2005, DEV BIOLOGICALS, V122, P171; Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473; Fleming BD, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-59; Getts DR, 2015, TRENDS IMMUNOL, V36, P419, DOI 10.1016/j.it.2015.05.007; Hansen JK, 2010, J IMMUNOTHER, V33, P297, DOI 10.1097/CJI.0b013e3181cd1164; Harding FA, 2005, MOL CANCER THER, V4, P1791, DOI 10.1158/1535-7163.MCT-05-0189; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Hassan R, 2007, CLIN CANCER RES, V13, P5144, DOI 10.1158/1078-0432.CCR-07-0869; Hassan R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006941; Hollevoet K, 2014, MOL CANCER THER, V13, P2040, DOI 10.1158/1535-7163.MCT-14-0089-T; Hwang WYK, 2005, METHODS, V36, P3, DOI 10.1016/j.ymeth.2005.01.001; Iwai LK, 2003, MOL MED, V9, P209, DOI 10.1007/BF03402131; Kaplan G, 2018, MOL CANCER THER, V17, P1486, DOI 10.1158/1535-7163.MCT-17-1041; Khan DA, 2016, ANN ALLERG ASTHMA IM, V117, P115, DOI 10.1016/j.anai.2016.05.013; King C, 2014, P NATL ACAD SCI USA, V111, P8577, DOI 10.1073/pnas.1321126111; Kishimoto TK, 2016, NAT NANOTECHNOL, V11, P890, DOI [10.1038/NNANO.2016.135, 10.1038/nnano.2016.135]; Koren E, 2007, CLIN IMMUNOL, V124, P26, DOI 10.1016/j.clim.2007.03.544; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Kreitman RJ, 2012, J CLIN ONCOL, V30, P1822, DOI 10.1200/JCO.2011.38.1756; Li XH, 2014, INT J GENOMICS, DOI 10.1155/2014/483905; Liu WM, 2012, P NATL ACAD SCI USA, V109, P490, DOI 10.1073/pnas.1110368109; Maldonado RA, 2015, P NATL ACAD SCI USA, V112, pE156, DOI 10.1073/pnas.1408686111; MAURER DH, 1987, J IMMUNOL, V139, P715; Mazor R, 2018, P NATL ACAD SCI USA, V115, pE733, DOI 10.1073/pnas.1717063115; Mazor R, 2017, CELL IMMUNOL, V313, P59, DOI 10.1016/j.cellimm.2017.01.003; Mazor R, 2017, AAPS J, V19, P117, DOI 10.1208/s12248-016-9986-y; Mazor R, 2016, ONCOTARGET, V7, P29916, DOI 10.18632/oncotarget.9171; Mazor R, 2017, CELL MOL IMMUNOL, V14, P432, DOI 10.1038/cmi.2015.91; Mazor R, 2016, IMMUNOL REV, V270, P152, DOI 10.1111/imr.12390; Mazor R, 2015, MOL CANCER THER, V14, P2789, DOI 10.1158/1535-7163.MCT-15-0532; Mazor R, 2015, J IMMUNOL METHODS, V425, P10, DOI 10.1016/j.jim.2015.06.003; Mazor R, 2014, P NATL ACAD SCI USA, V111, P8571, DOI 10.1073/pnas.1405153111; Mazor R, 2012, P NATL ACAD SCI USA, V109, pE3597, DOI 10.1073/pnas.1218138109; Meyer CG, 1997, IMMUNOL TODAY, V18, P58, DOI 10.1016/S0167-5699(96)30071-6; Moise L, 2012, CLIN IMMUNOL, V142, P320, DOI 10.1016/j.clim.2011.11.010; Mossoba ME, 2011, CLIN CANCER RES, V17, P3697, DOI 10.1158/1078-0432.CCR-11-0493; Onda M, 2008, P NATL ACAD SCI USA, V105, P11311, DOI 10.1073/pnas.0804851105; Onda M, 2006, J IMMUNOL, V177, P8822, DOI 10.4049/jimmunol.177.12.8822; Onda M, 2011, P NATL ACAD SCI USA, V108, P5742, DOI 10.1073/pnas.1102746108; Oseroff C, 2010, J IMMUNOL, V185, P943, DOI 10.4049/jimmunol.1000405; OTTENHOFF THM, 1985, HUM IMMUNOL, V13, P105, DOI 10.1016/0198-8859(85)90017-5; Pastan I, 2003, CANCER IMMUNOL IMMUN, V52, P338, DOI 10.1007/s00262-002-0353-8; Pastan I, 2006, NAT REV CANCER, V6, P559, DOI 10.1038/nrc1891; Salvat RS, 2015, BIOTECHNOL BIOENG, V112, P1306, DOI 10.1002/bit.25554; Salvat RS, 2014, CELL MOL LIFE SCI, V71, P4869, DOI 10.1007/s00018-014-1652-x; Sathiamurthy Muthuraman, 2005, Immunome Res, V1, P2, DOI 10.1186/1745-7580-1-2; Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236; SPURZEM JR, 1989, AM REV RESPIR DIS, V140, P89, DOI 10.1164/ajrccm/140.1.89; Stallone G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0916-7; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; Tangri S, 2005, J IMMUNOL, V174, P3187, DOI 10.4049/jimmunol.174.6.3187; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; Weldon JE, 2011, FEBS J, V278, P4683, DOI 10.1111/j.1742-4658.2011.08182.x; Weldon JE, 2009, BLOOD, V113, P3792, DOI 10.1182/blood-2008-08-173195; WHITE TJ, 1978, NATURE, V274, P92, DOI 10.1038/274092a0; Yeung VP, 2004, J IMMUNOL, V172, P6658, DOI 10.4049/jimmunol.172.11.6658; Zhang AH, 2016, CELL IMMUNOL, V301, P74, DOI 10.1016/j.cellimm.2015.11.004	63	6	6	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1736	1743		10.1016/j.ajpath.2018.04.016			8	Pathology	Pathology	GP3SI	WOS:000440773100001	29870741	Green Published			2019-10-28	
J	Pritchard, N; Kaitu'u-Lino, TJ; Gong, S; Dopierala, J; Smith, GCS; Charnock-Jones, DS; Tong, S				Pritchard, Natasha; Kaitu'u-Lino, Tu'uhevaha J.; Gong, Sungsam; Dopierala, Justyna; Smith, Gordon C. S.; Charnock-Jones, D. Stephen; Tong, Stephen			ELABELA/APELA Levels Are Not Decreased in the Maternal Circulation or Placenta among Women with Preeclampsia	AMERICAN JOURNAL OF PATHOLOGY			English	Article							APELIN RECEPTOR; HYPERTENSION; PREGNANCY; OUTCOMES	The genetic deletion of apelin receptor early endogenous ligand (Elabela; official name APELA) produces a preeclampsia-like phenotype in mice. However, evidence linking ELABELA with human disease is lacking. Therefore, we measured placental mRNA and circulating ELABELA in human samples. ELABELA mRNA (measured by RNA sequencing) was unchanged in 82 preeclamptic placentas compared with 82 matched controls (mean difference, 0.53%; 95% CI, -25.9 to 27.0; P = 0.78). We measured circulating ELABELA in 32 women with preterm preeclampsia (delivered at <34 weeks' gestation) and 32 matched controls sampled at the same gestational age. There was no difference in circulating ELABELA concentrations in the preeclamptic cohort compared with controls (median, 28.5 pg/mL; 95% CI, 5.3 to 63.2 versus median, 20.5 pg/mL; 95% CI, 9.2 to 58.0, respectively); the median difference was 8.0 pg/mL (95% CI, 17.7 to 12.1; P = 0.43). In contrast, soluble FLT1 (a protein with an established association with preeclampsia) mRNA was increased in placental tissue (mean difference, 34.9%; 95% CI, 16.6 to 53.1; P = 0.001), and circulating concentrations were 16.8-fold higher among the preeclamptic cohort (P < 0.0001). In conclusion, we were able to recapitulate the association between circulating soluble FLT1 and preeclampsia, but there was no association with ELABELA. The speculated clinical relevance of observations in the murine model linking ELABELA to preeclampsia likely are incorrect.	[Pritchard, Natasha; Kaitu'u-Lino, Tu'uhevaha J.; Tong, Stephen] Univ Melbourne, Dept Obstet & Gynaecol, Translat Obstet Grp, Heidelberg, Vic, Australia; [Pritchard, Natasha; Kaitu'u-Lino, Tu'uhevaha J.; Tong, Stephen] Mercy Hosp Women, Mercy Perinatal, Heidelberg, Vic, Australia; [Gong, Sungsam; Dopierala, Justyna; Smith, Gordon C. S.; Charnock-Jones, D. Stephen] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge, England; [Gong, Sungsam; Dopierala, Justyna; Smith, Gordon C. S.; Charnock-Jones, D. Stephen] Natl Inst Hlth Res Cambridge Comprehens Biomed Re, Cambridge, England; [Dopierala, Justyna; Smith, Gordon C. S.; Charnock-Jones, D. Stephen] Univ Cambridge, Ctr Trophoblast Res, Cambridge, England	Tong, S (reprint author), Univ Melbourne, Dept Obstet & Gynaecol, Mercy Hosp Women, Level 4,163 Studley Rd, Heidelberg, Vic 3084, Australia.	stong@unimelb.edu.au	Charnock-Jones, D. Stephen/B-3743-2009; Smith, Gordon/A-8070-2008	Charnock-Jones, D. Stephen/0000-0002-2936-4890; Smith, Gordon/0000-0003-2124-0997; Kaitu'u-Lino, Tu'uhevaha/0000-0001-6233-9737	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1062418, 1136418, 1150828]; National Institute for Health Research Cambridge Comprehensive Biomedical Research Center (Women's Health Theme) from the Medical Research Council (United Kingdom) [G1100221]; Stillbirth and Neonatal Death Society (Sands); GE HealthcareGE Healthcare; National Institute for Health Research Cambridge Clinical Research Facility	Supported by National Health and Medical Research Council of Australia grants 1062418 (T.J.K.-L.) and 1136418 (S.T.), and by postgraduate scholarship 1150828 from the National Health and Medical Research Council of Australia (N.P.). Some of the work described was supported by the National Institute for Health Research Cambridge Comprehensive Biomedical Research Center (Women's Health Theme), project grant G1100221 from the Medical Research Council (United Kingdom), and the Stillbirth and Neonatal Death Society (Sands). This study also was supported by GE Healthcare (donation of 2 Voluson i Ultrasound Systems) and by the National Institute for Health Research Cambridge Clinical Research Facility, where research visits took place.	Chen H, 2017, J AM SOC NEPHROL, V28, P2695, DOI 10.1681/ASN.2016111210; Chng SC, 2013, DEV CELL, V27, P672, DOI 10.1016/j.devcel.2013.11.002; Cindrova-Davies T, 2011, CARDIOVASC RES, V89, P671, DOI 10.1093/cvr/cvq346; Deng C, 2015, J BIOL CHEM, V290, P18261, DOI 10.1074/jbc.M115.648238; Gaccioli F, 2017, PLACENTA, V59, pS17, DOI 10.1016/j.placenta.2016.10.011; Ho LN, 2017, SCIENCE, V357, P707, DOI 10.1126/science.aam6607; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Martin M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Murza A, 2016, J MED CHEM, V59, P2962, DOI 10.1021/acs.jmedchem.5b01549; Pasupathy D, 2012, PAEDIATR PERINAT EP, V26, P543, DOI 10.1111/ppe.12002; Powe CE, 2011, CIRCULATION, V123, P2856, DOI 10.1161/CIRCULATIONAHA.109.853127; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; Santoso P, 2015, NEUROREPORT, V26, P820, DOI 10.1097/WNR.0000000000000431; Schreiber CA, 2016, CURR GENE THER, V16, P349, DOI 10.2174/1566523217666161121111906; Tomimatsu T, 2017, HYPERTENS RES, V40, P305, DOI 10.1038/hr.2016.152; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Wang Z, 2015, SCI REP-UK, V5, DOI 10.1038/srep08170; Yang PR, 2017, CIRCULATION, V135, P1160, DOI 10.1161/CIRCULATIONAHA.116.023218; Yung HW, 2014, J PATHOL, V234, P262, DOI 10.1002/path.4394; Zeisler H, 2016, NEW ENGL J MED, V374, P13, DOI 10.1056/NEJMoa1414838	22	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1749	1753		10.1016/j.ajpath.2018.04.008			5	Pathology	Pathology	GP3SI	WOS:000440773100003	29803833	Green Published, Other Gold			2019-10-28	
J	Zhao, F; Zhou, QY; Reinach, PS; Yang, JT; Ma, L; Wang, XJ; Wen, YY; Srinivasalu, N; Qu, J; Zhou, XT				Zhao, Fei; Zhou, Qingyi; Reinach, Peter S.; Yang, Jingtei; Ma, Li; Wang, Xiaojun; Wen, Yingying; Srinivasalu, Nethrajeith; Qu, Jia; Zhou, Xiangtian			Cause and Effect Relationship between Changes in Scleral Matrix Metallopeptidase-2 Expression and Myopia Development in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FORM-DEPRIVATION MYOPIA; MESSENGER-RNA EXPRESSION; TREE SHREW SCLERA; TIMP-2 EXPRESSION; LIVER FIBROSIS; CROSS-LINKING; AXIAL MYOPIA; GELATINASE-A; EYE GROWTH; METALLOPROTEINASE-2	Myopia is a serious sight-compromising condition in which decreases in scleral biomechanical strength are associated with protease up-regulation resulting in thinning of its collagenous framework and changes in the extracellular matrix composition. Matrix metallopeptidase (MMP)-2 is one of the known proteases mediating these alterations. To determine whether MMP-2 up-regulation precedes myopia development, the direct effects of gain and loss in Mmp2 gene function were evaluated on refractive development and form deprivation myopia in mice. Four weeks after injecting an adeno-associated virus serotype 8 packaged Mmp2 overexpression vector (AAV8-Mmp2), scleral MMP-2 up-regulation was accompanied by significant myopia in a normal visual environment. In contrast, AAV8 packaging with shRNA targeting Mmp2 inhibited rises in MMP-2 expression induced by form deprivation by 54% and reduced myopia development by 23% compared with eyes injected with an irrelevant scrambled sequence. Because opposing changes in MMP-2 protein expression levels had corresponding effects on myopia progression, up-regulation of this protease contributes to inducing this condition. This notion of a cause-and-effect relationship between MMP-2 up-regulation and myopia development is supported by showing that form-deprived myopia development was attenuated by 27% in fibroblast-specific Mmp2 deletion (S100 alpha 4(cre)Mmp(2fl/fl)) mice relative to Cre-negative littermates (Mmp(2fl/fl)). Therefore, MMP-2 is a potential drug target for inhibiting myopia progression.	[Zhao, Fei; Zhou, Qingyi; Reinach, Peter S.; Yang, Jingtei; Ma, Li; Wang, Xiaojun; Wen, Yingying; Srinivasalu, Nethrajeith; Qu, Jia; Zhou, Xiangtian] Wenzhou Med Univ, Sch Optometry & Ophthalmol, 270 W Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China; [Zhao, Fei; Zhou, Qingyi; Reinach, Peter S.; Yang, Jingtei; Ma, Li; Wang, Xiaojun; Wen, Yingying; Srinivasalu, Nethrajeith; Qu, Jia; Zhou, Xiangtian] Wenzhou Med Univ, Eye Hosp, 270 W Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China; [Zhao, Fei; Zhou, Qingyi; Reinach, Peter S.; Yang, Jingtei; Ma, Li; Wang, Xiaojun; Wen, Yingying; Srinivasalu, Nethrajeith; Qu, Jia; Zhou, Xiangtian] PR China & Zhejiang Prov Key Lab Ophthalmol & Opt, State Key Lab Optometry Ophthalmol & Vis Sci, Wenzhou, Zhejiang, Peoples R China	Zhou, XT (reprint author), Wenzhou Med Univ, Sch Optometry & Ophthalmol, 270 W Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China.; Zhou, XT (reprint author), Wenzhou Med Univ, Eye Hosp, 270 W Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China.	zxt@mail.eye.ac.cn			National Natural Science Foundation of China (National Science Foundation of China)National Natural Science Foundation of China [81700868, 81422007, 81470659, 81170870, 81670886]; Scientific Bureau of Wenzhou City [2016Y0728]; Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) [LQ16H120006, LZ14H120001]; Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents; National Young Excellent Talents Support Program	Supported by the National Natural Science Foundation of China (National Science Foundation of China) grants 81700868 (F.Z.), 81422007 (X.Z.), 81470659 (J.Q.), 81170870 (X.Z.), and 81670886 (X.Z.); the Scientific Bureau of Wenzhou City grant 2016Y0728 (F.Z.); the Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) grants LQ16H120006 (F.Z.) and LZ14H120001 (X.Z.); The Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents (X.Z.); and The National Young Excellent Talents Support Program (X.Z.).	Bates AL, 2015, J PATHOL, V235, P773, DOI 10.1002/path.4493; Campbell IC, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0014; Chassine T, 2015, EUR J OPHTHALMOL, V25, P280, DOI 10.5301/ejo.5000571; Chen S, 2017, INVEST OPHTH VIS SCI, V58, P2306, DOI 10.1167/iovs.16-20402; Chu YH, 2016, J OPHTHALMOL, DOI 10.1155/2016/3526153; Deng HW, 2016, J OCUL PHARMACOL TH, V32, P196, DOI 10.1089/jop.2015.0053; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009; Guggenheim JA, 1996, INVEST OPHTH VIS SCI, V37, P1380; Hori Y, 2012, AM J PHYSIOL-CELL PH, V303, pC947, DOI 10.1152/ajpcell.00401.2011; Iseli HP, 2016, GRAEF ARCH CLIN EXP, V254, P109, DOI 10.1007/s00417-015-3213-x; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Jia Y, 2014, INVEST OPHTH VIS SCI, V55, P3922, DOI 10.1167/iovs.14-13983; Jones BE, 1996, EXP EYE RES, V63, P369, DOI 10.1006/exer.1996.0127; Li XX, 2017, EXP EYE RES, V165, P1, DOI 10.1016/j.exer.2017.08.019; Liu HH, 2017, INVEST OPHTH VIS SCI, V58, P1971, DOI 10.1167/iovs.16-21181; Liu HH, 2010, INVEST OPHTH VIS SCI, V51, P2865, DOI 10.1167/iovs.09-4322; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McBrien NA, 2000, INVEST OPHTH VIS SCI, V41, P3713; McBrien NA, 2003, PROG RETIN EYE RES, V22, P307, DOI 10.1016/S1350-9462(02)00063-0; McBrien NA, 2001, INVEST OPHTH VIS SCI, V42, P2179; McBrien NA, 2013, EXP EYE RES, V114, P128, DOI 10.1016/j.exer.2013.01.014; NORTON TT, 1995, INVEST OPHTH VIS SCI, V36, pS760; Norton TT, 1996, INVEST OPHTH VIS SCI, V37, P1490; Onozuka I, 2011, BIOCHEM BIOPH RES CO, V406, P134, DOI 10.1016/j.bbrc.2011.02.012; Pardue MT, 2013, EXP EYE RES, V114, P96, DOI 10.1016/j.exer.2012.12.014; Phillips JR, 2000, INVEST OPHTH VIS SCI, V41, P2028; Qian LF, 2015, CELL BIOCHEM BIOPHYS, V71, P1373, DOI 10.1007/s12013-014-0359-9; RADA JA, 1995, INVEST OPHTH VIS SCI, V36, P1555; Rada JA, 2000, INVEST OPHTH VIS SCI, V41, P2050; Rada JA, 1999, INVEST OPHTH VIS SCI, V40, P3091; Rada JAS, 2006, EXP EYE RES, V82, P185, DOI 10.1016/j.exer.2005.08.009; Radbill BD, 2011, DIGEST DIS SCI, V56, P406, DOI 10.1007/s10620-010-1296-0; Schaeffel F, 2004, OPTOMETRY VISION SCI, V81, P99, DOI 10.1097/00006324-200402000-00008; Schippert R, 2006, EXP EYE RES, V82, P710, DOI 10.1016/j.exer.2005.09.010; Schippert R, 2007, INVEST OPHTH VIS SCI, V48, P11, DOI 10.1167/iovs.06-0851; Siegwart JT, 2001, INVEST OPHTH VIS SCI, V42, P1153; Wisard J, 2011, INVEST OPHTH VIS SCI, V52, P5804, DOI 10.1167/iovs.10-7129; Wollensak G, 2004, J CATARACT REFR SURG, V30, P689, DOI 10.1016/j.jcrs.2003.11.032; Yang Shu-ran, 2010, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V32, P55, DOI 10.3881/j.issn.1000-503X.2010.01.014; Zhou GM, 2001, MOL VIS, V7, P253; Zhou XT, 2012, MOL VIS, V18, P1312; Zhou XT, 2010, INVEST OPHTH VIS SCI, V51, P4362, DOI 10.1167/iovs.09-3998; Zhuang H, 2014, GRAEF ARCH CLIN EXP, V252, P1763, DOI 10.1007/s00417-014-2768-2; ZORN M, 1992, INVEST OPHTH VIS SCI, V33, P1053; Zou LL, 2014, MOL VIS, V20, P977	46	1	2	2	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1754	1767		10.1016/j.ajpath.2018.04.011			14	Pathology	Pathology	GP3SI	WOS:000440773100004	29803830				2019-10-28	
J	Yu, DL; Wang, YT; Yu, YJ; Zhong, YQ; Huang, LH; Zhang, MJ; Hu, LQ; Liu, XY; Gu, Y				Yu, Delong; Wang, Yuting; Yu, Yijun; Zhong, Yunqi; Huang, Lihua; Zhang, Mingjing; Hu, Liqun; Liu, Xiaoyan; Gu, Ye			Acute Beneficial Effects of Sodium Nitroprusside in a Rabbit Model of Massive Pulmonary Embolism Associated with Circulatory Shock	AMERICAN JOURNAL OF PATHOLOGY			English	Article							RIGHT-VENTRICULAR DYSFUNCTION; INHALED NITRIC-OXIDE; MANAGEMENT; HYPERTENSION	We established a rabbit model of acute massive pulmonary embolism (PE) with associated circulatory shock using autologous blood clots. Rabbits were randomly assigned to a sham operation group (S group), model group (M group; equal volume of saline intravenously after shock), and sodium nitroprusside group (SNP group; sodium nitroprusside intravenously after shock). SNP treatment significantly decreased mean pulmonary arterial pressure and increased mean arterial pressure and arterial partial pressure of oxygen and resulted in a partial reversal of the acute circulatory failure. The shock-reversal rate was 0% in the M group and 80% in the SNP group. Moreover, pulmonary artery angiography and echocardiography examinations evidenced alleviated PE-induced changes after SNP therapy. 5-Hydroxytryptamine was significantly reduced in both PE and non-PE tissues, thromboxane A(2) level was significantly reduced in PE and tended to be lower in non-PE tissues, neutrophil accumulation was significantly reduced in both PE and non-PE tissues after SNP therapy. Our study demonstrated that pulmonary vasospasm in the nonembolic region might be a major pathologic factor leading to reduced left ventricular filling and circulatory shock after massive PE. Reduction of pulmonary vasospasm in the nonembolic area after SNP might serve as a major therapeutic mechanism involved in the observed beneficial effects of SNP in this model.	[Yu, Delong; Wang, Yuting; Yu, Yijun; Zhong, Yunqi; Zhang, Mingjing; Hu, Liqun; Liu, Xiaoyan; Gu, Ye] Huazhong Univ Sci & Technol, Wuhan Puai Hosp, Dept Cardiol, Wuhan, Hubei, Peoples R China; [Huang, Lihua] Huazhong Univ Sci & Technol, Wuhan Puai Hosp, Dept Pathol, Wuhan, Hubei, Peoples R China	Gu, Y (reprint author), Huazhong Univ Sci & Technol, Puai Hosp, Dept Cardiol, HanZheng St 473, Wuhan 430033, Hubei, Peoples R China.	yegu2003cn@163.com			Nature Science Foundation (Hubei Province, China) [2015CFA081]	Supported by Nature Science Foundation (Hubei Province, China) grant 2015CFA081 (Y.G.).	Beam DM, 2015, COMPARATIVE MED, V65, P54; Chen HM, 2008, ULTRASOUND MED BIOL, V34, P221, DOI 10.1016/j.ultrasmedbio.2007.06.011; Dias CA, 2006, LIFE SCI, V79, P469, DOI 10.1016/j.lfs.2006.01.034; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; Kline JA, 2017, AM HEART J, V186, P100, DOI 10.1016/j.ahj.2017.01.011; Konstantinides SV, 2014, EUR HEART J, V35, P3033, DOI 10.1093/eurheartj/ehu283; Kudlicka J, 2013, PHYSIOL RES, V62, pS173; Lancellotti P, 2015, INT J CARDIOL, V197, P72, DOI 10.1016/j.ijcard.2015.06.035; LEE KY, 1983, CIRCULATION, V68, P1299, DOI 10.1161/01.CIR.68.6.1299; MCLEAN RF, 1990, ANESTH ANALG, V71, P35; Sanchez O, 2014, CURR OPIN PULM MED, V20, P393, DOI 10.1097/MCP.0000000000000089; Sousa-Santos O, 2013, THROMB RES, V132, P578, DOI 10.1016/j.thromres.2013.09.014; Tapson Victor F, 2012, F1000 Med Rep, V4, P9, DOI 10.3410/M4-9; Warntges S, 2015, CURR OPIN PULM MED, V21, P417, DOI 10.1097/MCP.0000000000000196; Wu J, 2016, SCI REP-UK, V6, DOI 10.1038/srep27493; Yan C, 2017, BIOMED RES INT, DOI 10.1155/2017/6516791; Zhao LB, 2015, THROMB RES, V135, P727, DOI 10.1016/j.thromres.2015.01.016	17	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1768	1778		10.1016/j.ajpath.2018.04.014			11	Pathology	Pathology	GP3SI	WOS:000440773100005	29803832	Other Gold			2019-10-28	
J	McDonald, WS; Jones, EE; Wojciak, JM; Drake, RR; Sabbadini, RA; Harris, NG				McDonald, Whitney S.; Jones, Elizabeth E.; Wojciak, Jonathan M.; Drake, Richard R.; Sabbadini, Roger A.; Harris, Neil G.			Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology	AMERICAN JOURNAL OF PATHOLOGY			English	Article							IMAGING MASS-SPECTROMETRY; SPINAL-CORD-INJURY; CONTROLLED CORTICAL IMPACT; SMOOTH-MUSCLE-CELLS; PHOSPHOLIPASE A(2); NEUROPATHIC PAIN; SUBARACHNOID HEMORRHAGE; INTRACELLULAR CALCIUM; THERAPEUTIC TARGET; RECEPTOR	Lysophosphatidic acid (LPA) levels increase in the cerebrospinal fluid and blood within 24 hours after traumatic brain injury (TBI), indicating it may be a biomarker for subsequent cellular pathology. However, no data exist that document this association after TBI. We, therefore, acquired matrix assisted laser desorption ionization imaging mass spectrometry data of LPA, major LPA metabolites, and hemoglobin from adult rat brains at 1 and 3 hours after controlled cortical impact injury. Data were semiquantitatively assessed by signal intensity analysis normalized to naive rat brains acquired concurrently. Gray and white matter pathology was assessed on adjacent sections using immunohistochemistry for cell death, axonal injury, and intracellular LPA, to determine the spatiotemporal patterning of LPA corresponding to pathology. The results revealed significant increases in LPA and LPA precursors at 1 hour after injury and robust enhancement in LPA diffusively throughout the brain at 3 hours after injury. Voxel-wise analysis of LPA by matrix-assisted laser desorption ionization and beta-amyloid precursor protein by immunohistochemistry in adjacent sections showed significant association, raising the possibility that LPA is linked to secondary axonal injury. Total LPA and metabolites were also present in remotely injured areas, including cerebellum and brain stem, and in particular thalamus, where intracellular LPA is associated with cell death. LPA may be a useful biomarker of cellular pathology after TBI.	[McDonald, Whitney S.; Harris, Neil G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Jones, Elizabeth E.; Drake, Richard R.] Med Univ South Carolina, Prote Ctr, Charleston, SC 29425 USA; [Wojciak, Jonathan M.; Sabbadini, Roger A.] Lpath Inc, San Diego, CA USA	Harris, NG (reprint author), UCLA, David Geffen Sch Med, Dept Neurosurg, 300 Stein Plaza,Ste 535,Box 956901, Los Angeles, CA 90095 USA.	ngharris@ucla.edu		Harris, Neil/0000-0002-1965-6750	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44 NS87641, R01 NS091222]; UCLA Brain Injury Research Center	Supported by NIH grants R44 NS87641 (R.A.S., N.G.H.) and R01 NS091222 (N.G.H.) and the UCLA Brain Injury Research Center.	Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Adibhatla Rao Muralikrishna, 2008, V49, P241, DOI 10.1007/978-1-4020-8831-5_9; Aichler M, 2015, LAB INVEST, V95, P422, DOI 10.1038/labinvest.2014.156; Anliker B, 2004, SEMIN CELL DEV BIOL, V15, P457, DOI 10.1016/j.semcdb.2004.05.005; Aoki J, 2008, BBA-MOL CELL BIOL L, V1781, P513, DOI 10.1016/j.bbalip.2008.06.005; Birgbauer E, 2006, CELL MOL LIFE SCI, V63, P2695, DOI 10.1007/s00018-006-6155-y; Bolen AL, 2011, J LIPID RES, V52, P958, DOI 10.1194/jlr.M013326; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Crack PJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-37; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Farooqui AA, 1997, J NEUROCHEM, V69, P889; Fernandis AZ, 2007, CURR OPIN LIPIDOL, V18, P121, DOI 10.1097/MOL.0b013e328082e4d5; Ferry G, 2003, J BIOL CHEM, V278, P18162, DOI 10.1074/jbc.M301158200; Fink KL, 2017, CELL REP, V18, P2687, DOI 10.1016/j.celrep.2017.02.058; Frisca F, 2013, J LIPID RES, V54, P1192, DOI 10.1194/jlr.M032284; Frugier T, 2011, CELL MOL NEUROBIOL, V31, P569, DOI 10.1007/s10571-011-9650-0; Furui T, 1999, CLIN CANCER RES, V5, P4308; Gessel M, 2015, J MASS SPECTROM, V50, P1288, DOI 10.1002/jms.3696; Gessel MM, 2014, J PROTEOMICS, V107, P71, DOI 10.1016/j.jprot.2014.03.021; Gierse J, 2010, J PHARMACOL EXP THER, V334, P310, DOI 10.1124/jpet.110.165845; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Goldshmit Y, 2012, AM J PATHOL, V181, P978, DOI 10.1016/j.ajpath.2012.06.007; Goldshmit Y, 2010, CELL TISSUE RES, V341, P23, DOI 10.1007/s00441-010-0977-5; Hasegawa Y, 2011, ACTA NEUROCHIR SUPPL, V110, P43, DOI 10.1007/978-3-7091-0353-1_8; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hildebrandt JP, 1997, GLIA, V19, P67, DOI 10.1002/(SICI)1098-1136(199701)19:1<67::AID-GLIA7>3.0.CO;2-7; Holschneider DP, 2013, J NEUROTRAUM, V30, P907, DOI 10.1089/neu.2012.2657; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Holtsberg FW, 1997, J NEUROCHEM, V69, P68; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Im DS, 2000, MOL PHARMACOL, V57, P753; Inoue M, 2008, NEUROSCIENCE, V152, P296, DOI 10.1016/j.neuroscience.2007.12.041; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jones EE, 2014, ANAL CHEM, V86, P8303, DOI 10.1021/ac501937d; Kadl A, 2004, ANTIOXID REDOX SIGN, V6, P311, DOI 10.1089/152308604322899378; Kagan VE, 2002, PHOSPHOLIPID METABOL; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Lai JM, 2001, BIOCHEM J, V359, P227, DOI 10.1042/0264-6021:3590227; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Ma L, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-29; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; Nagai J, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-78; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; On NH, 2013, J CEREB BLOOD FLOW M, V33, P1; Ostrowski RP, 2006, NEUROL RES, V28, P399, DOI 10.1179/016164106X115008; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Pages C, 2000, ANN NY ACAD SCI, V905, P159; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Roux A, 2016, J NEUROSCI METH, V272, P19, DOI 10.1016/j.jneumeth.2016.02.004; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Santos-Nogueira E, 2015, J NEUROSCI, V35, P10224, DOI 10.1523/JNEUROSCI.4703-14.2015; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shano S, 2008, NEUROCHEM INT, V52, P216, DOI 10.1016/j.neuint.2007.07.004; Shanta SR, 2011, ANAL CHEM, V83, P1252, DOI 10.1021/ac1029659; Shi H, 2015, EXP NEUROL, V272, P17, DOI 10.1016/j.expneurol.2015.03.017; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Spraggins JM, 2015, J AM SOC MASS SPECTR, V26, P974, DOI 10.1007/s13361-015-1147-5; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Steiner MR, 2002, BBA-MOL CELL BIOL L, V1582, P154, DOI 10.1016/S1388-1981(02)00150-6; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; Thomsen GM, 2014, STEM CELL RES, V13, P48, DOI 10.1016/j.scr.2014.04.013; Tigyi G, 1996, J NEUROCHEM, V66, P537; Titsworth WL, 2008, CNS NEUROL DISORD-DR, V7, P254, DOI 10.2174/187152708784936671; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Vereyken EJF, 2009, GLIA, V57, P1326, DOI 10.1002/glia.20852; Wang HYJ, 2012, ANAL BIOANAL CHEM, V404, P113, DOI 10.1007/s00216-012-6077-5; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Yalcin EB, 2015, J HISTOCHEM CYTOCHEM, V63, P762, DOI 10.1369/0022155415596202; Yano R, 2013, CELL MOL NEUROBIOL, V33, P1033, DOI 10.1007/s10571-013-9970-3; Ye XQ, 2002, BBA-MOL CELL BIOL L, V1585, P108, DOI 10.1016/S1388-1981(02)00330-X; Yoshida K, 2003, CIRCULATION, V108, P1746, DOI 10.1161/01.CIR.0000089374.35455.F3	82	0	0	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1779	1793		10.1016/j.ajpath.2018.05.00S			15	Pathology	Pathology	GP3SI	WOS:000440773100006	30037420				2019-10-28	
J	Batchu, SN; Dugbartey, GJ; Wadosky, KM; Mickelsen, DM; Ko, KA; Wood, RW; Zhao, YQ; Yang, X; Fowell, DJ; Korshunov, VA				Batchu, Sri N.; Dugbartey, George J.; Wadosky, Kristine M.; Mickelsen, Deanne M.; Ko, Kyung A.; Wood, Ronald W.; Zhao, Yuqi; Yang, Xia; Fowell, Deborah J.; Korshunov, Vyacheslav A.			Innate Immune Cells Are Regulated by Axl in Hypertensive Kidney	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SMOOTH-MUSCLE-CELLS; II-INDUCED HYPERTENSION; T-CELL; GENE-EXPRESSION; SYNTHETIC PHENOTYPE; VASCULAR INJURY; COMPLEMENT C3; ANGIOTENSIN; MICE; IDENTIFICATION	The balance between adaptive and innate immunity in kidney damage in salt-dependent hypertension is unclear. We investigated early renal dysfunction and the influence of Axl, a receptor tyrosine kinase, on innate immune response in hypertensive kidney in mice with lymphocyte deficiency (Ragl(-/-)). The data suggest that increased presence of CD11b(+) myeloid cells in the medulla might explain intensified salt and water retention as well as initial hypertensive response in Ragl(-/-) mice. Global deletion of Axl on Ragl(-/-) background reversed kidney dysfunction and accumulation of myeloid cells in the kidney medulla. Chimeric mice that tack Axl in innate immune cells (in the absence of lymphocytes) significantly improved kidney function and abolished early hypertensive response. The bioinformatics analyses of Axl-related gene-gene interaction networks established tissue-specific variation in regulatory pathways. It was confirmed that complement C3 is important for Axl-mediated interactions between myeloid and vascular cells in hypertensive kidney. In summary, innate immunity is crucial for renal dysfunction in early hypertension, and is highly influenced by the presence of Axl.	[Batchu, Sri N.; Dugbartey, George J.; Wadosky, Kristine M.; Mickelsen, Deanne M.; Ko, Kyung A.; Korshunov, Vyacheslav A.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; [Batchu, Sri N.; Dugbartey, George J.; Wadosky, Kristine M.; Mickelsen, Deanne M.; Ko, Kyung A.; Korshunov, Vyacheslav A.] Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, 601 Elmwood Ave,Box CVRI, Rochester, NY 14642 USA; [Wood, Ronald W.] Univ Rochester, Sch Med & Dent, Dept Obstet & Gynecol, Rochester, NY 14642 USA; [Korshunov, Vyacheslav A.] Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Rochester, NY 14642 USA; [Fowell, Deborah J.] Univ Rochester, Sch Med & Dent, Dept Microbiol & Immunol, Rochester, NY 14642 USA; [Fowell, Deborah J.] Univ Rochester, Sch Med & Dent, David H Smith Ctr Vaccine Biol & Immunol, Rochester, NY 14642 USA; [Zhao, Yuqi; Yang, Xia] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA USA; [Batchu, Sri N.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada; [Dugbartey, George J.] Univ Ghana, Sch Pharm, Dept Pharmacol & Toxicol, Legon, Ghana; [Wadosky, Kristine M.] Roswell Pk Canc Inst, Buffalo, NY USA; [Mickelsen, Deanne M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Korshunov, VA (reprint author), Univ Rochester, Sch Med & Dent, Aab Cardiovasc Res Inst, 601 Elmwood Ave,Box CVRI, Rochester, NY 14642 USA.	slava_korshunov@urmc.rochester.edu	Wadosky, Kristine/X-2968-2019; Wood, Ronald W/J-5481-2015; Zhao, Yuqi/L-5639-2016	Wadosky, Kristine/0000-0003-3952-9377; Wood, Ronald W/0000-0002-9691-5111; Zhao, Yuqi/0000-0003-0730-5854	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL105623, A1072690, DK104363]; American Heart AssociationAmerican Heart Association [13SDG17290032, 16POST31160044]	Supported by NIH grants HL105623 (V.A.K.), A1072690 (D.J.F.), and DK104363 (X.Y.); and American Heart Association grants 13SDG17290032 (X.Y.) and 16POST31160044 (Y.Z.).	Batchu N, 2013, HYPERTENSION, V62, P302, DOI 10.1161/HYPERTENSIONAHA.113.01382; Batchu SN, 2016, ARTERIOSCL THROM VAS, V36, P1638, DOI 10.1161/ATVBAHA.116.307848; Batchu SN, 2015, AM J PHYSIOL-HEART C, V309, pH1048, DOI 10.1152/ajpheart.00495.2015; Batchu SN, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001952; Chan CT, 2015, HYPERTENSION, V66, P1023, DOI 10.1161/HYPERTENSIONAHA.115.05779; Chessa F, 2016, KIDNEY INT, V89, P82, DOI 10.1038/ki.2015.292; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUID CAR US LAB AN 8; Deny JM, 2010, PLOS ONE, V5; Dimayuga P, 2002, ARTERIOSCL THROM VAS, V22, P644, DOI 10.1161/01.ATV.0000012455.62765.BF; Dimayuga PC, 2009, AM J PHYSIOL-REG I, V297, pR1593, DOI 10.1152/ajpregu.00114.2009; Dimayuga PC, 2005, ARTERIOSCL THROM VAS, V25, P2528, DOI 10.1161/01.ATV.0000190606.41121.00; EINSTEIN LP, 1977, J CLIN INVEST, V60, P963, DOI 10.1172/JCI108876; Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758; Fehrmann RSN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002197; Fujimori T, 2015, MUCOSAL IMMUNOL, V8, P1021, DOI 10.1038/mi.2014.129; Gerloff J, 2012, AM J PATHOL, V180, P2134, DOI 10.1016/j.ajpath.2012.01.036; Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259; Grobe JL, 2011, HYPERTENSION, V57, P600, DOI 10.1161/HYPERTENSIONAHA.110.165829; Guzik TJ, 2007, J EXP MED, V204, P2449, DOI 10.1084/jem.20070657; Han Y, 2012, AM J HYPERTENS, V25, P284, DOI 10.1038/ajh.2011.214; Harrison DG, 2012, CIRC RES, V110, P1543, DOI 10.1161/CIRCRESAHA.112.271411; HAUDENSCHILD CC, 1981, HYPERTENSION, V3, P148, DOI 10.1161/01.HYP.3.3_Pt_2.I148; Hoch NE, 2009, AM J PHYSIOL-REG I, V296, pR208, DOI 10.1152/ajpregu.90521.2008; Ji H, 2017, HYPERTENSION, V69, P1121, DOI 10.1161/HYPERTENSIONAHA.117.09063; Kessler MA, 1997, ANAL BIOCHEM, V248, P180, DOI 10.1006/abio.1997.2113; Kirabo A, 2014, J CLIN INVEST, V124, P4642, DOI 10.1172/JCI74084; Korshunov VA, 2007, HYPERTENSION, V50, P1057, DOI 10.1161/HYPERTENSIONAHA.107.096289; Lee IJ, 2015, CLIN IMMUNOL, V158, P231, DOI 10.1016/j.clim.2015.01.012; Lemke G, 2008, NAT REV IMMUNOL, V8, P327, DOI 10.1038/nri2303; Lin ZH, 2004, HYPERTENSION, V44, P42, DOI 10.1161/01.HYP.0000129540.83284.ca; Liu X, 2015, AM J HYPERTENS, V28, P1339, DOI 10.1093/ajh/hpv034; Maeda A, 2009, INT IMMUNOPHARMACOL, V9, P1183, DOI 10.1016/j.intimp.2009.06.006; Manhiani M, 2009, AM J PHYSIOL-RENAL, V297, pF740, DOI 10.1152/ajprenal.00098.2009; Mills CD, 2014, J INNATE IMMUN, V6, P716, DOI 10.1159/000364945; Park JK, 2009, HYPERTENSION, V54, P359, DOI 10.1161/HYPERTENSIONAHA.109.129460; Popovic ZV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00434-y; REID JL, 1975, CIRC RES, V37, P569, DOI 10.1161/01.RES.37.5.569; Rodriguez-Iturbe B, 2017, PHYSIOL REV, V97, P1127, DOI 10.1152/physrev.00031.2016; Ruan CC, 2010, ARTERIOSCL THROM VAS, V30, P2568, DOI 10.1161/ATVBAHA.110.215525; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Silva JL, 2011, MOL IMMUNOL, V48, P1835, DOI 10.1016/j.molimm.2011.05.008; Smolock EM, 2010, VASC PHARMACOL, V53, P185, DOI 10.1016/j.vph.2010.07.002; Stenvinkel P, 2010, J INTERN MED, V268, P456, DOI 10.1111/j.1365-2796.2010.02269.x; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Tu ZD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003107; Ueda Y, 1996, IMMUNOLOGY, V89, P183, DOI 10.1046/j.1365-2567.1996.d01-725.x; Wang SS, 2007, CIRC RES, V101, pE11, DOI 10.1161/CIRCRESAHA.107.152975; Wenzel U, 2016, J AM SOC NEPHROL, V27, P677, DOI 10.1681/ASN.2015050562; Yagil C, 2005, CIRC RES, V96, P617, DOI 10.1161/01.RES.0000160556.52369.61; Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693; Zhang JD, 2012, CIRC RES, V110, P1604, DOI 10.1161/CIRCRESAHA.111.261768; Zhou WD, 2006, BLOOD, V107, P2461, DOI 10.1182/blood-2005-08-3144; Zhu BH, 2002, ARTERIOSCL THROM VAS, V22, P450, DOI 10.1161/hq0302.105377; Zhu J, 2008, NAT GENET, V40, P854, DOI 10.1038/ng.167; Zhu J, 2007, PLOS COMPUT BIOL, V3, P692, DOI 10.1371/journal.pcbi.0030069	58	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1794	1806		10.1016/j.ajpath.2018.04.013			13	Pathology	Pathology	GP3SI	WOS:000440773100007	30033030	Green Published			2019-10-28	
J	Wang, JY; Kainrad, N; Shen, H; Zhou, Z; Rote, P; Zhang, YG; Nagy, LE; Wu, JS; You, M				Wang, Jiayou; Kainrad, Noah; Shen, Hong; Zhou, Zhou; Rote, Paula; Zhang, Yangiao; Nagy, Laura E.; Wu, Jiashin; You, Min			Hepatic Knockdown of Splicing Regulator Slu7 Ameliorates Inflammation and Attenuates Liver Injury in Ethanol-Fed Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ALCOHOLIC FATTY LIVER; PRE-MESSENGER-RNA; FACTOR HSLU7; HEPATOCELLULAR-CARCINOMA; DISEASE; LIPIN-1; SIRT1; STEATOHEPATITIS; ADIPOGENESIS; HEPATOCYTES	Aberrant precursor mRNA splicing plays a pivotal role in liver diseases. However, roles of splicing regulators in alcoholic liver disease are unknown. Herein, we investigated a splicing regulator, Slu7, in the development of alcoholic steatohepatitis. Adenovirus-mediated alteration of hepatic Slu7 expression in mice pair fed either with or without (as control) ethanol in their diet was used. Knockdown of hepatic Slu7 by adenovirus-Slu7shRNA treatment ameliorated inflammation and attenuated liver injury in mice after ethanol administration. Mechanistically, reducing liver Slu7 expression increased the expression of sirtuin 1 (SIRT1) full-length and repressed the splicing of SIRT1 into SIRT1-Delta Exon8 isoform in ethanol -fed mice. Knockdown of hepatic Slu7 in the ethanol -fed mice also ameliorated splicing of lipin-1 and serine/arginine-rich splicing factor 3 (Srsf3). In concordance with ameliorated splicing of SIRT1, lipin-1, and Srsf3, knockdown of hepatic Slu7 inhibited the activity of NF-kappa B, normalized iron and zinc homeostasis, reduced oxidative stress, and attenuated liver damage in ethanol-fed mice. In addition, hepatic Slu7 was significantly elevated in patients with alcoholic steatohepatitis. Our present study illustrates a novel role of Slu7 in alcoholic liver injury and suggests that dysregulated Slu7 may contribute to the pathogenesis of human alcoholic steatohepatitis.	[Wang, Jiayou; Kainrad, Noah; Shen, Hong; Zhou, Zhou; Wu, Jiashin; You, Min] Northeast Ohio Med Univ, Coll Pharm, Dept Pharmaceut Sci, 4209 State Rte 44, Rootstown, OH 44272 USA; [Rote, Paula; Zhang, Yangiao] Northeast Ohio Med Univ, Dept Integrat Med Sci, Rootstown, OH 44272 USA; [Wang, Jiayou] Guangzhou Univ Chinese Med, Sch Fundamental Med Sci, Dept Anat, Guangzhou, Guangdong, Peoples R China; [Shen, Hong] Guangdong Hosp Tradit Chinese Med Zhuhai, Dept Liver Dis, Zhuhai, Peoples R China; [Nagy, Laura E.] Cleveland Clin, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44106 USA	You, M (reprint author), Northeast Ohio Med Univ, Coll Pharm, Dept Pharmaceut Sci, 4209 State Rte 44, Rootstown, OH 44272 USA.	myou@neomed.edu		Rote, Paula/0000-0001-6453-7526	NIH/National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA015951, R01AA013623, P50AA024333, R21AA024946]	Supported, in part, by NIH/National Institute on Alcohol Abuse and Alcoholism grants R01AA015951 and R01AA013623 (M.Y.), P50AA024333 (L.E.N.), and R21AA024946 (Y.Z.).	Berasain C, 2010, WORLD J GASTROENTERO, V16, P3091, DOI 10.3748/wjg.v16.i25.3091; Bertola A, 2013, NAT PROTOC, V8, P627, DOI 10.1038/nprot.2013.032; Cai Y, 2016, AM J PATHOL, V186, P2417, DOI 10.1016/j.ajpath.2016.05.006; Castillo J, 2009, GASTROENTEROLOGY, V137, P1805, DOI 10.1053/j.gastro.2009.07.065; Chang HC, 2014, TRENDS ENDOCRIN MET, V25, P138, DOI 10.1016/j.tem.2013.12.001; Chen HQ, 2018, HEPATOLOGY, V68, P496, DOI 10.1002/hep.29849; Chua K, 1999, NATURE, V402, P207; Chua K, 1999, GENE DEV, V13, P841, DOI 10.1101/gad.13.7.841; Datz C, 2017, MINERVA ENDOCRINOL, V42, P173, DOI 10.23736/S0391-1977.16.02565-7; Elizalde M, 2014, J CLIN INVEST, V124, P2909, DOI 10.1172/JCI74382; Farooq MO, 2016, DIGEST DIS, V34, P347, DOI 10.1159/000444545; Gallego-Paez LM, 2017, HUM GENET, V136, P1015, DOI 10.1007/s00439-017-1790-y; Han GS, 2010, J BIOL CHEM, V285, P14628, DOI 10.1074/jbc.M110.117747; Harrison-Findik DD, 2007, WORLD J GASTROENTERO, V13, P4925, DOI 10.3748/wjg.v13.i37.4925; Hu M, 2013, HEPATOLOGY, V58, P1953, DOI 10.1002/hep.26589; Hu M, 2012, HEPATOLOGY, V55, P437, DOI 10.1002/hep.24708; Hu XD, 2016, J BIOL CHEM, V291, P22482, DOI 10.1074/jbc.M116.737015; James SA, 2002, RNA, V8, P1068, DOI 10.1017/S1355838202022033; Lareau LF, 2007, NATURE, V446, P926, DOI 10.1038/nature05676; Li Y, 2011, FASEB J, V25, P1664, DOI 10.1096/fj.10-173492; Lynch CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013502; Moreno-Navarrete JM, 2016, OBESITY, V24, P139, DOI 10.1002/oby.21334; McMullen MR, 2003, J BIOL CHEM, V278, P38333, DOI 10.1074/jbc.M304566200; Peterfy M, 2005, J BIOL CHEM, V280, P32883, DOI 10.1074/jbc.M503885200; Phan J, 2005, CELL METAB, V1, P73, DOI 10.1016/j.cmet.2004.12.002; Sen S, 2015, HEPATOLOGY, V61, P171, DOI 10.1002/hep.27380; Sen S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2342; Shomron N, 2005, J CELL SCI, V118, P1151, DOI 10.1242/jcs.01720; Shomron N, 2004, MOL BIOL CELL, V15, P3782, DOI 10.1091/mbc.E04-02-0152; Urtasun R, 2016, ONCOGENE, V35, P4719, DOI 10.1038/onc.2015.517; Xu JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep24277; Yin HQ, 2015, AM J PATHOL, V185, P1286, DOI 10.1016/j.ajpath.2015.01.030; Yin HQ, 2014, GASTROENTEROLOGY, V146, P801, DOI 10.1053/j.gastro.2013.11.008; You M, 2008, AM J PHYSIOL-GASTR L, V294, pG892, DOI 10.1152/ajpgi.00575.2007; You M, 2015, HEPATOBIL SURG NUTR, V4, P88, DOI 10.3978/j.issn.2304-3881.2014.12.06; Zhao WH, 2014, INT J MOL SCI, V15, P2946, DOI 10.3390/ijms15022946	36	1	1	2	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1807	1819		10.1016/j.ajpath.2018.05.004			13	Pathology	Pathology	GP3SI	WOS:000440773100008	29870742	Green Published			2019-10-28	
J	Duarte, S; Matian, P; Ma, S; Busuttil, RW; Coito, AJ				Duarte, Sergio; Matian, Patrick; Ma, Stacy; Busuttil, Ronald W.; Coito, Ana J.			Adeno-Associated Virus Mediated Gene Transfer of Tissue Inhibitor of Metalloproteinases-1 Impairs Neutrophil Extracellular Trap Formation and Ameliorates Hepatic Ischemia and Reperfusion Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INFLAMMATORY LIVER-INJURY; MATRIX METALLOPROTEINASES; ISCHEMIA/REPERFUSION INJURY; HEPATOCYTE TRANSDUCTION; TRANSGENE EXPRESSION; INNATE IMMUNITY; GELATINASE-B; TIMP-1; MICE; THERAPY	Matrix metalloproteinase-9 (MMP-9) is abundantly expressed by infiltrating leukocytes and contributes to the pathogenesis of hepatic ischemia and reperfusion injury (IRI). On the other hand, its physiological inhibitor, the tissue inhibitor of metalloproteinases-1 (TIMP-1), is available in insufficient levels to hamper MMP-9 activity during hepatic IRI. In this study, we generated recombinant adeno-associated virus type 8 vectors (rAAV8) encoding mouse TIMP-1 driven by a Liver specific thyroxine-binding globulin promoter as a strategy to increase the levels of TIMP-1 during liver IRI. Biodistribution analysis confirmed selective overexpression of TIMP-1 in livers of rAAV8-TIMP-1 vector treated C57BL/6 mice. rAAV8-TIMP-1-treated mice showed reduced MMP-9 activity, diminished leukocyte trafficking and activation, lowered transaminase levels, and improved histology after liver IRI. Moreover, the rAAV8-TIMP-1 vector therapy enhanced significantly the 7 day survival rate of TMIP-1(-/-) mice subjected to hepatic IRI. Neutrophils are the first cells recruited to inflamed tissues and, once activated, they release nuclear DNA-forming web-like structures, known as neutrophil extracellular traps. It was found that TIMP-1 has the ability to reduce formation of neutrophil extracellular traps and, consequently, limit the impact of neutrophil extra cellular trap mediated cytotoxicity in hepatic IRI. This is the first report demonstrating that TIMP-1 overexpression is hepatoprotective in ischemia and reperfusion injury. Hence, TIMP-1 may represent a promising molecule for drug development to treat Liver IRI.	[Duarte, Sergio; Matian, Patrick; Ma, Stacy; Busuttil, Ronald W.; Coito, Ana J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Liver & Pancreas Transplantat,Dumont UCLA Tra, Los Angeles, CA 90095 USA	Coito, AJ (reprint author), Dumont UCLA Transplant Ctr, 77-120 CHS,Box 957054, Los Angeles, CA 90095 USA.	acoito@mednet.ucla.edu			NIH, National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI057832]; American Society of Transplantation	Supported by the NIH, National Institute of Allergy and Infectious Diseases grant R01AI057832 (A.J.C.). S.D. received partial fellowship salary support from the American Society of Transplantation.	Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Bell P, 2011, MOL GENET METAB, V104, P395, DOI 10.1016/j.ymgme.2011.06.002; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Bramwell KKC, 2015, J IMMUNOL, V195, P1647, DOI 10.4049/jimmunol.1500212; Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987; Branzk N, 2013, SEMIN IMMUNOPATHOL, V35, P513, DOI 10.1007/s00281-013-0384-6; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Committee for the Update of the Guide for the Care and Use of Laboratory Animals;, 2011, NAT RES COUNC GUID C; de Vries MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047134; Duarte S, 2015, MATRIX BIOL, V44-46, P147, DOI 10.1016/j.matbio.2015.01.004; Duarte S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096913; Duarte S, 2012, HEPATOLOGY, V56, P1074, DOI 10.1002/hep.25710; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gardner J, 2003, J NEUROSCI RES, V74, P801, DOI 10.1002/jnr.10835; Gonzalez AS, 2014, METHODS MOL BIOL, V1124, P307, DOI 10.1007/978-1-62703-845-4_20; Guedez L, 2005, BLOOD, V105, P1660, DOI 10.1182/blood-2004-04-1385; Hamada T, 2008, HEPATOLOGY, V47, P186, DOI 10.1002/hep.21922; Henderson JM, 1999, HEPATO-GASTROENTEROL, V46, P1482; Hu C, 2012, GENE THER, V19, P1166, DOI 10.1038/gt.2011.200; Hu CH, 2010, J GENE MED, V12, P766, DOI 10.1002/jgm.1496; Huang H, 2015, HEPATOLOGY, V62, P600, DOI 10.1002/hep.27841; Iredale JP, 2017, DIGEST DIS, V35, P310, DOI 10.1159/000456581; Jackson HW, 2017, NAT REV CANCER, V17, P38, DOI 10.1038/nrc.2016.115; Jaeschke H, 2006, LIVER INT, V26, P912, DOI 10.1111/j.1478-3231.2006.01327.x; Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719; Kato H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137642; Kato H, 2014, J HEPATOL, V60, P1032, DOI 10.1016/j.jhep.2013.12.022; Kuyvenhoven JP, 2004, THROMB HAEMOSTASIS, V91, P506, DOI 10.1160/TH03-05-0272; Lingwal N, 2012, DIABETES, V61, P2045, DOI 10.2337/db11-1143; Liu FC, 2014, SHOCK, V41, P491, DOI 10.1097/SHK.0000000000000146; Martinod K, 2016, J THROMB HAEMOST, V14, P551, DOI 10.1111/jth.13239; Mook ORF, 2003, J HISTOCHEM CYTOCHEM, V51, P821, DOI 10.1177/002215540305100613; Moore C, 2007, AM J PATHOL, V170, P567, DOI 10.2353/ajpath.2007.060456; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; MUZYCZKA N, 1992, CURR TOP MICROBIOL, V158, P97; Nakai H, 2005, J VIROL, V79, P214, DOI 10.1128/JVI.79.1.214-224.2005; Naldini L, 2015, NATURE, V526, P351, DOI 10.1038/nature15818; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; Osawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065251; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Sands MS, 2011, METHODS MOL BIOL, V807, P141, DOI 10.1007/978-1-61779-370-7_6; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI [10.1089/neu.2009-0959, 10.1089/neu.2009.0959]; Turner RJ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00056; Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang B, 2000, P NATL ACAD SCI USA, V97, P13714, DOI 10.1073/pnas.240335297; Wang H, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-14; Yan ZH, 2012, GENE, V506, P289, DOI 10.1016/j.gene.2012.07.009	54	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1820	1832		10.1016/j.ajpath.2018.05.002			13	Pathology	Pathology	GP3SI	WOS:000440773100009	29870740	Green Published			2019-10-28	
J	Li, Y; Chao, XJ; Yang, L; Lu, Q; Li, TG; Ding, WX; Ni, HM				Li, Yuan; Chao, Xiaojuan; Yang, Li; Lu, Qian; Li, Tiangang; Ding, Wen-Xing; Ni, Hong-Min			Impaired Fasting-Induced Adaptive Lipid Droplet Biogenesis in Liver-Specific Atg5-Deficient Mouse Liver Is Mediated by Persistent Nuclear Factor-Like 2 Activation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DEFECTIVE HEPATIC AUTOPHAGY; TRANSCRIPTION FACTOR NRF2; DIET-INDUCED OBESITY; MITOCHONDRIAL-FUNCTION; MOLECULAR-MECHANISMS; INSULIN-RESISTANCE; SELF-DIGESTION; PPAR-ALPHA; MICE; STEATOSIS	Lipid droplets (LDs) are intracellular organelles that store neutral lipids as energy reservoir. Recent studies suggest that autophagy is important in maintaining the homeostasis of intracellular LDs by either regulating the biogenesis of LDs, mobilization of fatty acids, or degradation of LDs in cultured cells. Increasing evidence also supports a role of autophagy in regulating glucose and lipid metabolism in vivo in mammals. In response to fasting/starvation, lipids are mobilized from the adipose tissue to the liver, which increases the number of intracellular LDs and stimulates fatty acid oxidation and ketogenesis. However, it is still controversial and unclear how impaired autophagy in hepatocytes affects the biogenesis of LDs in mouse livers. In the present study, it was demonstrated that hepatic autophagy-deficient (L-Atg)5 knockout mice had impaired adaptation to fasting-induced hepatic biogenesis of LDs. The maladaptation to fasting-induced hepatic biogenesis of LDs in L-AtgS knockout mouse livers was not due to hepatic changes of de novo lipogenesis, secretion of very-low-density lipoprotein or fatty acid beta-oxidation, but it was due to persistent nuclear factor-like 2 activation because biogenesis of LDs restored in L-Atg5/nuclear factor-like 2 double-knockout mice.	[Li, Yuan; Chao, Xiaojuan; Li, Tiangang; Ding, Wen-Xing; Ni, Hong-Min] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, MS 1018,3901 Rainbow Blvd, Kansas City, KS 66160 USA; [Yang, Li; Lu, Qian] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai, Peoples R China	Ding, WX; Ni, HM (reprint author), Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, MS 1018,3901 Rainbow Blvd, Kansas City, KS 66160 USA.	wxding@kumc.edu; hni@kumc.edu	Li, Yuan/J-7786-2019	Li, Yuan/0000-0002-3171-8053	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AA 020518, R01 DK 102142, U01 AA 024733, P20 GM 103549, P30 GM 118247]; Centers for Biomedical Research Excellence (COBRE); University of Kansas Medical Center	Supported in part by NIH grants R01 AA 020518, R01 DK 102142, U01 AA 024733, P20 GM 103549, and P30 GM 118247 (W.-X.D.) and a pilot project from the Centers for Biomedical Research Excellence (COBRE) (H.-M.N.). Y.L. is a recipient of Biomedical Research Training Program funded by University of Kansas Medical Center.	Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Chartoumpekis DV, 2011, DIABETES, V60, P2465, DOI 10.2337/db11-0112; Czaja MJ, 2013, AUTOPHAGY, V9, P1131, DOI 10.4161/auto.25063; Ding WX, 2010, GASTROENTEROLOGY, V139, P1740, DOI 10.1053/j.gastro.2010.07.041; Ding WX, 2009, MOL CANCER THER, V8, P2036, DOI 10.1158/1535-7163.MCT-08-1169; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Dodson Matthew, 2017, Curr Pathobiol Rep, V5, P171, DOI 10.1007/s40139-017-0131-0; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Kim KH, 2013, NAT MED, V19, P83, DOI 10.1038/nm.3014; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li Y, 2017, AUTOPHAGY, V13, P1995, DOI 10.1080/15548627.2017.1371394; Lin CW, 2013, J HEPATOL, V58, P993, DOI 10.1016/j.jhep.2013.01.011; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Ma D, 2013, MOL ENDOCRINOL, V27, P1643, DOI 10.1210/me.2013-1153; Madrigal-Matute J, 2016, GASTROENTEROLOGY, V150, P328, DOI 10.1053/j.gastro.2015.09.042; Mei S, 2011, J PHARMACOL EXP THER, V339, P487, DOI 10.1124/jpet.111.184341; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nguyen TB, 2017, DEV CELL, V42, P9, DOI 10.1016/j.devcel.2017.06.003; Ni HM, 2014, J HEPATOL, V61, P617, DOI 10.1016/j.jhep.2014.04.043; Ni HM, 2012, TOXICOL SCI, V127, P438, DOI 10.1093/toxsci/kfs133; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Pol A, 2014, J CELL BIOL, V204, P635, DOI 10.1083/jcb.201311051; Ramadori P, 2016, FREE RADICAL BIO MED, V91, P114, DOI 10.1016/j.freeradbiomed.2015.12.014; Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029; Shibata M, 2009, BIOCHEM BIOPH RES CO, V382, P419, DOI 10.1016/j.bbrc.2009.03.039; Shin S, 2009, EUR J PHARMACOL, V620, P138, DOI 10.1016/j.ejphar.2009.08.022; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Sugimoto H, 2010, AM J PHYSIOL-GASTR L, V298, pG283, DOI 10.1152/ajpgi.00296.2009; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Williams JA, 2015, AM J PHYSIOL-GASTR L, V309, pG324, DOI 10.1152/ajpgi.00108.2015; Xu JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079841; Yang HY, 2012, CURR OPIN CELL BIOL, V24, P509, DOI 10.1016/j.ceb.2012.05.012; Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zechner R, 2017, NAT REV MOL CELL BIO, V18, P671, DOI 10.1038/nrm.2017.76; Zhang YKJ, 2010, TOXICOL APPL PHARM, V245, P326, DOI 10.1016/j.taap.2010.03.016	45	6	7	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1833	1846		10.1016/j.ajpath.2018.04.015			14	Pathology	Pathology	GP3SI	WOS:000440773100010	29803835	Green Published			2019-10-28	
J	Koeck, I; Gheinani, AH; Baumgartner, U; Vassella, E; Bruggmann, R; Burkhard, FC; Monastyrskaya, K				Koeck, Ivonne; Gheinani, Ali Hashemi; Baumgartner, Ulrich; Vassella, Erik; Bruggmann, Remy; Burkhard, Fiona C.; Monastyrskaya, Katia			Tumor Necrosis Factor-alpha Initiates miRNA-mRNA Signaling Cascades in Obstruction-Induced Bladder Dysfunction	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NF-KAPPA-B; OUTLET OBSTRUCTION; GENE-EXPRESSION; DOWN-REGULATION; IKK-BETA; MICRORNAS; MUSCLE; INFLAMMATION; ACTIVATION; PATHWAYS	Bladder outlet obstruction (BOO) and the ensuing clinical lower urinary tract dysfunction are common in elderly patients. BOO is accompanied by urodynamic changes in bladder function and Leads to organ fibrosis and ultimately loss of contractility. Comprehensive transcriptome analysis of bladder samples from human patients with different urodynamically defined phenotypes of BOO revealed tumor necrosis factor (TNF)-alpha as the top upstream signaling pathway regulator. Herein, we validated next-generation sequencing and pathway analysis in cell-based models using bladder smooth muscle and urothelial cells exposed to TNF-alpha. miRNA profiling and transcriptome analysis of TNF-alpha-treated bladder smooth muscle cells revealed striking similarities with human BOO. Using a comparative approach, TNF-specific and TNF-independent pathways were delineated in human biopsy specimens. Concomitant down-regulation of smooth muscle cell specific miRNAs and smooth muscle markers after TNF-alpha treatment was in accordance with the loss of contractility in humans in advanced obstruction induced bladder remodeling. The expression levels of four abundant TNF-regulated miRNAs were modulated; the compensatory up-regulation of miR-199a-5p reduced NF-kappa B signaling. Essential hubs of TNF-alpha signaling pathways mitogen-activated protein kinase kinase kinase (apoptosis signal-regulating kinase 1) and inhibitor of nuclear factor kappa B kinase subunit beta (I kappa B kinase beta) were targeted by miR-199a-5p. miR-199a-5p might be part of a negative feedback loop, reducing the impact of TNF, whereas its down regulation in acontractile bladders from BOO patients advances the disease. The compensatory up regulation of miR-199a-5p together with TNF-alpha inhibition may be therapeutically beneficial.	[Koeck, Ivonne; Gheinani, Ali Hashemi; Burkhard, Fiona C.; Monastyrskaya, Katia] Univ Bern, Urol Res Lab, Dept BioMed Res, Murtenstr 35, CH-3008 Bern, Switzerland; [Baumgartner, Ulrich; Vassella, Erik] Univ Bern, Inst Pathol, Bern, Switzerland; [Bruggmann, Remy] Univ Bern, Interfac Bioinformat Unit, Bern, Switzerland; [Burkhard, Fiona C.; Monastyrskaya, Katia] Univ Hosp Bern, Dept Urol, Bern, Switzerland	Monastyrskaya, K (reprint author), Univ Bern, Urol Res Lab, Dept BioMed Res, Murtenstr 35, CH-3008 Bern, Switzerland.	monastyk@dbmr.unibe.ch	Baumgartner, Ulrich/S-3863-2019	Baumgartner, Ulrich/0000-0001-8170-0567; Monastyrskaya, Katia/0000-0003-2042-1139	Swiss National Science FoundationSwiss National Science Foundation (SNSF) [320030_156161/1]; Velux Foundation [895]	Supported by the Swiss National Science Foundation grant 320030_156161/1 (K.M.) and the Velux Foundation grant 895 (K.M.).	Adegunsoye A, 2015, MEDIAT INFLAMM, DOI 10.1155/2015/510105; Ardekani Ali M., 2010, Avicenna Journal of Medical Biotechnology, V2, P161; Awad AS, 2015, KIDNEY INT, V88, P722, DOI 10.1038/ki.2015.162; Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293; Bechis SK, 2014, J UROLOGY, V192, P16, DOI 10.1016/j.juro.2014.01.114; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bielenberg DR, 2012, AM J PATHOL, V181, P548, DOI 10.1016/j.ajpath.2012.04.013; Burger ML, 2014, BLOOD, V123, P4089, DOI 10.1182/blood-2013-11-539411; Chancellor MB, 2014, INT UROL NEPHROL, V46, pS23, DOI 10.1007/s11255-014-0778-y; Chen JW, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2916-7; Chen R, 2008, ONCOGENE, V27, P4712, DOI 10.1038/onc.2008.112; Dai L, 2012, MOL HUM REPROD, V18, P136, DOI 10.1093/molehr/gar066; Djavan B, 2004, UROLOGY, V64, P1144, DOI 10.1016/j.urology.2004.08.049; Duan LJ, 2015, CELL SIGNAL, V27, P215, DOI 10.1016/j.cellsig.2014.11.001; Ekman M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082308; Findlay EG, 2012, MEDIAT INFLAMM, DOI 10.1155/2012/140937; Fiorillo AA, 2015, CELL REP, V12, P1678, DOI 10.1016/j.celrep.2015.07.066; Freire VS, 2010, AM J PATHOL, V176, P288, DOI 10.2353/ajpath.2010.090552; Frias B, 2011, CURR NEUROPHARMACOL, V9, P553, DOI 10.2174/157015911798376253; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Genemaras AA, 2016, J ORTHOP RES, V34, P779, DOI 10.1002/jor.23086; Gheinani AH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89560; Gheinani AH, 2013, CELL MOL LIFE SCI, V70, P3773, DOI 10.1007/s00018-013-1275-7; Gheinani AH, 2015, J BIOL CHEM, V290, P7067, DOI 10.1074/jbc.M114.618694; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Hakenberg OW, 2000, NEUROUROL URODYNAM, V19, P585, DOI 10.1002/1520-6777(2000)19:5<585::AID-NAU5>3.0.CO;2-U; Hayakawa R, 2012, P JPN ACAD B-PHYS, V88, P434, DOI 10.2183/pjab.88.434; Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023; Kanefsky J, 2006, AM J RESP CELL MOL, V34, P417, DOI 10.1165/rcmb.2005-0326OC; Karoor V, 2018, ARTERIOSCL THROM VAS, V38, P154, DOI 10.1161/ATVBAHA.117.310207; Khan MA, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-11; Koeck I, 2016, BIOCHEM PHARMACOL, V102, P7, DOI 10.1016/j.bcp.2015.09.012; Kojima M, 1997, J UROLOGY, V157, P476, DOI 10.1016/S0022-5347(01)65178-4; Kusakabe R, 2015, SEMIN CELL DEV BIOL, V47-48, P9, DOI 10.1016/j.semcdb.2015.10.020; Lapan B, 2017, J UROLOGY, V197, pE212, DOI 10.1016/j.juro.2017.02.591; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Ma XD, 2011, J MOL CELL BIOL, V3, P159, DOI 10.1093/jmcb/mjr007; Mace TA, 2013, J SURG RES, V184, P855, DOI 10.1016/j.jss.2013.04.061; McVary KT, 2006, AM J MANAG CARE, V12, pS122; Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005; Metcalfe PD, 2010, BJU INT, V106, P1686, DOI 10.1111/j.1464-410X.2010.09445.x; Mieczkowski J, 2015, ONCOTARGET, V6, P33077, DOI 10.18632/oncotarget.5310; Mirone V, 2007, EUR UROL, V51, P57, DOI 10.1016/j.eururo.2006.07.050; Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200; Mnich SJ, 2010, INT IMMUNOPHARMACOL, V10, P1170, DOI 10.1016/j.intimp.2010.06.023; Monastyrskaya K, 2013, AM J PATHOL, V182, P431, DOI 10.1016/j.ajpath.2012.10.020; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Sadegh MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116784; Sandoval J, 2016, J IMMUNOL, V197, P4137, DOI 10.4049/jimmunol.1502378; Schroder A, 2001, J UROLOGY, V165, P640, DOI 10.1097/00005392-200102000-00087; Sethu S, 2011, BIOSCIENCE REP, V31, P63, DOI 10.1042/BSR20100040; Shukla S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138710; Thomas AW, 2005, BJU INT, V96, P1301, DOI 10.1111/j.1464-410X.2005.05815.x; Vasquez E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90617; Wang ZW, 2012, DIABETES, V61, P2134, DOI 10.2337/db11-1763; Wiafe B, 2016, IN VITRO CELL DEV, V53, P58; Wilson AA, 2013, MOL THER, V21, P825, DOI 10.1038/mt.2013.19; Zhang S, 2012, AM J PATHOL, V181, P937, DOI 10.1016/j.ajpath.2012.05.035; Zhou L, 2017, NEUROUROL URODYNAM, V36, P1261, DOI 10.1002/nau.23104	61	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1847	1864		10.1016/j.ajpath.2018.05.008			18	Pathology	Pathology	GP3SI	WOS:000440773100011	29920227				2019-10-28	
J	Li, LM; Qi, LS; Qu, TY; Liu, CX; Cao, L; Huang, QJ; Song, WZ; Yang, LY; Qi, H; Wang, YL; Gao, B; Guo, YH; Sun, BC; Meng, B; Zhang, B; Cao, WF				Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Qi, Hui; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Zhang, Bin; Cao, Wenfeng			Epithelial Splicing Regulatory Protein 1 Inhibits the Invasion and Metastasis of Lung Adenocarcinoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TO-MESENCHYMAL TRANSITION; BREAST-CANCER; ESRP; PROGRESSION; MOTILITY; ADHESION; CELLS; EMT	Despite the development of various treatments, metastasis remains a significant problem with lung adenocarcinoma (ADC). The role and mechanism of epithelial splicing regulatory protein 1 (ESRP1), an epithelial-specific RNA binding protein, on promoting the invasion and metastasis of lung ADC remain to be fully elucidated. Immunohistochemical analysis in 125 human lung ADC tissue samples demonstrated that ESRP1 overexpression was inversely related to the presence of metastases, tumor size, and clinical stage of lung ADC. Impaired ESRP1 expression was also found to stimulate the invasion capacity of lung ADC cells both in vitro and in vivo. Functionally, overexpression of the ZEB1 gene decreased ESRP1 expression, and knockdown of the ZEB1 gene caused increased ESRP1 expression. On the basis of a gene array analysis, the expression of ESRP1 was associated with the regulation of the extracellular matrix. The expression of CD44 and fibroblast growth factor receptor, representatives that interact with the extracellular matrix, was studied. The CD44 subtypes promoted lung ADC cell invasion by regulating matrix metalloproteinase 2 expression. In conclusion, ESRP1 inhibits the invasion and metastasis of lung ADC and plays a role in regulating proteins involved in epithelial-to-mesenchymal transition.	[Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Cao, Wenfeng] Tianjin Med Univ Canc Inst & Hosp, Dept Pathol, Huanhuxi Rd, Tianjin 300060, Peoples R China; [Zhang, Bin] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Canc, Tianjin, Peoples R China; [Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Cao, Wenfeng] Tianjin Med Univ Canc Inst & Hosp, Natl Human Genet Resources Sharing Serv Plaffsonn, Tianjin, Peoples R China; [Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Zhang, Bin; Cao, Wenfeng] Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Zhang, Bin; Cao, Wenfeng] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Zhang, Bin; Cao, Wenfeng] Tianjin Med Univ, Minist Educ, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Li, Lingmei; Qi, Lisha; Qu, Tongyuan; Liu, Changxu; Cao, Lu; Huang, Qiujuan; Song, Wangzhao; Yang, Lingyi; Wang, Yalei; Gao, Bin; Guo, Yuhong; Sun, Baocun; Meng, Bin; Zhang, Bin; Cao, Wenfeng] Tianjin Med Univ, Minist Educ, Key Lab Breast Canc Prevent & Therapy, Tianjin, Peoples R China; [Qi, Hui] Tianjin Med Univ Gen Hosp, Dept Intens Care Med, Tianjin, Peoples R China	Cao, WF (reprint author), Tianjin Med Univ Canc Inst & Hosp, Dept Pathol, Huanhuxi Rd, Tianjin 300060, Peoples R China.	caowenfeng@tjmuch.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402420]; Tianjin Municipal Health Bureau Science and Technology Foundation [16KG125]; Tianjin Natural Science FoundationNatural Science Foundation of Tianjin [15JCQNJC12400]; Tumor Translational Medicine Seed Fund of Tianjin Medical University Cancer Institute and Hospital [1510]; Tianjin Municipal Health Bureau [2015KZ08]	Supported by National Natural Science Foundation of China grant 81402420 (W.C.), Tianjin Municipal Health Bureau Science and Technology Foundation grant 16KG125 (W.C.), Tianjin Natural Science Foundation grant 15JCQNJC12400 (W.C.), Tumor Translational Medicine Seed Fund of Tianjin Medical University Cancer Institute and Hospital grant 1510 (L.L.), and Tianjin Municipal Health Bureau grant 2015KZ08 (Y.W.).	Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Bojmar L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084815; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Dai J, 2016, TUMOR BIOL, V37, P12403, DOI 10.1007/s13277-016-5107-x; Deloria AJ, 2016, ONCOTARGET, V7, P73800, DOI 10.18632/oncotarget.12070; Desai A, 2016, CANCER BIOL MED, V13, P77, DOI 10.28092/j.issn.2095-3941.2016.0008; Dittmar KA, 2012, MOL CELL BIOL, V32, P1468, DOI 10.1128/MCB.06536-11; Dominguez C, 2010, NAT STRUCT MOL BIOL, V17, P853, DOI 10.1038/nsmb.1814; Dutertre M, 2010, RNA BIOL, V7, P403, DOI 10.4161/rna.7.4.12152; Fang WT, 2014, J THORAC DIS, V6, pS552, DOI 10.3978/j.issn.2072-1439.2014.06.09; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Hayakawa A, 2016, ADV EXP MED BIOL, V925, P33; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; Ishii H, 2014, J BIOL CHEM, V289, P27386, DOI 10.1074/jbc.M114.589432; Ishiwata T, 2016, PATHOL INT, V66, P601, DOI 10.1111/pin.12447; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Larsen JE, 2016, J CLIN INVEST, V126, P3219, DOI 10.1172/JCI76725; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Leontieva OV, 2009, CELL CYCLE, V8, P490, DOI 10.4161/cc.8.3.7679; Li LM, 2015, INT J MOL MED, V36, P113, DOI 10.3892/ijmm.2015.2222; Masuda A, 2016, WIRES RNA, V7, P330, DOI 10.1002/wrna.1338; Qi LS, 2016, ONCOTARGET, V7, P74015, DOI 10.18632/oncotarget.12187; Reinke LM, 2012, J BIOL CHEM, V287, P36435, DOI 10.1074/jbc.M112.397125; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Thiery JP, 2009, B ACAD NAT MED PARIS, V193, P1969, DOI 10.1016/S0001-4079(19)32372-6; Thiery JP, 2009, B ACAD NATL MED, V193, P1978; Ueda J, 2014, ONCOGENE, V33, P4485, DOI 10.1038/onc.2013.392; Voena C, 2016, ONCOTARGET, V7, P33316, DOI 10.18632/oncotarget.8955; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Witten JT, 2011, TRENDS GENET, V27, P89, DOI 10.1016/j.tig.2010.12.001; Yao J, 2016, CANCER IMMUNOL RES, V4, P552, DOI 10.1158/2326-6066.CIR-15-0255	34	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1882	1894		10.1016/j.ajpath.2018.04.012			13	Pathology	Pathology	GP3SI	WOS:000440773100013	29803834				2019-10-28	
J	Molina, L; Bell, D; Tao, JY; Preziosi, M; Pradhan-Sundd, T; Singh, S; Poddar, M; Luo, JH; Ranganathan, S; Chikina, M; Monga, SP				Molina, Laura; Bell, Danielle; Tao, Junyan; Preziosi, Morgan; Pradhan-Sundd, Tirthadipa; Singh, Sucha; Poddar, Minakshi; Luo, Jianhua; Ranganathan, Sarangarajan; Chikina, Maria; Monga, Satdarshan P.			Hepatocyte-Derived Lipocalin 2 Is a Potential Serum Biomarker Reflecting Tumor Burden in Hepatoblastoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GELATINASE-ASSOCIATED LIPOCALIN; ACUTE KIDNEY INJURY; TO-MESENCHYMAL TRANSITION; WNT/BETA-CATENIN; BETA-CATENIN; PROGNOSTIC-FACTORS; COLORECTAL-CANCER; LIVER; NGAL; GROWTH	Hepatoblastoma (HB) is the most common pediatric liver malignant tumor. Previously, we reported co-activation of beta-catenin and Yes-associated protein-1 (YAP1) in 80% of HB. Hepatic co-expression of active beta-catenin and YAP1 via sleeping beauty transposon/transposase and hydrodynamic tail vein injection led to HB development in mice. Here, we identify lipocalin 2 (Lcn2) as a target of beta-catenin and YAP1 in HB and show that serum Lcn2 values positively correlated with tumor burden. Lcn2 was strongly expressed in HB tumor cells in our mouse model. A tissue array of 62 HB cases showed highest LCN2 expression in embryonal and lowest in fetal, blastemal, and small cell undifferentiated forms of HB. Knockdown of LCN2 in HB cells had no effect on cell proliferation but reduced NE-kappa B reporter activity. Next, liver-specific Lcn2 knockout (KO) mice were generated. No difference in tumor burden was observed between Lcn2 KO mice and wild-type littermate controls after sleeping beauty transposon/transposase and hydrodynamic tail vein injection delivery of active YAP1 and beta-catenin, although Lcn2 KO mice with HB lacked any serum Lcn2 elevation, demonstrating that transformed hepatocytes are the source of serum Lcn2. More blastemal areas and inflammation were observed within HB in Lcn2 KO compared with wild-type tumors. In conclusion, Lcn2 expressed in hepatocytes appears to be dispensable for the pathogenesis of HB. However, transformed hepatocytes secrete serum Lcn2, making Lcn2 a valuable biomarker for HB.	[Molina, Laura; Tao, Junyan; Preziosi, Morgan; Pradhan-Sundd, Tirthadipa; Singh, Sucha; Poddar, Minakshi; Luo, Jianhua; Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, Div Expt Pathol, Dept Pathol, Pittsburgh, PA 15261 USA; [Chikina, Maria] Univ Pittsburgh, Sch Med, Dept Computat & Syst Biol, Pittsburgh, PA 15261 USA; [Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, Pittsburgh, PA 15261 USA; [Molina, Laura; Bell, Danielle; Tao, Junyan; Preziosi, Morgan; Pradhan-Sundd, Tirthadipa; Singh, Sucha; Poddar, Minakshi; Luo, Jianhua; Ranganathan, Sarangarajan; Chikina, Maria; Monga, Satdarshan P.] Univ Pittsburgh, Med Ctr, Pittsburgh Liver Res Ctr, Pittsburgh, PA 15261 USA; [Molina, Laura; Bell, Danielle; Tao, Junyan; Preziosi, Morgan; Pradhan-Sundd, Tirthadipa; Singh, Sucha; Poddar, Minakshi; Luo, Jianhua; Ranganathan, Sarangarajan; Chikina, Maria; Monga, Satdarshan P.] Univ Pittsburgh, Sch Med, 200 Lothrop St,S-422 BST, Pittsburgh, PA 15261 USA; [Bell, Danielle] Childrens Hosp Pittsburgh, Div Hematol Oncol, Dept Pediat, Pittsburgh, PA 15213 USA; [Ranganathan, Sarangarajan] Childrens Hosp Pittsburgh, Div Pediat Pathol, Dept Pathol, Pittsburgh, PA 15213 USA	Monga, SP (reprint author), Univ Pittsburgh, Sch Med, 200 Lothrop St,S-422 BST, Pittsburgh, PA 15261 USA.	smonga@pitt.edu		Monga, Satdarshan/0000-0002-8437-3378; Molina, Laura/0000-0002-3750-6561	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01DK62277, 1R01DK100287, 1R01CA204586]; Endowed Chair for Experimental Pathology; Cellular Approaches to Tissue Engineering and Regeneration grant [T32 EB001026]	Supported by NIH grants 1R01DK62277 (S.P.M.), 1R01DK100287 (S.P.M.), and 1R01CA204586 (S.P.M.), Endowed Chair for Experimental Pathology (S.P.M.), and in part by Cellular Approaches to Tissue Engineering and Regeneration grant T32 EB001026 (L.M.).	Aretz S, 2006, PEDIATR BLOOD CANCER, V47, P811, DOI 10.1002/pbc.20698; Asimakopoulou A, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00430; Bauer M, 2008, BREAST CANCER RES TR, V108, P389, DOI 10.1007/s10549-007-9619-3; Bell Danielle, 2017, Gene Expression, V17, P141, DOI 10.3727/105221616X693639; Cairo Stefano, 2012, Front Biosci (Elite Ed), V4, P480; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Candido S, 2014, ONCOTARGET, V5, P1576, DOI 10.18632/oncotarget.1738; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUID CAR US LAB AN 8; Czauderna P, 2016, EUR J CANCER, V52, P92, DOI 10.1016/j.ejca.2015.09.023; Dan YY, 2006, P NATL ACAD SCI USA, V103, P9912, DOI 10.1073/pnas.0603824103; Darbari A, 2003, HEPATOLOGY, V38, P560, DOI 10.1053/jhep.2003.50375; Devarajan P, 2008, AM J KIDNEY DIS, V52, P395, DOI 10.1053/j.ajkd.2008.07.008; Feng MB, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0564-9; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Guo H, 2014, MOL ENDOCRINOL, V28, P1616, DOI 10.1210/me.2014-1092; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Kienzl-Wagner K, 2015, LIVER INT, V35, P1195, DOI 10.1111/liv.12634; Kim Hyun-Ju, 2016, J Bone Metab, V23, P8, DOI 10.11005/jbm.2016.23.1.8; Kim SL, 2017, CANCER SCI, V108, P2176, DOI 10.1111/cas.13389; Koch A, 2004, J PATHOL, V204, P546, DOI 10.1002/path.1662; Koch A, 1999, CANCER RES, V59, P269; Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466; Lannetti A, 2008, P NATL ACAD SCI USA, V105, P14058, DOI 10.1073/pnas.0710846105; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Lopez-Terrada D, 2014, MODERN PATHOL, V27, P472, DOI 10.1038/modpathol.2013.80; Mahadevan NR, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-229; McLaughlin CC, 2006, AM J EPIDEMIOL, V163, P818, DOI 10.1093/aje/kwj104; Meyers RL, 2009, PEDIATR BLOOD CANCER, V53, P1016, DOI 10.1002/pbc.22088; Mishra J, 2006, PEDIATR NEPHROL, V21, P856, DOI 10.1007/s00467-006-0055-0; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; Nejak-Bowen Kari, 2017, Gene Expression, V17, P219, DOI 10.3727/105221617X695762; Ozemir Ibrahim Ali, 2016, Chirurgia (Bucur), V111, P414, DOI 10.21614/chirurgia.111.5.414; Perilongo G, 2000, CANCER-AM CANCER SOC, V89, P1845, DOI 10.1002/1097-0142(20001015)89:8<1845::AID-CNCR27>3.0.CO;2-D; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodvold JJ, 2012, CANCER LETT, V316, P132, DOI 10.1016/j.canlet.2011.11.002; Roli L, 2017, INT J BIOL MARKER, V32, pE53, DOI 10.5301/jbm.5000245; Sandberg R, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-48; Tan XP, 2006, GASTROENTEROLOGY, V131, P1561, DOI 10.1053/j.gastro.2006.08.042; Tang HC, 2016, J MOL MODEL, V22, DOI 10.1007/s00894-015-2897-5; Tao JY, 2014, GASTROENTEROLOGY, V147, P690, DOI 10.1053/j.gastro.2014.05.004; Tong ZM, 2008, CANCER RES, V68, P6100, DOI 10.1158/0008-5472.CAN-08-0540; Wang Y, 2014, GENET MOL RES, V13, P7102, DOI 10.4238/2014.February.21.11; Wang Y, 2013, BIOMED REP, V1, P479, DOI [10.3892/br.2013.89, 10.3892/br.2012.1]; Wang YP, 2013, HEPATOLOGY, V58, P1349, DOI 10.1002/hep.26467; Wheeler DS, 2008, CRIT CARE MED, V36, P1297, DOI 10.1097/CCM.0b013e318169245a; Xu B, 2013, WORLD J SURG, V37, P1892, DOI 10.1007/s00268-013-2009-6; Xu MJ, 2015, HEPATOLOGY, V61, P692, DOI 10.1002/hep.27447; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhou FF, 2016, EUR J CARDIO-THORAC, V49, P746, DOI 10.1093/ejcts/ezv199	52	1	2	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1895	1909		10.1016/j.ajpath.2018.05.006			15	Pathology	Pathology	GP3SI	WOS:000440773100014	29920228	Green Published			2019-10-28	
J	Borcherding, N; Cole, K; Kluz, P; Jorgensen, M; Kolb, R; Bellizzi, A; Zhang, WZ				Borcherding, Nicholas; Cole, Kimberly; Kluz, Paige; Jorgensen, Michael; Kolb, Ryan; Bellizzi, Andrew; Zhang, Weizhou			Re-Evaluating E-Cadherin and beta-Catenin A Pan-Cancer Proteomic Approach with an Emphasis on Breast Cancer	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INVASIVE LOBULAR CARCINOMA; DUCTAL CARCINOMA; N-CADHERIN; IN-SITU; MESENCHYMAL TRANSITION; POOR-PROGNOSIS; GASTRIC-CANCER; STEM-CELLS; EXPRESSION; METASTASIS	E-cadherin is conventionally considered to be a good prognostic marker in cancer. The Loss of E-cadherin is one of the key hallmarks of epithelial-to-mesenchymal transition, a biological process that promotes cancer cell invasiveness and metastasis. Recent evidence has cast doubt on the importance of epithelial-to-mesenchymal transition in metastasis. The availability of protein-level data in the Cancer Genome Atlas allows for the quantitative analysis of protein and prognosis. The prognostic values of E-cadherin and beta-catenin were revisited across 19 cancer types, and high E-cadherin was found to correlate with good prognosis in most cancers. Conversely, higher E-cadherin and beta-catenin correlated with shorter survival in invasive breast carcinoma. Stratifying breast cancers by histologic subtype revealed that the poor prognosis of E-cadherin and beta-catenin proteins was characteristic of infiltrating ductal, but not lobular, carcinomas. To further corroborate the protein findings and examine cellular Localization, immunohistochemistry was used for E-cadherin and p-catenin in 163 breast patient samples from the Iowa cohort. Most previous studies showing that reduced or absent E-cadherin and beta-catenin was inversely associated with tumor stages in ductal carcinomas were confirmed. Taken together, these results lead us to question the prognostic values of E-cadherin and beta-catenin in ductal carcinomas and indicate a complicated role of E-cadherin and beta-catenin in breast cancer progression.	[Borcherding, Nicholas; Cole, Kimberly; Kluz, Paige; Jorgensen, Michael; Kolb, Ryan; Bellizzi, Andrew; Zhang, Weizhou] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; [Borcherding, Nicholas; Zhang, Weizhou] Univ Iowa, Coll Med, Canc Biol Grad Program, Iowa City, IA 52242 USA; [Borcherding, Nicholas; Zhang, Weizhou] Univ Iowa, Coll Med, Med Scientist Training Program, Iowa City, IA 52242 USA; [Borcherding, Nicholas; Kolb, Ryan; Bellizzi, Andrew; Zhang, Weizhou] Univ Iowa, Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Kluz, Paige; Zhang, Weizhou] Univ Iowa, Coll Med, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	Bellizzi, A; Zhang, WZ (reprint author), Univ Iowa, Dept Pathol, 375 Newton Rd,MERF 4202, Iowa City, IA 52242 USA.	andrew-bellizzi@uiowa.edu; weizhou-zhang@uiowa.edu		Kolb, Ryan/0000-0001-6305-2885; Bellizzi, Andrew/0000-0002-8264-6379	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 CA200673, F30 CA206255, T32 AI007260]; Oberley Award; Cancer and Aging Award; National Cancer Institute of the NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA086862]	Supported by NIH grants R01 CA200673 (W.Z.), F30 CA206255 (N.B.), and T32 AI007260 (R.K.). This work benefited from an Oberley Award, Cancer and Aging Award, and National Cancer Institute of the NIH award P30CA086862.	ElMoneim HMA, 2011, CLINICS, V66, P1765, DOI 10.1590/S1807-59322011001000015; ABERLE H, 1994, J CELL SCI, V107, P3655; Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Adachi Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2275-4; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Arpino G, 2004, BREAST CANCER RES, V6, pR149, DOI 10.1186/bcr767; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bremnes RM, 2002, LUNG CANCER-J IASLC, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; BRINGUIER PP, 1993, CANCER RES, V53, P3241; Brzozowska A, 2012, ANN AGR ENV MED, V19, P541; Bukholm IK, 1998, J PATHOL, V185, P262, DOI 10.1002/(SICI)1096-9896(199807)185:3<262::AID-PATH97>3.0.CO;2-Y; Chen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103952; Chen ZL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182397; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dabbs DJ, 2007, AM J SURG PATHOL, V31, P427, DOI 10.1097/01.pas.0000213386.63160.3f; DeLeeuw WJF, 1997, J PATHOL, V183, P404, DOI 10.1002/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9; Dillon DA, 1998, AM J PATHOL, V152, P75; Dolled-Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008-5472.CAN-06-0100; DORUDI S, 1993, AM J PATHOL, V142, P981; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gillett CE, 2001, J PATHOL, V193, P433, DOI 10.1002/path.831; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Gonzalez MA, 1999, J PATHOL, V187, P523, DOI 10.1002/(SICI)1096-9896(199904)187:5<523::AID-PATH296>3.0.CO;2-3; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070858; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KATAGIRI A, 1995, BRIT J CANCER, V71, P376, DOI 10.1038/bjc.1995.76; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Klemm F, 2011, CARCINOGENESIS, V32, P434, DOI 10.1093/carcin/bgq269; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Li CI, 2003, ARCH INTERN MED, V163, P2149, DOI 10.1001/archinte.163.18.2149; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P1421, DOI 10.1001/jama.289.11.1421; Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]; Li Z, 2017, ONCOTARGET, V8, P16445, DOI 10.18632/oncotarget.14860; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; MAYER B, 1993, CANCER RES, V53, P1690; Nakagawa M, 2011, ANTICANCER RES, V31, P2389; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; OKA H, 1993, CANCER RES, V53, P1696; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rothberg BEG, 2006, BREAST CANCER RES TR, V100, P139, DOI 10.1007/s10549-006-9248-2; Sarrio D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197; Shamir ER, 2015, CURR TOP DEV BIOL, V112, P353, DOI 10.1016/bs.ctdb.2014.12.001; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; Sottoriva A, 2013, P NATL ACAD SCI USA, V110, P4009, DOI 10.1073/pnas.1219747110; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tan PH, 2013, AM J SURG PATHOL, V37, P1518, DOI 10.1097/PAS.0b013e318299f12e; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Toikkanen S, 1997, BRIT J CANCER, V76, P1234, DOI 10.1038/bjc.1997.540; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tung B, 2017, P NATL ACAD SCI USA, V114, pE707, DOI 10.1073/pnas.1610383114; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; UMBAS R, 1994, CANCER RES, V54, P3929; Xie YP, 2017, ONCOTARGET, V8, P62489, DOI 10.18632/oncotarget.19934; Xing XB, 2013, INT J CANCER, V132, P2589, DOI 10.1002/ijc.27947; Yoshida R, 2001, INT J ONCOL, V18, P513; Zheng XQ, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1143-5; Zschiesche W, 1997, ANTICANCER RES, V17, P561	69	1	1	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1910	1920		10.1016/j.ajpath.2018.05.003			11	Pathology	Pathology	GP3SI	WOS:000440773100015	29879416	Green Published			2019-10-28	
J	Kumaradevan, S; Lee, SY; Richards, S; Lyle, C; Zhao, Q; Tapan, U; Jiangliu, YL; Ghumman, S; Walker, J; Belghasem, M; Arinze, N; Kuhnen, A; Weinberg, J; Francis, J; Hartshorn, K; Kolachalama, VB; Cifuentes, D; Rahimi, N; Chitalia, VC				Kumaradevan, Sowmiya; Lee, Shin Yin; Richards, Sean; Lyle, Chimera; Zhao, Qing; Tapan, Umit; Jiangliu, Yilan; Ghumman, Shmyle; Walker, Joshua; Belghasem, Mostafa; Arinze, Nkiruka; Kuhnen, Angela; Weinberg, Janice; Francis, Jean; Hartshorn, Kevan; Kolachalama, Vijaya B.; Cifuentes, Daniel; Rahimi, Nader; Chitalia, Vipul C.			c-Cbl Expression Correlates with Human Colorectal Cancer Survival and Its Wnt/beta-Catenin Suppressor Function Is Regulated by Tyr371 Phosphorylation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; NUCLEAR BETA-CATENIN; COLON-CANCER; TYROSINE KINASES; E3 LIGASE; ACTIVATION; MET; UBIQUITINATION; CELLS; TRANSCRIPTION	The proto-oncogene beta-catenin drives colorectal cancer (CRC) tumorigenesis. Casitas B-lineage lymphoma (c-Cbl) inhibits CRC tumor growth through targeting nuclear beta-catenin by a poorly understood mechanism. In addition, the role of c-Cbl in human CRC remains largely underexplored. Using a novel quantitative histopathologic technique, we demonstrate that patients with high c-Cbl expressing tumors had significantly better median survival (3.7 years) compared with low c-Cbl expressing tumors (1.8 years; P = 0.0026) and were more than twice as likely to be alive at 3 years compared with low c-Cbl tumors (P = 0.0171). Our data further demonstrate that c-Cbl regulation of nuclear beta-catenin requires phosphorylation of c-Cbl Tyr371 because its mutation compromises its ability to target beta-catenin. The tyrosine 371 (Y371H) mutant interacted with but failed to ubiquitinate nuclear beta-catenin. The nuclear localization of the c-Cbl Y371H mutant contributed to its dominant negative effect on nuclear beta-catenin. The biological importance of c-Cbl Y371H was demonstrated in various systems, including a transgenic Wnt-8 zebrafish model. c-Cbl Y371H mutant showed augmented Wnt/beta-catenin signaling, increased Wnt target genes, angiogenesis, and CRC tumor growth. This study demonstrates a strong link between c-Cbl and overall survival of patients with CRC and provides new insights into a possible role of Tyr371 phosphorylation in Wnt/beta-catenin regulation, which has important implications in tumor growth and angiogenesis in CRC.	[Kumaradevan, Sowmiya; Richards, Sean; Lyle, Chimera; Jiangliu, Yilan; Ghumman, Shmyle; Walker, Joshua; Francis, Jean; Chitalia, Vipul C.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Zhao, Qing; Belghasem, Mostafa; Rahimi, Nader] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Arinze, Nkiruka; Kuhnen, Angela; Chitalia, Vipul C.] Boston Univ, Sch Med, Dept Surg, Boston, MA 02118 USA; [Cifuentes, Daniel] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Lee, Shin Yin; Tapan, Umit; Hartshorn, Kevan] Boston Univ, Sch Med, Hematol & Oncol Sect, Boston, MA 02118 USA; [Kolachalama, Vijaya B.] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA; [Weinberg, Janice] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA	Chitalia, VC (reprint author), Boston Univ, Med Ctr, Dept Med, Evans Biomed Res Ctr, X-530, Boston, MA 02118 USA.	vichital@bu.edu	Francis, Jean M/O-9968-2017	Weinberg, Janice/0000-0002-3503-0061; Rahimi, Nader/0000-0002-6745-1725	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [RO1CA175382]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL132325, R21CA191970, R21CA193958, R00HD071968-03]; Boston University Evans Faculty Merit award; Hariri Research Award from the Hariri Institute of Computing, Boston University [2016-10-009]; American Heart Association's Scientist Development GrantAmerican Heart Association [17SDG33670323]; American Heart Association's T32 training in renal biology grant [T32 DK007053-44]; American Heart Association's T32 training in cardiovascular biology grant [T32 HL007224-40]; American Heart Association's T32 training in immunobiology of trauma grant [T32 GM086308-06A1]; Undergraduate Research Opportunities Program award from Boston University	Supported by National Cancer Institute grant RO1CA175382 (V.C.C.), NIH grants R01 HL132325 (V.C.C.), R21CA191970 (N.R.), R21CA193958 (N.R.), and R00HD071968-03 (D.C.), the Boston University Evans Faculty Merit award (V.C.C.), Hariri Research Award 2016-10-009 from the Hariri Institute of Computing, Boston University (V.B.K.), American Heart Association's Scientist Development Grant 17SDG33670323 (V.B.K.), T32 training in renal biology grant T32 DK007053-44 (C.L.), T32 training in cardiovascular biology grant T32 HL007224-40 (J.W.), T32 training in immunobiology of trauma grant T32 GM086308-06A1 (N.A.), and Undergraduate Research Opportunities Program award from Boston University (S.G. and Y.J.).	Asbagh LA, 2014, ONCOTARGET, V5, P10070, DOI 10.18632/oncotarget.2458; Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978-1-59745-249-6_8; Cai PF, 2014, BIOMED PHARMACOTHER, V68, P285, DOI 10.1016/j.biopha.2013.10.012; Catenacci DVT, 2011, SEMIN ONCOL, V38, P284, DOI 10.1053/j.seminoncol.2011.01.001; Chen JZ, 2014, CLIN COLORECTAL CANC, V13, P5, DOI 10.1016/j.clcc.2013.10.003; Chitalia V, 2013, J BIOL CHEM, V288, P23505, DOI 10.1074/jbc.M113.473801; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Dejana E, 2010, CIRC RES, V107, P943, DOI 10.1161/CIRCRESAHA.110.223750; Dou H, 2012, NAT STRUCT MOL BIOL, V19, P184, DOI 10.1038/nsmb.2231; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Goessling W, 2008, DEV BIOL, V320, P161, DOI 10.1016/j.ydbio.2008.05.526; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Hartsough EJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004289; Herbst A, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-74; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hou PC, 2017, CANCER RES, V77, P4305, DOI 10.1158/0008-5472.CAN-16-2990; Kassenbrock CK, 2004, J BIOL CHEM, V279, P28017, DOI 10.1074/jbc.M404114200; Kircher SM, 2016, CANCER J, V22, P182, DOI 10.1097/PPO.0000000000000192; Kos Marek, 2002, Ann Univ Mariae Curie Sklodowska Med, V57, P556; Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144; Lai AZ, 2012, J BIOL CHEM, V287, P8048, DOI 10.1074/jbc.M112.339820; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mohapatra B, 2013, BBA-MOL CELL RES, V1833, P122, DOI 10.1016/j.bbamcr.2012.10.010; Morris SAL, 2016, GENES DIS, V3, P41, DOI 10.1016/j.gendis.2015.12.003; Nadeau SA, 2017, J BIOL CHEM, V292, P3666, DOI 10.1074/jbc.M116.772723; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Ogawa S, 2010, CELL CYCLE, V9, P1051, DOI 10.4161/cc.9.6.11034; Park JK, 2009, NEOPLASMA, V56, P119, DOI 10.4149/neo_2009_02_119; Qamsari ES, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699118; Rahimi N, 2009, BIOCHEM SOC T, V37, P1189, DOI 10.1042/BST0371189; Resnick MB, 2004, CLIN CANCER RES, V10, P3069, DOI 10.1158/1078-0432.CCR-03-0462; Robbins AS, 2012, J CLIN ONCOL, V30, P401, DOI 10.1200/JCO.2011.37.5527; Sekharam M, 2003, CANCER RES, V63, P7708; Shashar M, 2016, ONCOTARGET, V7, P71136, DOI 10.18632/oncotarget.12107; Shiba N, 2012, BLOOD, V119, P2612, DOI 10.1182/blood-2011-02-333435; Shivanna S, 2015, J BIOL CHEM, V290, P12537, DOI 10.1074/jbc.M114.616623; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Singh AJ, 2007, P NATL ACAD SCI USA, V104, P5413, DOI 10.1073/pnas.0700809104; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Song N, 2014, INT J MOL SCI, V15, P5838, DOI 10.3390/ijms15045838; Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057; Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006; Stein A, 2011, DRUGS, V71, P2257, DOI 10.2165/11594490-000000000-00000; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tan YHC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008972; Tapan U, 2017, CANCER EPIDEMIOL, V49, P30, DOI 10.1016/j.canep.2017.05.003; Ueno K, 2008, NEOPLASIA, V10, P697, DOI 10.1593/neo.08320; Vlahovic G, 2003, ONCOLOGIST, V8, P531, DOI 10.1634/theoncologist.8-6-531; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Weidinger G, 2005, CURR BIOL, V15, P489, DOI 10.1016/j.cub.2005.01.041; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yothers G, 2016, JAMA ONCOL, V2, P24, DOI 10.1001/jamaoncol.2015.3614	56	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1921	1933		10.1016/j.ajpath.2018.05.007			13	Pathology	Pathology	GP3SI	WOS:000440773100016	30029779	Green Published			2019-10-28	
J	Liu, LM; Zhang, LL; Zhang, L; Yang, F; Zhu, XD; Lu, ZJ; Yang, YM; Lu, HQ; Feng, LF; Wang, Z; Chen, H; Yan, S; Wang, L; Ju, ZY; Jin, HC; Zhu, XJ				Liu, Leiming; Zhang, Lingling; Zhang, Lin; Yang, Fan; Zhu, Xudong; Lu, Zhongjie; Yang, Yeming; Lu, Haiqi; Feng, Lifeng; Wang, Zhuo; Chen, Hui; Yan, Sheng; Wang, Lin; Ju, Zhenyu; Jin, Hongchuan; Zhu, Xianjun			Hepatic Tmem30a Deficiency Causes Intrahepatic Cholestasis by Impairing Expression and Localization of Bile Salt Transporters (vol 187, pg 2775, 2017)	AMERICAN JOURNAL OF PATHOLOGY			English	Correction									[Liu, Leiming; Lu, Haiqi; Feng, Lifeng; Wang, Zhuo; Jin, Hongchuan] Sir Runrun Shaw Hosp, Key Lab Biotherapy Zhejiang Prov, Lab Canc Biol, Hangzhou, Zhejiang, Peoples R China; [Chen, Hui; Yan, Sheng] Zhejiang Univ, Affiliated Hosp 1, Minist Publ Hlth,Div Hepatobiliary & Pancreat Sur, Key Lab Combined Multi Organ Transplantat,Sch Med, Hangzhou, Zhejiang, Peoples R China; [Liu, Leiming; Yang, Fan; Ju, Zhenyu] Jinan Univ, Inst Aging & Regenerat Med, Minist Educ, Key Lab Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Zhang, Lingling; Zhu, Xudong; Ju, Zhenyu] Hangzhou Normal Univ, Sch Med, Leibniz Link Partner Grp Stem Cell Aging, Inst Aging Res, Hangzhou, Zhejiang, Peoples R China; [Zhang, Lin; Yang, Yeming; Zhu, Xianjun] Sichuan Acad Med Sci, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu, Sichuan, Peoples R China; [Zhang, Lin; Yang, Yeming; Zhu, Xianjun] Sichuan Acad Med Sci, Sch Med, Chengdu, Sichuan, Peoples R China; [Zhang, Lin; Yang, Yeming; Zhu, Xianjun] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China; [Zhang, Lin; Yang, Yeming; Zhu, Xianjun] Univ Elect Sci & Technol China, Sch Med, Minist Educ, Key Lab NeuroInformat, Chengdu, Sichuan, Peoples R China; [Zhang, Lin; Yang, Yeming; Zhu, Xianjun] Univ Elect Sci & Technol China, Sch Med, Med Informat Ctr, Chengdu, Sichuan, Peoples R China; [Lu, Zhongjie; Wang, Lin] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China	Liu, LM (reprint author), Sir Runrun Shaw Hosp, Key Lab Biotherapy Zhejiang Prov, Lab Canc Biol, Hangzhou, Zhejiang, Peoples R China.; Liu, LM (reprint author), Jinan Univ, Inst Aging & Regenerat Med, Minist Educ, Key Lab Regenerat Med, Guangzhou, Guangdong, Peoples R China.						YANG F, 2017, AM J PATHOL, V187, P2775, DOI DOI 10.1016/J.AJPATH.2017.08.011	1	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	AUG	2018	188	8					1934	1934		10.1016/j.ajpath.2018.06.003			1	Pathology	Pathology	GP3SI	WOS:000440773100017		Bronze			2019-10-28	
J	Sasaki, A; Abe, H; Mochizuki, S; Shimoda, M; Okada, Y				Sasaki, Aya; Abe, Hitoshi; Mochizuki, Satsuki; Shimoda, Masayuki; Okada, Yasunori			SOX4, an epithelial-mesenchymal transition inducer, transactivates ADAM28 gene expression and co-localizes with ADAM28 at the invasive front of human breast and lung carcinomas	PATHOLOGY INTERNATIONAL			English	Article						ADAM28; breast carcinoma; epithelial-mesenchymal transition; invasive front; lung carcinoma; SOX4	FACTOR BINDING PROTEIN-3; TISSUE GROWTH-FACTOR; CELL-PROLIFERATION; TRANSCRIPTION FACTOR; METASTASIS; CANCER; METALLOPROTEINASES; PROGRESSION; COMPONENTS; CLEAVAGE	ADAM28 (a disintegrin and metalloproteinase 28) is abundantly expressed by carcinoma cells in the human breast and non-small cell lung carcinomas, and plays a role in carcinoma cell growth and metastasis. Although Src is an inducer of ADAM28 gene expression through the PI3K/AKT/mTOR and MEK/ERK pathways, direct transcriptional regulators for ADAM28 gene expression remain unknown. In this study, we performed the luciferase reporter assay and found that SOX4 (SRY-related HMG-box 4), an inducer of epithelial-mesenchymal transition (EMT), is a transcriptional activator for the ADAM28 gene. This activation required the SOX4-binding consensus sequence at the 5'-untranslated region of the mouse and human ADAM28 genes. Forced expression of SOX4 promoted the ADAM28 gene expression and migration in human breast and lung carcinoma cell lines. In the human breast and lung carcinoma tissues, ADAM28 and SOX4 were co-expressed at the invasive front of carcinoma cell nests. Our data demonstrate that SOX4 transactivates ADAM28 gene expression through direct binding to the ADAM28 promoter region and suggest the possibility that ADAM28 plays a role in invasion through SOX4-mediated EMT in the human breast and lung carcinomas.	[Sasaki, Aya; Abe, Hitoshi; Mochizuki, Satsuki; Shimoda, Masayuki; Okada, Yasunori] Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan; [Okada, Yasunori] Juntendo Univ, Grad Sch Med, Dept Pathophysiol Locomot & Neoplast Dis, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan	Sasaki, A (reprint author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.; Okada, Y (reprint author), Juntendo Univ, Grad Sch Med, Dept Pathophysiol Locomot & Neoplast Dis, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ayasasa@z6.keio.jp; ya-okada@juntendo.ac.jp	Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755	Adaptable & Seamless Technology Transfer Program through Target-driven RD from A-MED [AS2614150Q]	We thank Ms. A. Shiraishi and Ms. Y. Hashimoto for technical assistance. This work was supported by Adaptable & Seamless Technology Transfer Program through Target-driven R&D from A-MED (AS2614150Q) to S.M, M.S. and Y.O.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Abe H, 2013, AM J PATHOL, V183, P1667, DOI 10.1016/j.ajpath.2013.07.011; Beekman JM, 2012, ONCOGENE, V31, P2668, DOI 10.1038/onc.2011.445; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Jafarnejad SM, 2013, ONCOGENE, V32, P2131, DOI 10.1038/onc.2012.239; Kuroda H, 2010, INT J CANCER, V127, P1844, DOI 10.1002/ijc.25212; Malaguarnera R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00010; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; Matsuura S, 2010, HUM PATHOL, V41, P343, DOI 10.1016/j.humpath.2009.08.002; Mitsui Y, 2006, CANCER RES, V66, P9913, DOI 10.1158/0008-5472.CAN-06-0377; Mochizuki S, 2004, BIOCHEM BIOPH RES CO, V315, P79, DOI 10.1016/j.bbrc.2004.01.022; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Mochizuki S, 2012, J NATL CANCER I, V104, P906, DOI 10.1093/jnci/djs232; Mochizuki S, 2010, BIOCHEM BIOPH RES CO, V402, P651, DOI 10.1016/j.bbrc.2010.10.077; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Ohtsuka T, 2006, INT J CANCER, V118, P263, DOI 10.1002/ijc.21324; Ota M, 2016, CANCER SCI, V107, P433, DOI 10.1111/cas.12895; Ouyang GL, 2010, CELL MOL LIFE SCI, V67, P2605, DOI 10.1007/s00018-010-0338-2; Ramezani-Rad P, 2013, BLOOD, V121, P148, DOI 10.1182/blood-2012-05-428938; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Stewart CJR, 2013, HISTOPATHOLOGY, V62, P31, DOI 10.1111/his.12057; Stokes A, 2010, CLIN CANCER RES, V16, P2022, DOI 10.1158/1078-0432.CCR-09-2525; Sun BH, 2013, J IMMUNOL, V190, P2080, DOI 10.4049/jimmunol.1202736; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Tyan YC, 2011, RAPID COMMUN MASS SP, V25, P2851, DOI 10.1002/rcm.5169; Vervoort SJ, 2013, ONCOGENE, V32, P3397, DOI 10.1038/onc.2012.506; Weber S, 2012, DEVELOPMENT, V139, P3693, DOI 10.1242/dev.076398; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Wright CM, 2010, GENE CHROMOSOME CANC, V49, P688, DOI 10.1002/gcc.20779	41	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					449	458		10.1111/pin.12685			10	Pathology	Pathology	GP2JQ	WOS:000440657900001	29882245				2019-10-28	
J	Gopalan, V; Kasem, K; Pillai, S; Olveda, D; Ariana, A; Leung, M; Lam, AKY				Gopalan, Vinod; Kasem, Kais; Pillai, Suja; Olveda, David; Ariana, Armin; Leung, Melissa; Lam, Alfred K. Y.			Evaluation of multidisciplinary strategies and traditional approaches in teaching pathology in medical students	PATHOLOGY INTERNATIONAL			English	Article						digital; education; pathology; teaching; virtual microscopy	VIRTUAL MICROSCOPY; EDUCATION; INTEGRATION	This study aims to evaluate the impact on the implementation of multiple strategies to improve medical student's pathology learning experience. In two consecutive years, medical students after a whole year of enrolling in pathology teaching, were invited to complete questionnaires rating and commenting on the personal learning experience of multiple teaching resources delivered in pathology. In both years, the overall score was high (mean score=4.57 +/- 0.63 /5) for the newly introduced sessions, namely histology lectures, clinical integrations and virtual microscopy pre-practical sessions. However, this was only marginally different from that of traditional practical (mean=4.37 +/- 0.68/5) and pathology lecture sessions (mean=4.42 +/- 0.61 /5). In addition, 53% positive correlation was noted for the overall responses between virtual microscopy guided pathology modules and practical sessions indicating the benefit of virtual microscopy in better preparing students for these sessions (P < 0.001). Qualitative comments suggested that the virtual microscopy sessions along with clinical scenario based learning were extremely useful for students' learning in pathology. To conclude, a multidisciplinary approach by clinical integration and flexibility in the mode of delivery by the use of virtual microscopy has the potential to better engage students to the learning of pathology.	[Gopalan, Vinod; Kasem, Kais; Pillai, Suja; Olveda, David; Ariana, Armin; Leung, Melissa; Lam, Alfred K. Y.] Griffith Univ, Sch Med, Pathol, Gold Coast, Australia; [Kasem, Kais; Pillai, Suja] Univ Queensland, Sch Biomed Sci, Fac Med, Brisbane, Qld, Australia; [Lam, Alfred K. Y.] Gold Coast Univ Hosp, Pathol Queensland, Gold Coast, Australia	Gopalan, V (reprint author), Griffith Univ, Sch Med & Med Sci, Gold Coast Campus, Gold Coast, Qld 4222, Australia.; Lam, AKY (reprint author), Griffith Med Sch, Pathol, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	v.gopalan@griffith.edu.au; a.lam@griffith.edu.au	Lam, Alfred/C-1652-2008	Lam, Alfred/0000-0003-2771-564X	Griffith UniversityGriffith University	The authors thank the staff of Griffith University who facilitate the teaching of the pathology as well as the funding of the 2010 and 2015 Health Group Learning and Teaching Grant from Griffith University.	Burton JL, 2005, CURR DIAGN PATHOL, V11, P308, DOI [10.1016/j.cdip.2005.05.009, DOI 10.1016/J.CDIP.2005.05.009]; Carr NJ, 2008, VIRCHOWS ARCH, V453, P369, DOI 10.1007/s00428-008-0666-x; CHARLTON R, 1994, J ROY SOC MED, V87, P232; de Jong PGM, 2010, J INT ASS MED SCI ED, V20, P14; Dee FR, 2009, HUM PATHOL, V40, P1112, DOI 10.1016/j.humpath.2009.04.010; Diaz-Perez Julio A, 2014, J Pathol Inform, V5, P25, DOI 10.4103/2153-3539.137729; DONNER RS, 1993, B MED LIBR ASSOC, V81, P294; Fung KM, 2012, ANAL CELL PATHOL, V35, P37, DOI 10.3233/ACP-2011-0028; Gabril MY, 2010, MODERN PATHOL, V23, P349, DOI 10.1038/modpathol.2009.190; Gopalan V, 2016, PATHOL INT, V66, P511, DOI 10.1111/pin.12448; Hamilton PW, 2012, APMIS, V120, P305, DOI 10.1111/j.1600-0463.2011.02869.x; Hays Richard, 2005, Aust J Rural Health, V13, P232, DOI 10.1111/j.1440-1584.2005.00707.x; Holland L, 2006, HUM PATHOL, V37, P1, DOI 10.1016/j.humpath.2005.10.004; Kasem K, 2016, PATHOLOGY S1, V48, pS57; Kayser K, 2011, DIAGN PATHOL, V6, pS1; Koch LH, 2009, HUM PATHOL, V40, P662, DOI 10.1016/j.humpath.2008.10.009; Kumar K, 2001, HUM PATHOL, V32, P1147, DOI 10.1053/hupa.2001.29788; Lam AKY, 2005, PATHOLOGY, V37, P360, DOI 10.1080/00313020500253331; Leifer Zev, 2015, J Pathol Inform, V6, P30, DOI 10.4103/2153-3539.158063; Li L., 2010, J PATHOL INFORM, V1; Marchevsky AM, 2003, HUM PATHOL, V34, P423, DOI 10.1016/S0046-8177(03)00089-3; Mortimer R, 2008, AUST HEALTH REV, V32, P319, DOI 10.1071/AH080319; Sadofsky M, 2014, ARCH PATHOL LAB MED, V138, P328, DOI 10.5858/arpa.2013-0404-RA; Scoville SA, 2007, CLIN ANAT, V20, P565, DOI 10.1002/ca.20440; Tse MMY, 2008, TELEMED J E-HEALTH, V14, P919, DOI 10.1089/tmj.2008.0006; Weinstein RS, 2009, HUM PATHOL, V40, P1057, DOI 10.1016/j.humpath.2009.04.006	26	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					459	466		10.1111/pin.12706			8	Pathology	Pathology	GP2JQ	WOS:000440657900002	30043440				2019-10-28	
J	Nakajima, T; Uehara, T; Kobayashi, Y; Kinugawa, Y; Yamanoi, K; Maruyama, Y; Suga, T; Ota, H				Nakajima, Tomoyuki; Uehara, Takeshi; Kobayashi, Yukihiro; Kinugawa, Yasuhiro; Yamanoi, Kazuhiro; Maruyama, Yasuhiro; Suga, Tomoaki; Ota, Hiroyoshi			Leucine-rich repeat-containing G-protein-coupled receptor 5 expression and clinicopathological features of colorectal neuroendocrine neoplasms	PATHOLOGY INTERNATIONAL			English	Article						colorectal neuroendocrine neoplasms; Leucine-rich repeat-containing G-protein-coupled receptor 5; RNA in situ hybridization	STEM-CELLS; HUMAN COLON; LGR5; CARCINOMA; TUMORS; CATENIN; IDENTIFICATION; SURVIVAL	LGR5 is expressed in various tumors and has been identified as a putative intestinal stem cell marker. Here we investigated LGR5 expression in colorectal neuroendocrine neoplasms and analyzed the correlation with pathological characteristics. We evaluated the clinicopathological features of 8 neuroendocrine tumor (NET) grade 1 (NET G1), 4 NET Grade 2 (NET G2), and 8 NET Grade 3 (NET G3; also termed neuroendocrine carcinoma, or NEC) cases. We examined LGR5 expression using an RNAscope, a newly developed RNA in situ hybridization technique, with a tissue microarray of the neuroendocrine neoplasm samples. LGR5 staining in individual tumor cells was semi-quantitatively scored using an H-score scale. We also performed a combination of LGR5 RNA in situ hybridization and synaptophysin immunohistochemistry. All cases contained tumor cells with some LGR5-positive dots. For all cases, H-scores showed a positive correlation with nuclear beta-catenin expression. In the NEC group, there was a strong positive correlation between H-score and beta-catenin expression. Our findings suggest that LGR5 may serve as a stem cell marker in NEC, as is the case in colon adenocarcinoma. The positive correlation between H-score and beta-catenin expression suggests that LGR5 expression might be affected by beta-catenin expression in neuroendocrine neoplasms and especially in NEC.	[Nakajima, Tomoyuki; Uehara, Takeshi; Kobayashi, Yukihiro; Kinugawa, Yasuhiro; Ota, Hiroyoshi] Shinshu Univ, Sch Med, Dept Lab Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Yamanoi, Kazuhiro] Shinshu Univ, Inst Biomed Sci, Dept Adv Med Hlth Promot, Interdisciplinary Cluster Cutting Edge Res, Matsumoto, Nagano, Japan; [Maruyama, Yasuhiro] Suwa Red Cross Hosp, Dept Gastroenterol, Suwa, Japan; [Suga, Tomoaki] Shinshu Univ, Dept Gastroenterol, Sch Med, Matsumoto, Nagano, Japan; [Ota, Hiroyoshi] Shinshu Univ, Dept Biomed Lab Med, Sch Med, Matsumoto, Nagano, Japan	Uehara, T (reprint author), Shinshu Univ, Sch Med, Dept Lab Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tuehara@shinshu-u.ac.jp	Yamanoi, Kazuhiro/N-6147-2019	Yamanoi, Kazuhiro/0000-0002-5361-8053	Hokuto Foundation for BioscienceHokuto Foundation for Bioscience	We are grateful to Masanobu Momose, Yasuyo Shimojo, Naoko Ogiwara, Mieko Horikawa, Akiko Inamura, Chitoshi Arai, Marina Nuno, and Souya Ogasawara at Shinshu University Hospital for their excellent technical assistance. This study was supported by the Hokuto Foundation for Bioscience (Grant Award to T.U.). We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.	Al-Kharusi MRA, 2013, CARCINOGENESIS, V34, P1150, DOI 10.1093/carcin/bgt020; Baker AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep08654; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Bosman FT, 2010, WHO CLASSIFICATION T; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Fan XS, 2010, INT J COLORECTAL DIS, V25, P583, DOI 10.1007/s00384-010-0903-z; Fukuma M, 2013, EXP CELL RES, V319, P113, DOI 10.1016/j.yexcr.2012.10.011; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Jaks V, 2008, NAT GENET, V40, P1291, DOI 10.1038/ng.239; Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220; Jiang YY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1986-2; Li CC, 2002, VIRCHOWS ARCH, V440, P145, DOI 10.1007/s004280100529; McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521; Nakajima T, 2016, PATHOL INT, V66, P518, DOI 10.1111/pin.12451; Oberg K, 2010, ANN ONCOL, V21, pv223, DOI 10.1093/annonc/mdq192; Sei Y, 2016, GASTROENTEROLOGY, V151, P140, DOI 10.1053/j.gastro.2016.03.007; Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081; Takizawa N, 2015, HUM PATHOL, V46, P1890, DOI 10.1016/j.humpath.2015.08.006; Ukpo OC, 2011, AM J SURG PATHOL, V35, P1343, DOI 10.1097/PAS.0b013e318220e59d; Wu XS, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-244; Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08	23	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					467	472		10.1111/pin.12707			6	Pathology	Pathology	GP2JQ	WOS:000440657900003	30043418				2019-10-28	
J	Matsumoto, K; Udaka, N; Hasumi, H; Nakaigawa, N; Nagashima, Y; Tanaka, R; Kato, I; Yao, M; Furuya, M				Matsumoto, Kana; Udaka, Naoko; Hasumi, Hisashi; Nakaigawa, Noboru; Nagashima, Yoji; Tanaka, Reiko; Kato, Ikuma; Yao, Masahiro; Furuya, Mitsuko			Histopathological analysis of aggressive renal cell carcinoma harboring a unique germline mutation in fumarate hydratase	PATHOLOGY INTERNATIONAL			English	Article						exon skipping; fumarate hydratase; hereditary leiomyomatosis and renal cell cancer; Reed's syndrome; tricarboxylic acid cycle	HEREDITARY LEIOMYOMATOSIS; JAPANESE PATIENT; CANCER; FAMILIES; GENE; FH; SPECTRUM; TUMORS; HLRCC	Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a rare genetic disorder characterized by cutaneous and uterine leiomyomatosis with RCC. This disorder is caused by a germline mutation in the fumarate hydratase (FH) gene, which encodes an important enzyme of the tricarboxylic acid (TCA) cycle. This mutation distinguishes HLRCC from sporadic RCCs. Herein, we investigated a case of HLRCC in a 32-year-old man who underwent nephrectomy for treatment of a solid-cystic tumor in the left kidney. Histopathology demonstrated a variegated architecture of papillary, tubulocystic and cribriform patterns composed of high-grade tumor cells with enlarged nuclei and eosinophilic nucleoli. Immunostaining and western blotting revealed no FH expression in the tumor. Genomic DNA sequencing identified a heterozygous mutation involving deletion of the 3' end of exon 2 and intron 2 of the FH gene (c.251_267+7delTGACAGAACGCATGCCAGTAAGTG), and RT-PCR confirmed exon 2 skipping in FH mRNA. The somatic FH gene status of the tumor showed only the mutated allele, indicating loss of heterozygosity as the "second hit" of tumor suppressor gene inactivation. These data support that an FH mutation involving the splice site causes exon skipping, changing the conformation of the protein and accelerating carcinogenic cascades under impaired FH functioning in the TCA cycle.	[Matsumoto, Kana; Kato, Ikuma; Furuya, Mitsuko] Yokohama City Univ, Sch Med, Dept Mol Pathol, Yokohama, Kanagawa, Japan; [Udaka, Naoko] Yokohama City Univ Med, Dept Pathol, Yokohama, Kanagawa, Japan; [Hasumi, Hisashi; Nakaigawa, Noboru; Yao, Masahiro] Yokohama City Univ, Sch Med, Dept Urol, Yokohama, Kanagawa, Japan; [Nagashima, Yoji] Tokyo Womens Med Univ, Dept Surg Pathol, Tokyo, Japan; [Tanaka, Reiko] Chiba Univ, Med Mycol Res Ctr, Chiba, Japan	Furuya, M (reprint author), Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	mfuruya@yokohama-cu.ac.jp		Kato, Ikuma/0000-0002-7731-9509	JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [16K11020, 16K11021, 17K11162, 16K19085, 15K10600, 17K08745]	We thank Ms. Hiromi Soeda, Mr. Takayuki Akagi, and the members of the pathology laboratories of Yokohama City University Hospital for their excellent assistance. This work was supported by JSPS Grant-in-Aid for Scientific Research: grant numbers are 16K11020 (H.H.), 16K11021 (N.N.), 17K11162 (Y.N.), 16K19085 (I.K.), 15K10600 (M.Y.) and 17K08745 (M.F.).	Akita F, 2013, J DERMATOL, V40, P58, DOI 10.1111/1346-8138.12002; Carvajal-Carmona LG, 2006, J CLIN ENDOCR METAB, V91, P3071, DOI 10.1210/jc.2006-0183; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Gardie B, 2011, J MED GENET, V48, P226, DOI 10.1136/jmg.2010.085068; Kamai T, 2012, INT J MOL SCI, V13, P14518, DOI 10.3390/ijms131114518; Kuwada Masaomi, 2014, BMC Res Notes, V7, P203, DOI 10.1186/1756-0500-7-203; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Linehan WM, 2013, CLIN CANCER RES, V19, P3345, DOI 10.1158/1078-0432.CCR-13-0304; Makino T, 2007, J DERMATOL SCI, V48, P151, DOI 10.1016/j.jdermsci.2007.07.009; Matyakhina L, 2005, J CLIN ENDOCR METAB, V90, P3773, DOI 10.1210/jc.2004-2377; Merino MJ, 2007, AM J SURG PATHOL, V31, P1578, DOI 10.1097/PAS.0b013e31804375b8; REED WB, 1973, ACTA DERM-VENEREOL, V53, P409; Smit DL, 2011, CLIN GENET, V79, P49, DOI 10.1111/j.1399-0004.2010.01486.x; Smith SC, 2017, HISTOPATHOLOGY, V71, P42, DOI 10.1111/his.13183; Sugiura S, 2007, INT J UROL, V14, P555, DOI 10.1111/j.1442-2042.2006.01711.x; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506; Yoshinaga Y, 2016, J DERMATOL, V43, P85, DOI 10.1111/1346-8138.13019	18	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					473	478		10.1111/pin.12684			6	Pathology	Pathology	GP2JQ	WOS:000440657900004	29797630				2019-10-28	
J	Miyauchi, J; Ogura, M; Sato, M; Matsui, J				Miyauchi, Jun; Ogura, Masaharu; Sato, Michio; Matsui, Junichi			Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer?	PATHOLOGY INTERNATIONAL			English	Article						carcinosarcoma; collision cancer; esophageal cancer; squamous cell carcinoma; undifferentiated pleomorphic sarcoma	CYCLIN D1; EXPRESSION; TUMOR	Esophageal carcinosarcoma is a rare neoplasm with components of squamous cell carcinoma and sarcomatous spindle cell stroma. The latter may show overt mesenchymal differentiation but is thought to be derived from carcinoma cells in most cases. Here, we report a case of esophageal carcinosarcoma that appeared to be comprised of different origins of epithelial and mesenchymal tumor cells. The sarcomatous component formed an intralumial pedunculated large mass lesion that consisted of pleomorphic atypical histiocyte-like cells. The squamous epithelium exhibited features of mostly dysplasia with minor foci of microinvasive squamous cell carcinoma. The invasive carcinoma was apart from the sarcoma, and no transitions were observed between the epithelial and sarcomatous cells. Immunohistochemistry showed that the sarcoma cells did not express any lineage-specific markers, including those for epithelial cells and histiocytes, which lead to the diagnosis of undifferentiated pleomorphic sarcoma. Although cyclin D1 was overexpressed in the carcinoma cells, it was nearly negative in the sarcoma cells. These findings indicate that the tumor may be a collision carcinosarcoma. It is highly likely that the patient's history of heavy smoking and alcohol consumption were relevant to the pathogenesis, at least for the epithelial component, of the tumor.	[Miyauchi, Jun] Tokyo Dent Coll, Dept Pathol & Lab Med, Ichikawa Gen Hosp, Ichikawa, Chiba, Japan; [Ogura, Masaharu; Sato, Michio; Matsui, Junichi] Tokyo Dent Coll, Dept Surg, Ichikawa Gen Hosp, Ichikawa, Chiba, Japan; [Miyauchi, Jun] Saitama Municipal Hosp, Dept Cent Lab, Saitama, Saitama, Japan; [Sato, Michio] Int Goodwill Hosp, Dept Surg, Yokohama, Kanagawa, Japan	Miyauchi, J (reprint author), Saitama Municipal Hosp, Dept Cent Lab, Midori Ku, 2460 Mimuro, Saitama, Saitama 3368522, Japan.; Miyauchi, J (reprint author), Saitama Municipal Hosp, Dept Cent Lab, Saitama, Saitama, Japan.	miyauchi830@gmail.com					Ansari-Lari MA, 2002, AM J SURG PATHOL, V26, P1024, DOI 10.1097/01.PAS.0000018104-32686.56; Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; GAL AA, 1987, CANCER-AM CANCER SOC, V60, P2244, DOI 10.1002/1097-0142(19871101)60:9<2244::AID-CNCR2820600924>3.0.CO;2-O; GUARINO M, 1993, HISTOPATHOLOGY, V22, P493, DOI 10.1111/j.1365-2559.1993.tb00164.x; Handra-Luca A, 2001, HISTOPATHOLOGY, V39, P125, DOI 10.1046/j.1365-2559.2001.01174.x; Iascone C, 1999, WORLD J SURG, V23, P153, DOI 10.1007/PL00013169; IEZZONI JC, 1993, SEMIN DIAGN PATHOL, V10, P176; Ishiguro S, 2009, CANCER LETT, V275, P240, DOI 10.1016/j.canlet.2008.10.020; Iwaya T, 2006, DIS ESOPHAGUS, V19, P48, DOI 10.1111/j.1442-2050.2006.00538.x; Iwaya T, 1997, GASTROENTEROLOGY, V113, P973, DOI 10.1016/S0016-5085(97)70194-X; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; Kashiwabara K, 2001, PATHOL RES PRACT, V197, P41, DOI 10.1078/0344-0338-00006; Lau SK, 2004, AM J CLIN PATHOL, V122, P794, DOI 10.1309/QHD6YFN81KQXUUH6; Lauwers GY, 1998, HUM PATHOL, V29, P863, DOI 10.1016/S0046-8177(98)90458-0; LINDER J, 1987, HUM PATHOL, V18, P692, DOI 10.1016/S0046-8177(87)80240-X; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Montgomery E, 2010, WHO CLASSIFICATION T, P18; Nakagawa S, 1999, DIGEST DIS SCI, V44, P905, DOI 10.1023/A:1026640009829; Rosai J, 2011, ROSAI ACKEMANS SURGI, V1, P585; Shinozaki H, 1996, CLIN CANCER RES, V2, P1155; Thway Khin, 2015, Sarcoma, P812089, DOI 10.1155/2015/812089	21	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					479	484		10.1111/pin.12689			6	Pathology	Pathology	GP2JQ	WOS:000440657900005	29934989				2019-10-28	
J	Kiyasu, J; Arakawa, F; Haji, S; Tachikawa, Y; Tsuda, M; Tsukamoto, Y; Ikeda, M; Muta, H; Matsushima, T; Miyoshi, H; Shiratsuchi, M; Ogawa, Y; Ohshima, K; Yufu, Y				Kiyasu, Junichi; Arakawa, Fumiko; Haji, Shojiro; Tachikawa, Yoshimichi; Tsuda, Mariko; Tsukamoto, Yasuhiro; Ikeda, Motohiko; Muta, Hiroki; Matsushima, Takamitsu; Miyoshi, Hiroaki; Shiratsuchi, Motoaki; Ogawa, Yoshihiro; Ohshima, Kouichi; Yufu, Yuji			Methotrexate-associated lymphoproliferative disorders with angioimmunoblastic T-cell lymphoma-like features accompanied by gamma-heavy chain disease in a patient with rheumatoid arthritis	PATHOLOGY INTERNATIONAL			English	Article						arthritis; heavy chain disease; lymphoproliferative disorders; methotrexate; rheumatoid		Although gamma heavy chain disease (gamma-HCD) lesions occasionally morphologically resemble angioimmunoblastic T-cell lymphoma (AITL), no association has been described in detail due to the rarity of the disease. In this report, we present a rare manifestation of methotrexate (MTX)-associated lymphoproliferative disorders (LPDs) with AITL-like features accompanied by gamma-HCD in a 75-year-old man with rheumatoid arthritis (RA). A biopsy specimen was evaluated using immunohistochemistry, clonal analyses of immunoglobulin V-H and T-cell receptor gamma gene rearrangements by polymerase chain reaction, and Sanger sequencing for confirmation of the structure of deleted gamma-HCD clones. The histological features characterized by proliferation of CD4- and PD-1-positive medium-sized T cells and arborizing high endothelial venules together with numbers of small lymphocytes, eosinophils, plasma cells, and histiocytes in the background mimicked those of AITL, but did not completely fulfill the diagnostic criteria. Clonal analysis demonstrated that the specimen contained multiple LPDs of both B-cell and T-cell lineages. Sequence analysis confirmed the co-existence of a clone responsible for production of the abnormal heavy chain. This report provides new insights into the pathology of gamma-HCD. Multiple host-derived factors (e.g., RA and/or use of MTX) may be responsible for the occurrence of LPDs of multiple lineages within a single lymph node.	[Kiyasu, Junichi; Haji, Shojiro; Tachikawa, Yoshimichi; Tsuda, Mariko; Tsukamoto, Yasuhiro; Ikeda, Motohiko; Muta, Hiroki; Matsushima, Takamitsu; Yufu, Yuji] Iizuka Hosp, Dept Hematol, Yoshiomachi 3-83, Iizuka, Fukuoka 8208505, Japan; [Kiyasu, Junichi; Arakawa, Fumiko; Miyoshi, Hiroaki; Ohshima, Kouichi] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan; [Kiyasu, Junichi] Natl Hosp Org, Kyushu Natl Canc Ctr, Clin Res Inst, Fukuoka, Fukuoka, Japan; [Shiratsuchi, Motoaki; Ogawa, Yoshihiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Fukuoka, Japan	Kiyasu, J (reprint author), Iizuka Hosp, Dept Hematol, Yoshiomachi 3-83, Iizuka, Fukuoka 8208505, Japan.	jkiyasuh2@aih-net.com					Celis L, 1997, ARTHRITIS RHEUM-US, V40, P510, DOI 10.1002/art.1780400317; Cook JR, 2016, WHO CLASSIFICATION T, P237; FERMAND JP, 1989, MEDICINE, V68, P321, DOI 10.1097/00005792-198911000-00001; Gaulard P, 2016, WHO CLASSIFICATION T, P462; Hatanaka K, 2010, PATHOL RES PRACT, V206, P9, DOI 10.1016/j.prp.2009.03.005; Ichikawa A, 2013, EUR J HAEMATOL, V91, P20, DOI 10.1111/ejh.12116; Niino D, 2011, PATHOL INT, V61, P363, DOI 10.1111/j.1440-1827.2011.02662.x; Okamoto T, 2000, ACTA HAEMATOL-BASEL, V104, P128, DOI 10.1159/000039746; Pileri SA, 2016, WHO CLASSIFICATION T, P403; RAMASAMY I, 1992, J CLIN PATHOL, V45, P770, DOI 10.1136/jcp.45.9.770; Swerdlow SH, 2016, WHO CLASSIFICATION T, P453; Thomas E, 2000, INT J CANCER, V88, P497, DOI 10.1002/1097-0215(20001101)88:3<497::AID-IJC27>3.3.CO;2-A; Tran H, 2008, BLOOD REV, V22, P261, DOI 10.1016/j.blre.2008.03.009; Ueno H, 2016, CURR OPIN IMMUNOL, V43, P24, DOI 10.1016/j.coi.2016.08.003; Wahner-Roedler DL, 2003, MEDICINE, V82, P236, DOI 10.1097/00005792-200307000-00002	15	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					485	490		10.1111/pin.12703			6	Pathology	Pathology	GP2JQ	WOS:000440657900006	29987858				2019-10-28	
J	Morita, K; Mito, K; Niki, T; Fukushima, N				Morita, Kohei; Mito, Kumiko; Niki, Toshiro; Fukushima, Noriyoshi			Is an atypical flat lesion (AFL) a precursor lesion of the pancreatic ductal adenocarcinoma in human?	PATHOLOGY INTERNATIONAL			English	Letter							MICE		[Morita, Kohei; Mito, Kumiko; Niki, Toshiro; Fukushima, Noriyoshi] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi, Japan; [Morita, Kohei] Nara Med Univ, Dept Diagnost Pathol, Sch Med, Kashihara, Nara, Japan; [Mito, Kumiko] Toho Univ, Dept Internal Med, Ohashi Med Ctr, Tokyo, Japan	Morita, K (reprint author), Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi, Japan.; Morita, K (reprint author), Nara Med Univ, Dept Diagnost Pathol, Sch Med, Kashihara, Nara, Japan.		niki, toshiro/K-8917-2012		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26460425]	KM and NF contributed equally to this paper. JSPS KAKENHI Grant Number 26460425 supported this work.	Aichler M, 2012, J PATHOL, V226, P723, DOI 10.1002/path.3017; Chanjuan S, 2009, MOL CANCER RES, V7, P230; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					491	493		10.1111/pin.12670			3	Pathology	Pathology	GP2JQ	WOS:000440657900007	29664180				2019-10-28	
J	Kojima, F; Ueda, Y; Matsuzaki, I; Hara, I; Murata, S				Kojima, Fumiyoshi; Ueda, Yuko; Matsuzaki, Ibu; Hara, Isao; Murata, Shin-ichi			Loss of SWI/SNF complex expression in undifferentiated renal carcinoma in acquired cystic kidney	PATHOLOGY INTERNATIONAL			English	Letter							CELL CARCINOMA; TRACT; EVENT		[Kojima, Fumiyoshi; Matsuzaki, Ibu; Murata, Shin-ichi] Wakayama Med Univ, Dept Human Pathol, Wakayama, Japan; [Ueda, Yuko; Hara, Isao] Wakayama Med Univ, Dept Urol, Wakayama, Japan	Kojima, F (reprint author), Wakayama Med Univ, Dept Human Pathol, Wakayama, Japan.						Agaimy A, 2017, VIRCHOWS ARCH, V471, P599, DOI 10.1007/s00428-017-2148-5; Agaimy A, 2017, AM J SURG PATHOL, V41, P253, DOI 10.1097/PAS.0000000000000787; Agaimy A, 2016, VIRCHOWS ARCH, V469, P321, DOI 10.1007/s00428-016-1977-y; Agaimy A, 2016, AM J SURG PATHOL, V40, P544, DOI 10.1097/PAS.0000000000000554; Xia QY, 2014, HISTOPATHOLOGY, V64, P847, DOI 10.1111/his.12334	5	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					494	496		10.1111/pin.12671			3	Pathology	Pathology	GP2JQ	WOS:000440657900008	29671925				2019-10-28	
J	Yorita, K; Kuroda, N; Tanida, N; Kawada, A; Kitagawa, Y				Yorita, Kenji; Kuroda, Naoto; Tanida, Nobuyuki; Kawada, Ai; Kitagawa, Yoshitake			Acantholytic squamous cell carcinoma of the gallbladder mimicking adenocarcinoma	PATHOLOGY INTERNATIONAL			English	Letter							OSTEOCLAST-LIKE; GIANT-CELLS		[Yorita, Kenji; Kuroda, Naoto] Japanese Red Cross Kochi Hosp, Dept Diagnost Pathol, 2-13-51 Shinhonmachi, Kochi, Kochi 7808562, Japan; [Tanida, Nobuyuki] Japanese Red Cross Kochi Hosp, Dept Surg, 2-13-51 Shinhonmachi, Kochi, Kochi 7808562, Japan; [Kawada, Ai] Japanese Red Cross Kochi Hosp, Dept Internal Med, 2-13-51 Shinhonmachi, Kochi, Kochi 7808562, Japan; [Kitagawa, Yoshitake] JA Kochi Hosp, Dept Internal Med, 526-1 Nakano, Nangoku City, Kochi 7838509, Japan	Yorita, K (reprint author), Japanese Red Cross Kochi Hosp, Dept Diagnost Pathol, 2-13-51 Shinhonmachi, Kochi, Kochi 7808562, Japan.						Alwaheeb S, 2005, J CLIN PATHOL, V58, P987, DOI 10.1136/jcp.2004.025221; Jukic Z, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-5; Lee D, 2016, PATHOLOGY, V48, P281, DOI 10.1016/j.pathol.2016.02.011; Roa JC, 2011, MODERN PATHOL, V24, P1069, DOI 10.1038/modpathol.2011.68; Weedon D, 2005, WHO CLASSIFICATION S, P20	5	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					497	499		10.1111/pin.12675			3	Pathology	Pathology	GP2JQ	WOS:000440657900009	29671927				2019-10-28	
J	Okabayashi, Y; Kanzaki, G; Tsuboi, N; Haruhara, K; Koike, K; Ikegami, M; Shimizu, A; Yokoo, T				Okabayashi, Yusuke; Kanzaki, Go; Tsuboi, Nobuo; Haruhara, Kotaro; Koike, Kentaro; Ikegami, Masahiro; Shimizu, Akira; Yokoo, Takashi			Heterogeneous distribution of glomerular size in adult kidneys with normal renal function	PATHOLOGY INTERNATIONAL			English	Letter							DIFFERENT CORTICAL ZONES		[Okabayashi, Yusuke; Kanzaki, Go; Tsuboi, Nobuo; Haruhara, Kotaro; Koike, Kentaro; Yokoo, Takashi] Jikei Univ, Div Nephrol & Hypertens, Dept Internal Med, Sch Med, Tokyo, Japan; [Okabayashi, Yusuke; Shimizu, Akira] Nippon Med Sch, Dept Analyt Human Pathol, Tokyo, Japan; [Ikegami, Masahiro] Jikei Univ, Dept Pathol, Sch Med, Tokyo, Japan	Okabayashi, Y (reprint author), Jikei Univ, Div Nephrol & Hypertens, Dept Internal Med, Sch Med, Tokyo, Japan.; Okabayashi, Y (reprint author), Nippon Med Sch, Dept Analyt Human Pathol, Tokyo, Japan.			Haruhara, Kotaro/0000-0003-1918-0390; Okabayashi, Yusuke/0000-0001-7150-6947			Ito S, 2009, HYPERTENS RES, V32, P115, DOI 10.1038/hr.2008.27; Kanzaki G, 2013, PATHOL INT, V63, P169, DOI 10.1111/pin.12044; Okabayashi Y, 2016, KIDNEY INT REP, V1, P250, DOI [10.1016/j.ekir.2017.01.007, 10.1016/j.ekir.2016.08.006]; Puelles VG, 2015, J AM SOC NEPHROL, V26, P2277, DOI 10.1681/ASN.2014070641; Samuel T, 2005, J AM SOC NEPHROL, V16, P3102, DOI 10.1681/ASN.2005010123	5	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	AUG	2018	68	8					500	501		10.1111/pin.12681			2	Pathology	Pathology	GP2JQ	WOS:000440657900010	29749027				2019-10-28	
J	Costa, J				Costa, Jose			A brave new world	VIRCHOWS ARCHIV			English	Editorial Material						Academic pathology; Research in pathology; Diagnostic practice; Diagnostics; Postgraduate training		Whereas up to 1950s the two major activities of academic Pathology-diagnostic and experimental-were both practiced by a single individual, thereafter, scientific, academic and economic factors created the conditions that favored monothematic practitioners. In this white paper, I argue that now, at the beginning of the 21st century, this separation is detrimental to the discipline, and I propose changes that would reunite the two strands.	[Costa, Jose] Univ Lausanne, Lausanne, Switzerland; [Costa, Jose] Yale Sch Med, New Haven, CT 06510 USA	Costa, J (reprint author), Univ Lausanne, Lausanne, Switzerland.; Costa, J (reprint author), Yale Sch Med, New Haven, CT 06510 USA.	jose.costa@yale.edu					Costa J, 2008, NAT CLIN PRACT ONCOL, V5, P117, DOI 10.1038/ncponc1070	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					141	144		10.1007/s00428-018-2338-9			4	Pathology	Pathology	GO7VP	WOS:000440285100001	29569207				2019-10-28	
J	Cserni, G				Cserni, Gabor			Analysis of membranous Ki-67 staining in breast cancer and surrounding breast epithelium	VIRCHOWS ARCHIV			English	Article						Breast cancer; Ki-67; MIB-1; Membranous staining; Immunohistochemistry; HER2	INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; CELL-MEMBRANE; KI67; MIB-1; RECOMMENDATIONS; HIGHLIGHTS; CARCINOMA; ANTIBODY; INDEX	Membranous Ki-67 staining with the M1B-1 antibody has been described in hyalinising trabecular adenomas of the thyroid and sclerosing haemangiomas of the lung. Its relatively rare occurrence in breast tumours has also been documented. The aim of the present study was to assess the rate of any membranous MIB-1 staining in breast specimens. The staining was performed at room temperature with 1:100 dilution of the antibody. One hundred four core needle biopsies and 41 operative specimens were analysed. Membranous staining was noted in 36/144 invasive carcinomas, 20/42 in situ carcinomas and 46/99 cases of peritumoural benign/normal breast epithelium. Most often, it presented as focal and partial polarised luminal membranous staining although complete circumferential staining also occurred, and membranous labelling was sometimes accompanied by cytoplasmic staining, too. In a few cases tested, greater dilution of the primary antibody did not abolish the membranous staining, which was absent with the SP6 monoclonal Ki-67 antibody. The membranous staining of invasive tumours showed no association with histological grade, lumen formation, oestrogen or progesterone receptor status or the Ki-67 nuclear labelling. In contrast, it was associated with a HER2-positive status, although it occurred in all molecular subtypes approached by immunohistochemistry. The background of this membranous staining remains elusive. It is unlikely to represent an artefact. At least partial sharing of an epitope of the nuclear Ki-67 protein with an unidentified membranous protein and some functional differences between membranous staining producing tumours and tumours lacking this pattern of staining may both contribute to some extent.	[Cserni, Gabor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary; [Cserni, Gabor] Univ Szeged, Dept Pathol, Allomas U 1, H-6725 Szeged, Hungary	Cserni, G (reprint author), Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Nyiri Ut 38, H-6000 Kecskemet, Hungary.; Cserni, G (reprint author), Univ Szeged, Dept Pathol, Allomas U 1, H-6725 Szeged, Hungary.	cserni@freemail.hu		Cserni, Gabor/0000-0003-1344-7744	National Research, Development and Innovation Office [GINOP-2.3.2-15-2016-00020]	This study was partially funded by the National Research, Development and Innovation Office grant GINOP-2.3.2-15-2016-00020.	Acs B, 2017, HUM PATHOL, V65, P31, DOI 10.1016/j.humpath.2017.01.011; Cserni G, 2018, VIRCHOWS ARCH, V472, P697, DOI 10.1007/s00428-018-2301-9; Cserni Gabor, 2016, Magy Onkol, V60, P209; Cserni G, 2014, PATHOLOGY, V46, P527, DOI 10.1097/PAT.0000000000000144; Cserni G, 2014, BREAST, V23, P259, DOI 10.1016/j.breast.2014.02.003; Dowsett M, 2011, J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Faratian D, 2009, HISTOPATHOLOGY, V54, P254, DOI 10.1111/j.1365-2559.2008.03191.x; Gandara-Cortes M, 2018, VIRCHOWS ARCH, V472, P195, DOI 10.1007/s00428-017-2194-z; GERDES J, 1991, AM J PATHOL, V138, P867; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, pE48, DOI 10.1043/1543-2165-134.7.e48; Hattori H, 2002, HISTOPATHOLOGY, V40, P291, DOI 10.1046/j.1365-2559.2002.01330.x; Hirokawa M, 2000, AM J SURG PATHOL, V24, P575, DOI 10.1097/00000478-200004000-00013; Kovari B, 2015, PATHOBIOLOGY, V82, P259, DOI 10.1159/000440664; Laenkholm AV, 2018, ACTA ONCOL, V57, P83, DOI 10.1080/0284186X.2017.1404127; Leonardo E, 2007, APPL IMMUNOHISTO M M, V15, P220, DOI 10.1097/01.pai.0000213122.66096.f0; Niemiec J, 2015, AM J CLIN PATHOL, V143, P419, DOI 10.1309/AJCPHAEK82QWQORJ; Niemiec JA, 2012, APPL IMMUNOHISTO M M, V20, P550, DOI 10.1097/PAI.0b013e31824f21af; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; van Diest PJ, 2004, J CLIN PATHOL, V57, P675, DOI 10.1136/jcp.2003.010777; Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379; Wang D, 2016, APPL IMMUNOHISTO M M, V24, P447, DOI 10.1097/PAI.0000000000000202; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1	25	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					145	153		10.1007/s00428-018-2343-z			9	Pathology	Pathology	GO7VP	WOS:000440285100002	29594352	Green Accepted			2019-10-28	
J	Di Oto, E; Biserni, GB; Varga, Z; Morandi, L; Cucchi, MC; Masetti, R; Foschini, MP				Di Oto, Enrico; Biserni, Giovanni B.; Varga, Zsuzsanna; Morandi, Luca; Cucchi, Maria C.; Masetti, Riccardo; Foschini, Maria P.			X chromosome gain is related to increased androgen receptor expression in male breast cancer	VIRCHOWS ARCHIV			English	Article						Male breast cancer; Invasive ductal carcinoma; X chromosome; Genetic marker; FISH; Androgen receptor	PROSTATE-CANCER; KLINEFELTER-SYNDROME; GENE; MEN; PROGNOSIS; BIOMARKER; THERAPY; PROGRAM; COPIES; SERIES	X chromosome gain has been previously described in male breast cancer (MBC). Androgen receptor (AR) gene is located on X chromosome. The aim of this study was to investigate the role of the X chromosome gain in the development of MBC and its relation with AR gene copy number and expression. The X chromosome status was assessed in 66 cases of male invasive and in situ duct breast carcinoma, in 34 cases of gynecomastia associated with cancer, and in 11 cases of tumor-free gynecomastia. Cases were tested by fluorescence in situ hybridization (FISH) to assess the X chromosome status and AR amplification. AR expression was studied by immunohistochemistry (IHC). In addition, AR methylation status was assessed. X chromosome gain was observed in 74.7% of invasive duct carcinoma, in 20.6% of in situ duct carcinoma, and in 14.6% of gynecomastia when associated with cancer, while all cases of tumor-free gynecomastia showed wild X chromosome asset. AR gene copy number when increased paralleled the number of X chromosomes. AR IHC expression was observed in 100% of MBC tested. AR gene methylation status revealed low level or absence of methylation. These data suggest that X chromosome can play a role in the neoplastic transformation of male breast epithelium. X chromosome gain is paralleled by AR gene polysomy. Polysomic AR genes show low methylation levels and high AR protein expression on NC. These data should be taken into consideration for MBC treatment planning.	[Di Oto, Enrico; Biserni, Giovanni B.; Morandi, Luca; Foschini, Maria P.] Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Unit Anat Pathol M Malpighi, Via Altura 3, I-40139 Bologna, Italy; [Varga, Zsuzsanna] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Zurich, Switzerland; [Cucchi, Maria C.] AUSL Bologna, Dept Oncol, Unit Breast Surg, Bellaria Hosp, Bologna, Italy; [Masetti, Riccardo] Univ Cattolica Sacro Cuore, Multidisciplinary Breast Ctr, Rome, Italy	Foschini, MP (reprint author), Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Unit Anat Pathol M Malpighi, Via Altura 3, I-40139 Bologna, Italy.	enrico.dioto@live.it; Giovanni.biserni@studio.unibo.it; zsazsanna.varga@usz.ch; Luca.morandi2@unibo.it; mariacristina.cucchi@ausl.bologna.it; riccardo.masetti@policlinicogemelli.it; mariapia.foschini@unibo.it	Foschini, Maria P./A-6306-2016	Foschini, Maria P./0000-0001-7079-7260	Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna (Italy) (Fundamentally Oriented Funds for Research - RFO); Susan G. Komen Italia (Rome)	The study was supported by grants from the Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna (Italy) (Fundamentally Oriented Funds for Research - RFO) and from Susan G. Komen Italia (Rome).	Afgan E, 2016, NUCLEIC ACIDS RES, V44, pW3, DOI 10.1093/nar/gkw343; BROWN CJ, 1989, AM J HUM GENET, V44, P264; Callari M, 2011, BREAST CANCER RES TR, V127, P601, DOI 10.1007/s10549-010-1015-8; Chaligne R, 2015, GENOME RES, V25, P488, DOI 10.1101/gr.185926.114; Conteduca V, 2017, ANN ONCOL, V28, P1508, DOI 10.1093/annonc/mdx155; Di Lauro L, 2014, BREAST CANCER RES TR, V148, P73, DOI 10.1007/s10549-014-3138-9; Di Oto E, 2015, HUM PATHOL, V46, P1908, DOI 10.1016/j.humpath.2015.08.008; Doebar SC, 2017, MODERN PATHOL, V30, P509, DOI 10.1038/modpathol.2016.229; Graziano F, 2011, J CLIN ONCOL, V29, P4789, DOI 10.1200/JCO.2011.36.7706; Harlan LC, 2010, CANCER-AM CANCER SOC, V116, P3558, DOI 10.1002/cncr.25153; Humphries MP, 2017, SCI REP-UK, V7, DOI 10.1038/srep45293; Koivisto P, 1997, CANCER RES, V57, P314; Kornegoor R, 2015, HISTOPATHOLOGY, V67, P888, DOI 10.1111/his.12727; Lakhani SREI, 2012, WHO CLASSIFICATION T; Mallona I, 2014, SOURCE CODE BIOL MED, V9, DOI 10.1186/1751-0473-9-11; Morandi L, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0386-7; Morandi L, 2017, ENDOCR-RELAT CANCER, V24, P107, DOI 10.1530/ERC-16-0546; Nakopoulou L, 2007, J CLIN PATHOL, V60, P808, DOI 10.1136/jcp.2006.037838; Niewoehner CB, 2008, BMJ-BRIT MED J, V336, P709, DOI 10.1136/bmj.39511.493391.BE; Ottesen AM, 2007, MOL HUM REPROD, V13, P745, DOI 10.1093/molehr/gam053; Piscuoglio S, 2016, CLIN CANCER RES, V22, P4045, DOI 10.1158/1078-0432.CCR-15-2840; Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230; Ropke A, 2004, PROSTATE, V59, P59, DOI 10.1002/pros.10356; Salvi S, 2016, ONCOTARGET, V7, P37839, DOI 10.18632/oncotarget.9341; Severson TM, 2017, ENDOCR-RELAT CANCER, V24, pR27, DOI 10.1530/ERC-16-0225; Swerdlow AJ, 2005, J NATL CANCER I, V97, P1204, DOI 10.1093/jnci/dji240; Vermeulen MA, 2017, EUR J CANCER, V82, P219, DOI 10.1016/j.ejca.2017.01.034; Wolff AC, 2012, JNCI-J NATL CANCER I, V104, P957, DOI 10.1093/jnci/djs243; Zhu J, 2016, CRIT REV ONCOL HEMAT, V98, P358, DOI 10.1016/j.critrevonc.2015.11.013; Zimpfer A, 2007, J CLIN PATHOL, V60, P57, DOI 10.1136/jcp.2005.035758	30	1	1	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					155	163		10.1007/s00428-018-2377-2			9	Pathology	Pathology	GO7VP	WOS:000440285100003	29802469				2019-10-28	
J	Na, K; Lee, JY; Sung, JY; Kim, GM; Koo, JS; Kim, HS				Na, Kiyong; Lee, Jung-Yun; Sung, Ji-Youn; Kim, Gun Min; Koo, Ja Seung; Kim, Hyun-Soo			Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma	VIRCHOWS ARCHIV			English	Article						Peritoneal carcinomatosis; Metastatic breast carcinoma; Primary peritoneal/ovarian carcinoma; Peritoneal fluid cytology; Cytoreductive surgery	EFFUSION CYTOLOGY; OVARIAN-CANCER; ABDOMINAL CARCINOMATOSIS; MICROPAPILLARY CARCINOMA; SEROUS CARCINOMA; RISK-FACTORS; WOMEN; RECEPTOR; MARKERS; ORIGIN	Causes of peritoneal carcinomatosis (PC) in patients with a history of breast carcinoma include both metastatic breast carcinoma (MBC) and primary peritoneal/ovarian carcinoma (PPOC). The origin of PC is important to determine the appropriate treatment strategy. Cytological examination of the peritoneal fluid (PF), which may be the first diagnostic approach to PC, is of distinct value in confirming the presence of malignant cells and determining the origin of PC. We analyzed the clinicopathological and cytomorphological characteristics of 33 patients with a history of breast carcinoma whose PF cytology contained malignant cells. Cases showing positive immunoreactivity for PAX8 and a lack of GATA3 expression were considered as PPOC. Sixteen patients developed PC caused by PPOC. PPOC patients were characterized by early-stage primary breast carcinoma, absence of non-peritoneal MBC before PC, and normal serum levels of CEA and CA15-3. Fourteen PPOC patients had pathogenic germline BRCA mutations. Cytological examination revealed that most of the PPOC cases had a dominant papillary arrangement of the tumor cells with severe nuclear pleomorphism, occasional bizarre nuclei, and atypical mitotic figures. Patients with PPOC who underwent cytoreductive surgery had a significantly longer survival time compared to those who did not, or MBC patients. In patients with a history of breast carcinoma presenting with PC, the presence of early-stage primary breast carcinoma, no prior non-peritoneal MBC, and a dominant papillary cellular arrangement pattern in the PF cytology were independent predictors of PPOC. Cytoreductive surgery significantly improved survival for patients with PPOC.	[Na, Kiyong; Koo, Ja Seung; Kim, Hyun-Soo] Yonsei Univ, Severance Hosp, Coll Med, Dept Pathol, 50-1 Yonsei Ro, Seoul, South Korea; [Lee, Jung-Yun] Yonsei Univ, Inst Womens Life Med Sci, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea; [Sung, Ji-Youn] Kyung Hee Univ, Sch Med, Dept Pathol, Seoul, South Korea; [Kim, Gun Min] Yonsei Univ, Coll Med, Div Med Oncol, Dept Internal Med,Severance Hosp, Seoul, South Korea	Kim, HS (reprint author), Yonsei Univ, Severance Hosp, Coll Med, Dept Pathol, 50-1 Yonsei Ro, Seoul, South Korea.	hyunsookim@yuhs.ac	Na, Kiyong/V-1795-2018	Na, Kiyong/0000-0003-4220-6755; Lee, Jung-Yun/0000-0001-7948-1350; Kim, Gun Min/0000-0001-9167-8682; koo, ja seung/0000-0003-4546-4709	Basic Science Research Program through the National Research Foundation of Korea (NRF) by the Ministry of Education [2016R1D1A1B03935584]; Ministry of Science, ICT and Future Planning [2017R1A2B4007704]	This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) by the Ministry of Education (2016R1D1A1B03935584) and the Ministry of Science, ICT and Future Planning (2017R1A2B4007704).	Bayramoglu H, 2002, DIAGN CYTOPATHOL, V27, P214, DOI 10.1002/dc.10176; Bedrossian CWM, 1998, DIAGN CYTOPATHOL, V18, P141, DOI 10.1002/(SICI)1097-0339(199802)18:2<141::AID-DC11>3.0.CO;2-L; Bertozzi S, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1449-x; Bouganim N, 2013, BREAST CANCER RES TR, V139, P603, DOI 10.1007/s10549-013-2561-7; Cormio G, 2003, GYNECOL ONCOL, V90, P682, DOI 10.1016/S0090-8258(03)00400-1; CURTIN JP, 1994, OBSTET GYNECOL, V84, P449; Garg R, 2005, GYNECOL ONCOL, V99, P65, DOI 10.1016/j.ygyno.2005.05.013; Gown AM, 2016, HISTOPATHOLOGY, V68, P86, DOI 10.1111/his.12877; Gulhan I, 2009, INT J GYNECOL CANCER, V19, P648, DOI 10.1111/IGC.0b013e3181a12e8b; Hahnen E, 2017, BREAST CARE, V12, P15, DOI 10.1159/000455999; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Ingham SL, 2013, J MED GENET, V50, P368, DOI 10.1136/jmedgenet-2013-101607; Jaffer S, 2002, ACTA CYTOL, V46, P1081, DOI 10.1159/000327111; Jung HK, 2017, ANN SURG TREAT RES, V93, P287, DOI 10.4174/astr.2017.93.6.287; Kehl KL, 2016, BREAST CANCER RES TR, V155, P165, DOI 10.1007/s10549-015-3658-y; Kim YA, 2015, CANCER RES TREAT, V47, P583, DOI 10.4143/crt.2014.143; Kumar P, 2016, ARCH GYNECOL OBSTET, V293, P247, DOI 10.1007/s00404-015-3859-y; Lee BH, 2002, AM J CLIN PATHOL, V117, P745, DOI 10.1309/QLV6-HH0H-UCTF-WEF6; Li Qian, 2013, Zhonghua Zhong Liu Za Zhi, V35, P207, DOI 10.3760/cma.j.issn.0253-3766.2013.03.010; Manchanda R, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju380; Meyer P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038361; Na K, 2019, AM J SURG PATHOL, V43, P12, DOI 10.1097/PAS.0000000000000991; Na K, 2017, ANTICANCER RES, V37, P6697, DOI 10.21873/anticanres.12128; Na K, 2017, VIRCHOWS ARCH, V471, P363, DOI 10.1007/s00428-017-2186-z; Nakayama Y, 2016, BREAST CANCER-TOKYO, V23, P633, DOI 10.1007/s12282-015-0615-x; NANCE KV, 1992, DIAGN CYTOPATHOL, V8, P185, DOI 10.1002/dc.2840080219; Pereira TC, 2006, ADV ANAT PATHOL, V13, P174, DOI 10.1097/00125480-200607000-00004; Raptis S, 1996, DIAGN CYTOPATHOL, V15, P1; Rossi S, 2015, CLIN BREAST CANCER, V15, P307, DOI 10.1016/j.clbc.2015.03.010; Sheen-Chen SM, 2008, DIGEST DIS SCI, V53, P3043, DOI 10.1007/s10620-008-0529-y; Sheikh UN, 2016, DIAGN CYTOPATHOL, V44, P369, DOI 10.1002/dc.23448; Shield PW, 2014, CANCER CYTOPATHOL, V122, P307, DOI 10.1002/cncy.21393; Trentham-Dietz A, 2007, BREAST CANCER RES TR, V105, P195, DOI 10.1007/s10549-006-9446-y; Tserkezoglou A, 2006, ANTICANCER RES, V26, P2339; Tuthill M, 2009, EUR J CANCER, V45, P2146, DOI 10.1016/j.ejca.2009.04.027; Wang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-60; Waters L, 2014, ACTA CYTOL, V58, P60, DOI 10.1159/000356426; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Zhang M, 2013, SAUDI MED J, V34, P1270	40	6	6	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					165	175		10.1007/s00428-018-2390-5			11	Pathology	Pathology	GO7VP	WOS:000440285100004	29926183				2019-10-28	
J	Kato, N; Sakamoto, K; Murakami, K; Iwasaki, Y; Kamataki, A; Kurose, A				Kato, Noriko; Sakamoto, Kazuhiro; Murakami, Koutaro; Iwasaki, Yuri; Kamataki, Akihisa; Kurose, Akira			Genetic zygosity of mature ovarian teratomas, struma ovarii, and ovarian carcinoids	VIRCHOWS ARCHIV			English	Article						Genetic zygosity; Ovary; Mature teratoma; Struma ovarii; Carcinoid; Breast tissue; Lactational change	LACTATING BREAST-TISSUE; ORIGIN; BIOLOGY	Although ovarian monodermal teratomas, including struma ovarii and carcinoids, are closely associated with mature teratomas, their genetic basis is poorly understood. A series of mature and monodermal ovarian teratomas were analyzed by short tandem repeat genotyping to evaluate their genetic zygosity and its associations. Informative DNA genotyping data were obtained for ten mature teratomas, six struma ovarii, and three carcinoids (one insular, one trabecular, and one mucinous). A homozygous genotype was present in five of the ten (50%) mature teratomas, three of the six (50%) struma ovarii, and one of the three (33%) ovarian carcinoids. There was no significant difference in genetic zygosity between mature and monodermal teratomas. Patients' age was not correlated with the genetic zygosity: the youngest age in the homozygous tumor group of patients was 4 years. It is suggested that an oocyte after meiosis I, which has escaped from meiotic arrest, is a significant cause of these tumors. Although one mature teratoma was a rare case with lactating adenoma-like breast tissue, its genetic zygosity was concordant with that of the surrounding teratomatous tissue. In one ovarian carcinoid, the carcinoid and accompanying teratomatous components showed matching zygosity at all but one locus: the carcinoid was heterozygous but teratoma was homozygous at one pericentromeric locus. This suggests that not all carcinoids are secondary neoplasms arising from a filly developed mature teratoma: some are neoplasms deviating from a developing mature teratoma.	[Kato, Noriko; Murakami, Koutaro; Iwasaki, Yuri; Kamataki, Akihisa; Kurose, Akira] Hirosaki Univ, Grad Sch Med, Dept Anat Pathol, 5 Zaifu, Hirosaki, Aomori 0368562, Japan; [Sakamoto, Kazuhiro] Oosaki Citizen Hosp, Dept Pathol, Oosaki, Japan	Kato, N (reprint author), Hirosaki Univ, Grad Sch Med, Dept Anat Pathol, 5 Zaifu, Hirosaki, Aomori 0368562, Japan.	nor-kato@hirosaki-u.ac.jp					Alberts B, 2015, MOLECULAR BIOLOGY OF THE CELL, SIXTH EDITION, P963; DAHL N, 1990, CANCER GENET CYTOGEN, V46, P115, DOI 10.1016/0165-4608(90)90017-5; DEKA R, 1990, AM J HUM GENET, V47, P644; Devouassoux-Shisheboran M, 2000, LAB INVEST, V80, P81, DOI 10.1038/labinvest.3780011; Kleist B, 2015, WORLD J GASTROENTERO, V21, P11740, DOI 10.3748/wjg.v21.i41.11740; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; Ohtaki H, 2002, ELECTROPHORESIS, V23, P3332, DOI 10.1002/1522-2683(200210)23:19<3332::AID-ELPS3332>3.0.CO;2-8; OI RH, 1978, AM J OBSTET GYNECOL, V130, P729, DOI 10.1016/0002-9378(78)90342-3; Prat J, 2014, WHO CLASSIFICATION T, P63; Prat J, 2014, PATHOLOGY FEMALE REP, P670; Sitasuwan T, 2015, BMC ENDOCR DISORD, V15, DOI 10.1186/s12902-015-0060-z; Snir OL, 2017, MODERN PATHOL, V30, P1467, DOI 10.1038/modpathol.2017.66; SURTI U, 1990, AM J HUM GENET, V47, P635; ULIRSCH RC, 1982, OBSTET GYNECOL, V60, P400; Vortmeyer AO, 1999, AM J PATHOL, V154, P987, DOI 10.1016/S0002-9440(10)65350-3; WOODRUFF JD, 1966, OBSTET GYNECOL, V27, P194	16	2	2	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					177	182		10.1007/s00428-018-2319-z			6	Pathology	Pathology	GO7VP	WOS:000440285100005	29455317				2019-10-28	
J	Andruszkow, J; Meinhold-Heerlein, I; Winkler, B; Bruno, B; Knuchel, R; Jakel, J				Andruszkow, Julia; Meinhold-Heerlein, Ivo; Winkler, Brigitte; Bruno, Benjamin; Knuechel, Ruth; Jaekel, Joerg			The impact of complete embedding of remaining tissue in gynecological lymph node dissection specimen in surgical pathology on lymph node yield: is it clinically relevant?	VIRCHOWS ARCHIV			English	Article						Lymph nodes; Gynecology; Cancer; Metastases	ENDOMETRIAL CANCER; PELVIC LYMPHADENECTOMY; UTERINE-CANCER; SURVIVAL; HYSTERECTOMY; STANDARD; THERAPY; COUNTS; NUMBER; WOMEN	The assessment of nodal metastases in gynecological surgical specimen is an important staging parameter, directing further therapeutic procedures. Since the number of lymph nodes (LNs) removed is seen as an indicator of surgical and pathological quality, the demand for higher lymph node (LN) counts is raising. The goal of this prospective study was the comparison between lymph node counts of macroscopically detectable LNs and the LN yield by complete embedding and proceeding of all submitted LN-containing tissue in the pathology laboratory. One hundred six cases of cervical, uterine, or ovarian cancer, treated in three different hospitals within 3 years. were analyzed. All tissue submitted to the pathology from the surgically performed LN dissections was completely dissected and embedded in the institute of pathology. Subsequently, the amount of LN of all macroscopically detectable nodes was compared to the final histologically reached numbers of LN. Furthermore the histologically visible area of the LNs and their metastases was analyzed to assess the relation of LN numbers to the whole examined LN area. Complete embedding raises the average number of LN counted by 3 to 7 but did only minimally increase the LN area for microscopical examination by about 5% due to the small area of the additional LNs in the remaining fat tissue. The staging was in no case altered by complete embedding, even when additional nodal metastases were detected in the remaining fat tissue, since this was only seen in cases which had already metastatic nodes. Complete embedding of LN-containing tissue did not provide relevant additional staging information and seems therefore unnecessarily laborious, careful pathological work-up assumed.	[Andruszkow, Julia; Knuechel, Ruth; Jaekel, Joerg] Uniklin RWTH Aachen, Inst Pathol, Aachen, Germany; [Meinhold-Heerlein, Ivo; Winkler, Brigitte] Uniklin RWTH Aachen, Clin Gynecol & Obstet, Aachen, Germany; [Bruno, Benjamin] Acad Teaching Hosp RWTH Aachen, Luisenhosp Aachen, Clin Gynecol & Obstet, Aachen, Germany; [Jaekel, Joerg] Mainz Univ, Inst Pathol, Med Ctr, Mainz, Germany	Jakel, J (reprint author), Uniklin RWTH Aachen, Inst Pathol, Aachen, Germany.; Jakel, J (reprint author), Mainz Univ, Inst Pathol, Med Ctr, Mainz, Germany.	jojaekel@uni-mainz.de		Jakel, Jorg/0000-0003-2867-5360			Bell MC, 2008, GYNECOL ONCOL, V111, P407, DOI 10.1016/j.ygyno.2008.08.022; Chan JK, 2007, CANCER, V109, P2454, DOI 10.1002/cncr.22727; Cormier B, 2012, INT J GYNECOL CANCER, V22, P1361, DOI 10.1097/IGC.0b013e318269e29d; Eklind S, 2015, INT J GYNECOL CANCER, V25, P250, DOI 10.1097/IGC.0000000000000357; Euscher ED, 2011, AM J SURG PATHOL, V35, P913, DOI 10.1097/PAS.0b013e31821899be; Fleming ND, 2015, INT J GYNECOL CANCER, V25, P1437, DOI 10.1097/IGC.0000000000000510; Forde GK, 2011, INT J GYNECOL PATHOL, V30, P335, DOI 10.1097/PGP.0b013e31820dc39d; Frost JA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007585.pub4; Fujimoto T, 2009, CURR OPIN OBSTET GYN, V21, P10, DOI 10.1097/GCO.0b013e32831ac3ac; Hareyama H, 2012, INT J GYNECOL CANCER, V22, P1577, DOI 10.1097/IGC.0b013e31826fd644; Hiura M, 2010, INT J GYNECOL CANCER, V20, P1000, DOI 10.1111/IGC.0b013e3181d80aff; Johnson L, 2017, J ROBOT SURG, V11, P291, DOI 10.1007/s11701-016-0651-3; Kokka F, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010260.pub2; Lanowska M, 2010, ONCOLOGY-BASEL, V79, P161, DOI 10.1159/000322158; Lin JF, 2016, BJOG-INT J OBSTET GY, V123, P1846, DOI 10.1111/1471-0528.13726; Mariani A, 2008, GYNECOL ONCOL, V109, P11, DOI 10.1016/j.ygyno.2008.01.023; McMeekin D Scott, 2003, Curr Treat Options Oncol, V4, P121, DOI 10.1007/s11864-003-0013-z; Pereira A, 2013, EJSO-EUR J SURG ONC, V39, P290, DOI 10.1016/j.ejso.2012.12.006; Possover M, 1998, GYNECOL ONCOL, V71, P19, DOI 10.1006/gyno.1998.5107; Salman MC, 2010, J GYNECOL ONCOL, V21, P24, DOI 10.3802/jgo.2010.21.1.24; Santoso JT, 2009, GYNECOL ONCOL, V113, P159, DOI 10.1016/j.ygyno.2009.02.001; Scribner DR, 2001, GYNECOL ONCOL, V82, P498, DOI 10.1006/gyno.2001.6314; Stehman FB, 2009, GYNECOL ONCOL, V113, P52, DOI 10.1016/j.ygyno.2008.12.028; Vidal F, 2013, OBSTET GYNECOL INT, DOI 10.1155/2013/892465; Wong AT, 2016, GYNECOL ONCOL, V142, P514, DOI 10.1016/j.ygyno.2016.07.091; Zaal A, 2014, INT J GYNECOL CANCER, V24, P303, DOI 10.1097/IGC.0000000000000043	26	0	0	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					183	188		10.1007/s00428-018-2363-8			6	Pathology	Pathology	GO7VP	WOS:000440285100006	29705969				2019-10-28	
J	Martin, B; Schafer, E; Jakubowicz, E; Mayr, P; Ihringer, R; Anthuber, M; Schenkirsch, G; Schaller, T; Markl, B				Martin, Benedikt; Schaefer, Eva; Jakubowicz, Elzbieta; Mayr, Patrick; Ihringer, Regina; Anthuber, Matthias; Schenkirsch, Gerhard; Schaller, Tina; Maerkl, Bruno			Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?	VIRCHOWS ARCHIV			English	Article						Colon cancer; Tumor budding; Interobserver variability; Prognostic factor; Histology	HIGH-RISK PATIENTS; COLORECTAL-CANCER; SURVIVAL; MARKER; INDEX	Tumor budding is a mostly accepted adverse prognostic factor in colorectal carcinoma. It is on the cusp of a widespread use after agreement was reached recently on uniform assessment criteria. We investigated whether the interobserver variability has a direct influence on the prognostic relevance in pT3/4 colon cancer in the background of different levels of experience of the investigators. In total, six investigators with different levels of experience evaluated tumor budding on H&E slides in 244 cases with primary diagnosed (2002-2011) colon carcinoma (pT3/4, N+/-, MO). High-grade tumor budding/budding grade 3 (defined as majority assessment among the investigators) was significantly associated with an adverse outcome (overall survival p = 0.03, cancer-specific survivalp = 0.08) and the occurrence of distant metastasis (p = 0.009). However, a detailed analysis of the rating results of the individual investigators revealed that only ratings of one investigator (advanced resident) were associated with an adverse outcome (p = 0.01 cancer-specific survival, overall survivalp = 0.09, distant metastasisp = 0.002). The results of another investigator (consultant) were significantly associated with distant metastasis (p = 0.007). The kappa values among the investigators have a range between 0.077 and 0.357 (median 0.166). Total agreement of all investigators existed in 109 cases (44.7%). Our results demonstrate that the evaluation of tumor budding on H&E slides in pT3/4 colon cancer goes along with a considerable interobserver variability among investigators of different levels of experience. Furthermore, our results reveal that these findings directly influence the prognostic value.	[Martin, Benedikt; Schaefer, Eva; Jakubowicz, Elzbieta; Mayr, Patrick; Ihringer, Regina; Schaller, Tina; Maerkl, Bruno] Klinikum Augsburg, Inst Pathol, Stenglinstr 2, D-86156 Augsburg, Germany; [Anthuber, Matthias] Klinikum Augsburg, Dept Visceral Surg, Augsburg, Germany; [Schenkirsch, Gerhard] Clin & Populat Based Canc Registry Augsburg Augsb, Augsburg, Germany	Martin, B (reprint author), Klinikum Augsburg, Inst Pathol, Stenglinstr 2, D-86156 Augsburg, Germany.	benedikt.martin@klinikum-augsburg.de		, Benedikt/0000-0002-2314-3261	Hermann-Egger Foundation	The study was supported by the Hermann-Egger Foundation with 3000 Euro. The Hermann-Egger Foundation is a social foundation, which supports mainly regional projects (incl. science) in Augsburg.	Cappellesso R, 2017, HUM PATHOL, V65, P62, DOI 10.1016/j.humpath.2017.04.013; Choi HJ, 2007, INT J COLORECTAL DIS, V22, P863, DOI 10.1007/s00384-006-0249-8; Dawson H, 2017, J CLIN ONCOL, V35; Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504; HASE K, 1993, DIS COLON RECTUM, V36, P627, DOI 10.1007/BF02238588; Kai K, 2016, PATHOL INT, V66, P75, DOI 10.1111/pin.12374; Kanazawa H, 2008, COLORECTAL DIS, V10, P41, DOI 10.1111/j.1463-1318.2007.01240.x; Koelzer VH, 2017, J PATHOL CLIN RES, V3, P171, DOI 10.1002/cjp2.73; Koelzer VH, 2015, VIRCHOWS ARCH, V466, P485, DOI 10.1007/s00428-015-1740-9; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Markl B, 2010, J SURG ONCOL, V102, P235, DOI 10.1002/jso.21611; Markl B, 2017, GASTROENT RES PRACT, P1, DOI 10.1155/2017/6504960; Markl B, 2016, CANCER MED-US, V5, P1492, DOI 10.1002/cam4.737; Markl B, 2011, EXPERT REV ANTICANC, V11, P1521, DOI [10.1586/ERA.11.156, 10.1586/era.11.156]; Mitrovic B, 2012, MODERN PATHOL, V25, P1315, DOI 10.1038/modpathol.2012.94; Nakamura T, 2008, DIS COLON RECTUM, V51, P568, DOI 10.1007/s10350-008-9192-9; O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275; Ohtsuki K, 2008, ANTICANCER RES, V28, P1831; Okuyama T, 2003, DIS COLON RECTUM, V46, P1400, DOI 10.1097/01.DCR.0000084413.78455.89; Prall F, 2005, HISTOPATHOLOGY, V47, P17, DOI 10.1111/j.1365-2559.2005.02161.x; Puppa G, 2012, HISTOPATHOLOGY, V61, P562, DOI 10.1111/j.1365-2559.2012.04270.x; Rogers AC, 2016, BRIT J CANCER, V115, P831, DOI 10.1038/bjc.2016.274; Shinto E, 2006, DIS COLON RECTUM, V49, P1422, DOI 10.1007/s10350-006-0595-1; Suzuki A, 2009, AM J SURG PATHOL, V33, P1601, DOI 10.1097/PAS.0b013e3181ae29d6; Sy J, 2010, DIS COLON RECTUM, V53, P301, DOI 10.1007/DCR.0b013e3181c3ed05; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Ueno H, 2004, ANN SURG, V240, P832, DOI 10.1097/01.sla.0000143243.81014.f2; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55	30	3	3	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					189	197		10.1007/s00428-018-2341-1			9	Pathology	Pathology	GO7VP	WOS:000440285100007	29626253				2019-10-28	
J	Neumann, J; Heinemann, V; Engel, J; Kirchner, T; Stintzing, S				Neumann, Jens; Heinemann, Volker; Engel, Jutta; Kirchner, Thomas; Stintzing, Sebastian			The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer	VIRCHOWS ARCHIV			English	Article						Colorectal cancer; Distant metastasis; Survival; CDX2; MMR	COLON-CANCER; MICROSATELLITE INSTABILITY; SERRATED PATHWAY; HOMEOBOX GENE; REDUCED CDX2; STAGE-II; EXPRESSION; DEFICIENCY; PHENOTYPE; FEATURES	Loss of CDX2 expression has been proposed to be a prognostic biomarker in colorectal cancer (CRC) correlating with shorter overall (OS) and progression-free survival (PFS). Since metastatic disease, mismatch repair (MMR) deficiency, and the mutational status of BRAF are considered to be important prognostic determinants in CRC, the present study aimed to analyze CDX2 expression in correlation with these parameters. Immunohistochemistry for CDX2, hMLH1, and hMSH2 was applied to a study cohort of 503 CRC specimens (FIRE-3) and a matched case-control collection of 50 right-sided CRC specimens with synchronous distant metastases and 50 right-sided CRCs without distant metastases. Furthermore, the mutational status of BRAF gene was analyzed utilizing pyrosequencing. CDX2 expression significantly correlates with reduced OS (p = 0.008) within the study population. In both cohorts, a significant correlation of CDX2 expression and MMR deficiency as well as the presence of a BRAF mutation (each p > 0.001) was observed, whereas no correlation of CDX2 expression and synchronous metastasis could be obtained. In the case-control study, only patients with proficient MMR status showed a correlation of CDX2 loss and synchronous metastasis, whereas in patients with deficient MMR status and CDX2 loss, no distant metastases at the time of diagnosis were found (p = 0.003). We could demonstrate that the reduced OS of CDX2-negative CRC patients is not caused by higher rates of distant metastases. Furthermore, our data indicate that the prognostic impact of CDX2 depends on the MMR status and the BRAF mutational status of the tumors. Thus, it could be concluded that CDX2 is not an independent prognostic biomarker in CRC.	[Neumann, Jens; Kirchner, Thomas] Ludwig Maximilians Univ Munchen, Inst Pathol, Med Fac, Thalkirchner Str 36, D-80337 Munich, Germany; [Heinemann, Volker; Stintzing, Sebastian] Ludwig Maximiliams Univ Munchen, Univ Hosp Grosshadern, Dept Med 3, Munich, Germany; [Heinemann, Volker; Kirchner, Thomas] German Canc Consortium DKTK, D-69120 Heidelberg, Germany; [Heinemann, Volker; Kirchner, Thomas] German Canc Res Ctr, D-69120 Heidelberg, Germany; [Engel, Jutta] Ludwig Maximilians Univ Munchen, MCR, Munich Tumor Ctr TZM, Dept Med Informat Proc Biometry & Epidemiol IBE, Munich, Germany	Neumann, J (reprint author), Ludwig Maximilians Univ Munchen, Inst Pathol, Med Fac, Thalkirchner Str 36, D-80337 Munich, Germany.	jens.neumann@med.uni-muenchen.de			Merck Serono GmbH, an affiliate of Merck KGaA, Darmstadt, Germany	The study received support from Merck Serono GmbH, an affiliate of Merck KGaA, Darmstadt, Germany.	Baba Y, 2009, CLIN CANCER RES, V15, P4665, DOI 10.1158/1078-0432.CCR-09-0401; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Bosman FT, 2010, WHO CLASSIFICATION T; Brierley JD, 2017, TNM CLASSIFICATION M; Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597; Dawson H, 2014, INT J CANCER, V134, P2342, DOI 10.1002/ijc.28564; Dawson H, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00265; Desch CE, 2005, J CLIN ONCOL, V23, P8512, DOI 10.1200/JCO.2005.04.0063; Gkekas I, 2017, ANTICANCER RES, V37, P6563, DOI 10.21873/anticanres.12113; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Herr R, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2014.1002709; Hinoi T, 2001, AM J PATHOL, V159, P2239, DOI 10.1016/S0002-9440(10)63074-X; Hong KD, 2013, AM SURGEON, V79, P353; Hryniuk A, 2014, J BIOL CHEM, V289, P33343, DOI 10.1074/jbc.M114.583823; Kim CG, 2016, BRIT J CANCER, V115, P25, DOI 10.1038/bjc.2016.161; Landau MS, 2014, HUM PATHOL, V45, P1704, DOI 10.1016/j.humpath.2014.04.008; Lugli A, 2008, MODERN PATHOL, V21, P1403, DOI 10.1038/modpathol.2008.117; Malesci A, 2007, CLIN CANCER RES, V13, P3831, DOI 10.1158/1078-0432.CCR-07-0366; O'Brien MJ, 2015, HISTOPATHOLOGY, V66, P49, DOI 10.1111/his.12564; Olsen J, 2016, EXP MOL PATHOL, V100, P59, DOI 10.1016/j.yexmp.2015.11.009; Olsen J, 2014, SURG ONCOL, V23, P167, DOI 10.1016/j.suronc.2014.07.003; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Zarour LR, 2017, CELL MOL GASTROENTER, V3, P163, DOI 10.1016/j.jcmgh.2017.01.006	24	1	1	2	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					199	207		10.1007/s00428-018-2360-y			9	Pathology	Pathology	GO7VP	WOS:000440285100008	29675807				2019-10-28	
J	Zanini, B; Villanacci, V; Marullo, M; Cadei, M; Lanzarotto, F; Bozzola, A; Ricci, C				Zanini, Barbara; Villanacci, Vincenzo; Marullo, Monica; Cadei, Moris; Lanzarotto, Francesco; Bozzola, Anna; Ricci, Chiara			Duodenal histological features in suspected non-celiac gluten sensitivity: new insights into a still undefined condition	VIRCHOWS ARCHIV			English	Article							WHEAT SENSITIVITY; NONCELIAC GLUTEN; DISEASE; DIAGNOSIS; CRITERIA		[Zanini, Barbara; Marullo, Monica; Lanzarotto, Francesco; Ricci, Chiara] Univ Brescia, Dept Clin & Expt Sci, Gastroenterol Unit, Viale Europa 11, I-25123 Brescia, Italy; [Villanacci, Vincenzo; Cadei, Moris; Bozzola, Anna] Spedali Civil Brescia, Inst Pathol, Piazzale Spedali Civili 1, I-25123 Brescia, Italy	Zanini, B (reprint author), Univ Brescia, Dept Clin & Expt Sci, Gastroenterol Unit, Viale Europa 11, I-25123 Brescia, Italy.	barbara.zanini@unibs.it		Zanini, Barbara/0000-0002-1733-9938			Bardella Maria Teresa, 2016, Curr Gastroenterol Rep, V18, P63, DOI 10.1007/s11894-016-0536-7; Catassi C, 2015, NUTRIENTS, V7, P4966, DOI 10.3390/nu7064966; Corazza GR, 2007, CLIN GASTROENTEROL H, V5, P838, DOI 10.1016/j.cgh.2007.03.019; Gibson PR, 2017, J GASTROEN HEPATOL, V32, P86, DOI 10.1111/jgh.13705; Hayat M, 2002, J CLIN PATHOL, V55, P393, DOI 10.1136/jcp.55.5.393; Hurrell JM, 2011, ADV ANAT PATHOL, V18, P335, DOI 10.1097/PAP.0b013e318229bfe2; Lanzini A, 2009, ALIMENT PHARM THER, V29, P1299, DOI 10.1111/j.1365-2036.2009.03992.x; Molina-Infante J, 2015, ALIMENT PHARM THER, V41, P807, DOI 10.1111/apt.13155; Molina-Infante J, 2017, CLIN GASTROENTEROL H, V15, P339, DOI 10.1016/j.cgh.2016.08.007; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Ravelli A, 2012, PATHOL RES PRACT, V208, P197, DOI 10.1016/j.prp.2012.01.008; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Talley NJ, 2017, JAMA INTERN MED, V177, P615, DOI 10.1001/jamainternmed.2017.0695; Uhde M, 2016, GUT, V65, P1930, DOI 10.1136/gutjnl-2016-311964; Villanacci V, 2013, AM J GASTROENTEROL, V108, P619, DOI 10.1038/ajg.2013.22; Villanacci V, 2011, DIGEST LIVER DIS, V43, pS385, DOI 10.1016/S1590-8658(11)60594-X; Walker MM, 2010, GASTROENTEROLOGY, V139, P112, DOI 10.1053/j.gastro.2010.04.007; Watkins RD, 2017, PEDIATR CLIN N AM, V64, P563, DOI 10.1016/j.pcl.2017.01.013; Zanini B, 2015, ALIMENT PHARM THER, V42, P968, DOI 10.1111/apt.13372	19	8	8	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					229	234		10.1007/s00428-018-2346-9			6	Pathology	Pathology	GO7VP	WOS:000440285100011	29619556				2019-10-28	
J	Baur, V; Papadopoulos, T; Kazakov, DV; Agaimy, A; Hartmann, A; Isbary, G; Wirtz, RM; Schultz, ES				Baur, Vera; Papadopoulos, Thomas; Kazakov, Dmitry, V; Agaimy, Abbas; Hartmann, Arndt; Isbary, Georg; Wirtz, Ralph M.; Schultz, Erwin S.			A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib	VIRCHOWS ARCHIV			English	Article						CYLD; Vismodegib; Trichoepithelioma; Brooke syndrome; Hedgehog pathway	BROOKE-SPIEGLER-SYNDROME; TRICHOBLASTIC CARCINOMA; SOMATIC-MUTATIONS; CYLD GENE; CYLINDROMATOSIS	Multiple familial trichoepitheliomas (MFT) is an autosomal dominantly inherited disease characterized by multiple skin appendage tumors. We describe a patient showing a continuous spectrum of follicular differentiated neoplasms including classical trichoepitheliomas but also infiltrative growing and finally metastasizing malignant follicular differentiated tumors. Germline mutation analysis revealed a nonsense mutation in the cylindromatosis (CYLD) gene. Gene expression analysis by real-time PCR of tumor tissue showed overexpression of glioma-associated oncogene Glil mRNA. Treatment with the Hedgehog pathway inhibitor vismodegib resulted in a significant regression of the highly differentiated trichoepitheliomas. Gli upregulation is indicative of an active Hedgehog signaling pathway. We hypothesize that its upregulation is indirectly caused by CYLD mutation which promotes tumor development. Vismodegib treatment could thus provide a new treatment option for patients with this debilitating disorder.	[Baur, Vera; Schultz, Erwin S.] Paracelsus Med Univ Nuremberg, Dept Dermatol, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany; [Papadopoulos, Thomas] Paracelsus Med Univ Nuremberg, Inst Pathol, Prof Ernst Nathan Str 1, D-90482 Nurnberg, Germany; [Kazakov, Dmitry, V] Charles Univ Prague, Med Fac Pilsen, Dept Pathol, Alej Svobody 80, Plzen 30460, Czech Republic; [Agaimy, Abbas; Hartmann, Arndt] Friedrich Alexander Univ, Inst Pathol, Krankenhausstr 8-10, D-91054 Erlangen, Germany; [Isbary, Georg] Roche Pharma AG, Emil Barell Str 1, D-79639 Grenzach, Germany; [Wirtz, Ralph M.] STRATIFYER Mol Pathol GmbH, Werthmannstr 1, D-50935 Cologne, Germany; [Wirtz, Ralph M.] St Elizabeth Hosp, Inst Pathol, Werthmannstr 1, D-50935 Cologne, Germany	Schultz, ES (reprint author), Paracelsus Med Univ Nuremberg, Dept Dermatol, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany.	vera.baur@klinikum-nuernberg.de; Thomas.papadopoulos@klinikum-nuernberg.de; kazakov@medima.cz; abbas.agaimy@uk-erlangen.de; arndt.hartmann@uk-erlangen.de; georg.isbary@roche.com; ralph.wirtz@stratifyer.de; Erwin.Schultz@klinikum-nuernberg.de					Blake PW, 2009, HUM MUTAT, V30, P1025, DOI 10.1002/humu.21024; Bohmann K, 2009, CLIN CHEM, V55, P1719, DOI 10.1373/clinchem.2008.122572; Bowen S, 2005, J INVEST DERMATOL, V124, P919, DOI 10.1111/j.0022-202X.2005.23688.x; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Harada H, 1996, J INVEST DERMATOL, V107, P41, DOI 10.1111/1523-1747.ep12297860; HUNT SJ, 1991, AM J DERMATOPATH, V13, P275, DOI 10.1097/00000372-199106000-00010; Kazakov DV, 2010, J CUTAN PATHOL, V37, P886, DOI 10.1111/j.1600-0560.2010.01511.x; Lee KH, 2008, ACTA DERM-VENEREOL, V88, P43, DOI 10.2340/00015555-0322; Lepesant P, 2015, BRIT J DERMATOL, V173, P1059, DOI 10.1111/bjd.13919; Masoumi KC, 2011, J SKIN CANCER, DOI 10.1155/2011/614097; Schulz T, 2005, AM J DERMATOPATH, V27, P9, DOI 10.1097/01.dad.0000142240.93956.cb; Sima R, 2010, DIAGN MOL PATHOL, V19, P83, DOI 10.1097/PDM.0b013e3181ba2d96; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Varjosalo M, 2008, CELL, V133, P537, DOI 10.1016/j.cell.2008.02.047	14	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					241	246		10.1007/s00428-018-2397-y			6	Pathology	Pathology	GO7VP	WOS:000440285100013	29934657				2019-10-28	
J	Miyazaki, T; Aishima, S; Fujino, M; Ozono, K; Kubo, Y; Ushijima, Y; Osoegawa, T; Ihara, E; Tetsuhide, I; Ohtsuka, T; Nakamura, M; Oda, Y				Miyazaki, Tetsuyuki; Aishima, Shinichi; Fujino, Minoru; Ozono, Keigo; Kubo, Yuichiro; Ushijima, Yasuhiro; Osoegawa, Takashi; Ihara, Eikichi; Tetsuhide, Itou; Ohtsuka, Takao; Nakamura, Masafumi; Oda, Yoshinao			Neuroendocrine tumor of the pancreas with rhabdoid feature	VIRCHOWS ARCHIV			English	Article						Neuroendocrine tumor; Rhabdoid feature; Cytoplasmic inclusion; Pancreas	ENDOCRINE TUMORS; LINDAU-DISEASE; CARCINOMA; NEOPLASMS; CELLS; INCLUSIONS; PHENOTYPE; WHORLS	Imaging of a 53-year-old Japanese man revealed two tumors in the liver and a tumor in the head of the pancreas with a swelling lymph node. A needle biopsy for the liver tumors was performed, revealing a neuroendocrine tumor. Enucleation, lymphadenectomy, and partial hepatectomy were performed. The microscopic examination identified many tumor cells with intracytoplasmic inclusions arranged in a nested, cord, or tubular fashion. The intracytoplasmic inclusions displayed densely eosinophilic globules and displaced the nuclei toward the periphery, which constitutes "rhabdoid" features. The tumor cells were positive for synaptophysin and weakly positive for NCAM, but negative for chromogranin A. Epithelial markers (AEl/AE3 and CAM5.2) accentuated intracytoplasmic globules. Pancreatic neuroendocrine tumors with rhabdoid features are very rare. Generally, rhabdoid features are aggressive and dedifferentiated characteristics of various types of tumor. Pancreatic neuroendocrine tumors containing rhabdoid cells tend to display extrapancreatic spread at the time of presentation, although some of these tumors with rhabdoid features are not always associated with aggressive behavior.	[Miyazaki, Tetsuyuki; Ozono, Keigo; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan; [Miyazaki, Tetsuyuki; Fujino, Minoru; Ozono, Keigo; Ohtsuka, Takao; Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Fukuoka, Japan; [Aishima, Shinichi] Saga Univ, Fac Med, Dept Pathol & Microbiol, Saga, Japan; [Kubo, Yuichiro; Ushijima, Yasuhiro] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka, Fukuoka, Japan; [Osoegawa, Takashi; Ihara, Eikichi; Tetsuhide, Itou] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Fukuoka, Japan	Oda, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.	oda@surgpath.med.kyushu-u.ac.jp					Albores-Saavedra J, 2001, MODERN PATHOL, V14, P98, DOI 10.1038/modpathol.3880263; Amrikachi Mojghan, 2002, Ann Diagn Pathol, V6, P357, DOI 10.1053/adpa.2002.36657; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; Chetty R, 1997, EUR J SURG ONCOL, V23, P432, DOI 10.1016/S0748-7983(97)93725-2; Chetty R, 2004, J CLIN PATHOL, V57, P1106, DOI 10.1136/jcp.2004.018309; GOTCHALL J, 1987, HUM PATHOL, V18, P967, DOI 10.1016/S0046-8177(87)80278-2; Hoang MP, 2001, AM J SURG PATHOL, V25, P602, DOI 10.1097/00000478-200105000-00006; Klimstra DS, 2010, WHO CLASSIFICATION T, P281; Lubensky IA, 1998, AM J PATHOL, V153, P223, DOI 10.1016/S0002-9440(10)65563-0; Nappi O, 1999, SEMIN DIAGN PATHOL, V16, P82; Pacchioni D, 1996, ACTA CYTOL, V40, P742; Perez-Montiel MD, 2003, AM J SURG PATHOL, V27, P642, DOI 10.1097/00000478-200305000-00007; Serra S, 2006, ENDOCR PATHOL, V17, P75, DOI 10.1385/EP:17:1:75; Shia J, 2004, AM J SURG PATHOL, V28, P271, DOI 10.1097/00000478-200402000-00018; Shimazaki H, 2001, HISTOPATHOLOGY, V38, P425, DOI 10.1046/j.1365-2559.2001.01145.x; Terada R, 2004, SURG TODAY, V34, P177, DOI 10.1007/s00595-003-2650-z; WICK MR, 1995, SEMIN DIAGN PATHOL, V12, P233; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515	18	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					247	252		10.1007/s00428-018-2398-x			6	Pathology	Pathology	GO7VP	WOS:000440285100014	29938394	Other Gold, Green Published			2019-10-28	
J	Nasierowska-Guttmejer, A; Szawlowski, A				Nasierowska-Guttmejer, Anna; Szawlowski, Andrzej			How to standardize the evaluation of tumor regression grading of gastrointestinal cancers after neoadjuvant therapy?	VIRCHOWS ARCHIV			English	Letter							RECTAL-CANCER		[Nasierowska-Guttmejer, Anna] Jan Kochanowski Univ Humanities & Sci, Fac Med & Hlth Sci, Kielce, Poland; [Nasierowska-Guttmejer, Anna; Szawlowski, Andrzej] Cent Clin Hosp Minist Internal, Warsaw, Poland	Nasierowska-Guttmejer, A (reprint author), Jan Kochanowski Univ Humanities & Sci, Fac Med & Hlth Sci, Kielce, Poland.; Nasierowska-Guttmejer, A (reprint author), Cent Clin Hosp Minist Internal, Warsaw, Poland.	anna.guttmejer@gmail.com					Bujko K, 2013, RADIOTHER ONCOL, V107, P171, DOI 10.1016/j.radonc.2013.03.001; Bujko K, 2010, RADIOTHER ONCOL, V95, P298, DOI 10.1016/j.radonc.2010.04.005; Chmielik E, 2006, INT J RADIAT ONCOL, V65, P182, DOI 10.1016/j.ijrobp.2005.11.039; Nasierowska-Guttmejer A, 1995, DIS ESOPHAGUS, V8, P136	4	0	0	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					255	256		10.1007/s00428-018-2391-4			2	Pathology	Pathology	GO7VP	WOS:000440285100015	29931470				2019-10-28	
J	Langer, R; Becker, K				Langer, Rupert; Becker, Karen			Reply to the letter "How to standardize the evaluation of tumor regression grading of gastrointestinal cancers after neoadjuvant therapy?" by Dr. Nasierowska-Guttmejer and Dr. Szawlowski, VIAR-D-18-00181	VIRCHOWS ARCHIV			English	Letter							RECTAL-CANCER; CHEMORADIATION		[Langer, Rupert; Becker, Karen] Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland; [Becker, Karen] Tech Univ Munich, Inst Pathol, Munich, Germany	Langer, R (reprint author), Univ Bern, Inst Pathol, Murtenstr 31, CH-3008 Bern, Switzerland.	rupert.langer@pathology.unibe.ch					Bujko K, 2013, RADIOTHER ONCOL, V107, P171, DOI 10.1016/j.radonc.2013.03.001; Bujko K, 2010, RADIOTHER ONCOL, V95, P298, DOI 10.1016/j.radonc.2010.04.005; Chmielik E, 2006, INT J RADIAT ONCOL, V65, P182, DOI 10.1016/j.ijrobp.2005.11.039; Glynne-Jones R, 2006, INT J RADIAT ONCOL, V66, P319, DOI 10.1016/j.ijrobp.2006.05.047; Langer R, 2018, VIRCHOWS ARCH, V472, P175, DOI 10.1007/s00428-017-2232-x; MacGregor TP, 2012, J CLIN PATHOL, V65, P867, DOI 10.1136/jclinpath-2012-200958; Nasierowska-Guttmejer A, 1995, DIS ESOPHAGUS, V8, P136	7	0	0	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					257	258		10.1007/s00428-018-2392-3			2	Pathology	Pathology	GO7VP	WOS:000440285100016	29926186				2019-10-28	
J	Barresi, V				Barresi, Valeria			HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder	VIRCHOWS ARCHIV			English	Letter							URINARY-BLADDER; PROSTATE; MARKER; ADENOCARCINOMA; ORIGIN		[Barresi, Valeria] Univ Messina, Dept Human Pathol Adulthood & Evolut Age, Messina, Italy; [Barresi, Valeria] Polyclin G Martino, Dept Human Pathol, Via Consolare Valeria, I-98125 Messina, Italy	Barresi, V (reprint author), Univ Messina, Dept Human Pathol Adulthood & Evolut Age, Messina, Italy.; Barresi, V (reprint author), Polyclin G Martino, Dept Human Pathol, Via Consolare Valeria, I-98125 Messina, Italy.	vbarresi@unime.it		Barresi, Valeria/0000-0001-7086-1920			Barresi V, 2016, APMIS, V124, P188, DOI 10.1111/apm.12483; Larnaudie L, 2017, VIRCHOWS ARCH, V471, P133, DOI 10.1007/s00428-017-2134-y; Lopez-Beltran A, 2005, ARCH PATHOL LAB MED, V129, P683; Moch H, 2016, WHO CLASSIFICATION T; Parwani AV, 2006, AM J SURG PATHOL, V30, P1254, DOI 10.1097/01.pas.0000209841.77595.4b; Samaratunga H, 2016, HISTOPATHOLOGY, V68, P533, DOI 10.1111/his.12785; SHANNON RL, 1992, CANCER, V69, P2676, DOI 10.1002/1097-0142(19920601)69:11<2676::AID-CNCR2820691109>3.0.CO;2-P; Varinot J, 2013, VIRCHOWS ARCH, V463, P803, DOI 10.1007/s00428-013-1495-0; Zhuang YH, 1997, HISTOPATHOLOGY, V30, P556, DOI 10.1046/j.1365-2559.1997.5610801.x	9	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					259	260		10.1007/s00428-018-2394-1			2	Pathology	Pathology	GO7VP	WOS:000440285100017	29926185				2019-10-28	
J	Varinot, J; Comperat, E				Varinot, Justine; Comperat, Eva			Letter to the editor: reply to Valeria Barresi "HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder"	VIRCHOWS ARCHIV			English	Letter							USEFUL MARKER; PROSTATE; ORIGIN		[Varinot, Justine; Comperat, Eva] Sorbonne Univ, Serv Anat Pathol, Hop Tenon, HUEP, Paris, France	Varinot, J (reprint author), Sorbonne Univ, Serv Anat Pathol, Hop Tenon, HUEP, Paris, France.	justinevarinot@hotmail.com					Barresi V, 2016, APMIS, V124, P188, DOI 10.1111/apm.12483; Kristiansen I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061151; Larnaudie L, 2017, VIRCHOWS ARCH, V471, P133, DOI 10.1007/s00428-017-2134-y; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Varinot J, 2013, VIRCHOWS ARCH, V463, P803, DOI 10.1007/s00428-013-1495-0	5	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	AUG	2018	473	2					261	262		10.1007/s00428-018-2395-0			2	Pathology	Pathology	GO7VP	WOS:000440285100018	29934658				2019-10-28	
J	Wilson, ML				Wilson, Michael L.			The Future of Pathology and Laboratory Medicine-Again	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Editorial Material							PUBLIC-HEALTH; SYSTEM; DIRECTOR		[Wilson, Michael L.] Denver Hlth, Dept Pathol & Lab Serv, Denver, CO USA	Wilson, ML (reprint author), Denver Hlth Med Ctr, Dept Pathol & Lab Serv, Mail Code 0224,777 Bannock St, Denver, CO 80204 USA.	Michael.Wilson@dhha.org					Abayomi A, 2015, AM J CLIN PATHOL, V143, P325, DOI 10.1309/AJCP6K0DZCNVCSCI; Ali M, 2013, PLOS ONE, V8; Amukele TK, 2015, AM J CLIN PATHOL, V143, P50, DOI 10.1309/AJCPCYA54DWZQPQT; [Anonymous], 2008, CRIT VALUES, V1, P26; Association of American Medical Colleges, 2015, ACT PHYS LARG SPEC 2; Astles JR, 2010, PUBLIC HEALTH REP, V125, P18, DOI 10.1177/00333549101250S203; Branda JA, 2014, AM J CLIN PATHOL, V142, P144, DOI 10.1309/AJCP3NU7AOPPKYWO; Fleming KA, 2017, AM J CLIN PATHOL, V147, P15, DOI [10.1093/AJCP/AQW143, 10.1093/ajcp/aqw143]; Horton S, 2018, LANCET, V391, P1953, DOI 10.1016/S0140-6736(18)30460-4; Inhorn SL, 2010, PUBLIC HEALTH REP, V125, P4, DOI 10.1177/00333549101250S202; Looi Lai-Meng, 2008, Malays J Pathol, V30, P1; Marshall SA, 2010, PUBLIC HEALTH REP, V125, P110, DOI 10.1177/00333549101250S214; Nelson AM, 2016, J CLIN ONCOL, V34, P20, DOI 10.1200/JCO.2015.61.9767; Sayed S, 2018, LANCET, V391, P1939, DOI 10.1016/S0140-6736(18)30459-8; Semret M, CLIN MICROBIOL INFEC; Thomson RB, 2010, J CLIN MICROBIOL, V48, P3465, DOI 10.1128/JCM.01575-10; WHO: World Health Organization, CLASS DIG HLTH INT V; Wilson ML, 2018, LANCET, V391, P1927, DOI [10.1016/S0140-6736(18)30458-6, 10.1016/S0140-6736]; Wilson ML, 2016, AM J CLIN PATHOL, V145, P742, DOI [10.1093/AJCP/AQW108, 10.1093/ajcp/aqw108]; Wilson ML, 2010, PUBLIC HEALTH REP, V125, P118, DOI 10.1177/00333549101250S215	20	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					93	95		10.1093/AJCP/AQY058			3	Pathology	Pathology	GN4ZQ	WOS:000439051600001	29901689				2019-10-28	
J	Rosenbaum, MW; Flood, JG; Melanson, SEF; Baumann, NA; Marzinke, MA; Rai, AJ; Hayden, J; Wu, AHB; Ladror, M; Lifshitz, MS; Scott, MG; Peck-Palmer, OM; Bowen, R; Babic, N; Sobhani, K; Giacherio, D; Bocsi, GT; Herman, DS; Wang, P; Toffaletti, J; Handel, E; Kelly, KA; Albeiroti, S; Wang, SH; Zimmer, M; Driver, B; Yi, X; Wilburn, C; Lewandrowski, KB				Rosenbaum, Matthew W.; Flood, James G.; Melanson, Stacy E. F.; Baumann, Nikola A.; Marzinke, Mark A.; Rai, Alex J.; Hayden, Joshua; Wu, Alan H. B.; Ladror, Megan; Lifshitz, Mark S.; Scott, Mitchell G.; Peck-Palmer, Octavia M.; Bowen, Raffick; Babic, Nikolina; Sobhani, Kimia; Giacherio, Donald; Bocsi, Gregary T.; Herman, Daniel S.; Wang, Ping; Toffaletti, John; Handel, Elizabeth; Kelly, Kathleen A.; Albeiroti, Sami; Wang, Sihe; Zimmer, Melissa; Driver, Brandon; Yi, Xin; Wilburn, Clayton; Lewandrowski, Kent B.			Quality Control Practices for Chemistry and Immunochemistry in a Cohort of 21 Large Academic Medical Centers	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Quality control; Westgard rules; Quality control rules; Chemistry; Immunochemistry	REJECTION	Objectives: In the United States, minimum standards for quality control (QC) are specified in federal law under the Clinical Laboratory Improvement Amendment and its revisions. Beyond meeting this required standard, laboratories have flexibility to determine their overall QC program. Methods: We surveyed chemistry and immunochemistry QC procedures at 21 clinical laboratories within leading academic medical centers to assess if standardized QC practices exist for chemistry and immunochemistry testing. Results: We observed significant variation and unexpected similarities in practice across laboratories, including QC frequency, cutoffs, number of levels analyzed, and other features. Conclusions: This variation in practice indicates an opportunity exists to establish an evidence-based approach to QC that can be generalized across institutions.	[Rosenbaum, Matthew W.; Flood, James G.; Lewandrowski, Kent B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Melanson, Stacy E. F.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Baumann, Nikola A.] Mayo Clin, Dept Pathol, Rochester, MN USA; [Marzinke, Mark A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Rai, Alex J.] New York Presbyterian Columbia, Dept Pathol, New York, NY USA; [Hayden, Joshua] New York Presbyterian Cornell, Dept Pathol, New York, NY USA; [Wu, Alan H. B.] UCSF Med Ctr, Dept Pathol, San Francisco, CA USA; [Ladror, Megan] Northwestern Mem Hosp, Dept Pathol, Chicago, IL 60611 USA; [Lifshitz, Mark S.] NYU Langone Hlth, Dept Pathol, Tisch Hosp, New York, NY USA; [Scott, Mitchell G.] Washington Univ, Dept Pathol, Barnes Jewish Hosp, St Louis, MO 63130 USA; [Peck-Palmer, Octavia M.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Bowen, Raffick] Stanford Hosp, Dept Pathol, Stanford Hlth Care, Stanford, CA USA; [Babic, Nikolina] Mt Sinai Hosp, Dept Pathol, New York, NY 10029 USA; [Sobhani, Kimia] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA; [Giacherio, Donald] Univ Michigan Hosp & Hlth Ctr, Dept Pathol, Ann Arbor, MI USA; [Bocsi, Gregary T.] Univ Colorado, Dept Pathol, Sch Med, Aurora, CO USA; [Herman, Daniel S.; Wang, Ping] Hosp Univ Penn Penn Presbyterian, Dept Pathol, Philadelphia, PA USA; [Toffaletti, John; Handel, Elizabeth] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Kelly, Kathleen A.; Albeiroti, Sami] UCLA Med Ctr, Dept Pathol, Los Angeles, CA USA; [Wang, Sihe; Zimmer, Melissa] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA; [Driver, Brandon; Yi, Xin; Wilburn, Clayton] Houston Methodist Hosp, Dept Pathol, Houston, TX USA	Lewandrowski, KB (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Gray 5 Chem, Boston, MA 02114 USA.	klewandrowski@partners.org		Hayden, Joshua/0000-0003-0435-9275			Ben Harder AC, 2016, 2016 17 BEST HOSP HO; Brooks ZC, 2001, PERFORMANCE DRIVEN Q; Burtis CA, 2006, TIETZ TXB CLIN CHEM; Coskun A, 2006, CLIN CHEM LAB MED, V44, P1183, DOI 10.1515/CCLM.2006.233; Fleming JK, 2015, CLIN BIOCHEM, V48, P508, DOI 10.1016/j.clinbiochem.2014.12.016; Fraser CG, 2001, BIOL VARIATION PRINC; Kaplan AK, 2009, CLIN CHEM THEORY ANA; Liu JK, 2017, CLIN CHEM LAB MED, V55, P1709, DOI 10.1515/cclm-2016-0950; McPherson R.A., 2011, HENRYS CLIN DIAGNOSI; Ng D, 2016, CLIN CHEM, V62, P1361, DOI 10.1373/clinchem.2016.257055; Parvin CA, 2012, CLIN CHEM, V58, P925, DOI 10.1373/clinchem.2011.181818; WESTGARD JO, 1977, CLIN CHEM, V23, P1857; WESTGARD JO, 1981, CLIN CHEM, V27, P493; Wilson A, 2011, CLIN CHIM ACTA, V412, P1441, DOI 10.1016/j.cca.2011.04.024	14	6	6	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					96	104		10.1093/AJCP/AQY033			9	Pathology	Pathology	GN4ZQ	WOS:000439051600002	29850771	Bronze			2019-10-28	
J	Fenelus, M; Peerschke, EIB				Fenelus, Maly; Peerschke, Ellinor I. B.			HITTING the Diagnosis Testing for Heparin-Induced Thrombocytopenia in Cancer Patients	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						4Ts score; Cancer; Laboratory screening; Cost savings; Coagulation; Hematology; Heparin-induced thrombocytopenia; Management/administration; HIT GTI-PF4 ELISA; Thrombosis	OPTICAL-DENSITY; 4T SCORE; PATHOGENESIS; ANTIBODY; HIT	Objectives: To evaluate the use of a pretest probability score (4Ts score) in cancer patients to guide ordering of laboratory screening tests for heparin-induced thrombocytopenia (HIT). Methods: A retrospective chart review was conducted for patients (n = 140) in whom laboratory testing for HIT was requested. 4Ts scores were calculated and correlated with heparin-endogenous platelet factor 4 antibody enzyme-linked immunosorbent assay (ELISA) test results. Results: All patients with a high pretest probability of HIT (4Ts score = 6-7) had positive ELISA results, compared to 26.1% of patients with intermediate (4Ts score = 4-5) and 4.3% of patients with low (4Ts score = 3) pretest probability. No patients with 4Ts scores of 2 or less had positive ELISA results. Conclusions: HIT can be ruled out in cancer patients (negative predictive value and sensitivity = 100%) with low pretest probability, defined by 4Ts scores of 2 or less, significantly reducing the need for laboratory testing in this patient population.	[Fenelus, Maly; Peerschke, Ellinor I. B.] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 327 E 64th St, New York, NY 10065 USA	Fenelus, M (reprint author), Mem Sloan Kettering Canc Ctr, Dept Lab Med, 327 E 64th St, New York, NY 10065 USA.	fenelusm@mskcc.org			NIH/NCI Cancer Center Support Grant [P30 CA008748]	This work was supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748.	Berry CA, 2011, REPROD SCI, V18, P1092, DOI 10.1177/1933719111404609; Chan CM, 2015, CHEST, V148, P55, DOI 10.1378/chest.14-1417; Chaturvedi S, 2015, J THROMB THROMBOLYS, V40, P12, DOI 10.1007/s11239-014-1123-0; CINES DB, 1987, NEW ENGL J MED, V316, P581, DOI 10.1056/NEJM198703053161004; Cuker A, 2010, J THROMB HAEMOST, V8, P2642, DOI 10.1111/j.1538-7836.2010.04059.x; Cuker A, 2012, BLOOD, V120, P4160, DOI 10.1182/blood-2012-07-443051; Hasan M, 2016, J THROMB THROMBOLYS, V42, P441, DOI 10.1007/s11239-016-1396-6; Lillo-de Louet A, 2004, J THROMB HAEMOST, V2, P1882, DOI 10.1111/j.1538-7836.2004.00949.x; Lu BY, 2015, J BLOOD MED, V6, P277, DOI 10.2147/JBM.S90179; Prandoni P, 2007, THROMB RES, V120, pS137, DOI 10.1016/S0049-3848(07)70143-3; Rauova L, 2006, BLOOD, V107, P2346, DOI 10.1182/blood-2005-08-3122; Salter BS, 2016, J AM COLL CARDIOL, V67, P2519, DOI 10.1016/j.jacc.2016.02.073; VISENTIN GP, 1994, J CLIN INVEST, V93, P81, DOI 10.1172/JCI116987; Warkentin TE, 2008, J THROMB HAEMOST, V6, P1304, DOI 10.1111/j.1538-7836.2008.03025.x; Warkentin TE, 2003, BRIT J HAEMATOL, V121, P535, DOI 10.1046/j.1365-2141.2003.04334.x; Warkentin TE, 2015, AM J HEMATOL, V90, P564, DOI 10.1002/ajh.24006; Warkentin Theodore E, 2003, Curr Hematol Rep, V2, P148; Wong M, 2017, J THROMB THROMBOLYS, V44, P261, DOI 10.1007/s11239-017-1523-z	18	0	0	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					116	120		10.1093/AJCP/AQY040			5	Pathology	Pathology	GN4ZQ	WOS:000439051600004	29901688	Green Published			2019-10-28	
J	Tang, F; Malek, E; Math, S; Schmotzer, CL; Beck, RC				Tang, Felicia; Malek, Ehsan; Math, Susan; Schmotzer, Christine L.; Beck, Rose C.			Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma Frequency and Duration of Detection of Daratumumab and Elotuzumab	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Serum protein electrophoresis; Immunofixation; Myeloma; Therapeutic monoclonal antibodies; Monoclonal proteins	MINIMAL RESIDUAL DISEASE; MULTIPLE-MYELOMA; TARGETING CD38; IMMUNOGLOBULINS; DEXAMETHASONE	Objectives: We investigated the frequency and pattern of detection of therapeutic monoclonal antibodies (t-mAbs) daratumumab and elotuzumab by routine serum protein electrophoresis (SPE) and immunofixation (IF) in treated patients with myeloma. Methods: Detection of t-mAb was assessed in 22 patients by retrospective review of SPE/IF ordered prior to, during, and after 26 individual courses of therapy. Results: t-mAb was distinguishable from M-protein in 16 of 26 courses, with daratumumab detected in nine of nine and elotuzumab in six of seven patients. t-mAb was detected on first follow-up SPE/IF in 12 patients, with earliest detection 7 days after therapy initiation and latest detection 70 days after therapy. t-mAb persisted throughout induction therapy in most patients, with loss of detection during maintenance daratumumab. Conclusions: When distinguishable from M-protein, t-mAbs are detectable in 93% of treated patients as soon as 7 days after the initial dose and are consistently observed throughout induction therapy, warranting increased monitoring and careful interpretation of SPE/IF.	[Tang, Felicia; Malek, Ehsan; Schmotzer, Christine L.; Beck, Rose C.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Malek, Ehsan] Univ Hosp Cleveland, Med Ctr, Dept Hematol Oncol, Cleveland, OH 44106 USA; [Math, Susan; Schmotzer, Christine L.; Beck, Rose C.] Univ Hosp Cleveland, Med Ctr, Dept Pathol, RB&C 568C,11100 Euclid Ave, Cleveland, OH 44106 USA	Beck, RC (reprint author), Univ Hosp Cleveland, Med Ctr, Dept Pathol, RB&C 568C,11100 Euclid Ave, Cleveland, OH 44106 USA.	rose.beck@uhhospitals.org					An G, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.4729.4729; Barnidge DR, 2016, CLIN CHEM LAB MED, V54, P1073, DOI 10.1515/cclm-2015-0917; Chakraborty R, 2017, BIOL BLOOD MARROW TR, V23, P598, DOI 10.1016/j.bbmt.2017.01.076; Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Genzen JR, 2011, BRIT J HAEMATOL, V155, P123, DOI 10.1111/j.1365-2141.2011.08644.x; Harousseau JL, 2017, J CLIN ONCOL, V35, P2863, DOI 10.1200/JCO.2017.73.1331; Kapoor P, 2013, J CLIN ONCOL, V31, P4529, DOI 10.1200/JCO.2013.49.0086; Kyle RA, 2010, LEUKEMIA, V24, P1121, DOI 10.1038/leu.2010.60; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; Martin T, 2017, BLOOD, V129, P3294, DOI 10.1182/blood-2016-09-740787; McCudden C, 2016, CLIN CHEM LAB MED, V54, P1095, DOI 10.1515/cclm-2015-1031; Mills JR, 2015, METHODS, V81, P56, DOI 10.1016/j.ymeth.2015.04.020; Mills JR, 2017, J APPL LAB MED, V1, P421, DOI [10.1373/jalm.2016.020784, DOI 10.1373/JALM.2016.020784]; Moreau P, 2016, DRUGS, V76, P853, DOI 10.1007/s40265-016-0573-4; Murata K, 2018, CLIN BIOCHEM, V51, P66, DOI 10.1016/j.clinbiochem.2016.09.015; National Comprehensive Cancer Network, 2017, NCCN CLIN GUID ONC M; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Rosenberg AS, 2016, CLIN BIOCHEM, V49, P1202, DOI 10.1016/j.clinbiochem.2016.07.016; Rosenblatt J, 2017, BLOOD, V129, P275, DOI 10.1182/blood-2016-08-731885; Ruinemans-Koerts J, 2014, CLIN CHEM LAB MED, V52, pE235, DOI 10.1515/cclm-2013-0898; Tang F, 2017, JAMA ONCOL, V3, P1729, DOI 10.1001/jamaoncol.2017.2665; van de Donk NWCJ, 2016, CLIN CHEM LAB MED, V54, P1105, DOI 10.1515/cclm-2015-0888; van de Donk NWCJ, 2016, BLOOD, V127, P681, DOI 10.1182/blood-2015-10-646810; van de Donk NWCJ, 2016, IMMUNOL REV, V270, P95, DOI 10.1111/imr.12389; Willrich MAV, 2016, CLIN CHEM LAB MED, V54, P1085, DOI 10.1515/cclm-2015-1023	26	2	2	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					121	129		10.1093/AJCP/AQY037			9	Pathology	Pathology	GN4ZQ	WOS:000439051600005	29901687	Bronze			2019-10-28	
J	Lopez-Hisijos, N; Genco, I; Gorbonos, A; Pambuccian, SE; Barkan, GA				Lopez-Hisijos, Nicolas; Genco, Iskender; Gorbonos, Alex; Pambuccian, Stefan E.; Barkan, Guliz Akdas			Metastatic Involvement of the Prostatic Anterior Fat Pad Implications for the Pathologist	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						AP Uropathology; Prostatic anterior fat pad; Utilization management; Prostate	LYMPH-NODE DISSECTION; RADICAL PROSTATECTOMY; PELVIC LYMPHADENECTOMY; CANCER; DRAINAGE; PROGRESSION; MEN	Objectives: There is little information regarding the utility of pathologic evaluation of the prostatic anterior fat pad (PAFP) in patients with a low preoperative probability of recurrence. Our study aimed to determine the utility of PAFP pathologic examination, especially for this group of patients. Methods: We analyzed a tertiary care academic center's radical prostatectomy (RP) specimens from 2009 to 2017. Results: Of 602 RP specimens, 420(70%) included the PAFP; four of 420 (1%) had lymph node involvement (LNI) in the PAFP. In two of four cases with LNI in the PAFP, this was the only site of LNI. Of these two cases, one occurred in a patient with low probability of recurrence and involved a nonpalpable PAFP lymph node. Conclusions: Pathologic evaluation of the PAFP may be useful even in patients with low probability of recurrence because it may change staging by detecting metastatic involvement of small PAFP lymph nodes.	[Lopez-Hisijos, Nicolas; Genco, Iskender; Pambuccian, Stefan E.; Barkan, Guliz Akdas] Loyola Univ Med Ctr, Dept Pathol, 2160 S First Ave, Maywood, IL 60153 USA; [Gorbonos, Alex] Loyola Univ Med Ctr, Dept Urol, Maywood, IL 60153 USA	Lopez-Hisijos, N (reprint author), Loyola Univ Med Ctr, Dept Pathol, 2160 S First Ave, Maywood, IL 60153 USA.	Nicolas.Lopez-Hisijos@lumc.edu					Atmaca AF, 2015, CENT EUR J UROL, V68, P410, DOI 10.5173/ceju.2015.650; Bader P, 2002, J UROLOGY, V168, P514, DOI 10.1016/S0022-5347(05)64670-8; Ball MW, 2017, BJU INT, V119, P444, DOI 10.1111/bju.13654; Briganti A, 2006, EUR UROL, V49, P1019, DOI 10.1016/j.eururo.2006.01.043; Briganti A, 2009, EUR UROL, V55, P261, DOI 10.1016/j.eururo.2008.09.043; Brossner C, 2001, UROLOGY, V57, P389, DOI 10.1016/S0090-4295(00)00921-3; Cheng L, 2001, CANCER, V91, P66, DOI 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P; Egevad L, 2016, APMIS, V124, P433, DOI 10.1111/apm.12533; Epstein JI, 2010, J UROLOGY, V183, P433, DOI 10.1016/j.juro.2009.10.046; Finley DS, 2007, UROLOGY, V70, DOI 10.1016/j.urology.2007.09.028; GilVernet JM, 1996, BRIT J UROL, V78, P161, DOI 10.1046/j.1464-410X.1996.00841.x; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Jeong J, 2013, UROL ONCOL-SEMIN ORI, V31, P63, DOI 10.1016/j.urolonc.2010.09.003; Kim IY, 2013, J UROLOGY, V190, P527, DOI 10.1016/j.juro.2013.02.073; Kwon YS, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0070-1; Lewandrowski K, 2014, CLIN CHIM ACTA, V427, P107, DOI 10.1016/j.cca.2013.11.011; Masterson TA, 2006, J UROLOGY, V175, P1320, DOI 10.1016/S0022-5347(05)00685-3; Mattei A, 2011, CURR OPIN UROL, V21, P211, DOI 10.1097/MOU.0b013e3283449428; Palapattu GS, 2004, J UROLOGY, V172, P1860, DOI 10.1097/01.ju.0000139886.25848.4a; Pano B, 2011, RADIOGRAPHICS, V31, P135, DOI 10.1148/rg.311105072; Rees T, 2016, TURK J UROL, V42, P240, DOI 10.5152/tud.2016.52893; Salinas M, 2014, J CLIN PATHOL, V67, P797, DOI 10.1136/jclinpath-2014-202333; Seo Y, 2011, J NUCL MED, V52, P1068, DOI 10.2967/jnumed.110.085944; Swanson GP, 2013, CLIN GENITOURIN CANC, V11, P431, DOI 10.1016/j.clgc.2013.04.031; Weingartner K, 1996, J UROLOGY, V156, P1969, DOI 10.1016/S0022-5347(01)65406-5; Yuh B, 2012, BJU INT, V109, P603, DOI 10.1111/j.1464-410X.2011.10336.x	26	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					130	136		10.1093/AJCP/AQY048			7	Pathology	Pathology	GN4ZQ	WOS:000439051600006	29893778				2019-10-28	
J	Aisagbonhi, O; Birungi, A; Atwine, R; Behayo, P; Ayebaziwe, B; Roberts, D; Tambouret, R				Aisagbonhi, Omonigho; Birungi, Abraham; Atwine, Raymond; Behayo, Paddy; Ayebaziwe, Benon; Roberts, Drucilla; Tambouret, Rosemary			Modified Plasma-Thrombin Method of Cell Block Preparation for Fine-Needle Aspiration Biopsies in Resource-Limited Settings	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Fine-needle aspiration; Cell block; Plasma-thrombin; Resource limited	PRIMARY BREAST CARCINOMAS; NON-HODGKINS-LYMPHOMA; PROGESTERONE-RECEPTOR; IMMUNOHISTOCHEMISTRY; DIAGNOSIS; CYTOLOGY; EXPERIENCE; FNA; IMMUNOCYTOCHEMISTRY; EXPRESSION	Objectives: The plasma-thrombin method is commonly used to make cell blocks from fine-needle aspiration (FNA) samples but requires centrifugation. We describe a modification to this method that does not require centrifugation for use in resource-limited settings. Methods: Pooled fresh plasma is aliquoted into 2-mL Eppendorf tubes and the FNA sample directly rinsed into the plasma. Two drops of reconstituted thrombin are added and gently mixed. A cell clot is transferred to a tissue bag, fixed in formalin, and processed. This method was applied to FNA samples from 44 patients presenting to the Mbarara University of Science and Technology FNA clinic. Results: The cell blocks were less cellular than the smears but contained adequate material to confirm morphologic impression or perform immunocytochemistry in 36 of 44 cases (82% adequacy rate). Conclusions: The modified plasma-thrombin method is a reliable cell block preparation method that can be easily applied in resource-limited settings.	[Aisagbonhi, Omonigho; Roberts, Drucilla; Tambouret, Rosemary] Massachusetts Gen Hosp, Dept Pathol, Warren 105E,275 Charles St, Boston, MA 02114 USA; [Aisagbonhi, Omonigho; Birungi, Abraham; Atwine, Raymond; Behayo, Paddy; Ayebaziwe, Benon] Mbarara Univ Sci & Technol, Dept Pathol, Mbarara, Uganda	Tambouret, R (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 105E,275 Charles St, Boston, MA 02114 USA.	rtambouret@mgh.harvard.edu					Antimisiaris D, 2017, CONSULT PHARM, V32, P535, DOI 10.4140/TCP.n.2017.535; Balassanian R, 2016, CANCER CYTOPATHOL, V124, P508, DOI 10.1002/cncy.21722; Banik T, 2016, DIAGN CYTOPATHOL, V44, P235, DOI 10.1002/dc.23409; Becette V, 2011, BREAST J, V17, P121, DOI 10.1111/j.1524-4741.2010.01040.x; Bhaker P, 2015, CANCER CYTOPATHOL, V123, P557, DOI 10.1002/cncy.21584; Briffod M, 2000, MODERN PATHOL, V13, P841, DOI 10.1038/modpathol.3880149; Angela SPB, 2013, CYTOPATHOLOGY, V24, P26, DOI 10.1111/j.1365-2303.2011.00934.x; BURT AD, 1986, J CLIN PATHOL, V39, P114, DOI 10.1136/jcp.39.1.114-d; CRAPANZANO JP, 2014, CYTOJOURNAL, V11; Daramola AO, 2015, INT J BREAST CANCER, DOI 10.1155/2015/742573; Domanski AM, 2013, CYTOPATHOLOGY, V24, P21, DOI 10.1111/j.1365-2303.2012.00997.x; Dong JY, 2016, BREAST CANCER RES TR, V158, P297, DOI 10.1007/s10549-016-3886-9; Hajian-Tilaki K, 2014, J BIOMED INFORM, V48, P193, DOI 10.1016/j.jbi.2014.02.013; Jain D, 2014, CYTOPATHOLOGY, V25, P356, DOI 10.1111/cyt.12174; KARNAUCHOW PN, 1982, J CLIN PATHOL, V35, P688, DOI 10.1136/jcp.35.6.688; Khayyata S, 2009, DIAGN CYTOPATHOL, V37, P178, DOI 10.1002/dc.20975; Khurana U, 2009, DIAGN CYTOPATHOL, V37, P557, DOI 10.1002/dc.21057; Ko HM, 2017, CYTOPATHOLOGY, V28, P221, DOI 10.1111/cyt.12419; Kulkarni MB, 2009, DIAGN CYTOPATHOL, V37, P86, DOI 10.1002/dc.20963; Kulshrestha Ritu, 2009, Indian J Chest Dis Allied Sci, V51, P21; Kumar KS, 2012, CYTOPATHOLOGY, V23, P181, DOI 10.1111/j.1365-2303.2011.00853.x; Kwon MS, 2002, J KOREAN MED SCI, V17, P353, DOI 10.3346/jkms.2002.17.3.353; Lourido-Cebreiro T, 2014, ARCH BRONCONEUMOL, V50, P267, DOI 10.1016/j.arbres.2013.11.022; Mayall F, 2000, J CLIN PATHOL, V53, P451, DOI 10.1136/jcp.53.6.451; Mayall F, 2010, J CLIN PATHOL, V63, P837, DOI 10.1136/jcp.2010.078410; Nakayama Y, 2016, BREAST CANCER-TOKYO, V23, P633, DOI 10.1007/s12282-015-0615-x; Paul T, 2014, J CYTOL, V31, P123, DOI 10.4103/0970-9371.145577; Pfeiffer DF, 2006, ACTA CYTOL, V50, P553, DOI 10.1159/000326014; Pillai SB, 2008, INDIAN J PATHOL MICR, V51, P459, DOI 10.4103/0377-4929.42538; Prendeville S, 2014, CYTOPATHOLOGY, V25, P372, DOI 10.1111/cyt.12159; Razack R, 2012, DIAGN CYTOPATHOL, V40, P770, DOI 10.1002/dc.21624; Rollins SD, 2017, CAP TODAY; Sheefa Haq, 2016, Oman Med J, V31, P135, DOI 10.5001/omj.2016.26; Tajima S, 2016, DIAGN CYTOPATHOL, V44, P137, DOI 10.1002/dc.23395; Tian HY, 2015, J CANCER RES THER, V11, P234, DOI 10.4103/0973-1482.170544; Vohra P, 2016, CANCER CYTOPATHOL, V124, P828, DOI 10.1002/cncy.21745; Xie R, 2011, J HISTOCHEM CYTOCHEM, V59, P356, DOI 10.1369/0022155411398488; Yung RCW, 2012, CANCER CYTOPATHOL, V120, P185, DOI 10.1002/cncy.20199; Zhang SH, 2014, INT J CLIN EXP PATHO, V7, P7717	39	0	0	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					137	145		10.1093/AJCP/AQY031			9	Pathology	Pathology	GN4ZQ	WOS:000439051600007	29893770				2019-10-28	
J	Zare, S; Mirsadraei, L; Reisian, N; Liao, XY; Roma, A; Shabaik, A; Hasteh, F				Zare, Somaye; Mirsadraei, Leili; Reisian, Niloufar; Liao, Xiaoyan; Roma, Andres; Shabaik, Ahmed; Hasteh, Farnaz			A Single Institutional Experience With the Paris System for Reporting Urinary Cytology Correlation of Cytology and Histology in 194 Cases	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Urine; Cytology; Atypia; High-grade urothelial carcinoma; Follow-up	ATYPICAL UROTHELIAL CELLS; TERMINOLOGY; ACCURACY; BLADDER	Objectives: The Paris System for Reporting Urinary Cytology (TPS) is designed to standardize the criteria and terminology used in urinary tract cytology reporting. The aim of this study was to evaluate the impact of implementing TPS and to analyze the correlation with follow-up biopsies in order to assess its reproducibility. Methods: Urinary tract cytology specimens with follow-up biopsies over a 2-year period were reviewed and reclassified according to TPS criteria. Surgical follow-up diagnoses were correlated with the initial cytology diagnoses and TPS interpretations, and the results were compared. Results: Applying TPS in comparison to our previous reporting system resulted in fewer cases in the atypia category (11.8% vs 24.2%) and higher specificity, accuracy, and predictive value. We observed acceptable interobserver agreement in diagnostic categories of this reporting system. Conclusions: TPS improves the overall performance of urinary tract cytology by standardizing the criteria and terminology.	[Zare, Somaye; Mirsadraei, Leili; Reisian, Niloufar; Liao, Xiaoyan; Roma, Andres; Shabaik, Ahmed; Hasteh, Farnaz] Univ Calif San Diego, Dept Pathol, ECOB,9444 Med Ctr Dr,MC 7723, La Jolla, CA 92037 USA	Hasteh, F (reprint author), Univ Calif San Diego, Dept Pathol, ECOB,9444 Med Ctr Dr,MC 7723, La Jolla, CA 92037 USA.	fhasteh@ucsd.edu					Barkan GA, 2016, ADV ANAT PATHOL, V23, P193, DOI 10.1097/PAP.0000000000000118; Bastacky S, 1999, CANCER CYTOPATHOL, V87, P118, DOI 10.1002/(SICI)1097-0142(19990625)87:3<118::AID-CNCR4>3.0.CO;2-N; Brimo F, 2009, AM J CLIN PATHOL, V132, P785, DOI 10.1309/AJCPPRZLG9KT9AXL; Cowan ML, 2017, CANCER CYTOPATHOL, V125, P427, DOI 10.1002/cncy.21843; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Granados R, 2017, ACTA CYTOL, V61, P71, DOI 10.1159/000452092; Hassan M, 2016, AM J CLIN PATHOL, V146, P384, DOI [10.1093/ajcp/aqw127, 10.1093/AJCP/AQW127]; KOSS LG, 1985, ACTA CYTOL, V29, P810; Long T, 2017, CYTOJOURNAL, V14, DOI 10.4103/cytojournal.cytojournal_12_17; Malviya K, 2017, ACTA CYTOL, V61, P145, DOI 10.1159/000464270; Miki Y, 2017, CYTOPATHOLOGY, V28, P88, DOI 10.1111/cyt.12367; Owens CL, 2013, CANCER CYTOPATHOL, V121, P9, DOI 10.1002/cncy.21253; PAPANICOLAOU GN, 1947, J UROLOGY, V57, P375, DOI 10.1016/S0022-5347(17)69643-5; Piaton E, 2014, CYTOPATHOLOGY, V25, P27, DOI 10.1111/cyt.12050; Planz B, 2005, EJSO, V31, P304, DOI 10.1016/j.ejso.2004.12.008; Rosenthal D, 2016, PARIS SYSTEM REPORTI; Rosenthal DL, 2013, CANCER CYTOPATHOL, V121, P15, DOI 10.1002/cncy.21255; Roy M, 2017, CYTOPATHOLOGY, V28, P509, DOI 10.1111/cyt.12448; VandenBussche CJ, 2016, CYTOPATHOLOGY, V27, P153, DOI 10.1111/cyt.12345	19	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					162	167		10.1093/AJCP/AQY043			6	Pathology	Pathology	GN4ZQ	WOS:000439051600010	29878037				2019-10-28	
J	Fang, H; Kapoor, P; Gonsalves, WI; Frederick, LA; Viswanatha, D; Howard, MT; He, R; Morice, WG; McPhail, ED; Greipp, PT; Ansell, SM; Kyle, RA; Gertz, MA; Paludo, J; Abeykoon, J; King, RL				Fang, Hong; Kapoor, Prashant; Gonsalves, Wilson I.; Frederick, Lori A.; Viswanatha, David; Howard, Matthew T.; He, Rong; Morice, William G., II; McPhail, Ellen D.; Greipp, Patricia T.; Ansell, Stephen M.; Kyle, Robert A.; Gertz, Morie A.; Paludo, Jonas; Abeykoon, Jithma; King, Rebecca L.			Defining Lymphoplasmacytic Lymphoma Does MYD88(L265P) Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Lymphoplasmacytic lymphoma; IgM paraprotein; Waldenstrom macroglobulinemia; MYD88; Bone marrow	MARGINAL ZONE LYMPHOMA; MULTIPARAMETER FLOW-CYTOMETRY; L265P SOMATIC MUTATION; WALDENSTROMS MACROGLOBULINEMIA; MYD88 L265P; IMMUNOPHENOTYPIC FEATURES; PROLIFERATIVE DISORDERS; CXCR4	Objectives: Lymphoplasmacytic lymphoma (LPL) remains a poorly defined entity, even with the discovery of MYD88(L265P) mutations and association with Waldenstrom macroglobulinemia (WM). Among bone marrow (BM)-based, low-grade B-cell lymphoma with plasmacytic differentiation (LGBLPD) and immunoglobulin M (IgM) paraproteins, we sought to determine whether MYD88(L265P) defines a distinct entity and can help refine diagnostic criteria for LPL. Methods: BMs diagnosed with LGBLPD or LPL and serum IgM paraprotein were studied (2007-2013). Clinicopathologic features were reviewed and specimens were tested for MYD88(L265P). Results: In total, 138 (87%) of 159 cases had MYD88(L265P), and 158 of 159 were clinically considered WM. MYD88(L265P) cases had higher disease burden than MYD88(WT). Features associated with MYD88(L265P) include increased mast cells and lymphocyte (not plasma cell)-predominant infiltrate. Hemosiderin, Dutcher bodies, and paratrabecular growth were not associated with MYD88(L265P). Conclusions: Our data support a clinicopathologic approach to LPL diagnosis and recognition that it may manifest with varying morphologies, phenotypes, and molecular features.	[Fang, Hong; Frederick, Lori A.; Viswanatha, David; Howard, Matthew T.; He, Rong; Morice, William G., II; McPhail, Ellen D.; King, Rebecca L.] Mayo Clin, Div Hematopathol, Rochester, MN USA; [Kapoor, Prashant; Gonsalves, Wilson I.; Ansell, Stephen M.; Kyle, Robert A.; Gertz, Morie A.; Paludo, Jonas; Abeykoon, Jithma] Mayo Clin, Div Hematol, Rochester, MN USA; [Greipp, Patricia T.] Mayo Clin, Div Lab Genet, Rochester, MN USA	King, RL (reprint author), Mayo Clin, Hilton 8-17,200 First St SW, Rochester, MN 55905 USA.	rebecca.king98@gmail.com	Paludo, Jonas/I-4422-2019; Abeykoon, Jithma Prasad/S-4730-2019; Gertz, Morie/K-2873-2019	Paludo, Jonas/0000-0002-7350-5531; 			Abeykoon JP, 2018, AM J HEMATOL, V93, P187, DOI 10.1002/ajh.24955; Ansell SM, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.4; Bassarova A, 2015, AM J CLIN PATHOL, V143, P797, DOI 10.1309/AJCP6ZODWV1CIDME; Berger FO, 2005, CLIN LYMPHOMA, V5, P220, DOI 10.3816/CLM.2005.n.003; Braggio E, 2009, CLIN LYMPHOMA MYELOM, V9, P39, DOI 10.3816/CLM.2009.n.009; Dispenzieri A, 2015, MAYO CLIN PROC, V90, P1054, DOI 10.1016/j.mayocp.2015.06.009; Gachard N, 2013, LEUKEMIA, V27, P183, DOI 10.1038/leu.2012.257; Hoeve MA, 1999, LEUKEMIA, V13, P799, DOI 10.1038/sj.leu.2401404; Hunter ZR, 2017, J CLIN ONCOL, V35, P994, DOI 10.1200/JCO.2016.71.0814; Hunter ZR, 2014, BLOOD, V123, P1637, DOI 10.1182/blood-2013-09-525808; Jimenez C, 2013, LEUKEMIA, V27, P1722, DOI 10.1038/leu.2013.62; Kapoor P, 2017, JAMA ONCOL, V3, P1257, DOI 10.1001/jamaoncol.2016.5763; King RL, 2016, AM J CLIN PATHOL, V145, P843, DOI [10.1093/AJCP/AQW072, 10.1093/ajcp/aqw072]; Kyle RA, 2012, BLOOD, V119, P4462, DOI 10.1182/blood-2011-10-384768; Morice WG, 2007, LEUKEMIA, V21, P2043, DOI 10.1038/sj.leu.2404712; Morice WG, 2009, MODERN PATHOL, V22, P807, DOI 10.1038/modpathol.2009.34; Nguyen-Khac F, 2013, HAEMATOLOGICA, V98, P649, DOI 10.3324/haematol.2012.070458; Owen RG, 2003, SEMIN ONCOL, V30, P110, DOI 10.1053/sonc.2003.50082; Patkar N, 2015, LEUKEMIA LYMPHOMA, V56, P420, DOI 10.3109/10428194.2014.924123; Poulain S, 2013, BLOOD, V121, P4504, DOI 10.1182/blood-2012-06-436329; Rosado FG, 2015, BRIT J HAEMATOL, V169, P368, DOI 10.1111/bjh.13303; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tournilhac O, 2006, ANN ONCOL, V17, P1275, DOI 10.1093/annonc/mdl109; Treon SP, 2014, BLOOD, V123, P2791, DOI 10.1182/blood-2014-01-550905; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Varettoni M, 2013, BLOOD, V121, P2522, DOI 10.1182/blood-2012-09-457101; Xu L, 2013, BLOOD, V121, P2051, DOI 10.1182/blood-2012-09-454355	27	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					168	176		10.1093/AJCP/AQY041			9	Pathology	Pathology	GN4ZQ	WOS:000439051600011	29868855				2019-10-28	
J	Kouba, E; Ford, A; Brown, CG; Yeh, C; Siegal, GP; Manne, U; Eltoum, IE				Kouba, Erik; Ford, Andrew; Brown, Charmaine G.; Yeh, Chen; Siegal, Gene P.; Manne, Upender; Eltoum, Isam-Eldin			Detection of BRAF V600E Mutations With Next-Generation Sequencing in Infarcted Thyroid Carcinomas After Fine-Needle Aspiration	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						BRAF V600E; Thyroid carcinoma; Next-generation sequencing; Fine-needle aspiration; Fine-needle aspiration infarction	BRAF(V600E) MUTATION; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; HISTOLOGIC ALTERATIONS; BETHESDA SYSTEM; ADULT PATIENTS; CANCER; NODULES; BIOPSY; MANAGEMENT; DIAGNOSIS	Objectives: Fine-needle aspiration (FNA) of thyroid lesions may result in infarction and diagnostic difficulties on subsequent thyroidectomy specimens. Next-generation sequencing (NGS) methods for detection of hallmark driver BRAF V600E mutations may help characterize such tumors in which histologic alterations preclude definitive tissue diagnosis. Methods: Thyroidectomy specimens with both malignant FNA diagnoses and resultant infarction were identified from our institutional database. NGS methods were used to detect BRAF V600E mutations in the infarcted thyroid carcinomas. Results: Nine thyroid carcinomas with infarction were characterized as BRAF-like papillary thyroid carcinoma based on molecular driver categorization and histologic diagnosis. BRAF V600E mutations were detected in the infarcted tissue in four (67%) of six lesions. Conclusions: We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA. This suggests a potential ancillary method of characterizing infarcted thyroid carcinomas whose altered histology may be nondiagnostic.	[Kouba, Erik; Siegal, Gene P.; Manne, Upender; Eltoum, Isam-Eldin] Univ Alabama Birmingham, Dept Pathol, 508 20th St South HSB 149M, Birmingham, AL 35249 USA; [Ford, Andrew; Brown, Charmaine G.; Yeh, Chen] Circulogene, Birmingham, AL USA	Kouba, E (reprint author), Univ Alabama Birmingham, Dept Pathol, 508 20th St South HSB 149M, Birmingham, AL 35249 USA.	erikjkouba@gmail.com		kouba, erik/0000-0001-5430-8850	Department of Pathology at the University of Alabama-Birmingham	Partially supported by a grant from the Department of Pathology at the University of Alabama-Birmingham.	Abd Elmageed ZY, 2017, SURGERY, V161, P1122, DOI 10.1016/j.surg.2016.06.081; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; American Joint Committee on Cancer, 2017, AJCC CANC STAGING MA; Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830; Baloch ZW, 1999, AM J CLIN PATHOL, V112, P311; Bhatia P, 2016, GLAND SURG, V5, P270, DOI 10.21037/gs.2016.01.05; Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6; CHA YJ, 2016, J TRANSL MED, V14; Charles RP, 2014, MOL CANCER RES, V12, P979, DOI 10.1158/1541-7786.MCR-14-0158-T; Chen JC, 2012, SURGERY, V152, P1037, DOI 10.1016/j.surg.2012.08.052; Cohen RN, 2017, JAMA-J AM MED ASSOC, V317, P434, DOI 10.1001/jama.2016.18420; Daglar-Aday A, 2013, DNA CELL BIOL, V32, P13, DOI 10.1089/dna.2012.1776; Das DK, 2009, ACTA CYTOL, V53, P571, DOI 10.1159/000325386; Durante C, 2011, EUR J ENDOCRINOL, V165, P455, DOI 10.1530/EJE-11-0283; Epstein EJ, 2011, ENDOCRINE, V40, P322, DOI 10.1007/s12020-011-9498-6; Ersoz C, 1997, DIAGN CYTOPATHOL, V16, P230, DOI 10.1002/(SICI)1097-0339(199703)16:3<230::AID-DC7>3.0.CO;2-J; Eze OP, 2013, THYROID, V23, P194, DOI 10.1089/thy.2012.0157; Fagin JA, 2016, NEW ENGL J MED, V375, P1054, DOI 10.1056/NEJMra1501993; Fnais N, 2015, HUM PATHOL, V46, P1443, DOI 10.1016/j.humpath.2015.06.001; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hedegaard J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098187; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Vuong HG, 2017, ONCOTARGET, V8, P10637, DOI 10.18632/oncotarget.12885; Jang EK, 2013, EUR THYROID J, V2, P203, DOI 10.1159/000353624; Jolly LA, 2016, CANCER RES, V76, P1804, DOI 10.1158/0008-5472.CAN-15-2351; KASAIAN K, 2015, BMC CANCER, V15; Kholova I, 2016, DIAGN CYTOPATHOL, V44, P568, DOI 10.1002/dc.23479; Kim SY, 2015, SURGERY, V157, P354, DOI 10.1016/j.surg.2014.09.003; Kini SR, 1996, DIAGN CYTOPATHOL, V15, P211, DOI 10.1002/(SICI)1097-0339(199609)15:3<211::AID-DC7>3.0.CO;2-J; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Li C, 2012, J CLIN ENDOCR METAB, V97, P4559, DOI 10.1210/jc.2012-2104; Liu YF, 2014, JAMA OTOLARYNGOL, V140, P52, DOI 10.1001/jamaoto.2013.5650; Melck AL, 2010, ONCOLOGIST, V15, P1285, DOI 10.1634/theoncologist.2010-0156; Mon SY, 2014, ENDOCRIN METAB CLIN, V43, P345, DOI 10.1016/j.ecl.2014.02.015; Nucera C, 2011, CANCER RES, V71, P2417, DOI 10.1158/0008-5472.CAN-10-3844; Park JY, 2016, CANCER GENOM PROTEOM, V13, P171; Poiyzos SA, 2009, DIAGN CYTOPATHOL, V37, P455, DOI 10.1002/dc.21055; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Richmond BK, 2012, AM SURGEON, V78, P706; Riesco-Eizaguirre G, 2016, EUR J ENDOCRINOL, V175, pR203, DOI 10.1530/EJE-16-0202; Santarpia L, 2008, J CLIN ENDOCR METAB, V93, P278, DOI 10.1210/jc.2007-1076; Sharma C, 2008, ACTA CYTOL, V52, P56, DOI 10.1159/000325435; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun WY, 2016, TUMOR BIOL, V37, P8197, DOI 10.1007/s13277-015-4684-4; Swierniak M, 2016, MOL CELL ENDOCRINOL, V433, P130, DOI 10.1016/j.mce.2016.06.007; Tufano RP, 2012, MEDICINE, V91, P274, DOI 10.1097/MD.0b013e31826a9c71; Walts AE, 2014, HUM PATHOL, V45, P935, DOI 10.1016/j.humpath.2013.12.005; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xu B, 2017, THYROID, V27, P632, DOI 10.1089/thy.2016.0582; Xu B, 2016, ENDOCR PATHOL, V27, P205, DOI 10.1007/s12022-016-9445-4; Yip L, 2016, JAMA SURG, V151, P663, DOI 10.1001/jamasurg.2016.0825; Yoo SK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006239	53	0	0	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					177	185		10.1093/AJCP/AQY045			9	Pathology	Pathology	GN4ZQ	WOS:000439051600012	29868707				2019-10-28	
J	Bailey, DN				Bailey, David N.			Norbert W. Tietz: Scientist, Educator, and Icon (1926-2018) in memoriam	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Biographical-Item									[Bailey, David N.] Univ Calif San Diego, Pathol Emeritus, San Diego, CA 92103 USA	Bailey, DN (reprint author), Univ Calif San Diego, Pathol Emeritus, San Diego, CA 92103 USA.						TIETZ NW, PUBLICATION LIST	1	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					186	187		10.1093/AJCP/AQY072			2	Pathology	Pathology	GN4ZQ	WOS:000439051600013					2019-10-28	
J	Wilson, ML; Ayers, S; Berney, D				Wilson, M. L.; Ayers, S.; Berney, D.			Improving anatomic pathology in Sub-Saharan Africa to support cancer care (vol 149, pg 310, 2018)	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Correction																Wilson ML, 2018, AM J CLIN PATHOL, V149, P310, DOI [10.1093/AJCP/AQX158, 10.1093/ajcp/aqx158]	1	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	AUG	2018	150	2					188	188		10.1093/AJCP/AQY060			1	Pathology	Pathology	GN4ZQ	WOS:000439051600014					2019-10-28	
J	Stolnicu, S; Barsan, I; Hoang, L; Patel, P; Chiriboga, L; Terinte, C; Pesci, A; Aviel-Ronen, S; Kiyokawa, T; Alvarado-Cabrero, I; Pike, MC; Oliva, E; Park, KJ; Soslow, RA				Stolnicu, Simona; Barsan, Iulia; Hoang, Lien; Patel, Prusha; Chiriboga, Luis; Terinte, Cristina; Pesci, Anna; Aviel-Ronen, Sarit; Kiyokawa, Takako; Alvarado-Cabrero, Isabel; Pike, Malcolm C.; Oliva, Esther; Park, Kay J.; Soslow, Robert A.			Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						endocervical adenocarcinoma; cervical carcinoma; immunohistochemistry; HPV; human papilloma virus	SQUAMOUS-CELL CARCINOMA; FEMALE GENITAL-TRACT; PAPILLARY SEROUS ADENOCARCINOMA; UTERINE ENDOMETRIOID CARCINOMA; IN-SITU HYBRIDIZATION; HUMAN-PAPILLOMAVIRUS; CLEAR-CELL; MESONEPHRIC ADENOCARCINOMA; MUCINOUS ADENOCARCINOMA; GENE-MUTATIONS	The International Endocervical Adenocarcinoma Criteria and Classification was developed to separate endocervical adenocarcinomas (ECAs) into 2 main categories on the basis of morphology such as human papilloma virus-associated (HPVA) and non-human papilloma virus-associated adenocarcinomas. We aimed to improve the diagnostic accuracy of International Endocervical Adenocarcinoma Criteria and Classification by performing a comprehensive immunohistochemical evaluation and constructing objective immunohistochemical-based algorithms for the classification of these tumors. Tissue microarrays were constructed from 297 of 409 cases used to develop the original classification. Immunostains included p16, p53, estrogen receptor (ER), progesterone receptor, androgen receptor, Vimentin, CK7, CK20, HER2, HIK1083, MUC6, CA-IX, SATB2, HNF-1beta, napsin A, PAX8, CDX2, GATA3, p63, p40, and TTF-1. High-risk human papilloma virus (HR-HPV) was detected by in situ hybridization (ISH) using probes against E6 and E7 mRNA expressed in 18 different virus types. Vimentin, ER, and progesterone receptor were expressed in a significant minority of ECAs, mostly HPVAs, limiting their use in differential diagnosis of endometrioid carcinoma when unaccompanied by HPV-ISH or p16. HR-HPV ISH had superior sensitivity, specificity, and negative and positive predictive values compared with p16, as published previously. HNF-1beta did not have the anticipated discriminatory power for clear cell carcinoma, nor did MUC6 or CA-IX for gastric-type carcinoma. HNF-1beta and napsin A were variably expressed in clear cell carcinoma, with HNF-1beta demonstrating less specificity, as it was ubiquitously expressed in gastric-type carcinoma and in the majority of HPV-associated mucinous (predominantly intestinal-type and invasive ECA resembling stratified mucin-producing intraepithelial lesion [iSMILE]) and usual-type carcinomas. HIK1083 was expressed in nearly half of gastric-type carcinomas, but not in the vast majority of other subtypes. GATA3 was positive in 10% of usual-type adenocarcinomas and in single examples of other subtypes. Rare gastric-type and HPVA mucinous carcinomas displayed HER2 overexpression. Androgen receptor was positive in 6% of usual-type adenocarcinomas. Aberrant p53 expression was found in only 3.6% of usual-type HPVA carcinomas, but it was more prevalent in mucinous (intestinal type and iSMILE) HPVAs and non-human papilloma virus-associates (particularly in gastric-type carcinoma, >50% of cases). The following diagnostic classification algorithms were developed with the above data. Carcinomas without overt cytoplasmic mucin (endometrioid, usual-type endocervical, clear cell, and mesonephric carcinomas) can be subclassified using HR-HPV ISH, ER, and GATA3, whereas carcinomas with easily appreciated cytoplasmic mucin (endometrioid carcinoma with mucinous features, HPVA mucinous, and gastric-type carcinomas) can be subclassified with HR-HPV ISH and ER.	[Stolnicu, Simona; Barsan, Iulia] Univ Med & Pharm Targu Mures, Dept Pathol, Targu Mures, Romania; [Terinte, Cristina] Reg Inst Oncol, Iasi, Romania; [Hoang, Lien] Vancouver Gen Hosp, Vancouver, BC, Canada; [Pesci, Anna] Hosp Sacred Heart Don Calabria, Negrar, Italy; [Aviel-Ronen, Sarit] Sheba Med Ctr, Ramat Gan, Israel; [Kiyokawa, Takako] Jikei Univ, Sch Med, Tokyo, Japan; [Alvarado-Cabrero, Isabel] Hosp Oncol, Mexico City, DF, Mexico; [Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Patel, Prusha; Pike, Malcolm C.; Park, Kay J.; Soslow, Robert A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Chiriboga, Luis] NYU, Langone Hlth, 550 1St Ave, New York, NY USA	Soslow, RA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	soslowr@mskcc.org		Chiriboga, Luis/0000-0002-2028-6873; Stolnicu, Simona/0000-0002-4459-7019	NIH/NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]	This study was funded in part through the NIH/NCI Support Grant P30 CA008748 (R.A.S. and K.J.P.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abdul-Ghafar Jamshid, 2013, J Lifestyle Med, V3, P117; Ajila Vidya, 2015, J Sex Transm Dis, V2015, P791024, DOI 10.1155/2015/791024; Anagnostopoulos Antonios, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.01.2012.5632; Ansari-Lari MA, 2004, AM J SURG PATHOL, V28, P160, DOI 10.1097/00000478-200402000-00002; Bague S, 2004, AM J SURG PATHOL, V28, P601, DOI 10.1097/00000478-200405000-00006; Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Batistatou A, 2000, INT J GYNECOL CANCER, V10, P336, DOI 10.1046/j.1525-1438.2000.010004336.x; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Dong F, 2015, AM J SURG PATHOL, V39, P1045, DOI 10.1097/PAS.0000000000000454; Fadare O, 2015, PATHOLOGY, V47, P105, DOI 10.1097/PAT.0000000000000223; Fadare O, 2014, AM J SURG PATHOL, V38, P189, DOI 10.1097/PAS.0000000000000085; Fukunaga M, 2008, PATHOL RES PRACT, V204, P671, DOI 10.1016/j.prp.2008.01.008; GILKS CB, 1992, MODERN PATHOL, V5, P426; Gornick MC, 2010, CANCER CAUSE CONTROL, V21, P737, DOI 10.1007/s10552-010-9502-0; Hedvat CV, 2002, HUM PATHOL, V33, P968, DOI 10.1053/hupa.2002.127438; Hodgson A, 2018, USCAP US CAN AC PATH; HOLM R, 1993, J PATHOL, V169, P21, DOI 10.1002/path.1711690105; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Ingerslev K, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0087-4; INOUE M, 1994, AM J CLIN PATHOL, V102, P665, DOI 10.1093/ajcp/102.5.665; Iwamoto M, 2015, HUM PATHOL, V46, P957, DOI 10.1016/j.humpath.2015.03.008; JIKO K, 1994, INT J CANCER, V59, P601, DOI 10.1002/ijc.2910590505; Jones MW, 2013, INT J GYNECOL CANCER, V23, P380, DOI 10.1097/IGC.0b013e31825cc8ee; Ju BH, 2018, INT J GYNECOL PATHOL, V37, P388, DOI 10.1097/PGP.0000000000000430; Kato N, 2006, MODERN PATHOL, V19, P83, DOI 10.1038/modpathol.3800492; Kojima A, 2007, AM J SURG PATHOL, V31, P664, DOI 10.1097/01.pas.0000213434.91868.b0; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kurman RJ, 2014, WHO CLASSIFICATION T; LANG G, 1990, INT J GYNECOL PATHOL, V9, P145, DOI 10.1097/00004347-199004000-00006; Lastra RR, 2016, AM J SURG PATHOL, V40, P262, DOI 10.1097/PAS.0000000000000543; Lax SF, 1998, HUM PATHOL, V29, P924, DOI 10.1016/S0046-8177(98)90197-6; Liao CL, 2010, VIRCHOWS ARCH, V456, P377, DOI 10.1007/s00428-010-0892-x; Lim D, 2016, AM J SURG PATHOL, V40, P302, DOI 10.1097/PAS.0000000000000550; Lim D, 2015, AM J SURG PATHOL, V39, P1061, DOI 10.1097/PAS.0000000000000436; Lin EW, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006938; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; Malpica A, 2016, MODERN PATHOL, V29, pS29, DOI 10.1038/modpathol.2015.142; MASOOD S, 1993, CANCER-AM CANCER SOC, V72, P511, DOI 10.1002/1097-0142(19930715)72:2<511::AID-CNCR2820720230>3.0.CO;2-Q; McAlpine JN, 2017, HISTOPATHOLOGY, V71, P238, DOI 10.1111/his.13205; McCluggage WG, 2016, ADV ANAT PATHOL, V23, P58, DOI 10.1097/PAP.0000000000000095; McCluggage WG, 2002, INT J GYNECOL PATHOL, V21, P11, DOI 10.1097/00004347-200201000-00003; McHugh M, 1995, INT J SURG PATHOL, V2, P269; Molijn A, 2016, INT J CANCER, V138, P409, DOI 10.1002/ijc.29722; Moll UM, 1996, HUM PATHOL, V27, P1295, DOI 10.1016/S0046-8177(96)90340-8; Nofech-Mozes S, 2006, INT J GYNECOL CANCER, V16, P286, DOI 10.1111/j.1525-1438.2006.00514.x; Nofech-Mozes S, 2009, INT J GYNECOL PATHOL, V28, P140, DOI 10.1097/PGP.0b013e31818e30f6; Ordi J, 2003, AM J SURG PATHOL, V27, P178, DOI 10.1097/00000478-200302000-00005; Park HM, 2009, J KOREAN MED SCI, V24, P767, DOI 10.3346/jkms.2009.24.4.767; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Qiu WS, 2003, INT J GYNECOL PATHOL, V22, P261, DOI 10.1097/01.PGP.0000071043.12278.8D; RAHILLY MA, 1992, HISTOPATHOLOGY, V20, P351, DOI 10.1111/j.1365-2559.1992.tb00993.x; Reid-Nicholson M, 2006, MODERN PATHOL, V19, P1091, DOI 10.1038/modpathol.3800620; Roma AA, 2015, INT J GYNECOL PATHOL, V34, P480, DOI 10.1097/PGP.0000000000000167; Roma AA, 2014, INT J GYNECOL PATHOL, V33, P624, DOI 10.1097/PGP.0000000000000088; Sedghizadeh PP, 2016, ORAL ONCOL, V54, P15, DOI 10.1016/j.oraloncology.2016.01.002; Silver SA, 2001, AM J SURG PATHOL, V25, P379, DOI 10.1097/00000478-200103000-00013; Singh N, 2017, HISTOPATHOLOGY, V70, P56, DOI 10.1111/his.13080; Staebler A, 2002, AM J SURG PATHOL, V26, P998, DOI 10.1097/01.PAS.0000018103.32686.98; Stolnicu S, 2018, USCAP US CAN AC PATH; Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986; Stolnicu S, 2017, APPL IMMUNOHISTO M M, V25, pE18, DOI 10.1097/PAI.0000000000000376; Tashiro H, 1997, AM J PATHOL, V150, P177; Tjalma WAA, 2015, FACTS VIEWS VIS OBGY, V7, P101; Yao CC, 2009, ARCH GYNECOL OBSTET, V280, P405, DOI 10.1007/s00404-008-0859-1; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P914, DOI 10.1097/PAS.0b013e3181971fdd	65	11	11	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					989	1000		10.1097/PAS.0000000000001090			12	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000001	29851704	Green Accepted			2019-10-28	
J	Stoler, MH; Wright, TC; Ferenczy, A; Ranger-Moore, J; Fang, QJ; Kapadia, M; Ridder, R				Stoler, Mark H.; Wright, Thomas C., Jr.; Ferenczy, Alex; Ranger-Moore, James; Fang, Qijun; Kapadia, Monesh; Ridder, Ruediger			Routine Use of Adjunctive p16 Immunohistochemistry Improves Diagnostic Agreement of Cervical Biopsy Interpretation Results From the CERTAIN Study	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						cervical biopsy; squamous intraepithelial lesion; immunohistochemistry; p16; diagnostic agreement	P16(INK4A) IMMUNOHISTOCHEMISTRY; INTRAEPITHELIAL NEOPLASIA; REPRODUCIBILITY; VARIABILITY; SPECIMENS; LESIONS	The diagnosis of squamous intraepithelial lesions in cervical tissue specimens is subject to substantial variability. Adjunctive immunohistochemical (IHC) staining for p16 has been shown to add objective biomarker information to morphologic interpretation of hematoxylin and eosin (H&E)-stained tissues. In the CERvical Tissue AdjunctIve aNalysis (CERTAIN) study, we systematically analyzed the impact of adjunctive p16 IHC on the accuracy (agreement with reference pathology results) of diagnosing cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) in the United States. Eleven hundred cervical biopsies were divided into 4 sets of 275 cases by stratified randomization. All H&E slides from each set were interpreted by 17 to 18 individual surgical pathologists, for a total of 19,250 reads by 70 surgical pathologists. After a wash-out period and blinding to original results, cases were re-read by the same pathologists using H&E+p16-stained slides. Using expert consensus diagnoses on H&E+p16 as reference, adjunctive p16 IHC use significantly improved diagnostic agreement of surgical pathologists by 4.7% (95% confidence interval [CI], 3.9, 5.4; P<0.0001). This improvement was driven by an increase of 11.5% (95% CI, 9.3, 13.5; P<0.0001) in sensitivity and an increase of 3.0% (95% CI, 2.2, 3.7; P<0.0001) in specificity. Diagnostic performance was significantly increased as well when expert consensus diagnoses established on H&E only was used as reference. Furthermore, interobserver reliability improved significantly from moderate (H&E: kappa=0.58) to substantial (H&E+p16: kappa=0.73; P<0.0001). Adjunctive use of p16 IHC provides more accurate and reproducible diagnostic results in the interpretation of cervical biopsies, ensuring that more patients are treated correctly without treating more patients.	[Stoler, Mark H.] Univ Virginia Hlth Syst, Dept Pathol, 1215 Lee St, Charlottesville, VA 22908 USA; [Wright, Thomas C., Jr.] Columbia Univ, Dept Pathol, New York, NY USA; [Ferenczy, Alex] McGill Univ, Hlth Ctr, Dept Pathol, Montreal, PQ, Canada; [Ranger-Moore, James; Fang, Qijun; Kapadia, Monesh; Ridder, Ruediger] Ventana Med Syst Inc, Roche Tissue Diagnost, Tucson, AZ USA	Stoler, MH (reprint author), Univ Virginia Hlth Syst, Dept Pathol, 1215 Lee St, Charlottesville, VA 22908 USA.	mhs2e@virginia.edu			Ventana Medical Systems Inc. (Roche Tissue Diagnostics)	Supported by Ventana Medical Systems Inc. (Roche Tissue Diagnostics). The sponsor was responsible for developing the protocol in collaboration with the other study investigators. The sponsor oversaw all aspects of the study conduct including data collection and management, statistical analysis, and reporting of results. M.H.S., T.C.W., and A.F. are consultants to Roche Diagnostics and BD Diagnostics. J.R.M., Q.F., M.K., and R.R. are employees of Ventana Medical Systems Inc./Roche Tissue Diagnostics, which commercializes in vitro diagnostic products evaluated in this study.	Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM; Carreon JD, 2007, INT J GYNECOL PATHOL, V26, P441, DOI 10.1097/pgp.ob013e31805152ab; Darragh T, 2013, J LOW GENIT TRACT DI, V17, P368; Dijkstra MG, 2010, J CLIN PATHOL, V63, P972, DOI 10.1136/jcp.2010.078634; Gage JC, 2013, AM J CLIN PATHOL, V139, P330, DOI 10.1309/AJCPSD3ZXJXP7NNB; Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4; Gurrola-Diaz CM, 2008, GYNECOL ONCOL, V111, P120, DOI 10.1016/j.ygyno.2008.06.032; Horn LC, 2008, AM J SURG PATHOL, V32, P502, DOI 10.1097/PAS.0b013e31815ac420; ISMAIL SM, 1990, HISTOPATHOLOGY, V16, P371, DOI 10.1111/j.1365-2559.1990.tb01141.x; Kyrgiou M, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012847; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Malpica A, 2005, GYNECOL ONCOL, V99, pS38, DOI 10.1016/j.ygyno.2005.07.040; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; Meserve E, 2014, J LOW GENIT TRACT DI, V18, P266, DOI 10.1097/LGT.0000000000000001; Reuschenbach M, 2014, AM J CLIN PATHOL, V142, P767, DOI 10.1309/AJCP3TPHV4TRIZEK; ROBERTSON AJ, 1989, J CLIN PATHOL, V42, P231, DOI 10.1136/jcp.42.3.231; Sarian LO, 2006, GYNECOL ONCOL, V102, P537, DOI 10.1016/j.ygyno.2006.01.052; Sayed Kadria, 2007, J Low Genit Tract Dis, V11, P141, DOI 10.1097/01.lgt.0000265777.36797.e7; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Simoens C, 2012, BJOG-INT J OBSTET GY, V119, P1247, DOI 10.1111/j.1471-0528.2012.03429.x; Stoler M, 2014, WHO CLASSIFICATION T, P169; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; US Food and Drug Administration, 2011, EST PERF CHAR IN VIT; Wright TC, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.07.024	24	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1001	1009		10.1097/PAS.0000000000001072			9	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000002	29697437				2019-10-28	
J	Xie, Y; Xu, H; Fang, F; Li, ZH; Zhou, HT; Pan, J; Guo, WL; Zhu, XM; Wang, J; Wu, Y				Xie, Yi; Xu, Hua; Fang, Fang; Li, Zhiheng; Zhou, Huiting; Pan, Jian; Guo, Wanliang; Zhu, Xueming; Wang, Jian; Wu, Yi			A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						neuroblastoma; Msi1; ID1; PCNA; prognosis	CELL NUCLEAR ANTIGEN; PROGNOSTIC VALUE; GENE-EXPRESSION; LUNG-CANCER; MUSASHI1; DIFFERENTIATION; PCNA; ACTIVATION; CARCINOMA; SURVIVAL	Neuroblastoma (NB) is the most common extracranial solid tumor in children with contrasting outcomes. Precise risk assessment contributes to prognosis prediction, which is critical for treatment strategy decisions. In this study, we developed a 3-protein predictor model, including the neural stem cell marker Msi1, neural differentiation marker ID1, and proliferation marker proliferating cell nuclear antigen (PCNA), to improve clinical risk assessment of patients with NB. Kaplan-Meier analysis in the microarray data (GSE16476) revealed that low expression of ID1 and high expression of Msi1 and PCNA were associated with poor prognosis in NB patients. Combined application of these 3 markers to constitute a signature further stratified NB patients into different risk subgroups can help obtain more accurate prediction performance. Survival prognostic power of age and Msi1_ID1_PCNA signature by receiver operating characteristics analysis showed that this signature predicted more effectively and sensitively compared with classic risk stratification system, compensating for the deficiency of the prediction function of the age. Furthermore, we validated the expressions of these 3 proteins in neuroblastic tumor spectrum tissues by immunohistochemistry revealed that Msi1 and PCNA exhibited increased expression in NB compared with intermedial ganglioneuroblastoma and benign ganglioneuroma, whereas ID1 levels were reduced in NB. In conclusion, we established a robust risk assessment predictor model based on simple immunohistochemistry for therapeutic decisions of NB patients.	[Zhu, Xueming; Wu, Yi] Soochow Univ, Childrens Hosp, Dept Pathol, 92 Zhongnan St, Suzhou 215000, Jiangsu, Peoples R China; [Wang, Jian] Soochow Univ, Childrens Hosp, Dept Pediat Surg, Suzhou, Peoples R China; [Xu, Hua] Soochow Univ, Childrens Hosp, Dept Ophthalmol, Suzhou, Peoples R China; [Guo, Wanliang] Soochow Univ, Childrens Hosp, Dept Radiol, Suzhou, Peoples R China; [Xie, Yi; Fang, Fang; Li, Zhiheng; Zhou, Huiting; Pan, Jian] Soochow Univ, Childrens Hosp, Inst Pediat Res, Suzhou, Peoples R China	Wu, Y (reprint author), Soochow Univ, Childrens Hosp, Dept Pathol, 92 Zhongnan St, Suzhou 215000, Jiangsu, Peoples R China.	170330856@qq.com			National Natural Science FoundationNational Natural Science Foundation of China [81502500, 81500733, 8160101168, 81501703, 81570125, 81501840]; Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK20150293, BK20150292, BK2015643, BK20150294]; Talent's Subsidy Project in Science and Education of the Department of Public Health of Suzhou City [kjxw2015017]; Applied Foundational Research of Medical and Health Care of Suzhou City [SYS201563, SYS201646]; Jiangsu Provincial Medical Youth Talent project [QNRC2016768]	Supported by grants from the National Natural Science Foundation (Youth Foundation, No. 81502500, 81500733, 8160101168, 81501703, 81570125, 81501840), Natural Science Foundation of Jiangsu Province (No. BK20150293, BK20150292, BK2015643, BK20150294), Talent's Subsidy Project in Science and Education of the Department of Public Health of Suzhou City (kjxw2015017), Applied Foundational Research of Medical and Health Care of Suzhou City (SYS201563, SYS201646), and Jiangsu Provincial Medical Youth Talent project (QNRC2016768). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Abreu RD, 2009, J BIOL CHEM, V284, P12125, DOI 10.1074/jbc.M809605200; Bantis A, 2004, CYTOPATHOLOGY, V15, P25, DOI 10.1046/j.0956-5507.2003.00090.x; Brodeur G M, 1988, Prog Clin Biol Res, V271, P3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Castanon E, 2017, CANCER LETT, V402, P43, DOI 10.1016/j.canlet.2017.05.012; Damdinsuren B, 2005, INT J ONCOL, V26, P319; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Jin X, 2018, CLIN CANCER RES, V24, P383, DOI 10.1158/1078-0432.CCR-17-1529; Knelson EH, 2014, J CLIN INVEST, V124, P3016, DOI 10.1172/JCI74270; Knelson EH, 2013, J CLIN INVEST, V123, P4786, DOI 10.1172/JCI69657; Kudinov AE, 2017, CLIN CANCER RES, V23, P2143, DOI 10.1158/1078-0432.CCR-16-2728; Lee SB, 2016, NATURE, V529, P172, DOI 10.1038/nature16475; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Liu CY, 2011, J SURG ONCOL, V104, P181, DOI 10.1002/jso.21944; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; MATHEWS MB, 1984, NATURE, V309, P374, DOI 10.1038/309374a0; MATTHAY KK, 1993, J CLIN ONCOL, V11, P2226, DOI 10.1200/JCO.1993.11.11.2226; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; Morgan SC, 2010, STEM CELLS DEV, V19, P579, DOI 10.1089/scd.2009.0108; Moroz V, 2011, EUR J CANCER, V47, P561, DOI 10.1016/j.ejca.2010.10.022; Nikpour P, 2011, J CELL MOL MED, V15, P1210, DOI 10.1111/j.1582-4934.2010.01090.x; Polsky D, 2001, CANCER RES, V61, P6008; Schindl M, 2003, CLIN CANCER RES, V9, P779; Sharma P, 2010, NEURON, V68, P442, DOI 10.1016/j.neuron.2010.09.028; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; Weiss SWGJ, 2008, EWINGS SARCOMA PNET; Yin SC, 2017, ONCOTARGETS THER, V10, P319, DOI 10.2147/OTT.S126551	30	1	1	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1027	1035		10.1097/PAS.0000000000001082			9	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000004	29794872				2019-10-28	
J	Fine, SW; Al-Ahmadie, HA; Chen, YB; Gopalan, A; Tickoo, SK; Reuter, VE				Fine, Samson W.; Al-Ahmadie, Hikmat A.; Chen, Ying-Bei; Gopalan, Anuradha; Tickoo, Satish K.; Reuter, Victor E.			Comedonecrosis Revisited Strong Association With Intraductal Carcinoma of the Prostate	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						prostate; prostate cancer; grading; comedonecrosis; intraductal carcinoma	ATYPICAL CRIBRIFORM LESIONS; ISUP CONSENSUS CONFERENCE; INTRAEPITHELIAL NEOPLASIA; NEEDLE-BIOPSY; INTERNATIONAL-SOCIETY; INVASIVE CRIBRIFORM; CANCER; ADENOCARCINOMA; PATTERNS; IDENTIFICATION	From the advent of the Gleason grading system for prostate cancer, cancer displaying intraluminal necrotic cells and/or karyorrhexis within cribriform/solid architecture, a phenomenon termed "comedonecrosis," has been assigned pattern 5. Intraductal carcinoma (IDC-P) shows morphologic overlap with high-grade cribriform/solid adenocarcinoma architecturally and cytologically and may also show central necrosis, yet due to the presence of basal cells at the duct periphery is not currently assigned a grade in clinical practice. On the basis of observations from routine clinical cases, we hypothesized that comedonecrosis was more significantly associated with IDC-P than invasive disease. From a large series of mapped radical prostatectomy specimens (n=933), we identified 125 high-grade (>= Gleason score 4+3=7), high-volume tumors with available slides for review. All slides were examined for the presence of unequivocal comedonecrosis. Standard immunohistochemistry for basal cell markers was performed to detect basal cell labeling in these foci. In total, 19 of 125 (15%) cases showed some ducts with comedonecrosis-9 cases with 1 focus and 10 cases with >= 2 foci; in all, a total of 73 foci of true comedonecrosis were evaluated. Immunohistochemical stains revealed labeling for basal cell markers in a basal cell distribution for at least some comedonecrosis foci in 18 of 19 (95%) cases, 12 with IDC-P exclusively and 6 with a mix of IDC-P and invasive carcinoma comedonecrosis foci. These results suggest that comedonecrosis is strongly associated with IDC-P and hence, the routine assignment of pattern 5 to carcinoma exhibiting comedonecrosis should be reconsidered.	[Fine, Samson W.; Al-Ahmadie, Hikmat A.; Chen, Ying-Bei; Gopalan, Anuradha; Tickoo, Satish K.; Reuter, Victor E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room C502, New York, NY 10065 USA	Fine, SW (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave,Room C502, New York, NY 10065 USA.	fines@mskcc.org			MSK Cancer Center Core Grant [P30 CA008748]	Supported by MSK Cancer Center Core Grant (P30 CA008748). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Bailar J C 3rd, 1966, Cancer Chemother Rep, V50, P129; Cohen RJ, 2000, PROSTATE, V43, P11, DOI 10.1002/(SICI)1097-0045(20000401)43:1<11::AID-PROS3>3.0.CO;2-B; Cohen RJ, 2007, ARCH PATHOL LAB MED, V131, P1103; Eble JN, 2004, WHO CLASSIFICATION T, P183; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Fajardo DA, 2011, AM J SURG PATHOL, V35, P1706, DOI 10.1097/PAS.0b013e318228571d; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125; Gottipati S, 2012, AM J SURG PATHOL, V36, P900, DOI 10.1097/PAS.0b013e3182495dee; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Han B, 2010, AM J SURG PATHOL, V34, P478, DOI 10.1097/PAS.0b013e3181d6827b; Herawi M, 2007, AM J SURG PATHOL, V31, P889, DOI 10.1097/01.pas.0000213447.16526.7f; Iczkowski KA, 2014, ANN DIAGN PATHOL, V18, P333, DOI 10.1016/j.anndiagpath.2014.08.010; Kato M, 2016, MODERN PATHOL, V29, P166, DOI 10.1038/modpathol.2015.146; Kimura K, 2014, PROSTATE, V74, P680, DOI 10.1002/pros.22786; KOVI J, 1985, CANCER, V56, P1566, DOI 10.1002/1097-0142(19851001)56:7<1566::AID-CNCR2820560717>3.0.CO;2-Y; Kweldam CF, 2017, MODERN PATHOL, V30, P1126, DOI 10.1038/modpathol.2017.29; Kweldam CF, 2016, EUR J CANCER, V66, P26, DOI 10.1016/j.ejca.2016.07.012; Kweldam CF, 2016, MODERN PATHOL, V29, P630, DOI 10.1038/modpathol.2016.49; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Lotan TL, 2013, MODERN PATHOL, V26, P587, DOI 10.1038/modpathol.2012.201; McKenney JK, 2016, AM J SURG PATHOL, V40, P1439, DOI 10.1097/PAS.0000000000000736; MCNEAL JE, 1986, CANCER, V58, P1714, DOI 10.1002/1097-0142(19861015)58:8<1714::AID-CNCR2820580823>3.0.CO;2-M; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; Miyai K, 2014, HUM PATHOL, V45, P1572, DOI 10.1016/j.humpath.2014.03.011; Miyai K, 2014, INT J CLIN EXP PATHO, V7, P2518; Moch H, 2016, WHO CLASSIFICATION T; Morais CL, 2015, AM J SURG PATHOL, V39, P169, DOI 10.1097/PAS.0000000000000348; O'Brien BA, 2011, BJU INT, V107, P389, DOI 10.1111/j.1464-410X.2010.09539.x; Roberts JA, 2013, KOREAN J PATHOL, V47, P307, DOI 10.4132/KoreanJPathol.2013.47.4.307; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Rubin MA, 1998, AM J SURG PATHOL, V22, P840, DOI 10.1097/00000478-199807000-00006; Shah RB, 2010, AM J SURG PATHOL, V34, P470, DOI 10.1097/PAS.0b013e3181cfc44b; Varma M, 2016, J CLIN PATHOL, V69, P852, DOI 10.1136/jclinpath-2016-203658; Wilcox G, 1998, HUM PATHOL, V29, P1119, DOI 10.1016/S0046-8177(98)90423-3; Young RH, 2000, ATLAS TUMOR PATHOL, P143	38	4	5	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1036	1041		10.1097/PAS.0000000000001104			6	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000005	29878934	Green Accepted			2019-10-28	
J	VandenBoom, T; Quan, VL; Zhang, B; Garfield, EM; Kong, BY; Isales, MC; Panah, E; Igartua, C; Taxter, T; Beaubier, N; White, K; Gerami, P				VandenBoom, Timothy; Quan, Victor L.; Zhang, Bin; Garfield, Erin M.; Kong, Betty Y.; Isales, Maria C.; Panah, Elnaz; Igartua, Catherine; Taxter, Timothy; Beaubier, Nike; White, Kevin; Gerami, Pedram			Genomic Fusions in Pigmented Spindle Cell Nevus of Reed	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pigmented spindle cell nevus; Reed nevus; NTRK3; kinase fusions; melanocytic nevus; melanoma; spitz nevus; spitz tumor	RECEPTOR TYROSINE KINASE; ETV6-NTRK3 GENE FUSION; SPITZ TUMORS; GLIOBLASTOMA-MULTIFORME; CONGENITAL FIBROSARCOMA; MELANOCYTIC NEOPLASMS; CANCER-CELLS; ALK FUSIONS; MELANOMA; PITX3	Recent molecular studies of spitzoid neoplasms have identified mutually exclusive kinase fusions involving ROS1, ALK, RET, BRAF, NTRK1, MET, and NTRK3 as early initiating genomic events. Pigmented spindle cell nevus (PSCN) of Reed is a morphologic variant of Spitz and may be very diagnostically challenging, having histologic features concerning for melanoma. Their occurrence in younger patients, lack of association to sun exposure, and rapid early growth phase similar to Spitz nevi suggest fusions may also play a significant role in these lesions. However, to date, there is little data in the literature focused on the molecular characterization of PSCN of Reed with next-generation sequencing. We analyzed a total of 129 melanocytic neoplasms with RNA sequencing including 67 spitzoid neoplasms (10 Spitz nevi, 44 atypical Spitz tumors, 13 spitzoid melanomas) and 23 PSCN of Reed. Although only 2 of 67 (3.0%) of spitzoid lesions had NTRK3 fusions, 13 of 23 (57%) of PSCN of Reed harbored NTRK3 fusions with 5 partners ETV6 (12p13) in 2 cases and MYO5A (15q21) in 11 cases. NTRK3 fusions were confirmed with a fluorescent in situ hybridization break-apart probe. The presence of a NTRK3 fusion correlated with younger age (P=0.021) and adnexal extension (P=0.001). Other minor fusions identified in PSCN of Reed included MYO5A-MERTK (2), MYO5A-ROS1, MYO5A-RET, and ETV6-PITX3 leading to a total of 78% with fusions. Our study suggests that the majority of PSCN of Reed are the result of genomic fusions, and the most frequent and characteristic genomic aberration is an NTRK3 fusion.	[VandenBoom, Timothy; Quan, Victor L.; Zhang, Bin; Garfield, Erin M.; Kong, Betty Y.; Isales, Maria C.; Panah, Elnaz; Gerami, Pedram] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA; [Igartua, Catherine; Taxter, Timothy; Beaubier, Nike; White, Kevin] Tempus Labs Inc, Chicago, IL USA	Gerami, P (reprint author), Northwestern Univ, Dept Dermatol, 676 N St Clair St,Suite 1765, Chicago, IL 60611 USA.	pgerami1@nm.org		Zhang, Bin/0000-0001-6581-1910	IDP Foundation	Supported by the IDP Foundation. P.G. has served as a consultant for DermTech Int. and Castle Biosciences and has received honoraria for this. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Amin SM, 2017, AM J SURG PATHOL, V41, P491, DOI 10.1097/PAS.0000000000000761; BARNHILL RL, 1989, BRIT J DERMATOL, V121, P717, DOI 10.1111/j.1365-2133.1989.tb08214.x; Barnhill RL, 2018, WHO CLASSIFICATION T; Busam KJ, 2014, AM J SURG PATHOL, V38, P925, DOI 10.1097/PAS.0000000000000187; Chen H, 2017, ACTA NEUROL SCAND, V135, P373, DOI 10.1111/ane.12608; Cook MG, 2004, PATHOLOGY, V36, P414, DOI 10.1080/00313020412331283842; Cummings CT, 2013, CLIN CANCER RES, V19, P5275, DOI 10.1158/1078-0432.CCR-12-1451; Diaz A, 2011, AM J SURG PATHOL, V35, P1733, DOI 10.1097/PAS.0b013e318229cf66; Drilon A, 2017, CANCER DISCOV, V7, P963, DOI 10.1158/2159-8290.CD-17-0507; Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237; Evans RD, 2014, CURR BIOL, V24, P1743, DOI 10.1016/j.cub.2014.06.019; Gerami P, 2014, AM J SURG PATHOL, V38, P934, DOI 10.1097/PAS.0000000000000198; Hammer JA, 2012, NAT REV MOL CELL BIO, V13, P13, DOI 10.1038/nrm3248; Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166; Ho HY, 2009, MECH DEVELOP, V126, P18, DOI 10.1016/j.mod.2008.10.007; Holmes EE, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0270-x; Jimenez-Jimenez FJ, 2014, EUR NEUROL, V71, P49, DOI 10.1159/000353981; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Kiuru M, 2016, INT J SURG PATHOL, V24, P200, DOI 10.1177/1066896916630375; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Knubel KH, 2014, ONCOTARGET, V5, P1338, DOI 10.18632/oncotarget.1793; L'honore A, 2014, DEV CELL, V29, P392, DOI 10.1016/j.devcel.2014.04.006; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Lannon CL, 2004, J BIOL CHEM, V279, P6225, DOI 10.1074/jbc.M307388200; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Linger RMA, 2013, ONCOGENE, V32, P3420, DOI 10.1038/onc.2012.355; Massi GL, 2013, HISTOLOGICAL DIAGNOS; Nagasubramanian R, 2016, PEDIATR BLOOD CANCER, V63, P1468, DOI 10.1002/pbc.26026; Nguyen KQN, 2014, J BIOL CHEM, V289, P25737, DOI 10.1074/jbc.M114.570838; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Reed R J, 1975, Semin Oncol, V2, P119; REQUENA L, 1990, BRIT J DERMATOL, V123, P757, DOI 10.1111/j.1365-2133.1990.tb04193.x; Sailer V, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0317-7; Schlegel J, 2013, J CLIN INVEST, V123, P2257, DOI 10.1172/JCI67816; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Truzzi F, 2008, J INVEST DERMATOL, V128, P2031, DOI 10.1038/jid.2008.21; Tworkoski KA, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12110; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang L, 2017, J MOL DIAGN, V19, P387, DOI 10.1016/j.jmoldx.2016.11.005; Wang Y, 2013, ONCOGENE, V32, P872, DOI 10.1038/onc.2012.104; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wu G, 2016, MODERN PATHOL, V29, P359, DOI 10.1038/modpathol.2016.37; Wu YM, 2004, CANCER RES, V64, P7311, DOI 10.1158/0008-5472.CAN-04-0972; Xue GD, 2017, ONCOTARGET, V8, P69204, DOI 10.18632/oncotarget.18213; Yeh I, 2016, J PATHOL, V240, P282, DOI 10.1002/path.4775; Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387	54	8	8	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1042	1051		10.1097/PAS.0000000000001074			10	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000006	29794873				2019-10-28	
J	Lezcano, C; Shoushtari, AN; Ariyan, C; Hollmann, TJ; Busam, KJ				Lezcano, Cecilia; Shoushtari, Alexander N.; Ariyan, Charlotte; Hollmann, Travis J.; Busam, Klaus J.			Primary and Metastatic Melanoma With NTRK Fusions	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						NTRK; immunohistochemistry; melanoma; pathology	ACQUIRED-RESISTANCE; OPEN-LABEL; BRAF-MUTANT; SPITZ NEVI; SINGLE-ARM; CANCER; KIT; VEMURAFENIB; MUTATIONS; TRAF2	A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and NTRK3 have been reported in spitzoid melanocytic neoplasms leading to kinase-fusion proteins that result in immunohistochemically detectable ALK or NTRK expression. We have previously reported that ALK expression can be found in nonspitzoid primary and metastatic cutaneous melanomas. In this study we report that nonspitzoid metastasizing melanomas of adults may also harbor NTRK fusions and that NTRK expression can be immunohistochemically detected in these tumors. Of 751 melanomas analyzed by next-generation sequencing, 4 metastatic melanomas were identified with NTRK fusions, 3 involving NTRK1, 1 involving NTRK2. They occurred in 3 women and 1 man. Two of the corresponding primary tumors were from the trunk, 1 from an extremity and 1 tumor arose in anal skin. One primary tumor displayed features of superficial spreading melanoma and 3 were nodular melanomas. All tumors were cytologically characterized by the presence of large epithelioid melanocytes. All tumors were immunoreactive with anti-Trk antibody. Next-generation sequencing documented that the NTRK1 fusion partners included TRIM63, DDR2, and GON4L. One tumor harbored an NTRK2-TRAF2 fusion. Thus, our findings document that NTRK kinase fusions can occur in nonspitzoid metastasizing melanomas of adults. The presence of an NTRK family fusion in these tumors may provide a therapeutic opportunity in a small subset of patients with metastatic melanoma.	[Lezcano, Cecilia; Hollmann, Travis J.; Busam, Klaus J.] Mem Sloan Kettering Canc, Dept Pathol, New York, NY USA; [Shoushtari, Alexander N.] Mem Sloan Kettering Canc, Dept Med, New York, NY USA; [Ariyan, Charlotte] Mem Sloan Kettering Canc, Dept Surg, New York, NY USA	Busam, KJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	busamk@mskcc.org			Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute [P30CA008748]	Research reported in this publication was supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Agarwal N, 2016, CANCER RES, V76, P5175, DOI 10.1158/0008-5472.CAN-16-1099; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Bastian BC, 1999, J INVEST DERMATOL, V113, P1065, DOI 10.1046/j.1523-1747.1999.00787.x; Bastian BC, 2001, ARCH DERMATOL, V137, P1507; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer Jurgen, 2005, Adv Dermatol, V21, P81, DOI 10.1016/j.yadr.2005.04.002; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Botton T, 2014, CLIN CANCER RES, V20, P6631, DOI 10.1158/1078-0432.CCR-14-0058; Botton T, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12148; Busam KJ, 2016, AM J SURG PATHOL, V40, P786, DOI 10.1097/PAS.0000000000000611; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Coit DG, 2013, J NATL COMPR CANC NE, V11, P395, DOI 10.6004/jnccn.2013.0055; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dietel M, 2011, LUNG CANCER, V71, P241; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Drilon A, 2017, CANCER DISCOV, V7, P963, DOI 10.1158/2159-8290.CD-17-0507; Dummer R, 2017, LANCET ONCOL, V18, P435, DOI 10.1016/S1470-2045(17)30180-8; Fisher Rosalie, 2012, Cancer Manag Res, V4, P243, DOI 10.2147/CMAR.S25284; Flaherty L, 2014, CANCER J, V20, P18, DOI 10.1097/PPO.0000000000000024; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hantschke M, 2010, AM J SURG PATHOL, V34, P216, DOI 10.1097/PAS.0b013e3181c7d8b2; Hechtman JF, 2017, AM J SURG PATHOL, V41, P1547, DOI 10.1097/PAS.0000000000000911; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Hyman DM, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.LBA2501; Kainthla R, 2014, PHARMACOGEN PERS MED, V7, P21, DOI 10.2147/PGPM.S37220; Kalinsky K, 2017, CANCER-AM CANCER SOC, V123, P2688, DOI 10.1002/cncr.30663; Kiuru M, 2013, J CUTAN PATHOL, V40, P950, DOI 10.1111/cup.12197; Long GV, 2016, J CLIN ONCOL, V34, P871, DOI 10.1200/JCO.2015.62.9345; Lu P, 2010, J EXP MED, V207, P1359, DOI 10.1084/jem.20100147; Meldolesi J, 2017, PHYSL BIOCH PHARM; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Neumann LC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-380; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Park ES, 2015, J BIOL CHEM, V290, P9660, DOI 10.1074/jbc.M114.609685; Pavlick D, 2017, PEDIAT BLOOD CANC, V64, P8; Petersen SL, 2015, CELL DEATH DIFFER, V22, P1846, DOI 10.1038/cdd.2015.35; Prasad ML, 2016, CANCER-AM CANCER SOC, V122, P1097, DOI 10.1002/cncr.29887; Rambow F, 2015, CELL REP, V13, P840, DOI 10.1016/j.celrep.2015.09.037; Ribas A, 2011, NAT REV CLIN ONCOL, V8, P426, DOI 10.1038/nrclinonc.2011.69; Russo M, 2016, CANCER DISCOV, V6, P36, DOI 10.1158/2159-8290.CD-15-0940; Salama AKS, 2013, EXPERT OPIN PHARMACO, V14, P619, DOI 10.1517/14656566.2013.770475; Schmitt MW, 2016, NAT REV CLIN ONCOL, V13, P335, DOI 10.1038/nrclinonc.2015.175; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Shen RR, 2015, ONCOGENE, V34, P209, DOI 10.1038/onc.2013.543; Tiseo M, 2011, LUNG CANCER, V71, P241, DOI 10.1016/j.lungcan.2010.11.014; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; von Grabowiecki Y, 2016, ELIFE, V26, P5; WEIER HUG, 1995, GENOMICS, V26, P390, DOI 10.1016/0888-7543(95)80226-C; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wilmott JS, 2012, MOL CANCER THER, V11, P2704, DOI 10.1158/1535-7163.MCT-12-0530; Wilson MA, 2016, CLIN CANCER RES, V22, P374, DOI 10.1158/1078-0432.CCR-15-1162; Xu JK, 2014, CANCER BIOL THER, V15, P612, DOI 10.4161/cbt.28181; Yeh I, 2016, J PATHOL, V240, P282, DOI 10.1002/path.4775; Yeh I, 2015, AM J SURG PATHOL, V39, P581, DOI 10.1097/PAS.0000000000000387; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406	60	9	9	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1052	1058		10.1097/PAS.0000000000001070			7	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000007	29683819	Green Accepted			2019-10-28	
J	Mito, JK; Bishop, JA; Sadow, PM; Stelow, EB; Faquin, WC; Mills, SE; Krane, JF; French, CA; Fletcher, CDM; Hornick, JL; Sholl, LM; Jo, VY				Mito, Jeffrey K.; Bishop, Justin A.; Sadow, Peter M.; Stelow, Edward B.; Faquin, William C.; Mills, Stacey E.; Krane, Jeffrey F.; French, Christopher A.; Fletcher, Christopher D. M.; Hornick, Jason L.; Sholl, Lynette M.; Jo, Vickie Y.			Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						sinonasal undifferentiated carcinoma; IDH1; IDH2; SNUC; sinonasal carcinoma	MONOCLONAL-ANTIBODY MSMAB-1; ACUTE MYELOID-LEUKEMIA; NASOPHARYNGEAL CARCINOMA; MUTATIONS; CANCER; FREQUENT; TRACT; DIFFERENTIATION; GENOME; EXOME	Recent studies have identified recurrent isocitrate dehydrogenase 2 (IDH2) mutations in a subset of sinonasal undifferentiated carcinomas (SNUCs); however, the true frequency of IDH mutations in SNUC is unknown. We evaluated the utility of mutation-specific IDH1/2 immunohistochemistry (IHC) in a large multi-institutional cohort of SNUC and morphologic mimics. IHC using a multispecific antibody for IDH1/2 (R132/R172) mutant protein was performed on 193 sinonasal tumors including: 53 SNUCs, 8 poorly differentiated carcinomas (PDCARs) and 132 histologic mimics. Mutant IDH1/2 IHC was positive in 26/53 SNUCs (49%; 20 strongly positive and 6 weak) and 3/8 PDCARs (37.5%; 2 strong; 1 weak) but was absent in all other tumor types (0/132). Targeted next-generation sequencing (NGS) on a subset of SNUC/PDCAR (6 strong and 3 weak positive for IDH1/2 IHC; 7 negative) showed frequent IDH2 R172X mutations (10/16) and a single IDH1 R132C mutation. All 6 cases with strong positive mutant IDH1/2 staining and NGS had IDH2 R172S/G mutations. The 3 IHC-weak cases all had IDH2 R172T mutations. Among the 7 tested cases that were negative for mutant IDH1/2 IHC, NGS detected 1 case each with IDH2 R172T and IDH1 R132C mutation. IDH-mutant carcinomas also had frequent mutations in TP53 (55%) and activating mutations in KIT (45%) or the PI3K pathway (36%). Mutation-specific IDH1/2 IHC identifies IDH mutations in SNUC, however, it lacks sensitivity for the full range of IDH mutations. These findings suggest that IDH-mutant sinonasal carcinoma may represent a distinct pathobiological entity with therapeutic implications that can be identified by a combined approach of multispecific IDH1/2 IHC and sequencing.	[Mito, Jeffrey K.; Krane, Jeffrey F.; French, Christopher A.; Fletcher, Christopher D. M.; Hornick, Jason L.; Sholl, Lynette M.; Jo, Vickie Y.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Sholl, Lynette M.] Brigham & Womens Hosp, Ctr Adv Mol Diagnost, 75 Francis St, Boston, MA 02115 USA; [Sadow, Peter M.; Faquin, William C.; Sholl, Lynette M.] Harvard Med Sch, Boston, MA USA; [Sadow, Peter M.; Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Stelow, Edward B.; Mills, Stacey E.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA	Jo, VY (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	vjo@partners.org	Sadow, Peter/E-7691-2015	Sadow, Peter/0000-0003-1036-6367			Agaimy A, 2017, HEAD NECK PATHOL, V11, P541, DOI 10.1007/s12105-017-0783-4; Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Ali SM, 2017, CANCER-AM CANCER SOC, V123, P3628, DOI 10.1002/cncr.30781; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Bishop JA, 2017, AM J SURG PATHOL, V41, P1690, DOI 10.1097/PAS.0000000000000944; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2013, AM J SURG PATHOL, V37, P185, DOI 10.1097/PAS.0b013e3182698673; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Chambers KJ, 2015, J NEUROL SURG PART B, V76, P94, DOI 10.1055/s-0034-1390016; Clark O, 2016, CLIN CANCER RES, V22, P1837, DOI 10.1158/1078-0432.CCR-13-1333; Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013; Dogan S, 2017, J PATHOL, V242, P400, DOI 10.1002/path.4915; French CA, 2003, CANCER RES, V63, P304; FRIERSON HF, 1986, AM J SURG PATHOL, V10, P771, DOI 10.1097/00000478-198611000-00004; Garcia EP, 2017, ARCH PATHOL LAB MED, V141, P751, DOI 10.5858/arpa.2016-0527-OA; Griffin CT, 2011, P NATL ACAD SCI USA, V108, P2282, DOI 10.1073/pnas.1013751108; Guo J, 2017, ANN ONCOL, V28, P1380, DOI 10.1093/annonc/mdx079; Jo VY, 2017, MODERN PATHOL, V30, P650, DOI 10.1038/modpathol.2016.239; Kaneko MK, 2013, TOHOKU J EXP MED, V230, P103, DOI 10.1620/tjem.230.103; Kopinja J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14065-w; Lewis JS, 2017, WHO CLASSIFICATION H, P18; Li YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14121; Lin DC, 2014, NAT GENET, V46, P866, DOI 10.1038/ng.3006; Liu X, 2013, CANCER MED-US, V2, P803, DOI 10.1002/cam4.149; Lui VWY, 2018, CANCER-AM CANCER SOC, V124, P434, DOI 10.1002/cncr.31131; Llorente JL, 2014, NAT REV CLIN ONCOL, V11, P460, DOI 10.1038/nrclinonc.2014.97; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Reiersen DA, 2012, OTOLARYNG HEAD NECK, V147, P7, DOI 10.1177/0194599812440932; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; Singh L, 2014, ANN DIAGN PATHOL, V18, P261, DOI 10.1016/j.anndiagpath.2014.01.003; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Zheng H, 2016, P NATL ACAD SCI USA, V113, P11283, DOI 10.1073/pnas.1607606113	40	6	6	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1067	1075		10.1097/PAS.0000000000001064			9	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000009	29683816				2019-10-28	
J	Agaimy, A; Mueller, SK; Bumm, K; Iro, H; Moskalev, EA; Hartmann, A; Stoehr, R; Haller, F				Agaimy, Abbas; Mueller, Sarina K.; Bumm, Klaus; Iro, Heinrich; Moskalev, Evgeny A.; Hartmann, Arndt; Stoehr, Robert; Haller, Florian			Intraductal Papillary Mucinous Neoplasms of Minor Salivary Glands With AKT1 p.Glu17Lys Mutation	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						salivary glands; IPMN; intraductal papilloma; sialadenoma papilliferum; cystadenoma; AKT1 mutations	HIDRADENOMA PAPILLIFERUM; RECURRENT MUTATIONS; DUCT CARCINOMA; AKT1 MUTATIONS; PAROTID-GLAND; PANCREAS; TUMORS; ADENOCARCINOMA; EXPRESSION; MUC2	The spectrum of low-grade intraductal papillary proliferations of the salivary glands is heterogenous, and reproducible morphologic diagnostic criteria have not yet been established. Recognized types are sialadenoma papilliferum, inverted ductal papilloma, and intraductal papilloma, but some lesions have been possibly included in the morphologic spectrum of cystadenoma or low-grade intraductal carcinomas. We herein present detailed morphologic, immunophenotypic, and genotypic features of 3 minor salivary gland neoplasms affecting 2 men (aged 65 and 71 y) and 1 woman (aged 78 y). They ranged in size from 1 to 2.5 cm. All tumors showed atypical papillary intraductal growth that presented either as uninodular/unicystic lesions (intraductal papilloma-like; n=2) or as a discontinuous growth along the ductal system in a manner similar to pancreatic intraductal papillary mucinous neoplasm (n=1). Variable cytologic and architectural atypia was observed, ranging from bland intraductal papilloma-like features, to areas mimicking atypical ductal hyperplasia and low-grade ductal carcinoma in situ of the breast. Amplicon-based massive parallel sequencing revealed an identical AKT1 p.Glu17Lys mutation in all 3 cases, but absence of concurring mutations in other genes of the RAS or PI3K pathway. This small series represents the first genetic study on salivary intraductal papillary neoplasms. Our cases showed significant variation in the degree of cytologic and architectural atypia, which overlaps with intraductal papillomas at the one end and with low-grade intraductal carcinoma at the other end of the spectrum, suggesting a disease continuum. As the full biological and morphologic characteristics of these ductal papillary lesions remain to be defined, the noncommitted term intraductal papillary neoplasms might be more appropriate. Our novel genetic findings mirror similar activating mutations of AKT1 and other PI3K pathway members in intraductal papillary lesions of the breast and anogenital glands.	[Agaimy, Abbas; Moskalev, Evgeny A.; Hartmann, Arndt; Stoehr, Robert; Haller, Florian] Univ Hosp, Inst Pathol, Erlangen, Germany; [Mueller, Sarina K.; Iro, Heinrich] Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Erlangen, Germany; [Bumm, Klaus] Caritas Clin, Dept Otorhinolaryngol Head & Neck Surg, Saarbrucken, Germany	Agaimy, A (reprint author), Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de					Alos L, 2005, AM J SURG PATHOL, V29, P806, DOI 10.1097/01.pas.0000155856.84553.c9; Basturk O, 2016, VIRCHOWS ARCH, V469, P523, DOI 10.1007/s00428-016-2014-x; Brannon RB, 2001, ORAL SURG ORAL MED O, V92, P68, DOI 10.1067/moe.2001.115978; Budnick S, 2017, WHO CLASSIFICATION H, P192; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chiosea SI, 2015, AM J SURG PATHOL, V39, P744, DOI 10.1097/PAS.0000000000000410; Ellis GL, 2008, TUMORS SALIVARY GLAN, P144; Foschini MP, 2017, WHO CLASSIFICATION H, P192; Furukawa T, 2005, VIRCHOWS ARCH, V447, P794, DOI 10.1007/s00428-005-0039-7; Goto K, 2017, J CLIN PATHOL, V70, P424, DOI 10.1136/jclinpath-2016-204003; Handra-Luca A, 2005, AM J SURG PATHOL, V29, P881, DOI 10.1097/01.pas.0000159103.95360.e8; Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143; Iacobuzio-Donahue CA, 2000, AM J PATHOL, V157, P755, DOI 10.1016/S0002-9440(10)64589-0; Kelly PJ, 2012, AM J SURG PATHOL, V36, P696, DOI 10.1097/PAS.0b013e318249ce1c; Kojima Y, 1998, OTOLARYNG HEAD NECK, V118, P404, DOI 10.1016/S0194-5998(98)70326-2; Konstantinova AM, 2017, ANN DIAGN PATHOL, V28, P12, DOI 10.1016/j.anndiagpath.2017.02.004; Kusafuka K, 2008, PATHOL INT, V58, P524, DOI 10.1111/j.1440-1827.2008.02267.x; Kusafuka K, 2010, MED MOL MORPHOL, V43, P178, DOI 10.1007/s00795-009-0479-2; Liau JY, 2017, HISTOPATHOLOGY, V70, P195, DOI 10.1111/his.13043; Liau JY, 2016, HUM PATHOL, V55, P57, DOI 10.1016/j.humpath.2016.04.014; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Loening T, 2017, WHO CLASSIFICATION H, P170; Mannweiler S, 2003, APMIS, V111, P978, DOI 10.1034/j.1600-0463.2003.1111010.x; Nagao T, 2000, ARCH PATHOL LAB MED, V124, P291; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P113, DOI 10.1002/gcc.22315; Richardson M, 2017, WHO CLASSIFICATION H, P192; Shimura T, 2018, ONCOTARGET, V9, P1852, DOI 10.18632/oncotarget.22927; SHIOTANI A, 1994, ORL J OTO-RHINO-LARY, V56, P112, DOI 10.1159/000276621; Tjioe KC, 2015, HEAD NECK PATHOL, V9, P354, DOI 10.1007/s12105-014-0602-0; Tomonao A, 2009, ORAL SURG ORAL MED O, V107, pE34, DOI 10.1016/j.tripleo.2009.01.019; Troxell ML, 2010, MODERN PATHOL, V23, P27, DOI 10.1038/modpathol.2009.142; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Volckmar AL, 2017, GENE CHROMOSOME CANC, V56, P11, DOI 10.1002/gcc.22396; Weinreb I, 2018, AM J SURG PATHOL, V42, P442, DOI 10.1097/PAS.0000000000000952; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108	35	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1076	1082		10.1097/PAS.0000000000001080			7	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000010	29738361				2019-10-28	
J	Lee, HE; Wu, TT; Chandan, VS; Torbenson, MS; Mounajjed, T				Lee, Hee Eun; Wu, Tsung-Teh; Chandan, Vishal S.; Torbenson, Michael S.; Mounajjed, Taofic			Colonic Adenomatous Polyps Involving Submucosal Lymphoglandular Complexes A Diagnostic Pitfall	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						colorectal adenoma; lymphoglandular complex; pseudoinvasion; colorectal carcinoma mimicker; misplaced epithelium	MICRODIVERTICULA; PSEUDOINVASION; COLITIS; DISEASE	Lymphoglandular complexes (LGCs) are lymphoid nodules containing intestinal mucosa, present in close apposition to muscularis mucosae or submucosa. Rarely, colorectal adenomas involve submucosal LGCs, simulating invasive adenocarcinoma with associated submucosal lymphoid aggregates, and presenting a diagnostic pitfall. We aimed to identify distinctive histologic features between submucosal LGCs and true invasion. Seven adenomas (tubular/tubulovillous adenomas [n=6], including 4 with high-grade dysplasia and 1 with focal intramucosal adenocarcinoma, and sessile serrated adenoma [n=1]) were in the right (n=5) and left colon (n=2). Seven adenocarcinomas were in the right (n=3), left (n=2), and rectum/rectosigmoid colon (n=2). Adenomatous glands involving submucosal LGCs were invested in lamina propria, showed continuity with surface adenoma, were well rounded and contained within lymphoid tissue, and predominantly lacked classic features of pseudoinvasion. One case showed a herniation pattern carrying muscularis mucosae. Adenocarcinomas had at least one of the following features: infiltrating single cells/small clusters (n=5), poorly formed, fused, and irregular glands (n=2), solid tumor nests (n=1), desmoplastic reaction (n=5), intraluminal necrosis (n=3), or lymphovascular invasion (n=1). In contrast, no adenoma had these features. Adenocarcinomas showed no herniation, but connection to surface tumor (n=5) was seen. Five invasive adenocarcinomas extended into the submucosa beyond the lymphoid aggregate. In conclusion, adenomas involving LGCs are a rare, clinicopathologically distinct form of pseudoinvasion that mimics invasive adenocarcinoma; histologic features that distinguish them are a well-rounded contour contained within the lymphoid tissue, and lack of infiltrating single cells/small clusters, poorly formed, fused, and irregular glands, solid tumor nests, desmoplastic reaction, and lymphovascular invasion.	[Lee, Hee Eun; Wu, Tsung-Teh; Chandan, Vishal S.; Torbenson, Michael S.; Mounajjed, Taofic] Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA	Mounajjed, T (reprint author), Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA.	mounajjed.taofic@mayo.edu					Choi DH, 2009, DIS COLON RECTUM, V52, P438, DOI 10.1007/DCR.0b013e318197e37f; CLARK RM, 1969, CAN MED ASSOC J, V100, P1025; CLARK RM, 1970, CAN MED ASSOC J, V103, P24; DRUT R, 1992, PEDIATR PATHOL, V12, P575, DOI 10.3109/15513819209024208; Dukes C, 1926, J PATHOL BACTERIOL, V29, P111, DOI 10.1002/path.1700290113; DYSON JL, 1975, J CLIN PATHOL, V28, P189, DOI 10.1136/jcp.28.3.189; Jacobson BC, 2009, GEN PATHOLOGY GI TRA; KEALY WF, 1976, J CLIN PATHOL, V29, P241, DOI 10.1136/jcp.29.3.241; KEALY WF, 1976, J CLIN PATHOL, V29, P245, DOI 10.1136/jcp.29.3.245; Mansfield LS, 2004, COMPARATIVE MED, V54, P514; MUTO T, 1973, J CLIN PATHOL, V26, P25, DOI 10.1136/jcp.26.1.25; OLEARY AD, 1986, HISTOPATHOLOGY, V10, P267, DOI 10.1111/j.1365-2559.1986.tb02481.x; Panarelli NC, 2016, AM J SURG PATHOL, V40, P1075, DOI 10.1097/PAS.0000000000000641; PASCAL RR, 1990, AM J SURG PATHOL, V14, P694, DOI 10.1097/00000478-199007000-00010; Shepherd NA, 2015, MODERN PATHOL, V28, pS88, DOI 10.1038/modpathol.2014.138; Yantiss RK, 2001, MODERN PATHOL, V14, P869, DOI 10.1038/modpathol.3880403; Zhou SM, 2015, CASE REP PATHOL, DOI 10.1155/2015/646270	17	1	1	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1083	1089		10.1097/PAS.0000000000001081			7	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000011	29738362				2019-10-28	
J	Gradecki, SE; Grange, JS; Stelow, EB				Gradecki, Sarah E.; Grange, Jacob S.; Stelow, Edward B.			Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						NSCLC; PD-L1; core biopsy; immunotherapy	PEMBROLIZUMAB	The heterogeneity of programmed death ligand 1 (PD-L1) expression in non-small cell lung carcinomas (NSCLCs) is well studied; however, the method of tissue sampling needed to obtain adequate diagnostic material has not been established. This study aimed to determine whether core needle biopsy provides sufficient tissue for accurate PD-L1 evaluation despite tumor heterogeneity. A retrospective analysis comparing tumoral expression of PD-L1 in 51 lung core biopsies to subsequent resection specimens was performed. Scoring of membranous staining was categorized as 0%, 1% to 49%, and >= 50% of tumor cells. Staining >= 50% tumoral PD-L1 expression was detected in 8/51 (15.7%) of core biopsies and 8/51 (15.7%) of resection specimens. Core biopsy and resection results were concordant in 92.2% of cases (kappa, 0.70; 95% confidence interval, 0.43-0.98). Therefore, despite tumor heterogeneity, detection of tumoral PD-L1 expression in NSCLC appears to be largely concordant between core biopsies and resection specimens, with the caveat that it may be helpful to reassess resection specimens for low-level staining. These findings suggest that core biopsy may be adequate for determining PD-L1 expression in NSCLC.	[Gradecki, Sarah E.; Grange, Jacob S.; Stelow, Edward B.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA	Stelow, EB (reprint author), UVA Hlth Syst, Dept Pathol, POB 800214,1215 Lee St, Charlottesville, VA 22908 USA.	es7yj@virginia.edu		Gradecki, Sarah/0000-0002-7574-9011			Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Ferlay J., 2013, IARC, DOI DOI 10.1016/J.UCL.2013.01.011; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Ilie M, 2016, VIRCHOWS ARCH, V468, P511, DOI 10.1007/s00428-016-1910-4; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Soria JC, 2015, CLIN CANCER RES, V21, P2256, DOI 10.1158/1078-0432.CCR-14-2959; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130	14	6	6	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1090	1094		10.1097/PAS.0000000000001085			5	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000012	29794870				2019-10-28	
J	Allard, FD; Goldsmith, JD; Ayata, G; Challies, TL; Najarian, RM; Nasser, IA; Wang, H; Yee, EU				Allard, Felicia D.; Goldsmith, Jeffrey D.; Ayata, Gamze; Challies, Tracy L.; Najarian, Robert M.; Nasser, Imad A.; Wang, Helen; Yee, Eric U.			Intraobserver and Interobserver Variability in the Assessment of Dysplasia in Ampullary Mucosal Biopsies	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						ampulla of Vater; dysplasia; interobserver; intraobserver; biopsy; agreement; kappa values	OBSERVER VARIABILITY; ULCERATIVE-COLITIS; COLORECTAL POLYPS; DIAGNOSIS; ADENOMAS; AGREEMENT; ESOPHAGUS; TUMORS; VATER	Endoscopic mucosal biopsies of the ampulla of Vater (AmpBx) are obtained to histologically assess for dysplasia or carcinoma. However, biopsy material is often scant and a host of factors can induce histologic changes that pose diagnostic challenges. We sought to investigate observer variability in interpretation of AmpBx and the impact clinical data may have on diagnostic interpretation. Thirty-one cases from institutional archives were selected, including 12 cases of reactive atypia (RA), 8 indefinite for dysplasia (ID), and 11 showing low-grade dysplasia (LGD). Slides were independently reviewed at 3 time points with and without clinical information by 6 pathologists who categorized the biopsies RA, ID, or LGD. Following the reviews, intraobserver and interobserver agreement was assessed. Review of AmpBx without clinical data showed fair (kappa, 0.27), poor (kappa, 0.07), and good (kappa, 0.42) interobserver agreement for diagnoses of RA, ID, and LGD, respectively. Interobserver agreement improved for LGD (kappa, 0.66 and 0.73) when clinical information was provided; however, agreement remained fair for RA (kappa, 0.4 and 0.42) and poor-to-fair for ID (kappa, 0.17 and 0.25). When follow-up data were reviewed, all cases that reached unanimous agreement had that diagnosis substantiated by subsequent endoscopic or histologic findings. The same was true of 13 of 19 cases that reached majority consensus. Given the potential clinical consequences of these diagnoses combined with the significant intraobserver and interobserver variability found in this study, we conclude that better-defined diagnostic criteria and consensus reads on difficult cases would assist in the histologic assessment of these challenging cases.	[Allard, Felicia D.; Yee, Eric U.] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA; [Goldsmith, Jeffrey D.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Ayata, Gamze; Challies, Tracy L.; Najarian, Robert M.; Nasser, Imad A.; Wang, Helen] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA USA	Allard, FD (reprint author), Univ Arkansas Med Sci, Coll Med, 4301 W Markham St,Slot 517, Little Rock, AR 72205 USA.	fallard@UAMS.edu	Allard, Felicia D./S-1964-2019	Allard, Felicia D./0000-0001-9903-0944			Adler DG, 2006, GASTROINTEST ENDOSC, V64, P849, DOI 10.1016/j.gie.2006.08.044; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; Beger HG, 1999, ARCH SURG-CHICAGO, V134, P526, DOI 10.1001/archsurg.134.5.526; Chareton B, 1996, WORLD J SURG, V20, P707, DOI 10.1007/s002689900108; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; DIXON MF, 1988, HISTOPATHOLOGY, V13, P385, DOI 10.1111/j.1365-2559.1988.tb02055.x; Farris AB, 2008, AM J SURG PATHOL, V32, P30, DOI 10.1097/PAS.0b013e318093e40a; Foss FA, 2012, HISTOPATHOLOGY, V61, P47, DOI 10.1111/j.1365-2559.2011.04154.x; Glatz K, 2007, AM J CLIN PATHOL, V127, P938, DOI 10.1309/NXDB6FMTE9X5CD6Y; Hornick JR, 2011, SURGERY, V150, P169, DOI 10.1016/j.surg.2011.05.012; Kim JH, 2009, ANN SURG ONCOL, V16, P2547, DOI 10.1245/s10434-009-0509-2; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Limsui D, 2009, INFLAMM BOWEL DIS, V15, P35, DOI 10.1002/ibd.20538; MELVILLE DM, 1989, HUM PATHOL, V20, P1008, DOI 10.1016/0046-8177(89)90273-6; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Osmond A, 2014, J CLIN PATHOL, V67, P781, DOI 10.1136/jclinpath-2014-202177; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; Tsang P, 1999, AM J SURG PATHOL, V23, P423, DOI 10.1097/00000478-199904000-00006	18	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1095	1100		10.1097/PAS.0000000000001079			6	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000013	29738360				2019-10-28	
J	Borra, T; Custrin, A; Saggini, A; Fink-Puches, R; Cota, C; Vermi, W; Facchetti, F; Cerroni, L				Borra, Tiziana; Custrin, Ana; Saggini, Andrea; Fink-Puches, Regina; Cota, Carlo; Vermi, William; Facchetti, Fabio; Cerroni, Lorenzo			Pityriasis Lichenoides, Atypical Pityriasis Lichenoides, and Related Conditions A Study of 66 Cases	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						pityriasis lichenoides; pityriasis lichenoides et varioliformis acuta; mycosis fungoides; lymphomatoid papulosis; atypical pityriasis lichenoides; cutaneous T-cell lymphoma	PAPULAR MYCOSIS-FUNGOIDES; T-CELL CLONALITY; LYMPHOMATOID PAPULOSIS; VARIOLIFORMIS-ACUTA; BIOPSY SPECIMENS; CHRONICA; DISORDERS; CHILDHOOD; FEATURES; VARIANT	Pityriasis lichenoides (PLs) is an uncommon skin disease of unknown etiology. In recent years, an atypical form of PL has been described, showing overlapping features with mycosis fungoides (MF) and lymphomatoid papulosis. We studied 66 patients with an initial histopathologic diagnosis of PL (M:F=34:32; median age, 25 y; range, 7 to 85 y). According to clinical and phenotypic features, cases were classified into 4 categories: (1) Conventional PL (characteristic clinical features of PL without phenotypic aberrations) (n=20; M:F=8:12; median age, 37 y; range, 9 to 74 y); (2) Atypical form of PL (characteristic clinical features of PL with phenotypic aberrations) (n=25; M:F=16:9; median age, 21 y; range, 7 to 72 y). Four of these patients subsequently developed MF; (3) Lymphomatoid papulosis (waxing and waning lesions and positivity for CD30) (n=10; M:F=4:6; median age, 41 y; range, 16 to 83 y); (4) MF (clinical features typical of MF) (n=11; M:F=6:5; median age, 17 y; range, 8 to 85 y). Molecular analyses of clonality of the infiltrate did not reveal relevant differences among these 4 groups. Our study suggests that patients with an initial histopathologic diagnosis of PL may belong to different groups, showing that clinicopathologic correlation and complete phenotypic analyses are paramount in order to achieve proper classification. Although the relationship between PL and MF is yet a matter of debate, at the present state of knowledge, patients with a clinicopathologic presentation consistent with PL but with aberrant phenotypic features should be monitored in order to detect a possible evolution into MF.	[Borra, Tiziana; Custrin, Ana; Saggini, Andrea; Fink-Puches, Regina; Cerroni, Lorenzo] Med Univ Graz, Dept Dermatol, Res Unit Dermatopathol, Graz, Austria; [Borra, Tiziana; Vermi, William; Facchetti, Fabio] Univ Brescia, Dept Mol & Translat Med, Sect Pathol, Brescia, Italy; [Custrin, Ana] Univ Trieste, Inst Pathol Anat, Trieste, Italy; [Saggini, Andrea] Univ Roma Tor Vergata, Dept Biomed & Prevent, Inst Pathol Anat, Rome, Italy; [Cota, Carlo] San Gallicano Dermatol Inst, Rome, Italy	Cerroni, L (reprint author), Med Univ Graz, Dept Dermatol, Auenbruggerpl 8, A-8036 Graz, Austria.	lorenzo.cerroni@medunigraz.at					Boccara O, 2012, PEDIATR BLOOD CANCER, V58, P226, DOI 10.1002/pbc.23103; Bowers S, 2006, J AM ACAD DERMATOL, V55, P557, DOI 10.1016/j.jaad.2005.07.058; Cerroni L, 2014, SKIN LYMPHOMA ILLUST; Dereure O, 2000, ARCH DERMATOL, V136, P1483, DOI 10.1001/archderm.136.12.1483; Ersoy-Evans S, 2007, J AM ACAD DERMATOL, V56, P205, DOI 10.1016/j.jaad.2006.08.023; FORTSON JS, 1990, ARCH DERMATOL, V126, P1449, DOI 10.1001/archderm.126.11.1449; GELMETTI C, 1990, J AM ACAD DERMATOL, V23, P473, DOI 10.1016/0190-9622(90)70243-B; Herron MD, 2005, PEDIATR DERMATOL, V22, P360, DOI 10.1111/j.1525-1470.2005.22418.x; Jang KA, 2001, J CUTAN PATHOL, V28, P453, DOI 10.1034/j.1600-0560.2001.028009453.x; Jang MS, 2016, ANN DERMATOL, V28, P540, DOI 10.5021/ad.2016.28.5.540; Kempf W, 2012, AM J SURG PATHOL, V36, P1021, DOI 10.1097/PAS.0b013e31824f4f66; King RL, 2015, J CUTAN PATHOL, V42, P1012, DOI 10.1111/cup.12601; Kodama K, 2005, J AM ACAD DERMATOL, V52, P694, DOI 10.1016/j.jaad.2004.12.018; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Magro C, 2002, HUM PATHOL, V33, P788, DOI 10.1053/hupa.2002.125381; Magro CM, 2007, HUM PATHOL, V38, P479, DOI 10.1016/j.humpath.2006.09.013; Martinez-Escala ME, 2015, BRIT J DERMATOL, V172, P372, DOI 10.1111/bjd.13364; Massone C, 2005, AM J SURG PATHOL, V29, P550, DOI 10.1097/01.pas.0000153121.57515.c6; Niemczyk UM, 1997, BRIT J DERMATOL, V137, P983, DOI 10.1111/j.1365-2133.1997.tb01564.x; Panhans A, 1996, J AM ACAD DERMATOL, V35, P489, DOI 10.1016/S0190-9622(96)90639-8; Patterson J, 2016, WEEDONS SKIN PATHOLO, P261; Pileri A, 2012, PEDIATR BLOOD CANCER, V58, P306, DOI 10.1002/pbc.23260; Thurber SE, 2007, J AM ACAD DERMATOL, V57, P782, DOI 10.1016/j.jaad.2007.06.004; Tomasini D, 2002, DERMATOLOGY, V205, P176, DOI 10.1159/000063906; VARGA FJ, 1990, AM J PATHOL, V136, P979; Vonderheid EC, 2016, J CUTAN PATHOL, V43, P303, DOI 10.1111/cup.12653; Weinberg JM, 2002, ARCH DERMATOL, V138, P1063, DOI 10.1001/archderm.138.8.1063; WEISS LM, 1987, AM J PATHOL, V126, P417; Wood GS, 2018, DERMATOLOGY, P161; Zaaroura H, 2018, AM J DERMATOPATH, V40, P409, DOI 10.1097/DAD.0000000000001057; Zang JB, 2018, PEDIATR DERMATOL, V35, P213, DOI 10.1111/pde.13396	31	3	3	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1101	1112		10.1097/PAS.0000000000001093			12	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000014	29851705	Green Published			2019-10-28	
J	Hassan, O; Epstein, JI				Hassan, Oudai; Epstein, Jonathan I.			The Clinical Significance of a Small Component of Choriocarcinoma in Testicular Mixed Germ Cell Tumor (MGCT)	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						choriocarcinoma; germ cell tumor; metastasis	TROPHOBLASTIC TUMORS; TESTIS	The clinical significance of limited choriocarcinoma in a malignant mixed germ cell tumor (MGCT) is unknown. Men with a MGCT with <= 5% choriocarcinoma at radical orchiectomy (RO) between 2000 and 2016 from our consult service were studied. Of 50 men in our cohort, we had clinical information for 30 men. Median follow-up was 41 months (1 to 168 mo). Median tumor size was 4.5 cm (1.1 to 8.0 cm). In total, 22/30 (73%) cases were pT1, 6/30(20%) cases were pT2, and 2/30 (7%) cases were pT3. In total, 4/30(13%) cases had lymph node metastases and 2/30 (7%) cases had distant metastases at the time of RO. In 30 cases with RO we had information on immediate postorchiectomy treatment: 14/30 (46.7%) active surveillance, 4/30 (13.3%) retroperitoneal lymph node dissection, 10/30 (33.3%) chemotherapy (chemotherapy), 1/30 (3.3%) retroperitoneal lymph node dissection followed by chemotherapy, and 1/30 (3.3%) resection of a distant metastasis. Preoperative serum human chorionic gonadotropin (hCG) levels ranged between 0.1 and 60,715 mIU/mL (mean, 4796; median, 485). One patient had an hCG level of 6367 mIU/mL and another 60,715 mIU/mL with the remaining cases <5000 mIU/mL. In total, 4/30 (13%) patients had elevated serum markers after surgery, 3 of them normalized following chemotherapy while the fourth one continued to have elevated serum alpha fetoprotein levels after chemotherapy. All patients were alive at last follow-up. In total, 7/30 (23.3%) patients subsequently developed metastatic disease to lymph nodes or distal organs, the histology of the metastasis consisted mainly of teratoma and yolk sac tumor. Embryonal carcinoma was present in 2 metastatic sites. One lung metastasis was suggestive for choriocarcinoma. Definitive choriocarcinoma was not present in any of the metastasis. A small component of choriocarcinoma in a MGCT is typically associated with relatively low-level elevations of serum hCG levels, and is not associated with aggressive disease. The presence of limited choriocarcinoma (<= 5%) does not add to the prognostic information provided by standard TNM staging, which uses levels of serum markers (hCG, alpha fetoprotein, lactate dehydrogenase) as surrogates for extent of disease.	[Hassan, Oudai; Epstein, Jonathan I.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA	Epstein, JI (reprint author), Johns Hopkins Univ Hosp, Weinberg Bldg,Rm 2242,401 N Broadway St, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Alvarado-Cabrero I, 2014, AM J SURG PATHOL, V38, P111, DOI 10.1097/PAS.0b013e3182a2926e; BATATA MA, 1982, INT J RADIAT ONCOL, V8, P1287, DOI 10.1016/0360-3016(82)90577-6; Emerson RE, 2005, SEMIN DIAGN PATHOL, V22, P33, DOI 10.1053/j.semdp.2005.11.003; HENRY SC, 1974, J UROLOGY, V112, P105, DOI 10.1016/S0022-5347(17)59653-6; Idrees MT, 2015, AM J SURG PATHOL, V39, P1468, DOI 10.1097/PAS.0000000000000509; JENSEN JL, 1992, UROLOGY, V39, P237, DOI 10.1016/0090-4295(92)90297-A; Jiang F, 2014, ONCOTARGETS THER, V7, P1135, DOI 10.2147/OTT.S62561; LOGOTHETIS CJ, 1986, AM J MED, V81, P219, DOI 10.1016/0002-9343(86)90255-X; Mostofi FK, 1973, TUMORS MALE GENITAL; Ulbright TM, 1997, AM J SURG PATHOL, V21, P282, DOI 10.1097/00000478-199703000-00003; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; Ulbright TM, 2013, AFIP ATLAS TUMOR PAT, V2, P164	12	0	1	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1113	1120		10.1097/PAS.0000000000001088			8	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000015	29794869				2019-10-28	
J	Rooper, LM; Karantanos, T; Ning, Y; Bishop, JA; Gordon, SW; Kang, H				Rooper, Lisa M.; Karantanos, Theodoros; Ning, Yi; Bishop, Justin A.; Gordon, Sarah W.; Kang, Hyunseok			Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion Expanding the Molecular Spectrum of a Recently Described Entity	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						secretory carcinoma; mammary analogue secretory carcinoma; salivary gland carcinoma; ETV6; MET; cabozantinib	ETV6-NTRK3 GENE FUSION; HIGH-GRADE TRANSFORMATION; ACINIC CELL-CARCINOMA; MESOBLASTIC NEPHROMA; MAMMAGLOBIN IMMUNOHISTOCHEMISTRY; TARGETING MET; GLAND; TRANSLOCATION; DIAGNOSIS; SUBSET	Secretory carcinoma of the salivary glands, also known as mammary analogue secretory carcinoma, is a recently described tumor characterized by generally indolent clinical behavior and recurrent ETV6-NTRK3 fusions. However, a small subset of recent cases with high-grade histology, aggressive behavior, or alternate molecular findings are expanding the spectrum of this entity. In this case, a 59-year-old female presented with an infiltrative submandibular gland tumor that was originally classified as a high-grade acinic cell carcinoma, papillary-cystic variant. She developed persistent local disease and, 11 years after initial presentation, was found to have widespread metastases. Rereview of her primary tumor highlighted microcystic, papillary, and solid architecture, eosinophilic cytoplasm, vesicular nuclei with prominent nucleoli, abundant mitotic figures, and necrosis. Immunostains showed the tumor cells to be positive for S100 and mammaglobin and negative for DOG-1, and fluorescence in situ hybridization highlighted an ETV6 rearrangement, supporting a diagnosis of high-grade secretory carcinoma. Finally, next-generation sequencing demonstrated a novel ETV6-MET fusion. To our knowledge, this is the first ETV6-MET fusion reported in secretory carcinoma. This finding further expands the definition of secretory carcinoma while carrying implications for selecting appropriate targeted therapy.	[Rooper, Lisa M.; Ning, Yi] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; [Rooper, Lisa M.; Karantanos, Theodoros; Kang, Hyunseok] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; [Kang, Hyunseok] Johns Hopkins Med Inst, Dept Otolaryngol, Baltimore, MD 21205 USA; [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, VA USA; [Gordon, Sarah W.] Virginia Commonwealth Univ, Dept Oncol, Richmond, VA USA	Rooper, LM (reprint author), Johns Hopkins Med Inst, 401 N Broadway,Weinberg 2242, Baltimore, MD 21231 USA.	rooper@jhmi.edu		Rooper, Lisa/0000-0001-5636-9753			Ach T, 2013, VIRCHOWS ARCH, V462, P65, DOI 10.1007/s00428-012-1358-0; Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Baghai F, 2017, PATHOL RES PRACT, V213, P1112, DOI 10.1016/j.prp.2017.07.017; Bishop JA, 2013, HUM PATHOL, V44, P1982, DOI 10.1016/j.humpath.2013.03.017; Bishop JA, 2013, AM J SURG PATHOL, V37, P1053, DOI 10.1097/PAS.0b013e3182841554; Chiosea SI, 2012, HISTOPATHOLOGY, V61, P387, DOI 10.1111/j.1365-2559.2012.04232.x; Chiosea SI, 2012, AM J SURG PATHOL, V36, P343, DOI 10.1097/PAS.0b013e318242a5b0; Church AJ, 2018, MODERN PATHOL, V31, P463, DOI 10.1038/modpathol.2017.127; Cipriani NA, 2017, INT J SURG PATHOL, V25, P613, DOI 10.1177/1066896917709350; Connor A, 2012, AM J SURG PATHOL, V36, P27, DOI 10.1097/PAS.0b013e318231542a; De Braekeleer E, 2012, LEUKEMIA RES, V36, P945, DOI 10.1016/j.leukres.2012.04.010; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014; Drilon A, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-CT007; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Griffith C, 2011, VIRCHOWS ARCH, V459, P117, DOI 10.1007/s00428-011-1098-6; Hong DS, 2016, CANCER RES, V76, pCT008; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Jung MJ, 2013, KOREAN J PATHOL, V47, P36, DOI 10.4132/KoreanJPathol.2013.47.1.36; Khotskaya YB, 2017, PHARMACOL THERAPEUT, V173, P58, DOI 10.1016/j.pharmthera.2017.02.006; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; Luo WY, 2014, INT J CLIN EXP PATHO, V7, P9008; Majewska H, 2015, VIRCHOWS ARCH, V466, P245, DOI 10.1007/s00428-014-1701-8; Mo Hong-Nan, 2017, Chronic Dis Transl Med, V3, P148, DOI 10.1016/j.cdtm.2017.06.002; Naous Rana, 2017, Patholog Res Int, V2017, P1497023, DOI 10.1155/2017/1497023; Pinto A, 2014, MODERN PATHOL, V27, P30, DOI 10.1038/modpathol.2013.84; Projetti F, 2015, J ORAL PATHOL MED, V44, P244, DOI 10.1111/jop.12226; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Said-Al-Naief N, 2017, INT J SURG PATHOL, V25, P127, DOI 10.1177/1066896916670005; Serrano-Arevalo ML, 2015, MED ORAL PATOL ORAL, V20, pE23, DOI 10.4317/medoral.19874; Shah AA, 2015, HEAD NECK PATHOL, V9, P85, DOI 10.1007/s12105-014-0557-1; Shukla N, 2017, JCO PRECISION ONCOLO, V1, P1; Skalova A, 2018, AM J SURG PATHOL, V42, P234, DOI 10.1097/PAS.0000000000000972; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2014, AM J SURG PATHOL, V38, P23, DOI 10.1097/PAS.0000000000000088; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2015, MODERN PATHOL, V28, P1084, DOI 10.1038/modpathol.2015.64; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Urano M, 2015, HUM PATHOL, V46, P94, DOI 10.1016/j.humpath.2014.09.012; Wu EY, 2017, HISTOPATHOLOGY, V71, P665, DOI 10.1111/his.13268; Xu B, 2017, HEAD NECK PATHOL	45	6	6	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1121	1126		10.1097/PAS.0000000000001065			6	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000016	29683815				2019-10-28	
J	Boyle, B; Collins, M; Denson, L; Hyams, J				Boyle, Brendan; Collins, Margaret; Denson, Lee; Hyams, Jeff			Histologic Correlates of Clinical and Endoscopic Severity in Children Newly Diagnosed With Ulcerative Colitis Reply	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter									[Boyle, Brendan] Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Collins, Margaret; Denson, Lee] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Hyams, Jeff] Connecticut Childrens Med Ctr, Hartford, CT USA	Boyle, B (reprint author), Nationwide Childrens Hosp, Columbus, OH 43205 USA.				NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01 DK095745]			0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1127	1127		10.1097/PAS.0000000000001009			1	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000018	29309306				2019-10-28	
J	El-Matary, W				El-Matary, Wael			Tissue Eosinophilia and Severity of Colitis	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter						secretory carcinoma; mammary analogue secretory carcinoma; salivary gland carcinoma; ETV6; MET; cabozantinib	INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; CHILDREN	Secretory carcinoma of the salivary glands, also known as mammary analogue secretory carcinoma, is a recently described tumor characterized by generally indolent clinical behavior and recurrent ETV6-NTRK3 fusions. However, a small subset of recent cases with high-grade histology, aggressive behavior, or alternate molecular findings are expanding the spectrum of this entity. In this case, a 59-year-old female presented with an infiltrative submandibular gland tumor that was originally classified as a high-grade acinic cell carcinoma, papillary-cystic variant. She developed persistent local disease and, 11 years after initial presentation, was found to have widespread metastases. Rereview of her primary tumor highlighted microcystic, papillary, and solid architecture, eosinophilic cytoplasm, vesicular nuclei with prominent nucleoli, abundant mitotic figures, and necrosis. Immunostains showed the tumor cells to be positive for S100 and mammaglobin and negative for DOG-1, and fluorescence in situ hybridization highlighted an ETV6 rearrangement, supporting a diagnosis of high-grade secretory carcinoma. Finally, next-generation sequencing demonstrated a novel ETV6-MET fusion. To our knowledge, this is the first ETV6-MET fusion reported in secretory carcinoma. This finding further expands the definition of secretory carcinoma while carrying implications for selecting appropriate targeted therapy.	[El-Matary, Wael] Univ Manitoba, Max Rady Coll Med, Dept Pediat, Sect Pediat Gastroenterol, Winnipeg, MB, Canada	El-Matary, W (reprint author), Univ Manitoba, Max Rady Coll Med, Dept Pediat, Sect Pediat Gastroenterol, Winnipeg, MB, Canada.			EL-MATARY, WAEL/0000-0001-6417-7583			Al-Haddad S, 2005, GUT, V54, P1674, DOI 10.1136/gut.2005.072595; Boyle B, 2017, AM J SURG PATHOL, V41, P1491, DOI 10.1097/PAS.0000000000000939; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; Lampinen M, 2001, DIGEST DIS SCI, V46, P2004, DOI 10.1023/A:1010659803912; Sadi G, 2016, J PEDIATR GASTR NUTR, V62, P573, DOI 10.1097/MPG.0000000000000957; Woodruff SA, 2011, J PEDIATR GASTR NUTR, V52, P650, DOI 10.1097/MPG.0b013e3182128512; Zuo L, 2007, IMMUNOL ALLERGY CLIN, V27, P443, DOI 10.1016/j.iac.2007.06.002	7	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1127	1127		10.1097/PAS.0000000000001089			1	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000017	29266022	Green Accepted			2019-10-28	
J	Argani, P; Pawel, B; Szabo, S; Reyes-Mugica, M; Timmons, C; Antonescu, CR				Argani, Pedram; Pawel, Bruce; Szabo, Sara; Reyes-Mugica, Miguel; Timmons, Charles; Antonescu, Cristina R.			Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Letter							INTERNAL TANDEM DUPLICATIONS; BCOR-CCNB3 GENE FUSION; SYNOVIAL SARCOMA; ABNORMALITIES		[Argani, Pedram] Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Baltimore, MD 21218 USA; [Pawel, Bruce] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA; [Szabo, Sara] Univ Pittsburgh, Sch Med, Dept Pathol, Childrens Hosp Pittsburgh, Pittsburgh, PA USA; [Reyes-Mugica, Miguel] Cincinnati Childrens Hosp, Dept Pathol, Cincinnati, OH USA; [Timmons, Charles] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA; [Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Argani, P (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol & Oncol, Baltimore, MD 21218 USA.				Cycle for Survival; Kristin Ann Carr Foundation; Dahan Translocation Carcinoma Fund; Joey's Wings;  [P50 CA 140146-01];  [P30-CA008748]	P50 CA 140146-01 (C.R.A.), P30-CA008748 (C.R.A.), Cycle for Survival (C.R.A.), Kristin Ann Carr Foundation (C.R.A.), Dahan Translocation Carcinoma Fund (P.A.), Joey's Wings (P.A.). The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Argani P, 2000, AM J SURG PATHOL, V24, P1087, DOI 10.1097/00000478-200008000-00006; Argani P, 2000, AM J SURG PATHOL, V24, P4, DOI 10.1097/00000478-200001000-00002; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Argani P, 2015, AM J SURG PATHOL, V39, P365, DOI 10.1097/PAS.0000000000000338; Astolfi A, 2015, ONCOTARGET, V6, P40934, DOI 10.18632/oncotarget.5882; Aw SJ, 2015, PEDIATR DEVEL PATHOL, V18, P297, DOI 10.2350/14-12-1581-OA.1; Gooskens SLM, 2012, EUR J CANCER, V48, P2219, DOI 10.1016/j.ejca.2012.04.009; Kao YC, 2017, GENE CHROMOSOME CANC, V56, P296, DOI 10.1002/gcc.22435; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Mirkovic J, 2015, HISTOPATHOLOGY, V67, P306, DOI 10.1111/his.12641; O'Meara E, 2012, J PATHOL, V227, P72, DOI 10.1002/path.3985; Roy A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9891; Ueno-Yokohata H, 2015, NAT GENET, V47, P861, DOI 10.1038/ng.3338; Wong MK, 2018, HISTOPATHOLOGY, V72, P320, DOI 10.1111/his.13366	15	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	AUG	2018	42	8					1128	1131		10.1097/PAS.0000000000001089			4	Pathology; Surgery	Pathology; Surgery	GN9MU	WOS:000439526000019	29851702	Green Accepted			2019-10-28	
J	Ramanayake, N; Russell, P; Yang, V				Ramanayake, Nimeka; Russell, Peter; Yang, Vivian			High grade serous intraepithelial carcinoma arising in a benign ovarian serous cyst - a bridge too far?	PATHOLOGY			English	Editorial Material						Ovary; histology; immunohistochemistry; high grade serous carcinoma; benign serous cystadenoma; clinical presentation; dualistic theory of pathogenesis; aberrant P53	BORDERLINE TUMOR; FALLOPIAN-TUBES; LYMPHATIC PATHOGENESIS; OOPHORECTOMY SPECIMENS; HISTOLOGICALLY BENIGN; EARLY ADENOCARCINOMA; MUTATIONS; CANCER; NEOPLASMS; EXPRESSION		[Ramanayake, Nimeka; Russell, Peter] Douglass Hanly Moir Pathol, GynaePath, 14 Giffnock Ave, Macquaire Pk, NSW 2113, Australia; [Russell, Peter] Univ Sydney, Dept Obstet Gynaecol & Neonatol, Sydney, NSW, Australia; [Yang, Vivian] Private Clin Practice, Sydney, NSW, Australia	Russell, P (reprint author), Douglass Hanly Moir Pathol, GynaePath, 14 Giffnock Ave, Macquaire Pk, NSW 2113, Australia.	russell2@bigpond.net.au					AUSTIN RM, 1993, HUM PATHOL, V24, P562; Ayhan A, 2009, AM J SURG PATHOL, V33, P1220, DOI 10.1097/PAS.0b013e3181a24354; Banet N, 2015, INT J GYNECOL PATHOL, V34, P3, DOI 10.1097/PGP.0000000000000120; BANNATYNE P, 1981, DIAGN GYNECOL OBSTET, V3, P49; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Boyd C, 2012, AM J SURG PATHOL, V36, P368, DOI 10.1097/PAS.0b013e31823732a9; Callahan MJ, 2007, J CLIN ONCOL, V25, P3985, DOI 10.1200/JCO.2007.12.2622; Carcangiu ML, 2004, INT J GYNECOL PATHOL, V23, P35, DOI 10.1097/01.pgp.0000101082.35393.84; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; Curry EWJ, 2014, MODERN PATHOL, V27, P433, DOI 10.1038/modpathol.2013.130; Dehari R, 2007, AM J SURG PATHOL, V31, P1007, DOI 10.1097/PAS.0b013e31802cbbe9; Emmanuel C, 2014, CLIN CANCER RES, V20, P6618, DOI 10.1158/1078-0432.CCR-14-1292; Finch A, 2006, GYNECOL ONCOL, V100, P58, DOI 10.1016/j.ygyno.2005.06.065; Garg K, 2012, INT J GYNECOL PATHOL, V31, P423, DOI 10.1097/PGP.0b013e31824ae6f2; Guth U, 2007, CANCER, V110, P1272, DOI 10.1002/cncr.22919; Haas CJ, 1999, VIRCHOWS ARCH, V434, P117, DOI 10.1007/s004280050314; Ho CL, 2004, CANCER RES, V64, P6915, DOI 10.1158/0008-5472.CAN-04-2067; Hunter SM, 2011, CLIN CANCER RES, V17, P7273, DOI 10.1158/1078-0432.CCR-11-2080; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Koshiyama M, 2014, BIOMED RES INT, DOI 10.1155/2014/934261; Kurman RJ, 2013, ANN ONCOL, V24, P16, DOI 10.1093/annonc/mdt463; Kurman RJ, 2014, WHO CLASSIFICATION T; Kurman RJ, 2011, AM J SURG PATHOL, V35, P1605, DOI 10.1097/PAS.0b013e318229449f; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Li J., 2012, J HEMATOL ONCOL, V5; Mafficini A, 2016, ONCOTARGET, V7, P1076, DOI 10.18632/oncotarget.6834; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; McCluggage WG, 2011, PATHOLOGY, V43, P420, DOI 10.1097/PAT.0b013e328348a6e7; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; O'Neill CJ, 2007, HISTOPATHOLOGY, V50, P773, DOI 10.1111/j.1365-2559.2007.02682.x; O'Neill CJ, 2005, AM J SURG PATHOL, V29, P1034; Parker RL, 2004, INT J GYNECOL PATHOL, V23, P265, DOI 10.1097/01.gpg.0000130049-19643.f6; Penson RT, 2004, NEW ENGL J MED, V351, P2531, DOI 10.1056/NEJMcpc049022; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Pothuri B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010358; Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; PULS LE, 1992, GYNECOL ONCOL, V47, P53, DOI 10.1016/0090-8258(92)90075-T; Russell P, 2016, PATHOLOGY, V48, P72, DOI 10.1016/j.pathol.2015.11.004; Russell P, 2016, PATHOLOGY, V48, P1, DOI 10.1016/j.pathol.2015.11.024; Satgunaseelan L, 2016, PATHOLOGY, V48, P76, DOI 10.1016/j.pathol.2015.11.023; Seidman JD, 2005, GYNECOL ONCOL, V96, P395, DOI 10.1016/j.ygyno.2004.10.014; Serov SS, 1973, HISTOLOGICAL TYPING; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Sieben NLG, 2004, J PATHOL, V202, P336, DOI 10.1002/path.1521; Singer G, 2005, AM J SURG PATHOL, V29, P218, DOI 10.1097/01.pas.0000146025.91953.8d; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Wolf NG, 1996, AM J PATHOL, V149, P511; Zeller C, 2013, AM J PATHOL, V182, P668, DOI 10.1016/j.ajpath.2012.11.040; ZHENG JP, 1993, CANCER RES, V53, P4138	52	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					485	489		10.1016/j.pathol.2018.03.009			5	Pathology	Pathology	GN5VV	WOS:000439136500001	29960723				2019-10-28	
J	Green, C; Spagnolo, DV; Robbins, PD; Fermoyle, S; Wong, DD				Green, Celia; Spagnolo, Dominic V.; Robbins, Peter D.; Fermoyle, Soraya; Wong, Daniel D.			Clear cell sarcoma of the gastrointestinal tract and malignant gastrointestinal neuroectodermal tumour: distinct or related entities? A review	PATHOLOGY			English	Review						Clear cell sarcoma; clear cell sarcoma of gastrointestinal tract; clear cell sarcoma-like tumour of gastrointestinal tract; gastrointestinal neuroectodermal tumour; EWSR1; ATF1; CREB1	SOFT PARTS; MOLECULAR ANALYSIS; MELANOMA; FUSION; DIAGNOSIS; VARIANT; APONEUROSES; ASSOCIATION; TRANSCRIPTS; EWSR1-CREB1	Clear cell sarcoma is an uncommon sarcoma which rarely occurs as a primary tumour in the gastrointestinal tract (CCS-GIT). It shares common molecular genetic abnormalities with the more recently described entity, malignant gastrointestinal neuroectodermal tumour (GNET) but is distinguished by its morphological and immunohistochemical findings. The exact nosological relationship between these tumours continues to be debated. In this review, we present two cases of these rare neoplasms from our files and perform a statistical comparison of all published cases to determine if significant differences exist in their clinicopathological features and biological behaviour. Thirteen cases of CCS-GIT and 58 of GNET were included. CCS-GIT occurred more commonly in males (84.6% vs 46.6%, p = 0.01) and in an older age group (median 57 vs 33 years, p < 0.01). There was no significant difference in their location in the gastrointestinal tract, median tumour size and proportion of cases with an EWSR1-ATF1 vs EWSR1-CREB1 fusion. Median survival for CCS-GIT was 13.5 months and for GNET, 9.5 months (p = 0.78). There was no significant difference in the Kaplan-Meier survival curves for either time to first metastasis (p = 0.88) or overall survival (p = 0.18), including after controlling for tumour size using regression models. Our analysis confirms that aside from morphological variations between these tumours, they also exhibit epidemiological and clinical differences. Despite the prevalent perception that GNET is associated with a more aggressive clinical course, our findings indicate that there is no significant difference in their biological behaviour, although both clearly share a bleak prognosis. Further experience is awaited to determine optimal treatment strategies and whether CCS-GIT and GNET would differ in their response to various therapies.	[Green, Celia; Spagnolo, Dominic V.; Robbins, Peter D.; Wong, Daniel D.] QEII Med Ctr, PathWest Lab Med, Anat Pathol, Hosp Ave, Nedlands, WA 6009, Australia; [Fermoyle, Soraya] Fiona Stanley Hosp, PathWest Lab Med, Anat Pathol, Murdoch, WA, Australia; [Wong, Daniel D.] Univ Western Australia, Sch Pathol & Lab Med, Crawley, WA, Australia; [Wong, Daniel D.] Univ Western Australia, Lab Med, Crawley, WA, Australia	Wong, DD (reprint author), QEII Med Ctr, PathWest Lab Med, Anat Pathol, Hosp Ave, Nedlands, WA 6009, Australia.	daniel.wong@health.wa.gov.au					ALYOUSEF MJ, 2017, DIAGN PATHOL, V12; Antonescu CR, 2002, J MOL DIAGN, V4, P44, DOI 10.1016/S1525-1578(10)60679-4; Antonescu CR, 2007, GENE CHROMOSOME CANC, V46, P1051, DOI 10.1002/gcc.20491; Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078-0432.CCR-05-2811; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Ardakani AG, 2016, ANN R COLL SURG ENGL, V98, P37; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Bianchi G, 2014, EJSO-EUR J SURG ONC, V40, P505, DOI 10.1016/j.ejso.2014.01.016; Boland JM, 2016, HUM PATHOL, V57, P13, DOI 10.1016/j.humpath.2016.05.026; Bury T, 1997, EUR RESPIR J, V10, P2653, DOI 10.1183/09031936.97.10112653; Chen ZH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003890; Chen ZH, 2015, INT J CLIN EXP PATHO, V8, P8555; CHUNG EB, 1983, AM J SURG PATHOL, V7, P405, DOI 10.1097/00000478-198307000-00003; Coindre JM, 2006, CANCER, V107, P1055, DOI 10.1002/cncr.22099; Covinsky M, 2005, HUM PATHOL, V36, P74, DOI 10.1016/j.humpath.2004.10.015; Deenik W, 1999, CANCER, V86, P969, DOI 10.1002/(SICI)1097-0142(19990915)86:6<969::AID-CNCR11>3.3.CO;2-Q; EKFORS TO, 1993, HISTOPATHOLOGY, V22, P255, DOI 10.1111/j.1365-2559.1993.tb00115.x; ENZINGER FM, 1965, CANCER, V18, P1163, DOI 10.1002/1097-0142(196509)18:9<1163::AID-CNCR2820180916>3.0.CO;2-0; Flucke U, 2012, HUM PATHOL, V43, P764, DOI 10.1016/j.humpath.2011.08.004; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Insabato L, 2015, PATHOL RES PRACT, V211, P688, DOI 10.1016/j.prp.2015.06.001; Iwamoto R, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1046-7; Jin L, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-016-0594-z; Karamchandani DM, 2013, ADV ANAT PATHOL, V20, P398, DOI 10.1097/PAP.0b013e3182a92e42; Keditsu KK, 2017, INDIAN J SURG, V79, P166, DOI 10.1007/s12262-016-1499-5; Kim SB, 2015, WORLD J GASTROENTERO, V21, P5739, DOI 10.3748/wjg.v21.i18.5739; Kong J, 2014, ONCOL LETT, V8, P2687, DOI 10.3892/ol.2014.2524; LASKIN WB, 1991, AM J SURG PATHOL, V15, P1136, DOI 10.1097/00000478-199112000-00004; Lu BY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000393; Lyle PL, 2008, AM J SURG PATHOL, V32A, P858, DOI 10.1097/PAS.0b013e31815b8288; Matsukuma S, 2012, PATHOL INT, V62, P817, DOI 10.1111/pin.12014; Moslim MA, 2016, CASE REP MED, DOI 10.1155/2016/1534029; Raskin GA, 2015, GASTROINTEST TUMORS, V2, P83, DOI 10.1159/000430881; Rekhi B, 2015, APMIS, V123, P618, DOI 10.1111/apm.12395; Rosai J, 2005, INT J SURG PATHOL, V13, P309, DOI 10.1177/106689690501300401; SARA AS, 1990, CANCER-AM CANCER SOC, V65, P367, DOI 10.1002/1097-0142(19900115)65:2<367::AID-CNCR2820650232>3.0.CO;2-X; SAW D, 1986, HUM PATHOL, V17, P423, DOI 10.1016/S0046-8177(86)80468-3; Shen Q, 2014, VIRCHOWS ARCH, V465, P607, DOI 10.1007/s00428-014-1655-x; Shenjere P, 2012, INT J SURG PATHOL, V20, P378, DOI 10.1177/1066896911425485; Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac; Taminelli L, 2005, VIRCHOWS ARCH, V447, P772, DOI 10.1007/s00428-005-0019-y; Thway K, 2014, CASE REP MED, DOI 10.1155/2014/984369; Wang J, 2015, ARCH PATHOL LAB MED, V139, P407, DOI 10.5858/arpa.2013-0547-RS; Yang LL, 2012, HUM PATHOL, V43, P1463, DOI 10.1016/j.humpath.2011.10.022; Yegen G, 2015, INT J SURG PATHOL, V23, P61, DOI 10.1177/1066896914547046; Zambrano E, 2003, INT J SURG PATHOL, V11, P75, DOI 10.1177/106689690301100202; Zhao ZH, 2014, INT J CLIN EXP PATHO, V7, P8967	47	2	3	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					490	498		10.1016/j.pathol.2018.05.001			9	Pathology	Pathology	GN5VV	WOS:000439136500002	29970252				2019-10-28	
J	Mhawech-Fauceglia, P; Walia, S; Yessaian, A; Machida, H; Matsuo, K; Lawrenson, K				Mhawech-Fauceglia, Paulette; Walia, Saloni; Yessaian, Annie; Machida, Hiroko; Matsuo, Koji; Lawrenson, Kate			Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma	PATHOLOGY			English	Article						HOMER2; endometrial cancer; endometrioid adenocarcinoma; immunoexpression; low grade; prognostic factor	CANCER; CARCINOMA; RADIATION; FERTILITY; LANDSCAPE; THERAPY; WOMEN	We have previously shown that HOMER2 (Homer scaffolding protein 2), a protein coding gene, was highly expressed in low grade (LG) endometrioid adenocarcinoma (EAC) of the uterus. The role of HOMER2 in endometrial cancer (EC) is widely unknown; therefore, the aim of this study was to determine the expression and the predictive value of HOMER2 protein expression in series of patients with EC. HOMER2 protein expression was detected on paraffin-embedded tissues from 336 cases using immunohistochemistry (IHC). Tumours were categorised in two groups; group 1 (EAC, FIGO grade 1 and 2; n = 191) and group 2 (all other subtypes including grade 3 EAC; n = 145). Statistical analysis was performed to evaluate associations between HOMER2 protein expression and pathological parameters (histological type, grade, stage, lymphovascular invasion, myometrial depth of invasion) and patient outcome [progression-free survival (PFS) and cancer-specific survival (CSS)]. HOMER2 was significantly overexpressed in group 1 compared to group 2 cancers (67% versus 30%; p < 0.001) and with low tumour grade (p < 0.001). In group 1, HOMER2 overexpression was an independent prognostic factor for improved CSS (adjusted-hazard ratio 0.28; 95% confidence interval 0.08-0.96; p = 0.042). HOMER2 expression was not associated with survival in group 2 (p > 0.05). This is the first study of HOMER2 protein expression in EC. We speculate that HOMER2 may be involved in tumourigenesis of endometrioid uterine tumours and suggest that HOMER2 should be studied further for potential clinical and therapeutic applications.	[Mhawech-Fauceglia, Paulette; Walia, Saloni] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; [Yessaian, Annie; Machida, Hiroko; Matsuo, Koji] Univ Southern Calif, Dept Obstet & Gynecol, Div Gyneocl Oncol, Los Angeles, CA 90033 USA; [Lawrenson, Kate] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Womens Canc Program,Samuel Oschin Canc Inst, Los Angeles, CA 90048 USA; [Lawrenson, Kate] Cedars Sinai Med Ctr, Dept Biomed Sci, Ctr Bioinformat & Funct Genom, Los Angeles, CA 90048 USA	Mhawech-Fauceglia, P (reprint author), Univ Southern Calif, Keck Sch Med, Dept Med, 1200 N State St,Room 7A116, Los Angeles, CA 90033 USA.; Mhawech-Fauceglia, P (reprint author), Univ Southern Calif, Keck Sch Med, Dept Pathol, 1200 N State St,Room 7A116, Los Angeles, CA 90033 USA.	pfauceglia@hotmail.com		Matsuo, Koji/0000-0002-6232-8701			Ajima R, 2007, BIOCHEM BIOPH RES CO, V356, P851, DOI 10.1016/j.bbrc.2007.03.060; Ayeni TA, 2013, GYNECOL ONCOL, V129, P478, DOI 10.1016/j.ygyno.2013.03.011; Goulding SP, 2017, J PROTEOMICS, V166, P127, DOI 10.1016/j.jprot.2017.07.008; Hong B, 2015, CURR OPIN GENET DEV, V30, P25, DOI 10.1016/j.gde.2014.12.004; Kalogera E, 2014, IN J WOMENS HEALTH, V6, P691, DOI 10.2147/IJWH.S47232; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lawrenson K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130909; Le Gallo M, 2014, CLIN CHEM, V60, P98, DOI 10.1373/clinchem.2013.205740; Ly D, 2015, GYNECOL ONCOL, V138, P526, DOI 10.1016/j.ygyno.2015.06.022; Mhawech-Fauceglia P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018066; Mori Y, 2011, ENDOCR-RELAT CANCER, V18, P465, DOI 10.1530/ERC-11-0083; Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6; Park JY, 2013, OBSTET GYNECOL, V122, P7, DOI 10.1097/AOG.0b013e3182964ce3; Park JY, 2013, EUR J CANCER, V49, P868, DOI 10.1016/j.ejca.2012.09.017; Reynaers EAEM, 2015, J SURG ONCOL, V111, P790, DOI 10.1002/jso.23871; Shah PH, 2011, GYNECOL ONCOL, V122, P675, DOI 10.1016/j.ygyno.2011.05.018; Shiraishi Y, 2003, J NEUROCHEM, V87, P364, DOI 10.1046/j.1471-4159.2003.02003.x; Shiraishi-Yamaguchi Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-206; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Szumlinski KK, 2005, J NEUROSCI, V25, P7054, DOI 10.1523/JNEUROSCI.1529-05.2005; Wilkinson-Ryan I, 2014, GYNECOL ONCOL, V134, P24, DOI 10.1016/j.ygyno.2014.05.002	21	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					499	503		10.1016/j.pathol.2018.03.004			5	Pathology	Pathology	GN5VV	WOS:000439136500003	29891190				2019-10-28	
J	Ng, KL; Del Vecchio, SJ; Samaratunga, H; Morais, C; Rajandram, R; Vesey, DA; Wood, ST; Gobe, GC				Ng, K. L.; Del Vecchio, S. J.; Samaratunga, H.; Morais, C.; Rajandram, R.; Vesey, D. A.; Wood, S. T.; Gobe, G. C.			Leptin and its receptor: can they help to differentiate chromophobe renal cell carcinoma from renal oncocytoma?	PATHOLOGY			English	Article						Renal cell carcinoma; chromophobe; oncocytoma; immunohistochemistry; leptin; leptin receptor; kidney	SIGNALING PATHWAYS; SERUM LEPTIN; OBESITY; CANCER; ASSOCIATION; ADIPOCYTOKINES; INFLAMMATION; ADIPONECTIN; ACTIVATION; DIAGNOSIS	One of the challenges in differentiating chromophobe renal cell carcinoma (chRCC) from benign renal oncocytoma (RO) is overlapping morphology between the two subtypes. The aim of this study was to investigate the usefulness of expression of leptin (Ob) and its receptor (ObR) in discriminating chRCC from RO. Sections from paraffinembedded, formalin-fixed tumour nephrectomy specimens of 45 patients, made up of 30 chRCC (15 eosinophilic variant and 15 non-eosinophilic variant) and 15 RO, were used in this study. Samples (30) of clear cell RCC (ccRCC), the most common histological subtype, were used to verify staining patterns found by others in our cohort of Australasian patients. Matched morphologically normal non-cancer kidney tissues were included for each specimen. Sections were batch-immunostained using antibodies against Ob and ObR. Stained sections were digitally scanned using Aperio ImageScope, and the expression pattern of Ob and ObR was studied. In this cohort, male to female ratio was 2: 1; median age was 64 (45-88 years); and median tumour size was 3.8 cm (range 1.2-18 cm). There were 47 (62.7%) T1, seven T2, 20 T3 and one T4 stage RCC. Two patients with ccRCC presented with metastases. Nuclear expression of Ob was significantly higher in RO compared with chRCC. The increased nuclear expression of Ob in RO compared with chRCC may be a useful aid in the difficult histological differentiation of RO from chRCC, especially eosinophilic variants of chRCC.	[Ng, K. L.; Wood, S. T.] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld, Australia; [Ng, K. L.; Del Vecchio, S. J.; Morais, C.; Vesey, D. A.; Wood, S. T.; Gobe, G. C.] Univ Queensland, Fac Med, Ctr Kidney Dis Res, Translat Res Inst, Brisbane, Qld, Australia; [Ng, K. L.; Rajandram, R.] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur, Malaysia; [Samaratunga, H.] Aquesta Pathol, Toowong, Qld, Australia; [Gobe, G. C.] Univ Queensland, NHMRC Ctr Res Excellence, Ctr Chron Dis, Brisbane, Qld, Australia	Gobe, GC (reprint author), Univ Queensland, Kidney Dis Res Grp, UQ Diamantina Inst, Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.	g.gobe@uq.edu.au	Vesey, David A/C-2253-2011; Samaratunga, Hemamali M L/D-1559-2013; Rajandram, Retnagowri/O-6135-2019; Rajandram, Retnagowri/E-4709-2010; Rajandram, Retnagowri/E-1245-2012	Vesey, David A/0000-0002-2856-6650; Samaratunga, Hemamali M L/0000-0001-5796-1791; Rajandram, Retnagowri/0000-0001-5247-2817; Rajandram, Retnagowri/0000-0001-5247-2817; Rajandram, Retnagowri/0000-0001-5247-2817	University of MalayaUniversiti Malaya [BKS049-2017]	A University of Malaya, Grant BKS049-2017, funded this research. The authors state that there are no conflicts of interest to disclose.	Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Boguszewski CL, 2010, ENDOKRYNOL POL, V61, P194; CochandPriollet B, 1997, ARCH PATHOL LAB MED, V121, P1081; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Drabkin HA, 2010, ADV CANCER RES, V107, P39, DOI 10.1016/S0065-230X(10)07002-8; Duchene DA, 2003, UROLOGY, V62, P827, DOI 10.1016/S0090-4295(03)00658-7; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Fruhbeck G, 2006, BIOCHEM J, V393, P7, DOI 10.1042/BJ20051578; Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472; Horiguchi A, 2002, J UROLOGY, V168, P762, DOI 10.1016/S0022-5347(05)64741-6; Horiguchi A, 2006, J UROLOGY, V176, P1631, DOI 10.1016/j.juro.2006.06.039; Housa D, 2006, PHYSIOL RES, V55, P233; Hu JF, 2003, SOZ PRAVENTIV MED, V48, P178, DOI 10.1007/s00038-003-2046-2; Kawaguchi S, 2011, J UROLOGY, V186, P1218, DOI 10.1016/j.juro.2011.05.080; Kelesidis T, 2010, ANN INTERN MED, V152, P93, DOI 10.7326/0003-4819-152-2-201001190-00008; Leroy X, 2000, EUR UROL, V37, P484, DOI 10.1159/000020172; Li L, 2008, CANCER BIOL THER, V7, P1787, DOI 10.4161/cbt.7.11.6837; Liao LM, 2013, OBESITY, V21, P1478, DOI 10.1002/oby.20138; Liu L, 2007, ARCH PATHOL LAB MED, V131, P1290; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; McKiernan J, 2002, UROLOGY, V59, P816, DOI 10.1016/S0090-4295(02)01501-7; Ng KL, 2014, J CLIN PATHOL, V67, P97, DOI 10.1136/jclinpath-2013-201895; Paz G, 2011, FRONT BIOSCI-LANDMRK, V16, P1634, DOI 10.2741/3810; Proietti C, 2016, SCI REP-UK, V6, DOI 10.1038/srep38178; Renehan Andrew G., 2008, Archives of Physiology and Biochemistry, V114, P71, DOI [10.1080/13813450801954303, 10.1080/13813450801954303 ]; Spyridopoulos TN, 2009, HORM-INT J ENDOCRINO, V8, P39, DOI 10.14310/horm.2002.1220; Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937; Wobker SE, 2017, J KIDNEY CANCER VHL, V4, P1, DOI 10.15586/jkcvhl.2017.96; Zhang HP, 2017, ONCOL LETT, V13, P463, DOI 10.3892/ol.2016.5408	29	1	1	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					504	510		10.1016/j.pathol.2018.01.007			7	Pathology	Pathology	GN5VV	WOS:000439136500004	29970253				2019-10-28	
J	Ng, KL; Yap, NY; Rajandram, R; Small, D; Pailoor, J; Ong, TA; Razack, AH; Wood, ST; Morais, C; Gobe, GC				Ng, Keng Lim; Yap, Ning Yi; Rajandram, Retnagowri; Small, David; Pailoor, Jayalakshmi; Ong, Teng Aik; Razack, Azad Hassan; Wood, Simon Thomas; Morais, Christmas; Gobe, Glenda Carolyn			Nuclear factor-kappa B subunits and their prognostic cancer-specific survival value in renal cell carcinoma patients	PATHOLOGY			English	Article						Cancer specific survival; nuclear factor-kappa B; renal cell carcinoma	EXPRESSION; APOPTOSIS; PATHWAY	Better characterisation and understanding of renal cell carcinoma (RCC) development and progression lead to better diagnosis and clinical outcomes. In this study, expression of nuclear factor-kappa B (NF-kappa B) subunits: p65 (RelA), p105/p50, p100/p52, and cRel in RCC tissue were compared with corresponding normal kidney, along with tumour characteristics and survival outcome. Ninety-six cases of RCC with paired normal kidney were analysed. Clinicopathological data, demographics and survival data were available. Immunohistochemistry (IHC) for NF-kappa B subtypes was analysed using the Aperio digital pathology system for overall cellular expression and localisation. The prognostic cancer-specific survival value of the subunits in RCC patients was analysed. Approximately 50% of patients had clinical stage T1, with 22 patients having metastases at presentation. RCC subtypes were: clear cell (n = 76); papillary (n = 11); chromophobe (n = 5); clear cell tubulopapillary (n = 3); and one multilocular cystic RCC. Median follow up was 54.5 months (0.2-135), with 28 deaths at time of analysis. NF-kappa B p65 had higher overall and nuclear expressions, with lower overall and nuclear expressions of p50, p52 and cRel in RCC compared with normal kidney. Higher expressions of p65 (nuclear), p52 (overall and nuclear) and p50 (overall) correlated significantly with worse cancer-specific survival. This is the first large series of analysis of expression of NF-kappa B subunits in RCC. Especially with regards to the less studied subunits (p52, p50, cRel), our results allow a better understanding the role of NF-kappa B in RCC development and progression, and may pave the way for future targeted NF-kappa B subunit specific therapies.	[Ng, Keng Lim; Wood, Simon Thomas] Princess Alexandra Hosp, Dept Urol, Brisbane, Qld, Australia; [Ng, Keng Lim; Yap, Ning Yi; Rajandram, Retnagowri; Ong, Teng Aik; Razack, Azad Hassan] Univ Malaya, Dept Surg, Kuala Lumpur, Malaysia; [Ng, Keng Lim; Rajandram, Retnagowri; Small, David; Morais, Christmas; Gobe, Glenda Carolyn] Univ Queensland, Ctr Kidney Dis Res, Brisbane, Qld, Australia; [Rajandram, Retnagowri] Univ Malaya, Univ Malaya Canc Res Inst, Kuala Lumpur, Malaysia; [Pailoor, Jayalakshmi] Univ Malaya, Dept Pathol, Kuala Lumpur, Malaysia	Ng, KL (reprint author), Univ Queensland, Ctr Kidney Dis Res, Sch Med, Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.	kenglimng@yahoo.com	Razack, Azad HA/B-8152-2009; Rajandram, Retnagowri/E-4709-2010; Ong, Teng Aik/B-5321-2010; Rajandram, Retnagowri/E-1245-2012; Small, David M/E-6064-2019; Rajandram, Retnagowri/O-6135-2019; Small, David M/S-1969-2019	Razack, Azad HA/0000-0002-4237-6511; Rajandram, Retnagowri/0000-0001-5247-2817; Ong, Teng Aik/0000-0002-0207-8966; Rajandram, Retnagowri/0000-0001-5247-2817; Small, David M/0000-0003-3034-4747; Rajandram, Retnagowri/0000-0001-5247-2817; Small, David M/0000-0003-3034-4747	Fundamental Research Grant Scheme [FP012-2013B]; High Impact Research grant [UM.C/HIR/MOHE/06]	We would like to acknowledge research funding from Fundamental Research Grant Scheme FP012-2013B and High Impact Research grant UM.C/HIR/MOHE/06 for this research project. The authors state that there are no conflicts of interest to disclose.	Buczek M, 2014, BBA-REV CANCER, V1845, P31, DOI 10.1016/j.bbcan.2013.10.001; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Dordevic G, 2008, CROAT MED J, V49, P608, DOI 10.3325/cmj.2008.5.608; Kankaya D, 2015, PATHOL RES PRACT, V211, P505, DOI 10.1016/j.prp.2015.03.002; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Matusan-Ilijas K, 2011, PATHOL RES PRACT, V207, P104, DOI 10.1016/j.prp.2010.11.004; Meteoglu I, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-53; Morais C, 2011, INT J BIOCHEM CELL B, V43, P1537, DOI 10.1016/j.biocel.2011.08.003; Oya M, 2003, CARCINOGENESIS, V24, P377, DOI 10.1093/carcin/24.3.377; Ozbek Emin, 2012, Arch Ital Urol Androl, V84, P53; Peri S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076746; Qi H, 2003, CANCER RES, V63, P7076; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Znaor A, 2015, EUR UROL, V67, P519, DOI 10.1016/j.eururo.2014.10.002	18	2	2	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					511	518		10.1016/j.pathol.2018.03.003			8	Pathology	Pathology	GN5VV	WOS:000439136500005	29935727				2019-10-28	
J	Lao, IW; Sun, M; Zhao, M; Yu, L; Wang, J				Lao, I. Weng; Sun, Meng; Zhao, Ming; Yu, Lin; Wang, Jian			Lipofibromatosis-like neural tumour: a clinicopathological study of ten additional cases of an emerging novel entity	PATHOLOGY			English	Article						Lipofibromatosis; neural tumour; biphenotype; NTRK1	BIPHENOTYPIC SINONASAL SARCOMA; NTRK1 GENE FUSIONS; SUBSET	We present our experience with ten cases of lipofibromatosis-like tumour (LPF-NT) to further characterise this newly described neoplasm. There were six males and four females with a mean age of 12.8 years (range 2-37 years). Tumours occurred in the neck (n = 3), buttock (n = 2), chest wall, flank, hip, hand and foot (n = 1). Histologically, they were composed of cellular fascicles of mildly to moderately atypical spindle cells displaying an infiltrative pattern reminiscent of lipofibromatosis or dermatofibrosarcoma protuberans. Immunohistochemically, all cases co-expressed S100 protein and CD34. FISH analysis revealed NTRK1 gene rearrangement in four of five cases tested. Clinical follow-up showed local recurrence in three cases but no evidence of metastasis. This study further supports that LPF-NTrepresents a novel entity of NTRK1-associated neoplasms. Awareness of its clinicopathological features, immunophenotypes and cytogenetic abnormalities helps pathologists arrive at the correct diagnosis.	[Lao, I. Weng; Sun, Meng; Yu, Lin; Wang, Jian] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dong An St, Shanghai 200032, Peoples R China; [Lao, I. Weng; Sun, Meng; Yu, Lin; Wang, Jian] Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 Dong An St, Shanghai 200032, Peoples R China; [Zhao, Ming] Zhejiang Prov Peoples Hosp, Dept Pathol, Hangzhou, Zhejiang, Peoples R China	Wang, J (reprint author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, 270 Dong An St, Shanghai 200032, Peoples R China.; Wang, J (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 Dong An St, Shanghai 200032, Peoples R China.	softtissuetumour@163.com			Shanghai Key Developing Disciplines [2015ZB0201]; Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project [HDC12014105]	This study was supported in funding by Shanghai Key Developing Disciplines (2015ZB0201) and Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project (HDC12014105). The authors state that there are no conflicts of interest to disclose.	Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Al-Zaid T, 2017, VIRCHOWS ARCH, V471, P243, DOI 10.1007/s00428-017-2174-3; Amatu A, 2016, ESMO OPEN, V1; Davis JL, 2018, PEDIATR DEVEL PATHOL, V21, P68, DOI 10.1177/1093526617712639; Doebele RC, 2015, CANCER DISCOV, V5, P1049, DOI 10.1158/2159-8290.CD-15-0443; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Huang SC, 2016, AM J SURG PATHOL, V40, P51, DOI 10.1097/PAS.0000000000000492; Kohsaka S, 2018, HUM PATHOL, V72, P167, DOI 10.1016/j.humpath.2017.08.017; Lewis JT, 2012, AM J SURG PATHOL, V36, P517, DOI 10.1097/PAS.0b013e3182426886; Wang XK, 2014, NAT GENET, V46, P666, DOI 10.1038/ng.2989; WEIER HUG, 1995, GENOMICS, V26, P390, DOI 10.1016/0888-7543(95)80226-C; Wong V, 2015, JNCI-J NATL CANCER I, V108, P1; Wong WJ, 2016, GENE CHROMOSOME CANC, V55, P25, DOI 10.1002/gcc.22295	14	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					519	523		10.1016/j.pathol.2018.03.007			5	Pathology	Pathology	GN5VV	WOS:000439136500006	29958731				2019-10-28	
J	Wu, V; Auchman, M; Mollica, PA; Sachs, PC; Bruno, RD				Wu, Vivian; Auchman, Megan; Mollica, Peter A.; Sachs, Patrick C.; Bruno, Robert D.			ALDH1A1 positive cells are a unique component of the tonsillar crypt niche and are lost along with NGFR positive stem cells during tumourigenesis	PATHOLOGY			English	Article						ALDH1A1; NGFR; LGR5; aldehyde dehydrogenase; HPV; tonsillar crypts; OPSCC	HUMAN PALATINE TONSILS; MOUSE MAMMARY-GLAND; EPITHELIAL PROGENITOR; CANCER; HEAD; CARCINOMA; EXPRESSION; DIAGNOSIS	Interest into the cellular biology of human tonsillar crypts has grown in recent years because it is now known to be the site of origin of most human papilloma virus (HPV) induced oropharyngeal squamous cell carcinomas (OPSCC). Despite the interest, still relatively little is known regarding the cellular hierarchy and dynamics of this anatomical subsite. Here we evaluate normal tonsillar crypts for expression of putative stem cell markers. We found that ALDH1A1 was uniquely expressed in a subset of suprabasal tonsillar crypt epithelium. This cell population was unique from NGFR expressing cells, which were previously identified to have stem/progenitor activity in vitro. In vivo mitochondrial lineage tracing was consistent with a basal to luminal progression of cellular development. This provides support for NGFR cells as the resident stem/progenitor cells in tonsillar crypts, and suggests that the ALDH1A1 cells are not stem/progenitor cells, but merely a unique component of the crypt cellular microenvironment. Analysis of tumours found that both NGFR and ALDH1A1 are lost in HPV+ and HPV- tumours, while LGR5 expression is induced in the same tumours. These results identify a unique component of the tonsillar crypt epithelium-ALDH1A1 cells-and support a cellular model where NGFR+ cells are the long-lived progenitor cells within tonsillar crypts. They also provide evidence that NGFR and ALDH1A1+ cells are lost during tumourigenesis.	[Wu, Vivian] Eastern Virginia Med Sch, Dept Otolaryngol, Leroy T Canoles Jr Canc Res Ctr, Norfolk, VA 23501 USA; [Auchman, Megan; Mollica, Peter A.; Sachs, Patrick C.; Bruno, Robert D.] Old Dominion Univ, Sch Med Diagnost & Translat Sci, Coll Hlth Sci, Norfolk, VA USA; [Wu, Vivian] Henry Ford Hlth Syst, Detroit, MI USA	Bruno, RD (reprint author), 4211 Monarch Way,Suite 365, Norfolk, VA 23508 USA.	rbruno@odu.edu		Bruno, Robert/0000-0003-3329-9478; wu, vivian/0000-0003-0045-7097	Medarva Foundation; start-up funds by the College of Health Sciences	Funding for this project was provided by a grant from the Medarva Foundation to VW and RDB and by start-up funds provided by the College of Health Sciences to RDB. The authors state that there are no conflicts of interest to disclose.	Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; Boulanger CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062019; Boulanger CA, 2012, STEM CELLS DEV, V21, P948, DOI 10.1089/scd.2011.0148; Bruno RD, 2012, ONCOGENE, V31, P60, DOI 10.1038/onc.2011.215; Bruno RD, 2017, SCI REP-UK, V7, DOI 10.1038/srep40196; Bruno RD, 2014, J CELL SCI, V127, P27, DOI 10.1242/jcs.140749; Bruno RD, 2012, SEMIN CELL DEV BIOL, V23, P591, DOI 10.1016/j.semcdb.2012.03.007; Bruno RD, 2011, GENE EXPRESSION, V15, P133, DOI 10.3727/105221611X13176664479368; Bruno RD, 2011, STEM CELL REV REP, V7, P238, DOI 10.1007/s12015-010-9191-9; Clark MA, 2000, HISTOCHEM CELL BIOL, V114, P311; da Silva-Diz V, 2013, ONCOGENE, V32, P3732, DOI 10.1038/onc.2012.375; Dalley AJ, 2015, OR SURG OR MED OR PA, V119, P436, DOI 10.1016/j.oooo.2014.11.014; Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277; Gaisa NT, 2011, J PATHOL, V225, P163, DOI 10.1002/path.2945; Hildebrand LC, 2014, J ORAL PATHOL MED, V43, P499, DOI 10.1111/jop.12169; Humphries A, 2013, P NATL ACAD SCI USA, V110, pE2490, DOI 10.1073/pnas.1220353110; Kang SYC, 2015, STEM CELL REP, V5, P1210, DOI 10.1016/j.stemcr.2015.09.020; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Leong HS, 2014, STEM CELL TRANSL MED, V3, P1055, DOI 10.5966/sctm.2013-0214; Lopez Jacqueline, 2012, Open Virol J, V6, P232, DOI 10.2174/1874357901206010232; PERRY ME, 1994, J ANAT, V185, P111; Sturgis EM, 2011, J NATL COMPR CANC NE, V9, P665, DOI 10.6004/jnccn.2011.0055; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; Van Keymeulen A, 2012, J CELL BIOL, V197, P575, DOI 10.1083/jcb.201201041; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Vigneswaran N, 2014, ORAL MAXIL SURG CLIN, V26, P123, DOI 10.1016/j.coms.2014.01.001; Westra WH, 2012, HEAD NECK PATHOL, V6, pS48, DOI 10.1007/s12105-012-0371-6; Xu X, 2015, CANCER LETT, V369, P50, DOI 10.1016/j.canlet.2015.08.018; Zhang MC, 2014, CANCER-AM CANCER SOC, V120, P992, DOI 10.1002/cncr.28538; Zhao M, 2012, CANCER BIOL THER, V13, P782, DOI 10.4161/cbt.20561	32	0	0	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					524	529		10.1016/j.pathol.2018.03.002			6	Pathology	Pathology	GN5VV	WOS:000439136500007	29891189				2019-10-28	
J	Harms, A; Endris, V; Winter, H; Kriegsmann, M; Stenzinger, A; Schirmacher, P; Warth, A; Kazdal, D				Harms, Alexander; Endris, Volker; Winter, Hauke; Kriegsmann, Mark; Stenzinger, Albrecht; Schirmacher, Peter; Warth, Arne; Kazdal, Daniel			Molecular dissection of large cell carcinomas of the lung with null immunophenotype	PATHOLOGY			English	Article						Large cell carcinoma; lung; next generation sequencing	CANCER; CLASSIFICATION; ADENOCARCINOMA; SPECIMENS	The aim of this study was to subcategorise large cell carcinoma (LCC) with null immunophenotype according to the World Health Organization (WHO) Classification of 2015 into the existing groups of adenocarcinoma and squamous cell carcinoma by further molecular genetic analysis. Lineage-specific molecular alterations of these tumours could depict additional therapeutic approaches. We analysed a cohort of 35 LCC diagnosed according to the 2004 WHO classification and reclassified them according to the criteria of the 2015 WHO classification. Subsequently, tumours with a null immunophenotype were analysed by targeted next generation sequencing (42 marker genes including TP53, EGFR, KRAS, STK11 and SMARC4A) and fluorescence in situ hybridisation (ROS1, ALK). By applying the criteria of the 2015 WHO classification and subsequent molecular subtyping we could show that out of 35 previously diagnosed LCC, 16 cases could be reclassified into specific NSCLC subtypes using immunohistochemistry. Additionally, based on their mutational pattern, eight of the remaining 19 cases with null immunophenotype could be assigned as 'favour adenocarcinoma'. We demonstrate that molecular subtyping is helpful to further categorise LCC with null immunophenotype. Our findings argue for an algorithm including stratified molecular analysis of all respective cases.	[Harms, Alexander; Endris, Volker; Kriegsmann, Mark; Stenzinger, Albrecht; Schirmacher, Peter; Warth, Arne; Kazdal, Daniel] Univ Hosp Heidelberg, Inst Pathol, INF 224, D-69120 Heidelberg, Germany; [Harms, Alexander; Winter, Hauke; Warth, Arne; Kazdal, Daniel] German Ctr Lung Res DZL, Translat Lung Res Ctr TLRC Heidelberg, Heidelberg, Germany; [Winter, Hauke] Heidelberg Univ, Dept Thorac Surg, Thoraxklin, Heidelberg, Germany	Warth, A (reprint author), Univ Hosp Heidelberg, Inst Pathol, INF 224, D-69120 Heidelberg, Germany.	warth@patho-uegp.de		Kriegsmann, Mark/0000-0002-7319-3646			Barbareschi M, 2011, AM J CLIN PATHOL, V136, P773, DOI 10.1309/AJCPYY79XAGRAYCJ; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Pelosi G, 2015, J THORAC ONCOL, V10, P1560, DOI 10.1097/JTO.0000000000000658; Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P30, DOI 10.1002/gcc.22297; Rekhtman N, 2013, MODERN PATHOL, V26, P511, DOI 10.1038/modpathol.2012.195; Rekhtman N, 2011, MODERN PATHOL, V24, P1348, DOI 10.1038/modpathol.2011.92; Rossi G, 2014, VIRCHOWS ARCH, V464, P61, DOI 10.1007/s00428-013-1501-6; Seidel D, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006802; TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Warth A, 2014, HISTOPATHOLOGY, V65, P187, DOI 10.1111/his.12379	12	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					530	535		10.1016/j.pathol.2018.03.005			6	Pathology	Pathology	GN5VV	WOS:000439136500008	29958730				2019-10-28	
J	Pope, JD; Drummer, OH; Schneider, HG				Pope, Jeffrey D.; Drummer, Olaf H.; Schneider, Hans G.			The cocaine cutting agent levamisole is frequently detected in cocaine users	PATHOLOGY			English	Article						Levamisole; cocaine; urine drug screen; toxicology; high resolution mass spectrometry	ADULTERATED COCAINE; AMINOREX	Cocaine use in Australia is increasing, with approximately 2.5% of the surveyed population having used cocaine. In the USA, levamisole, a widely used anti-helminthic veterinary drug has been increasingly detected as a cutting agent in cocaine seizures. Levamisole is known to cause agranulocytosis in humans. We ascertained the prevalence of levamisole-adulterated cocaine, detectable in the urine from patients that had undergone a pathology request for a urine drug screen. We assayed routinely requested urines that were positive for cocaine on immunoassay with liquid chromatography high resolution quadrupole time of flight mass spectrometry (LC-QToF). We investigated available urine samples from a period of 2 years that had a positive result for cocaine. In addition, we examined samples that were below the cut-off for cocaine on immunoassay. Specimens were analysed for the presence of levamisole and other 'unknown' drugs. In the period under investigation the laboratory examined 3665 urine samples for cocaine: 1.4% (n = 51) of the samples were positive for cocaine by immunoassay and half of these (n = 26, 51%) were further examined by LC-QToF. In addition, we examined 10 samples that were negative by immunoassay (as defined by AS/NZS 4308: 2008). Levamisole was detected in the urine of cocaine users in approximately 75% of cases. Other illicit drugs were also frequently found in this cohort. The most common illicit drugs detected were methamphetamine, ecstasy and cannabis. Australian cocaine is widely adulterated with levamisole. Cocaine users are at risk of levamisole related health problems in addition to the problems related to cocaine.	[Pope, Jeffrey D.; Schneider, Hans G.] Alfred Hlth, Clin Biochem, Alfred Pathol Serv, Commercial Rd, Melbourne, Vic 3004, Australia; [Pope, Jeffrey D.; Drummer, Olaf H.] Monash Univ, Dept Forens Med, Melbourne, Vic, Australia; [Schneider, Hans G.] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia	Pope, JD (reprint author), Alfred Hlth, Clin Biochem, Alfred Pathol Serv, Commercial Rd, Melbourne, Vic 3004, Australia.	j.pope@alfred.org.au					Australian Institute of Health and Welfare [AIHW], 2017, NAT DRUG STRAT HOUS; Broseus J, 2016, FORENSIC SCI INT, V262, P73, DOI 10.1016/j.forsciint.2016.02.033; Drug Enforcement Administration (DEA) Intelligence Production Unit, 2010, DEA10001LEVAMISOLE; Eiden C, 2015, CLIN TOXICOL, V53, P604, DOI 10.3109/15563650.2015.1054499; Fishman AP, 1999, CIRCULATION, V99, P156, DOI 10.1161/01.CIR.99.1.156; Hofmaier T, 2014, NEUROCHEM INT, V73, P32, DOI 10.1016/j.neuint.2013.11.010; Indorato F, 2016, FORENSIC SCI INT, V265, P103, DOI 10.1016/j.forsciint.2016.01.005; Karch SB, 2016, FORENSIC SCI INT, V265, P96, DOI 10.1016/j.forsciint.2016.01.015; Karch SB, 2014, FORENSIC SCI INT, V240, pE7, DOI 10.1016/j.forsciint.2014.03.028; Karch SB, 2012, INT J CARDIOL, V158, P344, DOI 10.1016/j.ijcard.2011.06.105; Lee KC, 2012, MAYO CLIN PROC, V87, P581, DOI 10.1016/j.mayocp.2012.03.010; Pope JD, 2017, THER DRUG MONIT, V39, P457, DOI 10.1097/FTD.0000000000000417; Rosano TG, 2013, J ANAL TOXICOL, V37, P580, DOI 10.1093/jat/bkt071; Tallarida CS, 2015, DRUG ALCOHOL DEPEN, V149, P145, DOI 10.1016/j.drugalcdep.2015.01.035; THOMPSON JS, 1980, BLOOD, V56, P388; United Nations Office on Drugs and Crime (UNODC), 2016, WORLD DRUG REP 2016	16	4	4	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					536	539		10.1016/j.pathol.2018.03.006			4	Pathology	Pathology	GN5VV	WOS:000439136500009	29937233				2019-10-28	
J	Singh, A; Hungund, B; Kumar, L; Pattanshetti, M				Singh, Aneet; Hungund, Bhagyashri; Kumar, Lalit; Pattanshetti, Mallikarjun			Clinico-haematological profile of patients with bicytopenia	PATHOLOGY			English	Article						Bicytopenia; anaemia; thrombocytopenia; leukopenia; leukaemia	BONE-MARROW; CHILDREN; PREVALENCE; DISEASE; ANEMIA	Bicytopenia is the reduction of any of the two cell lines of blood, i.e., erythrocytes, leukocytes or platelets. Many studies are done on pancytopenia but very few studies exist in the literature evaluating the spectrum of aetiologies of bicytopenia. To date, no study is available on bicytopenia in adults. We aimed to study the clinico-haematological profile of patients with bicytopenia and to investigate the different aetiologies of bicytopenia. Four hundred patients with bicytopenia admitted to KLE Dr. Prabhakar Kore Charitable Hospital and Medical Research Centre were selected using systematic random sampling and included in the study. Their clinical profiles and haematological parameters were evaluated. Bicytopenia was observed in all ages with the mean age being 30.7 years. The occurrence of bicytopenia in different age groups was 6% in neonates, 7% in infants, 25% in children, 17% in teenagers, 85% in adults and 11% in elderly. The most common bicytopenia observed was anaemia with thrombocytopenia (61%) followed by anaemia with leukopenia (26%) and leukopenia with thrombocytopenia (13%). The male to female ratio was 1.6:1. The most common aetiology of bicytopenia was found to be non-malignant (56%) followed by infectious (31.7%), malignant (8.3%) and drug-induced (4%). Megaloblastic anaemia was the predominant aetiology among the non-malignant group, closely followed by immune thrombocytopenic purpura and alcoholic liver disease. The most common infectious disease was dengue (12%). Signs like lymphadenopathy, splenomegaly and hepatomegaly were most significantly associated with haematological malignancies (p < 0.001). Pallor, bleeding, hepatomegaly and splenomegaly were most frequent in non-malignant conditions (p < 0.001). Fever and lymphadenopathy were most frequent in the infectious category (p < 0.001). The most prevalent signs in drug-induced aetiology were lymphadenopathy, hepatomegaly and splenomegaly (p < 0.001). Bicytopenia is a good haematological indicator for many non-malignant and malignant diseases. Knowledge of its aetiologies can help in the diagnosis and efficient management of patients.	[Singh, Aneet; Hungund, Bhagyashri; Kumar, Lalit; Pattanshetti, Mallikarjun] Jawaharlal Nehru Med Coll, Belgaum, India	Singh, A (reprint author), House Q43, Bangalore 560008, Karnataka, India.	aneetsingh@outlook.com	Hungund, Bhagyashri/Q-9491-2019				Andrews NC, 2009, WINTROBES CLIN HEMAT, P810; Arceci RJ, 2009, WINTROBES CLIN HEMAT, P1919; Ayub T, 2009, GOMAL J MED SCI, V7, P62; Baer MR, 2009, WINTROBES CLIN HEMAT, P1845; Bates I, 2012, DACIE LEWIS PRACTICA, P549; Binesh F, 2013, IRAN J PEDIATR HEMAT, V3, P173; Borgna-Pignatti C, 2009, WINTROBES CLIN HEMAT, P1084; Charoo Bashir A, 2009, Hematol Oncol Stem Cell Ther, V2, P349; Coelho HCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063410; de Souza LJ, 2013, BRAZ J INFECT DIS, V17, P27, DOI 10.1016/j.bjid.2012.08.020; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Dictionary. com, BLOOD; Garg S, 2007, LABMEDICINE, V38, P23, DOI 10.1309/AB9CGH4785Y8MKPF; Haroon H, 2013, J INFECT DEV COUNTR, V7, P273, DOI 10.3855/jidc.2332; HEIMPEL H, 1987, BLOOD, V70, P1718; Hubbard J, 2010, CLIN LAB HEMATOLOGY, P31; Kaplan P, 2006, ARCH PEDIAT ADOL MED, V160, P603, DOI 10.1001/archpedi.160.6.603; Latvala J, 2004, ALCOHOL CLIN EXP RES, V28, P619, DOI 10.1097/01.ALC.0000122766.54544.3B; Means RT, 2009, WINTROBES CLIN HEMAT, P1241; Morel Z, 2014, REUMATOL CLIN, V10, P257, DOI 10.1016/j.reuma.2013.07.005; Naseem S, 2011, INDIAN J PATHOL MICR, V54, P75, DOI 10.4103/0377-4929.77329; SCHMIDT PM, 1983, SCHWEIZ MED WSCHR, V113, P1025; Shvidel L, 2013, ANN HEMATOL, V92, P661, DOI 10.1007/s00277-012-1663-3; Sifakis S, 2000, ANN NY ACAD SCI, V900, P125; Sloand EM, 2009, WINTROBES CLIN HEMAT, P1623; Songdej D, 2015, ACTA HAEMATOL-BASEL, V133, P226, DOI 10.1159/000363210; Swaminathan S, 2008, J BIOSCIENCES, V33, P527, DOI 10.1007/s12038-008-0071-2; Tefferi A, 2009, WINTROBES CLIN HEMAT, P4505; Williams JL, 2010, CLIN LAB HEMATOLOGY, P31	29	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					540	548		10.1016/j.pathol.2018.03.008			9	Pathology	Pathology	GN5VV	WOS:000439136500010	30032928				2019-10-28	
J	Sng, LH; Peh, JWL; Kee, MTL; Ya'akob, NBM; Ong, RTH; Wong, CW; Chee, CB; Wang, YT				Sng, Li-Hwei; Peh, Justine Woei Ling; Kee, Melody Tai Lee; Ya'akob, Nurhazirah Bte Mohd; Ong, Rick Twee-Hee; Wong, Christopher W.; Chee, Cynthia Bin Eng; Wang, Yee Tang			Clofazimine drug susceptibility testing for Mycobacterium tuberculosis: the case of using the right diluent	PATHOLOGY			English	Article						Tuberculosis; clofazimine; DMSO; MGIT; susceptibility testing; WGS	CROSS-RESISTANCE; BEDAQUILINE	Accurate and reliable drug susceptibility testing (DST) is essential for the effective treatment and control of tuberculosis. With the increase in drug-resistant organisms, newer and less conventional antimicrobial agents are used for treatment. Recently, we found an unprecedented rise in the number of clofazimine-resistant Mycobacterium tuberculosis isolates in our laboratory. An investigation found that this phenomenon was due to a change in the method of drug preparation. We performed studies to assess the impact of water and dimethyl sulfoxide (DMSO) as a final diluent for clofazimine drug testing. Based on our findings, the use of DMSO as a solvent for M. tuberculosis DST was optimised using the BACTEC MGIT 960 platform.	[Sng, Li-Hwei; Peh, Justine Woei Ling; Kee, Melody Tai Lee; Ya'akob, Nurhazirah Bte Mohd] Singapore Gen Hosp, Cent TB Lab, 20 Coll Rd, Singapore 169658, Singapore; [Ong, Rick Twee-Hee] Natl Univ Singapore, Natl Univ Hlth Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Wong, Christopher W.] Genome Inst Singapore, Singapore, Singapore; [Chee, Cynthia Bin Eng; Wang, Yee Tang] Tan Tock Seng Hosp, TB Control Unit, Singapore, Singapore	Sng, LH (reprint author), Singapore Gen Hosp, Cent TB Lab, 20 Coll Rd, Singapore 169658, Singapore.	sng.li.hwei@singhealth.com.sg			Ministry of Health, Singapore; Singapore Infectious Diseases Initiative grant [SIDI/2014/003]	The strain typing work was supported by the Ministry of Health, Singapore; and the WGS work by the Singapore Infectious Diseases Initiative grant SIDI/2014/003. The authors state that there are no conflicts of interest to disclose.	BASCH H, 1968, APPL MICROBIOL, V16, P1953; Blanco-Ruano D, 2015, METHODS MOL BIOL MYC; Chee CBE, 2013, EMERG INFECT DIS, V19, P1151, DOI 10.3201/eid1907.120372; CLSI, 2011, M24A2 CLSI; CLSI, 2017, M100 CLSI; Franzblau SG, 2012, TUBERCULOSIS, V92, P453, DOI 10.1016/j.tube.2012.07.003; Hartkoorn RC, 2014, ANTIMICROB AGENTS CH, V58, P2979, DOI 10.1128/AAC.00037-14; Kaniga K, 2016, J CLIN MICROBIOL, V54, P2963, DOI 10.1128/JCM.01138-16; Koser CU, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002824; MGIT&TRADE; 960 SIRE, 2002, MGIT 960 SIRE KIT AN; Ministry of Health, 2016, COMM DIS SURV SING 2; Ministry of Health, 2017, TUBERCULOSIS; O'Neill TE, 2014, PHYTOCHEM ANALYSIS, V25, P461, DOI 10.1002/pca.2516; Ollinger J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060531; Pfyffer GE, 1999, J CLIN MICROBIOL, V37, P3179; Somoskovi A, 2015, EUR RESPIR J, V45, P554, DOI [10, 10.1183/09031936.00142914]; Villellas C, 2017, J ANTIMICROB CHEMOTH, V72, P684, DOI 10.1093/jac/dkw502; Wells WA, 2013, LANCET INFECT DIS, V13, P449, DOI 10.1016/S1473-3099(13)70025-2; World Health Organization, 2016, GLOB TUB REP; World Health Organization, 2016, WHO TREATM GUID DRUG; Zhang S, 2015, J ANTIMICROB CHEMOTH, V70, P2507, DOI 10.1093/jac/dkv150	21	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					549	553		10.1016/j.pathol.2018.01.006			5	Pathology	Pathology	GN5VV	WOS:000439136500011	29891191				2019-10-28	
J	Thompson, G; Boan, P; Baumwol, J; Chakera, A; MacQuillan, G; Swaminathan, S; Lavender, M; Flexman, J; James, I; John, M				Thompson, Grace; Boan, Peter; Baumwol, Jay; Chakera, Aron; MacQuillan, Gerry; Swaminathan, Suda; Lavender, Melanie; Flexman, James; James, Ian; John, Mina			Analysis of the QuantiFERON-CMV assay, CMV viraemia and antiviral treatment following solid organ transplantation in Western Australia	PATHOLOGY			English	Article						Quantiferon-CMV; solid organ transplantation	CELL-MEDIATED-IMMUNITY; CYTOMEGALOVIRUS-INFECTION; KIDNEY-TRANSPLANTATION; RISK-STRATIFICATION; CLINICAL UTILITY; RECIPIENTS; PREDICTION; MANAGEMENT; RESPONSES; DISEASE	Prevention of cytomegalovirus (CMV) infection remains an important aspect of improving long term outcomes of solid organ transplantation and currently relies on prophylactic antiviral medication and early detection of viraemia or disease. Uptake of diagnostic tools to personalise assessment of CMV immunity and guide interpretation of viral testing remains low. We assessed the QuantiFERON-CMV assay in 54 Western Australian recipients of renal, heart, lung or liver allografts to determine the relationship between CMV-specific immunity, viraemia and disease following cessation of antiviral prophylaxis. We carried out an initial validation study which demonstrated that the QuantiFERON-CMV assay is highly precise and strongly correlated with CMV-specific antibodies in 30 healthy blood donors (sensitivity 82%, specificity 95%). In the solid organ transplant recipients we examined, the prevalence of asymptomatic CMV viraemia was high at 61% but only two patients ultimately developed CMV disease, both of whom had negative QuantiFERON-CMV responses, indicating lack of CMV T-cell immunity. The vast majority (94%) of patients who had spontaneous resolution or stability of asymptomatic CMV viraemia without any antiviral treatment had positive QuantiFERON-CMV responses. Positive QuantiFERON-CMV responses at cessation of antiviral prophylaxis were significantly associated with pre-transplant CMV seropositivity and the development of asymptomatic viraemia post-transplantation. Overall, 27% of patients were recommenced on antiviral therapy because of asymptomatic CMV viraemia. Patients with non-reactive QuantiFERON-CMV responses had earlier onset, higher level CMV viraemia compared to those with positive QuantiFERON-CMV responses, although the difference did not reach statistical significance. QuantiFERON-CMV results may contribute to decision making in concert with the serological risk profile, net state of immunosuppression and CMV viral load.	[Thompson, Grace] Sir Charles Gairdner Hosp, PathWest, Dept Immunol, Nedlands, WA, Australia; [Boan, Peter; Flexman, James] Fiona Stanley Hosp, Dept Infect Dis & Microbiol, PathWest Lab Med, Murdoch, WA, Australia; [Baumwol, Jay] Fiona Stanley Hosp, Adv Heart Failure & Cardiac Transplant Serv, Murdoch, WA, Australia; [Chakera, Aron] Sir Charles Gairdner Hosp, Dept Nephrol, Nedlands, WA, Australia; [MacQuillan, Gerry] Sir Charles Gairdner Hosp, Liver Transplantat Unit, Nedlands, WA, Australia; [Swaminathan, Suda] Fiona Stanley Hosp, Dept Nephrol, Murdoch, WA, Australia; [Lavender, Melanie] Fiona Stanley Hosp, Dept Resp Med, Murdoch, WA, Australia; [John, Mina] Fiona Stanley Hosp, Dept Immunol, PathWest, Murdoch, WA, Australia; [James, Ian; John, Mina] Murdoch Univ, IIID, Murdoch, WA, Australia; [John, Mina] Royal Perth Hosp, Dept Clin Immunol, Perth, WA, Australia	Thompson, G (reprint author), Sir Charles Gairdner Hosp, Level 3 PP Block,Hosp Ave, Nedlands, WA 6009, Australia.	Grace.thompson@health.wa.gov.au		Lavender, Melanie/0000-0002-3002-0868			Abate D, 2013, J CLIN MICROBIOL, V51, P2501, DOI 10.1128/JCM.00563-13; Briant JA, 2013, TRANSPLANTATION, V96, pE7, DOI 10.1097/TP.0b013e318297ae0e; Cantisan S, 2013, AM J TRANSPLANT, V13, P738, DOI 10.1111/ajt.12049; Chiereghin A, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.01040-17, 10.1128/jcm.01040-17]; Egli A, 2012, CLIN INFECT DIS, V55, P1678, DOI 10.1093/cid/cis818; Fernandez-Ruiz M, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.3; Hanley PJ, 2014, VIRUSES-BASEL, V6, P2242, DOI 10.3390/v6062242; Khanna R, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.02009-17; Kumar D, 2017, AM J TRANSPLANT, V17, P2468, DOI 10.1111/ajt.14347; Kumar D, 2009, AM J TRANSPLANT, V9, P1214, DOI 10.1111/j.1600-6143.2009.02618.x; Le Page AK, 2013, TRANSPLANTATION, V95, P1455, DOI 10.1097/TP.0b013e31828ee12e; Lisboa LF, 2012, TRANSPLANTATION, V93, P195, DOI 10.1097/TP.0b013e31823c1cd4; Lochmanova A, 2010, TRANSPL P, V42, P3574, DOI 10.1016/j.transproceed.2010.07.101; Lucia M, 2014, TRANSPL INT, V27, P643, DOI 10.1111/tri.12318; Macagno A, 2010, J VIROL, V84, P1005, DOI 10.1128/JVI.01809-09; Manuel O, 2013, CLIN INFECT DIS, V56, P817, DOI 10.1093/cid/cis993; Melendez D, 2014, EXPERT REV CLIN IMMU, V10, P1213, DOI 10.1586/1744666X.2014.943190; Selvey LA, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2599-y; Sood S, 2015, LIVER TRANSPLANT, V21, P1478, DOI 10.1002/lt.24216; Sylwester AW, 2005, J EXP MED, V202, P673, DOI 10.1084/jem.20050882; Tarasewicz A, 2016, TRANSPL P, V48, P1650, DOI 10.1016/j.transproceed.2016.01.046; Walker S, 2007, TRANSPL INFECT DIS, V9, P165, DOI 10.1111/j.1399-3062.2006.00199.x	22	2	2	2	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					554	561		10.1016/j.pathol.2018.04.002			8	Pathology	Pathology	GN5VV	WOS:000439136500012	29945729				2019-10-28	
J	Wagner, T; Grantham, M; Berney, D				Wagner, Thomas; Grantham, Marianne; Berney, Daniel			Metastatic spermatocytic tumour with hybrid genetics: breaking the rules in germ cell tumours	PATHOLOGY			English	Letter							EXTREMELY RARE DISEASE; SEMINOMA		[Wagner, Thomas] Rigshosp, Copenhagen Univ Hosp, Dept Pathol, Copenhagen, Denmark; [Grantham, Marianne] Royal London Hosp, Barts Hlth Natl Hlth Serv Trust, Cytogenet Dept, London, England; [Berney, Daniel] Queen Mary Univ London, Barts Canc Inst, London, England	Wagner, T (reprint author), Rigshosp, Copenhagen Univ Hosp, Dept Pathol, Copenhagen, Denmark.	wagnernielsen@gmail.com		Wagner, Thomas/0000-0002-0256-0074	Orchid	DB is supported by Orchid. The authors state that there are no conflicts of interest to disclose.	Aggarwal N, 2009, ARCH PATHOL LAB MED, V133, P1985, DOI 10.1043/1543-2165-133.12.1985; Chung PWM, 2004, EUR UROL, V45, P495, DOI 10.1016/j.eururo.2003.11.005; Giannoulatou E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178169; Horn T, 2011, MED ONCOL, V28, pS423, DOI 10.1007/s12032-010-9739-1; Looijenga LHJ, 2006, CANCER RES, V66, P290, DOI 10.1158/0008-5472.CAN-05-2936; MATOSKA J, 1988, CANCER-AM CANCER SOC, V62, P1197, DOI 10.1002/1097-0142(19880915)62:6<1197::AID-CNCR2820620626>3.0.CO;2-A; Mikuz G, 2014, ANAL QUANT CYTOPATHO, V36, P177; Moch H, 2016, WHO CLASSIFICATION T, P189; Rosenberg C, 1998, GENE CHROMOSOME CANC, V23, P286, DOI 10.1002/(SICI)1098-2264(199812)23:4<286::AID-GCC2>3.0.CO;2-6; Steiner H, 2006, EUR UROL, V49, P408, DOI 10.1016/j.eururo.2005.12.044; Steiner H, 2006, EUR UROL, V49, P183, DOI 10.1016/j.eururo.2005.08.020; Verdorfer R, 2004, J PATHOL, V204, P277, DOI 10.1002/path.1634	12	1	1	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					562	565		10.1016/j.pathol.2018.02.002			4	Pathology	Pathology	GN5VV	WOS:000439136500013	29937234				2019-10-28	
J	Chu, GJ; Henderson, C; Evans, L; Howlin, K; Murad, A				Chu, Gerard Joseph; Henderson, Christopher; Evans, Louise; Howlin, Kenneth; Murad, Ari			Chronic granulomatous interstitial nephritis and urothelial metaplasia associated with ritonavir-boosted atazanavir: a case study and literature review	PATHOLOGY			English	Letter							ANTIRETROVIRAL THERAPY		[Chu, Gerard Joseph; Evans, Louise; Murad, Ari] Liverpool Hosp, Dept Immunol, Liverpool, NSW, Australia; [Chu, Gerard Joseph] Univ Sydney, Camperdown, NSW, Australia; [Chu, Gerard Joseph; Henderson, Christopher; Evans, Louise] Univ New South Wales, Kensington, NSW, Australia; [Henderson, Christopher] Liverpool Hosp, Dept Anat Pathol, Liverpool, NSW, Australia; [Henderson, Christopher] Univ Western Sydney, Campbelltown, NSW, Australia; [Howlin, Kenneth] Liverpool Hosp, Dept Renal Med, Liverpool, NSW, Australia	Chu, GJ (reprint author), Liverpool Hosp, Dept Immunol, Liverpool, NSW, Australia.; Chu, GJ (reprint author), Univ Sydney, Camperdown, NSW, Australia.; Chu, GJ (reprint author), Univ New South Wales, Kensington, NSW, Australia.	gerardchu@gmail.com					Calza L, 2013, SCAND J INFECT DIS, V45, P147, DOI 10.3109/00365548.2012.712213; Coelho Silvia, 2012, Am J Kidney Dis, V59, pA27, DOI 10.1053/j.ajkd.2012.03.005; Dauchy FA, 2011, KIDNEY INT, V80, P302, DOI 10.1038/ki.2011.124; de Lastours V, 2013, J ANTIMICROB CHEMOTH, V68, P1850, DOI 10.1093/jac/dkt125; Hara M, 2015, CLIN KIDNEY J, V8, P137, DOI 10.1093/ckj/sfv015; Izzedine H, 2007, AIDS, V21, P2357, DOI 10.1097/QAD.0b013e3282f17503; Kanzaki G, 2012, INTERNAL MED, V51, P1543, DOI 10.2169/internalmedicine.51.7093; Kazmierski WM, 2011, ANTIVIRAL DRUGS: FROM BASIC DISCOVERY THROUGH CLINICAL TRIALS, pXIII; Marinescu CI, 2015, AIDS RES TREAT, DOI 10.1155/2015/106954; Mocroft Amanda, 2014, J Int AIDS Soc, V17, P19514, DOI 10.7448/IAS.17.4.19514; Ryom L, 2013, J INFECT DIS, V207, P1359, DOI 10.1093/infdis/jit043; Squibb Bristol-Myers, 2006, REYET PROD INF; Viglietti D, 2011, ANTIVIR THER, V16, P119, DOI 10.3851/IMP1700	13	1	1	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					565	568		10.1016/j.pathol.2018.01.009			5	Pathology	Pathology	GN5VV	WOS:000439136500014	29941201				2019-10-28	
J	Yeon, SY; Jung, SH; Kim, MS; Chung, YJ; Lee, SH				Yeon, Su Yeon; Jung, Seung Hyun; Kim, Min Sung; Chung, Yeun-Jun; Lee, Sug Hyung			Targeted sequencing of burn scar-related squamous cell carcinomas identified PIK3CA amplification	PATHOLOGY			English	Letter							MUTATIONS		[Yeon, Su Yeon; Kim, Min Sung; Lee, Sug Hyung] Catholic Univ Korea, Dept Pathol, Seoul, South Korea; [Yeon, Su Yeon; Jung, Seung Hyun; Kim, Min Sung; Lee, Sug Hyung] Catholic Univ Korea, Canc Evolut Res Ctr, Seoul, South Korea; [Jung, Seung Hyun; Chung, Yeun-Jun; Lee, Sug Hyung] Catholic Univ Korea, Precis Med Res Ctr, Seoul, South Korea; [Chung, Yeun-Jun] Catholic Univ Korea, Dept Microbiol, Seoul, South Korea; [Chung, Yeun-Jun] Catholic Univ Korea, Integrated Res Ctr Genome Polymorphism, Seoul, South Korea	Lee, SH (reprint author), Catholic Univ Korea, Dept Pathol, Seoul, South Korea.; Lee, SH (reprint author), Catholic Univ Korea, Canc Evolut Res Ctr, Seoul, South Korea.; Chung, YJ; Lee, SH (reprint author), Catholic Univ Korea, Precis Med Res Ctr, Seoul, South Korea.; Chung, YJ (reprint author), Catholic Univ Korea, Dept Microbiol, Seoul, South Korea.; Chung, YJ (reprint author), Catholic Univ Korea, Integrated Res Ctr Genome Polymorphism, Seoul, South Korea.	yejun@catholic.ac.kr; suhulee@catholic.ac.kr			National Research Foundation of KoreaNational Research Foundation of Korea [2012R1A5A 2047939, 2017R1E1A1A01074913, 2017R1A2B2002 314]	This work was supported by grants from National Research Foundation of Korea (2012R1A5A 2047939, 2017R1E1A1A01074913 and 2017R1A2B2002 314).	Al-Rohil RN, 2016, CANCER-AM CANCER SOC, V122, P249, DOI 10.1002/cncr.29738; Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103; Hong JH, 2017, PATHOLOGY, V49, P453, DOI 10.1016/j.pathol.2017.01.011; Huang CY, 2010, J DERMATOL TREAT, V21, P350, DOI 10.3109/09546630903386580; Jung SH, 2015, ONCOTARGET, V6, P4385, DOI 10.18632/oncotarget.2981; Kim HS, 2016, ONCOTARGET, V7, P30691, DOI 10.18632/oncotarget.8749; Kowal-Vern A, 2005, BURNS, V31, P403, DOI 10.1016/j.burns.2005.02.015; Li YY, 2015, CLIN CANCER RES, V21, P1447, DOI 10.1158/1078-0432.CCR-14-1773; Nakanishi H, 1999, JPN J CANCER RES, V90, P276, DOI 10.1111/j.1349-7006.1999.tb00744.x; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Yamamoto H, 2008, CANCER RES, V68, P6913, DOI 10.1158/0008-5472.CAN-07-5084	11	1	1	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					568	571		10.1016/j.pathol.2018.02.001			5	Pathology	Pathology	GN5VV	WOS:000439136500015	29941200				2019-10-28	
J	Leecy, T; Ardakani, NM; Harvey, NT; Wood, BA				Leecy, Tamazin; Ardakani, Nima Mesbah; Harvey, Nathan T.; Wood, Benjamin A.			Pilomatrical carcinosarcoma: report of a case with comparative genomic hybridisation analysis	PATHOLOGY			English	Letter							CUTANEOUS CARCINOSARCOMA; CARCINOMA; CHEEK		[Leecy, Tamazin; Ardakani, Nima Mesbah; Harvey, Nathan T.; Wood, Benjamin A.] QEII Med Ctr, PathWest Lab Med, Nedlands, WA, Australia	Leecy, T (reprint author), QEII Med Ctr, PathWest Lab Med, Nedlands, WA, Australia.	tamazin.leecy@health.wa.gov.au					Ardakani NM, 2017, PATHOLOGY, V49, P285, DOI 10.1016/j.pathol.2016.11.008; HANLY MG, 1994, AM J DERMATOPATH, V16, P196, DOI 10.1097/00000372-199404000-00018; Harms PW, 2015, HUM PATHOL, V46, P690, DOI 10.1016/j.humpath.2015.01.006; Harvey NT, 2014, AM J DERMATOPATH, V36, P483, DOI 10.1097/DAD.0000000000000017; ODONOVAN DG, 1993, HISTOPATHOLOGY, V23, P385, DOI 10.1111/j.1365-2559.1993.tb01226.x; Paniz-Mondolfi A, 2014, VIRCHOWS ARCH, V465, P339, DOI 10.1007/s00428-014-1628-0; Sassmannshausen J, 2001, J AM ACAD DERMATOL, V44, P358, DOI 10.1067/mjd.2001.105474; Scholl Peter, 2010, Otolaryngol Head Neck Surg, V143, pS36, DOI 10.1016/j.otohns.2010.06.901; Speiser JJ, 2015, AM J DERMATOPATH, V37, P950, DOI 10.1097/DAD.0000000000000208; Suyama T, 2017, PATHOL INT, V67, P324, DOI 10.1111/pin.12536; Tran TA, 2005, J CUTAN PATHOL, V32, P2, DOI 10.1111/j.0303-6987.2005.00260.x; VANDERWALT JD, 1984, AM J DERMATOPATH, V6, P63, DOI 10.1097/00000372-198402000-00014	12	1	1	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					571	573		10.1016/j.pathol.2018.02.003			4	Pathology	Pathology	GN5VV	WOS:000439136500016	29954591				2019-10-28	
J	Kawasaki, T; Kubota, T; Ichihara, S; Horibe, K; Hasebe, T				Kawasaki, Tomonori; Kubota, Toshinobu; Ichihara, Shu; Horibe, Keizo; Hasebe, Takahiro			Neuroendocrine cells associated with endocrine mucin-producing sweat gland carcinoma: a potential precursor lesion?	PATHOLOGY			English	Letter							IN-SITU; BREAST		[Kawasaki, Tomonori; Hasebe, Takahiro] Saitama Med Univ, Int Med Ctr, Dept Pathol, Saitama, Japan; [Kawasaki, Tomonori; Kubota, Toshinobu; Ichihara, Shu; Horibe, Keizo] Natl Hosp Org Nagoya Med Ctr, Clin Res Ctr, Aichi, Japan; [Kubota, Toshinobu] Natl Hosp Org Nagoya Med Ctr, Dept Ophthalmol, Aichi, Japan	Kawasaki, T (reprint author), Saitama Med Univ, Int Med Ctr, Dept Pathol, Saitama, Japan.; Kawasaki, T (reprint author), Natl Hosp Org Nagoya Med Ctr, Clin Res Ctr, Aichi, Japan.	tomo.kawasaki.14@gmail.com	Ichihara, Shu/L-2371-2019	Ichihara, Shu/0000-0001-6596-5725	Japanese Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [16K08654, 16H00668]	Tomonori Kawasaki is supported by Grants-in-Aid for Scientific Research (No. 16K08654 and No. 16H00668) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The authors state that there are no conflicts of interest to disclose.	Flieder A, 1997, AM J SURG PATHOL, V21, P1501, DOI 10.1097/00000478-199712000-00014; Inozume T, 2012, PATHOL INT, V62, P344, DOI 10.1111/j.1440-1827.2012.02793.x; Kawasaki T, 2008, HISTOPATHOLOGY, V53, P288, DOI 10.1111/j.1365-2559.2008.03093.x; Kawasaki T, 2011, CYTOPATHOLOGY, V22, P43, DOI 10.1111/j.1365-2303.2010.00742.x; Kawasaki T, 2012, BREAST, V21, P652, DOI 10.1016/j.breast.2012.01.016; Kawasaki T, 2012, J CLIN PATHOL, V65, P699, DOI 10.1136/jclinpath-2012-200765; NARISAWA Y, 1993, BRIT J DERMATOL, V129, P541, DOI 10.1111/j.1365-2133.1993.tb00481.x; PEARSE AGE, 1970, GUT, V11, P649, DOI 10.1136/gut.11.8.649; SIBLEY RK, 1980, AM J SURG PATHOL, V4, P211, DOI 10.1097/00000478-198006000-00001; WOLFE HJ, 1973, NEW ENGL J MED, V289, P437, DOI 10.1056/NEJM197308302890901; Zembowicz A, 2005, AM J SURG PATHOL, V29, P1330, DOI 10.1097/01.pas.0000170348.40057.60	11	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					573	575		10.1016/j.pathol.2018.01.008			4	Pathology	Pathology	GN5VV	WOS:000439136500017	29908841				2019-10-28	
J	Hakemi, Y; Pyne, J; Muljono, A; Myint, E				Hakemi, Yalda; Pyne, John; Muljono, Anita; Myint, Esther			Indolent primary cutaneous CD8 positive T-cell lymphoid proliferations	PATHOLOGY			English	Letter							ACRAL SITES; FEATURES; ENTITY; EAR		[Hakemi, Yalda; Muljono, Anita; Myint, Esther] Douglass Hanly Moir Pathol, Tissue Pathol, Macquarie Pk, NSW, Australia; [Pyne, John] Univ New South Wales, Sydney, NSW, Australia	Hakemi, Y (reprint author), Douglass Hanly Moir Pathol, Tissue Pathol, Macquarie Pk, NSW, Australia.	Yalda.Hakemi@Health.nsw.gov.au					Alberti-Violetti S, 2017, J CUTAN PATHOL, V44, P964, DOI 10.1111/cup.13020; Greenblatt D, 2013, J CUTAN PATHOL, V40, P248, DOI 10.1111/cup.12045; Kempf W, 2013, AM J DERMATOPATH, V35, P159, DOI 10.1097/DAD.0b013e31825c3a33; Kluk J, 2016, J CUTAN PATHOL, V43, P125, DOI 10.1111/cup.12633; Petrella T, 2007, AM J SURG PATHOL, V31, P1887, DOI 10.1097/PAS.0b013e318068b527; Suchak R, 2010, J CUTAN PATHOL, V37, P977, DOI 10.1111/j.1600-0560.2009.01448.x; VAILLANT L, 1993, ACTA DERM-VENEREOL, V73, P255; Virmani P, 2016, INT J DERMATOL, V55, P1248, DOI 10.1111/ijd.13340; Wobser M, 2015, BRIT J DERMATOL, V172, P1573, DOI 10.1111/bjd.13628; Zeng WF, 2012, J CUTAN PATHOL, V39, P696, DOI 10.1111/j.1600-0560.2012.01917.x	10	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					575	578		10.1016/j.pathol.2017.12.345			5	Pathology	Pathology	GN5VV	WOS:000439136500018	29908842				2019-10-28	
J	AbdullGaffar, B; Raman, L				AbdullGaffar, Badr; Raman, Lakshmiah			Spontaneous breast haematoma in a woman with Bernard-Soulier giant platelet disorder	PATHOLOGY			English	Letter									[AbdullGaffar, Badr] Rashid Hosp, Dubai, U Arab Emirates; [Raman, Lakshmiah] Dubai Hosp, Dubai, U Arab Emirates	AbdullGaffar, B (reprint author), Rashid Hosp, Dubai, U Arab Emirates.	gaffarbadr@hotmail.com		AbdullGaffar, Badr/0000-0001-6350-1214			ENZMANN DR, 1981, AM J NEURORADIOL, V2, P517; Gollentz B, 1990, J Radiol, V71, P33; Gundes E, 2017, ULUS TRAVMA ACIL CER, V23, P72, DOI 10.5505/tjtes.2016.01657; Kanegusuku M S, 2001, Rev Hosp Clin Fac Med Sao Paulo, V56, P179; Mhawech P, 2000, AM J CLIN PATHOL, V113, P176; Pignatelli V, 1995, Radiol Med, V89, P36; Sarabia AR, 2015, RADIOLOGIA-MADRID, V57, P445, DOI 10.1016/j.rx.2015.05.001; Salemis Nikolaos S, 2012, Breast Dis, V34, P25, DOI 10.3233/BD-130344; SHROTRIA S, 1994, BRIT J CLIN PRACT, V48, P214	9	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					578	580		10.1016/j.pathol.2018.01.010			4	Pathology	Pathology	GN5VV	WOS:000439136500019	29910046				2019-10-28	
J	Ho, WK; Rigano, J				Ho, Wai Khoon; Rigano, Joseph			Prevalence of antiphospholipid antibodies in an Australian cohort of patients with unprovoked venous thromboembolism	PATHOLOGY			English	Letter							THROMBOPHILIA		[Ho, Wai Khoon; Rigano, Joseph] Austin Hosp, Austin Pathol Coagulat Lab, Melbourne, Vic, Australia	Ho, WK (reprint author), Austin Hosp, Austin Pathol Coagulat Lab, Melbourne, Vic, Australia.	wai.ho@austin.org.au					Favaloro EJ, 2012, INTERN MED J, V42, P427, DOI 10.1111/j.1445-5994.2010.02329.x; Keeling D, 2012, BRIT J HAEMATOL, V157, P47, DOI 10.1111/j.1365-2141.2012.09037.x; Merriman L, 2006, POSTGRAD MED J, V82, P699, DOI 10.1136/pgmj.2006.048090; Pernod G, 2009, J MAL VASCUL, V34, P156, DOI 10.1016/j.jmv.2009.02.005; Pottier P, 2005, CLIN APPL THROMB-HEM, V11, P243, DOI 10.1177/107602960501100302; Roldan V, 2009, THROMB RES, V124, P174, DOI 10.1016/j.thromres.2008.11.003; Salomon O, 1999, ARTERIOSCL THROM VAS, V19, P511, DOI 10.1161/01.ATV.19.3.511; Sebastiani GD, 2015, LUPUS, V24, P1276, DOI 10.1177/0961203315585817	8	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					580	581		10.1016/j.pathol.2017.12.344			3	Pathology	Pathology	GN5VV	WOS:000439136500020	29954590				2019-10-28	
J	Tate, C; McKinley, M; Seymour, L				Tate, Courtney; McKinley, Mark; Seymour, Louise			An unusual case of myeloma	PATHOLOGY			English	Letter							MULTIPLE-MYELOMA; CELLS; CD138; IMMATURE		[Tate, Courtney; McKinley, Mark; Seymour, Louise] Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia	Tate, C (reprint author), Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia.	courtmodra@hotmail.com		Tate, Courtney/0000-0003-3558-0589			Castillo JJ, 2015, BLOOD, V125, P2323, DOI 10.1182/blood-2014-10-567479; Chang CC, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-47; Christensen JH, 2012, HAEMATOL-HEMATOL J, V97, pE18, DOI 10.3324/haematol.2011.043125; Gabrea A, 2008, GENE CHROMOSOME CANC, V47, P573, DOI 10.1002/gcc.20563; Gole L, 2014, CANCER GENET-NY, V207, P31, DOI 10.1016/j.cancergen.2013.12.001; GREIPP PR, 1985, BLOOD, V65, P305; Kawano Y, 2013, INT J ONCOL, V43, P1809, DOI 10.3892/ijo.2013.2134; Kawano Y, 2012, INT J ONCOL, V41, P876, DOI 10.3892/ijo.2012.1545; Muz B, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.82; Rao Seema, 2008, Indian J Hematol Blood Transfus, V24, P188, DOI 10.1007/s12288-008-0046-3; Reid S, 2010, INT J LAB HEMATOL, V32, pE190, DOI 10.1111/j.1751-553X.2010.01222.x; Vega F, 2005, MODERN PATHOL, V18, P806, DOI 10.1038/modpathol.3800355	12	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					581	584		10.1016/j.pathol.2018.01.011			5	Pathology	Pathology	GN5VV	WOS:000439136500021	29921449				2019-10-28	
J	Fang, YT; Grabsch, EA; Leroi, MJ; Sherry, NL; Ward, PB				Fang, Yen-Ting; Grabsch, Elizabeth A.; Leroi, Marcel J.; Sherry, Norelle L.; Ward, Peter B.			Optimising early identification of blood culture isolates by MALDI-TOF and use of multiple target wells	PATHOLOGY			English	Letter							DESORPTION IONIZATION-TIME; FLIGHT MASS-SPECTROMETRY; RAPID IDENTIFICATION; SOLID MEDIUM; INCUBATION; BACTERIA; SYSTEM		[Fang, Yen-Ting; Grabsch, Elizabeth A.; Leroi, Marcel J.; Sherry, Norelle L.; Ward, Peter B.] Austin Hlth, Microbiol Dept, Heidelberg, Vic, Australia	Fang, YT (reprint author), Austin Hlth, Microbiol Dept, Heidelberg, Vic, Australia.	tina.fang@austin.org.au					Bhatti MM, 2014, J CLIN MICROBIOL, V52, P4334, DOI 10.1128/JCM.01788-14; Buchan BW, 2012, J CLIN MICROBIOL, V50, P346, DOI 10.1128/JCM.05021-11; Foster AGW, 2013, J CLIN MICROBIOL, V51, P3717, DOI 10.1128/JCM.01679-13; Idelevich EA, 2014, CLIN MICROBIOL INFEC, V20, P1001, DOI 10.1111/1469-0691.12640; Kohlmann R, 2015, INT J MED MICROBIOL, V305, P469, DOI 10.1016/j.ijmm.2015.04.004; Lupetti A, 2013, EUR J CLIN MICROBIOL, V32, P493, DOI 10.1007/s10096-012-1762-z; Stevenson LG, 2010, J CLIN MICROBIOL, V48, P444, DOI 10.1128/JCM.01541-09	7	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					584	587		10.1016/j.pathol.2017.12.346			5	Pathology	Pathology	GN5VV	WOS:000439136500022	30031561				2019-10-28	
J	Haran, H; Choy, KW; Wijeratne, N; Tudball, R; Doery, J; Grigoriadis, G; Lu, Z				Haran, Harini; Choy, Kay Weng; Wijeratne, Nilika; Tudball, Ronald; Doery, James; Grigoriadis, George; Lu, Zhong			Concentrating non-dilute urine before protein electrophoresis for the detection of monoclonal free light chains is unnecessary and wasteful	PATHOLOGY			English	Letter									[Haran, Harini; Choy, Kay Weng; Wijeratne, Nilika; Tudball, Ronald; Doery, James; Grigoriadis, George; Lu, Zhong] Monash Med Ctr, Clayton, Vic, Australia	Choy, KW (reprint author), Monash Med Ctr, Clayton, Vic, Australia.	kayweng.choy@gmail.com		Wijeratne, Nilika/0000-0003-4214-5868; Doery, James C G/0000-0002-1235-9913			Dispenzieri A, 2009, LEUKEMIA, V23, P215, DOI 10.1038/leu.2008.307; Holding S, 2011, CLIN CHEM LAB MED, V49, P83, DOI 10.1515/CCLM.2011.010; Levinson SS, 2000, ANN CLIN LAB SCI, V30, P79	3	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					587	588		10.1016/j.pathol.2018.02.004			3	Pathology	Pathology	GN5VV	WOS:000439136500023	29970254				2019-10-28	
J	Keating, P; Van Voorthuizen, M; Liu, J; Chua, I; O'Donnell, J				Keating, Paula; Van Voorthuizen, Mark; Liu, John; Chua, Ignatius; O'Donnell, John			Response to: New immunoassays for anti-HMG-CoA reductase antibodies may lead to incorrect diagnosis in inflammatory myositis	PATHOLOGY			English	Letter									[Keating, Paula; Van Voorthuizen, Mark; Liu, John; Chua, Ignatius; O'Donnell, John] Canterbury Hlth Labs, Immunol, Canterbury, New Zealand	Keating, P (reprint author), Canterbury Hlth Labs, Immunol, Canterbury, New Zealand.	paula.keating@cdhb.health.nz					Droney L, 2017, PATHOLOGY, V49, P638, DOI 10.1016/j.pathol.2017.04.013; Kennedy N, 2016, INTERN MED J, V46, P622, DOI 10.1111/imj.13023; Mammen AL, 2012, ARTHRIT CARE RES, V64, P269, DOI 10.1002/acr.20662; O'donnell J, 2017, ANN RHEUM DIS, V76, P637, DOI 10.1136/annrheumdis-2017-eular.2329; Spellerberg M, 2017, PATHOLOGY, V49, P565, DOI 10.1016/j.pathol.2017.07.006	5	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0031-3025	1465-3931		PATHOLOGY	Pathology	AUG	2018	50	5					588	590		10.1016/j.pathol.2018.04.001			4	Pathology	Pathology	GN5VV	WOS:000439136500024	29945730				2019-10-28	
J	Hamza, A; Alrajjal, A; Edens, J; Khawar, S; Khurram, MS; Szpunar, S; Bonnett, M				Hamza, Ameer; Alrajjal, Ahmed; Edens, Jacob; Khawar, Sidrah; Khurram, Muhammad Siddique; Szpunar, Susanna; Bonnett, Michelle			Utility of Additional Tissue Sections in Surgical Pathology	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						surgical pathology; tissue sampling; grossing; pathologic diagnosis; pathologic stage	CARCINOMA IN-SITU; MICROINVASIVE BREAST-CANCER; FOLLICULAR THYROID CARCINOMAS; ACTIVE SURVEILLANCE; PROSTATE-CANCER; MANAGEMENT; SPECIMENS; SURVIVAL; OVARIAN; METASTASES	Background. To avoid diagnostic errors such as missed diagnosis and errors in staging tumors due to inadequate tissue sampling, pathologists submit additional sections (AS). Objective. This study assessed frequency, diagnostic yield, distribution, and cost of AS. Method. Among 1542 AS cases, we calculated mean AS per case; fraction of AS that altered diagnosis or stage; AS variation by tissue, malignant versus benign lesions, presence or absence of neoadjuvant therapy, mass, margin, lymph nodes, or other source, resident versus pathologist assistant (PA) dissector; and AS cost per case. Results. Overall 9.2 +/- 8.8 AS were collected per case. In only 3.8% (58/1542) of cases AS altered diagnosis or stage. Urinary bladder cases provoked the most AS: 19.5 +/- 15.1 per case. Significantly more AS came from malignant versus benign lesions (10.8 +/- 9.7 vs 7.6 +/- 7.5, P = <.0001) and from specimens treated with neoadjuvant therapy versus malignant lesions not so treated (12.3 +/- 9.4 vs 10.3 +/- 9.8, P = .02). Lymph nodes were sampled more heavily compared with mass, margin, and other sites combined (11.8 +/- 11.4 vs 8.9 +/- 8.4, P = .003), but in 78.4% (1209/1542) of cases, AS were from mass. Of diagnosis or stage altering AS cases, two thirds (38/58) were from masses, one fifth (11/58) from lymph nodes, a 10th (6/58) from margins, and a 20th (3/58) from other specimen sites. Resident versus pathologist assistant dissection caused no significant AS difference. AS contributed 40% cost per case. Conclusions. AS per case ranged widely; their diagnostic yield was low; they were highest in urinary bladder specimens, in malignant and particularly neoadjuvant-treated lesions. Although lymph nodes were most heavily sampled, most AS were from masses. Resident dissection did not increase AS and cost of AS was high.	[Hamza, Ameer; Alrajjal, Ahmed; Edens, Jacob; Khawar, Sidrah; Khurram, Muhammad Siddique; Szpunar, Susanna; Bonnett, Michelle] St John Hosp & Med Ctr, Detroit, MI USA	Hamza, A (reprint author), St John Hosp & Med Ctr, Dept Pathol, 22101 Moross Rd, Detroit, MI 48236 USA.	ameerhamza7@hotmail.com					Aarons CB, 2014, WORLD J GASTROENTERO, V20, P16178, DOI 10.3748/wjg.v20.i43.16178; Amin MB, 2016, AJCC CANC STAGING MA; Askin FB, 2003, SURG PATHOLOGY DISSE; Assoc Directors Anatomic Surgical, 2005, AM J CLIN PATHOL, V123, P494, DOI 10.1309/LGO6G3YEL1LU195X; Ban EJ, 2012, ANZ J SURG, V82, P136, DOI 10.1111/j.1445-2197.2011.05979.x; Bianchi S, 2008, PATHOL ONCOL RES, V14, P105, DOI 10.1007/s12253-008-9054-8; Bozzini A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-275; Byun Jung Mi, 2015, Obstet Gynecol Sci, V58, P468, DOI 10.5468/ogs.2015.58.6.468; Chandra V, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e8; Chitkara YK, 2005, AM J CLIN PATHOL, V123, P886, DOI 10.1309/MGRXLQG9QVRVVMCG; Choyke PL, 2017, ONCOLOGY-NY, V31, P67; Chui MH, 2014, AM J SURG PATHOL, V38, P1173, DOI 10.1097/PAS.0000000000000298; College of American Pathologists, CANC PROT TEMPL; Collins LC, DUCTAL CARCINOMA SIT; Goldblum J, 2017, ROSAI ACKERMANS SURG; Gray RJ, 2007, AM J SURG, V194, P845, DOI 10.1016/j.amjsurg.2007.08.034; Guth AA, 2008, BREAST J, V14, P335, DOI 10.1111/j.1524-4741.2008.00594.x; Heitz F, 2014, INT J GYNECOL CANCER, V24, P54, DOI 10.1097/IGC.0000000000000019; Huang CC, 2011, SURG ONCOL, V20, P1, DOI 10.1016/j.suronc.2009.06.006; Jain S, 2009, PATHOLOGY, V41, P57, DOI 10.1080/00313020802563502; Lester SC., 2010, MANUAL SURG PATHOLOG; Liszka L, 2017, HISTOL HISTOPATHOL, V32, P177, DOI 10.14670/HH-11-781; Luo YHV, 2002, ARCH PATHOL LAB MED, V126, P1205; Lynch SP, 2012, ANN ONCOL, V23, P3063, DOI 10.1093/annonc/mds136; Lyons JM, 2012, ANN SURG ONCOL, V19, P3416, DOI 10.1245/s10434-012-2376-5; Matsen CB, 2014, ANN SURG ONCOL, V21, P3330, DOI 10.1245/s10434-014-3920-2; MCDOWELL PR, 1994, HUM PATHOL, V25, P493, DOI 10.1016/0046-8177(94)90121-X; Meier FA, 2015, ERROR REDUCTION PREV, P3, DOI [10.1007/978-1-4939-2339-7_2., DOI 10.1007/978-1-4939-2339-7_2]; Mitsuzuka K, 2015, INT J UROL, V22, P754, DOI 10.1111/iju.12813; Montironi R, 2011, HISTOPATHOLOGY, V59, P1006, DOI 10.1111/j.1365-2559.2011.03908.x; MYERS C, 2016, AM J CLIN PATHOL S1, V146, DOI DOI 10.1093/AJCP/AQW161.037.; Nakhleh RE, 2016, ARCH PATHOL LAB MED, V140, P29, DOI 10.5858/arpa.2014-0511-SA; NCCN Clinical Practice Guidelines in Oncology, NCCN CLIN PRACT GUID; Nielsen JA, 2013, AM J CLIN PATHOL, V140, P231, DOI 10.1309/AJCPPXU66QZAZNYN; O'Neill CJ, 2011, EJSO-EUR J SURG ONC, V37, P181, DOI 10.1016/j.ejso.2010.11.005; Oyasu R, 2008, QUESTIONS DAILY UROL, P21; Parikh RR, 2012, INT J RADIAT ONCOL, V82, P7, DOI 10.1016/j.ijrobp.2010.08.027; Park TS, 2016, ONCOLOGY-NY, V30, P823; Pimiento JM, 2011, J ONCOL PRACT, V7, P309, DOI 10.1200/JOP.2010.000096; Rabinowitz AD, 1996, J CUTAN PATHOL, V23, P194, DOI 10.1111/j.1600-0560.1996.tb01295.x; Rezo A, 2011, BREAST, V20, P259, DOI 10.1016/j.breast.2011.01.005; Samaratunga H, 2011, MODERN PATHOL, V24, P6, DOI 10.1038/modpathol.2010.178; Shatat L, 2013, HUM PATHOL, V44, P2684, DOI 10.1016/j.humpath.2013.07.010; Silverberg SG, 2000, MODERN PATHOL, V13, P309, DOI 10.1038/modpathol.3880053; Stenson G, 2016, ENDOCRINE, V53, P505, DOI 10.1007/s12020-016-0876-y; Stuart LN, 2014, J CUTAN PATHOL, V41, P81, DOI 10.1111/cup.12267; Williams MG, 2009, OBSTET GYNECOL, V113, P783, DOI 10.1097/AOG.0b013e31819c7bdf; Young E Scott, 2005, Ann Diagn Pathol, V9, P202, DOI 10.1016/j.anndiagpath.2005.04.017; Young E Scott, 2002, Ann Diagn Pathol, V6, P188, DOI 10.1053/adpa.2002.32382; Zavagno G, 2007, BREAST, V16, P146, DOI 10.1016/j.breast.2006.08.002	50	4	4	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					392	401		10.1177/1066896918755008			10	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500001	29390920				2019-10-28	
J	Chen, JH; Deshpande, V				Chen, Jonathan H.; Deshpande, Vikram			Inflammatory Nodules Identify Steroid-Responsive Primary Sclerosing Cholangitis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						primary sclerosing cholangitis; IgG4-related disease; steroids; autoimmunity; liver; inflammation	IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS; IGG4-RELATED DISEASE; URSODEOXYCHOLIC ACID; OVERLAP SYNDROME; DOUBLE-BLIND; THERAPY; LIVER; PANCREATITIS; BUDESONIDE; DIAGNOSIS	Primary sclerosing cholangitis (PSC) is a cholangiopathyusually associated with inflammatory bowel diseasethat leads to cirrhosis and liver failure. Based on a multitude of clinical trials, there is general consensus that PSC progression is unchanged by current therapies, including steroids. However, there are scattered reports in the literature of PSC patients responsive to steroids. Recently, several steroid-responsive PSC mimics have been described, most notably immunoglobulin G4-related sclerosing cholangitis. Following these discoveries, many assume that cases in the literature previously reported as steroid-responsive PSC would now be classified as one of these mimics. We reviewed liver biopsies and the medical histories of patients diagnosed with PSC with documented response to steroids. We identified 3 cases of steroid-responsive PSC in patients with inflammatory bowel disease that do not fit criteria of known PSC mimics. All 3 were adults (age range = 18-44 years) with inflammatory bowel disease, and included 2 males and 1 female. All 3 patients had abnormal liver function tests that normalized on prednisone. Histologically, these 3 cases share a common feature, hepatic fibroinflammatory nodules in a collagen-rich background. They lacked clinical, serologic, and histologic features of immunoglobulin G4-related sclerosing cholangitis. These cases suggest that fibroinflammatory nodules may identify a unique subset of PSC patients who are responsive to steroids.	[Chen, Jonathan H.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Chen, Jonathan H.; Deshpande, Vikram] Harvard Med Sch, Boston, MA USA	Deshpande, V (reprint author), Massachusetts Gen Hosp, Pathol Serv, 55 Fruit St,Warren 256, Boston, MA 02114 USA.	vikramdirdeshpande@gmail.com		deshpande, Vikram/0000-0003-4230-9308			Abdalian R, 2006, HEPATOLOGY, V44, P1063, DOI 10.1002/hep.21405; Angulo P, 2000, AM J GASTROENTEROL, V95, P2333; Angulo P, 1999, AM J GASTROENTEROL, V94, P3310, DOI 10.1111/j.1572-0241.1999.01543.x; Barnabas Ashley, 2012, Curr Gastroenterol Rep, V14, P17, DOI 10.1007/s11894-011-0230-8; BARTHOLOMEW LG, 1963, NEW ENGL J MED, V269, P8, DOI 10.1056/NEJM196307042690102; Boberg KM, 2011, J HEPATOL, V54, P374, DOI 10.1016/j.jhep.2010.09.002; Boberg KM, 2003, SCAND J GASTROENTERO, V38, P991, DOI 10.1080/00365520310005172; Chapman R, 2010, HEPATOLOGY, V51, P660, DOI 10.1002/hep.23294; Chen JH, 2017, GASTROENTEROL CLIN N, V46, P195, DOI 10.1016/j.gtc.2017.01.001; Czaja AJ, 2000, HEPATOLOGY, V31, P1231, DOI 10.1053/jhep.2000.7878; Deneau MR, 2017, HEPATOLOGY, V66, P518, DOI 10.1002/hep.29204; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Deshpande V, 2009, MODERN PATHOL, V22, P1287, DOI 10.1038/modpathol.2009.94; Epstein MP, 2004, DIGEST DIS SCI, V49, P1, DOI 10.1023/B:DDAS.0000011827.87103.2e; Erkelens GW, 1999, LANCET, V354, P43, DOI 10.1016/S0140-6736(99)00603-0; FOSTER GS, 1982, NEW ENGL J MED, V306, P349; Ghazale A, 2008, GASTROENTEROLOGY, V134, P706, DOI 10.1053/j.gastro.2007.12.009; Grammatikopoulos T, 2013, J PEDIATR GASTR NUTR, V56, pE3, DOI 10.1097/MPG.0b013e3182487173; Gregorio GV, 2001, HEPATOLOGY, V33, P544, DOI 10.1053/jhep.2001.22131; Gupta RK, 2016, HUM PATHOL, V48, P154, DOI 10.1016/j.humpath.2015.09.017; Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3; Hommes DW, 2008, J CLIN GASTROENTEROL, V42, P522, DOI 10.1097/MCG.0b013e3181662426; KAPLAN MM, 1991, SEMIN LIVER DIS, V11, P56, DOI 10.1055/s-2008-1040423; KAPLAN MM, 1987, ANN INTERN MED, V106, P231, DOI 10.7326/0003-4819-106-2-231; Lazaridis KN, 2016, NEW ENGL J MED, V375, P1161, DOI 10.1056/NEJMra1506330; LEE YM, 1995, NEW ENGL J MED, V332, P924, DOI 10.1056/NEJM199504063321406; Lindor KD, 2015, AM J GASTROENTEROL, V110, P646, DOI 10.1038/ajg.2015.112; Lindor KD, 2009, HEPATOLOGY, V50, P808, DOI 10.1002/hep.23082; Mendes F, 2010, NAT REV GASTRO HEPAT, V7, P611, DOI 10.1038/nrgastro.2010.155; Mileti E, 2012, CLIN GASTROENTEROL H, V10, P417, DOI 10.1016/j.cgh.2011.11.030; MYERS RN, 1970, AM J GASTROENTEROL, V53, P527; Oseini AM, 2011, HEPATOLOGY, V54, P940, DOI 10.1002/hep.24487; Parkes M, 2001, J CLIN GASTROENTEROL, V33, P319, DOI 10.1097/00004836-200110000-00013; Schramm C, 1999, ANN INTERN MED, V131, P943, DOI 10.7326/0003-4819-131-12-199912210-00006; Sekhon JS, 2005, DIGEST DIS SCI, V50, P1839, DOI 10.1007/s10620-005-2948-3; Stone JH, 2015, MAYO CLIN PROC, V90, P927, DOI 10.1016/j.mayocp.2015.03.020; Talwalkar JA, 2007, LIVER INT, V27, P451, DOI 10.1111/j.1478-3231.2007.01441.x; Tischendorf JJW, 2007, AM J GASTROENTEROL, V102, P107, DOI 10.1111/j.1572-0241.2006.00872.x; van Hoogstraten HJF, 2000, AM J GASTROENTEROL, V95, P2015, DOI 10.1016/S0002-9270(00)01059-5; Zen Y, 2012, AM J SURG PATHOL, V36, P1555, DOI 10.1097/PAS.0b013e31825faae0; Zen Y, 2012, HISTOPATHOLOGY, V60, P261, DOI 10.1111/j.1365-2559.2011.04078.x; Zenouzi R, 2014, J HEPATOL, V61, P1189, DOI 10.1016/j.jhep.2014.08.002	42	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					402	409		10.1177/1066896918758451			8	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500002	29464971				2019-10-28	
J	Liu, CH; Lin, CH; Tsai, MJ; Chen, YH; Yang, SF; Tsai, KB				Liu, Chia-Hsing; Lin, Chih-Hung; Tsai, Min-Jan; Chen, Yu-Hsuan; Yang, Sheau-Fang; Tsai, Kun-Bow			Melanin Bleaching With Warm Hydrogen Peroxide and Integrated Immunohistochemical Analysis: An Automated Platform	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						melanin pigment; melanin bleaching; cytomorphology; immunohistochemistry; automated platform	PIGMENTED MELANOCYTIC NEOPLASMS; IMMUNOPEROXIDASE; LESIONS	Objective. Diagnosing melanocytic lesions is among the most challenging problems in the practice of pathology. The difficulty of physically masking melanin pigment and the similarity of its color to commonly used chromogens often complicate examination of the cytomorphology and immunohistochemical staining results for tumor cells. Melanin bleach can be very helpful for histopathological diagnosis of heavily pigmented melanocytic lesions. Although various depigmentation methods have been reported, no standardized methods have been developed. This study developed a fully automated platform that incorporates hydrogen peroxide-based melanin depigmentation in an automated immunohistochemical analysis. Methods and Materials. The utility of the method was tested in 1 cell block of malignant melanoma cells in pleural effusion, 10 ocular melanoma tissue samples, and 10 cutaneous melanoma tissue samples. Our results demonstrated that the proposed method, which can be performed in only 3 hours, effectively preserves cell cytomorphology and immunoreactivity. Results. The method is particularly effective for removing melanin pigment to facilitate histopathological examination of cytomorphology and for obtaining an unmasked tissue section for immunohistochemical analysis.	[Liu, Chia-Hsing; Lin, Chih-Hung; Yang, Sheau-Fang] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan; [Tsai, Min-Jan; Tsai, Kun-Bow] Kaohsiung Municipal Hsiaokang Hosp, Kaohsiung, Taiwan; [Chen, Yu-Hsuan] Taipei Cheng Hsin Gen Hosp, Taipei, Taiwan; [Yang, Sheau-Fang; Tsai, Kun-Bow] Kaohsiung Med Univ, Kaohsiung, Taiwan	Tsai, KB (reprint author), Kaohsiung Municipal Hsiaokang Hosp, Dept Pathol, 482 Shanming Rd, Kaohsiung 812, Taiwan.	kbtsai@kmu.edu.tw					Alexander RA, 1996, BRIT J BIOMED SCI, V53, P170; ALEXANDER RA, 1986, MED LAB SCI, V43, P121; FOSS AJE, 1995, BRIT J BIOMED SCI, V52, P22; Kivela T, 1995, BRIT J BIOMED SCI, V52, P325; Kligora CJ, 1999, MODERN PATHOL, V12, P1143; KORYTOWSKI W, 1990, J BIOL CHEM, V265, P12410; Li LXL, 1999, HISTOCHEM J, V31, P237; Liu CH, 2013, APPL IMMUNOHISTO M M, V21, P275, DOI 10.1097/PAI.0b013e31826d81db; Manicam C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102512; MCGOVERN J, 1987, AM J CLIN PATHOL, V88, P480, DOI 10.1093/ajcp/88.4.480; Momose M, 2011, PATHOL INT, V61, P345, DOI 10.1111/j.1440-1827.2011.02667.x; Orchard GE, 2007, BRIT J BIOMED SCI, V64, P89; Orchard GE, 1999, BRIT J BIOMED SCI, V56, P188; Orchard GE, 1998, AM J DERMATOPATH, V20, P357, DOI 10.1097/00000372-199808000-00006; Seagle BLL, 2005, P NATL ACAD SCI USA, V102, P8978, DOI 10.1073/pnas.0501971102; Strauss A., 1932, Z WISS MIKROSK, V49, P123	16	3	3	6	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					410	416		10.1177/1066896918756998			7	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500003	29466906				2019-10-28	
J	Yan, L; Sethi, S; Bitterman, P; Reddy, V; Gattuso, P				Yan, Lei; Sethi, Shenon; Bitterman, Pincas; Reddy, Vijaya; Gattuso, Paolo			Umbilical Lesions: Clinicopathologic Features of 99 Tumors	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						umbilical mass; umbilicus; umbilical metastasis; Sister Mary Joseph's nodule; umbilical nodule	MARY-JOSEPHS-NODULE; CERVICAL-CANCER; SISTER; METASTASIS; CARCINOMA	Background. Umbilical lesions are rare, and can be benign or malignant. This retrospective study was conducted to assess the epidemiological, clinical, and histologic characteristics of umbilical masses. Methods. Cases of umbilical masses from January 1994 to August 2016 were retrieved from our institution's pathology databases, and their clinicopathological features were reviewed. Results. There were a total of 99 cases of umbilical masses, 78 women (78.8%) and 21 men (21.2%). Of these, 59 were malignant (59.6%) and 40 were benign (40.4%). Among the malignant cases, 48 were women with a mean age of 65 years and 11 were men with a mean age of 66 years. All malignant lesions were secondary tumors. Twenty-five patients (42.3%) had a metastatic tumor to the umbilicus with an average of 7 months from the original diagnosis (12 gynecological, 8 pancreatic/gastrointestinal, 2 lymphomas, and a case each of breast, prostate, and melanoma). Of the patients with a benign diagnosis, 30 were women (75%) with a mean age of 52 years and 10 were men (25%) with a mean age of 43 years. The benign lesions included epidermal inclusion cysts (15/40), endometriosis (11/40), lipomas (3/40), neurofibromas (3/40), fibromas (3/40), abscesses (2/40), and 1 case each of tubular apocrine adenoma, serous cystadenoma, and calcified nodule. Conclusion. The most common metastatic tumors to the umbilicus are from the adjacent organs with the gynecologic tract as the most frequent primary followed by the gastrointestinal system. Primary malignant tumors of the umbilical region are rarely identified in clinical practice.	[Yan, Lei; Sethi, Shenon; Bitterman, Pincas; Reddy, Vijaya; Gattuso, Paolo] Rush Univ, Med Ctr, Chicago, IL 60612 USA	Yan, L (reprint author), Rush Univ, Med Ctr, Dept Pathol, Jelke 579,600 S Paulina St, Chicago, IL 60612 USA.	lei_yan@rush.edu					Agur AMR, 1999, GRANTS ATLAS ANATOMY, P106; Ching ASC, 2002, ABDOM IMAGING, V27, P746, DOI 10.1007/s00261-002-0018-2; Dubreuil A, 1998, INT J DERMATOL, V37, P7, DOI 10.1046/j.1365-4362.1998.00326.x; Gabriele R., 2005, WORLD J SURG ONCOL, V3, P13, DOI DOI 10.1186/1477-7819-3-13; Iavazzo C, 2012, Case Rep Obstet Gynecol, V2012, P467240, DOI 10.1155/2012/467240; IMACHI M, 1993, GYNECOL ONCOL, V48, P349, DOI 10.1006/gyno.1993.1061; Khan AJ, 1997, CUTIS, V60, P297; Levine D, 2010, OBSTET GYNECOL SURV, V65, P455, DOI 10.1097/OGX.0b013e3181efb12a; Meine JG, 2003, DERMATOL SURG, V29, P404, DOI 10.1097/00042728-200304000-00016; Nolan Christy, 2012, Gynecol Oncol Case Rep, V2, P110, DOI 10.1016/j.gynor.2012.06.003; Palaniappan M, 2010, CURR ONCOL, V17, P78; Papalas JA, 2011, ANN DIAGN PATHOL, V15, P237, DOI 10.1016/j.anndiagpath.2010.12.004; Pertzborn S, 2000, GYNECOL ONCOL, V76, P416, DOI 10.1006/gyno.1999.5704; POWELL FC, 1984, J AM ACAD DERMATOL, V10, P610, DOI 10.1016/S0190-9622(84)80265-0; Sadler TW, 2000, LANGMANS MED EMBRYOL, P243; Sankaranarayanan R, 2015, INT J GYNECOL OBSTET, V131, pS33, DOI 10.1016/j.ijgo.2015.02.014; SCHNEIDER V, 1990, ACTA CYTOL, V34, P555; SCHWARTZ IS, 1987, NEW ENGL J MED, V316, P1348; SHETTY MR, 1990, J SURG ONCOL, V45, P212, DOI 10.1002/jso.2930450316; Steensma DP, 2000, ANN INTERN MED, V133, P237, DOI 10.7326/0003-4819-133-3-200008010-00022; Trebing D, 2004, HAUTARZT, V55, P186, DOI 10.1007/s00105-003-0675-2; Tso S, 2013, BRIT J GEN PRACT, V63, P551, DOI 10.3399/bjgp13X673900; Yendluri V, 2007, PANCREAS, V34, P161, DOI 10.1097/01.mpa.0000240602.18688.43; Yu JS, 2001, RADIOGRAPHICS, V21, P451, DOI 10.1148/radiographics.21.2.g01mr02451	24	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					417	422		10.1177/1066896918758916			6	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500004	29484912				2019-10-28	
J	Creytens, D; Ferdinande, L; Van Dorpe, J				Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo			Multifocal Cytokeratin Expression in a Dedifferentiated Solitary Fibrous Tumor With Heterologous Rhabdomyosarcomatous Differentiation: A Challenging Diagnosis!	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						solitary fibrous tumor; dedifferentiation; dedifferentiated solitary fibrous tumor; STAT6; GRIA2; cytokeratin; rhabdomyosarcomatous	NUCLEAR EXPRESSION; RISK-ASSESSMENT; STAT6; PITFALL; MODEL	We report the case of a dedifferentiated solitary fibrous tumor with heterologous rhabdomyosarcomatous differentiation in a 74-year-old male presenting with a rapidly growing, large soft tissue tumoral mass in the gluteal muscles of the right hip. Dedifferentiation in solitary fibrous tumor had not been recognized until very recently and is an extremely rare phenomenon in this tumor type. In the present case, the diagnosis of dedifferentiated solitary fibrous tumor was difficult because of the absence of areas of conventional solitary fibrous tumor with a predominantly poorly differentiated, anaplastic tumor component in the incision biopsy composed of heterogeneous areas with small blue round cell (Ewing sarcoma-like), rhabdoid, epithelioid, and pleomorphic morphology. Moreover, the unforeseen strong patchy to multifocal positivity for cytokeratin AE1/AE3 and desmin made the diagnosis of a dedifferentiated solitary fibrous tumor even more challenging in this case. The morphology (presence of branching thin-walled, hemangiopericytoma-like blood vessels) and the immunohistochemical profile (including STAT6 and GRIA2 positivity) were very useful to differentiate this very challenging case of a cytokeratin-positive dedifferentiated solitary fibrous tumor with heterologous rhabdomyosarcomatous differentiation from a broad list of differential diagnoses.	[Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Ghent Univ Hosp, Ghent, Belgium; [Creytens, David; Ferdinande, Liesbeth; Van Dorpe, Jo] Univ Ghent, Ghent, Belgium	Creytens, D (reprint author), Ghent Univ Hosp, Dept Pathol, De Pintelaan 185, B-9000 Ghent, Belgium.	david.creytens@uzgent.be					Collini P, 2012, AM J SURG PATHOL, V36, P1202, DOI 10.1097/PAS.0b013e31825748f0; Creytens D, 2015, APPL IMMUNOHISTO M M, V23, P462, DOI 10.1097/PAI.0000000000000081; Dagrada GP, 2015, MODERN PATHOL, V28, P1074, DOI 10.1038/modpathol.2015.70; Demicco EG, 2017, MODERN PATHOL, V30, P1433, DOI 10.1038/modpathol.2017.54; Demicco EG, 2012, MODERN PATHOL, V25, P1298, DOI 10.1038/modpathol.2012.83; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Lecoutere E, 2015, VIRCHOWS ARCH, V467, P119, DOI 10.1007/s00428-015-1768-x; Mosquera JM, 2009, AM J SURG PATHOL, V33, P1314, DOI 10.1097/PAS.0b013e3181a6cd33; Schneider N, 2017, INT J SURG PATHOL, V25, P58, DOI 10.1177/1066896916650257; Thway K, 2016, INT J SURG PATHOL, V24, P281, DOI 10.1177/1066896915627485; Thway K, 2013, ANN DIAGN PATHOL, V17, P457, DOI 10.1016/j.anndiagpath.2012.08.006; Vivero M, 2014, HISTOPATHOLOGY, V65, P71, DOI 10.1111/his.12377	14	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					423	427		10.1177/1066896918758452			5	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500005	29482421				2019-10-28	
J	Linnik, Y; Nicka, C; Lansigan, F; Loo, E; Liu, XY				Linnik, Yevgeniy; Nicka, Catherine; Lansigan, Frederick; Loo, Eric; Liu, Xiaoying			Intravascular Large B-Cell Lymphoma Within a Thyroid Nodule: A Diagnostic Pitfall	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						intravascular large B-cell lymphoma; IVLBCL; thyroid lymphoma; diagnostic pitfall	RITUXIMAB; DISEASE; VARIANT	Intravascular large B-cell lymphoma (IVLBCL) is a subtype of diffuse large B-cell lymphoma, where the neoplastic lymphoid proliferation resides predominantly within the lumens of blood vessels but with no or few circulating neoplastic cells in the peripheral circulation. Focal or subtle involvement in some cases can cause the diagnosis to be misinterpreted or even overlooked, delaying the initiation of appropriate treatment. Our report focuses on a 78-year-old woman with a progressively enlarging thyroid mass, verified by ultrasound. She underwent a hemithyroidectomy, and microscopic evaluation demonstrated nodular thyroid parenchyma with atypical large cells in an intravascular distribution pattern identified on high magnification. Thorough evaluation showed that the large intravascular cells were positive CD20, PAX-5, and Ki-67 by immunoperoxidase staining, which lead to the diagnosis of IVLBCL. This case emphasizes the subtle appearance of IVLBCL, which may be missed on low-power light microscopy, and the need for careful evaluation of thyroid resection specimens.	[Linnik, Yevgeniy; Nicka, Catherine; Loo, Eric; Liu, Xiaoying] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; [Lansigan, Frederick] Norris Cotton Canc Ctr, Lebanon, NH USA	Linnik, Y (reprint author), Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, One One Med Ctr Dr, Lebanon, NH 03756 USA.	yevgeniy.a.linnik@hitchcock.org		Linnik, Yevgeniy/0000-0003-2413-433X			Alzouebi M, 2012, INT J ONCOL, V40, P2075, DOI 10.3892/ijo.2012.1387; Bell D, 2017, HEART LUNG CIRC, V26, pE4, DOI 10.1016/j.hlc.2016.07.010; Chai YJ, 2015, ANN SURG TREAT RES, V89, P295, DOI 10.4174/astr.2015.89.6.295; Cui J, 2014, J CLIN PATHOL, V67, DOI 10.1136/jclinpath-2013-201980; Graff-Baker A, 2009, SURGERY, V146, P1105, DOI 10.1016/j.surg.2009.09.020; Katalinic D, 2006, COLLEGIUM ANTROPOL, V30, P239; Kato M, 2009, J AM ACAD DERMATOL, V61, P888, DOI 10.1016/j.jaad.2009.02.007; Klyachkin ML, 1998, AM SURGEON, V64, P234; Luo B, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0656-x; MEDEIROS LJ, 1989, CANCER, V63, P255, DOI 10.1002/1097-0142(19890115)63:2<255::AID-CNCR2820630209>3.0.CO;2-V; Monteiro M, 2005, BREAST, V14, P75, DOI 10.1016/j.breast.2004.04.010; Murase T, 1997, BRIT J HAEMATOL, V99, P656, DOI 10.1046/j.1365-2141.1997.4623265.x; Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253; Onal C, 2011, ANN ONCOL, V22, P156, DOI 10.1093/annonc/mdq310; PFLEGER L, 1959, Hautarzt, V10, P359; Ponzoni M, 2000, HUM PATHOL, V31, P220, DOI 10.1016/S0046-8177(00)80223-3; SANGUEZA O, 1992, J CUTAN PATHOL, V19, P226, DOI 10.1111/j.1600-0560.1992.tb01664.x; Shimada K, 2008, J CLIN ONCOL, V26, P3189, DOI 10.1200/JCO.2007.15.4278; Shimazaki C, 1999, BRIT J HAEMATOL, V104, P672, DOI 10.1111/j.1365-2141.1999.01239.x; Shimizu I, 2007, INTERNAL MED, V46, P1381, DOI 10.2169/internalmedicine.46.0066; Stein SA, 2013, J CLIN ENDOCR METAB, V98, P3131, DOI 10.1210/jc.2013-1428; Stonecypher M, 2014, ENDOCR PATHOL, V25, P359, DOI 10.1007/s12022-013-9266-7; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; TATEYAMA H, 1991, CANCER, V67, P2131, DOI 10.1002/1097-0142(19910415)67:8<2131::AID-CNCR2820670821>3.0.CO;2-I; Thieblemont C, 2002, J CLIN ENDOCR METAB, V87, P105, DOI 10.1210/jc.87.1.105; Watanabe N, 2011, BRIT J HAEMATOL, V153, P236, DOI 10.1111/j.1365-2141.2011.08606.x; Yao X, 2010, LEUKEMIA RES, V34, pE275, DOI 10.1016/j.leukres.2010.05.016	27	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					428	431		10.1177/1066896918763282			4	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500006	29569516				2019-10-28	
J	Singh, K; Falkenberry, S; Eklund, B; Quddus, MR				Singh, Kamaljeet; Falkenberry, Stephen; Eklund, Brendan; Quddus, M. Ruhul			Cystic Hypersecretory Hyperplasia of Breast	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							PREGNANCY-LIKE; CARCINOMA; LESIONS		[Singh, Kamaljeet; Falkenberry, Stephen; Quddus, M. Ruhul] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Singh, Kamaljeet; Falkenberry, Stephen; Eklund, Brendan; Quddus, M. Ruhul] Women & Infants Hosp Rhode Isl, 101 Dudley St, Providence, RI 02908 USA	Singh, K (reprint author), Women & Infants Hosp Rhode Isl, 101 Dudley St, Providence, RI 02908 USA.	ksingh@wihri.org					GUERRY P, 1988, CANCER-AM CANCER SOC, V61, P1611, DOI 10.1002/1097-0142(19880415)61:8<1611::AID-CNCR2820610819>3.0.CO;2-O; Shin SJ, 2000, AM J SURG PATHOL, V24, P1670, DOI 10.1097/00000478-200012000-00012; Shin SJ, 2004, AM J SURG PATHOL, V28, P789, DOI 10.1097/01.pas.0000126060.20455.27	3	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					432	433		10.1177/1066896917741979			2	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500007	29198159				2019-10-28	
J	Abdelkader, A; Jorns, JM				Abdelkader, Amrou; Jorns, Julie M.			Pleomorphic Lobular Carcinoma: A Controversially Aggressive Variant of Invasive Lobular Carcinoma of the Breast	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Abdelkader, Amrou; Jorns, Julie M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA	Jorns, JM (reprint author), Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA.	jjorns@mcw.edu					Middleton LP, 2000, AM J SURG PATHOL, V24, P1650, DOI 10.1097/00000478-200012000-00009; Narendra S, 2015, ANN DIAGN PATHOL, V19, P64, DOI 10.1016/j.anndiagpath.2015.01.005; Rakha EA, 2013, MODERN PATHOL, V26, P496, DOI 10.1038/modpathol.2012.197; Simpson PT, 2008, J PATHOL, V215, P231, DOI 10.1002/path.2358; WEIDNER N, 1992, HUM PATHOL, V23, P1167, DOI 10.1016/0046-8177(92)90035-2	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					434	436		10.1177/1066896917744878			3	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500008	29198145				2019-10-28	
J	Zanelli, M; Mengoli, MC; Fanni, D; Froio, E; De Marco, L; Ascani, S				Zanelli, Magda; Mengoli, Maria Cecilia; Fanni, Daniela; Froio, Elisabetta; De Marco, Loredana; Ascani, Stefano			Multiple Myeloma With Multilobated Plasma Cells: An Unusual and Challenging Morphological Variant	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Zanelli, Magda; Mengoli, Maria Cecilia; Froio, Elisabetta; De Marco, Loredana] Azienda Unita Sanitaria Locale IRCCS, Reggio Emila, Italy; [Fanni, Daniela] Univ Cagliari, Osped S Giovanni Dio, Cagliari, Italy; [Ascani, Stefano] Univ Perugia, Osped Terni, Perugia, Italy	Mengoli, MC (reprint author), Azienda Unita Sanitaria Locale IRCCS, Pathol Unit, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy.	cecilia.mengoli@gmail.com		Mengoli, Maria Cecilia/0000-0002-1437-8747; zanelli, Magda/0000-0002-8733-9933				0	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					439	439		10.1177/1066896917750471			1	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500010	29279032				2019-10-28	
J	Stevens, TM; Qarmali, M; Morlote, D; Mikhail, FM; Swensen, J; Gatalica, Z; Siegal, GP; Conry, RM				Stevens, Todd M.; Qarmali, Morad; Morlote, Diana; Mikhail, Fady M.; Swensen, Jeffrey; Gatalica, Zoran; Siegal, Gene P.; Conry, Robert M.			Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						myoepithelial carcinoma; EWSR1-KLF15; Ewing-like sarcoma	SOFT-TISSUE; CYTOKERATIN IMMUNOREACTIVITY; FAMILY TUMORS; DIAGNOSIS; CANCER; KLF15; GENE	We present a case of a malignant Ewing-like neoplasm of the parotid gland in a 20-year-old woman with an EWSR1-KLF15 gene fusion that presented with pulmonary metastasis. Despite the fact that the tumor was essentially immunohistochemically negative for keratins, p63, and p40, we interpret this neoplasm as an unusual form of a high-grade myoepithelial carcinoma based on its focal plasmacytoid cytology, chondromyxoid matrix, SOX10, S100 protein, and calponin expression, and the knowledge that the EWSR1-KLF15 gene fusion has, to date, only been identified in 2 tumors, both myoepithelial carcinomas of the kidney. We also present a cytogenetic analysis of this unusual tumor. This Ewing-like myoepithelial carcinoma initially did not respond to 2 cycles of ifosfamide and etoposide alternated with a cycle of cytoxan, adriamycin, and vincristine, a standard regimen for Ewing sarcoma. Subsequent oral pazopanib therapy did result in a reduction of the patient's pulmonary and nodal disease.	[Stevens, Todd M.; Qarmali, Morad; Morlote, Diana; Mikhail, Fady M.; Siegal, Gene P.; Conry, Robert M.] Univ Alabama Birmingham, Birmingham, AL USA; [Swensen, Jeffrey; Gatalica, Zoran] Caris Life Sci, Phoenix, AZ USA	Stevens, TM (reprint author), Univ Alabama Birmingham, Dept Pathol, 3548 North Pavil,1802 6th Ave South, Birmingham, AL 35249 USA.	tstevens@uabmc.edu		Morlote, Diana/0000-0001-9226-8001			Antonescu C, 2014, HISTOPATHOLOGY, V64, P26, DOI 10.1111/his.12281; Antonescu CR, 2010, GENE CHROMOSOME CANC, V49, P1114, DOI 10.1002/gcc.20819; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Brandal P, 2009, GENE CHROMOSOME CANC, V48, P1051, DOI 10.1002/gcc.20706; Cajaiba MM, 2016, AM J SURG PATHOL, V40, P386, DOI 10.1097/PAS.0000000000000545; Collini P, 2001, AM J SURG PATHOL, V25, P273, DOI 10.1097/00000478-200102000-00022; Fletcher C, 2013, WHO CLASSIFICATION T; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Gu M, 2000, AM J SURG PATHOL, V24, P410, DOI 10.1097/00000478-200003000-00010; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Lezcano C, 2015, HEAD NECK PATHOL, V9, P280, DOI 10.1007/s12105-014-0558-0; Machado I, 2011, VIRCHOWS ARCH, V459, P409, DOI 10.1007/s00428-011-1138-2; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Stewenius Y, 2008, GENE CHROMOSOME CANC, V47, P845, DOI 10.1002/gcc.20587; Sun CQ, 2017, DIGEST DIS SCI, V62, P1518, DOI 10.1007/s10620-017-4558-2; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Yoda T, 2015, CELL ONCOL, V38, P227, DOI 10.1007/s13402-015-0226-8	17	0	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					440	447		10.1177/1066896918755009			8	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500011	29390927				2019-10-28	
J	Maryamchik, E; Lyapichev, KA; Halliday, B; Rosenberg, AE				Maryamchik, Elena; Lyapichev, Kirill A.; Halliday, Bradford; Rosenberg, Andrew E.			Dedifferentiated Liposarcoma With Rhabdomyosarcomatous Differentiation Producing HCG: A Case Report of a Diagnostic Pitfall	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						paratesticular liposarcoma; dedifferentiated liposarcoma; HCG production by rhabdomyosarcoma; rhabdomyosarcomatous differentiation of liposarcoma; paraneoplastic HCG production	HUMAN CHORIONIC-GONADOTROPIN; ECTOPIC PRODUCTION; BETA-HCG; TROPHOBLASTIC HORMONES; SPERMATIC CORD; LEIOMYOSARCOMA; OSTEOSARCOMA; EXPRESSION; SARCOMA; CARCINOMA	We report a first case of paraneoplastic human chorionic gonadotropin (HCG) production in a dedifferentiated liposarcoma with rhabdosarcomatous differentiation in an 83-year-old man with a retroperitoneal mass, unilateral scrotal enlargement, and a serum HCG level of 843 IU/L. Core biopsy of the retroperitoneal mass revealed rhabdomyosarcoma. Orchiectomy revealed a paratesticular dedifferentiated liposarcoma with rhabdosarcomatous differentiation. Fluorescence in situ hybridization analysis performed on both the retroperitoneal and paratesticular masses revealed amplification of MDM2. The retroperitoneal tumor was interpreted as metastatic dedifferentiated liposarcoma with the dedifferentiated component represented by rhabdomyosarcoma. HCG production is a common feature of testicular germ cell tumors, less common in carcinomas, and extremely rare in sarcomas. Accordingly, sarcomas secreting HCG are a potential diagnostic pitfall, and raise the differential diagnosis of germ cell tumors and a variety of carcinomas. HCG production by carcinomas is a known poor prognostic finding, however the significance of its production in sarcomas is unknown.	[Maryamchik, Elena] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Maryamchik, Elena] Harvard Med Sch, Boston, MA USA; [Lyapichev, Kirill A.; Rosenberg, Andrew E.] Univ Miami, Jackson Mem Hosp, Miller Sch Med, Miami, FL 33136 USA; [Halliday, Bradford] Scottsdale Pathol Consultants, Scottsdale, AZ USA	Rosenberg, AE (reprint author), Univ Miami, Dept Pathol, Holtz Ctr, 1611 NW 12th Ave, Miami, FL 33136 USA.	arosenberg@med.miami.edu		Lyapichev, Kirill/0000-0001-9983-9735			Acevedo HF, 1996, CANCER, V78, P2388, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2388::AID-CNCR18>3.0.CO;2-X; Bidart JM, 1997, ANN ENDOCRINOL-PARIS, V58, P125; BIRKENFELD S, 1989, EUR J SURG ONCOL, V15, P103; Cole LA, 2012, AM J CANCER RES, V2, P22; Cui S, 1999, PATHOL INT, V49, P62, DOI 10.1046/j.1440-1827.1999.00825.x; Dirnhofer S, 1998, HUM PATHOL, V29, P377, DOI 10.1016/S0046-8177(98)90119-8; Dirnhofer S, 2000, HUM PATHOL, V31, P966, DOI 10.1053/hupa.2000.9831; Froehner M, 2000, Sarcoma, V4, P179, DOI 10.1080/13577140020025904; GAILANI S, 1976, CANCER-AM CANCER SOC, V38, P1684, DOI 10.1002/1097-0142(197610)38:4<1684::AID-CNCR2820380440>3.0.CO;2-T; HAINSWORTH JD, 1985, CANCER, V56, P1337, DOI 10.1002/1097-0142(19850915)56:6<1337::AID-CNCR2820560620>3.0.CO;2-P; Inoue N, 2011, PEDIATR BLOOD CANCER, V57, P1244, DOI 10.1002/pbc.23271; Izumo A, 2003, ONCOL REP, V10, P515; KALRA JK, 1984, CANCER, V53, P2125, DOI 10.1002/1097-0142(19840515)53:10<2125::AID-CNCR2820531022>3.0.CO;2-U; Lee AF, 2014, PEDIATR DEVEL PATHOL, V17, P278, DOI 10.2350/14-02-1436-OA.1; Leidinger B, 2004, J CANCER RES CLIN, V130, P357, DOI 10.1007/s00432-004-0541-3; Liang S, 2006, INT J GYNECOL PATHOL, V25, P257, DOI 10.1097/01.pgp.0000192270.22289.af; MACK GR, 1977, J BONE JOINT SURG AM, V59, P1107, DOI 10.2106/00004623-197759080-00021; Mansi IA, 2002, AM J MED SCI, V324, P104, DOI 10.1097/00000441-200208000-00010; Masrouha KZ, 2012, J BONE JOINT SURG BR, V94B, P419, DOI 10.1302/0301-620X.94B3.27679; MEREDITH RF, 1986, CANCER, V58, P131, DOI 10.1002/1097-0142(19860701)58:1<131::AID-CNCR2820580123>3.0.CO;2-9; Oda Y, 2017, PATHOL INT, V67, P435, DOI 10.1111/pin.12565; ORDONEZ NG, 1989, ARCH PATHOL LAB MED, V113, P416; Oshrine BR, 2014, J PEDIAT HEMATOL ONC, V36, pE202, DOI 10.1097/MPH.0000000000000037; Ou SM, 2006, J ANDROL, V27, P643, DOI 10.2164/jandrol.106.000224; Russell Michael J., 2008, Sarcoma, P1, DOI 10.1155/2008/658090; Seidl C, 1998, PATHOLOGE, V19, P146, DOI 10.1007/s002920050267; Stevens EE, 2013, OBSTET GYNECOL, V121, P468, DOI [10.1097/AOG.0b013e31826d3121, http://10.1097/AOG.0b013e31826d3121]; Ulbright TM, 2005, MODERN PATHOL, V18, pS61, DOI 10.1038/modpathol.3800310; Wong YP, 2015, MALAYS J MED SCI, V22, P76; YAMAGUCHI A, 1989, BRIT J CANCER, V60, P382, DOI 10.1038/bjc.1989.289; YOSHIMURA M, 1994, CANCER, V73, P2745, DOI 10.1002/1097-0142(19940601)73:11<2745::AID-CNCR2820731116>3.0.CO;2-V; Yu HL, 2017, ONCOTARGETS THER, V10, P3017, DOI 10.2147/OTT.S132071	32	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					448	452		10.1177/1066896918760192			5	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500012	29532681				2019-10-28	
J	Drobysheva, A; Fuller, J; Pfeifer, CM; Rakheja, D				Drobysheva, Anastasia; Fuller, Julie; Pfeifer, Cory M.; Rakheja, Dinesh			Orbital Granulomatosis With Polyangiitis Mimicking IgG4-Related Disease in a 12-Year-Old Male	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						orbital granulomatosis with polyangiitis; IgG4-related disease; orbital mass; Wegener's granulomatosis; ANCA-associated vasculitis; orbital inflammation; orbital pseudotumor	WEGENERS-GRANULOMATOSIS; INITIAL MANIFESTATION; VASCULITIDES; CHILDREN; DIAGNOSIS; FEATURES; TUMORS	Granulomatosis with polyangiitis is rare in children. We report a case of a 12-year-old male who presented with new symptoms of left eyelid swelling and ptosis. Magnetic resonance imaging showed an enhancing orbital mass suspicious for a neoplasm. Excisional biopsy was performed. Microscopic examination revealed fibrovascular tissue with dense collagenous fibrosis and mixed inflammatory infiltrate that included many plasma cells. Many small and medium-sized blood vessels showed granulomatous and necrotizing vasculitis with disruption of the vessel walls and fibrinoid necrosis. Immunostain for IgG highlighted the numerous plasma cells, approximately 50% of which were positive for IgG4 immunostain. A diagnosis of granulomatosis with polyangiitis was suggested, with recommendation of serologic testing for anti-neutrophil cytoplasmic antibodies. Serum anti-neutrophil cytoplasmic antibodies were borderline high with a cytoplasmic staining pattern. The patient improved with steroid and methotrexate therapy. Granulomatosis with polyangiitis can present as an orbital mass in up to 30% of children. It may be misdiagnosed as IgG4-related disease since the inflammatory background in both conditions may be rich in plasma cells with a high proportion of IgG4+ plasma cells, and accompanied by fibrosis and obliterated blood vessels. The differential diagnosis in this location should also include inflammatory pseudotumor and inflammatory myofibroblastic tumor. Knowledge of this unusual manifestation of granulomatosis with polyangiitis and its diagnostic pitfalls can facilitate early diagnosis and treatment.	[Drobysheva, Anastasia; Fuller, Julie; Pfeifer, Cory M.; Rakheja, Dinesh] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Drobysheva, Anastasia; Fuller, Julie; Pfeifer, Cory M.; Rakheja, Dinesh] Childrens Hlth, Dallas, TX USA	Rakheja, D (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dinesh.rakheja@utsouthwestern.edu		Rakheja, Dinesh/0000-0001-6888-7902			Ahmed Muna, 2008, International Ophthalmology, V28, P35, DOI 10.1007/s10792-007-9109-y; Bohm M, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-18; Cabral DA, 2016, ARTHRITIS RHEUMATOL, V68, P2514, DOI 10.1002/art.39729; Castillo BV, 2003, PEDIATR CLIN N AM, V50, P149, DOI 10.1016/S0031-3955(02)00115-3; Chang SY, 2012, INT J RHEUMATOL, DOI 10.1155/2012/121702; Chipczynska B, 2009, MED SCI MONITOR, V15, pCS135; Cotch MF, 1996, ARTHRITIS RHEUM, V39, P87, DOI 10.1002/art.1780390112; Dey M, 2011, J ROY SOC MED, V104, P332, DOI 10.1258/jrsm.2011.110050; Fechner FP, 2002, LARYNGOSCOPE, V112, P1945, DOI 10.1097/00005537-200211000-00007; Filocamo G, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0150-8; FRIEDMANN I, 1982, J LARYNGOL OTOL, V96, P1; Gajic-Veljic M, 2013, PEDIATR DERMATOL, V30, pE37, DOI 10.1111/pde.12034; Holle JU, 2013, RHEUMATOLOGY, V52, P875, DOI 10.1093/rheumatology/kes382; James KE, 2017, CLIN EXP RHEUMATOL, V35, pS202; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; KALINA PH, 1992, OPHTHALMOLOGY, V99, P120; Kosalka Joanna, 2014, Folia Med Cracov, V54, P5; McBride P, 1991, J Laryngol Otol, V105, P1120, DOI 10.1017/S0022215100118407; Muller K, 2014, ARCH PATHOL LAB MED, V138, P1110, DOI 10.5858/arpa.2013-0006-RS; Ozen S, 2010, ANN RHEUM DIS, V69, P798, DOI 10.1136/ard.2009.116657; Pakalniskis MG, 2015, AM J ROENTGENOL, V205, pW619, DOI 10.2214/AJR.14.13864; Parelhoff E S, 1985, J Pediatr Ophthalmol Strabismus, V22, P100; Perry SR, 1997, OPHTHALMOLOGY, V104, P683, DOI 10.1016/S0161-6420(97)30251-6; Rothschild PR, 2013, SEMIN ARTHRITIS RHEU, V42, P507, DOI 10.1016/j.semarthrit.2012.08.003; Sacri AS, 2015, NEPHROL DIAL TRANSPL, V30, pi104, DOI 10.1093/ndt/gfv011; Shields JA, 2004, OPHTHALMOLOGY, V111, P997, DOI 10.1016/j.ophtha.2003.01.002; SPALTON DJ, 1981, BRIT J OPHTHALMOL, V65, P553, DOI 10.1136/bjo.65.8.553; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Twilt M, 2014, CURR OPIN RHEUMATOL, V26, P50, DOI 10.1097/BOR.0000000000000013; Wardyn KA, 2003, CLIN RHEUMATOL, V22, P472, DOI 10.1007/s10067-003-0778-2; Woywodt A, 2006, LANCET, V367, P1362, DOI 10.1016/S0140-6736(06)68583-8; Ziakas NG, 2004, EYE, V18, P658, DOI 10.1038/sj.eye.6700734	32	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					453	458		10.1177/1066896917754252			6	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500013	29366363				2019-10-28	
J	Liao, HH; Khan, A; Miron, PM; Cornejo, KM				Liao, Haihui; Khan, Ashraf; Miron, Patricia M.; Cornejo, Kristine M.			Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						mammary analogue secretory carcinoma; thyroid; ETV6; immunohistochemistry; fluorescent in situ hybridization	SALIVARY-GLANDS; MASC; IDENTIFICATION; FUSION; BREAST	Mammary analogue secretory carcinoma (MASC) harboring ETV6 gene rearrangements was first described in the salivary gland with a relatively favorable prognosis and a possible molecular therapeutic target with pan-Trk inhibitors. Recently, primary MASC of the thyroid gland has been reported. We report a case of a 4.0 cm MASC arising from the left thyroid of a 58-year-old female with extrathyroidal extension. Initially, it was diagnosed by fine needle aspiration as suspicious for papillary thyroid carcinoma (PTC) and subsequently called a poorly differentiated carcinoma on resection. A final diagnosis of primary MASC of the thyroid was confirmed after an expanded immunohistochemical panel and identification of an ETV6 gene rearrangement by fluorescence in situ hybridization. Morphologically, the tumor was composed of solid, microcystic and focally papillary growth with dense fibrotic stroma and necrosis. Overlapping cytological features with PTC were identified, including foci of enlarged cells with irregular nuclear membranes/grooves. However, most of the cells contained prominent nucleoli with intraluminal and intracytoplasmic eosinophilic secretions. Immunohistochemically, the tumor cells were strongly positive for pancytokeratin, cytokeratin 7, PAX8, mammaglobin, and GCDFP-15, with rare staining for GATA3 and S100 and negative for TTF-1 and thyroglobulin. We report a rare case of a primary thyroid MASC, initially misdiagnosed as PTC. Pathologists should be aware of this entity and, given the similarities to PTC, have a high index of suspicion, prompting the addition of immunohistochemical and molecular studies. Furthermore, an accurate diagnosis is important because of the possible prognostic and treatment implications.	[Liao, Haihui; Khan, Ashraf; Miron, Patricia M.; Cornejo, Kristine M.] Univ Massachusetts, Med Sch, UMass Mem Med Ctr, Worcester, MA USA; [Miron, Patricia M.] Quest Diagnost, Marlborough, MA USA	Cornejo, KM (reprint author), UMass Mem Healthcare, Dept Pathol, One Innovat Dr,Biotech 3, Worcester, MA 01605 USA.	kcornejo@partners.org					Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Dettloff J, 2017, HEAD NECK PATHOL, V11, P124, DOI 10.1007/s12105-016-0741-6; Dogan S, 2016, MODERN PATHOL, V29, P985, DOI 10.1038/modpathol.2016.115; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Gonzalez MF, 2018, CYTOPATHOLOGY, V29, P100, DOI 10.1111/cyt.12465; Ito Y, 2015, AM J SURG PATHOL, V39, P602, DOI 10.1097/PAS.0000000000000392; Kai K, 2017, ACTA CYTOL, V61, P469, DOI 10.1159/000477390; Ozguroglu M, 2005, ONCOLOGY-BASEL, V68, P263, DOI 10.1159/000086782; Reynolds S, 2016, HEAD NECK PATHOL, V10, P405, DOI 10.1007/s12105-016-0715-8; Ricarte JC, 2013, J CLIN INVEST, V123, P4935, DOI 10.1172/JCI69766; Rodriguez-Urrego PA, 2017, DIAGN CYTOPATHOL, V45, P552, DOI 10.1002/dc.23692; Rupp AP, 2017, DIAGN CYTOPATHOL, V45, P45, DOI 10.1002/dc.23608; Seethala RR, 2017, AM J SURG PATHOL, V41, P446, DOI 10.1097/PAS.0000000000000814; Skalova A, 2016, AM J SURG PATHOL, V40, P3, DOI 10.1097/PAS.0000000000000537; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Stevens TM, 2016, ARCH PATHOL LAB MED, V140, P997, DOI 10.5858/arpa.2015-0075-RS	16	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					459	463		10.1177/1066896917747076			5	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500014	29228842				2019-10-28	
J	Miyaoka, M; Hatanaka, K; Iwazaki, M; Nakamura, N				Miyaoka, Masashi; Hatanaka, Kazuhito; Iwazaki, Masayuki; Nakamura, Naoya			CK7/CK20 Double-Negative Pulmonary Enteric Adenocarcinoma With Histopathological Evaluation of Transformation Zone Between Enteric Adenocarcinoma and Conventional Pulmonary Adenocarcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						pulmonary enteric adenocarcinoma; transformation zone; immunohistochemistry; CK7; CK20	METASTATIC COLORECTAL-CARCINOMA; DIFFERENTIATION; SATB2	We report a rare case of pulmonary enteric adenocarcinoma (PEA) exhibiting a immunohistochemical feature of CK7/CK20 double-negativity by evaluating the transformation zone between PEA and conventional pulmonary adenocarcinoma (CPA). A 75-year-old man was found to have a mass, 40 mm in diameter, in the right lower lobe on chest computed tomography, and underwent right lower lobectomy. Histologically, the tumor was composed of a PEA and CPA component. The dominant PEA component had medium to large complex glands with tall columnar cells with eosinophilic cytoplasm and brush-border. The CPA component comprised small to medium glands with cuboidal cells. Moreover, intermediate glands (INT), which had cuboidal to tall columnar cells, with morphological features between PEA and CPA, was also observed in the transformation area. Immunohistochemically, the PEA component was negative for CK7, CK20, and TTF-1, and positive for CDX2 and SATB2 (weak): the CPA component was negative for CK20, CDX2, and SATB2, and positive for CK7 and TTF-1: the INT were negative for SATB2, with intermingled positive signals for CK7, CK20, TTF-1, and CDX2. The final diagnosis was PEA based on the CPA component and not colorectal carcinoma. To distinguish CK7-negative PEA from metastatic colorectal carcinoma, careful examination for a CPA component is very useful along with clinical information. There are no reports that discuss about process of oncogenesis, de novo sequence or transformation from CPA of PEA. This is the first reported case of CK7/CK20 double-negative PEA, with analysis of the transformation zone between PEA and CPA components.	[Miyaoka, Masashi; Hatanaka, Kazuhito; Iwazaki, Masayuki; Nakamura, Naoya] Tokai Univ, Sch Med, Isehara, Kanagawa, Japan	Hatanaka, K (reprint author), Tokai Univ, Sch Med, Dept Pathol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	kazhatanaka@tokai.ac.jp					Bian TT, 2017, ONCOTARGET, V8, P63442, DOI 10.18632/oncotarget.18828; Choi HR, 2003, HUM PATHOL, V34, P1101, DOI 10.1053/S0046-8177(03)00516-1; Dragomir A, 2014, AM J CLIN PATHOL, V141, P630, DOI 10.1309/AJCPWW2URZ9JKQJU; Hatanaka K, 2011, PATHOL RES PRACT, V207, P188, DOI 10.1016/j.prp.2010.07.005; Inamura K, 2005, AM J SURG PATHOL, V29, P660, DOI 10.1097/01.pas.0000160438.00652.8b; LASH RH, 1987, AM J SURG PATHOL, V11, P114, DOI 10.1097/00000478-198702000-00005; Laszlo T, 2014, HISTOPATHOLOGY, V65, P283, DOI 10.1111/his.12403; Li HC, 2009, AM J CLIN PATHOL, V131, P129, DOI 10.1309/AJCPB04XWICTFERL; Magnusson K, 2011, AM J SURG PATHOL, V35, P937, DOI 10.1097/PAS.0b013e31821c3dae; Matsushima J, 2017, HUM PATHOL, V64, P179, DOI 10.1016/j.humpath.2017.04.006; Travis WD, 2015, WHO CLASSIFICATION T; TSAO MS, 1991, CANCER-AM CANCER SOC, V68, P1754, DOI 10.1002/1097-0142(19911015)68:8<1754::AID-CNCR2820680818>3.0.CO;2-E; Yousem SA, 2005, MODERN PATHOL, V18, P816, DOI 10.1038/modpathol.3800358	13	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					464	468		10.1177/1066896918756737			5	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500015	29411669				2019-10-28	
J	Herrera-Goepfert, R				Herrera-Goepfert, Roberto			Postradiation Synovial Sarcoma of the Common Bile Duct: A Previously Unreported Anatomic Site	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						synovial sarcoma; radiotherapy; translocation; SS18; SSX; extrahepatic biliary tree	RADIATION-THERAPY; LUNG; CELL; SEMINOMA; PATIENT	Synovial sarcoma is a ubiquitous neoplasm predominantly affecting soft tissues of young adults of any gender; few cases have been described in the digestive system, mostly in the stomach. The (X;18)(p11.2; q11.2) translocation yields unique SS18-SSX fusion genes. Synovial sarcoma has been related to radiotherapy, but no synovial sarcoma has been associated with the digestive system. This article describes the case of a synovial sarcoma arising along the extrahepatic biliary tree, 10 years after the application of an abdominal radiotherapy schedule due to a retroperitoneal metastatic seminoma in a male who developed progressive obstructive jaundice. Ninety percent of the analyzed cells carried the SS18 gene with separation of sequences, thus denoting a translocation. There are only 8 post-radiotherapy synovial sarcomas that have been reported previously, and this is the first report of a radiotherapy-related synovial sarcoma arising from the extrahepatic biliary tree, and the second case described in this anatomic region.	[Herrera-Goepfert, Roberto] Inst Nacl Cancerol, Mexico City, DF, Mexico	Herrera-Goepfert, R (reprint author), Inst Nacl Cancerol, Dept Pathol, Ave San Fernando 22,Col Secc 16, Mexico City 14080, DF, Mexico.	rhgoepfert@gmail.com		Herrera-Goepfert, Roberto/0000-0001-7901-2378			Bachaud JM, 1999, RADIOTHER ONCOL, V50, P191, DOI 10.1016/S0167-8140(98)00101-7; Barcellos-Hoff MH, 2005, SEMIN CANCER BIOL, V15, P138, DOI 10.1016/j.semcancer.2004.08.010; Braunstein S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00073; CAHAN WG, 1948, CANCER, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7; CHAO CKS, 1995, INT J RADIAT ONCOL, V33, P831, DOI 10.1016/0360-3016(95)00200-8; Deraedt K, 2006, HISTOPATHOLOGY, V48, P473, DOI 10.1111/j.1365-2559.2005.02270.x; Egger JF, 2002, MODERN PATHOL, V15, P998, DOI 10.1097/01.MP.0000026616.41545.FF; Falavigna Asdrubal, 2016, Surg Neurol Int, V7, pS108, DOI 10.4103/2152-7806.176131; Hayakawa K, 2013, BIOCHEM BIOPH RES CO, V432, P713, DOI 10.1016/j.bbrc.2013.01.003; HUVOS AG, 1985, CANCER-AM CANCER SOC, V55, P1244, DOI 10.1002/1097-0142(19850315)55:6<1244::AID-CNCR2820550617>3.0.CO;2-1; Kubouchi Y, 2013, ANN THORAC CARDIOVAS, V19, P144, DOI 10.5761/atcs.cr.12.01908; Lenze U, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0027-x; Mavrogenis AF, 2012, EEXOT, V63, P161; MISCHLER NE, 1978, ARCH OTOLARYNGOL, V104, P482; Mullah-Ali A, 2008, J PEDIAT HEMATOL ONC, V30, P553, DOI 10.1097/MPH.0b013e31816e22e3; Nielsen TO, 2015, CANCER DISCOV, V5, P124, DOI 10.1158/2159-8290.CD-14-1246; Qayum A, 2008, J GASTROINTEST SURG, V12, P609, DOI 10.1007/s11605-007-0260-6; Romeo S, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0021-3; Sultan I, 2009, CANCER-AM CANCER SOC, V115, P3537, DOI 10.1002/cncr.24424; Tamaki S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142991; vandeRijn M, 1997, HUM PATHOL, V28, P1325, DOI 10.1016/S0046-8177(97)90213-6; Vora A, 2013, THYROID, V23, P371, DOI 10.1089/thy.2012.0472	22	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					469	474		10.1177/1066896917752863			6	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500016	29336183				2019-10-28	
J	Walls, T; Cavuoti, D; Channabasappa, N; Yang, M; Southern, P; Gill, MA; Park, JY				Walls, Timothy; Cavuoti, Dominick; Channabasappa, Nandini; Yang, Mary; Southern, Paul; Gill, Michelle A.; Park, Jason Y.			Abdominal Angiostrongyliasis: A Presentation of Eosinophilic Granulomatous Colitis	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						Angiostrongylus costaricensis; abdominal angiostrongyliasis; eosinophilic granulomatous colitis; granuloma; egg; inclusion	MIMICKING ACUTE APPENDICITIS; COSTARICENSIS MORERA; UNITED-STATES; 1ST REPORT; ENTEROCOLITIS; INFECTIONS; CESPEDES	We present a case of a 4-year-old girl with abdominal angiostrongyliasis who presented with persistent fevers, hepatosplenomegaly, acute abdominal pain, and eosinophilia. Computed tomography scan identified thickening of the ascending colon with a narrowed lumen. Endoscopic evaluation revealed ulcerations and erythema in the ascending colon. The microscopic findings in biopsies included active chronic inflammation with prominent eosinophils and granulomas. A subset of granulomas contained the eggs of Angiostrongylus costaricensis. The definitive method of diagnosing A costaricensis is histology; peripheral blood serology has low specificity and the stool from infected patients does not contain eggs or larvae. Pathologists from endemic regions (Central and South America) are familiar with the typical histologic changes; however, because of increasing global travel, all pathologists should become familiar with A costaricensis, which may mimic common gastrointestinal diseases such as Crohn's disease, appendicitis, and Meckel's diverticulum.	[Walls, Timothy; Cavuoti, Dominick; Channabasappa, Nandini; Yang, Mary; Southern, Paul; Gill, Michelle A.; Park, Jason Y.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Walls, Timothy; Channabasappa, Nandini; Yang, Mary; Gill, Michelle A.; Park, Jason Y.] Childrens Med Ctr, Childrens Hlth, Dallas, TX 75235 USA	Park, JY (reprint author), Childrens Med Ctr, Dept Pathol & Lab Med, Childrens Hlth, Dallas, TX 75235 USA.	Jason.Park@childrens.com		Park, Jason/0000-0001-6797-4000			Centers for Disease Control and Prevention, DPDX LAB ID PAR DIS; Centre for Disease Control and Prevention, PAR ANG ALS KNOWN AN; Cross JH, 2011, TROPICAL INFECT DIS, P774; HULBERT TV, 1992, CLIN INFECT DIS, V14, P836, DOI 10.1093/clinids/14.4.836; Incani Renzo Nino, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P197, DOI 10.1590/S0036-46652007000300012; Kramer MH, 1998, CLIN INFECT DIS, V26, P365, DOI 10.1086/516325; Kroner PT, 2015, ENDOSCOPY, V47, pE179, DOI 10.1055/s-0034-1391501; LIACOURAS CA, 1993, J PEDIATR GASTR NUTR, V16, P203, DOI 10.1097/00005176-199302000-00020; Miller CL, 2006, J PARASITOL, V92, P406, DOI 10.1645/GE-653R.1; Montgomery EA, 2018, BIOPSY INTERPRETATIO, V1, P242; MORERA P, 1973, AM J TROP MED HYG, V22, P613, DOI 10.4269/ajtmh.1973.22.613; NEAFIE RC, 1993, CLIN MICROBIOL REV, V6, P34; Orihel TC, 1995, PARASITES HUMAN TISS, P132; Palominos PE, 2008, MEM I OSWALDO CRUZ, V103, P93, DOI 10.1590/S0074-02762008005000002; Palominos PE, 2009, INT J RHEUM DIS, V12, P267, DOI 10.1111/j.1756-185X.2009.01421.x; Rebello KM, 2013, ACTA TROP, V127, P191, DOI 10.1016/j.actatropica.2013.05.002; UBELAKER JE, 1979, J PARASITOL, V65, P307, DOI 10.2307/3280170; VAZQUEZ JJ, 1993, GASTROENTEROLOGY, V105, P1544, DOI 10.1016/0016-5085(93)90163-7; Wu SS, 1997, ARCH PATHOL LAB MED, V121, P989	19	1	1	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					475	478		10.1177/1066896917749929			4	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500017	29278974				2019-10-28	
J	Bolzacchini, E; Chini, C; Cortelezzi, CC; Vallini, I; Pinotti, G; La Rosa, S; Uccella, S				Bolzacchini, Elena; Chini, Claudio; Cortelezzi, Claudio Camillo; Vallini, Ilaria; Pinotti, Graziella; La Rosa, Stefano; Uccella, Silvia			Poorly Differentiated Neuroendocrine Carcinoma of the Sigmoid Tract in Long-Standing Ulcerative Colitis: Report of a Case and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						ulcerative colitis; neuroendocrine carcinoma; inflammatory bowel disease; cancer	INFLAMMATORY-BOWEL-DISEASE; SMALL-CELL CARCINOMA; RECTUM; PATIENT; COLON; TUMOR; NEOPLASMS	A 37-year-old male with long-standing and extensive ulcerative pancolitis developed a rapidly lethal poorly differentiated neuroendocrine carcinoma (NEC) in the sigmoid colon. Prior biopsies obtained from multiple sites of the colon during endoscopic surveillance showed minimal inflammatory changes and no sign of dysplasia. Patients with inflammatory bowel disease (IBD) are at increased risk of colorectal malignancies, and adenocarcinoma is the most common type of colorectal neoplasm associated with ulcerative colitis and Crohn's disease, but other types of epithelial and nonepithelial tumors have also been described in IBD. NECs arising in the setting of ulcerative colitis are very rare and are reported as anecdotic findings. We describe the clinicopathological features of an IBD-related NEC and review the previously reported cases.	[Bolzacchini, Elena; Chini, Claudio; Cortelezzi, Claudio Camillo; Vallini, Ilaria; Pinotti, Graziella] Osped Circolo Varese, Varese, Italy; [La Rosa, Stefano] Lausanne Univ Hosp, Lausanne, Switzerland; [Uccella, Silvia] Univ Insubria, Varese, Italy	Uccella, S (reprint author), Univ Insubria, Dept Med & Surg, Unit Pathol, Via O Rossi 9, I-21100 Varese, Italy.	silvia.uccella@uninsubria.it		uccella, silvia/0000-0002-5714-7295			Annese V, 2013, J CROHNS COLITIS, V7, P982, DOI 10.1016/j.crohns.2013.09.016; Burisch J, 2015, SCAND J GASTROENTERO, V50, P942, DOI 10.3109/00365521.2015.1014407; CLERY AP, 1961, ARCH SURG-CHICAGO, V83, P164, DOI 10.1001/archsurg.1961.01300140006002; Di Sabatino A, 2011, INFLAMM BOWEL DIS, V17, pE106, DOI 10.1002/ibd.21774; Freeman HJ, 2009, WORLD J GASTROENTERO, V15, P5882, DOI 10.3748/wjg.15.5882; Grassia R, 2009, WORLD J GASTROENTERO, V15, P4193, DOI 10.3748/wjg.15.4193; Greenstein AJ, 1997, AM J GASTROENTEROL, V92, P682; Hayashi H, 2012, J CROHNS COLITIS, V6, P112, DOI 10.1016/j.crohns.2011.08.009; Kosmidis C, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-100; La Rosa S, 2016, ENDOCR PATHOL, V27, P284, DOI 10.1007/s12022-016-9432-9; Lacerda A, 2016, J CROHNS COLITIS, V10, P1125, DOI 10.1093/ecco-jcc/jjw057; Marchioni Beery Renee M, 2014, Gastrointest Cancer Res, V7, P119; Oberg K, 2012, ANN ONCOL, V23, P124, DOI 10.1093/annonc/mds295; OWEN DA, 1981, AM J CLIN PATHOL, V76, P333; Riddell R, 2014, LEWIN WEINSTEIN RIDD; Riddell R H, 1976, Curr Top Pathol, V63, P179; RUBIN A, 1990, HISTOPATHOLOGY, V16, P95, DOI 10.1111/j.1365-2559.1990.tb01070.x; Sawano M, 2016, DIGEST ENDOSC, V28, P611, DOI 10.1111/den.12640; Shigaki K, 2013, HUM PATHOL, V44, P2393, DOI 10.1016/j.humpath.2013.06.008; Sigel JE, 1998, MODERN PATHOL, V11, P537; Uccella Silvia, 2015, Turk Patoloji Derg, V31 Suppl 1, P113, DOI 10.5146/tjpath.2015.01319; WICK MR, 1987, HUM PATHOL, V18, P9, DOI 10.1016/S0046-8177(87)80187-9; Yaziji H, 1996, SOUTHERN MED J, V89, P921, DOI 10.1097/00007611-199609000-00016; Yoshihara T, 2016, GASTROINTEST ENDOSC, V84, P1075, DOI 10.1016/j.gie.2016.01.062; Zerboni G, 2016, DIGEST LIVER DIS, V48, P822, DOI 10.1016/j.dld.2016.03.025	25	2	2	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	AUG	2018	26	5					479	483		10.1177/1066896917752443			5	Pathology; Surgery	Pathology; Surgery	GM9OF	WOS:000438578500018	29361862				2019-10-28	
J	Concalves, LB; Miot, HA; Domingues, MAC; Oliveira, CC				Concalves, Lucas Braz; Miot, Helio Amante; Custodio Domingues, Maria Aparecida; Oliveira, Cristiano Claudino			Autopsy Patients With Obesity or Metabolic Syndrome as Basic Cause of Death: Are There Pathological Differences Between These Groups?	CLINICAL MEDICINE INSIGHTS- PATHOLOGY			English	Article						Autopsy; metabolic X syndrome; obesity		BACKGROUND: The objectives of this study were the evaluation of pathological characteristics of patients with obesity or metabolic syndrome (MS) as basic cause of death, associating the autopsy findings with some clinical aspects and the abdominal adipose panicle thickness. METHODS: A total of 88 autopsy cases were studied, divided into 2 groups based on the main cause of death: group 1 (n=15) obesity and group 2 (n=73) MS. Clinical summaries of autopsy requests. macroscopic findings. and histologic sections were reviewed. RESULTS: The definition of obesity as the basic cause of death is associated with larger thickness of the abdominal adipose panicle, being 8.5cm (P= .001) the best measurement, according to the receiver operating characteristic curve. Hypertensive cardiopathy (P=.001), ischemic cardiopathy (P=.003), coronary (P= .008)/systemic (P=.005) atherosclerosis, and arterial (P=.014)/arteriolar (P=.027) nephrosclerosis are associated with the diagnosis of MS. Steatohepatitis is associated with the diagnosis of obesity (P=.030); however, its association with the thickness of the abdominal adipose panicle is not statistically significant (P=.211). CONCLUSIONS: In the context of an obese patient in autopsy, pathologist may use the information about abdominal adipose panicle associated with heart. kidney. and liver findings. even macroscopic ones, to decide the basic cause death between obesity and MS.	[Concalves, Lucas Braz] Sao Paulo State Univ, Sch Med Botucatu, FMB UNESP, Botucatu, SP, Brazil; [Miot, Helio Amante] Sao Paulo State Univ, Sch Med Botucatu, FMB UNESP, Dept Dermatol & Radiotherapy, Botucatu, SP, Brazil; [Custodio Domingues, Maria Aparecida; Oliveira, Cristiano Claudino] Sao Paulo State Univ, Sch Med Botucatu, FMB UNESP, Dept Pathol, BR-18618687 Botucatu, SP, Brazil; [Oliveira, Cristiano Claudino] Sao Luiz DOr Hosp, Sao Paulo, Brazil	Oliveira, CC (reprint author), Sao Paulo State Univ, Sch Med Botucatu, FMB UNESP, Dept Pathol, BR-18618687 Botucatu, SP, Brazil.	cristiano_c_oliveira@hotmail.com	Miot, Helio/F-6744-2012	Miot, Helio/0000-0002-2596-9294; Custodio Domingues, Maria Aparecida/0000-0002-4023-3410	Brazilin National Council for Scientific and Technological Development (CNPq); CNPq (PIBIC)National Council for Scientific and Technological Development (CNPq)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by Brazilin National Council for Scientific and Technological Development (CNPq). L.B.G. is undergraduate student in medicine (FMB-UNESP) and was awarded a scholarship from CNPq (PIBIC) during this research.	Byard Roger W, 2008, J Forensic Leg Med, V15, P356, DOI 10.1016/j.jflm.2007.12.015; Castro AVB, 2014, ARQ BRAS ENDOCRINOL, V58, P600, DOI 10.1590/0004-2730000003223; Cooper H, 2009, INT J OBESITY, V33, P181, DOI 10.1038/ijo.2008.199; Fryer E, 2014, HISTOPATHOLOGY, V64, P200, DOI 10.1111/his.12224; Mandal R, 2012, AM J FOREN MED PATH, V33, P382, DOI 10.1097/PAF.0b013e3182518e5f; Ministerio da Saude, 2009, VIG FAT RISC PROT DO; Ministerio da Saude Secretaria de Vigilancia em Saude Departamento de Doencas e Agravos nAo transmissiveis e PromocAo da Saud, 2014, VIG FAT RISC PROT DO; Nakanishi T, 2014, PATHOL RES PRACT, V210, P1018, DOI 10.1016/j.prp.2014.04.008; Peres Luiz Cesar, 2017, Autops Case Rep, V7, P1, DOI 10.4322/acr.2017.017; Rezende Edna Maria, 2004, Cad. Saúde Pública, V20, P1223, DOI 10.1590/S0102-311X2004000500016; Rodriguez-Flores M, 2013, CARDIOVASC PATHOL, V22, P332, DOI 10.1016/j.carpath.2013.01.008; WHO, 2015, OB OV	12	0	0	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1179-5557	2632-010X		CLIN MED INSIGHTS-PA	Clin. Med. Insights-Pathol.	JUL 30	2018	11								UNSP 1179555718791575	10.1177/1179555718791575			7	Pathology	Pathology	GP9NL	WOS:000441243600001	30083067	DOAJ Gold, Green Published			2019-10-28	
J	Oyama, Y; Nishida, H; Kusaba, T; Kadowaki, H; Arakane, M; Wada, J; Urabe, S; Hirano, T; Kawano, K; Suzuki, M; Yokoyama, S; Daa, T				Oyama, Yuzo; Nishida, Haruto; Kusaba, Takahiro; Kadowaki, Hiroko; Arakane, Motoki; Wada, Junpei; Urabe, Shogo; Hirano, Takashi; Kawano, Kenji; Suzuki, Masashi; Yokoyama, Shigeo; Daa, Tsutomu			Difference in transducin-like enhancer of split 1 protein expression between basal cell adenomas and basal cell adenocarcinomas - an immunohistochemical study	DIAGNOSTIC PATHOLOGY			English	Article						TLE1; Basal cell adenoma; Basal cell adenocarcinoma; beta catenin	SALIVARY-GLANDS; TUMORS	Background: Basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC) are benign and malignant, basaloid salivary gland neoplasms, respectively. These tumors show a dual cell proliferation of inner luminal/ductal cells and outer abluminal/myoepithelial or basal cells. The only difference between them is defined as a malignant morphology such as invasion. Recently, the nuclear expression of beta-catenin and a catenin beta-1 (CTNNB1) mutation were found in BCA. Transducin-like enhancer of split 1 (TLE1) belongs to the Groucho/TLE family, and it functions in the "off" state in the Wnt/beta-catenin signaling pathway. We hypothesized that if the dysregulation of the Wnt beta-catenin signaling pathway could be attributed to the tumorigenesis of BCA/BCAC, there might be differences in TLE1 expression between BCA and BCAC Method: The study included 35 BCA and 4 BCAC cases. We performed immunohistochemistry to detect TLE1 and beta-catenin and investigated the catenin beta-1 (CTNNB1) mutational profile among BCA and BCAC cases. Results: In BCA, the expression of TLE1 was confined to luminal cells of glandular structures, in contrast to the expression of beta-catenm in abluminal cells. The BCA cases harbored CTNNB1 gene mutations (12/35). In BCAC, luminal cell staining ofTLEI was identical to BCA in non-invasive areas (4/4) but indistinct in invasive areas (3/4). The BCAC cases were beta-catenin positive for abluminal cells in both areas. The BCAC cases had CTNNB1 mutation (2/4) and the laser-captured microdissection allowed the separate collection of infiltrative and non-infiltrative areas to detect the same mutation. Conclusions: Immunohistochemical analysis for TLE1 can identify BCA and BCAC by luminal cell staining difference, especially indistinct luminal cell expression forTLEl in invasive areas of BCAC. Moreover, TLE1 can be luminal/ductal cell markers.	[Oyama, Yuzo; Nishida, Haruto; Kusaba, Takahiro; Kadowaki, Hiroko; Arakane, Motoki; Yokoyama, Shigeo; Daa, Tsutomu] Oita Univ, Fac Med, Dept Diagnost Pathol, 1-1 Idaigaoka,Hasama Machi, Yufu, Japan; [Wada, Junpei; Urabe, Shogo] Oita Preferectual Hosp, Oita, Japan; [Hirano, Takashi; Suzuki, Masashi] Oita Univ, Fac Med, Dept Otolaryngol, Yufu, Japan; [Kawano, Kenji] Oita Univ, Fac Med, Dept Oral & Maxillofacial Surg, Yufu, Japan	Nishida, H (reprint author), Oita Univ, Fac Med, Dept Diagnost Pathol, 1-1 Idaigaoka,Hasama Machi, Yufu, Japan.	nharuto@oita-u.ac.jp					Cironi L, 2016, SCI REP-UK, V6, DOI 10.1038/srep22113; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Fonsera I, 2017, WHO CLASSIFICATION H, P169; Hai B, 2010, STEM CELLS DEV, V19, P1793, DOI 10.1089/scd.2009.0499; Jo VY, 2016, AM J SURG PATHOL, V40, P1143, DOI 10.1097/PAS.0000000000000669; Jung MJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-171; Kawahara A, 2011, J ORAL PATHOL MED, V40, P460, DOI 10.1111/j.1600-0714.2011.01010.x; Lee JH, 2016, J GASTRIC CANCER, V16, P364; Lee JH, 2017, J BREAST CANCER, V20, P45, DOI 10.4048/jbc.2017.20.1.45; Li J, 2017, WHO CLASSIFICATION H, P187; Muller S, 1996, CANCER, V78, P2471; Nagao T, 1998, CANCER, V82, P439, DOI 10.1002/(SICI)1097-0142(19980201)82:3<439::AID-CNCR3>3.0.CO;2-K; Queimado L, 2008, ARCH OTOLARYNGOL, V134, P94, DOI 10.1001/archotol.134.1.94; Shah Amisha Ashok Kumar, 2016, J Oral Maxillofac Pathol, V20, P480; Terry J, 2007, AM J SURG PATHOL, V31, P240, DOI 10.1097/01.pas.0000213330.71745.39; Wilson TC, 2016, HEAD NECK PATHOL, V10, P494, DOI 10.1007/s12105-016-0730-9; Wilson TC, 2015, HEAD NECK PATHOL, V9, P205, DOI 10.1007/s12105-014-0562-4; Zhan KY, 2016, LARYNGOSCOPE, V126, P1086, DOI 10.1002/lary.25713	18	1	1	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUL 27	2018	13								48	10.1186/s13000-018-0726-8			8	Pathology	Pathology	GO4UX	WOS:000440013200001	30053869	DOAJ Gold, Green Published			2019-10-28	
J	Wright, JR				Wright, James R., Jr.			When Pathology and Laboratory Medicine Becomes a Commodity and Health Care Becomes Both Its Customer and Owner	ACADEMIC PATHOLOGY			English	Editorial Material						Alberta; Calgary Laboratory Service; health-care regionalization; merger; model	SERVICES; PROVISION; CANADA; MODEL		[Wright, James R., Jr.] Univ Calgary, Dept Pathol & Lab Med, Cumming Sch Med, Calgary Lab Serv,Alberta Childrens Hosp Site, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada; [Wright, James R., Jr.] Univ Calgary, Cumming Sch Med, Dept Paediat, Calgary, AB, Canada; [Wright, James R., Jr.] Ohio State Univ, Med Heritage Ctr, Columbus, OH 43210 USA	Wright, JR (reprint author), Univ Calgary, Dept Pathol & Lab Med, Cumming Sch Med, Calgary Lab Serv,Alberta Childrens Hosp Site, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.; Wright, JR (reprint author), Univ Calgary, Dept Paediat, Cumming Sch Med, Calgary Lab Serv,Alberta Childrens Hosp Site, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	jim.wright@cls.ab.ca					Fagg KL, 1999, CLIN CHIM ACTA, V290, P73, DOI 10.1016/S0009-8981(99)00178-3; Marchildon GP, 2017, CAN MED ASSOC J, V189, pE1147, DOI 10.1503/cmaj.170164; Wright Jr, 2015, ACAD PATHOL, V2, DOI 10.1177/2374289515619944; Wright JR, 2017, ARCH PATHOL LAB MED, V141, P704, DOI 10.5858/arpa.2016-0348-HP; Wright JR, 2016, ARCH PATHOL LAB MED, V140, P983, DOI 10.5858/arpa.2016-0113-HP	5	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUL 26	2018	5								UNSP 2374289518785373	10.1177/2374289518785373			6	Pathology	Pathology	GO4WL	WOS:000440018000001	30083594	DOAJ Gold, Green Published			2019-10-28	
J	Kano, R; Masaie, H; Hino, A; Yasuoka, H; Nagata, S; Ishikawa, J; Nakatsuka, S				Kano, Rieko; Masaie, Hiroaki; Hino, Akihisa; Yasuoka, Hironao; Nagata, Shigenori; Ishikawa, Jun; Nakatsuka, Shin-ichi			Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities	DIAGNOSTIC PATHOLOGY			English	Article						CD5-positive diffuse large B-cell lymphoma; Intravascular large B-cell lymphoma; Asian variant; Random skin biopsy	CLINICAL PRESENTATION; RICHTERS-SYNDROME; CHEMOTHERAPY; MANAGEMENT; EXPRESSION; RITUXIMAB; SURVIVAL; DISTINCT; VARIANT	Background: CD5-positive diffuse large B-cell lymphoma (DLBCL) and intravascular large B-cell lymphoma (IVL) are recognized as rare subsets of large B-cell lymphoma with poor prognosis. These two categories have similar clinicopathological features suggesting that they might overlap. Case presentation: We present a case of a 72-year-old man with submental tumors. Positron emission tomography/computed tomography (PET/CT) showed tumors in the nasal and paranasal region and multiple submental and jugular swollen lymph nodes with abnormal uptake of F-18-fluorodeoxyglucose (FDG). Histology of biopsy from nasal tumors showed diffuse infiltration of large lymphoid cells, which showed positive expressions for CD20, CD79a, CD5 and negative for CD3 on immunohistochemistry. Thus, a CD5-positive DLBCL was diagnosed. After administration of 8 cycles of R-THPCOP (rituximab, pirarubicin, cyclophosphamide, vincristine and prednisolone), complete remission was achieved. Eight months after the first chemotherapy dose, local recurrence occurred. After salvage chemotherapy, nasal and paranasal tumors and lymph node swelling disappeared on PET/CT images, although the patient suffered from respiratory disturbance. A random skin biopsy revealed IVL, which was consistent with intravascular recurrence of CD5-positive DLBCL. Bone marrow smears showed hemophagocytosis. Conclusion: We present a rare case of primary CD5-positive DLBCL that relapsed as pure IVL after chemotherapy. Our case suggests that CD5-positive DLBCL is closely related to IVL.	[Kano, Rieko; Nagata, Shigenori; Nakatsuka, Shin-ichi] Osaka Int Canc Inst Hosp, Dept Diagnost Pathol & Cytol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan; [Masaie, Hiroaki; Hino, Akihisa; Ishikawa, Jun] Osaka Int Canc Inst Hosp, Dept Hematol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan; [Yasuoka, Hironao] Osaka Police Hosp, Dept Pathol, Tenno Ji Ku, 10-31 Kitayama Town, Osaka 5430035, Japan	Kano, R (reprint author), Osaka Int Canc Inst Hosp, Dept Diagnost Pathol & Cytol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan.	kano-ri@mc.pref.osaka.jp					Ferreri AJM, 2004, BRIT J HAEMATOL, V127, P173, DOI 10.1111/j.1365-2141.2004.05177.x; Ferreri AJM, 2007, HAEMATOL-HEMATOL J, V92, P486, DOI 10.3324/haematol.10829; Filipovich Alexandra H, 2009, Hematology Am Soc Hematol Educ Program, P127, DOI 10.1182/asheducation-2009.1.127; Hans CP, 2005, MODERN PATHOL, V18, P1377, DOI 10.1038/modpathol.3800434; Igawa T, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-81; Kasuya A, 2011, J DERMATOL, V38, P571, DOI 10.1111/j.1346-8138.2010.01127.x; Katz Deborah A, 2010, Clin Adv Hematol Oncol, V8, P637; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; MATOLCSY A, 1995, AM J PATHOL, V147, P207; McKelvie PA, 2013, LEUKEMIA LYMPHOMA, V54, P2745, DOI 10.3109/10428194.2013.786071; Miyazaki K, 2011, ANN ONCOL, V22, P1601, DOI 10.1093/annonc/mdq627; Murase T, 2004, BLOOD, V104, p383A; Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253; Niitsu N, 2010, ANN ONCOL, V21, P2069, DOI 10.1093/annonc/mdq057; Ponzoni M, 2007, J CLIN ONCOL, V25, P3168, DOI 10.1200/JCO.2006.08.2313; Puckrin R, 2017, CLIN CASE REP, V5, P1444, DOI 10.1002/ccr3.1087; Rajyaguru DJ, 2017, LEUKEMIA LYMPHOMA, V58, P2080, DOI 10.1080/10428194.2017.1287363; Swerdlow SH, 2017, WHO CLASSIFICATION T; Tagawa H, 2005, BLOOD, V106, P1770, DOI 10.1182/blood-2005-02-0542; Xu-Monette ZY, 2015, ONCOTARGET, V6, P5615, DOI 10.18632/oncotarget.3479; Yamaguchi M, 2002, BLOOD, V99, P815, DOI 10.1182/blood.V99.3.815; Yamaguchi M, 2008, HAEMATOL-HEMATOL J, V93, P1195, DOI 10.3324/haematol.12810; Yegappan S, 2001, MODERN PATHOL, V14, P1147, DOI 10.1038/modpathol.3880450	23	0	1	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUL 24	2018	13								46	10.1186/s13000-018-0724-x			6	Pathology	Pathology	GO1KV	WOS:000439711100001	30041681	DOAJ Gold, Green Published			2019-10-28	
J	Scorer, P; Scott, M; Lawson, N; Ratcliffe, MJ; Barker, C; Rebelatto, MC; Walker, J				Scorer, Paul; Scott, Marietta; Lawson, Nicola; Ratcliffe, Marianne J.; Barker, Craig; Rebelatto, Marlon C.; Walker, Jill			Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay	DIAGNOSTIC PATHOLOGY			English	Article						PD-L1; Heterogeneity; Assay; Concordance; Consistency; Reproducibility; Immunohistochemistry; SP263; Intra-block; Intra-case	SQUAMOUS-CELL; LUNG-CANCER; PD-L1 EXPRESSION; SINGLE-ARM; OPEN-LABEL; CHECKPOINT INHIBITOR; CARCINOMA; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER	Background: Several anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) therapies have shown encouraging safety and clinical activity in a variety of tumor types. A potential role for PD-L1 testing in identifying patients that are more likely to respond to treatment is emerging. PD-L1 expression in clinical practice is determined by testing one tumor section per patient. Therefore, it is critical to understand the impact of tissue sampling variability on patients' PD-L1 classification. Methods: Resected non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial carcinoma (UC) tissue samples (five samples per tumor type) were obtained from commercial sources and two tumor blocks were taken from each. Three sections from each block (similar to 100 mu m apart) were stained using the VENTANA PD-L1 (SP263) assay, and scored based on the percentage of PD-L1-staining tumor cells (TCs) or tumor-infiltrating immune cells (ICs) present. Each section was categorized as PD-L1 high or low/negative using a variety of cut-off values, and intra-block and intra-case (between blocks of the same tumor) concordance (overall percentage agreement [ OPA]) were evaluated. An additional 200 commercial NSCLC samples were also analyzed, and intra-block concordance determined by scoring two sections per sample (>= 70 mu m apart). Results: Concordance in TC PD-L1 classification was high at all applied cut-offs. Intra-block and intra-case OPA for the 15 NSCLC, HNSCC or UC samples were 100% and 80-100%, respectively, across all cut-offs; intra-block OPA for the 200 NSCLC samples was 91.0-98.5% across all cut-offs. IC PD-L1 classification was less consistent; intra-block and intra-case OPA for the 15 NSCLC, HNSCC or UC samples ranged between 70 and 100% and between 60 and 100%, respectively, with similar observations in the intra-block analysis of the 200 NSCLC samples. Conclusions: These results show the reproducibility of TC PD-L1 classification across the depth of the tumor using the VENTANA PD-L1 (SP263) assay. Practically, this means that treatment decisions based on TC PD-L1 classification can be made confidently, following analysis of one tumor section. Although more variable than TC staining, consistent IC PD-L1 classification was also observed within and between blocks and across cut-offs.	[Scorer, Paul; Scott, Marietta; Lawson, Nicola; Barker, Craig] AstraZeneca, HODGKIN, IMED Biotech Unit, Precis Med Labs,Precis Med & Genom, CO B310 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WG, England; [Ratcliffe, Marianne J.; Walker, Jill] AstraZeneca, Oncol Compan Diagnost Unit, IMED Biotech Unit, Precis Med & Genom, Cambridge, England; [Rebelatto, Marlon C.] MedImmune, Translat Sci, Res, Gaithersburg, MD USA	Scorer, P (reprint author), AstraZeneca, HODGKIN, IMED Biotech Unit, Precis Med Labs,Precis Med & Genom, CO B310 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0WG, England.	Paul.Scorer@astrazeneca.com			AstraZenecaAstraZeneca	This study was sponsored by AstraZeneca. The sponsor contributed to the design and implementation of the study, collection, analysis and interpretation of data, and writing of the report. The authors had final responsibility for the decision to submit for publication.	Bauml J, 2017, J CLIN ONCOL, V35, P1542, DOI 10.1200/JCO.2016.70.1524; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Cohen E, 2017, EUR SOC MED ONC ESMO; Dako, 2015, PD L1 IHC 28 8 PHARM; Dako, 2015, PD L1 IHC 22C3 PHARM; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252; Food and Drug Administration, 2007, GUID IND FDA STAFF S; Food and Drug Administration (FDA), 2015, DAK 28 8 SUMM SAF EF; Food and Drug Administration (FDA), 2015, DAK 22C3 SUMM SAF EF; Food and Drug Administration (FDA), 2016, VENT SP142 SUMM SAF; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Heymann JJ, 2017, CANCER CYTOPATHOL, V125, P896, DOI 10.1002/cncy.21937; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Ilie M, 2016, ANN ONCOL, V27, P147, DOI 10.1093/annonc/mdv489; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Larkins E, 2017, ONCOLOGIST, V22, P873, DOI 10.1634/theoncologist.2016-0496; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Merck Sharp & Dohme, KEYTR PEMBR HIGHL PR; Nanda R, 2016, J CLIN ONCOL, V34, P2460, DOI 10.1200/JCO.2015.64.8931; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Rebelatto MC, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0545-8; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Scheel AH, 2016, MODERN PATHOL, V29, P1165, DOI 10.1038/modpathol.2016.117; Scott M, 2017, ASCO SITC CLIN IMM O; Scott ML, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e14503; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Skov BG, 2017, APPL IMMUNOHISTO M M, V25, P453, DOI 10.1097/PAI.0000000000000540; VENTANA, VENTANA PD L1 SP263; VENTANA, VENTANA PD L1 SP142; Ventana Medical Systems, VENTANA PD L1 SP263; Zou WP, 2008, NAT REV IMMUNOL, V8, P467, DOI 10.1038/nri2326	42	4	4	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUL 24	2018	13								47	10.1186/s13000-018-0725-9			10	Pathology	Pathology	GO1KV	WOS:000439711100002	30041679	DOAJ Gold, Green Published			2019-10-28	
J	Borowitz, MJ; Moliterno, A				Borowitz, Michael J.; Moliterno, Alison			Educational Case: Iron Overload and Hemochromatosis	ACADEMIC PATHOLOGY			English	Article						pathology competencies; organ system pathology; hematopathology; anemia; iron overload; hemochromatosis; genetic mechanisms; inheritance patterns		The following fictional case is intended as a learning tool within the Pathology Competencies for Medical Education (PCME), a set of national standards for teaching pathology. These are divided into three basic competencies: Disease Mechanisms and Processes, Organ System Pathology, and Diagnostic Medicine and Therapeutic Pathology. For additional information, and a full list of learning objectives for all three competencies, see http://journals.sagepub.com/doi/10.1177/ 2374289517715040.	[Borowitz, Michael J.; Moliterno, Alison] Johns Hopkins Sch Med, 401 N Broadway, Baltimore, MD 21287 USA	Borowitz, MJ (reprint author), Johns Hopkins Sch Med, 401 N Broadway, Baltimore, MD 21287 USA.	mborowit@jhmi.edu					Beutler E, 2007, BLOOD CELL MOL DIS, V39, P140, DOI 10.1016/j.bcmd.2007.03.009; Hollerer I, 2017, HAEMATOLOGICA, V102, P809, DOI 10.3324/haematol.2016.160432	2	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUL 23	2018	5								UNSP 2374289518779944	10.1177/2374289518779944			3	Pathology	Pathology	GO4BY	WOS:000439946800001	30057941	DOAJ Gold, Green Published			2019-10-28	
J	Haeggblom, L; Ursu, RG; Mirzaie, L; Attoff, T; Gahm, C; Nordenvall, LH; Nasman, A				Haeggblom, Linnea; Ursu, Ramona Gabriela; Mirzaie, Leila; Attoff, Tove; Gahm, Caroline; Nordenvall, Lalle Hammarstedt; Nasman, Anders			No evidence for human papillomavirus having a causal role in salivary gland tumors	DIAGNOSTIC PATHOLOGY			English	Article						Salivary gland tumors; Salivary gland malignancies; Human papilloma virus; HPV; Tumor viruses	RISK HUMAN-PAPILLOMAVIRUS; ADENOID CYSTIC CARCINOMA; TONSILLAR CANCER; UNKNOWN PRIMARY; NECK CANCERS; HEAD; PREVALENCE; EXPRESSION; SWEDEN; VIRUS	Background: Salivary gland malignancies are a very heterogeneous group of cancers, with histologically > 20 different subtypes, and prognosis varies greatly. Their etiology is unknown, however, a few small studies show presence of human papillomavirus (HPV) in some subtypes, although the evidence for HPV having a causal role is weak. The aim of this study was to investigate if HPV plays a causal role in the development of different parotid salivary gland tumor subtypes. Methods: DNA was extracted from 107 parotid salivary gland formalin fixed paraffin embedded tumors and 10 corresponding metastases, and tested for 27 different HPV types using a multiplex bead based assay. HPV DNA positive tumors were stained for p16(INK4a) overexpression by immunohistochemistry. Results: One of the 107 malignant parotid salivary gland tumors (0.93%) and its corresponding metastasis on the neck were positive for HPV16 DNA, and both also overexpressed p16(INK4a). The HPV positive primary tumor was a squamous cell carcinoma; neither mucoepidermoid nor adenoid cystic tumors were found HPV positive. Conclusions: In conclusion, HPV DNA analysis in a large number of malignant parotid salivary gland tumors, including 12 different subtypes, did not show any strong indications that tested HPV types have a causal role in the studied salivary gland tumor types.	[Haeggblom, Linnea; Mirzaie, Leila; Attoff, Tove; Nasman, Anders] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Univ Hosp, R8 01, S-17176 Stockholm, Sweden; [Ursu, Ramona Gabriela] Univ Med & Pharm Grigore T Popa Iasi, Dept Microbiol, Iasi 700115, Romania; [Gahm, Caroline; Nordenvall, Lalle Hammarstedt] Karolinska Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, S-17176 Stockholm, Sweden; [Gahm, Caroline; Nordenvall, Lalle Hammarstedt] Karolinska Inst, Dept Clin Sci Intervent & Technol, S-17176 Stockholm, Sweden; [Nasman, Anders] Karolinska Univ Hosp, Dept Clin Pathol, S-17176 Stockholm, Sweden	Haeggblom, L (reprint author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Karolinska Univ Hosp, R8 01, S-17176 Stockholm, Sweden.	linnea.haeggblom@ki.se		Nasman, Anders/0000-0003-4602-4297	Stiftelsen Clas Groschinskys minnesfond; Stiftelsen Tornspiran; Stiftelsen Dagmar Ferbs minnesfond; Svenska lakaresallskapet (SLS); Stiftelsen Sigurd och Elsa Goljes Minne; Magnus Bergvalls stiftelse; Eva och Oscar Ahrens stiftelse; Tore Nilssons Stiftelse for medicinsk forskning; Svenska Sallskapet for Medicinsk Forskning (SSMF); Stockholm County Council (SLL)Stockholm County Council; Karolinska InstitutetKarolinska Institutet; University of Medicine and Pharmacy Grigore T Popa Iasi [30336 / 28.12.2017]	This work was supported by Stiftelsen Clas Groschinskys minnesfond, Stiftelsen Tornspiran, Stiftelsen Dagmar Ferbs minnesfond, Svenska lakaresallskapet (SLS), Stiftelsen Sigurd och Elsa Goljes Minne, Magnus Bergvalls stiftelse, Eva och Oscar Ahrens stiftelse, Tore Nilssons Stiftelse for medicinsk forskning, Svenska Sallskapet for Medicinsk Forskning (SSMF), the Stockholm County Council (SLL) and Karolinska Institutet. RGU was funded by the University of Medicine and Pharmacy Grigore T Popa Iasi, based on contract no. 30336 / 28.12.2017. The funding bodies had no role in the study design, data collection, analysis, interpretation of data, or in writing the manuscript.	Barnes L., 2005, PATHOLOGY GENETICS H, P209; Begum S, 2003, CLIN CANCER RES, V9, P6469; Bersani C, 2017, ONCOTARGET, V8, P35339, DOI 10.18632/oncotarget.15240; Boland JM, 2012, MODERN PATHOL, V25, P529, DOI 10.1038/modpathol.2011.186; Cancercentrum R, 2015, NAT VARDPR HUV HALSC; Dahstrand HM, 2005, ADV CANCER RES, V93, P59, DOI 10.1016/S0065-230X(05)93002-9; Dalianis T, 2015, ORAL ONCOL, V51, P857, DOI 10.1016/j.oraloncology.2015.06.002; Du J, 2012, EMERG INFECT DIS, V18, P1468, DOI 10.3201/eid1809.111731; Gillespie MB, 2012, CURR TREAT OPTION ON, V13, P58, DOI 10.1007/s11864-011-0174-0; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Grunewald I, 2015, ONCOTARGET, V6, P18224; Hafed L, 2012, ARCH ORAL BIOL, V57, P1194, DOI 10.1016/j.archoralbio.2012.03.009; International Agency for Research on Cancer, 2007, IARC MONOGRAPHS EVAL, V90; Isayeva T, 2012, HEAD NECK PATHOL, V6, pS104, DOI 10.1007/s12105-012-0368-1; Lin FCF, 2014, J INT MED RES, V42, P1093, DOI 10.1177/0300060514543041; Lindquist D, 2007, MOL ONCOL, V1, P350, DOI 10.1016/j.molonc.2007.08.005; Nordfors C, 2013, SCAND J INFECT DIS, V45, P878, DOI 10.3109/00365548.2013.821626; Qian X, 2016, INT J ONCOL, V49, P803, DOI 10.3892/ijo.2016.3563; Schmitt M, 2008, J CLIN MICROBIOL, V46, P1050, DOI 10.1128/JCM.02227-07; Sivars L, 2014, CANCER MED-US, V3, P376, DOI 10.1002/cam4.199; Skalova Alena, 2013, Cesk Patol, V49, P72; Vageli D, 2007, INT J BIOL MARKER, V22, P239; Xu B, 2016, HISTOPATHOLOGY, V69, P921, DOI 10.1111/his.13027	23	2	2	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUL 18	2018	13								44	10.1186/s13000-018-0721-0			5	Pathology	Pathology	GN5UE	WOS:000439131600001	30021645	DOAJ Gold, Green Published			2019-10-28	
J	Zhu, B; Wang, YC; Wang, XL; Wu, SW; Zhou, L; Gong, XM; Song, WQ; Wang, DN				Zhu, Bo; Wang, Yichao; Wang, Xiaolin; Wu, Shiwu; Zhou, Lei; Gong, Xiaomeng; Song, Wenqing; Wang, Danna			Evaluation of the correlation of MACC1, CD44, Twist1, and KiSS-1 in the metastasis and prognosis for colon carcinoma	DIAGNOSTIC PATHOLOGY			English	Article						CAC; MACC1; CD44; Twist1; KiSS-1	CANCER STATISTICS; GASTRIC-CANCER; EXPRESSION; REGULATOR; PREDICTS; ORAOV1; CELLS; KAI1; MET	Background: Metastasis-associated in colon cancer 1 (MACC1) has been reported to promote tumor cell invasion and metastasis. Cancer stem cells and epithelial-mesenchymal transition (EMT) have also been reported to promote tumor cell proliferation, invasion, and metastasis. KiSS-1, a known suppressor of metastasis, has been reported to be down-regulated in various tumors. However, the associations of MACC1, CD44, Twist1, and KiSS-1 in colonic adenocarcinoma (CAC) invasion and metastasis remain unclear. The purpose of this study is to investigate the roles of MACC1, CD44, Twist1, and KiSS-1 in CAC invasion and metastasis and their associations with each other and with the clinicopathological characteristics of CAC patients. Methods: Immunohistochemistry and multivariate analysis were carried out to explore the expression of MACC1, CD44, Twist1, and KiSS-1 in 212 whole-CAC-tissue specimens and the corresponding normal colon mucosa tissues. Demographic, clinicopathological, and follow-up data were also collected. Results: The results of this study showed MACC1, CD44, and Twist1 expression to be up-regulated, and KiSS-1 expression was down-regulated in CAC tissues. Positive expression of MACC1, CD44, and Twist1 was found to be positively correlated with invasion, tumor grades, and lymph-node-metastasis (LNM) stages and tumor-nodemetastasis (TNM) stages for patients with CAC. Positive expression of KiSS-1 was inversely associated with invasion, tumor size, LNM stage, and TNM stage. The KiSS-1-positive expression group had significantly more favorable OS than did the KiSS-1-negative group. Univariate analysis indicated that overexpression of MACC1, CD44, and Twists1 was negatively associated with longer overall survival (OS) time, and there was a positive relationship between KiSS-1-positive expression and OS time for patients with CAC. Multivariate Cox analysis demonstrated that overexpression of MACC1, CD44, Twist1, and low expression of KiSS-1 and LNM and TNM stages were independent predictors of prognosis in patients with CAC. Conclusions: The results in this study indicated that levels of expression of MACC1, CD44, Twist1, and KiSS-1 are related to the duration of OS in patients with CAC. MACC1, CD44, Twist1, and KiSS-1 may be suitable for use as biomarkers and therapeutic targets in CAC.	[Zhu, Bo; Wang, Yichao; Wang, Xiaolin; Wu, Shiwu; Zhou, Lei; Gong, Xiaomeng; Song, Wenqing; Wang, Danna] Bengbu Med Coll, Affiliated Hosp 1, Dept Pathol, Bengbu, Peoples R China; [Zhu, Bo; Wang, Yichao; Wang, Xiaolin; Wu, Shiwu; Zhou, Lei; Gong, Xiaomeng; Song, Wenqing; Wang, Danna] Bengbu Med Univ, Dept Pathol, Bengbu, Peoples R China	Wu, SW (reprint author), Bengbu Med Coll, Affiliated Hosp 1, Dept Pathol, Bengbu, Peoples R China.; Wu, SW (reprint author), Bengbu Med Univ, Dept Pathol, Bengbu, Peoples R China.	wushiwu@bbmc.edu.cn			Nature Science Foundation of Anhui ProvinceNatural Science Foundation of Anhui Province [1708085MH230]; Nature Science Key Program of Bengbu Medical College [BYKY1711ZD]; Key projects of support program for outstanding young talents in Colleges and Universities of Anhui Province [gxyqZD2016160]; Nature Science Key Program of College and University of Anhui Province [KJ2018A1029]	This work was supported by the Nature Science Foundation of Anhui Province (No. 1708085MH230) and the Nature Science Key Program of Bengbu Medical College (No. BYKY1711ZD) and Key projects of support program for outstanding young talents in Colleges and Universities of Anhui Province (No. gxyqZD2016160) and the Nature Science Key Program of College and University of Anhui Province (No. KJ2018A1029).	Bai X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111622; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Cao F, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005296; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Choi SI, 2017, ONCOTARGET, V8, P101284, DOI 10.18632/oncotarget.21021; Quevedo EGC, 2015, DIS MARKERS, DOI 10.1155/2015/365845; Duan Y, 2016, ONCOTARGET, V8, P1; Fang C, 2016, ONCOTARGET, V7, P77389, DOI 10.18632/oncotarget.12675; Gu CD, 2011, ANTICANCER RES, V31, P1141; Iseki Y, 2017, ONCOL LETT, V14, P1025, DOI 10.3892/ol.2017.6269; Koelzer VH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1150-z; Lu GY, 2017, INT J CLIN EXP PATHO, V10, P8916; Lu GY, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1033-z; Mitra R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01781-0; Navenot JM, 2009, MOL PHARMACOL, V75, P1300, DOI 10.1124/mol.109.055095; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Song WQ, 2017, INT J CLIN EXP MED, V10, P14623; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang HH, 2017, AM J TRANSL RES, V9, P4785; Wang L, 2013, INT J CANCER, V133, P1419, DOI 10.1002/ijc.28140; Wang W, 2016, ONCOL REP, V30, P1449; WELCH DR, 1994, ONCOGENE, V9, P255; WU Q, 2015, DIAGN PATHOL, V10; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang YP, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-41; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Yu L, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0612-9; Yusup A, 2017, WORLD J GASTROENTERO, V23, P110, DOI 10.3748/wjg.v23.i1.110; Zhou L, 2017, INT J CLIN EXP PATHO, V10, P7542; Zhou LL, 2016, JMMB, V16, P1	34	3	3	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JUL 18	2018	13								45	10.1186/s13000-018-0722-z			10	Pathology	Pathology	GN5UE	WOS:000439131600002	30021598	DOAJ Gold, Green Published			2019-10-28	
J	Gupta, N; Das, K				Gupta, Neha; Das, Kasturi			Pleural effusion in a 7-year-old child - with unique cells	CYTOJOURNAL			English	Editorial Material							SYSTEMIC-LUPUS-ERYTHEMATOSUS; ONSET		[Gupta, Neha; Das, Kasturi] Hofstra Northwell Sch Med, Dept Pathol & Lab Med, New Hyde Pk, NY 11042 USA	Gupta, N (reprint author), Hofstra Northwell Sch Med, Dept Pathol & Lab Med, New Hyde Pk, NY 11042 USA.	ngupta4@northwell.edu; kdas1@northwell.edu					DUBOIS EL, 1964, JAMA-J AM MED ASSOC, V190, P104; Efrati Ori, 2002, Pediatr Rev, V23, P417; Hepburn AL, 2001, RHEUMATOLOGY, V40, P826, DOI 10.1093/rheumatology/40.7.826; Hersh AO, 2010, ARTHRIT CARE RES, V62, P1152, DOI 10.1002/acr.20179; Mina R, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4256; NOSANCHUK JS, 1976, JAMA-J AM MED ASSOC, V236, P2883, DOI 10.1001/jama.236.25.2883; OGRYZLO M A, 1956, Can Med Assoc J, V75, P980; Park JY, 2007, DIAGN CYTOPATHOL, V35, P806, DOI 10.1002/dc.20758; SCHUMACHER HR, 1995, LUPUS, V4, P353, DOI 10.1177/096120339500400505; Silva CA, 2012, ARTHRIT CARE RES, V64, P1787, DOI 10.1002/acr.21757; Wan KS, 2008, RHEUMATOL INT, V28, P1257, DOI 10.1007/s00296-008-0598-4	11	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JUL 13	2018	15								16	10.4103/cytojournal.cytojournal_13_17			4	Pathology	Pathology	GT3IP	WOS:000444395500001	30112014	DOAJ Gold, Green Published			2019-10-28	
J	Kishore, M; Gupta, P; Malhotra, AK; Kumar, V; Singh, S; Bhardwaj, M				Kishore, Manjari; Gupta, Prajwala; Malhotra, A. K.; Kumar, Vijay; Singh, Sanchit; Bhardwaj, Minakshi			Cytodiagnosis of extramedullary hematopoiesis in serous effusion: A rare presentation unfolding the underlying etiology	CYTOJOURNAL			English	Article						Cytology; effusion; extramedullary hematopoiesis; peritoneal fluid; pleural fluid; serous	IDIOPATHIC MYELOFIBROSIS; ASCITES; PATIENT	Extramedullary hematopoiesis (EMH) usually involves reticuloendothelial system. However, it rarely may be present in the serous body effusions. In our case, the fluid cytology of both peritoneal and pleural fluid was diagnostic of the EMH in a patient with an undiagnosed underlying etiology.	[Kishore, Manjari; Gupta, Prajwala; Kumar, Vijay; Bhardwaj, Minakshi] Post Grad Inst Med Educ & Res, Dept Pathol, Dr RML Hosp, New Delhi, India; [Malhotra, A. K.; Singh, Sanchit] Post Grad Inst Med Educ & Res, Dept Med, Dr RML Hosp, New Delhi, India	Gupta, P (reprint author), Post Grad Inst Med Educ & Res, Dept Pathol, Dr RML Hosp, New Delhi, India.	drmanjarik@gmail.com; prajwala2000@yahoo.com; dr.akmalhotra@yahoo.in; vijaypgi@gmail.com; snchtsingh05@gmail.com; minakshi.bh@gmail.com					Banerji JS, 2013, CUAJ-CAN UROL ASSOC, V7, pE436, DOI 10.5489/cuaj.1389; Cervantes F, 2009, BLOOD, V113, P2895, DOI 10.1182/blood-2008-07-170449; Koch M, 2016, DIAGN CYTOPATHOL, V44, P41, DOI 10.1002/dc.23390; Luo Y, 2013, CASE REP HEMATOL, DOI 10.1155/2013/857610; Miyata T, 2008, J DERMATOL, V35, P456, DOI 10.1111/j.1346-8138.2008.00502.x; Oren I, 1999, AM J MED SCI, V318, P286, DOI 10.1097/00000441-199910000-00009; Schwarz C, 2009, RESPIRATION, V78, P110, DOI 10.1159/000150913; Wei XQ, 2014, WORLD J GASTROENTERO, V20, P11921, DOI 10.3748/wjg.v20.i33.11921; Wiest R, 2004, SCAND J GASTROENTERO, V39, P389, DOI 10.1080/00365520310007521; Yotsumoto M, 2003, INTERNAL MED, V42, P525, DOI 10.2169/internalmedicine.42.525	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JUL 13	2018	15								18	10.4103/cytojournal.cytojournal_33_17			4	Pathology	Pathology	GT3IP	WOS:000444395500003	30112016	DOAJ Gold, Green Published			2019-10-28	
J	Sung, S; Tazelaar, HD; Crapanzano, JP; Nassar, A; Saqi, A				Sung, Simon; Tazelaar, Henry D.; Crapanzano, John P.; Nassar, Aziza; Saqi, Anjali			Adult exogenous lipoid pneumonia: A rare and underrecognized entity in cytology - A case series	CYTOJOURNAL			English	Article						Bronchoalveolar lavage; fine needle aspiration; lipid laden macrophages; lipoid pneumonia; lung; neoplasm	CHILDREN FOLLOWING ASPIRATION; BRONCHOALVEOLAR LAVAGE; MACROPHAGES; MANIFESTATIONS; COMPLICATION; INHALATION; SECONDARY; PARAFFIN; LUNG	Background: Exogenous lipoid pneumonia (ELP) is a rare benign entity without specific clinical or imaging presentation. Although cytological studies - either bronchoalveolar lavage (BAL) or fine-needle aspiration (FNA) - may be pursued in patients with ELP, a definitive diagnosis is frequently rendered only on histology. The aim of this study is to highlight the cytological features of ELP. Methods: A search of cytopathology (CP) and surgical pathology (SP) diagnoses of ELP was conducted. The corresponding clinical and imaging features were obtained, and the morphology, particularly the presence and size of the intracytoplasmic vacuoles and background, was assessed. Results: Nine cases of ELP were identified, including eight with corresponding CP and SP. A neoplasm was suspected in three based on imaging, but ELP was not in the differential clinically or radiographically in any. Among the cases, six patients had BALs and three FNAs. All of the samples showed multiple large vacuoles within macrophages with at least some equal to or larger than the size of the cell nucleus. Similar vacuoles were noted extracellularly on smears. Conclusions: ELP is typically described in case reports in the clinical or radiological literature. To the best of our knowledge, this represents the largest series of adult ELP in CP. When large vacuoles are present in macrophages in cytology specimens, at least a suspicion of ELP can be suggested to initiate appropriate therapy, identify/remove the inciting agent, and preclude a more invasive procedure.	[Sung, Simon; Crapanzano, John P.; Saqi, Anjali] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Tazelaar, Henry D.] Mayo Clin, Dept Pathol, Scottsdale, AZ USA; [Nassar, Aziza] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA	Saqi, A (reprint author), Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA.	ss3768@cumc.columbia.edu; tazelaar.henry@mayo.edu; jpc2141@cumc.columbia.edu; nassar.aziza@mayo.edu; aas177@cumc.columbia.edu					ANNOBIL SH, 1991, ANN TROP PAEDIATR, V11, P87, DOI 10.1080/02724936.1991.11747483; Bandla HPR, 1999, PEDIATRICS, V103, part. no., DOI 10.1542/peds.103.2.e19; Baron SE, 2003, J THORAC IMAG, V18, P217, DOI 10.1097/00005382-200310000-00002; Basset-Leobon C, 2010, CYTOPATHOLOGY, V21, P245, DOI 10.1111/j.1365-2303.2009.00677.x; BECTON DL, 1984, J PEDIATR-US, V105, P421, DOI 10.1016/S0022-3476(84)80017-7; Bell MM, 2015, CAN FAM PHYSICIAN, V61, P775; Bernabeu Mora R, 2000, Arch Bronconeumol, V36, P485; Betancourt SL, 2010, AM J ROENTGENOL, V194, P103, DOI 10.2214/AJR.09.3040; BROWN AC, 1994, CHEST, V105, P968, DOI 10.1378/chest.105.3.968; COLLINS KA, 1995, ARCH PATHOL LAB MED, V119, P229; DAVIS EW, 1954, J THORAC SURG, V28, P212; Albuquerque Filho Alfredo Pereira Leite de, 2006, J. bras. pneumol., V32, P596, DOI 10.1590/S1806-37132006000600020; Sias SMD, 2009, J BRAS PNEUMOL, V35, P839, DOI 10.1590/S1806-37132009000900004; Ganso M, 2016, LARYNGO RHINO OTOL, V95, P534, DOI 10.1055/s-0042-108445; GATTUSO P, 1991, CYTOPATHOLOGY, V2, P315, DOI 10.1111/j.1365-2303.1991.tb00507.x; Gibeon D, 2014, RESP MED, V108, P71, DOI 10.1016/j.rmed.2013.10.005; GLYNN KP, 1990, CHEST, V97, P1265, DOI 10.1378/chest.97.5.1265; Gupta RK, 2004, DIAGN CYTOPATHOL, V30, P290, DOI 10.1002/dc.10402; Hadda Vijay, 2010, Expert Rev Respir Med, V4, P799, DOI 10.1586/ers.10.74; Hadda Vijay, 2009, Cases J, V2, P9332, DOI 10.1186/1757-1626-2-9332; Hopkins PM, 2010, J HEART LUNG TRANSPL, V29, P859, DOI 10.1016/j.healun.2010.03.015; HUGOSSON CO, 1991, PEDIATR RADIOL, V21, P193, DOI 10.1007/BF02011045; LAUQUE D, 1990, CHEST, V98, P1149, DOI 10.1378/chest.98.5.1149; Laurent F, 1999, EUR RADIOL, V9, P1190, DOI 10.1007/s003300050815; Suarez PCL, 2015, ARCH BRONCONEUMOL, V51, P530, DOI 10.1016/j.arbres.2014.12.015; Lococo F, 2012, HEART LUNG, V41, P184, DOI 10.1016/j.hrtlng.2011.01.003; Majori M, 2014, J BRONCHOL INTERN PU, V21, P271, DOI 10.1097/LBR.0000000000000084; Marchiori E, 2011, RESP MED, V105, P659, DOI 10.1016/j.rmed.2010.12.001; Meltzer E, 2005, Eur J Intern Med, V16, P615, DOI 10.1016/j.ejim.2005.06.014; Mokhlesi B, 2007, ANN NUCL MED, V21, P411, DOI 10.1007/s12149-007-0042-y; Nguyen Christopher D, 2013, Respir Care, V58, pe23, DOI 10.4187/respcare.01727; Osman GA, 2016, CLIN RESPIR  J, V12, P524; Reyes CV, 1998, DIAGN CYTOPATHOL, V19, P98, DOI 10.1002/(SICI)1097-0339(199808)19:2<98::AID-DC5>3.0.CO;2-J; Salgado IA, 2012, REV ASSOC MED BRAS, V58, P135, DOI 10.1590/S0104-42302012000200006; Saqi A, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.126223; SILVERMAN JF, 1989, DIAGN CYTOPATHOL, V5, P3, DOI 10.1002/dc.2840050103; Simmons A, 2007, J GEN INTERN MED, V22, P1613, DOI 10.1007/s11606-007-0280-7; Tahon F, 2002, EUR RADIOL, V12, pS171, DOI 10.1007/s00330-002-1659-9; Wang YN, 2011, DIAGN CYTOPATHOL, V39, P272, DOI 10.1002/dc.21390; Worringer E, 2015, AM J MED SCI, V349, P72, DOI 10.1097/MAJ.0b013e3182945762; Yampara Guarachi GI, 2014, CASE REP PULMONOL, V2014; Zanetti G, 2007, PEDIATR RADIOL, V37, P1135, DOI 10.1007/s00247-007-0603-1	42	0	0	1	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JUL 13	2018	15								17	10.4103/cytojournal.cytojournal_29_17			9	Pathology	Pathology	GT3IP	WOS:000444395500002	30112015	DOAJ Gold, Green Published			2019-10-28	
J	Ehlers, A; Dyson, RL; Hodgson, CK; Davis, SR; Krasowski, MD				Ehlers, Alexandra; Dyson, Richard L.; Hodgson, Christina K.; Davis, Scott R.; Krasowski, Matthew D.			Impact of Daylight Saving Time on the Clinical Laboratory	ACADEMIC PATHOLOGY			English	Article						clinical chemistry tests; clinical laboratory information system; electronic health record; hematology; software; transfusion medicine	EXPERIENCE; ACCIDENTS; CRASHES; SHIFT	Daylight saving time is a practice in some countries and local regions to set clocks forward (typically 1 hour) during the longer days of summer and back again in autumn. Time changes resulting from daylight saving time have the potential to impact clinical laboratory instruments, computer interfaces, and information systems. We analyzed turnaround time data for an academic medical center clinical laboratories (chemistry, hematology, blood gas analyzer, and transfusion medicine), examining how turnaround time was impacted by the daylight saving time shifts in 2017. We also determined whether the daylight saving time shift on November 5, 2017 (fall back by 1 hour) resulted in any absurd time combinations such as a receipt time occurring before a normally later time such as final result. We also describe challenges resulting from daylight saving time changes over a 5-year period. The only significant impact on turnaround time was for clinical chemistry samples during the autumn daylight saving time change, but the overall impact was low. Four instances of absurd time combinations occurred in the autumn time change with only a transfusion medicine example resulting in an interface error (a Type and Screen resulted before receipt in laboratory). Over a 5-year period, other daylight saving time impacts included problems of reestablishing interface to instruments, inadvertent discrepancies in manual time changes at different points of the core laboratory automation line, and time change errors in instruments with older operating systems lacking patches that updated daylight saving time rules after 2007. Clinical laboratories should be aware that rare problems may occur due to issues with daylight saving time changes.	[Ehlers, Alexandra; Hodgson, Christina K.; Davis, Scott R.; Krasowski, Matthew D.] Univ Iowa Hosp & Clin, Dept Pathol, 200 Hawkins Dr,C671 GH, Iowa City, IA 52242 USA; [Dyson, Richard L.] Univ Iowa Hosp & Clin, Hlth Care Informat Syst, Iowa City, IA 52242 USA	Krasowski, MD (reprint author), Univ Iowa Hosp & Clin, Dept Pathol, 200 Hawkins Dr,C671 GH, Iowa City, IA 52242 USA.	matthew-krasowski@uiowa.edu					Aldasouqi Saleh A, 2014, J Diabetes Sci Technol, V8, P1215, DOI 10.1177/1932296814541811; [Anonymous], 2018, DAYLIGHT SAVING TIME; Barnes CM, 2015, PERSPECT PSYCHOL SCI, V10, P733, DOI 10.1177/1745691615598509; Blau John Larry, 2017, J Pathol Inform, V8, P47, DOI 10.4103/jpi.jpi_31_17; Coren S, 1996, PERCEPT MOTOR SKILL, V83, P921, DOI 10.2466/pms.1996.83.3.921; Coren S, 1996, NEW ENGL J MED, V334, P924, DOI 10.1056/NEJM199604043341416; Downing Michael, 2005, SPRING FORWARD ANN M; Grieme CV, 2017, CLIN LAB, V63, P561, DOI 10.7754/Clin.Lab.2016.160932; Hansen BT, 2017, EPIDEMIOLOGY, V28, P346, DOI 10.1097/EDE.0000000000000580; Hicks GJ, 1998, PERCEPT MOTOR SKILL, V86, P879, DOI 10.2466/pms.1998.86.3.879; Jiddou MR, 2013, AM J CARDIOL, V111, P631, DOI 10.1016/j.amjcard.2012.11.010; Krasowski MD, 2017, ACAD PATHOL, V4, DOI 10.1177/2374289517722152; Krasowski Matthew D, 2016, J Pathol Inform, V7, P7, DOI 10.4103/2153-3539.175798; Krasowski MD, 2015, BMC MED INFORM DECIS, V15, DOI 10.1186/s12911-015-0137-7; Krasowski Matthew D, 2014, J Pathol Inform, V5, P13, DOI 10.4103/2153-3539.129450; Lambe M, 2000, ACCIDENT ANAL PREV, V32, P609, DOI 10.1016/S0001-4575(99)00088-3; Prerau David, 2005, SEIZE DAYLIGHT CURIO; Prerau David, 2005, SAVING DAYLIGHT WHY; Sandhu A, 2014, OPEN HEART, V1, DOI 10.1136/openhrt-2013-000019; Varughese J, 2001, SLEEP MED, V2, P31, DOI 10.1016/S1389-9457(00)00032-0; Vincent A, 1998, NEW ENGL J MED, V339, P1167	21	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUL 11	2018	5								UNSP 2374289518784222	10.1177/2374289518784222			7	Pathology	Pathology	GM9FF	WOS:000438549400001	30023429	DOAJ Gold, Green Published			2019-10-28	
J	[Anonymous]				[Anonymous]			Association of Pathology Chairs: Abstracts of the 2018 Annual Meeting: Educating Stakeholders on the Roles of Pathologists, July 15 to 19, 2018, Hotel del Coronado, San Diego, CA Abstracts	ACADEMIC PATHOLOGY			English	Article								The following abstracts were accepted by the Association of Pathology Chairs, without modification, for poster presentation at the 2018 APC Annual Meeting. This content was not peer reviewed by Academic Pathology. Presenting authors' names are bolded throughout.				Koteeswaran, Rajasekaran/B-8836-2015	Koteeswaran, Rajasekaran/0000-0001-7902-9145				0	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JUL 9	2018	5								UNSP 2374289518788096	10.1177/2374289518788096			22	Pathology	Pathology	GM4BR	WOS:000438058900001		DOAJ Gold, Green Published			2019-10-28	
J	Gupta, R; Cooper, WA; Selinger, C; Mahar, A; Anderson, L; Buckland, ME; O'Toole, SA				Gupta, Ruta; Cooper, Wendy A.; Selinger, Christina; Mahar, Annabelle; Anderson, Lyndal; Buckland, Michael E.; O'Toole, Sandra A.			Fluorescent In Situ Hybridization in Surgical Pathology Practice	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						differential diagnoses; fluorescent in situ hybridization; formalin fixation; in situ hybridization; predictive utility; quality control; tissue selection	SMALL-CELL-CARCINOMA; OF-AMERICAN-PATHOLOGISTS; GASTROESOPHAGEAL ADENOCARCINOMA GUIDELINE; HEALTH-ORGANIZATION CLASSIFICATION; GESTATIONAL TROPHOBLASTIC DISEASE; CLINICAL DECISION-MAKING; CENTRAL-NERVOUS-SYSTEM; SOFT-TISSUE TUMORS; HYPERCALCEMIC TYPE; BREAST-CANCER	There have been rapid and significant advances in diagnostic and predictive molecular techniques in recent years with profound impact on patient care. In situ hybridization (ISH) studies have become well entrenched in surgical pathology practice and their role in the evaluation of HER2 in breast carcinoma and their diagnostic utility in soft tissue pathology are well known. Fluorescent ISH is being increasingly used in other sites such as the head and neck and the gynecologic tract. Like most tests in surgical pathology, ISH studies require good quality tissue, correlation with clinical and histopathologic findings, and adherence to guidelines for optimal assay performance and interpretation. Although ISH studies are largely performed in tertiary centers, the tissue is often processed by a variety of laboratories and the referring pathologists are required to discuss the need, relevance, and significance of these tests and the results with their clinical colleagues. Here we review the predictive and diagnostic utility of fluorescent ISH studies in a variety of organ systems, the preanalytical factors that may affect the results, and the pitfalls in the interpretation that all practicing surgical pathologists should be aware of.	[Gupta, Ruta; Cooper, Wendy A.; Selinger, Christina; Mahar, Annabelle; Anderson, Lyndal; Buckland, Michael E.] Univ Sydney, Sydney Med Sch, Royal Prince Alfred, Dept Tissue Pathol & Diagnost Oncol, Sydney, NSW 2050, Australia; [Gupta, Ruta; Cooper, Wendy A.; Buckland, Michael E.; O'Toole, Sandra A.] Univ Sydney, Sydney Med Sch, Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Cooper, Wendy A.; Anderson, Lyndal] Western Sydney Univ, Sch Med, Sydney, NSW, Australia; [Buckland, Michael E.] Royal Prince Alfred Hosp, Dept Neuropathol, Sydney, NSW, Australia; [O'Toole, Sandra A.] Garvan Inst Med Res, Sydney, NSW, Australia; [O'Toole, Sandra A.] Australian Clin Labs, Sydney, NSW, Australia	Gupta, R (reprint author), Univ Sydney, Royal Prince Alfred Hosp, Dept Tissue Pathol & Diagnost Oncol, Bld 94, Sydney, NSW 2050, Australia.	ruta.gupta@health.nsw.gov.au		Anderson, Lyndal/0000-0002-9405-8195; Gupta, Ruta/0000-0003-2940-313X			Amatu A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000023; Antonescu CR, 2017, AM J SURG PATHOL, V41, P941, DOI 10.1097/PAS.0000000000000846; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003; Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP; Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836; Bartley AN, 2016, ARCH PATHOL LAB MED, V140, P1345, DOI 10.5858/arpa.2016-0331-CP.s1; Bifuleo C, 2008, AM J SURG PATHOL, V32, P445, DOI 10.1097/PAS.0b013e3181520034; Buza N, 2014, SEMIN DIAGN PATHOL, V31, P223, DOI 10.1053/j.semdp.2014.03.004; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; Chou A, 2013, GENOME MED, V5, DOI 10.1186/gm482; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Clay MR, 2015, AM J SURG PATHOL, V39, P1433, DOI 10.1097/PAS.0000000000000468; Conlon N, 2016, AM J SURG PATHOL, V40, P395, DOI 10.1097/PAS.0000000000000558; Cooper WA, 2013, J THORAC DIS, V5, pS479, DOI 10.3978/j.issn.2072-1439.2013.08.03; Croce S, 2013, MODERN PATHOL, V26, P1390, DOI 10.1038/modpathol.2013.69; Do HD, 2015, CLIN CHEM, V61, P64, DOI 10.1373/clinchem.2014.223040; Downs-Kelly E, 2009, DIAGN MOL PATHOL, V18, P138, DOI 10.1097/PDM.0b013e31818c2ea4; Doyle LA, 2016, AM J SURG PATHOL, V40, P94, DOI 10.1097/PAS.0000000000000511; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Doyle LA, 2012, AM J SURG PATHOL, V36, P1444, DOI 10.1097/PAS.0b013e3182562bf8; Dubbink HJ, 2016, J MOL DIAGN, V18, P775, DOI 10.1016/j.jmoldx.2016.06.002; Duhamel LAE, 2012, HISTOPATHOLOGY, V60, P357, DOI 10.1111/j.1365-2559.2011.04023.x; Einaga N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176280; Erickson-Johnson MR, 2011, LAB INVEST, V91, P1427, DOI 10.1038/labinvest.2011.118; Ferry JA, 2006, ONCOLOGIST, V11, P375, DOI 10.1634/theoncologist.11-4-375; Fisher C, 2014, HISTOPATHOLOGY, V64, P134, DOI 10.1111/his.12269; Fletcher C, 2013, WHO CLASSIFICATION T; Foulkes WD, 2014, J PATHOL, V233, P209, DOI 10.1002/path.4362; Gong Y, 2005, MODERN PATHOL, V18, P1015, DOI 10.1038/modpathol.3800432; Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023; Gowrishankar B, 2015, J UROLOGY, V193, P1479, DOI 10.1016/j.juro.2014.11.099; Gozzetti A, 2000, SEMIN HEMATOL, V37, P320, DOI 10.1016/S0037-1963(00)90013-1; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Gupta M, 2012, AM J SURG PATHOL, V36, P1747, DOI 10.1097/PAS.0b013e31825ea736; Gupta R, 2015, OR SURG OR MED OR PA, V119, P661, DOI 10.1016/j.oooo.2015.02.481; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Hui P, 2010, EXPERT REV MOL DIAGN, V10, P1023, DOI [10.1586/erm.10.93, 10.1586/ERM.10.93]; Italiano A, 2016, LANCET ONCOL, V17, P532, DOI 10.1016/S1470-2045(15)00583-5; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Kinney SN, 2015, MODERN PATHOL, V28, P1236, DOI 10.1038/modpathol.2015.81; Kobel M, 2009, CANCER RES, V69, P9160, DOI 10.1158/0008-5472.CAN-09-2669; Kohno T, 2015, TRANSL LUNG CANCER R, V4, P156, DOI 10.3978/j.issn.2218-6751.2014.11.11; Kupryjanczyk J, 2013, POL J PATHOL, V64, P238, DOI 10.5114/PJP.2013.39331; Lai CYL, 2004, MODERN PATHOL, V17, P40, DOI 10.1038/modpathol.3800010; Li BT, 2016, J THORAC ONCOL, V11, P414, DOI 10.1016/j.jtho.2015.10.025; Lindeman NI, 2013, J THORAC ONCOL, V8, P823, DOI 10.1097/JTO.0b013e318290868f; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Luk PP, 2016, HEAD NECK S1, V38, pE1838; Mardis ER, 2011, NATURE, V470, P198, DOI 10.1038/nature09796; Marino-Enriquez A, 2011, GENE CHROMOSOME CANC, V50, P146, DOI 10.1002/gcc.20839; McAlpine JN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-433; Meldrum Cliff, 2011, Clin Biochem Rev, V32, P177; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; Nikiforova MN, 2016, NEURO-ONCOLOGY, V18, P379, DOI 10.1093/neuonc/nov289; Noujaim J, 2017, BRIT J CANCER, V116, P669, DOI 10.1038/bjc.2017.4; Nucci MR, 2007, AM J SURG PATHOL, V31, P65, DOI 10.1097/01.pas.0000213327.86992.d1; Papouchado BG, 2010, AM J SURG PATHOL, V34, P767, DOI 10.1097/PAS.0b013e3181d96231; Peled N, 2012, J THORAC ONCOL, V7, pE14, DOI 10.1097/JTO.0b013e3182614ab5; Perry A, 2004, CANCER, V101, P2318, DOI 10.1002/cncr.20625; Perry A, 2009, BRAIN PATHOL, V19, P81, DOI 10.1111/j.1750-3639.2008.00167.x; Petersson F, 2010, VIRCHOWS ARCH, V456, P355, DOI 10.1007/s00428-010-0898-4; Press MF, 2016, J CLIN ONCOL, V34, P3518, DOI 10.1200/JCO.2016.66.6693; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Remstein ED, 2006, AM J SURG PATHOL, V30, P1546, DOI 10.1097/01.pas.0000213275.60962.2a; Rosario R, 2013, GYNECOL ONCOL, V131, P325, DOI 10.1016/j.ygyno.2013.08.031; Ruschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198; Salgado R, 2011, GENE CHROMOSOME CANC, V50, P510, DOI 10.1002/gcc.20874; Schoolmeester JK, 2015, INT J GYNECOL PATHOL, V34, P576, DOI 10.1097/PGP.0000000000000187; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Selinger C, 2015, HISTOPATHOLOGY, V67, P654, DOI 10.1111/his.12708; Selinger CI, 2017, HISTOPATHOLOGY, V70, P402, DOI 10.1111/his.13076; Selinger CI, 2013, MODERN PATHOL, V26, P1545, DOI 10.1038/modpathol.2013.87; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Singh VM, 2013, ANN DIAGN PATHOL, V17, P322, DOI 10.1016/j.anndiagpath.2013.02.001; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Smith JS, 2000, J CLIN ONCOL, V18, P636, DOI 10.1200/JCO.2000.18.3.636; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Sukov WR, 2008, SKELETAL RADIOL, V37, P321, DOI 10.1007/s00256-007-0442-z; Sukov WR, 2012, MODERN PATHOL, V25, P1516, DOI 10.1038/modpathol.2012.107; Summersgill BM, 2010, METHODS MOL BIOL, V659, P51, DOI 10.1007/978-1-60761-789-1_4; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Vargas AC, 2016, HISTOPATHOLOGY, V69, P1000, DOI 10.1111/his.13031; Virk SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124178; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; Weller M, 2015, ACTA NEUROPATHOL, V129, P679, DOI 10.1007/s00401-015-1409-0; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Woehrer A, 2011, CLIN NEUROPATHOL, V30, P47, DOI 10.5414/NPP30047; Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yamada Y, 2017, VIRCHOWS ARCH, V470, P373, DOI 10.1007/s00428-017-2072-8; Yoon SO, 2008, HISTOPATHOLOGY, V53, P205, DOI 10.1111/j.1365-2559.2008.03076.x; Yoshida A, 2010, MODERN PATHOL, V23, P1279, DOI 10.1038/modpathol.2010.124; Zacher A, 2017, BRAIN PATHOL, V27, P146, DOI 10.1111/bpa.12367	100	1	2	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JUL	2018	25	4					223	237		10.1097/PAP.0000000000000194			15	Pathology	Pathology	GJ4AY	WOS:000435290000002	29727321				2019-10-28	
J	Jiang, W; Austin, RM; Li, L; Yang, KX; Zhao, CQ				Jiang, Wei; Austin, R. Marshall; Li, Lei; Yang, Kaixuan; Zhao, Chengquan			Extended Human Papillomavirus Genotype Distribution and Cervical Cytology Results in a Large Cohort of Chinese Women With Invasive Cervical Cancers and High-Grade Squamous Intraepithelial Lesions	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Cervical cancer; Cervical intraepithelial 2/3; HPV test; HPV genotypes; Papanicolaou test	HIGH-RISK HPV; PREVALENCE; NEOPLASIA; METAANALYSIS; PERSISTENCE; WORLDWIDE; INFECTION; CARCINOMA; PROVINCE; HISTORY	Objectives: To study the human papillomavirus (HPV) genotype distribution of cervical cancer (CxCa) and cervical intraepithelial neoplasia grade 2/3 (CIN2/3). Methods: Patients with CxCa and CIN 2/3 diagnoses and HPV genotype testing in the prior 6 months were documented. Available prior Papanicolaou (Pap) results were also recorded. Results: Three hundred and seventy CxCa cases and 2,774 CIN 2/3 cases with recent prior HPV test results were documented. The high-risk (hr) HPV-positive rate was 88.4% for CxCa and 90.1% for CIN 2/3. Among 327 HPV-positive CxCa cases, the most common HPV types were HPV 16 (70.3%), 18 (7.0%), 58 (5.7%), and 33 (4.1%). Among 2,499 hrHPV-positive CIN 2/3 cases, the most common HPV types were HPV 16 (53.3%), 58 (21.4%), 52 (11%), 33 (10.6%) and 18 (5.1%). For the cotested cases hrHPV-negative results were reported in 12.4% of CxCa and 10.1% of CIN 2/3 cases compared to cytology-negative results reported in 15.5% of CxCa and 4.3% of CIN 2/3. Conclusions: HPV 16/18/59/39 genotypes were significantly more prevalent in CxCa cases than in CIN 2/3 cases, consistent with the more limited progressive potential of some CIN 2/3 lesions. 10% to 12% of CIN 2/3 and CxCa cases had recent negative hrHPV test results, pointing to the limitation of primary HPV screening.	[Jiang, Wei; Li, Lei; Yang, Kaixuan] Sichuan Univ, West China Univ Hosp 2, Dept Pathol, 20,Sect 3,Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China; [Jiang, Wei; Li, Lei; Yang, Kaixuan] Sichuan Univ, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ, Chengdu, Sichuan, Peoples R China; [Austin, R. Marshall; Zhao, Chengquan] Univ Pittsburgh, Dept Pathol, Med Ctr, 300 Halket St, Pittsburgh, PA 15213 USA	Jiang, W (reprint author), Sichuan Univ, West China Univ Hosp 2, Dept Pathol, 20,Sect 3,Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.; Zhao, CQ (reprint author), Univ Pittsburgh, Dept Pathol, Med Ctr, 300 Halket St, Pittsburgh, PA 15213 USA.	jervis@126.com; zhaoc@upmc.edu					Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; Ault KA, 2011, INT J CANCER, V128, P1344, DOI 10.1002/ijc.25723; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Chen HC, 2011, JNCI-J NATL CANCER I, V103, P1387, DOI 10.1093/jnci/djr283; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Clifford GM, 2003, BRIT J CANCER, V89, P101, DOI 10.1038/sj.bjc.6601024; de Gonzalez AB, 2007, INT J CANCER, V120, P885, DOI 10.1002/ijc.22357; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Di Jiangli, 2015, Asian Pac J Cancer Prev, V16, P7401; Ding XR, 2014, J MED VIROL, V86, P1937, DOI 10.1002/jmv.24044; Gustafsson L, 1997, CANCER CAUSE CONTROL, V8, P755, DOI 10.1023/A:1018435522475; Kinney W, 2011, GYNECOL ONCOL, V121, P309, DOI 10.1016/j.ygyno.2010.12.361; Kjaer SK, 2002, BRIT MED J, V325, P572, DOI 10.1136/bmj.325.7364.572; Kosinski AS, 2003, BIOMETRICS, V59, P163, DOI 10.1111/1541-0420.00019; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396; Liang Haiyan, 2016, J Am Soc Cytopathol, V5, P64, DOI 10.1016/j.jasc.2015.06.001; Malila N, 2013, INT J CANCER, V132, P2141, DOI 10.1002/ijc.27850; Maucort-Boulch D, 2008, CANCER EPIDEM BIOMAR, V17, P717, DOI 10.1158/1055-9965.EPI-07-2691; McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7; Quek SC, 2013, INT J GYNECOL CANCER, V23, P148, DOI 10.1097/IGC.0b013e31827670fd; Safaeian M, 2009, CANCER RES, V69, P3262, DOI 10.1158/0008-5472.CAN-08-4192; Schiffman M, 2018, JNCI-J NATL CANCER I, V110, P501, DOI 10.1093/jnci/djx225; Serrano B, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-38; Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457; Stoler MH, 2015, J CLIN MICROBIOL, V53, P2798, DOI 10.1128/JCM.01087-15; Sun PM, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e50; Tao X, 2015, CANCER CYTOPATHOL, V123, P421, DOI 10.1002/cncy.21545; Tjalma WA, 2013, INT J CANCER, V132, P854, DOI 10.1002/ijc.27713; Wang LQ, 2015, J MED VIROL, V87, P516, DOI 10.1002/jmv.24094; Wright TC, 2003, NEW ENGL J MED, V348, P489, DOI 10.1056/NEJMp020178; Xu XX, 2015, INT J ENV RES PUB HE, V12, P10794, DOI 10.3390/ijerph120910794; Zeng ZY, 2016, J CANCER, V7, P1037, DOI 10.7150/jca.14971; Zhao FH, 2012, INT J CANCER, V131, P2929, DOI 10.1002/ijc.27571; Zheng Baowen, 2017, J Am Soc Cytopathol, V6, P120, DOI 10.1016/j.jasc.2017.03.005; Zheng BW, 2015, CANCER CYTOPATHOL, V123, P428, DOI 10.1002/cncy.21557	37	0	0	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JUL	2018	150	1					43	50		10.1093/AJCP/AQY022			8	Pathology	Pathology	GI0VP	WOS:000434088700006	29746625				2019-10-28	
J	Tutturen, AEV; Dorum, S; Clancy, T; Reims, HM; Christophersen, A; Lundin, KEA; Sollid, LM; de Souza, GA; Stamnaes, J				Tutturen, Astrid E., V; Dorum, Ski; Clancy, Trevor; Reims, Henrik M.; Christophersen, Asbjorn; Lundin, Knut E. A.; Sollid, Ludvig M.; de Souza, Gustavo A.; Stamnaes, Jorunn			Characterization of the Small Intestinal Lesion in Celiac Disease by Label-Free Quantitative Mass Spectrometry	AMERICAN JOURNAL OF PATHOLOGY			English	Article							TERM GLUTEN CHALLENGE; RESTRICTED T-CELLS; SERUM I-FABP; JEJUNAL-MUCOSA; PLASMA-CELLS; PROTEIN QUANTIFICATION; INTERACTION NETWORKS; SIGNALING PATHWAY; PERIPHERAL-BLOOD; DIETARY GLUTEN	Global characterization of tissue proteomes from small amounts of biopsy material has become feasible because of advances in mass spectrometry and bioinformatics tools. In celiac disease (CD), dietary gluten induces an immune response that is accompanied by pronounced remodeling of the small intestine. Removal of gluten from the diet abrogates the immune response, and the tissue architecture normalizes. In this study, differences in global protein expression of small intestinal biopsy specimens from CD patients were quantified by analyzing formalin-fixed, paraffin-embedded material using liquid chromatography-mass spectrometry and label-free protein quantitation. Protein expression was compared in biopsy specimens collected from the same patients before and after 1-year treatment with gluten-free diet (n = 10) or before and after 3-day gluten provocation (n = 4). Differential expression of proteins in particular from mature enterocytes, neutrophils, and plasma cells could distinguish untreated from treated CD mucosa, and Ig variable region IGHV5-51 expression was found to serve as a CD-specific marker of ongoing immune activation. In patients who had undergone gluten challenge, coordinated up-regulation of wound response proteins, including the CD autoantigen transglutaminase 2, was observed. Our study provides a global and unbiased assessment of antigen-driven changes in protein expression in the celiac intestinal mucosa.	[Tutturen, Astrid E., V; Dorum, Ski; Sollid, Ludvig M.; Stamnaes, Jorunn] Univ Oslo, Ctr Immune Regulat, Oslo, Norway; [Tutturen, Astrid E., V; Dorum, Ski; Sollid, Ludvig M.; Stamnaes, Jorunn] Univ Oslo, Dept Immunol, Oslo, Norway; [Tutturen, Astrid E., V; Dorum, Ski; Sollid, Ludvig M.; Stamnaes, Jorunn] Oslo Univ Hosp, Rikshosp, Oslo, Norway; [Tutturen, Astrid E., V; de Souza, Gustavo A.] Oslo Univ Hosp, Rikshosp, Prote Core Facil, Oslo, Norway; [Lundin, Knut E. A.] Oslo Univ Hosp, Rikshosp, Dept Gastroenterol, Oslo, Norway; [Clancy, Trevor] Oslo Univ Hosp, Inst Canc Res, Dept Immunol, Radiumhosp, Oslo, Norway; [Reims, Henrik M.] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Christophersen, Asbjorn; Lundin, Knut E. A.; Sollid, Ludvig M.] Univ Oslo, KG Jebsen Coeliac Dis Res Ctr, Oslo, Norway; [de Souza, Gustavo A.] Univ Fed Rio Grande do Norte, Brain Inst, Natal, RN, Brazil	Stamnaes, J (reprint author), Oslo Univ Hosp, Rikshosp, Dept Immunol, Sognsvannsveien 20, N-0372 Oslo, Norway.	stamnas@medisin.uio.no	de Souza, Gustavo A/J-1502-2015	de Souza, Gustavo A/0000-0001-8372-9451; Clancy, Trevor/0000-0001-9896-0613; Lundin, Knut E A/0000-0003-1713-5545	South-Eastern Norway Regional Health Authority; Research Council of Norway through its Center of Excellence funding scheme [179573/V40]	Supported by the South-Eastern Norway Regional Health Authority and the Research Council of Norway through its Center of Excellence funding scheme (project number 179573/V40). The Proteomics Core Facility is supported by a Norwegian Southeastern Health Organization Core Facility fund.	Adriaanse MPM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07242-4; Adriaanse MPM, 2013, ALIMENT PHARM THER, V37, P482, DOI 10.1111/apt.12194; Adriaanse MPM, 2016, AM J GASTROENTEROL, V111, P1014, DOI 10.1038/ajg.2016.162; BAKLIEN K, 1977, SCAND J GASTROENTERO, V12, P149, DOI 10.1080/00365521.1977.12031127; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Beitnes ACR, 2011, SCAND J IMMUNOL, V74, P186, DOI 10.1111/j.1365-3083.2011.02549.x; Beitnes ACR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033556; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bodd M, 2010, MUCOSAL IMMUNOL, V3, P594, DOI 10.1038/mi.2010.36; Bodd M, 2013, EUR J IMMUNOL, V43, P2605, DOI 10.1002/eji.201343382; Bragde H, 2011, PEDIATR RES, V69, P530, DOI 10.1203/PDR.0b013e318217ecec; Brottveit M, 2013, AM J GASTROENTEROL, V108, P842, DOI 10.1038/ajg.2013.91; Brottveit M, 2011, AM J GASTROENTEROL, V106, P1318, DOI 10.1038/ajg.2011.23; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Deeb SJ, 2012, MOL CELL PROTEOMICS, V11, P77, DOI 10.1074/mcp.M111.015362; Derikx JPM, 2009, J CLIN GASTROENTEROL, V43, P727, DOI 10.1097/MCG.0b013e31819194b0; Di Niro R, 2012, NAT MED, V18, P441, DOI 10.1038/nm.2656; Diosdado B, 2007, CLIN GASTROENTEROL H, V5, P574, DOI 10.1016/j.cgh.2006.11.014; Dorum S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014056; DOUGLAS AP, 1970, GASTROENTEROLOGY, V59, P414; Gustafsson OJR, 2015, BBA-PROTEINS PROTEOM, V1854, P559, DOI 10.1016/j.bbapap.2014.10.003; Haere P, 2016, SCAND J GASTROENTERO, V51, P1439, DOI 10.1080/00365521.2016.1218540; HALLGREN R, 1989, AM J MED, V86, P56, DOI 10.1016/0002-9343(89)90230-1; Han A, 2013, P NATL ACAD SCI USA, V110, P13073, DOI 10.1073/pnas.1311861110; Iversen R, 2017, CELL REP, V20, P2357, DOI 10.1016/j.celrep.2017.08.036; LANCASTERSMITH M, 1976, J CLIN PATHOL, V29, P592, DOI 10.1136/jcp.29.7.592; Lefranc MP, 1999, NUCLEIC ACIDS RES, V27, P209, DOI 10.1093/nar/27.1.209; Lilja JJ, 1998, CLIN PHARMACOL THER, V64, P477, DOI 10.1016/S0009-9236(98)90130-8; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Matzke MM, 2013, PROTEOMICS, V13, P493, DOI 10.1002/pmic.201200269; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 1997, SCAND J IMMUNOL, V46, P103, DOI 10.1046/j.1365-3083.1997.d01-93.x; Monteleone G, 2001, GUT, V48, P425, DOI 10.1136/gut.48.3.425; Moran CJ, 2012, AM J SURG PATHOL, V36, P1339, DOI 10.1097/PAS.0b013e318254f413; Moron B, 2013, AM J GASTROENTEROL, V108, P1344, DOI 10.1038/ajg.2013.151; NILSEN EM, 1995, GUT, V37, P766, DOI 10.1136/gut.37.6.766; Oberhuber G, 2000, BIOMED PHARMACOTHER, V54, P368, DOI 10.1016/S0753-3322(01)80003-2; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Plotkin JB, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.63; Raki M, 2013, MUCOSAL IMMUNOL, V6, P985, DOI 10.1038/mi.2012.136; Raki M, 2007, P NATL ACAD SCI USA, V104, P2831, DOI 10.1073/pnas.0608610104; Razick S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-405; Roy B, 2017, J IMMUNOL, V199, P782, DOI 10.4049/jimmunol.1700169; Sama VK, 2017, GUT, DOI [10.1136/gutjn1-2017-314461, DOI 10.1136/GUTJN1-2017-314461]; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SCOTT H, 1980, SCAND J GASTROENTERO, V15, P81, DOI 10.3109/00365528009181436; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; SHINER M, 1973, GUT, V14, P1, DOI 10.1136/gut.14.1.1; SHINER M, 1972, LANCET, V1, P1202; Simula MP, 2010, MOL MED, V16, P199, DOI 10.2119/molmed.2009.00173; Snir O, 2015, J IMMUNOL, V194, P5703, DOI 10.4049/jimmunol.1402611; Sollid LM, 2013, NAT REV IMMUNOL, V13, P294, DOI 10.1038/nri3407; Steiner C, 2014, PROTEOMICS, V14, P441, DOI 10.1002/pmic.201300311; Steinsbo O, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5041; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Vizcaino JA, 2016, NUCLEIC ACIDS RES, V44, pD447, DOI 10.1093/nar/gkv1145; Wilhelm M, 2014, NATURE, V509, P582, DOI 10.1038/nature13319; Wisniewski JR, 2013, PROTEOM CLIN APPL, V7, P225, DOI 10.1002/prca.201200046	63	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1563	1579		10.1016/j.ajpath.2018.03.017			17	Pathology	Pathology	GL7NE	WOS:000437387800007	29684362				2019-10-28	
J	Mateer, SW; Mathe, A; Bruce, J; Liu, G; Maltby, S; Fricker, M; Goggins, BJ; Tay, HL; Marks, E; Burns, G; Kim, RY; Minahan, K; Walker, MM; Callister, RC; Foster, PS; Horvat, JC; Hansbro, PM; Keely, S				Mateer, Sean W.; Mathe, Andrea; Bruce, Jessica; Liu, Gang; Maltby, Steven; Fricker, Michael; Goggins, Bridle J.; Tay, Hock L.; Marks, Ellen; Burns, Grace; Kim, Richard Y.; Minahan, Kyra; Walker, Marjorie M.; Callister, Robert C.; Foster, Paul S.; Horvat, Jay C.; Hansbro, Philip M.; Keely, Simon			IL-6 Drives Neutrophil-Mediated Pulmonary Inflammation Associated with Bacteremia in Murine Models of Colitis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DEXTRAN SODIUM-SULFATE; BOWEL-DISEASE; MOUSE MODEL; IN-VIVO; MANIFESTATIONS; CELLS; INTERLEUKIN-6; LUNG; INVOLVEMENT; CYTOKINES	Inflammatory bowel disease (IBD) is associated with several immune-mediated extraintestinal manifestations. More than half of all IBD patients have some form of respiratory pathology, most commonly neutrophil-mediated diseases, such as bronchiectasis and chronic bronchitis. Using murine models of colitis, we aimed to identify the immune mechanisms driving pulmonary manifestations of IBD. We found increased neutrophil numbers in lung tissue associated with the pulmonary vasculature in both trinitrobenzenesulfonic acid- and dextran sulfate sodium-induced models of colitis. Analysis of systemic inflammation identified that neutrophilia was associated with bacteremia and pyrexia in animal models of colitis. We further identified IL-6 as a systemic mediator of neutrophil recruitment from the bone marrow of dextran sulfate sodium animals. Functional inhibition of IL-6 led to reduced systemic and pulmonary neutrophilia, but it did not attenuate established colitis pathology. These data suggest that systemic bacteremia and pyrexia drive IL-6 secretion, which is a critical driver for pulmonary manifestation of IBD. Targeting IL-6 may reduce neutrophil-associated extraintestinal manifestations in IBD patients.	[Mateer, Sean W.; Mathe, Andrea; Bruce, Jessica; Liu, Gang; Maltby, Steven; Fricker, Michael; Goggins, Bridle J.; Tay, Hock L.; Marks, Ellen; Burns, Grace; Kim, Richard Y.; Minahan, Kyra; Callister, Robert C.; Foster, Paul S.; Horvat, Jay C.; Hansbro, Philip M.; Keely, Simon] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW, Australia; [Mateer, Sean W.; Mathe, Andrea; Bruce, Jessica; Liu, Gang; Goggins, Bridle J.; Marks, Ellen; Burns, Grace; Minahan, Kyra; Walker, Marjorie M.; Callister, Robert C.; Keely, Simon] Univ Newcastle, Prior Res Ctr Digest Hlth & Neurogastroenterol, Callaghan, NSW, Australia; [Fricker, Michael; Walker, Marjorie M.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia; [Mateer, Sean W.; Mathe, Andrea; Bruce, Jessica; Liu, Gang; Maltby, Steven; Fricker, Michael; Goggins, Bridle J.; Tay, Hock L.; Marks, Ellen; Burns, Grace; Kim, Richard Y.; Minahan, Kyra; Walker, Marjorie M.; Foster, Paul S.; Horvat, Jay C.; Hansbro, Philip M.; Keely, Simon] Hunter Med Res Inst, New Lambton Hts, NSW, Australia	Keely, S (reprint author), Univ Newcastle, Sch Biomed Sci & Pharm, Hunter Med Res Insti, Lot 1 Kookaburra Circuit, New Lambton Hts, NSW 2305, Australia.	simon.keely@newcastle.edu.au		Fricker, Michael/0000-0002-8587-1774; Liu, Gang/0000-0002-0489-2638; Keely, Simon/0000-0002-1248-9590	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [APP1128487]; Cancer Institute NSW Career Development Fellowship; Hunter Medical Research Institute Bowel of the Ball grant; Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship	Supported by National Health and Medical Research Council project grant APP1128487 and Cancer Institute NSW Career Development Fellowship (S.K.); Hunter Medical Research Institute Bowel of the Ball grant (S.K., A.M., and G.L.); and Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship (B.J.G.).	Al-Mendalawi MD, 2017, ANN THORAC MED, V12, P129, DOI 10.4103/atm.ATM_350_16; Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753; Ando K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102436; Ates F, 2011, TURK J GASTROENTEROL, V22, P293, DOI 10.4318/tjg.2011.0215; Aydin B, 2016, KOREAN J INTERN MED, V31, P853, DOI 10.3904/kjim.2014.238; Beckett EL, 2013, J ALLERGY CLIN IMMUN, V131, P752, DOI 10.1016/j.jaci.2012.11.053; Black H, 2007, CHEST, V131, P524, DOI 10.1378/chest.06-1074; BONNIERE P, 1986, GUT, V27, P919, DOI 10.1136/gut.27.8.919; Campbell EL, 2010, P NATL ACAD SCI USA, V107, P14298, DOI 10.1073/pnas.0914730107; Capitano ML, 2012, BLOOD, V120, P2600, DOI 10.1182/blood-2012-02-409805; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Chou DB, 2012, J LEUKOCYTE BIOL, V92, P123, DOI 10.1189/jlb.1011527; Danese S, 2005, WORLD J GASTROENTERO, V11, P7227, DOI 10.3748/wjg.v11.i46.7227; Diao H, 2005, INFECT IMMUN, V73, P3745, DOI 10.1128/IAI.73.6.3745-3748.2005; EADE OE, 1980, AM J GASTROENTEROL, V73, P154; ELLER J, 1994, ANN NY ACAD SCI, V725, P331, DOI 10.1111/j.1749-6632.1994.tb39816.x; Evans SS, 2015, NAT REV IMMUNOL, V15, P335, DOI 10.1038/nri3843; Fricker M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94040; GARDINER KR, 1995, GUT, V36, P897, DOI 10.1136/gut.36.6.897; Gelberg J, 2013, CAN RESPIR J, V20, P84, DOI 10.1155/2013/202376; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Gut G, 2016, EUR J GASTROEN HEPAT, V28, P708, DOI 10.1097/MEG.0000000000000606; Herrlinger KR, 2002, AM J GASTROENTEROL, V97, P377; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; Ji XQ, 2016, ANN THORAC MED, V11, P249, DOI 10.4103/1817-1737.191877; Ji XQ, 2014, WORLD J GASTROENTERO, V20, P13501, DOI 10.3748/wjg.v20.i37.13501; Keely S, 2014, MUCOSAL IMMUNOL, V7, P114, DOI 10.1038/mi.2013.29; Keely S, 2012, MUCOSAL IMMUNOL, V5, P7, DOI 10.1038/mi.2011.55; Kozak W, 1998, ANN NY ACAD SCI, V856, P33, DOI 10.1111/j.1749-6632.1998.tb08310.x; Levine Jonathan S, 2011, Gastroenterol Hepatol (N Y), V7, P235; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Liu G, 2017, J PATHOL, V243, P510, DOI 10.1002/path.4979; Liu G, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86380; Liu Y, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/124530; Lodes MJ, 2004, J CLIN INVEST, V113, P1296, DOI 10.1172/JCI200420295; Majewski S, 2015, ARCH MED SCI, V11, P1179, DOI 10.5114/aoms.2015.56343; Maltby S, 2014, J IMMUNOL, V193, P4072, DOI 10.4049/jimmunol.1400669; Marks E, 2017, MUCOSAL IMMUNOL, V10, P1224, DOI 10.1038/mi.2016.135; Marks E, 2015, INFLAMM BOWEL DIS, V21, P267, DOI 10.1097/MIB.0000000000000277; Marvisi M, 2000, EUR RESPIR J, V16, P965, DOI 10.1183/09031936.00.16596500; Mateer SW, 2015, J LEUKOCYTE BIOL, V98, P727, DOI 10.1189/jlb.3RU1114-563R; Miyabe Y, 2016, METHODS MOL BIOL, V1407, P179, DOI 10.1007/978-1-4939-3480-5_14; Naito Y, 2004, INT J MOL MED, V14, P191; Netea MG, 2000, CLIN INFECT DIS, V31, pS178, DOI 10.1086/317513; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Rojo OP, 2007, INFLAMM BOWEL DIS, V13, P269, DOI 10.1002/ibd.20019; Pietrzak D, 2017, ARCH DERMATOL RES, V309, P679, DOI 10.1007/s00403-017-1775-7; Rice P, 2005, J IMMUNOL, V174, P3676, DOI 10.4049/jimmunol.174.6.3676; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413; Romano C, 2016, EXPERT OPIN DRUG SAF, V15, P1001, DOI 10.1080/14740338.2016.1186640; Rose CE, 2003, MICROCIRCULATION, V10, P273, DOI 10.1038/sj.mn.7800193; Sander LE, 2008, J IMMUNOL, V181, P3586, DOI 10.4049/jimmunol.181.5.3586; SCHINDLER R, 1990, BLOOD, V75, P40; Seibold F, 1996, EUR J GASTROEN HEPAT, V8, P1095, DOI 10.1097/00042737-199611000-00012; Sheth T, 2014, J CLIN GASTROENTEROL, V48, P308, DOI 10.1097/MCG.0000000000000067; Singh IS, 2008, AM J RESP CELL MOL, V39, P235, DOI 10.1165/rcmb.2007-0294OC; Sommer J, 2014, INT J MOL MED, V34, P651, DOI 10.3892/ijmm.2014.1825; Tornai T, 2017, WORLD J GASTROENTERO, V23, P5412, DOI 10.3748/wjg.v23.i29.5412; Trottier MD, 2012, P NATL ACAD SCI USA, V109, P16594, DOI 10.1073/pnas.1213854109; Tulapurkar ME, 2012, AM J RESP CELL MOL, V46, P807, DOI 10.1165/rcmb.2011-0378OC; Tzanakis N, 1998, RESP MED, V92, P516, DOI 10.1016/S0954-6111(98)90301-8; van Zoelen MAD, 2011, MOL IMMUNOL, V48, P1468, DOI 10.1016/j.molimm.2011.04.001; Wang H, 2013, WORLD J GASTROENTERO, V19, P6794, DOI 10.3748/wjg.v19.i40.6794; Zhao YJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006808	65	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1625	1639		10.1016/j.ajpath.2018.03.016			15	Pathology	Pathology	GL7NE	WOS:000437387800011	29684360				2019-10-28	
J	Hata, T; Suenaga, M; Marchionni, L; Macgregor-Das, A; Yu, J; Shindo, K; Tamura, K; Hruban, RH; Goggins, M				Hata, Tatsuo; Suenaga, Masaya; Marchionni, Luigi; Macgregor-Das, Anne; Yu, Jun; Shindo, Koji; Tamura, Koji; Hruban, Ralph H.; Goggins, Michael			Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SINGLE-NUCLEOTIDE; DUCTAL ADENOCARCINOMA; CLASSIFICATION-SYSTEM; GENETIC ALTERATIONS; PRECURSOR LESIONS; HIGH-RESOLUTION; FAMILY-HISTORY; OCCURS LATE; CANCER; CHROMOTHRIPSIS	To obtain a better understanding of the genetic alterations of high-grade pancreatic intraepithelial neoplasia (HG-PanIN), we performed whole-genome copy number analysis by using single nucleotide polymorphism microarrays and targeted next-generation sequencing of 11 microdissected HG-PanIN and two low-grade PanIN lesions associated with HG-PanIN. HG-PanIN mutation profiles were compared with those of their associated invasive pancreatic ductal adenocarcinoma. All PanIN lesions harbored somatic KRAS mutations. The most common copy number Losses in the HG-PanIN were at the CDKN2A (9p21), TP53 (17p13), and SMAD4 (18q21) loci. Chromosomal losses in HG-PanIN were also found at 6p25-p24, 6q11-q27, 12q24, and 17q23-q24. Biallelic inactivation of CDKN2A and TP53 was detected in five of eight and in three of eight evaluable PanIN lesions, respectively. None of the HG-PanIN lesions had SMAD4 mutations or homozygous deletion. Copy number gains were noted at the MYC (8q24) and CCNE1 (19q12) loci and at 1q25-q31. Four HG-PanINs and one low-grade PanIN harbored chromothripsis-like regions. Five of seven pancreatic ductal adenocarcinomas evaluated had additional mutations that were not found in their associated HG-PanIN. HG-PanIN harbors widespread copy number alterations and commonly shows evidence of biallelic inactivation of CDKN2A and TP53 but not SMAD4. Chromothripsis events contribute to the copy number alterations of HG-PanIN.	[Hata, Tatsuo; Suenaga, Masaya; Macgregor-Das, Anne; Shindo, Koji; Tamura, Koji; Hruban, Ralph H.; Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Marchionni, Luigi; Hruban, Ralph H.; Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Yu, Jun] Johns Hopkins Univ, Sch Med, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA	Goggins, M (reprint author), Johns Hopkins Med Inst, Dept Pathol, CRB2 351,1550 Orleans St, Baltimore, MD 21231 USA.	mgoggins@jhmi.edu	Marchionni, Luigi/S-6774-2017	Marchionni, Luigi/0000-0002-7336-8071; Yu, Jun/0000-0003-3435-6550	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA62924, R01CA176828, U01CA210170]	Supported by NIH grants CA62924, R01CA176828, and U01CA210170 (M.G.); and funding from Susan Wojcicki and Dennis Troper.	Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101; Alberici Paola, 2008, Pathogenetics, V1, P2, DOI 10.1186/1755-8417-1-2; Amin MB, 2017, AJCC CANC STAGING MA; Andea A, 2003, MODERN PATHOL, V16, P996, DOI 10.1097/01.MP.0000087422.24733.62; Bagchi A, 2008, CANCER RES, V68, P2551, DOI 10.1158/0008-5472.CAN-07-2095; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Brune K, 2006, AM J SURG PATHOL, V30, P1067; Cancer Genome Atlas Research Network, 2017, CANCER CELL, V32, DOI DOI 10.1016/J.CCELL.2017.07.007; Cole AJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26191; Di Marco M, 2015, MOL MED REP, V12, P7479, DOI 10.3892/mmr.2015.4344; Diskin SJ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn556; Edge SB, 2010, AJCC CANC STAGING HD; Forment JV, 2012, NAT REV CANCER, V12, P663, DOI 10.1038/nrc3352; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harada T, 2007, BRIT J CANCER, V96, P373, DOI 10.1038/sj.bjc.6603563; Hong SM, 2012, CLIN CANCER RES, V18, P4303, DOI 10.1158/1078-0432.CCR-12-1075; Hosoda W, 2017, J PATHOL, V242, P16, DOI 10.1002/path.4884; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Huang L, 2015, ANNU REV GENOM HUM G, V16, P79, DOI 10.1146/annurev-genom-090413-025352; Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017; Jones MJK, 2012, DEV CELL, V23, P908, DOI 10.1016/j.devcel.2012.10.010; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Lin LJ, 2008, ONCOLOGY-BASEL, V75, P102, DOI 10.1159/000155813; Matsuda Y, 2018, GENE CHROMOSOME CANC, V57, P12, DOI 10.1002/gcc.22479; Matsuda Y, 2017, PANCREAS, V46, P658, DOI 10.1097/MPA.0000000000000786; Murphy SJ, 2016, CANCER RES, V76, P749, DOI 10.1158/0008-5472.CAN-15-2198; Murphy SJ, 2013, GASTROENTEROLOGY, V145, P1098, DOI 10.1053/j.gastro.2013.07.049; Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Real FX, 2003, GASTROENTEROLOGY, V124, P1958, DOI 10.1016/S0016-5085(03)00389-5; Reiter JG, 2017, NAT REV GASTRO HEPAT, V14, P7, DOI 10.1038/nrgastro.2016.190; Rosty C, 2003, AM J SURG PATHOL, V27, P1495, DOI 10.1097/00000478-200312000-00001; Rozenblum E, 1997, CANCER RES, V57, P1731; Shi CJ, 2009, CLIN CANCER RES, V15, P7737, DOI 10.1158/1078-0432.CCR-09-0004; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; van de Wiel MA, 2007, BIOINFORMATICS, V23, P892, DOI 10.1093/bioinformatics/btm030; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Wilentz RE, 2000, CANCER RES, V60, P2002; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yang J, 2016, NUCLEIC ACIDS RES, V44, pW252, DOI 10.1093/nar/gkw434; Yu J, 2017, GUT, V66, P1677, DOI 10.1136/gutjnl-2015-311166; Yu J, 2015, GUT, V64, P1783, DOI 10.1136/gutjnl-2014-308653; Zong CH, 2012, SCIENCE, V338, P1622, DOI 10.1126/science.1229164	51	3	3	3	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1723	1733		10.1016/j.ajpath.2018.03.012			11	Pathology	Pathology	GL7NE	WOS:000437387800019	29684357	Green Published			2019-10-28	
J	Rudzinski, ER; Lockwood, CM; Stohr, BA; Vargas, SO; Sheridan, R; Black, JO; Rajaram, V; Laetsch, TW; Davis, JL				Rudzinski, Erin R.; Lockwood, Christina M.; Stohr, Bradley A.; Vargas, Sara O.; Sheridan, Rachel; Black, Jennifer O.; Rajaram, Veena; Laetsch, Theodore W.; Davis, Jessica L.			Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						NTRK; Trk; immunohistochemistry; soft tissue sarcoma; pediatric	ETV6-NTRK3 GENE FUSION; INFANTILE FIBROSARCOMA; SUBSET	Activating neurotrophic receptor kinase (NTRK) fusions define certain pediatric mesenchymal tumors, including infantile fibrosarcoma and cellular mesoblastic nephroma. Traditionally, molecular confirmation of these fusions has included either fluorescent in situ hybridization for ETV6 rearrangements or reverse-transcriptase polymerase chain reaction for the classic ETV6-NTRK3 fusion. However, these methods overlook variant NTRK rearrangements, which are increasingly appreciated as recurrent events in a subset of pediatric mesenchymal tumors. New therapeutic agents successfully target these fusions and may prevent morbid surgeries in very young children, making recognition of tumors harboring NTRK rearrangements of increasing importance. We evaluated the performance of immunohistochemical (IHC) staining using pan-Trk and TrkA antibodies in 79 pediatric mesenchymal tumors. Negative controls included pediatric mesenchymal tumors not harboring (n=28) or not expected to harbor (n=22) NTRK fusions. NTRK rearrangements were detected predominantly by DNA-based next-generation sequencing assays, specifically UW OncoPlex and UCSF500 Cancer Gene Panel. Pan-Trk IHC (EPR17341) was 97% sensitive and 98% specific for the presence of an NTRK rearrangement, and TrkA IHC (EP1058Y) was 100% sensitive and 63% specific for the presence of an NTRK rearrangement. Tumors with NTRK1 or NTRK2 rearrangements showed cytoplasmic staining, whereas tumors with NTRK3 rearrangements showed nuclear +/- cytoplasmic staining. We conclude that pan-Trk IHC is a highly sensitive and specific marker for NTRK rearrangements in pediatric mesenchymal tumors.	[Rudzinski, Erin R.] Seattle Childrens Hosp, Dept Labs, OC-8-720,4800 Sandpoint Way NE, Seattle, WA 98105 USA; [Lockwood, Christina M.] Univ Washington, Med Ctr, Dept Lab Med, Seattle, WA 98195 USA; [Stohr, Bradley A.; Davis, Jessica L.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Vargas, Sara O.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA; [Sheridan, Rachel] Cincinnati Childrens Hosp, Dept Pathol, Cincinnati, OH USA; [Black, Jennifer O.] Childrens Hosp Colorado, Dept Pathol, Aurora, CO USA; [Rajaram, Veena] Univ Texas Dallas, Southwestern & Childrens Hlth, Dept Pathol, Dallas, TX USA; [Laetsch, Theodore W.] Univ Texas Dallas, Southwestern & Childrens Hlth, Dept Pediat, Dallas, TX USA; [Laetsch, Theodore W.] Univ Texas Dallas, Southwestern & Childrens Hlth, Simmons Comprehens Canc Ctr, Dallas, TX USA; [Davis, Jessica L.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA	Rudzinski, ER (reprint author), Seattle Childrens Hosp, Dept Labs, OC-8-720,4800 Sandpoint Way NE, Seattle, WA 98105 USA.	erin.rudzinski@seattlechildrens.org		Lockwood, Christina/0000-0001-9036-7604			Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Amatu A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000023; Church AJ, 2018, MODERN PATHOL, V31, P463, DOI 10.1038/modpathol.2017.127; Davis JL, 2018, PEDIATR DEVEL PATHOL, V21, P68, DOI 10.1177/1093526617712639; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Hechtman JF, 2017, AM J SURG PATHOL, V41, P1547, DOI 10.1097/PAS.0000000000000911; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Laetsch TW, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26593; Laetsch TW, 2018, LANCET ONCOL; Lee CY, 2017, AM J DERMATOPATH, V39, P181, DOI 10.1097/DAD.0000000000000629; Nagasubramanian R, 2016, PEDIATR BLOOD CANCER, V63, P1468, DOI 10.1002/pbc.26026; Parikh AR, 2017, CANCER DISCOV, V7, P934, DOI 10.1158/2159-8290.CD-17-0704; Pavlick D, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26433; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116	17	22	22	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					927	935		10.1097/PAS.0000000000001062			9	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600010	29683818				2019-10-28	
J	Chen, YR; Chen, YJ; Wang, MC; Medeiros, LJ; Chang, KC				Chen, Ying-Ren; Chen, Yi-Ju; Wang, Ming-Chung; Medeiros, L. Jeffrey; Chang, Kung-Chao			A Newly Recognized Histologic Pattern of IgG4-related Lymphadenopathy Expanding the Morphologic Spectrum	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						IgG4-related sclerosing disease; IgG4-related lymphadenopathy; infectious mononucleosis-like; new morphologic spectrum	EPSTEIN-BARR-VIRUS; INFLAMMATORY MYOFIBROBLASTIC TUMOR; T-CELL LYMPHOMAS; SERUM IGG4; SCLEROSING PANCREATITIS; AUTOIMMUNE-DISEASE; ENTITY; PSEUDOTUMOR; PATHOLOGY; SPLEEN	Immunoglobulin (Ig)G4-related sclerosing disease is a fibroinflammatory disorder characterized by tumor-forming lesions at multiple anatomic sites and by increased serum levels of IgG4. IgG4-related lymphadenopathy, defined as lymphadenopathy developing in patients with IgG4-related sclerosing disease, is known to manifest in 5 histologic patterns: (1) multicentric Castleman disease-like; (2) reactive follicular hyperplasia; (3) interfollicular plasmacytosis with immunoblasts; (4) progressive transformation of germinal centers-like; and (5) inflammatory pseudotumor-like. Herein, we describe a 37-year-old man with an additional pattern of IgG4-related lymphadenopathy that we designate as infectious mononucleosis-like. This pattern is characterized by effacement of the nodal architecture by an infiltrate composed of numerous mature plasma cells, plasmacytoid cells, large basophilic transformed lymphocytes (immunoblasts), and small-sized to medium-sized lymphocytes and histiocytes. Perivascular fibrosis and karyorrhectic debris with fibrin deposition were also focally identified. Epstein-Barr virus-encoded small RNA in situ hybridization showed scattered positive small lymphocytes, 1% to 2%. The initial spike of IgG4 in serum (>4400mg/dL) decreased by half after 1 month of steroid therapy. His condition was stable during 1 year of follow-up. We report this case because the findings expand the morphologic spectrum of IgG4-related lymphadenopathy.	[Chen, Ying-Ren; Chang, Kung-Chao] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan; [Chen, Yi-Ju] I Shou Univ, E DA Hosp, Dept Anat Pathol, Kaohsiung, Taiwan; [Wang, Ming-Chung] Chang Gung Univ, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med,Div Hematol Oncol,Coll Med, Kaohsiung, Taiwan; [Medeiros, L. Jeffrey] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	Chang, KC (reprint author), Natl Cheng Kung Univ & Hosp, Coll Med, Dept Pathol, 138 Sheng Li Rd, Tainan 704, Taiwan.	changkc@mail.ncku.edu.tw	Medeiros, L. Jeffrey/AAB-1018-2019				Carruthers MN, 2015, ANN RHEUM DIS, V74, P14, DOI 10.1136/annrheumdis-2013-204907; Chang KC, 2005, HUM PATHOL, V36, P747, DOI 10.1016/j.humpath.2005.05.003; Chang KC, 2016, AM J SURG PATHOL, V40, P1343, DOI 10.1097/PAS.0000000000000716; Chen CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115836; Chen YP, 2014, LEUKEMIA LYMPHOMA, V55, P2038, DOI 10.3109/10428194.2013.861068; Chen YL, 2010, LEUKEMIA LYMPHOMA, V51, P650, DOI 10.3109/10428191003660631; Cheuk W, 2008, AM J SURG PATHOL, V32, P671, DOI 10.1097/PAS.0b013e318157c068; Cheuk W, 2012, SEMIN DIAGN PATHOL, V29, P226, DOI 10.1053/j.semdp.2012.07.001; Dehner LP, 2004, AM J SURG PATHOL, V28, P1652, DOI 10.1097/00000478-200412000-00016; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Hao MJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003785; Kamisawa T, 2003, J GASTROENTEROL, V38, P982, DOI 10.1007/s00535-003-1175-y; Kamisawa T, 2015, LANCET, V385, P1460, DOI 10.1016/S0140-6736(14)60720-0; KAWAGUCHI K, 1991, HUM PATHOL, V22, P387, DOI 10.1016/0046-8177(91)90087-6; KOO CH, 1984, MEDICINE, V63, P274; Kutok JL, 2001, HUM PATHOL, V32, P1382, DOI 10.1053/hupa.2001.29679; Sato Y, 2010, PATHOL INT, V60, P247, DOI 10.1111/j.1440-1827.2010.02524.x; SHACKS SJ, 1985, ANN ALLERGY, V54, P284; Stone JH, 2012, NEW ENGL J MED, V366, P539, DOI 10.1056/NEJMra1104650; Takeuchi M, 2014, AM J SURG PATHOL, V38, P946, DOI 10.1097/PAS.0000000000000206; Wada Y, 2013, MOD RHEUMATOL, V23, P597, DOI 10.1007/s10165-012-0695-9	23	0	0	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JUL	2018	42	7					977	982		10.1097/PAS.0000000000001076			6	Pathology; Surgery	Pathology; Surgery	GJ6CY	WOS:000435472600015	29738364				2019-10-28	
J	Li, XZ; Feng, CY; Liu, JJ; Liu, J; Li, CY; Xu, C; Niu, Y				Li, Xiaozhen; Feng, Changyun; Liu, Junjun; Liu, Jian; Li, Congying; Xu, Cong; Niu, Yun			The importance of EGFR as a biomarker in molecular apocrine breast cancer	HUMAN PATHOLOGY			English	Article						Molecular apocrine subtype; Epidermal growth factor receptor; Androgen receptor; Prognosis; Therapeutic target	GROWTH-FACTOR RECEPTOR; RANDOMIZED PHASE-II; ANDROGEN RECEPTOR; EXPRESSION; CARCINOMA; COMBINATION; CELLS; AMPLIFICATION; INVOLVEMENT; MUTATIONS	Molecular apocrine breast cancer (MABC) is a molecular subtype with a poor prognosis, and there is urgent need to find new therapeutic targets. Epidermal growth factor receptor (EGFR) plays an important part in regulating the biological behavior of tumor cells, and EGFR-targeted drugs have already been used in therapy for lung and colorectal cancers. The purpose of this study was to analyze the significance of EGFR expression in MABC. A total of 400 patients with invasive breast cancer were analyzed, including 200 MABC and 200 non-MABC cases. Immunohistochemistry and immunofluorescence were carried out to evaluate the expression of estrogen receptor, progesterone receptor, androgen receptor (AR), EGFR, epidermal growth factor receptor 2 (HER2), and other biomarkers. Two hundred twelve (53%) cases were positive for EGFR expression, including 173 MABC and 39 non-MABC cases. EGFR expression was positively associated with AR expression in MABC, as well as with more advanced tumor stage and high Ki67 expression. Patients with EGFR expression had worse outcomes than those without. As a prognosis biomarker, EGFR was significantly associated with poorer clinical outcomes, and the co-expression of EGFR and HER2 often predicted worse outcomes in MABC. This study suggests that the identification of new targets such as HER2 and EGFR may help with assessing the prognosis of patients with MABC. Using both AR and EGFR as therapeutic targets may be especially important in MABC and may help to guide the choice of suitable treatments for individual breast cancer patients. (C) 2018 Elsevier Inc. All rights reserved.	[Li, Xiaozhen; Liu, Junjun; Liu, Jian; Li, Congying; Xu, Cong; Niu, Yun] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp,Minist Educ,Key, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjins Clin Res Ctr Canc,Dept Breast Canc Patho, Tianjin 300060, Peoples R China; [Feng, Changyun] Hosp Linyi, Dept Maternal & Child Hlth, Luozhuang Dist 276016, Linyi, Peoples R China	Niu, Y (reprint author), Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp,Minist Educ,Key, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjins Clin Res Ctr Canc,Dept Breast Canc Patho, Tianjin 300060, Peoples R China.	yunniu2017@126.com			National Science Foundation of ChinaNational Natural Science Foundation of China [81172532]	This work was financially supported by National Science Foundation of China (81172532).	Abd El-Rehim DM, 2004, BRIT J CANCER, V91, P1532, DOI 10.1038/sj.bjc.6602184; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Baselga J, 2013, J CLIN ONCOL, V31, P2586, DOI 10.1200/JCO.2012.46.2408; Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438; Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Changavi Arathi A, 2015, J Lab Physicians, V7, P79, DOI 10.4103/0974-2727.163129; Chen C, 2014, INT J NANOMED, V9, P1039, DOI 10.2147/IJN.S58270; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Cuenca-Lopez MD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-302; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Feng X, 2017, ONCOTARGET, V8, P33365, DOI 10.18632/oncotarget.16497; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Gumuskaya B, 2010, CANCER GENET CYTOGEN, V203, P222, DOI 10.1016/j.cancergencyto.2010.07.118; Lamy PJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2824; Li QQ, 2007, CANCER SCI, V98, P1064, DOI 10.1111/j.1349-7006.2007.00487.x; Liu XZ, 2016, ONCOTARGET, V7, P48905, DOI 10.18632/oncotarget.10211; Migliaccio A, 2005, CANCER RES, V65, P10585, DOI 10.1158/0008-5472.CAN-05-0912; Mishra AK, 2012, INDIAN J MED RES, V135, P843; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Secq V, 2014, BRIT J CANCER, V110, P1045, DOI 10.1038/bjc.2013.794; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Xu JW, 2011, INT J ONCOL, V39, P1501, DOI 10.3892/ijo.2011.1143; Yu Q, 2011, ANN ONCOL, V22, P1288, DOI 10.1093/annonc/mdq586	27	3	3	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						1	10		10.1016/j.humpath.2018.01.016			10	Pathology	Pathology	GM6ZA	WOS:000438326300001	29409930				2019-10-28	
J	Agaimy, A; Amin, MB; Gill, A; Popp, B; Reis, A; Berney, DM; Magi-Galluzzi, C; Sibony, M; Smith, SC; Suster, S; Trpkov, K; Hes, O; Hartmann, A				Agaimy, Abbas; Amin, Mahul B.; Gill, Anthony; Popp, Bernt; Reis, Andre; Berney, Daniel M.; Magi-Galluzzi, Cristina; Sibony, Mathilde; Smith, Steven C.; Suster, Saul; Trpkov, Kiril; Hes, Ondrej; Hartmann, Arndt			SWI/SNF protein expression status in fumarate hydratase-deficient renal cell. carcinoma: immunohisto-chemical analysis of 32 tumors from 28 patients	HUMAN PATHOLOGY			English	Article						SWI/SNF complex; HLRCC; Fumarate hydratase; Renal cell carcinoma; SMARCB1; INI1; ARID1A	COLLECTING DUCT CARCINOMA; HEREDITARY LEIOMYOMATOSIS; MEDULLARY CARCINOMA; DOWN-REGULATION; CANCER; MUTATION; FEATURES; PBRM1	Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive RCC type, originally described in the setting of hereditary leiomyomatosis and RCC syndrome, which is defined by germline FH gene inactivation. Inactivation of components of the switch/sucrose nonfermentable (SWI/ SNF) chromatin remodeling complex is involved in renal medullary carcinoma (SMARCB1/INI1 loss), clear cell RCC (PBRM1 loss), and subsets of dedifferentiated RCC of clear cell, chromophobe, and papillary types (loss of different SWI/SNF components). FH-RCC and SWI/SNF-deficient RCC share anaplastic nuclear features and highly aggressive course. We analyzed 32 FH-RCCs from 28 patients using 7 commercially available SWI/SNF antibodies (SMARCB1/INI1, SMARCA2, SMARCA4, SMARCC1, SMARCC2, PBRM1, and ARID1A). Variable loss of SMARCB1, ARID1A, and SMARCC1 was observed in 1 of 31, 2 of 31, and 1 of 29 evaluable cases, respectively; 3 of these 4 SWI/SNF-deficient tumors had confirmed FH mutations. No correlation of SWI/SNF loss with solid or sarcomatoid features was observed. Two Minors with SMARCB1 and ARID IA deficiency had available SWI/SNF molecular data; both lacked SMARCB1 and ARIDIA mutations. The remaining 5 SWI/SNF components were intact in all cases. Especially PBRM1 seems not to be involved in the pathogenesis or progression of FH-RCC. Our data showed that a subset of FH-RCC (12%) have a variable loss of SWI/SNF complex subunits, likely as secondary genetic events. This should not be confused with SWI/SNF-deficient RCC of other types. Evaluation of FH and SWI/SNF together with comprehensive molecular genetic profiling is needed to explore possible prognostic implications of FH/SWI-SNF double deficiency and to better understand the somatic mutation landscape in high-grade RCC. (C) 2018 Elsevier Inc. All rights reserved.	[Agaimy, Abbas; Hartmann, Arndt] Friedrich Alexander Univ Erlangen Nuremberg, Inst Pathol, Univ Hosp Erlangen, D-91054 Erlangen, Germany; [Amin, Mahul B.] Univ Tennessee Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38103 USA; [Gill, Anthony] Univ Sydney, Sydney, NSW 2006, Australia; [Gill, Anthony] Royal North Shore Hosp, Kolling Inst, Canc Diag & Pathol Grp, St Leonards, NSW 2065, Australia; [Gill, Anthony] Royal North Shore Hosp, Dept Anat Pathol, NSW Hlth Pathol, St Leonards, NSW 2065, Australia; [Popp, Bernt; Reis, Andre] Friedrich Alexander Univ Erlangen Nurnberg FAU Er, Inst Human Genet, Erlangen, Germany; [Berney, Daniel M.] Queen Mary Univ London, Barts Canc Inst, London ECIM 6BQ, England; [Magi-Galluzzi, Cristina] Cleveland Clin, Cleveland, OH 44195 USA; [Sibony, Mathilde] Hosp Cochin, F-75679 Paris, France; [Smith, Steven C.] VCU Sch Med, Dept Pathol, Richmond, VA 23298 USA; [Suster, Saul] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Trpkov, Kiril] Calgary Lab Serv, Calgary, AB, Canada; [Trpkov, Kiril] Univ Calgary, Calgary, AB, Canada; [Hes, Ondrej] Charles Univ Prague, Plzen 30460, Czech Republic; [Hes, Ondrej] Univ Hosp Plzen, Plzen 30460, Czech Republic	Agaimy, A (reprint author), Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de	Reis, Andre/D-2309-2009; Popp, Bernt/M-2157-2019; Gill, Anthony J./M-5015-2019	Reis, Andre/0000-0002-6301-6363; Popp, Bernt/0000-0002-3679-1081; 			Agaimy A, 2017, AM J SURG PATHOL, V41, P253, DOI 10.1097/PAS.0000000000000787; Agaimy A, 2014, ADV ANAT PATHOL, V21, P394, DOI 10.1097/PAP.0000000000000038; Al Refae M, 2007, NAT CLIN PRACT ONCOL, V4, P256, DOI 10.1038/ncponc0773; Alaghehbandan R, 2017, ANN DIAGN PATHOL, V29, P17, DOI 10.1016/j.anndiagpath.2017.04.007; Amin MB, 2014, AM J SURG PATHOL, V38, P871, DOI 10.1097/PAS.0000000000000222; Chen YB, 2014, AM J SURG PATHOL, V38, P627, DOI 10.1097/PAS.0000000000000163; Cheng JX, 2008, MODERN PATHOL, V21, P647, DOI 10.1038/modpathol.2008.44; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035; DAVIS CJ, 1995, AM J SURG PATHOL, V19, P1, DOI 10.1097/00000478-199501000-00001; Gao WH, 2017, P NATL ACAD SCI USA, V114, P1027, DOI 10.1073/pnas.1619726114; Kothandapani A, 2012, EXP CELL RES, V318, P1973, DOI 10.1016/j.yexcr.2012.06.011; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Liu XM, 2013, HUM MUTAT, V34, pE2393, DOI 10.1002/humu.22376; Llamas-Velasco M, 2014, J CUTAN PATHOL, V41, P859, DOI 10.1111/cup.12396; Marquez SB, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00372; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Moch H, 2016, WHO CLASSIFICATION T; Ohe C, 2018, AM J SURG PATHOL, V42, P279, DOI 10.1097/PAS.0000000000001000; Sciacovelli M, 2016, NATURE, V540, DOI 10.1038/nature20144; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Smith SC, 2016, AM J SURG PATHOL, V40, P1457, DOI 10.1097/PAS.0000000000000719; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wang XF, 2014, CLIN CANCER RES, V20, P21, DOI 10.1158/1078-0432.CCR-13-0280; Yan HB, 2014, CARCINOGENESIS, V35, P867, DOI 10.1093/carcin/bgt398	28	3	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						139	146		10.1016/j.humpath.2018.04.004			8	Pathology	Pathology	GM6ZA	WOS:000438326300017	29689242				2019-10-28	
J	Kuwahara, K; Kudo, K; Yashima-Abo, A; Katayama, K; Kojima, K; Tone, K; Ito, E; Nakazawa, A; Iwafuchi, H; Kurose, A				Kuwahara, Kazuhiko; Kudo, Ko; Yashima-Abo, Akiko; Katayama, Kosuke; Kojima, Keiko; Tone, Kiyoshi; Ito, Etsuro; Nakazawa, Atsuko; Iwafuchi, Hideto; Kurose, Akira			Classic Hodgkin lymphoma with osseous involvement mimicking Langerhans cell histiocytosis in a child	HUMAN PATHOLOGY			English	Article						Classic Hodgkin lymphoma; Osseous involvement by lymphoma; Langerhans cell histiocytosis; Intraoperative cytology; Intraoperative frozen-section analysis	PRIMARY BONE LYMPHOMA; OF-THE-LITERATURE; RARE CASE-REPORT; DISEASE	Hodgkin lymphoma (HL) commonly presents superficial lymphadenopathy. In addition, HI, cells can arise in various organs including the liver and spleen as an extranodal lymphoma. HI, in bone is unusual at the initial diagnosis, although some cases show late-stage localization of lymphoma cells to bone. We report the rare case of a young patient with cranial bone classic HL, presumably originating from the skull without any involvement of lymph nodes. As the main clinical manifestation was only tumor mass in the skull without osteoscopic pain, the tentative diagnosis of Langerhans cell histiocytosis was histologically confirmed by an excisional biopsy. Before the final pathological diagnosis as classic HL, we noticed several small lesions in extranodal regions through systemic surveys, suggesting that the cranial lesion appeared antecedent to those lesions. This is a rare and instructive case of cranial bone HL for which a histological diagnosis has been meticulously made. (C) 2018 Elsevier Inc. All rights reserved.	[Kuwahara, Kazuhiko; Kojima, Keiko; Tone, Kiyoshi; Kurose, Akira] Hirosaki Univ, Dept Anat Pathol, Grad Sch Med, 5 Zaifu, Hirosaki, Aomori 0368562, Japan; [Kuwahara, Kazuhiko] Aichi Canc Ctr Res Inst, Div Immunol, Nagoya, Aichi 4648681, Japan; [Kudo, Ko; Ito, Etsuro] Hirosaki Univ, Dept Pediat, Grad Sch Med, Hirosaki, Aomori 0368562, Japan; [Yashima-Abo, Akiko] Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 0283694, Japan; [Katayama, Kosuke] Hirosaki Univ, Dept Neurosurg, Grad Sch Med, Hirosaki, Aomori 0368562, Japan; [Nakazawa, Atsuko] Saitama Childrens Med Ctr, Dept Clin Res, Saitama 3308777, Japan; [Iwafuchi, Hideto] Shizuoka Childrens Hosp, Dept Pathol, Shizuoka 4208660, Japan; [Kuwahara, Kazuhiko] Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol & Cellular Pathol, Niigata 9518510, Japan; [Tone, Kiyoshi] Shizuoka Canc Ctr, Div Pathol, Shizuoka 4118777, Japan	Kuwahara, K; Kurose, A (reprint author), Hirosaki Univ, Dept Anat Pathol, Grad Sch Med, 5 Zaifu, Hirosaki, Aomori 0368562, Japan.; Kuwahara, K (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Mol & Cellular Pathol, Niigata 9518510, Japan.	kkuwahara@med.niigata-u.ac.jp; akurose@hirosaki-u.ac.jp					Binesh F, 2012, BMJ CASE REP, V2012; Gallamini A, 2016, SEMIN HEMATOL, V53, P148, DOI 10.1053/j.seminhematol.2016.05.005; Gebert C, 2005, J CANCER RES CLIN, V131, P163, DOI 10.1007/s00432-004-0641-0; Gouri SRM, 2014, J CLIN DIAGN RES, V8, P162, DOI 10.7860/JCDR/2014/6716.3954; Janjetovic Snjezana, 2013, Tumori, V99, pe96, DOI 10.1700/1334.14813; Kluge R, 2017, SEMIN NUCL MED, V47, P242, DOI 10.1053/j.semnuclmed.2017.01.001; Li Y, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-64; Liu Y, 2014, OTOL NEUROTOL, V35, pE95, DOI 10.1097/MAO.0000000000000177; Mandal PK, 2015, BLOOD RES, V50, P256, DOI 10.5045/br.2015.50.4.256; Mauz-Korholz C, 2010, J CLIN ONCOL, V28, P3680, DOI 10.1200/JCO.2009.26.9381; Ostrowski ML, 1999, CANCER, V85, P1166, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1166::AID-CNCR22>3.0.CO;2-V; Rosenberg AE, 2013, CURR OPIN ONCOL, V25, P571, DOI 10.1097/01.cco.0000432522.16734.2d; Sato TSP, 2008, PEDIATR RADIOL, V38, P1338, DOI 10.1007/s00247-008-0964-0; Tone K, 2015, DIAGN CYTOPATHOL, V43, P366, DOI 10.1002/dc.23240; Wang J, 2016, ONCOTARGETS THER, V9, P4923, DOI 10.2147/OTT.S108000; Yang P, 2017, ONCOL LETT, V13, P1288, DOI 10.3892/ol.2017.5553	16	0	0	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						147	151		10.1016/j.humpath.2017.12.016			5	Pathology	Pathology	GM6ZA	WOS:000438326300018	29307624				2019-10-28	
J	O'Brien, O; Ryan, E; Creavin, B; Kelly, ME; Mohan, HM; Geraghty, R; Winter, DC; Sheahan, K				O'Brien, Odharnaith; Ryan, Eanna; Creavin, Ben; Kelly, Michael E.; Mohan, Helen M.; Geraghty, Robert; Winter, Des C.; Sheahan, Kieran			Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens	JOURNAL OF CLINICAL PATHOLOGY			English	Article							MICROSATELLITE INSTABILITY; LYNCH-SYNDROME; CLINICAL MANAGEMENT; BREAST-CANCER; CORE BIOPSY; GUIDELINES; RISK; RECOMMENDATIONS; HISTOPATHOLOGY; METAANALYSIS	Background Microsatellite instability is reflective of a deficient mismatch repair system (dMMR), which may be due to either sporadic or germline mutations in the relevant mismatch repair (MMR) gene. MMR status is frequently determined by immunohistochemistry (IHC) for mismatch repair proteins (MMRPs) on colorectal cancer (CRC) resection specimens. However, IHC testing performed on endoscopic biopsy may be as reliable as that performed on surgical resections. Aim We aimed to evaluate the reliability of MMR IHC staining on preoperative CRC endoscopic biopsies compared with matched-surgical resection specimens. Methods A retrospective search of our institution's histopathology electronic database was performed. Patients with CRC who had MMR IHC performed on both their preoperative endoscopic biopsy and subsequent resection from January 2010 to January 2016 were included. Concordance of MMR staining between biopsy and resection specimens was assessed. Results From 2000 to 2016, 53 patients had MMR IHC performed on both their preoperative colorectal endoscopic biopsy and resection specimens; 10 patients (18.87%) demonstrated loss of >= 1 MMRP on their initial endoscopic tumour biopsy. The remainder (81.13%) showed preservation of staining for all MMRPs. There was complete agreement in MMR IHC status between the preoperative endoscopic biopsies and corresponding resection specimens in all cases (kappa=1.000, P<0.000) with a sensitivity of 100% (95% CI 69.15 to 100) and specificity of 100% (95% CI 91.78 to 100) for detection of dMMR. Conclusion Endoscopic biopsies are a suitable source of tissue for MMR IHC analysis. This may provide a number of advantages to both patients and clinicians in the management of CRC.	[O'Brien, Odharnaith; Geraghty, Robert; Sheahan, Kieran] St Vincents Univ Hosp, Dept Histopathol, Dublin D04 Y8V0, Ireland; [Ryan, Eanna; Creavin, Ben; Kelly, Michael E.; Mohan, Helen M.; Winter, Des C.] St Vincents Univ Hosp, Dept Surg, Dublin, Ireland	O'Brien, O (reprint author), St Vincents Univ Hosp, Dept Histopathol, Dublin D04 Y8V0, Ireland.	odharnaithobrien@gmail.com	Ryan, Eanna J./H-6829-2019	Ryan, Eanna J./0000-0003-2609-0836; Creavin, Ben/0000-0001-8209-4810			Andre T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3531; ASCO, 2017, ARCH PATHOL LAB MED, V141; Balmana J, 2013, ANN ONCOL, V24, P73, DOI 10.1093/annonc/mdt209; Beamer LC, 2012, J CLIN ONCOL, V30, P1058, DOI 10.1200/JCO.2011.38.4719; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Carethers JM, 1999, GASTROENTEROLOGY, V117, P123, DOI 10.1016/S0016-5085(99)70558-5; Daly MB, 2014, J NATL COMPR CANC NE, V12, P1326, DOI 10.6004/jnccn.2014.0127; Des Guetz G, 2009, EUR J CANCER, V45, P1890, DOI 10.1016/j.ejca.2009.04.018; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Giardiello FM, 2014, GASTROINTEST ENDOSC, V80, P197, DOI 10.1016/j.gie.2014.06.006; Guastadisegni C, 2010, EUR J CANCER, V46, P2788, DOI 10.1016/j.ejca.2010.05.009; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hagan Suzanne, 2013, EPMA J, V4, P3, DOI 10.1186/1878-5085-4-3; Haraldsdottir S, 2016, FAM CANCER, V15, P253, DOI 10.1007/s10689-015-9856-2; Heneghan HM, 2015, COLORECTAL DIS, V17, P382, DOI 10.1111/codi.12868; Hodi Z, 2007, J CLIN PATHOL, V60, P299, DOI 10.1136/jcp.2006.036665; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; Joost P, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-126; Kim JH, 2014, WORLD J GASTROENTERO, V20, P4230, DOI 10.3748/wjg.v20.i15.4230; Kumarasinghe AP, 2010, PATHOLOGY, V42, P414, DOI 10.3109/00313025.2010.493862; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043; Morton UKD, 2012, LANCET ONCOL, V13, P1152, DOI 10.1016/S1470-2045(12)70348-0; Mukherjee A, 2010, HERED CANCER CLIN PR, V8, DOI 10.1186/1897-4287-8-9; NCCN (National Comprehensive Cancer Network), 2015, GEN FAM HIGH RISK AS; NICE, 2017, MOL TEST STRAT LYNCH; Ouakrim DA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4970; Overman MJ, 2017, J CLIN ONCOL, V35; Palomaki GE, 2009, GENET MED, V11, P42, DOI 10.1097/GIM.0b013e31818fa2db; Park SY, 2009, AM J SURG, V197, P266, DOI 10.1016/j.amjsurg.2007.11.024; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.186; Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571; Rubenstein JH, 2015, GASTROENTEROLOGY, V149, P777, DOI 10.1053/j.gastro.2015.07.036; Ryan E, 2017, CRIT REV ONCOL HEMAT, V116, P38, DOI 10.1016/j.critrevonc.2017.05.006; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Shia J, 2003, AM J SURG PATHOL, V27, P1407, DOI 10.1097/00000478-200311000-00002; Shia J, 2008, J MOL DIAGN, V10, P293, DOI 10.2353/jmoldx.2008.080031; Shia JR, 2011, AM J SURG PATHOL, V35, P447, DOI 10.1097/PAS.0b013e31820a091d; Sinicrope FA, 2013, CANCER-AM CANCER SOC, V119, P2765, DOI 10.1002/cncr.28133; Sinicrope FA, 2011, FUTURE ONCOL, V7, P467, DOI [10.2217/FON.11.5, 10.2217/fon.11.5]; Suraweera N, 2002, GASTROENTEROLOGY, V123, P1804, DOI 10.1053/gast.2002.37070; Syngal S, 2015, AM J GASTROENTEROL, V110, P223, DOI 10.1038/ajg.2014.435; Vasen HFA, 2007, J MED GENET, V44, P353, DOI 10.1136/jmg.2007.048991; Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356; Vilkin A, 2015, HUM PATHOL, V46, P1705, DOI 10.1016/j.humpath.2015.07.009; Vilkin A, 2014, HUM PATHOL, V45, P2029, DOI 10.1016/j.humpath.2014.07.005; Warrier SK, 2011, DIS COLON RECTUM, V54, P1480, DOI 10.1097/DCR.0b013e318231db1f; Wright CL, 2003, AM J SURG PATHOL, V27, P1393, DOI 10.1097/00000478-200311000-00001	49	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					631	636		10.1136/jclinpath-2017-204946			6	Pathology	Pathology	GR3CP	WOS:000442466600010	29419411				2019-10-28	
J	Jama, N; Farquhar, N; Butt, Z; Coupland, SE; Sacco, JJ; Scase, T; Fielding, AB; Coulson, JM; Kalirai, H; Killick, DR				Jama, N.; Farquhar, N.; Butt, Z.; Coupland, S. E.; Sacco, J. J.; Scase, T.; Fielding, A. B.; Coulson, J. M.; Kalirai, H.; Killick, D. R.			Altered Nuclear Expression of the Deubiquitylase BAP1 Cannot be Used as a Prognostic Marker for Canine Melanoma	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						BAP1; dog; immunohistochemistry; melanoma	BRCA1-ASSOCIATED PROTEIN-1; UBIQUITIN HYDROLASE; TUMOR-SUPPRESSOR; UVEAL MELANOMA; MUTATION; MESOTHELIOMA; DISTINCT	BRCA1-associated protein-1 (BAP1) is a nuclear localized deubiquitylating enzyme that belongs to the ubiquitin c-terminal hydrolase subfamily. The encoded protein is highly homologous between man and dogs, suggesting a functional significance preserved by evolution. BAP1 has multiple properties, including tumour suppressor activity. Loss of BAP1 function is implicated in the oncogenesis of several types of cancers including uveal, mucosal and some cutaneous melanomas in humans, as well as in mesothelioma. In this study we investigate the significance of BAP1 in canine melanoma. Nuclear BAP1 protein was detected in five canine oral melanoma cell lines using an antibody commonly used for analysis of human tissues. BAP1 loss of function mutations often lead to loss of nuclear BAP1 (nBAP1) expression in humans; this is associated with a poorer prognosis in uveal and mucosal melanoma. Therefore, as a prelude to a study evaluating the prognostic significance of nBAP1 expression in dogs, immunohistochemistry (IHC) was used to assess cases of canine melanoma for nBAP1 expression. In 89 cases where tumour cells were identified by melan-A labelling, 100% of tumour cells were positive for nBAP1 expression, including eight uveal tract and 29 oral mucosal melanomas. This finding indicates that BAP1 IHC cannot be used as a prognostic marker in canine uveal and mucosal melanoma. Moreover, this observation suggests that either BAP1 has a different functional significance in canine melanoma or that loss of BAP1 function is achieved by a different route. This is a novel finding that warrants further investigation to determine the comparative biological relevance. (C) 2018 The Authors. Published by Elsevier Ltd.	[Jama, N.; Killick, D. R.] Univ Liverpool, Inst Vet Sci, Dept Small Anim Clin Sci, Liverpool, Merseyside, England; [Jama, N.; Farquhar, N.; Coupland, S. E.; Sacco, J. J.; Kalirai, H.] Univ Liverpool, Inst Translat Med, Mol & Clin Canc Med, Liverpool, Merseyside, England; [Jama, N.; Butt, Z.; Fielding, A. B.; Coulson, J. M.] Univ Liverpool, Inst Translat Med, Cellular & Mol Physiol, Liverpool, Merseyside, England; [Scase, T.] Bridge Pathol Ltd, 637 Gloucester Rd, Bristol, Avon, England	Killick, DR (reprint author), Univ Liverpool, Inst Vet Sci, Dept Small Anim Clin Sci, Liverpool, Merseyside, England.	drk@livcrpool.ac.uk		Coulson, Judy/0000-0003-2191-2001; Fielding, Andrew/0000-0002-3170-9966	Fight for Sight [1497/98]; Wellcome [102382/Z/13/Z]; NWCR [CR1050]	This project was undertaken as a University of Liverpool MRes project by N. Jama. This specific research project did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors, but co-authors are supported by the following organisations: N. Farquhar, Fight for Sight, 1497/98, Z. Butt, Wellcome, 102382/Z/13/Z, and A. Fielding, NWCR, CR1050.	Abdel-Rahman MH, 2011, J MED GENET, V48, P856, DOI 10.1136/jmedgenet-2011-100156; Aina OH, 2011, VET IMMUNOL IMMUNOP, V143, P11, DOI 10.1016/j.vetimm.2011.05.018; Andrici J, 2016, HUM PATHOL, V51, P9, DOI 10.1016/j.humpath.2015.12.012; Carbone M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-179; Cigognetti M, 2015, MODERN PATHOL, V28, P1043, DOI 10.1038/modpathol.2015.65; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Dey A, 2012, SCIENCE, V337, P1541, DOI 10.1126/science.1221711; Farquhar N, 2018, J PATHOL CLIN RES, V4, P26, DOI 10.1002/cjp2.86; Gillard M, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12170; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kalirai H, 2014, BRIT J CANCER, V111, P1373, DOI 10.1038/bjc.2014.417; Komander D, 2009, BIOCHEM SOC T, V37, P937, DOI 10.1042/BST0370937; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Koopmans AE, 2014, MODERN PATHOL, V27, P1321, DOI 10.1038/modpathol.2014.43; Machida YJ, 2009, J BIOL CHEM, V284, P34179, DOI 10.1074/jbc.M109.046755; Misaghi S, 2009, MOL CELL BIOL, V29, P2181, DOI 10.1128/MCB.01517-08; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ramos-Vara JA, 2011, VET PATHOL, V48, P443, DOI 10.1177/0300985810382095; Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009; Sacco JJ, 2015, ONCOTARGET, V6, P13757, DOI 10.18632/oncotarget.3765; Schiffman JD, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0231; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Smith SH, 2002, VET PATHOL, V39, P651, DOI 10.1354/vp.39-6-651; Song H, 2017, ONCOTARGET, V8, P29080, DOI 10.18632/oncotarget.16175; Sun Xiao-Xin, 2014, World J Biol Chem, V5, P75, DOI 10.4331/wjbc.v5.i2.75; Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912; Ventii KH, 2008, CANCER RES, V68, P6953, DOI 10.1158/0008-5472.CAN-08-0365; Wiesner T, 2012, AM J SURG PATHOL, V36, P818, DOI 10.1097/PAS.0b013e3182498be5; Yoshikawa Y, 2012, CANCER SCI, V103, P868, DOI 10.1111/j.1349-7006.2012.02223.x	33	0	0	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						50	58		10.1016/j.jcpa.2018.06.007			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400007	30060843	Green Published, Other Gold			2019-10-28	
J	Liu, C; Xiao, FZ; Hoisington-Lopez, J; Lang, K; Quenzel, P; Duffy, B; Mitra, RD				Liu, Chang; Xiao, Fangzhou; Hoisington-Lopez, Jessica; Lang, Kathrin; Quenzel, Philipp; Duffy, Brian; Mitra, Robi D.			Accurate Typing of Human Leukocyte Antigen Class I Genes by Oxford Nanopore Sequencing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							REAL-TIME; CANDIDATES; RESOLUTION	Oxford Nanopore Technologies' MinION has expanded the current DNA sequencing toolkit by delivering long read lengths and extreme portability. The MinION has the potential to enable expedited point-of-care human leukocyte antigen (HLA) typing, an assay routinely used to assess the immunologic compatibility between organ donors and recipients, but the platform's high error rate makes it challenging to type alleles with accuracy. We developed and validated accurate typing of HLA by Oxford nanopore (Athlon), a bioinformatic pipeline that i) maps nanopore reads to a database of known HLA alleles, ii) identifies candidate alleles with the highest read coverage at different resolution levels that are represented as branching nodes and leaves of a tree structure, iii) generates consensus sequences by remapping the reads to the candidate alleles, and iv) calls the final diploid genotype by blasting consensus sequences against the reference database. Using two independent data sets generated on the R9.4 flow cell chemistry, Athlon achieved a 100% accuracy in class I HLA typing at the two-field resolution.	[Liu, Chang] Washington Univ, Sch Med, Dept Pathol & Immunol, Div Lab & Genom Med, St Louis, MO 63110 USA; [Hoisington-Lopez, Jessica; Mitra, Robi D.] Washington Univ, Sch Med, Dept Genet, Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA; [Xiao, Fangzhou] CALTECH, Div Biol & Biol Engn, Pasadena, CA 91125 USA; [Lang, Kathrin; Quenzel, Philipp] DKMS Life Sci Lab GmbH, Dresden, Germany; [Duffy, Brian] Barnes Jewish Hosp, HLA Lab, St Louis, MO USA	Liu, C (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, Div Lab & Genom Med, St Louis, MO 63110 USA.; Mitra, RD (reprint author), Washington Univ, Sch Med, Dept Genet, Ctr Genome Sci & Syst Biol, St Louis, MO 63110 USA.	cliu32@wustl.edu; rmitra@genetics.wustl.edu			Washington University Hematology Scholars [K12-HL087107-07]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U0IMH109133, R01NS076993]; Children's Discovery Institute [MC-II-2016-533]	Supported by the Washington University Hematology Scholars K12 award K12-HL087107-07 (C.L.), NIH grants U0IMH109133 and R01NS076993 (R.D.M.), and Children's Discovery Institute grant MC-II-2016-533 (R.D.M.).	Ammar Ron, 2015, F1000Res, V4, P17, DOI 10.12688/f1000research.6037.2; Ashton PM, 2015, NAT BIOTECHNOL, V33, P296, DOI 10.1038/nbt.3103; Baxter-Lowe LA, 2016, HUM IMMUNOL, V77, P395, DOI 10.1016/j.humimm.2016.03.003; Benitez-Paez A, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix043; Benitez-Paez A, 2016, GIGASCIENCE, V5, DOI 10.1186/s13742-016-0111-z; Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421; Chaisson MJ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-238; Deamer D, 2016, NAT BIOTECHNOL, V34, P518, DOI 10.1038/nbt.3423; Duquesnoy RJ, 2015, AM J TRANSPLANT, V15, P923, DOI 10.1111/ajt.13167; Erlich H, 2012, TISSUE ANTIGENS, V80, P1, DOI 10.1111/j.1399-0039.2012.01881.x; GARRISON E, 2012, GENOMICS, V1207, P3907, DOI DOI 10.1101/1207.3907; Greninger AL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0220-9; Hosomichi K, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-355; Hou L, 2017, HLA, V89, P39, DOI 10.1111/tan.12942; Howard CA, 2015, BIOL BLOOD MARROW TR, V21, P4, DOI 10.1016/j.bbmt.2014.09.017; Ip Camilla L C, 2015, F1000Res, V4, P1075, DOI 10.12688/f1000research.7201.1; Jain M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1103-0; Jain M, 2015, NAT METHODS, V12, P351, DOI [10.1038/NMETH.3290, 10.1038/nmeth.3290]; Kerkhof LJ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0336-9; Lan JH, 2015, HUM IMMUNOL, V76, P166, DOI 10.1016/j.humimm.2014.12.016; Leggett R, 2017, PEERJ PREPRINTS, V5; Li CH, 2016, GIGASCIENCE, V5, DOI 10.1186/s13742-016-0140-7; Loman NJ, 2015, NAT METHODS, V12, P733, DOI [10.1038/NMETH.3444, 10.1038/nmeth.3444]; Loman NJ, 2014, BIOINFORMATICS, V30, P3399, DOI 10.1093/bioinformatics/btu555; Norris AL, 2016, CANCER BIOL THER, V17, P246, DOI 10.1080/15384047.2016.1139236; Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Shin J, 2016, SCI REP-UK, V6, DOI 10.1038/srep29681; Szalay T, 2015, NAT BIOTECHNOL, V33, P1087, DOI 10.1038/nbt.3360	30	2	2	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					428	435		10.1016/j.jmoldx.2018.02.006			8	Pathology	Pathology	GN0MH	WOS:000438662200004	29625249	Green Published			2019-10-28	
J	Kang, HJ; Jeong, HJ; Kim, SW; Yu, E; Lee, YJ; Kim, SY; Kim, J				Kang, Hyo Jeong; Jeong, Hui Jeong; Kim, So-Woon; Yu, Eunsil; Lee, Young-Joo; Kim, So Yeon; Kim, Jihun			Hepatocellular Carcinoma Arising in a Huge Hepatocellular Adenoma with Bone Marrow Metaplasia	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Carcinoma; hepatocellular; Adenoma; liver cell; Bone marrow metaplasia; beta-catenin	CLASSIFICATION; TUMORS	Hepatocellular adenoma (HCA) is the most common type of benign liver tumor, and its major complication is malignant transformation to hepatocellular carcinoma (HCC). Here, we report a case of HCC arising in HCA with bone marrow metaplasia in a 24-year-old Korean woman who presented with abdominal discomfort. A huge liver mass was found on abdominal ultrasonography. She underwent surgical hepatic resection, and the resected specimen was entirely involved by a 20-cm-sized tumor. Histological review revealed a well differentiated HCC arising from inflammatory HCA with beta-catenin nuclear positivity and bone marrow metaplasia that contained hematopoietic cells. This case was unique because malignant transformation, inflammatory type HCA, beta-catenin nuclear staining, and bone marrow metaplasia were simultaneously observed. Additionally, it should be noted that a large HCA with beta-catenin activation can undergo malignant transformation and should be surgically resected in a timely manner.	[Kang, Hyo Jeong; Jeong, Hui Jeong; Kim, So-Woon; Yu, Eunsil; Kim, Jihun] Univ Ulsan, Coll Med, Dept Pathol, Seoul, South Korea; [Kang, Hyo Jeong] Univ Ulsan, Coll Med, Dept Physiol, Seoul, South Korea; [Yu, Eunsil] Univ Ulsan, Coll Med, Asan Liver Ctr, Seoul, South Korea; [Lee, Young-Joo] Univ Ulsan, Coll Med, Dept Surg, Asan Med Ctr, Seoul, South Korea; [Kim, So Yeon] Univ Ulsan, Coll Med, Dept Radiol, Asan Med Ctr, Seoul, South Korea	Kim, J (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	Jihunkim@amc.seoul.kr					Bioulac-Sage P, 2017, SEMIN DIAGN PATHOL, V34, P112, DOI 10.1053/j.semdp.2016.12.007; Bioulac-Sage P, 2010, DIGEST SURG, V27, P39, DOI 10.1159/000268406; Chang CY, 2013, INT J HEPATOL, DOI 10.1155/2013/604860; Chu HH, 2013, CLIN MOL HEPATOL, V19, P185, DOI 10.3350/cmh.2013.19.2.185; Copin P, 2015, CLIN GASTROENTEROL H, V13, pE26, DOI 10.1016/j.cgh.2014.09.034; Dokmak S, 2009, GASTROENTEROLOGY, V137, P1698, DOI 10.1053/j.gastro.2009.07.061; Franco LM, 2005, J INHERIT METAB DIS, V28, P153, DOI 10.1007/s10545-005-7500-2; Gorayski P, 2008, BRIT J SPORT MED, V42, DOI [10.1136/bjsm.2007.039321, 10.1136/bjsm.2007.03932]; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Hirata Eri, 2015, Nihon Shokakibyo Gakkai Zasshi, V112, P1696, DOI 10.11405/nisshoshi.112.1696; Iguchi T, 2016, MOL CLIN ONCOL, V5, P599, DOI 10.3892/mco.2016.1034; Margolskee E, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0475-5; Moriura S, 1996, J GASTROEN HEPATOL, V11, P556, DOI 10.1111/j.1440-1746.1996.tb01702.x; Ramacciato Giovanni, 2006, World J Surg Oncol, V4, P58, DOI 10.1186/1477-7819-4-58; Stoot JHMB, 2010, HPB, V12, P509, DOI 10.1111/j.1477-2574.2010.00222.x; Stueck AE, 2015, SEMIN LIVER DIS, V35, P444, DOI 10.1055/s-0035-1567827; Terkivatan T, 2001, ARCH SURG-CHICAGO, V136, P1033, DOI 10.1001/archsurg.136.9.1033; Vaithianathan R, 2013, J CLIN DIAGN RES, V7, P2962, DOI [10.7860/JCDR/2013.6773.3706, 10.7860/JCDR/2013/6773.3706]; Velazquez I, 2004, AM J HEMATOL, V77, P257, DOI 10.1002/ajh.20183; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	20	0	0	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					226	231		10.4132/jptm.2017.11.12			6	Pathology	Pathology	GM8FQ	WOS:000438456900003	29281780	DOAJ Gold, Green Published			2019-10-28	
J	Kwon, HJ; Kim, JW; Kim, H; Choi, Y; Ahn, S				Kwon, Hyun Jung; Kim, Ji-Won; Kim, Haeryoung; Choi, YoungRok; Ahn, Soomin			Combined Hepatocellular Carcinoma and Neuroendocrine Carcinoma with Ectopic Secretion of Parathyroid Hormone: A Case Report and Review of the Literature	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Review						Combined; Liver; Carcinoma; hepatocellular; Carcinoma; neuroendocrine	LIVER; TUMOR; HYPERCALCEMIA; FEATURES	Primary combined hepatocellular carcinoma (HCC) and neuroendocrine carcinoma is a rare entity, and so is hypercalcemia due to ectopic parathyroid hormone (PTH) secretion by tumor. A 44-year old man with hepatitis B virus associated chronic liver disease presented with a hepatic mass. Hemihepatectomy discovered the mass as combined HCC and poorly differentiated cholangio-carcinoma. During adjuvant chemoradiation therapy, he presented with nausea, and multiple systemic metastases were found. Laboratory tests revealed hypercalcemia with markedly elevated PTH and neuron specific enolase. Parathyroid scan showed normal uptake in parathyroid glands, suggestive of ectopic PTH secretion. Subsequently, immunohistochemistry of neuroendocrine marker was performed on the primary lesion, and confirmed the neuroendocrine differentiation in non-HCC component. The patient died 71 days after surgery. This report may suggest the possibility of ectopic PTH secretion by neuroendocrine carcinoma of hepatic origin causing hypercalcemia. Caution for neuroendocrine differentiation should be exercised when diagnosing poorly differentiated HCC.	[Kwon, Hyun Jung; Ahn, Soomin] Seoul Natl Univ, Dept Pathol, Bundang Hosp, 82 Gumi Ro 173beon Gil, Seongnam 13620, South Korea; [Kim, Ji-Won] Seoul Natl Univ, Div Hematol & Med Oncol, Bundang Hosp, Dept Internal Med, Seongnam, South Korea; [Kim, Haeryoung] Seoul Natl Univ Hosp, Dept Pathol, Seoul, South Korea; [Choi, YoungRok] Seoul Natl Univ, Dept Surg, Bundang Hosp, Seongnam, South Korea	Ahn, S (reprint author), Seoul Natl Univ, Dept Pathol, Bundang Hosp, 82 Gumi Ro 173beon Gil, Seongnam 13620, South Korea.	suminy317@gmail.com	Choi, YoungRok/D-5532-2012	Choi, YoungRok/0000-0003-2408-7086			Abe Y, 2011, INTERNAL MED, V50, P329, DOI 10.2169/internalmedicine.50.4389; Aboelenen A, 2014, INT J SURG CASE REP, V5, P26, DOI 10.1016/j.ijscr.2013.10.018; ARTOPOULOS JG, 1994, HEPATO-GASTROENTEROL, V41, P442; Baker E, 2016, AM SURGEON, V82, P1121; BARSKY SH, 1984, HUM PATHOL, V15, P892, DOI 10.1016/S0046-8177(84)80152-5; BURTIS WJ, 1987, J BIOL CHEM, V262, P7151; Choi GH, 2016, WORLD J GASTROENTERO, V22, P9229, DOI 10.3748/wjg.v22.i41.9229; Doyle MA, 2014, INT J GEN MED, V7, P21, DOI 10.2147/IJGM.S51302; Garcia MT, 2006, VIRCHOWS ARCH, V449, P376, DOI 10.1007/s00428-006-0251-0; Huh Uh Young, 2005, Korean J Hepatol, V11, P275; Ishida M, 2003, SURG TODAY, V33, P214, DOI 10.1007/s005950300048; Koyama Y, 1999, ABDOM IMAGING, V24, P144, DOI 10.1007/s002619900463; Liu YJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007868; Mahoney Eric J, 2006, Endocr Pract, V12, P302; Nakanishi C, 2012, HEPATOL RES, V42, P1141, DOI 10.1111/j.1872-034X.2012.01017.x; Nishino H, 2016, CLIN J GASTROENTEROL, V9, P272, DOI 10.1007/s12328-016-0669-0; Nomura Y, 2017, J CLIN PATHOL, V70, P563, DOI 10.1136/jclinpath-2016-203941; Tazi El Mehdi, 2011, World J Oncol, V2, P37, DOI 10.4021/wjon276e; Yamaguchi R, 2004, PATHOL INT, V54, P861, DOI 10.1111/j.1440-1827.2004.01770.x; Yang CS, 2009, J CHIN MED ASSOC, V72, P430, DOI 10.1016/S1726-4901(09)70400-9	20	0	0	0	2	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					232	237		10.4132/jptm.2018.05.17			6	Pathology	Pathology	GM8FQ	WOS:000438456900004	29794961	DOAJ Gold, Green Published			2019-10-28	
J	Rhee, YY; Jung, HK; Kim, SH; Kim, SH				Rhee, Ye-Young; Jung, Hong Kyu; Kim, Se Hoon; Kim, Soo Hee			Hyalinizing Trabecular Tumor of the Thyroid Gland, a Diagnostic Challenge in Fine-Needle Aspiration Cytology: Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Hyalinizing trabecular tumor; Thyroid gland; Liquid-based cytology	ULTRASONOGRAPHY; ADENOMA; SMEARS; BIOPSY	Hyalinizing trabecular tumor (HTT) is a rare thyroid tumor with low to minimal malignant potential. HTT is often misinterpreted as other thyroid tumors, including papillary thyroid carcinoma (PTC) and medullary thyroid carcinoma (MTC), on fine-needle aspiration (FNA) cytology, because of its overlapping cytologic features, such as nuclear grooves and intranulcear pseudoinclusions. Although cytopathologists cannot definitely conclude HTT by FNA cytology, suspicion of HTT is necessary to avoid misdiagnosing HTT as PTC or MTC and to avoid unnecessary aggressive treatment. Here, we report a case of HTT with novel cytologic features in CellPrep liquid based cytology that was diagnosed as suspicious for papillary carcinoma by FNA and finally diagnosed as HTT in the surgical specimen.	[Rhee, Ye-Young; Kim, Soo Hee] Seegene Med Fdn, Pathol Ctr, 320 Cheonho Daero, Seoul 04805, South Korea; [Jung, Hong Kyu] Seran Hosp, Dept Surg, Seoul, South Korea; [Jung, Hong Kyu] Seran Hosp, Hlth Care Ctr, Seoul, South Korea; [Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, Severance Hosp, Seoul, South Korea	Kim, SH (reprint author), Seegene Med Fdn, Pathol Ctr, 320 Cheonho Daero, Seoul 04805, South Korea.	kshpath@gmail.com					Bakula-Zalewska E, 2015, DIAGN CYTOPATHOL, V43, P710, DOI 10.1002/dc.23224; Carney JA, 2008, AM J SURG PATHOL, V32, P1877, DOI 10.1097/PAS.0b013e31817a8f1b; CARNEY JA, 1987, AM J SURG PATHOL, V11, P583, DOI 10.1097/00000478-198708000-00001; Casey MB, 2004, AM J CLIN PATHOL, V122, P506, DOI 10.1309/KLJU9LVBLLA6CL76; Choi WJ, 2015, ACTA RADIOL, V56, P1113, DOI 10.1177/0284185114549225; Gaffney RL, 2003, AM J SURG PATHOL, V27, P494, DOI 10.1097/00000478-200304000-00009; Howard BE, 2013, ORL J OTO-RHINO-LARY, V75, P309, DOI 10.1159/000355291; Jang H, 2016, ULTRASONOGRAPHY, V35, P131, DOI 10.14366/usg.15054; Jones DJ, 2017, THYROID RES, V10, DOI 10.1186/s13044-017-0042-5; Kim T, 2011, CYTOPATHOLOGY, V22, P407, DOI 10.1111/j.1365-2303.2011.00886.x; Lee S, 2011, THYROID, V21, P253, DOI 10.1089/thy.2010.0202; Park HS, 2014, J CLIN PATHOL, V67, P835, DOI 10.1136/jclinpath-2014-202339; Saglietti C, 2017, J CLIN PATHOL, V70, P641, DOI 10.1136/jclinpath-2017-204360; Salvatore G, 2005, EUR J CANCER, V41, P816, DOI 10.1016/j.ejca.2005.01.004; Sung SY, 2014, J CHIN MED ASSOC, V77, P573, DOI 10.1016/j.jcma.2014.08.006; Takada N, 2018, ENDOCR J, V65, P239, DOI 10.1507/endocrj.EJ17-0413; Zipkin R, 1905, VIRCHOWS ARCH A, V182, P374, DOI 10.1007/BF01994414	17	2	2	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					252	256		10.4132/jptm.2018.04.28			5	Pathology	Pathology	GM8FQ	WOS:000438456900008	29890568	DOAJ Gold, Green Published			2019-10-28	
J	Bonnefoy, PB; Margelidon-Cozzolino, V; Glenat, M				Bonnefoy, P. -B.; Margelidon-Cozzolino, V.; Glenat, M.			Contribution of CT acquisition coupled with lung scan in exploration of pulmonary embolism suspicion	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						SPECT/CT; Lung scan; Radiological semiology; Pulmonary embolism	EMISSION COMPUTED-TOMOGRAPHY; VENTILATION-PERFUSION SCINTIGRAPHY; FLEISCHNER SOCIETY; DIAGNOSIS; DISEASE; RECOMMENDATIONS; MANAGEMENT	Pulmonary embolism is a frequent disease difficult to diagnose because of heterogeneous clinical presentation. Pulmonary embolism diagnosis requires additional examinations, which are guided by clinical probability scores. The ventilation/perfusion scintigraphy is a validated technic in pulmonary embolism diagnosis strategies, which represents one of its most important indications. In the past years, the technique of scintigraphy evolved with the appearance of hybrid cameras, allowing the realization of tomoscintigraphy coupled with computerised tomodensitometry (CT). One of the major interests of this technique is the possibility of considering alternative diagnosis in case of negative result of scintigraphy. The purpose of this article is to offer nuclear medicine physicians a review of the alternative diagnoses that can be found during pulmonary ventilation/perfusion tomoscintigraphy according to the underlying scintigraphic and morphological abnormalities. In this review, we will first on diseases responsible for: a mismatch (pathological perfusion and normal ventilation), an inverted mismatch (normal perfusion and pathological ventilation) and for associated disorders in ventilation and in perfusion patterns (identically abnormal perfusion and ventilation). The final part will address some specific CT features that can be encountered on a low dose CT centered on thorax. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Bonnefoy, P. -B.] CHU St Etienne, Serv Med Nucl, F-42055 St Etienne, France; [Margelidon-Cozzolino, V.] CHU St Etienne, Serv Med Vasc & Therapeut, F-42055 St Etienne, France; [Glenat, M.] CHU St Etienne, Serv Radiol, F-42055 St Etienne, France	Bonnefoy, PB (reprint author), CHU St Etienne, Serv Med Nucl, F-42055 St Etienne, France.	pierre.benoit.bonnefoy@gmail.com					Austin JHM, 1996, RADIOLOGY, V200, P327, DOI 10.1148/radiology.200.2.8685321; Bajc M, 2009, EUR J NUCL MED MOL I, V36, P1356, DOI 10.1007/s00259-009-1170-5; Burge AJ, 2008, CLIN RADIOL, V63, P381, DOI 10.1016/j.crad.2007.10.004; GARG A, 1983, EUR J NUCL MED, V8, P167; GOTTSCHALK A, 1993, J NUCL MED, V34, P1109; GOTTSCHALK A, 1993, J NUCL MED, V34, P1119; Hess S, 2016, SEMIN THROMB HEMOST, V42, P833, DOI 10.1055/s-0036-1593376; JAMES JM, 1991, BRIT J RADIOL, V64, P711, DOI 10.1259/0007-1285-64-764-711; Jogi J, 2008, NUCL MED COMMUN, V29, P666, DOI 10.1097/MNM.0b013e328302cd26; Konstantinides SV, 2014, EUR HEART J, V35, P3033, DOI 10.1093/eurheartj/ehu283; Lynch DA, 2015, RADIOLOGY, V277, P192, DOI 10.1148/radiol.2015141579; MacMahon H, 2017, RADIOLOGY, V284, P228, DOI 10.1148/radiol.2017161659; Musset D, 2002, LANCET, V360, P1914, DOI 10.1016/S0140-6736(02)11914-3; Phillips JJ, 2015, EUR J RADIOL, V84, P1392, DOI 10.1016/j.ejrad.2015.03.013; Raskob GE, 2014, ARTERIOSCL THROM VAS, V34, P2363, DOI 10.1161/ATVBAHA.114.304488; Righini M, 2008, LANCET, V371, P1343, DOI 10.1016/S0140-6736(08)60594-2; Shemesh J, 2010, RADIOLOGY, V257, P541, DOI 10.1148/radiol.10100383; SOSTMAN HD, 1992, RADIOLOGY, V184, P455, DOI 10.1148/radiology.184.2.1620847; Tillie-Leblond I, 2006, ANN INTERN MED, V144, P390, DOI 10.7326/0003-4819-144-6-200603210-00005; Toney LK, 2017, ACAD EMERG MED, V24, P1110, DOI 10.1111/acem.13247; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010	22	0	0	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					248	261		10.1016/j.mednuc.2018.06.003			14	Pathology	Pathology	GU5JX	WOS:000445322900006					2019-10-28	
J	Albuquerque, A; Rios, E; Dias, CC; Nathan, M				Albuquerque, Andreia; Rios, Elisabete; Dias, Claudia Camila; Nathan, Mayura			p16 immunostaining in histological grading of anal squamous intraepithelial lesions: a systematic review and meta-analysis	MODERN PATHOLOGY			English	Review							IN-SITU-HYBRIDIZATION; HIV-POSITIVE MEN; PREMALIGNANT LESIONS; PREDICTIVE-VALUE; NEOPLASIA; P16(INK4A); EXPRESSION; RISK; IMMUNOHISTOCHEMISTRY; CLASSIFICATION	p16 is the most widely studied biomarker in lower anogenital tract squamous intraepithelial lesions and, currently the only recommended biomarker for histological grade assessment. The aim of this systematic review and meta-analysis was to evaluate p16-positive rates according to anal squamous intraepithelial lesions/anal intraepithelial neoplasia (AIN) grade. Two investigators independently searched four electronic databases: PubMed, Web of Sciences, Scopus, and Embase from inception until August 2017. Studies that evaluated p16 immunostaining in histological samples of anal and/or perianal squamous intraepithelial lesions and defined a p16-positive result as diffuse block staining with nuclear or nuclear plus cytoplasmic staining were included. A meta-analysis was performed using a random effects model. Fifteen studies consisting of 790 samples were included. The proportion of p16 expression increased with the severity of histological grade. p16 positivity was 2% (95% CI: 0.2-5%) in normal histology, 12% (95% CI: 2-27%) in low-grade squamous intraepithelial lesions (LSILs)/AIN1 (excluding condylomas), 7% (95% CI: 2-13%) in all LSIL (AIN1/LSIL/condyloma), 76% (95% CI: 61-88%) in AIN2, and 90% (95% CI: 82-95%) in AIN3. For anal high-grade squamous intraepithelial lesions (HSILs), in studies using a two-tiered nomenclature, p16 positivity was 84% (95% CI: 66-96%) and for all HSIL (AIN2, AIN3, HSIL combined) it was 82% (95% CI: 72-91%). In summary, p16 positivity in anal squamous intraepithelial lesions appears to be in a similar range to the commonly described cervical squamous intraepithelial lesions, however, for anal low-grade lesions positivity seems to be lower.	[Albuquerque, Andreia; Nathan, Mayura] Homerton Univ Hosp, HANS, London, England; [Albuquerque, Andreia; Rios, Elisabete] Univ Porto, Fac Med, Porto, Portugal; [Rios, Elisabete] Ctr Hosp Sao Joao, Dept Pathol, Porto, Portugal; [Rios, Elisabete] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Porto, Portugal; [Dias, Claudia Camila] Univ Porto, Fac Med, Dept Community Med Informat & Hlth Decis Sci, Porto, Portugal; [Dias, Claudia Camila] Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal	Albuquerque, A (reprint author), Homerton Univ Hosp, HANS, London, England.; Albuquerque, A (reprint author), Univ Porto, Fac Med, Porto, Portugal.	a.albuquerque.dias@gmail.com	Dias, Claudia Camila/N-7130-2014	Dias, Claudia Camila/0000-0001-9356-3272			Albuquerque A, 2017, AM J SURG PATHOL, V41, P1151, DOI 10.1097/PAS.0000000000000858; Bala R, 2013, AM J SURG PATHOL, V37, P659, DOI 10.1097/PAS.0b013e31828706c0; Bean SM, 2007, AM J SURG PATHOL, V31, P555, DOI 10.1097/PAS.0b013e31802ca3f4; Bean SM, 2009, J LOW GENIT TRACT DI, V13, P145, DOI 10.1097/LGT.0b013e3181934486; Bernard JE, 2008, APPL IMMUNOHISTO M M, V16, P215, DOI 10.1097/PAI.0b013e3181454a95; Clavero O, 2017, PAPILLOMAVIRUS RES, V3, P11, DOI 10.1016/j.pvr.2016.12.001; Cortecchia S, 2013, INT J GYNECOL CANCER, V23, P1663, DOI 10.1097/IGC.0b013e3182a80b14; Cotter MB, 2014, COLORECTAL DIS, V16, P777, DOI 10.1111/codi.12679; Darragh TM, 2012, J LOW GENIT TRACT DI, V16, P205, DOI 10.1097/LGT.0b013e31825c31dd; del Pino M, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.05.046; Hissong E, 2019, APPL IMMUNOHISTO M M, V27, P134, DOI 10.1097/PAI.0000000000000547; Hui Y, 2017, AM J SURG PATHOL, V41, P382, DOI 10.1097/PAS.0000000000000809; Kreuter A, 2007, BRIT J DERMATOL, V157, P523, DOI 10.1111/j.1365-2133.2007.08004.x; Kreuter A, 2016, JAMA DERMATOL, V152, P1225, DOI 10.1001/jamadermatol.2016.2503; Kreuter A, 2010, J AM ACAD DERMATOL, V63, P490, DOI 10.1016/j.jaad.2009.08.043; Larson BK, 2016, APMIS, V124, P175, DOI 10.1111/apm.12481; Liao GD, 2014, INT J CANCER, V134, P1715, DOI 10.1002/ijc.28485; Ma CQ, 2015, SEMIN DIAGN PATHOL, V32, P334, DOI 10.1053/j.semdp.2015.02.014; Mahajan A, 2016, HUM PATHOL, V51, P64, DOI 10.1016/j.humpath.2015.12.021; Maniar KP, 2015, AM J SURG PATHOL, V39, P1708, DOI 10.1097/PAS.0000000000000494; Maniar KP, 2014, ADV ANAT PATHOL, V21, P341, DOI 10.1097/PAP.0000000000000035; Mills AM, 2017, AM J SURG PATHOL, V41, P607, DOI 10.1097/PAS.0000000000000800; Mills AM, 2015, AM J SURG PATHOL, V39, P611, DOI 10.1097/PAS.0000000000000374; Negri G, 2004, VIRCHOWS ARCH, V445, P616, DOI 10.1007/s00428-004-1127-9; Ozaki S, 2011, HUM PATHOL, V42, P1007, DOI 10.1016/j.humpath.2010.10.021; Patil DT, 2015, AM J CLIN PATHOL, V144, P113, DOI 10.1309/AJCPD8U4FQEXXIZS; Pirog EC, 2015, SEMIN DIAGN PATHOL, V32, P409, DOI 10.1053/j.semdp.2015.02.015; Pirog EC, 2010, AM J SURG PATHOL, V34, P1449, DOI 10.1097/PAS.0b013e3181f0f52a; Quint KD, 2013, EUR J OBSTET GYN R B, V2115, P319; Ruel J, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.8; Smittenaar CR, 2016, BRIT J CANCER, V115, P1147, DOI 10.1038/bjc.2016.304; Tsoumpou I, 2009, CANCER TREAT REV, V35, P210, DOI 10.1016/j.ctrv.2008.10.005; van Heukelom MLS, 2016, BRIT J DERMATOL, V175, P735, DOI 10.1111/bjd.14567; Walker F, 2009, HUM PATHOL, V40, P1517, DOI 10.1016/j.humpath.2009.05.010; Walts AE, 2006, AM J SURG PATHOL, V30, P795, DOI 10.1097/01.pas.0000208283.14044.a9; Walts Ann E, 2008, Clin Med Pathol, V1, P7; Yang EJ, 2015, MODERN PATHOL, V28, P994, DOI 10.1038/modpathol.2015.54	37	2	2	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1026	1035		10.1038/s41379-018-0026-6			10	Pathology	Pathology	GP1HY	WOS:000440567300003	29434342				2019-10-28	
J	Rocken, C				Roecken, C.			Journal Club Neues Format in Der Pathologe	PATHOLOGE			German	Editorial Material									[Roecken, C.] Christian Albrechts Univ Kiel, Inst Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany	Rocken, C (reprint author), Christian Albrechts Univ Kiel, Inst Pathol, Arnold Heller Str 3-14, D-24105 Kiel, Germany.	christoph.roecken@uksh.de	Rocken, Christoph/A-9239-2010	Rocken, Christoph/0000-0002-6989-8002				0	0	0	3	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					287	287		10.1007/s00292-018-0457-3			1	Pathology	Pathology	GL7ZV	WOS:000437430200001	29946851	Bronze			2019-10-28	
J	Furuta, T; Shi, L; Toyokuni, S				Furuta, Takahiro; Shi, Lei; Toyokuni, Shinya			Non-thermal plasma as a simple ferroptosis inducer in cancer cells: A possible role of ferritin	PATHOLOGY INTERNATIONAL			English	Letter							OXIDATIVE STRESS; IRON; CARCINOGENESIS; PATHOLOGY; DISEASE		[Furuta, Takahiro; Shi, Lei; Toyokuni, Shinya] Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Nagoya, Aichi, Japan	Furuta, T (reprint author), Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Responses, Nagoya, Aichi, Japan.		Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109	JSPS KakenhiMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP17H04064, JP16K15257]; JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [JP17H04064, JP16K15257]	This work was supported by a JSPS Kakenhi (JP17H04064; JP16K15257).	Fridman A., 2013, PLASMA MED; Ishida C, 2016, FREE RADICAL RES, V50, P1131, DOI 10.1080/10715762.2016.1211273; Ito F, 2016, BIOCHEM BIOPH RES CO, V476, P600, DOI 10.1016/j.bbrc.2016.06.003; Kurake N, 2016, ARCH BIOCHEM BIOPHYS, V605, P102, DOI 10.1016/j.abb.2016.01.011; Okazaki Y, 2014, J CLIN BIOCHEM NUTR, V55, P207, DOI 10.3164/jcbn.14-40; Shi L, 2017, FREE RADICAL BIO MED, V108, P904, DOI 10.1016/j.freeradbiomed.2017.04.368; Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021; Tanaka H, 2015, PHYS PLASMAS, V22, DOI 10.1063/1.4933402; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Toyokuni S, 2017, FREE RADICAL BIO MED, V108, P610, DOI 10.1016/j.freeradbiomed.2017.04.024; Toyokuni S, 2016, PATHOL INT, V66, P245, DOI 10.1111/pin.12396; Toyokuni S, 2009, CANCER SCI, V100, P9, DOI 10.1111/j.1349-7006.2008.01001.x	13	6	6	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					442	443		10.1111/pin.12665			2	Pathology	Pathology	GL2IH	WOS:000436942800008	29624784				2019-10-28	
J	Cui, GL; Yuan, AP; Sun, ZL; Zheng, W; Pang, ZG				Cui, Guanglin; Yuan, Aping; Sun, Zhenglu; Zheng, Wei; Pang, Zhigang			IL-1 beta/IL-6 network in the tumor microenvironment of human colorectal cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Interleukin-1 beta; Interlukin-6; Carcinogenesis; Colorectum	INTESTINAL EPITHELIAL-CELLS; ADENOMA-CARCINOMA SEQUENCE; NF-KAPPA-B; INFLAMMATORY CYTOKINES; INTERLEUKIN-6 PRODUCTION; HOST INTERACTIONS; IL-6 PRODUCTION; UP-REGULATION; EXPRESSION; CYCLOOXYGENASE-2	Objectives: Recent studies suggest that the interaction between interleukin (IL)-1 beta and IL-6 in the microenvironment might be involved in the development and progression of human colorectal cancer (CRC). However, the expression of IL-1 beta/IL-6 network within the CRC microenvironment is not fully understood. Materials and methods: The level of IL-1 beta/IL-6 network expression in 40 biopsies of sporadic CRC and 15 biopsies of controls was assessed using quantitative real-time polymerase chain reaction (PCR) assay, immunohistochemistry (IHC) and double immunofluorescence staining. Results: Quantitative results obtained by real-time PCR revealed that both IL-1 beta and IL-6 mRNA expressions were increased in CRC tissues compared with expressions in controls. In which, IL-6 mRNA expression in primary CRC tissues showed a statistically significant relationship with tumor invasion depth. IHC observations confirmed that increased expression of IL-1 beta and IL-6 immunoreactivities was located in both the CRC epithelium and stroma. Furthermore, IHC results also revealed that increased expression of IL-1 beta receptor type 1 (IL1R1) and IL-6 receptor (IL-6R) were observed in both CRC epithelial and stromal cells. IHCs in serial CRC sections and double immunofluorescence staining revealed a highly co-expression of IL-1R1 immunoreactivity with IL-6 immunoreactivity in the same cells, which confirmed a histological fundament of IL-1 beta /IL-6 network. Conclusion: The IL-1 beta /11.-6 network is highly expressed in the CRC microenvironment, indicating that this network is important in the progression of CRC.	[Cui, Guanglin; Yuan, Aping; Sun, Zhenglu; Zheng, Wei; Pang, Zhigang] Zhengzhou Univ, Affiliated Hosp 2, Res Grp Gastrointestinal Dis, Zhengzhou, Henan, Peoples R China; [Yuan, Aping] Norwegian Univ Life Sci, Dept Chem Biotechnol & Food Sci, Lab Mol Cell Biol, As, Norway; [Pang, Zhigang] Zhengzhou Univ, Affiliated Hosp 2, Dept Gen Surg, Zhengzhou, Henan, Peoples R China	Cui, GL (reprint author), Zhengzhou Univ, Affiliated Hosp 2, Res Grp Gastrointestinal Dis, Zhengzhou, Henan, Peoples R China.	guanglin.cui@yahoo.com		Cui, Guanglin/0000-0001-7408-4751	programs of Innovation Scientists and Technicians Troop Construction Projects of Henan Province [CXTD20150009]; Nature and Science Foundation of Henan Province [182300410326]; Scientific and Technological Research Project of Henan Province, China [182102310383]	This research was supported by the programs of Innovation Scientists and Technicians Troop Construction Projects of Henan Province (Program No. CXTD20150009), Nature and Science Foundation of Henan Province (Program No. 182300410326) and Scientific and Technological Research Project of Henan Province, China (Program No. 182102310383).	Apte RN, 2006, EUR J CANCER, V42, P751, DOI 10.1016/j.ejca.2006.01.010; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Burke SJ, 2011, CELL IMMUNOL, V271, P379, DOI 10.1016/j.cellimm.2011.08.004; Chen Z, 1998, CANCER RES, V58, P3668; Chung YC, 2003, J SURG ONCOL, V83, P222, DOI 10.1002/jso.10269; Cui G, 2006, SCAND J CLIN LAB INV, V66, P249, DOI 10.1080/00365510600590472; Cui GL, 2007, CANCER IMMUNOL IMMUN, V56, P985, DOI 10.1007/s00262-006-0259-y; Cui GL, 2017, CLIN IMMUNOL, V183, P266, DOI 10.1016/j.clim.2017.09.003; Cui GL, 2015, CANCER IMMUNOL IMMUN, V64, P181, DOI 10.1007/s00262-014-1624-x; Cui GL, 2015, PATHOL ONCOL RES, V21, P139, DOI 10.1007/s12253-014-9799-1; Cui GL, 2012, SCAND J GASTROENTERO, V47, P1304, DOI 10.3109/00365521.2012.725089; Cui GL, 2009, CANCER IMMUNOL IMMUN, V58, P1899, DOI 10.1007/s00262-009-0702-y; De Vita F, 2001, J INTERF CYTOK RES, V21, P45, DOI 10.1089/107999001459150; Dubois Raymond N, 2014, Trans Am Clin Climatol Assoc, V125, P358; Duque J, 2006, CELL SIGNAL, V18, P1262, DOI 10.1016/j.cellsig.2005.10.009; Edge B.D., 2010, AJCC CANC STAGING MA; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Hansen TF, 2009, MOL MED REP, V2, P787, DOI 10.3892/mmr_00000173; Hua W, 2016, PATHOL RES PRACT, V212, P106, DOI 10.1016/j.prp.2015.12.002; Hubbard J, 2010, CURR OPIN ONCOL, V22, P374, DOI 10.1097/CCO.0b013e328339524e; Kim S, 2008, CANCER RES, V68, P323, DOI 10.1158/0008-5472.CAN-07-2924; Kosumi K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284720; Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956; Krzystek-Korpacka M, 2013, CANCER LETT, V337, P107, DOI 10.1016/j.canlet.2013.05.033; Lewis AM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-48; Liu WV, 2003, CANCER RES, V63, P3632; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu CC, 2015, INT J MOL SCI, V16, P159, DOI 10.3390/ijms16010159; Mahmoud AS, 2014, ASIAN PAC J CANCER P, V15, P6787, DOI 10.7314/APJCP.2014.15.16.6787; Maihofner C, 2003, CARCINOGENESIS, V24, P665, DOI 10.1093/carcin/bgg006; Mantovani A, 2001, NOVART FDN SYMP, V234, P120; Mantovani A, 2008, NOVART FDN SYMP, DOI [10.1002/0470868678.ch8, DOI 10.1002/0470868678.CH8]; Matsuo K, 2003, J INT MED RES, V31, P69, DOI 10.1177/147323000303100202; Mertz KD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062966; Miki C, 2002, CANCER-AM CANCER SOC, V94, P1584, DOI 10.1002/cncr.10324; Mild C., 2004, DIGEST DIS SCI, V49, P970; Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748; Nakagoe T, 2003, CANCER LETT, V202, P109, DOI 10.1016/j.canlet.2003.09.008; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Parikh AA, 1997, SHOCK, V8, P249, DOI 10.1097/00024382-199710000-00003; Parikh AA, 1997, J SURG RES, V69, P139, DOI 10.1006/jsre.1997.5061; Parikh AA, 2000, SHOCK, V13, P8, DOI 10.1097/00024382-200013010-00002; Qi HL, 2015, IMMUNOBIOLOGY, V220, P54, DOI 10.1016/j.imbio.2014.09.002; Rose-John S, 2007, EXPERT OPIN THER TAR, V11, P613, DOI 10.1517/14728222.11.5.613; Ryll A, 2011, MOL BIOSYST, V7, P3253, DOI 10.1039/c1mb05261f; Scheller J, 2006, SCAND J IMMUNOL, V63, P321, DOI 10.1111/j.1365-3083.2006.01750.x; Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002; Street ME, 2003, J ENDOCRINOL, V179, P405, DOI 10.1677/joe.0.1790405; TOSATO G, 1990, BLOOD, V75, P1305; Voronov E, 2007, ADV EXP MED BIOL, V601, P265; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Wang Q, 1998, J SURG RES, V76, P27, DOI 10.1006/jsre.1998.5288; Yang H, 2014, INT J INFLAMM, DOI 10.1155/2014/130981	55	6	6	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					986	992		10.1016/j.prp.2018.05.011			7	Pathology	Pathology	GN6YY	WOS:000439254000010	29803656				2019-10-28	
J	Zainun, K; Hope, K; Nicholson, AG; Cohen, MC				Zainun, K.; Hope, K.; Nicholson, A. G.; Cohen, M. C.			WITHDRAWN: Abnormal Muscularization of Intra Acinar Pulmonary Arteries in 2 Cases Presenting as Sudden Infant Death (SIDS) (vol 20, pg 49, 2017)	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Correction																Zainun K, 2017, PEDIATR DEVEL PATHOL, V20, P49, DOI 10.1177/1093526616689311	1	0	0	0	3	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					430	430		10.1177/1093526617698597			1	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400013					2019-10-28	
J	Troth, SP; Everds, NE; Siska, W; Knight, B; Lamb, M; Hutt, J				Troth, Sean P.; Everds, Nancy E.; Siska, William; Knight, Brian; Lamb, Martin; Hutt, Julie			Scientific and Regulatory Policy Committee Points to Consider: Data Visualization for Clinical and Anatomic Pathologists	TOXICOLOGIC PATHOLOGY			English	Article						graphical display; data visualization; data analysis; toxicologic pathology	NONCLINICAL DATA; TOXICOLOGY; PRINCIPLES	Assessment and communication of toxicology data are fundamental components of the work performed by veterinary anatomic and clinical pathologists involved in toxicology research. In recent years, there has been an evolution in the number and variety of software tools designed to facilitate the evaluation and presentation of toxicity study data. A working group of the Society of Toxicologic Pathology Scientific and Regulatory Policy Committee reviewed existing and emerging visualization technologies. This Points to Consider article reviews some of the currently available data visualization options, describes the utility of different types of graphical displays, and explores potential areas of controversy and ambiguity encountered with the use of these tools.	[Troth, Sean P.] Merck & Co Inc, WP8I-404, West Point, PA 19486 USA; [Everds, Nancy E.] Seattle Genet, Bothell, WA USA; [Siska, William] Charles River Labs Inc, Reno, NV USA; [Knight, Brian] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA; [Lamb, Martin] Biogen, Cambridge, MA USA; [Hutt, Julie] Lovelace Biomed, Albuquerque, NM USA	Troth, SP (reprint author), Merck & Co Inc, WP8I-404, West Point, PA 19486 USA.	sean_troth@merck.com	Troth, Sean/R-6885-2019	Troth, Sean/0000-0002-4696-5129			[Anonymous], 2000, GALLERY DATA VISUALI; Briggs K, 2017, REGUL TOXICOL PHARM, V91, P77, DOI 10.1016/j.yrtph.2017.10.012; Brown AP, 2016, REGUL TOXICOL PHARM, V82, P167, DOI 10.1016/j.yrtph.2016.10.009; Duke SP, 2015, STAT MED, V34, P3040, DOI 10.1002/sim.6549; Hamadeh HK, 2002, TOXICOL PATHOL, V30, P470, DOI 10.1080/01926230290105712; Keenan CM, 2014, TOXICOL PATHOL, V42, P807, DOI 10.1177/0192623313485451; Kropp TJ, 2013, THER INNOV REGUL SCI, V47, P41, DOI 10.1177/0092861512466398; Lobenhofer EK, 2006, TOXICOL PATHOL, V34, P921, DOI 10.1080/01926230601072319; Mann PC, 2012, TOXICOL PATHOL, V40, P7, DOI 10.1177/0192623312438738; PhUSE (Pharmaceutical Users Software Exchange; Nonclinical Topics Working Group), 2015, VIS GROUP REL DIFF H; Raddatz BB, 2017, VET PATHOL, V54, P734, DOI 10.1177/0300985817709887; Sharapova T, 2016, VET PATHOL, V53, P211, DOI 10.1177/0300985815591076; Snyder PW, 2016, TOXICOL PATHOL, V44, P874, DOI 10.1177/0192623316649258; US Food and Drug Administration, 2014, DRAFT GUID IND PROV; Vlasakova K, 2014, TOXICOL SCI, V138, P3, DOI 10.1093/toxsci/kft330; Weissgerber TL, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002128; Xu EY, 2008, CHEM RES TOXICOL, V21, P1548, DOI 10.1021/tx800061w	17	2	2	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					476	487		10.1177/0192623318778733			12	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500001	29843574	Bronze			2019-10-28	
J	Imai, DM; Pesapane, R; Conroy, CJ; Alarcon, CN; Allan, N; Okino, RA; Fung, J; Murphy, BG; Verstraete, FJM; Foley, JE				Imai, Denise M.; Pesapane, Risa; Conroy, Christopher J.; Alarcon, Christina N.; Allan, Nora; Okino, Russell A.; Fung, Jennifer; Murphy, Brian G.; Verstraete, Frank J. M.; Foley, Janet E.			Apical Elongation of Molar Teeth in Captive Microtus Voles	VETERINARY PATHOLOGY			English	Article						amargosa vole; Microtus californicus scirpensis; elodont; elodontoma; odontogenic dysplasia; pseudo-odontoma; dental pathology; teeth	ORAL-CAVITY; DENTAL EVOLUTION; CALIFORNIA VOLE; GUINEA-PIGS; TOOTH; ELODONTOMA; DISORDERS; ANATOMY; RODENTS; DEGUS	Molar apical elongation (MAE) was the leading cause for euthanasia or death in a captive breeding colony of endangered Amargosa voles (Microtus californicus scirpensis). Clinical signs included ocular discharge, abnormal mastication, dyspnea, abnormal mentation, weight loss, and death. Although the severity varied, all molars in all quadrants were affected. When severe, the overgrown molar reserve crown and apex protruded into the nasal meatuses, the orbit, the calvarial vault and through the ventral margin of the mandible. Overall prevalence in the colony was 63% (92/146 voles) and increased to 77% in aged voles (>1 year). Mean age of onset was 5.3 months (1.7-11.2 months). Progression to extreme severity occurred over 1 to 3 months. Mean survival was 10.9 months (7.1-21.7 months). Histologically, the lesion was characterized by odontogenic hyperplasia and dysplasia. MAE was also documented in museum specimens of 2 other M. californicus subspecies (M. californicus californicus, M. californicus vallicola) and 3 other Microtus species (M. montanus, M. pennsylvanicus, M. socialis). In the M. californicus californicus collection, overall prevalence was 35.1% (129/368 skulls) and increased to 77.3% in aged voles (>1 year). A probable genetic influence was identified in the museum collection of M. californicus californicus. The etiopathogenesis of MAE is likely multifactorial, due to (1) inherent continuous odontogenic proliferation, (2) inadequate occlusal attrition, and (3) possible heritable disease susceptibility. In captivity, dietary or other management of occlusal attrition to prevent or delay MAE is a fundamental concern.	[Imai, Denise M.; Alarcon, Christina N.] Univ Calif Davis, Comparat Pathol Lab, Biomed Engn, 1000 Old Davis Rd,Bldg R-1, Davis, CA 95616 USA; [Pesapane, Risa; Fung, Jennifer] Univ Calif Davis, Dept Med & Epidemiol, Davis, CA 95616 USA; [Pesapane, Risa; Fung, Jennifer] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA; [Conroy, Christopher J.; Okino, Russell A.] Univ Calif Berkeley, Museum Vertebrate Zool, Berkeley, CA 94720 USA; [Allan, Nora] Calif Dept Fish & Wildlife, Wildlife Invest Lab, Rancho Cordova, CA USA; [Murphy, Brian G.] Univ Calif Davis, Pathol Microbiol & Immunol, Biomed Engn, Davis, CA 95616 USA; [Verstraete, Frank J. M.] Univ Calif Davis, Surg & Radiol Sci, Biomed Engn, Davis, CA 95616 USA; [Foley, Janet E.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA; [Foley, Janet E.] Univ Calif Davis, Ctr Mol & Genom Imaging, Biomed Engn, Davis, CA 95616 USA	Imai, DM (reprint author), Univ Calif Davis, Comparat Pathol Lab, Biomed Engn, 1000 Old Davis Rd,Bldg R-1, Davis, CA 95616 USA.	dmimai@ucdavis.edu		Pesapane, Risa/0000-0001-9318-9911; Alarcon, Christina/0000-0002-2244-1312	California Department of Fish and Wildlife; Bureau of Land Management; US Fish and Wildlife Service Palm Springs Field Office and Cooperative Endangered Species Conservation Fund [F14AP01006]	Funds for vole colony management and disease assessment were provided by the California Department of Fish and Wildlife, the Bureau of Land Management, and the US Fish and Wildlife Service Palm Springs Field Office and Cooperative Endangered Species Conservation Fund Award No. F14AP01006.	Boy SC, 2006, J COMP PATHOL, V135, P56, DOI 10.1016/j.jcpa.2006.03.002; Capello V., 2005, RABBIT RODENT DENT, P113; Capello V, 2015, J VET DENT, V32, P111, DOI 10.1177/089875641503200205; CHALINE J, 1987, EVOL BIOL, V21, P237; Crossley D A, 1995, J Vet Dent, V12, P131; Cudworth Nichole L., 2010, Mammalian Species, P230, DOI 10.1644/868.1; Dixon P, 2011, EQUINE DENT, P108; Fernandez JRR, 2010, J ZOO WILDLIFE MED, V41, P555, DOI 10.1638/2009-0244.1; Foley J, 2014, CAPTIVE PROPAGATION; Ganjgahi H, 2015, NEUROIMAGE, V115, P256, DOI 10.1016/j.neuroimage.2015.03.005; GILL AE, 1982, J MAMMAL, V63, P96, DOI 10.2307/1380675; Harvey SB, 2009, J AM ASSOC LAB ANIM, V48, P412; Head KW, 2003, HISTOLOGICAL CLASSIF, V10, P46; Ida-Yonemochi H, 2002, J ORAL PATHOL MED, V31, P361, DOI 10.1034/j.1600-0714.2002.00087.x; Imbschweiler I, 2011, VET J, V188, P365, DOI 10.1016/j.tvjl.2010.05.017; Jekl V, 2013, J SMALL ANIM PRACT, V54, P481, DOI 10.1111/jsap.12124; Jekl V, 2008, J EXOT PET MED, V17, P216, DOI 10.1053/j.jepm.2008.04.001; Jheon AH, 2015, INT J ORAL SCI, V7, P23, DOI 10.1038/ijos.2014.75; Legendre Loic, 2016, Vet Clin North Am Exot Anim Pract, V19, P825, DOI 10.1016/j.cvex.2016.04.006; LIDICKER WZ, 1969, AM MIDL NAT, V82, P450, DOI 10.2307/2423790; LIDICKER WZ, 1963, EVOLUTION, V17, P340, DOI 10.2307/2406163; Mancinelli Elisabetta, 2016, Veterinary Clinics of North America Exotic Animal Practice, V19, P871, DOI 10.1016/j.cvex.2016.04.008; Mans Christoph, 2016, Veterinary Clinics of North America Exotic Animal Practice, V19, P843, DOI 10.1016/j.cvex.2016.04.007; Maser C, 1970, Murrelet, V51, P11; Newkirk KM, 2017, PATHOLOGIC BASIS VET, P289; Ohshima H, 2005, ARCH ORAL BIOL, V50, P153, DOI 10.1016/j.archoralbio.2004.09.008; PHILLIPS CJ, 1972, J MAMMAL, V53, P1, DOI 10.2307/1378823; RENVOISE E, 2015, EVOLUTION RODENTS AD, P478; SUGITA S, 1995, EXP ANIM TOKYO, V43, P769; Tapaltsyan V, 2016, EVOL DEV, V18, P31, DOI 10.1111/ede.12132; Therneau T., 2012, KINSHIP2 PEDIGREE FU; Tummers M, 2003, DEVELOPMENT, V130, P1049, DOI 10.1242/dev.00332; U. S. Fish and Wildlife Service, 1997, AM VOL MICR CAL SCIR	33	2	2	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					572	583		10.1177/0300985818758469			12	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800014	29665753				2019-10-28	
J	Ward, JM; Meyerholz, DK				Ward, Jerrold M.; Meyerholz, David K.			Citation Index Is Not Critically Important to Veterinary Pathology, Medicine, and Research	VETERINARY PATHOLOGY			English	Letter						citation index; high-impact journals; citations; impact factor; bibliometrics	IMPACT FACTOR		[Ward, Jerrold M.] Global VetPathol, Montgomery Village, MD USA; [Meyerholz, David K.] Roy J & Lucille A Carver Coll Med, Dept Pathol, Iowa City, IA USA	Ward, JM (reprint author), Global VetPathol, Montgomery Village, MD USA.	veterinarypathology@gmail.com	Meyerholz, David/J-8131-2019	Meyerholz, David/0000-0003-1552-3253			Casadevall A, 2016, INFECT IMMUN, V84, P2407, DOI 10.1128/IAI.00564-16; Meyerholz DK, 2017, VET PATHOL, V54, P721, DOI 10.1177/0300985817690209	2	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					595	596		10.1177/0300985818758472			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800017	29890927	Bronze			2019-10-28	
J	Calio, A; Mengoli, MC; Cavazza, A; Rossi, G; Ghimenton, C; Brunelli, M; Pea, M; Chilosi, M; Marcolini, L; Martignoni, G				Calio, Anna; Mengoli, Maria Cecilia; Cavazza, Alberto; Rossi, Giulio; Ghimenton, Claudio; Brunelli, Matteo; Pea, Maurizio; Chilosi, Marco; Marcolini, Lisa; Martignoni, Guido			Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung	VIRCHOWS ARCHIV			English	Article						Clear cell "sugar" tumor; PEComa; Immunohistochemistry; Cathepsin K	PERIVASCULAR EPITHELIOID CELL; TUBEROUS SCLEROSIS; GENE REARRANGEMENT; TFE3; LYMPHANGIOLEIOMYOMATOSIS; FAMILY; IMMUNOREACTIVITY; ANGIOMYOLIPOMA; NEOPLASMS; SPECTRUM	Clear cell "sugar" tumor is a rare benign neoplasm arising in the lung, considered as a part of the PEComa family. As PEComas of other sites, this tumor expresses melanocytic markers such as HMB45 and Melan-A. Despite cathepsin K, MITF and CD68 staining are known to be positive in a large number of PEComas and TFE3 rearrangement has been reported in a subset of PEComas, no data is available regarding the expression of these markers and the occurrence of TFE3 and TFEB rearrangement in clear cell "sugar" tumor of the lung. We have investigated the immunolabeling of cathepsin K, MITF, and CD68 in five cases of clear cell "sugar" tumor. Moreover, we have also sought the presence of TFE3 and TFEB rearrangement by fluorescence in situ hybridization (FISH) assay. In all tumors, strong immunoreactivity of cathepsin K and CD68 (PG-M1 and KP1 clone) was demonstrated, whereas none of them labeled for MITF staining and showed TFE3 or TFEB rearrangement. These findings widen the immunohistochemical profile of clear cell "sugar" tumor providing useful new markers for challenging cases. The expression of lysosomal markers, such as cathepsin K and CD68, strengthens the hypothesis that this tumor is part of the PEComa family.	[Calio, Anna; Ghimenton, Claudio; Brunelli, Matteo; Martignoni, Guido] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Largo L Scuro 10, I-37134 Verona, Italy; [Mengoli, Maria Cecilia; Cavazza, Alberto] Arcispedale S Maria Nuova IRCCS, Dept Pathol, Reggio Emilia, Italy; [Rossi, Giulio] Azienda Romagna, Hosp S Maria delle Croci, Operat Unit Pathol Anat, Ravenna, Italy; [Pea, Maurizio] Orlandi Hosp, Dept Pathol, Verona, Italy; [Chilosi, Marco; Marcolini, Lisa; Martignoni, Guido] Pederzoli Hosp, Dept Pathol, Peschiera Del Garda, Italy	Martignoni, G (reprint author), Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Largo L Scuro 10, I-37134 Verona, Italy.	guido.martignoni@univr.it	Calio, Anna/Y-1465-2018; Cavazza, Alberto/K-2531-2018; Brunelli, Matteo/AAA-7679-2019	Calio, Anna/0000-0001-7352-6327; Cavazza, Alberto/0000-0003-3590-319X; Mengoli, Maria Cecilia/0000-0002-1437-8747			Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; BONETTI F, 1992, AM J SURG PATHOL, V16, P307, DOI 10.1097/00000478-199203000-00013; BONETTI F, 1994, PATHOLOGY, V26, P230, DOI 10.1080/00313029400169561; Calio A, 2017, MOD PATHOL; Chilosi M, 2009, MODERN PATHOL, V22, P161, DOI 10.1038/modpathol.2008.189; Cho HY, 2008, HISTOPATHOLOGY, V53, P236, DOI 10.1111/j.1365-2559.2008.03057.x; Flieder DB, 1997, AM J SURG PATHOL, V21, P1242, DOI 10.1097/00000478-199710000-00017; GAFFEY MJ, 1991, AM J SURG PATHOL, V15, P644, DOI 10.1097/00000478-199107000-00005; GAFFEY MJ, 1990, AM J SURG PATHOL, V14, P248, DOI 10.1097/00000478-199003000-00006; Krueger DA, 2013, PEDIATR NEUROL, V49, P255, DOI 10.1016/j.pediatrneurol.2013.08.002; Kuroda N, 2009, PATHOL INT, V59, P769, DOI 10.1111/j.1440-1827.2009.02443.x; Lee M, 2012, ANN DIAGN PATHOL, V16, P306, DOI 10.1016/j.anndiagpath.2011.01.007; Lee SE, 2012, HUM PATHOL, V43, P1126, DOI 10.1016/j.humpath.2011.10.008; LIEBOW AA, 1963, AM J PATHOL, V43, pA13; Malinowska I, 2012, AM J SURG PATHOL, V36, P783, DOI 10.1097/PAS.0b013e31824a8a37; Martignoni G, 2009, MODERN PATHOL, V22, P1016, DOI 10.1038/modpathol.2009.58; Martignoni G, 2008, VIRCHOWS ARCH, V452, P119, DOI 10.1007/s00428-007-0509-1; Martignoni G, 2015, SEMIN DIAGN PATHOL, V32, P140, DOI 10.1053/j.semdp.2015.02.006; Martignoni G, 2012, MODERN PATHOL, V25, P100, DOI 10.1038/modpathol.2011.136; Martignoni G, 2010, ARCH PATHOL LAB MED, V134, P33, DOI 10.1043/2008-0542-RAR1.1; Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298; Ohe C, 2012, MED MOL MORPHOL, V45, P234, DOI 10.1007/s00795-012-0584-5; Pea M, 1996, AM J SURG PATHOL, V20, P1149, DOI 10.1097/00000478-199609000-00012; PEA M, 1991, AM J SURG PATHOL, V15, P199, DOI 10.1097/00000478-199102000-00020; Rao Q, 2013, HISTOPATHOLOGY, V62, P642, DOI 10.1111/his.12059; Rapa I, 2006, AM J CLIN PATHOL, V125, P847, DOI 10.1309/Q96AYDAAJ3E1TNVVF; Tanaka M, 2009, AM J SURG PATHOL, V33, P1416, DOI 10.1097/PAS.0b013e3181a9cd6c; Williamson SR, 2013, AM J SURG PATHOL, V37, P1619, DOI 10.1097/PAS.0b013e318293729d; Zheng G, 2013, AM J CLIN PATHOL, V139, P151, DOI 10.1309/AJCPDTRTO2Z4UEXD	29	0	0	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					55	59		10.1007/s00428-018-2325-1			5	Pathology	Pathology	GK9JO	WOS:000436563100007	29516164				2019-10-28	
J	Shields, T; Delcroix, O				Shields, T.; Delcroix, O.			Editorial	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Editorial Material									[Shields, T.; Delcroix, O.] CHRU Brest, Serv Med Nucl, 2 Ave Foch, F-29200 Brest, France	Shields, T (reprint author), CHRU Brest, Serv Med Nucl, 2 Ave Foch, F-29200 Brest, France.	revue-junior@hotmail.com						0	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					205	205		10.1016/j.mednuc.2018.07.001			1	Pathology	Pathology	GU5JX	WOS:000445322900001					2019-10-28	
J	Gonzalez, S; Mundler, O; Doddoli, C; Barlesi, F; Tessonnier, T; Farman, B; Cammilleri, S; Boyer, L; Guedj, E; Tessonnier, L				Gonzalez, S.; Mundler, Olivier; Doddoli, Christophe; Barlesi, Fabrice; Tessonnier, Thomas; Farman, Bardia; Cammilleri, Serge; Boyer, Laurent; Guedj, Eric; Tessonnier, Laurent			No diagnostic impact of routinely use of respiratory gating to characterize lung nodules with F-18-FDG PET/CT	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			English	Article						PET/CT; FDG; Respiratory gating; Lung nodule; Lung cancer	INSPIRATION BREATH-HOLD; POSITRON-EMISSION-TOMOGRAPHY; PULMONARY NODULES; LIVER METASTASES; GATED PET/CT; LESIONS; CANCER; CT; MANAGEMENT	Purpose. - To evaluate diagnostic impact of routinely use of respiratory gated (RG) (18)FDG PET/CT to distinguish benign and malignant lung nodules. Methods. - We analyzed retrospectively data of 76 patients referred for metabolic characterization of lung nodules who underwent whole body (18)FDG PET/CT scan followed by RG PET/CT (deep-inspiration breath-hold, DIBH). RG was prospectively planned without knowledge of WB PET/CT results. Independent reading of PET/CT scans with or without respiratory gating was separately conducted by two nuclear medicine physicians. Uptake of lung nodules was evaluated visually (positive if nodule's uptake superior to pulmonary background uptake), and quantitatively (SUVmax, SUVmean, metabolic volume, tumor to background ratio). Reference standard was obtained for all patients by histology (n = 37) or clinico-radiological follow-up (n = 39). Sub-groups were also evaluated (nodule < 15 mm, lower lobe nodules). Results. - Nodules were classified positives without RG scans in 43/76 (59.7%) patients and with RG scans in 41/75 (54.6%) patients. Results were discordant for 5/75 (6.7%) patients. According to the reference standard, 35/39 cancers were correctly identified by PET/CT without RG, and 34/38 by RG PET/CT. Without RG PET, sensitivity, specificity and accuracy were 89.7%, 78.4% and 84.2% respectively. With RG PET, sensitivity, specificity and accuracy were 89.5%, 81.1% and 85.3% respectively, not statistically different. Concerning quantitative analysis, results were not statistically better with RG than without RG and were not better than visual analysis. Sub-groups analysis showed no added value of RG scans in specific groups (lower lobes and smaller nodules). Conclusion. - Routinely use of RG did not help in the diagnosis of neoplastic lung nodules. Others evaluations are needed to assess the contribution of RG for others selective indications (therapeutic evaluation, radiotherapy planning, characterization of liver lesions). (C) 2018 Elsevier Masson SAS. All rights reserved.	[Gonzalez, S.; Mundler, Olivier; Tessonnier, Thomas; Farman, Bardia; Cammilleri, Serge; Guedj, Eric] Aix Marseille Univ, Dept Nucl Med, La Timone Univ Hosp, European & Ctr Res Med Imaging, F-13305 Marseille, France; [Tessonnier, Laurent] Ctr Hosp Intercommunal, Dept Nucl Med, F-83100 Toulon, France; [Doddoli, Christophe] North Hosp, Dept Thorac Surg, F-13015 Marseille, France; [Barlesi, Fabrice] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, AP HM, F-13015 Marseille, France; [Boyer, Laurent] Aix Marseille Univ, Dept Publ Hlth, AP HM, F-13015 Marseille, France	Gonzalez, S (reprint author), Univ Aix Marseille, Ctr Hosp Univ la Timone, AP HM, 264 Rue St Pierre, F-13385 Marseille 5, France.	sandra-gonzalez@live.fr					Bundschuh RA, 2012, STRAHLENTHER ONKOL, V188, P592, DOI 10.1007/s00066-012-0094-3; Caobelli F, 2014, REV ESP MED NUCL IMA, V33, P136, DOI 10.1016/j.remn.2013.08.006; Daisaki H, 2010, ANN NUCL MED, V24, P179, DOI 10.1007/s12149-009-0340-7; Daouk J, 2013, MED NUCL, V37, P189, DOI 10.1016/j.mednuc.2013.03.002; Daouk J, 2009, ACTA RADIOL, V50, P144, DOI 10.1080/02841850802627437; Daouk J, 2011, ACTA RADIOL, V52, P651, DOI 10.1258/ar.2011.110018; Farid K, 2015, NUCL MED COMMUN, V36, P722, DOI 10.1097/MNM.0000000000000311; Fin L, 2008, EUR J NUCL MED MOL I, V35, P1971, DOI 10.1007/s00259-008-0858-2; Vicente AMG, 2010, ANN NUCL MED, V24, P207, DOI 10.1007/s12149-010-0345-2; Vicente AMG, 2011, J NUCL MED TECHNOL, V39, P91, DOI 10.2967/jnmt.110.082719; Grootjans W, 2015, LUNG CANCER, V90, P217, DOI 10.1016/j.lungcan.2015.09.016; Guerra L, 2012, EUR J NUCL MED MOL I, V39, P1381, DOI 10.1007/s00259-012-2148-2; Hassler S, 2014, CLIN NUCL MED, V39, pE7, DOI 10.1097/RLU.0b013e31828e96dd; Kawano T, 2008, J NUCL MED, V49, P1223, DOI 10.2967/jnumed.107.049296; Lamb JM, 2011, MED PHYS, V38, P5732, DOI 10.1118/1.3633896; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; Lupi A, 2009, ANN NUCL MED, V23, P191, DOI 10.1007/s12149-008-0225-1; Meirelles GSP, 2007, J NUCL MED, V48, P712, DOI 10.2967/jnumed.106.038034; Morvan J, 2008, MED NUCL, V32, P600, DOI 10.1016/j.mednuc.2008.07.011; Muirhead R, 2010, RADIOTHER ONCOL, V95, P172, DOI 10.1016/j.radonc.2010.02.002; Nehmeh SA, 2007, J NUCL MED, V48, P22; Pepin A, 2014, NUCL MED COMMUN, V35, P113, DOI 10.1097/MNM.0000000000000048; Revheim ME, 2015, ACTA RADIOL, V56, P397, DOI 10.1177/0284185114529563; Suenaga Y, 2013, EUR J RADIOL, V82, P1696, DOI 10.1016/j.ejrad.2013.05.019; Tahari AK, 2014, J MED IMAG RADIAT ON, V58, P277, DOI 10.1111/1754-9485.12154; Tessonnier T, 2012, MED NUCL, V36, P188; Torizuka T, 2009, J NUCL MED, V50, P1579, DOI 10.2967/jnumed.109.064246; Van Der Gucht A, 2014, EUR J RADIOL, V83, P509, DOI 10.1016/j.ejrad.2013.11.010; Werner MK, 2009, AM J ROENTGENOL, V193, P1640, DOI 10.2214/AJR.09.2516; Yamashita S, 2014, ANN NUCL MED, V28, P1, DOI 10.1007/s12149-013-0774-9	30	0	0	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					206	213		10.1016/j.mednuc.2018.06.006			8	Pathology	Pathology	GU5JX	WOS:000445322900002					2019-10-28	
J	Shields, T				Shields, T.			Fibrous dysplasia of the bone in SPECT/CT hybrid imaging	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Fibrous dysplasia; SPECT/CT; Bone scan; (18)FDG PET/CT	MCCUNE-ALBRIGHT-SYNDROME; OF-THE-LITERATURE; GIANT-CELL TUMOR; PATHOLOGICAL CORRELATION; EOSINOPHILIC GRANULOMA; MAZABRAUDS-SYNDROME; PAGET-DISEASE; ARCHIVES; AFIP; CHONDROSARCOMA	Fibrous dysplasia of the bone (FDB) is a benign congenital but non-hereditary bone disorder in which normal bone is replaced by pseudofibrous tissue containing an immature osteogenesis. It is frequently fortuitously discovered during a radiological or nuclear medicine scan. The main goal of this article is to give useful clinical and imaging information for the diagnosis of FDB in the daily practice of Nuclear Medicine. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Shields, T.] CHU Amiens Picardie, Serv Med Nucl, F-80000 Amiens 1, France	Shields, T (reprint author), Serv Med Nucl Nancy, 105 Rue St Honore,App H2, F-80000 Amiens, France.	shields.trevor@chu-amiens.fr					Aras M, 2013, IRAN J RADIOL, V10, P41, DOI 10.5812/iranjradiol.10303; Barral PA, 2012, MED NUCL, V36, P208; Berrebi O, 2008, CLIN NUCL MED, V33, P469, DOI 10.1097/RLU.0b013e3181779259; Blaz M, 2011, POL J RADIOL, V76, P32; Cabral CEL, 1998, SKELETAL RADIOL, V27, P278; CAMPANACCI M, 1976, Italian Journal of Orthopaedics and Traumatology, V2, P221; Campbell RSD, 2003, SKELETAL RADIOL, V32, P209, DOI 10.1007/s00256-002-0616-7; Chapurlat RD, 2000, BEST PRACT RES CL RH, V14, P385, DOI 10.1053/berh.1999.0071; Chapurlat RD, 2008, BEST PRACT RES CL RH, V22, P55, DOI 10.1016/j.berh.2007.11.004; Coley BL, 1962, NEOPLASMS BONE RELAT; DAVID R, 1989, AM J ROENTGENOL, V153, P1021, DOI 10.2214/ajr.153.5.1021; Dumitrescu CE, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-12; Fitzpatrick KA, 2004, AM J ROENTGENOL, V182, P1389, DOI 10.2214/ajr.182.6.1821389; Geirnaerdt MJA, 1997, AM J ROENTGENOL, V169, P1097, DOI 10.2214/ajr.169.4.9308471; ISHIDA T, 1993, AM J SURG PATHOL, V17, P924, DOI 10.1097/00000478-199309000-00009; Jain D, 2008, DIAGN PATHOL, V3, DOI 10.1186/1746-1596-3-8; Kabukcuoglu F, 2004, PATHOL ONCOL RES, V10, P121, DOI 10.1007/BF02893467; Kao CH, 2007, CLIN NUCL MED, V32, P409, DOI 10.1097/01.rlu.0000259614.93782.cf; Kaul R, 2009, J CYTOL, V26, P156, DOI 10.4103/0970-9371.62188; KRANSDORF MJ, 1995, AM J ROENTGENOL, V164, P573, DOI 10.2214/ajr.164.3.7863874; KRANSDORF MJ, 1990, RADIOGRAPHICS, V10, P519, DOI 10.1148/radiographics.10.3.2188311; LAFFORGUE P, 1990, REV RHUM, V57, P359; Lokiec F, 1998, J PEDIATR ORTHOP B, V7, P262, DOI 10.1097/01202412-199810000-00004; Mazabraud A, 1967, Presse Med, V75, P2223; Mirra JM, 1989, BONE TUMORS CLIN RAD; Munksgaard PS, 2013, ACTA RADIOL OPEN, V2, DOI 10.1177/2047981613492532; Murphey MD, 2002, RADIOLOGY, V225, P215, DOI 10.1148/radiol.2251011627; Murphey MD, 2001, RADIOGRAPHICS, V21, P1283, DOI 10.1148/radiographics.21.5.g01se251283; Murphey MD, 1998, RADIOGRAPHICS, V18, P1213, DOI 10.1148/radiographics.18.5.9747616; Qu N, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000369; RITSCHL P, 1988, SKELETAL RADIOL, V17, P8, DOI 10.1007/BF00361448; RUGGIERI P, 1994, CANCER, V73, P1411, DOI 10.1002/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T; Smith SE, 2002, RADIOGRAPHICS, V22, P1191, DOI 10.1148/radiographics.22.5.g02se281191; Sobti A, 2016, ARCH BONE JT SURG-AB, V4, P2; Theodorou DJ, 2011, AM J ROENTGENOL, V196, pS64, DOI 10.2214/AJR.10.7222; Ullah Ekram, 2012, Indian J Endocrinol Metab, V16, P1040, DOI 10.4103/2230-8210.103037; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Yuan ZB, 2004, CLIN NUCL MED, V29, P177, DOI 10.1097/01.rlu.0000113856.77103.7e; Zhang LQ, 2017, BMC MED IMAGING, V17, DOI 10.1186/s12880-017-0218-4	39	0	0	1	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					214	223		10.1016/j.mednuc.2018.05.001			10	Pathology	Pathology	GU5JX	WOS:000445322900003					2019-10-28	
J	Fagart, A				Fagart, A.			Inflammatory sacroiliitis in bone SPECT/CT	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Sacroiliitis; Spondylarthropathy; Osteoarthritis; Bone scan; SPECT/CT	LOW-BACK-PAIN; AXIAL SPONDYLOARTHRITIS; ANKYLOSING-SPONDYLITIS; PSORIATIC-ARTHRITIS; JOINT DYSFUNCTION; DIAGNOSTIC-VALUE; TOMOGRAPHY; CLASSIFICATION; CRITERIA; MRI	In this review paper, which deals with inflammatory sacroiliitis, first, we present the anatomy of the sacroiliac joint and list the main etiologies of inflammatory sacroiliitis with the diagnostic criteria. The radiographic, CT, MRI and scintigraphic aspects are then detailed and clinical cases illustrate the usual presentation of an inflammatory sacroiliitis as well as its principal radiological differential diagnosis: degenerative sacroiliac joint disease. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Fagart, A.] CHRU Lille, Hop Roger Salengro, Serv Med Nucl, Lille, France	Fagart, A (reprint author), Ave Prof Emile Laine, F-59037 Lille, France.	alexandre.fagart@gmail.com					BERNARD TN, 1987, CLIN ORTHOP RELAT R, P266; Berthelot JM, 2009, REV RHUM, V76, P741, DOI DOI 10.1016/J.RHUM.2009.01.010; Braun J, 2002, BEST PRACT RES CL RH, V16, P573, DOI 10.1053/berh.2002.0250; Cevik R, 2000, ROMATIZMA, V60-65, P99; Cotten A, 2013, IMAGERIE MUSCULOSQUE; Cusi M, 2013, EUR SPINE J, V22, P1674, DOI 10.1007/s00586-013-2725-5; Elgafy H, 2001, CLIN ORTHOP RELAT R, P112; Elsevier Masson, 2011, COLL FRANCAIS ENSEIG; Gupta AD, 2009, J BACK MUSCULOSKELET, V22, P91, DOI 10.3233/BMR-2009-0221; Hamdy M, 2015, EUR J RHEUMATOL, V2, P10, DOI 10.5152/eurjrheumatol.2015.0075; Irwin RW, 2007, AM J PHYS MED REHAB, V86, P37, DOI 10.1097/PHM.0b013e31802b8554; Jans L, 2014, JBR-BTR, V97, P202, DOI 10.5334/jbr-btr.94; Kanyik JPM, 2017, CLIN RHEUMATOL, V36, P2501, DOI 10.1007/s10067-017-3810-7; Karreman Maren C, 2016, J CROHNS COLITIS ADV, V119, P4; Kim YI, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0465-x; Kwiatkowska B, 2009, POLSKIE ARCHIWUM MED, V209, P119; Manchikanti L, 2001, Pain Physician, V4, P308; Marchesoni A, 2018, RHEUMATOLOGY, V57, P32, DOI 10.1093/rheumatology/kex079; Parghane RV, 2017, J NUCL MED TECHNOL, V45, P280, DOI 10.2967/jnmt.117.193094; Pertuiset E., 2009, REV RHUM EDITION FR, V76, P761, DOI 10.1016/j.rhum.2009.05.002; Pialat JB, 2016, DIAGN INTERV IMAG, V97, P697, DOI 10.1016/j.diii.2016.02.013; Pipikos T, 2017, MOL IMAGING RADIONUC, V26, P101, DOI 10.4274/mirt.50570; Poley RE, 2008, PHYSICIAN SPORTSMED, V36, P42, DOI 10.3810/psm.2008.12.10; Raychaudhuri SP, 2014, J AUTOIMMUN, V48-49, P128, DOI 10.1016/j.jaut.2014.01.015; Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233; SCHWARZER AC, 1995, SPINE, V20, P31, DOI 10.1097/00007632-199501000-00007; Song IH, 2008, ANN RHEUM DIS, V67, P1535, DOI 10.1136/ard.2007.083089; Tofuku K, 2015, EUR SPINE J, V24, P859, DOI 10.1007/s00586-014-3375-y; Vinceneux P, 2016, REV RHUM, V73, P177; Vinceneux Ph, 2006, REV RHUM, V73, P177; Williamson L, 2004, RHEUMATOLOGY, V43, P85, DOI 10.1093/rheumatology/keg475	31	0	0	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					224	236		10.1016/j.mednuc.2018.05.002			13	Pathology	Pathology	GU5JX	WOS:000445322900004					2019-10-28	
J	Salomon, T; Houdu, B				Salomon, T.; Houdu, B.			Characterization of mediastinal lymphadenopathies using F-18-FDG PET/CT	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						PET/CT; (18)FDG; Lymphadenopathy; Mediastinum	CELL LUNG-CANCER; POSITRON-EMISSION-TOMOGRAPHY; RESPONSE ASSESSMENT; STAGING PROJECT; 8TH EDITION; LYMPHOMA; MANIFESTATIONS; SARCOIDOSIS	The mediastinum is a complex anatomical region located at the junction of the cervical, thoracic and abdominal regions. It is an important lymphatic gateway that has an impact in many pathologies with nodal involvement and for which F-18-FDG PET/CT is a central examination. In this review article, we propose to recall the normal and pathological lymphatic drainage, mediastinum anatomy, the International Association for the Study of Lung Cancer (IASLC) lymph node classification and its implications in lung cancer. Then we will detail the morphological and metabolic characteristics, principal etiologies and the procedures to access mediastinal lymph nodes. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Salomon, T.; Houdu, B.] CHU Caen, Serv Med Nucl, Ave Cote de Nacre, F-14033 Caen 9, France	Salomon, T (reprint author), CHU Caen, Serv Med Nucl, Ave Cote de Nacre, F-14033 Caen 9, France.	Thibault.salomon@wanadoo.fr					Aide N, 2009, MOL IMAGING BIOL, V11, P224, DOI 10.1007/s11307-008-0191-y; Al-Jahdali H, 2013, ANN THORAC MED, V8, P186, DOI 10.4103/1817-1737.118490; [Anonymous], 2014, ECHO ENDOSCOPIEBRONC; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Bonniaud P, 2005, REV MAL RESPIR, V22, pS101, DOI [10.1019/200530147, 10.1019/200530077]; Brown JR, 2004, ONCOLOGIST, V9, P406, DOI 10.1634/theoncologist.9-4-406; Cancer du poumon, 2011, CANC POUMON BILAN IN; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Criado E, 2010, RADIOGRAPHICS, V30, P1567, DOI 10.1148/rg.306105512; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; Gould MK, 2003, ANN INTERN MED, V139, P879, DOI 10.7326/0003-4819-139-11-200311180-00013; Jung JI, 2000, J COMPUT ASSIST TOMO, V24, P706, DOI 10.1097/00004728-200009000-00007; Meignan M, 2015, LEUKEMIA LYMPHOMA, V56, P1229, DOI 10.3109/10428194.2015.1029748; National Collaborating Centre for Cancer, 2011, DIAGN TREATM LUNG CA; Nin CS, 2016, RESP MED, V112, P10, DOI 10.1016/j.rmed.2016.01.021; Rami-Porta R, 2017, CA-CANCER J CLIN, V67, P138, DOI 10.3322/caac.21390; Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334; Ronson RS, 2000, SURG CLIN N AM, V80, P157, DOI 10.1016/S0039-6109(05)70400-X; Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e; Silvestri GA, 2007, CHEST, V132, p178S, DOI 10.1378/chest.07-1360; Soumerai JD, 2014, CANCER CONTROL, V21, P266, DOI 10.1177/107327481402100403; Walker CM, 2012, AM J ROENTGENOL, V199, pW54, DOI 10.2214/AJR.11.7446	22	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					237	247		10.1016/j.mednuc.2018.06.001			11	Pathology	Pathology	GU5JX	WOS:000445322900005					2019-10-28	
J	Cadour, N				Cadour, N.			Benefits of SPECT-CT hybrid imaging in aseptic hip prosthesis loosening	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						Bone scan; SPECT/CT; Loosening; Prosthesis; Hip	FEMORAL COMPONENTS; ARTHROPLASTY; REPLACEMENT; FIXATION	Hip prosthesis loosening detection is a common indication for bone scan, however, the diagnosis can be difficult to confirm based solely on bone scan information which have a low specificity. The development of bone SPECT/CT hybrid imaging allows the correlation of two complementary modalities to palliate the low sensitivity of CT caused by metallic artefacts and the moderate specificity of bone scan. It becomes a necessity for nuclear medicine physicians to master the bases of pathological hip prosthesis radiological semiology. We propose in this review article to recall the physiopathology of prosthesis loosening then we will describe the radiological and scintigraphic characteristics of hip prosthesis loosening as well as its differential diagnoses and the benefits of other imaging modalities. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Cadour, N.] Serv Med Nucl Nancy, Nice, France	Cadour, N (reprint author), Serv Med Nucl Nancy, Nice, France.	nour.cadour@hotmail.fr					Arican P, 2015, NUCL MED COMMUN, V36, P931, DOI 10.1097/MNM.0000000000000348; Berber R, 2015, J ARTHROPLASTY, V30, P687, DOI 10.1016/j.arth.2014.11.019; Caton J, 2012, E-MEM ACAD NATL CHIR, V11, P1, DOI 10.14607/emem.2012.2.001; DELEE JG, 1976, CLIN ORTHOP RELAT R, P20; Dobrindt O, 2015, BMC MED IMAGING, V15, DOI 10.1186/s12880-015-0056-1; ENGH CA, 1990, CLIN ORTHOP RELAT R, P107; Girma A, 2013, MED NUCL, V37, P338, DOI 10.1016/j.mednuc.2013.07.003; GRUEN TA, 1979, CLIN ORTHOP RELAT R, P17; Kim HS, 1997, CLIN NUCL MED, V22, P6, DOI 10.1097/00003072-199701000-00002; Manaster BJ, 1996, RADIOGRAPHICS, V16, P645, DOI 10.1148/radiographics.16.3.8897629; MIAN SW, 1992, CLIN ORTHOP RELAT R, P206; ONEILL DA, 1984, J BONE JOINT SURG AM, V66A, P540, DOI 10.2106/00004623-198466040-00007; Querellou S, 2016, MED NUCL, V40, P404, DOI 10.1016/j.mednuc.2016.09.001; Roth TD, 2012, RADIOGRAPHICS, V32, P1089, DOI 10.1148/rg.324115183; Tam HH, 2014, CLIN RADIOL, V69, P82, DOI 10.1016/j.crad.2013.08.003; Teixeira PAG, 2014, SKELETAL RADIOL, V43, P1237, DOI 10.1007/s00256-014-1923-5; Temmerman OPP, 2005, J BONE JOINT SURG BR, V87B, P781, DOI 10.1302/0301-620X.87B6; Vaz Sofia, 2017, Eur J Orthop Surg Traumatol, V27, P147, DOI 10.1007/s00590-016-1884-6; Verburg JM, 2012, PHYS MED BIOL, V57, DOI 10.1088/0031-9155/57/9/2803	19	0	0	1	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					262	270		10.1016/j.mednuc.2018.06.005			9	Pathology	Pathology	GU5JX	WOS:000445322900007					2019-10-28	
J	Delcroix, O				Delcroix, O.			Adrenal disease with 18F-FDG PET/CT: A daily challenge for nuclear physicians	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Review						PET/CT; 18F-FDG; Adrenal disease; Incidentaloma; Adrenocortical adenoma; Adrenocortical carcinoma; Metastasis; Myelolipoma; Pheochromocytoma	POSITRON-EMISSION-TOMOGRAPHY; ADRENOCORTICAL CARCINOMA; FDG-PET/CT; COMPUTED-TOMOGRAPHY; F-18-FDG PET/CT; LUNG-CANCER; CT; TUMORS; LESIONS; BENIGN	Adrenal masses are common in adult population and are a daily challenge for nuclear physicians. The aim for physicians is to differentiate benign from malignant lesions when therapeutic management is impacted. 18F-FDG PET/CT combines complementary modalities, providing structural and functional information, superior to that provided by CT or PET alone. The purpose of this review is to provide some keys that will help to be familiar with the common as well as the atypical manifestations of adrenal disease. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Delcroix, O.] CHRU Brest, Serv Med Nucl, 2 Ave Foch, F-29200 Brest, France	Delcroix, O (reprint author), CHRU Brest, Serv Med Nucl, 2 Ave Foch, F-29200 Brest, France.	delcroixolivier@hotmail.fr					Abiven G, 2006, J CLIN ENDOCR METAB, V91, P2650, DOI 10.1210/jc.2005-2730; Aktas GE, 2016, REV ESP MED NUCL IMA, V35, P118, DOI 10.1016/j.remn.2015.08.011; Allolio B, 2006, J CLIN ENDOCR METAB, V91, P2027, DOI 10.1210/jc.2005-2639; Altinmakas E, 2017, ABDOM RADIOL, V42, P577, DOI 10.1007/s00261-016-0915-4; Anis M, 2008, RADIOL CLIN N AM, V46, P265, DOI 10.1016/j.rcl.2008.04.001; Ansquer C, 2013, MED NUCL, V37, P215, DOI 10.1016/j.mednuc.2013.03.001; Assie G, 2007, J CLIN ENDOCR METAB, V92, P148, DOI 10.1210/jc.2006-0706; Berland LL, 2010, J AM COLL RADIOL, V7, P754, DOI 10.1016/j.jacr.2010.06.013; Blake MA, 2010, AM J ROENTGENOL, V194, P1450, DOI 10.2214/AJR.10.4547; Boland GWL, 2011, RADIOLOGY, V259, P117, DOI 10.1148/radiol.11100569; Boland GWL, 2008, RADIOLOGY, V249, P756, DOI 10.1148/radiol.2493070976; Boland GWL, 1998, AM J ROENTGENOL, V171, P201, DOI 10.2214/ajr.171.1.9648789; Brady MJ, 2009, RADIOLOGY, V250, P523, DOI 10.1148/radiol.2502080219; BURKS DW, 1992, AM J ROENTGENOL, V158, P503, DOI 10.2214/ajr.158.3.1738984; Carvounis E, 2006, ARCH PATHOL LAB MED, V130, P1722; Chong S, 2006, RADIOGRAPHICS, V26; Chong S, 2006, RADIOGRAPHICS, V26, P1811, DOI 10.1148/rg.266065057; Chrisoulidou A, 2007, ENDOCR-RELAT CANCER, V14, P569, DOI 10.1677/ERC-07-0074; DOBBIE JW, 1969, J PATHOL, V99, P1, DOI 10.1002/path.1710990102; Egbert N, 2010, CANCER IMAGING, V10, P198, DOI 10.1102/1470-7330.2010.0029; Fassnacht M, 2009, CANCER, V115, P243, DOI 10.1002/cncr.24030; FERROZZI F, 1995, ABDOM IMAGING, V20, P272, DOI 10.1007/BF00200415; FISHMAN EK, 1987, AM J ROENTGENOL, V148, P531, DOI 10.2214/ajr.148.3.531; Garrett RW, 2016, AM J ROENTGENOL, V206, P1170, DOI 10.2214/AJR.15.15475; Ghander C, 2012, J CLIN ENDOCR METAB, V97, P1096, DOI 10.1210/jc.2011-3039; Groussin L, 2009, J CLIN ENDOCR METAB, V94, P1713, DOI 10.1210/jc.2008-2302; Guerin C, 2017, J CLIN ENDOCR METAB, V102, P2465, DOI 10.1210/jc.2017-00254; Heye S, 2005, ABDOM IMAGING, V30, P641, DOI 10.1007/s00261-004-0281-5; Ilias L, 2007, ENDOCR-RELAT CANCER, V14, P587, DOI 10.1677/ERC-07-0045; Jana S, 2006, EUR J NUCL MED MOL I, V33, P29, DOI 10.1007/s00259-005-1915-8; Jinguji M, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150950; Johnson PT, 2009, RADIOGRAPHICS, V29, P1333, DOI 10.1148/rg.295095027; Joshi P, 2014, CLIN NUCL MED, V39, P57, DOI 10.1097/RLU.0b013e318286ff53; Kandathil A, 2015, ENDOCRINE, V49, P6, DOI 10.1007/s12020-014-0440-6; Kenney PJ, 1998, RADIOLOGY, V208, P87, DOI 10.1148/radiology.208.1.9646797; Kim BS, 2015, ANN NUCL MED, V29, P276, DOI 10.1007/s12149-014-0937-3; Kim SJ, 2018, BR J RADIOL, V91; Kitayama K, 2015, BMC SURG, V15, DOI 10.1186/s12893-015-0041-1; KLOOS RT, 1995, ENDOCR REV, V16, P460, DOI 10.1210/er.16.4.460; Korobkin M, 1998, AM J ROENTGENOL, V170, P747, DOI 10.2214/ajr.170.3.9490968; Kudva YC, 1999, ENDOCRINOLOGIST, V9, P77, DOI 10.1097/00019616-199903000-00002; Kumar R, 2004, J NUCL MED, V45, P2058; Lam KY, 2002, CLIN ENDOCRINOL, V56, P95, DOI 10.1046/j.0300-0664.2001.01435.x; Lam KY, 2001, CLIN ENDOCRINOL, V54, P633, DOI 10.1046/j.1365-2265.2001.01266.x; Lattin GE, 2014, RADIOGRAPHICS, V34, P805, DOI 10.1148/rg.343130127; Launay N, 2015, INT J ENDOCRINOL, DOI 10.1155/2015/213875; Leboulleux S, 2011, EUR J ENDOCRINOL, V164, P89, DOI 10.1530/EJE-10-0666; LEE MJ, 1991, RADIOLOGY, V179, P415, DOI 10.1148/radiology.179.2.2014283; Low G, 2012, CLIN RADIOL, V67, P988, DOI 10.1016/j.crad.2012.02.005; LUTON JP, 1990, NEW ENGL J MED, V322, P1195, DOI 10.1056/NEJM199004263221705; Mallappa A, 2017, J ENDOCR SOC, V1, P1110, DOI 10.1210/js.2017-00270; Meier JM, 2007, SEMIN NUCL MED, V37, P154, DOI 10.1053/j.semnuclmed.2007.02.001; Menegaux F, 2014, J CHIR VISC, V151, P366; MIYAKE H, 1989, AM J ROENTGENOL, V152, P1005, DOI 10.2214/ajr.152.5.1005; Nakajo M, 2015, ABDOM IMAGING, V40, P1655, DOI 10.1007/s00261-014-0291-x; OLSSON CA, 1973, SURGERY, V73, P665; PALING MR, 1983, AM J ROENTGENOL, V141, P303, DOI 10.2214/ajr.141.2.303; Papadakis GZ, 2016, ENDOCRINE, V54, P269, DOI 10.1007/s12020-016-0969-7; Park SY, 2014, AM J ROENTGENOL, V202, pW153, DOI 10.2214/AJR.13.10873; Pavon-Paz I, 2016, MED CLIN-BARCELONA, V146, P104, DOI 10.1016/j.medcli.2015.05.018; Raynal G, 2010, PROG UROL, V20, P1192, DOI 10.1016/j.purol.2010.06.004; Ricci Z, 2013, AM J ROENTGENOL, V201, P1009, DOI 10.2214/AJR.12.9202; ROSENBERG S, 1961, MEDICINE, V40, P31, DOI 10.1097/00005792-196102000-00002; Rowe Steven P, 2017, World J Nucl Med, V16, P271, DOI 10.4103/1450-1147.215499; RUSSELL RP, 1970, ANN INTERN MED, V73, P195, DOI 10.7326/0003-4819-73-2-195; Sandev A, 2017, BR J RADIOL, V90; Schlamp A, 2007, NAT CLIN PRACT ENDOC, V3, P191, DOI 10.1038/ncpendmet0391; Soon PSH, 2008, ONCOLOGIST, V13, P548, DOI 10.1634/theoncologist.2007-0243; Sturgeon C, 2006, J AM COLL SURGEONS, V202, P423, DOI 10.1016/j.jamcollsurg.2005.11.005; Sturgeon C, 2004, SURG CLIN N AM, V84, P755, DOI 10.1016/j.suc.2004.02.003; Tabarin A, 2008, ANN ENDOCRINOL, V69, pe1; Tessonnier L, 2013, WORLD J SURG, V37, P107, DOI 10.1007/s00268-012-1802-y; Timmers HJLM, 2007, J CLIN ONCOL, V25, P2262, DOI 10.1200/JCO.2006.09.6297; Watanabe H, 2013, ANN NUCL MED, V27, P648, DOI 10.1007/s12149-013-0730-8; WELCH TJ, 1994, RADIOLOGY, V193, P341, DOI 10.1148/radiology.193.2.7972740	75	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					271	284		10.1016/j.mednuc.2018.06.004			14	Pathology	Pathology	GU5JX	WOS:000445322900008					2019-10-28	
J	Zhang-Yin, J				Zhang-Yin, J.			Indications and performance of sodium [F-18] fluoride PET/CT	MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE			French	Article						PET/CT; 18F-FNA	PLANAR BONE-SCINTIGRAPHY; PROSTATE-CANCER; F-18-FLUORIDE PET/CT; METASTASES; SPECT; CT; FLUOROCHOLINE; LUNG	18F-NAF PET/CT is a relatively uncommon imaging procedure in France, for which indications are similar to those for bone scan and that shows substantial advantages when compared to it. In this review article, we propose to introduce this poorly known radiotracer, its validated indications, performances and some tips for interpretation that will be illustrated by 6 case reports. (C) 2018 Elsevier Masson SAS. All rights reserved.	[Zhang-Yin, J.] AP HP, Serv Med Nucl Tenon, 4 Rue Chine, F-75020 Paris, France	Zhang-Yin, J (reprint author), AP HP, Serv Med Nucl Tenon, 4 Rue Chine, F-75020 Paris, France.	tianyuzhang777@msn.com					Beheshti M, 2008, EUR J NUCL MED MOL I, V35, P1766, DOI 10.1007/s00259-008-0788-z; Beheshti M, 2009, SEMIN NUCL MED, V39, P396, DOI 10.1053/j.semnuclmed.2009.05.003; BLAU M, 1962, J NUCL MED, V3, P332; Cazeau AL, 2012, MED NUCL, V36, P469; Chua S, 2009, SEMIN NUCL MED, V39, P416, DOI 10.1053/j.semnuclmed.2009.07.002; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Even-Sapir E, 2006, J NUCL MED, V47, P287; Garzon JRG, 2013, MED NUCL, V37, P78, DOI 10.1016/j.mednuc.2012.12.003; Grant FD, 2008, J NUCL MED, V49, P68, DOI 10.2967/jnumed.106.037200; Joshi NV, 2014, LANCET, V383, P705, DOI 10.1016/S0140-6736(13)61754-7; Kawaguchi M, 2010, ANN NUCL MED, V24, P241, DOI 10.1007/s12149-010-0363-0; Kruger S, 2009, EUR J NUCL MED MOL I, V36, P1807, DOI 10.1007/s00259-009-1181-2; Langsteger W, 2011, Q J NUCL MED MOL IM, V55, P448; Li Y, 2012, BONE, V50, P128, DOI 10.1016/j.bone.2011.09.053; Ouichka R, 2016, MED NUCL, V40, P184; Poulsen MH, 2014, BJU INT, V114, P818, DOI 10.1111/bju.12599; Sabbah N, 2015, CLIN NUCL MED, V40, pE228, DOI 10.1097/RLU.0000000000000633; Thang S P, 2011, World J Nucl Med, V10, P139, DOI 10.4103/1450-1147.89782; Yen RF, 2010, NUCL MED COMMUN, V31, P637, DOI 10.1097/MNM.0b013e3283399120	19	0	0	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0928-1258	1878-6820		MED NUCL	Med. Nucl.-Imag. Fonct. Metab.	JUL-AUG	2018	42	4					285	292		10.1016/j.mednuc.2018.06.002			8	Pathology	Pathology	GU5JX	WOS:000445322900009					2019-10-28	
J	McCarthy, AJ; Karamchandani, DM; Chetty, R				McCarthy, Aoife J.; Karamchandani, Dipti M.; Chetty, Runjan			Neural and neurogenic tumours of the gastroenteropancreaticobiliary tract	JOURNAL OF CLINICAL PATHOLOGY			English	Review							NERVE-SHEATH TUMORS; GASTROINTESTINAL STROMAL TUMORS; CLEAR-CELL SARCOMA; OF-THE-LITERATURE; DUODENAL GANGLIOCYTIC PARAGANGLIOMA; BENIGN FIBROBLASTIC POLYPS; SOFT-TISSUE PERINEURIOMA; OSTEOCLAST-RICH TUMOR; NEUROFIBROMATOSIS TYPE-1; NEUROECTODERMAL TUMOR	Neural lesions occur uncommonly in the gastroenteropancreaticobiliary tract. However, due to the growing number of screening colonoscopy procedures, polypoid neural lesions of the colon are being recognised increasingly and range from benign tumours to high-grade malignant neoplasms. Morphological variability of neural tumours can be wide, although some entities share pathological features, and, as such, these lesions can be diagnostically challenging. We review the spectrum of pathology of neural tumours in the gastroenteropancreaticobiliary tract, with the goal of providing a practical approach for practising surgical pathologists.	[McCarthy, Aoife J.; Chetty, Runjan] Univ Hlth Network, Lab Med Program, Dept Pathol, Toronto, ON M5G 2C4, Canada; [McCarthy, Aoife J.; Chetty, Runjan] Univ Toronto, Toronto, ON M5G 2C4, Canada; [Karamchandani, Dipti M.] Penn State Hlth Milton S Hershey Med Ctr, Div Anat Pathol, Dept Pathol, Hershey, PA USA	McCarthy, AJ (reprint author), Univ Hlth Network, Lab Med Program, Dept Pathol, Toronto, ON M5G 2C4, Canada.; McCarthy, AJ (reprint author), Univ Toronto, Toronto, ON M5G 2C4, Canada.	aoife.mccarthy@uhn.ca					Agaimy A, 2010, AM J SURG PATHOL, V34, P1; Agaimy A, 2014, HISTOPATHOLOGY, V64, P777, DOI 10.1111/his.12325; Agaimy A, 2012, INT J CLIN EXP PATHO, V5, P852; Agaimy A, 2010, VIRCHOWS ARCH, V456, P411, DOI 10.1007/s00428-010-0886-8; Ahrens WA, 2008, HUM PATHOL, V39, P1519, DOI 10.1016/j.humpath.2008.03.002; Alyousef MJ, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0620-9; An S, 2015, HUM PATHOL, V46, P813, DOI 10.1016/j.humpath.2015.02.005; Andersson J, 2005, AM J SURG PATHOL, V29, P1170, DOI 10.1097/01.pas.0000159775.77912.15; Anghileri M, 2006, CANCER-AM CANCER SOC, V107, P1065, DOI 10.1002/cncr.22098; Antonescu CR, 2006, CLIN CANCER RES, V12, P5356, DOI 10.1158/1078-0432.CCR-05-2811; ARIZA A, 1988, AM J SURG PATHOL, V12, P678, DOI 10.1097/00000478-198809000-00004; AUNG W, 1995, J CLIN PATHOL, V48, P84, DOI 10.1136/jcp.48.1.84; Baek SJ, 2013, INT SURG, V98, P315, DOI 10.9738/INTSURG-D-13-00015.1; Basile U, 2010, J GASTROINTEST SURG, V14, P186, DOI 10.1007/s11605-009-0940-5; Boland JM, 2016, HUM PATHOL, V57, P13, DOI 10.1016/j.humpath.2016.05.026; Brekke HR, 2009, NEURO-ONCOLOGY, V11, P514, DOI 10.1215/15228517-2008-127; Bridge RS, 2004, J CLIN PATHOL, V57, P1172, DOI 10.1136/jcp.2004.019026; Bucher P, 2004, SCAND J GASTROENTERO, V39, P291, DOI 10.1080/00365520310007503; Cakir T, 2015, BMJ CASE REP, V2015; Card S, 2014, DIAGN HISTOPATHOL, V20, P326; CARNEY JA, 1990, AM J SURG PATHOL, V14, P206, DOI 10.1097/00000478-199003000-00002; Cathcart SJ, 2017, WORLD J CLIN CASES, V5, P222, DOI 10.12998/wjcc.v5.i6.222; Chan OTM, 2006, ARCH PATHOL LAB MED, V130, P1561; CHANDRASOMA P, 1985, GASTROINTEST RADIOL, V10, P161, DOI 10.1007/BF01893092; Cheng Yao, 2014, Dig Liver Dis, V46, pe3, DOI 10.1016/j.dld.2013.10.014; CHETTY R, 1993, J CLIN PATHOL, V46, P1061, DOI 10.1136/jcp.46.11.1061; Chetty R, 2011, ANN DIAGN PATHOL, V15, P198, DOI 10.1016/j.anndiagpath.2010.02.011; Curran T, 2016, GASTROENTEROL REP, V4, P331, DOI 10.1093/gastro/gov023; DAIMARU Y, 1985, AM J SURG PATHOL, V9, P434, DOI 10.1097/00000478-198506000-00005; DAIMARU Y, 1988, HUM PATHOL, V19, P257, DOI 10.1016/S0046-8177(88)80518-5; DUCATMAN BS, 1984, CANCER, V54, P1049, DOI 10.1002/1097-0142(19840915)54:6<1049::AID-CNCR2820540620>3.0.CO;2-1; DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6; EMORY TS, 1995, AM J CLIN PATHOL, V103, P696; Eslami-Varzaneh F, 2004, AM J SURG PATHOL, V28, P374, DOI 10.1097/00000478-200403000-00010; Fanburg-Smith JC, 2006, MODERN PATHOL, V19, P115, DOI 10.1038/modpathol.3800489; Fanburg-Smith JC, 1998, AM J SURG PATHOL, V22, P779, DOI 10.1097/00000478-199807000-00001; Farid M, 2014, ONCOLOGIST, V19, P193, DOI 10.1634/theoncologist.2013-0328; FERRY JA, 1988, AM J CLIN PATHOL, V89, P546, DOI 10.1093/ajcp/89.4.546; Fetsch JF, 2000, AM J SURG PATHOL, V24, P331, DOI 10.1097/00000478-200003000-00001; Fetsch JF, 1997, AM J SURG PATHOL, V21, P1433, DOI 10.1097/00000478-199712000-00005; Fine SW, 2004, AM J CLIN PATHOL, V122, P552, DOI 10.1309/AGBGTBRJ4WDBC7LN; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Folpe AL, 2002, AM J SURG PATHOL, V26, P1620, DOI 10.1097/00000478-200212000-00010; Fuchs Bruno, 2005, J Surg Orthop Adv, V14, P168; FULLER CE, 1991, HISTOPATHOLOGY, V19, P1; Giannini C, 1997, AM J SURG PATHOL, V21, P164, DOI 10.1097/00000478-199702000-00005; Gibson JA, 2009, AM J SURG PATHOL, V33, P781, DOI 10.1097/PAS.0b013e31818dd6ca; GOLDBLUM JR, 1994, AM J SURG PATHOL, V18, P266, DOI 10.1097/00000478-199403000-00006; Grobmyer SR, 2008, J SURG ONCOL, V97, P340, DOI 10.1002/jso.20971; Groisman G, 2010, INT J SURG PATHOL, V18, P292, DOI 10.1177/1066896909350883; Groisman GM, 2008, AM J SURG PATHOL, V32, P1088, DOI 10.1097/PAS.0b013e318160df3f; Groisman GM, 2006, HISTOPATHOLOGY, V48, P431, DOI 10.1111/j.1365-2559.2006.02357.x; Han J, 2017, J PATHOL TRANSL MED, V51, P187, DOI 10.4132/jptm.2016.07.02; HERRERA GA, 1984, DIGEST DIS SCI, V29, P275, DOI 10.1007/BF01296263; Hirose T, 2003, MODERN PATHOL, V16, P293, DOI 10.1097/01.MP.0000062654.83617.B7; Hirose T, 1998, ULTRASTRUCT PATHOL, V22, P227, DOI 10.3109/01913129809033473; Hornick JL, 2005, AM J SURG PATHOL, V29, P859, DOI 10.1097/01.pas.0000154130.87219.2c; Hsu M, 2009, AM J SURG PATHOL, V33, P1515, DOI 10.1097/PAS.0b013e3181abe31b; Hytiroglou P, 2016, PATHOL INT, V66, P242, DOI 10.1111/pin.12376; Iddings DM, 2008, AM SURGEON, V74, P47; James AW, 2016, SURG ONCOL CLIN N AM, V25, P789, DOI 10.1016/j.soc.2016.05.009; Jass JR, 2006, HISTOPATHOLOGY, V49, P121, DOI 10.1111/j.1365-2559.2006.02466.x; Kakizaki S, 2016, INTERNAL MED, V55, P245, DOI 10.2169/internalmedicine.55.5456; Karamchandani DM, 2013, ADV ANAT PATHOL, V20, P398, DOI 10.1097/PAP.0b013e3182a92e42; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; KAWAHARA E, 1988, AM J SURG PATHOL, V12, P115, DOI 10.1097/00000478-198802000-00004; Kim EY, 2015, INT J SURG PATHOL, V23, P505, DOI 10.1177/1066896915573570; Kindblom LG, 1998, AM J SURG PATHOL, V22, P762, DOI 10.1097/00000478-199806000-00015; Kobori L, 2008, PATHOL ONCOL RES, V14, P329, DOI 10.1007/s12253-008-9078-0; Kong J, 2014, ONCOL LETT, V8, P2687, DOI 10.3892/ol.2014.2524; Kosemehmetoglu K, 2010, J CLIN PATHOL, V63, P416, DOI 10.1136/jcp.2008.057471; Laskin WB, 2005, AM J SURG PATHOL, V29, P39, DOI 10.1097/01.pas.0000146044.90901.4c; Lasota J, 2003, LAB INVEST, V83, P1361, DOI 10.1097/01.LAB.0000087591.29639.E3; Lee JR, 2001, AM J SURG PATHOL, V25, P979, DOI 10.1097/00000478-200108000-00001; Lee SM, 2009, PATHOLOGY, V41, P595, DOI 10.1080/00313020903071512; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Lee YJ, 2006, J PEDIATR SURG, V41, DOI 10.1016/j.jpedsurg.2005.11.039; Levy AD, 2005, RADIOGRAPHICS, V25, P455, DOI 10.1148/rg.252045176; Lewin MR, 2005, AM J SURG PATHOL, V29, P1310, DOI 10.1097/01.pas.0000162762.03068.7a; Liegl B, 2008, AM J SURG PATHOL, V32, P1080, DOI 10.1097/PAS.0b013e318160cfda; Manger T, 2000, DIGEST SURG, V17, P627, DOI 10.1159/000051973; Marwah S, 2013, CLIN J GASTROENTEROL, V6, P429, DOI 10.1007/s12328-013-0422-x; Matsukuma S, 2010, VIRCHOWS ARCH, V457, P651, DOI 10.1007/s00428-010-0999-0; Matsuo K, 2005, J GASTROENTEROL, V40, P306, DOI 10.1007/s00535-004-1540-5; MENNEMEYER RP, 1979, AM J SURG PATHOL, V3, P3, DOI 10.1097/00000478-197902000-00001; MENTZEL T, 1994, HISTOPATHOLOGY, V25, P261, DOI 10.1111/j.1365-2559.1994.tb01326.x; Meshikhes AWN, 2015, J GASTROINTEST SURG, V19, P1144, DOI 10.1007/s11605-015-2798-z; Miettinen M, 2000, AM J SURG PATHOL, V24, P1339, DOI 10.1097/00000478-200010000-00003; Miettinen M, 2006, AM J SURG PATHOL, V30, P90, DOI 10.1097/01.pas.0000176433.81079.bd; Miettinen M, 2001, MODERN PATHOL, V14, P950, DOI 10.1038/modpathol.3880417; Miettinen M, 2001, AM J SURG PATHOL, V25, P846, DOI 10.1097/00000478-200107000-00002; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Mohtaram A, 2013, CASE REP ONCOL MED, V2013, P1; Na JI, 2014, HISTOPATHOLOGY, V65, P764, DOI 10.1111/his.12487; Nagai T, 2004, J GASTROENTEROL, V39, P277, DOI 10.1007/s00535-003-1289-2; Nakamura T, 2002, GASTROINTEST ENDOSC, V55, P270, DOI 10.1067/mge.2002.120782; Nasser H, 2011, PATHOL RES PRACT, V207, P164, DOI 10.1016/j.prp.2010.12.007; Navez J, 2016, CLIN TRANSPLANT, V30, P1366, DOI 10.1111/ctr.12802; Nie L, 2014, INT J CLIN EXP PATHO, V7, P4000; Nonaka D, 2008, AM J SURG PATHOL, V32, P1291, DOI 10.1097/PAS.0b013e3181658c14; Nozu T, 1995, INTERNAL MED, V34, P1101, DOI 10.2169/internalmedicine.34.1101; O'Brien MJ, 2006, AM J SURG PATHOL, V30, P1491, DOI 10.1097/01.pas.0000213313.36306.85; OLSEN BS, 1987, HISTOPATHOLOGY, V11, P843, DOI 10.1111/j.1365-2559.1987.tb01887.x; Pai RK, 2011, AM J SURG PATHOL, V35, P1373, DOI 10.1097/PAS.0b013e318224d9df; Pandey D, 2015, J CLIN DIAGN RES, P9; Paquette IM, 2009, J GASTROINTEST SURG, V13, P1517, DOI 10.1007/s11605-009-0814-x; Park YoungS., 2002, The Korean Journal of Pathology, V36, P179; Pasquini P, 2009, WORLD J GASTROENTERO, V15, P2287, DOI 10.3748/wjg.15.2287; Pekmezci M, 2015, MODERN PATHOL, V28, P187, DOI 10.1038/modpathol.2014.109; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Pettus JR, 2012, MODERN PATHOL, V25, p175A; Plaza JA, 2006, AM J SURG PATHOL, V30, P337; Prevot S, 1999, AM J SURG PATHOL, V23, P431, DOI 10.1097/00000478-199904000-00007; Reuss DE, 2014, ACTA NEUROPATHOL, V127, P565, DOI 10.1007/s00401-014-1246-6; RICCI A, 1984, AM J SURG PATHOL, V8, P19, DOI 10.1097/00000478-198401000-00002; Rittershaus AC, 2011, ARCH PATHOL LAB MED, V135, P1311, DOI 10.5858/arpa.2011-0038-RA; Rocco EG, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-68; Rodriguez FJ, 2007, ACTA NEUROPATHOL, V113, P705, DOI 10.1007/s00401-006-0171-8; Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P295, DOI 10.1007/s00401-012-0954-z; Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P349, DOI 10.1007/s00401-011-0935-7; Rosai J, 2005, INT J SURG PATHOL, V13, P309, DOI 10.1177/106689690501300401; Rosati G, 2000, TUMORI, V86, P85; ROSE DSC, 1992, HISTOPATHOLOGY, V21, P287, DOI 10.1111/j.1365-2559.1992.tb00392.x; Sakuma T, 2011, INT J SURG PATHOL, V19, P524, DOI 10.1177/1066896908324129; Schreibman IR, 2005, AM J GASTROENTEROL, V100, P476, DOI 10.1111/j.1572-0241.2005.40237.x; SHEKITKA KM, 1994, AM J SURG PATHOL, V18, P250, DOI 10.1097/00000478-199403000-00004; Singhi AD, 2010, AM J SURG PATHOL, V34, P1186, DOI 10.1097/PAS.0b013e3181e5af9d; STANLEY MW, 1986, AM J SURG PATHOL, V10, P801, DOI 10.1097/00000478-198611000-00008; Stockl T, 2013, INT J SURG PATHOL, V21, P603, DOI 10.1177/1066896913494795; Stockman DL, 2012, AM J SURG PATHOL, V36, P857, DOI 10.1097/PAS.0b013e31824644ac; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Sundararajan Vanitha, 2003, Arch Pathol Lab Med, V127, pe139; Takawira C, 2014, ANN CLIN LAB SCI, V44, P324; Takemura Masashi, 2012, J Med Case Rep, V6, P37, DOI 10.1186/1752-1947-6-37; Tawbi H, 2008, ONCOLOGIST, V13, P459, DOI 10.1634/theoncologist.2007-0166; Telem DA, 2008, J GASTROINTEST SURG, V12, P1609, DOI 10.1007/s11605-007-0395-5; Tucker T, 2005, NEUROLOGY, V65, P205, DOI 10.1212/01.wnl.0000168830.79997.13; Ueno Y, 2008, ABDOM IMAGING, V33, P560, DOI 10.1007/s00261-007-9318-x; Uhr A, 2016, AM SURGEON, V82, P1183; Verdijk RM, 2010, J NEUROPATH EXP NEUR, V69, P16, DOI 10.1097/NEN.0b013e3181c55d55; WALKER P, 1986, ARCH PATHOL LAB MED, V110, P309; Watanabe T, 2001, HISTOPATHOLOGY, V39, P187, DOI 10.1046/j.1365-2559.2001.01176.x; Weinrach DM, 2004, HUM PATHOL, V35, P1288, DOI 10.1016/j.humpath.2004.07.013; WEISS SW, 1983, LAB INVEST, V49, P299; WICK MR, 1987, AM J CLIN PATHOL, V87, P425, DOI 10.1093/ajcp/87.4.425; Witkiewicz A, 2007, J GASTROINTEST SURG, V11, P1351, DOI 10.1007/s11605-007-0217-9; WOODRUFF JM, 1994, AM J SURG PATHOL, V18, P882, DOI 10.1097/00000478-199409000-00003; Zambrano E, 2003, INT J SURG PATHOL, V11, P75, DOI 10.1177/106689690301100202; Zhu LB, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1101-z; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	150	3	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					565	578		10.1136/jclinpath-2017-204895			14	Pathology	Pathology	GR3CP	WOS:000442466600001	29419412	Bronze			2019-10-28	
J	Jeong, W; Kim, HJ				Jeong, Wonju; Kim, Ha-Jeong			Biomarkers of chondrosarcoma	JOURNAL OF CLINICAL PATHOLOGY			English	Review							METHYLACYL-COA RACEMASE; LOW-GRADE CHONDROSARCOMA; BREAST-CANCER RISK; PROSTATE-CANCER; SIGNALING PATHWAY; AMACR EXPRESSION; LEPTIN RECEPTOR; CELLS; METASTASIS; DIAGNOSIS	Clinical outcome prediction is major concern to patients with cancer. Various molecular markers in various carcinomas have been identified in the past few decades. However, accurate predictors in chondrosarcoma have not been developed, even though chondrosarcoma is the second most common primary bone tumour. Chondrosarcoma is the cartilage-forming malignancy and shows a wide spectrum of clinicopathological behaviours. The majority of chondrosarcoma grows slowly and rarely metastasises, and adequate surgery leads to a good prognosis. However, wide surgical excision is acquired in high-grade chondrosarcoma, because this tumour is highly resistant to chemotherapy and radiotherapy. To decide best therapy, accurate diagnostic markers are also necessary in chondrosarcoma. It is reported that angiogenesis and lymphangiogenesis increase by chondrosarcoma staging, and they are promoted by leptin and adiponectin. Several microRNAs to regulate vascular endothelial growth factor (VEGF)-A and VEGF-C are also reported. Alpha-methylacyl-CoA racemase and periostin are proposed as new biomarkers for differential diagnosis of enchondroma and chondrosarcoma. This review summarises that chondrosarcoma diagnostic markers are currently reported.	[Jeong, Wonju] Daegu Top Hosp, Dept Orthoped Surg, Daegu, South Korea; [Kim, Ha-Jeong] Kyungpook Natl Univ, Sch Med, Dept Physiol, Daegu 41944, South Korea; [Kim, Ha-Jeong] Kyungpook Natl Univ, Sch Med, Dept Biomed Sci, Plus KNU Biomed Convergence Program BK21, Daegu, Daegu, South Korea	Kim, HJ (reprint author), Kyungpook Natl Univ, Sch Med, Dept Physiol, Daegu 41944, South Korea.	kimhajeong@knu.ac.kr			Biomedical Research Institute grant, Kyungpook National University Hospital	This work was supported by Biomedical Research Institute grant, Kyungpook National University Hospital (2014).	Ahlmann ER, 2006, CLIN ORTHOP RELAT R, P201, DOI 10.1097/01.blo.0000229293.98850.5d; Altieri DC, 2015, SEMIN CELL DEV BIOL, V39, P91, DOI 10.1016/j.semcdb.2014.12.007; Ananthanarayanan V, 2005, PROSTATE, V63, P341, DOI 10.1002/pros.20196; Aviel-Ronen S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21277; Bao X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.31; Boeuf S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-488; Borsig L, 2014, ONCOGENE, V33, P3217, DOI 10.1038/onc.2013.272; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chao SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03635-7; DAHLIN DC, 1956, J BONE JOINT SURG AM, V38, P1025, DOI 10.2106/00004623-195638050-00007; de Jong Y, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.33; Dieterich LC, 2014, ANGIOGENESIS, V17, P359, DOI 10.1007/s10456-013-9406-1; Feng HL, 2017, SCI REP-UK, V7, DOI 10.1038/srep41203; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Ferrer-Santacreu EM, 2012, J ONCOL, V2012, P1; Gelderblom H, 2008, ONCOLOGIST, V13, P320, DOI 10.1634/theoncologist.2007-0237; Goktas S, 2005, UROLOGY, V65, P1168, DOI 10.1016/j.urology.2004.12.053; Gomez-Brouchet A, 2010, HUM PATHOL, V41, P1220, DOI 10.1016/j.humpath.2009.10.028; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Hogendoorn PCW, 2010, ANN ONCOL, V21, pv204, DOI 10.1093/annonc/mdq223; Huang CY, 2016, CLIN SCI, V130, P1523, DOI 10.1042/CS20160117; Huang K, 2017, CANCER BIOMARK, V18, P231, DOI 10.3233/CBM-160102; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jamil N, 2010, INT J EXP PATHOL, V91, P387, DOI 10.1111/j.1365-2613.2010.00749.x; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jiang Z, 2003, HUM PATHOL, V34, P792, DOI 10.1016/S0046-8177(03)00268-5; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Karamchandani JR, 2012, APPL IMMUNOHISTO M M, V20, P445, DOI 10.1097/PAI.0b013e318244ff4b; Lai XY, 2015, PROTEOMICS, V15, P2358, DOI 10.1002/pmic.201400528; Lee HP, 2015, ONCOTARGET, V6, P36746, DOI 10.18632/oncotarget.5479; Lin CY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.354; Liu GT, 2015, CANCER LETT, V357, P476, DOI 10.1016/j.canlet.2014.11.015; Lu N, 2015, TUMOR BIOL, V36, P3843, DOI 10.1007/s13277-014-3026-2; Machado I, 2016, PATHOL RES PRACT, V212, P811, DOI 10.1016/j.prp.2016.06.012; Mak IWY, 2015, J CELL BIOCHEM, V116, P37, DOI 10.1002/jcb.24940; Martinez-Sanchez A, 2012, J BIOL CHEM, V287, P916, DOI 10.1074/jbc.M111.302430; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Mosher DF, 2015, CRIT REV BIOCHEM MOL, V50, P427, DOI 10.3109/10409238.2015.1069791; Nota Sjoerd P. F. T., 2015, Sarcoma, P623746, DOI 10.1155/2015/623746; Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200; Pyne Nigel J., 2015, Advances in Biological Regulation, V60, P151, DOI 10.1016/j.jbior.2015.09.001; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Sangoi AR, 2017, INT J GYNECOL PATHOL, V36, P140, DOI 10.1097/PGP.0000000000000301; Scully S P, 1997, Sarcoma, V1, P79; Sekine S, 2011, HISTOPATHOLOGY, V58, P712, DOI 10.1111/j.1365-2559.2011.03798.x; Shen J, 2015, J ORTHOP, V12, pS223, DOI 10.1016/j.jor.2015.10.001; Shinohara N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13994-w; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Sun YN, 2007, LUNG CANCER, V58, P21, DOI 10.1016/j.lungcan.2007.05.013; Surmacz E, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1638; Tang CH, 2010, BIOCHEM PHARMACOL, V79, P209, DOI 10.1016/j.bcp.2009.08.006; Tang CH, 2009, PROSTATE, V69, P1781, DOI 10.1002/pros.21029; Tang Xian-ye, 2016, Drug Des Devel Ther, V10, P571, DOI 10.2147/DDDT.S90530; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Trieb K, 2003, EUR J SURG ONCOL, V29, P379, DOI 10.1053/ejso.2002.1415; Tsai CH, 2017, MOL ONCOL, V11, P1380, DOI 10.1002/1878-0261.12106; Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068; Wang CQ, 2017, CANCER LETT, V385, P261, DOI 10.1016/j.canlet.2016.10.010; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Weiner Scott D, 2004, Instr Course Lect, V53, P645; Yang J, 2016, TUMOR BIOL, V37, P11645, DOI 10.1007/s13277-016-5140-9; Yang K, 2016, AM J CANCER RES, V6, P1302; Yang SN, 2009, CARCINOGENESIS, V30, P566, DOI 10.1093/carcin/bgp023; Yang WH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28647; Yang WH, 2014, BBA-GEN SUBJECTS, V1840, P3483, DOI 10.1016/j.bbagen.2014.09.012; Zaiss DMW, 2015, IMMUNITY, V42, P216, DOI 10.1016/j.immuni.2015.01.020; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490; Zhang P, 2017, CELL PHYSIOL BIOCHEM, V42, P242, DOI 10.1159/000477323; Zhu Z, 2014, ASIAN PAC J CANCER P, V15, P917, DOI 10.7314/APJCP.2014.15.2.917	70	3	4	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					579	583		10.1136/jclinpath-2018-205071			5	Pathology	Pathology	GR3CP	WOS:000442466600002	29593061	Other Gold, Green Published			2019-10-28	
J	dos Santos, MT; de Souza, BF; Carcano, FM; Vidal, RD; Scapulatempo-Neto, C; Viana, CR; Carvalho, AL				dos Santos, Marcos Tadeu; de Souza, Bruno Feres; Carcano, Flavio Mavignier; Vidal, Ramon de Oliveira; Scapulatempo-Neto, Cristovam; Viana, Cristiano Ribeiro; Carvalho, Andre Lopes			An integrated tool for determining the primary origin site of metastatic tumours	JOURNAL OF CLINICAL PATHOLOGY			English	Article							UNKNOWN PRIMARY SITE; CANCER CLASSIFIER; THYROID-CANCER; DIAGNOSIS; PERFORMANCE; TISSUE; IMMUNOHISTOCHEMISTRY; IDENTIFICATION; ACCURACY	Aims Cancers of unknown primary sites account for 3%-5% of all malignant neoplasms. Current diagnostic workflows based on immunohistochemistry and imaging tests have low accuracy and are highly subjective. We aim to develop and validate a gene-expression classifier to identify potential primary sites for metastatic cancers more accurately. Methods We built the largest Reference Database (RefDB) reported to date, composed of microarray data from 4429 known tumour samples obtained from 100 different sources and divided into 25 cancer superclasses formed by 58 cancer subclass. Based on specific profiles generated by 95 genes, we developed a gene-expression classifier which was first trained and tested by a cross-validation. Then, we performed a double-blinded retrospective validation study using a real-time PCR-based assay on a set of 105 metastatic formalin-fixed, paraffin-embedded (FFPE) samples. A histopathological review performed by two independent pathologists served as a reference diagnosis. Results The gene-expression classifier correctly identified, by a cross-validation, 86.6% of the expected cancer superclasses of 4429 samples from the RefDB, with a specificity of 99.43%. Next, the performance of the algorithm for classifying the validation set of metastatic FFPE samples was 83.81%, with 99.04% specificity. The overall reproducibility of our gene-expression-classifier system was 97.22% of precision, with a coefficient of variation for inter-assays and intra-assays and intra-lots <4.1%. Conclusion We developed a complete integrated workflow for the classification of metastatic tumour samples which may help on tumour primary site definition.	[dos Santos, Marcos Tadeu] ONKOS Mol Diagnost, Ribeirao Preto, SP, Brazil; [dos Santos, Marcos Tadeu; Vidal, Ramon de Oliveira] Fleury Grp, Dept Res & Dev R&D, Sao Paulo, Brazil; [de Souza, Bruno Feres] Univ Fed Maranhao, UFMA, Sao Luis, Maranhao, Brazil; [Carcano, Flavio Mavignier] Barretos Canc Hosp, Dept Med Oncol, Barretos, Brazil; [Vidal, Ramon de Oliveira; Scapulatempo-Neto, Cristovam; Viana, Cristiano Ribeiro; Carvalho, Andre Lopes] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil	dos Santos, MT (reprint author), ONKOS Mol Diagnost, Dept Res & Dev R&D, BR-14056680 Ribeirao Preto, SP, Brazil.	marcos@onkos.com.br	Carvalho, Andre Lopes/S-7053-2016; CARCANO, FLAVIO MAVIGNIER/Q-3156-2019	Carvalho, Andre Lopes/0000-0001-7214-6402; CARCANO, FLAVIO MAVIGNIER/0000-0002-0002-3507	FINEPCiencia Tecnologia e Inovacao (FINEP) [02.12.0223.00]	This study was supported by FINEP (02.12.0223.00).	ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; Anderson GG, 2010, APPL IMMUNOHISTO M M, V18, P3, DOI 10.1097/PAI.0b013e3181a75e6d; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2; Erlander MG, 2011, J MOL DIAGN, V13, P493, DOI 10.1016/j.jmoldx.2011.04.004; Greco FA, 2013, JNCI-J NATL CANCER I, V105, P782, DOI 10.1093/jnci/djt099; Hainsworth JD, 2013, J CLIN ONCOL, V31, P217, DOI 10.1200/JCO.2012.43.3755; Hall RD, 2014, CANCER CONTROL, V21, P221, DOI 10.1177/107327481402100307; Handorf CR, 2013, AM J SURG PATHOL, V37, P1067, DOI 10.1097/PAS.0b013e31828309c4; Hashimoto K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031181; Kerr SE, 2012, CLIN CANCER RES, V18, P3952, DOI 10.1158/1078-0432.CCR-12-0920; Kim KW, 2013, AM J ROENTGENOL, V200, P484, DOI 10.2214/AJR.12.9363; Kwee TC, 2009, EUR RADIOL, V19, P731, DOI 10.1007/s00330-008-1194-4; Maman S, 2013, TUMOR IMMUNOENVIRONM, P15; Massard C, 2011, NAT REV CLIN ONCOL, V8, P701, DOI 10.1038/nrclinonc.2011.158; Maugeri-Sacca M, 2014, BREAST CANCER RES TR, V147, P227, DOI 10.1007/s10549-014-3087-3; Monzon FA, 2010, ARCH PATHOL LAB MED, V134, P216, DOI 10.1043/1543-2165-134.2.216; Natoli C, 2011, BBA-REV CANCER, V1816, P13, DOI 10.1016/j.bbcan.2011.02.002; Pavlidis N, 2012, LANCET, V379, P1428, DOI 10.1016/S0140-6736(11)61178-1; Pramesh CS, 2003, JPN J CLIN ONCOL, V33, P86, DOI 10.1093/jjco/hyg022; Romano E, 2011, LANCET ONCOL, V12, P913, DOI 10.1016/S1470-2045(10)70274-6; Rosove MH, 2013, NEW ENGL J MED, V368, P684, DOI 10.1056/NEJMc1215697; Stella GM, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-12; Varadhachary GR, 2014, NEW ENGL J MED, V371, P757, DOI 10.1056/NEJMra1303917; Weiss LM, 2013, J MOL DIAGN, V15, P263, DOI 10.1016/j.jmoldx.2012.10.001; Xing MZ, 2013, LANCET, V381, P1058, DOI 10.1016/S0140-6736(13)60109-9	26	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					584	593		10.1136/jclinpath-2017-204887			10	Pathology	Pathology	GR3CP	WOS:000442466600003	29248889	Green Published, Other Gold			2019-10-28	
J	Dumas, C; Bienvenu, AL; Girard, S; Picot, S; Debize, G; Durand, B				Dumas, Cecile; Bienvenu, Anne-Lise; Girard, Sandrine; Picot, Stephane; Debize, Gisele; Durand, Brigitte			Automated Plasmodium detection by the Sysmex XN hematology analyzer	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ABNORMAL WBC SCATTERGRAM; MALARIA DETECTION; XE-2100; DIAGNOSIS; PSEUDOEOSINOPHILIA	Background Malaria is a potentially severe disease affecting nearly 200 million people per year. Early detection of the parasite even in unsuspected patients remains the challenging aim for effective patient care. Automated complete blood counts that are usually performed for any febrile patient might represent a tool to ascertain malaria infection. Aims To evaluate the ability of the new generation of the Sysmex hematology analyzer (XN-series) to detect malaria. Methods We retrospectively studied 100 blood samples performed with the recent Sysmex XN analyzer that were positive for Plasmodium and explored its ability to detect the parasite. 100 samples from patients uninfected by malaria were used as control group. Results Specific abnormalities such as additional events in the mature neutrophil/eosinophil area of the white blood cells differential (WDF) scattergram were noted for 1.1% of Plasmodium falciparum samples and 56.2% of other Plasmodium species samples. Mature parasite stages (schizonts or gametocytes) were observed on blood smears among those samples. WDF scattergrams were able to detect 80.0% (12/15) of Plasmodium mature stages. Furthermore, the differential in white blood counts between WDF and white cell nucleated (WNR) channels was a predictive signal of Plasmodium mature stages in 73.3% (11/15) of samples and may be explained by a differential destruction of particles with the analyzer reagent. Conclusion Associated to thrombocytopaenia, a Sysmex XN Plasmodium pattern may represent a useful warning for Plasmodium detection in unsuspected patients, particularly when mature parasite stages are present.	[Dumas, Cecile; Bienvenu, Anne-Lise; Debize, Gisele; Durand, Brigitte] Hosp Civils Lyon, Grp Hosp Nord, Serv Hematol, Lyon, France; [Bienvenu, Anne-Lise; Picot, Stephane] Univ Lyon 1, Malaria Res Unit, Lyon, France; [Girard, Sandrine] Hosp Civils Lyon, Grp Hosp Est, Serv Hematol, Lyon, France	Dumas, C (reprint author), Hosp Civils Lyon, Ctr Biol & Pathol Nord, F-69004 Lyon, France.	cecile.dumas@chu-lyon.fr	PICOT, Stephane/F-5973-2014	PICOT, Stephane/0000-0002-5735-6759; Dumas, Cecile/0000-0003-0462-2010			Campuzano-Zuluaga G, 2010, AM J TROP MED HYG, V82, P402, DOI 10.4269/ajtmh.2010.09-0464; Centre National de Reference du Paludisme pour la France metropolitaine, 2015, CTR NAT REF PAL FRAN; Dubreuil P, 2014, INT J LAB HEMATOL, V36, P124, DOI 10.1111/ijlh.12145; Erhart LM, 2004, AM J TROP MED HYG, V70, P8, DOI 10.4269/ajtmh.2004.70.8; Fourcade C, 2004, CLIN LAB HAEMATOL, V26, P367, DOI 10.1111/j.1365-2257.2004.00648.x; Hanscheid T, 2000, CLIN LAB HAEMATOL, V22, P259, DOI 10.1046/j.1365-2257.2000.00327.x; Huh HJ, 2008, ANN HEMATOL, V87, P755, DOI 10.1007/s00277-008-0486-8; Kotepui M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121057; Mendelow BV, 1999, BRIT J HAEMATOL, V104, P499, DOI 10.1046/j.1365-2141.1999.01199.x; Mubeen KH, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.034; Mukry SN, 2017, CAN J INFECT DIS MED, P1, DOI 10.1155/2017/9286392; Park G Bo Rae, 2006, Korean J Lab Med, V26, P77; Rojanasthien Sophark, 1992, Journal of the Medical Association of Thailand, V75, P190; Sharma S, 2013, HEMATOLOGY, V18, P101, DOI 10.1179/1607845412Y.0000000029; Wever PC, 2002, J CLIN MICROBIOL, V40, P4729, DOI 10.1128/jcm.40.12.4729-4731.2002; WHO, OV DIAGN TEST; Yoo JH, 2010, AM J TROP MED HYG, V82, P412, DOI 10.4269/ajtmh.2010.09-0560	17	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					594	599		10.1136/jclinpath-2017-204878			6	Pathology	Pathology	GR3CP	WOS:000442466600004	29298814				2019-10-28	
J	Fujimoto, M; Matsuzaki, I; Nishino, M; Iwahashi, Y; Warigaya, K; Kojima, F; Ono, K; Murata, SI				Fujimoto, Masakazu; Matsuzaki, Ibu; Nishino, Masaru; Iwahashi, Yoshifumi; Warigaya, Kenji; Kojima, Fumiyoshi; Ono, Kazuo; Murata, Shin-Ichi			HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types	JOURNAL OF CLINICAL PATHOLOGY			English	Article							IN-SITU HYBRIDIZATION; ALPHA-FETOPROTEIN; CLINICOPATHOLOGICAL FEATURES; LUNG ADENOCARCINOMA; PROTEIN EXPRESSION; STEM-CELLS; CANCER; SALL4; IMMUNOHISTOCHEMISTRY; STOMACH	Aims alpha-Fetoprotein (AFP)-producing gastric carcinoma (AFPGC) is one of the most aggressive GC subtypes. Frequent expression of human epidermal growth factor receptor 2 (HER2) has previously been reported in hepatoid adenocarcinoma (HAC), a major histological subtype of AFPGC originating from common-type GC (CGC). However, HER2 expression levels in other AFPGC histological subtypes are unknown. In this study, we analysed HER2 expression in GCs with primitive phenotypes in addition to HAC. Methods HER2 expression was evaluated in representative complete sections from 16 HACs, 19 GCs with enteroblastic differentiation (GCEDs) and 334 GCs of other histological types as controls. The Ruschoff/Hofmann method was used to score HER2 immunohistochemistry. Samples with a HER2 score of 2+ were further assessed using fluorescence in situ hybridisation. Oncofetal protein (OFP) expression in HAC and GCED was tested via immunohistochemical staining for AFP, glypican 3 and Sal-like protein 4. Results Thirty of 35 HAC/GCED cases comprised more than two histological patterns. The HER2 positivity rates of each histological component in the HACs/GCEDs were 25.0% for HAC (n=16), 34.6% for GCED (n=26) and 48.1% for CGC (n=27), which were higher than those of the control group (13.8%). Additionally, the majority of CGC components in HACs/GCEDs were positive for OFP (88.9%). Conclusions HER2 is frequently overexpressed not only in HAC but also in GCED and CGC components of HACs/GCEDs, which suggests an association between HER2 and OFP expression. Moreover, our findings suggest that HER2-positive CGC has a higher risk of progression to HAC/GCED than HER2-negative GC.	[Fujimoto, Masakazu; Matsuzaki, Ibu; Nishino, Masaru; Iwahashi, Yoshifumi; Warigaya, Kenji; Kojima, Fumiyoshi; Murata, Shin-Ichi] Wakayama Med Univ, Dept Diagnost Pathol, Wakayama 6418510, Japan; [Ono, Kazuo] Japanese Red Cross Wakayama Med Ctr, Dept Diagnost Pathol, Wakayama, Japan	Murata, SI (reprint author), Wakayama Med Univ, Dept Diagnost Pathol, Wakayama 6418510, Japan.	smurata@wakayama-med.ac.jp					Akiyama S, 2003, INT J CANCER, V106, P510, DOI 10.1002/ijc.11246; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Brierley JD, 2017, TNM CLASSIFICATION M; Cancer Information Service, 2016, PROJ CANC STAT; Cancer Today, CANC FACT SHEETS STO; CHANG YC, 1992, AM J GASTROENTEROL, V87, P321; Finicelli M, 2014, ONCOTARGET, V5, P9678, DOI 10.18632/oncotarget.1936; Fujimoto M, 2014, HISTOPATHOLOGY, V64, P309, DOI 10.1111/his.12241; Fusco N, 2013, MODERN PATHOL, V26, P816, DOI 10.1038/modpathol.2012.228; Giuffre G, 2012, J CLIN PATHOL, V65, P237, DOI 10.1136/jclinpath-2011-200345; Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x; Horita Y, 2013, ANN ONCOL, V24, P31, DOI 10.1093/annonc/mdt459.1; Ieni A, 2014, INT J MOL SCI, V15, P22331, DOI 10.3390/ijms151222331; Kanai Masashi, 2005, Int J Gastrointest Cancer, V35, P77, DOI 10.1385/IJGC:35:1:077; Kanayama K, 2016, CANCER SCI, V107, P536, DOI 10.1111/cas.12886; Kilic E, 2016, VIRCHOWS ARCH, V468, P483, DOI 10.1007/s00428-016-1908-y; Kim KC, 2011, ANN SURG ONCOL, V18, P2833, DOI 10.1245/s10434-011-1695-2; Kim WH, 2016, APPL IMMUNOHISTOCHEM; Kinjo T, 2012, AM J SURG PATHOL, V36, P56, DOI 10.1097/PAS.0b013e31823aafec; Kochi M, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-191; Kono K, 2002, DIGEST SURG, V19, P359, DOI 10.1159/000065838; Kurokawa Y, 2015, GASTRIC CANCER, V18, P691, DOI 10.1007/s10120-014-0430-7; Laforest A, 2014, EUR J CANCER, V50, P1740, DOI 10.1016/j.ejca.2014.04.007; Lauwers G, 2010, WHO CLASSIFICATION T, P48; MATSUNOU H, 1994, CANCER, V73, P534, DOI 10.1002/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X; Matsusaka S, 2016, GASTRIC CANCER, V19, P839, DOI 10.1007/s10120-015-0518-8; Miettinen M, 2014, AM J SURG PATHOL, V38, P410, DOI 10.1097/PAS.0000000000000116; Mitsuma K, 2016, PATHOL INT, V66, P230, DOI 10.1111/pin.12402; Morita S, 2013, AM J SURG PATHOL, V37, P924, DOI 10.1097/PAS.0b013e31827e1e83; Murakami T, 2016, GASTRIC CANCER, V19, P498, DOI 10.1007/s10120-015-0497-9; Rahmatpanah FB, 2015, ONCOTARGET, V6, P1286, DOI 10.18632/oncotarget.2676; Roh JH, 2010, AM J SURG PATHOL, V34, P1139, DOI 10.1097/PAS.0b013e3181e7043b; Rokutan-Kurata M, 2017, CLIN LUNG CANCER, V18, pE273, DOI 10.1016/j.cllc.2016.11.013; Tatetsu H, 2016, GENE, V584, P111, DOI 10.1016/j.gene.2016.02.019; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Van Cutsem E, 2015, GASTRIC CANCER, V18, P476, DOI 10.1007/s10120-014-0402-y; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Yamazawa S, 2017, AM J SURG PATHOL, V41, P989, DOI 10.1097/PAS.0000000000000869; Yan M, 2015, CANCER METAST REV, V34, P157, DOI 10.1007/s10555-015-9552-6; Yano T, 2006, ONCOL REP, V15, P65	41	1	1	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					600	607		10.1136/jclinpath-2017-204928			8	Pathology	Pathology	GR3CP	WOS:000442466600005	29305518				2019-10-28	
J	Reynolds, TM; Mewies, C; Hamilton, J; Wierzbicki, AS				Reynolds, Timothy M.; Mewies, Clare; Hamilton, John; Wierzbicki, Anthony S.		PATHFINDER Project Collaboration	Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy	JOURNAL OF CLINICAL PATHOLOGY			English	Article							LIPASE DEFICIENCY; FAMILIAL HYPERCHOLESTEROLEMIA; CLINICAL-FEATURES; PREVALENCE; CIRRHOSIS; COHORT	Aims Lysosomal acid lipase deficiency (LALD) is an autosomal recessive disorder of cholesterol ester storage associated with hepatic disease, cirrhosis and accelerated atherosclerosis. Its prevalence in the general population, patients with dyslipidaemia and raised transaminases is unclear. This study attempted to identify the prevalence of LALD from patients with abnormal results in laboratory databases. Methods Electronic laboratory databases were interrogated to identify from clinical biochemistry records patients with a phenotype of low high-density lipoprotein-cholesterol (<= 0.85 mmol/L; 33 mg/dL) and with elevated alanine or aspartate transaminases (>= 60 IU/L) on one occasion or more over a 3-year time interval. Patients were recalled, and a dried blood spot sample was collected for lysosomal acid lipase determination by a fluorimetric enzyme assay. Histopathology databases of liver biopsies were interrogated for patients with features of 'microvesicular cirrhosis' or 'cryptogenic cirrhosis' in the report. Histological blocks were sampled, and samples were analysed by next-generation sequencing for the presence of mutations in the LAL gene. Results Samples were obtained from 1825 patients with dyslipidaemia and elevated transaminases. No cases of LALD were identified. Liver biopsies were obtained from six patients. DNA extraction was successful from four patients. Two patients were homozygous for the LAL c.46A>C;p.Thr16Pro unclassified variant in exon 2. Conclusions Pathology databases hold routine information that can be used to identify patients with specific patterns of results or those who had biopsies to allow targeted testing for possible causes of disease. Biochemical screening suggests that the gene frequency of LAL deficiency in adults is less than 1 in 100.	[Reynolds, Timothy M.; Mewies, Clare] Queens Hosp, Dept Chem Pathol, Burton Upon Trent DE13 0RB, England; [Reynolds, Timothy M.] Wolverhampton Univ, Div Hlth Sci, Wolverhampton, W Midlands, England; [Hamilton, John] Queen Elizabeth Univ, Biochem Dept, Hosp Lab, Glasgow, Lanark, Scotland; [Wierzbicki, Anthony S.] Guys & St Thomas Hosp, Dept Metab Med Chem Pathol, London, England	Reynolds, TM (reprint author), Queens Hosp, Dept Chem Pathol, Burton Upon Trent DE13 0RB, England.	tim.reynolds@burtonft.nhs.uk			Synageva BioPharma Ltd., UK; National Institute of Health ResearchNational Institute for Health Research (NIHR)	This work was supported by an investigator grant from Synageva BioPharma Ltd., 1A Local Board Road, Watford, Hertfordshire, WD17 2JP, UK. Research nurses funded by the National Institute of Health Research.	Angelico F, 2017, ATHEROSCLEROSIS, V262, P179, DOI 10.1016/j.atherosclerosis.2017.03.038; Ashfield-Watt P, 2016, ATHEROSCLEROSIS, V255, pE1; Baratta F, 2015, EBIOMEDICINE, V2, P750, DOI 10.1016/j.ebiom.2015.05.018; Bernstein DL, 2013, J HEPATOL, V58, P1230, DOI 10.1016/j.jhep.2013.02.014; Burton BK, 2015, NEW ENGL J MED, V373, P1010, DOI 10.1056/NEJMoa1501365; Burton BK, 2015, J PEDIATR GASTR NUTR, V61, P619, DOI 10.1097/MPG.0000000000000935; Cancer Research UK, CERV CANC DIAGN TREA; Hamilton J, 2012, CLIN CHIM ACTA, V413, P1207, DOI 10.1016/j.cca.2012.03.019; Jones SA, 2016, GENET MED, V18, P452, DOI 10.1038/gim.2015.108; Muntoni S, 2007, ARTERIOSCL THROM VAS, V27, P1866, DOI 10.1161/ATVBAHA.107.146639; National Center for Biotechnology Information Genetics & Medicine, CLIN VAR DAT SEC CLI; National Institute for Health Research, UT ALT HDL ID LYS AC; National Institute of Health and Clinical Excellence, 2016, LYS AC LIP DEF SEB A; Pullinger CR, 2015, J CLIN LIPIDOL, V9, P716, DOI 10.1016/j.jacl.2015.07.008; Reiner Z, 2014, ATHEROSCLEROSIS, V235, P21, DOI 10.1016/j.atherosclerosis.2014.04.003; Reynolds T, 2013, J CLIN PATHOL, V66, P918, DOI 10.1136/jclinpath-2012-201302; Ruiz-Andres C, 2017, JIMD REP; Sjouke B, 2015, NETH J MED, V73, P129; Sjouke B, 2016, ATHEROSCLEROSIS, V251, P263, DOI 10.1016/j.atherosclerosis.2016.07.008; Zhang BN, 2013, J PEDIATR GASTR NUTR, V56, P682, DOI 10.1097/MPG.0b013e31828b36ac	20	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					608	613		10.1136/jclinpath-2017-204727			6	Pathology	Pathology	GR3CP	WOS:000442466600006	29358478				2019-10-28	
J	Wu, X; Li, L; Ding, QL; Wang, XF; Wu, F; Wu, WM				Wu, Xi; Li, Lei; Ding, Qiulan; Wang, Xuefeng; Wu, Fang; Wu, Wenman			Screening and functional exploration of prothrombin Arg596 related mutations in Chinese venous thromboembolism patients	JOURNAL OF CLINICAL PATHOLOGY			English	Article							CONVEYING ANTITHROMBIN RESISTANCE; THROMBOMODULIN RESISTANCE; THROMBIN; COAGULATION; GENE; FLOW; DEFICIENCY; ACTIVATION; PLASMA; REGION	Aims Dysfunctional prothrombin residue Arg596 associated mutation has been found to precipitate venous thromboembolism (VTE). In the current study we investigated the prevalence of Arg596 associated mutations in Chinese patients with VTE and explored the functional impact of Arg596Gln mutation on coagulation function in affected patients. Methods Prothrombin clotting activity was measured in 267 unrelated patients with unprovoked VTE. Patients with moderately decreased activities underwent further analysis of the F2 gene. Prothrombin amidolytic activity and antigen levels were detected in mutation carriers. Specific family members were investigated about their VTE histories and clinical phenotypes. The thrombin generation test (TGT) was used to evaluate thrombin function and antithrombin resistance assay was applied to assess the extent of impaired antithrombin inhibition of mutation carriers. Results Two heterozygous mutation carriers of prothrombin Arg596Gln were identified, both of whom had moderately decreased clotting activities but normal amidolytic activities and antigen levels. Among the families of the two probands, nine out of 13 mutation carriers experienced episodes of VTE. TGTs showed that patients had elevated endogenous thrombin potential and prolonged start tail time. Thrombin generation could be inhibited in the presence of thrombomodulin. The thrombin Arg596Gln variant in patients' plasma presented strong resistance to antithrombin inhibition. Conclusion Prothrombin Arg596Gln mutation is a risk factor for Chinese patients with VTE due to its moderately decreased clotting activity but strong resistance to antithrombin inhibition. Prothrombin clotting activity screening and its encoding gene sequencing should be considered in patients with VTE when other established risk factors are absent.	[Wu, Xi; Ding, Qiulan; Wang, Xuefeng; Wu, Wenman] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China; [Li, Lei] Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol, State Key Lab Med Genom,Sch Med, Shanghai, Peoples R China; [Wu, Fang] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Geriatr, Sch Med, Shanghai 200025, Peoples R China; [Wu, Wenman] Shanghai Jiao Tong Univ, Ruijin Hosp, Fac Med Lab Sci, Sch Med, Shanghai, Peoples R China	Wu, WM (reprint author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Lab Med, Sch Med, Shanghai 200025, Peoples R China.; Wu, F (reprint author), Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Geriatr, Sch Med, Shanghai 200025, Peoples R China.	wufangrjh@163.com; wenmanwu@shsmu.edu.cn			National Natural Science Foundation of China NSFCNational Natural Science Foundation of China [81670130]	This work was supported by the National Natural Science Foundation of China NSFC 81670130 (WW).	Bulato C, 2016, ARTERIOSCL THROM VAS, V36, P1022, DOI 10.1161/ATVBAHA.115.306914; Colace TV, 2012, ARTERIOSCL THROM VAS, V32, P1466, DOI 10.1161/ATVBAHA.112.249789; Crawley JTB, 2007, J THROMB HAEMOST, V5, P95, DOI 10.1111/j.1538-7836.2007.02500.x; Davie EW, 2006, SEMIN THROMB HEMOST, V32, P3, DOI 10.1055/s-2006-939550; Ding QL, 2017, THROMB HAEMOSTASIS, V117, P479, DOI 10.1160/TH16-10-0750; Ding QL, 2013, BLOOD CELL MOL DIS, V50, P53, DOI 10.1016/j.bcmd.2012.08.004; Djordjevic V, 2013, J THROMB HAEMOST, V11; GRINNELL BW, 1994, BIOCHEM J, V303, P929, DOI 10.1042/bj3030929; Huang SS, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15017644; Kishimoto M, 2016, ANN HEMATOL, V95, P541, DOI 10.1007/s00277-015-2533-6; Lancellotti S, 2013, SEMIN THROMB HEMOST, V39, P596, DOI 10.1055/s-0033-1348948; Leiderman K, 2011, MATH MED BIOL, V28, P47, DOI 10.1093/imammb/dqq005; Lu YH, 2002, THROMB RES, V106, P7, DOI 10.1016/S0049-3848(02)00064-6; Miljic P, 2017, J THROMB HAEMOST, V15, P670, DOI 10.1111/jth.13618; Miyawaki Y, 2012, NEW ENGL J MED, V366, P2390, DOI 10.1056/NEJMoa1201994; Murata M, 2014, THROMB RES, V133, P293, DOI 10.1016/j.thromres.2013.11.021; Okorie UM, 2008, BLOOD, V111, P3507, DOI 10.1182/blood-2007-08-106229; Peyvandi F, 2002, HAEMOPHILIA, V8, P308, DOI 10.1046/j.1365-2516.2002.00633.x; Peyvandi F, 1999, THROMB HAEMOSTASIS, V82, P1207; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Rezaie AR, 2003, P NATL ACAD SCI USA, V100, P12051, DOI 10.1073/pnas.2135346100; Sivasundar S, 2013, BLOOD CELL MOL DIS, V50, P182, DOI 10.1016/j.bcmd.2012.11.008; Takagi Y, 2016, THROMB HAEMOSTASIS, V116, P1022, DOI 10.1160/TH16-03-0223; Takagi Y, 2014, THROMB RES, V134, P914, DOI 10.1016/j.thromres.2014.07.040; Tamura S, 2017, THROMB RES, V159, P33, DOI 10.1016/j.thromres.2017.09.020; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854	26	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					614	619		10.1136/jclinpath-2017-204888			6	Pathology	Pathology	GR3CP	WOS:000442466600007	29331940				2019-10-28	
J	Bosello, S; Basile, U; De Lorenzis, E; Gulli, F; Canestrari, G; Napodano, C; Parisi, F; Pocino, K; Di Mario, C; Tolusso, B; Ferraccioli, G; Gremese, E				Bosello, Silvia; Basile, Umberto; De Lorenzis, Enrico; Gulli, Francesca; Canestrari, Giovanni; Napodano, Cecilia; Parisi, Federico; Pocino, Krizia; Di Mario, Clara; Tolusso, Barbara; Ferraccioli, Gianfranco; Gremese, Elisa			Free light chains of immunoglobulins in patients with systemic sclerosis: correlations with lung involvement and inflammatory milieu	JOURNAL OF CLINICAL PATHOLOGY			English	Article							RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; LUPUS-ERYTHEMATOSUS; MULTIPLE-SCLEROSIS; B-CELLS; SERUM; INTERLEUKIN-6; PATHOGENESIS; ACTIVATION; MARKERS	Aim Humoral immunity and b cells are thought to play an important role in the pathophysiology of the systemic sclerosis (SSc). The production of free light chains (FLC) of immunoglobulins is abnormally high in several pathological autoimmune conditions and reflects B cell activation. Furthermore, FLCs demonstrated different biological activities including their capability to modulate the immune system, proteolytic activity and complement cascade activation. The aims of this study are to determine the FLC levels in patients with SSc compared with healthy controls (HC) and to study their possible association with organ involvement and disease characteristics. Methods Sixty-five patients with SSc and 20 HC were studied. Clinical and immunological inflammatory characteristics were assessed for all the patients with SSc. kappa-FLC and lambda-FLC, interleukin 6 (IL-6) and B cell activating factor levels were measured. Results The mean serum kappa-FLC levels and FLC ratio were significantly higher in patients with SSc compared with HC, while the serum lambda-FLC levels were comparable. The levels of FLC were comparable in patients with diffuse skin disease and limited skin involvement, while kappa-FLC levels were increased in patients with restrictive lung (forced vital capacity (FVC) <80%) disease (26.4 +/- 7.4 mg/L) when compared with patients with FVC >= 80% (19.6 +/- 7.3 mg/L, P=0.009). In patients with SSc, the levels of serum kappa-FLC level directly correlated with the IL-6 levels (R=0.3, P=0.001) and disease activity (R=0.4, P=0.003). Conclusions FLC levels are elevated in SSc and high levels are associated with lung involvement and with a higher degree of inflammation, supporting a possible role of B cell activation in the pathophysiology of the disease.	[Bosello, Silvia; De Lorenzis, Enrico; Canestrari, Giovanni; Parisi, Federico; Di Mario, Clara; Tolusso, Barbara; Ferraccioli, Gianfranco; Gremese, Elisa] Univ Cattolica Sacro Cuore, Inst Rheumatol & Affine Sci, Sch Med, Dept Rheumatol,Fdn Policlin Univ Agostino Gemelli, Rome, Italy; [Basile, Umberto; Gulli, Francesca; Napodano, Cecilia; Pocino, Krizia] Univ Cattolica Sacro Cuore, Dept Lab Med, Fdn Policlin Univ Agostino Gemelli, Rome, Italy	Ferraccioli, G (reprint author), Univ Cattolica Sacro Cuore, Inst Rheumatol & Affine Sci, UOC Rheumatol, Fdn Policlin Univ Agostino Gemelli, I-00168 Rome, Italy.	gianfranco.ferraccioli@unicatt.it	basile, umberto/E-1720-2018	basile, umberto/0000-0002-8328-2570; Napodano, Cecilia/0000-0002-8720-6284			Aggarwal R, 2011, ARTHRIT CARE RES, V63, P891, DOI 10.1002/acr.20446; Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; Behr J, 2008, RHEUMATOLOGY, V47, pV65, DOI 10.1093/rheumatology/ken313; Boivin D, 2004, ARCH BIOCHEM BIOPHYS, V431, P197, DOI 10.1016/j.abb.2004.08.022; Bosello S, 2011, AUTOIMMUN REV, V10, P624, DOI 10.1016/j.autrev.2011.04.013; Brebner Judith A, 2013, F1000 Med Rep, V5, P4, DOI 10.3410/M5-4; De Santis M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-96; Derk CT, 2003, AUTOIMMUN REV, V2, P181, DOI 10.1016/S1568-9972(03)00005-3; Draborg AH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138753; DUNCAN MR, 1991, J INVEST DERMATOL, V97, P686, DOI 10.1111/1523-1747.ep12483971; Erdem BK, 2015, RENAL FAILURE, V37, P1057, DOI 10.3109/0886022X.2015.1052980; FAMULARO G, 1989, J CLIN LAB IMMUNOL, V29, P59; Fuschiotti P, 2016, IMMUNOTARGETS THER, V5, P21, DOI 10.2147/ITT.S82037; Gottenberg JE, 2007, ANN RHEUM DIS, V66, P23, DOI 10.1136/ard.2006.052159; Gottenberg JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059868; Gottenberg JE, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2773; Gu YS, 2008, SEMIN ARTHRITIS RHEU, V38, P132, DOI 10.1016/j.semarthrit.2007.10.010; Hasegawa M, 1998, J RHEUMATOL, V25, P308; Hasegawa M, 2010, J DERMATOL, V37, P3, DOI 10.1111/j.1346-8138.2009.00763.x; Hassan-Smith G, 2014, J NEUROIMMUNOL, V276, P175, DOI 10.1016/j.jneuroim.2014.08.003; Jackson CE, 2015, JACC-HEART FAIL, V3, P618, DOI 10.1016/j.jchf.2015.03.014; Jolly M, 2014, LUPUS, V23, P881, DOI 10.1177/0961203314530793; Kaplan B, 2011, THESCIENTIFICWORLDJO, V11, P726, DOI 10.1100/tsw.2011.65; Kaplan B, 2010, J NEUROIMMUNOL, V229, P263, DOI 10.1016/j.jneuroim.2010.09.002; KISHIMOTO T, 1989, BLOOD, V74, P1; Kormelink TG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025392; Lafyatis R, 2007, ARTHRITIS RHEUM, V56, P3167, DOI 10.1002/art.22847; Lanteri A, 2014, AUTOIMMUN REV, V13, P974, DOI 10.1016/j.autrev.2014.07.003; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; LEROY EC, 1988, J RHEUMATOL, V15, P202; Medsger TA, 2003, CLIN EXP RHEUMATOL, V21, pS42; MERI S, 1992, J EXP MED, V175, P939, DOI 10.1084/jem.175.4.939; Ramsden DB, 2017, ANN CLIN BIOCHEM, V54, P5, DOI 10.1177/0004563216652175; Redegeld FA, 2002, NAT MED, V8, P694, DOI 10.1038/nm722; Rijnierse A, 2010, J IMMUNOL, V185, P653, DOI 10.4049/jimmunol.0901129; Sato S, 2000, J IMMUNOL, V165, P6635, DOI 10.4049/jimmunol.165.11.6635; Sato S, 2004, ARTHRITIS RHEUM, V50, P1918, DOI 10.1002/art.20274; Scala E, 2004, CLIN EXP IMMUNOL, V138, P540, DOI 10.1111/j.1365-2249.2004.02642.x; SOLLING K, 1981, ACTA MED SCAND, V209, P473; SUN M, 1994, J BIOL CHEM, V269, P734; SUN M, 1994, J IMMUNOL, V153, P5121; Thio M, 2008, TRENDS PHARMACOL SCI, V29, P170, DOI 10.1016/j.tips.2008.01.004; Valentini G, 2003, CLIN EXP RHEUMATOL, V21, pS39; van der Heijden M, 2006, EUR J PHARMACOL, V533, P319, DOI 10.1016/j.ejphar.2005.12.065; Wardemann H, 2004, J EXP MED, V200, P191, DOI 10.1084/jem.20040818; Ye Y, 2013, KAOHSIUNG J MED SCI, V29, P547, DOI 10.1016/j.kjms.2013.01.013	49	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					620	625		10.1136/jclinpath-2017-204656			6	Pathology	Pathology	GR3CP	WOS:000442466600008	29447111				2019-10-28	
J	Sfeir, MM; Schuetz, A; Van Besien, K; Borczuk, AC; Soave, R; Jenkins, SG; Walsh, TJ; Small, CB				Sfeir, Maroun M.; Schuetz, Audrey; Van Besien, Koen; Borczuk, Alain C.; Soave, Rosemary; Jenkins, Stephen G.; Walsh, Thomas J.; Small, Catherine B.			Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; FINE-NEEDLE-ASPIRATION; INFLAMMATORY PSEUDOTUMOR; AVIUM-INTRACELLULARE; TRANSPLANT PATIENT; KAPOSIS-SARCOMA; LYMPH-NODES; INFECTION; TUBERCULOSIS; MIMICKING	Introduction Mycobacterial spindle cell pseudotumour (MSP) is a rare disease characterised by tumour-like local proliferation of spindle-shaped histiocytes containing acid-fast positive mycobacteria. The aim of this literature review is to describe the clinical parameters and treatment outcomes of patients with MSP. Methods A literature search was conducted using the search terms related to mycobacteria and spindle cell tumours. A previously unreported stem cell transplant recipient from our institution diagnosed with MSP was also included. Demographics, comorbidities, site of infection, treatment and clinical outcomes were analysed. Results Fifty-one patients were analysed. Twenty-six (51%) had HIV infection. Mycobacterium avium complex was the most frequent organism isolated in 24 (47.1%) followed by Mycobacterium tuberculosis complex in eight (16%) cases. Lymph nodes were the most common site of infection (45.1%). Twenty (39.2%) patients received antimycobacterial agents, 12 (23.5%) underwent surgical resection and six (11.8%) received antimycobacterial agents plus surgery. Treatment was successful in 24 (47.1%) patients and failed in 15 (29.4%); 13 of these 15 patients died. Antimycobacterial therapy was significantly associated with successful outcome compared with surgical resection or no treatment (P<0.001). Conclusion MSP is a rare condition associated primarily with immunodeficiencies. Antimycobacterial therapy is significantly associated with successful outcome.	[Sfeir, Maroun M.; Soave, Rosemary; Walsh, Thomas J.; Small, Catherine B.] Weill Cornell Med, Dept Med, Div Infect Dis, New York, NY USA; [Sfeir, Maroun M.; Van Besien, Koen; Borczuk, Alain C.; Soave, Rosemary; Jenkins, Stephen G.; Walsh, Thomas J.; Small, Catherine B.] New York Presbyterian Hosp, New York, NY USA; [Sfeir, Maroun M.] Weill Cornell Med, Dept Healthcare Policy & Res, New York, NY USA; [Schuetz, Audrey] Mayo Clin, Dept Pathol, Rochester, NY USA; [Van Besien, Koen] Weill Cornell Med, Div Hematol Oncol, New York, NY USA; [Borczuk, Alain C.; Jenkins, Stephen G.] Weill Cornell Med, Dept Pathol, New York, NY USA; [Soave, Rosemary; Walsh, Thomas J.; Small, Catherine B.] Weill Cornell Med, Transplantat Oncol Infect Dis Program, New York, NY USA; [Walsh, Thomas J.] Weill Cornell Med, Dept Pediat, New York, NY USA; [Walsh, Thomas J.] Weill Cornell Med, Dept Microbiol & Immunol, New York, NY USA	Sfeir, MM (reprint author), Cornell Univ, Weill Cornell Med, Dept Med, Div Infect Dis, New York, NY 10065 USA.	mas9469@med.cornell.edu					Alves A, 2012, VIRCHOWS ARCH, V461, pS332; Androulaki A, 2008, INT J INFECT DIS, V12, P607, DOI 10.1016/j.ijid.2007.12.011; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; Basilio-de-Oliveira C, 2001, Braz J Infect Dis, V5, P98; BRANDWEIN M, 1990, VIRCHOWS ARCH A, V416, P281, DOI 10.1007/BF01605288; Charnot-Katsikas A, 2008, HISTOPATHOLOGY, V53, P410; CHEN KTK, 1992, AM J SURG PATHOL, V16, P276, DOI 10.1097/00000478-199203000-00008; Coelho R, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12656; CORKILL M, 1995, ACTA CYTOL, V39, P125; Franco M, 2015, TRANSPL INFECT DIS, V17, P424, DOI 10.1111/tid.12390; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; Gunia S, 2005, RHINOLOGY, V43, P70; Holmes BJ, 2014, DIAGN CYTOPATHOL, V42, P772, DOI 10.1002/dc.23013; Ilyas S, 2011, HEAD NECK PATHOL, V5, P296, DOI 10.1007/s12105-011-0248-0; Prieto-Nieto MI, 2014, WORLD J GASTRO SURG, V6, P248, DOI 10.4240/wjgs.v6.i12.248; KUMAR S, 1994, AM J CLIN PATHOL, V102, P863, DOI 10.1093/ajcp/102.6.863; Lim MS, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.02.082; Liou JH, 2003, J FORMOS MED ASSOC, V102, P342; Logani S, 1999, AM J SURG PATHOL, V23, P656, DOI 10.1097/00000478-199906000-00004; Manitsas S, 2008, AM J GASTROENTEROL, V103, pS235, DOI 10.14309/00000434-200809001-00606; McArthur James R, 2003, Hematology, V8, P125, DOI 10.1080/1024533031000072072; McGoldrick C, 2010, BMJ CASE REP, V2010; Minhas V, 2014, VIRUSES-BASEL, V6, P4178, DOI 10.3390/v6114178; Morrison A, 1999, AM J SURG PATHOL, V23, P1294, DOI 10.1097/00000478-199910000-00017; Nair SP, 2006, INT J DERMATOL, V45, P433, DOI 10.1111/j.1365-4632.2006.02669.x; Ohara K, 2013, PATHOL INT, V63, P266, DOI 10.1111/pin.12059; PERRIN C, 1993, AM J DERMATOPATH, V15, P553, DOI 10.1097/00000372-199312000-00007; Philip J, 2012, CHEST, V142, P783, DOI 10.1378/chest.11-2503; Phowthongkum P, 2008, INT J INFECT DIS, V12, P421, DOI 10.1016/j.ijid.2007.11.010; Rahmani M, 2013, VIRCHOWS ARCH, V463, P843, DOI 10.1007/s00428-013-1491-4; Rogers H, 2007, 96 ANN M US AND CAN, V87, p269A; SEKOSAN M, 1994, AM J SURG PATHOL, V18, P1065, DOI 10.1097/00000478-199410000-00010; Shiomi T, 2007, J CUTAN PATHOL, V34, P346, DOI 10.1111/j.1600-0560.2006.00611.x; Sideras PA, 2013, CLIN IMAG, V37, P802, DOI 10.1016/j.clinimag.2013.02.012; Suchitha S, 2009, Indian J Tuberc, V56, P104; SUSTER S, 1994, AM J CLIN PATHOL, V101, P539; Tan GC, 2009, BMJ CASE REP BMJ CAS, V11, P1221; UMLAS J, 1991, AM J SURG PATHOL, V15, P1181, DOI 10.1097/00000478-199112000-00009; Vaos G, 2007, J PEDIATR SURG, V42, DOI 10.1016/j.jpedsurg.2007.05.011; WADE H W, 1963, Int J Lepr, V31, P129; WOLF DA, 1995, ARCH PATHOL LAB MED, V119, P811; WOOD C, 1985, AM J CLIN PATHOL, V83, P524, DOI 10.1093/ajcp/83.4.524; Woodhouse S, 2002, ARCH PATHOL LAB MED, V126, P1547; Yeh I, 2011, AM J DERMATOPATH, V33, pE66, DOI 10.1097/DAD.0b013e3182120ae3; Yin H, 2001, Zhonghua Bing Li Xue Za Zhi, V30, P89	45	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					626	630		10.1136/jclinpath-2017-204777			5	Pathology	Pathology	GR3CP	WOS:000442466600009	29367301				2019-10-28	
J	Bagir, EK; Acikalin, A; Avci, A; Gumurdulu, D; Paydas, S				Bagir, Emine Kilic; Acikalin, Arbil; Avci, Alper; Gumurdulu, Derya; Paydas, Semra			PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus	JOURNAL OF CLINICAL PATHOLOGY			English	Article							DEATH-LIGAND 1; EVIDENCE-BASED PATHOLOGY; MERKEL CELL-CARCINOMA; PROGNOSTIC-SIGNIFICANCE; PROGRAMMED DEATH-1; CANCER-THERAPY; THYMOMAS	Aims We explored the relationships between programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression and the pathological and clinical features of thymic epithelial tumours and thymic hyperplasia. Methods We evaluated PD-1 and PDL-1 expressions within epithelial and microenvironmental components in thymic epithelial tumours (n=44) and thymic hyperplasias (n=8), immunohistochemically. We compared the results with demographic, clinical and histopathological features of the cases. Results We found 48% epithelial expression and 82.7% microenvironment expression for PD-1 and 11.5% epithelial expression and 34.6% microenvironment expression for PD-L1. There was no PD-1 expression, in either the epithelial or microenvironment, in the thymic hyperplasia group. PD-1 and PD-L1 positivity was more significant in thymic epithelial tumours than thymic hyperplasia. Patients with PD-1-positive microenvironments exhibited significantly shorter mean estimated survival time than their negative counterparts. Conclusion These findings suggest that anti-PD-1 and anti-PD-L1 therapies may benefit patients due to high release of PD-1 and PD-L1 in thymic epithelial tumours.	[Bagir, Emine Kilic; Acikalin, Arbil; Gumurdulu, Derya] Cukurova Univ, Dept Pathol, Fac Med, TR-01130 Adana, Turkey; [Avci, Alper] Cukurova Univ, Dept Chest Surg, Fac Med, Adana, Turkey; [Paydas, Semra] Cukurova Univ, Dept Med Oncol, Fac Med, Adana, Turkey	Bagir, EK (reprint author), Cukurova Univ, Dept Pathol, Fac Med, TR-01130 Adana, Turkey.	eminebagir@yahoo.com	avci, alper/AAA-5448-2019				Chen KY, 2016, ONCOTARGET, V7, P30772, DOI 10.18632/oncotarget.8956; D'Incecco A, 2015, BRIT J CANCER, V112, P95, DOI 10.1038/bjc.2014.555; Katsuya Y, 2016, LUNG CANCER, V99, P4, DOI 10.1016/j.lungcan.2016.05.007; Katsuya Y, 2015, LUNG CANCER, V88, P154, DOI 10.1016/j.lungcan.2015.03.003; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lipson EJ, 2013, CANCER IMMUNOL RES, V1, P54, DOI 10.1158/2326-6066.CIR-13-0034; Marchevsky AM, 2008, CANCER-AM CANCER SOC, V112, P2780, DOI 10.1002/cncr.23492; Marchevsky AM, 2017, HUM PATHOL, V60, P16, DOI 10.1016/j.humpath.2016.09.023; Muenst S, 2010, DIS MARKERS, V29, P47, DOI 10.3233/DMA-2010-0725; Naidoo J, 2014, BRIT J CANCER, V111, P2214, DOI 10.1038/bjc.2014.348; Nishimura H, 2000, J EXP MED, V191, P891, DOI 10.1084/jem.191.5.891; Padda SK, 2015, J THORAC ONCOL, V10, P500, DOI 10.1097/JTO.0000000000000429; Paydas S, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0807-z; Paydas S, 2015, ANN HEMATOL, V94, P1545, DOI 10.1007/s00277-015-2403-2; Rao P, 2010, ARCH PATHOL LAB MED, V134, P341, DOI 10.1043/1543-2165-134.3.341; Rosai J, 2008, ARCH PATHOL LAB MED, V132, P1859, DOI 10.1043/1543-2165-132.12.1859.a; Swaika A, 2015, MOL IMMUNOL, V67, P4, DOI 10.1016/j.molimm.2015.02.009; Tang YY, 2017, ONCOTARGET, V8, P39001, DOI 10.18632/oncotarget.16545; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Tiseo M, 2017, LUNG CANCER, V104, P24, DOI 10.1016/j.lungcan.2016.12.005; Weissferdt A, 2017, MODERN PATHOL, V30, P826, DOI 10.1038/modpathol.2017.6; Yokoyama S, 2016, CLIN CANCER RES, V22, P4727, DOI 10.1158/1078-0432.CCR-16-0434; Yokoyama S, 2016, ANN THORAC SURG, V101, P1361, DOI 10.1016/j.athoracsur.2015.10.044; Zheng H, 2016, ONCOTARGET, V7, P56233, DOI 10.18632/oncotarget.9316; Zhu L, 2016, J THORAC DIS, V8, P718, DOI 10.21037/jtd.2016.03.24	25	1	1	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					637	641		10.1136/jclinpath-2017-204788			5	Pathology	Pathology	GR3CP	WOS:000442466600011	29439008				2019-10-28	
J	Gao, LW; Zhang, H; Zhang, B; Zhu, JF; Chen, C; Liu, WR				Gao, Liuwei; Zhang, Hua; Zhang, Bin; Zhu, Jinfang; Chen, Chen; Liu, Weiran			B3GNT3 overexpression is associated with unfavourable survival in non-small cell lung cancer	JOURNAL OF CLINICAL PATHOLOGY			English	Article							E-CADHERIN; EXPRESSION; BETA-3GNT8; METASTASIS; RECEPTORS; VIMENTIN; THERAPY; S100A4	Objective The aim of this study was to evaluate the expression of beta-1,3-N-acetylglucosaminyltransferase-3 (B3GNT3) in non-small cell lung cancer (NSCLC) patients and to investigate the relevance of B3GNT3 expression in tumour prognosis. Methods In this study, B3GNT3 expression was examined in five pairs of resectable NSCLC tissue by Western blot and in 42 pairs of resectable NSCLC tissue by quantitative real-time PCR (qRT-PCR). Immunohistochemistry and statistical analysis were performed to assess the relationship between B3GNT3 expression scores and clinicopathological parameters, as well as clinical prognosis in a retrospective cohort of 176 NSCLC patients. Results Both B3GNT3 mRNA and protein expression levels were significantly higher in NSCLC tissue than in adjacent normal tissue. In the 176 NSCLC cases, a high B3GNT3 expression level was positively correlated with lymph node metastasis (P<0.001) and advanced TNM stage (P=0.043). Kaplan-Meier analysis indicated that patients with high B3GNT3 expression had significantly lower disease-free survival (DFS) (P<0.001) and overall survival (OS) (P<0.001) than those with low B3GNT3 expression. Moreover, in the multivariate analyses, B3GNT3 expression was an independent prognostic factor for DFS (HR 0.329, 95% CI 0.213 to 0.508, P<0.001) and OS (HR 0.383, 95% CI 0.249 to 0.588, P<0.001). Conclusions Our study demonstrated that high expression of B3GNT3 was associated with unfavourable DFS and OS in NSCLC patients, suggesting that B3GNT3 might be a potential prognostic biomarker for NSCLC.	[Gao, Liuwei; Zhang, Hua; Zhang, Bin; Zhu, Jinfang; Chen, Chen] Tianjin Med Univ, Canc Inst & Hosp, Tianjin Lung Canc Ctr,Tianjins Clin Res Ctr Canc, Dept Lung Canc,Natl Clin Res Ctr Canc,Key Lab Can, Tianjin, Peoples R China; [Liu, Weiran] Tianjin Med Univ, Canc Inst & Hosp, Tianjins Clin Res Ctr Canc,Dept Anesthesiol, Key Lab Canc Prevent & Therapy,Natl Clin Res Ctr, Tianjin, Peoples R China	Liu, WR (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Dept Anesthesiol, Tianjin, Peoples R China.	wrliu@tmu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472182]; Tianjin Municipal Science and Technology Commission [15JCQNJC11800]; Tianjin Science and Technology Major Project [12ZCDZSY15400]	This study was supported by grants from the National Natural Science Foundation of China (81472182), the Tianjin Municipal Science and Technology Commission (15JCQNJC11800) and the Tianjin Science and Technology Major Project (12ZCDZSY15400).	Cerhan JR, 2007, BLOOD, V110, P4455, DOI 10.1182/blood-2007-05-088682; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Gromova I, 2001, MOL CARCINOGEN, V32, P61, DOI 10.1002/mc.1065; Hakomori S, 1996, CANCER RES, V56, P5309; He MA, 2014, GUT, V63, P143, DOI 10.1136/gutjnl-2012-303434; Ho WL, 2013, CANCER SCI, V104, P1600, DOI 10.1111/cas.12294; Hua D, 2012, ASIAN PAC J CANCER P, V13, P2087, DOI 10.7314/APJCP.2012.13.5.2087; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; Liang JX, 2016, ONCOTARGETS THER, V9, P3113, DOI 10.2147/OTT.S102389; Liu J, 2014, INT J MOL MED, V33, P1459, DOI 10.3892/ijmm.2014.1736; Liu Z, MOL MED REP; Lu CH, 2014, GLYCOBIOLOGY, V24, P359, DOI 10.1093/glycob/cwu002; MCCLELLAND RA, 1990, CANCER RES, V50, P3545; Mitoma J, 2003, J BIOL CHEM, V278, P9953, DOI 10.1074/jbc.M212756200; Rosell R, 2013, NAT REV CLIN ONCOL, V10, P549, DOI 10.1038/nrclinonc.2013.152; Shen L, 2014, INT J ONCOL, V45, P2560, DOI 10.3892/ijo.2014.2672; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536; Sun RW, 2014, ONCOTARGET, V5, P12398, DOI 10.18632/oncotarget.2643; Travis WD, 2015, WHO CLASSIFICATION T; Tsim S, 2010, RESP MED, V104, P1767, DOI 10.1016/j.rmed.2010.08.005; Walker J, 2013, LUNG CANCER, V79, P46, DOI 10.1016/j.lungcan.2012.09.014; Witz IP, 2008, CANCER METAST REV, V27, P19, DOI 10.1007/s10555-007-9101-z; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zhai XL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0970-z; Zhang H, 2013, J CLIN PATHOL, V66, P937, DOI 10.1136/jclinpath-2013-201467; Zhang WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144360	29	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					642	647		10.1136/jclinpath-2017-204860			6	Pathology	Pathology	GR3CP	WOS:000442466600012	29483137				2019-10-28	
J	Jamwal, M; Aggarwal, A; Sachdeva, MUS; Sharma, P; Malhotra, P; Maitra, A; Das, R				Jamwal, Manu; Aggarwal, Anu; Sachdeva, Man Updesh Singh; Sharma, Prashant; Malhotra, Pankaj; Maitra, Arindam; Das, Reena			Overhydrated stomatocytosis associated with a complex RHAG genotype including a novel de novo mutation	JOURNAL OF CLINICAL PATHOLOGY			English	Article							AMINO-ACID SUBSTITUTIONS; FUNCTIONAL-CHARACTERIZATION; CELL-VOLUME; CATION LEAK; GLYCOPROTEIN; DISORDERS	Overhydrated stomatocytosis is a rare autosomal dominant disorder known to cause variably severe haemolytic anaemia due to heterozygous mutations in the RHAG gene. We report a 26-year-old man with recurring jaundice, splenohepatomegaly and mild chronic haemolytic anaemia with significant stomatocytosis. Extensive haemolytic work-up including flow cytometry for eosin-5'-maleimide and CD47 expression levels was carried out. Targeted resequencing revealed two probably causative heterozygous mutations in RHAG (Leu336Ser and Ile149Met) and one heterozygous mutation in ANK1 (G1u1046Lys). RHAG involvement was confirmed by decreased RhAG macrocomplex component indicated by the reduced CD47 expression on erythrocytes. In silico analysis concordantly flagged RHAG:Leu336Ser and ANK1:Glu1046Lys as likely deleterious mutation, whereas RHAG:Ile149Met was reported as likely neutral by PROVEAN. Family screening by Sanger sequencing revealed RHAG:Leu336Ser in a mother and ANK1:G1u1046Lys in a father who were both asymptomatic, excluding them as causative dominant events, thus establishing RHAG:Ile149Met, novel de novo mutation as probably causative. This case illustrates the importance of family screening in interpreting next-generation sequencing (NGS) data, as in silico analysis alone can be misleading. Erudite generation of diagnostic possibilities based on a thorough baseline clinical and laboratory work-up remains as important as ever, even as NGS brings about a paradigm shift in the diagnostic work-up of rare haemolytic anaemias.	[Jamwal, Manu; Aggarwal, Anu; Sachdeva, Man Updesh Singh; Sharma, Prashant; Das, Reena] Post Grad Inst Med Educ & Res, Dept Hematol, Chandigarh 160012, India; [Malhotra, Pankaj] Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India; [Maitra, Arindam] Natl Inst Biomed Genom, Kalyani, W Bengal, India	Das, R (reprint author), Post Grad Inst Med Educ & Res, Dept Hematol, Chandigarh 160012, India.	reenadaspgi@hotmail.com			Department of Biotechnology, Ministry of Science and Technology, New DelhiDepartment of Science & Technology (India) [BT/PR12682/MED/12/689/2015]; Indian Council of Medical Research (ICMR), New DelhiIndian Council of Medical Research	This work was supported by institutional funds and Department of Biotechnology, Ministry of Science and Technology, New Delhi (BT/PR12682/MED/12/689/2015). MJ and AA received fellowship from the Indian Council of Medical Research (ICMR), New Delhi.	Andolfo I, 2016, HAEMATOLOGICA, V101, P909, DOI 10.3324/haematol.2016.142372; Badens C, 2016, BRIT J HAEMATOL, V174, P674, DOI 10.1111/bjh.14197; Bruce LJ, 2009, BLOOD, V113, P1350, DOI 10.1182/blood-2008-07-171140; Ciepiela O, 2018, CYTOMETRY B, V94; Gallagher PG, 2017, BLOOD, V130, P2699, DOI 10.1182/blood-2017-04-590810; Genetet S, 2012, AM J PHYSIOL-CELL PH, V302, pC419, DOI 10.1152/ajpcell.00092.2011; Glogowska E, 2015, INT J LAB HEMATOL, V37, P85, DOI 10.1111/ijlh.12357; Huang CH, 1999, AM J HEMATOL, V62, P25, DOI 10.1002/(SICI)1096-8652(199909)62:1<25::AID-AJH5>3.0.CO;2-K; Jamwal M, 2017, CLIN CHIM ACTA, V468, P81, DOI 10.1016/j.cca.2017.02.012; Liao L, 2014, HEMATOLOGY, V19, P393, DOI 10.1179/1607845413Y.0000000149; LOCK SP, 1961, BRIT J HAEMATOL, V7, P303, DOI 10.1111/j.1365-2141.1961.tb00341.x; Polin H, 2016, TRANSFUSION, V56, P950, DOI 10.1111/trf.13476; Rasool J, 2015, MED J DR DY PATIL U, V8, P347; Stewart AK, 2011, AM J PHYSIOL-CELL PH, V300, pC1034, DOI 10.1152/ajpcell.00447.2010; Stewart GW, 1996, BRIT J HAEMATOL, V93, P303, DOI 10.1046/j.1365-2141.1996.4881033.x; Tilley L, 2010, VOX SANG, V98, P151, DOI 10.1111/j.1423-0410.2009.01243.x	16	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					648	652		10.1136/jclinpath-2018-205018			5	Pathology	Pathology	GR3CP	WOS:000442466600013	29559519				2019-10-28	
J	Keegan, A; Charest, K; Schmidt, R; Briggs, D; Deangelo, DJ; Li, B; Morgan, EA; Pozdnyakova, O				Keegan, Alissa; Charest, Karry; Schmidt, Ryan; Briggs, Debra; Deangelo, Daniel J.; Li, Betty; Morgan, Elizabeth A.; Pozdnyakova, Olga			Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease	JOURNAL OF CLINICAL PATHOLOGY			English	Article							BONE-MARROW; MRD; TRANSPLANTATION; CHILDREN; THERAPY	Objectives To evaluate peripheral blood (PB) for minimal residual disease (MRD) assessment in adults with acute lymphoblastic leukaemia (ALL). Methods We analysed 76 matched bone marrow (BM) aspirate and PB specimens independently for the presence of ALL MRD by six-colour flow cytometry (FC). Results The overall rate of BM MRD-positivity was 24% (18/76) and PB was also MRD-positive in 22% (4/18) of BM-positive cases. We identified two cases with evidence of leukaemic cells in PB at the time of the extramedullary relapse that were interpreted as MRD-negative in BM. Conclusions The use of PB MRD as a non-invasive method for monitoring of systemic relapse may have added clinical and diagnostic value in patients with high risk of extramedullary disease.	[Keegan, Alissa; Charest, Karry; Schmidt, Ryan; Li, Betty; Morgan, Elizabeth A.; Pozdnyakova, Olga] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Keegan, Alissa; Charest, Karry; Schmidt, Ryan; Li, Betty; Morgan, Elizabeth A.; Pozdnyakova, Olga] Harvard Med Sch, Boston, MA 02115 USA; [Briggs, Debra; Deangelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Pozdnyakova, O (reprint author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	opozdnyakova@bwh.harvard.edu					Bassan R, 2009, BLOOD, V113, P4153, DOI 10.1182/blood-2008-11-185132; Borowitz MJ, 2008, BLOOD, V111, P5477, DOI 10.1182/blood-2008-01-132837; Brisco MJ, 1997, BRIT J HAEMATOL, V99, P314, DOI 10.1046/j.1365-2141.1997.3723186.x; Bruggemann M, 2010, LEUKEMIA, V24, P521, DOI 10.1038/leu.2009.268; Chen W, 2007, AM J CLIN PATHOL, V127, P39, DOI 10.1309/7R6MU7R9YWJBY5V4; Coustan-Smith E, 2002, BLOOD, V100, P2399, DOI 10.1182/blood-2002-04-1130; Dworzak MN, 2002, BLOOD, V99, P1952, DOI 10.1182/blood.V99.6.1952; Gokbuget N, 2017, HAEMATOLOGICA, V102, pE132, DOI 10.3324/haematol.2016.153957; Gokbuget N, 2012, BLOOD, V120, P1868, DOI 10.1182/blood-2011-09-377713; Kantarjian HM, 2016, NEW ENGL J MED, V375, P740, DOI 10.1056/NEJMoa1509277; Martins VC, 2014, NATURE, V509, P465, DOI 10.1038/nature13317; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Ribera JM, 2014, J CLIN ONCOL, V32, P1595, DOI 10.1200/JCO.2013.52.2425; Sanchez R, 2017, ANN HEMATOL, V96, P1069, DOI 10.1007/s00277-017-3002-1; Theunissen P, 2017, BLOOD, V129, P347, DOI 10.1182/blood-2016-07-726307; van der Velden VHJ, 2002, LEUKEMIA, V16, P1432, DOI 10.1038/sj.leu.2402636; van Dongen JJM, 2015, BLOOD, V125, P3996, DOI 10.1182/blood-2015-03-580027; Vidriales MB, 2003, BLOOD, V101, P4695, DOI 10.1182/blood-2002-08-2613; Wells DA, 1998, AM J CLIN PATHOL, V110, P84	19	2	2	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					653	658		10.1136/jclinpath-2017-204828			6	Pathology	Pathology	GR3CP	WOS:000442466600014	29588374				2019-10-28	
J	Mayall, FG; Bodger, I; Pepperell, J; Stevanato, L; Hustler, A; Mumford, KM				Mayall, Frederick George; Bodger, Ian; Pepperell, Justin; Stevanato, Lara; Hustler, Arianna; Mumford, Kyra Mhairi			The precious cell block	JOURNAL OF CLINICAL PATHOLOGY			English	Letter									[Mayall, Frederick George; Bodger, Ian] Musgrove Pk Hosp, Dept Cellular Pathol, Taunton TA1 5DA, Somerset, England; [Pepperell, Justin] Musgrove Pk Hosp, Dept Resp Med, Taunton, Somerset, England; [Stevanato, Lara; Hustler, Arianna; Mumford, Kyra Mhairi] ANGLE Europe Ltd, Res & Dev, Guildford, Surrey, England	Mayall, FG (reprint author), Musgrove Pk Hosp, Dept Cellular Pathol, Taunton TA1 5DA, Somerset, England.	DrMayall@me.com			ANGLE Europe Ltd. [209687]	This work was funded by ANGLE Europe Ltd (commercial funding), IRAS Project ID: 209687.		0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					659	+		10.1136/jclinpath-2018-205151			2	Pathology	Pathology	GR3CP	WOS:000442466600015	29588371	Green Published			2019-10-28	
J	Mahe, E; Pugh, TJ; Kamel-Reid, S				Mahe, E.; Pugh, Trevor J.; Kamel-Reid, S.			T cell clonality assessment: past, present and future (vol 71, pg 195, 2018)	JOURNAL OF CLINICAL PATHOLOGY			English	Correction																Mahe E, 2018, J CLIN PATHOL, V71, P195, DOI 10.1136/jclinpath-2017-204761	1	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JUL	2018	71	7					660	660		10.1136/jclinpath-2017-204761corr1			1	Pathology	Pathology	GR3CP	WOS:000442466600016		Green Published, Bronze			2019-10-28	
J	Mik, P; Tonar, Z; Maleckova, A; Eberlova, L; Liska, V; Palek, R; Rosendorf, J; Jirik, M; Mirka, H; Kralickova, M; Witter, K				Mik, P.; Tonar, Z.; Maleckova, A.; Eberlova, L.; Liska, V.; Palek, R.; Rosendorf, J.; Jirik, M.; Mirka, H.; Kralickova, M.; Witter, K.			Distribution of Connective Tissue in the Male and Female Porcine Liver: Histological Mapping and Recommendations for Sampling	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						connective tissue; histology; liver; pig	PRIMARY SCLEROSING CHOLANGITIS; PORTAL-VEIN LIGATION; CHRONIC HEPATITIS-C; NONALCOHOLIC STEATOHEPATITIS; ANIMAL-MODEL; STAGED HEPATECTOMY; MR ELASTOGRAPHY; FIBROSIS; CIRRHOSIS; DISEASE	The pig is a large animal model that is often used in experimental medicine. The aim of this study was to assess, in normal pig livers, sexual dimorphism in the normal fraction of hepatic interlobular and intralobular connective tissue (CT) in six hepatic lobes and in three macroscopical regions of interest (ROIs) with different positions relative to the liver vasculature. Using stereological point grids, the fractions of CT were quantified in histological sections stained with aniline blue and nuclear fast red. Samples (415 tissue blocks) were collected from healthy piglets, representing paracaval, paraportal and peripheral ROIs. There was considerable variability in the CT fraction at all sampling levels. In males the mean fraction of interlobular CT was 4.7 +/- 2.4% (mean +/- SD) and ranged from 0% to 11.4%. In females the mean fraction of the interlobular CT was 3.6 +/- 2.2% and ranged from 0% to 12.3%. The mean fraction of intralobular (perisinusoidal summed with pericentral) CT was <0.2% in both sexes. The interlobular CT represented >99.8% of the total hepatic CT and the fractions were highly correlated (Spearman r = 0.998, P <0.05). The smallest CT fraction was observed in the left medial lobe and in the paracaval ROI and the largest CT fraction was detected in the quadrate lobe and in the peripheral ROI. For planning experiments involving the histological quantification of liver fibrosis and requiring comparison between the liver lobes, these data facilitate the power analysis for sample size needed to detect the expected relative increase or decrease in the fraction of CT. (C) 2018 Elsevier Ltd. All rights reserved.	[Mik, P.; Eberlova, L.] Charles Univ Prague, Fac Med Pilsen, Dept Anat, Karlovarska 48, Plzen, Czech Republic; [Tonar, Z.; Kralickova, M.] Charles Univ Prague, Fac Med Pilsen, Dept Histol & Embryol, Karlovarska 48, Plzen, Czech Republic; [Liska, V.; Palek, R.; Rosendorf, J.] Charles Univ Prague, Fac Med Pilsen, Dept Surg, Alej Svobody 80, Plzen, Czech Republic; [Liska, V.; Palek, R.; Rosendorf, J.] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Alej Svobody 80, Plzen, Czech Republic; [Maleckova, A.; Jirik, M.] Univ West Bohemia, Fac Sci Appl, European Ctr Excellence NTIS, Univ 22, Plzen, Czech Republic; [Mirka, H.] Charles Univ Prague, Univ Hosp Pilsen, Fac Med Pilsen, Dept Imaging Methods, Plzen, Czech Republic; [Mirka, H.] Charles Univ Prague, Univ Hosp Pilsen, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Witter, K.] Univ Vet Med Vienna, Dept Pathobiol, Inst Anat Histol & Embryol, Vet Pl 1, Vienna, Austria	Tonar, Z (reprint author), Charles Univ Prague, Fac Med Pilsen, Dept Histol & Embryol, Karlovarska 48, Plzen, Czech Republic.	Zbynek.Tonar@lfp.cuni.cz	Maleckova, Anna/R-2499-2017; Mik, Patrik/R-8167-2016; Tonar, Zbynek/I-2728-2017	Maleckova, Anna/0000-0003-2674-6268; Palek, Richard/0000-0002-3546-808X; Rosendorf, Jachym/0000-0003-2125-0685; Mik, Patrik/0000-0001-9780-650X; Witter, Kirsti/0000-0001-5388-8208; Tonar, Zbynek/0000-0002-7200-9894	National Sustainability Programme I (NPU I) by Ministry of Education, Youth and Sports of the Czech Republic [LO1503, LO1506]; Charles University Research Fund [Q39]; Charles University [SVV 260390/2017, SVV 260392/2017, GAUK 1206417]; project of the Centre of Clinical and Experimental Liver Surgery [UNCE/MED/006]; Ministry of Education, Youth and Sports under project FIND [CZ.02.1.01/0.0/0.0/16_019/0000787];  [CZ.02.1.01/0.0/0.0/17_048/0007280]	This study was supported by the National Sustainability Programme I (NPU I) number LO1503 and number LO1506 provided by the Ministry of Education, Youth and Sports of the Czech Republic and by the Charles University Research Fund (Progres Q39). The project also received support from Charles University Project numbers SVV 260390/2017, SVV 260392/2017 and GAUK 1206417 and from the project of the Centre of Clinical and Experimental Liver Surgery UNCE/MED/006 and Application of Modern Technologies in Medicine and Industry CZ.02.1.01/0.0/0.0/17_048/0007280. The study also received support from the Ministry of Education, Youth and Sports under the project FIND, number CZ.02.1.01/0.0/0.0/16_019/0000787. Skillful technical support from Ms. A. Flemming, Ms. C. Hochsmann and Ms. B. Machac is gratefully acknowledged.	Anstee QM, 2006, INT J EXP PATHOL, V87, P1, DOI 10.1111/j.0959-9673.2006.00465.x; Arkadopoulos N, 2011, J SURG RES, V170, pE233, DOI 10.1016/j.jss.2011.06.006; Avritscher R, 2011, J VASC INTERV RADIOL, V22, P1329, DOI 10.1016/j.jvir.2011.04.016; BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201; Besusparis J, 2014, ANAL CELL PATHOL, V2014; Boykov Y, 2000, LECT NOTES COMPUT SC, V1935, P276; Bruha J, 2015, IN VIVO, V29, P327; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1016/S0002-9270(99)00433-5; Budai A, 2017, EUR SURG RES, V58, P140, DOI 10.1159/000453108; Chen XL, 2013, HEPATOL RES, V43, P1231, DOI 10.1111/hepr.12076; Chow S-C, 2008, SAMPLE SIZE CALCULAT, P49; Croome KP, 2015, HPB, V17, P1130, DOI 10.1111/hpb.12465; de Vries EMG, 2015, J HEPATOL, V63, P1212, DOI 10.1016/j.jhep.2015.06.008; Eberlova L, 2016, FOLIA MORPHOL, V75, P154, DOI 10.5603/FM.a2015.0094; Eberlova L, 2017, ANN ANAT, V213, P69, DOI 10.1016/j.aanat.2017.05.005; Emerson M, 2010, BRIT J PHARMACOL, V161, P749, DOI 10.1111/j.1476-5381.2010.00959.x; Fakhoury-Sayegh N, 2015, NUTR RES PRACT, V9, P350, DOI 10.4162/nrp.2015.9.4.350; Forbes SJ, 2011, BEST PRACT RES CL GA, V25, P207, DOI 10.1016/j.bpg.2011.02.006; George J, 2003, J HEPATOL, V39, P756, DOI 10.1016/S0168-8278(03)00376-3; Ghodsizad A, 2012, ASAIO J, V58, P255, DOI 10.1097/MAT.0b013e31824cc922; Gnutzmann DM, 2015, J VASC INTERV RADIOL, V26, P746, DOI 10.1016/j.jvir.2014.12.016; Gohlke F, 1996, J HEPATOL, V24, P699, DOI 10.1016/S0168-8278(96)80266-2; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3; Hosoyamada Y, 2000, J ANAT, V196, P327, DOI 10.1046/j.1469-7580.2000.19630327.x; Huang SY, 2014, J MAGN RESON IMAGING, V39, P590, DOI 10.1002/jmri.24189; Huang Y, 2017, LIVER INT, V37, P121, DOI 10.1111/liv.13116; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Jirik M, 2018, MICROSC RES TECHNIQ, V81, P551, DOI 10.1002/jemt.23011; Junatas KL, 2017, J ANAT, V230, P575, DOI 10.1111/joa.12585; Kawamura Y, 2014, HEPATOL RES, V44, P1234, DOI 10.1111/hepr.12240; Kisseleva T, 2017, HEPATOLOGY, V65, P1039, DOI 10.1002/hep.28948; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Komine M, 2008, J COMP PATHOL, V139, P202, DOI 10.1016/j.jcpa.2008.07.002; Komori A, 2014, HEPATOL RES, V44, P71, DOI 10.1111/hepr.12270; Kubikova T, 2017, ANN ANAT, V212, P17, DOI 10.1016/j.aanat.2017.03.004; Lee KS, 2017, RADIOLOGY, V285, P114, DOI 10.1148/radiol.2017162617; Lee YH, 2010, J COMP PATHOL, V142, P187, DOI 10.1016/j.jcpa.2009.10.025; Lefkowitch JH, 2007, ARCH MED RES, V38, P634, DOI 10.1016/j.arcmed.2006.08.005; Lepreux S, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00173; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Lossi L, 2016, ANN ANAT, V204, P11, DOI 10.1016/j.aanat.2015.10.002; Lua I, 2015, AM J PATHOL, V185, P3258, DOI 10.1016/j.ajpath.2015.08.009; Machado MV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127991; Mak KM, 2013, ANAT REC, V296, P953, DOI 10.1002/ar.22694; Mak KM, 2012, ANAT REC, V295, P1159, DOI 10.1002/ar.22504; Marcos R, 2015, HEPATOLOGY, V61, P1093, DOI 10.1002/hep.27336; Marcos R, 2012, J ANAT, V220, P303, DOI 10.1111/j.1469-7580.2012.01475.x; MATTFELDT T, 1990, J MICROSC-OXFORD, V159, P301, DOI 10.1111/j.1365-2818.1990.tb03036.x; Mouton PR, 2011, UNBIASED STEREOLOGY, P55; Muehlfeld C, 2010, CARDIOVASC PATHOL, V19, P65, DOI 10.1016/j.carpath.2008.10.015; Nowatzky J, 2013, HEPATOL RES, V43, P535, DOI 10.1111/j.1872-034X.2012.01086.x; Nygard IE, 2015, BIOMED RES INT, DOI 10.1155/2015/248920; Panasevich MR, 2018, AM J PHYSIOL-ENDOC M, V314, pE78, DOI 10.1152/ajpendo.00015.2017; Peterson TC, 1996, IMMUNOPHARMACOLOGY, V31, P183, DOI 10.1016/0162-3109(95)00048-8; Sakhuja P, 2014, WORLD J GASTROENTERO, V20, P16474, DOI 10.3748/wjg.v20.i44.16474; Saxena R, 2011, PRACTICAL HEPATIC PA, P203; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; Standish RA, 2006, GUT, V55, P569, DOI 10.1136/gut.2005.084475; Stasi C, 2016, WORLD J GASTROENTERO, V22, P1711, DOI 10.3748/wjg.v22.i4.1711; Takahashi Y, 2014, WORLD J GASTROENTERO, V20, P15539, DOI 10.3748/wjg.v20.i42.15539; Theise Neil D, 2013, Clin Liver Dis (Hoboken), V2, P64, DOI 10.1002/cld.172; Tonar Z, 2015, ANN ANAT, V201, P79, DOI 10.1016/j.aanat.2015.05.005; Vrtkova I., 2015, Archives Animal Breeding, V58, P115, DOI 10.5194/aab-58-115-2015; Wang L, 2015, WORLD J GASTROENTERO, V21, P9544, DOI 10.3748/wjg.v21.i32.9544; Watson AL, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00078; Yang JD, 2014, HEPATOLOGY, V59, P1406, DOI 10.1002/hep.26761; Yi XR, 2012, DIGEST DIS SCI, V57, P2079, DOI 10.1007/s10620-012-2168-6; Yin M, 2017, RADIOLOGY, V284, P694, DOI 10.1148/radiol.2017160622; Zaitoun AAM, 1998, ACTA STEREOL, V17, P49; Zaitoun AM, 2001, J CLIN PATHOL, V54, P461, DOI 10.1136/jcp.54.6.461; Zhang JJ, 2009, EUR SURG RES, V42, P35, DOI 10.1159/000167855; Zhang ZL, 2015, HEPATOL RES, V45, P162, DOI 10.1111/hepr.12415; Zhao YL, 2016, BIOMED REP, V4, P269, DOI 10.3892/br.2016.578; Zhou L, 2014, J MAGN RESON IMAGING, V39, P872, DOI 10.1002/jmri.24248	76	1	1	3	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						1	13		10.1016/j.jcpa.2018.05.004			13	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400001	30060837				2019-10-28	
J	Elbahi, A; Kipar, A; Ressel, L				Elbahi, A.; Kipar, A.; Ressel, L.			Histocytic-like Atypical Mast Cell Tumours in Horses	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						atypical; histiocytic-like; horse; mast cell tumour		This report describes a series of four equine mast cell tumours (MCTs) with atypical morphological features. The tumours were 1-2 cm in diameter and mostly localized to the eyes (one eyelid, two conjunctiva). Histologically, they were composed of very large (up to 35 mu m) round pleomorphic cells with a large central to paracentral nucleus and abundant granular cytoplasm. A large number of viable mature eosinophils were detected intermingled with the large round cells. Histochemical staining (toluidine blue and Perls' Prussian blue) and immunohistochemistry (KIT, mast cell tryptase, lysozyme and proliferating cell nuclear antigen) confirmed the mast cell origin of the atypical cells and identified an aberrant KIT protein expression in three cases. Based on morphological and immunohistochemical features, we propose to call the lesions equine histiocytic-like atypical MCTs. (C) 2018 Elsevier Ltd. All rights reserved.	[Elbahi, A.; Ressel, L.] Univ Liverpool, Inst Vet Sci, Dept Vet Pathol & Publ Hlth, Leahurst Campus,Chester High Rd, Neston, England; [Kipar, A.] Univ Zurich, Vetsuisse Fac, Inst Vet Pathol, Winterthurerstr 268, Zurich, Switzerland; [Elbahi, A.; Kipar, A.; Ressel, L.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool Sci Pk IC2, Liverpool, Merseyside, England	Ressel, L (reprint author), Univ Liverpool, Inst Vet Sci, Dept Vet Pathol & Publ Hlth, Leahurst Campus,Chester High Rd, Neston, England.; Ressel, L (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool Sci Pk IC2, Liverpool, Merseyside, England.	l.ressel@liverpool.ae.uk			Libyan Government [200948995]	The authors are grateful to the staff of the Histology Laboratory, Veterinary Laboratory Services, Department of Veterinary Pathology and Public Health, University of Liverpool, for excellent technical support. Thanks are due to the clinical colleagues who contributed the cases and retrieved the clinical information. A. Elbahi was supported by a PhD studentship (200948995) from the Libyan Government.	Clarke L, 2014, VET PATHOL, V51, P560, DOI 10.1177/0300985813493931; Goldschmidt M. H., 2002, Tumors in domestic animals, P45, DOI 10.1002/9780470376928.ch2; Henry C, 2013, J FELINE MED SURG, V15, P41, DOI 10.1177/1098612X12470343; HUM S, 1989, AUST VET J, V66, P32, DOI 10.1111/j.1751-0813.1989.tb09712.x; Kiupel M., 2017, Tumors in domestic animals, P176; Ressel L, 2015, J COMP PATHOL, V153, P236, DOI 10.1016/j.jcpa.2015.07.006; Sabattini S, 2010, VET PATHOL, V21, P643; Scott DW, 2011, EQUINE DERMATOLOGY, P496; Valentine BA, 2006, J VET DIAGN INVEST, V18, P123, DOI 10.1177/104063870601800121	9	1	1	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						14	17		10.1016/j.jcpa.2018.05.003			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400002	30060838				2019-10-28	
J	Anjaneya, A; Singh, KP; Cherian, S; Saminathan, M; Singh, R; Ramakrishnan, MA; Maan, S; Maan, NS; Hemadri, D; Rao, PP; Putty, K; Krishnajyothi, Y; Mertens, PP				Anjaneya, A.; Singh, K. P.; Cherian, S.; Saminathan, M.; Singh, R.; Ramakrishnan, M. A.; Maan, S.; Maan, N. S.; Hemadri, D.; Rao, P. P.; Putty, K.; Krishnajyothi, Y.; Mertens, P. P.			Comparative Neuropathology of Major Indian Bluetongue Virus Serotypes in a Neonatal BALB/c Mouse Model	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						BALB/c mice; bluetongue virus; histopathology; ncuropathogcnicity	AVIRULENT STRAINS; BOVINE FETUSES; SHEEP; INFECTION; MICE; RESPONSES; VIRULENCE; GENE; NEUROVIRULENCE; ASSOCIATION	Bluetongue virus (BTV) is neurotropic in nature, especially in ruminant fetuses and in-utero infection results in abortion and congenital brain malformations. The aim of the present study was to compare the neuropathogenicity of major Indian BTV serotypes 1, 2, 10, 16 and 23 by gross and histopathological lesions and virus distribution in experimentally infected neonatal BALB/c mice. Each BTV serotypc (20 mu l of inoculum containing 1 x 10(5) tissue culture infectious dose [TCID](50)/ml of virus) was inoculated intracerebrally into 3-day-old mice, while a control group was inoculated with mock-infected cell culture medium. Infection with BTV serotypes 1, 2 and 23 led to 65-70% mortality at 7-9 days post infection (dpi) and caused severe necrotizing encephalitis with neurodegenerative changes in neurons, swelling and proliferation of vascular endothelial cells in the cerebral cortex, cerebellum, midbrain and brainstem. In contrast, infection with BTV serotypes 10 and 16 led to 25-30% mortality at 9-11 dpi and caused mild neuropathological lesions. BTV antigen was detected by immunohistochemistry, direct fluorescence antibody technique and confocal microscopy in the cytoplasm of neuronal cells of the hippocampus, grey matter of the cerebral cortex and vascular endothelial cells in the midbrain and brainstem of BTV-1, -2, -10, -16 and -23 infected groups from 3 to 20 dpi. BTV nucleic acid was detected in the infected brain tissues from as early as 24 h up to 20 dpi by VP7 gene segment-based one-step reverse transcriptase polymerase chain reaction. This study of the relative neurovirulence of BTV serotypes is likely to help design suitable vaccination and control strategies for the disease. (C) 2018 Elsevier Ltd. All rights reserved.	[Anjaneya, A.; Singh, K. P.] ICAR Indian Vet Res Inst, Ctr Anim Dis Res & Diagn, Bareilly 243122, Uttar Pradesh, India; [Cherian, S.; Saminathan, M.; Singh, R.] ICAR Indian Vet Res Inst, Div Pathol, Bareilly 243122, Uttar Pradesh, India; [Ramakrishnan, M. A.] ICAR Indian Vet Res Inst, Reg Stn, Mukteswar, Uttarkhand, India; [Maan, S.; Maan, N. S.] LLR Univ Vet & Anim Sci, Hisar, Haryana, India; [Hemadri, D.] Natl Inst Vet Epidemiol & Dis Informat, Bengaluru, Karnataka, India; [Rao, P. P.] Ella Fdn, Hyderabad, Telangana, India; [Putty, K.] SPV NR Telangana Vet Univ, Hyderabad, Telangana, India; [Krishnajyothi, Y.] Vet Biol & Res Inst, Vijayawada, Andhra Pradesh, India; [Mertens, P. P.] Univ Nottingham, Sch Vet Med & Sci, Nottingham, England	Singh, KP (reprint author), ICAR Indian Vet Res Inst, Ctr Anim Dis Res & Diagn, Bareilly 243122, Uttar Pradesh, India.	karam.singh@rediffmail.com	Ramakrishnan, Muthannan Andavar/Y-3338-2019	Saminathan, Mani/0000-0003-0557-7194	Indo-UK/DBT-BBSRC; ICAR-NICRA; Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar	The authors are grateful for Indo-UK/DBT-BBSRC and ICAR-NICRA projects for funding. The authors also thank the Director, Joint Directors and Head of the Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, for the facilities and support provided to carry out the present work.	Ayanur A, 2016, VET ITAL, V52, P305, DOI [10.12834/VetIt.569.2715.2, 10.12834/Vet|t.569.2715.2]; BARNARD B J H, 1976, Onderstepoort Journal of Veterinary Research, V43, P155; Bommineni YR, 2008, VET REC, V163, P545, DOI 10.1136/vr.163.18.545; Bonneau KR, 2002, VIRUS RES, V84, P59, DOI 10.1016/S0168-1702(01)00415-4; Brewer AW, 1998, ARCH VIROL, V143, P145, DOI 10.1007/s007050050274; Caporale M, 2011, J VIROL, V85, P11479, DOI 10.1128/JVI.05226-11; CARR MA, 1994, J VIROL, V68, P1255; CARR MA, 1995, ARCH VIROL, V140, P915, DOI 10.1007/BF01314967; Channappanavar R, 2012, VET IMMUNOL IMMUNOP, V145, P485, DOI 10.1016/j.vetimm.2011.10.013; Chauhan HC, 2014, REV SCI TECH OIE, V33, P803, DOI 10.20506/rst.33.3.2319; DEMATTOS CCP, 1994, VIROLOGY, V201, P173, DOI 10.1006/viro.1994.1281; ENRIGHT FM, 1980, AM J VET RES, V41, P224; GOULD AR, 1990, VIRUS RES, V17, P31, DOI 10.1016/0168-1702(90)90078-P; GOWLAND G, 1965, BRIT MED BULL, V21, P123, DOI 10.1093/oxfordjournals.bmb.a070379; GROOCOCK CM, 1982, VET MICROBIOL, V7, P189, DOI 10.1016/0378-1135(82)90033-5; Hamblin C, 1998, AUST VET J, V76, P622, DOI 10.1111/j.1751-0813.1998.tb10244.x; HUISMANS H, 1981, ONDERSTEPOORT J VET, V48, P51; Janowicz A, 2015, J VIROL, V89, P5238, DOI 10.1128/JVI.00395-15; Jenckel M, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00016-15; Luedke A J, 1985, Prog Clin Biol Res, V178, P71; Luna LG, 1968, MANUAL HISTOLOGIC ST, P25; Maan NS, 2012, J VIROL, V86, P5404, DOI 10.1128/JVI.00420-12; Maclachlan NJ, 2009, J COMP PATHOL, V141, P1, DOI 10.1016/j.jcpa.2009.04.003; MacLachlan NJ, 2010, VET RES, V41, DOI 10.1051/vetres/2010007; MACLACHLAN NJ, 1983, VET PATHOL, V20, P563, DOI 10.1177/030098588302000508; MACLACHLAN NJ, 1985, VET PATHOL, V22, P415, DOI 10.1177/030098588502200418; Maximova OA, 2008, J VIROL, V82, P5255, DOI 10.1128/JVI.00172-08; Maximova OA, 2010, VACCINE, V28, P8315, DOI 10.1016/j.vaccine.2010.07.070; MELLOR PS, 1990, CURR TOP MICROBIOL, V162, P143; NARAYAN O, 1972, AM J PATHOL, V68, P1; OSBURN BI, 1971, LAB INVEST, V25, P197; PRASAD G, 1994, REV SCI TECH OIE, V13, P935, DOI 10.20506/rst.13.3.809; Prasad G, 2009, BIOL ANIM INFECT, P167, DOI 10.1016/B978-012369368-6.50012-5; Pringle CR, 1999, ARCH VIROL, V144, P421, DOI 10.1007/s007050050515; Ranjan K, 2015, ACTA VIROL, V59, P317, DOI 10.4149/av_2015_04_317; Ranjan K, 2016, J MICROBIOLOGY RELAT, V2, P43; Rao PP, 2016, TRANSBOUND EMERG DIS, V63, pE151, DOI 10.1111/tbed.12258; Reddy Y. K., 2010, Indian Veterinary Journal, V87, P434; REED L. J., 1938, AMER JOUR HYG, V27, P493; RICHARDS WP, 1967, SCIENCE, V156, P530, DOI 10.1126/science.156.3774.530; RICHARDSON C, 1985, AM J VET RES, V46, P1912; Saminathan M, 2016, J EXP BIOL AGRIC SCI, V4, P338, DOI 10.18006/2016.4(3S).338.367; Sanchez-Cordon PJ, 2015, VET MICROBIOL, V177, P95, DOI 10.1016/j.vetmic.2015.02.022; Sanchez-Cordon PJ, 2013, VET MICROBIOL, V166, P184, DOI 10.1016/j.vetmic.2013.05.032; Shaw AE, 2013, J VIROL, V87, P543, DOI 10.1128/JVI.02266-12; Tembhurne PA, 2010, ARCH VIROL, V155, P89, DOI 10.1007/s00705-009-0553-z; Umeshappa CS, 2011, VET IMMUNOL IMMUNOP, V141, P230, DOI 10.1016/j.vetimm.2011.03.005; Umeshappa CS, 2010, VACCINE, V28, P2522, DOI 10.1016/j.vaccine.2010.01.039; van der Sluijs MTW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081429; WALDVOGEL AS, 1986, J GEN VIROL, V67, P765, DOI 10.1099/0022-1317-67-4-765; WALDVOGEL AS, 1987, VET PATHOL, V24, P404, DOI 10.1177/030098588702400507; WALDVOGEL AS, 1992, COMP IMMUNOL MICROB, V15, P53, DOI 10.1016/0147-9571(92)90102-W; WALDVOGEL AS, 1992, J COMP PATHOL, V106, P333, DOI 10.1016/0021-9975(92)90019-Q	53	1	1	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						18	28		10.1016/j.jcpa.2018.06.001			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400003	30060839				2019-10-28	
J	Donovan, TA; Balakrishnan, N; Barbosa, IC; Mccoy, T; Breitschwerdt, EB; Fox, PR				Donovan, T. A.; Balakrishnan, N.; Barbosa, I. Carvalho; McCoy, T.; Breitschwerdt, E. B.; Fox, P. R.			Bartonella spp. as a Possible Cause or Cofactor of Feline Endomyocarditis-Left Ventricular Endocardial Fibrosis Complex	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						Barlonella; cat; endocardial fibrosis; endomyocarditis	IN-SITU HYBRIDIZATION; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY; PANLEUKOPENIA VIRUS; INFECTIOUS-DISEASE; CATS; HENSELAE; MYOCARDITIS; IDENTIFICATION; PATHOGENESIS	Endomyocarditis is a commonly detected post-mortem finding in domestic cats presenting for sudden onset cardiovascular death, yet the aetiology remains unresolved. Cats are documented reservoir hosts for Bartonella henselae, the infectious cause of cat scratch disease in man. Various Bartonella spp. have been associated with culture-negative endocarditis, myocarditis and sudden death in man and animals. We hypothesized that Bartonella spp. DNA could be amplified more often from the hearts of cats with feline endomyocarditis-left ventricular endocardial fibrosis (FEMC-LVEF) complex compared with cats with hypertrophic cardiomyopathy (HCM) or cats with grossly and microscopically unremarkable hearts (designated non-cardiac disease controls). Formalin-fixed and paraffin wax-embedded, cardiac tissues from 60 domestic and purebred cats aged 3 months to 18 years were examined, and histological features were recorded. Cardiac tissue sections were tested for Bartonella DNA using multiple 16-23S intergenic transcribed spacer region polymerase chain reaction (PCR) primer sets, including two Bartonella genera, a Bartonella koehlerae species-specific and a Bartonella vinsonii subsp. berkhoffii-specific assay, followed by DNA sequence confirmation of the species or genotype. Special precautions were taken to avoid DNA cross-contamination between tissues. Bartonella spp. DNA was amplified by PCR and sequenced from 18 of 36 cats (50%) with FEMC-LVEF and 1/12 (8.3%) cats with HCM. Bartonella spp. DNA was not amplified from any non-cardiac disease control hearts. Based on PCR/DNA sequencing, one Bartonella spp. was amplified from 10 cats, while the remaining eight were coinfected with more than one Bartonella spp. To our knowledge, this study represents the first documentation of B. vinsonii subsp. berkhoffii genotype I infection in cats (n = 11). Fluorescence in-situ hybridization testing facilitated visualization of Bartonella bacteria within the myocardium of four of seven PCR-positive FEMC-LVEF hearts. Collectively, these findings support the hypothesis that Bartonella spp. may play a primary role or act as a cofactor in the pathogenesis of FEMC-LVEF. Studies involving cats from other geographical regions and definitive demonstration of Bartonella spp. within regions of inflammation are needed to confirm an association between Bartonella spp. and FEMC-LVEF induced morbidity and mortality in cats. (C) 2018 Elsevier Ltd. All rights reserved.	[Donovan, T. A.] Anim Med Ctr, Dept Anat Pathol, New York, NY 10065 USA; [Balakrishnan, N.] North Carolina Dept Hlth & Human Serv, Clin Microbiol Unit, State Lab Publ Hlth, Raleigh, NC USA; [Barbosa, I. Carvalho; McCoy, T.; Breitschwerdt, E. B.] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC USA; [Barbosa, I. Carvalho; McCoy, T.; Breitschwerdt, E. B.] North Carolina State Univ, Coll Vet Med, Comparat Med Inst, Intracellular Pathogens Res Lab, Raleigh, NC USA; [Fox, P. R.] Anim Med Ctr, Dept Cardiol, New York, NY USA	Donovan, TA (reprint author), Anim Med Ctr, Dept Anat Pathol, New York, NY 10065 USA.	Taryn.Donovan@amcny.org		Breitschwerdt, Edward/0000-0002-3506-0279	North Carolina State University; Caspary Research Institute of the Animal Medical Center; Schiff Foundation; NCSU-CVM Foundation Bartonella/Vector Borne Disease Research Fund	We gratefully acknowledge Ms. A. Ramkissoon for data acquisition, histological specimen preparation and special stains, and Ms. A. Jackson for review of historical data. T. McCoy was supported by a North Carolina State University undergraduate research scholarship. This work was supported by grants from the Caspary Research Institute of the Animal Medical Center, Schiff Foundation and the NCSU-CVM Foundation Bartonella/Vector Borne Disease Research Fund.	Balakrishnan N, 2016, J VET CARDIOL, V18, P271, DOI 10.1016/j.jvc.2016.04.005; Bouhsira E, 2013, APPL ENVIRON MICROB, V79, P7439, DOI 10.1128/AEM.02598-13; Breitschwerdt EB, 2013, J COMP PATHOL, V148, P115, DOI 10.1016/j.jcpa.2012.12.003; Breitschwerdt EB, 2016, VASCULAR RESPONSE PA, P61; Breitschwerdt EB, 2017, VET DERMATOL, V28, P96, DOI 10.1111/vde.12413; Breitschwerdt EB, 2010, J VET EMERG CRIT CAR, V20, P8, DOI 10.1111/j.1476-4431.2009.00496.x; Buchmann AU, 2010, J CLIN MICROBIOL, V48, P3295, DOI 10.1128/JCM.00750-10; Caponetti GC, 2009, AM J CLIN PATHOL, V131, P250, DOI 10.1309/AJCPMNULMO9GPLYU; Chomel BB, 2010, J APPL MICROBIOL, V109, P743, DOI 10.1111/j.1365-2672.2010.04679.x; Chomel BB, 2003, ANN NY ACAD SCI, V990, P267, DOI 10.1111/j.1749-6632.2003.tb07376.x; Chomel BB, 2003, J CLIN MICROBIOL, V41, P5337, DOI 10.1128/JCM.41.11.5337-5339.2003; Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952; Chomel BB, 2009, ANN NY ACAD SCI, V1166, P120, DOI 10.1111/j.1749-6632.2009.04523.x; Dixon-Jimenez A, 2011, J AM ANIM HOSP ASSOC, V47, pE121, DOI 10.5326/JAAHA-MS-5568; Dubey JP, 1996, VET PATHOL, V33, P290, DOI 10.1177/030098589603300305; Elsheikha Hany M., 2006, Journal of the Egyptian Society of Parasitology, V36, P1071; Fox Philip R, 2004, J Vet Cardiol, V6, P25, DOI 10.1016/S1760-2734(06)70061-3; Fox PR, 2018, J VET INTERN MED, V32, P930, DOI 10.1111/jvim.15122; Fox Philip R, 2003, J Vet Cardiol, V5, P39, DOI 10.1016/S1760-2734(06)70051-0; Fox PR, 2014, CARDIOVASC PATHOL, V23, P28, DOI 10.1016/j.carpath.2013.08.001; Guptill L, 1997, J INFECT DIS, V176, P206, DOI 10.1086/514026; Hur K, 2001, VET REC, V149, P490, DOI 10.1136/vr.149.16.490; Kimura Y, 2016, J COMP PATHOL, V155, P190, DOI 10.1016/j.jcpa.2016.06.003; Kordick DL, 1998, EMERG INFECT DIS, V4, P325, DOI 10.3201/eid0402.980225; KORDICK DL, 1995, J CLIN MICROBIOL, V33, P3245; Kordick DL, 1999, J CLIN MICROBIOL, V37, P1536; Kornreich BG, 2012, J COMP PATHOL, V146, P298, DOI 10.1016/j.jcpa.2011.07.006; Liu S K, 1975, Recent Adv Stud Cardiac Struct Metab, V10, P681; Liu S K, 1985, Heart Vessels Suppl, V1, P122, DOI 10.1007/BF02072377; LIU SK, 1993, AM J CARDIOL, V72, P944, DOI 10.1016/0002-9149(93)91112-U; LIU SK, 1984, J AM VET MED ASSOC, V185, P52; LIU SK, 1981, AM J PATHOL, V102, P388; Rolim VM, 2016, J COMP PATHOL, V154, P3, DOI 10.1016/j.jcpa.2015.10.180; Malik R, 1999, J Feline Med Surg, V1, P171, DOI 10.1016/S1098-612X(99)90206-1; Matsuu A, 2007, J VET MED SCI, V69, P1171, DOI 10.1292/jvms.69.1171; McEndaffer L, 2017, VET PATHOL, V54, P669, DOI 10.1177/0300985817695516; Merrell DS, 2004, NATURE, V430, P250, DOI 10.1038/nature02760; Meurs KM, 2000, CARDIOVASC PATHOL, V9, P119, DOI 10.1016/S1054-8807(00)00031-4; Mylonakis ME, 2014, VET MICROBIOL, V174, P272, DOI 10.1016/j.vetmic.2014.08.035; Nakamura Reid K, 2011, J Vet Cardiol, V13, P277, DOI 10.1016/j.jvc.2011.08.004; Nelson CA, 2017, ZOONOSES PUBLIC HLTH, V9, P119; Nicklas JL, 2010, J CLIN MICROBIOL, V48, P2814, DOI 10.1128/JCM.00916-09; Palerme JS, 2016, J VET CARDIOL, V18, P213, DOI 10.1016/j.jvc.2016.04.003; Payne JR, 2013, J VET INTERN MED, V27, P1427, DOI 10.1111/jvim.12215; Payne JR, 2015, J VET CARDIOL, V17, pS244, DOI 10.1016/j.jvc.2015.03.008; Perez C, 2010, J FELINE MED SURG, V12, P483, DOI 10.1016/j.jfms.2009.12.018; Pesavento PA, 2005, VET PATHOL, V42, P370, DOI 10.1354/vp.42-3-370; Petersen BL, 2004, APPL IMMUNOHISTO M M, V12, P259, DOI 10.1097/00129039-200409000-00013; Pultorak EL, 2015, J COMP PATHOL, V153, P14, DOI 10.1016/j.jcpa.2015.04.001; Regier Y, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1546-x; Simpson KE, 2005, J FELINE MED SURG, V7, P203, DOI 10.1016/j.jfms.2004.08.004; STALIS IH, 1995, VET PATHOL, V32, P122, DOI 10.1177/030098589503200204; Sura R, 2008, VET REC, V162, P450, DOI 10.1136/vr.162.14.450; Varanat M, 2012, VET PATHOL, V49, P608, DOI 10.1177/0300985811404709; Varanat M, 2009, VET PATHOL, V46, P940, DOI 10.1354/vp.08-VP-0259-B-BC; YAMAGUCHI RA, 1983, J AM VET MED ASSOC, V183, P118	56	4	4	2	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						29	42		10.1016/j.jcpa.2018.05.002			14	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400004	30060840				2019-10-28	
J	Nordio, L; Fattori, S; Vascellari, M; Giudice, C				Nordio, L.; Fattori, S.; Vascellari, M.; Giudice, C.			Evidence of Vasculogenic Mimicry in a Palpebral Melanocytoma in a Dog	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; immunohistochemistry; melanocytoma; vasculogenic mimicry	MELANOMA; CANCER; ANGIOGENESIS; TUMORS; CELLS	A 7-year-old neutered female Doberman pinscher was presented with a palpebral nodule on the haired eyelid of the left eye. The nodule was removed surgically. Microscopically, the nodule was consistent with eyelid melanocytoma. The tumour was characterized by the presence of numerous lacunar and slit-like spaces filled by erythrocytes and interspersed throughout the neoplastic melanocytes. Immunohistochemically, these spaces were lined by cells expressing PNL2 and factor VIII, but the cells were negative for CD31. These findings were consistent with neoplastic melanocytes without endothelial cell participation. This feature was interpreted as 'vasculogenic mimicry', a mechanism of tumour angiogenesis that is well-recognized in human melanomas, but has not yet been reported in melanomas in animals. (C) 2018 Elsevier Ltd. All rights reserved.	[Nordio, L.; Giudice, C.] Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy; [Vascellari, M.] Ist Zooprofilatt Sperimentale Venezie, Lab Histopathol, Viale Univ 10, Legnaro, Italy	Nordio, L (reprint author), Univ Milan, Dept Vet Med, Via Celoria 10, Milan, Italy.	laura.nordio@unimi.it	Nordio, Laura/Q-4529-2019; GIUDICE, CHIARA/I-7842-2012	Nordio, Laura/0000-0002-6511-4071; GIUDICE, CHIARA/0000-0001-9195-4085; Vascellari, Marta/0000-0002-4537-4386			Clemente M, 2010, VET PATHOL, V47, P265, DOI 10.1177/0300985809353167; Demitsu Toshio, 1998, Journal of Dermatology (Tokyo), V25, P143; Guo JQ, 2014, INT J ONCOL, V45, P1065, DOI 10.3892/ijo.2014.2500; Hendrix MJC, 2016, PHARMACOL THERAPEUT, V159, P83, DOI 10.1016/j.pharmthera.2016.01.006; Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Pulford E, 2016, PATHOLOGY, V48, P650, DOI 10.1016/j.pathol.2016.07.009; Rasotto R, 2012, VET PATHOL, V49, P330, DOI 10.1177/0300985811409253; Spiliopoulos K, 2017, ANTICANCER RES, V37, P1113, DOI 10.21873/anticanres.11424; Spiliopoulos K, 2015, IN VIVO, V29, P309; Wang H, 2016, J CANCER, V7, P1114, DOI 10.7150/jca.14120; Zang MD, 2015, BBA-MOL BASIS DIS, V1852, P1020, DOI 10.1016/j.bbadis.2015.02.005; Zhao N, 2015, INT J CLIN EXP PATHO, V8, P15759	13	2	2	1	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						43	46		10.1016/j.jcpa.2018.06.003			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400005	30060841				2019-10-28	
J	Kokosinska, A; Rissi, DR				Kokosinska, A.; Rissi, D. R.			Diffuse Infiltrative Colonic Lipomatosis in a Vietnamese Pot-bellied Pig	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						diffuse infiltrative colonic lipomatosis; gastrointestinal lipomatosis; pig		Diffuse infiltrative gastrointestinal lipomatosis (DIGIL) is characterized by widespread proliferation of adipose tissue within the submucosal and subserosal layers of the gastrointestinal tract. Here we describe a case of diffuse infiltrative colonic lipomatosis in a 3-year-old male Vietnamese pot-bellied pig. Gross anatomical changes included obesity with sparse small intestinal contents and no colonic contents. The colonic lumen was narrowed and the colonic wall was diffusely thickened (similar to 5 mm), white, homogeneous and soft. Other findings were vesical uroliths and mild fibrinous pneumonia. Histologically, the colonic submucosa and muscle layers were expanded and almost completely replaced by sheets of adipose tissue admixed with scant fibrovascular tissue. Other minor changes included mild fibrinous pneumonia, splenic lymphoid depletion and testicular atrophy. The colonic changes in the current case are consistent with those described for DIGIL. This is a rare condition in human beings and animals and has never been described in pigs. (C) 2018 Elsevier Ltd. All rights reserved.	[Kokosinska, A.; Rissi, D. R.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA; [Rissi, D. R.] Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA	Rissi, DR (reprint author), Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA.; Rissi, DR (reprint author), Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA.	rissi@uga.edu					Beninson JA, 2015, COMPARATIVE MED, V65, P420; ELSEBAIE A, 1995, BERL MUNCH TIERARZTL, V108, P427; Garcia-Seco E, 2005, JAVMA-J AM VET MED A, V226, P1529, DOI 10.2460/javma.2005.226.1529; HENRY GA, 1995, J VET DIAGN INVEST, V7, P578, DOI 10.1177/104063879500700435; Jeong IH, 2010, J GASTRIC CANCER, V10, P254, DOI 10.5230/jgc.2010.10.4.254; Komagata Takanobu, 2007, Radiat Med, V25, P480, DOI 10.1007/s11604-007-0162-2; MARGOLIN FR, 1980, GASTROINTEST RADIOL, V5, P59, DOI 10.1007/BF01888602; Reed SD, 2010, VET MED INT, V2010; Sandhu PS, 2011, INDIAN J SURG, V73, P155, DOI 10.1007/s12262-010-0204-3; Tatsuguchi A, 1999, GASTROINTEST ENDOSC, V49, P118, DOI 10.1016/S0016-5107(99)70460-8; Uzal F.A., 2016, JUBB KENNEDY PALMERS, V2, P1, DOI [10.1016/B978-0-7020-5318-4.00007-3, DOI 10.1016/B978-0-7020-5318-4.00007-3]; VITOVEC J, 1975, J COMP PATHOL, V85, P53, DOI 10.1016/0021-9975(75)90084-5	12	0	0	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						47	49		10.1016/j.jcpa.2018.06.002			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400006	30060842				2019-10-28	
J	Kim, SH; Seung, BJ; Cho, SH; Lim, HY; Hwang, JH; Sur, JH				Kim, S. -H.; Seung, B. -J.; Cho, S. -H.; Lim, H. -Y.; Hwang, J. -H.; Sur, J. -H.			Expression of Oestrogen Receptor, Progesterone Receptor and Akt in Canine Circumanal Gland Tumours	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						circumanal gland tumours; dog; immunohistochemistry; sex steroid hormone receptor	NEGATIVE BREAST-CANCER; MAMMARY-TUMORS; ANDROGEN RECEPTOR; PERIANAL GLAND; GROWTH-HORMONE; PATHWAY; ACTIVATION; ALPHA	We investigated the expression of oestrogen receptor alpha (OR-alpha), progesterone receptor (PR) and Akt in canine circumanal gland tumours. Immunohistochemistry was conducted on seven normal circumanal glands, 30 circumanal gland adenomas and 40 circumanal gland carcinomas. The expression of OR-alpha and PR was significantly lower in circumanal gland carcinomas than in circumanal gland adenomas. In contrast, the expression of Akt was markedly higher in circumanal gland carcinomas than in circumanal gland adenomas. These results indicate that the progression of canine circumanal gland tumours is influenced by changes in the expression levels of OR-alpha, PR and Akt. Identifying the molecular mechanisms of canine circumanal gland tumours requires further study. (C) 2018 Elsevier Ltd. All rights reserved.	[Kim, S. -H.; Seung, B. -J.; Cho, S. -H.; Lim, H. -Y.; Hwang, J. -H.; Sur, J. -H.] Konkuk Univ, Coll Vet Med, Dept Vet Pathol, Small Anim Tumour Diagnost Ctr, 120 Neungdong Ro, Seoul, South Korea	Sur, JH (reprint author), Konkuk Univ, Coll Vet Med, Dept Vet Pathol, Small Anim Tumour Diagnost Ctr, 120 Neungdong Ro, Seoul, South Korea.	jsur@konkuk.ac.kr		Sur, Jung-Hyang/0000-0003-4496-7582	Bio & Medical Technology Development Program of the NRF - Korean government, MSIT [2016M3A9B6903437]	The authors thank Ms. E.-M. Yu for technical assistance and the participating private veterinary clinics for providing access to tissue samples. This work was supported by the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIT [grant number 2016M3A9B6903437]	Baker KP, 1967, THESIS; Berrocal A, 1989, Zentralbl Veterinarmed A, V36, P739; Bhat-Nakshatri P, 2008, MOL CELL BIOL, V28, P7487, DOI 10.1128/MCB.00799-08; Campos M, 2014, J VET INTERN MED, V28, P1814, DOI 10.1111/jvim.12435; CHAISIRI N, 1979, J SMALL ANIM PRACT, V20, P405, DOI 10.1111/j.1748-5827.1979.tb06745.x; Chang CC, 2009, JAVMA-J AM VET MED A, V235, P391, DOI 10.2460/javma.235.4.391; Check JH, 2017, EXPERT REV ENDOCRINO, V12, P187, DOI 10.1080/17446651.2017.1314783; Chen YT, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-73; de las Mulas JM, 2005, VET PATHOL, V42, P200, DOI 10.1354/vp.42-2-200; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Goldschmidt MH, 1998, WHO INT HISTOLOGICAL, P26; Goldschmidt MH, 2016, TUMORS DOMESTIC ANIM, P88, DOI [DOI 10.1002/9781119181200.CH4, 10.1002/9781119181200.ch4]; Gracanin A, 2012, REPROD DOMEST ANIM, V47, P313, DOI 10.1111/rda.12045; Ha S, 2011, ENDOCR-RELAT CANCER, V18, P245, DOI 10.1530/ERC-10-0204; HAYES HM, 1977, CANCER RES, V37, P2068; Lee I, 2016, ONCOGENE, V35, P5191, DOI 10.1038/onc.2016.56; Leslie KK, 2005, GYNECOL ONCOL, V96, P32, DOI 10.1016/j.ygyno.2004.09.057; MAITA K, 1975, JPN J VET SCI, V37, P349; Mikhailova M, 2008, ADV EXP MED BIOL, V617, P397, DOI 10.1007/978-0-387-69080-3_38; Mundi PS, 2016, BRIT J CLIN PHARMACO, V82, P943, DOI 10.1111/bcp.13021; NIELSEN SW, 1964, J AM VET MED ASSOC, V144, P127; Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239; Pakhrin B, 2007, J VET SCI, V8, P229, DOI 10.4142/jvs.2007.8.3.229; Pena L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388; Petterino C, 2004, J VET MED SCI, V66, P569, DOI 10.1292/jvms.66.569; Pisani G, 2006, RES VET SCI, V81, P231, DOI 10.1016/j.rvsc.2005.11.001; Platet N, 2004, CRIT REV ONCOL HEMAT, V51, P55, DOI 10.1016/j.critrevonc.2004.02.001; Rodriguez S, 2012, J COMP PATHOL, V147, P171, DOI 10.1016/j.jcpa.2011.12.003; SARTIN EA, 1992, AM J VET RES, V53, P2196; Tsai EM, 2001, CANCER RES, V61, P8390; vanGarderen E, 1997, AM J PATHOL, V150, P1037; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; WILSON GP, 1979, J AM VET MED ASSOC, V174, P1301; Withrow SJ, 2012, WITHROW MACEWENS SMA, P305	35	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JUL	2018	162						59	65		10.1016/j.jcpa.2018.06.006			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GQ4PO	WOS:000441655400008	30060844				2019-10-28	
J	Liang, YX; Naber, SP; Chatterjee, A				Liang, Yuanxin; Naber, Stephen P.; Chatterjee, Abhishek			Anatomic and terminological description and processing of breast pathologic specimens from oncoplastic large volume displacement surgeries	MODERN PATHOLOGY			English	Review							CONSERVING SURGERY; CANCER PATIENTS; CONSERVATION; OUTCOMES; MASTECTOMY; QUADRANT; MARGINS	Oncoplastic surgery provides breast cancer patients with greater aesthetic satisfaction without compromising disease-free survival or overall survival rate. Large volume displacement oncoplastic surgical techniques have become increasingly popular as a strategy for improving aesthetic outcomes and extending the option of breast conservation therapy. They often involve breast reduction or mastopexy reconstructive techniques to facilitate resection of large breast volumes on the side of the breast cancer and accompanied with symmetry contralateral breast reductions or mastopexies. However, dissection of large volume displacement oncoplastic surgical specimens presents unique challenges. Compared with traditional mastectomy specimens, they are relatively complicated, which requires the pathologist to understand the surgical procedure and the anatomy of the specimens. Given this, we introduce the standard anatomical and terminological description for the breast pathologic specimens of five large volume displacement oncoplastic surgical techniques commonly performed in our institution for breast cancer management. The individual surgical specimen is composed of one or several components, which include lateral wall, superior keyhole, medial wall, lateral wing, inferior pole, and medial wing. We also present specimen documentation and sectioning procedures used in our institution. The advantages for the patient provided by large volume reduction oncoplastic surgery must be supported by proper evaluation of the surgical pathology specimen. Therefore, we recommend that each section taken from the oncoplastic specimen be labeled as to its specific location in the specimen components. Standardized nomenclature and technique will assist pathologists in accurately evaluating the surgical margins.	[Liang, Yuanxin; Naber, Stephen P.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA; [Chatterjee, Abhishek] Tufts Med Ctr, Dept Surg, Boston, MA USA	Naber, SP (reprint author), Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA 02111 USA.	snaber@tuftsmedicalcenter.org					Anderson BO, 2005, LANCET ONCOL, V6, P145, DOI 10.1016/S1470-2045(05)01765-1; Audretsch W., 1998, SURG BREAST PRINCIPL, P155; Barnea Y, 2014, CAN J SURG, V57, pE134, DOI 10.1503/cjs.031213; Carter SA, 2016, ANN SURG ONCOL, V23, P3190, DOI 10.1245/s10434-016-5407-9; Chatterjee A, 2016, PPRS PSRC PODIUMPROO, V4, P35; Chatterjee A, 2018, GLAND SURG, V7, P366, DOI 10.21037/gs.2017.10.09; Chatterjee A, 2017, CANCER CONTROL, V24, DOI 10.1177/1073274817729043; Clough KB, 2012, BRIT J SURG, V99, P1389, DOI 10.1002/bjs.8877; Clough KB, 2015, ANN SURG ONCOL, V22, P4247, DOI 10.1245/s10434-015-4514-3; Clough KB, 2010, ANN SURG ONCOL, V17, P1375, DOI 10.1245/s10434-009-0792-y; Crown A, 2015, ANN SURG ONCOL, V22, P3363, DOI 10.1245/s10434-015-4738-2; De La Cruz L, 2016, ANN SURG ONCOL, V23, P3247, DOI 10.1245/s10434-016-5313-1; Franceschini G, 2015, G CHIR, V36, P145, DOI 10.11138/gchir/2015.36.4.145; Hansen JE, 2016, CLIN PLAST SURG, V43, P349, DOI 10.1016/j.cps.2015.12.003; Huo L, 2011, ANN DIAGN PATHOL, V15, P291, DOI 10.1016/j.anndiagpath.2011.03.005; Institute NC, 2016, SEER STAT FACT SHEET; Losken A, 2017, PLAST RECONSTR SURG, V140, p14S, DOI 10.1097/PRS.0000000000003951; Losken A, 2014, ANN PLAS SURG, V72, P145, DOI 10.1097/SAP.0b013e3182605598; Losken A, 2012, PLAST RECONSTR SURG, V129, p382E, DOI 10.1097/PRS.0b013e31823aef32; Moran MS, 2014, INT J RADIAT ONCOL, V88, P553, DOI 10.1016/j.ijrobp.2013.11.012; Morrow M, 2016, J CLIN ONCOL, V34, P4040, DOI 10.1200/JCO.2016.68.3573; Piper ML, 2016, ANN PLAS SURG, V76, pS222, DOI 10.1097/SAP.0000000000000720; Spear SL, 2011, SURG BREAST PRINCIPL; van Deventer PV, 2016, PLAST RECONSTR SURG, V137, P1388, DOI 10.1097/PRS.0000000000002048; Yang JD, 2012, J BREAST CANCER, V15, P1, DOI 10.4048/jbc.2012.15.1.1	25	3	3	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1004	1011		10.1038/s41379-018-0020-z			8	Pathology	Pathology	GP1HY	WOS:000440567300001	29449682				2019-10-28	
J	Agahozo, MC; Hammerl, D; Debets, R; Kok, M; van Deurzen, CHM				Agahozo, Marie Colombe; Hammerl, Dora; Debets, Reno; Kok, Marleen; van Deurzen, Carolien H. M.			Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?	MODERN PATHOLOGY			English	Review							TERTIARY LYMPHOID STRUCTURES; INFLAMMATORY CELL INFILTRATE; PROGNOSTIC-SIGNIFICANCE; T-LYMPHOCYTES; NEOADJUVANT CHEMOTHERAPY; IMMUNE MICROENVIRONMENT; INVASIVE-CARCINOMA; CANCER SUBTYPES; B-LYMPHOCYTES; GRADE	In the past three decades, the detection rate of ductal carcinoma in situ of the breast has dramatically increased due to breast screening programs. As a consequence, about 20% of all breast cancer cases are detected in this early in situ stage. Some ductal carcinoma in situ cases will progress to invasive breast cancer, while other cases are likely to have an indolent biological behavior. The presence of tumor-infiltrating lymphocytes is seen as a promising prognostic and predictive marker in invasive breast cancer, mainly in HER2-positive and triple-negative subtypes. Here, we summarize the current understanding regarding immune infiltrates in invasive breast cancer and highlight recent observations regarding the presence and potential clinical significance of such immune infiltrates in patients with ductal carcinoma in situ. The presence of tumor-infiltrating lymphocytes, their numbers, composition, and potential relationship with genomic status will be discussed. Finally, we propose that a combination of genetic and immune markers may better stratify ductal carcinoma in situ subtypes with respect to tumor evolution.	[Agahozo, Marie Colombe; van Deurzen, Carolien H. M.] Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands; [Hammerl, Dora; Debets, Reno] Erasmus MC Canc Inst, Dept Med Oncol, Lab Tumor Immunol, Rotterdam, Netherlands; [Kok, Marleen] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Kok, Marleen] Netherlands Canc Inst, Dept Immunol, Amsterdam, Netherlands	Agahozo, MC (reprint author), Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands.	m.agahozo@erasmusmc.nl			BMSBristol-Myers Squibb	MK: Unrestricted research grant of BMS to the institute, travel support by Roche to the institute. The remaining authors declare that they have no conflict of interest.	AALTOMAA S, 1992, EUR J CANCER, V28A, P859, DOI 10.1016/0959-8049(92)90134-N; Abba MC, 2016, CANC RES TUMOR STEM, V18, P3980; Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Allen MD, 2015, INT J ONCOL, V47, P797, DOI 10.3892/ijo.2015.3075; Angelova M, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0620-6; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Baker K, 2011, HISTOPATHOLOGY, V58, P1107, DOI 10.1111/j.1365-2559.2011.03846.x; Barnes NLP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e797; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Bense RD, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw192; Bleyer A, 2012, NEW ENGL J MED, V367, P1998, DOI 10.1056/NEJMoa1206809; Bogels M, 2012, ONCOIMMUNOLOGY, V1, P798, DOI 10.4161/onci.20427; Brown JP, 2012, DIAGN HISTOPATHOL, V18, P112, DOI DOI 10.1016/j.mpdhp.2012.01.001; Budczies J, 2015, J PATHOL CLIN RES, V1, P225, DOI 10.1002/cjp2.25; Burugu S, 2017, BREAST CANCER-TOKYO, V24, P3, DOI 10.1007/s12282-016-0698-z; Calabro A, 2009, BREAST CANCER RES TR, V116, P69, DOI 10.1007/s10549-008-0105-3; Campbell MJ, 2017, BREAST CANCER RES TR, V161, P17, DOI 10.1007/s10549-016-4036-0; Campbell MJ, 2011, BREAST CANCER RES TR, V128, P703, DOI 10.1007/s10549-010-1154-y; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chivukula M, 2009, APPL IMMUNOHISTO M M, V17, P495, DOI 10.1097/PAI.0b013e3181a1743a; Clark SE, 2010, BRIT J CANCER, V104, P120; Collins LC, 2005, CANCER-AM CANCER SOC, V103, P1778, DOI 10.1002/cncr.20979; Czerniecki BJ, 2007, CANCER RES, V67, P6531, DOI 10.1158/0008-5472.CAN-07-0878; de la Cruz-Merino L, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/785317; Del Alcazar CRG, 2017, CANCER DISCOV, V7, P1098, DOI 10.1158/2159-8290.CD-17-0222; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006; Doebar SC, 2016, BREAST CANCER RES TR, V158, P179, DOI 10.1007/s10549-016-3862-4; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dushyanthen S, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0431-3; Figenschau SL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1116-1; Fracol M, 2013, ANN SURG ONCOL, V20, P3233, DOI 10.1245/s10434-013-3119-y; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gisterek I, 2008, REP PRACT ONCOL RADI, V13, P206, DOI 10.1016/S1507-1367(10)60011-9; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428; Hammerl D, 2017, SEMIN CANCER BIOL, V6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hendrickx W, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1253654; Hendry S, 2017, CLIN CANCER RES, V23, P5210, DOI 10.1158/1078-0432.CCR-17-0743; Hussein MR, 2006, J CLIN PATHOL, V59, P972, DOI 10.1136/jcp.2005.031252; Kim A, 2016, AM J CLIN PATHOL, V146, P137, DOI 10.1093/ajcp/aqw097; Knopfelmacher A, 2015, MODERN PATHOL, V28, P1167, DOI 10.1038/modpathol.2015.79; Lal A, 2013, BREAST CANCER RES TR, V139, P381, DOI 10.1007/s10549-013-2556-4; Lee AHS, 2006, HISTOPATHOLOGY, V48, P692, DOI 10.1111/j.1365-2559.2006.02410.x; Lee AHS, 1997, J PATHOL, V181, P200; Lee HJ, 2016, J CLIN PATHOL, V69, P422, DOI 10.1136/jclinpath-2015-203089; Lee HJ, 2013, J BREAST CANCER, V16, P32, DOI 10.4048/jbc.2013.16.1.32; Liu FF, 2011, BREAST CANCER RES TR, V130, P645, DOI 10.1007/s10549-011-1647-3; Liu S, 2012, BREAST CANCER RES, V48, P14; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Lowenfeld L, 2016, CLIN CANCER RES, P1924; Luen S, 2016, BREAST, V29, P241, DOI 10.1016/j.breast.2016.07.015; Mahmoud SMA, 2012, BREAST CANCER RES TR, V132, P545, DOI 10.1007/s10549-011-1620-1; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mahmoud SMA, 2011, BREAST CANCER RES TR, V127, P99, DOI 10.1007/s10549-010-0987-8; Mao YP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161506; Markowitz J, 2013, BREAST CANCER RES TR, V140, P13, DOI 10.1007/s10549-013-2618-7; Martinet L, 2011, CANCER RES, V71, P5678, DOI 10.1158/0008-5472.CAN-11-0431; Menard S, 1997, CLIN CANCER RES, V3, P817; Miligy I, 2017, HISTOPATHOLOGY, V71, P258, DOI 10.1111/his.13217; Miyashita M, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0632-x; Mohammed ZMA, 2012, BRIT J CANCER, V107, P864, DOI 10.1038/bjc.2012.347; Mohammed ZMA, 2012, CANCER TREAT REV, V38, P943, DOI 10.1016/j.ctrv.2012.04.011; Morita M, 2016, CANC MED, V5, P1; Oda N, 2012, BREAST CANCER RES TR, V136, P107, DOI 10.1007/s10549-012-2245-8; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Parise CA, 2014, J CANCER EPIDEMIOL, DOI 10.1155/2014/469251; Perez EA, 2015, J CLIN ONCOL, V33, P701, DOI 10.1200/JCO.2014.57.6298; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pruneri G, 2017, ANN ONCOL, V28, P321, DOI 10.1093/annonc/mdw623; Pupa SM, 1996, J CLIN ONCOL, V14, P85, DOI 10.1200/JCO.1996.14.1.85; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Rody A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2234; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sanders ME, 2005, CANCER, V103, P2481, DOI 10.1002/cncr.21069; Sautes-Fridman C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00407; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Scholl S, 1996, BREAST, V5, P21, DOI 10.1016/S0960-9776(96)90045-4; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Semeraro M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1218106; Seo AN, 2013, BRIT J CANCER, V109, P2705, DOI 10.1038/bjc.2013.634; Shah SP, 2012, NATURE, V486, P486; Sharma A, 2012, CANCER-AM CANCER SOC, V118, P4354, DOI 10.1002/cncr.26734; Sharma M, 2010, BREAST CANCER RES TR, V123, P397, DOI 10.1007/s10549-009-0654-0; Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0621-0; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Thompson E, 2016, MODERN PATHOL, V29, P249, DOI 10.1038/modpathol.2015.158; Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324; Vincent-Salomon A, 2008, CLIN CANCER RES, V14, P1956, DOI 10.1158/1078-0432.CCR-07-1465; Virnig Beth A., 2010, Journal of the National Cancer Institute Monographs, P113, DOI 10.1093/jncimonographs/lgq024; Wasserman JK, 2015, AM J CLIN PATHOL, V144, P503, DOI 10.1309/AJCPW4EADZ9BNXXM; West NR, 2013, BRIT J CANCER, V108, P155, DOI 10.1038/bjc.2012.524; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zhang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031230; Zhou W, 2012, BMC CANCER, V512, P1	105	7	7	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1012	1025		10.1038/s41379-018-0030-x			14	Pathology	Pathology	GP1HY	WOS:000440567300002	29463884				2019-10-28	
J	Roy-Chowdhuri, S; Mehrotra, M; Bolivar, AM; Kanagal-Shamanna, R; Barkoh, BA; Hannigan, B; Zalles, S; Ye, WR; Duose, D; Broaddus, R; Staerkel, G; Wistuba, I; Medeiros, LJ; Luthra, R				Roy-Chowdhuri, Sinchita; Mehrotra, Meenakshi; Bolivar, Ana Maria; Kanagal-Shamanna, Rashmi; Barkoh, Bedia A.; Hannigan, Brette; Zalles, Stephanie; Ye, Wenrui; Duose, Dzifa; Broaddus, Russell; Staerkel, Gregg; Wistuba, Ignacio; Medeiros, L. Jeffrey; Luthra, Rajyalakshmi			Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling	MODERN PATHOLOGY			English	Article							FINE-NEEDLE-ASPIRATION; CELL LUNG-CANCER; CYTOLOGY SPECIMENS; INSTITUTIONAL EXPERIENCE; ORGAN MALIGNANCIES; MASS LESIONS; SAMPLES; FLUID; FNA; SUCCESS	With the expanding role of targeted therapy in patients with solid tumors, pathologists face the daunting task of having to maximize limited volume tissue obtained by fine needle aspiration for a variety of molecular tests. While most molecular studies on fine needle aspiration samples have been reported using cellular material, recent studies have shown that a substantial amount of DNA can be retrieved from the supernatant fluid of aspirate needle rinses after cell pelleting for cytospin or cell block preparations. In routine clinical workflow, the supernatant is discarded; however this fluid may provide a complementary source of DNA for tumor mutational profiling. In this study, we evaluated the post-centrifuged supernatant from 25 malignant and 10 benign fine needle aspiration needle rinses. The mean and median DNA yields from the supernatants were 445 ng and 176.4 ng (range, 15.1-2958 ng), respectively. Next generation sequencing using the Ion AmpliSeq Cancer Hotspot Panel v2 detected somatic mutations in all 25 malignant samples. No mutations were detected in any of the benign samples tested. When available, mutations detected in the supernatant fluid were compared to the next generation sequencing analysis performed on a prior or concurrent surgical specimen from the same patient and showed 100% concordance. In a subset of cases (n = 19) mutations in EGFR, KRAS, BRAF, PIK3CA, and NRAS were successfully confirmed by droplet digital PCR, providing an orthogonal platform for mutation analysis. In summary, in this study we show that post centrifuged supernatants from fine needle aspiration needle rinses can provide a robust substrate for expanded mutation profiling by next generation sequencing, as well as hotspot mutation testing by droplet digital PCR. The ability to detect somatic mutations from otherwise discarded supernatant fluids offers the ability to triage and effectively utilize limited volume fine needle aspiration samples when multiple molecular tests are requested, without the need to re-biopsy for additional tissue samples.	[Roy-Chowdhuri, Sinchita; Broaddus, Russell; Staerkel, Gregg] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA; [Mehrotra, Meenakshi; Kanagal-Shamanna, Rashmi; Barkoh, Bedia A.; Medeiros, L. Jeffrey; Luthra, Rajyalakshmi] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Div Pathol & Lab Med, Houston, TX 77030 USA; [Bolivar, Ana Maria; Hannigan, Brette; Zalles, Stephanie; Ye, Wenrui] Univ Texas MD Anderson Canc Ctr, Sch Hlth Profess, Diagnost Genet, Houston, TX 77030 USA; [Duose, Dzifa; Wistuba, Ignacio; Luthra, Rajyalakshmi] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA	Roy-Chowdhuri, S (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA.	sroy2@mdanderson.org	Medeiros, L. Jeffrey/AAB-1018-2019	Bolivar, Ana M/0000-0001-5664-9659	University of Texas MD Anderson Cancer Center Shirley Stein Scientific Endowed Research Award	This work was supported in part by The University of Texas MD Anderson Cancer Center Shirley Stein Scientific Endowed Research Award. We want to thank Kim-Anh Vu for technical assistance with graphics design.	Aisner DL, 2016, ARCH PATHOL LAB MED, V140, P1206, DOI 10.5858/arpa.2016-0156-RA; Baum JE, 2017, CANCER CYTOPATHOL, V125, P398, DOI 10.1002/cncy.21844; Bellevicine C, 2016, CANCER CYTOPATHOL, V124, P776, DOI 10.1002/cncy.21780; Billah S, 2011, CANCER CYTOPATHOL, V119, P111, DOI 10.1002/cncy.20151; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Brown AE, 2017, CYTOJOURNAL, V13, DOI 10.4103/1742-6413.200935; Chen H, 2015, CANCERS, V7, P1699, DOI 10.3390/cancers7030859; Coley SM, 2015, CANCER CYTOPATHOL, V123, P318, DOI 10.1002/cncy.21527; Deftereos G, 2014, MODERN PATHOL, V27, P594, DOI 10.1038/modpathol.2013.147; Finkelstein SD, 2014, DIAGN CYTOPATHOL, V42, P719, DOI 10.1002/dc.23048; Finkelstein SD, 2012, ACTA CYTOL, V56, P439, DOI 10.1159/000339638; Fuller MY, 2017, ARCH PATHOL LAB MED; Gailey MP, 2015, CANCER CYTOPATHOL, V123, P30, DOI 10.1002/cncy.21476; Gleeson FC, 2015, CLIN GASTROENTEROL H, V13, P37, DOI 10.1016/j.cgh.2014.10.017; Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023; Hu YB, 2017, CLIN CANCER RES, V23, P7351, DOI 10.1158/1078-0432.CCR-17-1745; Hwang DH, 2017, CANCER CYTOPATHOL, V125, P786, DOI 10.1002/cncy.21897; Kanagal-Shamanna R, 2014, MODERN PATHOL, V27, P314, DOI 10.1038/modpathol.2013.122; Karnes HE, 2014, CANCER CYTOPATHOL, V122, P104, DOI 10.1002/cncy.21361; Kipp BR, 2012, HUM PATHOL, V43, P1552, DOI 10.1016/j.humpath.2011.12.007; Malhotra N, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-135; Mehrotra M, 2017, J MOL DIAGN, V19, P514, DOI 10.1016/j.jmoldx.2017.03.003; Nikiforov YE, 2014, CANCER-AM CANCER SOC, V120, P3627, DOI 10.1002/cncr.29038; Nikiforova MN, 2013, J CLIN ENDOCR METAB, V98, pE1852, DOI 10.1210/jc.2013-2292; Rekhtman N, 2016, ARCH PATHOL LAB MED, V140, P1189, DOI 10.5858/arpa.2016-0379-ED; Reynolds JP, 2017, CANCER CYTOPATHOL, V125, P178, DOI 10.1002/cncy.21812; Roh MH, 2015, J PATHOL TRANSL MED, V49, P300, DOI 10.4132/jptm.2015.06.16; Roy-Chowdhuri S, 2017, MODERN PATHOL, V30, P499, DOI 10.1038/modpathol.2016.228; Roy-Chowdhuri S, 2016, ARCH PATHOL LAB MED, V140, P1191, DOI 10.5858/arpa.2016-0117-RA; Roy-Chowdhuri S, 2015, CANCER CYTOPATHOL, V123, P659, DOI 10.1002/cncy.21597; Scarpa A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080478; Sukari A, 2017, J NATL COMPR CANC NE, V15, P1188, DOI 10.6004/jnccn.2017.7014; Tian SK, 2016, ARCH PATHOL LAB MED, V140, P1200, DOI 10.5858/arpa.2016-0108-RA; Treece AL, 2016, CANCER CYTOPATHOL, V124, P406, DOI 10.1002/cncy.21699; Underhill HR, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006162; VanderLaan PA, 2015, CANCER CYTOPATHOL, V123, P454, DOI 10.1002/cncy.21560; Velizheva NP, 2017, CANCER CYTOPATHOL, V125, P30, DOI 10.1002/cncy.21771; Vigliar E, 2015, CYTOPATHOLOGY, V26, P271, DOI 10.1111/cyt.12265; Wei SZ, 2016, ENDOCR PATHOL, V27, P359, DOI 10.1007/s12022-016-9446-3; Wei S, 2016, CANCER CYTOPATHOL, V124, P324, DOI 10.1002/cncy.21666; Young G, 2013, CANCER CYTOPATHOL, V121, P688, DOI 10.1002/cncy.21338	41	9	9	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1036	1045		10.1038/s41379-018-0006-x			10	Pathology	Pathology	GP1HY	WOS:000440567300004	29463880	Bronze			2019-10-28	
J	Khanlari, M; Ramos, JC; Sanchez, SP; Cho-Vega, JH; Amador, A; Campuzano-Zuluaga, G; Vega, F; Chapman, JR				Khanlari, Mahsa; Ramos, Juan Carlos; Sanchez, Sandra Patricia; Cho-Vega, Jeong Hee; Amador, Alexandra; Campuzano-Zuluaga, German; Vega, Francisco; Chapman, Jennifer R.			Adult T-cell leukemia/lymphoma can be indistinguishable from other more common T-cell lymphomas. The University of Miami experience with a large cohort of cases	MODERN PATHOLOGY			English	Article							SOUTHERN BLOT ANALYSIS; LEUKEMIA-LYMPHOMA; MYCOSIS-FUNGOIDES; EXPRESSION; FEATURES; INTEGRATION; LESIONS; HTLV-1; FOXP3; ATL	Adult T-cell leukemia/lymphoma, an aggressive T-cell neoplasm, is causally linked to human T-cell lymphotropic virus type 1 and based on this association has a distinct geographic distribution. In our United States-based practice, whose population is enriched for immigrants from human T-cell lymphotropic virus type 1 endemic areas, we have identified that a subset of adult T-cell leukemia/lymphoma, in the absence of human T-cell lymphotropic virus type 1 identification, are indistinguishable from other more common T-cell neoplasms. We retrospectively gathered serology results for antihuman T-cell lymphotropic virus type 1/2 antibody in patients diagnosed with T-cell neoplasms at our institution. A total of 220 human T-cell lymphotropic virus type 1/2 positive patients with T-cell neoplasms were identified; 199 (91%) were correctly classified as adult T-cell leukemia/lymphoma or provisionally as peripheral T-cell lymphoma (serology testing pending). Twenty-one cases (9%) were initially misclassified, including the following: 13 presenting with skin +/-peripheral blood involvement and misclassified as mycosis fungoides/Sezary syndrome; 7 with lymphomatous disease, absence of leukemic involvement, and diffuse CD30 expression, misclassified as ALK-negative anaplastic large-cell lymphoma; 1 thought to represent T-prolymphocytic leukemia with TCL-1 gene rearrangement and diffuse marrow involvement. We also present an example of adult T-cell leukemia/lymphoma, which mimicked lymphoepithelioid variant of peripheral T-cell lymphoma also with diffuse marrow involvement. A subset of adult T-cell leukemia/lymphoma can closely mimic a variety of other more common T-cell neoplasms. Due to its extreme clinicopathologic heterogeneity, identification of adult T-cell leukemia/lymphoma requires a high level of suspicion based on patient demographic alone, which should prompt anti-human T-cell lymphotropic virus type 1/2 serology testing in all T-cell neoplasms developing in patients of appropriate demographic. Absence of high level of suspicion, adult T-cell leukemia/lymphoma is easily misclassified.	[Khanlari, Mahsa; Sanchez, Sandra Patricia; Amador, Alexandra; Campuzano-Zuluaga, German; Vega, Francisco; Chapman, Jennifer R.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol, Div Hematopathol, Miami, FL 33136 USA; [Khanlari, Mahsa; Ramos, Juan Carlos; Sanchez, Sandra Patricia; Cho-Vega, Jeong Hee; Amador, Alexandra; Campuzano-Zuluaga, German; Vega, Francisco; Chapman, Jennifer R.] Jackson Mem Hosp, Miami, FL 33136 USA; [Ramos, Juan Carlos; Vega, Francisco] Univ Miami, Dept Med, Div Hematol, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Cho-Vega, Jeong Hee] Univ Miami, Dept Pathol, Div Dermatopathol, Sylvester Comprehens Canc Ctr, Miami, FL USA	Chapman, JR (reprint author), Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol, Div Hematopathol, Miami, FL 33136 USA.; Chapman, JR (reprint author), Jackson Mem Hosp, Miami, FL 33136 USA.	jchapman@med.miami.edu					AKAMATSU M, 1994, VIRCHOWS ARCH, V425, P33; Asano N, 2010, INT J HEMATOL, V91, P426, DOI 10.1007/s12185-010-0513-0; Bangham CRM, 2011, ADV CANCER RES, V111, P163, DOI 10.1016/B978-0-12-385524-4.00004-0; Bittencourt AL, 2013, AM J CLIN PATHOL, V140, P348, DOI 10.1309/AJCPL52QGQPZWFHE; Bittencourt A, 2009, ACTA ONCOL, V48, P598, DOI 10.1080/02841860802657235; Campuzano-Zuluaga G, 2014, RETROVIROLOGY S1, V11, P129; Chen XY, 2013, AM J CLIN PATHOL, V140, P727, DOI 10.1309/AJCPG71KYOXTKLQW; DOSAKA N, 1991, J INVEST DERMATOL, V96, P196, DOI 10.1111/1523-1747.ep12461033; Fujihara K, 1997, IMMUNOL INVEST, V26, P231, DOI 10.3109/08820139709048929; Fujimura T, 2008, BRIT J DERMATOL, V158, P1256, DOI 10.1111/j.1365-2133.2008.08504.x; Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388; Gjerdrum LM, 2008, EUR J HAEMATOL, V80, P483, DOI 10.1111/j.1600-0609.2008.01064.x; Hallermann C, 2008, G Ital Dermatol Venereol, V143, P15; Ishida T, 2003, CLIN CANCER RES, V9, P3625; Ito Masanori, 2011, Int J Biomed Sci, V7, P181; Janik JE, 2004, BLOOD, V104, P3355, DOI 10.1182/blood-2003-11-3922; Johno M, 2000, Nihon Rinsho, V58, P660; Lyra-da-Silva JO, 2012, DERMATOL PRACT CONCE, V2, P3; Ohshima K, 2015, ONCOLOGY-BASEL, V89, P7, DOI 10.1159/000431058; Ohtsubo H, 1997, EXP HEMATOL, V25, P1246; Satou A, 2016, HISTOPATHOLOGY, V68, P1099, DOI 10.1111/his.12885; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; TAKAHASHI K, 1988, ARCH DERMATOL, V124, P399, DOI 10.1001/archderm.124.3.399; TAKESHITA M, 1995, HISTOPATHOLOGY, V26, P539, DOI 10.1111/j.1365-2559.1995.tb00272.x; TAKESHITA M, 1995, HUM PATHOL, V26, P614, DOI 10.1016/0046-8177(95)90165-5; TAKIMOTO Y, 1994, LEUKEMIA, V8, P507; UCHIYAMA T, 1977, BLOOD, V50, P481; Yamaguchi T, 2005, BRIT J DERMATOL, V152, P76, DOI 10.1111/J.1365-2133.2004.06274.X; Yao JJ, 2013, AM J SURG PATHOL, V37, P1407, DOI 10.1097/PAS.0b013e31828f2322; Yoshino T, 2016, HEMATOPATHOLOGY, P619	30	3	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1046	1063		10.1038/s41379-018-0037-3			18	Pathology	Pathology	GP1HY	WOS:000440567300005	29449683				2019-10-28	
J	Rito, M; Mitani, Y; Bell, D; Mariano, FV; Almalki, ST; Pytynia, KB; Fonseca, I; El-Naggar, AK				Rito, Miguel; Mitani, Yoshitsugu; Bell, Diana; Mariano, Fernanda Viviane; Almalki, Salman T.; Pytynia, Kristen B.; Fonseca, Isabel; El-Naggar, Adel K.			Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression	MODERN PATHOLOGY			English	Article							MULTIPLE FAMILIAL TRICHOEPITHELIOMA; BROOKE-SPIEGLER-SYNDROME; KAPPA-B ACTIVATION; SUPPRESSOR GENE; MONOMORPHIC ADENOMA; DOWN-REGULATION; CHROMOSOME 16Q; GROWTH-CONTROL; CYLINDROMATOSIS; GLAND	Basal cell salivary neoplasms display similar cyto-morphologic features and are classified into adenoma and adenocarcinoma based on the presence or absence of tumor invasion at diagnosis. These neoplasms also share considerable phenotypic resemblance and co-exist with certain dermal adnexal tumors harboring the CYLD gene mutations inferring common genetic association. We sequenced the CYLD gene in both basal cell adenomas and adenocarcinomas and correlated the findings with CYLD, NF-kappa B, and beta-catenin expression levels and clinicopathologic factors. Twenty mutations were identified and comprised of 3 synonymous and 17 non-synonymous (missense) types involving the coding exons of the CYLD gene. Mutations in exons 9-11 were identified in both adenomas and adenocarcinomas, while mutations in exons 12-20, encoding the USP domain, were exclusively found in carcinomas. Although no significant correlation between CYLD mutations and expression levels of CYLD, NF-kappa B, and beta-catenin or clinicopathologic parameters was found, basal cell adenocarcinomas with multiple mutations showed reduction in CYLD protein expression and pursued aggressive clinical behavior. Our study revealed high incidence and sequential CYLD mutations in both basal cell adenoma and adenocarcinoma supporting a single neoplastic continuum for their evolution and provides evidence for potential diagnostic and therapeutic utility.	[Rito, Miguel; Fonseca, Isabel] Univ Lisbon, Fac Med, Inst Pathol, Lisbon, Portugal; [Rito, Miguel; Fonseca, Isabel] Inst Portugues Oncol Francisco Gentil, Serv Anat Patol, Lisbon, Portugal; [Mitani, Yoshitsugu; Bell, Diana; El-Naggar, Adel K.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Mariano, Fernanda Viviane] Univ Campinas UNICAMP, Fac Med Sci, Dept Pathol, Campinas, SP, Brazil; [Almalki, Salman T.] King Fahad Med City, Riyadh, Saudi Arabia; [Pytynia, Kristen B.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA	El-Naggar, AK (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	anaggar@mdanderson.org	Fonseca, Isabel/A-7396-2008	Fonseca, Isabel/0000-0002-1359-6494; Rito, Miguel/0000-0002-0226-5905	NIH National Institute of Dental and Craniofacial ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR); NIH Office of Rare Diseases Research grant [U01DE019765]; SGTB (Salivary Gland Tumor Biorepository) [HHSN268200900039C 04]; Head and Neck SPORE Program [P50CA097007, R21DE023656]; Kenneth D. Muller professorship; NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672]	The study is supported in part by the NIH National Institute of Dental and Craniofacial Research and the NIH Office of Rare Diseases Research grant number U01DE019765, the SGTB (Salivary Gland Tumor Biorepository, HHSN268200900039C 04), the Head and Neck SPORE Program grant number P50CA097007, R21DE023656, The Kenneth D. Muller professorship, and NCI Grant P30CA016672.	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Antonescu CR, 1997, J CUTAN PATHOL, V24, P449, DOI 10.1111/j.1600-0560.1997.tb00822.x; BARE JW, 1992, CANCER RES, V52, P1494; BATSAKIS JG, 1991, ANN OTO RHINOL LARYN, V100, P687, DOI 10.1177/000348949110000818; BATSAKIS JG, 1991, ANN OTO RHINOL LARYN, V100, P785, DOI 10.1177/000348949110000918; BIGGS PJ, 1995, NAT GENET, V11, P441, DOI 10.1038/ng1295-441; Biggs PJ, 1996, ONCOGENE, V12, P1375; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Blake PW, 2009, HUM MUTAT, V30, P1025, DOI 10.1002/humu.21024; Bowen S, 2005, J INVEST DERMATOL, V124, P919, DOI 10.1111/j.0022-202X.2005.23688.x; CHEN KTK, 1985, AM J OTOLARYNG, V6, P39, DOI 10.1016/S0196-0709(85)80007-7; Choi HR, 2002, AM J SURG PATHOL, V26, P778, DOI 10.1097/01.PAS.0000015962.68135.30; Cranston A, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1812-z; El-Naggar AK, 2017, HUM PATHOL, V66, P10, DOI 10.1016/j.humpath.2017.05.014; Espinosa L, 2010, CANCER CELL, V18, P268, DOI 10.1016/j.ccr.2010.08.006; Gutierrez PP, 2002, J INVEST DERMATOL, V119, P527, DOI 10.1046/j.1523-1747.2002.01839.x; Harada H, 1996, J INVEST DERMATOL, V107, P41, DOI 10.1111/1523-1747.ep12297860; Hayashi M, 2014, BREAST CANCER RES TR, V143, P447, DOI 10.1007/s10549-013-2824-3; HRYNCHAK M, 1994, CANCER GENET CYTOGEN, V75, P133, DOI 10.1016/0165-4608(94)90165-1; Inoue Kazushi, 2017, Adv Med Biol, V118, P83; Jo VY, 2016, AM J SURG PATHOL, V40, P1143, DOI 10.1097/PAS.0000000000000669; Kakagia D, 2004, EUR J DERMATOL, V14, P139; Kazakov DV, 2009, HUM PATHOL, V40, P1499, DOI 10.1016/j.humpath.2009.02.015; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Komander D, 2008, MOL CELL, V29, P451, DOI 10.1016/j.molcel.2007.12.018; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; LUNA MA, 1989, J LARYNGOL OTOL, V103, P756, DOI 10.1017/S0022215100109995; Massoumi R, 2007, BIOESSAYS, V29, P1203, DOI 10.1002/bies.20677; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.06.041; Massoumi R, 2010, TRENDS BIOCHEM SCI, V35, P392, DOI 10.1016/j.tibs.2010.02.007; Muller S, 1996, CANCER, V78, P2471; Nagao T, 1998, CANCER, V82, P439, DOI 10.1002/(SICI)1097-0142(19980201)82:3<439::AID-CNCR3>3.0.CO;2-K; Nagy N, 2015, EUR J MED GENET, V58, P271, DOI 10.1016/j.ejmg.2015.02.010; Pan SA, 2010, CLIN CANCER RES, V16, P442, DOI 10.1158/1078-0432.CCR-09-2574; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Rajan N, 2011, ONCOGENE, V30, P4243, DOI 10.1038/onc.2011.133; Saggar S, 2008, J MED GENET, V45, P298, DOI 10.1136/jmg.2007.056127; Saito K, 2004, STRUCTURE, V12, P1719, DOI 10.1016/j.str.2004.07.012; Saluja K, 2016, HUM PATHOL, V54, P189, DOI 10.1016/j.humpath.2016.03.019; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Sun L, 2010, J PATHOL, V221, P425, DOI 10.1002/path.2723; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Thomson SAM, 1999, HUM GENET, V105, P171, DOI 10.1007/s004399900077; Toida M, 2001, CANCER GENET CYTOGEN, V127, P34, DOI 10.1016/S0165-4608(00)00410-6; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Urbanik T, 2011, INT J ONCOL, V38, P121, DOI 10.3892/ijo_00000831; Wickstrom SA, 2010, EMBO J, V29, P131, DOI 10.1038/emboj.2009.317; Wilson TC, 2016, HEAD NECK PATHOL, V10, P494, DOI 10.1007/s12105-016-0730-9; Wilson TC, 2015, HEAD NECK PATHOL, V9, P205, DOI 10.1007/s12105-014-0562-4; Yang YF, 2016, J CELL SCI, V129, P2289, DOI 10.1242/jcs.183319; Young AL, 2006, CLIN GENET, V70, P246, DOI 10.1111/j.1399-0004.2006.00667.x; Zhang XJ, 2004, J INVEST DERMATOL, V122, P658, DOI 10.1111/j.0022-202X.2004.22321.x; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.3.CO;2-P	54	2	2	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1064	1072		10.1038/s41379-018-0018-6			9	Pathology	Pathology	GP1HY	WOS:000440567300006	29463883				2019-10-28	
J	Slodkowska, E; Nofech-Mozes, S; Xu, B; Parra-Herran, C; Lu, FI; Raphael, S; Zubovits, J; Hanna, W				Slodkowska, Elzbieta; Nofech-Mozes, Sharon; Xu, Bin; Parra-Herran, Carlos; Lu, Fang-I; Raphael, Simon; Zubovits, Judit; Hanna, Wedad			Fibroepithelial lesions of the breast: a comprehensive morphological and outcome analysis of a large series	MODERN PATHOLOGY			English	Article							PHYLLODES TUMORS; SURGICAL MARGINS; FEATURES; BENIGN; BEHAVIOR	Mammary fibroepithelial lesions encompass a wide spectrum of tumors ranging from an indolent fibroadenoma to potentially fatal malignant phyllodes tumor. The criteria used for their classification based on morphological assessment are often challenging to apply and there is no consensus as to what constitutes an adequate resection margin. We studied a retrospective cohort of 213 fibroepithelial lesions in 178 patients (80 fibroadenomas with unusual features and 133 phyllodes tumors: 63 benign, 41 borderline, and 29 malignant) in order to describe the spectrum of changes within each group, with special emphasis on margin evaluation. Outcome data were available for 153 fibroepithelial lesions in 139 patients (median 56 months, range 3-249 months). Positive final margin (tumor transected), age < 50 years and a predominantly myxoid stroma were statistically significant predictors of local recurrence, while age > 50, stromal overgrowth, diffuse marked atypia, necrosis and mitotic index of >= 10 per 10 HPF were predictive of distant metastases. Tumors with satellite/bulging nodules were at a significantly higher risk to have a final positive resection margin. Our findings highlight important aspects of the interpretation and reporting of fibroepithelial lesions: the amount of myxoid stroma and the presence of satellite nodules are clinically relevant and should be routinely assessed and reported; infiltrative border might not be a prerequisite for the diagnosis of malignant phyllodes tumor, while the presence of tumor necrosis, massive stromal overgrowth or mitotic index of >= 25 per 10 HPF is diagnostic of malignant phyllodes tumor. On the other hand, increased mitotic index outside of the range of the World Health Organization guidelines in the absence of other worrisome features should be treated with caution, as it can be found in benign tumors.	[Slodkowska, Elzbieta; Nofech-Mozes, Sharon; Xu, Bin; Parra-Herran, Carlos; Lu, Fang-I; Hanna, Wedad] Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON, Canada; [Slodkowska, Elzbieta; Nofech-Mozes, Sharon; Xu, Bin; Parra-Herran, Carlos; Lu, Fang-I; Raphael, Simon; Zubovits, Judit; Hanna, Wedad] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Raphael, Simon] North York Gen Hosp, Toronto, ON, Canada; [Raphael, Simon] Markham Stouffville Hosp, Markham, ON, Canada; [Zubovits, Judit] Scarborough & Rouge Hosp, Scarborough, ON, Canada	Slodkowska, E (reprint author), Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON, Canada.; Slodkowska, E (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	elzbieta.slodkowska@sunnybrook.ca		Parra-Herran, Carlos/0000-0003-1420-7291; Xu, Bin/0000-0003-4638-9835			Azzopardi JG, 1979, PROBLEMS BREAST PATH, P346; Barrio AV, 2007, ANN SURG ONCOL, V14, P2961, DOI 10.1245/s10434-007-9439-z; Brogi E, 2014, ROSENS BREAST PATHOL, P213; Cowan ML, 2016, MODERN PATHOL, V29, P259, DOI 10.1038/modpathol.2015.157; Foucar CE, 2012, CLIN BREAST CANCER, V12, P373, DOI 10.1016/j.clbc.2012.07.011; Ginter PS, 2016, HUM PATHOL, V49, P90, DOI 10.1016/j.humpath.2015.10.012; Hodges KB, 2009, APPL IMMUNOHISTO M M, V17, P345, DOI 10.1097/PAI.0b013e318194d992; Kleer CG, 2001, MODERN PATHOL, V14, P185, DOI 10.1038/modpathol.3880282; Koerner FC, 2009, DIAGNOSTIC PROBLEMS, P329; Korcheva VB, 2011, APPL IMMUNOHISTO M M, V19, P119, DOI 10.1097/PAI.0b013e3181f5349a; Kuijper A, 2002, J PATHOL, V197, P575, DOI 10.1002/path.1161; Lawton TJ, 2014, INT J SURG PATHOL, V22, P695, DOI 10.1177/1066896914548763; Lee BJ, 1931, AM J CANCER, V15, P2583; MOFFAT CJC, 1995, HISTOPATHOLOGY, V27, P205, DOI 10.1111/j.1365-2559.1995.tb00212.x; NORRIS HJ, 1967, CANCER, V20, P2090, DOI 10.1002/1097-0142(196712)20:12<2090::AID-CNCR2820201206>3.0.CO;2-L; Ross DS, 2017, BREAST J, V23, P182, DOI 10.1111/tbj.12706; Shaaban M, 2017, EJSO-EUR J SURG ONC, V43, P1186, DOI 10.1016/j.ejso.2016.10.019; Tan BY, 2016, HISTOPATHOLOGY, V68, P5, DOI 10.1111/his.12876; Tan PH, 2005, AM J CLIN PATHOL, V123, P529, DOI 10.1309/U6DVBFM81MLJC1FN; Tan PH, 2012, WHO CLASSIFICATION T, P142; Tan PH, 2012, J CLIN PATHOL, V65, P69, DOI 10.1136/jclinpath-2011-200368; Tay TKY, 2015, J CLIN PATHOL, V68, P633, DOI 10.1136/jclinpath-2015-202956; Yom CK, 2015, ANN SURG ONCOL, V22, P2912, DOI 10.1245/s10434-015-4395-5	23	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1073	1084		10.1038/s41379-018-0032-8			12	Pathology	Pathology	GP1HY	WOS:000440567300007	29449684				2019-10-28	
J	Chollet-Hinton, L; Puvanesarajah, S; Sandhu, R; Kirk, EL; Midkiff, BR; Ghosh, K; Brandt, KR; Scott, CG; Gierach, GL; Sherman, ME; Vachon, CM; Troester, MA				Chollet-Hinton, Lynn; Puvanesarajah, Samantha; Sandhu, Rupninder; Kirk, Erin L.; Midkiff, Bentley R.; Ghosh, Karthik; Brandt, Kathleen R.; Scott, Christopher G.; Gierach, Gretchen L.; Sherman, Mark E.; Vachon, Celine M.; Troester, Melissa A.			Stroma modifies relationships between risk factor exposure and age-related epithelial involution in benign breast	MODERN PATHOLOGY			English	Article							LOBULAR INVOLUTION; CANCER RISK; MAMMOGRAPHIC DENSITY; TISSUE COMPOSITION; ASSOCIATION	Delayed age-related lobular involution has been previously associated with elevated breast cancer risk. However, intraindividual variability in epithelial involution status within a woman is undefined. We developed a novel measure of age-related epithelial involution, density of epithelial nuclei in epithelial areas using digital image analysis in combination with stromal characteristics (percentage of section area comprising stroma). Approximately 1800 hematoxylin and eosin stained sections of benign breast tissue were evaluated from 416 participants having breast surgery for cancer or benign conditions. Two to sixteen slides per woman from different regions of the breast were studied. Epithelial involution status varied within a woman and as a function of stromal area. Percentage stromal area varied between samples from the same woman (median difference between highest and lowest stromal area within a woman was 7.5%, but ranged from 0.01 to 86.7%). Restricting to women with at least 10% stromal area (N = 317), epithelial nuclear density decreased with age (-637.1 cells/mm(2) per decade of life after age 40, p < 0.0001), increased with mammographic density (457.8 cells/mm(2) per increasing BI-RADs density category p = 0.002), and increased non-significantly with recent parity, later age at first pregnancy, and longer and more recent oral contraceptive use. These associations were attenuated in women with mostly fat samples (< 10% stroma (N = 99)). Thirty-one percent of women evaluated had both adequate stroma (>= 10%) and mostly fat (< 10% stroma) regions of breast tissue, with the probability of having both types increasing with the number breast tissue samplings. Several breast cancer risk factors are associated with elevated age-related epithelial content, but associations depend upon stromal context. Stromal characteristics appear to modify relationships between risk factor exposures and breast epithelial involution.	[Chollet-Hinton, Lynn; Puvanesarajah, Samantha; Kirk, Erin L.; Troester, Melissa A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Sandhu, Rupninder; Midkiff, Bentley R.; Troester, Melissa A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Ghosh, Karthik] Mayo Clin, Coll Med, Dept Internal Med, Rochester, MN USA; [Brandt, Kathleen R.] Mayo Clin, Coll Med, Dept Radiol, Rochester, MN USA; [Scott, Christopher G.] Mayo Clin, Coll Med, Dept Hlth Sci, Div Biostat, Rochester, MN USA; [Gierach, Gretchen L.; Sherman, Mark E.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Vachon, Celine M.] Mayo Clin, Coll Med, Dept Hlth Sci, Div Epidemiol, Rochester, MN USA; [Troester, Melissa A.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA	Troester, MA (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA.; Troester, MA (reprint author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Troester, MA (reprint author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27515 USA.	troester@unc.edu	Gierach, Gretchen/E-1817-2016	Gierach, Gretchen/0000-0002-0165-5522; Midkiff, Bentley/0000-0002-6565-9055; Scott, Christopher/0000-0003-1340-0647	Avon Foundation; North Carolina University Cancer Research Fund; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA179715]; National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [U01 ES019472-01]; Intramural Research Program at the National Cancer Institute; University of North Carolina LCCC Cancer Control and Education Program training grant from the National Cancer Institute [NIH/NCI 5R25CA057726-24]	We gratefully acknowledge the support of all Normal Breast Study and Mayo Study staff and participants. This work was supported by the Avon Foundation, North Carolina University Cancer Research Fund, National Cancer Institute (R01 CA179715), National Institute of Environmental Health Sciences (U01 ES019472-01), and the Intramural Research Program at the National Cancer Institute. LCH was supported in part by the University of North Carolina LCCC Cancer Control and Education Program training grant from the National Cancer Institute (NIH/NCI 5R25CA057726-24).	Baer HJ, 2009, CANCER, V115, P1404, DOI 10.1002/cncr.24167; Boyd N F, 2001, IARC Sci Publ, V154, P163; Boyd NF, 2011, J CLIN ONCOL, V29, P2985, DOI 10.1200/JCO.2010.33.7964; Casbas-Hernandez P, 2015, CANCER EPIDEM BIOMAR, V24, P406, DOI 10.1158/1055-9965.EPI-14-0934; Figueroa JD, 2016, BREAST CANCER RES TR, V159, P163, DOI 10.1007/s10549-016-3908-7; Figueroa JD, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju286; Gertig DM, 1999, CANCER EPIDEM BIOMAR, V8, P873; Ghosh K, 2012, BREAST CANCER RES TR, V131, P267, DOI 10.1007/s10549-011-1727-4; Ghosh K, 2010, JNCI-J NATL CANCER I, V102, P1716, DOI 10.1093/jnci/djq414; Gierach GL, 2016, CANCER PREV RES, V9, P149, DOI 10.1158/1940-6207.CAPR-15-0282; Ginsburg OM, 2008, BRIT J CANCER, V99, P1369, DOI 10.1038/sj.bjc.6604635; Hawes D, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1408; HENSON DE, 1994, CANCER, V74, P424, DOI 10.1002/cncr.2820741330; HUTSON SW, 1985, J CLIN PATHOL, V38, P281, DOI 10.1136/jcp.38.3.281; Jinda S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3633; Kim JB, 2005, TUMOR BIOL, V26, P173, DOI 10.1159/000086950; LEE J, 1989, COMPUT BIOL MED, V19, P61, DOI 10.1016/0010-4825(89)90036-X; Li T, 2005, CANCER EPIDEM BIOMAR, V14, P343, DOI 10.1158/1055-9965.EPI-04-0490; Milanese TR, 2006, J NATL CANCER I, V98, P1600, DOI 10.1093/jnci/djj439; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P219; Sandhu R, 2016, HUM PATHOL, V48, P60, DOI 10.1016/j.humpath.2015.09.031; Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580; Sickles E, 2013, ACR BI RADS ATLAS BR; Sun XZ, 2014, CANCER EPIDEM BIOMAR, V23, P2810, DOI 10.1158/1055-9965.EPI-14-0507; Sun XZ, 2013, CLIN CANCER RES, V19, P4972, DOI 10.1158/1078-0432.CCR-13-0029; Ursin G, 2005, BREAST CANCER RES, V7, pR605, DOI 10.1186/bcr1260; Vierkant RA, 2009, BREAST CANCER RES TR, V117, P193, DOI 10.1007/s10549-008-0082-6; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Yang XHR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3170	29	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1085	1096		10.1038/s41379-018-0033-7			12	Pathology	Pathology	GP1HY	WOS:000440567300008	29463881	Green Accepted			2019-10-28	
J	McCroskey, Z; Sneige, N; Herman, CR; Miller, RA; Venta, LA; Ro, JY; Schwartz, MR; Ayala, AG				McCroskey, Zulfia; Sneige, Nour; Herman, Carolyn R.; Miller, Ross A.; Venta, Luz A.; Ro, Jae Y.; Schwartz, Mary R.; Ayala, Alberto G.			Flat epithelial atypia in directional vacuum-assisted biopsy of breast microcalcifications: surgical excision may not be necessary	MODERN PATHOLOGY			English	Article							COLUMNAR CELL LESIONS; CORE-NEEDLE-BIOPSY; CARCINOMA-IN-SITU; DUCTAL INTRAEPITHELIAL NEOPLASIA; MALIGNANT POTENTIAL B3; CLINGING CARCINOMA; TUBULAR CARCINOMA; FOLLOW-UP; CANCER; HYPERPLASIA	The aim of this study was to analyze the clinicopathological features of patients with flat epithelial atypia, diagnosed in directional vacuum-assisted biopsy targeting microcalcifications, to identify upgrade rate to in situ ductal or invasive breast carcinoma, and determine factors predicting carcinoma in the subsequent excision. We retrospectively evaluated the histological, clinical, and mammographic features of 69 cases from 65 women, with directional vacuum-assisted biopsy-diagnosed flat epithelial atypia with or without atypical ductal hyperplasia or atypical lobular hyperplasia, which underwent subsequent surgical excision. The extent and percentage of microcalcifications sampled by directional vacuum-assisted biopsy were evaluated by mammography. All biopsy and surgical excision slides were reviewed. The age of the women ranged from 40 to 85 years (mean 57 years). All patients presented with mammographically detected microcalcifications only, except in one case that had associated architectural distortion. Extent of calcifications ranged from < 1 cm (n = 47), 1-3 cm (n = 15) to > 3 cm (n = 6), and no measurement (n = 1). A mean of 11 cores (range 6-25) was obtained from each lesion. Post-biopsy mammogram revealed > 90% removal of calcifications in 81% of cases. Pure flat epithelial atypia represented nearly two-thirds of directional vacuum-assisted biopsy specimens (n = 43, 62%), while flat epithelial atypia coexisted with atypical ductal hyperplasia (18 cases, 26%), or atypical lobular hyperplasia (8 cases, 12%). Upon excision, none of the cases were upgraded to in situ ductal or invasive breast cancer. In one case, however, an incidental, tubular carcinoma (4 mm) was found away from biopsy site. Excluding this case, the upgrade rate was 0%. Our study adds to the growing evidence that diagnosis of flat epithelial atypia on directional vacuum-assisted biopsy for microcalcifications as the only imaging finding is not associated with a significant upgrade to carcinoma on excision, and therefore, excision may not be necessary. Additionally, excision may not be necessary for flat epithelial atypia with atypical ductal hyperplasia limited to = 2 terminal duct-lobular units, if at least 90% of calcifications have been removed on biopsy.	[McCroskey, Zulfia; Sneige, Nour; Miller, Ross A.; Ro, Jae Y.; Schwartz, Mary R.; Ayala, Alberto G.] Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77098 USA; [Herman, Carolyn R.; Venta, Luz A.] Houston Methodist Hosp, Methodist Breast Ctr Imaging, Houston, TX 77098 USA	Sneige, N (reprint author), Houston Methodist Hosp, Dept Pathol & Genom Med, Houston, TX 77098 USA.	NSneige@houstonmethodist.org					Abdel-Fatah TMA, 2008, AM J SURG PATHOL, V32, P513, DOI 10.1097/PAS.0b013e318161d1a5; Aulmann S, 2009, AM J SURG PATHOL, V33, P1646, DOI 10.1097/PAS.0b013e3181adfdcf; Azzopardi J G, 1979, Major Probl Pathol, V11, pi; Becker AK, 2013, AM J ROENTGENOL, V200, P682, DOI 10.2214/AJR.11.8090; Berry JS, 2016, J CANCER, V7, P1, DOI 10.7150/jca.12781; Bianchi S, 2012, VIRCHOWS ARCH, V461, P405, DOI 10.1007/s00428-012-1279-y; Biggar MA, 2012, BREAST J, V18, P578, DOI 10.1111/tbj.12039; Bijker N, 2001, J CLIN ONCOL, V19, P2263, DOI 10.1200/JCO.2001.19.8.2263; Boulos FI, 2008, CANCER-AM CANCER SOC, V113, P2415, DOI 10.1002/cncr.23873; Brandt SM, 2008, ADV ANAT PATHOL, V15, P140, DOI 10.1097/PAP.0b013e31816ff313; Calhoun BC, 2015, MODERN PATHOL, V28, P670, DOI 10.1038/modpathol.2014.159; Ceugnart L, 2013, Diagn Interv Imaging, V94, P861, DOI 10.1016/j.diii.2013.01.011; Chivukula M, 2009, AM J CLIN PATHOL, V131, P802, DOI 10.1309/AJCPLDG6TT7VAHPH; Dabbs DJ, 2006, MODERN PATHOL, V19, P344, DOI 10.1038/modpathol.3800538; de Mascarel I, 2007, VIRCHOWS ARCH, V451, P1, DOI 10.1007/s00428-007-0408-5; de van Vijver MJ, 2012, WHO CLASSIFICATION T, P87; Dialani V, 2014, BREAST J, V20, P606, DOI 10.1111/tbj.12332; El Khoury M, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20160750; Ely KA, 2001, AM J SURG PATHOL, V25, P1017, DOI 10.1097/00000478-200108000-00005; EUSEBI V, 1989, SEMIN DIAGN PATHOL, V6, P165; Khoumais NA, 2013, ANN SURG ONCOL, V20, P133, DOI 10.1245/s10434-012-2591-0; Lavoue V, 2011, BREAST CANCER RES TR, V125, P121, DOI 10.1007/s10549-010-1208-1; Martel M, 2007, VIRCHOWS ARCH, V451, P883, DOI 10.1007/s00428-007-0499-z; Moinfar F, 2000, CANCER-AM CANCER SOC, V88, P2072, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2072::AID-CNCR13>3.3.CO;2-8; Moinfar F, 2009, ARCH PATHOL LAB MED, V133, P879, DOI 10.1043/1543-2165-133.6.879; Mooney KL, 2016, MODERN PATHOL, V29, P1471, DOI 10.1038/modpathol.2016.127; Nguyen CV, 2011, ANN SURG ONCOL, V18, P752, DOI 10.1245/s10434-010-1127-8; Noel JC, 2010, SURG ONCOL, V19, P243, DOI 10.1016/j.suronc.2009.08.002; Noske A, 2010, HUM PATHOL, V41, P522, DOI 10.1016/j.humpath.2009.09.005; Peres A, 2012, BREAST CANCER RES TR, V133, P659, DOI 10.1007/s10549-011-1839-x; Piubello Q, 2009, AM J SURG PATHOL, V33, P1078, DOI 10.1097/PAS.0b013e31819d0a4d; Prowler VL, 2014, BREAST, V23, P352, DOI 10.1016/j.breast.2014.01.013; Rakha EA, 2011, INT J CANCER, V129, P1417, DOI 10.1002/ijc.25801; Said SM, 2015, CANCER-AM CANCER SOC, V121, P1548, DOI 10.1002/cncr.29243; Saladin C, 2016, ACTA RADIOL, V57, P815, DOI 10.1177/0284185115610931; Schnitt SJ, 2003, ADV ANAT PATHOL, V10, P113, DOI 10.1097/00125480-200305000-00001; Schnitt SJ, 2010, SEMIN DIAGN PATHOL, V27, P31, DOI 10.1053/j.semdp.2009.12.006; Senetta R, 2009, MODERN PATHOL, V22, P762, DOI 10.1038/modpathol.2009.21; Simpson PT, 2005, AM J SURG PATHOL, V29, P734, DOI 10.1097/01.pas.0000157295.93914.3b; Sneige N, 2003, AM J CLIN PATHOL, V119, P248, DOI 10.1309/0GYV4F2LLJAV4GFN; Solorzano S, 2011, AM J ROENTGENOL, V197, P740, DOI 10.2214/AJR.10.5265; Tomasino RM, 2009, J CELL PHYSIOL, V221, P343, DOI 10.1002/jcp.21858; Uzoaru I, 2012, VIRCHOWS ARCH, V461, P419, DOI 10.1007/s00428-012-1312-1; Verschuur-Maes AHJ, 2014, CELL ONCOL, V37, P147, DOI 10.1007/s13402-014-0170-z; Verschuur-Maes AHJ, 2012, ANN SURG, V255, P259, DOI 10.1097/SLA.0b013e318233523f; Verschuur-Maes AHJ, 2011, INT J CANCER, V129, P2674, DOI 10.1002/ijc.25926; Villa A, 2013, CLIN BREAST CANCER, V13, P450, DOI 10.1016/j.clbc.2013.08.008	47	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1097	1106		10.1038/s41379-018-0035-5			10	Pathology	Pathology	GP1HY	WOS:000440567300009	29467479				2019-10-28	
J	Pilsworth, JA; Cochrane, DR; Xia, ZCY; Aubert, G; Farkkila, AEM; Horlings, HM; Yanagida, S; Yang, WN; Lim, JLP; Wang, YK; Bashashati, A; Keul, J; Wong, A; Norris, K; Brucker, SY; Taran, FA; Kramer, B; Staebler, A; van Meurs, H; Oliva, E; Shah, SP; Kommoss, S; Kommoss, F; Gilks, CB; Baird, DM; Huntsman, DG				Pilsworth, Jessica A.; Cochrane, Dawn R.; Xia, Zhouchunyang; Aubert, Geraldine; Farkkila, Anniina E. M.; Horlings, Hugo M.; Yanagida, Satoshi; Yang, Winnie; Lim, Jamie L. P.; Wang, Yi Kan; Bashashati, Ali; Keul, Jacqueline; Wong, Adele; Norris, Kevin; Brucker, Sara Y.; Taran, Florin-Andrei; Kraemer, Bernhard; Staebler, Annette; van Meurs, Hannah; Oliva, Esther; Shah, Sohrab P.; Kommoss, Stefan; Kommoss, Friedrich; Gilks, C. Blake; Baird, Duncan M.; Huntsman, David G.			TERT promoter mutation in adult granulosa cell tumor of the ovary	MODERN PATHOLOGY			English	Article							TELOMERASE ACTIVITY; CANCER; FOXL2; MELANOMA; PATHOGENESIS; ASSOCIATION; MECHANISMS; EXPRESSION; FOLLICLES; CARCINOMA	The telomerase reverse transcriptase (TERT) gene is highly expressed in stem cells and silenced upon differentiation. Cancer cells can attain immortality by activating TERT to maintain telomere length and telomerase activity, which is a crucial step of tumorigenesis. Two somatic mutations in the TERT promoter (C228T; C250T) have been identified as gain-of-function mutations that promote transcriptional activation of TERT in multiple cancers, such as melanoma and glioblastoma. A recent study investigating TERT promoter mutations in ovarian carcinomas found C228T and C250T mutations in 15.9% of clear cell carcinomas. However, it is unknown whether these mutations are frequent in other ovarian cancer subtypes, in particular, sex cord-stromal tumors including adult granulosa cell tumors. We performed whole-genome sequencing on ten adult granulosa cell tumors with matched normal blood and identified a TERT C228T promoter mutation in 50% of tumors. We found that adult granulosa cell tumors with mutated TERT promoter have increased expression of TERT mRNA and exhibited significantly longer telomeres compared to those with wild-type TERT promoter. Extension cohort analysis using allelic discrimination revealed the TERT C228T mutation in 51 of 229 primary adult granulosa cell tumors (22%), 24 of 58 recurrent adult granulosa cell tumors (41%), and 1 of 22 other sex cord-stromal tumors (5%). There was a significant difference in overall survival between patients with TERT C228T promoter mutation in the primary tumors and those without it (p=0.00253, log-rank test). In seven adult granulosa cell tumors, we found the TERT C228T mutation present in recurrent tumors and absent in the corresponding primary tumor. Our data suggest that TERT C228T promoter mutations may have an important role in progression of adult granulosa cell tumors.	[Pilsworth, Jessica A.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; [Pilsworth, Jessica A.; Cochrane, Dawn R.; Xia, Zhouchunyang; Horlings, Hugo M.; Yang, Winnie; Lim, Jamie L. P.; Wang, Yi Kan; Bashashati, Ali; Shah, Sohrab P.; Huntsman, David G.] British Columbia Canc Agcy, Dept Mol Oncol, Vancouver, BC, Canada; [Xia, Zhouchunyang; Horlings, Hugo M.; Gilks, C. Blake; Huntsman, David G.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Aubert, Geraldine] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC, Canada; [Farkkila, Anniina E. M.] Univ Helsinki, Childrens Hosp, Helsinki, Finland; [Farkkila, Anniina E. M.] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland; [Farkkila, Anniina E. M.] Helsinki Univ Hosp, Helsinki, Finland; [Farkkila, Anniina E. M.] Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA; [Yanagida, Satoshi] Jikei Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan; [Keul, Jacqueline; Brucker, Sara Y.; Taran, Florin-Andrei; Kraemer, Bernhard; Kommoss, Stefan] Tubingen Univ Hosp, Dept Womens Hlth, Tubingen, Germany; [Wong, Adele; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Norris, Kevin; Baird, Duncan M.] Cardiff Univ, Sch Med, Div Canc & Genet, Cardiff, S Glam, Wales; [Staebler, Annette] Tubingen Univ Hosp, Inst Pathol, Tubingen, Germany; [van Meurs, Hannah] Acad Med Ctr, Ctr Gynecol Oncol Amsterdam, Dept Gynecol, NL-1100 DD Amsterdam, Netherlands; [Shah, Sohrab P.] Univ British Columbia, Dept Comp Sci, Vancouver, BC, Canada; [Kommoss, Friedrich] Inst Pathol, Campus Bodensee, Friedrichshafen, Germany	Huntsman, DG (reprint author), British Columbia Canc Agcy, Dept Mol Oncol, Vancouver, BC, Canada.; Huntsman, DG (reprint author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.	dhuntsma@bccancer.bc.ca	Baird, Duncan M/C-9671-2011	Baird, Duncan M/0000-0001-8408-5467	Terry Fox Research Institute Program Project grant [1021]; British Columbia Cancer Foundation; Vancouver General Hospital - University of British Columbia Hospital Foundation; Cancer Research UKCancer Research UK [C17199/A18246]; University of British Columbia Four-Year Doctoral Fellowship	We thank all the women who generously donated the samples used in this study. This work is supported by the Terry Fox Research Institute Program Project grant #1021, the British Columbia Cancer Foundation, Vancouver General Hospital - University of British Columbia Hospital Foundation (to the OvCaRe ovarian cancer research team, Vancouver) and Cancer Research UK (C17199/A18246). JAP is supported by the University of British Columbia Four-Year Doctoral Fellowship. We are grateful for the clinicians from each institution for patient recruitment. We thank the pathologists, Drs. C. Blake Gilks, Friedrich Kommoss, Ralf Buzow, Hugo M. Horlings, Anthony N. Karnezis, Hector Li Chang, Basile Tessier-Cloutier, and Lien Hoang, for reviewing slides. We also thank our technicians, Amy Lum and Janine Senz, for their advice.	Akincilar SC, 2016, CELL MOL LIFE SCI, V73, P1659, DOI 10.1007/s00018-016-2146-9; Al-Agha OM, 2011, AM J SURG PATHOL, V35, P484, DOI 10.1097/PAS.0b013e31820a406c; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Cheng L, 2016, HISTOPATHOLOGY, V69, P107, DOI 10.1111/his.12920; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Flynn RL, 2015, SCIENCE, V347, P273, DOI 10.1126/science.1257216; Fuller PJ, 2017, CLIN GENET, V91, P285, DOI 10.1111/cge.12917; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.39; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x; Jamieson S, 2012, ENDOCR REV, V33, P109, DOI 10.1210/er.2011-0014; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kim MS, 2010, J PATHOL, V221, P147, DOI 10.1002/path.2688; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim T, 2010, HISTOPATHOLOGY, V56, P408, DOI 10.1111/j.1365-2559.2010.03487.x; Kobel M, 2009, CANCER RES, V69, P9160, DOI 10.1158/0008-5472.CAN-09-2669; Kossowska-Tomaszczuk K, 2009, STEM CELLS, V27, P210, DOI 10.1634/stemcells.2008-0233; Lavranos TC, 1999, BIOL REPROD, V61, P358, DOI 10.1095/biolreprod61.2.358; Leung DTH, 2016, INT J BIOCHEM CELL B, V72, P51, DOI 10.1016/j.biocel.2016.01.003; Lin TT, 2010, BLOOD, V116, P1899, DOI 10.1182/blood-2010-02-272104; Liu JP, 2010, REPRODUCTION, V140, P215, DOI 10.1530/REP-10-0008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McConechy MK, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw134; Nagore E, 2016, INT J CANCER, V139, P75, DOI 10.1002/ijc.30042; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Roger L, 2013, JNCI-J NATL CANCER I, V105, P1202, DOI 10.1093/jnci/djt191; Rosario R, 2014, GYNECOL ONCOL, V133, P382, DOI 10.1016/j.ygyno.2013.12.012; Russo V, 2006, J HISTOCHEM CYTOCHEM, V54, P443, DOI 10.1369/jhc.4A6603.2006; Schrader KA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007988; Scott GA, 2014, MODERN PATHOL, V27, P516, DOI 10.1038/modpathol.2013.167; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shay JW, 2013, CANCER DISCOV, V3, P1096, DOI 10.1158/2159-8290.CD-13-0506; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Wang YK, 2017, NAT GENET, V49, P856, DOI 10.1038/ng.3849; Wu RC, 2014, J PATHOL, V232, P473, DOI 10.1002/path.4315; Yamagata Y, 2002, ENDOCR J, V49, P589, DOI 10.1507/endocrj.49.589; Zhang Q, 2011, P NATL ACAD SCI USA, V108, P20325, DOI 10.1073/pnas.1100279108	42	9	9	3	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1107	1115		10.1038/s41379-018-0007-9			9	Pathology	Pathology	GP1HY	WOS:000440567300010	29449679	Green Accepted			2019-10-28	
J	Nguyen, NMP; Khawajkie, Y; Mechtouf, N; Rezaei, M; Breguet, M; Kurvinen, E; Jagadeesh, S; Solmaz, AE; Aguinaga, M; Hemida, R; Harma, MI; Rittore, C; Rahimi, K; Arseneau, J; Hovanes, K; Clisham, R; Lenzi, T; Scurry, B; Addor, MC; Bagga, R; Nendaz, GG; Finci, V; Poke, G; Grimes, L; Gregersen, N; York, K; Bolze, PA; Patel, C; Mozdarani, H; Puechberty, J; Scotchie, J; Fardaei, M; Harma, M; Gardner, RJM; Sahoo, T; Dudding-Byth, T; Srinivasan, R; Sauthier, P; Slim, R				Ngoc Minh Phuong Nguyen; Khawajkie, Yassemine; Mechtouf, Nawel; Rezaei, Maryam; Breguet, Magali; Kurvinen, Elvira; Jagadeesh, Sujatha; Solmaz, Asli Ece; Aguinaga, Monica; Hemida, Reda; Harma, Mehmet Ibrahim; Rittore, Cecile; Rahimi, Kurosh; Arseneau, Jocelyne; Hovanes, Karine; Clisham, Ronald; Lenzi, Tiffanee; Scurry, Bonnie; Addor, Marie-Claude; Bagga, Rashmi; Nendaz, Genevieve Girardet; Finci, Vildana; Poke, Gemma; Grimes, Leslie; Gregersen, Nerine; York, Kayla; Bolze, Pierre-Adrien; Patel, Chirag; Mozdarani, Hossein; Puechberty, Jacques; Scotchie, Jessica; Fardaei, Majid; Harma, Muge; Gardner, R. J. McKinlay; Sahoo, Trilochan; Dudding-Byth, Tracy; Srinivasan, Radhika; Sauthier, Philippe; Slim, Rima			The genetics of recurrent hydatidiform moles: new insights and lessons from a comprehensive analysis of 113 patients	MODERN PATHOLOGY			English	Article							GESTATIONAL TROPHOBLASTIC DISEASE; NLRP7 MUTATIONS; SUBSEQUENT PREGNANCY; REPRODUCTIVE WASTAGE; MOLAR PREGNANCIES; RISK; CONCEPTIONS; PHENOTYPE; OUTCOMES; CONFER	Hydatidiform mole is an aberrant human pregnancy characterized by early embryonic arrest and excessive trophoblastic proliferation. Recurrent hydatidiform moles are defined by the occurrence of at least two hydatidiform moles in the same patient. Fifty to eighty percent of patients with recurrent hydatidiform moles have biallelic pathogenic variants in NLRP7 or KHDC3L. However, in the remaining patients, the genotypic types of the moles are unknown. We characterized 80 new hydatidiform mole tissues, 57 of which were from patients with no mutations in the known genes, and we reviewed the genotypes of a total of 123 molar tissues. We also reviewed mutation analysis in 113 patients with recurrent hydatidiform moles. While all hydatidiform moles from patients with biallelic NLRP7 or KHDC3L mutations are diploid biparental, we demonstrate that those from patients without mutations are highly heterogeneous and only a small minority of them are diploid biparental (8%). The other mechanisms that were found to recur in patients without mutations are diploid androgenetic monospermic (24%) and triploid dispermic (32%); the remaining hydatidiform moles were misdiagnosed as moles due to errors in the analyses and/or their unusual mechanisms. We compared three parameters of genetic susceptibility in patients with and without mutations and show that patients without mutations are mostly from non-familial cases, have fewer reproductive losses, and more live births. Our data demonstrate that patients with recurrent hydatidiform moles and no mutations in the known genes are, in general, different from those with mutations; they have a milder genetic susceptibility and/or a multifactorial etiology underlying their recurrent hydatidiform moles. Categorizing these patients according to the genotypic types of their recurrent hydatidiform moles may facilitate the identification of novel genes for this entity.	[Ngoc Minh Phuong Nguyen; Mechtouf, Nawel; Rezaei, Maryam; Slim, Rima] McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ, Canada; [Khawajkie, Yassemine; Slim, Rima] McGill Univ, Ctr Hlth, Div Expt Med, Montreal, PQ, Canada; [Breguet, Magali; Sauthier, Philippe] CHUM, Dept Obstet & Gynecol, Ctr Integre Cancerol, Registre Malad Trophoblast Quebec, Montreal, PQ, Canada; [Kurvinen, Elvira] Tartu Univ Hosp, United Labs, Dept Clin Genet, 6 Hariduse St, EE-10119 Tallinn, Estonia; [Jagadeesh, Sujatha] Mediscan Syst, 197 Dr Natesan Rd, Madras 4, Tamil Nadu, India; [Solmaz, Asli Ece] Ege Univ, Fac Med, Dept Med Genet, Izmir, Turkey; [Aguinaga, Monica] Inst Nacl Perinatol, Genet & Genom Dept, Mexico City, DF, Mexico; [Hemida, Reda] Mansoura Univ, Obstet & Gynecol, Mansoura, Egypt; [Harma, Mehmet Ibrahim; Harma, Muge] Bulent Ecevit Univ, Dept Obstet & Gynecol, TR-67100 Kozlu, Zonguldak, Turkey; [Harma, Mehmet Ibrahim; Harma, Muge] Bulent Ecevit Univ, Dept Gynecol Oncol, TR-67100 Kozlu, Zonguldak, Turkey; [Rittore, Cecile] Hop Arnaud de Villeneuve, Unite Med Malad Autoinflammatoires, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France; [Rahimi, Kurosh] Univ Montreal, Hop Notre Dame, Dept Pathol, Montreal, PQ, Canada; [Arseneau, Jocelyne] McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ, Canada; [Hovanes, Karine; Sahoo, Trilochan] CombiMatrix Diagnost, Irvine, CA USA; [Clisham, Ronald] Tulane Univ, Sch Med, Dept Obstet, Los Angeles, CA USA; [Clisham, Ronald] Tulane Univ, Sch Med, Dept Gynecol, Los Angeles, CA USA; [Lenzi, Tiffanee] Tennessee Maternal Fetal Med PLC, Maternal Fetal Med & Genet, 300 20th Ave North,Suite 702, Nashville, TN 37203 USA; [Scurry, Bonnie] Royal Brisbane & Womens Hosp, Pathol Queensland, Brisbane, Qld, Australia; [Scurry, Bonnie] Lady Cilento Childrens Hosp, Brisbane, Qld, Australia; [Addor, Marie-Claude] CHU Vaudois, Serv Med Genet, CH-1011 Lausanne, Switzerland; [Bagga, Rashmi] PGIMER, Dept Obstet & Gynecol, Chandigarh, India; [Nendaz, Genevieve Girardet] FMH Gynecol Obstet, Geneva, Switzerland; [Finci, Vildana] CMU, Serv Pathol Clin, Dept Med Genet & Lab, CH-1211 Geneva 4, Switzerland; [Poke, Gemma; Gardner, R. J. McKinlay] Wellington Hosp, Cent Hub, Genet Hlth Serv, Private Bag 7902, Wellington 6242, New Zealand; [Grimes, Leslie] Univ Colorado Hosp, Aurora, CO USA; [Gregersen, Nerine] Auckland City Hosp, Genet Hlth Serv New Zealand Northern Hub, P Bag 92024, Auckland 1142, New Zealand; [York, Kayla] Duluth Clin, Essentia Hlth, Duluth, MN 55805 USA; [Bolze, Pierre-Adrien] Univ Hosp Lyon, Dept Gynecol Surg & Oncol, Obstet, Lyon, France; [Bolze, Pierre-Adrien] Univ Hosp Lyon, French Ctr Trophoblast Dis, Lyon, France; [Patel, Chirag] Royal Brisbane & Womens Hosp, Genet Hlth Queensland, Brisbane, Qld, Australia; [Mozdarani, Hossein] Tarbiat Modares Univ, Dept Med Genet, Fac Med Sci, Tehran, Iran; [Puechberty, Jacques] Hop Arnaud de Villeneuve, Dept Genet Med, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France; [Scotchie, Jessica] Tennessee Reprod Med, 6031 Shallowford Rd,Suite 101, Chattanooga, TN 37421 USA; [Fardaei, Majid] Shiraz Univ Med Sci, Dept Med Genet, Shiraz, Iran; [Gardner, R. J. McKinlay; Slim, Rima] McGill Univ, Ctr Hlth, Dept Obstet, Montreal, PQ, Canada; [Gardner, R. J. McKinlay; Slim, Rima] McGill Univ, Ctr Hlth, Dept Gynecol, Montreal, PQ, Canada; [Dudding-Byth, Tracy] Hunter Genet, Newcastle, NSW, Australia; [Dudding-Byth, Tracy] Univ Newcastle, GrowUpWell Prior Res Ctr, Newcastle, NSW, Australia; [Srinivasan, Radhika] PGIMER, Cytol & Gynecol Pathol, Chandigarh, India	Slim, R (reprint author), McGill Univ, Ctr Hlth, Dept Human Genet, Montreal, PQ, Canada.; Slim, R (reprint author), McGill Univ, Ctr Hlth, Div Expt Med, Montreal, PQ, Canada.; Slim, R (reprint author), McGill Univ, Ctr Hlth, Dept Obstet, Montreal, PQ, Canada.; Slim, R (reprint author), McGill Univ, Ctr Hlth, Dept Gynecol, Montreal, PQ, Canada.	rima.slim@muhc.mcgill.ca	Slim, Rima/J-4104-2019; Bagga, Rashmi/Y-1680-2019; Fardaei, Majid/A-9720-2009	Slim, Rima/0000-0002-4060-2159; Bagga, Rashmi/0000-0003-2693-2343; Fardaei, Majid/0000-0002-8393-0371	Reseau Quebecois en Reproduction; McGill Faculty of Medicine; RI-MUHC Desjardins Studentship in Child Health Research; CRRD; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-86546, POP-122897, MOP-130364]	NMPN was supported by fellowships from Reseau Quebecois en Reproduction, McGill Faculty of Medicine, RI-MUHC Desjardins Studentship in Child Health Research, and CRRD. Yassemine Khawajkie was supported by a CRRD trainee fellowship. RS is supported by the Canadian Institute of Health Research (MOP-86546, POP-122897, and MOP-130364).	Baergen RN, 1996, HUM PATHOL, V27, P731, DOI 10.1016/S0046-8177(96)90406-2; Berkowitz RS, 1998, J REPROD MED, V43, P81; Boufettal H, 2011, J GYNECOL OBST BIO R, V40, P419, DOI 10.1016/j.jgyn.2011.02.008; Castrillon DH, 2001, AM J SURG PATHOL, V25, P1225, DOI 10.1097/00000478-200110000-00001; Deveault C, 2009, HUM MOL GENET, V18, P888, DOI 10.1093/hmg/ddn418; Dixon PH, 2012, J MED GENET, V49, P206, DOI 10.1136/jmedgenet-2011-100602; Eagles N, 2015, HUM REPROD, V30, P2055, DOI 10.1093/humrep/dev169; Fallahian M, 2013, HUM MUTAT, V34, P301, DOI 10.1002/humu.22228; GRIMES DA, 1984, AM J OBSTET GYNECOL, V150, P309, DOI 10.1016/S0002-9378(84)90370-3; Gupta M, 2012, AM J SURG PATHOL, V36, P1747, DOI 10.1097/PAS.0b013e31825ea736; Hayward BE, 2009, HUM MUTAT, V30, pE629, DOI 10.1002/humu.20993; HEDLEY DW, 1989, CYTOMETRY, V10, P229, DOI 10.1002/cyto.990100302; Horn LC, 2006, EUR J OBSTET GYN R B, V128, P10, DOI 10.1016/j.ejogrb.2006.01.024; Khawajkie Y, 2017, GENE CHROMOSOME CANC, V56, P832, DOI 10.1002/gcc.22484; Kim JH, 1998, GYNECOL ONCOL, V71, P108, DOI 10.1006/gyno.1998.5167; Kronfol N M, 1969, J Med Liban, V22, P507; Messaed C, 2011, J MED GENET, V48, P540, DOI 10.1136/jmg.2011.089144; Murdoch S, 2006, NAT GENET, V38, P300, DOI 10.1038/ng1740; Murphy KM, 2009, J MOL DIAGN, V11, P598, DOI 10.2353/jmoldx.2009.090039; Nguyen NMP, 2014, J MED GENET, V51, P623, DOI 10.1136/jmedgenet-2014-102546; Pallares-Ruiz N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014096; Parry DA, 2011, AM J HUM GENET, V89, P451, DOI 10.1016/j.ajhg.2011.08.002; Qian JH, 2011, MOL HUM REPROD, V17, P612, DOI 10.1093/molehr/gar027; Qian JH, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9498; Reddy R, 2016, EUR J HUM GENET, V24, P1516, DOI 10.1038/ejhg.2016.96; Reddy R, 2013, EUR J HUM GENET, V21, P957, DOI 10.1038/ejhg.2012.274; Rezaei Maryam, 2016, Hum Genome Var, V3, P16027, DOI 10.1038/hgv.2016.27; Sahoo T, 2017, GENET MED, V19, P83, DOI 10.1038/gim.2016.69; Savage P, 2010, J REPROD MED, V55, P341; Sebire NJ, 2013, PLACENTA, V34, P50, DOI 10.1016/j.placenta.2012.11.005; Sebire NJ, 2003, BJOG-INT J OBSTET GY, V110, P22, DOI 10.1046/j.1471-0528.2003.02388.x; Slim R, 2009, CLIN GENET, V76, P292, DOI 10.1111/j.1399-0004.2009.01189.x; Sunde L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001776; Surti U, 2006, INT J GYNECOL PATHOL, V25, P366, DOI 10.1097/01.pgp.0000215295.45738.ed; SZULMAN AE, 1978, AM J OBSTET GYNECOL, V132, P20, DOI 10.1016/0002-9378(78)90792-5; Ulker V, 2013, EUR J OBSTET GYN R B, V170, P188, DOI 10.1016/j.ejogrb.2013.06.028; Wang CM, 2009, J MED GENET, V46, P569, DOI 10.1136/jmg.2008.064196; Zaragoza MV, 1997, AM J MED GENET, V70, P273, DOI 10.1002/(SICI)1096-8628(19970613)70:3<273::AID-AJMG11>3.0.CO;2-I	38	2	2	3	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1116	1130		10.1038/s41379-018-0031-9			15	Pathology	Pathology	GP1HY	WOS:000440567300011	29463882				2019-10-28	
J	Goyal, A; Zhang, G; Yang, B				Goyal, Abha; Zhang, Gloria; Yang, Bin			Differential expression patterns of GATA3 in usual and differentiated types of vulvar intraepithelial neoplasia: potential diagnostic implications	MODERN PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; LICHEN-SCLEROSUS; TP53 MUTATIONS; P53 EXPRESSION; BREAST; LESIONS; EPIDERMIS; MARKER; VIN	The two main precursors of vulvar squamous cell carcinoma, usual and differentiated vulvar intraepithelial neoplasia (VIN), have distinctive etiology, pathogenesis, and natural history. Usual type VIN is often associated with high-risk HPV and differentiated VIN has de novo p53 genetic alterations that are unrelated to HPV infection. GATA-binding protein 3 (GATA3) is a tumor suppressor that shows increased expression in several types of human malignancies including breast and bladder carcinomas. Little is known regarding the expression of GATA3 in vulvar squamous neoplasms. We have systematically examined the expression of GATA3 in 119 vulvar lesions and neoplasms including 20 cases of lichen sclerosus, 12 cases of lichen simplex chronicus, 30 cases of usual type VIN, 34 cases of differentiated VIN, and 23 cases of squamous cell carcinoma. Similar to adjacent non-neoplastic epidermis, moderate to strong GATA3 expression was retained in all cases of lichen sclerosus, lichen simplex chronicus, and usual type VIN. However, in comparison, the GATA3 immunostaining pattern in differentiated VIN was distinct. Partial/complete loss of GATA3 expression in the basal layer with or without loss in the parabasal layer was observed in 30/34 (88%) of differentiated VIN cases. Significant loss of GATA3 expression was also observed in all (7/7) squamous cell carcinomas associated with usual type VIN and in 13/16 (81%) of those associated with differentiated VIN. There was no significant correlation between loss of GATA3 expression and overexpression of p53 in differentiated VIN. Our study shows that loss of GATA3 expression is seen in the vast majority (87%) of vulvar squamous cell carcinomas. Downregulation of GATA3 may be an early event during tumorigenesis in differentiated VIN but not in HPV-related usual type VIN. Our data suggests that application of GATA3 immunohistochemistry along with p53 may be a useful tool in facilitating the accurate diagnosis of VIN.	[Goyal, Abha] New York Presbyterian Hosp, Weill Cornell Med, 525 East 68th St,F766, New York, NY 10065 USA; [Zhang, Gloria; Yang, Bin] Cleveland Clin, Dept Pathol, Robert J Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA	Yang, B (reprint author), Cleveland Clin, Dept Pathol, Robert J Tomsich Pathol & Lab Med Inst, 9500 Euclid Ave,L25, Cleveland, OH 44195 USA.	yangb@ccf.org					ABELL MR, 1965, SURG CLIN N AM, V45, P1179; Bonin F, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-417; Chang A, 2012, AM J SURG PATHOL, V36, P1472, DOI 10.1097/PAS.0b013e318260cde7; Choschzick M, 2011, INT J GYNECOL PATHOL, V30, P497, DOI 10.1097/PGP.0b013e3182184c7a; Clark BZ, 2014, AM J CLIN PATHOL, V142, P64, DOI 10.1309/AJCP8H2VBDSCIOBF; de Sanjose S, 2013, EUR J CANCER, V49, P3450, DOI 10.1016/j.ejca.2013.06.033; del Pino M, 2013, HISTOPATHOLOGY, V62, P161, DOI 10.1111/his.12034; Hantschmann P, 2005, ANTICANCER RES, V25, P1739; Hart WR, 2001, INT J GYNECOL PATHOL, V20, P16, DOI 10.1097/00004347-200101000-00003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Leonard B, 2014, BIOMED RES INT, DOI 10.1155/2014/480573; Liegl B, 2006, HISTOPATHOLOGY, V48, P268, DOI 10.1111/j.1365-2559.2005.02321.x; Masse I, 2014, ARCH DERMATOL RES, V306, P201, DOI 10.1007/s00403-013-1435-5; McCleskey BC, 2015, AM J CLIN PATHOL, V144, P756, DOI [10.1309/AJCP5MMR1FJVVIPK, 10.1309/AJCP5MMR1FJVVTPK]; Mertens RB, 2015, AM J DERMATOPATH, V37, P885, DOI 10.1097/DAD.0000000000000306; Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f; Nakayama A, 2016, END SOS 98 ANN M EXP, DOI [10.1210/endo-meetings.2016.TB.1.FRI-060, DOI 10.1210/ENDO-MEETINGS.2016.TB.1.FRI-060]; Pinto AP, 2010, MODERN PATHOL, V23, P404, DOI 10.1038/modpathol.2009.179; Reyes MC, 2014, J CLIN PATHOL, V67, P290, DOI 10.1136/jclinpath-2013-202117; Rolfe KJ, 2003, BRIT J CANCER, V89, P2249, DOI 10.1038/sj.bjc.6601444; Singh N, 2015, AM J SURG PATHOL, V39, P52, DOI 10.1097/PAS.0000000000000291; Smith JS, 2009, OBSTET GYNECOL, V113, P917, DOI 10.1097/AOG.0b013e31819bd6e0; Solus JF, 2016, J CUTAN PATHOL, V43, P347, DOI 10.1111/cup.12667; Steenbergen RDM, 2002, AM J PATHOL, V160, P1945, DOI 10.1016/S0002-9440(10)61143-1; Trietsch MD, 2015, GYNECOL ONCOL, V136, P143, DOI 10.1016/j.ygyno.2014.11.002; van de Nieuwenhof HP, 2011, MODERN PATHOL, V24, P297, DOI 10.1038/modpathol.2010.192; van de Nieuwenhof HP, 2009, EUR J CANCER, V45, P851, DOI 10.1016/j.ejca.2008.11.037; van den Einden LCG, 2013, MODERN PATHOL, V26, P874, DOI 10.1038/modpathol.2012.235; Wilkinson EJ, BLAUSTEINS PATHOLOGY; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yang B, 2000, AM J SURG PATHOL, V24, P429, DOI 10.1097/00000478-200003000-00013; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223	32	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1131	1140		10.1038/s41379-018-0021-y			10	Pathology	Pathology	GP1HY	WOS:000440567300012	29434343				2019-10-28	
J	Kurt, H; Zheng, L; Kantarjian, HM; Tang, GL; Ravandi-Kashani, F; Garcia-Manero, G; Gong, ZM; Amin, HM; Konoplev, SN; Routbort, MJ; Han, X; Wang, W; Medeiros, LJ; Hu, SM				Kurt, Habibe; Zheng, Lan; Kantarjian, Hagop M.; Tang, Guilin; Ravandi-Kashani, Farhad; Garcia-Manero, Guillermo; Gong, Zimu; Amin, Hesham M.; Konoplev, Sergej N.; Routbort, Mark J.; Han, Xin; Wang, Wei; Medeiros, L. Jeffery; Hu, Shimin			Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome	MODERN PATHOLOGY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE BIPHENOTYPIC LEUKEMIA; POLYMERASE-CHAIN-REACTION; FUSION GENE TRANSCRIPTS; BCR-ABL TRANSCRIPT; TYROSINE KINASE; LATE APPEARANCE; BLAST CRISIS	The Philadelphia chromosome resulting from t(9;22)(q34;q11.2) or its variants is a defining event in chronic myeloid leukemia. It is also observed in several types of de novo acute leukemia, commonly in B lymphoblastic leukemia, and rarely in acute myeloid leukemia, acute leukemia of ambiguous lineage, and T lymphoblastic leukemia. Acquisition of the Philadelphia chromosome during therapy of acute leukemia and myelodysplastic syndrome is rare. We reported 19 patients, including 11 men and 8 women with a median age of 53 years at initial diagnosis. The diagnoses at initial presentation were acute myeloid leukemia (n = 11), myelodysplastic syndrome (n = 5), B lymphoblastic leukemia (n = 2), and T lymphoblastic leukemia (n = 1); no cases carried the Philadelphia chromosome. The Philadelphia chromosome was detected subsequently at relapse, or at refractory stage of acute leukemia or myelodysplastic syndrome. Of 14 patients evaluated for the BCR-ABL1 transcript subtype, 12 had the e1a2 transcript. In 11 of 14 patients, the diseases before and after emergence of the Philadelphia chromosome were clonally related by karyotype or shared gene mutations. Of 15 patients with treatment information available, 7 received chemotherapy alone, 5 received chemotherapy plus tyrosine kinase inhibitors, 2 received tyrosine kinase inhibitors only, and 1 patient was not treated. Twelve patients had follow-up after acquisition of the Philadelphia chromosome; all had persistent/refractory acute leukemia. Thirteen of 15 patients died a median of 3 months after the emergence of the Philadelphia chromosome. In summary, secondary Philadelphia chromosome acquired during therapy is rare, and is associated with the e1a2 transcript subtype, terminal disease stage, and poor outcome.	[Kurt, Habibe; Zheng, Lan; Tang, Guilin; Gong, Zimu; Amin, Hesham M.; Konoplev, Sergej N.; Routbort, Mark J.; Wang, Wei; Medeiros, L. Jeffery; Hu, Shimin] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Kantarjian, Hagop M.; Ravandi-Kashani, Farhad; Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Han, Xin] Univ Texas MD Anderson Canc Ctr, Dept Lab Med, Houston, TX 77030 USA	Hu, SM (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA.	shu1@mdanderson.org	Hu, Shimin/H-3427-2019				ABE S, 1979, CANCER, V43, P2352, DOI 10.1002/1097-0142(197906)43:6<2352::AID-CNCR2820430628>3.0.CO;2-6; Adriana Z, 2013, Gulf J Oncolog, V1, P81; Aoki J, 2012, LEUKEMIA RES, V36, pE41, DOI 10.1016/j.leukres.2011.10.008; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145; Bacher U, 2011, BRIT J HAEMATOL, V152, P713, DOI 10.1111/j.1365-2141.2010.08472.x; Bai S, 2017, BRIT J HAEMATOL, V176, P514, DOI 10.1111/bjh.14484; Borowitz MJ, 2008, WHO CLASSIFICATION T, P5; Campbell LJ, 1999, AUST NZ J MED, V29, P707, DOI 10.1111/j.1445-5994.1999.tb01619.x; Carbonell F, 1996, LEUKEMIA, V10, P1283; Chen L, 2004, CANCER GENET CYTOGEN, V152, P132, DOI 10.1016/j.cancergencyto.2003.11.006; Chen Z, 1998, CANCER GENET CYTOGEN, V101, P148, DOI 10.1016/S0165-4608(97)00262-8; COAD JE, 1994, LEUKEMIA, V8, P889; Dai HP, 2012, INT J HEMATOL, V96, P814, DOI 10.1007/s12185-012-1190-y; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DHINGRA K, 1991, LEUKEMIA, V5, P191; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Drummond MW, 2003, LEUKEMIA, V17, P463, DOI 10.1038/sj.leu.2402814; Fielding Adele K, 2015, Am Soc Clin Oncol Educ Book, pe352, DOI 10.14694/EdBook_AM.2015.35.e352; Fielding AK, 2014, BLOOD, V123, P843, DOI 10.1182/blood-2013-09-529008; FUJIMURA T, 1993, CANCER GENET CYTOGEN, V68, P143, DOI 10.1016/0165-4608(93)90012-B; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Gong Z, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.62; Hamaguchi H, 1997, BRIT J HAEMATOL, V98, P399, DOI 10.1046/j.1365-2141.1997.2143029.x; Hato A, 2005, HEMATOLOGY, V10, P379, DOI 10.1080/10245330500226787; Inokuchi K, 1998, GENE CHROMOSOME CANC, V23, P227, DOI 10.1002/(SICI)1098-2264(199811)23:3<227::AID-GCC4>3.0.CO;2-3; Jabbour E, 2016, AM J HEMATOL, V91, P253, DOI 10.1002/ajh.24275; JACOBSEN RJ, 1986, BRIT J HAEMATOL, V63, P392; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KATSUNO M, 1994, BRIT J HAEMATOL, V87, P51, DOI 10.1111/j.1365-2141.1994.tb04869.x; Kelemen K, 2014, CANCER GENET-NY, V207, P268, DOI 10.1016/j.cancergen.2014.05.013; Keung YK, 2004, LEUKEMIA RES, V28, P579, DOI 10.1016/j.leukres.2003.10.027; Killick S, 1999, HAEMATOLOGICA, V84, P699; KOHN G, 1975, BLOOD, V45, P653; Kohno T, 1996, BRIT J HAEMATOL, V93, P389, DOI 10.1046/j.1365-2141.1996.4931034.x; Konoplev S, 2013, LEUKEMIA LYMPHOMA, V54, P138, DOI 10.3109/10428194.2012.701739; Lesesve JF, 1996, BRIT J HAEMATOL, V95, P372, DOI 10.1046/j.1365-2141.1996.d01-1898.x; Luthra Rajyalakshmi, 2006, V335, P135; Luthra R, 2014, HAEMATOLOGICA, V99, P465, DOI 10.3324/haematol.2013.093765; MATSUE K, 1995, AM J HEMATOL, V49, P341, DOI 10.1002/ajh.2830490413; MELO JV, 1994, LEUKEMIA, V8, P208; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Merzianu M, 2005, AM J CLIN PATHOL, V124, P807, DOI 10.1309/3HFE16DKMB1DBFMN; MILLER BA, 1984, BRIT J HAEMATOL, V56, P139, DOI 10.1111/j.1365-2141.1984.tb01279.x; Nacheva EP, 2013, BRIT J HAEMATOL, V161, P541, DOI 10.1111/bjh.12301; Najfeld V, 1998, LEUKEMIA, V12, P517, DOI 10.1038/sj.leu.2400974; NAKAMURA K, 1991, BRIT J HAEMATOL, V78, P130, DOI 10.1111/j.1365-2141.1991.tb04399.x; Neuendorff NR, 2015, ACTA HAEMATOL-BASEL, V133, P237, DOI 10.1159/000368176; Ok CY, 2015, LEUKEMIA RES, V39, P348, DOI 10.1016/j.leukres.2014.12.006; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; Pane F, 1996, BLOOD, V88, P2410, DOI 10.1182/blood.V88.7.2410.bloodjournal8872410; Patel KP, 2011, J MOL DIAGN, V13, P678, DOI 10.1016/j.jmoldx.2011.06.004; Prebet T, 2004, BONE MARROW TRANSPL, V33, P247, DOI 10.1038/sj.bmt.1704308; Raanani P, 2005, ACTA HAEMATOL-BASEL, V113, P181, DOI 10.1159/000084448; Reboursiere Emilie, 2015, Hematol Oncol Stem Cell Ther, V8, P28, DOI 10.1016/j.hemonc.2014.09.002; Roumier C, 1999, HAEMATOLOGICA, V84, P1075; Salem A, 2017, AM J HEMATOL, V92, P520, DOI 10.1002/ajh.24710; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; SESSAREGO M, 1990, CANCER GENET CYTOGEN, V48, P35, DOI 10.1016/0165-4608(90)90213-T; Shah N, 2008, PEDIATR BLOOD CANCER, V50, P1052, DOI 10.1002/pbc.21317; SHIMAMOTO T, 1995, LEUKEMIA, V9, P640; Simons A, 2013, CYTOGENET GENOME RES, V141, P1, DOI 10.1159/000353118; SMADJA N, 1985, CANCER, V55, P1477, DOI 10.1002/1097-0142(19850401)55:7<1477::AID-CNCR2820550710>3.0.CO;2-A; Soupir CP, 2007, AM J CLIN PATHOL, V127, P642, DOI 10.1309/B4NVER1AJJ84CTUU; Tchirkov A, 1998, ANN HEMATOL, V77, P55, DOI 10.1007/s002770050412; TSUCHIYA H, 1995, LEUKEMIA, V9, P1689; VANDENBERGHE E, 1991, LEUKEMIA, V5, P683; Vardiman JW, 2008, WHO CLASSIFICATION T, P32; VERHOEF G, 1992, CANCER GENET CYTOGEN, V59, P161, DOI 10.1016/0165-4608(92)90209-Q; VONCKEN JW, 1992, CANCER RES, V52, P4534; Warren M, 2012, MODERN PATHOL, V25, P1405, DOI 10.1038/modpathol.2012.88; Wassmann B, 2006, BLOOD, V108, P1469, DOI 10.1182/blood-2005-11-4386; Yamashita S, 1996, ACTA HAEMATOL-BASEL, V96, P99; You MJ, 2015, AM J CLIN PATHOL, V144, P411, DOI 10.1309/AJCPMF03LVSBLHPJ	75	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1141	1154		10.1038/s41379-018-0014-x			14	Pathology	Pathology	GP1HY	WOS:000440567300013	29449681				2019-10-28	
J	Cottrell, TR; Duong, AT; Gocke, CD; Xu, HY; Ogurtsova, A; Taube, JM; Belchis, DA				Cottrell, Tricia R.; Duong, Anh T.; Gocke, Christopher D.; Xu, Haiying; Ogurtsova, Aleksandra; Taube, Janis M.; Belchis, Deborah A.			PD-L1 expression in inflammatory myofibroblastic tumors	MODERN PATHOLOGY			English	Article							SOFT-TISSUE SARCOMA; LUNG-CANCER; ALK; FUSIONS; ROS1; REARRANGEMENTS; MUTATIONS; BLOCKADE; EGFR	Inflammatory myofibroblastic tumor is a rare mesenchymal tumor occurring at many anatomic sites, with a predilection for children and young adults. Often indolent, they can be locally aggressive and can metastasize, resulting in significant morbidity and mortality. Therapeutic options are often limited. The identification of underlying kinase mutations has allowed the use of targeted therapy in a subset of patients. Unfortunately, not all tumors harbor mutations and resistance to tyrosine kinase inhibitor therapy is a potential problem. We hypothesized that these tumors may be amenable to PD-L1 therapy given the immune nature of the tumor. PD-L1 expression in inflammatory myofibroblastic tumors has not yet been defined. The purpose of this study was to explore PD-L1 expression in inflammatory myofibroblastic tumors, as adaptive PD-L1 expression is known to enrich for response to anti-PD-1/PD-L1 therapies. Expression of PD-L1 (clone SP142) was assessed in 35 specimens from 28 patients. Positivity was defined as membranous expression in >= 5% of cells and evaluated separately in tumor and immune cells. Adaptive vs. constitutive patterns of tumor cell PD-L1 expression were assessed. PD-L1 status was correlated with clinicopathologic features. CD8(+) T cell infiltrates were quantified by digital image analysis. ALK status was assessed by immunohistochemistry and/or FISH. Twenty-four (69%) tumors had PD-L1(+) tumor cells and 28 (80%) showed PD-L1(+) immune cells. Most recurrent and metastatic tumors (80%) and ALK(-) tumors (88%) were PD-L1(+). Adaptive PD-L1 expression was present in 23 (96%) of PD-L1(+) tumors, which also showed a three-four fold increase in CD87(+) T cell infiltration relative to PD-L1(-) tumors. Constitutive PD-L1 expression was associated with larger tumor size (p = 0.002). Inflammatory myofibroblastic tumors show frequent constitutive and adaptive PD-L1 expression, the latter of which is thought to be predictive of response to anti-PD-1. These data support further investigation into PD-1/PD-L1 blockade in this tumor type.	[Cottrell, Tricia R.; Gocke, Christopher D.; Belchis, Deborah A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Cottrell, Tricia R.; Duong, Anh T.; Taube, Janis M.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA; [Duong, Anh T.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Xu, Haiying; Ogurtsova, Aleksandra; Taube, Janis M.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA	Belchis, DA (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.	dbelchi1@jhmi.edu			Melanoma Research Alliance; Bristol-Myers SquibbBristol-Myers Squibb; Sidney Kimmel Cancer Center [P30 CA006973]; National Cancer Institute NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA142779]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 CA193145]; Bloombergsimilar toKimmel Institute for Cancer Immunotherapy; Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant [SU2C-AACR-DT1012]	We would like to thank Drs. Hao Wang and Ludmila Danilova for statistical consultation, and Jessica Esandrio for administrative assistance. This work was supported by the Melanoma Research Alliance (JMT); Bristol-Myers Squibb (JMT); Sidney Kimmel Cancer Center Core Grant P30 CA006973 (JMT); the National Cancer Institute NIH Grant R01 CA142779 (JMT); NIH Grant T32 CA193145 (TRC). We were also supported by the Bloomberg similar to Kimmel Institute for Cancer Immunotherapy and a Stand Up To Cancer-Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.	Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Antonescu CR, 2015, AM J SURG PATHOL, V39, P957, DOI 10.1097/PAS.0000000000000404; Bertucci F, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1278100; Butrynski JE, 2010, NEW ENGL J MED, V363, P1727, DOI 10.1056/NEJMoa1007056; Coffin CM, 2007, AM J SURG PATHOL, V31, P509, DOI 10.1097/01.pas.0000213393.57322.c7; Coffin CM, 2013, WHO CLASSIFICATION T; D'Angelo SP, 2015, HUM PATHOL, V46, P357, DOI 10.1016/j.humpath.2014.11.001; Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101; Gaule P, 2017, JAMA ONCOL, V3, P256, DOI 10.1001/jamaoncol.2016.3015; Habib L, 2017, ORBIT, V36, P178, DOI 10.1080/01676830.2017.1279645; Hirsch FR, 2017, J THORAC ONCOL, V12, P208, DOI 10.1016/j.jtho.2016.11.2228; Hong SD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1094598; Kim C, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2451-6; Kim J, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0060505, 10.1371/journal.pone.0077972]; Koh J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1108514; Lee JC, 2017, J PATHOL, V241, P316, DOI 10.1002/path.4836; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Marino-Enriquez A, 2011, AM J SURG PATHOL, V35, P135, DOI 10.1097/PAS.0b013e318200cfd5; McDermott M, 2016, SEMIN DIAGN PATHOL, V33, P358, DOI 10.1053/j.semdp.2016.08.007; Rangachari D, 2017, J THORAC ONCOL, V12, P878, DOI 10.1016/j.jtho.2016.12.026; Ratcliffe MJ, 2017, CLIN CANCER RES, V23, P3585, DOI 10.1158/1078-0432.CCR-16-2375; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011; Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Toulmonde M, 2016, P AN M AM SOC CLIN, V15, P11008; Toulmonde M, 2018, JAMA ONCOL, V4, P93, DOI 10.1001/jamaoncol.2017.1617; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Yamamoto H, 2016, HISTOPATHOLOGY, V69, P72, DOI 10.1111/his.12910; Yanik EL, 2017, JAMA ONCOL, V3, P974, DOI 10.1001/jamaoncol.2017.0115	32	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JUL	2018	31	7					1155	1163		10.1038/s41379-018-0034-6			9	Pathology	Pathology	GP1HY	WOS:000440567300014	29449680	Green Accepted			2019-10-28	
J	Janardhan, KS; Jensen, H; Clayton, NP; Herbert, RA				Janardhan, Kyathanahalli S.; Jensen, Heather; Clayton, Natasha P.; Herbert, Ronald A.			Immunohistochemistry in Investigative and Toxicologic Pathology	TOXICOLOGIC PATHOLOGY			English	Review						IHC; controls; rat; mice; antibodies; reproducibility; fixation	PROLIFERATOR-ACTIVATED RECEPTORS; PARAFFIN-EMBEDDED TISSUES; INDUCED ANTIGEN RETRIEVAL; MONOCLONAL-ANTIBODIES; HORSERADISH-PEROXIDASE; SIGNAL AMPLIFICATION; TECHNICAL ASPECTS; LABELED ANTIBODY; MAST-CELLS; STANDARDIZATION	Immunohistochemistry (IHC) is a valuable tool in pathology. This review provides a brief description of the technical aspects of IHC and a detailed discussion on the variables that affect the results, interpretation, and reproducibility of IHC results. Lists of antibodies that have and have not worked in IHC on various mouse and rat tissues in our laboratory are provided as a guidance for selection of antibodies. An approach to IHC method optimization is presented. Finally, the critical information that should be included as a part of peer-reviewed manuscript is also discussed.	[Janardhan, Kyathanahalli S.] Integrated Lab Syst Inc, MS B3-06,POB 12233, Morrisville, NC 27709 USA; [Jensen, Heather; Clayton, Natasha P.; Herbert, Ronald A.] NIEHS, Div Natl Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA	Janardhan, KS (reprint author), Integrated Lab Syst Inc, MS B3-06,POB 12233, Morrisville, NC 27709 USA.	janardhank@niehs.nih.gov			NIH, National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the NIH, National Institute of Environmental Health Sciences.	Alkan SS, 2004, NAT REV IMMUNOL, V4, P153, DOI 10.1038/nri1265; Baker M, 2015, NATURE, V521, P274, DOI 10.1038/521274a; Bandrowski A, 2016, BRAIN BEHAV, V6, DOI 10.1002/brb3.417; Barrionuevo FJ, 2016, ELIFE, V5, DOI 10.7554/eLife.15635; BOBROW MN, 1992, J IMMUNOL METHODS, V150, P145, DOI 10.1016/0022-1759(92)90073-3; Bordeaux J, 2010, BIOTECHNIQUES, V48, P197, DOI 10.2144/000113382; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Bratthauer G. L., 1995, IMMUNOCYTOCHEMICAL M, V34, P185; Buchwalow I, 2013, ACTA HISTOCHEM, V115, P587, DOI 10.1016/j.acthis.2012.12.008; Buchwalow I, 2011, SCI REP-UK, V1, DOI 10.1038/srep00028; Burry RW, 2011, J HISTOCHEM CYTOCHEM, V59, P6, DOI 10.1369/jhc.2010.956920; BUSSOLATI G, 1983, J HISTOCHEM CYTOCHEM, V31, P1419, DOI 10.1177/31.12.6195216; Coons AH, 1942, J IMMUNOL, V45, P159; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAVEY FR, 1970, AM J CLIN PATHOL, V53, P531, DOI 10.1093/ajcp/53.4.531; Delpire E, 2015, AM J PHYSIOL-CELL PH, V309, pC707, DOI 10.1152/ajpcell.zh0-7843-editorial.2015; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; EISENBARTH GS, 1981, ANAL BIOCHEM, V111, P1, DOI 10.1016/0003-2697(81)90221-9; Elias J., 1990, IMMUNOHISTOPATHOLOGY, P1; FOX CH, 1985, J HISTOCHEM CYTOCHEM, V33, P845, DOI 10.1177/33.8.3894502; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Goldstein NS, 2007, APPL IMMUNOHISTO M M, V15, P124, DOI 10.1097/PAI.0b013e31804c7283; Greenfield E., 2012, ANTIBODIES LAB MANUA, P201; Harley R, 2002, J COMP PATHOL, V127, P228, DOI 10.1053/jcpa.2002.0583; Hayat M. A, 2002, MICROSCOPY IMMUNOHIS, P53; Helander KG, 1999, J HISTOTECHNOL, V22, P317; Hewitt SM, 2014, J HISTOCHEM CYTOCHEM, V62, P693, DOI 10.1369/0022155414545224; Holmseth S, 2012, J HISTOCHEM CYTOCHEM, V60, P174, DOI 10.1369/0022155411434828; Howat WJ, 2014, METHODS, V70, P12, DOI 10.1016/j.ymeth.2014.01.022; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG SN, 1975, LAB INVEST, V33, P88; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krenacs L, 2010, METHODS MOL BIOL, V588, P103, DOI 10.1007/978-1-59745-324-0_14; Leong TYM, 2010, ADV ANAT PATHOL, V17, P404, DOI 10.1097/PAP.0b013e3181f8957c; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Marx V, 2013, NAT METHODS, V10, P703, DOI 10.1038/nmeth.2570; NAKANE PK, 1967, J CELL BIOL, V33, P307, DOI 10.1083/jcb.33.2.307; Paavilainen L, 2010, J HISTOCHEM CYTOCHEM, V58, P237, DOI 10.1369/jhc.2009.954321; Pileri SA, 1997, J PATHOL, V183, P116; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Ramos-Vara JA, 2005, VET PATHOL, V42, P405, DOI 10.1354/vp.42-4-405; Sabattini E, 1998, J CLIN PATHOL, V51, P506, DOI 10.1136/jcp.51.7.506; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHI SR, 1995, J HISTOCHEM CYTOCHEM, V43, P193, DOI 10.1177/43.2.7822775; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Taylor CR, 2006, HISTOPATHOLOGY, V49, P411, DOI 10.1111/j.1365-2559.2006.02513.x; TAYLOR CR, 1974, J CLIN PATHOL, V27, P14, DOI 10.1136/jcp.27.1.14; Taylor CT, 2011, DIAGNOSTIC IMMUNOHIS, P1; Torlakovic EE, 2015, APPL IMMUNOHISTO M M, V23, P1, DOI 10.1097/PAI.0000000000000163; Torlakovic EE, 2014, APPL IMMUNOHISTO M M, V22, P241, DOI 10.1097/PAI.0000000000000069; Torlakovic EE, 2015, J CLIN PATHOL, V68, P879, DOI 10.1136/jclinpath-2014-202705; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Ward JM, 2014, VET PATHOL, V51, P88, DOI 10.1177/0300985813503571; Yamashita S, 2007, PROG HISTOCHEM CYTO, V41, P141, DOI 10.1016/j.proghi.2006.09.001; Zeineddine D, 2014, AM J STEM CELLS, V3, P74	56	2	2	2	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					488	510		10.1177/0192623318776907			23	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500002	29966501	Green Accepted, Bronze			2019-10-28	
J	Varela, A; Jolette, J				Varela, Aurore; Jolette, Jacquelin			Bone Toolbox: Biomarkers, Imaging Tools, Biomechanics, and Histomorphometry	TOXICOLOGIC PATHOLOGY			English	Review						skeleton; bone biomarkers; osteodensitometry; DXA; pQCT; micro-CT; HR-pQCT; histomorphometry; biomechanics	QUANTITATIVE COMPUTED-TOMOGRAPHY; OVARIECTOMIZED RHESUS-MONKEYS; PARATHYROID-HORMONE 1-84; FINITE-ELEMENT-ANALYSIS; CYNOMOLGUS MONKEYS; CORTICAL BONE; MICROCOMPUTED TOMOGRAPHY; SCLEROSTIN ANTIBODY; MINERAL DENSITY; TRABECULAR BONE	Bone is a unique tissue with turnover, metabolic, and cellular activities that vary through development to aging and with a mineralized matrix in which the current state and the history of a bone coexist. Qualitative histopathology often lacks sensitivity to detect changes in bone formation, mineralization and resorption, which often requires chronic dosing to result in structural changes such as variation in bone mass and geometry. A large panel of modalities can be used to fully analyze the health of the skeleton, including biomarker evaluation in serum or urine, imaging techniques ranging from radiology to computed tomography, bio-mechanical testing, and undecalcified tissue processing with bone histomorphometry. The use of clinically relevant biomarkers provides an important noninvasive, sensitive, rapid, and real-time tool to monitor bone activity at the whole skeleton level when conducting safety assessments in a preclinical setting. Imaging modalities also allow in vivo longitudinal assessments with a powerful, noninvasive and clinically translatable tools to monitor drug effects. Different imaging modalities are used in the preclinical studies to evaluate the bone tissues: standard radiography, dual-energy X-ray absorptiometry, peripheral quantitative computed tomography (pQCT), micro-computed tomography, and high-resolution pQCT. Bone histomorphometry is an important tool that provides sensitive evaluation to detect effects of test articles on bone resorption, formation, mineralization, remodeling rates and growth to address a potential target-or class-related theoretical bone liability. Ultimately, the measurement of bone mechanical properties in pharmaceutical testing is critical to understand the potential effects of that pharmaceutical on bone health and fracture risk. Important considerations are required for including these different techniques in toxicology rodents and nonrodent studies, to actually integrate these into safety assessment.	[Varela, Aurore; Jolette, Jacquelin] Charles River Labs Montreal ULC, 22022 Transcanadienne, Senneville, PQ H9X 3R3, Canada	Varela, A (reprint author), Charles River Labs Montreal ULC, 22022 Transcanadienne, Senneville, PQ H9X 3R3, Canada.	aurore.varela@crl.com					Bahtiri E, 2016, J BONE MINER METAB, V34, P571, DOI 10.1007/s00774-015-0699-6; BARON R, 1984, ANAT REC, V208, P137, DOI 10.1002/ar.1092080114; Binkovitz LA, 2007, PEDIATR RADIOL, V37, P21, DOI 10.1007/s00247-006-0153-y; Blake G., 2013, PRIMER METABOLIC BON, P251; Blake GM, 2008, J BONE MINER RES, V23, P457, DOI 10.1359/JBMR.071119; Bolotin HH, 2007, BONE, V41, P138, DOI 10.1016/j.bone.2007.02.022; Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Boyce RW, 2014, BONE, V64, P314, DOI 10.1016/j.bone.2014.04.002; Boyd SK, 2006, BONE, V39, P854, DOI 10.1016/j.bone.2006.04.017; Cabal A, 2013, BONE, V56, P497, DOI 10.1016/j.bone.2013.06.011; Castillo AB, 2002, J ORTHOPAED RES, V20, P1185, DOI 10.1016/S0736-0266(02)00074-8; Cheung AM, 2012, LANCET ONCOL, V13, P275, DOI 10.1016/S1470-2045(11)70389-8; Chouinard L, 2016, REGUL TOXICOL PHARM, V81, P212, DOI 10.1016/j.yrtph.2016.08.010; Cui GL, 2001, SCAND J GASTROENTERO, V36, P1011; de Mello WG, 2012, BONE, V50, P893, DOI 10.1016/j.bone.2011.12.009; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; EMA (European Medicines Agency CHMP), 2006, GUID EV MED PROD TRE; EMEA, 2008, EUR MED AG EMEA NONC; Erben R. G., 2017, BONE TOXICOLOGY MOL, P253; Erben R. G, 2003, HDB HISTOLOGY METHOD, P99; Erben RG, 2012, METHODS MOL BIOL, V816, P279, DOI 10.1007/978-1-61779-415-5_19; Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154-010-9153-1; FDA, 2016, OST NONCL EV DRUGS I; FDA (Food and Drug Administration), 2006, US FOOD DRUG ADM FDA; FERRETTI JL, 1995, BONE, V16, P119, DOI 10.1016/S8756-3282(94)00018-2; Fox J, 2008, CALCIFIED TISSUE INT, V82, P212, DOI 10.1007/s00223-008-9108-7; Fox J, 2007, BONE, V41, P321, DOI 10.1016/j.bone.2007.04.197; Fox J, 2007, J BONE MINER RES, V22, P260, DOI 10.1359/JBMR.061101; Geiger M, 2014, J EVOLUTION BIOL, V27, P98, DOI 10.1111/jeb.12279; GLUER CC, 1989, J COMPUT ASSIST TOMO, V13, P1023, DOI 10.1097/00004728-198911000-00015; Gunson D, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P2761, DOI 10.1016/B978-0-12-415759-0.00063-7; ISCD (International Society for Clinical Densitometry), 2015, OFF POS AD PED OFF P; Jayakar RY, 2012, BONE, V50, P1379, DOI 10.1016/j.bone.2012.03.017; [JMHW Management BoH], 1999, GUID CONC CLIN EV ME; Johansson S, 2002, BONE, V31, P685, DOI 10.1016/S8756-3282(02)00910-9; Jolette J, 2006, TOXICOL PATHOL, V34, P929, DOI 10.1080/01926230601072301; Jolette J, 2017, REGUL TOXICOL PHARM, V86, P356, DOI 10.1016/j.yrtph.2017.04.001; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kazakia GJ, 2008, MED PHYS, V35, P3170, DOI 10.1118/1.2924210; Kumar S, 2013, J BONE MINER RES, V28, P1653, DOI 10.1002/jbmr.1918; Kwak HB, 2009, BIOL PHARM BULL, V32, P45, DOI 10.1248/bpb.32.45; Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006-1587; Li XD, 2009, J BONE MINER RES, V24, P578, DOI [10.1359/jbmr.081206, 10.1359/JBMR.081206]; MacNeil JA, 2008, MED ENG PHYS, V30, P792, DOI 10.1016/j.medengphy.2007.11.003; Martin EA, 2003, BONE, V32, P261, DOI 10.1016/S8756-3282(02)00983-3; McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756-3282(02)00737-8; MHLW, 2012, JAP MIN HLTH LAB WEL; National Osteoporosis Foundation (NOF), 2014, CLIN GUID PREV TREAT; Nyman JS, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.31; Ohlsson C, 1998, ENDOCR REV, V19, P55, DOI 10.1210/er.19.1.55; Ominsky MS, 2017, J BONE MINER RES, V32, P788, DOI 10.1002/jbmr.3036; Ominsky MS, 2011, BONE, V49, P162, DOI 10.1016/j.bone.2011.04.001; Ominsky MS, 2010, J BONE MINER RES, V25, P948, DOI 10.1002/jbmr.14; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Peake NJ, 2014, OSTEOARTHR CARTILAGE, V22, P1800, DOI 10.1016/j.joca.2014.07.018; Pouliot L, 2013, BIRTH DEFECTS RES B, V98, P374, DOI 10.1002/bdrb.21080; Roach HI, 2003, J HISTOCHEM CYTOCHEM, V51, P373, DOI 10.1177/002215540305100312; Rohde CM, 2003, J NUTR, V133, P777; SCHOCK C C, 1972, Henry Ford Hospital Medical Journal, V20, P131; Schoeller DA, 2005, AM J CLIN NUTR, V81, P1018; Shepherd J A, 2006, Osteoporos Int, V17, P1303, DOI 10.1007/s00198-006-0127-9; Smith BB, 2003, INT J TOXICOL, V22, P403, DOI 10.1080/10915810390232213; Smith SY, 2011, OSTEOPOROSIS RESEARCH: ANIMAL MODELS, P135, DOI 10.1007/978-0-85729-293-3_12; Szulc P, 2013, PRIMER METABOLIC BON, P297, DOI DOI 10.1002/9781118453926; TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756-3282(93)90081-K; Turner CH, 2002, OSTEOPOROSIS INT, V13, P97, DOI 10.1007/s001980200000; Varela A., 2017, BONE TOXICOLOGY MOL, P203; Varela A, 2017, BONE, V95, P143, DOI 10.1016/j.bone.2016.11.027; Varela A, 2017, J BONE MINER RES, V32, P24, DOI 10.1002/jbmr.3003; Vestergaard P, 2008, CALCIFIED TISSUE INT, V82, P92, DOI 10.1007/s00223-007-9099-9; WALKER KVR, 1972, CELL TISSUE KINET, V5, P409, DOI 10.1111/j.1365-2184.1972.tb00379.x; Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109; Yu EW, 2012, J BONE MINER RES, V27, P119, DOI 10.1002/jbmr.506; Zemel B, 2008, J CLIN DENSITOM, V11, P59, DOI 10.1016/j.jocd.2007.12.006	75	1	1	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					511	529		10.1177/0192623318779565			19	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500003	29973125	Bronze			2019-10-28	
J	Murayama, H; Eguchi, A; Nakamura, M; Kawashima, M; Nagahara, R; Mizukami, S; Kimura, M; Makino, E; Takahashi, N; Ohtsuka, R; Koyanagi, M; Hayashi, S; Maronpot, RR; Shibutani, M; Yoshida, T				Murayama, Hirotada; Eguchi, Ayumi; Nakamura, Misato; Kawashima, Masahi; Nagahara, Rei; Mizukami, Sayaka; Kimura, Masayuki; Makino, Emi; Takahashi, Naofumi; Ohtsuka, Ryoichi; Koyanagi, Mihoko; Hayashi, Shim-mo; Maronpot, Robert R.; Shibutani, Makoto; Yoshida, Toshinori			Spironolactone in Combination with alpha-glycosyl Isoquercitrin Prevents Steatosis-related Early Hepatocarcinogenesis in Rats through the Observed NADPH Oxidase Modulation	TOXICOLOGIC PATHOLOGY			English	Article						isoquercitrin; high-fat diet; NADPH oxidase; spironolactone; steatosis	ENZYMATICALLY MODIFIED ISOQUERCITRIN; FATTY LIVER-DISEASE; EXPERIMENTAL NONALCOHOLIC STEATOHEPATITIS; HIGH-FRUCTOSE DIET; OXIDATIVE STRESS; LIPID-METABOLISM; ANGIOTENSIN-II; UP-REGULATION; QUERCETIN; ALDOSTERONE	Administration of the diuretic, spironolactone (SR), can inhibit chronic liver diseases. We determined the effects of SR alone or in combination with the antioxidant alpha-glycosyl isoquercitrin (AGIQ) on hyperlipidemia- and steatosis-related precancerous lesions in high-fat diet (HFD)-fed rats subjected to a two-stage hepatocarcinogenesis model. Rats were fed with control basal diet or HFD, which was administered with SR alone or in combination with an antioxidant AGIQ in drinking water. An HFD increased body weight, intra-abdominal fat (adipose) tissue weight, and plasma lipids, which were reduced by coadministration of SR and AGIQ. SR and AGIQ coadministration also reduced hepatic steatosis and preneoplastic glutathione S-transferase placental form-positive foci, in association with decrease in NADPH oxidase (NOX) subunit p22phox-positive cells and an increase in active-caspase-3-positive cells in the foci. Hepatic gene expression analysis revealed that the coadministration of SR and AGIQ altered mRNA levels of lipogenic enzymes (Scdl and Fasn), antioxidant-related enzymes (Catalase), NOX component (P67phox), and anti-inflammatory transcriptional factor (Pparg). Our results indicated that SR in combination with AGIQ had the potential of suppressing hyperlipidemia- and steatosis-related early hepatocarcinogenesis through the reduced expression of NOX subunits.	[Murayama, Hirotada; Eguchi, Ayumi; Nakamura, Misato; Kawashima, Masahi; Nagahara, Rei; Mizukami, Sayaka; Kimura, Masayuki; Shibutani, Makoto; Yoshida, Toshinori] Tokyo Univ Agr & Technol, Lab Vet Pathol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan; [Mizukami, Sayaka; Kimura, Masayuki] Gifu Univ, United Grad Sch Vet Sci, Pathogenet Vet Sci, Gifu, Gifu, Japan; [Makino, Emi; Takahashi, Naofumi; Ohtsuka, Ryoichi] Inst Environm Toxicol, Joso, Ibaraki, Japan; [Koyanagi, Mihoko; Hayashi, Shim-mo] San Ei Gen FFI Inc, Global Sci & Regulatory Affairs, Toyonaka, Osaka, Japan; [Maronpot, Robert R.] Maronpot Consulting LLC, Raleigh, NC USA	Yoshida, T (reprint author), Tokyo Univ Agr & Technol, Lab Vet Pathol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	yoshida7@cc.tuat.ac.jp	Yoshida, Toshinori/B-7255-2015; Shibutani, Makoto/C-2510-2013		Japan Food Chemical Research FoundationJapan Food Chemical Research Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Japan Food Chemical Research Foundation.	Granado-Serrano AB, 2006, J NUTR, V136, P2715; Brieger K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13659; Carr RM, 2016, EXP CELL RES, V340, P187, DOI 10.1016/j.yexcr.2015.10.021; Chalasani N, 2012, AM J GASTROENTEROL, V107, P811, DOI 10.1038/ajg.2012.128; Chatterjee S, 2013, J HEPATOL, V58, P778, DOI 10.1016/j.jhep.2012.11.035; Dattaroy D, 2015, AM J PHYSIOL-GASTR L, V308, pG298, DOI 10.1152/ajpgi.00346.2014; FOLEY J, 1993, ENVIRON HEALTH PERSP, V101, P199, DOI 10.2307/3431868; Fujii Y, 2013, TOXICOLOGY, V305, P30, DOI 10.1016/j.tox.2013.01.002; Fujisawa G, 2006, TRANSL RES, V148, P149, DOI 10.1016/j.trsl.2006.03.007; Gabele E, 2011, J HEPATOL, V55, P1391, DOI 10.1016/j.jhep.2011.02.035; Gupte RS, 2009, FREE RADICAL BIO MED, V47, P219, DOI 10.1016/j.freeradbiomed.2009.01.028; Hall AP, 2012, TOXICOL PATHOL, V40, P971, DOI 10.1177/0192623312448935; Hara S, 2014, EXP TOXICOL PATHOL, V66, P225, DOI 10.1016/j.etp.2014.02.002; Ito N, 2003, CANCER SCI, V94, P3; Iwashima F, 2008, ENDOCRINOLOGY, V149, P1009, DOI 10.1210/en.2007-0864; Janevski Mile, 2011, Comp Hepatol, V10, P10, DOI 10.1186/1476-5926-10-10; Jones HS, 2016, MOL NUTR FOOD RES, V60, P787, DOI 10.1002/mnfr.201500751; Kim BH, 2013, MOL CELLS, V35, P410, DOI 10.1007/s10059-013-0031-z; Kim JY, 2008, J CELL BIOCHEM, V105, P1386, DOI 10.1002/jcb.21958; King S, 2014, INT J EXP PATHOL, V95, P244, DOI 10.1111/iep.12074; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kobori M, 2011, MOL NUTR FOOD RES, V55, P530, DOI 10.1002/mnfr.201000392; Kumamoto R, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-54; Kuwata K, 2011, TOXICOLOGY, V283, P8, DOI 10.1016/j.tox.2011.01.020; Lalles JP, 2012, J NUTR BIOCHEM, V23, P1490, DOI 10.1016/j.jnutbio.2011.10.001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034230; Makino T, 2009, BIOL PHARM BULL, V32, P2034, DOI 10.1248/bpb.32.2034; Marcolin E, 2012, J NUTR, V142, P1821, DOI 10.3945/jn.112.165274; Nyska A, 2016, FOOD CHEM TOXICOL, V97, P354, DOI 10.1016/j.fct.2016.09.030; Paravicini TM, 2012, J AM SOC HYPERTENS, V6, P169, DOI 10.1016/j.jash.2012.01.002; Pisonero-Vaquero S, 2015, MOL NUTR FOOD RES, V59, P879, DOI 10.1002/mnfr.201400913; Pizarro M, 2015, LIVER INT, V35, P2129, DOI 10.1111/liv.12794; Ruiz ML, 2007, DRUG METAB DISPOS, V35, P2060, DOI 10.1124/dmd.107.016519; Sheedfar F, 2013, AGING CELL, V12, P950, DOI 10.1111/acel.12128; Shibata S, 2007, HYPERTENSION, V49, P355, DOI 10.1161/01.HYP.0000255636.11931.a2; Softic S, 2016, DIGEST DIS SCI, V61, P1282, DOI 10.1007/s10620-016-4054-0; Sudan S, 2014, ANTICANCER RES, V34, P1691; Tsuji H, 2016, WORLD J UROL, V34, P89, DOI 10.1007/s00345-015-1563-y; Valentova K, 2014, FOOD CHEM TOXICOL, V68, P267, DOI 10.1016/j.fct.2014.03.018; Vedanarayanan MS, 2011, J ACUPUNCT MERIDIAN, V4, P236, DOI 10.1016/j.jams.2011.09.014; Wada T, 2013, AM J PHYSIOL-ENDOC M, V305, pE1415, DOI 10.1152/ajpendo.00419.2013; Wada T, 2010, ENDOCRINOLOGY, V151, P2040, DOI 10.1210/en.2009-0869; Wang W, 2017, HEPATOLOGY, V66, P108, DOI 10.1002/hep.29129; Wang Y, 2009, INT J CANCER, V124, P540, DOI 10.1002/ijc.23995; Whaley-Connell A, 2010, PROG CARDIOVASC DIS, V52, P401, DOI 10.1016/j.pcad.2009.12.004; Yoshida T, 2017, EXP TOXICOL PATHOL, V69, P9, DOI 10.1016/j.etp.2016.10.003; Yu J, 2010, HEPATOLOGY, V51, P2008, DOI 10.1002/hep.23550	48	0	0	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					530	539		10.1177/0192623318778508			10	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500004	29843569	Bronze			2019-10-28	
J	Pervin, M; Karim, MR; Kuramochi, M; Izawa, T; Kuwamura, M; Yamate, J				Pervin, Munmun; Karim, Mohammad Rabiul; Kuramochi, Mizuki; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji			Macrophage Populations and Expression of Regulatory Inflammatory Factors in Hepatic Macrophage-depleted Rat Livers under Lipopolysaccharide (LPS) Treatment	TOXICOLOGIC PATHOLOGY			English	Article						cytokines; immunohistochemistry; lipopolysaccharide; liver; macrophages; rats	THIOACETAMIDE TAA; INJURY; CELLS; POLARIZATION; ACTIVATION; HEPATOTOXICITY; GALECTIN-3; CLODRONATE; ENDOTOXIN; DEFENSE	To investigate the significance of the appearance of hepatic macrophages and expression of inflammatory factors in normal and macrophage-depleted livers, hepatic macrophages were depleted with liposome (Lipo)-encapsulated clodronate (CLD; 50 mg/kg, i.v.) followed by lipopolysaccharide (LPS) administration (0.1 mg/kg, i.p.) in F344 rats (CLD + LPS). Vehicle control rats (Lipo + LPS) received empty-Lipo before LPS. The low dose of LPS did not result in microscopic changes in the liver in either treatment group but did modulate M1 and M2 macrophage activity in Lipo + LPS rats without altering repopulating hepatic macrophages in CLD + LPS rats. LPS treatment in Lipo + LPS rats dramatically increased the M1 (IL-1 beta, IL-6, TNF-alpha, and MCP-1) but not M2 macrophage-related factors (IL-4 and CSF-1) compared to CLD + LPS rats. In the CLD LPS rats, the M2 macrophage-related factors IL-4 and CSF-1 were elevated. In conclusion, low-dose LPS activated hepatic macrophages in rat livers without causing liver injury or stimulating repopulating hepatic macrophages. These data suggest that LPS may alter the liver microenvironment by modulating M1 or M2 macrophage-related inflammatory mediators and macrophage-based hepatotoxicity.	[Pervin, Munmun; Karim, Mohammad Rabiul; Kuramochi, Mizuki; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, 1-58 Rinku Ourai Kita, Izumisano City, Osaka 5988531, Japan	Yamate, J (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, 1-58 Rinku Ourai Kita, Izumisano City, Osaka 5988531, Japan.	yamate@vet.osakafu-u.ac.jp					Anders LC, 2016, TOXICOL SCI, V151, P312, DOI 10.1093/toxsci/kfw045; Dong S, 1997, GLYCOCONJUGATE J, V14, P267, DOI 10.1023/A:1018554124545; Ganey PE, 2001, TOXICOLOGY, V169, P195, DOI 10.1016/S0300-483X(01)00523-6; Golbar HM, 2012, EXP TOXICOL PATHOL, V64, P1, DOI 10.1016/j.etp.2010.05.011; Golbar HM, 2016, TOXICOL PATHOL, V44, P246, DOI 10.1177/0192623315621191; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; Ide M, 2005, J COMP PATHOL, V133, P92, DOI 10.1016/j.jcpa.2005.01.011; Ju C, 2016, CELL MOL IMMUNOL, V13, P316, DOI 10.1038/cmi.2015.104; Laskin DL, 2011, ANNU REV PHARMACOL, V51, P267, DOI 10.1146/annurev.pharmtox.010909.105812; Liu J, 2000, TOXICOLOGY, V147, P167, DOI 10.1016/S0300-483X(00)00193-1; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; Martinez FO, 2011, EUR J IMMUNOL, V41, P1531, DOI 10.1002/eji.201141670; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mori Y, 2009, TOXICOL PATHOL, V37, P463, DOI 10.1177/0192623309335634; Novak ML, 2013, J LEUKOCYTE BIOL, V93, P875, DOI 10.1189/jlb.1012512; Patel NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041024; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Pervin M, 2016, EXP TOXICOL PATHOL, V68, P113, DOI 10.1016/j.etp.2015.11.003; Polfliet MMJ, 2006, IMMUNOBIOLOGY, V211, P419, DOI 10.1016/j.imbio.2006.05.015; Radi ZA, 2011, AM J PATHOL, V179, P240, DOI 10.1016/j.ajpath.2011.03.029; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schwabe RF, 2006, GASTROENTEROLOGY, V130, P1886, DOI 10.1053/j.gastro.2006.01.038; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Takahashi K, 1996, PATHOL INT, V46, P473, DOI 10.1111/j.1440-1827.1996.tb03641.x; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; Vodovotz Y, 2001, J ENDOTOXIN RES, V7, P365, DOI 10.1179/096805101101532936; Wijesundera KK, 2014, EXP MOL PATHOL, V96, P382, DOI 10.1016/j.yexmp.2014.04.003; Yamate J, 2000, VET PATHOL, V37, P168, DOI 10.1354/vp.37-2-168; Yamate J., 2016, FOOD SAFETY, V3, P61; Yee SB, 2000, TOXICOL APPL PHARM, V166, P173, DOI 10.1006/taap.2000.8968; Zhu L, 2012, GLIA, V60, P1417, DOI 10.1002/glia.22362; Zizzo G, 2012, J IMMUNOL, V189, P3508, DOI 10.4049/jimmunol.1200662	34	2	2	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					540	552		10.1177/0192623318776898			13	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500005	29938593	Bronze			2019-10-28	
J	Gu, YZ; Vlasakova, K; Troth, SP; Peiffer, RL; Tournade, H; dos Santos, FRP; Glaab, WE; Sistare, FD				Gu, Yi-Zhong; Vlasakova, Katerina; Troth, Sean P.; Peiffer, Robert L.; Tournade, Herve; dos Santos, Flavia R. Pasello; Glaab, Warren E.; Sistare, Frank D.			Performance Assessment of New Urinary Translational Safety Biomarkers of Drug-induced Renal Tubular Injury in Tenofovir-treated Cynomolgus Monkeys and Beagle Dogs	TOXICOLOGIC PATHOLOGY			English	Article						translational renal tubular safety biomarkers; tenofovir; drug-induced renal tubular injury	KIDNEY INJURY; DISOPROXIL FUMARATE; NEXT-GENERATION; CLUSTERIN; MOLECULE-1; IDENTIFICATION; QUALIFICATION; OSTEOPONTIN; EXPRESSION; CHAPERONE	Newer urinary protein kidney safety biomarkers can outperform the conventional kidney functional biomarkers blood urea nitrogen (BUN) and serum creatinine (SCr) in rats. However, there is far less experience with the relative performance of these biomarkers in dogs and nonhuman primates. Here, we report urine protein biomarker performance in tenofovir-treated cynomolgus monkeys and beagle dogs. Tenofovir intravenous daily dosing in monkeys for 2 or 4 weeks at 30 mg/kg/day resulted in minimal to moderate tubular degeneration and regeneration, and tenofovir disoproxil fumarate oral dosing in dogs for 10 days at 45 mg/kg/day resulted in mild to marked tubular degeneration, necrosis, and regeneration. Among biomarkers tested, kidney injury molecule I (Kim-1) and clusterin (CLU) clearly outperformed BUN and SCr and were the most reliable in detecting the onset and progression of tenofovir-induced tubular injury. Cystatin C, retinol binding protein 4, beta 2-microglobulin, neutrophil gelatinase-associated lipocalin, albumin, and total protein also performed better than BUN and SCr and added value when considered together with Kim- I and CLU. These findings demonstrate the promising utility of these urinary safety biomarkers in monkeys and dogs and support their further evaluation in human to improve early detection of renal tubular injury.	[Gu, Yi-Zhong; Vlasakova, Katerina; Troth, Sean P.; Peiffer, Robert L.; Glaab, Warren E.; Sistare, Frank D.] Merck & Co Inc, Safety Assessment & Lab Anim Resources, 770 Sumneytown Pike,WP45-3554E, West Point, PA 19446 USA; [Tournade, Herve; dos Santos, Flavia R. Pasello] MSD, Riom, France	Gu, YZ (reprint author), Merck & Co Inc, Safety Assessment & Lab Anim Resources, 770 Sumneytown Pike,WP45-3554E, West Point, PA 19446 USA.	yi-zhong.eddie.gu@merck.com	Troth, Sean/R-6885-2019	Troth, Sean/0000-0002-4696-5129			Amin RA, 2004, ENVIRON HEALTH PERSP, V112, P465, DOI 10.1289/txg.6683; Bonventre JV, 2010, NAT BIOTECHNOL, V28, P436, DOI 10.1038/nbt0510-436; Bonventre JV, 2009, NEPHROL DIAL TRANSPL, V24, P3265, DOI 10.1093/ndt/gfp010; Brott DA, 2014, DRUG DES DEV THER, V8, P227, DOI 10.2147/DDDT.S54956; Dieterle F., 2010, BIOMARKERS MED DRUG, P237; Dieterle F, 2010, NAT BIOTECHNOL, V28, P463, DOI 10.1038/nbt.1622; Dieterle F, 2010, NAT BIOTECHNOL, V28, P455, DOI 10.1038/nbt.1625; Ennulat D, 2015, TOXICOL PATHOL, V43, P62, DOI 10.1177/0192623314554840; FDA (Food and Drug Administration), 2001, FOOD DRUG ADM APPR P; Fernandez-Fernandez B, 2011, AIDS RES TREAT, DOI 10.1155/2011/354908; Fung HB, 2002, CLIN THER, V24, P1515, DOI 10.1016/S0149-2918(02)80058-3; Hudkins KL, 1999, J AM SOC NEPHROL, V10, P444; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Ichimura T, 2008, J CLIN INVEST, V118, P1657, DOI 10.1172/JCI34487; Lebrecht D, 2009, JAIDS-J ACQ IMM DEF, V51, P258, DOI 10.1097/QAI.0b013e3181a666eb; Liangos O, 2007, J AM SOC NEPHROL, V18, P904, DOI 10.1681/ASN.2006030221; Naboulsi W., 2018, SOC TOX ANN M SAN AN; Pavkovic M, 2016, TOXICOL SCI, V152, P205, DOI 10.1093/toxsci/kfw077; Phillips JA, 2016, TOXICOL SCI, V151, P214, DOI 10.1093/toxsci/kfw038; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; Ray AS, 2016, ANTIVIR RES, V125, P63, DOI 10.1016/j.antiviral.2015.11.009; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Sistare FD, 2010, NAT BIOTECHNOL, V28, P446, DOI 10.1038/nbt.1634; Vlasakova K, 2014, TOXICOL SCI, V138, P3, DOI 10.1093/toxsci/kft330; Wadey RM, 2014, TOXICOL PATHOL, V42, P591, DOI 10.1177/0192623313492044	25	2	3	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					553	563		10.1177/0192623318775023			11	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500006	29807506	Bronze			2019-10-28	
J	Yamashita, H; Hoenerhoff, MJ; Shockley, KR; Peddada, SD; Gerrish, KE; Sutton, D; Cummings, CA; Wang, Y; Julie, FF; Behl, M; Waidyanatha, S; Sills, RC; Pandiri, AR				Yamashita, Haruhiro; Hoenerhoff, Mark J.; Shockley, Keith R.; Peddada, Shyamal D.; Gerrish, Kevin E.; Sutton, Deloris; Cummings, Connie A.; Wang, Yu; Julie, Foley F.; Behl, Mamta; Waidyanatha, Suramya; Sills, Robert C.; Pandiri, Arun R.			Reduced Disc Shedding and Phagocytosis of Photoreceptor Outer Segment Contributes to Kava Kava Extract-induced Retinal Degeneration in F344/N Rats	TOXICOLOGIC PATHOLOGY			English	Article						retinal degeneration; light-induced exacerbation; melatonin signaling; kava kava extract; carcinogenicity bioassay; photoreceptor outer segment phagocytosis; disc shedding	HUMAN INFANT FORMULA; GENE-EXPRESSION DATA; ALBINO-RATS; TAURINE DEFICIENCY; LIGHT; DAMAGE; ROD; PHOTOTOXICITY; TOPOGRAPHY; DEPLETION	There was a significant increase in the incidence of retinal degeneration in F344/N rats chronically exposed to Kava kava extract (KKE) in National Toxicology Program (NTP) bioassay. A retrospective evaluation of these rat retinas indicated a similar spatial and morphological alteration as seen in light-induced retinal degeneration in albino rats. Therefore, it was hypothesized that KKE has a potential to exacerbate the light-induced retinal degeneration. To investigate the early mechanism of retinal degeneration, we conducted a 90-day F344/N rat KKE gavage study at doses of 0 and 1.0 g/kg (dose which induced retinal degeneration in the 2-year NTP rat KKE bioassay). The morphological evaluation indicated reduced number of phagosomes in the retinal pigment epithelium (RPE) of the superior retina. Transcriptomic alterations related to retinal epithelial homeostasis and melatoninergic signaling were observed in microarray analysis. Phagocytosis of photoreceptor outer segment by the underlying RPE is essential to maintain the homeostasis of the photoreceptor layer and is regulated by melatonin signaling. Therefore, reduced photoreceptor outer segment disc shedding and subsequent lower number of phagosomes in the RPE and alterations in the melatonin pathway may have contributed to the increased incidences of retinal degeneration observed in F344/N rats in the 2-year KKE bioassay.	[Yamashita, Haruhiro; Hoenerhoff, Mark J.; Sutton, Deloris; Wang, Yu; Julie, Foley F.; Behl, Mamta; Waidyanatha, Suramya; Sills, Robert C.; Pandiri, Arun R.] NIEHS, Natl Toxicol Program, 111 TW Alexander Dr,POB 12233,MD B3-06, Res Triangle Pk, NC 27709 USA; [Yamashita, Haruhiro] Taisho Pharmaceut Co Ltd, Saitama, Japan; [Shockley, Keith R.; Peddada, Shyamal D.] NIEHS, Biostat & Computat Biol Branch, Res Triangle Pk, NC 27709 USA; [Gerrish, Kevin E.] NIEHS, Mol Genom Core Lab, Res Triangle Pk, NC 27709 USA; [Cummings, Connie A.] UltraPath Imaging, Res Triangle Pk, NC USA; [Hoenerhoff, Mark J.] Univ Michigan, Sch Med, In Vivo Anim Core, Unit Lab Anim Med, Ann Arbor, MI USA	Pandiri, AR (reprint author), NIEHS, Natl Toxicol Program, 111 TW Alexander Dr,POB 12233,MD B3-06, Res Triangle Pk, NC 27709 USA.	pandiriak@niehs.nih.gov		Peddada, Shyamal/0000-0002-5014-6513	DNTP; DIR, NIEHS	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was funded by DNTP and DIR, NIEHS.	Atlasz T, 2011, J MOL NEUROSCI, V43, P51, DOI 10.1007/s12031-010-9392-3; BECHTOLD LS, 2002, SYSTEMATIC EVALUATIO, P272; Bernard M, 2008, J NEUROCHEM, V105, P595, DOI 10.1111/j.1471-4159.2007.05150.x; Besharse J. C., 1988, PROGR RETINAL RES, P21; BOATRIGHT JH, 1994, VISUAL NEUROSCI, V11, P1013, DOI 10.1017/S0952523800003941; BORGES JM, 1990, CURR EYE RES, V9, P799, DOI 10.3109/02713689008999576; COCKER SE, 1989, VISUAL NEUROSCI, V3, P33, DOI 10.1017/S0952523800012487; European Medicines Agency, 1999, CPMP135799 EUR MED A; FDA (US Food and Drug Administration), 1997, PHARM REV; FDA (US Food and Drug Administration), 2013, MIR PRAM DIH; GARNER LF, 1985, J ETHNOPHARMACOL, V13, P307, DOI 10.1016/0378-8741(85)90076-5; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Giusto NM, 2000, PROG LIPID RES, V39, P315, DOI 10.1016/S0163-7827(00)00009-6; Guo WG, 2010, BIOMETRICS, V66, P485, DOI 10.1111/j.1541-0420.2009.01292.x; Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x; IMAKI H, 1987, J NEUROSCI RES, V18, P602, DOI 10.1002/jnr.490180414; Izumi Y, 2004, EPILEPSIA, V45, P1043, DOI 10.1111/j.0013-9580.2004.01004.x; Jammoul F, 2009, ANN NEUROL, V65, P98, DOI 10.1002/ana.21526; Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LAVAIL MM, 1987, INVEST OPHTH VIS SCI, V28, P1043; LAVAIL MM, 1987, CURR EYE RES, V6, P825, DOI 10.3109/02713688709034850; Lee NY, 2004, BRAIN RES, V1023, P141, DOI 10.1016/j.brainres.2004.07.033; Leon A, 1995, EXP EYE RES, V61, P731, DOI 10.1016/S0014-4835(05)80024-7; Naash MI, 1997, INVEST OPHTH VIS SCI, V38, P2344; National Toxicology Program, 2012, Natl Toxicol Program Tech Rep Ser, P1; NEURINGER M, 1987, J NEUROSCI RES, V18, P597, DOI 10.1002/jnr.490180413; Peddada S, 2005, BIOINFORMATICS, V21, P3933, DOI 10.1093/bioinformatics/bti637; Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002; RAPP LM, 1988, EXP EYE RES, V46, P229, DOI 10.1016/S0014-4835(88)80080-0; Reglodi D, 2011, CURR PHARM DESIGN, V17, P962, DOI 10.2174/138161211795589355; Ripps H, 2012, MOL VIS, V18, P2673; SHIMODA K, 1993, TOXICOL PATHOL, V21, P554, DOI 10.1177/019262339302100606; Singh YN, 2002, CNS DRUGS, V16, P731, DOI 10.2165/00023210-200216110-00002; Tanito M, 2008, EXP EYE RES, V87, P292, DOI 10.1016/j.exer.2008.06.002; Ulbricht Catherine, 2005, Expert Opin Drug Saf, V4, P779, DOI 10.1517/14740338.4.4.779; US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2005, GUID IND EST MAX SAF; WEISS I, 1971, ARZNEI-FORSCHUNG, V21, P821; WHITE MP, 1989, VISION RES, V29, P167, DOI 10.1016/0042-6989(89)90122-3; Xia QS, 2012, AM J CHINESE MED, V40, P1271, DOI 10.1142/S0192415X12500942; Yamashita H, 2016, TOXICOL PATHOL, V44, P892, DOI 10.1177/0192623316650050; YOUNG RW, 1968, J CELL BIOL, V39, P169, DOI 10.1083/jcb.39.1.169	42	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					564	573		10.1177/0192623318778796			10	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500007	29806545	Green Accepted, Bronze			2019-10-28	
J	Suen, AA; Jefferson, WN; Williams, CJ; Wood, CE				Suen, Alisa A.; Jefferson, Wendy N.; Williams, Carmen J.; Wood, Charles E.			Differentiation Patterns of Uterine Carcinomas and Precursor Lesions Induced by Neonatal Estrogen Exposure in Mice	TOXICOLOGIC PATHOLOGY			English	Article						estrogen; uterine cancer; differentiation; early-life exposure; diethylstilbestrol; genistein; development; progenitor cell; mouse model	ENDOMETRIAL EPITHELIAL-CELLS; FEMALE REPRODUCTIVE-TRACT; DIETHYLSTILBESTROL EXPOSURE; HORMONAL CARCINOGENESIS; MAMMARY EPITHELIUM; VAGINAL ADENOSIS; MOUSE UTERUS; IN-UTERO; ADENOCARCINOMA; EXPRESSION	Developmental exposure to estrogenic chemicals is an established risk factor for cancer of the female reproductive tract. This increase in risk has been associated with disruption of normal patterns of cellular differentiation during critical stages of morphogenesis. The goal of this study was to document uterine epithelial phenotypes over time following neonatal treatment with the synthetic estrogen diethylstilbestrol (DES) or the soy phytoestrogen genistein (GEN) in female CD-I mice. Both DES and GEN induced three distinct populations of abnormal endometrial epithelial cells: luminal (SIX1+/P63-/CK14-/CK18+), basal (SIX1+/ P63+/CKI4+/CK18-), and mixed/bipotential (SIX1+/P63-/CK14+/CK 18+), which were all established by early adulthood. In older animals, DES and GEN resulted in uterine carcinomas with mixed glandular, basal, and squamous cell elements. All carcinomas were composed largely of the three abnormal cell types. These findings identify novel epithelial differentiation patterns in the uterus and support the idea that disruption of cellular programming in early development can influence cancer risk later in life.	[Suen, Alisa A.; Jefferson, Wendy N.; Williams, Carmen J.] NIEHS, Reprod & Dev Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Suen, Alisa A.; Wood, Charles E.] US EPA, Off Res & Dev, Mail Code B105-03,109 TW Alexander Dr, Res Triangle Pk, NC 27709 USA	Wood, CE (reprint author), US EPA, Off Res & Dev, Mail Code B105-03,109 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	charleswood99@gmail.com	Williams, Carmen J/E-2170-2013; Suen, Alisa/J-3392-2016	Williams, Carmen J/0000-0001-6440-7086; Suen, Alisa/0000-0002-0639-9177	NIH, NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [1ZIAES102405]; U.S. Environmental Protection Agency Office of Research and DevelopmentUnited States Environmental Protection Agency; Oak Ridge Institute for Science and Education program	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the Intramural Research Program of the NIH, NIEHS, 1ZIAES102405 (CJW), the U.S. Environmental Protection Agency Office of Research and Development (CEW), and the Oak Ridge Institute for Science and Education program (AAS).	[Anonymous], 1972, Calif Med, V116, P85; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Cooke PS, 2013, MOL HUM REPROD, V19, P547, DOI 10.1093/molehr/gat031; Couse JF, 1997, MOL CARCINOGEN, V19, P236, DOI 10.1002/(SICI)1098-2744(199708)19:4<236::AID-MC4>3.0.CO;2-A; Couse JF, 2001, DEV BIOL, V238, P224, DOI 10.1006/dbio.2001.0413; Dixon D, 2014, J TOXICOL PATHOL, V27, p1S, DOI 10.1293/tox.27.1S; GIUSTI RM, 1995, ANN INTERN MED, V122, P778, DOI 10.7326/0003-4819-122-10-199505150-00008; Hatch EE, 2001, CANCER CAUSE CONTROL, V12, P837, DOI 10.1023/A:1012229112696; Hendry WJ, 1999, BIOL REPROD, V61, P91, DOI 10.1095/biolreprod61.1.91; Herceg Z, 2018, INT J CANCER, V142, P874, DOI 10.1002/ijc.31014; Ho SM, 2017, REPROD TOXICOL, V68, P85, DOI 10.1016/j.reprotox.2016.07.011; Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961; International Agency for Research on Cancer, 2012, PHARM DIETH, p100A; Jefferson WN, 2013, MOL ENDOCRINOL, V27, P1666, DOI 10.1210/me.2013-1211; Jefferson WN, 2011, ENVIRON HEALTH PERSP, V119, P1575, DOI 10.1289/ehp.1104018; Kurita T, 2004, DEVELOPMENT, V131, P1639, DOI 10.1242/dev.01038; Kurita T, 2001, ANN NY ACAD SCI, V948, P9; Kurita T, 2011, DIFFERENTIATION, V82, P117, DOI 10.1016/j.diff.2011.04.008; Laronda MM, 2012, DIFFERENTIATION, V84, P252, DOI 10.1016/j.diff.2012.05.004; Masse J, 2009, INT J DEV BIOL, V53, P411, DOI 10.1387/ijdb.082680jm; Newbold RR, 2001, CANCER RES, V61, P4325; NEWBOLD RR, 1982, CANCER RES, V42, P2003; NEWBOLD RR, 1990, CANCER RES, V50, P7677; OSTRANDER PL, 1985, J NATL CANCER I, V74, P121; Painter JT, 2010, TOXICOL PATHOL, V38, P131, DOI 10.1177/0192623309356449; Reed CE, 2013, BIRTH DEFECTS RES C, V99, P134, DOI 10.1002/bdrc.21035; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; Suen AA, 2016, MOL CANCER RES, V14, P849, DOI 10.1158/1541-7786.MCR-16-0084; Verloop J, 2010, CANCER CAUSE CONTROL, V21, P999, DOI 10.1007/s10552-010-9526-5; Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Wu WJ, 2015, INT J CANCER, V136, P1245, DOI 10.1002/ijc.28755; Yajima H, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-40; Yoshida A, 1999, TOXICOL PATHOL, V27, P325, DOI 10.1177/019262339902700308; Yoshida A, 2000, TOXICOL PATHOL, V28, P237, DOI 10.1177/019262330002800203	36	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					574	596		10.1177/0192623318779326			23	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500008	29895210	Bronze, Green Accepted			2019-10-28	
J	Ackerman, Z; Skarzinski, G; Link, G; Glazer, M; Pappo, O; Grozovski, M				Ackerman, Zvi; Skarzinski, Galina; Link, Gabriela; Glazer, Maya; Pappo, Orit; Grozovski, Maria			The Effects of Chronic Iron Overload in Rats with Acute Acetaminophen Overdose	TOXICOLOGIC PATHOLOGY			English	Article						acetaminophen; hepatocellular and sinusoidal cell iron overload; oxidative/antioxidative milieu; metallothionein; nitrotyrosine	INDUCED OXIDATIVE STRESS; INDUCED LIVER-INJURY; MITOCHONDRIAL DYSFUNCTION; HEPATOCELLULAR INJURY; MOUSE HEPATOCYTES; KUPFFER CELLS; HEPATOTOXICITY; MICE; TOXICITY; PURIFICATION	Background and Aims: Rats are resistant to acetaminophen (APAP) hepatotoxicity. In this study, we evaluated whether by augmentation of the hepatic oxidative stress, through the induction of hepatic iron overload (IO), it will be feasible to overcome the resistance of rats to the toxic effects of APAP. Method: Rats with no or increased hepatic IO. Results: Providing iron by diet induced hepatocellular IO, while parenteral iron administration induced combined hepatocellular and sinusoidal cell IO. APAP administration to rats with no IO caused an increase in hepatic oxidative stress and a decrease in the hepatic antioxidative markers but no hepatic cell damage. APAP administration to rats with hepatocellular IO further amplified the hepatic oxidative stress but induced only hepatocyte feathery degeneration without any increase in serum aminotransaminases. APAP administration to rats with combined hepatocellular and sinusoidal cell IO caused an unexpected decrease in hepatic oxidative stress and increase in the hepatic antioxidative markers and no hepatic cell damage. No hepatic expression of activated c-jun-N-terminal kinase was detected in any of the rats. Conclusions: The hepatic distribution of iron may affect its oxidative/antioxidative milieu. Augmentation of hepatic oxidative stress did not increase the rats' vulnerability to APAP.	[Ackerman, Zvi; Skarzinski, Galina; Glazer, Maya] Hadassah Hebrew Univ, Med Ctr, Dept Med, Mt Scopus Campus,POB 24035, IL-91240 Jerusalem, Israel; [Skarzinski, Galina; Pappo, Orit] Hadassah Hebrew Univ, Med Ctr, Dept Pathol, Jerusalem, Israel; [Link, Gabriela] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Human Nutr & Metab, Jerusalem, Israel; [Grozovski, Maria] Ort Braude Coll Engn, Dept Biotechnol, Karmiel, Israel	Ackerman, Z (reprint author), Hadassah Hebrew Univ, Med Ctr, Dept Med, Mt Scopus Campus,POB 24035, IL-91240 Jerusalem, Israel.	zackerman@hadassah.org.il					Ackerman Z, 2015, BIOL TRACE ELEM RES, V163, P169, DOI 10.1007/s12011-014-0110-9; Akerboom T P, 1981, Methods Enzymol, V77, P373; Bahde R, 2010, BRIT J SURG, V97, P1461, DOI 10.1002/bjs.7176; BAKER H, 1980, NUTR REP INT, V21, P531; Bessems JGM, 2001, CRIT REV TOXICOL, V31, P55, DOI 10.1080/20014091111677; BEUTLER E, 1975, RED CELL METABOLISM, P71; Brown KE, 2003, LIVER INT, V23, P232, DOI 10.1034/j.1600-0676.2003.00832.x; Brown KE, 2007, TOXICOL APPL PHARM, V223, P180, DOI 10.1016/j.taap.2007.05.011; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Choi DY, 2015, ARCH TOXICOL, V89, P211, DOI 10.1007/s00204-014-1253-3; DEUGNIER YM, 1993, HEPATOLOGY, V17, P30, DOI 10.1016/0270-9139(93)90187-R; Du K, 2015, FOOD CHEM TOXICOL, V86, P253, DOI 10.1016/j.fct.2015.10.016; FOLCH J, 1957, J BIOL CHEM, V226, P497; Galaris D, 2008, CRIT REV CL LAB SCI, V45, P1, DOI [10.1080/10408360701713104, 10.1080/10408360701713104 ]; Galleano M, 2002, TOXICOL LETT, V133, P193, DOI 10.1016/S0378-4274(02)00196-0; Galleano M, 2011, LIFE SCI, V89, P221, DOI 10.1016/j.lfs.2011.06.005; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Jaeschke H, 2015, DIGEST DIS, V33, P464, DOI 10.1159/000374090; Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001; Ju C, 2002, CHEM RES TOXICOL, V15, P1504, DOI 10.1021/tx0255976; Kon K, 2010, TOXICOL SCI, V117, P101, DOI 10.1093/toxsci/kfq175; Lee WM, 2013, CLIN LIVER DIS, V17, P575, DOI 10.1016/j.cld.2013.07.001; Martin-Murphy BV, 2013, HEPATOLOGY, V57, P1575, DOI 10.1002/hep.26134; Matot I, 2008, SHOCK, V29, P16, DOI 10.1097/shk.0b013e3180556964; McGill MR, 2012, TOXICOL APPL PHARM, V264, P387, DOI 10.1016/j.taap.2012.08.015; Michael SL, 1999, HEPATOLOGY, V30, P186, DOI 10.1002/hep.510300104; Moon MS, 2011, TOXICOL SCI, V124, P348, DOI 10.1093/toxsci/kfr231; Moon MS, 2010, TOXICOL SCI, V118, P119, DOI 10.1093/toxsci/kfq230; Nayak NC, 1996, VIRCHOWS ARCH, V428, P353; Olynyk JK, 2001, J GASTROEN HEPATOL, V16, P438, DOI 10.1046/j.1440-1746.2001.02456.x; Selzner N, 2003, GASTROENTEROLOGY, V125, P917, DOI 10.1016/S0016-5085(03)01048-5; Somparn N, 2007, EUR J CLIN PHARMACOL, V63, P43, DOI 10.1007/s00228-006-0224-x; Stal P, 1996, J HEPATOL, V25, P538, DOI 10.1016/S0168-8278(96)80214-5; TORRANCE J D, 1968, South African Journal of Medical Sciences, V33, P9; Uchiyama A, 2008, HEPATOLOGY, V48, P1644, DOI 10.1002/hep.22498; Videla LA, 2010, IUBMB LIFE, V62, P460, DOI 10.1002/iub.345; Wood JC, 2008, MAGN RESON MED, V60, P82, DOI 10.1002/mrm.21660; Xie YC, 2014, TOXICOL APPL PHARM, V279, P266, DOI 10.1016/j.taap.2014.05.010; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Zhang Y, 2012, EUR J PHARMACOL, V680, P95, DOI 10.1016/j.ejphar.2012.01.010	40	1	1	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					597	607		10.1177/0192623318776887			11	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500009	29929444				2019-10-28	
J	Pardo, ID; Shoieb, AM; Garman, R; Mirsky, M; Santos, R; Houle, C				Pardo, Ingrid D.; Shoieb, Ahmed M.; Garman, Robert; Mirsky, Michael; Santos, Rosemary; Houle, Christopher			Spontaneous Ectopic Choroid Plexus with Sclerosis in Adult Beagle Dogs	TOXICOLOGIC PATHOLOGY			English	Article						ectopic tissue; brain; choroid plexus; canine; hamartoma	TOXICITY; SYSTEM	Microscopic examination of the brain of adult Beagle dogs from four different general toxicity studies revealed the presence of ectopic choroid plexus tissue in six individual dogs (4 females and 2 males) with ages ranging from 12 to 18 months. In each dog, this finding was characterized by a well-circumscribed mass localized to a region above and along the corpus callosum without any apparent compression of adjacent brain tissue. Each mass was composed of columnar ependymal cells forming tubular structures surrounded by variable amounts of fibrovascular connective tissue and had the appearance of small rests of ependymal cells that had been penetrated by the leptomeninges during neural development. There were no associated clinical signs or macroscopic correlates. Based on morphologic appearance, a diagnosis of spontaneous ectopic choroid plexus with secondary sclerosis was made. To the authors' knowledge, ectopic choroid plexus has not been reported in Beagle dogs and is rare in humans and horses.	[Pardo, Ingrid D.; Shoieb, Ahmed M.; Mirsky, Michael; Houle, Christopher] Pfizer Inc, Dept Toxicol Pathol, 1 Eastern Point Rd, Groton, CT 06340 USA; [Garman, Robert] Vet Pathol Inc, Murrysville, PA USA; [Santos, Rosemary] Pfizer Inc, Dept Comparat Med, Groton, CT 06340 USA	Pardo, ID (reprint author), Pfizer Inc, Dept Toxicol Pathol, 1 Eastern Point Rd, Groton, CT 06340 USA.	ingrid.d.pardo@pfizer.com					BAKER JR, 1981, EQUINE VET J, V13, P43, DOI 10.1111/j.2042-3306.1981.tb03448.x; Bolon B, 2013, TOXICOL PATHOL, V41, P1028, DOI 10.1177/0192623312474865; Ha YS, 2014, CHILD NERV SYST, V30, P1109, DOI 10.1007/s00381-013-2311-5; Liddelow SA, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00032; Lun MP, 2015, NAT REV NEUROSCI, V16, P445, DOI 10.1038/nrn3921; Sato J, 2012, J TOXICOL PATHOL, V25, P103, DOI 10.1293/tox.25.103	6	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0192-6233	1533-1601		TOXICOL PATHOL	Toxicol. Pathol.	JUL	2018	46	5					608	609		10.1177/0192623318776885			2	Pathology; Toxicology	Pathology; Toxicology	GP2PE	WOS:000440676500010	29843561	Bronze			2019-10-28	
J	Kobel, M; Anglesio, MS; Brenton, JD				Kobel, Martin; Anglesio, Michael S.; Brenton, James D.			You won't believe this old test ... that does cheap single-cell mutation detection	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Editorial Material						Immunohistochemistry; Female reproductive system; Ovary; Mutation; Testing	OVARIAN CLEAR-CELL; ENDOMETRIAL CARCINOMAS; HYPERCALCEMIC TYPE; SMARCA4 MUTATIONS; ARID1A; CANCER; EXPRESSION; TUMORS; ROLES	Detecting mutations in single cells from cancer specimens is now a major area of translational research. In a recent article in this journal, Khalique et al validated an immunohistochemistry assay for ARID1A that reliably identifies loss of function mutations in single cells in tissue sections. This work exemplifies best practice for developing and orthogonally validating immunohistochemical assays to provide clearly interpretable mutational results with spatial context.	[Kobel, Martin] Univ Calgary, Dept Pathol & Lab Med, Foothills Med Ctr, Calgary, AB, Canada; [Anglesio, Michael S.] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC, Canada; [Brenton, James D.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England	Kobel, M (reprint author), Univ Calgary, Dept Pathol & Lab Med, 1304 S29 St NW, Calgary, AB 2TN 2T9, Canada.; Kobel, M (reprint author), Calgary Lab Serv, 1304 S29 St NW, Calgary, AB 2TN 2T9, Canada.	martin.koebel@cls.ab.ca	Brenton, James D/B-3174-2008	Brenton, James D/0000-0002-5738-6683; Anglesio, Michael/0000-0003-1639-5003			Allo G, 2014, MODERN PATHOL, V27, P255, DOI 10.1038/modpathol.2013.144; Anglesio MS, 2017, NEW ENGL J MED, V376, P1835, DOI 10.1056/NEJMoa1614814; Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen WQ, 2017, INT J GYNECOL PATHOL, V36, P128, DOI 10.1097/PGP.0000000000000291; Chene G, 2015, INT J GYNECOL OBSTET, V130, P27, DOI 10.1016/j.ijgo.2015.02.021; Coons AH, 1942, J IMMUNOL, V45, P159; de Matos LL, 2010, BIOMARK INSIGHTS, V5, P9; Gibson WJ, 2016, NAT GENET, V48, P848, DOI 10.1038/ng.3602; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Khalique S, 2018, J PATHOL CLIN RES, V4, P154, DOI 10.1002/cjp2.103; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; Kobel M, 2016, INT J GYNECOL PATHOL, V35, P430, DOI 10.1097/PGP.0000000000000274; Kobel M, 2018, AM J SURG PATHOL, V42, P76, DOI 10.1097/PAS.0000000000000941; Kupryjanczyk J, 2013, POL J PATHOL, V64, P238, DOI 10.5114/PJP.2013.39331; Marrack J, 1934, NATURE, V133, P292, DOI 10.1038/133292b0; McBride MJ, 2018, J PATHOL, V244, P638, DOI 10.1002/path.5042; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Samartzis EP, 2012, MODERN PATHOL, V25, P885, DOI 10.1038/modpathol.2011.217; Stamp JP, 2016, INT J GYNECOL CANCER, V26, P825, DOI 10.1097/IGC.0000000000000698; Wang YK, 2017, NAT GENET, V49, P856, DOI 10.1038/ng.3849; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; Wu RC, 2014, CANCER BIOL THER, V15, P655, DOI 10.4161/cbt.28411; Ye JQ, 2014, HUM PATHOL, V45, P2430, DOI 10.1016/j.humpath.2014.08.007	32	2	2	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JUL	2018	4	3					149	153		10.1002/cjp2.108			5	Pathology	Pathology	GO6OR	WOS:000440168100001	30003713	DOAJ Gold, Green Published			2019-10-28	
J	Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R				Khalique, Saira; Naidoo, Kalnisha; Attygalle, Ayoma D.; Kriplani, Divya; Daley, Frances; Lowe, Anne; Campbell, James; Jones, Thomas; Hubank, Michael; Fenwick, Kerry; Matthews, Nicholas; Rust, Alistair G.; Lord, Christopher J.; Banerjee, Susana; Natrajan, Rachael			Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						ARID1A immunohistochemistry; clear cell ovarian cancer; next generation sequencing; biomarker	OVARIAN; ENDOMETRIOSIS; EVOLUTION; BINDING; TUMORS	ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ARID1A defects. However, the accuracy of ARID1A immunohistochemistry (IHC) as a surrogate for mutation status has not fully been established for patient stratification in clinical trials. Here we tested whether ARID1A IHC could reliably predict ARID1A mutations identified by next-generation sequencing. Three commercially available antibodies - EPR13501 (Abcam), D2A8U (Cell Signaling), and HPA005456 (Sigma) - were optimised for IHC using cell line models and human tissue, and screened across a cohort of 45 gynaecological tumours. IHC was scored independently by three pathologists using an immunoreactive score. ARID1A mutation status was assessed using two independent sequencing platforms and the concordance between ARID1A mutation and protein expression was evaluated using Receiver Operating Characteristic statistics. Overall, 21 ARID1A mutations were identified in 14/43 assessable tumours (33%), the majority of which were predicted to be deleterious. Mutations were identified in 6/17 (35%) ovarian clear cell carcinomas, 5/8 (63%) ovarian endometrioid carcinomas, 2/5 (40%) endometrial carcinomas, and 1/7 (14%) carcinosarcomas. ROC analysis identified greater than 95% concordance between mutation status and IHC using a modified immunoreactive score for all three antibodies allowing a definitive cut-point for ARID1A mutant status to be calculated. Comprehensive assessment of concordance of ARID1A IHC and mutation status identified EPR13501 as an optimal antibody, with 100% concordance between ARID1A mutation status and protein expression, across different gynaecological histological subtypes. It delivered the best inter-rater agreement between all pathologists, as well as a clear cost-benefit advantage. This could allow patients to be accurately stratified based on their ARID1A IHC status into early phase clinical trials.	[Khalique, Saira; Naidoo, Kalnisha; Kriplani, Divya; Daley, Frances; Lowe, Anne; Lord, Christopher J.; Natrajan, Rachael] Inst Canc Res, Div Breast Canc, Breast Canc Now Toby Robins Res Ctr, London, England; [Khalique, Saira; Lord, Christopher J.; Natrajan, Rachael] Inst Canc Res, Div Mol Pathol, London, England; [Attygalle, Ayoma D.; Banerjee, Susana] Royal Marsden NHS Fdn Trust, Gynaecol Unit, 203 Fulham Rd, London SW3 6JJ, England; [Attygalle, Ayoma D.] Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England; [Campbell, James] Inst Canc Res, ICR Core Bioinformat Facil, Sutton, Surrey, England; [Jones, Thomas; Hubank, Michael] Royal Marsden NHS Fdn Trust, Mol Diagnost Dept, Ctr Mol Pathol, Sutton, Surrey, England; [Fenwick, Kerry; Matthews, Nicholas; Rust, Alistair G.] Inst Canc Res, Tumour Profiling Unit, London, England; [Lord, Christopher J.] Inst Canc Res, CRUK Gene Funct Lab, London, England; [Banerjee, Susana] Inst Canc Res, Div Clin Studies, London, England	Banerjee, S (reprint author), Royal Marsden NHS Fdn Trust, Gynaecol Unit, 203 Fulham Rd, London SW3 6JJ, England.; Natrajan, R (reprint author), Inst Canc Res, Breast Canc Now Toby Robins Res Ctr, Mary Jean Mitchell Green Bldg,237 Fulham Rd, London SW3 6JB, England.	Susana.Banerjee@rmh.nhs.uk; rachael.natrajan@icr.ac.uk	Hubank, Michael/C-1837-2008; Lord, Christopher/B-3295-2012	Hubank, Michael/0000-0002-2901-0742; Khalique, Saira/0000-0001-8015-9764; Lord, Christopher/0000-0002-3226-0515; Natrajan, Rachael/0000-0002-9987-2946	Gynaecological Cancer Fund; Royal Marsden Cancer CharityRoyal Society of New ZealandMarsden Fund (NZ); Breast Cancer Now; Cancer Research UKCancer Research UK; NHS; NIHR Royal Marsden Hospital Biomedical Research Centre	We thank Breast Cancer Now Histopathology Unit, The Centre for Molecular Pathology, and the Gynaecology Research Team at The Royal Marsden NHS Foundation Trust, The Breast Cancer Now Bioinformatics Core and members of the The Functional Genomics Laboratory at the Institute for Cancer Research. This work was funded by the Gynaecological Cancer Fund, The Royal Marsden Cancer Charity, Breast Cancer Now, as part of programmatic funding for RN and CJL, Cancer Research UK as part of programme grant funding to CJL and The Monument Trust. We acknowledge NHS funding to the NIHR Royal Marsden Hospital Biomedical Research Centre. Raw-targeted sequencing data have been deposited into the NCBI Sequence Read Archive under the accession PRJNA432413 and PRJNA432343.	Anglesio MS, 2017, NEW ENGL J MED, V376, P1835, DOI 10.1056/NEJMoa1614814; Anglesio MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072162; [Anonymous], 2008, JJR ONLINE KAPPA CAL; [Anonymous], 2016, 201300210973 EUDRACT; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Coatham M, 2016, MODERN PATHOL, V29, P1586, DOI 10.1038/modpathol.2016.156; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gibson WJ, 2016, NAT GENET, V48, P848, DOI 10.1038/ng.3602; Grivas P, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.6_suppl.334; Guan B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju146; Guan B, 2012, NEOPLASIA, V14, P986, DOI 10.1593/neo.121218; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Guru S, 2017, J CLIN ONCOL, V35, P149; Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480; Hembree TN, 2016, CANCER CONTROL, V23, P61, DOI 10.1177/107327481602300111; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jones S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6006; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kobel M, 2016, J PATHOL CLIN RES, V2, P247, DOI 10.1002/cjp2.53; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lheureux S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.5522; Maeda D, 2010, INT J MOL SCI, V11, P5121, DOI 10.3390/ijms11125120; Miller RE, 2016, MOL CANCER THER, V15, P1472, DOI 10.1158/1535-7163.MCT-15-0554; Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225; Nagy RJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.4528; Sadakatsu I, 2017, J CLIN ONCOL, V35, P298; Samartzis EP, 2012, MODERN PATHOL, V25, P885, DOI 10.1038/modpathol.2011.217; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Takai E, 2015, SCI REP-UK, V5, DOI 10.1038/srep18425; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wu RC, 2014, CANCER BIOL THER, V15, P655, DOI 10.4161/cbt.28411	35	5	5	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JUL	2018	4	3					154	166		10.1002/cjp2.103			13	Pathology	Pathology	GO6OR	WOS:000440168100002	29659191	DOAJ Gold, Green Published			2019-10-28	
J	Bah, I; Fahiminiya, S; Begin, LR; Hamel, N; D'Agostino, MD; Tanguay, S; Foulkes, WD				Bah, Ismael; Fahiminiya, Somayyeh; Begin, Louis R.; Hamel, Nancy; D'Agostino, Maria D.; Tanguay, Simon; Foulkes, William D.			Atypical tuberous sclerosis complex presenting as familial renal cell carcinoma with leiomyomatous stroma	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						tuberous sclerosis complex; renal cell carcinoma; TSC2; renal cell carcinoma with (angio)leiomyomatous stroma; renal angiomyoadenomatous tumour	FOLLICULAR LYMPHOMA; SEQUENCING DATA; MUTATIONS; GENE; PATHOLOGY; CHILDREN; PATHWAY; LESIONS; TUMORS; TSC2	We report an atypical tuberous sclerosis complex (TSC) phenotype presenting as familial multiple renal cell carcinomas (RCCs) with (angio)leiomyomatous stroma (RCCLS) (5/7 familial RCCs) on a background of multiple angiomyolipomas, hypopigmented skin macules, and absence of neurological anomalies. In the index case and three relatives, germline genetic testing identified a heterozygous TSC2 missense pathogenic variant [c.2714 G>A, (p.Arg905Gln)], a rare TSC-associated alteration which has previously been associated with a milder TSC phenotype. Whole-exome sequencing of five RCCs from the index case and one RCC from his mother demonstrated either unique tumour-specific deleterious second hits in TSC2 or significant allelic imbalance at the TSC2 gene locus (5/6 RCCs). This study confirms the key tumourigenic role of tumour-specific TSC2 second hits in TSC-associated RCCs and supports the notion that RCCLS may be strongly related to abnormalities of the mTOR pathway.	[Bah, Ismael] McGill Univ, Ctr Hlth, Dept Pathol, Montreal, PQ, Canada; [Fahiminiya, Somayyeh; Hamel, Nancy; Foulkes, William D.] McGill Univ, Ctr Hlth, Res Inst, Canc Res Program, Montreal, PQ, Canada; [Fahiminiya, Somayyeh] McGill Univ, Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Begin, Louis R.] Hop Sacre Coeur Montreal, Div Anat Pathol, Montreal, PQ, Canada; [D'Agostino, Maria D.; Foulkes, William D.] McGill Univ, Dept Human Genet, Montreal, PQ, Canada; [D'Agostino, Maria D.] McGill Univ, Ctr Hlth, Dept Med Genet, Montreal, PQ, Canada; [Tanguay, Simon] McGill Univ, Ctr Hlth, Div Urol, Montreal, PQ, Canada; [Foulkes, William D.] Jewish Gen Hosp, Lady Davis Inst, Dept Med Genet, Segal Canc Ctr, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada; [Foulkes, William D.] McGill Univ, Dept Oncol & Human Genet, Program Canc Genet, Montreal, PQ, Canada	Foulkes, WD (reprint author), Jewish Gen Hosp, Lady Davis Inst, Dept Med Genet, Segal Canc Ctr, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	william.foulkes@mcgill.ca	Hamel, Nancy/L-5122-2016; Bah, Ismael/C-8239-2016	Hamel, Nancy/0000-0001-8971-0428; Bah, Ismael/0000-0003-2035-9048	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [FDN-148390]	The authors thank the patients for participating in this study. This work was supported by a grant from the Canadian Institutes of Health Research (FDN-148390) to WDF.	Adriaensen MEAPM, 2009, RADIOLOGY, V253, P359, DOI 10.1148/radiol.2533082118; Brakemeier S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19399-7; Ceylan C, 2003, J EUR ACAD DERMATOL, V17, P616, DOI 10.1046/j.1468-3083.2003.00825.x; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; DiMario FJ, 2015, PEDIATR CLIN N AM, V62, P633, DOI 10.1016/j.pcl.2015.03.005; Dixon BP, 2011, NEPHRON EXP NEPHROL, V118, pE15, DOI 10.1159/000320891; Fahiminiya S, 2015, HUM MOL GENET, V24, P516, DOI 10.1093/hmg/ddu471; Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet-2013-101567; Giannikou K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006242; Guo J, 2014, AM J SURG PATHOL, V38, P1457, DOI 10.1097/PAS.0000000000000248; Hakimi AA, 2015, MODERN PATHOL, V28, P845, DOI 10.1038/modpathol.2015.6; Islam MP, 2016, BRADLEYS NEUROLOGY C, P1538; Jansen AC, 2006, ANN NEUROL, V60, P528, DOI 10.1002/ana.21037; Jozwiak S, 1998, INT J DERMATOL, V37, P911; Kong Y, 2016, CLIN CANCER RES, V22, P1018, DOI 10.1158/1078-0432.CCR-15-1110; Lam HC, 2017, J PATHOL, V241, P219, DOI 10.1002/path.4827; Leseux L, 2008, BLOOD, V111, P285, DOI 10.1182/blood-2007-04-085092; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu MY, 2003, CANCER RES, V63, P2675; Ljungberg B, 2011, EUR UROL, V60, P615, DOI 10.1016/j.eururo.2011.06.049; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Merino MJ, 2010, INT J SURG PATHOL, V18, p98S, DOI 10.1177/1066896910370469; Nadaf J, 2015, BIOINFORMATICS, V31, P429, DOI 10.1093/bioinformatics/btu665; Nathan N, 2017, BRIT J DERMATOL, V176, P220, DOI 10.1111/bjd.14724; Nikaido T, 2004, PATHOL INT, V54, P1, DOI 10.1111/j.1440-1827.2004.01577.x; Northrup H, 2013, PEDIATR NEUROL, V49, P243, DOI 10.1016/j.pediatrneurol.2013.08.001; Rahman N, 2014, NATURE, V505, P302, DOI 10.1038/nature12981; Rakowski SK, 2006, KIDNEY INT, V70, P1777, DOI 10.1038/sj.ki.5001853; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; Shaaya EA, 2013, AM J MED GENET A, V161A, P1662, DOI 10.1002/ajmg.a.36037; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Tresoldi S, 2015, RADIOLOGY, V277, P398, DOI 10.1148/radiol.2015141890; Tsao H, 2012, DERMATOLOGY, P925; Tyburczy ME, 2015, HUM MOL GENET, V24, P1836, DOI 10.1093/hmg/ddu597; Tyburczy ME, 2014, HUM MOL GENET, V23, P2023, DOI 10.1093/hmg/ddt597; Verkarre V, 2014, Prog Urol, V24, P835, DOI 10.1016/j.purol.2014.08.115; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Williamson SR, 2018, HUM PATHOL, V75, P10, DOI 10.1016/j.humpath.2017.11.013; Yang P, 2014, AM J SURG PATHOL, V38, P895, DOI 10.1097/PAS.0000000000000237; Ying ZX, 2016, CLIN CANCER RES, V22, P5383, DOI 10.1158/1078-0432.CCR-16-0609	42	2	2	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JUL	2018	4	3					167	174		10.1002/cjp2.104			8	Pathology	Pathology	GO6OR	WOS:000440168100003	29659200	DOAJ Gold, Green Published			2019-10-28	
J	Arndt, A; Steinestel, K; Rump, A; Sroya, M; Bogdanova, T; Kovgan, L; Port, M; Abend, M; Eder, S				Arndt, Annette; Steinestel, Konrad; Rump, Alexis; Sroya, Manveer; Bogdanova, Tetiana; Kovgan, Leonila; Port, Matthias; Abend, Michael; Eder, Stefan			Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						Chernobyl; papillary thyroid carcinoma; ionising radiation; ALK; RET; BRAF	ATOMIC-BOMB SURVIVORS; THERAPEUTIC TARGET; YOUNG-PATIENTS; CANCER; CHILDHOOD; MUTATIONS; RET/PTC; BRAF; ACTIVATION; EXPOSURE	Childhood radiation exposure has been associated with increased papillary thyroid carcinoma (PTC) risk. The role of anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related PTC remains unclear, but STRN-ALK fusions have recently been detected in PTCs from radiation exposed persons after Chernobyl using targeted next-generation sequencing and RNA-seq. We investigated ALK and RET gene rearrangements as well as known driver point mutations in PTC tumours from 77 radiation-exposed patients (mean age at surgery 22.4 years) and PTC tumours from 19 non-exposed individuals after the Chernobyl accident. ALK rearrangements were detected by fluorescence in situ hybridisation (FISH) and confirmed with immunohistochemistry (IHC); point mutations in the BRAF and RAS genes were detected by DNA pyrosequencing. Among the 77 tumours from exposed persons, we identified 7 ALK rearrangements and none in the unexposed group. When combining ALK and RET rearrangements, we found 24 in the exposed (31.2%) compared to two (10.5%) in the unexposed group. Odds ratios increased significantly in a dose-dependent manner up to 6.2 (95%CI: 1.1, 34.7; p=0.039) at Iodine-131 thyroid doses >500 mGy. In total, 27 cases carried point mutations of BRAF or RAS genes, yet logistic regression analysis failed to identify significant dose association. To our knowledge we are the first to describe ALK rearrangements in post-Chernobyl PTC samples using routine methods such as FISH and IHC. Our findings further support the hypothesis that gene rearrangements, but not oncogenic driver mutations, are associated with ionising radiation-related tumour risk. IHC may represent an effective method for ALK-screening in PTCs with known radiation aetiology, which is of clinical value since oncogenic ALK activation might represent a valuable target for small molecule inhibitors.	[Arndt, Annette; Steinestel, Konrad] Bundeswehrkrankenhaus Ulm, Inst Pathol & Mol Pathol, Ulm, Germany; [Rump, Alexis; Port, Matthias; Abend, Michael; Eder, Stefan] Bundeswehr Inst Radiobiol, Neuherbergstr 11, D-80937 Munich, Germany; [Sroya, Manveer] Imperial Coll London, Charing Cross Hosp, London, England; [Bogdanova, Tetiana] Natl Acad Med Sci Ukraine, State Inst VP Kommissarenko Inst Endocrinol & Met, Kiev, Ukraine; [Kovgan, Leonila] Sci Res Ctr Radiat Med, Div Dosimetry & Radiat Hyg, Kiev, Ukraine; [Eder, Stefan] Univ Hosp Munich LMU, Inner City Clin, Inst & Outpatient Clin Occupat Social & Environm, Munich, Germany	Eder, S (reprint author), Bundeswehr Inst Radiobiol, Neuherbergstr 11, D-80937 Munich, Germany.	stefanfriedricheder@bundeswehr.org		Sroya, Manveer/0000-0003-3251-2986	National Cancer Institute (NCI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5U24CA082102]; SMHF of Japan; Qiagen team for Personalized Healthcare (PHC)	The authors gratefully acknowledge the confirmation of diagnosis provided by the International Pathology Panel of the Chernobyl Tissue Bank: A. Abrosimov, T. Bogdanova, N. Dvinskikh, G. Fadda, J. Hunt, M. Ito, V. LiVolsi, J. Rosai, E. Williams. The authors thank Dr. Zurnadzhy and Dr. Voskoboinyk for providing the FFPE samples, Dres Puchkarov for preparing the DNA samples, the staff of the Imperial College for excellent organisation and Claudia Schlosser as well as Wiebke Hemmer of the Institute of Pathology and Molecular Pathology, Bundeswehrkrankenhaus Ulm for expert technical assistance. The CTB is supported by grants from the National Cancer Institute (NCI; 5U24CA082102) and the SMHF of Japan. The project was supported by the Qiagen team for Personalized Healthcare (PHC).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bastos AU, 2018, EUR J ENDOCRINOL, V178, P83, DOI 10.1530/EJE-17-0499; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Brenner AV, 2011, ENVIRON HEALTH PERSP, V119, P933, DOI 10.1289/ehp.1002674; Cardis E, 2005, JNCI-J NATL CANCER I, V97, P724, DOI 10.1093/jnci/dji129; Demeure MJ, 2014, WORLD J SURG, V38, P1296, DOI 10.1007/s00268-014-2485-3; Efanov AA, 2018, JNCI-J NATL CANCER I, V110, P371, DOI 10.1093/jnci/djx209; Fenton CL, 2000, J CLIN ENDOCR METAB, V85, P1170, DOI 10.1210/jc.85.3.1170; Gruber K, 2015, J THORAC ONCOL, V10, P713, DOI 10.1097/JTO.0000000000000427; Hamatani K, 2008, CANCER RES, V68, P7176, DOI 10.1158/0008-5472.CAN-08-0293; Hamatani K, 2012, THYROID, V22, P1153, DOI 10.1089/thy.2011.0511; Kelly LM, 2014, P NATL ACAD SCI USA, V111, P4233, DOI 10.1073/pnas.1321937111; Kruczynski A, 2012, EXPERT OPIN THER TAR, V16, P1127, DOI 10.1517/14728222.2012.719498; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Leeman-Neill RJ, 2013, CANCER-AM CANCER SOC, V119, P1792, DOI 10.1002/cncr.27893; Likhtarev I, 2006, RADIAT RES, V166, P271, DOI 10.1667/RR3545.1; Likhtarov I, 2013, RADIAT PROT DOSIM, V156, P407, DOI 10.1093/rpd/nct096; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; Paik JH, 2011, J THORAC ONCOL, V6, P466, DOI 10.1097/JTO.0b013e31820b82e8; Penko K, 2005, THYROID, V15, P320, DOI 10.1089/thy.2005.15.320; Perot G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087170; Rosenbaum E, 2005, MODERN PATHOL, V18, P898, DOI 10.1038/modpathol.3800252; Sassolas G, 2012, THYROID, V22, P17, DOI 10.1089/thy.2011.0215; Schneider AB, 2005, NAT CLIN PRACT ENDOC, V1, P82, DOI 10.1038/ncpendmet0022; Sun JM, 2012, J THORAC ONCOL, V7, pE36, DOI 10.1097/JTO.0b013e318274694e; Suzuki K, 2015, CANCER SCI, V106, P127, DOI 10.1111/cas.12583; Werner MT, 2017, BLOOD, V129, P823, DOI 10.1182/blood-2016-05-717793; Williams D, 2008, Oncogene, V27 Suppl 2, pS9, DOI 10.1038/onc.2009.349; Yamashita S, 2007, NAT CLIN PRACT ENDOC, V3, P422, DOI 10.1038/ncpendmet0499	29	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JUL	2018	4	3					175	183		10.1002/cjp2.102			9	Pathology	Pathology	GO6OR	WOS:000440168100004	29633575	DOAJ Gold, Green Published			2019-10-28	
J	Lazaris, A; Amri, A; Petrillo, SK; Zoroquiain, P; Ibrahim, N; Salman, A; Gao, ZH; Vermeulen, PB; Metrakos, P				Lazaris, Anthoula; Amri, Abdellatif; Petrillo, Stephanie K.; Zoroquiain, Paublo; Ibrahim, Nisreen; Salman, Ayat; Gao, Zu-Hua; Vermeulen, Peter B.; Metrakos, Peter			Vascularization of colorectal carcinoma liver metastasis: insight into stratification of patients for anti-angiogenic therapies	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						hepatobiliary and pancreas; liver; colorectal; carcinoma computerized image analysis; immunocytochemistry	VESSEL CO-OPTION; MICROVESSEL DENSITY; MEDIATES RESISTANCE; CANCER; BEVACIZUMAB; SURVIVAL; CHEMOTHERAPY; GLIOBLASTOMA; PATTERNS	Current treatment for metastatic disease targets angiogenesis. With the increasing data demonstrating that cancer cells do not entirely rely on angiogenesis but hijack the existing vasculature through mechanisms such as co-option of existing blood vessels, identification of targets has become of utmost importance. Our study looks at the vasculature of chemonaive and treated colorectal carcinoma liver metastases (CRCLMs) to obtain a basic understanding of the microvessel density, type of vasculature (mature versus immature), and correlation with histopathological growth patterns that demonstrate unique patterns of angiogenesis. We performed immunohistochemistry on chemonaive sections of desmoplastic histopathological growth pattern (DHGP) and replacement histopathological growth patterns (RHGP) lesions with CD31 [endothelial cell (EC) marker] and CD34/Ki67 double staining, which denotes proliferating ECs. The CD31 stains demonstrated a lower microvascular CD31 +ve capillary density in the DHGP versus RHGP lesions; and integrating both immunostains with CD34/Ki67 staining on serial sections revealed proliferating vessels in DHGP lesions and co-option of mature existing blood vessels in RHGP lesions. Interestingly, upon treatment with chemotherapy and bevacizumab, the RHGP lesions showed no necrosis whereas the DHGP lesions had almost 100% necrosis of the cancer cells and in most cases there was a single layer of viable cancer cells, just under or within the desmoplastic ring. The survival of these cells may be directly related to spatial location and possibly a different microenvironment, which may involve adhesion to different extracellular matrix components and/or different oxygen/nutrient availability. This remains to be elucidated. We provide evidence that DHGP CRCLMs obtain their blood supply via sprouting angiogenesis whereas RHGP lesions obtain their blood supply via co-option of existing vasculature. Furthermore current treatment regimens do not affect RHGP lesions and although they kill the majority of the cancer cells in DHGP lesions, there are cells surviving within or adjacent to the desmoplastic ring which could potentially give rise to a growing lesion.	[Lazaris, Anthoula; Amri, Abdellatif; Petrillo, Stephanie K.; Zoroquiain, Paublo; Salman, Ayat; Metrakos, Peter] McGill Univ, Ctr Hlth, Res Inst, Dept Surg,Canc Res Program, Quebec City, PQ, Canada; [Ibrahim, Nisreen; Metrakos, Peter] McGill Univ, Dept Anat & Cell Biol, Quebec City, PQ, Canada; [Gao, Zu-Hua] McGill Univ, Ctr Hlth, Dept Pathol, Quebec City, PQ, Canada; [Vermeulen, Peter B.] GZA Hosp St Augustinus, Translat Canc Res Unit, Antwerp, Belgium	Lazaris, A (reprint author), McGill Univ, Ctr Hlth, Res Inst, Dept Surg,Canc Res Program, Quebec City, PQ, Canada.	anthoula.lazaris@mail.mcgill.ca		Lazaris, Anthoula/0000-0002-2173-7891			Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16; Bridgeman VL, 2017, J PATHOL, V241, P362, DOI 10.1002/path.4845; de Groot JF, 2010, NEURO-ONCOLOGY, V12, P233, DOI 10.1093/neuonc/nop027; di Tomaso E, 2011, CANCER RES, V71, P19, DOI 10.1158/0008-5472.CAN-10-2602; Donnem T, 2013, CANCER MED-US, V2, P427, DOI 10.1002/cam4.105; Eefsen RL, 2016, INT J CANCER, V138, P1777, DOI 10.1002/ijc.29904; Fernando NH, 2004, ONCOLOGIST, V9, P11, DOI 10.1634/theoncologist.9-suppl_1-11; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Fusai G, 2003, DIGEST SURG, V20, P481, DOI 10.1159/000073535; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; JASS JR, 1987, LANCET, V1, P1303; Kuczynski EA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw030; Leenders WPJ, 2004, CLIN CANCER RES, V10, P6222, DOI 10.1158/1078-0432.CCR-04-0823; Nuttall R., 2017, CANADIAN CANC STAT 2; Prall F, 2003, HISTOPATHOLOGY, V42, P482, DOI 10.1046/j.1365-2559.2003.01610.x; Rajaganeshan R, 2007, BRIT J CANCER, V96, P1112, DOI 10.1038/sj.bjc.6603677; Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102; Samani AA, 2004, CANCER RES, V64, P3380, DOI 10.1158/0008-5472.CAN-03-3780; Tanigawa N, 1997, CANCER RES, V57, P1043; Terayama N, 1996, JPN J CLIN ONCOL, V26, P24, DOI 10.1093/oxfordjournals.jjco.a023174; Turan N, 2013, ONCOLOGY-BASEL, V84, P14, DOI 10.1159/000342429; van Dam PJ, 2017, BRIT J CANCER, V117, P1427, DOI 10.1038/bjc.2017.334; Van den Eynden GG, 2012, CLIN EXP METASTAS, V29, P541, DOI 10.1007/s10585-012-9469-1; Vermeulen PB, 1999, BRIT J CANCER, V79, P316, DOI 10.1038/sj.bjc.6690051; Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966; Vollmar B, 2009, PHYSIOL REV, V89, P1269, DOI 10.1152/physrev.00027.2008	26	5	5	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JUL	2018	4	3					184	192		10.1002/cjp2.100			9	Pathology	Pathology	GO6OR	WOS:000440168100005	29654716	DOAJ Gold, Green Published			2019-10-28	
J	Pedersen, HL; Horvei, KD; Thiyagarajan, D; Norby, GE; Seredkina, N; Moroni, G; Eilertsen, GO; Holdaas, H; Strom, EH; Bakland, G; Meroni, PL; Rekvig, OP				Pedersen, Hege L.; Horvei, Kjersti D.; Thiyagarajan, Dhivya; Norby, Gudrun E.; Seredkina, Natalya; Moroni, Gabriella; Eilertsen, Gro O.; Holdaas, Hallvard; Strom, Erik H.; Bakland, Gunnstein; Meroni, Pier-Luigi; Rekvig, Ole P.			Lupus nephritis: low urinary DNase I levels reflect loss of renal DNase I and may be utilized as a biomarker of disease progression	JOURNAL OF PATHOLOGY CLINICAL RESEARCH			English	Article						lupus nephritis; DNase I; urine; biomarker; biopsy	MURINE; ERYTHEMATOSUS; MICE; CLASSIFICATION; NUCLEOSOMES; ANTIBODIES; UPDATE; SERUM	Renal DNase I is lost in advanced stages of lupus nephritis. Here, we determined if loss of renal DNase I reflects a concurrent loss of urinary DNase I, and whether absence of urinary DNase I predicts disease progression. Mouse and human DNase I protein and DNase I endonuclease activity levels were determined by western blot, gel, and radial activity assays at different stages of the murine and human forms of the disease. Cellular localization of DNase I was analyzed by immunohistochemistry, immunofluorescence, confocal microscopy, and immunoelectron microscopy. We further compared DNase I levels in human native and transplanted kidneys to determine if the disease depended on autologous renal genes, or whether the nephritic process proceeded also in transplanted kidneys. The data indicate that reduced renal DNase I expression level relates to serious progression of lupus nephritis in murine, human native, and transplanted kidneys. Notably, silencing of renal DNase I correlated with loss of DNase I endonuclease activity in the urine samples. Thus, urinary DNase I levels may therefore be used as a marker of lupus nephritis disease progression and reduce the need for renal biopsies.	[Pedersen, Hege L.; Horvei, Kjersti D.; Thiyagarajan, Dhivya; Seredkina, Natalya; Rekvig, Ole P.] UiT Arctic Univ Norway, Dept Med Biol, Tromso, Norway; [Norby, Gudrun E.] OUH Oslo Univ Hosp, Dept Rheumatol, Oslo, Norway; [Moroni, Gabriella] Osped Maggiore, Nephrol Unit, Fdn Ca Granda IRCCS, Milan, Italy; [Eilertsen, Gro O.] UiT Arctic Univ Norway, Dept Clin Med, Tromso, Norway; [Holdaas, Hallvard] OUH Oslo Univ Hosp, Dept Med, Oslo, Norway; [Strom, Erik H.] OUH Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Bakland, Gunnstein] Univ Hosp North Norway, Dept Rheumatol, Tromso, Norway; [Meroni, Pier-Luigi] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy; [Meroni, Pier-Luigi] Ist Auxol Italiano, IRCCS, Milan, Italy	Pedersen, HL (reprint author), UiT Arctic Univ Norway, Fac Hlth Sci, Dept Med Biol, RNA & Mol Pathol Grp, N-9037 Tromso, Norway.	hege.lynum.pedersen@uit.no	Rekvig, Ole Petter/V-7113-2019		Norwegian Extra Foundation for Health and Rehabilitation [2013/FOM5607]; Northern Norway Regional Health Authority (Helse Nord RHF) [HNF1343-17]	The authors would like to thank Randi Olsen for excellent help with the electron microscopy studies. This project has been made possible by the Norwegian Extra Foundation for Health and Rehabilitation (2013/FOM5607) and the Northern Norway Regional Health Authority (Helse Nord RHF, HNF1343-17).	Bendiksen S, 2004, J IMMUNOL, V173, P7630, DOI 10.4049/jimmunol.173.12.7630; Davidson A, 2015, IMMUNOL RES, V63, P187, DOI 10.1007/s12026-015-8693-6; Salgado AD, 2012, AUTOIMMUN DIS, DOI 10.1155/2012/849684; Fenton K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008474; Fismen S, 2013, AM J PATHOL, V182, P688, DOI 10.1016/j.ajpath.2012.11.013; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Hogan J, 2013, CURR OPIN NEPHROL HY, V22, P224, DOI 10.1097/MNH.0b013e32835d921c; Horvei KD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188863; Kalaaji M, 2007, KIDNEY INT, V71, P664, DOI 10.1038/sj.ki.5002133; Kalaaji M, 2006, ARTHRITIS RHEUM-US, V54, P914, DOI 10.1002/art.21622; Koizumi T, 1996, EXP ANIM TOKYO, V45, P245, DOI 10.1538/expanim.45.245; Ludwig S, 2009, INT J BIOCHEM CELL B, V41, P1079, DOI 10.1016/j.biocel.2008.09.030; Macanovic M, 1997, CLIN EXP IMMUNOL, V108, P220, DOI 10.1046/j.1365-2249.1997.3571249.x; Mjelle JE, 2011, AUTOIMMUNITY, V44, P373, DOI 10.3109/08916934.2010.541170; Napirei M, 2004, BIOCHEM J, V380, P929, DOI 10.1042/BJ20040046; Norby GE, 2010, ANN RHEUM DIS, V69, P1484, DOI 10.1136/ard.2009.122796; Parsiegla G, 2012, BIOCHEMISTRY-US, V51, P10250, DOI 10.1021/bi300873f; Podolska MJ, 2015, J INFLAMM RES, V8, P161, DOI 10.2147/JIR.S70325; Rekvig OP, 2016, AM J PATHOL, V186, P2772, DOI 10.1016/j.ajpath.2016.06.026; Seredkina N, 2013, MOL MED, V19, P161, DOI 10.2119/molmed.2013.00010; Seredkina N, 2011, AM J PATHOL, V179, P1120, DOI 10.1016/j.ajpath.2011.05.011; Seredkina N, 2009, AM J PATHOL, V175, P97, DOI 10.2353/ajpath.2009.080943; Thiyagarajan D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129485; Tveita AA, 2008, KIDNEY INT, V74, P1150, DOI 10.1038/ki.2008.308; Weening JJ, 2004, J AM SOC NEPHROL, V15, P241, DOI 10.1097/01.ASN.0000108969.21691.5D; WOESSNER JF, 1995, METHOD ENZYMOL, V248, P510; Zabaleta-Lanz M, 2003, LUPUS, V12, P26, DOI 10.1191/0961203303lu259oa; Zubair A, 2013, CURR ALLERGY ASTHM R, V13, P580, DOI 10.1007/s11882-013-0394-4	28	2	2	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2056-4538			J PATHOL CLIN RES	J. Pathol. Clin. Res.	JUL	2018	4	3					193	203		10.1002/cjp2.99			11	Pathology	Pathology	GO6OR	WOS:000440168100006	29624903	DOAJ Gold, Green Published			2019-10-28	
J	Agrawal, R				Agrawal, Ranjan			From the Editor's desk	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							EXPRESSION; HEAD		[Agrawal, Ranjan] Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India	Agrawal, R (reprint author), Rohilkhand Med Coll & Hosp, Dept Pathol, Bareilly, Uttar Pradesh, India.	chiefeditor.ijpm@gmail.com					D'Antonio A, 2018, INDIAN J PATHOL MICR, V61, P311, DOI 10.4103/IJPM.IJPM_236_18; Gonul II, 2018, INDIAN J PATHOL MICR, V61, P350, DOI 10.4103/IJPM.IJPM_12_18; Gupta RK, 2018, INDIAN J PATHOL MICR, V61, P345, DOI 10.4103/IJPM.IJPM_240_17; Iyengar JN, 2018, INDIAN J PATHOL MICR, V61, P418, DOI 10.4103/IJPM.IJPM_17_17; Kumar V, 2018, INDIAN J PATHOL MICR, V61, P410, DOI 10.4103/IJPM.IJPM_849_16; Mazumder S, 2018, INDIAN J PATHOL MICR, V61, P356, DOI 10.4103/IJPM.IJPM_821_16; Nair IR, 2018, INDIAN J PATHOL MICR, V61, P330, DOI 10.4103/IJPM.IJPM_741_17; Pant I, 2018, INDIAN J PATHOL MICR, V61, P339, DOI 10.4103/IJPM.IJPM_402_17; Vats S, 2018, INDIAN J PATHOL MICR, V61, P313, DOI 10.4103/0377-4929.236599	9	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					309	310		10.4103/0377-4929.236639			2	Pathology	Pathology	GN7CT	WOS:000439282500001	30004044	DOAJ Gold			2019-10-28	
J	D'Antonio, A; Caputo, A				D'Antonio, Antonio; Caputo, Alessandro			HER2 as a prospective novel biomarker in squamous cell carcinomas of the head and neck	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material							EXPRESSION		[D'Antonio, Antonio] Univ Hosp S Giovanni di Dio & Ruggi DAragona, Dept Pathol & Cytopathol, Salerno, Italy; [Caputo, Alessandro] Univ Salerno, Dept Med & Surg, Salerno, Italy	D'Antonio, A (reprint author), Univ Hosp S Giovanni di Dio & Ruggi DAragona, Dept Pathol & Cytopathol, Salerno, Italy.	ada66@inwind.it		Caputo, Alessandro/0000-0001-5139-3869			[Anonymous], 2018, INDIAN J PATHOL MICR; Cavalot A, 2007, HEAD NECK-J SCI SPEC, V29, P655, DOI 10.1002/hed.20574; Pollock NI, 2015, CLIN CANCER RES, V21, P526, DOI 10.1158/1078-0432.CCR-14-1432; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Thomposn LD., 2014, WORLD CANC REPORT 20, P422; Tse GM, 2009, OTOLARYNG HEAD NECK, V141, P467, DOI 10.1016/j.otohns.2009.06.747; Wei QC, 2008, ANN SURG ONCOL, V15, P1193, DOI 10.1245/s10434-007-9771-3; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442	9	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					311	312		10.4103/IJPM.IJPM_236_18			2	Pathology	Pathology	GN7CT	WOS:000439282500002	30004045	DOAJ Gold			2019-10-28	
J	Vats, S; Ganesh, MS; Agarwal, A				Vats, Sumedha; Ganesh, M. S.; Agarwal, Arjun			Human epidermal growth factor receptor 2 neu expression in head and neck squamous cell cancers and its clinicopathological correlation: Results from an Indian cancer center	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Head and neck; human epidermal growth factor receptor 2/neu; prognosis; squamous cell cancer; targeted therapy	IN-SITU HYBRIDIZATION; BREAST-CANCER; HER2/NEU EXPRESSION; CARCINOMA; HER-2/NEU; IMMUNOHISTOCHEMISTRY; TONGUE	Background: Human epidermal growth factor receptor 2 (HER2)/neuprotooncogene (neu) is a proven molecular prognostic marker in breast, ovarian, gastric, and ovarian cancers. In head-and-neck cancers, varied expression is documented and therefore its prognostic role is debatable. Aim of the Study: To find the rate of overexpression of HER2/neu in head-and-neck cancers and to understand its prognostic role by evaluating its association with nodal stage and overall stage of the patient. Methodology: A total of 70 surgically resected cases of head-and-neck cancers were evaluated for expression of HER2/neu by immunohistochemistry. Scoring was done according to the American Society of Clinical Oncologists/College of American Pathologistsguidelines for Her2/neu testing in breast cancer. Results: Of the 70 cases studied, 57 were of oral cavity and 13 were laryngeal squamous cell cancers and 14 (20%) were Her2/neu positive. On correlating the expression of HER2/neu in T1/T2 (41 cases) versus T3/T4 (27 cases), the P value was found to be 0.8273 which was statistically insignificant. Furthermore, no statistically significant difference in expression of HER2/neu was found in between node negative and node positive cases (49 vs. 19 cases, respectively), with P = 0.512. Conclusion: In the current settings, HER2/neu is not found to be a prognostic marker in head-and-neck cancers. Standard immunohistochemistry staining protocols need to be established like in breast cancers to aid uniform reporting and further evaluate the role of this important protooncogene in head-and-neck cancers.	[Vats, Sumedha] Univ Birmingham, Robert Atiken Inst Clin Res, Royal Orthoped Hosp NHS, Dept Musculoskeletal Pathol, Birmingham, W Midlands, England; [Ganesh, M. S.; Agarwal, Arjun] Vydehi Inst Med Sci, Dept Surg Oncol, Bengaluru, Karnataka, India	Ganesh, MS (reprint author), Mallya Hosp, Vydehi Inst Oncol, Dept Surg Oncol, 82 EPIP Area,Vittal Mallya Rd, Bengaluru 560066, Karnataka, India.	msganesh1965@gmail.com					Akhter M, 2011, J Oral Maxillofac Pathol, V15, P168, DOI 10.4103/0973-029X.84485; Akimoto T, 1999, CLIN CANCER RES, V5, P2884; Angiero F, 2008, J ORAL PATHOL MED, V37, P145, DOI 10.1111/j.1600-0714.2007.00603.x; Bernardes VF, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002077; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Cavalot A, 2007, HEAD NECK-J SCI SPEC, V29, P655, DOI 10.1002/hed.20574; CRAVEN JM, 1992, ANTICANCER RES, V12, P2273; FIELD JK, 1992, ANTICANCER RES, V12, P613; Gonzalez-Angulo AM, 2006, ONCOLOGIST, V11, P857, DOI 10.1634/theoncologist.11-8-857; Goon PKC, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-36; Grimminger CM, 2011, EUR ARCH OTO-RHINO-L, V268, P5, DOI 10.1007/s00405-010-1369-x; Guerry M, 1998, BRIT J CANCER, V77, P1932, DOI 10.1038/bjc.1998.320; Gupta AK, 2002, CLIN CANCER RES, V8, P885; Hsueh CT., 2012, J HEMATOL ONCOL, V5, P83; Huang HJ, 2005, J CLIN PATHOL, V58, P611, DOI 10.1136/jcp.2004.022772; Kedrin D, 2009, CLIN CANCER RES, V15, P3733, DOI 10.1158/1078-0432.CCR-08-2163; Khan AJ, 2002, CLIN CANCER RES, V8, P540; Lebeau A, 2001, J CLIN ONCOL, V19, P354, DOI 10.1200/JCO.2001.19.2.354; Matta A, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-6; Nagai MA, 1999, BRAZ J MED BIOL RES, V32, P897, DOI 10.1590/S0100-879X1999000700015; Paik S, 2002, J NATL CANCER I, V94, P852, DOI 10.1093/jnci/94.11.852; Papavasileiou D, 2009, HEAD NECK PATHOL, V3, P263, DOI 10.1007/s12105-009-0134-1; Rath GK, 2014, INDIAN J MED PAEDIAT, V35, P288, DOI 10.4103/0971-5851.144991; Sardari Y, 2012, ASIAN PAC J CANCER P, V13, P2891, DOI 10.7314/APJCP.2012.13.6.2891; Seifi S, 2009, ASIAN PAC J CANCER P, V10, P661; Ulanovski D, 2004, ORAL ONCOL, V40, P532, DOI 10.1016/j.oraloncology.2003.11.004; Xia WY, 1997, CLIN CANCER RES, V3, P3; Yan W, 2011, AM J CANCER RES, V1, P275; Zorab R, 2002, DIAGNOSTIC IMMUNOHIS, P3	29	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					313	318		10.4103/0377-4929.236599			6	Pathology	Pathology	GN7CT	WOS:000439282500003	30004046	DOAJ Gold			2019-10-28	
J	Kucuk, U; Sarioglu, S; Cetin, P; Sari, I; Birlik, M				Kucuk, Ulku; Sarioglu, Sulen; Cetin, Pinar; Sari, Ismail; Birlik, Merih			Histopathological differences between primary Sjogren's syndrome and Sjogren's syndrome accompanied by scleroderma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Differences; histopathological; scleroderma; Sjogren's syndrome	SALIVARY-GLAND BIOPSY; SICCA-SYNDROME; PREVALENCE; DIAGNOSIS; STILL	Background: Investigation of morphological differences in relation with serological variables between primary versus secondary Sjogren's syndrome associated with systemic scleroderma (Scl-SS). Materials and Methods: A total of 69 primary Sjogren's syndrome (pSS) and Scl-SS patients were grouped according to the American-European Consensus Group criteria. Serum autoantibody information was obtained from the patient records. Hematoxylin and eosin sections of the minor salivary gland biopsy were reevaluated, and the lymphocyte focus score (FS), plasma cell focus, and fibrosis rates were all evaluated. Results: There were 43 pSS and 26 Scl-SS cases. Both biopsy and autoantibody were positive in 16 pSS cases while only biopsy was positive in 25 cases and only antibody in 1 case. Both biopsy and antibody were positive in 5 Scl-SS cases while only biopsy was positive in 18 and only antibody in 3 cases. The plasma cell focus was statistically significantly higher in pSS cases (P = 0.003). No difference was seen between Sjogren' syndrome (SS) subtypes in terms of lymphocyte FS, fibrosis, and autoantibody positivity. Conclusion: We found that plasma cell focuses could be found more frequently in pSS than Scl-SS. In addition, our study reveals that the coexistence of SS and systemic scleroderma decreases the incidence of FS value = 1 compared to pSS.	[Kucuk, Ulku] Tepecik Res & Training Hosp, Dept Pathol, Izmir, Turkey; [Sarioglu, Sulen] Dokuz Eylul Univ, Fac Med, Dept Pathol, Izmir, Turkey; [Cetin, Pinar; Sari, Ismail; Birlik, Merih] Dokuz Eylul Univ, Fac Med, Dept Rheumatol, Izmir, Turkey	Kucuk, U (reprint author), Tepecik Res & Training Hosp, Dept Pathol, Izmir, Turkey.	kucukulku@hotmail.com	SARI, Ismail/E-1778-2011	SARI, Ismail/0000-0001-7737-4180			Akiyama Y, 2000, INTERNAL MED, V39, P451, DOI 10.2169/internalmedicine.39.451; Al-Hashimi I, 2001, J ORAL PATHOL MED, V30, P408, DOI 10.1034/j.1600-0714.2001.300705.x; Avouac J, 2006, ARTHRITIS RHEUM, V54, P2243, DOI 10.1002/art.21922; Birlik M, 2009, INT J CLIN PRACT, V63, P954, DOI 10.1111/j.1742-1241.2008.01749.x; BODEUTSCH C, 1992, PATHOL RES PRACT, V188, P599, DOI 10.1016/S0344-0338(11)80063-4; CHISHOLM DM, 1968, J CLIN PATHOL, V21, P656, DOI 10.1136/jcp.21.5.656; COLL J, 1987, ANN RHEUM DIS, V46, P286, DOI 10.1136/ard.46.4.286; DROSOS AA, 1988, J RHEUMATOL, V15, P965; Manthorpe R, 2002, ANN RHEUM DIS, V61, P482, DOI 10.1136/ard.61.6.482; MASI A T, 1980, Arthritis and Rheumatism, V23, P581, DOI 10.1002/art.1780230510; Maslinska M, 2015, RHEUMATOL INT, V35, P233, DOI 10.1007/s00296-014-3072-5; MOUTSOPOULOS HM, 1979, AM J MED, V66, P733, DOI 10.1016/0002-9343(79)91110-0; Salliot C, 2007, RHEUMATOLOGY, V46, P321, DOI 10.1093/rheumatology/kel252; Salomonsson S, 2009, J ORAL PATHOL MED, V38, P282, DOI 10.1111/j.1600-0714.2008.00697.x; Stewart CM, 2008, ORAL SURG ORAL MED O, V106, P392, DOI 10.1016/j.tripleo.2008.04.018; Streifler Jonathan Y, 2014, Handb Clin Neurol, V119, P463, DOI 10.1016/B978-0-7020-4086-3.00030-8; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Yarom N, 2007, ORAL DIS, V13, P274, DOI 10.1111/j.1601-0825.2006.01278.x; Zandbelt MM, 2002, RHEUMATOLOGY, V41, P819, DOI 10.1093/rheumatology/41.7.819	19	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					319	322		10.4103/IJPM.IJPM_416_17			4	Pathology	Pathology	GN7CT	WOS:000439282500004	30004047	DOAJ Gold			2019-10-28	
J	Akoz, G; Diniz, G; Ekmekci, S; Ekin, ZY; Uncel, M				Akoz, Gamze; Diniz, Gulden; Ekmekci, Sumeyye; Ekin, Zubeyde Yildirim; Uncel, Melek			Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Breast cancer; human epididymal secretory protein 4; immunohistochemistry; molecular groups	OVARIAN-CARCINOMA; HE-4 EXPRESSION; SERUM HE-4; TUMOR; ADENOCARCINOMAS; CA125; LUNG	Background/Aims: Human epididymal secretory protein 4 (HE4) is originally described as an epididymis-specific protein but more recently suggested to be a putative serum tumor marker for some tumors, including breast carcinomas. In this study, we aimed to investigate the interactions between HE4 expression and molecular subtypes of breast carcinomas. Methods: HE4 expressions were studied in 242 formalin-fixed, paraffin-embedded breast carcinoma specimens and their association with different pathological and clinical parameters was evaluated. Results: Immunohistochemical (IHC) staining for HE4 was negative in 3 (1.2%) cases, weakly positive (1+) in 7 (2.9%) cases, moderately positive (2+) in 58 (24.0%) cases, and strongly positive (3+) in 174 (71.9%) cases. A correlation between IHC HE4 staining grade and molecular groups was detected (P = 0.005). Furthermore, it was found that HE4 expression was strongly associated with histological tumor grade, c-erbB2 expression, and positive fluorescence in situ hybridization test results that detect human epidermal growth factor receptor 2 (HER2)/neu amplification (P = 0.022, P = 0.014, and P = 0.011). Conclusion: This study showed that HE4 expression is associated with HER2/neu amplification in breast cancers. These results may be commented as HE4 expression rises in patients with HER2/neu amplification. As is known, HER2/neu amplification is a poor diagnostic factor in breast cancer and HE4 expression is possibly associated with poor prognosis.	[Akoz, Gamze; Diniz, Gulden; Ekmekci, Sumeyye; Ekin, Zubeyde Yildirim; Uncel, Melek] Tepecik Educ & Res Hosp, Dept Pathol, Izmir, Turkey	Diniz, G (reprint author), Kibris Sehitleri Caddesi 51-11, TR-35220 Izmir, Turkey.	agdiniz@gmail.com					Bingle L, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-61; Donegan W. L., 2006, BREAST CANC, P1; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Galgano MT, 2006, MODERN PATHOL, V19, P847, DOI 10.1038/modpathol.3800612; Gunduz UR, 2016, MOL CLIN ONCOL, V5, P355, DOI 10.3892/mco.2016.919; Guo YD, 2015, TUMOR BIOL, V36, P2457, DOI 10.1007/s13277-014-2858-0; Hellstrom I, 2003, CANCER RES, V63, P3695; Howlader N., 2014, SEER CANC STAT REV; Jiang YZ, 2014, INT J CLIN EXP MED, V7, P5568; Kamei M, 2010, ANTICANCER RES, V30, P4779; Karlsen NS, 2014, CANCER EPIDEM BIOMAR, V23, P2285, DOI 10.1158/1055-9965.EPI-14-0447; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Moore RG, 2008, GYNECOL ONCOL, V108, P402, DOI 10.1016/j.ygyno.2007.10.017; O'Neal RL, 2013, HUM PATHOL, V44, P734, DOI 10.1016/j.humpath.2012.07.017; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rosai J, 2011, ROSAI ACKERMANS SURG, P1659, DOI DOI 10.20471/ACC.2016.55.04.13; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tamakoshi K, 1996, GYNECOL ONCOL, V62, P67, DOI 10.1006/gyno.1996.0191; Vallius T, 2014, TUMOR BIOL, V35, P12389, DOI 10.1007/s13277-014-2553-1; Vuong D, 2014, VIRCHOWS ARCH, V465, P1, DOI 10.1007/s00428-014-1593-7; Zhu LC, 2016, ONCOTARGET, V7, P729, DOI 10.18632/oncotarget.6327	22	1	1	1	3	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					323	329		10.4103/IJPM.IJPM_465_17			7	Pathology	Pathology	GN7CT	WOS:000439282500005	30004048	DOAJ Gold			2019-10-28	
J	Nair, IR; Mathew, AJ; Kottarathil, VD				Nair, Indu Ramachandran; Mathew, Anand John; Kottarathil, Vijaykumar Dehannaparambil			Detection of micrometastasis in axillary lymph nodes of breast carcinoma patients and its association with clinical outcome	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Micrometastasis; node-negative breast carcinoma; ultrastaging	MACROMETASTASES; CANCER	Context: There is heterogeneity in the clinical behavior of breast carcinoma patients with node negativity. Studies have analyzed different factors influencing the outcome in such patients. It is suggested that the presence of nodal micrometastasis can act as a tool in predicting the aggressiveness of these tumors. Aims: The aim of this study is to assess the yield of micrometastasis/isolated tumor cell (ITC) by ultrastaging the morphologically negative axillary nodes and staining them with immunohistochemistry for epithelial membrane antigen. The association of such metastasis with the clinical outcome is determined. Settings and Design: This was a retrospective analytical study. One hundred cases of node-negative breast carcinoma patients who underwent surgery along with axillary lymph node dissection were selected. Materials and Methods: The largest node from the axillary dissection was selected and subjected to ultrastaging and immunohistochemical staining (as sentinel node dissection was not a routine practice at that time), to look for occult metastasis in the form of micrometastasis or ITCs. Statistical Analysis: Occurrence of events in the form of recurrence or death was noted. Association of the parameters was analyzed using Fisher's exact test. Results: Among the 100 cases, 79 patients were followed up for a minimum period of 5 years. Two cases had micromets in one node each. These two patients were among the eight, who developed events subsequently (25%). Hence, a statistically significant association was found between the presence of micromets with events. Conclusions: There is a statistically significant association between the presence of micromets and disease recurrence. Hence, we suggest that ultrastaging of the negative axillary node (now sentinel node, as it is being routinely done) might prove effective in predicting the events/prognosis in clinically and morphologically node-negative breast carcinoma patients	[Nair, Indu Ramachandran] Amrita Inst Med Sci, Dept Pathol, Kochi 682041, Kerala, India; [Kottarathil, Vijaykumar Dehannaparambil] Amrita Inst Med Sci, Dept Breast & Gynaecol Oncol, Kochi, Kerala, India; [Mathew, Anand John] Reg Publ Hlth Lab, Kochi, Kerala, India	Nair, IR (reprint author), Amrita Inst Med Sci, Dept Pathol, Kochi 682041, Kerala, India.	indurn@aims.amrita.edu					American Cancer Society, 2017, CANC FACTS FIG; [Anonymous], 2014, BREAST CANC MORT STA; BYRNE J, 1987, EUR J SURG ONCOL, V13, P409; Cote R, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.cra504; Cserni G, 1999, J CLIN PATHOL, V52, P922, DOI 10.1136/jcp.52.12.922; Dowlatshahi K, 1997, CANCER, V80, P1188, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H; Galimberti V, 2013, LANCET ONCOL, V14, P297, DOI 10.1016/S1470-2045(13)70035-4; Gnant M, 2011, BREAST CARE, V6, P136, DOI 10.1159/000328054; HUVOS AG, 1971, ANN SURG, V173, P44, DOI 10.1097/00000658-197101000-00006; Park Hyeli, 2014, Chonnam Med J, V50, P96, DOI 10.4068/cmj.2014.50.3.96; Parkin DM, 2006, BREAST J, V12, pS70, DOI 10.1111/j.1075-122X.2006.00205.x; ROSEN PP, 1981, ANN SURG, V194, P585, DOI 10.1097/00000658-198111000-00006	12	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					330	333		10.4103/IJPM.IJPM_741_17			4	Pathology	Pathology	GN7CT	WOS:000439282500006	30004049	DOAJ Gold			2019-10-28	
J	Das, I; Das, RN; Paul, B; Mandal, B; Mukherjee, S; Chatterjee, U				Das, Indranil; Das, Ram Narayan; Paul, Biswanath; Mandal, Bappa; Mukherjee, Suchandra; Chatterjee, Uttara			A study of spectrum of pulmonary pathology and expression of thyroid transcription factor-1 during neonatal period	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Hyaline membrane disease; neonatal autopsy; thyroid transcription factor-1	LUNG; INFECTION	Context: Neonatal period is the single most hazardous period of life. The major causes of neonatal death are prematurity and respiratory distress syndrome. We report a series of neonatal autopsies in our Neonatal Intensive Care Unit with special emphasis on pulmonary pathology. The spectrum of pathological changes in the lungs and thyroid transcription factor-1 (TTF-1) expression was studied in detail with reference to its spatial distribution. Aims: This study aims to analyze the causes of neonatal death with special attention to pulmonary pathology along with associated histopathological changes in lungs. We also evaluated the expression of TTF-1 at different levels of the airway. Materials and Methods: After taking consent and anthropometric measurements, autopsy was performed. Weights of all organs were taken, and histological sections were examined under hematoxylin and eosin stain. TTF-1 immunostaining was done on lung sections. Localization of TTF-1 was evaluated at the intrapulmonary level of terminal bronchioles (TBs), distal bronchioles, and alveoli. Results: We performed a series of 25 autopsies in neonates. In our series, most of the neonates were preterm (64%), had low birth weight (44%), and died within the first 7 days of life (80%). Majority (60%) of the neonates died due to pulmonary causes, followed by septicemia (24%), congenital anomalies (12%), and birth injury (4%). Among the respiratory causes, hyaline membrane disease (HMD) was diagnosed in maximum number of cases (32%), followed by pneumonia (12%) and pulmonary hemorrhage (12%). The TTF-1 expression in TBs, distal airways, and alveoli was significantly reduced or absent in cases of HMD compared to the control group. Conclusions: In this study, we observed that HMD is the most common cause of perinatal death among respiratory disorders, and in this disease, the expression of TTF-1 is significantly reduced in TBs, distal airways, and alveoli compared to the control group.	[Das, Indranil] NRS Med Coll, Dept Pathol, Kolkata, India; [Das, Ram Narayan; Chatterjee, Uttara] IPGME & R, Dept Pathol, Kolkata, India; [Mandal, Bappa; Mukherjee, Suchandra] IPGME & R, Dept Neonatol, Kolkata, India; [Paul, Biswanath] Midnapore Med Coll, Dept Pathol, Midnapore, W Bengal, India	Das, RN (reprint author), 265 Purba Sinthee Bye Lane, Kolkata 700030, W Bengal, India.	rndasmaliandi@gmail.com		chatterjee, Uttara/0000-0002-9346-1695			Baqui AH, 2006, B WORLD HEALTH ORGAN, V84, P706, DOI 10.2471/BLT.05.026443; Burri PH, 1997, LUNG GROWTH DEV, P1; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; Dalal S. R., 2002, Indian Journal of Pediatrics, V69, P23, DOI 10.1007/BF02723770; Decosta GF, 2006, LANCET, V342, P71; Dubell GG, 2004, NELSONS TXB PAEDIAT, P732; Khetarpal SK, 1988, INDIAN J PEDIATR, V32, P110; Li Y, 2007, CANCER RES, V67, P8494, DOI 10.1158/0008-5472.CAN-07-0647; MILLER HC, 1950, PEDIATRICS, V5, P184; Pryse-Davies J, 1981, HISTOPATHOLOGY, V11, P65; SPEER M, 1978, J PEDIATR-US, V93, P295, DOI 10.1016/S0022-3476(78)80525-3; Stahlman MT, 1996, J HISTOCHEM CYTOCHEM, V44, P673, DOI 10.1177/44.7.8675988; van den Berg A, 2001, EUR J OBSTET GYN R B, V98, P9, DOI 10.1016/S0301-2115(01)00292-5; YEUNG CY, 1976, CAN MED ASSOC J, V114, P135	14	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					334	338		10.4103/IJPM.IJPM_650_17			5	Pathology	Pathology	GN7CT	WOS:000439282500007	30004050	DOAJ Gold			2019-10-28	
J	Pant, I; Jha, K; Singh, R; Kushwaha, S; Chaturvedi, S				Pant, Ishita; Jha, Karuna; Singh, Ritika; Kushwaha, Suman; Chaturvedi, Sujata			Peripheral neuropathy and the role of nerve biopsy: A revisit	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Nerve biopsy; peripheral neuropathy; sural nerve	INFLAMMATORY DEMYELINATING POLYNEUROPATHY; VASCULITIC NEUROPATHY; SOUTH-INDIA; DIAGNOSIS; CRITERIA; EXPERIENCE; UNIVERSITY; LEPROSY; YIELD	Background: Nerve biopsy has been widely used to investigate patients with peripheral neuropathy and in many centers, it is still a part of the diagnostic armamentarium. In this study, the histopathological spectrum of the nerve biopsies received is being revisited to analyze the various clinical and pathologic features and also to assess their relevance. Materials and Methods: Retrospective analysis of the data retrieved was done for 74 cases of nerve biopsies. Results: On the basis of the data and histopathological features, broad diagnoses were obtained in 52 cases and further categorized into biopsies being supportive for patient management (including acute and chronic axonopathies and demyelinating neuropathies) and biopsies considered essential for patient management (including vasculitic neuropathies, leprous neuropathies, hereditary neuropathies, and chronic inflammatory demyelinating neuropathies). Nine nerve biopsies did not show any abnormal histopathological features, while 13 nerve biopsies were found to be inadequate for diagnosis, both these groups were categorized as noncontributory. Conclusion: With advanced nerve conduction studies available, nerve biopsy is losing its relevance. However, in our experience, nerve biopsy did complement the clinical findings and nerve conduction studies, with which a close correlation is required to make the histopathology of nerve biopsy more relevant in terms of guiding further specific workup and management.	[Pant, Ishita; Jha, Karuna; Singh, Ritika; Chaturvedi, Sujata] Inst Human Behav & Allied Sci, Dept Pathol, New Delhi 110095, India; [Kushwaha, Suman] Inst Human Behav & Allied Sci, Dept Neurol, New Delhi, India	Chaturvedi, S (reprint author), Inst Human Behav & Allied Sci, Dept Pathol, New Delhi 110095, India.	drsujatacv@gmail.com					ARGOV Z, 1989, ACTA NEUROL SCAND, V79, P243, DOI 10.1111/j.1600-0404.1989.tb03745.x; Chia L, 1996, BRAIN, V119, P1091; Collins MP, 2000, NEUROLOGY, V55, P636, DOI 10.1212/WNL.55.5.636; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; De Freitas MRG, 1998, ARQ NEURO-PSIQUIAT, V56, P585, DOI 10.1590/S0004-282X1998000400011; Deprez M, 2000, ACTA NEUROL BELG, V100, P162; DYCK PJ, 1966, MAYO CLIN PROC, V41, P778; Haq RU, 2000, ARCH NEUROL-CHICAGO, V57, P1745, DOI 10.1001/archneur.57.12.1745; HELLMANN DB, 1988, MEDICINE, V67, P145, DOI 10.1097/00005792-198805000-00001; Hui M, 2015, ANN INDIAN ACAD NEUR, V18, P292, DOI 10.4103/0972-2327.162284; Kulkarni GB, 2010, NEUROL INDIA, V58, P542, DOI 10.4103/0028-3886.68673; Lawrence A, 2016, ANN INDIAN ACAD NEUR, V19, P323, DOI 10.4103/0972-2327.179982; Midroni G, 1995, BIOPSY DIAGNOSIS PER, P1; NEUNDORFER B, 1990, EUR NEUROL, V30, P350, DOI 10.1159/000117372; Oh S J, 1990, Yonsei Med J, V31, P1; Patidar SP, 2016, J NEUROL NEUROSCI, V6, P1; RAPPAPORT WD, 1993, AM J SURG, V166, P252, DOI 10.1016/S0002-9610(05)80968-7; SAID G, 1988, ANN NEUROL, V23, P461, DOI 10.1002/ana.410230506; Schenone A, 2005, HEREDITARY PERIPHERAL NEUROPATHIES, P41, DOI 10.1007/3-7985-1586-7_4; Schweikert K, 2007, EUR NEUROL, V57, P86, DOI 10.1159/000098057	20	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					339	344		10.4103/IJPM.IJPM_402_17			6	Pathology	Pathology	GN7CT	WOS:000439282500008	30004051	DOAJ Gold			2019-10-28	
J	Gupta, RK; Sakhuja, P; Majumdar, K; Ali, S; Srivastava, S; Sachdeva, S; Sharma, BC; Puri, AS				Gupta, Rakesh Kumar; Sakhuja, Puja; Majumdar, Kaushik; Ali, Shahajad; Srivastava, Siddharth; Sachdeva, Sanjeev; Sharma, Barjesh C.; Puri, Amarender S.			Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Fibrosis; hepatitis; hepatitis C virus; histology; liver biopsy	LIVER FIBROSIS; TRANSIENT ELASTOGRAPHY; UNITED-STATES; STEATOSIS; DIAGNOSIS; STIFFNESS; INDIA	Background and Aims: Liver biopsy may be considered in patients with hepatitis C virus (HCV) infection to assess the severity of liver injury and stage of fibrosis, thereby guiding therapeutic decisions. In addition, advanced stage also necessitates surveillance for hepatocellular carcinoma. The aim of this study was to assess whether transaminase (alanine transaminase [ALT]) levels and RNA titers correlate with the histological activity index (HAI) and fibrosis (F) stage in asymptomatic patients with incidentally detected HCV (IDHCV). Patients and Methods: Retrospective evaluation of liver biopsies was done in 113 patients with IDHCV, diagnosed during routine screening. Decision of liver biopsy was made on the basis of age, genotype, acceptable clinical, hematological, and biochemical profiles, and willingness of the patients to undergo treatment. Serum ALT levels, HCV RNA titers, and genotypes were correlated with HAI and F stage. Results: Genotyping was done in 77 of the 113 patients, of which genotype 3 was seen in 43 and genotype 1 in 25 patients. A higher fibrosis stage (Ishak's >F2) was noted in 23.8% of the biopsies. Serum ALT showed a significant correlation with the HAI score on liver biopsy (P = 0.01) but not with the stage of fibrosis (P = 0.52). HCV RNA titers did not reveal any correlation with HAI score or fibrosis stage. Conclusion: Serum transaminases and HCV RNA titers are poor predictors of disease severity and fibrosis. Since HCV shows a slow disease progression, higher stage may predict a worse prognosis irrespective of the low viral RNA load. Liver biopsy may help guide therapeutic decisions in IDHCV infection.	[Gupta, Rakesh Kumar; Sakhuja, Puja; Majumdar, Kaushik; Ali, Shahajad] GB Pant Inst Post Grad Med Educ & Res, Dept Pathol, Acad Block,Jawaharlal Nehru Marg, New Delhi 110002, India; [Srivastava, Siddharth; Sachdeva, Sanjeev; Sharma, Barjesh C.; Puri, Amarender S.] GB Pant Inst Post Grad Med Educ & Res, Dept Gastroenterol, New Delhi, India	Gupta, RK (reprint author), GB Pant Inst Post Grad Med Educ & Res, Dept Pathol, Acad Block,Jawaharlal Nehru Marg, New Delhi 110002, India.	rakesh.newjobi@gmail.com					Afdhal NH, 2015, CLIN GASTROENTEROL H, V13, P772, DOI 10.1016/j.cgh.2014.12.014; Castera L, 2011, LIVER INT, V31, P13, DOI 10.1111/j.1478-3231.2010.02380.x; Chen SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140554; Chen SH, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-105; Deffieux T, 2015, J HEPATOL, V62, P317, DOI 10.1016/j.jhep.2014.09.020; Di Bisceglie AM, 2003, AM J GASTROENTEROL, V98, P2060, DOI 10.1016/S0002-9270(03)00552-5; Fraquelli M, 2011, J HEPATOL, V54, P621, DOI 10.1016/j.jhep.2010.07.017; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Goossens N, 2014, HEPATOLOGY, V59, P2403, DOI 10.1002/hep.26905; Hazari S, 2004, J GASTROEN HEPATOL, V19, P1058, DOI 10.1111/j.1440-1746.2004.03405.x; Hissar SS, 2006, J MED VIROL, V78, P452, DOI 10.1002/jmv.20561; Huffman MM, 2014, J AM BOARD FAM MED, V27, P284, DOI 10.3122/jabfm.2014.02.130165; Kamal SM, 2008, AM J GASTROENTEROL, V103, P1283, DOI 10.1111/j.1572-0241.2008.01825.x; Kumar M, 2013, HEPATOL INT, V7, P134, DOI 10.1007/s12072-012-9380-5; Lebovics E, 2014, AM J MED, V127, pE11, DOI 10.1016/j.amjmed.2014.10.004; Macaluso FS, 2014, J HEPATOL, V61, P523, DOI 10.1016/j.jhep.2014.04.045; Puri P, 2015, J CLIN EXP HEPATOL, V5, P221, DOI 10.1016/j.jceh.2015.09.002; Shah SR, 2011, CLIN GASTROENTEROL H, V9, P688, DOI 10.1016/j.cgh.2011.04.029; Smith Bryce D., 2012, Morbidity and Mortality Weekly Report, V61, P1; Vispo E, 2009, ANTIVIR THER, V14, P187; Zeuzem S, 2004, GASTROENTEROLOGY, V127, P1724, DOI 10.1053/j.gastro.2004.09.050	21	2	2	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					345	349		10.4103/IJPM.IJPM_240_17			5	Pathology	Pathology	GN7CT	WOS:000439282500009	30004052	DOAJ Gold			2019-10-28	
J	Gonul, II; Cakir, A; Sozen, S				Gonul, Ipek Isik; Cakir, Asli; Sozen, Sinan			Immunohistochemical expression profiles of MUC1 and MUC2 mucins in urothelial tumors of bladder	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Bladder; grading; mucin expression; prognosis; urothelial carcinomas	CARCINOMA IN-SITU; PROGNOSTIC-SIGNIFICANCE; EPISIALIN MUC1; CELL-ADHESION; E-CADHERIN; CANCER; ORGANIZATION; NEOPLASMS; MUC5AC	Background: Mucins may show aberrant expression, localization, and/or glycosylation in multiple malignancies. However, information regarding expression of these mucins is mostly unknown in urothelial tumors. Aim: This study was conducted for examining the expressions of membrane associated and secreted mucin (MUC1) and a secreted gel-forming mucin (MUC2) in urothelial tumors of the urinary bladder. Subjects and Methods: Archival transurethral resection materials of 97 urothelial carcinoma cases were reexamined light microscopically and graded according to the 2004 WHO Classification. Pathological stage was given as pTa, pT1, and pT2. Demonstrative sections were recut for immunohistochemistry for MUC1 and MUC2. The results were statistically analyzed, and P < 0.05 was considered statistically significant. Results: The positivity for MUC1 and MUC2 was 89.7% and 44.3%, respectively. Independent from pathological stage of the tumor, MUC1 expression showed statistically significant correlation with tumor grade (P < 0.05). We did not find any correlation between pathological stage and MUC1 and MUC2 expression (P > 0.05). MUC1 staining pattern in papillary urothelial neoplasm of low malignant potential cases was more commonly apical and superficial (luminal cell layer only). Intermediate cells +/- basal cells or isolated cells or islands of tumor cells with cytoplasmic and/or circumferential membrane positivity for MUC1 and MUC2 were more commonly observed in both low- and high-grade carcinomas. The difference between groups in terms of MUC1 and MUC2 staining was statistically significant (P < 0.05). Conclusions: The staining patterns of both mucins are different between urothelial papillary tumors and may be used to make a differentiation, especially for low-grade papillary urothelial lesions. This difference may also be important in the carcinomatous transformation of urothelial neoplastic and preneoplastic lesions.	[Gonul, Ipek Isik] Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkey; [Sozen, Sinan] Gazi Univ, Sch Med, Dept Urol, Ankara, Turkey; [Cakir, Asli] Istanbul Medipol Univ, Sch Med, Dept Pathol, Istanbul, Turkey	Gonul, II (reprint author), Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkey.	dripek@gmail.com		Cakir, Asli/0000-0003-0128-6947			Abd Elazeez TA, 2011, UROL ANNALS, V3, P8, DOI 10.4103/0974-7796.75857; Agrawal R, 2017, INDIAN J PATHOL MICR, V60, P462, DOI 10.4103/IJPM.IJPM_474_17; Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003; Cardillo MR, 2000, J EXP CLIN CANC RES, V19, P225; Cheng LA, 2011, HUM PATHOL, V42, P455, DOI 10.1016/j.humpath.2010.07.007; Garbar C, 2011, ANAL QUANT CYTOL, V33, P277; He YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076495; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Jacobs BL, 2010, CA-CANCER J CLIN, V60, P244, DOI 10.3322/caac.20077; Kaur S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092742; Kaymaz E, 2017, INDIAN J PATHOL MICR, V60, P510, DOI 10.4103/IJPM.IJPM_204_16; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Levi E, 2004, J CLIN PATHOL, V57, P456, DOI 10.1136/jcp.2003.013292; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Murray A, 2001, J NUCL MED, V42, P726; Nassar H, 2004, MODERN PATHOL, V17, P1045, DOI 10.1038/modpathol.3800166; Patriarca C, 2009, INT J SURG PATHOL, V17, P99, DOI 10.1177/1066896908326918; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Scholfield DP, 2003, BJU INT, V91, P560, DOI 10.1046/j.1464-4096.2003.04132.x; Stojnev S, 2014, INT J CLIN EXP PATHO, V7, P4945; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; WALSH MD, 1994, BRIT J UROL, V73, P256, DOI 10.1111/j.1464-410X.1994.tb07514.x; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; Witjes JA, 2004, EUR UROL, V45, P142, DOI 10.1016/j.eururo.2003.09.013; Yonezawa Suguru, 2002, J Hepatobiliary Pancreat Surg, V9, P328, DOI 10.1007/s005340200037; Yonezawa S, 2011, PATHOL INT, V61, P697, DOI 10.1111/j.1440-1827.2011.02734.x; Yuan SF, 2005, WORLD J GASTROENTERO, V11, P4661, DOI 10.3748/wjg.v11.i30.4661	30	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					350	355		10.4103/IJPM.IJPM_12_18			6	Pathology	Pathology	GN7CT	WOS:000439282500010	30004053	DOAJ Gold			2019-10-28	
J	Mazumder, S; Ramya, BS; Biligi, DS				Mazumder, Sujaya; Ramya, B. S.; Biligi, Dayananda S.			eUtility of urine reagent strips in cerebrospinal fluid analysis: An aid to bedside diagnosis of meningitis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Cerebrospinal fluid; meningitis; urine reagent strips	ACUTE BACTERIAL-MENINGITIS; RAPID DIAGNOSIS; MANAGEMENT; ADULTS	Context: The provision of initial treatment to a patient with suspected meningitis depends greatly on early recognition and rapid diagnostic evaluation of cerebrospinal fluid (CSF) leukocytes, proteins, and glucose. The diagnosis is time critical and timely intervention has an implication on the prognosis and outcome. Reasonably, sound laboratorial setups are not available in our country in the primary health-care level and, even in the settings where they are available, long waiting periods precede the availability of results. Aims: We conducted this study to emphasize the role of urine reagent strip test as a rapid diagnostic tool in CSF analysis. Settings and Design: This is a prospective single-blinded study on 100 consecutive CSF samples received with in 1h of tap. Subjects and Methods: All the 100 samples were subjected to definitive test being CSF microscopy and biochemical analysis of proteins and sugar and index test being a semi quantitative analysis of CSF leukocytes, proteins, and sugar by urinary reagent strips. Statistical Analysis Used: The diagnostic accuracy of the reagent strip for different cutoff levels was estimated and tabulated in the form of sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio. Results: 77% of cases were in the pediatric age group and 23% cases were adults. The sensitivity and specificity for leukocytes by the strip method for >= 15 cells/cumm were 89.28% and 98.61%, respectively, which increased to 100% with an increase in the counts. The reagent strip test had a sensitivity of 85.71% and a specificity of 95.65% for the protein levels >30 mg/dl which increased to 100% with an increase in protein levels. The reagent strip test for glucose was highly specific (100%) but less sensitive. Conclusions: The results indicate that urine reagent strip is instrumental in bedside CSF analysis and has a future stand in the diagnosis of meningitis.	[Mazumder, Sujaya; Ramya, B. S.; Biligi, Dayananda S.] Bangalore Med Coll & Res Inst, Dept Pathol, Bengaluru, Karnataka, India	Mazumder, S (reprint author), 4D,Jeno Sougoumaran Apartment, Reddiyarpalayam 605010, Puducherry, India.	suji0206@gmail.com					Brancusi F, 2012, FUTURE MICROBIOL, V7, P1101, DOI [10.2217/fmb.12.86, 10.2217/FMB.12.86]; Chaudhuri A, 2008, EUR J NEUROL, V15, P649, DOI 10.1111/j.1468-1331.2008.02193.x; Chikkannaiah P, 2016, NEUROL INDIA, V64, P50, DOI 10.4103/0028-3886.173641; de Louvois J, 2007, ARCH DIS CHILD, V92, P959, DOI 10.1136/adc.2006.105916; Krebs VLJ, 2007, ARQ NEURO-PSIQUIAT, V65, P1149, DOI 10.1590/S0004-282X2007000700011; Joshi Deepti, 2013, J Neurosci Rural Pract, V4, P140, DOI 10.4103/0976-3147.112737; Kumar A, 2015, INDIAN J PEDIATR, V82, P311, DOI 10.1007/s12098-014-1357-z; Maclennan C, 2004, TROP DOCT, V34, P231, DOI 10.1177/004947550403400417; Molyneux Elizabeth, 2013, J Neurosci Rural Pract, V4, P117, DOI 10.4103/0976-3147.112729; MOOSA AA, 1995, LANCET, V345, P1290, DOI 10.1016/S0140-6736(95)90931-1; Oses Salvador J M, 1988, An Esp Pediatr, V29, P105; Parmar Ramesh C, 2004, Indian J Med Sci, V58, P62; Ray P, 2007, AM J EMERG MED, V25, P179, DOI 10.1016/j.ajem.2006.07.012; Romanelli R, 2001, J PEDIAT RIO J, V77, P203, DOI DOI 10.2223/JPED.207; Scarborough M, 2008, LANCET NEUROL, V7, P637, DOI 10.1016/S1474-4422(08)70139-X; VALMARI P, 1987, EUR J PEDIATR, V146, P515, DOI 10.1007/BF00441607	16	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					356	359		10.4103/IJPM.IJPM_821_16			4	Pathology	Pathology	GN7CT	WOS:000439282500011	30004054	DOAJ Gold			2019-10-28	
J	Palur, K; Arakeri, SU				Palur, Katyayani; Arakeri, Surekha U.			Effectiveness of the International Consensus Group criteria for manual peripheral smear review	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Automated hematology analyzers; International Consensus Group for Hematology Review criteria (ICGHR); manual peripheral smear review		Context: The International Consensus Group for Hematology Review (ICGHR) are essentially review criteria designed to reduce the number of manual smear reviews following analysis in automated hematology analyzers (AHAs). Although AHAs are an indispensable part of the present-day clinical laboratory, manual smear reviews still play an integral role in identifying morphological abnormalities and to confirm the results of the analyzers. Aims: The aim of this study is to evaluate the efficacy of the ICGHR criteria and our laboratory criteria using the Sysmex XN-1000 for manual peripheral smear review (MSR). Study Design: A prospective cross-sectional comparative study between the two sets of criteria for MSR was performed. Material and Methods: A total of 860 whole blood samples sent over a period of 19 months for complete blood count testing to our laboratory were collected using systematic random sampling. Truth tables were prepared for each set of criteria. Tests of proportion were used to compare performance specifications between both sets of criteria. Results: Using ICGHR criteria, sensitivity was 81.58%, specificity was 84.61%, 83.38% positive predictive value, and 82.92% negative predictive value. The microscopic smear review rate was 47.56% and efficiency was 83.14%. Using our laboratory criteria, sensitivity was 98.80%, specificity was 41.40%, positive predictive value of 61.46%, and negative predictive value of 97.34%. The microscopic smear review rate was 78.14% and efficiency 69.30%. Conclusions: There was a significant reduction in the microscopic smear review rates using the ICGHR criteria compared to our laboratory criteria. The ICGHR criteria can thus be adapted to daily laboratory practice provided they are first optimized and locally validated before use.	[Palur, Katyayani; Arakeri, Surekha U.] BLDEUs Shri BM Patil Med Coll, Dept Pathol, Vijayapura, Karnataka, India	Palur, K (reprint author), BLDEUs Shri BM Patil Med Coll, Dept Pathol, Vijayapura, Karnataka, India.	katyayani53@gmail.com					Barnes P W, 2005, Lab Hematol, V11, P83, DOI 10.1532/LH96.05019; Bates I, 2012, DACIE LEWIS PRACTICA, P11; Comar Samuel Ricardo, 2014, Rev. Bras. Hematol. Hemoter., V36, P219, DOI 10.1016/j.bjhh.2014.03.011; Cui W, 2010, CHINESE MED J-PEKING, V123, P3231, DOI 10.3760/cma.j.issn.0366-6999.2010.22.011; Eldanasoury AS, 2016, INT J SCI RES RAIPUR, V5, P484; Geaghan SM, 2009, WINTROBES CLIN HEMAT, V2, P2585; Kaznowska-Bystryk I, 2011, ANN UMCS SECT DDD, VXXIV, P63; Kim SJ, 2012, ARCH PATHOL LAB MED, V136, P1408, DOI 10.5858/arpa.2010-0757-OA; Novis DA, 2006, ARCH PATHOL LAB MED, V130, P596; Pratumvinit B, 2013, ARCH PATHOL LAB MED, V137, P408, DOI 10.5858/arpa.2011-0535-OA; Sireci A, 2010, ARCH PATHOL LAB MED, V134, P1528, DOI 10.1043/2009-0531-OA.1	11	0	0	1	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					360	365		10.4103/IJPM.IJPM_142_17			6	Pathology	Pathology	GN7CT	WOS:000439282500012	30004055	DOAJ Gold			2019-10-28	
J	Langer, S; Dass, J; Saraf, A; Kotwal, J				Langer, Sabina; Dass, Jasmita; Saraf, Amrita; Kotwal, Jyoti			Platelet function tests: A 5-year audit of platelet function tests done for bleeding disorders in a tertiary care center of a developing country	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Bleeding disorders; light transmission aggregometry; platelet function test	ASSESSMENT-TOOL; DIAGNOSIS; AGGREGOMETRY; UTILITY	Introduction: The platelet function disorders remain largely undiagnosed or incompletely diagnosed in developing nations due to lack of availability of tests like lumiaggregometry, granule release assay or molecular testing. We performed a retrospective analysis of all the platelet function test (PFT) carried out in past 5 years by Light transmission aggregometery (LTA) using a panel of agonist. The indications and the test results were analyzed by two hematopathologist with the aim to look into the present diagnostic facilities or lack of it for correct diagnosis. This is essential for better management and genetic counselling. Materials and Methods: The PFT was performed both on patients and healthy unrelated age specific controls by light transmission aggregometry on Chronolog platelet aggregometer using platelet rich plasma. The panel of agonists included ADP (10 mu m/l and 2.0 mu m/l), epinephrine (10.0 mu m/l), collagen (2 mu g/ml), arachidonic acid (0.75 mM) and ristocetin (1.25 mg/ml & 0.25 mg/l). Results: The 5 years records of 110 cases were audited, 101 of these were tested for clinical bleeding, 35 adults and 66 children. The adults included 29 women and 6 men, 17 to 82 years of age. The children were 16 years to 3 months of age, 30 girls and 36 boys. Platelet function test abnormality was found in 31.6% (32/101) cases, a majority remained undiagnosed of these about 21% had clinically significant bleeding. The cases diagnosed included Glanzmann Thromboasthenia-11, von Willebrand Disease-6, Bernard Soulier'syndrome-1, storage pool disorder-6, mild defect of Epinephrine-3, isolated defect with collagen in1. Conclusion: An epidemiologically large proportion of platelet function disorders amongst people living in developing nations remain undiagnosed. This lacunae needs to be highlighted and addressed on larger scale. The options available are to increase the available armamentarium of tests or international collaboration with a specialized laboratory to aid in complete diagnosis.	[Langer, Sabina; Dass, Jasmita; Saraf, Amrita; Kotwal, Jyoti] Sir Ganga Ram Hosp, Dept Hematol & Clin Pathol, New Delhi, India	Langer, S (reprint author), Sir Ganga Ram Hosp, New Delhi 110060, India.	sabinapost@yahoo.com					Ahmad F, 2008, THROMB RES, V121, P835, DOI 10.1016/j.thromres.2007.07.015; Bolton-Maggs PHB, 2006, BRIT J HAEMATOL, V135, P603, DOI 10.1111/j.1365-2141.2006.06343.x; Cattaneo M, 2013, J THROMB HAEMOST, V11, P1183, DOI 10.1111/jth.12231; Elbatarny M, 2014, HAEMOPHILIA, V20, P831, DOI 10.1111/hae.12503; Ghosh K, 2003, PLATELETS, V14, P351, DOI 10.1080/09537100310001598792; Glembotsky AC, 2012, J THROMB HAEMOST, V10, P1653, DOI 10.1111/j.1538-7836.2012.04805.x; Gresele P, 2014, J THROMB HAEMOST, V12, P1562, DOI 10.1111/jth.12650; Hayward CPM, 2009, J THROMB HAEMOST, V7, P676, DOI 10.1111/j.1538-7836.2009.03273.x; Kotru M, 2016, MEDITERR J HEMATOL I, V8, DOI 10.4084/MJHID.2016.049; Lowe GC, 2013, J THROMB HAEMOST, V11, P1663, DOI 10.1111/jth.12332; Pai M, 2011, AM J CLIN PATHOL, V136, P350, DOI 10.1309/AJCP9IPR1TFLUAGM; Quiroga T, 2007, HAEMATOL-HEMATOL J, V92, P357, DOI 10.3324/haematol.10816; Rodeghiero F, 2010, J THROMB HAEMOST, V8, P2063, DOI 10.1111/j.1538-7836.2010.03975.x; Sanchez-Guiu I, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0213-6	14	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					366	370		10.4103/IJPM.IJPM_758_17			5	Pathology	Pathology	GN7CT	WOS:000439282500013	30004056	DOAJ Gold			2019-10-28	
J	Singh, K; Sazawal, S; Chhikara, S; Mahapatra, M; Saxena, R				Singh, Kanwaljeet; Sazawal, Sudha; Chhikara, Sunita; Mahapatra, Manoranjan; Saxena, Renu			Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Chronic myeloproliferative neoplasms; JAK2V617F mutation; thrombosis	ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; COAGULATION ACTIVATION; JAK2(V617F) MUTATION; INCREASED PLATELET; RISK-FACTORS; JAK2; LEUKOCYTOSIS; COMPLICATIONS; MECHANISMS	Background: It is still a matter of debate regarding the association of JAK2V617F mutation with thrombosis in BCR-ABL negative CMPN patients. The role of JAK2V617F mutation in increasing the thrombotic risk in CMPNs is yet unequivocal. Aims: To clarify the contribution of JAK2V617F mutation in thrombosis in CMPN patients. Settings and Design: This retrospective study was done to evaluate role of JAK2V617F mutation in thrombosis in CMPNs. Materials and Methods: 65 CMPN patients (PV, ET and PMF) were analyzed for JAK2V617F mutation using ARMS-PCR and detailed history of thrombosis was recorded in these patients. Statistical Analysis: P values were 2 tailed, and statistical significance was set at P < 0.05. Results: 46/65 were males and 19/65 were females [M:F: 2.4: 1] with median age 46 years [range, 14-80 years]. Patients had median Hb 15.6 g/dl [range, 5.1-20.3], median TLC 10.7 x 10(9)/l [range 2.4-216] and platelet count 360 x 10(9)/l [range, 20-1859]. 32 were JAK2V617F positive and 33 were negative for this mutation. On comparing the prevalence of thrombosis in JAK2V617F positive patients with JAK2V617F negative patients, we observed that 20/32 (62.5%) JAK2V617F positive patients had thrombosis as compared to 16/33 (48%) in JAK2V617F negative patients (P = 0.04). We observed significant association of JAK2V617F mutation with thrombosis, however no association of this mutation with thrombosis was observed among the JAK2V617F negative patients. Conclusion: Our study suggests that JAK2V617F mutation may increase the risk of thrombosis in CMPNs. This finding could lead to risk stratification, setting up the treatment strategy in CMPNs.	[Singh, Kanwaljeet; Sazawal, Sudha; Chhikara, Sunita; Mahapatra, Manoranjan; Saxena, Renu] All India Inst Med Sci, Dept Hematol, New Delhi 110029, India	Singh, K (reprint author), All India Inst Med Sci, Dept Hematol, New Delhi 110029, India.	kanwaljeet2009@gmail.com					Alvarez-Larran A, 2008, ANN HEMATOL, V87, P269, DOI 10.1007/s00277-007-0386-3; Arellano-Rodrigo E, 2006, HAEMATOL-HEMATOL J, V91, P169; Campbell PJ, 2006, NEW ENGL J MED, V355, P2452, DOI 10.1056/NEJMra063728; Carobbio A, 2007, BLOOD, V109, P2310, DOI 10.1182/blood-2006-09-046342; Cheung B, 2006, BRIT J HAEMATOL, V132, P244, DOI 10.1111/j.1365-2141.2005.05858.x; Cross NCP, 2011, HEMATOL-AM SOC HEMAT, P208, DOI 10.1182/asheducation-2011.1.208; De Stefano V, 2008, HAEMATOL-HEMATOL J, V93, P372, DOI 10.3324/haematol.12053; Elliott MA, 2005, BRIT J HAEMATOL, V128, P275, DOI 10.1111/j.1365-2141.2004.05277.x; Finazzi G, 2004, PATHOL BIOL, V52, P285, DOI 10.1016/j.patbio.2004.02.007; Harrison CN, 1999, BLOOD, V93, P417, DOI 10.1182/blood.V93.2.417.402a33_417_424; Hsiao HH, 2007, EXP HEMATOL, V35, P1704, DOI 10.1016/j.exphem.2007.08.011; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Landolfi R, 2007, BLOOD, V109, P2446, DOI 10.1182/blood-2006-08-042515; Marchetti M, 2008, BLOOD, V112, P4061, DOI 10.1182/blood-2008-06-164087; Niittyvuopio R, 2004, EUR J HAEMATOL, V72, P245, DOI 10.1111/j.1600-0609.2004.00219.x; Ohyashiki K, 2007, LEUKEMIA, V21, P1570, DOI 10.1038/sj.leu.2404666; Perea G, 2001, HAEMATOLOGICA, V86, P543; Robertson B, 2007, J THROMB HAEMOST, V5, P1679, DOI 10.1111/j.1538-7836.2007.02626.x; Royer Y, 2005, J BIOL CHEM, V280, P27251, DOI 10.1074/jbc.M501376200; Tefferi A, 2006, CANCER, V106, P631, DOI 10.1002/cncr.21645; Tefferi A, 2011, J CLIN ONCOL, V29, P573, DOI 10.1200/JCO.2010.29.8711; Vannucchi AM, 2009, CA-CANCER J CLIN, V59, P171, DOI 10.3322/caac.20009; Wautier MP, 2007, BLOOD, V110, P894, DOI 10.1182/blood-2006-10-048298; Wolanskyj AP, 2006, MAYO CLIN PROC, V81, P159, DOI 10.4065/81.2.159	24	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					371	374		10.4103/IJPM.IJPM_781_17			4	Pathology	Pathology	GN7CT	WOS:000439282500014	30004057	DOAJ Gold			2019-10-28	
J	Patro, S; Sarangi, G; Das, P; Mahapatra, A; Mohapatra, D; Paty, BP; Chayani, N				Patro, Somi; Sarangi, Gitanjali; Das, Padma; Mahapatra, Ashoka; Mohapatra, Dharitri; Paty, Bimoch Projna; Chayani, Nirupama			Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospital	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Multidrug resistant; risk factors; ventilator-associated pneumonia	STAPHYLOCOCCUS-AUREUS; PSEUDOMONAS-SPP.; EPIDEMIOLOGY; DIAGNOSIS; RESISTANT	Background: Ventilator-associated pneumonia (VAP) is the most frequent intensive care unit (ICU)-acquired infection. The etiology of VAP and their antimicrobial susceptibility pattern varies with different patient populations and types of ICUs. Materials and Methods: An observational cross-sectional study was performed over a period of 2 years in a tertiary care hospital to determine the various etiological agents causing VAP and to detect the presence of multidrug-resistant (MDR) pathogens in these VAP patients. Combination disk method, Modified Hodge test, ethylenediaminetetraacetic acid disk synergy test, and AmpC disk test were performed for the detection of extended-spectrum beta-lactamase (ESBL), carbapenemases, metallo-beta-lactamases (MBL), and AmpC beta-lactamases, respectively. Results: The prevalence of VAP was 35%. Enterobacteriaceae (66.66%) and Staphylococcus aureus (20%) were common in early-onset VAP, while nonfermenters (50%) and Enterobacteriaceae (40.61%) were predominant from late-onset VAP. Nearly 60.87% of the bacterial pathogens were MDR. ESBL was produced by 21.74% of Enterobacteriaceae. AmpC beta-lactamase was positive in 35.29% nonfermenters and 26.08% Enterobacteriaceae. MBL was positive in 17.64% nonfermenters and 17.39% Enterobacteriaceae. Among the S. aureus isolates, 75% were cefoxitin resistant. Prior antibiotic therapy (P = 0.001) and hospitalization of 5 days or more (P = 0.001) were independent risk factors for VAP by MDR pathogens. polymyxin B, tigecycline, and vancomycin were the most sensitive drugs for Gram-negative and positive isolates respectively from VAP. Statistical Analysis: SPSS for Windows Version SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and Chi-square with Yates correction. Conclusion: Late-onset VAP is increasingly associated with MDR pathogens. Treatment with polymyxin B, tigecycline, and vancomycin should be kept as last-line reserve drugs against most of the MDR pathogens.	[Patro, Somi; Sarangi, Gitanjali; Mohapatra, Dharitri; Paty, Bimoch Projna; Chayani, Nirupama] SCB Med Coll, Dept Microbiol, Cuttack, Orissa, India; [Das, Padma] AIIMS, Dept Microbiol, Raipur, Chhattisgarh, India; [Mahapatra, Ashoka] AIIMS, Dept Microbiol, Bhubaneswar, Odisha, India	Mahapatra, A (reprint author), AIIMS, Dept Microbiol, Bhubaneswar, Odisha, India.	meetasoka@yahoo.co.in					[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Balakrishnan I, 2006, PRINCIPLES PRACTICE, P41; Black JA, 2005, J CLIN MICROBIOL, V43, P3110, DOI 10.1128/JCM.43.7.3110-3113.2005; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/rccm.2105078; Chawla R, 2008, AM J INFECT CONTROL, V36, pS93, DOI 10.1016/j.ajic.2007.05.011; Clinical and Laboratory Standards Institute, 2011, M100S21 CLSI; Collee JG, 1996, MACKIE MCCARTNEY PRA, P978; Cook D, 2000, CHEST, V117, p195S, DOI 10.1378/chest.117.4_suppl_2.195S; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Dey Arindam, 2007, Ann Thorac Med, V2, P52, DOI 10.4103/1817-1737.32230; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; Fartoukh M, 2003, AM J RESP CRIT CARE, V168, P173, DOI 10.1164/rccm.200212-1449OC; Joseph NM, 2010, J INFECT DEV COUNTR, V4, P218, DOI 10.3855/jidc.634; Kuti JL, 2008, CLIN MICROBIOL INFEC, V14, P116, DOI 10.1111/j.1469-0691.2007.01885.x; Lee K, 2003, EMERG INFECT DIS, V9, P868; Porzecanski I, 2006, CHEST, V130, P597, DOI 10.1378/chest.130.2.597; Quale J, 2003, CLIN INFECT DIS, V37, P214, DOI 10.1086/375821; Rajasekhar T, 2006, Indian J Med Microbiol, V24, P107; RELLO J, 1994, AM J RESP CRIT CARE, V150, P1545, DOI 10.1164/ajrccm.150.6.7952612; Swenson JA, 1999, MANUAL CLIN MICROBIO, P1563; Yong DE, 2002, J CLIN MICROBIOL, V40, P3798, DOI 10.1128/JCM.40.10.3798-3801.2002	22	3	3	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					375	379		10.4103/IJPM.IJPM_487_16			5	Pathology	Pathology	GN7CT	WOS:000439282500015	30004058	DOAJ Gold			2019-10-28	
J	Fonseca, D; Bhuyan, S; Murthy, SS; Rao, V; Rao, C; Raju, KVVN; Sundaram, C				Fonseca, Daphne; Bhuyan, Srutimala; Murthy, Sudha S.; Rao, Vishal; Rao, Chandrasekhara; Raju, K. V. V. N.; Sundaram, Challa			Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: A distinct clinicopathologic entity	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Encapsulated follicular variant of papillary thyroid carcinoma; indolent behavior; noninvasive follicular thyroid tumor with papillary-like nuclear features; revised nomenclature	CARCINOMA; VARIANT; OVERTREATMENT	Objective: The objective of this study is to retrospectively evaluate follicular variant of papillary thyroid carcinoma (FVPTC) and reclassify encapsulated FVPTC as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) according to the criteria proposed by The Endocrine Pathology Society working group in 2015 to correlate with outcome. Materials and Methods: Retrospective review of case records of all patients diagnosed as carcinoma of thyroid between 2015 and 2016 was done for the histologic subtype. Gross and microscopic features on resected specimens of FVPTC were reviewed and subtyped as invasive and encapsulated based on capsular/vascular invasion; the encapsulated forms were further studied for size, number, follicular architecture, nuclear features, presence of psammoma bodies, stromal fibrosis, necrosis, mitoses, and lymph node status. Results: Out of the 383 patients with thyroid carcinomas in the study period, 349 were PTC which included 106 FVPTC. Thirty-three patients fulfilled the criteria to be labeled as NIFTP. Total thyroidectomy was performed in 8 patients and hemithyroidectomy in 25 patients. Lymph node dissection along with total thyroidectomy was done in 3 and completion thyroidectomy following hemithyroidectomy was done in 9. There were 29 single and 4 multiple lesions with size varying from 0.2 to 7 cm including 5 lesions measuring < 1 cm. The involvement was confined to one lobe in 31 and both lobes in 2 specimens. Patients are on follow-up with no recurrence till date. Conclusion: Thyroid carcinomas currently diagnosed as FVPTC should be evaluated for criteria of NIFTP to avoid overtreatment as they have an indolent behavior.	[Fonseca, Daphne; Bhuyan, Srutimala; Murthy, Sudha S.; Rao, Vishal; Sundaram, Challa] Basavatarakam Indo Amer Canc Hosp & Res Inst, Dept Pathol & Lab Med, Hyderabad, Telangana, India; [Rao, Chandrasekhara; Raju, K. V. V. N.] Basavatarakam Indo Amer Canc Hosp & Res Inst, Dept Surg Oncol, Hyderabad, Telangana, India	Fonseca, D (reprint author), Basavatarakam Indo Amer Canc Hosp & Res Inst, Dept Lab Med, Hyderabad, Telangana, India.	daf_doc_2005@hotmail.com					Chernock R. D., 2016, DIAGN HISTOPATHOL, V22, P184; LiVolsi VA, 2011, MODERN PATHOL, V24, pS1, DOI 10.1038/modpathol.2010.129; Moghaddam PA, 2016, ARCH PATHOL LAB MED, V140, P158, DOI 10.5858/arpa.2014-0468-RA; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Poller DN, 2016, J CLIN PATHOL; Rosario PW, 2017, CLIN ENDOCRINOL, V87, P635, DOI 10.1111/cen.13317; Thompson LDR, 2016, DIAGNOSTIC HISTOPATH, V22, P171, DOI [10.1016/j.mpdhp.2016.04.009, DOI 10.1016/J.MPDHP.2016.04.009]; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65	8	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					380	382		10.4103/IJPM.IJPM_185_17			3	Pathology	Pathology	GN7CT	WOS:000439282500016	30004059	DOAJ Gold			2019-10-28	
J	Misra, P; Jassar, A; Ghosh, AK				Misra, Pratibha; Jassar, Aneeta; Ghosh, Arijit Kumar			A 54-year-old male with diabetic nephropathy and suspected disseminated tuberculosis: Clinicopathologic correlation in a rare diagnosis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Antitubercular treatment; disseminated tuberculosis; T-cell non-Hodgkins lymphoma	NON-HODGKINS-LYMPHOMA; PERIPHERAL T-CELL; PATHOLOGISTS VIEW POINT	Tuberculosis (TB) and Non-Hodgkins lymphoma (NHL) share similar clinical and radiological features, which make diagnosis a challenge. It is often difficult to rule out a diagnosis of extrapulmonary and/or disseminated TB because of its paucibacillary nature and difficulty in accessing the involved organs. In countries with high prevalence of TB like ours, empirical antitubercular treatment (ATT) is started, and the patient is followed up closely for response. We present a rare case of a 54-year old diabetic male who was suspected to be a case of disseminated TB but had a rapid downhill course despite ATT. A postmortem revealed features of a rare, aggressive T-cell NHL masquerading as disseminated TB.	[Misra, Pratibha; Ghosh, Arijit Kumar] Mil Hosp, Dept Pathol, Jalandhar 144005, Punjab, India; [Jassar, Aneeta] Mil Hosp, Dept Med, Jalandhar, Punjab, India	Jassar, A (reprint author), Mil Hosp, Dept Med, Jalandhar, Punjab, India.	draneetajassar@gmail.com					Burad DK, 2012, INDIAN J PATHOL MICR, V55, P429, DOI 10.4103/0377-4929.107770; COGGINS CH, 1980, KIDNEY INT, V17, P847, DOI 10.1038/ki.1980.97; Dres M, 2012, RESPIR MED CASE REP, V7, P15, DOI 10.1016/j.rmcr.2012.10.002; Intragumtornchai T, 2003, CLIN LYMPHOMA, V4, P52, DOI 10.3816/CLM.2003.n.014; Lopez-Guillermo A, 1998, ANN ONCOL, V9, P849, DOI 10.1023/A:1008418727472; Pileri SA, 2000, HAEMATOLOGICA, V85, P1308; Pileri SA, 2000, HAEMATOLOGICA, V85, P1291; Puvaneswaran B, 2013, SAMJ S AFR MED J, V103, P32, DOI [10.7196/SAMJ.6093, 10.7196/samj.6093]; Ranjan Piyush, 2015, J Family Med Prim Care, V4, P280, DOI 10.4103/2249-4863.154677; RISDALL R, 1979, CANCER, V44, P529, DOI 10.1002/1097-0142(197908)44:2<529::AID-CNCR2820440222>3.0.CO;2-Y; Steensma DP, 1999, BRIT J HAEMATOL, V107, P463, DOI 10.1046/j.1365-2141.1999.01786.x; Uy AB, 2016, INT J CANC RES MOL M, V2, P1; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200/JCO.2008.16.4558	13	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					383	388		10.4103/IJPM.IJPM_728_17			6	Pathology	Pathology	GN7CT	WOS:000439282500017	30004060	DOAJ Gold			2019-10-28	
J	Agale, SV; Binayke, R; Kumari, G; D'Costa, GF				Agale, Shubhangi Vinayak; Binayke, Rachana; Kumari, Geeta; D'Costa, Grace F.			Idiopathic granulomatous hypophysitis: A report of an uncommon disorder	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Granulomatous hypophysitis; idiopathic; pituitary		Hypophysitis of the pituitary gland is a rare inflammatory disorder and broadly classified as primary and secondary hypophysitis. Primary hypophysitis is mainly of lymphocytic, granulomatous, and xanthomatous types. Among the various primary hypophysitis, granulomatous hypophysitis is rare type with an incidence of 1 in 10 million. The various forms of hypophysitis are misdiagnosed as pituitary adenoma in 40% cases. Idiopathic granulomatous hypophysitis is even rarer inflammatory disorder accounting for < 1% of cases involving panhypopituitarism with headache and visual disturbances. We report idiopathic granulomatous hypophysitis in a 28-year-old female presenting with blurring of vision and headache.	[Agale, Shubhangi Vinayak; Binayke, Rachana; Kumari, Geeta; D'Costa, Grace F.] Grant Govt Med Coll, Dept Pathol, Mumbai 400008, Maharashtra, India	Agale, SV (reprint author), Grant Govt Med Coll, Dept Pathol, Mumbai 400008, Maharashtra, India.	shubhagale@hotmail.com					Cheung CC, 2001, J CLIN ENDOCR METAB, V86, P1048, DOI 10.1210/jc.86.3.1048; Chung CH, 2012, KOREAN J INTERN MED, V27, P346, DOI 10.3904/kjim.2012.27.3.346; Guadagno E, 2016, J MED SURG PATHOL, V1, P1; Guo SX, 2016, ONCOL LETT, V11, P1315, DOI 10.3892/ol.2015.4046; Hunn BHM, 2014, PITUITARY, V17, P357, DOI 10.1007/s11102-013-0510-4; Kong XY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001099; Lury Kenneth M, 2005, Top Magn Reson Imaging, V16, P301, DOI 10.1097/01.rmr.0000224686.21748.ea; Rao S, 2016, APMIS, V124, P1072, DOI 10.1111/apm.12603; Shukla S, 2010, J NEUROSCI RURAL PRA, V1, P30, DOI [10.4103/0976-3147.63099, 10.4103/0976-3147.71727]; Su SB, 2011, ENDOCR J, V58, P467, DOI 10.1507/endocrj.K10E-357; Xu Y, 2016, CHIN NEUROSURG J, V2, P1, DOI DOI 10.1186/s12951-016-0184-y	11	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					389	392		10.4103/IJPM.IJPM_77_17			4	Pathology	Pathology	GN7CT	WOS:000439282500018	30004061	DOAJ Gold			2019-10-28	
J	Batrani, M; Kubba, A; Sundharam, J				Batrani, Meenakshi; Kubba, Asha; Sundharam, Joseph			Fluoroscopy-induced chronic radiation dermatitis masquerading as morphea: A diagnostic pitfall	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Fluoroscopy; radiation dermatitis; radiodermatitis	SKIN INJURY	Chronic radiodermatitis is a rare complication of fluoroscopy-guided procedures. The diagnosis of fluoroscopy-induced chronic radiation dermatitis is challenging because of its rarity, late insidious onset, and close clinicopathological resemblance to morphea. We report two cases of fluoroscopy-induced chronic radiodermatitis following cardiac procedures to highlight the clinicopathological features. The diagnosis relies on recognizing the characteristic clinical presentation of well-demarcated, rectangular-or square-shaped indurated plaque with depigmentation, telangiectasia, and ulceration located on the scapula, back, or axilla; supported by the histological identification of radiation fibroblasts in a sclerotic dermis.	[Batrani, Meenakshi; Kubba, Asha] Delhi Dermatol Grp, Delhi Dermpath Lab, New Delhi, India; [Sundharam, Joseph] Sundharam, Dermatol & Pediat Ctr, New Delhi, India	Batrani, M (reprint author), 10,Aradhana Enclave,Sect 13, New Delhi 110066, India.	meenakshibatrani@yahoo.co.in	Batrani, Meenakshi/H-8115-2019				Balter S, 2010, RADIOLOGY, V254, P326, DOI 10.1148/radiol.2542082312; Boncher J, 2012, J CUTAN PATHOL, V39, P63, DOI 10.1111/j.1600-0560.2011.01754.x; Bray FN, 2016, DERMATOLOGY THER, V6, P185, DOI 10.1007/s13555-016-0120-y; Falay T, 2016, J DERMATOL RES THER, V2, P31; Frazier TH, 2007, ARCH DERMATOL, V143, P637, DOI 10.1001/archderm.143.5.637; Minni JP, 2013, CUTIS, V91, P230; Mundi Jyoti P, 2013, Dermatol Online J, V19, P20712; Patterson JW, 2016, WEEDONS SKIN PATHOLO, P612; Singh M, 2016, AM J CLIN DERMATOL, V17, P277, DOI 10.1007/s40257-016-0186-4; Spiker A, 2012, AM J CARDIOL, V110, P1861, DOI 10.1016/j.amjcard.2012.08.023; Takikawa M, 2012, WOUNDS, V24, P91; Vance AZ, 2013, AM J NEURORADIOL, V34, P1513, DOI 10.3174/ajnr.A3185; Wagner Lk, 2007, Biomed Imaging Interv J, V3, pe22, DOI 10.2349/biij.3.2.e22; Wei KC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002178; Wei YA, 2016, MED IMAGING INTERV R, V2, pe1415	15	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					393	396		10.4103/IJPM.IJPM_566_17			4	Pathology	Pathology	GN7CT	WOS:000439282500019	30004062	DOAJ Gold			2019-10-28	
J	Gill, S; Mohan, A; Aggarwal, S; Varshney, A				Gill, Sharanjeet; Mohan, Amit; Aggarwal, Shivani; Varshney, Anchal			Mucoepidermoid carcinoma of hard palate	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Malignant tumor; mucoepidermoid carcinoma; salivary gland neoplasms; surgical excision	SALIVARY-GLAND TUMORS; SURGICAL-MANAGEMENT; PAROTID-GLAND	Salivary gland tumors are clinically diverse group of neoplasms, of which pleomorphic adenoma and mucoepidermoid carcinoma (MEC) are most common benign and malignant tumors, respectively. Besides the major salivary glands, these tumors can affect the minor salivary gland tissues in the posterior part of the hard palate. Minor salivary gland tumor accounts for about 15% of all the salivary gland neoplasm, of which MEC accounts to about 35.9%. MEC appears as asymptomatic swellings and shows a variety of biological behaviors and variable natural history. This article reports a case of MEC involving the posterior part of the hard palate. The lesion was treated by wide surgical excision with a regular follow-up and no recurrence was noted.	[Gill, Sharanjeet; Aggarwal, Shivani; Varshney, Anchal] Manav Rachna Dent Coll, Dept Oral Pathol & Microbiol, Faridabad, Haryana, India; [Mohan, Amit] Manav Rachna Dent Coll, Dept Oral & Maxillofacial Surg, Faridabad, Haryana, India	Gill, S (reprint author), C-504,Phase 1, New Delhi 110017, India.	sharangrewal07@gmail.com					Boahene DKO, 2004, ARCH OTOLARYNGOL, V130, P849, DOI 10.1001/archotol.130.7.849; EVERSOLE LR, 1970, J ORAL SURG, V28, P490; Flaitz Catherine M., 2000, Pediatric Dentistry, V22, P292; JAKOBSSON PA, 1968, CANCER-AM CANCER SOC, V22, P111, DOI 10.1002/1097-0142(196807)22:1<111::AID-CNCR2820220114>3.0.CO;2-J; Moore BA, 2008, OCHSNER J, V8, P172; Munhoz Etiene de Andrade, 2009, Gen Dent, V57, pe51; Pires FR, 2007, ORAL ONCOL, V43, P463, DOI 10.1016/j.oraloncology.2006.04.008; Ritwik Priyanshi, 2012, J Med Case Rep, V6, P182, DOI 10.1186/1752-1947-6-182; SEIFERT G, 1990, PATHOL RES PRACT, V186, P555, DOI 10.1016/S0344-0338(11)80220-7; Truitt TO, 1999, OTOLARYNG HEAD NECK, V121, P548, DOI 10.1016/S0194-5998(99)70084-7	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					397	398		10.4103/IJPM.IJPM_617_17			2	Pathology	Pathology	GN7CT	WOS:000439282500020	30004063	DOAJ Gold			2019-10-28	
J	Mallya, V; Narayan, S; Jain, S				Mallya, Varuna; Narayan, Shubhra; Jain, Shyama			Metastatic squamous cell carcinoma in autotransplanted thyroid: A diagnostic dilemma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Autotransplanted thyroid; thyroid metastasis; thyroid neoplasm	GLAND	Metastasis to the thyroid is uncommon. Mostly, they are tumors that originate in the lung or head or neck. Metastases from breast or kidney carcinomas and metastatic melanoma have also been reported. Autotransplantation of benign thyroid tissue is a surgical procedure designed to achieve normal thyroid hormonal status following surgery. Metastasis into autotransplanted thyroid tissue has not been reported earlier. We report a case of squamous cell carcinoma (SCC) metastatic to autotrasplanted thyroid diagnosed on fine-needle aspiration. Further workup revealed a primary oral cavity SCC.	[Mallya, Varuna; Jain, Shyama] Dept Pathol, New Delhi, India; [Narayan, Shubhra] Maulana Azad Med Coll, Room 269, New Delhi 110002, India	Mallya, V (reprint author), Maulana Azad Med Coll, Room 269, New Delhi 110002, India.	varunamallya@gmail.com					Charous D, 2004, OTOLARYNGOL HEAD NEC, V131, P183; Chavan RN, 2015, CASE REP PATHOL, DOI 10.1155/2015/838079; Fang QG, 2013, MOL CLIN ONCOL, V1, P531, DOI 10.3892/mco.2013.86; Gerges Amani S, 2006, J Egypt Natl Canc Inst, V18, P67; Kaliszewski K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168654; Khandelia BK, 2013, THYROID RES PRACT, V10, P111; Kundu R, 2014, J CYTOL, V31, P210, DOI 10.4103/0970-9371.151135; Nakhjavani M, 1999, Endocr Pract, V5, P69; Nixon IJ, 2017, ANN SURG ONCOL, V24, P1533, DOI 10.1245/s10434-016-5683-4; Willis RAW, 1931, AM J PATHOL, V7, P187	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					399	400		10.4103/IJPM.IJPM_418_17			2	Pathology	Pathology	GN7CT	WOS:000439282500021	30004064	DOAJ Gold			2019-10-28	
J	Shamila, MA; Reddy, PS				Shamila, M. A.; Reddy, P. Somasekhara			Duodenal neuroendocrine tumor, adenocarcinoma and gastrointestinal stromal tumor in association with neurofibromatosis type 1: An unique occurrence	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Gastrointestinal stromal tumor; mixed endocrine-nonendocrine neoplasms; neurofibromatosis-1	PERIAMPULLARY ADENOCARCINOMA; SOMATOSTATINOMA	Mixed endocrine-nonendocrine neoplasms are rare tumors and pose challenges in diagnosis and management. Neurofibromatosis-1 ( NF-1) patients are known to develop malignancies. Although neuroendocrine tumors and gastro-intestinal stromal tumors are seen in NF-1, its association with adenocarcinoma is rare. The existence of these three entities with NF-1 is extremely rare. NF1 patients presenting with symptoms suggestive of malignancies should alert the physician for a detailed clinical work up. Diagnosis of these malignancies often requires a meticulous histopathological and immunohistochemical examination. We report the first case from Indian experience.	[Shamila, M. A.; Reddy, P. Somasekhara] Sagar Hosp, Dept Pathol, Bengaluru, Karnataka, India	Reddy, PS (reprint author), Sagar Hosp, Dept Lab Med, Bengaluru 560041, Karnataka, India.	psreddy70@hotmail.com					Behranwala Kasim A, 2004, World J Surg Oncol, V2, P1, DOI 10.1186/1477-7819-2-1; Costi R, 2001, MODERN PATHOL, V14, P1169, DOI 10.1038/modpathol.3880454; Deschamps L, 2010, J PANCREAS, V11, P64; Gregersen T, 2012, CASE REP GASTROINTES, DOI 10.1155/2012/185730; JONES TJ, 1987, GUT, V28, P1173, DOI 10.1136/gut.28.9.1173; Kistler CA, 2014, J GASTROINTEST ONCOL, V5, pE96, DOI 10.3978/j.issn.2078-6891.2014.047; Lodish MB, 2010, BEST PRACT RES CL EN, V24, P439, DOI 10.1016/j.beem.2010.02.002; Rastogi Rajul, 2008, Saudi J Gastroenterol, V14, P80, DOI 10.4103/1319-3767.39623; Salvi PF, 2013, INT J SURG ONCOL, DOI 10.1155/2013/398570; Tewari N, 2014, J PANCREAS, V15, P600, DOI 10.6092/1590-8577/2844; Uusitalo E, 2016, J CLIN ONCOL, V34, P1978, DOI 10.1200/JCO.2015.65.3576	11	0	0	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					401	403		10.4103/IJPM.IJPM_534_17			3	Pathology	Pathology	GN7CT	WOS:000439282500022	30004065	DOAJ Gold			2019-10-28	
J	Khare, M; Gupta, MK; Sharma, UB; Garg, KM				Khare, Manika; Gupta, Manish Kumar; Sharma, Umesh Babu; Garg, K. M.			Paraganglioma with a very rare presentation	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Bilateral ovaries; malignant; paraganglioma	HEPATIC DUCT; PHEOCHROMOCYTOMA	Paragangliomas (PGLs) are rare tumors of neural crest origin, with a malignancy rate of approximately 10% and a 5-year survival rate of < 50%. We present a case of malignant PGL arising from the porta hepatis with metastasis to the portal lymph node and bilateral ovaries. PGLs arising from the porta hepatis are very rare. As per our knowledge, only three cases of hepatic duct PGL have been reported. It is important to detect it earlier because the treatment modality and prognosis of benign and malignant PGL differs and defines the prognosis of the patient.	[Khare, Manika; Sharma, Umesh Babu] JNUIMSRC, Dept Pathol, Jaipur, Rajasthan, India; [Gupta, Manish Kumar; Garg, K. M.] JNUIMSRC, Dept Surg, Jaipur, Rajasthan, India	Khare, M (reprint author), JNUIMSRC, Dept Pathol, Jaipur, Rajasthan, India.	drmanika09@gmail.com					Hayry V, 2009, ENDOCR-RELAT CANCER, V16, P1211, DOI 10.1677/ERC-09-0049; Higa B, 2012, PATHOLOGY, V44, P53, DOI 10.1097/PAT.0b013e32834e42b6; HITANANT S, 1984, AM J GASTROENTEROL, V79, P485; Kimura N, 2014, ENDOCR-RELAT CANCER, V21, P405, DOI 10.1530/ERC-13-0494; Lai EW, 2009, J CLIN ENDOCR METAB, V94, P2952, DOI 10.1210/jc.2009-0309; MILLER TA, 1972, ARCH SURG-CHICAGO, V105, P637; Rosai J, 1996, ACKERMANS SURG PATHO, P1115; SARMA DP, 1980, SOUTHERN MED J, V73, P1677, DOI 10.1097/00007611-198012000-00050; SCLAFANI LM, 1990, SURGERY, V108, P1124; Zografos GN, 2009, JSLS-J SOC LAPAROEND, V13, P196	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					404	406		10.4103/IJPM.IJPM_334_17			3	Pathology	Pathology	GN7CT	WOS:000439282500023	30004066	DOAJ Gold			2019-10-28	
J	Wang, XJ; Zhang, LZ; Wang, YF; Jia, XZ; Wang, JL; Zhang, H				Wang, Xiaojun; Zhang, Lizhi; Wang, Yanfu; Jia, Xuzhao; Wang, Jiali; Zhang, Hua			Sclerosing pneumocytoma with metastasis to the mediastinal and regional lymph nodes	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Immunohistochemistry; lymph node metastasis; sclerosing pneumocytoma; vimentin	HEMANGIOMA; EXPRESSION	Sclerosing pneumocytoma (SP) is an uncommon benign tumor, and metastasis of SP has been rarely reported. Here, we report the case of a 26-year-old woman with surgically confirmed SP. The tumor diameter was 40 mm, and metastasis to mediastinal and regional lymph nodes was observed. Immunohistochemically, both surface and round cells were positive for epithelial membrane antigen, thyroid transcription factor 1, and vimentin. Only surface cells expressed creatine kinase, carcinoembryonic antigen, napsin A, and cytokeratin 7, and only round cells expressed progesterone receptor. Ki-67 was detected in similar to 3% of cells, and the rate of weak positive p53 staining was 3%. Both cell types were negative for chromogranin A, synaptophysin, CD3, and CK20. Multiple metastases in a young SP patient are very rare, and potential mechanisms of metastasis may be related to epithelial-mesenchymal transformation.	[Wang, Xiaojun; Wang, Yanfu; Jia, Xuzhao; Wang, Jiali; Zhang, Hua] Dalian Med Univ, Affiliated Hosp 1, Dept Geratol, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China; [Zhang, Lizhi] Dalian Med Univ, Affiliated Hosp 1, Dept Pathol, Dalian, Peoples R China	Zhang, H (reprint author), Dalian Med Univ, Affiliated Hosp 1, Dept Geratol, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.	zhanghua2233@126.com					Chan N G, 2003, Can Respir J, V10, P391; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Kalhor N, 2010, ANN DIAGN PATHOL, V14, P60, DOI 10.1016/j.anndiagpath.2009.07.002; Kim KH, 2003, YONSEI MED J, V44, P150, DOI 10.3349/ymj.2003.44.1.150; Lin XY, 2012, HISTOPATHOLOGY, V61, P178, DOI 10.1111/j.1365-2559.2011.04088.x; McInroy L, 2007, BIOCHEM BIOPH RES CO, V360, P109, DOI 10.1016/j.bbrc.2007.06.036; Nicholson AG, 2002, HISTOPATHOLOGY, V41, P404, DOI 10.1046/j.1365-2559.2002.01522.x; Pokharel S, 2016, J THORAC ONCOL, V11, P1802, DOI 10.1016/j.jtho.2016.06.005; Sun Yu, 2012, Chinese Journal of Pathology, V41, P239, DOI 10.3760/cma.j.issn.0529-5807.2012.04.006; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Xu HM, 2015, INT J CLIN EXP PATHO, V8, P8619	11	1	1	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					407	409	PMID 30004067	10.4103/IJPM.IJPM_98_17			3	Pathology	Pathology	GN7CT	WOS:000439282500024	30004067	DOAJ Gold			2019-10-28	
J	Farias, GMN; Pinto, JR; Melo, JC; Tavora, LGF; Lima, DM; Correia, FJV; da Silva, GB				Nogueira Farias, Geysa Maria; Pinto, Jose Reginaldo; Melo, Juliana Carneiro; Fernandes Tavora, Lara Gurgel; Lima, Danielle Malta; Viana Correia, Fernanda Judith; da Silva Junior, Geraldo Bezerra			Kyrle's disease associated with HIV infection, diabetes, and chronic kidney disease	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Diabetes; HIV; kidney disease; Kyrle's disease; rare diseases		Kyrle's disease (KD) is a rare skin pathology characterized by transepidermal elimination of abnormal keratin. The aim of this article is to report a rare case of KD associated with diabetes mellitus, chronic kidney disease, and HIV. A 51-year-old male patient complained of diarrhea for 8 months. He was submitted to HIV testing, which showed a positive result. He started antiretroviral therapy with zidovudine, lamivudine, and lopinavir. The diagnostic investigation was negative for opportunistic diseases. After 2 months, skin lesions started appearing, characterized by hyperchromic, pruritic macules and papules distributed in the trunk, back, and upper limbs. He also developed erythematous, scaly lesions in the facial region. A biopsy of the skin was performed, of which histopathological report consisted of perforating disorder, favoring a diagnosis of KD. Treatment with keratolytic soap (Actine) was started, with skin lesion improvement. In this reported case, it is possible that, in addition to diabetes and renal failure, HIV infection played an important role in the genesis of the lesions.	[Nogueira Farias, Geysa Maria; Pinto, Jose Reginaldo; Melo, Juliana Carneiro; Lima, Danielle Malta; da Silva Junior, Geraldo Bezerra] Univ Fortaleza, Postgrad Program Publ Hlth, Fortaleza, Ceara, Brazil; [Melo, Juliana Carneiro; Fernandes Tavora, Lara Gurgel; Lima, Danielle Malta; da Silva Junior, Geraldo Bezerra] Univ Fortaleza, Hlth Sci Ctr, Sch Med, Fortaleza, Ceara, Brazil; [Viana Correia, Fernanda Judith] Haroldo Juacaba Hosp, Canc Inst Ceara, Fortaleza, Ceara, Brazil	da Silva, GB (reprint author), Av Washington Soares 1321,Bloco S-01, BR-60811905 Fortaleza, Ceara, Brazil.	geraldobezerrajr@unifor.br	PINTO, JOSE REGINALDO/F-8283-2019	PINTO, JOSE REGINALDO/0000-0001-8682-7559			Bodman M, 2015, J AM PODIAT MED ASSN, V105, P451, DOI 10.7547/14-009; Diaz-Jave C, 2014, DERMATOL PERU, V24, P172; Lupi O, 2011, AN BRAS DERMATOL, V86, P319, DOI 10.1590/S0365-05962011000200015; Nair Pragya A, 2015, J Family Med Prim Care, V4, P284, DOI 10.4103/2249-4863.154678; Persechino S, 2013, EUR J INFLAMM, V11, P245, DOI 10.1177/1721727X1301100124; Rubio FA, 1999, J AM ACAD DERMATOL, V40, P300, DOI 10.1016/S0190-9622(99)70470-6; Sahoo AK, 2014, J MED, V15, P144; Swetha C, 2014, J DIABETOL, V2, P6; Thomas E A, 2012, Indian J Nephrol, V22, P116, DOI 10.4103/0971-4065.97127; VERMA R, 2015, INDIAN J DERMATOL, V60	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					414	417	PMID 30004069	10.4103/IJPM.IJPM_532_17			4	Pathology	Pathology	GN7CT	WOS:000439282500026	30004069	DOAJ Gold			2019-10-28	
J	Iyengar, JN; Reddy, BKKR				Iyengar, Jayaram N.; Reddy, Bharath Kumar K. R.			Pulmonary alveolar proteinosis in children: An unusual presentation with significant clinical impact	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Alveolar proteinosis; respiratory failure; therapeutic lavage		Pulmonary alveolar proteinosis (PAP)-an unusual diffuse lung disease characterized by alveolar accumulation of phospholipoprotein material, with a peak incidence in third to fourth decade and male predominance is also described in children. Recorded prevalence is 0.1/100,000 individuals. Major clinicopathogenetic subtypes include autoimmune (idiopathic) associated with granulocyte-macrophage colony-stimulating factor autoantibodies, secondary form, and the congenital form (associated with surfactant gene mutations). Common presenting features include dyspnea, cough, low-grade fever, inspiratory crackles, and digital clubbing. Pulmonary function shows a restrictive ventilatory defect. X-rays show bilateral patchy to extensive consolidations, and bronchial lavage yields a milky fluid. Characteristic microscopic findings on lung biopsy include filling of terminal bronchioles and alveolar spaces by deep pink granular PAS-positive material. Whole lung lavage is the safest and most effective form of treatment. We present brief profiles of two young children identified as having PAP, along with follow-up data on one of them.	[Iyengar, Jayaram N.; Reddy, Bharath Kumar K. R.] Anand Diagnost Lab, Dept Pathol, Bengaluru, Karnataka, India	Iyengar, JN (reprint author), Anand Diagnost Lab, Bowring Tower,54 Bowring Hosp Rd, Bengaluru 560001, Karnataka, India.	jayaram@anandlab.com					Campo I, 2012, MULTIDISCIP RESP MED, V7, DOI 10.1186/2049-6958-7-4; Holbert JM, 2001, AM J ROENTGENOL, V176, P1287, DOI 10.2214/ajr.176.5.1761287; Mahut B, 1996, PEDIATRICS, V97, P117; Mazzone PJ, 2002, SEM RESP CRIT CARE M, V23, P115, DOI 10.1055/s-2002-25375; Shah PL, 2000, THORAX, V55, P67, DOI 10.1136/thorax.55.1.67; Tabatabaei SA, 2010, J RES MED SCI, V15, P120; Trapnell BC, 2003, NEW ENGL J MED, V349, P2527, DOI 10.1056/NEJMra023226	7	1	1	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					418	420	PMID 30004070	10.4103/IJPM.IJPM_17_17			3	Pathology	Pathology	GN7CT	WOS:000439282500027	30004070	DOAJ Gold			2019-10-28	
J	Rekhi, B; Banerjee, D; Gala, K; Gulia, A				Rekhi, Bharat; Banerjee, Devmalya; Gala, Kunal; Gulia, Ashish			Superficial CD34-positive fibroblastic tumor in the forearm of a middle-aged patient: A newly described, rare soft-tissue tumor	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						CD34; myxoinflammatory fibroblastic sarcoma; newly described soft-tissue tumors; superficial CD34-positive fibroblastic tumor		Superficial CD34-positive fibroblastic tumor is a recently described soft-tissue tumor entity. A 48 year-old-male presented with a gradually increasing soft-tissue mass in his right forearm of 2 years' duration, along with multiple subcutaneous soft-tissue nodular lesions, and reminiscent of lipomas over his body. He underwent a wide excision of his forearm mass. Microscopic sections showed a circumscribed tumor in the dermis and subcutaneous fat, composed of spindle cells, inflammatory cells, including lymphocytes, plasma cells, and eosinophils, along with interspersed markedly pleomorphic giant cells containing moderate-to-abundant "glassy" cytoplasm, vesicular nuclei, exhibiting prominent nucleoli, and intranuclear pseudoinclusions. There were no significant mitotic figures, areas of hemorrhage, necrosis, or pigment histiocytes. By immunohistochemistry, the tumor cells were diffusely positive for CD34 while negative for cytokeratin (CK), pan CK (AE1/AE3), S100 protein, CD30, and CD31. MIB1/Ki-67 was low and highlighted 4%-5% tumor nuclei. Diagnosis of superficial CD34-positive fibroblastic tumor was offered. Sections from the various resection margins were free of tumor. Postresection, the patient is alive with no evidence of disease for the past 8 months. This constitutes as one of the first case reports of this rare tumor entity from our country. Its diagnostic and treatment implications are discussed herewith.	[Rekhi, Bharat; Banerjee, Devmalya] Tata Mem Hosp, Bone & Soft Tissue Dis Management Grp, Dept Surg Pathol, Bombay, Maharashtra, India; [Gala, Kunal] Tata Mem Hosp, Bone & Soft Tissue Dis Management Grp, Dept Radiodiag, Bombay, Maharashtra, India; [Gulia, Ashish] Tata Mem Hosp, Bone & Soft Tissue Dis Management Grp, Dept Surg Oncol, Bombay, Maharashtra, India	Rekhi, B (reprint author), Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Bombay 400012, Maharashtra, India.	rekhi.bharat@gmail.com					Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P757, DOI 10.1002/gcc.20897; Carter JM, 2014, MODERN PATHOL, V27, P294, DOI 10.1038/modpathol.2013.139; Hallor KH, 2009, J PATHOL, V217, P716, DOI 10.1002/path.2513; Hendry SA, 2015, PATHOLOGY, V47, P479, DOI 10.1097/PAT.0000000000000281; Lao IW, 2017, HISTOPATHOLOGY, V70, P394, DOI 10.1111/his.13088; Sood N, 2017, INDIAN J PATHOL MICR, V60, P377, DOI 10.4103/IJPM.IJPM_589_16; Wada N, 2016, J DERMATOL, V43, P934, DOI 10.1111/1346-8138.13327	7	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					421	424	PMID 30004071	10.4103/IJPM.IJPM_221_17			4	Pathology	Pathology	GN7CT	WOS:000439282500028	30004071	DOAJ Gold			2019-10-28	
J	Seo, BF; Choi, JS; Shim, HS				Seo, Bommie Florence; Choi, Ji Seon; Shim, Hyung-Sup			Cutaneous intramuscular lipoma: A new subtype of intramuscular lipoma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Cutaneous lipoma; intramuscular lipoma; pedunculated lipoma		Intramuscular lipoma is an uncommon variant of lipoma that occurs inside muscle tissue. Pathogenesis is thought to be related to neoplastic activity of mesenchymal stem cells, but there still is not an established theory. This entity can be found in almost all areas of the body, mostly within or in connection with skeletal muscle tissue. We have encountered an atypical intramuscular lipoma located in the epidermal layer of the right thigh of an otherwise healthy 35-year-old female. The superficial, protruding skin mass resembled a sebaceous nevus or skin malignancy but was histologically composed of well-defined adipocytes between a mixture of muscle fibers, corresponding with the diagnosis of intramuscular lipoma. Intramuscular lipoma of the skin has never been reported before; thus, the authors suggest the classification "cutaneous" intramuscular lipoma to describe lesions located in the dermal or epidermal layer.	[Seo, Bommie Florence; Choi, Ji Seon; Shim, Hyung-Sup] Catholic Univ Korea, Coll Med, Dept Plast & Reconstruct Surg, Seoul, South Korea	Shim, HS (reprint author), Catholic Univ Korea, St Vincents Hosp, Dept Plast & Reconstruct Surg, 91-6 Joongbu Daero, Suwon, South Korea.	sharpshim@catholic.ac.kr					FLETCHER CDM, 1988, HISTOPATHOLOGY, V12, P275, DOI 10.1111/j.1365-2559.1988.tb01942.x; GREENBERG SD, 1963, AM J CLIN PATHOL, V39, P66; Han HH, 2016, J CRANIOFAC SURG, V27, pE350, DOI 10.1097/SCS.0000000000002516; Kalmar G, 2017, J AM PODIAT MED ASSN, V107, P80, DOI 10.7547/15-082; Lee Young Ho, 2004, Hand Surg, V9, P49, DOI 10.1142/S0218810404002005; Mai KT, 1996, AM J SURG PATHOL, V20, P1145, DOI 10.1097/00000478-199609000-00011; Mori K, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-20; REGAN J M, 1946, West J Surg Obstet Gynecol, V54, P87; Silistreli OK, 2005, BRIT J PLAST SURG, V58, P394, DOI 10.1016/j.bjps.2004.09.005; Vincent J, 2017, PEDIATR DERMATOL, V34, pE135, DOI 10.1111/pde.13103	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					425	427	PMID 30004072	10.4103/IJPM.IJPM_446_16			3	Pathology	Pathology	GN7CT	WOS:000439282500029	30004072	DOAJ Gold			2019-10-28	
J	Masamatti, SS; Vijaya, C; Narasimha, A				Masamatti, Smita S.; Vijaya, C.; Narasimha, Aparna			A rare case of hyaline cell-rich atypical chondroid syringoma with divergent differentiation	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Chondroid syringoma; cutaneous mixed tumor; histopathology; hyaline cells	MIXED TUMOR; SKIN	Chondroid syringoma (CS) also known as mixed tumor of the skin, is a rare benign adnexal tumor accounting for < 0.098%. Epithelial cells arranged in cords and tubules set in myxoid or chondroid stroma. Differentiation such as osteoid, sebaceous or mature adipocytes can be seen rarely. Hyaline cell rich is a rare variant of CS composed of cells with eosinophilic hyaline cytoplasm and plasmacytoid features. CS can have benign, atypical and malignant variants. The term atypical mixed tumor is recommended for those tumors which have histological features of malignancy such as infiltrative margin, satellite tumor nodules and tumor necrosis but without proven metastasis. Very few case reports of hyaline cellrich benign CS have been reported in the past, but to the best of our knowledge, possibly it is the first case of atypical hyaline cellrich CS of the little finger in a 65 year-old female showing divergent differentiation.	[Masamatti, Smita S.; Vijaya, C.; Narasimha, Aparna] Sapthagiri Inst Med Sci & Res Ctr, Dept Pathol, Bengaluru, Karnataka, India	Masamatti, SS (reprint author), Sapthagiri Hosp, DQ 14,Hesarghatta Main Rd, Bengaluru 560090, Karnataka, India.	smitamas@yahoo.co.in					Barman DC, 2016, INDIAN J PATHOL MICR, V59, P362, DOI 10.4103/0377-4929.188111; Bates AW, 1998, AM J DERMATOPATH, V20, P35, DOI 10.1097/00000372-199802000-00007; HIRSCH P, 1961, ARCH DERMATOL, V84, P835, DOI 10.1001/archderm.1961.01580170129018; Lakshmi T S, 1998, Indian J Dermatol Venereol Leprol, V64, P83; LOMAXSMITH JD, 1978, HISTOPATHOLOGY, V2, P77, DOI 10.1111/j.1365-2559.1978.tb01697.x; Markoc F, 2016, BALK MED J, V33, P243, DOI 10.5152/balkanmedj.2015.151027; MILLS SE, 1984, J CUTAN PATHOL, V11, P382, DOI 10.1111/j.1600-0560.1984.tb00395.x; Narasimha Aparna, 2013, Int J Appl Basic Med Res, V3, P129, DOI 10.4103/2229-516X.117097; Ramaswamy A S, 2011, Indian J Dermatol, V56, P217, DOI 10.4103/0019-5154.80424; Salama ME, 2004, ARCH PATHOL LAB MED, V128, P986	10	0	0	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					428	430	PMID 30004073	10.4103/IJPM.IJPM_101_17			3	Pathology	Pathology	GN7CT	WOS:000439282500030	30004073	DOAJ Gold			2019-10-28	
J	Liao, GJ; Zhang, XK; Li, ZJ; Lan, S; Huang, ML; Huang, WJ				Liao, Guangjie; Zhang, Xinke; Li, Zhongjian; Lan, Su; Huang, Miaoli; Huang, Weijian			Renal-type clear cell carcinoma of prostate: A case report and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Clear cell carcinoma; prostate; prostate specific antigen; renal cell carcinoma; renal-type		We analyzed the clinicopathological features of renal-type clear cell carcinoma (RTCCC) in the prostate and its diagnosis according to the example in our hospital and review of the literature. Clinicopathological features of RTCCC in the prostate were observed in a patient from our hospital combining with a review of the literature. Microscopically, the tumor was composed of cells with abundant and translucent cytoplasm, arranged in the form of the vesicular nest or glandular structure. Therefore, it was necessary to distinguish between metastatic clear cell renal cell carcinoma and primary RTCCC in the prostate. Immunohistochemistry (IHC) of this case showed tumor cells were positive expression for cytokeratin (CKpan), low-molecular weight cytokeratin, epithelial membrane antigen, and prostate-specific antigen (PSA), P504S, prostate-specific membrane antigen and partial positive expression for vimentin and CD10. The tumor cells displayed negative expression of high molecular weight cytokeratin, cytokeratin 7 (CK7), CK34, PAX8, and renal cell carcinoma. The morphological and immunohistochemical features of this tumor were in correspondence with RTCCC of the prostate. This tumor is a rare variant of the prostate carcinomas. To the best of our knowledge, this type of extrarenal tumor has only been reported in six previous studies. Combination of histology, IHC, imaging, and serum PSA is needed to perform a suitable diagnosis.	[Liao, Guangjie; Li, Zhongjian; Lan, Su; Huang, Miaoli; Huang, Weijian] Red Cross Hosp Yulin, Dept Pathol, 1 Jin Wang Rd, Yulin, Guangxi Provinc, Peoples R China; [Zhang, Xinke] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Pathol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China	Liao, GJ (reprint author), Red Cross Hosp Yulin, Dept Pathol, 1 Jin Wang Rd, Yulin, Guangxi Provinc, Peoples R China.	lgj8757@sina.com		guangjie, liao/0000-0001-6258-1566			CIHAK RW, 1980, J UROLOGY, V123, P791, DOI 10.1016/S0022-5347(17)56135-2; Eble John, 2004, PATHOLOGY GENETICS T, P4; Flanigan Robert C, 2003, Curr Treat Options Oncol, V4, P385, DOI 10.1007/s11864-003-0039-2; KING DHC, 1995, UROLOGY, V46, P722, DOI 10.1016/S0090-4295(99)80310-0; Pal DK, 2007, INDIAN J SURG, V69, P81; Patne SCU, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0432-8; Permi Harish S, 2011, J Lab Physicians, V3, P132, DOI 10.4103/0974-2727.86853; Sato Y, 2016, UROL CASE REP, V5, P9, DOI 10.1016/j.eucr.2015.11.008; Singh H, 2003, AM J SURG PATHOL, V27, P407, DOI 10.1097/00000478-200303000-00016; Wang QL, 2015, ONCOL LETT, V9, P2149, DOI 10.3892/ol.2015.3062	10	2	2	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					431	433		10.4103/IJPM.IJPM_396_17			3	Pathology	Pathology	GN7CT	WOS:000439282500031	30004074	DOAJ Gold			2019-10-28	
J	Vyas, Y; Salkar, A; Bothale, AK				Vyas, Yelda; Salkar, Akanksha; Bothale, A. Kalpana			Coexisting prostate adenocarcinoma with multiple myeloma: A rare case report	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Microenvironment; multiple myeloma; prostate adenocarcinoma	CANCER	We report a rare case of an 83-year-old male with synchronous occurrence of prostate adenocarcinoma and multiple myeloma. He presented with lower back pain and incontinence of urine for the past 6 months. Routine hematological and biochemical investigations were performed which pointed toward prostate adenocarcinoma. Transrectal ultrasonography and magnetic resonance imaging showed prostatomegaly along with osteolytic lesions in the skull and vertebrae. Prostate biopsy was performed and adenocarcinoma was confirmed. To rule out metastatic deposits in the bone and to rule out bone marrow infiltration, bone marrow aspiration and biopsy of the patient was done, and unexpectedly, it showed multiple myeloma. The association between these two disorders is poorly understood, but some studies show that bone marrow microenvironment plays an important role.	[Vyas, Yelda] NKP Salve Inst Med Sci & Res Ctr, Dr Lal Path Labs, Nagpur, Maharashtra, India; [Bothale, A. Kalpana] NKP Salve Inst Med Sci & Res Ctr, Dept Pathol, Nagpur, Maharashtra, India; [Salkar, Akanksha] Care Hosp, Hyderabad, Telangana, India	Vyas, Y (reprint author), Vyas Hosp, Opposite Police Stn Sakkardara, Nagpur 440009, Maharashtra, India.	yeldapuri@gmail.com					De Raeve HR, 2005, HISTOL HISTOPATHOL, V20, P1227, DOI 10.14670/HH-20.1227; Huang Eugene, 2002, Urology, V60, P1111, DOI 10.1016/S0090-4295(02)02074-5; Kao J, 2004, MED HYPOTHESES, V63, P226, DOI 10.1016/j.mehy.2003.10.029; Kim NY, 2011, KOREAN J LAB MED, V31, P285, DOI 10.3343/kjlm.2011.31.4.285; Kyle R A, 1990, Adv Clin Chem, V28, P145, DOI 10.1016/S0065-2423(08)60137-7; Lynch HT, 2001, J NATL CANCER I, V93, P1479, DOI 10.1093/jnci/93.19.1479; Perez Lopez ME, 2007, ACTAS UROL ESP, V31, P157; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Sehgal T, 2014, INDIAN J HEMATOL BLO, V30, pS359, DOI 10.1007/s12288-014-0410-4; Terris MK, 1997, J UROLOGY, V158, P1457, DOI 10.1016/S0022-5347(01)64242-3	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					434	436	PMID 30004075	10.4103/IJPM.IJPM_591_17			3	Pathology	Pathology	GN7CT	WOS:000439282500032	30004075	DOAJ Gold			2019-10-28	
J	Pandey, V; Khatib, Y; Khade, AL; Pandey, R; Khare, MS				Pandey, Vinita; Khatib, Yasmeen; Khade, Archana Laxman; Pandey, Rahul; Khare, Manisha S.			Spermatocytic seminoma with rhabdomyoblastic differentiation: Case report and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Rhabdomyosarcoma; spermatocytic seminoma; testis	RHABDOMYOSARCOMATOUS DIFFERENTIATION; TRANSFORMATION; SARCOMA; TESTIS	Spermatocytic seminoma (SCS) is an indolent germ cell tumor of the testis. It has an excellent prognosis and orchidectomy is generally curative. Very rarely, it can be complicated by a sarcomatous transformation which is associated with a very aggressive behavior and requires adjuvant therapy. SCS with sarcomatous component is a very rare occurrence with <20 cases described in the world literature of which eight showed rhabdomyoblastic differentiation. We report a case of SCS with rhabdomyosarcomatous differentiation in a 60-year-old male along with a short review of literature.	[Pandey, Vinita; Khatib, Yasmeen; Khade, Archana Laxman; Khare, Manisha S.] HBT Med Coll, Dept Pathol, 1st Floor,Hosp Bldg, Mumbai 400056, Maharashtra, India; [Khade, Archana Laxman; Khare, Manisha S.] Dr RN Cooper Hosp, Mumbai, Maharashtra, India; [Khade, Archana Laxman; Khare, Manisha S.] Dr RN Cooper Municipal Gen Hosp, Mumbai 400056, Maharashtra, India; [Pandey, Rahul] Tata Mem Hosp, Dept Pathol, Mumbai, Maharashtra, India	Khade, AL (reprint author), HBT Med Coll, Dept Pathol, 1st Floor,Hosp Bldg, Mumbai 400056, Maharashtra, India.; Khade, AL (reprint author), Dr RN Cooper Municipal Gen Hosp, Mumbai 400056, Maharashtra, India.	arck115@gmail.com					Chelly I, 2006, PROG UROL, V16, P218; FLOYD C, 1988, CANCER-AM CANCER SOC, V61, P409, DOI 10.1002/1097-0142(19880115)61:2<409::AID-CNCR2820610234>3.0.CO;2-6; MATOSKA J, 1990, AM J CLIN PATHOL, V94, P89, DOI 10.1093/ajcp/94.1.89; Menon S, 2009, J CANCER RES THER, V5, P213, DOI 10.4103/0973-1482.57131; Narang V, 2012, INDIAN J UROL, V28, P430, DOI 10.4103/0970-1591.105760; Robinson A, 2007, AM J CLIN ONCOL-CANC, V30, P440, DOI 10.1097/01.coc.0000180384.40865.f7; TALERMAN A, 1980, CANCER-AM CANCER SOC, V45, P2169, DOI 10.1002/1097-0142(19800415)45:8<2169::AID-CNCR2820450827>3.0.CO;2-U; Trivedi P, 2011, INDIAN J PATHOL MICR, V54, P138, DOI 10.4103/0377-4929.77369; TRUE LD, 1988, AM J SURG PATHOL, V12, P75, DOI 10.1097/00000478-198802000-00001	9	1	1	0	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					437	439		10.4103/IJPM.IJPM_243_17			3	Pathology	Pathology	GN7CT	WOS:000439282500033	30004076	DOAJ Gold			2019-10-28	
J	Patnayak, R; Rukmangadha, N; Architha, P; Reddy, GS; Lakshmi, AY; Kannan, T; Jena, A				Patnayak, Rashmi; Rukmangadha, Nandyala; Architha, Pabbu; Reddy, Gajjala Sivanath; Lakshmi, Amarchala Yadagiri; Kannan, Thiruvengadaswamy; Jena, Amitabh			Metastasizing uterine mullerian adenosarcoma in a young female: Diagnostic enigma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Lymph node metastasis; mullerian adenosarcoma; premenopausal female; uterine sarcomas	CLINICOPATHOLOGICAL ANALYSIS; SARCOMATOUS OVERGROWTH; UTERUS	Uterine adenosarcomas are uncommon tumors. It is a biphasic tumor with both epithelial and mesenchymal component. The epithelial component is benign in nature, and the mesenchymal component is malignant. Metastasis is rare in adenosarcoma. We report a case of adenosarcoma with lymph nodal metastasis. A 20-year-old female presented with history of per vaginal bleeding for 1 month. Per vaginal examination revealed a fungating mass protruding through the cervical os. Ultrasonography and magnetic resonance imaging showed a large intrauterine mass. Biopsy of the mass done at an outside hospital was reported as rhabdomyosarcoma. Hence, she was given one cycle of neoadjuvant chemotherapy. Following this, she had profuse bleeding. Emergency hysterectomy with pelvic lymph nodal dissection was performed. The final histopathology was reported as adenosarcoma. One pelvic lymph node showed metastatic deposit of rhabdomyosarcomatous element. In young females presenting with polypoidal mass, uterine adenosarcoma can be considered in the differential diagnosis.	[Patnayak, Rashmi; Rukmangadha, Nandyala; Architha, Pabbu] Sri Venkateswara Inst Med Sci, Dept Pathol, Tirupati 517507, Andhra Pradesh, India; [Reddy, Gajjala Sivanath; Jena, Amitabh] Sri Venkateswara Inst Med Sci, Dept Surg Oncol, Tirupati, Andhra Pradesh, India; [Lakshmi, Amarchala Yadagiri] Sri Venkateswara Inst Med Sci, Dept Radiol, Tirupati, Andhra Pradesh, India; [Kannan, Thiruvengadaswamy] Sri Venkateswara Inst Med Sci, Dept Med Oncol, Tirupati, Andhra Pradesh, India	Patnayak, R (reprint author), Sri Venkateswara Inst Med Sci, Dept Pathol, Tirupati 517507, Andhra Pradesh, India.	rashmipatnayak2002@yahoo.co.in	patnayak, rashmi/H-8683-2019				Choi YJ, 2011, EUR J GYNAECOL ONCOL, V32, P91; CLEMENT PB, 1989, AM J SURG PATHOL, V13, P28, DOI 10.1097/00000478-198901000-00004; CLEMENT PB, 1974, CANCER-AM CANCER SOC, V34, P1138, DOI 10.1002/1097-0142(197410)34:4<1138::AID-CNCR2820340425>3.0.CO;2-9; D'Angelo E, 2011, BEST PRACT RES CL OB, V25, P705, DOI 10.1016/j.bpobgyn.2011.05.010; McCluggage WG, 2010, ADV ANAT PATHOL, V17, P122, DOI 10.1097/PAP.0b013e3181cfe732; Seidman JD, 1999, AM J SURG PATHOL, V23, P809, DOI 10.1097/00000478-199907000-00009; Soslow RA, 2008, AM J SURG PATHOL, V32, P1013, DOI 10.1097/PAS.0b013e318161d1be; Tinar Sivekar, 2004, MedGenMed, V6, P51; Verschraegen CF, 1998, ONCOL REP, V5, P939; ZALOUDEK CJ, 1981, CANCER-AM CANCER SOC, V48, P354, DOI 10.1002/1097-0142(19810715)48:2<354::AID-CNCR2820480222>3.0.CO;2-Q	10	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					440	442	PMID 30004077	10.4103/IJPM.IJPM_1_18			3	Pathology	Pathology	GN7CT	WOS:000439282500034	30004077	DOAJ Gold			2019-10-28	
J	Aslan, F; Yazici, H; Altun, E				Aslan, Figen; Yazici, Hasmet; Altun, Eren			Psammomatoid variant of juvenile ossifying fibroma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Fibro-osseous lesion; juvenile ossifying fibroma; psammomatoid		Juvenile ossifying fibroma (JOF) is a rare benign tumor of the craniofacial bones differing from other fibro-osseous lesions in terms of early age of onset, aggressive clinical behavior, and high recurrence rate. Histopathologically, it is divided into two as trabecular JOF (TrJOF) and psammomatoid JOF (PsJOF). In PsJOF, psammoma-like spherical ossicles constitute pathognomonic histopathological images, whereas TrJOF has trabeculae of fibrillary osteoid and woven bone. Despite the histopathologic separation, both lesions have similar clinical behavior, thus the treatment procedure is also the same. Complete surgical resection is preferred for the treatment. We report a rare case of PsJOF involving the maxillary sinus and resultant facial symmetry in a 13-year-old female child.	[Aslan, Figen; Altun, Eren] Balikesir Univ, Sch Med, Dept Pathol, Balikesir, Turkey; [Yazici, Hasmet] Balikesir Univ, Sch Med, Dept Otolaryngol, Balikesir, Turkey	Aslan, F (reprint author), Balikesir Univ, Tip Fak, Sch Med, Dept Pathol, Cagis Yerleskesi,Bigadic Yolu 17 Km Altieylul, TR-10145 Balikesir, Turkey.	fgenaslan@gmail.com	ALTUN, EREN/P-1338-2019	ALTUN, EREN/0000-0001-9110-8364			Cubukcu CE, 2011, DENTISTRY, V1, P3; Deshingkar SA, 2014, SAUDI J DENT RES, V5, P5135; El-Mofty S, 2002, ORAL SURG ORAL MED O, V93, P296, DOI 10.1067/moe.2002.121545; Figueiredo LMG, 2014, ORAL MAXILLOFAC SURG, V18, P87, DOI 10.1007/s10006-013-0400-y; Guttikonda Vr, 2013, J Oral Maxillofac Pathol, V17, P302, DOI 10.4103/0973-029X.119751; Marglani OA, 2014, SAUDI MED J, V35, P872; Ranganath K, 2014, J MAXILLOFAC ORAL SU, V13, P109, DOI 10.1007/s12663-013-0479-6; Sun G, 2007, INT J ORAL MAX SURG, V36, P82, DOI 10.1016/j.ijom.2006.06.024; Thankappan Simi, 2009, Indian J Radiol Imaging, V19, P116, DOI 10.4103/0971-3026.50832; Vamanshankar H, 2017, REV ESPANOLA CIRUGIA, V39, P229	10	0	0	1	1	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					443	445	PMID 30004078	10.4103/IJPM.IJPM_577_17			3	Pathology	Pathology	GN7CT	WOS:000439282500035	30004078	DOAJ Gold			2019-10-28	
J	Amita, K; Suma, MN; Shankar, SV; Premalata, CS; Sanjay, M				Amita, K.; Suma, M. N.; Shankar, S. Vijay; Premalata, C. S.; Sanjay, M.			Primary follicular lymphoma of disguised as multiple miliary like lesions: A case report and review of literature	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Review						Gastrointestinal tract; lymphoma; non-Hodgkin	GASTROINTESTINAL-TRACT	Primary follicular lymphoma (PFL) of gastrointestinal tract (GIT) is rare and account for 1%-3% of non-Hodgkin lymphoma. Within the small intestine, the PFL is more common in jejunum than in the ileum. Due to low prevalence of the disease, the clinical manifestations are not well known, and diagnosis is usually delayed leading to complications. We herein report a case of PFL of GIT who presented with intestinal obstruction and unique gross morphology. Diagnosis was made by morphology and supported by immunohistochemistry.	[Amita, K.; Shankar, S. Vijay; Sanjay, M.] Adichunchanagiri Inst Med Sci, Dept Pathol, Mandya 571448, Karnataka, India; [Suma, M. N.; Premalata, C. S.] Kidwai Canc Inst, Dept Pathol, Bengaluru, Karnataka, India	Amita, K (reprint author), Adichunchanagiri Inst Med Sci, Dept Pathol, Mandya 571448, Karnataka, India.	dramitay@gmail.com	K, Amita/P-5020-2019				Iwamuro M, 2014, CASE REP ONCOL MED, DOI 10.1155/2014/549248; Jaffe E. S., 2001, PATHOLOGY GENETICS T, V3; Misdraji J, 2011, AM J SURG PATHOL, V35, P1255, DOI 10.1097/PAS.0b013e318224e661; Nakamura S, 2013, DIGESTION, V87, P182, DOI 10.1159/000350051; Shia J, 2002, AM J SURG PATHOL, V26, P216, DOI 10.1097/00000478-200202000-00008; Takata K, 2011, CANCER SCI, V102, P1532, DOI 10.1111/j.1349-7006.2011.01980.x; Yaranal PJ, 2014, INDIAN J CANCER, V51, P306, DOI 10.4103/0019-509X.146791	7	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					446	449		10.4103/IJPM.IJPM_126_17			4	Pathology	Pathology	GN7CT	WOS:000439282500036	30004079	DOAJ Gold			2019-10-28	
J	Vaiphei, K; Kumar, R; Bahl, A				Vaiphei, Kim; Kumar, Rajesh; Bahl, Ajay			A rare case of accessory mitral valve tissue	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Vaiphei, Kim; Kumar, Rajesh] Post Grad Inst Med Educ & Res, Dept Histopathol, Chandigarh 160012, India; [Bahl, Ajay] Post Grad Inst Med Educ & Res, Dept Cardiol, Chandigarh, India	Vaiphei, K (reprint author), Post Grad Inst Med Educ & Res, Dept Histopathol, Chandigarh 160012, India.	kvaiphei2009@gmail.com					Hisatomi K, 2016, GEN THORAC CARDIOVAS, V64, P105, DOI 10.1007/s11748-014-0399-5; Manganaro R, 2014, EUR HEART J-CARD IMG, V15, P489, DOI 10.1093/ehjci/jet163; Panduranga P, 2011, HEART INT, V6, P18, DOI 10.4081/hi.2011.e6; Uslu N, 2006, CARDIOLOGY, V105, P155, DOI 10.1159/000091290	4	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					450	451		10.4103/IJPM.IJPM_368_17			2	Pathology	Pathology	GN7CT	WOS:000439282500037	30004080	DOAJ Gold			2019-10-28	
J	Adhya, AK; Pradhan, MR				Adhya, Amit Kumar; Pradhan, Manas Ranjan			Ectopic prostatic tissue presenting as a mucosal tumor in urinary bladder	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Adhya, Amit Kumar] All India Inst Med Sci, Dept Pathol & Lab Med, Bhubaneswar 751019, Odisha, India; [Pradhan, Manas Ranjan] Kalinga Hosp, Dept Urol, Bhubaneswar, Odisha, India	Adhya, AK (reprint author), All India Inst Med Sci, Dept Pathol & Lab Med, Bhubaneswar 751019, Odisha, India.	amitadhya2003@yahoo.com					Backhouse A, 2014, PATHOLOGY, V46, P655, DOI 10.1097/PAT.0000000000000171; Bellezza G, 2005, INT J UROL, V12, P1066, DOI 10.1111/j.1442-2042.2005.01210.x; DELLADETSIMA J, 1990, UROLOGY, V36, P445, DOI 10.1016/S0090-4295(90)80293-V; Dogra P. N., 2002, International Urology and Nephrology, V34, P525, DOI 10.1023/A:1025646314201; Fulton RS, 2001, ARCH PATHOL LAB MED, V125, P286	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					452	453		10.4103/IJPM.IJPM_131_18			2	Pathology	Pathology	GN7CT	WOS:000439282500038	30004081	DOAJ Gold			2019-10-28	
J	Giriyan, SS; Navyashree, N				Giriyan, Sujata S.; Navyashree, N.			An unusual presentation of hydatid cyst in the neck: A cytological diagnosis	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Giriyan, Sujata S.; Navyashree, N.] Karnataka Inst Med Sci, Dept Pathol, Hubli, Karnataka, India	Navyashree, N (reprint author), Karnataka Inst Med Sci, Dept Pathol, PB Rd, Hubballi 580021, Karnataka, India.	nav.sourabha@gmail.com					Ghartimagar D, 2015, CLIN MED J, V1, P134; Gossios KJ, 1997, EUR RADIOL, V7, P1303, DOI 10.1007/s003300050293; Goyal P, 2014, HEAD NECK PATHOL, V8, P334, DOI 10.1007/s12105-013-0502-8; Hallac Keser S, 2017, TURK J PATHOL, V33, P30, DOI 10.5146/tjpath.2016.01369; Khalifa R, 2016, EGYPT J EAR NOSE THR, V17, P103; Mittal Mahesh Kumar, 2012, Indian J Radiol Imaging, V22, P334, DOI 10.4103/0971-3026.111488	6	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					454	455		10.4103/IJPM.IJPM_9_18			2	Pathology	Pathology	GN7CT	WOS:000439282500039	30004082	DOAJ Gold			2019-10-28	
J	Mohan, BP; Letha, V; Pothen, L; Bhat, S				Mohan, Bhavya P.; Letha, V.; Pothen, Lillykkutty; Bhat, Suresh			Metastasizing pleomorphic adenoma of parotid presenting as a huge renal mass	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							SALIVARY-GLAND		[Mohan, Bhavya P.; Letha, V.; Pothen, Lillykkutty] Govt Med Coll, Dept Pathol, Kottayam, Kerala, India; [Bhat, Suresh] Govt Med Coll, Dept Genitourinary Surg, Kottayam, Kerala, India	Mohan, BP (reprint author), Govt Med Coll, Dept Pathol, Kottayam, Kerala, India.	bhavyasharath80@gmail.com	Mohan, Bhavya/R-5643-2019				AUCLAIR PL, 1986, CANCER, V58, P1305, DOI 10.1002/1097-0142(19860915)58:6<1305::AID-CNCR2820580621>3.0.CO;2-K; Knight J, 2015, INT J SURG, V19, P137, DOI 10.1016/j.ijsu.2015.04.084; Manucha V, 2008, ARCH PATHOL LAB MED, V132, P1445, DOI 10.1043/1543-2165(2008)132[1445:MPAOTS]2.0.CO;2; Moonim M, 2015, CASE REPORT CLIN PAT, V2, P74; WENIG BM, 1992, AM J SURG PATHOL, V16, P845, DOI 10.1097/00000478-199209000-00003	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					456	+		10.4103/IJPM.IJPM_111_17			2	Pathology	Pathology	GN7CT	WOS:000439282500040	30004083	DOAJ Gold			2019-10-28	
J	Mukherjee, U; Khurana, A; Patil, N				Mukherjee, Urmi; Khurana, Anuj; Patil, Nayana			An unusual intra-abdominal tumor of the gastrointestinal tract	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							SARCOMA-LIKE TUMOR		[Mukherjee, Urmi; Khurana, Anuj; Patil, Nayana] Max Super Special Hosp, Dept Lab Med, New Delhi 110017, India	Patil, N (reprint author), Max Super Special Hosp, Dept Lab Med, New Delhi 110017, India.	dr.nayana04@gmail.com					Gahanbani Ardakani A, 2016, Ann R Coll Surg Engl, V98, pe37, DOI 10.1308/rcsann.2016.0073; Raskin GA, 2015, GASTROINTEST TUMORS, V2, P83, DOI 10.1159/000430881; Thway K, 2014, CASE REP MED, DOI 10.1155/2014/984369; Wang J, 2015, ARCH PATHOL LAB MED, V139, P407, DOI 10.5858/arpa.2013-0547-RS; Yegen G, 2015, INT J SURG PATHOL, V23, P61, DOI 10.1177/1066896914547046	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					457	458		10.4103/IJPM.IJPM_658_17			2	Pathology	Pathology	GN7CT	WOS:000439282500041	30004084	DOAJ Gold			2019-10-28	
J	Pallavi, BD; Maithili, KM; Khandeparkar, SGS; Jadhav, AB				Pallavi, Bhayekar Dinesh; Maithili, Kulkarni Mandar; Khandeparkar, Siddhi G. Sinai; Jadhav, Amruta B.			Sertoliform endometrioid carcinoma of the ovary in a young female	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Pallavi, Bhayekar Dinesh; Maithili, Kulkarni Mandar; Khandeparkar, Siddhi G. Sinai; Jadhav, Amruta B.] Shrimati Kashibai Navale Med Coll & Gen Hosp, Dept Pathol, Pune, Maharashtra, India	Pallavi, BD (reprint author), Flat 306,Kumthekar Rd, Pune 411030, Maharashtra, India.	drpallavibhayekar@gmail.com					Bakshi N, 2013, INDIAN J PATHOL MICR, V56, P327, DOI 10.4103/0377-4929.120419; Kankaya D, 2015, ANKARA U TIP FAK MEC, V68, P133; Lee KR, 2003, PATHOLOGY GENETICS T, P131; Misir A, 2007, ARCH PATHOL LAB MED, V131, P979; Ordi J, 1999, MODERN PATHOL, V12, P933	5	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					459	460		10.4103/IJPM.IJPM_675_17			2	Pathology	Pathology	GN7CT	WOS:000439282500042	30004085	DOAJ Gold			2019-10-28	
J	Sinha, M; Saini, S; Gupta, P; Gulati, NS; Das, A; Kumar, A; Mehndiratta, MM; Shekhar, C				Sinha, Madhu; Saini, Sneha; Gupta, Poonam; Gulati, Natasha S.; Das, Abhijit; Kumar, Ashok; Mehndiratta, Man Mohan; Shekhar, Chandra			Current status and way forward for National Accreditation Board for Testing and Calibration Laboratories Accreditation of Laboratories in Government Organizations	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter									[Sinha, Madhu; Saini, Sneha; Gulati, Natasha S.; Das, Abhijit] Janakpuri Super Specialty Hosp Soc, Dept Pathol, C-2B, New Delhi 110058, India; [Gupta, Poonam] Janakpuri Super Specialty Hosp Soc, Dept Microbiol, New Delhi, India; [Kumar, Ashok; Mehndiratta, Man Mohan] Janakpuri Super Specialty Hosp Soc, Dept Neurol, New Delhi, India; [Shekhar, Chandra] Dr BSA Med Coll & Hosp, Dept Surg, New Delhi, India	Sinha, M (reprint author), Janakpuri Super Specialty Hosp Soc, Dept Pathol, C-2B, New Delhi 110058, India.	madhushekharnath@rediffmail.com					Heigrujam RS, 2014, J MED SOC, V28, P1; Kanagasabapathy AS, 2005, INDIAN J CLIN BIOCHE, V20, P186, DOI 10.1007/BF02867425; Kapil A, 2013, INDIAN J MED MICROBI, V31, P217, DOI 10.4103/0255-0857.115622; Wadhwa V, 2012, INDIAN J MED MICROBI, V30, P131, DOI 10.4103/0255-0857.96647	4	1	1	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					461	463		10.4103/IJPM.IJPM_630_17			3	Pathology	Pathology	GN7CT	WOS:000439282500043	30004086	DOAJ Gold			2019-10-28	
J	Liu, KY; Zhou, FL; Fu, ZX; Yin, JP; Li, W				Liu, Keyu; Zhou, Fengling; Fu, Zexian; Yin, Junping; Li, Wei			Coexistence of T-cell lymphoblastic lymphoma and acute myeloid leukemia mimicking acute lymphocytic leukemia	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Letter							LOW-DOSE CYTARABINE		[Liu, Keyu; Yin, Junping] Univ Hebei, Affiliated Hosp Engn, Dept Clin Lab, Handan, Hebei, Peoples R China; [Zhou, Fengling] Univ Hebei, Affiliated Hosp Engn, Dept Hematol, Handan, Hebei, Peoples R China; [Fu, Zexian] Univ Hebei, Affiliated Hosp Engn, Dept Sci & Educ, Handan, Hebei, Peoples R China; [Li, Wei] Univ Hebei, Affiliated Hosp Engn, Dept Obstet, Congtai St Number 81, Handan, Hebei, Peoples R China	Li, W (reprint author), Univ Hebei, Affiliated Hosp Engn, Dept Obstet, Congtai St Number 81, Handan, Hebei, Peoples R China.	liweifuchanke@163.com	fu, zexian/K-5530-2013	fu, zexian/0000-0002-6945-0486	Foundation of Health and family planning Commission of Hebei [20180804]	Foundation of Health and family planning Commission of Hebei No. 20180804.	Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; Borowitz MJ, 2017, WHO CLASSIFICATION T, P212; Burnett AK, 2007, CANCER, V109, P1114, DOI 10.1002/cncr.22496; Kantarjian H, 2012, LANCET ONCOL, V13, P1096, DOI 10.1016/S1470-2045(12)70436-9; Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429; Natarajan S, 2010, NATURE PRECEDINGS; Neumann M, 2013, BLOOD, V121, P4749, DOI 10.1182/blood-2012-11-465138; Tokuhira M, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-27	9	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					464	467		10.4103/IJPM.IJPM_6_18			4	Pathology	Pathology	GN7CT	WOS:000439282500044	30004087	DOAJ Gold			2019-10-28	
J	Yadav, AK				Yadav, Anil Kumar			Remembering the genius on her birth anniversary: Professor Janet Davidson Rowley, MD (05.04.1925-17.12.2013) TRIBUTE	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Biographical-Item									[Yadav, Anil Kumar] Medanta, Dept Hematol Cytogenet, Gurgaon, Haryana, India	Yadav, AK (reprint author), Medanta, Dept Hematol Cytogenet, Gurgaon, Haryana, India.	akyadav.biotech@gmail.com					YADAV AK, PUBLICATION LIST	1	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					468	469		10.4103/IJPM.IJPM_394_18			2	Pathology	Pathology	GN7CT	WOS:000439282500045	30004088	DOAJ Gold			2019-10-28	
J	Rekhi, B				Rekhi, Bharat			Catechism (Quiz)	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Editorial Material									[Rekhi, Bharat] Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Mumbai 400012, Maharashtra, India	Rekhi, B (reprint author), Tata Mem Hosp, Dept Surg Pathol, Room 818,8th Floor,Annex Bldg,Dr EB Rd, Mumbai 400012, Maharashtra, India.	rekhi.bharat@gmail.com						0	0	0	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JUL-SEP	2018	61	3					470	470		10.4103/IJPM.IJPM_318_18			1	Pathology	Pathology	GN7CT	WOS:000439282500046		DOAJ Gold			2019-10-28	
J	Li, J; Hui, L; Kang, QY; Li, R				Li, Jing; Hui, Liang; Kang, Qianyan; Li, Rong			Down-regulation of microRNA-27b promotes retinal pigment epithelial cell proliferation and migration by targeting Nox2	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-27b; PDGF-BB; Retinal pigment epithelium; Proliferation and migration; Nox2	NADPH OXIDASE; CHOROIDAL NEOVASCULARIZATION; ENDOTHELIAL-CELLS; RPE CELLS; GROWTH; MIR-27B; ARPE-19; ANGIOGENESIS; DEGENERATION; INHIBITION	Aberrant proliferation and migration of retinal pigment epithelium (RPE) cells contributes to the pathology of various ocular diseases. miR-27b has been reported to be crucial in the regulation of cell differentiation, proliferation, apoptosis, and migration. However, the role of miR-27b on RPE proliferation and migration remains largely unknown. Here the effect of miR-27b on ARPE-19 cells under platelet-derived growth factor (PDGF)-BB stimulation was explored. In this study, we found that the expression level of miR-27b was significantly reduced in ARPE-19 cells under PDGF-BB stimulation. Ectopic expression of miR-27b remarkably inhibited PDGF-BBinduced proliferation and migration in ARPE-19 cells. Furthermore, bioinfonnatic analysis and luciferase reporter assay showed that NADPH oxidase 2 (Nox2) was a direct target for miR-27b, and that knockdown of Nox2 expression mimicked the inhibitory effect of miR-27b on PDGF-BB - induced proliferation and migration in ARPE-19 cells, whereas, restoration of Nox2 expression showed an opposite effect. In addition, the ROS production and the activation of P13K/AKT/mTOR signaling induced by PDGF-BB were also suppressed by miR-27b overexpression or Nox2 silencing. Thus, these findings indicated that miR-27b exerted its protective role in RPE cells under PDGF-BB stimulation was partially through regulation of Nox2 and its downstream P13K/AKT/mTOR signaling, which might be a potential therapeutic approach for treatment of diseases caused by RPE proliferation, and migration.	[Li, Jing; Kang, Qianyan] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, 277 Yantai West Rd, Xian 710061, Shaanxi, Peoples R China; [Li, Jing] Shaanxi Prov Peoples Hosp, Dept Ophthalmol, Xian 710068, Shaanxi, Peoples R China; [Hui, Liang] Second Hosp Yulin, Dept Ophthalmol, Yulin 719000, Shaanxi, Peoples R China; [Li, Rong] Xian Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian 710077, Shaanxi, Peoples R China	Kang, QY (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, 277 Yantai West Rd, Xian 710061, Shaanxi, Peoples R China.	kangqy@mail.xjtu.edu.cn			Science&Technology project for Social development of Shaanxi Province in China [2018SF-155]; Science&Technology project for Social development of Xi'an in China [2016051SF/YX07]	This study was supported by Science&Technology project for Social development of Shaanxi Province in China (No.2018SF-155) and Science&Technology project for Social development of Xi'an in China (No. 2016051SF/YX07).	Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5; Alexander P, 2015, EYE, V29, P992, DOI 10.1038/eye.2015.89; Ayaz L., 2017, CUTAN OCUL TOXICOL, V31, P1; Bhatt L, 2010, MOL VIS, V16, P283; Biyashev D, 2012, BLOOD, V119, P2679, DOI 10.1182/blood-2011-07-370635; Chakraborty C, 2014, WIRES RNA, V5, P697, DOI 10.1002/wrna.1240; Chan CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056819; Chan EC, 2013, INVEST OPHTH VIS SCI, V54, P7061, DOI 10.1167/iovs.13-12883; Chang J H, 2001, Korean J Ophthalmol, V15, P74; Charteris DG, 2002, EYE, V16, P369, DOI 10.1038/sj.eye.6700194; Du L, 2017, BIOMED PHARMACOTHER, V85, P136, DOI 10.1016/j.biopha.2016.11.108; Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020; Ertekin S, 2014, MOL VIS, V20, P1057; Fuhrmann S, 2014, EXP EYE RES, V123, P141, DOI 10.1016/j.exer.2013.09.003; Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001; He SK, 2010, INVEST OPHTH VIS SCI, V51, P543, DOI 10.1167/iovs.09-3475; Hollborn M, 2006, BIOCHEM BIOPH RES CO, V344, P912, DOI 10.1016/j.bbrc.2006.03.185; Jiang C, 2016, ONCOTARGET, V7, P52340, DOI 10.18632/oncotarget.10566; Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162; Kuznetsova AV, 2014, J OPHTHALMOL, DOI 10.1155/2014/801787; Lam GY, 2010, SEMIN IMMUNOPATHOL, V32, P415, DOI 10.1007/s00281-010-0221-0; Li R, 2007, INVEST OPHTH VIS SCI, V48, P5722, DOI 10.1167/iovs.07-0327; Li YS, 2014, OXID MED CELL LONGEV, DOI 10.1155/2014/581732; Liu HT, 2015, ONCOTARGET, V6, P37467, DOI 10.18632/oncotarget.6059; Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116; Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166; Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878; Ohana R, 2015, DEVELOPMENT, V142, P2487, DOI 10.1242/dev.121533; Paravicini TM, 2008, DIABETES CARE, V31, pS170, DOI 10.2337/dc08-s247; ROBBINS SG, 1994, INVEST OPHTH VIS SCI, V35, P3649; Samuel W, 2017, MOL VIS, V23, P60; Santamaria D, 2006, FRONT BIOSCI-LANDMRK, V11, P1164, DOI 10.2741/1871; Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724; Skonieczna M, 2017, OXID MED CELL LONGEV, DOI 10.1155/2017/9420539; Song HM, 2016, INVEST OPHTH VIS SCI, V57, P2864, DOI 10.1167/iovs.15-18974; Sundermeier TR, 2016, FASEB J, V30, P23, DOI 10.1096/fj.15-279745; Tane S, 2014, BIOCHEM BIOPH RES CO, V443, P1105, DOI 10.1016/j.bbrc.2013.12.109; Veliceasa D, 2015, VASC CELL, V7, DOI 10.1186/s13221-015-0031-1; Wahid F, 2014, BIOCHIMIE, V104, P12, DOI 10.1016/j.biochi.2014.05.004; Wan L, 2014, MOL CELL BIOCHEM, V390, P85, DOI 10.1007/s11010-013-1959-1; Wang LY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050626; Xie MY, 2014, MOL VIS, V20, P921; Yang J, 2018, INT J MOL MED, V42, P123, DOI 10.3892/ijmm.2018.3612; Ye J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060687; Yokota H., 2011, INVEST OPHTH VIS SCI, V52, P1823; Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108	46	3	3	2	11	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					925	933		10.1016/j.prp.2018.05.025			9	Pathology	Pathology	GN6YY	WOS:000439254000001	29858119				2019-10-28	
J	Iwamuro, M; Urata, H; Tanaka, T; Kawano, S; Kawahara, Y; Kimoto, K; Okada, H				Iwamuro, Masaya; Urata, Haruo; Tanaka, Takehiro; Kawano, Seiji; Kawahara, Yoshiro; Kimoto, Katsuhiko; Okada, Hiroyuki			Lanthanum deposition corresponds to white lesions in the stomach	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hyperphosphatemia; Lanthanum carbonate; Scanning electron microscopy analysis; Esophagogastroduodenoscopy	DIALYSIS PATIENTS; PHOSPHATE DEPOSITION; GASTRIC-MUCOSA; CARBONATE	Objective: Although lanthanum deposition in the stomach has been most frequently reported to occur as white lesions, no study has investigated whether the white lesions observed during esophagogastroduodenoscopy are truly lanthanum-related. Here, we retrospectively investigated the amount of lanthanum in endoscopic biopsy specimens. Methods: We reviewed four patients showing gastric white spots or annular whitish mucosa in the gastric white lesions (Bw) and peripheral mucosa where the white substance was not endoscopically observed (Bp) during biopsy. We also reviewed three patients with diffuse whitish mucosa and three patients with no whitish lesions. We performed scanning electron microscopy and energy dispersive X-ray spectrometry to quantify the lanthanum elements (wt%) in the biopsy specimens. Results: The amount of lanthanum in the Bw ranged from 0.15-0.31 wt%, whereas that of Bp was 0.00-0.13 wt %. The difference was statistically significant (P < 0.05). The amount of lanthanum in the Bw, endoscopically presented with white spots or annular whitish mucosa, was significantly higher than that of no whitish lesions (0.05-0.14 wt%, P < 0.05). The amount of lanthanum was also higher in the diffuse whitish mucosa (0.21-0.23 wt%) compared with no whitish lesions (P < 0.01). Conclusions: This study is the first to reveal that pathological lanthanum deposition corresponds to the endoscopically observed white lesions in the gastric mucosa. Therefore, during esophagogastroduodenoscopy, physicians should pay attention to possible presence of white lesions in patients treated with oral lanthanum carbonate to ensure prompt identification of associated issues.	[Iwamuro, Masaya; Kawano, Seiji; Okada, Hiroyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama 7008558, Japan; [Urata, Haruo] Okayama Univ, Med Sch, Cent Res Lab, Okayama 7008558, Japan; [Tanaka, Takehiro] Okayama Univ Hosp, Dept Pathol, Okayama 7008558, Japan; [Kawahara, Yoshiro] Okayama Univ Hosp, Dept Endoscopy, Okayama 7008558, Japan; [Kimoto, Katsuhiko] Kimoto Naika Clin, Okayama 7000912, Japan	Iwamuro, M (reprint author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Gastroenterol & Hepatol, Okayama 7008558, Japan.	pr145h2k@okayama-u.ac.jp					Ban S, 2017, ANN DIAGN PATHOL, V26, P6, DOI 10.1016/j.anndiagpath.2016.10.001; Goto K, 2016, INT J SURG PATHOL, V24, P89, DOI 10.1177/1066896915613434; Haratake J, 2015, AM J SURG PATHOL, V39, P767, DOI 10.1097/PAS.0000000000000385; Hattori K, 2017, PATHOL INT, V67, P447, DOI 10.1111/pin.12564; Hoda RS, 2017, HISTOPATHOLOGY, V70, P1072, DOI 10.1111/his.13178; Hutchison AJ, 2016, NEPHROLOGY, V21, P987, DOI 10.1111/nep.12864; Iwamuro M, 2017, GASTROENTEROL ENDOSC, V59, P1428; Iwamuro M, 2018, INTERNAL MED, V57, P801, DOI 10.2169/internalmedicine.9665-17; Iwamuro M, 2017, PATHOL INT, V67, P649, DOI 10.1111/pin.12602; Iwamuro M, 2017, GASTROINTEST ENDOSC, V85, P1103, DOI 10.1016/j.gie.2016.06.012; Iwamuro M, 2017, ACTA MED OKAYAMA, V71, P73, DOI 10.18926/AMO/54828; Iwamuro M, 2016, GASTROENTEROLOGY, V150, P322, DOI 10.1053/j.gastro.2015.11.013; Ji R, 2012, GASTROINTEST ENDOSC, V75, P980, DOI 10.1016/j.gie.2011.12.016; Komatsu-Fujii T, 2017, INT J SURG PATHOL, V25, P674, DOI 10.1177/1066896917718623; Murakami N, 2017, INTERNAL MED, V56, P2089, DOI 10.2169/internalmedicine.8720-16; Nishikawa Y., QJM; Rothenberg ME, 2015, ACG CASE REP J, V2, P187, DOI 10.14309/crj.2015.50; St Peter WL, 2017, DRUGS, V77, P1155, DOI 10.1007/s40265-017-0758-5; Tonooka A, 2015, CLIN KIDNEY J, V8, P572, DOI 10.1093/ckj/sfv062; Yabuki K., BIOL TRACE ELEM RES; Yabuki K, 2016, PATHOL RES PRACT, V212, P919, DOI 10.1016/j.prp.2016.07.017	21	1	1	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					934	939		10.1016/j.prp.2018.05.024			6	Pathology	Pathology	GN6YY	WOS:000439254000002	29843926				2019-10-28	
J	Li, XR; Pu, J; Liu, JX; Chen, YJ; Li, Y; Hou, P; Shi, BY; Yang, Q				Li, Xinru; Pu, Jun; Liu, Jiaxin; Chen, Yijun; Li, Yu; Hou, Peng; Shi, Bingyin; Yang, Qi			The prognostic value of DAPK1 hypermethylation in gliomas: A site-specific analysis	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Gliomas; Death associated protein kinase 1 (DAPK1); Site-specific methylation; Pyrosequencing	DNA HYPOMETHYLATION; GENE METHYLATION; MULTIPLE GENES; GASTRIC-CANCER; DIFFUSE GLIOMA; MUTATION; TUMORS; TEMOZOLOMIDE; GLIOBLASTOMA; CHEMOTHERAPY	Background and aims: The gene of death associated protein kinase 1 (DAPK1) has been reported to be methylated in various cancers including gliomas. However, its prognostic value for gliomas is still controversy, and the methylation at specific CpG sites of DAPK1 has not been investigated. The aim of this study was to prognostically evaluate the methylation level of different CpG sites within DAPK1 promoter region in gliomas. Methods: Based on sodium bisulfite treated DNA products, we made use of DNA pyrosequencing method to evaluate overall and site-specific methylation of DAPK1 in 143 gliomas and 26 benign tumors (meningeomas) or normal brain tissues. We both statistically analyzed the association between methylation levels of each CpG site and the clinicopathological characteristics, and estimated the prognosis predictive value of site-specific methylation for glioma patients. Results: Methylation status of DAPK1 site -1527, -1543, and the overall five sites concerned was higher in gliomas than controlled subjects (p < 0.001). Hypermethylation at site -1527 or together with site -1543 associated with better survival in patients taken postoperative therapies (-1527: p = 0.002; -1527 & -1543: p = 0.023), as well as in patients just underwent radiotherapy after surgery (-1527: p = 0.015; -1527 & -1543: p = 0.030). However, Cox regression analysis indicated the site-specific methylation was not independent contributor for gliomas prognosis. Conclusion: Analysis of DAPK1 gene promoter by quantitative pyrosequencing provided more detailed information of methylation status of CpG sites. DAPK1 methylation level is associated with gliomas clinical features and outcomes. Interestingly, the hypermethylation at site -1527 or together with site -1543 indicated good sensitivity of postoperative therapies, especially radiotherapy. Thus, site specifically analysis of DAPK1 methylation may be a valuable diagnostic and prognostic estimation for gliomas.	[Li, Xinru; Pu, Jun; Chen, Yijun; Li, Yu; Hou, Peng; Shi, Bingyin; Yang, Qi] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China; [Liu, Jiaxin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Surg, Xian 710061, Shaanxi, Peoples R China; [Hou, Peng; Shi, Bingyin; Yang, Qi] Xi An Jiao Tong Univ, Affiliated Hosp 1, Key Lab Tumor Precis Med Shaanxi Prov, Xian 710061, Shaanxi, Peoples R China	Yang, Q (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Endocrinol, Xian 710061, Shaanxi, Peoples R China.	yangqi2015@mail.xjtu.edu.cn			Natural Science Basic Research Plan in Shaanxi Province of China [2015JM8390]; China International Medical Foundation [2016-N-07-12]	This study was supported by the Natural Science Basic Research Plan in Shaanxi Province of China (Program No. 2015JM8390), and China International Medical Foundation (Program No. 2016-N-07-12).	Agodi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135078; Alonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7; Balss J, 2008, ACTA NEUROPATHOL, V116, P597, DOI 10.1007/s00401-008-0455-2; Bralten Linda B C, 2011, Cancers (Basel), V3, P1129, DOI 10.3390/cancers3011129; Calmon MF, 2007, CANCER GENET CYTOGEN, V173, P31, DOI 10.1016/j.cancergencyto.2006.09.008; Chan MWY, 2002, CLIN CANCER RES, V8, P464; Chen RZ, 1998, NATURE, V395, P89; Delaney C, 2015, METHODS MOL BIOL, V1343, P249, DOI 10.1007/978-1-4939-2963-4_19; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hou P, 2011, ENDOCR-RELAT CANCER, V18, P687, DOI 10.1530/ERC-11-0212; Huang YD, 2014, APOPTOSIS, V19, P371, DOI 10.1007/s10495-013-0919-2; Huse JT, 2014, CLIN CANCER RES, V20, P5601, DOI 10.1158/1078-0432.CCR-14-0831; Jayaprakash C, 2017, ARCH ORAL BIOL, V80, P117, DOI 10.1016/j.archoralbio.2017.03.024; Kristensen LS, 2014, ONCOTARGET, V5, P9798, DOI 10.18632/oncotarget.2394; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ostrom QT, 2013, NEUROONCOL S2, V15, piil; Quillien V, 2012, CANCER-AM CANCER SOC, V118, P4201, DOI 10.1002/cncr.27392; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Ronaghi M, 2001, GENOME RES, V11, P3, DOI 10.1101/gr.11.1.3; Shi J, 2012, AM J CANCER RES, V2, P116; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sugita H, 2011, ONCOL REP, V25, P513, DOI 10.3892/or.2010.1085; Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085; Turkalp Z, 2014, JAMA NEUROL, V71, P1319, DOI 10.1001/jamaneurol.2014.1205; Wang D, 2014, AM J CANCER RES, V4, P725; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wick W, 2014, NAT REV NEUROL, V10, P372, DOI 10.1038/nrneurol.2014.100; Wick W, 2012, LANCET ONCOL, V13, P707, DOI 10.1016/S1470-2045(12)70164-X; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Zhang LZ, 2014, J NEURO-ONCOL, V116, P349, DOI 10.1007/s11060-013-1301-5; Zhao J, 2015, J CLIN INVEST, V125, P2707, DOI 10.1172/JCI70805	36	0	0	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					940	948		10.1016/j.prp.2018.05.023			9	Pathology	Pathology	GN6YY	WOS:000439254000003	29807777				2019-10-28	
J	Val-Bernal, JF; Martino, M; Romay, F; Yllera, E				Val-Bernal, Jose-Fernando; Martino, Maria; Romay, Felix; Yllera, Elena			Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal metastases of clear cell renal cell carcinoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Bronchoscopy; Mediastinal lymph node; Renal cell carcinoma; Ultrasound-guided cytology	TUMORS; DISTINGUISH; RESECTION; SURVIVAL; CANCER	Evaluation of mediastinal lymphadenopathy in patients with a previous diagnosis of renal cell carcinoma (RCC) is critical for the determination of further treatment. A minimally invasive method of cytology sampling of mediastinal lymph nodes using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has emerged as a useful tool in diagnosis. Between January 2010 and April 2018, we performed 1744 EBUS-TBNA studies of mediastinal and hilar lymph nodes for a variety of clinical indications including mediastinal malignancy. Sixteen patients (93.7% males, mean age 59.1 years, range 44-81 years) were diagnosed by cytological and cell block study to have metastatic clear cell RCC. Twelve patients had been diagnosed with clear cell RCC in the past (mean 39 months, range 4-89 months) while in four, the tumor was primarily diagnosed in the staging phase on the basis of EBUS-TBNA. The EBUS features of the mediastinal nodal masses included increase of size (mean 2.5 cm, range 1.6-3.8 cm), irregular, inhomogeneous, hypervascular, and hyperechoic echotexture. EBUS-TBNA is a procedure safe and effective for evaluating mediastinal lymphadenopathy in patients with clear cell RCC. Immunohistochemistry in the cell block is decisive for proper diagnosis. The cytologist plays a key role in the diagnosis of metastatic clear cell RCC due to the treatment implications that this neoplasm encompasses.	[Val-Bernal, Jose-Fernando] Univ Cantabria, Med & Surg Sci Dept, Pathol Unit, Avda Cardenal Herrera Oria S-N, Santander 39011, Spain; [Val-Bernal, Jose-Fernando; Martino, Maria] IDIVAL Res Inst, Santander, Spain; [Martino, Maria] Univ Cantabria, Marques de Valdecilla Univ Hosp, Anat Pathol Serv, Santander, Spain; [Romay, Felix] Marques de Valdecilla Univ Hosp, Neumol Serv, Santander, Spain; [Yllera, Elena] Marques de Valdecilla Univ Hosp, Radiodiag Serv, Santander, Spain	Val-Bernal, JF (reprint author), Univ Cantabria, Med & Surg Sci Dept, Pathol Unit, Avda Cardenal Herrera Oria S-N, Santander 39011, Spain.	fernando.val@unican.es		MARTINO, MARIA/0000-0002-1751-5524			Asano F, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-50; Bianchi M, 2012, ANN ONCOL, V23, P973, DOI 10.1093/annonc/mdr362; Carvalho JC, 2012, HISTOPATHOLOGY, V60, P597, DOI 10.1111/j.1365-2559.2011.04093.x; Eapen GA, 2013, CHEST, V143, P1044, DOI 10.1378/chest.12-0350; Evison M, 2015, J BRONCHOL INTERN PU, V22, P55, DOI 10.1097/LBR.0000000000000124; Fritscher-Ravens A, 2000, ENDOSCOPY, V32, P531, DOI 10.1055/s-2000-3815; FUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655, DOI 10.1097/00000478-198210000-00007; Hoang LL, 2015, APPL IMMUNOHISTO M M, V23, P711, DOI 10.1097/PAI.0000000000000143; Jain D, 2018, ARCH PATHOL LAB MED, V142, P253, DOI 10.5858/arpa.2017-0114-SA; Jamil LH, 2014, DIGEST DIS SCI, V59, P2191, DOI 10.1007/s10620-014-3164-9; Kanzaki Ryu, 2009, Interact Cardiovasc Thorac Surg, V8, P485, DOI 10.1510/icvts.2008.191114; Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005; Mattana J, 1996, J MED, V27, P205; MERINE D, 1988, CT-J COMPUT TOMOGR, V12, P216, DOI 10.1016/0149-936X(88)90012-4; Miyazaki K, 2016, ONCOL LETT, V11, P1600, DOI 10.3892/ol.2016.4090; Moriyama S, 2016, INT J CLIN EXP MED, V9, P20345; Motzer RJ, 1996, NEW ENGL J MED, V335, P865, DOI 10.1056/NEJM199609193351207; Nakajima T, 2007, RESPIROLOGY, V12, P302, DOI 10.1111/j.1440-1843.2006.01023.x; Nappi O, 1997, SEMIN DIAGN PATHOL, V14, P164; Brufau BP, 2013, RADIOGRAPHICS, V33, P1691, DOI 10.1148/rg.336125110; Park J, 2011, J KOREAN MED SCI, V26, P274, DOI 10.3346/jkms.2011.26.2.274; Reuter VE, 2014, AM J SURG PATHOL, V38, pE35, DOI 10.1097/PAS.0000000000000258; Reznek Rodney H, 2004, Cancer Imaging, V4 Spec No A, pS25, DOI 10.1102/1470-7330.2004.0012; Rubin P., 2012, TNM STAGING ATLAS ON; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Takanami I, 1998, J THORAC CARDIOV SUR, V115, P1218, DOI 10.1016/S0022-5223(98)70426-X; Vermassen T, 2017, ACTA CLIN BELG, V72, P12, DOI 10.1080/17843286.2016.1193269; Whitson BA, 2008, J THORAC CARDIOV SUR, V135, P1022, DOI 10.1016/j.jtcvs.2007.12.016; Xu KY, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0030-7; Yamashita K, 2000, Jpn J Thorac Cardiovasc Surg, V48, P194; Zhou M, 2005, CLIN LAB MED, V25, P247, DOI 10.1016/j.cll.2005.01.004	31	1	1	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					949	956		10.1016/j.prp.2018.05.021			8	Pathology	Pathology	GN6YY	WOS:000439254000004	29807776	Green Accepted			2019-10-28	
J	Zhong, Q; Wagner, U; Kurt, H; Molinari, F; Cathomas, G; Komminoth, P; Barman-Aksozen, J; Schneider-Yin, X; Rey, JP; Vassella, E; Rogel, U; Diebold, J; Mckee, T; Jochum, W; Kashofer, K; Hofman, P; Zischka, M; Moch, H; Rechsteiner, M; Wild, PJ				Zhong, Qing; Wagner, Ulrich; Kurt, Henriette; Molinari, Francesca; Cathomas, Gieri; Komminoth, Paul; Barman-Aksozen, Jasmin; Schneider-Yin, Xiaoye; Rey, Jean-Philippe; Vassella, Erik; Rogel, Uwe; Diebold, Joachim; McKee, Thomas; Jochum, Wolfram; Kashofer, Karl; Hofman, Paul; Zischka, Melanie; Moch, Holger; Rechsteiner, Markus; Wild, Peter J.			Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Next Generation Sequencing; Proficiency Testing; Multi-Laboratory Test; Lung Cancer; Colon Cancer; Molecular Pathology	QUALITY; LUNG; ADENOCARCINOMA; VALIDATION; PATHOLOGY; MEDICINE; ONCOLOGY	Next-generation sequencing (NGS) enables parallel analysis of multiple genomic targets. The increasing demand for NGS-based multiplexed molecular diagnostics requires standardized protocols and recommendations to ensure reproducibility and accuracy of test results for routine clinical decision making. However, the lack of clinical NGS data from multi-laboratory tests and the absence of inter-laboratory comparisons have hampered the establishment of instructive clinical NGS standards. To fill the gap, we set up Proficiency Testing (PT) for inter-laboratory comparison, in which formalist-fixed paraffin-embedded specimens from eight lung and eight colon cancers were analyzed by 15 European molecular diagnostic laboratories on three different platforms using multiple target enrichment systems. We first performed platform, test, and informatics pipeline validation and conducted sensitivity and specificity analysis by random in silica down-sampling. We then implemented a multi-level filtering strategy based on performance tests of base substitution, replicate runs, and Sanger sequencing verified variants. We finally applied the filter criteria to the NGS data from the respective PT participants and obtained high inter-laboratory agreement. We demonstrated accuracy, scalability, and robustness of NGS by means of PT, serving as a benchmark for detecting clinically actionable molecular alterations in research and diagnostic laboratories. In conclusion, this study strongly highlights the importance of establishing standards for NGS-based testing, particularly when the test results impact on clinical decisions, and systematically provides data sets from multiple different labs to infer such standards.	[Zhong, Qing; Wagner, Ulrich; Moch, Holger; Rechsteiner, Markus; Wild, Peter J.] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Kurt, Henriette] Viollier AG, CH-4123 Allschwil, Switzerland; [Molinari, Francesca] Inst Pathol, CH-6600 Locarno, Switzerland; [Cathomas, Gieri] Hosp Baselland, Inst Pathol, CH-4410 Liestal, Switzerland; [Komminoth, Paul] Hosp Triernli, Inst Pathol, CH-8063 Zurich, Switzerland; [Barman-Aksozen, Jasmin; Schneider-Yin, Xiaoye] Hosp Triernli, Inst Lab Med, CH-8063 Zurich, Switzerland; [Rey, Jean-Philippe] Hosp Valais, Inst Pathol, CH-1951 Sion, Switzerland; [Vassella, Erik] Univ Bern, Inst Pathol, CH-3010 Bern, Switzerland; [Rogel, Uwe] Hosp Baden, Inst Pathol, CH-5404 Baden, Switzerland; [Diebold, Joachim] Hosp Luzern, Inst Pathol, CH-6000 Luzern, Switzerland; [McKee, Thomas] Univ Geneva, Inst Pathol, CH-1211 Geneva, Switzerland; [Jochum, Wolfram] Hosp St Gallen, Inst Pathol, CH-9007 St Gallen, Switzerland; [Kashofer, Karl] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria; [Hofman, Paul] Hosp Nice, Inst Pathol, F-91179 Nice, France; [Zischka, Melanie] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany; [Wild, Peter J.] Univ Hosp Frankfurt, Senckenberg Inst Pathol, D-60590 Frankfurt, Germany; [Zhong, Qing] Univ Sydney, Childrens Med Res Inst, Westmead, NSW 2145, Australia	Rechsteiner, M (reprint author), Univ Hosp Zurich, Dept Pathol & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.; Wild, PJ (reprint author), Univ Hosp Frankfurt, Senckenberg Inst Pathol, D-60590 Frankfurt, Germany.	markus.rechsteiner@usz.ch; peter.wild@kgu.de	Hofman, Paul/P-7654-2018	Hofman, Paul/0000-0003-0431-9353; McKee, Thomas/0000-0002-2147-3136; Zhong, Qing/0000-0002-5340-301X	University Hospital; Promedica foundation grant	This work was supported by an innovation pool grant provided by the University Hospital to P.J.W. Q.Z. was supported by a Promedica foundation grant to H.M. We thank Alexandra Veloudios, Annette Bohnert, Martina Storz, Susanne Dettwiler, Christiane Mittmann, Andre Fitsche, Norbert Wey, Andre Wethmar, and Monika Bieri, for their excellent technical assistance, and Peter Schraml, Tumor Tissue Bank of the University Hospital Zurich, for help with DNA preparation. Members of the Wild lab are thanked for helpful discussions.	Atreya CE, 2015, J CLIN ONCOL, V33, P682, DOI 10.1200/JCO.2014.58.9325; Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP; Davies KD, 2016, J MOL DIAGN, V18, P572, DOI 10.1016/j.jmoldx.2016.03.002; Duncavage EJ, 2016, ARCH PATHOL LAB MED, V140, P1085, DOI 10.5858/arpa.2016-0194-CP; Endris V, 2016, VIRCHOWS ARCH, V468, P697, DOI 10.1007/s00428-016-1919-8; Endrullat C, 2016, APPL TRANSL GENOM, V10, P2, DOI 10.1016/j.atg.2016.06.001; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; Garraway LA, 2013, J CLIN ONCOL, V31, P1803, DOI 10.1200/JCO.2013.49.4799; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Ivanov M, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1125-8; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Kerr KM, 2014, ANN ONCOL, V25, P1681, DOI 10.1093/annonc/mdu145; Kohlmann A., 2012, BLOOD, V120, P833; McDermott U, 2011, NEW ENGL J MED, V364, P340, DOI 10.1056/NEJMra0907178; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Muller CR, 2001, EUR J PEDIATR, V160, P464, DOI 10.1007/s004310100767; Rechsteiner M, 2013, J MOL DIAGN, V15, P299, DOI 10.1016/j.jmoldx.2013.02.001; Shao D, 2016, SCI REP-UK, V6, DOI 10.1038/srep22338; Shi CJ, 2012, AM J CLIN PATHOL, V137, P847, DOI 10.1309/AJCPI83DINULUJNI; Siu LL, 2015, CLIN CANCER RES, V21, P4536, DOI 10.1158/1078-0432.CCR-14-3215; Velizheva NP, 2017, CANCER CYTOPATHOL, V125, P30, DOI 10.1002/cncy.21771; Vrijenhoek T, 2015, EUR J HUM GENET, V23, P1270, DOI 10.1038/ejhg.2015.44	23	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					957	963		10.1016/j.prp.2018.05.020			7	Pathology	Pathology	GN6YY	WOS:000439254000005	29807778				2019-10-28	
J	Baek, JA; Song, PH; Ko, Y; Gu, MJ				Baek, Jin A.; Song, Phil Hyun; Ko, YoungHwii; Gu, Mi Jin			High expression of QSOX1 is associated with tumor invasiveness and high grades groups in prostate cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Immunohistochemistry; QSOX1; Prostate cancer	MOLECULAR BIOMARKERS; SULFHYDRYL OXIDASES; PROGNOSTIC-FACTORS; SURVIVAL; INVASION; LEADS	Prostate cancer is the most common malignancy in men, and biologically shows highly heterogeneous clinical outcomes, despite early detection. Therefore, the identification of novel molecular markers that are associated with biological aggressiveness is very important for prostatic cancer clinical outcome predictions and treatment choices. Here, we investigate quiescin sulfhydryl oxidase 1 (QSOX1) expression and evaluate its clinicopathological significance and prognostic impact in prostate cancers, with immunohistochemistry on tissue microarrays. QSOX1 over-expression was observed in 12 (11.2%) of prostate cancers. High QSOX1 expression significantly associated with prostate cancer with vascular invasion, neural invasion, extra prostatic extension, higher pT stage, higher pathological tumor stage, higher prognostic grouping, and higher grades groups, but did not associated with worse overall survival. High QSOX1 expression correlates with tumor invasiveness and Gleason grade, reflects aggressive tumor features, and could be an important biomarker and therapeutic target.	[Baek, Jin A.; Gu, Mi Jin] Yeungnam Univ, Coll Med, Dept Pathol, 170 Hyeonchung Ro, Daegu 42415, South Korea; [Song, Phil Hyun; Ko, YoungHwii] Yeungnam Univ, Coll Med, Dept Urol, Daegu 2415, South Korea	Gu, MJ (reprint author), Yeungnam Univ, Coll Med, Dept Pathol, 170 Hyeonchung Ro, Daegu 42415, South Korea.	mjgu@yu.ac.kr			Yeungnam University	This study was supported by a Yeungnam University Research Grant (2017).	Araujo DGB, 2014, EUR J HISTOCHEM, V58, P52, DOI 10.4081/ejh.2014.2228; Bostrom PJ, 2015, EUR UROL, V68, P1033, DOI 10.1016/j.eururo.2015.04.008; Bostwick DG, 2000, ARCH PATHOL LAB MED, V124, P995; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Grossman I, 2013, J MOL BIOL, V425, P4366, DOI 10.1016/j.jmb.2013.07.011; Hanavan PD, 2015, ONCOTARGET, V6, P18418, DOI 10.18632/oncotarget.4099; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Ilani T, 2013, SCIENCE, V341, P74, DOI 10.1126/science.1238279; Katchman BA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3407; Katchman BA, 2011, MOL CANCER RES, V9, P1621, DOI 10.1158/1541-7786.MCR-11-0018; Knntsvik G, 2016, MODERN PATHOL, V29, P1485, DOI 10.1038/modpathol.2016.148; Kretschmer A, 2017, UROLOGE, V56, P933, DOI 10.1007/s00120-017-0418-0; Kristiansen G, 2012, HISTOPATHOLOGY, V60, P125, DOI 10.1111/j.1365-2559.2011.04083.x; Lahdensuo K, 2016, MODERN PATHOL, V29, P1565, DOI 10.1038/modpathol.2016.154; Lake DF, 2014, ANTIOXID REDOX SIGN, V21, P485, DOI 10.1089/ars.2013.5572; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Pernodet N, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3341; Shah RB, 2009, ARCH PATHOL LAB MED, V133, P1810, DOI 10.1043/1543-2165-133.11.1810; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soloviev M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057327; Song H, 2009, ONCOGENE, V28, P3307, DOI 10.1038/onc.2009.181; Thorpe C, 2002, ARCH BIOCHEM BIOPHYS, V405, P1, DOI 10.1016/S0003-9861(02)00337-5	22	1	1	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					964	967		10.1016/j.prp.2018.05.019			4	Pathology	Pathology	GN6YY	WOS:000439254000006	29804717				2019-10-28	
J	Liu, ZX; Guan, CQ; Lu, CH; Liu, YM; Ni, RZ; Xiao, MB; Bian, ZL				Liu, Zhaoxiu; Guan, Chengqi; Lu, Cuihua; Liu, Yanmei; Ni, Runzhou; Xiao, Mingbing; Bian, Zhaolian			High NUSAP1 expression predicts poor prognosis in colon cancer	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Colon cancer; Immunohistochemistry; Nucleolar and spindle-associated protein 1; Prognosis	MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; COLORECTAL-CANCER; PROSTATE-CANCER; MICROTUBULES; OVEREXPRESSION; TARGET; RISK; E2F1	Background and aim: Nucleolar and spindle-associated protein 1 (NUSAP1) is an indispensable mitotic regulator. Aberrant NUSAP1 expression is associated with perturbed mitosis and tumorigenesis. In this study, we investigated the clinical significance of NUSAP1 expression in colon cancer. Methods and materials: Immunohistochemical staining was performed to determine NUSAP1 protein levels in paraffin colon tumor specimens. Real-time fluorescent quantitative polymerase chain reaction (RT-qPCR) was conducted to detect NUSAP1 mRNA levels in colon tumor samples. The association between NUSAP1 protein expression and clinicopathological characteristics of patients with colon cancer was assessed. A Kaplan-Meier analysis was performed to determine the prognostic significance of NUSAP1 in colon cancer. A Cox proportional hazards model was used to calculate univariate and multivariate hazard ratios for the NUSAP1 and other clinicopathological variables. Result NUSAP1 protein and mRNA levels were significantly higher in colon tumor tissues than in paired noncancerous adjacent tissues (P < 0.001, respectively). NUSAP1 protein expression was significantly correlated with histopathological grading (P < 0.001), depth of invasion (P = 0.001), lymph node metastasis (P < 0.001) and TNM stage (P < 0.001). The overall survival rate of patients with high NUSAP1 expression was significantly lower than for patients with low NUSAP1 expression (log-rank test, P < 0.001). A multivariate Cox model demonstrated that NUSAP1 is an independent risk factor for overall survival (P = 0.025). Conclusion: NUSAP1 is overexpressed in colon cancer and high expression of NUSAP1 acts as an independent predictive factor for poor prognosis in colon cancer.	[Liu, Zhaoxiu; Guan, Chengqi; Lu, Cuihua; Ni, Runzhou; Xiao, Mingbing] Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China; [Liu, Yanmei] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu 610000, Sichuan, Peoples R China; [Xiao, Mingbing] Nantong Univ, Affiliated Hosp, Res Ctr Clin Med, Nantong 226001, Jiangsu, Peoples R China; [Bian, Zhaolian] Nantong Univ, Affiliated Hosp 3, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China	Xiao, MB (reprint author), Nantong Univ, Affiliated Hosp, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.; Xiao, MB (reprint author), Nantong Univ, Affiliated Hosp, Res Ctr Clin Med, Nantong 226001, Jiangsu, Peoples R China.; Bian, ZL (reprint author), Nantong Univ, Affiliated Hosp 3, Dept Gastroenterol, Nantong 226001, Jiangsu, Peoples R China.	xmb73@163.com; bianzhaolian1998@163.com		ni, runzhou/0000-0001-8187-185X; Xiao, Mingbing/0000-0003-3372-1069	Health Project of Jiangsu Province [H201624]; Project of Jiangsu Province Youth Medical Talent Development [QNRC2016697]; Natural Youth Science Foundation of China [81502055]	This work was supported by the Health Project of Jiangsu Province [grant number H201624 to ZX.L.], the Project of Jiangsu Province Youth Medical Talent Development [grant number QNRC2016697 to ZX.L.], and the Natural Youth Science Foundation of China [grant number 81502055 to CQ.G.].	Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Cario G, 2008, ANN HEMATOL, V87, P709, DOI 10.1007/s00277-008-0504-x; Chen LW, 2015, PLOS ONE, V10; Fei WQ, 2016, AM J CANCER RES, V6, P2722; Gordon CA, 2017, ONCOTARGET, V8, P29935, DOI 10.18632/oncotarget.15604; Gordon CA, 2015, PROSTATE, V75, P517, DOI 10.1002/pros.22938; Gulzar ZG, 2013, ONCOGENE, V32, P70, DOI 10.1038/onc.2012.27; Hughes LAE, 2017, CURR COLORECT CANC R, V13, P455, DOI 10.1007/s11888-017-0395-0; Islami F, 2018, CA-CANCER J CLIN, V68, P31, DOI 10.3322/caac.21440; Iwamoto M, 2004, CANCER BIOL THER, V3, P395, DOI 10.4161/cbt.3.4.733; Iyer J, 2011, CELL SIGNAL, V23, P991, DOI 10.1016/j.cellsig.2010.11.006; Li CY, 2016, SCI REP-UK, V6, DOI 10.1038/srep18773; Li L, 2007, CELL SIGNAL, V19, P2046, DOI 10.1016/j.cellsig.2007.05.017; Lopes-Ramos C. M., PLOS ONE, V12; Marie SKN, 2008, INT J CANCER, V122, P807, DOI 10.1002/ijc.23189; Muller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3; Ogino S, 2018, GUT; Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182; Okamoto A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142252; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Recchia FM, 2010, INVEST OPHTH VIS SCI, V51, P1098, DOI 10.1167/iovs.09-4006; Ribbeck K, 2007, CURR BIOL, V17, P230, DOI 10.1016/j.cub.2006.11.050; Ribbeck K, 2006, MOL BIOL CELL, V17, P2646, DOI 10.1091/mbc.E05-12-1178; Satow R, 2010, CLIN CANCER RES, V16, P2518, DOI 10.1158/1078-0432.CCR-09-2214; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Sipos F, 2016, WORLD J GASTROENTERO, V22, P7938, DOI 10.3748/wjg.v22.i35.7938; Sobin LH, 2010, CANCER-AM CANCER SOC, V116, P5336, DOI 10.1002/cncr.25537; Vanden Bosch A, 2010, J CELL SCI, V123, P3244, DOI 10.1242/jcs.063875; Wadia PP, 2010, BLOOD, V115, P2077, DOI 10.1182/blood-2009-03-211375; Wu XQ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0597-y; Yang ZX, 2017, CHINESE J CANCER RES, V29, P385, DOI 10.21147/j.issn.1000-9604.2017.05.02	32	2	3	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					968	973		10.1016/j.prp.2018.05.017			6	Pathology	Pathology	GN6YY	WOS:000439254000007	29853313				2019-10-28	
J	Diao, YG; Zhang, P; Dai, RH; Xu, JF; Feng, HL				Diao, Yugiao; Zhang, Ping; Dai, Ruoheng; Xu, Jianfa; Feng, Helin			H3K27me3 and VEGF is associated with poor prognosis in patients with synovial sarcoma	PATHOLOGY RESEARCH AND PRACTICE			English	Article						H3K27me3; VEGF; Synovial sarcoma; Prognostic indicator	EXPRESSION	Purpose: Previous studies have shown a correlation between the expression of H3K27me3 and pathological characteristics of malignant tumors. This study aimed to investigate the association of H3K27me3 and VEGF expression with clinical outcomes of synovial sarcoma patients. Methods: This study included 48 patients with synovial sarcoma. H3K27me3 and VEGF levels were evaluated by immunohistochemical staining, and their correlation with clinical parameters was analyzed by Spearman's and Pearson's test. Univariate and multivariate Cox regression analyses were used to identify potential prognostic factors. Kaplan-Meier method was used to analyze overall survival. Results: Protein levels of both H3K27me3 and VEGF were significantly associated with histologic grade (P = 0.004, P = 0.042, respectively), metastasis (P = 0.009, P = 0.028, respectively), and AJCC staging (P < 0.001, P = 0.003, respectively). H3K27me3 and VEGF expression showed positive correlation (P < 0.001, R = 0.618). Both H3K27me3 and VEGF expression were significantly associated with shorter overall survival by univariate analysis, but the association was significant for H3K27me3 [P = 0.26, HR = 2.640 (1.124-6.200)] only by multivariate analysis. Conclusions: H3K27me3 and VEGF expression are both significantly associated with overall survival of synovial sarcoma, and H3K27me3 is a significant independent prognostic indicator in patients with synovial sarcoma.	[Diao, Yugiao; Dai, Ruoheng] Hebei Med Univ, Hosp 4, Dept Pediat, 12 Hlth Rd, Shijiazhuang 050011, Hebei, Peoples R China; [Zhang, Ping] Tianjin 5th Ctr Hosp, Dept Hematol Oncol, Tianjin 300450, Peoples R China; [Xu, Jianfa; Feng, Helin] Hebei Med Univ, Hosp 4, Dept Orthoped, 12 Hlth Rd, Shijiazhuang 050011, Hebei, Peoples R China	Feng, HL (reprint author), Hebei Med Univ, Hosp 4, Dept Orthoped, 12 Hlth Rd, Shijiazhuang 050011, Hebei, Peoples R China.	helinfeng0311@163.com					Bianchi G, 2017, EJSO-EUR J SURG ONC, V43, P1733, DOI 10.1016/j.ejso.2017.05.020; Bonvini P, 2013, BRIT J CANCER, V109, P3084, DOI 10.1038/bjc.2013.653; Huang CC, 2014, DIAGN CYTOPATHOL, V42, P170, DOI 10.1002/dc.22912; Iqbal N, 2016, CLIN TRANSL ONCOL, V18, P310, DOI 10.1007/s12094-015-1369-9; Jiang D., 2017, VIRCHOWS ARCH; Kakkar A, 2016, APPL IMMUNOHISTO M M, V24, P729, DOI 10.1097/PAI.0000000000000247; Karamchandani DM, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0473-7; Kunisada M, 2017, J INVEST DERMATOL, V137, P1975, DOI 10.1016/j.jid.2017.04.034; Liu QY, 2017, CANCER LETT, V403, P165, DOI 10.1016/j.canlet.2017.06.017; Mentzel T., 2017, VIRCHOWS ARCH; Rapp J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2943-4; Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236; Sharma V, 2017, CARCINOGENESIS, V38, P152, DOI 10.1093/carcin/bgw126; Tao J., 2017, J CANC RES CLIN ONCO; Thou Y., 2017, ONCOL REP, V37, P3351; Vig T., 2018, J STOMATOL ORAL MAXI; Zhuang M, 2017, J BUON, V22, P714	17	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					974	977		10.1016/j.prp.2018.05.015			4	Pathology	Pathology	GN6YY	WOS:000439254000008	29803658				2019-10-28	
J	Toth, L; Nagy, B; Mehes, G; Laszlo, E; Molnar, PP; Poka, R; Hernadi, Z				Toth, Laszlo; Nagy, Bence; Mehes, Gabor; Laszlo, Eszter; Molnar, Peter Pal; Poka, Robert; Hernadi, Zoltan			Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Ovarian cancer; Ascites; E-cadherin- beta-catenin; Proliferative activity; Cytology microarray (CMA)	E-CADHERIN; HIGH-THROUGHPUT; BETA-CATENIN; CANDIDATE BIOMARKERS; SEROUS CARCINOMAS; LOW-GRADE; TECHNOLOGY; TUMORS; VALIDATION; EFFUSIONS	Introduction: Peritoneal dissemination accompanied by ascites formation is common in epithelial ovarian cancer (EOC). Adhesion molecules are crucial in metastatic spread and the latter involves epithelial-mesenchymal transition (EMT). This study aimed at: (1) clarifying whether E-cadherin and beta-catenin expression and proliferative activity in metastatic ovarian cancer are inter-related; (2) Identifying possible correlations between cell adhesion molecular expression profiles, the proliferative activity and p53 expression of tumor cells and tumor grade and stage; (3) testing the cytology microarray (CMA) technique in analyzing metastasis formation. Material and methods: Both tumorous and ascitic samples from 27 EOC patients were examined by using tissue microarray (TMA) and cytology microarray (CMA), respectively. CMA blocks were constructed using cores from each cell block of the ascitic specimens. Expression of E-cadherin, beta-catenin, Ki-67 and p53 was immunohistochemically detected both in TMA and CMA blocks. Results: E-cadherin expression was higher in ascitic cells than in primary tumor cells (p = .294). beta-catenin expression was significantly lower in ascitic cells than in primary tumor cells (p = .006). Expression of Ki-67 was lower and expression of p53 was higher in primary tumors than in ascitic cells, for p53 the difference was significant (p = .001). Both Ki-67 and p53 expression elevated significantly in high-grade primary tumor cells and in ascites cells (p = .039, and p = .004, respectively). Conclusion: Epithelial-mesenchymal transition- mesenchymal-epithelial transition is suggested as the best descriptive term for our IHC observations which accompany increased proliferative activity of ascitic cells. The CMA method is an adequate and reliable method for the analysis of ascitic tumor cells disseminating from ovarian malignancies.	[Toth, Laszlo; Mehes, Gabor; Molnar, Peter Pal] Univ Debrecen, Clin Ctr, Dept Pathol, Debrecen, Hungary; [Nagy, Bence] Univ Szeged, Dept Pathol, Szeged, Hungary; [Laszlo, Eszter] Univ Debrecen, Dept Med Imaging, Debrecen, Hungary; [Poka, Robert; Hernadi, Zoltan] Univ Debrecen, Clin Ctr, Dept Obstet & Gynecol, Debrecen, Hungary	Toth, L (reprint author), Univ Debrecen, Dept Pathol, Nagyerdei St 98, H-4032 Debrecen, Hungary.	tothlasz@med.unideb.hu		Poka, Robert/0000-0003-1836-1579			Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Bar JK, 2004, GYNECOL ONCOL, V95, P23, DOI 10.1016/j.ygyno.2004.06.046; Bar JK, 2001, TUMOR BIOL, V22, P83, DOI 10.1159/000050601; BATTIFORA H, 1986, LAB INVEST, V55, P244; Bubendorf L, 2006, ACTA CYTOL, V50, P121, DOI 10.1159/000325918; Cardano M, 2013, J HISTOCHEM CYTOCHEM, V61, P116, DOI 10.1369/0022155412470455; Daidone MG, 1996, EUR J CANCER, V32A, P1388, DOI 10.1016/0959-8049(96)00101-3; Davidson B, 2000, J PATHOL, V192, P460; Egervari K, 2007, PATHOL RES PRACT, V203, P169, DOI 10.1016/j.prp.2006.12.004; El Hag MI, 2016, DIAGN CYTOPATHOL, V44, P731, DOI 10.1002/dc.23521; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoos A, 2001, AM J PATHOL, V158, P1245, DOI 10.1016/S0002-9440(10)64075-8; Hu Q, 2015, CYTOPATHOLOGY, V26, P44, DOI 10.1111/cyt.12138; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kildal W, 2005, EUR J CANCER, V41, P1127, DOI 10.1016/j.ejca.2005.01.022; Kim G, 2012, CANCER-AM CANCER SOC, V118, P1543, DOI 10.1002/cncr.26449; Kim MS, 2012, J PROTEOME RES, V11, P5556, DOI 10.1021/pr300483r; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Li LN, 2015, PHARMACOL THERAPEUT, V150, P33, DOI 10.1016/j.pharmthera.2015.01.004; Mishra SK, 2010, INT J GYNECOL CANCER, V20, P537, DOI 10.1111/IGC.0b013e3181d6de3f; Moskaluk CA, 2002, DIAGN MOL PATHOL, V11, P234, DOI 10.1097/00019606-200212000-00007; Nagy B, 2017, PATHOL RES PRACT, V213, P915, DOI 10.1016/j.prp.2017.05.011; O'Neill CJ, 2005, AM J SURG PATHOL, V29, P1034; Paget S.J.T.L., 1889, LANCET, V133, P571, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Pu RT, 2008, CANCER CYTOPATHOL, V114, P300, DOI 10.1002/cncr.23797; Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265; Reid BM, 2017, CANCER BIOL MED, V14, P9, DOI 10.20892/j.issn.2095-3941.2016.0084; Rosso M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184439; Sapino A, 2006, VIRCHOWS ARCH, V449, P288, DOI 10.1007/s00428-006-0233-2; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1605::AID-CNCR28>3.0.CO;2-2; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soltermann Alex, 2011, J Clin Bioinforma, V1, P25, DOI 10.1186/2043-9113-1-25; Steinestel K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-17; Sun F, 2017, ONCOL LETT, V14, P6991, DOI 10.3892/ol.2017.7149; Sundov D, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-21; Tewari KS, 2000, GYNECOL ONCOL, V78, P130, DOI 10.1006/gyno.2000.5837; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; VEATCH AL, 1994, INT J CANCER, V58, P393, DOI 10.1002/ijc.2910580315; Waterworth A, 2005, IN VITRO CELL DEV-AN, V41, P185; Wen CH, 2007, ACTA CYTOL, V51, P42, DOI 10.1159/000325681; Worzfeld T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00024; Wu D, 2016, ONCOL LETT, V11, P1463, DOI 10.3892/ol.2016.4092; Wu XY, 2014, CANCER BIOL THER, V15, P1593, DOI 10.4161/15384047.2014.961886	47	1	2	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					978	985		10.1016/j.prp.2018.05.014			8	Pathology	Pathology	GN6YY	WOS:000439254000009	29801775				2019-10-28	
J	Kinra, P; Gahlot, GPS; Yadav, R; Baloda, V; Makharia, GK; Gupta, SD; Das, P				Kinra, Prateek; Gahlot, Gaurav P. S.; Yadav, Rajni; Baloda, Vandana; Makharia, Govind K.; Gupta, Siddhartha Datta; Das, Prasenjit			Histological assessment & use of immunohistochemical markers for detection of dysplasia in Barrett's esophageal mucosa	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Barrett; Esophagus; Dysplasia; Histology; Immunohistochemistry; Agreement	HIGH-GRADE DYSPLASIA; P53 PROTEIN OVEREXPRESSION; FOLLOW-UP; VIENNA CLASSIFICATION; DISEASE PROGRESSION; CYCLIN D1; ADENOCARCINOMA; EXPRESSION; DIAGNOSIS; SURVEILLANCE	Background: Histological assessment of dysplasia in Barrett's esophagus (BE) has high inter-observer variability. Hence, use of ancillary markers for early detection of dysplasia in BE is an important clinical question. Methods: In this retrospective study consecutive cases of BE (n = 59), over a period of 4 years were included. Hematoxylin and eosin stained sections were reviewed independently by 3 senior qualified pathologists, who graded the dysplasia according to the Vienna Classification system and inter-observer agreement was analysed using the Kappa statistics. Subsequently Alpha-Methyl Acyl-CoA Racemase (AMACR), p53, CyclinD1, beta-catenin, H2AX and M30 immunohistochemical (IHC) stains were examined on the following disease categories: BE with no dysplasia [NFD] (45), BE with indefinite for dysplasia (IFD) (4), low grade dysplasia (LGD) (3), high grade dysplasia (HGD) (2) and in adenocarcinomas (5). H score was calculated by adding up products of different grades of stain distribution and stain intensities (range of scores 0-300). Results: Among the 3 pathologists, overall agreement was poor (k 0.06; 95% CI -0.089 to 0.145), with highest disagreement noted for differentiating the LGD and IFDs (k = 0.21). After revising the histological criteria, the kappa improved to 0.53. Among the IHC stains performed, p53, beta-catenin, H2AX and M30 stains were significantly useful to differentiate between IFD and LGD (P values: 0.04, 0.004, 0.05 & 0.04, respectively). AMACR and beta-catenin stains though were up-regulated in HGD/adenocarcinomas than in other categories, their expression were not statistically different between the IFD and LGDs. Conclusions: A detail histological scoring system may bring uniformity in histological interpretation of dysplasia in BE. Using a combined panel of IHC stains seems helpful in detection of dysplasia in BE, especially to differentiate the IFD and LGD changes in BE.	[Kinra, Prateek; Gahlot, Gaurav P. S.; Yadav, Rajni; Baloda, Vandana; Makharia, Govind K.; Gupta, Siddhartha Datta; Das, Prasenjit] All India Inst Med Sci, Dept Pathol & Gastroenterol & Human Nutr, New Delhi, India	Das, P (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	prasenjitdaspath@aiims.ac.in		Makharia, Govind K/0000-0002-2474-2194; Gahlot, Gaurav/0000-0003-4313-8977; kinra, prateek/0000-0002-2412-074X			Ausch C, 2009, EJSO-EUR J SURG ONC, V35, P1164, DOI 10.1016/j.ejso.2009.02.007; Bailey T, 1998, AM J PATHOL, V152, P135; Bani-Hani K, 2000, J NATL CANCER I, V92, P1316, DOI 10.1093/jnci/92.16.1316; BLOUNT PL, 1991, CANCER RES, V51, P5482; BURKE AP, 1991, MODERN PATHOL, V4, P336; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Buttar NS, 2001, GASTROENTEROLOGY, V120, P1630, DOI 10.1053/gast.2001.25111; Cameron AJ, 1997, AM J GASTROENTEROL, V92, P586; CASSON AG, 1991, CANCER RES, V51, P4495; Chatelain D, 2003, VIRCHOWS ARCH, V442, P18, DOI 10.1007/s00428-002-0674-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Conio M, 2003, AM J GASTROENTEROL, V98, P1931, DOI 10.1016/S0002-9270(03)00629-4; Corley DA, 2002, GASTROENTEROLOGY, V122, P633, DOI 10.1053/gast.2002.31879; Das P, 2016, DIGEST LIVER DIS, V48, P1290, DOI 10.1016/j.dld.2016.06.013; Dorer R, 2006, AM J SURG PATHOL, V30, P871, DOI 10.1097/01.pas.0000213268.30468.b4; Hage M, 2004, SCAND J GASTROENTERO, V39, P1175, DOI 10.1080/00365520410003524; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HAMILTON SR, 1987, AM J CLIN PATHOL, V87, P301, DOI 10.1093/ajcp/87.3.301; Izzo JG, 2007, J CLIN ONCOL, V25, P698, DOI 10.1200/JCO.2006.08.0283; Kaye PV, 2009, HISTOPATHOLOGY, V54, P699, DOI 10.1111/j.1365-2559.2009.03288.x; Kerkhof M, 2007, HISTOPATHOLOGY, V50, P920, DOI 10.1111/j.1365-2559.2007.02706.x; KRISHNADATH KK, 1995, J PATHOL, V175, P175, DOI 10.1002/path.1711750204; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ma M, 2017, DIS ESOPHAGUS, V30, DOI 10.1093/dote/dow025; Montgomery E, 2001, HUM PATHOL, V32, P379, DOI 10.1053/hupa.2001.23511; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Odze RD, 2006, J CLIN PATHOL, V59, P1029, DOI 10.1136/jcp.2005.035337; RAMEL S, 1992, GASTROENTEROLOGY, V102, P1220; Raynaud CM, 2008, ANN ONCOL, V19, P1875, DOI 10.1093/annonc/mdn405; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Scheil-Bertram S, 2008, MODERN PATHOL, V21, P961, DOI 10.1038/modpathol.2008.73; Schlemper RJ, 2000, GUT, V47, P251, DOI 10.1136/gut.47.2.251; Shi XY, 2008, APPL IMMUNOHISTO M M, V16, P447, DOI 10.1097/PAI.0b013e318168598b; Sikkema M, 2009, AM J GASTROENTEROL, V104, P2673, DOI 10.1038/ajg.2009.437; Skacel M, 2002, AM J GASTROENTEROL, V97, P2508; Spechler SJ, 2011, GASTROENTEROLOGY, V140, P1084, DOI 10.1053/j.gastro.2011.01.030; van Dekken H, 2001, BARRETT'S ESOPHAGUS, P159; van Dekken H, 2008, AM J CLIN PATHOL, V130, P745, DOI 10.1309/AJCPO31THGVEUIDH; Wang KK, 2008, AM J GASTROENTEROL, V103, P788, DOI 10.1111/j.1572-0241.2008.01835.x; Washington K, 1998, MODERN PATHOL, V11, P805; Weston AP, 2001, AM J GASTROENTEROL, V96, P1355, DOI 10.1111/j.1572-0241.2001.03851.x; Whittles CE, 1999, J PATHOL, V187, P535, DOI 10.1002/(SICI)1096-9896(199904)187:5<535::AID-PATH302>3.0.CO;2-G; Yousef F, 2008, AM J EPIDEMIOL, V168, P237, DOI 10.1093/aje/kwn121	45	0	0	0	2	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					993	999		10.1016/j.prp.2018.05.006			7	Pathology	Pathology	GN6YY	WOS:000439254000011	29764708				2019-10-28	
J	Zayed, H; Petersen, I				Zayed, Heba; Petersen, Iver			Stem cell transcription factor SOX2 in synovial sarcoma and other soft tissue tumors	PATHOLOGY RESEARCH AND PRACTICE			English	Article						SOX2; H3K27me3; Synovial sarcoma; Soft tissue tumors	CANCER DEVELOPMENT; LUNG-CANCER; EXPRESSION; CARCINOMA; PATTERNS; GENE; ADENOCARCINOMA; IDENTIFICATION; PROGRESSION; COMPLEXES	Background: SOX2 has gained considerable interest as a pluripotency inducing gene. Co-transfection of SOX2 together with NANOG, KLF4 and c-MYC into adult fibroblasts was able to generate pluripotent stem cells. SOX2 has been reported to be expressed in synovial sarcoma, a tumor being characterized by the SS18-SSX gene fusion forming part of the SWI/SNF chromatin remodeling complex that affects histone methylation. The role of SOX2 in this tumor type as well as other soft tissue tumor entities however is still poorly characterized. We analyzed SOX2 protein expression in soft tissue tumors. Alongside we tested Histone H3 expression (H3K27me3) in SOX2 positive cases to investigate this epigenetic mark and its correlation with the SOX2 status and clinicopathological parameters. Methodology: In total, 60 samples of synovial sarcomas from the reference center for soft tissue tumors at the institute of pathology of the Jena University hospital were included into the study along with 343 other tissue tumors. Protein analysis was done by immunohistochemistry of tissue microarrays. All synovial sarcoma cases were confirmed by molecular testing using SS18 FISH break apart probes. Results: SOX2 reactivity was detectable in 35 synovial sarcoma cases (58.3%) while 25 (41.7%) were negative. Only 13 cases of the other 343 soft tissue tumors, varying from nodular fasciitis to undifferentiated pleomorphic sarcoma, revealed a SOX2 expression, 12 out of these were undifferentiated high grade sarcoma. There was no obvious correlation with the clinicopathological data. H3K27me3 immunohistochemistry of the synovial sarcoma cases revealed a high statistically significant correlation between SOX2 and H3K27me3 expression (p < 0,0005, Chi square test). Similar to SOX2, there was no correlation between H3K27me3 expression and tumor grade. Six SOX2 positive synovial sarcoma cases were analyzed by FISH using a SOX2/CEN3 dual color FISH probe. None of these cases revealed an amplification of the SOX2 gene. Conclusion: The data confirms previous studies reporting SOX2 and H3K27me3 expression in synovial sarcoma and reveals that both biomarkers are related to each other. It strengthens the notion that the tumor type is driven by epigenetic processes similar to those that are operating in pluripotent stem cells. The relevance of these parameters in the pathway pathology of synovial sarcoma, i.e. the timing and dosing of SOX2 and H3K27me3 expression initiated by the SS18-SSX driver mutation together with the interplay of these events with other signaling pathways, cellular mechanisms and additional mutations in tumor progression, will require further studies.	[Zayed, Heba; Petersen, Iver] Jena Univ Hosp, Inst Pathol, Jena, Germany; [Zayed, Heba] Cairo Univ, Natl Canc Inst, Cairo, Egypt	Petersen, I (reprint author), SRH Wald Klinikum Gera, Inst Pathol, Str Friedens 122, D-07548 Gera, Germany.	iver.petersen@gmail.com					Amary M. F., 2018, MODERN PATHOL, V20, P482; Bae WK, 2015, MOL CARCINOGEN, V54, P1172, DOI 10.1002/mc.22188; Banito A., 2018, CANCER CELL, DOI [10.1016/j.cce11.2018.01.018pii:S1535-6108(18)30018-7, DOI 10.1016/J.CCE11.2018.01.018PII:S1535-6108(18)30018-7]; Benard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108265; Bergh P., 2018, CANCER, V85, P2596; Biermann Katharina, 2007, Cancer Genomics & Proteomics, V4, P359; Bockmuhl U, 1996, CANCER RES, V56, P5325; Cao SG, 2015, CHINESE MED J-PEKING, V128, P384, DOI 10.4103/0366-6999.150112; Chan JA, 2003, HISTOPATHOLOGY, V43, P72, DOI 10.1046/j.1365-2559.2003.01643.x; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Changchien YC, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-216; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chen S, 2014, CARCINOGENESIS, V35, P613, DOI 10.1093/carcin/bgt371; Chen SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036784; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; de Necochea-Campion R, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0083-x; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; FETSCH JF, 1993, CANCER, V72, P469, DOI 10.1002/1097-0142(19930715)72:2<469::AID-CNCR2820720224>3.0.CO;2-Q; Fisher C, 2004, HISTOPATHOLOGY, V45, P245, DOI 10.1111/j.1365-2559.2004.01950.x; Fletcher C, 2013, WHO CLASSIFICATION T; Garcia CB, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-189; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Gutierrez-Aranda I, 2010, STEM CELLS, V28, P1568, DOI 10.1002/stem.471; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Janssen EAM, 2003, J PATHOL, V201, P555, DOI 10.1002/path.1475; Kadoch C, 2016, BIOCHEMISTRY-US, V55, P1600, DOI 10.1021/acs.biochem.5b01191; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Karachaliou N, 2013, TRANSL LUNG CANCER R, V2, P172, DOI 10.3978/j.issn.2218-6751.2013.01.01; Katenkamp K, 2005, PATHOLOGE, V26, P111, DOI 10.1007/s00292-004-0741-2; Kim BR, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002581; Kimura T, 2016, ONCOGENE, V35, P3932, DOI 10.1038/onc.2015.461; Knosel T, 2010, EUR J CANCER, V46, P1170, DOI 10.1016/j.ejca.2010.01.032; Koelsche C, 2018, MODERN PATHOL, V31, P1246, DOI 10.1038/s41379-018-0045-3; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kristensen DG, 2012, CANCER GENET-NY, V205, P425, DOI 10.1016/j.cancergen.2012.05.003; Kushwaha R, 2016, STEM CELL REP, V6, P772, DOI 10.1016/j.stemcr.2016.04.002; Lagarde P, 2013, J CLIN ONCOL, V31, P608, DOI 10.1200/JCO.2012.46.0147; Lehnhardt M, 2009, CHIRURG, V80, P341, DOI 10.1007/s00104-008-1562-2; Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42; Lewis JJ, 2000, J CLIN ONCOL, V18, P2087, DOI 10.1200/JCO.2000.18.10.2087; Lu YJ, 1999, J PATHOL, V187, P490, DOI 10.1002/(SICI)1096-9896(199903)187:4<490::AID-PATH274>3.0.CO;2-X; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022; MAGNUSON T, 1982, NATURE, V298, P750, DOI 10.1038/298750a0; MILLS SE, 1995, MODERN PATHOL, V8, P347; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Neumann J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-518; Nielsen TO, 2015, CANCER DISCOV, V5, P124, DOI 10.1158/2159-8290.CD-14-1246; Ohnishi K, 2014, CELL, V156, P663, DOI 10.1016/j.cell.2014.01.005; Okita K, 2011, PHILOS T R SOC B, V366, P2198, DOI 10.1098/rstb.2011.0016; Pelmus M, 2002, AM J SURG PATHOL, V26, P1434, DOI 10.1097/00000478-200211000-00005; Pen AE, 2017, ACTA NEUROL SCAND, V135, P57, DOI 10.1111/ane.12545; Petersen I, 2018, TRAUMA BERUFSKRANKH, V20, P25, DOI 10.1007/s10039-017-0339-6; Petersen I, 2011, PATHOLOGE, V32, P40, DOI 10.1007/s00292-010-1399-6; Petersen I, 1997, CANCER RES, V57, P2331; Rizzino A, 2009, WIRES SYST BIOL MED, V1, P228, DOI 10.1002/wsbm.12; ROTH JA, 1975, CANCER, V35, P1243, DOI 10.1002/1097-0142(197504)35:4<1243::AID-CNCR2820350432>3.0.CO;2-A; Rothenberg SM, 2015, ELIFE, V4, DOI 10.7554/eLife.06132; Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405; Ruping K, 2014, J CANCER RES CLIN, V140, P1315, DOI 10.1007/s00432-014-1700-9; Sanada Y, 2006, PANCREAS, V32, P164, DOI 10.1097/01.mpa.0000202947.80117.a0; Sandberg AA, 2002, CANCER GENET CYTOGEN, V133, P1, DOI 10.1016/S0165-4608(01)00626-4; SHMOOKLER BM, 1982, CANCER, V50, P269, DOI 10.1002/1097-0142(19820715)50:2<269::AID-CNCR2820500217>3.0.CO;2-7; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Sun C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0503-1; Surface LE, 2010, CELL STEM CELL, V7, P288, DOI 10.1016/j.stem.2010.08.004; Suster S, 2005, AM J SURG PATHOL, V29, P569, DOI 10.1097/01.pas.0000157934.50936.3e; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tsukamoto T, 2005, HISTOPATHOLOGY, V46, P649, DOI 10.1111/j.1365-2559.2005.02170.x; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Zollner S, 2015, CANCER METAST REV, V34, P417, DOI 10.1007/s10555-015-9575-z; Zullig L, 2013, EUR J CANCER, V49, P1915, DOI 10.1016/j.ejca.2013.01.005	74	2	2	0	0	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1000	1007		10.1016/j.prp.2018.05.004			8	Pathology	Pathology	GN6YY	WOS:000439254000012	29773426				2019-10-28	
J	Yang, GS; Zhou, XY; An, XF; Liu, XJ; Zhang, YJ; Yu, D				Yang, Guo-shuai; Zhou, Xiao-yan; An, Xue-Fang; Liu, Xuan-Jun; Zhang, Yan-Jun; Yu, Dan			Mild hypothermia inhibits the Notch 3 and Notch 4 activation and seizure after stroke in the rat model	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Mild hypothermia; Notch3; Notch4; Seizures; Stroke	NF-KAPPA-B; STATUS EPILEPTICUS; POSTISCHEMIC SEIZURES; BRAIN; EXPRESSION; EPILEPSY; MALFORMATIONS; NEUROGENESIS; TRANSPORTER; PILOCARPINE	Ischemic brain injury is an important cause for seizure. Mild hypothermia of the brain or the whole body is an effective way to remit the post-stroke seizure. Our previous study revealed an implication of Notch 1 and 2 in the post-stroke seizure. This study further investigated the involvement of Notch 3 and 4 in post-stroke seizure and the effect of mild hypothermia on these two factors. A global cerebral ischemia (GCI) model was conducted in Sprague Dawley rats. Seizure activity was evaluated by the frequency of seizure attacks, seizure severity scores, and seizure discharges. Seizures were frequently occurred in the first and the second 24 h after GCI, however active whole-body cooling (mild hypothermia) and DAPT (Notch inhibitor) injection into the hippocampus, alone or in combination, alleviated seizure activity after GCI. Immunohistochemistry and Western blot assays revealed the up-regulation of Notch intracellular domain (NICD) 3 and 4 in the cerebral cortex and hippocampus following GCI, but mild hypothermia and DAPT inhibited the up-regulation of NICD 3 and 4. NF-kappa B, PPAR alpha, PPAR gamma, cyclin Dl, Sox2 and Pax6 are associated with the pathogenesis of diverse type of seizures. GCI induced NF-kappa B, cyclin Dl, and Pax6 activity, but suppressed PPAR gamma. These effects of GCI were abolished by both mild hypothermia and DAPT treatment. This indicated the implication of Notch signaling in the effects of GCI. Collectively, mild hypothermia inhibits Notch 3 and Notch 4 activation and seizure after stroke in the rat model. This study adds to the further understanding of the pathogenesis of post-stroke seizures and the protective mechanism of mild hypothermia.	[Yang, Guo-shuai; Zhou, Xiao-yan; An, Xue-Fang; Liu, Xuan-Jun; Zhang, Yan-Jun; Yu, Dan] Cent S Univ, Xiangya Sch Med, Affiliated Haikou Hosp, Dept Neurol, Haikou 570208, Hainan, Peoples R China	Yang, GS (reprint author), Cent S Univ, Xiangya Sch Med, Affiliated Haikou Hosp, Dept Neurol, Haikou 570208, Hainan, Peoples R China.	ygs_hk@163.com			Key Program of Science and Techonogy Planning of Haikou [2014-73]; Hainan Provincial Natural Science Foundation [20158272]	This work was supported by the Key Program of Science and Techonogy Planning of Haikou (No.2014-73) and Hainan Provincial Natural Science Foundation (No.20158272).	Buczek J, 2016, NEUROL NEUROCHIR POL, V50, P262, DOI 10.1016/j.pjnns.2016.04.008; Cao L, 2015, CELL PHYSIOL BIOCHEM, V35, P1633, DOI 10.1159/000373977; Ching J, 2015, ONCOTARGET, V6, P21301, DOI 10.18632/oncotarget.4019; de Assis TMR, 2015, ARQ NEURO-PSIQUIAT, V73, P510, DOI 10.1590/0004-282X20150043; Delev D, 2017, J NEUROSURG, V126, P1552, DOI 10.3171/2016.3.JNS151731; Fu CY, 2015, CELL PHYSIOL BIOCHEM, V37, P2023, DOI 10.1159/000438562; Grabenstatter HL, 2014, NEUROBIOL DIS, V62, P73, DOI 10.1016/j.nbd.2013.09.003; Harbert MJ, 2011, J CHILD NEUROL, V26, P1126, DOI 10.1177/0883073811408092; Hill-Felberg S, 2015, J CELL MOL MED, V19, P1986, DOI 10.1111/jcmm.12580; Jacobs S, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003311.PUB2; Jung DE, 2015, PEDIATR NEUROL, V53, P135, DOI 10.1016/j.pediatrneurol.2015.04.009; KAWAI K, 1992, J CEREBR BLOOD F MET, V12, P238, DOI 10.1038/jcbfm.1992.34; Kim KC, 2014, MOL NEUROBIOL, V49, P512, DOI 10.1007/s12035-013-8535-2; Koeller HB, 2008, NEUROBIOL DIS, V31, P230, DOI 10.1016/j.nbd.2008.04.010; Li ZX, 2016, TRANSL STROKE RES, V7, P132, DOI 10.1007/s12975-015-0441-7; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Marathe S, 2015, CELL DEATH DIFFER, V22, P1775, DOI 10.1038/cdd.2015.23; Payandemehr B, 2015, PROG NEURO-PSYCHOPH, V57, P140, DOI 10.1016/j.pnpbp.2014.11.005; Rosiles A, 2016, CNS NEUROL DISORD-DR, V15, P3, DOI 10.2174/1871527314666150821105001; Rutten JW, 2016, BRAIN, V139, P1123, DOI 10.1093/brain/aww011; Saha Lekha, 2014, J Epilepsy Res, V4, P45; Sedaghat R, 2017, BIOMED PHARMACOTHER, V87, P200, DOI 10.1016/j.biopha.2016.12.109; Sha LZ, 2014, MOL NEUROBIOL, V49, P633, DOI 10.1007/s12035-013-8545-0; Shao YY, 2016, NEUROCHEM RES, V41, P3399, DOI 10.1007/s11064-016-2074-y; Simeone TA, 2017, EXP NEUROL, V287, P54, DOI 10.1016/j.expneurol.2016.08.006; Sisodiya SM, 2006, EPILEPSIA, V47, P534, DOI 10.1111/j.1528-1167.2006.00464.x; Srinivasakumar P, 2013, J PEDIATR-US, V163, P465, DOI 10.1016/j.jpeds.2013.01.041; Tao H, 2017, MEDIAT INFLAMM, DOI 10.1155/2017/6512620; Wong SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144806; Wu CP, 2015, EXP NEUROL, V271, P1, DOI 10.1016/j.expneurol.2015.04.018; Yang GS, 2017, BIOMED PHARMACOTHER, V96, P675, DOI 10.1016/j.biopha.2017.10.036; Zhang JW, 2017, APOPTOSIS, V22, P877, DOI 10.1007/s10495-017-1368-0; Zhang RR, 2018, CELL TISSUE RES, V371, P73, DOI 10.1007/s00441-017-2641-9	33	0	0	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1008	1016		10.1016/j.prp.2018.05.003			9	Pathology	Pathology	GN6YY	WOS:000439254000013	29754932				2019-10-28	
J	Yu, WW; Yang, X; Chu, L; Zhao, K; Chen, HQ; Xiang, JQ; Zhang, YW; Li, HC; Zhao, WX; Sun, MH; Wei, Q; Fu, XL; Xie, CY; Zhu, ZF				Yu, Weiwei; Yang, Xi; Chu, Li; Zhao, Kuaile; Chen, Haiquan; Xiang, Jiaqing; Zhang, Yawei; Li, Hecheng; Zhao, Weixin; Sun, Menghong; Wei, Qiao; Fu, Xiaolong; Xie, Congying; Zhu, Zhengfei			Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Esophageal cancer; Esophageal squamous cell carcinoma; Epidermal growth factor receptor; Prognostic factor; Lymph node-negative	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; CANCER; ERBB4; THERAPY; OVEREXPRESSION; HER2; PROLIFERATION; AMPLIFICATION; METASTASIS	The human epidermal growth factor receptor (EGFR) family has been widely studied in cancer, however, the prognostic role of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma (ESCC) patients have not been invalidated. This study was designed to determine the prognostic value of EGFR family expression in a population of lymph node-negative ESCC patients treated with curative resection. EGFR family protein expression was examined by immunohistochemical analysis of tissue microarrays of 94 patients with lymph node-negative ESCC after radical esophagectomy with three-field lymphadenectomy. Survival differences were compared using Kaplan-Meier analysis. Cox regression analyses were performed to determine the prognostic factors for overall survival and disease-free survival (DFS). ErbB4 expression was found to be an independent prognostic factor for DFS in patients without lymph node metastasis; increased ErbB4 expression was associated with decreased DFS. Additionally, patients with high ErbB4 expression tended to have worse overall survival. EGFR, ErbB2 and ErbB3 expression were not significantly associated with survival in lymph node-negative ESCC patients. Increased ErbB4 immunohistochemical expression was associated with poor prognosis in lymph node-negative ESCC patients.	[Yu, Weiwei; Yang, Xi; Chu, Li; Zhao, Kuaile; Zhao, Weixin; Fu, Xiaolong; Zhu, Zhengfei] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China; [Yu, Weiwei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Radiat Oncol, Shanghai, Peoples R China; [Chen, Haiquan; Xiang, Jiaqing; Zhang, Yawei; Li, Hecheng] Fudan Univ, Shanghai Canc Ctr, Dept Thorac Surg, Shanghai, Peoples R China; [Sun, Menghong; Wei, Qiao] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Yang, Xi; Chu, Li; Zhao, Kuaile; Chen, Haiquan; Xiang, Jiaqing; Zhang, Yawei; Li, Hecheng; Zhao, Weixin; Sun, Menghong; Wei, Qiao; Zhu, Zhengfei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Fu, Xiaolong] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Radiat Oncol, Shanghai, Peoples R China; [Xie, Congying] Wenzhou Med Univ, Affiliated Hosp 1, Radiotherapy & Chemotherapy Dept, Wenzhou, Peoples R China	Zhu, ZF (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China.	fuscczzf@163.com			Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee; Natural Science Foundation of Shanghai, ChinaNatural Science Foundation of Shanghai [15ZR1432100]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education MinistryScientific Research Foundation for the Returned Overseas Chinese Scholars; Foundation of Shanghai Municipal Commission of Health and Family Planning [201540211]	This work was sponsored by the Shanghai Committee of Science and Technology, Natural Science Foundation of Shanghai, China (No. 15ZR1432100), and Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry, and Foundation of Shanghai Municipal Commission of Health and Family Planning (No. 201540211). We thank James P. Mahaffey, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.	Chen JQ, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-110; Chen Y, 2016, ONCOL LETT, V11, P745, DOI 10.3892/ol.2015.3975; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Delektorskaya VV, 2009, B EXP BIOL MED+, V148, P241, DOI 10.1007/s10517-009-0659-z; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Friess H, 1999, WORLD J SURG, V23, P1010, DOI 10.1007/s002689900616; Jiang DX, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1393-8; Kato H, 2013, INT J ONCOL, V42, P1151, DOI 10.3892/ijo.2013.1830; Lee CM, 2005, GYNECOL ONCOL, V99, P415, DOI 10.1016/j.ygyno.2005.05.045; Lin G, 2015, ONCOL LETT, V10, P901, DOI 10.3892/ol.2015.3277; Ma G, 2015, EJSO-EUR J SURG ONC, V41, P541, DOI 10.1016/j.ejso.2015.01.013; Mendoza-Naranjo A, 2013, EMBO MOL MED, V5, P1087, DOI 10.1002/emmm.201202343; Ohashi Y, 2016, OR SURG OR MED OR PA, V122, P313, DOI 10.1016/j.oooo.2016.04.017; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; Riese DJ, 1996, ONCOGENE, V12, P345; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Skliris GP, 2008, HISTOPATHOLOGY, V52, P355, DOI 10.1111/j.1365-2559.2007.02955.x; Starr A, 2006, INT J CANCER, V119, P269, DOI 10.1002/ijc.21818; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Wang HX, 2016, TUMOR BIOL, V37, P9771, DOI 10.1007/s13277-015-4692-4; Wang J, 2016, ONCOTARGET, V7, P76693, DOI 10.18632/oncotarget.12485; Wei QC, 2007, INT J ONCOL, V31, P493; Williams CS, 2015, CARCINOGENESIS, V36, P710, DOI 10.1093/carcin/bgv049; Xu S, 2008, J SURG ONCOL, V97, P44, DOI 10.1002/jso.20892; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu T, 2015, ONCOGENE, V34, P413, DOI 10.1038/onc.2013.574; Yu WW, 2011, HEPATO-GASTROENTEROL, V58, P426; Zhan N, 2012, MED ONCOL, V29, P933, DOI 10.1007/s12032-011-9850-y; Zhang GY, 2010, J CANCER RES CLIN, V136, P587, DOI 10.1007/s00432-009-0693-2; ZHANG MX, 2014, J EXP CLIN CANC RES, V33; Zhu ZF, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0212-z; Zhu ZF, 2014, ANN SURG ONCOL, V21, P2857, DOI 10.1245/s10434-014-3665-y; Zhu ZF, 2013, ANN SURG ONCOL, V20, P3052, DOI 10.1245/s10434-013-2987-5	33	1	1	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1017	1023		10.1016/j.prp.2018.04.017			7	Pathology	Pathology	GN6YY	WOS:000439254000014	29729836				2019-10-28	
J	Wang, YZ; Xie, YT; Li, XF; Lin, JB; Zhang, SC; Li, Z; Huo, L; Gong, RY				Wang, Yizhou; Xie, Yanting; Li, Xifeng; Lin, Jianbo; Zhang, Shichao; Li, Zheng; Huo, Lei; Gong, Renyan			MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A	PATHOLOGY RESEARCH AND PRACTICE			English	Article						miR-876-5p; DNMT3A; Proliferation; Metastasis; HCC	CELL-PROLIFERATION; MICRORNAS; CANCER; TUMORIGENESIS; INVASION	Hepatocellular carcinoma (HCC) is one of the biggest challenges that human beings faced with in 21st century. Previous researches have revealed that miRNAs can serve as regulators in various cancers. MiR-876-5p, a member of miRNA family, has been studied in lung cancer for its anti-oncogenic function. However, the exact function of it is not reported in HCC. Our study aims to find out the effects of miR-876-5p expression on HCC progression. Two HCC cells were chosen to do functional assays after miR-876-5p expression was detected in cell lines by qRT-PCR. HepG2 cell was transfected with miR-876-5p mimics, whereas LM3 cell was transfected with miR-876-5p inhibitors. Next, cell activities of these two indicated cells were analyzed by means of MTT assay, colony forming assay, transwell migration assay and western blot analysis. Consequently, we found that miR-876-5p could inhibit both cell proliferation and metastasis. Moreover, we found out a target gene (DNMT3A) of miR-876-5p by performing bioinformatics analysis, dual luciferase reporter assay and biotin-avidin pull-down assay. Finally, rescue assays were carried out in HepG2 cells. We found that DNMT3A could reverse miR-876-5p mimics-induced inhibition. Therefore, we concluded that miR-876-5p suppressed hepatocellular carcinoma progression by targeting DNMT3A.	[Wang, Yizhou; Xie, Yanting; Li, Xifeng; Lin, Jianbo; Zhang, Shichao; Li, Zheng; Huo, Lei; Gong, Renyan] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, 225 Changhai Rd, Shanghai 200438, Peoples R China	Gong, RY (reprint author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 4, 225 Changhai Rd, Shanghai 200438, Peoples R China.	renyangong_gyr@163.com					Bao L, 2017, J BIOSCIENCES, V42, P671, DOI 10.1007/s12038-017-9722-5; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bruix J, 2015, LANCET ONCOL, V16, P1344, DOI 10.1016/S1470-2045(15)00198-9; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dhanasekaran R., 2016, F1000RESEARCH, V5; Du XQ, 2018, GENE, V657, P30, DOI 10.1016/j.gene.2018.03.003; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; HE L, 2004, NAT REV GENET, V5, P522; Hu X., 2017, CLIN CANCER RES, V24, P1748; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Khan S.M. Ayub, 2018, MOL MED REP; Lin JG, 2018, BIOMED PHARMACOTHER, V98, P433, DOI 10.1016/j.biopha.2017.12.058; Ma L, 2008, TRENDS GENET, V24, P448, DOI 10.1016/j.tig.2008.06.004; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Nelson KM, 2008, MOL CANCER THER, V7, P3655, DOI 10.1158/1535-7163.MCT-08-0586; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Paydas S, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0749-5; Sprinzl MF, 2013, J HEPATOL, V59, P9, DOI 10.1016/j.jhep.2013.04.002; Sun JB, 2015, INT J CLIN EXP PATHO, V8, P4755; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Worns MA, 2014, NAT REV GASTRO HEPAT, V11, P447, DOI 10.1038/nrgastro.2014.10; Zhang Q, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711312; Zhang W, 2018, GENE, V659, P22, DOI 10.1016/j.gene.2018.03.053; Zheng QL, 2014, MOL CELL BIOCHEM, V389, P187, DOI 10.1007/s11010-013-1940-z; Zhu YH, 2017, CELL DEATH DIFFER, V24, P2199, DOI 10.1038/cdd.2017.151	26	10	10	0	5	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1024	1030		10.1016/j.prp.2018.04.012			7	Pathology	Pathology	GN6YY	WOS:000439254000015	29724530				2019-10-28	
J	Kim, MK; Park, JY; Kang, YN				Kim, Min-Kyung; Park, Jee Young; Kang, Yu Na			Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Hepatocellular carcinoma; In vitro; Prognosis; SHP2; Tissue microarray; YAP	YES-ASSOCIATED PROTEIN; HIPPO PATHWAY; POOR-PROGNOSIS; ORGAN SIZE; TUMOR; OVEREXPRESSION; INACTIVATION; INHIBITION; EXPRESSION	Yes-associated protein (YAP) is a nuclear effector of the cell-density sensing Hippo pathway and interacts with Src homology phosphotyrosine phosphatase 2 (SHP2), which controls cell proliferation and survival. The tumor promoting/suppressing activities of YAP and SHP2 during liver tumorigenesis remain controversial. This study aimed to investigate the tumorigenic roles of YAP and SHP2 in hepatocellular carcinogenesis. Cell density associated subcellular distributions of YAP and SHP2 in normal human hepatocytes (THLE-2) and hepatocellular carcinoma (HCC) cells (SK-Hepl, SNU-182) were investigated by Western blotting and cell block im-munohistochemistry. The effects of YAP knockdown on proliferation, migration and invasion were studied using YAP-specific siRNAs. The prognostic significance of YAP and SHP2 expressions was investigated im-munohistochemically using a tissue microarray (TMA) from 50 HCC cases. High-cell density decreased the nuclear expression of YAP and SHP2 in normal hepatocytes as compared with low-cell density. However, in HCC cells, nuclear YAP and SHP2 were observed regardless of cell density. Nuclear YAP influenced SHP2 expression and cell proliferation. In particular, YAP knockdown impacted nuclear levels of SHP2 protein in SK-Hepl cells. In HCC tissues, nuclear YAP expression was elevated and cytoplasmic SHP2 expression was diminished as compared with adjacent non-tumor tissues. Notably, these expressions were found to be significantly associated with poor recurrence-free and overall survival rate in patients with HCC. Consequently, the tumor promoting role of YAP is involved in SHP2 which functions as a tumor promoter in vitro but as a tumor suppressor in vivo. YAP and SHP2 can be unfavorable prognostic markers in HCC.	[Kim, Min-Kyung] Dongguk Univ, Dept Pathol, Coll Med, Gyeongju, South Korea; [Park, Jee Young; Kang, Yu Na] Keimyung Univ, Sch Med, Dept Pathol, 1095 Dalgubeoldae Ro, Daegu 42601, South Korea; [Park, Jee Young; Kang, Yu Na] Keimyung Univ, Inst Canc Res, Daegu, South Korea	Kang, YN (reprint author), Keimyung Univ, Sch Med, Dept Pathol, 1095 Dalgubeoldae Ro, Daegu 42601, South Korea.	yunakang@dsmc.or.kr		Kang, Yu Na/0000-0002-5536-8828	Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health Welfare, Korea [HI16C1501]	This work was supported by grants (HI16C1501) from the Korea Health technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Korea.	Bai Nan, 2013, Cancer Biol Ther, V14, P511, DOI 10.4161/cbt.24345; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Bertini E, 2009, CELL CYCLE, V8, P49, DOI 10.4161/cc.8.1.7259; Chan SW, 2011, J CELL PHYSIOL, V226, P928, DOI 10.1002/jcp.22435; Han SX, 2014, J IMMUNOL RES, DOI 10.1155/2014/261365; Han T, 2015, J HEPATOL, V63, P651, DOI 10.1016/j.jhep.2015.03.036; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jiang CY, 2012, J CANCER RES CLIN, V138, P637, DOI 10.1007/s00432-011-1143-5; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Kim DH, 2013, HISTOL HISTOPATHOL, V28, P1483, DOI 10.14670/HH-28.1483; Kim JS, 2010, DIGEST DIS SCI, V55, P1565, DOI 10.1007/s10620-009-0924-z; Kim SK, 2014, INT J CLIN EXP PATHO, V7, P3224; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; Mauviel A, 2012, ONCOGENE, V31, P1743, DOI 10.1038/onc.2011.363; Miyamoto D, 2008, ONCOGENE, V27, P3508, DOI 10.1038/sj.onc.1211019; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Park JH, 2006, AM J SURG, V192, P29, DOI 10.1016/j.amjsurg.2005.11.010; Sohn BH, 2016, CLIN CANCER RES, V22, P1256, DOI 10.1158/1078-0432.CCR-15-1447; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Tsutsumi R, 2013, DEV CELL, V26, P658, DOI 10.1016/j.devcel.2013.08.013; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yu SJ, 2013, CLIN CANCER RES, V19, P1389, DOI 10.1158/1078-0432.CCR-12-1959; Yu SJ, 2011, WORLD J GASTROENTERO, V17, P2028, DOI 10.3748/wjg.v17.i15.2028; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54	32	1	1	0	4	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1031	1039		10.1016/j.prp.2018.04.010			9	Pathology	Pathology	GN6YY	WOS:000439254000016	29699904				2019-10-28	
J	Chen, BF; Li, JF; Yi, C; Jiao, YW; Gu, XL; Feng, XH				Chen, Bifeng; Li, Jinfeng; Yi, Can; Jiao, Yuwei; Gu, Xiuli; Feng, Xianhong			Long non-coding RNA POLR2E rs3787016 is associated with the risk of papillary thyroid carcinoma in Chinese population	PATHOLOGY RESEARCH AND PRACTICE			English	Article						POLR2E; rs3787016; Papillary thyroid carcinoma; Meta-analysis; Chinese population	PROSTATE-CANCER RISK; RADIOIODINE THERAPY; POLYMORPHISMS; DISEASE; SNPS; METAANALYSIS; STATISTICS	Long non-coding RNAs (LncRNAs) have been shown to be involved in cancer tumorigenesis and progression. Single nucleotide polymorphisms (SNPs) in the lncRNAs also play a vital role in carcinogenesis. We here explored the association between POLR2E rs3787016 and risk of papillary thyroid carcinoma (PTC) in a Chinese population, which was followed by a meta-analysis of POLR2E rs3787016 and cancer risk in Chinese population. A total of 409 PTC patients and 800 healthy individuals were enrolled in the present study. The POLR2E rs3787016 was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and was confirmed by sequencing. The POLR2E rs3787016T allele increased the PTC risk in Chinese population, particular in Chinese females. The meta-analysis further revealed that POLR2E rs3787016T allele was associated with an increased cancer risk in Chinese population. Collectively, the POLR2E rs3787016 may be used as a genetic biomarker to predict cancer risk in Chinese population.	[Chen, Bifeng; Li, Jinfeng; Yi, Can; Jiao, Yuwei] Wuhan Univ Technol, Sch Chem Chem Engn & Life Sci, Dept Biol Sci & Technol, Wuhan, Hubei, Peoples R China; [Gu, Xiuli] Huazhong Univ Sci & Technol, Tongji Med Coll, Ctr Reprod Med, Wuhan, Hubei, Peoples R China; [Gu, Xiuli] Wuhan Tongji Reprod Med Hosp, Wuhan, Hubei, Peoples R China; [Feng, Xianhong] Wuhan Xinzhou Dist Peoples Hosp, Clin Lab, Wuhan, Hubei, Peoples R China	Chen, BF (reprint author), Wuhan Univ Technol, Sch Chem Chem Engn & Life Sci, Dept Biol Sci & Technol, Wuhan, Hubei, Peoples R China.; Feng, XH (reprint author), Wuhan Xinzhou Dist Peoples Hosp, Clin Lab, Wuhan, Hubei, Peoples R China.	cbifeng@whut.edu.cn; 772657166@qq.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81502427]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [WUT: 2017IVA106, 2018IB023]	The authors thank all the participants and investigators enrolled in this study. This work was supported by grants from National Natural Science Foundation of China (81502427), and by the Fundamental Research Funds for the Central Universities (WUT: 2017IVA106 and 2018IB023).	Baralle D, 2005, J MED GENET, V42, P737, DOI 10.1136/jmg.2004.029538; Buratti E, 2006, NUCLEIC ACIDS RES, V34, P3494, DOI 10.1093/nar/gkl498; Cao DL, 2014, PROSTATE CANCER P D, V17, P315, DOI 10.1038/pcan.2014.34; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chu HY, 2017, ONCOTARGET, V8, P43271, DOI 10.18632/oncotarget.14920; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Ito Y, 2013, NAT REV ENDOCRINOL, V9, P178, DOI 10.1038/nrendo.2012.257; Jin GF, 2011, CARCINOGENESIS, V32, P1655, DOI 10.1093/carcin/bgr187; Kang MQ, 2015, TUMOR BIOL, V36, P6401, DOI 10.1007/s13277-015-3328-z; Lee ML, 2005, CANCER J, V11, P113, DOI 10.1097/00130404-200503000-00006; Li J, 2016, EUR J NUCL MED MOL I, V43, P1034, DOI 10.1007/s00259-015-3305-1; MANTEL N, 1959, J NATL CANCER I, V22, P719; Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296; Nikolic ZZ, 2013, INT J CLIN EXP MED, V6, P57; Prescott JD, 2015, CANCER-AM CANCER SOC, V121, P2137, DOI 10.1002/cncr.29044; Shastry BS, 2009, METHODS MOL BIOL, V578, P3, DOI 10.1007/978-1-60327-411-1_1; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tan H, 2017, EBIOMEDICINE, V16, P8, DOI 10.1016/j.ebiom.2017.01.047; Thakur MK, 2009, HORM RES, V71, P194, DOI 10.1159/000201107; Xu T, 2017, J CANCER, V8, P1162, DOI 10.7150/jca.18055	21	2	2	1	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1040	1044		10.1016/j.prp.2018.04.008			5	Pathology	Pathology	GN6YY	WOS:000439254000017	29724531				2019-10-28	
J	Li, Q; Teng, YF; Wang, J; Yu, M; Li, YQ; Zheng, H				Li, Qin; Teng, Yunfei; Wang, Jian; Yu, Miao; Li, Yiqing; Zheng, Hong			Rapl promotes proliferation and migration of vascular smooth muscle cell via the ERK pathway	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Vascular smooth muscle cell; Rap1; Rap1-GAP; Proliferation; Migration	ENDOTHELIAL-CELLS; DOWN-REGULATION; RAP1GAP; ACTIVATION; INVASION; DIFFERENTIATION; APOPTOSIS; MAPK/ERK; CANCER; EPAC1	Background: Rap1 is involved in a multitude of cellular signal transduction pathways, which has extensively been linked to cell proliferation and migration. It has been shown to be important in the regulation of physiological and pathological processes. The present study aims to elucidate its detailed mechanistic in proliferation and migration. Material/methods: Vascular smooth muscle cells (VSMCs) were transfected with pcDNA3.1(empty vector), pcDNA3.1 containing Myc-Tagged-Rap1V12 (Rap1V12) or pcDNA3.1 containing Flag-Tagged-Rap1GAP (Rap1GAP).The cells were presence or absence with 8CPT-2'OMe-cAMP or SDF-1 before transfection. The proliferation and migration were examined by 3- [4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MIT) and transwell analysis, respectively. Afterwards, western blot was performed to detect the expression of ERK, phosphorylated-ERK, Rapl, Rap1GAP and Rap1GTP. Results: The results showed that proliferation, migration and the expression of Rap1, Rap1GAP, p-EKR were boosted in treatment of Rap1V12-transfection. However, Rap1GAP presented the opposite effects. Subsequently, VSMCs were pretreatment with stimulators Rapl guanine exchange factor (Rap1GEF), 8CPT-2'OMe-cAMP and stromal cell-derived factor 1 (SDF-1), then transfected with different vectors and the expression of Rapi, Rap1GAP and p-EKR were obviously decreased. Conclusions: Taken together, these findings indicated for the first time that Rapl was essential for the VSMCs in proliferation and migration by ERK signaling pathway.	[Li, Qin; Teng, Yunfei; Wang, Jian; Yu, Miao; Li, Yiqing; Zheng, Hong] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Vasc Surg, 1277 Jiefang Ave, Wuhan, Hubei, Peoples R China	Zheng, H (reprint author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Vasc Surg, 1277 Jiefang Ave, Wuhan, Hubei, Peoples R China.	1651283602@qq.com					Baurrier Y., 2017, ATHEROSCLEROSIS, V256, P105; Chiong Mario, 2014, Front Cell Dev Biol, V2, P72, DOI 10.3389/fcell.2014.00072; Fang Y, 2007, J PHARMACOL EXP THER, V322, P1189, DOI 10.1124/jpet.107.119933; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Li WY, 2011, J HUAZHONG U SCI-MED, V31, P721, DOI 10.1007/s11596-011-0667-x; Liang D, 2013, CELL SIGNAL, V25, P1126, DOI 10.1016/j.cellsig.2013.02.003; Misra UK, 2008, CELL SIGNAL, V20, P1459, DOI 10.1016/j.cellsig.2008.04.002; Rodriguez-Nieves JA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159490; Rzucidlo EM, 2007, J VASC SURG, V45, p25A, DOI 10.1016/j.jvs.2007.03.001; Strazza M, 2017, P NATL ACAD SCI USA, V114, P2693, DOI 10.1073/pnas.1612900114; Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412; Zhang LZ, 2006, CANCER RES, V66, P898, DOI 10.1158/0008-5472.CAN-05-3025; Zhang YL, 2017, CANCER BIOL MED, V14, P90, DOI 10.20892/j.issn.2095-3941.2016.0086; Zheng H, 2009, CANCER RES, V69, P449, DOI 10.1158/0008-5472.CAN-08-2399; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	16	1	1	2	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1045	1050		10.1016/j.prp.2018.04.007			6	Pathology	Pathology	GN6YY	WOS:000439254000018	29789158				2019-10-28	
J	Furuya, G; Abe, H; Shinozaki-Ushiku, A; Yamashita, A; Ihara, S; Hirata, Y; Chiba, A; Fujioka, Y; Kurokawa, M; Koike, K; Fukayama, M				Furuya, Genta; Abe, Hiroyuki; Shinozaki-Ushiku, Aya; Yamashita, Aya; Ihara, Sozaburo; Hirata, Yoshihiro; Chiba, Akira; Fujioka, Yosei; Kurokawa, Mineo; Koike, Kazuhiko; Fukayama, Masashi			Extranodal NK/T-cell lymphoma of the nasal cavity developed in a patient with intestinal Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Epstein-Barr virus; T/NK-cell; Lymphoma; Lymphoproliferative disorder; Digestive tract; Crohn's disease	INFLAMMATORY-BOWEL-DISEASE; INFECTION; ADULTS	Extranodal NK/T cell lymphoma, nasal type (ENKL) developed in a patient with intestinal Epstein-Barr virus (EBV)-positive T/NK-cell lymphoproliferative disorder (LPD). The patient was a 46-year-old Chinese man who complained of diarrhea and abdominal pain without immune-deficiency. Endoscopy demonstrated ileum ulcers like Crohn's disease, without histological granulomas. His symptoms continued waxing and waning for 3 years until he developed overt lymphoma (ENKL) in the nasal cavity. The ileum lesions exacerbated into a large deep ulcer, and the biopsy specimens from the ileum, including the one 3 years ago, showed infiltration of small lymphocytes containing many EBV-positive T/NK cells without atypia. Thus, the patient illness of intestine was revealed as intestinal EBV-positive T/NK-cell LPD, which might be closely associated with development of ENKL in this patient. In cases of inflammatory bowel disease without typical clinical courses and histological findings, check-up of EBV in the biopsy might help correct diagnosis.	[Furuya, Genta; Abe, Hiroyuki; Shinozaki-Ushiku, Aya; Fukayama, Masashi] Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan; [Yamashita, Aya; Ihara, Sozaburo; Hirata, Yoshihiro; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan; [Chiba, Akira; Fujioka, Yosei; Kurokawa, Mineo] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan	Fukayama, M (reprint author), Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	mfukayama-tky@umin.org			Japan Society for the Promotion of Science (JSPS)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26253021]	This work was supported by Japan Society for the Promotion of Science (JSPS) [grant number 26253021].	Abdul-Ghafar J, 2011, J KOREAN MED SCI, V26, P1103, DOI 10.3346/jkms.2011.26.8.1103; Chen  Haiyan, 2016, MEDICINE, V95; Du J, 2015, INT J CLIN EXP PATHO, V8, P9620; Hu LM, 2017, HISTOPATHOLOGY, V70, P1052, DOI 10.1111/his.13172; Isobe Y, 2012, J CLIN PATHOL, V65, P278, DOI 10.1136/jclinpath-2011-200523; Kimura H, 2012, BLOOD, V119, P673, DOI 10.1182/blood-2011-10-381921; Na HK, 2013, J CROHNS COLITIS, V7, P649, DOI 10.1016/j.crohns.2012.09.018; Ohshima K, 2008, PATHOL INT, V58, P209, DOI 10.1111/j.1440-1827.2008.02213.x; Okano M, 2005, AM J HEMATOL, V80, P64, DOI 10.1002/ajh.20398; Perry AM, 2013, BLOOD, V122, P3599, DOI 10.1182/blood-2013-07-512830; Spieker T, 2000, AM J PATHOL, V157, P51, DOI 10.1016/S0002-9440(10)64516-6; Takeuchi K, 2010, BLOOD, V116, P5631, DOI 10.1182/blood-2010-06-290650; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Yanai H, 1999, AM J GASTROENTEROL, V94, P1582; Zheng XD, 2015, INT J CLIN EXP PATHO, V8, P8598	15	1	1	1	3	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JUL	2018	214	7					1051	1055		10.1016/j.prp.2018.05.022			5	Pathology	Pathology	GN6YY	WOS:000439254000019	29843925				2019-10-28	
J	Warren, M; Shimada, H				Warren, Mikako; Shimada, Hiroyuki			Cytologic and Ultrastructural Findings of Bronchoalveolar Lavage in Patients With Chronic Granulomatous Disease	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						chronic granulomatous disease; bronchoalveolar lavage; alveolar macrophage; cytology; ultrastructure	NIEMANN-PICK-DISEASE; INTERSTITIAL LUNG-DISEASE; PULMONARY INVOLVEMENT; LADEN HISTIOCYTES; CHILDHOOD; FEATURES; MANIFESTATIONS; PNEUMONIA; PATHOLOGY; LESIONS	Background: Chronic granulomatous disease (CGD) is a hereditary immunodeficiency caused by mutations in genes encoding nicotinamide adenine dinucleotide phosphate oxidase enzyme complex, which lead to the inability to kill intracellular pathogens. Patients with CGD are susceptible to recurrent bacterial and fungal infections in their early lives. Although the recent survival rate has been significantly improved, early diagnosis is critical to prevent multiple organ impairment. In 1950s, CGD was first described as a disease with recurrent infections and visceral infiltration of granulomas and pigmented histiocytes. Bronchoalveolar lavage (BAL) is commonly performed for patients with CGD; however, no study has described the cytologic features of alveolar macrophages. Methods: Cytology of 20 BALs from II CGD patients was examined. The greatest diameters of randomly selected 100 alveolar macrophages in each BAL were measured using image analysis and compared with 20 disease control BALs from non-CGD patients. Macrophages from 2 groups were compared with repeated measures mixed-model analysis. Ultrastructural analysis was performed on a representative CGD BAL. Results: BALs from CGD patients showed variable numbers of neutrophils and lipid-laden macrophages. Macrophages in CGD BALs were significantly larger than disease control BALs (P <.0001) and showed "foamy" vacuolated cytoplasm. Ultrastructural analysis revealed the macrophages filled with enlarged lysosomes containing lipofuscin-like materials, which made their appearance "foamy". Conclusion: In this study, we demonstrate novel BAL findings in CGD patients. The presence of enlarged "foamy" alveolar macrophages is not specific for CGD, but CGD should be considered as a differential diagnosis when foamy macrophages are present.	[Warren, Mikako; Shimada, Hiroyuki] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, 43,4650 Sunset Blvd, Los Angeles, CA 90027 USA; [Warren, Mikako; Shimada, Hiroyuki] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA	Warren, M (reprint author), Childrens Hosp Los Angeles, Dept Pathol & Lab Med, 43,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	miwarren@chla.usc.edu			NIH/NCRR SC-CTSI [UL1 RR031986]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The statistic work of this publication was supported by NIH/NCRR SC-CTSI (Grant Number UL1 RR031986). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Abati A, 1996, DIAGN CYTOPATHOL, V15, P98, DOI 10.1002/(SICI)1097-0339(199608)15:2<98::AID-DC3>3.3.CO;2-H; Alimchandani M, 2013, AM J SURG PATHOL, V37, P1365, DOI 10.1097/PAS.0b013e318297427d; Allen TC, 2008, ARCH PATHOL LAB MED, V132, P1171, DOI 10.1043/1543-2165(2008)132[1171:PLCHAO]2.0.CO;2; Amir G, 1999, HUM PATHOL, V30, P666, DOI 10.1016/S0046-8177(99)90092-8; BAEHNER RL, 1967, SCIENCE, V155, P835, DOI 10.1126/science.155.3764.835; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bedrossian C W, 1997, Ann Diagn Pathol, V1, P47, DOI 10.1016/S1092-9134(97)80008-1; BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; Chiriaco M, 2016, PEDIAT ALLERG IMM-UK, V27, P242, DOI 10.1111/pai.12527; Citti A, 2013, ULTRASTRUCT PATHOL, V37, P356, DOI 10.3109/01913123.2013.811454; Cordeiro CR, 2007, SEMIN RESP CRIT CARE, V28, P504, DOI 10.1055/s-2007-991523; Costabel U, 2007, SEMIN RESP CRIT CARE, V28, P514, DOI 10.1055/s-2007-991525; Dohil M, 1997, J AM ACAD DERMATOL, V36, P899, DOI 10.1016/S0190-9622(97)80269-1; Goldblatt D, 2014, J INFECTION, V69, pS32, DOI 10.1016/j.jinf.2014.07.013; GROSSNIKLAUS HE, 1988, RETINA-J RET VIT DIS, V8, P270, DOI 10.1097/00006982-198808040-00009; HADFIELD MG, 1991, ACTA NEUROPATHOL, V81, P467, DOI 10.1007/BF00293469; HEYNE K, 1972, PATHOL MICROBIOL, V38, P133, DOI 10.1159/000162398; Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002; JANEWAY CA, 1954, AMA AM J DIS CHILD, V88, P388; Kawai T, 2014, J CLIN IMMUNOL, V34, P933, DOI 10.1007/s10875-014-0089-1; Khaldi H, 2009, EUR RESPIR J, V33, P1498, DOI 10.1183/09031936.00138107; Khangura SK, 2016, CLIN GASTROENTEROL H, V14, P395, DOI 10.1016/j.cgh.2015.10.030; LANDING BH, 1957, PEDIATRICS, V20, P431; Levine S, 2005, HISTOPATHOLOGY, V47, P508, DOI 10.1111/j.1365-2559.2005.02258.x; LONG RG, 1977, AM J MED, V62, P627, DOI 10.1016/0002-9343(77)90426-0; Mahdaviani SA, 2013, EXPERT REV CLIN IMMU, V9, P153, DOI [10.1586/eci.12.98, 10.1586/ECI.12.98]; Meyer KC, 2012, AM J RESP CRIT CARE, V185, P1004, DOI 10.1164/rccm.201202-0320ST; Nakatani Y, 2000, VIRCHOWS ARCH, V437, P304, DOI 10.1007/s004280000241; NAKHLEH RE, 1992, ARCH PATHOL LAB MED, V116, P71; Nicholson AG, 2006, HISTOPATHOLOGY, V48, P596, DOI 10.1111/j.1365-2559.2006.02355.x; Obayashi N, 2016, J PEDIATR GASTR NUTR, V62, P56, DOI 10.1097/MPG.0000000000000905; PARK SH, 1992, PEDIATR PATHOL, V12, P839, DOI 10.3109/15513819209024241; QUIE PG, 1967, J CLIN INVEST, V46, P668, DOI 10.1172/JCI105568; REPINE JE, 1974, J CLIN INVEST, V54, P83, DOI 10.1172/JCI107752; RIGGS JE, 1989, J CHILD NEUROL, V4, P61, DOI 10.1177/088307388900400111; Roos D, 2014, CLIN EXP IMMUNOL, V175, P139, DOI 10.1111/cei.12202; Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781; TANAKA T, 1984, ACTA PATHOL JAPON, V34, P1385; von Ranke FM, 2016, LUNG, V194, P511, DOI 10.1007/s00408-016-9893-0	39	0	0	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					347	354		10.1177/1093526617736188			8	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400001	29050515				2019-10-28	
J	Terzic, T; Cordeau, M; Herblot, S; Teira, P; Cournoyer, S; Beaunoyer, M; Peuchmaur, M; Duval, M; Sartelet, H				Terzic, Tatjana; Cordeau, Martine; Herblot, Sabine; Teira, Pierre; Cournoyer, Sonia; Beaunoyer, Mona; Peuchmaur, Michel; Duval, Michel; Sartelet, Herve			Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						disialoganglioside; GD2; neuroblastoma; immunotherapy; immunohistochemistry	ANTIBODY THERAPY; CLASSIFICATION; INTERLEUKIN-2; MORTALITY; SYSTEM	Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with an immunotherapy based on a chimeric monoclonal antibody ch 14.18. Although the use of ch 14.18 monoclonal antibody has significantly increased the survival rate of high-risk neuroblastoma patients, about 33% of these patients still relapse and die from their disease. Ch 14.18 targets the disialoganglioside, GD2, expressed on neuroblasts tumor (NT) cells. To better understand the causes of tumor relapse following ch 14.18 immunotherapy, we have analyzed the expression of GD2 in 152 tumor samples from patients with NTs using immunohistochemical stainings. We observed GD2 expression in 146 of 152 samples (96%); however, the proportion of GD2-positive cells varied among samples. Interestingly, low percentage of GD2-positive cells before immunotherapy was associated with relapse in patients receiving ch 14.18 immunotherapy. In addition, we demonstrated in vitro that the sensitivity of neuroblastoma cell lines to natural killer-mediated lysis was dependent on the proportion of GD2-positive cells, in the presence of ch 14.18 antibody. In conclusion, our results indicate that the proportion of tumor cells expressing GD2 in NTs should be taken in consideration, as a prognostic marker, for high-risk neuroblastoma patients receiving anti-GD2 immunotherapy.	[Terzic, Tatjana; Cordeau, Martine; Herblot, Sabine; Cournoyer, Sonia; Duval, Michel; Sartelet, Herve] Ctr Hosp Univ St Justine, Res Ctr, Dept Pathol, Montreal, PQ, Canada; [Teira, Pierre] Ctr Hosp Univ St Justine, Dept Oncol, Montreal, PQ, Canada; [Beaunoyer, Mona] Ctr Hosp Univ St Justine, Dept Surg, Montreal, PQ, Canada; [Peuchmaur, Michel; Sartelet, Herve] Univ Joseph Fourier, CHU Grenoble, Dept Pathol, Grenoble, France	Sartelet, H (reprint author), CHU Grenoble, Dept Pathol, Ave Maquis Gresivaudan, Grenoble, France.	hsartelet@chu-grenoble.fr			Charles-Bruneau Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work has been supported by the Charles-Bruneau Foundation.	Cao LF, 2010, CYTOM PART A, V77A, P534, DOI 10.1002/cyto.a.20887; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Delgado DC, 2010, CANCER RES, V70, P9554, DOI 10.1158/0008-5472.CAN-10-2211; Gilman AL, 2009, J CLIN ONCOL, V27, P85, DOI 10.1200/JCO.2006.10.3564; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kramer K, 1998, CLIN CANCER RES, V4, P2135; Linet MS, 1999, JNCI-J NATL CANCER I, V91, P1051, DOI 10.1093/jnci/91.12.1051; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Modak S, 2010, CANCER TREAT REV, V36, P307, DOI 10.1016/j.ctrv.2010.02.006; Mugishima H, 2012, INT J CLIN ONCOL, V17, P189, DOI 10.1007/s10147-012-0423-7; MUJOO K, 1989, CANCER RES, V49, P2857; Navid F, 2010, CURR CANCER DRUG TAR, V10, P200, DOI 10.2174/156800910791054167; Navid F, 2009, CANCER BIOL THER, V8, P874, DOI 10.4161/cbt.8.10.8358; Park JR, 2013, PEDIATR BLOOD CANCER, V60, P985, DOI 10.1002/pbc.24433; Parsons K, 2013, ANN PHARMACOTHER, V47, P210, DOI 10.1345/aph.1R353; Schleiermacher G, 2012, BRIT J CANCER, V107, P1418, DOI 10.1038/bjc.2012.375; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Tarek N, 2012, J CLIN INVEST, V122, P3260, DOI 10.1172/JCI62749; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387; WU ZL, 1986, CANCER RES, V46, P440; Yu AL, 2010, NEW ENGL J MED, V363, P1324, DOI 10.1056/NEJMoa0911123	23	5	5	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					355	362		10.1177/1093526617723972			8	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400002	29067879				2019-10-28	
J	Thaker, AI; Kapur, RP				Thaker, Ameet, I; Kapur, Raj P.			Colonic Adventitial Fibromuscular Dysplasia: A Nonspecific Arteriopathy Associated With Hirschsprung Disease and Other Obstructive Disorders	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						Hirschsprung; artery; vascular; colon; adventitia; fibromuscular	ARTERIES	Background: Smooth muscle differentiation ("adventitial fibromuscular dysplasia," AFD) was purported as specific to arteries in the transition zone of Hirschsprung disease (HSCR) patients.We investigated AFD in an HSCR population and controls and consider the pathogenesis and significance of the vascular pathology. Design: Vascular histology in sections from colonic HSCR resections (n = 55) was compared with age- and site-matched controls with (n = 19) and without (n = 28) non-HSCR obstructive conditions. Vascular pathology was mapped, and correlations were sought between the vascular findings and bowel distension, inflammation, neuromuscular anatomy, preoperative clinical variables, and postsurgical complications. Results: One of 2 forms of AFD was identified in 42% (23/55) of the HSCR resections: the previously described "mature" form with adventitial bundles of differentiated smooth muscle cells (7/23, all submucosal) and a newly described "immature" AFD characterized by densely packed myofibroblasts in the arterial adventitia (16/23, 3 submucosal, 3 serosal, and 10 both). Adventitial inflammation and/or medial necrosis was present in the immature form (6/16) Mature submucosal AFD was present in 2/28 (7.1%) nonobstructive and 5/19 (26%) obstructive non-HSCR controls (P =.10). Immature AFD was only found in less than 1-month-olds, and mature AFD only in older patients, including the 7 affected controls. AFD did not correlate with sex, syndromic status, length of the aganglionic segment, or postoperative complications. AFD was present in grossly dilated (17/23) and narrowed (10/23) regions and in the aganglionic (2/23), ganglionic (14/23), or both (7/23) segments. In several cases, AFD existed proximal to the histological transition zone. Conclusion: AFD occurs in HSCR and other obstructive conditions but is significantly less common in the colons of patients with no history of dysmotility. The pathology likely progresses from a reversible accumulation of myofibroblasts in neonates to a stable population of mature smooth muscle cells. The distribution of vascular lesions does not correlate with neuropathologies findings and suggests a nonspecific form of vascular injury, possibly related to bowel distension. AFD in HSCR resections has not been shown to be clinically significant and should not influence management.	[Thaker, Ameet, I] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Childrens Med Ctr Dallas, Dallas, TX USA; [Kapur, Raj P.] Univ Washington, Dept Pathol, Seattle Childrens Hosp, Seattle, WA 98195 USA	Kapur, RP (reprint author), Seattle Childrens Hosp, Dept Labs, OC 8-720,4800 Sand Point Way NE, Seattle, WA 98115 USA.	raj.kapur@seattlechildrens.org			Seattle Children's Hospital Academic Enrichment Fund Award	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was partially supported by a Seattle Children's Hospital Academic Enrichment Fund Award (RPK).	Diaz-Flores L, 2014, HISTOL HISTOPATHOL, V29, P831, DOI 10.14670/HH-29.831; Eyden B, 2008, J CELL MOL MED, V12, P22, DOI 10.1111/j.1582-4934.2007.00213.x; Holzer P, 2012, PHYSL GASTROINTESTIN, P817; Kapur RP, 2016, AM J SURG PATHOL, V40, P1637, DOI 10.1097/PAS.0000000000000711; Kotiloglu E, 1997, EUR J PEDIATR SURG, V7, P52, DOI 10.1055/s-2008-1071052; LISTER J, 1966, ARCH DIS CHILD, V41, P149; Lowichik A, 1997, PEDIATR PATHOL LAB M, V17, P885, DOI 10.1080/107710497174336; Patil DT, 2016, AM J SURG PATHOL, V40, P1316, DOI 10.1097/PAS.0000000000000710; Polin RA, 2017, FETAL NEONATAL PHYSL; Pratap A, 2007, EUR SURG RES, V39, P148, DOI 10.1159/000100279; Rolle U, 2003, PEDIATR SURG INT, V19, P345, DOI 10.1007/s00383-003-1008-3; TAGUCHI T, 1994, J PEDIATR GASTR NUTR, V18, P200, DOI 10.1097/00005176-199402000-00013; TAGUCHI T, 1985, GASTROENTEROLOGY, V88, P1099, DOI 10.1016/S0016-5085(85)80066-4	13	0	0	0	2	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					363	370		10.1177/1093526617739772			8	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400003	29108502				2019-10-28	
J	Wyand, R; Cramer, SF; Oshri, A; Heller, DS				Wyand, Rachel; Cramer, Stewart F.; Oshri, Assaf; Heller, Debra S.			Association of Retroplacental Blood With Basal Plate Myofibers	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						placenta; basal plate myofibers; abruption; accrete	MORBIDLY ADHERENT PLACENTA; MYOMETRIAL FIBERS; ACCRETA; PATHOGENESIS; TROPHOBLAST; DIAGNOSIS; INCRETA; RISK	Objectives: Diagnosed clinical abruption showing blood clot should be signed out in the pathology report as retroplacental hemorrhage with or without parenchymal indentation, and submitted clot separate from the placenta should be weighed. In our experience, some cases sent as clinical abruptions have been cases of morbid adherence. This study was undertaken to evaluate the association of retroplacental blood with basal plate myofibers (BPMF). Methods: One hundred fifty-six placentas reviewed by a board-certified pediatric pathologist at a community hospital were evaluated for significant retroplacental blood. Basal plates were reviewed for deviations from normal. Results: Of the 156 placentas, 33 (21%) had significant retroplacental blood; 21/156 (13%) had a separate clot, of which 11/21 (52%) had BPMF. Eleven BPMF-associated separate clots ranged from 10.5 to 60g (average 23), while the clots of 10 cases with no demonstrated BPMF ranged from 19 to 440g (average 82), tending to be larger (p < .03). Basal plate damage prior to delivery was noted in both sets of placentas. BPMF placentas could have myometrial damage prior to delivery. Conclusions: Since BPMF may confer a risk for accreta in a subsequent pregnancy, submission of a separate clot with the placenta should lead the pathologist to evaluate for basal plate myofibers on H&E and consider if there is an evidence-based indication to do an actin stain, before presuming a diagnosis of abruption.	[Wyand, Rachel; Cramer, Stewart F.] Univ Rochester, Dept Pathol, Rochester Gen Hosp, Sch Med, Rochester, NY 14627 USA; [Oshri, Assaf] Univ Georgia, Dept Human Dev & Family Sci, Athens, GA 30602 USA; [Heller, Debra S.] Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, 185 South Orange Ave, Newark, NJ 07103 USA	Heller, DS (reprint author), Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, 185 South Orange Ave, Newark, NJ 07103 USA.	hellerds@njms.rutgers.edu			Genesee Hospital Foundation; Rochester General Hospital Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by a grant for tissue research from The Genesee Hospital Foundation and Rochester General Hospital Foundation, approved by the Clinical Investigation Committee (Institutional Review Board) of Rochester General Hospital.	Cramer SF, 2017, PEDIATR DEVEL PATHOL, V20, P152, DOI 10.1177/1093526616681939; Cramer SF, 2016, PEDIATR DEVEL PATHOL, V19, P320, DOI 10.2350/15-05-1641-OA.1; Ernst LM, 2017, PEDIATR DEVEL PATHOL, V20, P387, DOI 10.1177/1093526617698600; Faye-Petersen OM, 2006, HDB PLACENTAL PATHOL, P88; Heller DS, 2012, J REPROD MED, V57, P459; Jacques SM, 1996, INT J GYNECOL PATHOL, V15, P28, DOI 10.1097/00004347-199601000-00005; Kaplan CG, 1996, PERSPECT PED PATHOL, V19, P20; Khong TY, 2016, ARCH PATHOL LAB MED, V140, P698, DOI 10.5858/arpa.2015-0225-CC; Khong TY, 2001, AM J CLIN PATHOL, V116, P703; Kraus FT, 2007, SEMIN DIAGN PATHOL, V24, P1, DOI 10.1053/j.semdp.2007.02.001; Kraus FT, 2003, HUM PATHOL, V34, P517, DOI 10.1016/S0046-8177(03)00227-2; Linn RL, 2015, PLACENTA, V36, P1419, DOI 10.1016/j.placenta.2015.10.004; Miller ES, 2016, BJOG-INT J OBSTET GY, V123, P2140, DOI 10.1111/1471-0528.13579; Morison J E, 1978, Obstet Gynecol Annu, V7, P107; Redline RW, 2004, PEDIATR DEVEL PATHOL, V7, P237, DOI 10.1007/s10024-003-8083-2; Roeca C, 2017, OBSTET GYNECOL, V129, P321, DOI 10.1097/AOG.0000000000001843; Roeder HA, 2012, REPROD SCI, V19, P463, DOI 10.1177/1933719111426603; Sherer DM, 1996, OBSTET GYNECOL, V87, P444, DOI 10.1016/0029-7844(95)00426-2; Stanek J, 2007, PEDIATR DEVEL PATHOL, V10, P266, DOI 10.2350/06-10-0174.1; Tantbirojn P, 2008, PLACENTA, V29, P639, DOI 10.1016/j.placenta.2008.04.008; Warshak CR, 2006, OBSTET GYNECOL, V108, P573, DOI 10.1097/01.AOG.0000233155.62906.6d	21	3	3	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					371	379		10.1177/1093526617741071			9	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400004	29153056				2019-10-28	
J	Cole, BL; Pritchard, CC; Anderson, M; Leary, SES				Cole, Bonnie L.; Pritchard, Colin C.; Anderson, Maia; Leary, Sarah E. S.			Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						pediatric brain tumors; genetics; supratentorial; malignant	CENTRAL-NERVOUS-SYSTEM; MOLECULAR CLASSIFICATION; HISTONE H3.3; SUBGROUPS; CHILDREN; GLIOMAS; MEDULLOBLASTOMA; IMPLEMENTATION; EXPRESSION; RADIATION	Pediatric brain tumors cause more deaths than any other childhood malignancy, and the identification of potentially actionable genomic alterations in this rare heterogeneous group of tumors may improve treatment and outcome. The genetic landscape of common posterior fossa tumors has been described in the past several years, yet the classification of malignant pediatric supratentorial tumors remains controversial. Next-generation sequencing (NGS) is a promising tool to evaluate multiple genes concurrently. The clinical utility of NGS has not been proven in pediatric brain tumors. We identified patients diagnosed with high-grade supratentorial pediatric brain tumors resected between 2008 and 2012 at our institution. DNA from 12 formalin-fixed paraffin-embedded tumor samples from 9 patients was analyzed, including 3 paired samples from diagnosis and relapse. A panel of 194 cancer-related genes was sequenced using targeted next-generation deep sequencing. Genetic findings were correlated with histology, immunohistochemistry, treatment, and survival. We found one or more pathologic genetic change (mutation, amplification, or deletion) in 8 of 9 (89%) of patients studied. Epidermal Growth Factor Receptor (EGFR) mutations were found in 3 patients, 2 of which had an exon 20 insertion not previously described in pediatric malignancy. Additional genetic changes were found in EGFR and Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) at relapse not present in the initial samples. Familial cancer predisposition syndromes were suggested by mutations found in 3 genes in 4 patients, including TP53, MSH2, and CHEK2. Seven of 9 patients in this study died of their disease. In summary, targeted deep sequencing may be used in rare pediatric brain tumors to identify driver mutations for targeted therapy, suggest constitutional and familial testing for cancer predisposition syndromes, and select molecular targets worthy of further study.	[Cole, Bonnie L.] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA; [Cole, Bonnie L.] Univ Washington, Dept Anat Pathol, Seattle, WA 98195 USA; [Pritchard, Colin C.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Anderson, Maia; Leary, Sarah E. S.] Seattle Childrens Hosp, Canc & Blood Disorders Ctr, Seattle, WA USA; [Leary, Sarah E. S.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Leary, Sarah E. S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA	Cole, BL (reprint author), 4800 Sand Point Way NE,M-S OC 8-720, Seattle, WA 98105 USA.	Bonnie.cole2@seattlechildrens.org			Seattle Children's Hospital Cancer Research Pilot Funds; Clinical Research Scholars Program	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors thank the Seattle Children's Hospital Cancer Research Pilot Funds and Clinical Research Scholars Program for funding this project.	Bouffet E, 2016, J CLIN ONCOL, V34, P2206, DOI 10.1200/JCO.2016.66.6552; Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Downing JR, 2012, NAT GENET, V44, P619, DOI 10.1038/ng.2287; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lynch HT, 2009, CLIN GENET, V76, P1, DOI 10.1111/j.1399-0004.2009.01230.x; Mangold E, 2005, J PATHOL, V207, P385, DOI 10.1002/path.1858; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Mody RJ, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26288; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189; Packer RJ, 2006, J CLIN ONCOL, V24, P4202, DOI 10.1200/JCO.2006.06.4980; Pajtler KW, 2015, CANCER CELL, V27, P728, DOI 10.1016/j.ccell.2015.04.002; Park AK, 2012, NEURO-ONCOLOGY, V14, P203, DOI 10.1093/neuonc/nor196; Park JY, 2016, AM J SURG PATHOL, V40, P1713, DOI 10.1097/PAS.0000000000000729; Pediatric Brain Tumor Consortium, PALB IS TREAT YOUNG; Perry A, 2009, BRAIN PATHOL, V19, P81, DOI 10.1111/j.1750-3639.2008.00167.x; Peyrl A, 2009, PEDIATR BLOOD CANCER, V52, P476, DOI 10.1002/pbc.21881; Picard D, 2012, LANCET ONCOL, V13, P838, DOI 10.1016/S1470-2045(12)70257-7; Pollack IF, 2007, NEURO-ONCOLOGY, V9, P145, DOI 10.1215/15228517-2006-031; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Reddy AT, 2000, CANCER, V88, P2189, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2189::AID-CNCR27>3.0.CO;2-G; Relling MV, 2011, CLIN PHARMACOL THER, V89, P387, DOI 10.1038/clpt.2010.320; Sallinen SL, 2005, J NEURO-ONCOL, V74, P93, DOI 10.1007/s11060-005-5953-7; Samuel N, 2014, NAT REV CLIN ONCOL, V11, P723, DOI 10.1038/nrclinonc.2014.169; Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833; Sidney Kummel Comprehensive Cancer Center, STUD ASS FEAS SURG C; St Jude Children's Research Hospital, CLIN MOL RISK DIR TH; Stefanaki K, 2012, PEDIATR NEUROSURG, V48, P271, DOI 10.1159/000351546; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Weischer M, 2008, J CLIN ONCOL, V26, P542, DOI 10.1200/JCO.2007.12.5922; Yasuda H, 2012, LANCET ONCOL, V13, pE23, DOI 10.1016/S1470-2045(11)70129-2; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054	34	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					380	388		10.1177/1093526617743905			9	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400005	29173061				2019-10-28	
J	Tan, SY; Szymanski, LJ; Galliani, C; Parham, D; Zambrano, E				Tan, Serena Y.; Szymanski, Linda J.; Galliani, Carlos; Parham, David; Zambrano, Eduardo			Solitary Fibrous Tumors in Pediatric Patients: A Rare and Potentially Overdiagnosed Neoplasm, Confirmed by STAT6 Immunohistochemistry	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						solitary fibrous tumor; STAT6 immunohistochemistry; soft tissue neoplasms	NTRK1 GENE FUSIONS; NAB2-STAT6 FUSION; BETA-CATENIN; EXPRESSION; HEMANGIOPERICYTOMA; SUBSET; LIPOSARCOMA; DIAGNOSIS; MIMICS	Pathological diagnosis of solitary fibrous tumor (SFT) in the pediatric population is challenging, as it occurs uncommonly in this age-group and resembles other spindle cell neoplasms. SFT contains a NAB2-STAT6 fusion gene, which can be reliably detected using STAT6 immunohistochemistry. Positive staining is highly sensitive and specific. We sought to investigate the utility of STAT6 immunohistochemistry, to show how commonly SFT was historically recognized at 3 academic pediatric institutions, to reclassify them when appropriate, and to demonstrate features of major mimics of SFT. Our series included cases with a previous diagnosis of SFT or for which SFT was among key considerations, from 3 major academic pediatric hospitals seen over the past 30 years. Of 18 tumors identified, only 3 tumors from 2 patients demonstrated positive STAT6 staining as well as the typical histology and immunophenotype seen in SFT. The remaining 15 tumors were reclassified based on morphology, additional immunohistochemistry and fluorescence in situ hybridization as desmoid-type fibromatosis (3 tumors), nerve sheath/neural tumors (3 tumors), low-grade fibromyxoid sarcoma, medallion-like dermal fibroma, poorly differentiated Sertoli cell tumor, nodular/proliferative fasciitis, calcifying fibrous tumor, aneurysmal bone cyst of soft tissue, STAT6-negative SFT with adipocytic differentiation, undifferentiated small round blue cell tumor, and scar (1 tumor each). Our study confirms that SFT is rare in the pediatric population and that it is potentially overdiagnosed STAT6 immunohistochemistry is recommended to confirm the diagnosis of SFT in the pediatric population.	[Tan, Serena Y.; Zambrano, Eduardo] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; [Szymanski, Linda J.; Parham, David] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90027 USA; [Galliani, Carlos] Childrens Hosp & Clin Minnesota, Dept Pathol, Minneapolis, MN USA	Tan, SY (reprint author), Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.	serenayt@stanford.edu					Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Akiyama T, 2000, CYTOKINE GROWTH F R, V11, P273, DOI 10.1016/S1359-6101(00)00011-3; Althof PA, 2004, MODERN PATHOL, V17, P518, DOI 10.1038/modpathol.3800090; Bhattacharya B, 2005, AM J SURG PATHOL, V29, P653, DOI 10.1097/01.pas.0000157938.95785.da; Cheah AL, 2014, PATHOLOGY, V46, P389, DOI 10.1097/PAT.0000000000000122; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Cook JR, 2001, AM J SURG PATHOL, V25, P1364, DOI 10.1097/00000478-200111000-00003; Creytens D, 2016, APPL IMMUNOHISTO M M, V24, pE12, DOI 10.1097/PAI.0000000000000166; Dagrada GP, 2015, MODERN PATHOL, V28, P1074, DOI 10.1038/modpathol.2015.70; Debelenko LV, 2010, PEDIATR DEVEL PATHOL, V13, P218, DOI 10.2350/09-08-0694-OA.1; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Doyle LA, 2011, AM J SURG PATHOL, V35, P733, DOI 10.1097/PAS.0b013e318210c268; ENZINGER FM, 1976, HUM PATHOL, V7, P61, DOI 10.1016/S0046-8177(76)80006-8; Fletcher C, 1994, CURRENT DIAGNOSTIC P, V1, P19; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Gengler C, 2006, HISTOPATHOLOGY, V48, P63, DOI 10.1111/j.1365-2559.2005.02290.x; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Kashima T, 2012, MODERN PATHOL, V25, P1384, DOI 10.1038/modpathol.2012.90; Koelsche C, 2014, HISTOPATHOLOGY, V65, P613, DOI 10.1111/his.12431; Madala Jayakiran, 2015, J Oral Maxillofac Pathol, V19, P92, DOI 10.4103/0973-029X.157209; Mohajeri A, 2013, GENE CHROMOSOME CANC, V52, P873, DOI 10.1002/gcc.22083; NIELSEN GP, 1995, AM J SURG PATHOL, V19, P748, DOI 10.1097/00000478-199507000-00002; Panagopoulos I, 2007, GENE CHROMOSOME CANC, V46, P181, DOI 10.1002/gcc.20395; Rakheja D, 2005, ARCH PATHOL LAB MED, V129, P776; Rizk T, 2013, J NEUROSURG-PEDIATR, V11, P79, DOI 10.3171/2012.10.PEDS11250; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rubacha M, 2015, CHILD NERV SYST, V31, P2379, DOI 10.1007/s00381-015-2761-z; Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6; Stout AP, 1942, ANN SURG, V116, P26, DOI 10.1097/00000658-194207000-00004; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	32	2	2	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					389	400		10.1177/1093526617745431			12	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400006	29228868				2019-10-28	
J	Brundler, MA; Kurek, KC; Patel, K; Jester, I				Brundler, Marie-Anne; Kurek, Kyle C.; Patel, Kamlesh; Jester, Ingo			Submucosal Colonic Lipoblastoma Presenting With Colo-colonic Intussusception in an Infant	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						lipoblastoma; PLAGI; immunohistochemistry; intussusception; pathological lead point; pediatric; colon	MESENCHYMAL TUMORS; LEAD POINT; LIPOMA; EXPRESSION; VOLVULUS; TISSUE; HMGA2	Lipoblastoma is a benign adipose tumor typically presenting in infancy in superficial soft tissues of extremities. Intestinal complications secondary to intraabdominal or retroperitoneal involvement are exceedingly rare. We describe a unique case of a primary intestinal lipoblastoma arising from the submucosa of the transverse colon in an otherwise healthy 18-month-old boy. He presented with a history of reducible rectal prolapse, rectal bleeding, and episodic abdominal pain and was initially treated for constipation. Imaging identified a short colo-colonic intussusception, confirmed at laparotomy, and a fatty mass thought to arise from the mesentery. Pathological examination of the resected transverse colon revealed a submucosal tumor composed of a mixture of mature adipose tissue, foci of myxoid mesenchymal tissue with desmin positive, HMGA2 negative spindle cells, and scattered lipoblasts, characteristic of lipoblastoma. Lipoblastoma should be considered as a potential albeit rare cause of intussusception in young children, where a pathologic lead point is infrequently identified.	[Brundler, Marie-Anne] Birmingham Childrens Hosp, Dept Histopathol, Birmingham, W Midlands, England; [Brundler, Marie-Anne; Kurek, Kyle C.] Univ Calgary, Cumming Sch Med, Dept Pathol & Lab Med, Calgary, AB T3B 6A8, Canada; [Brundler, Marie-Anne] Univ Calgary, Cumming Sch Med, Dept Pediat, Calgary, AB T3B 6A8, Canada; [Patel, Kamlesh; Jester, Ingo] Birmingham Childrens Hosp, Dept Paediat Surg, Birmingham, W Midlands, England	Brundler, MA (reprint author), Univ Calgary, Cumming Sch Med, Dept Pathol & Lab Med, Calgary, AB T3B 6A8, Canada.; Brundler, MA (reprint author), Univ Calgary, Cumming Sch Med, Dept Pediat, Calgary, AB T3B 6A8, Canada.	marie-anne.brundler@cls.ab.ca					Asaumi Y, 2014, GASTROENTEROL REP, V2, P70, DOI 10.1093/gastro/got032; Blakelock RT, 1998, PEDIATR SURG INT, V14, P163, DOI 10.1007/s003830050475; Coffin MC, 2012, PEDIAT DEV PATHOL, V15, pS239; Cviko A, 2009, PEDIAT DEV PATHOL, V12, P322; Debelenko L, 2009, PEDIAT DEV PATHOL, V12, P321; Draus JM, 2008, J PEDIATR GASTR NUTR, V47, P372, DOI 10.1097/MPG.0b013e318076b489; Dreux N, 2010, MODERN PATHOL, V23, P1657, DOI 10.1038/modpathol.2010.174; Fetsch JF, 2000, AM J SURG PATHOL, V24, P1491, DOI 10.1097/00000478-200011000-00004; Gisselsson D, 2001, AM J PATHOL, V159, P955, DOI 10.1016/S0002-9440(10)61771-3; Kubota F, 2013, PATHOL INT, V63, P353, DOI 10.1111/pin.12077; Matsuyama A, 2012, PATHOL INT, V62, P1, DOI 10.1111/j.1440-1827.2011.02740.x; MCGRATH FP, 1991, PEDIATR RADIOL, V21, P590, DOI 10.1007/BF02012606; Mendez-Gallart R, 2007, J PEDIATR SURG, V42, P1149, DOI 10.1016/j.jpedsurg.2007.02.031; Nagano Y, 2017, ASIAN J SURG, V40, P70, DOI 10.1016/j.asjsur.2013.01.009; Pedeutour F, 2012, PEDIATR BLOOD CANCER, V58, P798, DOI 10.1002/pbc.23335; Saad AG, 2007, MODERN PATHOL, V20, p314A; Weiss SW, 2014, ENZINGER WEISSS SOFT, P443; Yu DC, 2009, J PEDIATR SURG, V44, pE25, DOI 10.1016/j.jpedsurg.2008.11.037	18	1	1	1	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					401	405		10.1177/1093526617705271			5	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400007	28420321				2019-10-28	
J	Camille, A; Anne-Sophie, B; Cecile, P; Severine, BC; Gaelle, P; Olivier, D; Geraldine, SS; Mc Leer-Florin, A; Eleni, N; Christian, P; Chantal, D; Dominique, P; Herve, S				Camille, Allirot; Anne-Sophie, Bidaut; Cecile, Perret; Severine, Bobillier-Chaumont; Gaelle, Pierron; Olivier, Delattre; Geraldine, Saada-Sebag; Mc Leer-Florin, Anne; Eleni, Nika; Christian, Piolat; Chantal, Durand; Dominique, Plantaz; Herve, Sartelet			Sarcoma With CIC-DUX4 Gene Fusion: Case Report of Kidney Tumor Location in a 12-year-old Boy	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						renal sarcoma; CIC-DUX4 rearrangement; Ewing sarcoma; child; fluorescence in situ hybridization; reverse transcriptase polymerase chain reaction	ROUND-CELL SARCOMA; EWING-LIKE SARCOMAS; SOFT-TISSUE TUMORS; T(4/19)(Q35,Q13.1); TRANSLOCATION; ENTITIES; FEATURES; VARIANT; FAMILY	Recent molecular advances have identified a novel sarcoma defined molecularly by oncogenic fusion of the genes CIC and DUX4 termed CIC-DUX4 sarcomas. The most common site of involvement was the trunk but some cases have been described in the head and neck and extremities. We report one of the first cases of primitive renal CIC-DUX4 sarcoma: a 12-year-old boy who presented a renal tumor, a vena cava thrombus, and lung metastases. The morphological and immunohistochemical analysis showed an undifferentiated sarcoma. Molecular analysis demonstrated a CIC-DUX4 translocation, confirmed by fluorescence in situ hybridization. Despite treatment with chemotherapy, the evolution was unfavorable and the patient died 17 months after the diagnosis in a context of brain metastases. The diagnosis of sarcoma with CIC-DUX4 gene fusion is difficult in lack of specific pathological characteristics emphasizing the need for molecular analysis. Treatment has not yet been codified for these very aggressive tumors.	[Camille, Allirot; Cecile, Perret; Severine, Bobillier-Chaumont; Dominique, Plantaz] CHU Grenoble, Dept Oncol Pediat, Grenoble, France; [Anne-Sophie, Bidaut; Geraldine, Saada-Sebag; Mc Leer-Florin, Anne; Eleni, Nika; Herve, Sartelet] CHU Grenoble, Dept Pathol, Grenoble, France; [Gaelle, Pierron; Olivier, Delattre] Inst Curie, Lab Genet & Biol Canc, INSERM U830, Paris, France; [Christian, Piolat] CHU Grenoble, Dept Chirurg, Grenoble, France; [Chantal, Durand] CHU Grenoble, Dept Radiol, Grenoble, France	Herve, S (reprint author), CHU Grenoble, Dept Anat & Cytol Pathol, Ave Marquis Gresivaudan, F-38700 La Tronche, France.	hsartelet@chu-grenoble.fr	McLEER, Anne/C-6711-2013	McLEER, Anne/0000-0001-9638-4085; delattre, olivier/0000-0002-8730-2276			Bagatell R, 2002, J PEDIAT HEMATOL ONC, V24, P397, DOI 10.1097/00043426-200206000-00015; Bergerat S, 2017, PATHOL RES PRACT, V213, P154, DOI 10.1016/j.prp.2016.11.015; Bielle F, 2014, ACTA NEUROPATHOL, V128, P309, DOI 10.1007/s00401-014-1312-0; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Chebib I, 2016, CANCER CYTOPATHOL, V124, P350, DOI 10.1002/cncy.21685; Choi EYK, 2013, AM J SURG PATHOL, V37, P1379, DOI 10.1097/PAS.0b013e318297a57d; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; Gambarotti M, 2016, HISTOPATHOLOGY, V69, P624, DOI 10.1111/his.12985; Haidar A, 2015, AM J CASE REP, V16, P87, DOI 10.12659/AJCR.892551; Hoot AC, 2004, AM J SURG PATHOL, V28, P1485, DOI 10.1097/01.pas.0000141390.14548.34; Huang CC, 2006, PEDIATR BLOOD CANCER, V46, P728, DOI 10.1002/pbc.20773; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Machado I, 2016, HISTOL HISTOPATHOL, V31, P1169, DOI 10.14670/HH-11-792; Machado I, 2013, VIRCHOWS ARCH, V463, P837, DOI 10.1007/s00428-013-1499-9; Mangray S, 2016, AM J SURG PATHOL, V40, P1298, DOI 10.1097/PAS.0000000000000688; Richkind KE, 1996, CANCER GENET CYTOGEN, V87, P71, DOI 10.1016/0165-4608(95)00240-5; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Tardio JC, 2015, PATHOL RES PRACT, V211, P877, DOI 10.1016/j.prp.2015.08.003; Yamada Y, 2017, VIRCHOWS ARCH, V470, P373, DOI 10.1007/s00428-017-2072-8	20	1	1	0	0	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					406	410		10.1177/1093526617706818			5	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400008	28466754				2019-10-28	
J	Donahue, JE; Yakirevich, E; Zhong, S; Treaba, DO; Lakis, NS; Ali, SM; de la Monte, SM; Mangray, S				Donahue, John E.; Yakirevich, Evgeny; Zhong, Shan; Treaba, Diana O.; Lakis, Nelli S.; Ali, Siraj M.; de la Monte, Suzanne M.; Mangray, Shamlal			Primary Spinal Epidural CIC-DUX4 Undifferentiated Sarcoma in a Child	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						CIC-DUX4; comprehensive genomic profiling; spinal dura; undifferentiated sarcoma	ROUND-CELL SARCOMA; SOFT-TISSUE; EWING SARCOMAS; GENE FUSION; TUMOR; TRANSLOCATION; ENTITIES; VARIANT; FAMILY; KIDNEY	Primitive round- or spindle-cell EWSRI-negative undifferentiated sarcomas harboring CIC-DUX4 gene fusion are the most common form of Ewing-like sarcomas. These tumors primarily occur in peripheral soft tissues, but examples have been described within viscera and the brain. As far as we are aware, CIC-DUX4 positive primary epidural spinal sarcoma has not been reported. Herein, we describe a T5-T6 epidural tumor in a 15-year-old girl in which many neoplastic cells had moderate and focally abundant cytoplasm, including plasmacytoid or rhabdoid cells, rather than the more common Ewing-like morphology described in the majority of such tumors. The diagnosis was confirmed by fluorescent in situ hybridization after the tumor was found to be WT-1 positive, and comprehensive genomic profiling demonstrated breakpoints in exon 20 and exon 1 of the CIC and DUX4 genes, respectively. After treatment with local radiation and systemic chemotherapy, resected recurrent tumor demonstrated more pleomorphic neoplastic cells as well as intracytoplasmic eosinophilic globules and nuclear pseudoinclusions which may reflect therapy-related changes. Unfortunately, there was further progression of tumor including the development of intracranial lesions, and the patient succumbed to her tumor 22 months after the original resection.	[Donahue, John E.; Yakirevich, Evgeny; Treaba, Diana O.; Lakis, Nelli S.; de la Monte, Suzanne M.; Mangray, Shamlal] Brown Univ, Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA; [Donahue, John E.; Yakirevich, Evgeny; Treaba, Diana O.; Lakis, Nelli S.; de la Monte, Suzanne M.; Mangray, Shamlal] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA; [Zhong, Shan; Ali, Siraj M.] Fdn Med Inc, Cambridge, MA USA	Mangray, S (reprint author), Rhode Isl Hosp, APC 12,593 Eddy St, Providence, RI 02903 USA.	smangray@lifespan.org	de la monte, suzanne/L-7670-2019		NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37 AA011431]		Argani P, 2016, WHO CLASSIFICATION T, P54; Bielle F, 2014, ACTA NEUROPATHOL, V128, P309, DOI 10.1007/s00401-014-1312-0; Choi EYK, 2013, AM J SURG PATHOL, V37, P1379, DOI 10.1097/PAS.0b013e318297a57d; Fletcher CDM, 2013, WHO CLASSIFICATION T, P236; Gambarotti M, 2016, HISTOPATHOLOGY, V69, P624, DOI 10.1111/his.12985; Graham C, 2012, HUM PATHOL, V43, P180, DOI 10.1016/j.humpath.2011.04.023; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P207, DOI 10.1002/gcc.20945; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Kawamura-Saito M, 2006, HUM MOL GENET, V15, P2125, DOI 10.1093/hmg/ddl136; Mangray S, 2016, AM J SURG PATHOL, V40, P1298, DOI 10.1097/PAS.0000000000000688; Smith SC, 2015, MODERN PATHOL, V28, P57, DOI 10.1038/modpathol.2014.83; Specht K, 2014, GENE CHROMOSOME CANC, V53, P622, DOI 10.1002/gcc.22172; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Sugita S, 2014, AM J SURG PATHOL, V38, P1571, DOI 10.1097/PAS.0000000000000286; Yan Y, 2011, J CLIN NEUROSCI, V18, P601, DOI 10.1016/j.jocn.2010.09.012; Yoshida A, 2016, AM J SURG PATHOL, V40, P313, DOI 10.1097/PAS.0000000000000570; Yoshimoto M, 2009, CANCER GENET CYTOGEN, V195, P1, DOI 10.1016/j.cancergencyto.2009.06.015	18	3	4	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					411	417		10.1177/1093526617707856			7	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400009	28474974	Green Accepted			2019-10-28	
J	Ma, J; Pan, C; Yin, MZ				Ma, Jing; Pan, Ci; Yin, Minzhi			Translocation Renal Cell Carcinoma in a Child Previously Treated for Infantile Fibrosarcoma	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						TFE3/Xp11.2 translocation renal cell carcinoma; infantile fibrosarcoma; secondary tumor; pediatric; chemotherapy	CHEMOTHERAPY	We report a child who developed a TFE3/Xp11.2 translocation renal cell carcinoma (RCC) when he was 3 years and 3 months old, after previous treatment for infantile fibrosarcoma (IFS). When he was 3 months old, a left axilla mass has been detected, which was tan and solid, was 1.5 cm in greatest dimension, and composed of sheets of spindle cells that was positive for vimentin and fibronectin. Fluorescence in situ hybridization showed positive result in ETV6 gene rearrangements. The final diagnosis was IFS. After surgery and chemotherapy, he remained disease-free until 3 years; later, he was detected to have a tumor in right kidney which measured 2.5 x 2 x 1.5 cm. The tumor comprised clear-cell features that were arranged in papillary and adenoid architecture. The tumor cells were positive for TFE3 and CK. The diagnosis was TFE3/Xp11.2 translocation RCC. Previous research has reported that the radio/chemotherapy for the first tumor might be involved in the pathogenesis of translocation RCC. In our report, this is the first time the IFS is included in the disease spectrum which can cause secondary translocation RCC.	[Ma, Jing; Yin, Minzhi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Pathol, Shanghai, Peoples R China; [Pan, Ci] Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Hematol & Oncol, Shanghai, Peoples R China	Yin, MZ (reprint author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Childrens Med Ctr, Dept Pathol, Shanghai, Peoples R China.	mzhyin@hotmail.com					Akyuz C, 2010, J PERINATOL, V30, P63, DOI 10.1038/jp.2009.92; Argani P, 2006, J CLIN ONCOL, V24, P1529, DOI 10.1200/JCO.2005.04.4693; Brassesco MS, 2011, CANCER GENET-NY, V204, P108, DOI 10.1016/j.cancergencyto.2010.10.006; Friedman DL, 2010, JNCI-J NATL CANCER I, V102, P1083, DOI 10.1093/jnci/djq238; Harms D, 1995, Curr Top Pathol, V89, P31; Kim SH, 2011, VIRCHOWS ARCH, V459, P299, DOI 10.1007/s00428-011-1127-5; Knezevich SR, 1998, CANCER RES, V58, P5046; Medeiros LJ, 2004, WHO CLASSIFICATION T, P37; Minard-Colin V, 2009, ARCH PEDIATRIE, V16, P1039, DOI 10.1016/j.arcped.2009.03.005; Pflueger D, 2013, NEOPLASIA, V15, P1231, DOI 10.1593/neo.131544; Ramphal R, 2006, AM J CLIN PATHOL, V126, P349, DOI 10.1309/98YE9E442ARLX2X; Ross H, 2010, PATHOLOGY, V42, P369, DOI 10.3109/00313021003767348; Sausville JE, 2009, J PEDIATR UROL, V5, P308, DOI 10.1016/j.jpurol.2009.04.007	13	0	0	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					418	422		10.1177/1093526617707849			5	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400010	28478739				2019-10-28	
J	Yu, WM; Brundler, MA; Wright, Jr				Yu, Weiming; Brundler, Marie-Anne; Wright, James R., Jr.			Polyglucosan Bodies in Placental Extravillious Trophoblast for the Diagnosis of Fatal Perinatal Neuromuscular-type Glycogen Storage Disease Type IV	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						glycogen storage disease IV; inherited metabolic disease; placental pathology; polyglucosan bodies; extravillous trophoblast; metabolic storage disease		The fatal infantile neuromuscular type is the most severe form of glycogen storage disease type IV (GSD IV). We report a case of a 22-day-old female neonate born at 34 weeks gestation with polyhyramnios, fetal hydrops, and severe hypotonia. Placental examination revealed numerous periodic acid schiff-positive diastase-resistant polyglucosan bodies in the cytoplasm of extravillous trophoblast predominantly in the placental basal plate. Muscle biopsy and autopsy findings supported a diagnosis of neuromuscular-type glycogen storage disease type IV with extensive involvement of skeletal muscle, heart, and liver. The diagnosis was confirmed by molecular genetic testing. We could only find I prior report in the English literature that describes placental pathological changes. Our findings suggest that placental examination can be a useful adjunct for early diagnosis, as placentas are often received for pathological examination shortly after birth and usually before a diagnostic muscle biopsy can be performed. Pathologists need to be aware of characteristic placental features.	[Yu, Weiming; Brundler, Marie-Anne; Wright, James R., Jr.] Univ Calgary, Dept Pathol & Lab Med, Cumming Sch Med, Calgary, AB, Canada; [Yu, Weiming; Brundler, Marie-Anne; Wright, James R., Jr.] Univ Calgary, Dept Paediat, Cumming Sch Med, Calgary, AB, Canada; [Yu, Weiming; Brundler, Marie-Anne; Wright, James R., Jr.] Calgary Lab Serv, Calgary, AB, Canada	Wright, Jr (reprint author), Univ Calgary, Calgary Lab Serv, 2888 Shaganappi Trail NW, Calgary, AB T2N 1N4, Canada.	jim.wright@cls.ab.ca					Baergen RN, 2011, MANUAL OF PATHOLOGY OF THE HUMAN PLACENTA, SECOND EDITION, P1, DOI 10.1007/978-1-4419-7494-5; BENDON RW, 1985, AM J OBSTET GYNECOL, V152, P1021, DOI 10.1016/0002-9378(85)90551-4; Benirschke K, 2006, PATHOLOGY HUMAN PLAC, P577; Fox H, 2007, PATHOLOGY PLACENTA, P257; Heerema-McKenney A., 2015, DIAGNOSTIC PATHOLOGY; JONES CJP, 1990, PLACENTA, V11, P395, DOI 10.1016/S0143-4004(05)80215-2; Joshi VV, 1994, HDB PLACENTAL PATHOL, P110; Konstantinidou AE, 2008, PLACENTA, V29, P378, DOI 10.1016/j.placenta.2008.01.005; Kraus FT, 2004, PLACENTAL PATHOLOGY, V3, P65; Magoulas PL, 2012, HUM PATHOL, V43, P943, DOI 10.1016/j.humpath.2011.10.001; Taratuto AL, 2010, NEUROMUSCULAR DISORD, V20, P783, DOI 10.1016/j.nmd.2010.07.275	11	0	0	0	1	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					423	427		10.1177/1093526617707852			5	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400011	28497716				2019-10-28	
J	Herwig-Carl, MC; Gembruch, U; Kuchelmeister, K; Loeffler, KU; Muller, AM				Herwig-Carl, M. C.; Gembruch, U.; Kuchelmeister, K.; Loeffler, K. U.; Mueller, A. M.			Optic Nerve Calcifications of Unknown Etiology in a 24-week-old Fetus	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Letter									[Herwig-Carl, M. C.; Loeffler, K. U.] Univ Bonn, Dept Ophthalmol, Div Ophthalm Pathol, Bonn, Germany; [Gembruch, U.] Univ Bonn, Dept Obstet & Prenatal Med, Bonn, Germany; [Kuchelmeister, K.] Univ Bonn, Dept Neuropathol, Bonn, Germany; [Mueller, A. M.] Univ Clin Bonn, MVZ Venusberg, Ctr Pediat Pathol & Pathol, Bonn, Germany	Herwig-Carl, MC (reprint author), Univ Eye Hosp Bonn, Dept Ophthalmol, Div Ophthalm Pathol, Ernst Abbe Str 2, D-53127 Bonn, Germany.	martina.herwig@ukbonn.de					Ascaso Francisco J, 2011, Ophthalmic Surg Lasers Imaging, V42 Online, pe53, DOI 10.3928/15428877-20110602-03; Monteiro MLR, 2012, CASE REP OPHTHALM, V3, P270, DOI 10.1159/000342261; Phadke RV, 1996, CLIN RADIOL, V51, P359, DOI 10.1016/S0009-9260(96)80116-4	3	0	0	0	4	ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS	LAWRENCE	810 EAST 10TH STREET, LAWRENCE, KS 66044 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JUL-AUG	2018	21	4					428	429		10.1177/1093526617707874			2	Pathology; Pediatrics	Pathology; Pediatrics	GN3FU	WOS:000438890400012	28497717				2019-10-28	
J	Selim, AG; Moore, AS				Selim, Adrian G.; Moore, Andrew S.			Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia Challenges and Future Directions	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Review							DROPLET DIGITAL PCR; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYMERASE-CHAIN-REACTION; DNA COPY NUMBER; CELL TRANSPLANTATION; GENE-MUTATIONS; STANDARD-RISK; RQ-PCR; QUANTIFICATION	The ability to sensitively monitor minimal residual disease (MRD) has played a key role in improving the management and outcomes for a number of leukemias, particularly acute promyelocytic leukemia and childhood acute lymphoblastic leukemia. By contrast, MRD monitoring in acute myeloid leukemia (AML) has been Limited by variable assay methodologies and a relative paucity of patient-specific MRD markers. Inter- and intratumor genetic heterogeneity poses significant challenges for the identification of molecular markers suitable for MRD monitoring in AML, particularly for those cases without structural chromosomal rearrangements associated with fusion genes. Furthermore, the need to discriminate which mutations may be suitable for MRD monitoring creates additional complexity. The mainstay of current molecular MRD monitoring is real-time quantitative PCR, targeting fusion genes, mutations, and gene overexpression. New technologies, particularly next-generation sequencing approaches, offer new ways to overcome these limitations. Here, the authors review the techniques available for molecular MRD monitoring in AML and discuss their utility in clinical practice.	[Selim, Adrian G.; Moore, Andrew S.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia; [Moore, Andrew S.] Childrens Hlth Queensland Hosp & Hlth Serv, Oncol Serv Grp, Brisbane, Qld, Australia; [Moore, Andrew S.] Univ Queensland, UQ Child Hlth Res Ctr, Brisbane, Qld, Australia	Moore, AS (reprint author), Ctr Childrens Hlth Res, Childrens Hlth Queensland Res Directorate, Level 7,62 Graham St, South Brisbane, Qld 4101, Australia.	andy.moore@health.gld.gov.au	Moore, Andrew S/I-6275-2012	Moore, Andrew S/0000-0001-8062-1779	Children's Hospital Foundation, Queensland	Supported by the Children's Hospital Foundation, Queensland (A.S.M.).	Afrin S, 2018, MOL CANCER RES, V16, P279, DOI 10.1158/1541-7786.MCR-17-0569; Al-Issa K, 2016, CANCER BIOL MED, V13, P474, DOI 10.20892/j.issn.2095-3941.2016.0061; Alikian Mary, 2017, Biomol Detect Quantif, V11, P4, DOI 10.1016/j.bdq.2017.01.001; Brambati C, 2016, HAEMATOLOGICA, V101, DOI 10.3324/haematol.2015.135467; Brunetti C, 2017, J MOL DIAGN, V19, P437, DOI 10.1016/j.jmoldx.2017.01.004; Buckley SA, 2017, HAEMATOLOGICA, V102, P865, DOI 10.3324/haematol.2016.159343; Butturini A, 2003, LEUKEMIA RES, V27, P293, DOI 10.1016/S0145-2126(02)00166-2; Cilloni D, 2009, J CLIN ONCOL, V27, P5195, DOI 10.1200/JCO.2009.22.4865; Daniel S, 2015, TRANSCRIPTOME SEQUEN, P31; Della Starza I, 2016, BRIT J HAEMATOL, V174, P541, DOI 10.1111/bjh.14082; Dulery R, 2017, BONE MARROW TRANSPL, V52, P539, DOI 10.1038/bmt.2016.318; Duployez N, 2014, AM J HEMATOL, V89, P610, DOI 10.1002/ajh.23696; Farrar JE, 2016, CANCER RES, V76, P2197, DOI 10.1158/0008-5472.CAN-15-1015; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Gough SM, 2011, BLOOD, V118, P6247, DOI 10.1182/blood-2011-07-328880; Grimwade D, 2014, BLOOD, V124, P3345, DOI 10.1182/blood-2014-05-577593; Grimwade D, 2009, J CLIN ONCOL, V27, P3650, DOI 10.1200/JCO.2008.20.1533; Guseva NV, 2016, CANCER GENET-NY, V209, P303, DOI 10.1016/j.cancergen.2016.05.071; Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633; Hokland P, 2012, BRIT J HAEMATOL, V158, P569, DOI 10.1111/j.1365-2141.2012.09203.x; Hourigan CS, 2017, LEUKEMIA, V31, P1482, DOI 10.1038/leu.2017.113; Ivey A, 2016, NEW ENGL J MED, V374, P422, DOI [10.1056/NEJMc1603847, 10.1056/NEJMoa1507471]; Jaso JM, 2014, BONE MARROW TRANSPL, V49, P1129, DOI 10.1038/bmt.2014.99; Jennings LJ, 2014, J MOL DIAGN, V16, P174, DOI 10.1016/j.jmoldx.2013.10.007; Kayser S, 2015, BLOOD, V125, P2331, DOI 10.1182/blood-2014-11-578815; Klco JM, 2015, JAMA-J AM MED ASSOC, V314, P811, DOI 10.1001/jama.2015.9643; Kronke J, 2013, BLOOD, V122, P100, DOI 10.1182/blood-2013-01-479188; Liang DC, 2013, BLOOD, V121, P2988, DOI 10.1182/blood-2012-06-436782; Maier J., 2014, BLOOD, V124, P1792; Malmberg EBR, 2017, EUR J HAEMATOL, V98, P26, DOI 10.1111/ejh.12780; Marani C, 2013, LEUKEMIA RES, V37, P1606, DOI 10.1016/j.leukres.2013.07.005; Mencia-Trinchant N, 2017, J MOL DIAGN, V19, P537, DOI 10.1016/j.jmoldx.2017.03.005; Metzeler KH, 2016, BLOOD, V128, P686, DOI 10.1182/blood-2016-01-693879; Meyer C, 2018, LEUKEMIA, V32, P273, DOI 10.1038/leu.2017.213; Miotke L, 2014, ANAL CHEM, V86, P2618, DOI 10.1021/ac403843j; Ommen HB, 2016, THER ADV HEMATOL, V7, P3, DOI 10.1177/2040620715614529; Patel JL, 2017, LEUKEMIA RES, V56, P7, DOI 10.1016/j.leukres.2017.01.027; Pinheiro LB, 2012, ANAL CHEM, V84, P1003, DOI 10.1021/ac202578x; Ross DM, 2009, LEUKEMIA, V23, P819, DOI 10.1038/leu.2008.330; Rubnitz JE, 2010, LANCET ONCOL, V11, P543, DOI 10.1016/S1470-2045(10)70090-5; Salipante SJ, 2014, MODERN PATHOL, V27, P1438, DOI 10.1038/modpathol.2014.57; Sallman David A, 2016, Hematol Oncol Stem Cell Ther, V9, P89, DOI 10.1016/j.hemonc.2016.04.003; Steensma DP, 2015, BLOOD, V126, P9, DOI 10.1182/blood-2015-03-631747; Steinbach D, 2015, CLIN CANCER RES, V21, P1353, DOI 10.1158/1078-0432.CCR-14-1999; Struski S, 2017, LEUKEMIA, V31, P565, DOI 10.1038/leu.2016.267; Vora A, 2014, LANCET ONCOL, V15, P809, DOI 10.1016/S1470-2045(14)70243-8; Wang QG, 2013, BRIEF BIOINFORM, V14, P506, DOI 10.1093/bib/bbs044; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Willekens C, 2016, HAEMATOLOGICA, V101, P328, DOI 10.3324/haematol.2015.131946; Wong TN, 2016, BLOOD, V127, P893, DOI 10.1182/blood-2015-10-677021; Yang LX, 2016, AM J HUM GENET, V98, P843, DOI 10.1016/j.ajhg.2016.03.017; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729	52	2	2	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					389	397		10.1016/j.jmoldx.2018.03.005			9	Pathology	Pathology	GN0MH	WOS:000438662200001	29689379				2019-10-28	
J	Gurtler, C; Laible, M; Schwabe, W; Steinhauser, H; Li, XM; Liu, SJ; Schlombs, K; Sahi, U				Guertler, Claudia; Laible, Mark; Schwabe, Wolfgang; Steinhaeuser, Heike; Li, Xingmin; Liu, Shujin; Schlombs, Kornelia; Sahi, Ugur			Transferring a Quantitative Molecular Diagnostic Test to Multiple Real-Time Quantitative PCR Platforms	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CLINICAL-PRACTICE GUIDELINE; ADJUVANT SYSTEMIC THERAPY; CANCER AMERICAN SOCIETY; STAGE BREAST-CANCER; RT-QPCR; REGRESSION PROCEDURES; DIGITAL PCR; EXPRESSION; RELIABILITY; AGREEMENT	Quantitative gene expression assays are increasingly used for diagnosis and research, but are often restricted to specific instrumentation. We propose a robust technical and statistical framework that enables transferring of established real-time quantitative PCR assays across real-time quantitative PCR platforms without compromising analytical and clinical validity. The feasibility of our approach was tested on MammaTyper, an in vitro diagnostic assay that quantifies breast cancer biomarkers and dichotomizes results according to cutoff points. CFX96, Applied Biosystems 7500 Fast, and Mx3000P were chosen as the candidate platforms, whereas the LightCycler 480 II was used as a reference. Two instruments were used per platform, and they were tested initially for equivalence via Bland-Altman and Deming regression analyses. A method comparison approach was adapted to adjust cutoffs for the new systems and the cross-platform agreement was evaluated. Finally, precision was estimated for each platform. The performance on the candidate devices was highly comparable to the reference platform, with a 7 log quantification range and amplification efficiencies of 97% to 103%. The equivalence tests successfully prequalified instruments, preventing constant and proportional errors and enabling reliable adjustments of cutoffs, which resulted in cross-platform marker and subtype agreements of 91% to 100% and kappa values between 0.78 and 1.00. Provided that platform-specific adjustments are implemented, the described process can help expand the operability of quantitative diagnostic tests while maintaining assay performance characteristics.	[Guertler, Claudia; Laible, Mark; Schlombs, Kornelia; Sahi, Ugur] BioNTech Diagnost GmbH, Goldgrube 12, D-55131 Mainz, Germany; [Schwabe, Wolfgang; Steinhaeuser, Heike] Synlab Jena Oncoscreen, Synlab MVZ Weiden GmbH, Jena, Germany; [Li, Xingmin; Liu, Shujin] Shuwen Biotech Co Ltd, Hangzhou, Zhejiang, Peoples R China	Gurtler, C (reprint author), BioNTech Diagnost GmbH, Goldgrube 12, D-55131 Mainz, Germany.	claudia.guertler@biontech.de		Liu, Shujin/0000-0002-4174-5100	BioNTech Diagnostics GmbH	Supported by BioNTech Diagnostics GmbH, manufacturer of the RNXtract and MammaTyper kits, who provided free reagents to Synlab MVZ Weiden GmbH and Shuwen Biotech Co Ltd to perform part of the experimental work.	Alikian M, 2017, CLIN CHEM, V63, P525, DOI 10.1373/clinchem.2016.262824; ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Bartlett JW, 2008, ULTRASOUND OBST GYN, V31, P466, DOI 10.1002/uog.5256; BLAND JM, 1986, LANCET, V1, P307; Braun P, 2017, J CLIN VIROL, V92, P75, DOI 10.1016/j.jcv.2017.05.003; Budd JR., 2013, EP09A3 CLSI, V33, P11; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cardoso F, 2016, NEW ENGL J MED, V375, P717, DOI 10.1056/NEJMoa1602253; Cheng Q, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3168; Cherpillod P, 2016, J CLIN VIROL, V77, P9, DOI 10.1016/j.jcv.2016.01.017; Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286; CORNBLEET PJ, 1979, CLIN CHEM, V25, P432; De Smith M. J., 2015, STATSREF STAT ANAL H; Denkert C, 2013, ANN ONCOL, V24, P2786, DOI 10.1093/annonc/mdt350; Denkert C, 2013, ANN ONCOL, V24, P632, DOI 10.1093/annonc/mds339; ELIASZIW M, 1994, PHYS THER, V74, P777, DOI 10.1093/ptj/74.8.777; Emmadi R, 2011, J MOL DIAGN, V13, P583, DOI 10.1016/j.jmoldx.2011.05.011; Field AP, 2013, DISCOVERING STAT USI; Filipits M, 2011, CLIN CANCER RES, V17, P6012, DOI 10.1158/1078-0432.CCR-11-0926; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Forootan Amin, 2017, Biomol Detect Quantif, V12, P1, DOI 10.1016/j.bdq.2017.04.001; Fumagalli D, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1008; Gisev N, 2013, RES SOC ADMIN PHARM, V9, P330, DOI 10.1016/j.sapharm.2012.04.004; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Hinkle D. E., 2003, APPL STAT BEHAV SCI; Hollis S, 1996, ANN CLIN BIOCHEM, V33, P1; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Keller T, 2011, 49 CCLM IFCC WORLDLA; Kennedy S, 2010, PCR TROUBLESHOOTING; Kirkegaard T, 2006, HISTOPATHOLOGY, V48, P787, DOI 10.1111/j.1365-2559.2006.02412.x; Kos Z, 2016, HISTOPATHOLOGY, V68, P70, DOI 10.1111/his.12795; Krop I, 2017, J CLIN ONCOL, V35, P2838, DOI 10.1200/JCO.2017.74.0472; Laible M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2476-x; Lamy PJ, 2015, J MOL DIAGN, V17, P366, DOI 10.1016/j.jmoldx.2015.02.004; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LINNET K, 1993, CLIN CHEM, V39, P424; LINNET K, 1990, STAT MED, V9, P1463, DOI 10.1002/sim.4780091210; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma XJ, 2008, CLIN CANCER RES, V14, P2601, DOI 10.1158/1078-0432.CCR-07-5026; Mcenroe RJ, 2014, EP05A3 CLSI; Murphy J, 2009, EXPERT REV MOL DIAGN, V9, P187, DOI 10.1586/14737159.9.2.187; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; PASSING H, 1983, J CLIN CHEM CLIN BIO, V21, P709; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pierson-Perry JF, 2012, EP17A2 CLSI, V32, P8; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sinn HP, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3111-1; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stahlberg A, 2014, EXPERT REV MOL DIAGN, V14, P323, DOI 10.1586/14737159.2014.901154; Svec David, 2015, Biomol Detect Quantif, V3, P9, DOI 10.1016/j.bdq.2015.01.005; Teutsch SM, 2009, GENET MED, V11, P3, DOI 10.1097/GIM.0b013e318184137c; Tholen DW., 2003, EP06A CLSI NCCLS, V23, P16; Tsongalis GJ, 2006, CLIN CHIM ACTA, V369, P188, DOI 10.1016/j.cca.2006.02.044; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Varga Z, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0848-z; Vermehren J, 2017, J CLIN MICROBIOL, V55, P1131, DOI 10.1128/JCM.02193-16; Vermeulen J, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp721; Walker E, 2011, J GEN INTERN MED, V26, P192, DOI 10.1007/s11606-010-1513-8; Wilson TR, 2014, BREAST CANCER RES TR, V148, P315, DOI 10.1007/s10549-014-3163-8; Wirtz RM, 2016, BREAST CANCER RES TR, V157, P437, DOI 10.1007/s10549-016-3835-7	63	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					398	414		10.1016/j.jmoldx.2018.02.004			17	Pathology	Pathology	GN0MH	WOS:000438662200002	29625248				2019-10-28	
J	Vargas, DY; Marras, SAE; Tyagi, S; Kramer, FR				Vargas, Diana Y.; Marras, Salvatore A. E.; Tyagi, Sanjay; Kramer, Fred R.			Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays that Utilize SuperSelective Primers for the Detection of Rare Somatic Mutations	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MOLECULAR BEACONS; CANCER-PATIENTS; NUCLEIC-ACIDS; LUNG-CANCER; DNA; HYBRIDIZATION; SPECIFICITY; PLASMA; PROBES	In PCR assays designed to detect rare somatic mutations, SuperSelective primers, by virtue of their short 3'-foot sequences, selectively initiate synthesis on mutant DNA target fragments, while suppressing the synthesis of related wild-type fragments, and the resulting threshold cycle reflects the quantity of mutant targets present. However, when there are <= 10 mutant target fragments in a sample, the threshold cycle that is observed occurs so Late that it can be confused with the threshold cycle that arises from samples that contain only abundant related wild-type fragments. We report here that the inclusion of the selectivity enhancing agents tetramethylammonium chloride or bis-tetramethyl-ammonium oxalate in SuperSelective PCR assays substantially suppresses the amplification of related wild-type fragments. As a result of this selective suppression, assay sensitivity is increased to such an extent that multiplex PCR assays can be performed in which it is highly unlikely that there will be a false-positive or false-negative result. This advance provides a foundation for the development of rapid, Low-cost, multiplex PCR assays for noninvasively assessing the presence of relevant mutations in cancer patients, thereby enabling individually appropriate therapy.	[Vargas, Diana Y.; Marras, Salvatore A. E.; Tyagi, Sanjay; Kramer, Fred R.] Rutgers State Univ, New Jersey Med Sch, Publ Hlth Res Inst, Newark, NJ USA; [Marras, Salvatore A. E.; Kramer, Fred R.] Rutgers State Univ, New Jersey Med Sch, Dept Microbiol, Newark, NJ USA; [Marras, Salvatore A. E.; Kramer, Fred R.] Rutgers State Univ, New Jersey Med Sch, Dept Biochem & Mol Genet, Newark, NJ USA; [Tyagi, Sanjay] Rutgers State Univ, New Jersey Med Sch, Dept Med, Newark, NJ USA	Kramer, FR (reprint author), Publ Hlth Res Inst, 225 Warren St, Newark, NJ 07103 USA.	fred.kramer@rutgers.edu		Tyagi, Sanjay/0000-0001-7303-5827	PHRI Properties, Inc. from nonexclusive licensing of molecular beacons technology	Supported by fees and royalties received by PHRI Properties, Inc. (a nonprofit corporation wholly owned by Rutgers University) from the nonexclusive licensing of molecular beacons technology.	Bonnet G, 1998, P NATL ACAD SCI USA, V95, P8602, DOI 10.1073/pnas.95.15.8602; CHEVET E, 1995, NUCLEIC ACIDS RES, V23, P3343, DOI 10.1093/nar/23.16.3343; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HUNG T, 1990, NUCLEIC ACIDS RES, V18, P4953, DOI 10.1093/nar/18.16.4953; Kovarova M, 2000, Nucleic Acids Res, V28, pE70, DOI 10.1093/nar/28.13.e70; Kurz Matthias, 2008, Saline Systems, V4, P6, DOI 10.1186/1746-1448-4-6; Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI 10.1016/j.jmoldx.2017.11.004; LOMELI H, 1989, CLIN CHEM, V35, P1826; Markham NR, 2005, NUCLEIC ACIDS RES, V33, pW577, DOI 10.1093/nar/gki591; Muller JN, 2017, J THORAC ONCOL, V12, P1503, DOI 10.1016/j.jtho.2017.07.014; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Pierce KE, 2005, P NATL ACAD SCI USA, V102, P8609, DOI 10.1073/pnas.0501946102; Poddar SK, 2000, MOL CELL PROBE, V14, P25, DOI 10.1006/mcpr.1999.0278; Sacher AG, 2017, J THORAC ONCOL, V12, P1344, DOI 10.1016/j.jtho.2017.05.022; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49; Vargas DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156546	20	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					415	427		10.1016/j.jmoldx.2018.03.004			13	Pathology	Pathology	GN0MH	WOS:000438662200003	29698835	Other Gold			2019-10-28	
J	Roepman, P; ten Heuvel, A; Scheidel, KC; Sprong, T; Heideman, DAM; Seldenrijk, KA; Herder, GJM; Kummer, JA				Roepman, Paul; ten Heuvel, Alexandra; Scheidel, Karen C.; Sprong, Tobias; Heideman, Danielle A. M.; Seldenrijk, Kees A.; Herder, Gerarda J. M.; Kummer, J. Alain			Added Value of 50-Gene Panel Sequencing to Distinguish Multiple Primary Lung Cancers from Pulmonary Metastases A Systematic Investigation	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MUTATIONS; THERAPY; TUMORS; CLASSIFICATION; CARCINOMAS; EDITION; IMPACT; P53	Differentiation between multiple primary lung cancers and pulmonary metastases (PM) has important implications in staging, prognosis, and treatment strategies. Clinical and immunohistopathologic criteria have been standardized; however, a substantial number of cases remain difficult to classify. Using next-generation sequencing, it is now possible to improve the classification of multiple lung cancer lesions. This study systematically investigated the value of routine morphologic and IHC characteristics, p53 protein expression, TP53 mutation analysis, and 50-gene panel sequencing (GPS) in 111 lesions from 50 patients with multiple lung lesions. Based on immunohistopathologic criteria, 32 paired lesions were classified as multiple primary lung cancer (MPLC) and 21 as PM. TP53 mutation analysis indicated MPLC in 23 and PM in 6 pairs, but in the majority of cases (n = 28, 49%) no mutation was observed and no conclusion could be drawn. In contrast, only 2 pairs were not conclusive using GPS. In a significant number of matching tumor samples (n = 19, 39%), sequencing results were contradictory to the initial immunohistopathology diagnosis. No separation in overall survival for classifications based on immunohistopathology was observed, while a clear but nonsignificant trend was observed concerning survival in MPLC patients (hazard ratio = 3.98) using 50-gene GPS. In about one-third of the patients, GPS provided additional information to improve the differentiation between MPLC and PM.	[Roepman, Paul; Scheidel, Karen C.; Sprong, Tobias; Seldenrijk, Kees A.; Kummer, J. Alain] St Antonius Hosp, Pathol DNA, POB 2500, NL-3430 EM Nieuwegein, Netherlands; [ten Heuvel, Alexandra; Herder, Gerarda J. M.] St Antonius Hosp, Dept Pulm Dis, Nieuwegein, Netherlands; [Heideman, Danielle A. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands	Roepman, P (reprint author), St Antonius Hosp, Pathol DNA, POB 2500, NL-3430 EM Nieuwegein, Netherlands.	moleculair@pathologie-dna.nl			St. Antonius Hospital Innovation Fund	Supported by the St. Antonius Hospital Innovation Fund.	Adebonojo SA, 1997, CHEST, V112, P693, DOI 10.1378/chest.112.3.693; Arai J, 2012, LUNG CANCER, V77, P281, DOI 10.1016/j.lungcan.2012.04.003; Detterbeck FC, 2016, J THORAC ONCOL, V11, P651, DOI 10.1016/j.jtho.2016.01.025; Dietel M, 2015, CANCER GENE THER, V22, P417, DOI 10.1038/cgt.2015.39; Gagan J, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0203-x; Gazdar AF, 2009, J NATL CANCER I, V101, P541, DOI 10.1093/jnci/djp059; Girard N, 2009, AM J SURG PATHOL, V33, P1752, DOI 10.1097/PAS.0b013e3181b8cf03; Girard N, 2009, CLIN CANCER RES, V15, P5184, DOI 10.1158/1078-0432.CCR-09-0594; Jesinghaus M, 2015, AM J SURG PATHOL, V39, P1140, DOI 10.1097/PAS.0000000000000423; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Mitsudomi T, 1997, J THORAC CARDIOV SUR, V114, P354, DOI 10.1016/S0022-5223(97)70180-6; Oklibo K, 2009, J THORAC ONCOL, V4, P203, DOI 10.1097/JTO.0b013e3181949c6a; PAIROLERO PC, 1984, ANN THORAC SURG, V38, P331, DOI 10.1016/S0003-4975(10)62281-3; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Saab J, 2017, TRANSL ONCOL, V10, P442, DOI 10.1016/j.tranon.2017.02.009; Scheinin I, 2014, GENOME RES, V24, P2022, DOI 10.1101/gr.175141.114; Schneider F, 2016, MODERN PATHOL, V29, P735, DOI 10.1038/modpathol.2016.66; Shen KR, 2007, CHEST, V132, p290S, DOI 10.1378/chest.07-1382; Shimizu S, 2000, CLIN CANCER RES, V6, P3994; Sikkink SK, 2003, INT J ONCOL, V22, P589; Smits AJJ, 2012, CELL ONCOL, V35, P189, DOI 10.1007/s13402-012-0078-4; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Tang XN, 2005, CANCER RES, V65, P7568, DOI 10.1158/0008-5472.CAN-05-1705; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Wang XY, 2009, JNCI-J NATL CANCER I, V101, P560, DOI 10.1093/jnci/djp054	26	3	3	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					436	445		10.1016/j.jmoldx.2018.02.007			10	Pathology	Pathology	GN0MH	WOS:000438662200005	29625247	Bronze			2019-10-28	
J	Hashiguchi, J; Onozawa, M; Oguri, S; Fujisawa, S; Tsuji, M; Okada, K; Nakagawa, M; Hashimoto, D; Kahata, K; Kondo, T; Shimizu, C; Teshima, T				Hashiguchi, Junichi; Onozawa, Masahiro; Oguri, Satoshi; Fujisawa, Shinichi; Tsuji, Masahisa; Okada, Kohei; Nakagawa, Masao; Hashimoto, Daigo; Kahata, Kaoru; Kondo, Takeshi; Shimizu, Chikara; Teshima, Takanori			Development of a Fluorescence in Situ Hybridization Probe for Detecting IKZF1 Deletion Mutations in Patients with Acute Lymphoblastic Leukemia	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							ILLEGITIMATE V(D)J RECOMBINATION; PROGNOSIS; IKAROS; GENE; ANTIBODIES; ANTIGENS; FREQUENT	Intragenic deletion of IKZF1 is a recurrent genomic alteration in acute lymphoblastic leukemia. The deletions are mediated by illegitimate variable(diversity)joining recombination via cryptic recombination signal sequences (RSSs). We developed a fluorescence in situ hybridization (FISH) probe set that can detect any type of IKZF1 deletion, including the commonly deleted exon 4 to 7 region. The probe set consists of a designed probe for the commonly deleted region (Cy3; red) and a bacterial artificial chromosomes clone probe for detecting the 3' flanking region (Spectrum Green). Intact IKZF1 showed a fusion signal, and the deleted allele showed loss of the red signal (0R1G1F). The FISH probes worked correctly for human leukemic cell lines and clinical samples. One case showed an atypical break-apart signal (1R1G1F). Inverse PCR of the case revealed rearrangement of the excised IKZF1 fragment into a legitimate RSS site at Ig kappa on chromosome 2, suggesting a pathogenic role of this recombination-activating gene 1/2-mediated event. In this study, we established FISH probe detecting IKZF1 deletion in a quick, quantitative, and cost-effective manner, and the results provided a novel insight into B-cell receptor editing by rearrangement of a cryptic RSS-mediated genomic fragment in acute lymphoblastic leukemia pathology.	[Hashiguchi, Junichi; Onozawa, Masahiro; Okada, Kohei; Nakagawa, Masao; Hashimoto, Daigo; Kahata, Kaoru; Kondo, Takeshi; Teshima, Takanori] Hokkaido Univ, Fac Med, Grad Sch Med, Dept Hematol, Sapporo, Hokkaido, Japan; [Oguri, Satoshi; Fujisawa, Shinichi; Shimizu, Chikara] Hokkaido Univ Hosp, Div Lab & Transfus Med, Sapporo, Hokkaido, Japan; [Tsuji, Masahisa] Chromosome Sci Lab, Sapporo, Hokkaido, Japan	Onozawa, M (reprint author), Hokkaido Univ, Fac Med, Dept Hematol, Grad Sch Med,Kita Ku, Kita 15,Nishi 7, Tokyo, Hokkaido 0608638, Japan.	masahiro.onozawa@nifty.ne.jp	Kondo, Takeshi/G-2103-2012	Kondo, Takeshi/0000-0001-7455-5824	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [17K16174, 16K09836]	Supported by the Japan Society for the Promotion of Science, grant-in-aid for young scientists (B) 17K16174 (K.O.) and scientific research (C) 16K09836 (M.O.).	APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; Boer JM, 2016, LEUKEMIA, V30, P32, DOI 10.1038/leu.2015.199; Caye A, 2013, HAEMATOLOGICA, V98, P597, DOI 10.3324/haematol.2012.073965; Clappier E, 2014, LEUKEMIA, V28, P70, DOI 10.1038/leu.2013.277; Dupuis A, 2013, LEUKEMIA, V27, P503, DOI 10.1038/leu.2012.204; Gaballa A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101705; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Ghazavi F, 2015, HAEMATOLOGICA, V100, P1311, DOI 10.3324/haematol.2015.126953; Hazenberg MD, 2001, J MOL MED-JMM, V79, P631, DOI 10.1007/s001090100271; Iacobucci I, 2009, BLOOD, V114, P2159, DOI 10.1182/blood-2008-08-173963; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kobitzsch B, 2017, HAEMATOLOGICA, V102, P1739, DOI 10.3324/haematol.2016.161273; Martinelli G, 2009, J CLIN ONCOL, V27, P5202, DOI 10.1200/JCO.2008.21.6408; Meissner B, 2014, HUM MOL GENET, V23, P590, DOI 10.1093/hmg/ddt447; Mendes RD, 2014, BLOOD, V124, P567, DOI 10.1182/blood-2014-03-562751; Mi JQ, 2012, LEUKEMIA, V26, P1507, DOI 10.1038/leu.2012.23; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253; National Comprehensive Cancer Network (NCCN), 2017, NCCN CLIN PRACT GUID; Onozawa M, 2012, GENE CHROMOSOME CANC, V51, P525, DOI 10.1002/gcc.21942; Ou ZS, 2016, CYTOGENET GENOME RES, V150, P242, DOI 10.1159/000456572; Pieper K, 2017, NATURE, V548, P597, DOI 10.1038/nature23670; Rommel PC, 2017, J EXP MED, V214, P815, DOI 10.1084/jem.20161638; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Tan J, 2016, NATURE, V529, P105, DOI 10.1038/nature16450; Venn NC, 2012, LEUKEMIA, V26, P1414, DOI 10.1038/leu.2011.348; Waanders E, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002533; Xie JD, 2014, CANCER GENET-NY, V207, P226, DOI 10.1016/j.cancergen.2014.05.003	28	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					446	454		10.1016/j.jmoldx.2018.02.005			9	Pathology	Pathology	GN0MH	WOS:000438662200006	29957452	Bronze, Green Published			2019-10-28	
J	Dufraing, K; De Hertogh, G; Tack, V; Keppens, C; Dequeker, EMC; van Krieken, JH				Dufraing, Kelly; De Hertogh, Gert; Tack, Veronique; Keppens, Cleo; Dequeker, Elisabeth M. C.; van Krieken, J. Han			External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							COLORECTAL-CANCER; MOLECULAR-PATHOLOGY; MUTATION ANALYSIS; LOW PERCENTAGE; KRAS; VALIDATION; GUIDELINES; THERAPY; BRAF	Neoplastic cell content determination is crucial for biomarker testing. It is known that interobserver variation exists, but largescale data are missing about variation in tumor delineation and cell content determination. Results were obtained from the external quality assessment program for metastatic colorectal cancer from the European Society of Pathology (N = 5776 observations). The study included three parts: current practices were surveyed, neoplastic cell content estimations and delineations were retrieved from stained slides, and clinical reports were analyzed. Seventeen of 43 pathologists determined the neoplastic cell content in a tumor-rich area for DNA extraction and took immune cells (n = 37), tumor cell distribution (n = 33), desmoplastic stroma (n = 30), necrosis (n = 29), and mucus (n = 23) into account. The selected area was highly variable, and the average difference between the highest and lowest estimation ranged between 51% and 78% (2011 to 2017). The number of overestimations was alarmingly high in samples containing <30% tumor cells. Of concern is that 33 of 105 laboratories reported a wildtype result in a sample without tumor in 2017. Standardization of neoplastic cell content determination is needed for test outcome interpretation. The authors' data show variation in estimation practices, tumor delineations and estimations, and interpretation problems (n = 226 reports). Further training for selecting the most suitable block and creating clear reports is urgently needed.	[Dufraing, Kelly; Tack, Veronique; Keppens, Cleo; Dequeker, Elisabeth M. C.] Katholieke Univ Leuven, Biomed Qual Assurance Res Unit, Dept Publ Hlth & Primary Care, Kapucijnenvoer 35 Block D,Box 7001, B-3000 Leuven, Belgium; [Dufraing, Kelly; van Krieken, J. Han] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, Nijmegen, Netherlands; [De Hertogh, Gert] Univ Hosp Leuven, Dept Pathol, Leuven, Belgium	Dequeker, EMC (reprint author), Katholieke Univ Leuven, Biomed Qual Assurance Res Unit, Dept Publ Hlth & Primary Care, Kapucijnenvoer 35 Block D,Box 7001, B-3000 Leuven, Belgium.	els.dequeker@kuleuven.be	van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040; van Krieken, Joannes/0000-0002-8105-0450; Keppens, Cleo/0000-0002-4498-8386; Dufraing, Kelly/0000-0002-0418-587X			[Anonymous], 2012, 151892012 ISO; Bellon E, 2011, ONCOLOGIST, V16, P467, DOI 10.1634/theoncologist.2010-0429; Boleij A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2810-3; Dibben SM, 2012, J MOL DIAGN, V14, P130, DOI 10.1016/j.jmoldx.2011.10.002; Dijkstra JR, 2013, VIRCHOWS ARCH, V462, P39, DOI 10.1007/s00428-012-1356-2; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Hamilton PW, 2015, ONCOTARGET, V6, P27938, DOI 10.18632/oncotarget.4391; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Kazanis I, 2013, HEALTH POLICY, V109, P46, DOI 10.1016/j.healthpol.2012.03.020; Lamy A, 2011, MODERN PATHOL, V24, P1090, DOI 10.1038/modpathol.2011.60; Lewandowska MA, 2013, MOL DIAGN THER, V17, P193, DOI 10.1007/s40291-013-0025-8; Lhermitte B, 2017, VIRCHOWS ARCH, V470, P21, DOI 10.1007/s00428-016-2042-6; Lin MT, 2014, AM J CLIN PATHOL, V141, P856, DOI 10.1309/AJCPMWGWGO34EGOD; Loree JM, 2017, J GASTROINTEST ONCOL, V8, P199, DOI 10.21037/jgo.2017.01.01; Nichols Larry, 2016, Autops Case Rep, V6, P1; Nielsen SL, 2017, APPL IMMUNOHISTO M M, V25, P320, DOI 10.1097/PAI.0000000000000463; Nowak F, 2012, NAT REV CLIN ONCOL, V9, P479, DOI 10.1038/nrclinonc.2012.42; Robboy SJ, 2015, ARCH PATHOL LAB MED, V139, P1413, DOI 10.5858/arpa.2014-0559-OA; Smits AJJ, 2014, MODERN PATHOL, V27, P168, DOI 10.1038/modpathol.2013.134; Strom SP, 2016, CANCER BIOL MED, V13, P3, DOI 10.28092/j.issn.2095-3941.2016.0004; Tack V, 2017, VIRCHOWS ARCH, V471, P199, DOI 10.1007/s00428-017-2108-0; Tack V, 2015, ONCOLOGIST, V20, P257, DOI 10.1634/theoncologist.2014-0382; Tembuyser L, 2014, J MOL DIAGN, V16, P371, DOI 10.1016/j.jmoldx.2014.01.003; van Krieken JH, 2013, VIRCHOWS ARCH, V462, P27, DOI 10.1007/s00428-012-1354-4; Viray H, 2013, ARCH PATHOL LAB MED, V137, P1545, DOI 10.5858/arpa.2012-0561-CP; Warth A, 2016, VIRCHOWS ARCH, V468, P101, DOI 10.1007/s00428-015-1869-6; Weichert W, 2010, J MOL DIAGN, V12, P35, DOI 10.2353/jmoldx.2010.090079; Zarkavelis G, 2017, ANN GASTROENTEROL, V30, P613, DOI 10.20524/aog.2017.0191	28	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					455	464		10.1016/j.jmoldx.2018.03.003			10	Pathology	Pathology	GN0MH	WOS:000438662200007	29625250	Green Published			2019-10-28	
J	Yauy, K; Baux, D; Pegeot, H; Van Goethem, C; Mathieu, C; Guignard, T; Morales, RJ; Lacourt, D; Krahn, M; Lehtokari, VL; Bonne, G; Tuffery-Giraud, S; Koenig, M; Cossee, M				Yauy, Kevin; Baux, David; Pegeot, Henri; Van Goethem, Charles; Mathieu, Charly; Guignard, Thomas; Morales, Raul Juntas; Lacourt, Delphine; Krahn, Martin; Lehtokari, Vilma-Lotta; Bonne, Gisele; Tuffery-Giraud, Sylvie; Koenig, Michel; Cossee, Mireille			MoBiDiC Prioritization Algorithm, a Free, Accessible, and Efficient Pipeline for Single-Nucleotide Variant Annotation and Prioritization for Next-Generation Sequencing Routine Molecular Diagnosis	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							IN-SILICO PREDICTION; MUTATION DATABASE; GENETIC-VARIATION; HUMAN GENOMES; UPDATE; GUIDELINES; DISORDERS; STANDARDS; CLINVAR; TOOLS	Interpretation of next-generation sequencing constitutes the main limitation of molecular diagnostics. In diagnosing myopathies and muscular dystrophies, another issue is efficiency in predicting the pathogenicity of variants identified in large genes, especially TTN; current in silico prediction tools show limitations in predicting and ranking the numerous variants of such genes. We propose a variant-prioritization tool, the MoBiDiC prioritization algorithm (MPA). MPA is based on curated interpretation of data on previously reported variants, biological assumptions, and splice and missense predictors, and is used to prioritize all types of single-nucleotide variants. MPA was validated by comparing its sensitivity and specificity to those of dbNSFP database prediction tools, using a data set composed of DYSF, DMD, LMNA, NEB, and TTN variants extracted from expert-reviewed and ExAC databases. MPA obtained the best annotation rates for missense and splice variants. As MPA aggregates the results from several predictors, individual predictor errors are counterweighted, improving the sensitivity and specificity of missense and splice variant predictions. We propose a sequential use of MPA, beginning with the selection of variants with higher scores and followed by, in the absence of candidate pathologic variants, consideration of variants with lower scores. We provide scripts and documentation for free academic use and a validated annotation pipeline scaled for panel and exome sequencing to prioritize single-nucleotide variants from a VCF file.	[Yauy, Kevin; Baux, David; Pegeot, Henri; Mathieu, Charly; Morales, Raul Juntas; Lacourt, Delphine; Koenig, Michel; Cossee, Mireille] CHU Montpellier, Hop Arnaud de Villeneuve, Lab Genet Mol, Montpellier, France; [Guignard, Thomas] CHU Montpellier, Hop Arnaud de Villeneuve, Ctr Reference Anomalies Dev & Syndromes Malformat, Plateforme Rech Microremaniements Chromosom, Montpellier, France; [Van Goethem, Charles] CHU Montpellier, Hop Arnaud de Villeneuve, Dept Genet Med Malad Rares & Med Personnalisee, Montpellier, France; [Van Goethem, Charles] CHU Montpellier, Hop Arnaud de Villeneuve, Lab Biopathol Cellulaire & Tissulaire Tumeurs, Montpellier, France; [Guignard, Thomas] Univ Montpellier, Fac Med Montpellier Nimes, Montpellier, France; [Tuffery-Giraud, Sylvie; Koenig, Michel; Cossee, Mireille] Univ Montpellier, Lab Genet Malad Rares, EA7402, Montpellier, France; [Krahn, Martin] Univ Aix Marseille, INSERM, Unite Genet Med & Genom Fonct, UMRS910, Marseille, France; [Krahn, Martin] Hop Timone Enfants, AP HM, Dept Genet Med, Marseille, France; [Lehtokari, Vilma-Lotta] Univ Helsinki, Haartman Inst, Folkhalsan Inst Genet, Helsinki, Finland; [Lehtokari, Vilma-Lotta] Univ Helsinki, Haartman Inst, Dept Med Genet, Helsinki, Finland; [Bonne, Gisele] Sorbonne Univ, Univ Pierre & Marie Curie, Therapie Malad Muscle Striee, Unite INSERM U974, Paris, France; [Bonne, Gisele] Sorbonne Univ, Univ Pierre & Marie Curie, Inst Myol, Ctr Res Myol, Paris, France	Yauy, K (reprint author), Univ Montpellier, CHU Montpellier, Lab Genet Mol, Inst Univ Rech Clin, 641 Ave Doyen Gaston Giraud, F-34093 Montpellier 5, France.	k-yauy@chu-montpellier.fr	Bonne, Gisele/G-3121-2013	Bonne, Gisele/0000-0002-2516-3258; Yauy, Kevin/0000-0001-6901-1670; Baux, David/0000-0003-3423-1221; Lehtokari, Vilma-Lotta/0000-0002-8276-0972			Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Bendl J, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004962; Beroud C, 2005, HUM MUTAT, V26, P184, DOI 10.1002/humu.20210; Bland A, 2018, GENET MED, V20, P369, DOI 10.1038/gim.2017.212; Blandin G, 2012, HUM MUTAT, V33, pE2317, DOI 10.1002/humu.22015; Chauveau C, 2014, HUM MUTAT, V35, P1046, DOI 10.1002/humu.22611; Chisholm C, 2018, GENET MED, V20, P365, DOI 10.1038/gim.2017.191; Choi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046688; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Endrullat C, 2016, APPL TRANSL GENOM, V10, P2, DOI 10.1016/j.atg.2016.06.001; Eng L, 2004, HUM MUTAT, V23, P67, DOI 10.1002/humu.10295; Fokkema IFAC, 2011, HUM MUTAT, V32, P557, DOI 10.1002/humu.21438; Geoffroy V, 2015, PEERJ, V3, DOI 10.7717/peerj.796; Grimm DG, 2015, HUM MUTAT, V36, P513, DOI 10.1002/humu.22768; Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514; Hasin-Brumshtein Y, 2009, TRENDS GENET, V25, P178, DOI 10.1016/j.tig.2009.02.002; Jagadeesh KA, 2016, NAT GENET, V48, P1581, DOI 10.1038/ng.3703; Jian XQ, 2017, METHODS MOL BIOL, V1498, P191, DOI 10.1007/978-1-4939-6472-7_13; Jian XQ, 2014, NUCLEIC ACIDS RES, V42, P13534, DOI 10.1093/nar/gku1206; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Lehtokari VL, 2014, HUM MUTAT, V35, P1418, DOI 10.1002/humu.22693; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lelieveld SH, 2016, HUM GENET, V135, P603, DOI 10.1007/s00439-016-1658-6; Liu XM, 2016, HUM MUTAT, V37, P235, DOI 10.1002/humu.22932; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; O'Leary NA, 2016, NUCLEIC ACIDS RES, V44, pD733, DOI 10.1093/nar/gkv1189; Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Scholz MB, 2012, CURR OPIN BIOTECH, V23, P9, DOI 10.1016/j.copbio.2011.11.013; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Shihab HA, 2015, BIOINFORMATICS, V31, P1536, DOI 10.1093/bioinformatics/btv009; Shihab HA, 2014, HUM GENOMICS, V8, DOI 10.1186/1479-7364-8-11; Shihab HA, 2013, HUM MUTAT, V34, P57, DOI 10.1002/humu.22225; Stenson PD, 2017, HUM GENET, V136, P665, DOI 10.1007/s00439-017-1779-6; Sterne-Weiler T, 2014, GENOME BIOL, V15, DOI 10.1186/gb4150; Sudmant PH, 2015, NATURE, V526, P75, DOI 10.1038/nature15394; Tarailo-Graovac M, 2017, GENET MED, V19, P1300, DOI 10.1038/gim.2017.50; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; Vigeland MD, 2016, BIOINFORMATICS, V32, P1592, DOI 10.1093/bioinformatics/btw046; Vihinen M, 2013, HUM MUTAT, V34, P275, DOI 10.1002/humu.22253; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang W, 2012, J MED GENET, V49, P753, DOI 10.1136/jmedgenet-2012-101001; Whiffin N, 2017, GENET MED, V19, P1151, DOI 10.1038/gim.2017.26; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yang H, 2015, NAT METHODS, V12, P841, DOI [10.1038/NMETH.3484, 10.1038/nmeth.3484]; Yang S, 2017, GENET MED, V19, P1118, DOI 10.1038/gim.2017.60	51	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					465	473		10.1016/j.jmoldx.2018.03.009			9	Pathology	Pathology	GN0MH	WOS:000438662200008	29689380	Bronze			2019-10-28	
J	Coccaro, N; Anelli, L; Zagaria, A; Casieri, P; Tota, G; Orsini, P; Impera, L; Minervini, A; Minervini, CF; Cumbo, C; Parciante, E; Carluccio, P; Brunetti, C; Specchia, G; Albano, F				Coccaro, Nicoletta; Anelli, Luisa; Zagaria, Antonella; Casieri, Paola; Tota, Giuseppina; Orsini, Paola; Impera, Luciana; Minervini, Angela; Minervini, Crescenzio F.; Cumbo, Cosimo; Parciante, Elisa; Carluccio, Paola; Brunetti, Claudia; Specchia, Giorgina; Albano, Francesco			Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; ACUTE PROMYELOCYTIC LEUKEMIA; POLYMERASE-CHAIN-REACTION; FUSION GENE TRANSCRIPTS; REAL-TIME-PCR; MOLECULAR RESPONSE; ABSOLUTE QUANTIFICATION; IMATINIB; CHEMOTHERAPY	The breakpoint cluster region-abelson 1 p190 fusion transcript is the most frequent variant observed in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). Qualitative-PCR and real-time quantitative PCR are the currently used methods to monitor minimal residual disease (MRD) in Ph+ ALL patients; for the latter, full standardization and an international quality validation are lacking. Here, we developed a droplet digital PCR (ddPCR) assay for MRD monitoring in p190+ ALL cases. The analytical performance was assessed by the limit-of-detection determination, showing a reliability, sensitivity, and precision of the assay of up to 0.001%. Comparison of results obtained with qualitative PCR and ddPCR in 117 follow-up samples from 16 of 26 Ph+ ALL patients showed discordant results in 27% of cases (32 of 117). Real-time quantitative PCR analysis of 19 ddPCR-positive samples with a low tumor burden failed to provide quantitative results in 63% of cases (12 of 19). These results highlight that in p190+ ALL the ddPCR method has a sufficient analytical performance for very low MRD monitoring and for predicting molecular relapse several months before hematologic relapse. In conclusion, MRD monitoring by ddPCR may better stratify Ph+ ALL patients at risk of disease progression.	[Coccaro, Nicoletta; Anelli, Luisa; Zagaria, Antonella; Casieri, Paola; Tota, Giuseppina; Orsini, Paola; Impera, Luciana; Minervini, Angela; Minervini, Crescenzio F.; Cumbo, Cosimo; Parciante, Elisa; Carluccio, Paola; Brunetti, Claudia; Specchia, Giorgina; Albano, Francesco] Univ Bari, Dept Emergency & Organ Transplantat, Hematol Sect, Piazza G Cesare 11, I-70124 Bari, Italy	Albano, F (reprint author), Univ Bari, Dept Emergency & Organ Transplantat, Hematol Sect, Piazza G Cesare 11, I-70124 Bari, Italy.	francesco.albano@uniba.it	Albano, Francesco/J-2352-2016; CUMBO, COSIMO/S-5834-2019	Albano, Francesco/0000-0001-7926-6052; CUMBO, COSIMO/0000-0002-2509-6200; Minervini, Crescenzio/0000-0002-4382-9906	Associazione Italiana contro le Leucemie-Bari	Supported by the Associazione Italiana contro le Leucemie-Bari.	Albano F, 2007, CANCER GENET CYTOGEN, V174, P121, DOI 10.1016/j.cancergencyto.2006.09.025; Albano F, 2015, ONCOTARGET, V6, P13269, DOI 10.18632/oncotarget.3773; Albano F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-120; Anelli L, 2016, ANN HEMATOL, V95, P1559, DOI 10.1007/s00277-016-2739-2; Baker M, 2012, NAT METHODS, V9, P541, DOI 10.1038/nmeth.2027; Branford S, 2016, HEMATOL-AM SOC HEMAT, P156, DOI 10.1182/asheducation-2016.1.156; Brunetti C, 2017, J MOL DIAGN, V19, P437, DOI 10.1016/j.jmoldx.2017.01.004; Burmeister T, 2008, BLOOD, V112, P918, DOI 10.1182/blood-2008-04-149286; Chiaretti S, 2016, HAEMATOLOGICA, V101, P1544, DOI 10.3324/haematol.2016.144535; Coccaro N, 2017, LEUKEMIA LYMPHOMA, V18, P1; Coccaro N, 2016, ONCOL LETT, V12, P1460, DOI 10.3892/ol.2016.4759; Cross NCP, 2016, LEUKEMIA, V30, P1844, DOI 10.1038/leu.2016.90; Cross NCP, 2015, LEUKEMIA, V29, P999, DOI 10.1038/leu.2015.29; Cross NCP, 2012, LEUKEMIA, V26, P2172, DOI 10.1038/leu.2012.104; Della Starza I, 2016, BRIT J HAEMATOL, V174, P541, DOI 10.1111/bjh.14082; Drandi D, 2015, J MOL DIAGN, V17, P652, DOI 10.1016/j.jmoldx.2015.05.007; Faderl S, 2003, CANCER-AM CANCER SOC, V98, P1337, DOI 10.1002/cncr.11664; Fielding Adele K, 2015, Am Soc Clin Oncol Educ Book, pe352, DOI 10.14694/EdBook_AM.2015.35.e352; Fielding AK, 2010, BLOOD, V116, P3409, DOI 10.1182/blood-2010-01-242750; Foa R, 2011, BLOOD, V118, P6521, DOI 10.1182/blood-2011-05-351403; Foroni L, 2011, BRIT J HAEMATOL, V153, P179, DOI 10.1111/j.1365-2141.2011.08603.x; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Iacobucci I, 2014, LEUKEMIA RES, V38, P581, DOI 10.1016/j.leukres.2014.02.005; Jennings LJ, 2014, J MOL DIAGN, V16, P174, DOI 10.1016/j.jmoldx.2013.10.007; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kim DY, 2015, BLOOD, V126, P746, DOI 10.1182/blood-2015-03-636548; Ladetto M, 2016, LEUKEMIA, V30, P1211, DOI 10.1038/leu.2015.269; Lee S, 2012, LEUKEMIA, V26, P2367, DOI 10.1038/leu.2012.164; Lee S, 2003, BRIT J HAEMATOL, V120, P145, DOI 10.1046/j.1365-2141.2003.03988.x; Lim SN, 2015, AM J HEMATOL, V90, P1013, DOI 10.1002/ajh.24137; Liu-Dumlao T, 2012, CURR ONCOL REP, V14, P387, DOI 10.1007/s11912-012-0247-7; Malagola M, 2016, ANN HEMATOL, V95, P681, DOI 10.1007/s00277-016-2617-y; Minervini A, 2016, ONCOTARGET, V7, P86469, DOI 10.18632/oncotarget.13246; Ottmann O, 2007, BLOOD, V110, P2309, DOI 10.1182/blood-2007-02-073528; Ravandi F, 2013, BLOOD, V122, P1214, DOI 10.1182/blood-2012-11-466482; Ravandi F, 2009, HEMATOL ONCOL CLIN N, V23, P1043, DOI 10.1016/j.hoc.2009.07.007; Shaffer LG, 2013, ISCN 2013 INT SYSTEM; Short NJ, 2016, BLOOD, V128, P504, DOI 10.1182/blood-2016-03-707562; Stahl T, 2015, EXP HEMATOL, V43, P462, DOI 10.1016/j.exphem.2015.02.006; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; van der Velden VHJ, 2007, LEUKEMIA, V21, P604, DOI 10.1038/sj.leu.2404586; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; Vignetti M, 2007, BLOOD, V109, P3676, DOI 10.1182/blood-2006-10-052746; Wassmann B, 2005, BLOOD, V106, P458, DOI 10.1182/blood-2004-05-1746; Wetzler M, 1999, BLOOD, V93, P3983; Yoon JH, 2016, ANN ONCOL, V27, P1081, DOI 10.1093/annonc/mdw123; Zagaria A, 2015, VIRCHOWS ARCH, V467, P357, DOI 10.1007/s00428-015-1802-z	49	7	7	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					474	482		10.1016/j.jmoldx.2018.03.002			9	Pathology	Pathology	GN0MH	WOS:000438662200009	29625246				2019-10-28	
J	Keppens, C; Palma, JF; Das, PM; Scudder, S; Wen, W; Normanno, N; van Krieken, JH; Sacco, A; Fenizia, F; de Castro, DG; Honigschnabl, S; Kern, I; Lopez-Rios, F; Lozano, MD; Marchetti, A; Halfon, P; Schuuring, E; Setinek, U; Sorensen, B; Taniere, P; Tiemann, M; Vosmikova, H; Dequeker, EMC				Keppens, Cleo; Palma, John F.; Das, Partha M.; Scudder, Sidney; Wen, Wei; Normanno, Nicola; van Krieken, J. Han; Sacco, Alessandra; Fenizia, Francesca; de Castro, David Gonzalez; Hoenigschnabl, Selma; Kern, Izidor; Lopez-Rios, Fernando; Lozano, Maria D.; Marchetti, Antonio; Halfon, Philippe; Schuuring, Ed; Setinek, Ulrike; Sorensen, Boe; Taniere, Phillipe; Tiemann, Markus; Vosmikova, Hana; Dequeker, Elisabeth M. C.			Detection of EGFR Variants in Plasma A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CELL LUNG-CANCER; CLINICAL-PRACTICE GUIDELINES; CIRCULATING TUMOR DNA; NSCLC PATIENTS; LIQUID BIOPSIES; ONCOLOGY; GEFITINIB; CTDNA	Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFR variants at six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes.	[Keppens, Cleo; Dequeker, Elisabeth M. C.] Univ Leuven, Dept Publ Hlth & Primary Care, Biomed Qual Assurance Res Unit, Kapucijnenvoer 35d, B-3000 Leuven, Belgium; [Palma, John F.] Roche Sequencing Solut, Pleasanton, CA USA; [Das, Partha M.; Scudder, Sidney; Wen, Wei] Roche Mol Syst, Genom & Oncol, Pleasanton, CA USA; [Normanno, Nicola; Sacco, Alessandra; Fenizia, Francesca] Ist Nazl Tumori Fdn G Pascale IRCCS, Cell Biol & Biotherapy Unit, Naples, Italy; [van Krieken, J. Han] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, Nijmegen, Netherlands; [de Castro, David Gonzalez] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [de Castro, David Gonzalez] Royal Marsden, Surrey, England; [Hoenigschnabl, Selma] SMZO Donauspital, Pathol & Bacteriol, Vienna, Austria; [Kern, Izidor] Univ Clin Resp & Allerg Dis Golnik, Golnik, Slovenia; [Lopez-Rios, Fernando] Hosp Univ HM Sanchinarro, Madrid, Spain; [Lozano, Maria D.] Univ Navarra, Clin Univ Navarra, Pamplona, Spain; [Marchetti, Antonio] Univ G dAnnunzio, Ctr Predict Mol Med, CeSI Met, Chieti, Italy; [Halfon, Philippe] Lab Alphabio, Marseille, France; [Schuuring, Ed] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands; [Setinek, Ulrike] Otto Wagner Spital, Inst Pathol & Bacteriol, Vienna, Austria; [Sorensen, Boe] Aarhus Univ Hosp, Dept Clin Biochem, Aarhus, Denmark; [Taniere, Phillipe] Queen Elizabeth Hosp, Mol Pathol Diagnost Serv, Birmingham, W Midlands, England; [Tiemann, Markus] Inst Haematopathol, Hamburg, Germany; [Vosmikova, Hana] Fac Hosp Hradec Kralove, Hradec Kralove, Czech Republic	Dequeker, EMC (reprint author), Univ Leuven, Dept Publ Hlth & Primary Care, Biomed Qual Assurance Res Unit, Kapucijnenvoer 35d, B-3000 Leuven, Belgium.	els.dequeker@kuleuven.be	Fenizia, Francesca/AAC-1394-2019; van Krieken, Joannes H J M/D-4138-2009	van Krieken, Joannes H J M/0000-0001-6544-1040; Keppens, Cleo/0000-0002-4498-8386; Sacco, Alessandra/0000-0003-2676-0983; Fenizia, Francesca/0000-0003-0523-1919; van Krieken, Joannes/0000-0002-8105-0450			Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Deans ZC, 2017, VIRCHOWS ARCH, V471, P809, DOI 10.1007/s00428-017-2222-z; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Huang Z, 2012, THORAC CANCER, V3, P334, DOI 10.1111/j.1759-7714.2012.00133.x; Karlovich C, 2016, CLIN CANCER RES, V22, P2386, DOI 10.1158/1078-0432.CCR-15-1260; Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Malapelle U, 2017, EXPERT REV MOL DIAGN, V17, P209, DOI 10.1080/14737159.2017.1288568; Marchetti A, 2015, J THORAC ONCOL, V10, P1437, DOI 10.1097/JTO.0000000000000643; Mok T, 2015, CLIN CANCER RES, V21, P3196, DOI 10.1158/1078-0432.CCR-14-2594; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Molina-Vila MA, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00069; Normanno N, 2017, ONCOTARGET, V8, P12501, DOI 10.18632/oncotarget.13915; Normanno N, 2013, J CELL BIOCHEM, V114, P514, DOI 10.1002/jcb.24401; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; O'Brien CP, 2014, LUNG CANCER, V83, P309, DOI 10.1016/j.lungcan.2013.12.010; Reed GF, 2002, CLIN DIAGN LAB IMMUN, V9, P1235, DOI 10.1128/CDLI.9.6.1235-1239.2002; Rolfo C, 2014, BBA-REV CANCER, V1846, P539, DOI 10.1016/j.bbcan.2014.10.001; Stuart BW, 2014, WORLD CANC REPORT; Thress KS, 2015, LUNG CANCER, V90, P509, DOI 10.1016/j.lungcan.2015.10.004; Weber B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-294	23	4	4	4	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					483	494		10.1016/j.jmoldx.2018.03.006			12	Pathology	Pathology	GN0MH	WOS:000438662200010	29704571	Bronze			2019-10-28	
J	Winter, JL; Davila, JI; McDonald, AM; Nair, AA; Fadra, N; Wehrs, RN; Thomas, BC; Balcom, JR; Jin, L; Wu, XL; Voss, JS; Klee, EW; Oliver, GR; Graham, RP; Neff, JL; Rumilla, KM; Aypar, U; Kipp, BR; Jenkins, RB; Jen, J; Halling, KC				Winter, Jennifer L.; Davila, Jaime, I; McDonald, Amber M.; Nair, Asha A.; Fadra, Numrah; Wehrs, Rebecca N.; Thomas, Brittany C.; Balcom, Jessica R.; Jin, Long; Wu, Xianglin; Voss, Jesse S.; Klee, Eric W.; Oliver, Gavin R.; Graham, Rondell P.; Neff, Jadee L.; Rumilla, Kandelaria M.; Aypar, Umut; Kipp, Benjamin R.; Jenkins, Robert B.; Jen, Jin; Halling, Kevin C.			Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							REGULATORY REGION; PROSTATE-CANCER; SOLID TUMORS; HUMAN GENOME; LUNG-CANCER; IDENTIFICATION; AMPLIFICATION; TRANSCRIPTS; ACTIVATION; COMPLEXITY	We assessed the performance characteristics of an RNA sequencing (RNA-Seq) assay designed to detect gene fusions in 571 genes to help manage patients with cancer. Polyadenylated RNA was converted to cDNA, which was then used to prepare next-generation sequencing libraries that were sequenced on an Illumina HiSeq 2500 instrument and analyzed with an in-house developed bioinformatic pipeline. The assay identified 38 of 41 gene fusions detected by another method, such as fluorescence in situ hybridization or RT-PCR, for a sensitivity of 93%. No false-positive gene fusions were identified in 15 normal tissue specimens and 10 tumor specimens that were negative for fusions by RNA sequencing or Mate Pair NGS (100% specificity). The assay also identified 22 fusions in 17 tumor specimens that had not been detected by other methods. Eighteen of the 22 fusions had not previously been described. Good intra-assay and interassay reproducibility was observed with complete concordance for the presence or absence of gene fusions in replicates. The analytical sensitivity of the assay was tested by diluting RNA isolated from gene fusion-positive cases with fusion-negative RNA. Gene fusions were generally detectable down to 12.5% dilutions for most fusions and as little as 3% for some fusions. This assay can help identify fusions in patients with cancer; these patients may in turn benefit from both US Food and Drug Administration-approved and investigational targeted therapies.	[Winter, Jennifer L.; McDonald, Amber M.; Wehrs, Rebecca N.; Thomas, Brittany C.; Balcom, Jessica R.; Jin, Long; Wu, Xianglin; Voss, Jesse S.; Klee, Eric W.; Graham, Rondell P.; Rumilla, Kandelaria M.; Aypar, Umut; Kipp, Benjamin R.; Jenkins, Robert B.; Jen, Jin; Halling, Kevin C.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Davila, Jaime, I; Nair, Asha A.; Fadra, Numrah; Klee, Eric W.; Oliver, Gavin R.] Mayo Clin, Dept Hlth Sci Res, Div Lab Genet, Rochester, MN 55905 USA; [Davila, Jaime, I; Nair, Asha A.; Fadra, Numrah; Klee, Eric W.; Oliver, Gavin R.] Mayo Clin, Dept Hlth Sci Res, Div Expt Pathol, Rochester, MN 55905 USA; [Jen, Jin] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA; [Jen, Jin] Mayo Clin, Genome Anal Core, Ctr Individualized Med, Med Genome Facil, Rochester, MN 55905 USA; [Neff, Jadee L.] Duke Univ, Dept Pathol, Durham, NC 27706 USA	Halling, KC (reprint author), Mayo Clin, 200 First St SW,Hilton 920B, Rochester, MN 55905 USA.	kevin@mayo.edu		Graham, Rondell/0000-0002-8686-4867	Department of Laboratory Medicine and Pathology; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota	Supported jointly by the Department of Laboratory Medicine and Pathology and the Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota.	Akiva P, 2006, GENOME RES, V16, P30, DOI 10.1101/gr.4137606; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Annala MJ, 2013, CANCER LETT, V340, P192, DOI 10.1016/j.canlet.2013.01.011; Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128; Chew SK, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0455-6; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Clay MR, 2015, AM J SURG PATHOL, V39, P1433, DOI 10.1097/PAS.0000000000000468; Costa R, 2016, ONCOTARGET, V7, P55924, DOI 10.18632/oncotarget.10482; Davila JI, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3161-9; Drucker TM, 2014, BIOINFORMATICS, V30, P1627, DOI 10.1093/bioinformatics/btu078; Gingeras TR, 2009, NATURE, V461, P206, DOI 10.1038/nature08452; Gostissa M, 2009, NATURE, V462, P803, DOI 10.1038/nature08633; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Jividen K, 2014, GENE CHROMOSOME CANC, V53, P963, DOI 10.1002/gcc.22207; Kalari KR, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-224; Kalyana-Sundaram S, 2012, NEOPLASIA, V14, P702, DOI 10.1593/neo.12914; Kihara R, 2014, LEUKEMIA, V28, P1586, DOI 10.1038/leu.2014.55; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080; Kumar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21597; Latysheva NS, 2016, NUCLEIC ACIDS RES, V44, P4487, DOI 10.1093/nar/gkw282; Linardic CM, 2008, CANCER LETT, V270, P10, DOI 10.1016/j.canlet.2008.03.035; Maher CA, 2009, NATURE, V458, P97, DOI 10.1038/nature07638; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; NILBERT M, 1995, CANCER GENET CYTOGEN, V83, P32, DOI 10.1016/S0165-4608(95)00016-X; Parra G, 2006, GENOME RES, V16, P37, DOI 10.1101/gr.4145906; Reeser JW, 2017, J MOL DIAGN, V19, P682, DOI 10.1016/j.jmoldx.2017.05.006; Reifenberger G, 1996, CANCER RES, V56, P5141; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466; Strong MJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004437; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; West H, 2017, JAMA ONCOL, V3, P423, DOI 10.1001/jamaoncol.2016.5299; Yoon JK, 2012, CELL SIGNAL, V24, P369, DOI 10.1016/j.cellsig.2011.09.023; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhao SR, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1308-8	46	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					495	511		10.1016/j.jmoldx.2018.03.007			17	Pathology	Pathology	GN0MH	WOS:000438662200011	29929942	Other Gold			2019-10-28	
J	Herman, DS; Smith, C; Liu, C; Vaughn, CP; Paaniappan, S; Pritchard, CC; Shirts, BH				Herman, Daniel S.; Smith, Christina; Liu, Chang; Vaughn, Cecily P.; Paaniappan, Selvi; Pritchard, Colin C.; Shirts, Brian H.			Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							LYNCH SYNDROME; CANCER; DELETIONS; COLOSEQ; GENE	Detection of 3' PMS2 copy-number mutations that cause Lynch syndrome is difficult because of highly homologous pseudogenes. To improve the accuracy and efficiency of clinical screening for these mutations, we developed a new method to analyze standard capture-based, next-generation sequencing data to identify deletions and duplications in PMS2 exons 9 to 15. The approach captures sequences using PMS2 targets, maps sequences randomly among regions with equal mapping quality, counts reads aligned to homologous exons and introns, and flags read count ratios outside of empirically derived reference ranges. The method was trained on 1352 samples, including 8 known positives, and tested on 719 samples, including 17 known positives. Clinical implementation of the first version of this method detected new mutations in the training (N = 7) and test (N = 2) sets that had not been identified by our initial clinical testing pipeline. The described final method showed complete sensitivity in both sample sets and false-positive rates of 5% (training) and 7% (test), dramatically decreasing the number of cases needing additional mutation evaluation. This approach Leveraged the differences between gene and pseudogene to distinguish between PMS2 and PMS2CL copy-number mutations. These methods enable efficient and sensitive Lynch syndrome screening for 3' PMS2 copy-number mutations and may be applied similarly to other genomic regions with highly homologous pseudogenes.	[Herman, Daniel S.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Herman, Daniel S.; Smith, Christina; Liu, Chang; Pritchard, Colin C.; Shirts, Brian H.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Vaughn, Cecily P.] ARUP Labs, Salt Lake City, UT USA; [Paaniappan, Selvi] Ambry Genet, Dept Clin Genom, Aliso Viejo, CA USA; [Vaughn, Cecily P.] Ancestry, Lehi, UT USA	Herman, DS (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, Founders 7-103,3400 Spruce St, Philadelphia, PA 19104 USA.	daniel.herman2@uphs.upenn.edu			National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA015704]; Fred Hutch/University of Washington Cancer Consortium; Damon Runyon Cancer Research Foundation [DRR-33-15]	Supported by National Cancer Institute grant P30 CA015704 (awarded to the Department of Laboratory Medicine, University of Washington), the Fred Hutch/University of Washington Cancer Consortium (B.H.S.), and the Damon Runyon Cancer Research Foundation grant DRR-33-15 (B.H.S.).	Beamer LC, 2012, J CLIN ONCOL, V30, P1058, DOI 10.1200/JCO.2011.38.4719; Burnham KP, 2002, MODEL SELECTION MULT; Clendenning M, 2006, HUM MUTAT, V27, P490, DOI 10.1002/humu.20318; De Vos M, 2004, AM J HUM GENET, V74, P954, DOI 10.1086/420796; Giardiello FM, 2014, GASTROENTEROLOGY, V147, P502, DOI 10.1053/j.gastro.2014.04.001; Haraldsdottir S, 2014, GASTROENTEROLOGY, V147, P1308, DOI 10.1053/j.gastro.2014.08.041; Hayward BE, 2007, HUM MUTAT, V28, P424, DOI 10.1002/humu.20457; Hegde M, 2013, GENET MED, V5, P166; Herman DS, 2012, NEW ENGL J MED, V366, P619, DOI 10.1056/NEJMoa1110186; Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146; Li JL, 2015, J MOL DIAGN, V17, P545, DOI 10.1016/j.jmoldx.2015.04.001; LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Pritchard CC, 2012, J MOL DIAGN, V14, P357, DOI 10.1016/j.jmoldx.2012.03.002; Shirts BH, 2014, J MOL DIAGN, V16, P699; van der Klift HM, 2016, HUM MUTAT, V37, P1162, DOI 10.1002/humu.23052; Vaughn CP, 2013, GENE CHROMOSOME CANC, V52, P107, DOI 10.1002/gcc.22011; Vaughn CP, 2011, HUM MUTAT, V32, P1063, DOI 10.1002/humu.21540; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108	19	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					512	521		10.1016/j.jmoldx.2018.03.010			10	Pathology	Pathology	GN0MH	WOS:000438662200012	29792936	Green Published			2019-10-28	
J	Kang, WJ; Kadri, S; Puranik, R; Wurst, MN; Patil, SA; Mujacic, I; Benhamed, S; Niu, NF; Zhen, CJ; Ameti, B; Long, BC; Galbo, F; Montes, D; Iracheta, C; Gamboa, VL; Lopez, D; Yourshaw, M; Lawrence, CA; Aisner, DL; Fitzpatrick, C; McNerney, ME; Wang, YL; Andrade, J; Volchenboum, SL; Furtado, LV; Ritterhouse, LL; Segal, JP				Kang, Wenjun; Kadri, Sabah; Puranik, Rutika; Wurst, Michelle N.; Patil, Sushant A.; Mujacic, Ibro; Benhamed, Sonia; Niu, Nifang; Zhen, Chao Jie; Ameti, Bekim; Long, Bradley C.; Galbo, Filipo; Montes, David; Iracheta, Crystal; Gamboa, Venessa L.; Lopez, Daisy; Yourshaw, Michael; Lawrence, Carolyn A.; Aisner, Dara L.; Fitzpatrick, Carrie; McNerney, Megan E.; Wang, Y. Lynn; Andrade, Jorge; Volchenboum, Samuel L.; Furtado, Larissa, V; Ritterhouse, Lauren L.; Segal, Jeremy P.			System for Informatics in the Molecular Pathology Laboratory An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CANCER; VALIDATION; MUTATION; CAPTURE	Next-generation sequencing (NGS) diagnostic assays increasingly are becoming the standard of care in oncology practice. As the scale of an NGS laboratory grows, management of these assays requires organizing large amounts of information, including patient data, laboratory processes, genomic data, as well as variant interpretation and reporting. Although several Laboratory Information Systems and/or Laboratory Information Management Systems are commercially available, they may not meet all of the needs of a given Laboratory, in addition to being frequently cost-prohibitive. Herein, we present the System for Informatics in the Molecular Pathology Laboratory (SIMPL), a free and open-source Laboratory Information System/Laboratory Information Management System for academic and nonprofit molecular pathology NGS laboratories, developed at the Genomic and Molecular Pathology Division at the University of Chicago Medicine. SIMPL was designed as a modular end-to-end information system to handle all stages of the NGS laboratory workload from test order to reporting. We describe the features of SIMPL, its clinical validation at University of Chicago Medicine, and its installation and testing within a different academic center laboratory (University of Colorado), and we propose a platform for future community co-development and interlaboratory data sharing.	[Kang, Wenjun; Andrade, Jorge; Volchenboum, Samuel L.] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA; [Kadri, Sabah; Puranik, Rutika; Wurst, Michelle N.; Patil, Sushant A.; Mujacic, Ibro; Benhamed, Sonia; Niu, Nifang; Zhen, Chao Jie; Ameti, Bekim; Long, Bradley C.; Galbo, Filipo; Montes, David; Iracheta, Crystal; Gamboa, Venessa L.; Lopez, Daisy; Fitzpatrick, Carrie; McNerney, Megan E.; Wang, Y. Lynn; Furtado, Larissa, V; Ritterhouse, Lauren L.; Segal, Jeremy P.] Univ Chicago, Div Genom & Mol Pathol, Chicago, IL 60637 USA; [McNerney, Megan E.; Andrade, Jorge; Volchenboum, Samuel L.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [McNerney, Megan E.; Andrade, Jorge; Volchenboum, Samuel L.] Univ Chicago, Dept Pediat, Biol Sci Div, Chicago, IL 60637 USA; [Yourshaw, Michael; Lawrence, Carolyn A.; Aisner, Dara L.] Univ Colorado, Dept Pathol, Anschutz Med Campus, Aurora, CO USA; [Yourshaw, Michael; Lawrence, Carolyn A.; Aisner, Dara L.] Univ Colorado, Colorado Ctr Personalized Med, Anschutz Med Campus, Aurora, CO USA; [McNerney, Megan E.] Univ Chicago Med, Comprehens Canc Ctr, Chicago, IL USA; [Segal, Jeremy P.] Assoc Mol Pathol, Informat Subdiv Leadership, Bethesda, MD USA	Segal, JP (reprint author), Univ Chicago, Div Genom & Mol Pathol, Dept Pathol, 5841 S Maryland Ave,MC 1089,Room N-339, Chicago, IL 60637 USA.	jsega15@bsd.uchicago.edu	Andrade, Jorge/H-3104-2019	Andrade, Jorge/0000-0003-3210-2186; Kang, Wenjun/0000-0002-9207-4239	Biological Sciences Division at the University of ChicagoUniversity of Chicago; Institute for Translational Medicine; NW Clinical and Translational Science Awards [UL1 TR000430]	Supported by the Biological Sciences Division at the University of Chicago, the Institute for Translational Medicine, and NW Clinical and Translational Science Awards grant UL1 TR000430 (awarded to the Division of Genomic and Molecular Pathology, The University of Chicago).	Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Aronson SJ, 2011, HUM MUTAT, V32, P532, DOI 10.1002/humu.21470; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Kadri S, 2017, J MOL DIAGN, V19, P43, DOI 10.1016/j.jmoldx.2016.07.012; Kamps R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020308; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Roy S, 2014, J MOL DIAGN, V16, P11, DOI 10.1016/j.jmoldx.2013.08.005; Sharma Mukesh K, 2013, AMIA Jt Summits Transl Sci Proc, V2013, P156; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	12	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					522	532		10.1016/j.jmoldx.2018.03.008			11	Pathology	Pathology	GN0MH	WOS:000438662200013	29698836	Green Published			2019-10-28	
J	Zenagui, R; Lacourt, D; Pegeot, H; Yauy, K; Morales, RJ; Theze, C; Rivier, F; Cances, C; Sole, G; Renard, D; Walther-Louvier, U; Ferrer-Monasterio, X; Espil, C; Arne-Bes, MC; Cintas, P; Uro-Coste, E; Negrier, MLM; Rigau, V; Bieth, E; Goizet, C; Claustres, M; Koenig, M; Cossee, M				Zenagui, Reda; Lacourt, Delphine; Pegeot, Henri; Yauy, Kevin; Morales, Raul Juntas; Theze, Corine; Rivier, Francois; Cances, Claude; Sole, Guilhem; Renard, Dimitri; Walther-Louvier, Ulrike; Ferrer-Monasterio, Xavier; Espil, Caroline; Arne-Bes, Marie-Christine; Cintas, Pascal; Uro-Coste, Emmanuelle; Negrier, Marie-Laure Martin; Rigau, Valerie; Bieth, Eric; Goizet, Cyril; Claustres, Mireille; Koenig, Michel; Cossee, Mireille			A Reliable Targeted Next-Generation Sequencing Strategy for Diagnosis of Myopathies and Muscular Dystrophies, Especially for the Giant Titin and Nebulin Genes	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							MUTATIONS; GENOME; EXOME; DNA; PERFORMANCE; GUIDELINES; DELETIONS; CONSENSUS; VARIANTS; SEVERITY	Myopathies and muscular dystrophies (M-MDs) are genetically heterogeneous diseases, with >100 identified genes, including the giant and complex titin (TTN) and nebulin (NEB) genes. Next-generation sequencing technology revolutionized M-MD diagnosis and revealed high frequency of TTN and NEB variants. We developed a next-generation sequencing diagnostic strategy targeted to the coding sequences of 135 M-MD genes. Comparison of two targeted capture technologies (SeqCap EZ Choice library capture kit and Nextera Rapid Capture Custom Enrichment kit) and of two whole-exome sequencing kits (SureSelect V5 and TruSeq RapidExome capture) revealed best coverage with the SeqCap EZ Choice protocol. A marked decrease in coverage was observed with the other kits, affecting mostly the first exons of genes and the repeated regions of TTN and NEB. Bioinformatics analysis strategy was fine-tuned to achieve optimal detection of variants, including small insertions/deletions (INDELs) and copy number variants (CNVs). Analysis of a cohort of 128 patients allowed the detection of 52 substitutions, 13 INDELs (including a trinucleotide repeat expansion), and 3 CNVs. Two INDELs were localized in the repeated regions of NEB, suggesting that these mutations may be frequent but underestimated. A large deletion was also identified in TTN that is, to our knowledge, the first published CNV in this gene.	[Zenagui, Reda; Lacourt, Delphine; Pegeot, Henri; Yauy, Kevin; Theze, Corine] CHU Montpellier, Mol Diagnost Lab, Montpellier, France; [Morales, Raul Juntas] CHU Montpellier, Dept Neurol, Montpellier, France; [Rigau, Valerie] CHU Montpellier, Dept Pathol, Montpellier, France; [Rivier, Francois; Walther-Louvier, Ulrike] CHU Montpellier, Dept Neuropaediat, Montpellier, France; [Morales, Raul Juntas; Rivier, Francois; Cances, Claude; Sole, Guilhem; Renard, Dimitri; Walther-Louvier, Ulrike; Ferrer-Monasterio, Xavier; Espil, Caroline; Arne-Bes, Marie-Christine; Cintas, Pascal; Uro-Coste, Emmanuelle; Negrier, Marie-Laure Martin; Rigau, Valerie; Bieth, Eric; Goizet, Cyril; Cossee, Mireille] AOC Atlantique Occitanie Caraibe Reference Ctr Ne, Aquitaine, France; [Rivier, Francois] Univ Montpellier, PhyMedExp, Montpellier, France; [Claustres, Mireille; Koenig, Michel; Cossee, Mireille] Univ Montpellier, INSERM, CNRS, Equipe Accueil EA7402, Montpellier, France; [Claustres, Mireille; Koenig, Michel; Cossee, Mireille] Univ Montpellier, Rare Dis Genet Lab, Equipe Accueil EA7402, Montpellier, France; [Cances, Claude] Ctr Hosp Univ, Dept Neuropaediat, Toulouse, France; [Arne-Bes, Marie-Christine; Cintas, Pascal] Ctr Hosp Univ, Dept Neurol, Toulouse, France; [Uro-Coste, Emmanuelle] Ctr Hosp Univ, Dept Pathol, Toulouse, France; [Bieth, Eric] Ctr Hosp Univ, Dept Genet, Toulouse, France; [Sole, Guilhem; Ferrer-Monasterio, Xavier] Ctr Hosp Univ, Serv Neurol, Bordeaux, France; [Negrier, Marie-Laure Martin] Ctr Hosp Univ, Serv Pathol, Bordeaux, France; [Espil, Caroline] Ctr Hosp Univ, Dept Neuropaediat, Bordeaux, France; [Goizet, Cyril] Ctr Hosp Univ, Dept Genet, Bordeaux, France; [Renard, Dimitri] Ctr Hosp Univ, Dept Neurol, Nimes, France	Cossee, M (reprint author), Inst Univ Rech Clin, EA 7402, Lab Genet, 641 Ave Doyen Gaston Giraud, F-34093 Montpellier 5, France.	mireille.cossee@inserm.fr		Sole, Guilhem/0000-0001-9599-6573; pascal, cintas/0000-0002-0242-4849; Yauy, Kevin/0000-0001-6901-1670	Agence de la Biomedecine Appel d'Offre Recherche Assistance Medicale a la Procreation, Diagnostic Prenatal et Diagnostic Genetique	Supported by Agence de la Biomedecine Appel d'Offre Recherche Assistance Medicale a la Procreation, Diagnostic Prenatal et Diagnostic Genetique (M.C.).	Aigrain L, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2757-4; Alame M, 2016, J MOL DIAGN, V18, P731, DOI 10.1016/j.jmoldx.2016.05.003; Baux D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16846-9; Evila A, 2016, NEUROMUSCULAR DISORD, V26, P7, DOI 10.1016/j.nmd.2015.10.003; Fang H, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0089-z; Fernandez-Marmiesse A, 2017, NEUROMUSCULAR DISORD, V27, P188, DOI 10.1016/j.nmd.2016.11.002; Garcia-Garcia G, 2016, SCI REP-UK, V6, DOI 10.1038/srep20948; Ghoneim Dalia H, 2014, BMC Res Notes, V7, P864, DOI 10.1186/1756-0500-7-864; Guo XL, 2014, AM J RESP CELL MOL, V50, P223, DOI 10.1165/rcmb.2013-0235OC; Hasan MS, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0042-2; Hehir-Kwa JY, 2015, EUR J HUM GENET, V23, P1601, DOI 10.1038/ejhg.2015.111; Herman GE, 2002, HUM MUTAT, V19, P114, DOI 10.1002/humu.10033; Kaplan JC, 2014, NEUROMUSCULAR DISORD, V24, P1123, DOI 10.1016/j.nmd.2014.11.001; Lamble S, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-104; Lehtokari VL, 2014, HUM MUTAT, V35, P1418, DOI 10.1002/humu.22693; Lelieveld SH, 2015, HUM MUTAT, V36, P815, DOI 10.1002/humu.22813; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lucarelli M, 2017, J MOL DIAGN, V19, P788, DOI 10.1016/j.jmoldx.2017.06.002; Malfatti E, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-44; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meienberg J, 2015, NUCLEIC ACIDS RES, V43, pE76, DOI 10.1093/nar/gkv216; Mullaney JM, 2010, HUM MOL GENET, V19, pR131, DOI 10.1093/hmg/ddq400; Nectoux J, 2015, EUR J HUM GENET, V23, P929, DOI 10.1038/ejhg.2014.223; Nigro Vincenzo, 2014, Acta Myol, V33, P1; Parkinson NJ, 2012, GENOME RES, V22, P125, DOI 10.1101/gr.124016.111; Richard P, 2017, NEUROLOGY, V88, P359, DOI 10.1212/WNL.0000000000003554; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445; Savarese M, 2015, NEUROMUSCULAR DISORD, V25, P533, DOI 10.1016/j.nmd.2015.03.011; Savarese M, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0100-3; Shigemizu D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12742; Strom CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136419; Trabelsi M, 2008, EUR J HUM GENET, V16, P793, DOI 10.1038/ejhg.2008.9; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI 10.1002/0471250953.bi1110s43; van der Pol WL, 2014, MOL GENET GENOM MED, V2, P134, DOI 10.1002/mgg3.52; Vasli N, 2012, ACTA NEUROPATHOL, V124, P273, DOI 10.1007/s00401-012-0982-8; Vasson A, 2013, EUR J HUM GENET, V21, P977, DOI 10.1038/ejhg.2012.279; Weiss MM, 2013, HUM MUTAT, V34, P1313, DOI 10.1002/humu.22368; Zhao M, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S11-S1	39	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					533	549		10.1016/j.jmoldx.2018.04.001			17	Pathology	Pathology	GN0MH	WOS:000438662200014	29792937				2019-10-28	
J	Legras, A; Barritault, M; Tallet, A; Fabre, E; Guyard, A; Rance, B; Digan, W; Pecuchet, N; Giroux-Leprieur, E; Julie, C; Jouveshomme, S; Duchatelle, V; Giraudet, V; Gibault, L; Cazier, A; Pastre, J; Le Pimpec-Barthes, F; Laurent-Puig, P; Blons, H				Legras, Antoine; Barritault, Marc; Tallet, Anne; Fabre, Elizabeth; Guyard, Alice; Rance, Bastien; Digan, William; Pecuchet, Nicolas; Giroux-Leprieur, Etienne; Julie, Catherine; Jouveshomme, Stephane; Duchatelle, Veronique; Giraudet, Veronique; Gibault, Laure; Cazier, Alain; Pastre, Jean; Le Pimpec-Barthes, Francoise; Laurent-Puig, Pierre; Blons, Helene			Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer Results of a 2-Year Experience on 1343 Samples	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							TYROSINE KINASE INHIBITORS; FACTOR RECEPTOR MUTATIONS; EGFR MUTATION; THERAPEUTIC OPTIONS; GENETIC-VARIABILITY; ADENOCARCINOMA; BRAF; REARRANGEMENTS; VALIDATION; GEFITINIB	Theranostic assays are based on single-gene testing, but the ability of next-generation sequencing (NGS) to interrogate numerous genetic alterations will progressively replace single-gene assays. Although NGS was evaluated to screen for theranostic mutations, its usefulness in clinical practice on large series of samples remains to be demonstrated. NGS performance was assessed following guidelines. TaqMan probes and NGS were compared for their ability to detect EGFR and KRAS mutations, and NGS mutation profiles were analyzed on a large series of non-small-cell lung cancers (n = 1343). The R-2 correlation between expected and measured allelic ratio, using commercial samples, was >0.96. Mutation detection threshold was 2% for 10 ng of DNA input. kappa Scores for TaqMan versus NGS were 0.99 (95% CI, 0.97-1.00) for EGFR and 0.98 (95% CI, 0.97-1.00) for KRAS after exclusion of rare EGFR (n = 40) and KRAS (n = 60) mutations. NGS identified 693 and 292 mutations in validated and potential oncogenic drivers, respectively. Significant associations were found between EGFR and PI3KCA or CTNNB1 and between KRAS and STK11. Potential oncogenic driver mutations or gene amplifications were more frequent in validated oncogenic driver nonmutated samples. This work is a proof of concept that targeted NGS is accessible in routine screening, including large screening, at reasonable cost. Clinical data should be collected and implemented in specific databases to make molecular data meaningful for direct patients' benefit.	[Legras, Antoine; Fabre, Elizabeth; Pecuchet, Nicolas; Laurent-Puig, Pierre; Blons, Helene] Sorbonne Paris Cite Univ, INSERM UMR S1147, Paris, France; [Legras, Antoine; Le Pimpec-Barthes, Francoise] Georges Pompidou European Hosp, Dept Thorac Surg, Paris, France; [Fabre, Elizabeth; Pecuchet, Nicolas] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France; [Gibault, Laure] Georges Pompidou European Hosp, Dept Pathol, Paris, France; [Pastre, Jean] Georges Pompidou European Hosp, Dept Pulmonol, Paris, France; [Barritault, Marc; Tallet, Anne; Guyard, Alice; Giraudet, Veronique; Laurent-Puig, Pierre; Blons, Helene] Georges Pompidou European Hosp, Dept Biochem, Unit Pharmacogenet & Mol Oncol, Paris, France; [Rance, Bastien; Digan, William] Georges Pompidou European Hosp, Dept Med Informat, Paris, France; [Giroux-Leprieur, Etienne] Ambroise Pare Hosp, AP HP, Dept Pulmonol, Paris, France; [Julie, Catherine] Ambroise Pare Hosp, AP HP, Dept Pathol, Paris, France; [Jouveshomme, Stephane] Paris St Joseph Hosp Grp, Dept Pulmonol, Paris, France; [Duchatelle, Veronique] Paris St Joseph Hosp Grp, Dept Pathol, Paris, France; [Cazier, Alain] South Oise Publ Hosp Grp, Dept Pathol, Creil, France	Blons, H (reprint author), Paris Descartes Univ, Sorbonne Paris Cite Univ, INSERM UMR S1147, 45 Rue St Peres, F-75006 Paris, France.	blons@parisdescartes.fr	Laurent-Puig, Pierre/K-3641-2019; Leprieur, Etienne Giroux/H-6345-2015	Laurent-Puig, Pierre/0000-0001-8475-5459; Legras, Antoine/0000-0002-5271-6946; Rance, Bastien/0000-0003-4417-1197; Pecuchet, Nicolas/0000-0002-3321-5791	Site de Recherche Integree sur le Cancer (SIRIC) CAncer Research for PErsonnalized Medicine (CARPEM); French National Cancer Institute (INCa, Institut National Du Cancer); French Government General Direction of Care Organization (DGOS)	Supported by the Site de Recherche Integree sur le Cancer (SIRIC) CAncer Research for PErsonnalized Medicine (CARPEM), French National Cancer Institute (INCa, Institut National Du Cancer), and French Government General Direction of Care Organization (DGOS).	Arcila ME, 2015, CLIN CANCER RES, V21, P1935, DOI 10.1158/1078-0432.CCR-14-2124; Baik CS, 2017, ONCOLOGIST, V22, P786, DOI 10.1634/theoncologist.2016-0458; Bennett NC, 2014, CANCERS, V6, P2296, DOI 10.3390/cancers6042296; Blons H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068945; Blow N, 2007, NATURE, V448, P959, DOI 10.1038/448959a; Buzyn A, 2016, NAT REV CLIN ONCOL, V13, P385, DOI 10.1038/nrclinonc.2016.31; de Leng WWJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149405; Deeb KK, 2015, ARCH PATHOL LAB MED, V139, P913, DOI 10.5858/arpa.2014-0095-OA; DiBardino DM, 2017, CYTOJOURNAL, V13, DOI 10.4103/1742-6413.202602; Didelot A, 2012, EXP MOL PATHOL, V92, P275, DOI 10.1016/j.yexmp.2012.03.001; Digan W, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix099; Do HD, 2012, ONCOTARGET, V3, P546; Dreas A, 2017, CURR MED CHEM, V24, P3025, DOI 10.2174/0929867324666170203123427; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Frega S, 2016, J THORAC ONCOL, V11, pE63, DOI 10.1016/j.jtho.2016.01.023; Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Hibi M, 2016, CANCER SCI, V107, P1667, DOI 10.1111/cas.13071; Ibrahim U, 2017, LUNG CANCER, V108, P45, DOI 10.1016/j.lungcan.2017.02.023; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kim EY, 2016, CANCER BIOL THER, V17, P237, DOI 10.1080/15384047.2016.1139235; Kobayashi Y, 2016, CANCER SCI, V107, P1179, DOI 10.1111/cas.12996; Lee GD, 2017, J THORAC ONCOL, V12, P1233, DOI 10.1016/j.jtho.2017.04.031; Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI 10.1016/j.jmoldx.2017.11.004; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Martorell PM, 2017, CLIN LUNG CANCER, V18, pE395, DOI 10.1016/j.cllc.2017.04.006; Mazieres J, 2015, J CLIN ONCOL, V33, P992, DOI 10.1200/JCO.2014.58.3302; Mazieres J, 2013, J CLIN ONCOL, V31, P1997, DOI 10.1200/JCO.2012.45.6095; Mazza V, 2017, APPL CLIN GENET, V10, P49, DOI 10.2147/TACG.S103471; McCall CM, 2014, J MOL DIAGN, V16, P541, DOI 10.1016/j.jmoldx.2014.06.001; McCourt CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069604; Molina-Vila MA, 2014, CLIN CANCER RES, V20, P4647, DOI 10.1158/1078-0432.CCR-13-2391; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pant S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00078; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Pecuchet N, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002199; Peng L, 2015, ONCOTARGETS THER, V8, P905, DOI 10.2147/OTT.S78984; Pilotto S, 2018, CLIN LUNG CANCER, V19, P93, DOI 10.1016/j.cllc.2017.05.016; Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4; Richtig G, 2017, BRIT J DERMATOL, V177, P936, DOI 10.1111/bjd.15436; Scheffler M, 2015, ONCOTARGET, V6, P10577, DOI 10.18632/oncotarget.3387; Shao D, 2016, SCI REP-UK, V6, DOI 10.1038/srep22338; Socinski MA, 2013, CHEST, V143, pE341, DOI 10.1378/chest.12-2361; Solomon B, 2009, J THORAC ONCOL, V4, P1450, DOI 10.1097/JTO.0b013e3181c4dedb; Song ZB, 2016, LUNG CANCER, V101, P16, DOI 10.1016/j.lungcan.2016.09.002; Tan CS, 2016, LUNG CANCER, V93, P59, DOI 10.1016/j.lungcan.2016.01.003; Vaishnavi A, 2013, NAT MED, V19, P1469, DOI 10.1038/nm.3352; Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23; Wu JY, 2011, CLIN CANCER RES, V17, P3812, DOI 10.1158/1078-0432.CCR-10-3408; Ye X, 2013, J THORAC ONCOL, V8, P1118, DOI 10.1097/JTO.0b013e31829f691f; Yu GH, 2015, INT J CLIN EXP PATHO, V8, P8603	53	1	2	2	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JUL	2018	20	4					550	564		10.1016/j.jmoldx.2018.04.002			15	Pathology	Pathology	GN0MH	WOS:000438662200015	29787863				2019-10-28	
J	Sim, J; Koh, HH; Choi, S; Chu, J; Kim, TS; Kim, H; Han, J				Sim, Jongmin; Koh, Hyun Hee; Choi, Sangjoon; Chu, Jinah; Kim, Tae Sung; Kim, Hojoong; Han, Joungho			Pulmonary Nodular Lymphoid Hyperplasia with Mass-Formation: Clinicopathologic Characteristics of Nine Cases and Review of the Literature	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Review						Pseudolymphoma; Pulmonary nodular lymphoid hyperplasia	LUNG; DISORDERS; DISEASE	Background: Pulmonary nodular lymphoid hyperplasia (PNLH) is a non-neoplastic pulmonary lymphoid disorder that can be mistaken for malignancy on radiography. Herein, we present nine cases of PNLH, emphasizing clinicoradiological findings and histological features. Methods: We analyzed radiological and clinicopathological features from the electronic medical records of nine patients (eight females and one male) diagnosed with PNLH. IgG and IgG4 immunohistochemical staining was performed in three patients. Results: Two of the nine patients had experienced tuberculosis 40 and 30 years prior, respectively. Interestingly, none were current smokers, although two were ex-smokers. Three patients complaining of persistent cough underwent computed tomography of the chest. PNLH was incidentally discovered in five patients during examination for other reasons. The remaining patient was diagnosed with the disease following treatment for pneumonia. Imaging studies revealed consolidation or a mass-like lesion in eight patients. First impressions included invasive adenocarcinoma and mucosal-associated lymphoid tissue-type lymphoma. Aspergillosis was suspected in the remaining patient based on radiological images. Resection was performed in all patients. Microscopically, the lesions consisted of nodular proliferation of reactive germinal centers accompanied by infiltration of neutrophils and macrophages in various degrees and surrounding fibrosis. Ultimately, all nine patients were diagnosed with PNLH and showed no evidence of recurrence on follow-up. Conclusions: PNLH is an uncommon but distinct entity with a benign nature, and understanding the radiological and clinicopathological characteristics of PNLH is important.	[Sim, Jongmin; Koh, Hyun Hee; Choi, Sangjoon; Chu, Jinah; Han, Joungho] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pathol & Translat Genom, 81 Irwon Ro, Seoul 06351, South Korea; [Kim, Tae Sung] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Radiol, Seoul, South Korea; [Kim, Hojoong] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea	Han, J (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Pathol & Translat Genom, 81 Irwon Ro, Seoul 06351, South Korea.	hanjho@skku.edu		Sim, Jongmin/0000-0002-7106-1279			Abbondanzo SL, 2000, AM J SURG PATHOL, V24, P587, DOI 10.1097/00000478-200004000-00015; Arcadu A, 2016, SEMIN RESP CRIT CARE, V37, P406, DOI 10.1055/s-0036-1580691; Atzeni F, 2018, EXPERT REV CLIN IMMU, V14, P69, DOI 10.1080/1744666X.2018.1411190; Begueret H, 2002, AM J SURG PATHOL, V26, P76, DOI 10.1097/00000478-200201000-00009; Bois MC, 2017, HUM PATHOL, V59, P80, DOI 10.1016/j.humpath.2016.09.016; Guinee DG, 2013, AM J SURG PATHOL, V37, P699, DOI 10.1097/PAS.0b013e318282d0fa; Guinee DG, 2010, ARCH PATHOL LAB MED, V134, P691, DOI 10.1043/1543-2165-134.5.691; KRADIN RL, 1983, HUM PATHOL, V14, P857, DOI 10.1016/S0046-8177(83)80161-0; Mittoo S, 2009, RESP MED, V103, P1152, DOI 10.1016/j.rmed.2009.02.009; Poletti V, 2013, EUR RESPIR REV, V22, P427, DOI 10.1183/09059180.00004313; SALTZSTEIN SL, 1963, CANCER-AM CANCER SOC, V16, P928, DOI 10.1002/1097-0142(196307)16:7<928::AID-CNCR2820160709>3.0.CO;2-H; Sirajuddin A, 2016, RADIOGRAPHICS, V36, P53, DOI 10.1148/rg.2016140339; Song Moo-Kon, 2007, Korean J Intern Med, V22, P192; Tashtoush B, 2015, J CLIN DIAGN RES, V9, pOE1, DOI 10.7860/JCDR/2015/13873.6496; Travis WD, 2001, THORAX, V56, P964, DOI 10.1136/thorax.56.12.964; Yi E, 2010, ARCH PATHOL LAB MED, V134, P417, DOI 10.1043/1543-2165-134.3.417	16	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					211	218		10.4132/jptm.2018.04.27			8	Pathology	Pathology	GM8FQ	WOS:000438456900001	29902913	DOAJ Gold, Green Published			2019-10-28	
J	Nakra, T; Kakkar, A; Agarwal, S; Madan, K; Sharma, SC; Jain, D				Nakra, Tripti; Kakkar, Aanchal; Agarwal, Shipra; Madan, Karan; Sharma, Suresh C.; Jain, Deepali			Endobronchial Smooth Muscle Tumors: A Series of Five Cases Highlighting Pitfalls in Diagnosis	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Endobronchial; Leiomyoma; Leiomyosarcoma; Smooth muscle tumor; Immunohistochemistry	LEIOMYOMA; LEIOMYOSARCOMA; LUNG	Background: Primary endobronchial smooth muscle tumors (SMTs), which are extremely rare, include endobronchial leiomyomas and leiomyosarcomas. Clinically, SMTs present with signs and symptoms of bronchial obstruction, and lack specific radiological findings. Thus, histopathological examination is required for accurate diagnosis as well as for tumor grading. We examined the histomorphological and immunohistochemical features of endobronchial SMTs and highlighted pitfalls in diagnosis, particularly when using small biopsies. Methods: Cases of primary endobronchial SMTs diagnosed at our Institute over the last 6 years (2012-2017) were retrieved from the departmental archives. Histopathological features and immunohistochemistry performed for establishing the diagnosis were reviewed. Results: Five cases of SMTs occurring in endobronchial locations were identified. These included three cases of leiomyoma, and two cases of leiomyosarcoma. The age distribution of patients ranged from 13 to 65 years. Leiomyomas showed more consistent staining with smooth muscle markers (smooth muscle actin, desmin, and smooth muscle myosin heavy chain), while tumors of higher grade showed variable, focal staining, leading to erroneous diagnosis, especially on small biopsies. Conclusions: The diagnosis of endobronchial SMTs relies on histopathological examination, for both confirmation of smooth muscle lineage and determination of the malignant potential of the lesion. Appropriate immunohistochemical panels including more than one marker of smooth muscle differentiation are extremely valuable for differential diagnosis from morphological mimics, which is necessary for instituting appropriate management.	[Nakra, Tripti; Kakkar, Aanchal; Agarwal, Shipra; Jain, Deepali] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Madan, Karan] All India Inst Med Sci, Dept Pulm Med, New Delhi, India; [Sharma, Suresh C.] All India Inst Med Sci, Dept Otorhinolaryngol, New Delhi, India	Jain, D (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	deepalijain76@gmail.com	Madan, Karan/H-1035-2014	Madan, Karan/0000-0002-5330-6391			Attanoos RL, 1996, HISTOPATHOLOGY, V29, P29, DOI 10.1046/j.1365-2559.1996.d01-481.x; Awasthi A, 2016, INDIAN J PATHOL MICR, V59, P87, DOI 10.4103/0377-4929.174830; Cardenas-Garcia J, 2014, RESPIR MED CASE REP, V12, P59, DOI 10.1016/j.rmcr.2014.04.004; Dacic S, 2015, WHO CLASSIFICATION T, P132; Dmello D, 2009, J BRONCHOL INTERN PU, V16, P49, DOI 10.1097/LBR.0b013e318193bc71; Elouazzani H, 2012, J CLIN IMAG SCI, V2, DOI 10.4103/2156-7514.97757; HARRIS PF, 1967, SOUTHERN MED J, V60, P1223, DOI 10.1097/00007611-196711000-00018; JANSSEN JP, 1994, ANN THORAC SURG, V58, P1151, DOI 10.1016/0003-4975(94)90476-6; Kim YK, 2007, AM J ROENTGENOL, V189, P393, DOI 10.2214/AJR.07.2079; Kwon YS, 2008, RESPIROLOGY, V13, P908, DOI 10.1111/j.1440-1843.2008.01366.x; Lee MC, 2008, ANN THORAC CARDIOVAS, V14, P105; Lee SH, 2001, RESPIRATION, V68, P99, DOI 10.1159/000050472; Litzky Leslie, 2003, Chest Surg Clin N Am, V13, P1, DOI 10.1016/S1052-3359(02)00045-5; Moran CA, 2013, DIAGNOSTIC HISTOPATH, P207; Purgina B, 2011, PATHOLOG RES INT, V2011, DOI DOI 10.4061/2011/561548; Swarnakar Rajesh, 2013, Lung India, V30, P57, DOI 10.4103/0970-2113.106175; Vaz AP, 2011, REV PORT PNEUMOL, V17, P228, DOI 10.1016/j.rppneu.2011.01.002	17	1	1	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					219	225		10.4132/jptm.2018.05.16			7	Pathology	Pathology	GM8FQ	WOS:000438456900002	30021251	DOAJ Gold, Green Published			2019-10-28	
J	Oh, SJ; Kim, YO				Oh, Sun-Ju; Kim, Young-Ok			Primary Cutaneous Mucinous Carcinoma with Extramammary Paget's Disease: Eccrine or Apocrine?	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Cutaneous mucinous carcinoma; Skin adnexal tumor; Apocrine carcinoma; Paget's disease; extramammary	SKIN; ADENOCARCINOMA; GROIN	Primary cutaneous mucinous carcinoma (PCMC) is an uncommon tumor of the sweat gland origin. The occurrence of PCMC is mostly in middle-aged and older patients, with a slight male predominance. Most cases of PCMC arise on the head, with a preference for eyelids. The histogenesis of PCMC, whether eccrine or apocrine, remains controversial. We report a rare case of PCMC with secondary extramammary Paget's disease in the groin of a 75-year-old man, which favored an apocrine origin. Furthermore, based on a review of the literature, we provide several histologic clues that can be used to differentiate PCMC from metastatic mucinous carcinoma.	[Oh, Sun-Ju; Kim, Young-Ok] Kosin Univ, Dept Pathol, Gospel Hosp, 262 Gamcheon Ro, Busan 49267, South Korea	Oh, SJ (reprint author), Kosin Univ, Dept Pathol, Gospel Hosp, 262 Gamcheon Ro, Busan 49267, South Korea.	10highpowerfield@gmail.com					Aso K, 1989, JPN J CLIN DERMATOL, V43, P117; Bowling JCR, 2005, BRIT J DERMATOL, V153, P676, DOI 10.1111/j.1365-2133.2005.06802.x; HEADINGTON JT, 1977, CANCER, V39, P1055, DOI 10.1002/1097-0142(197703)39:3<1055::AID-CNCR2820390308>3.0.CO;2-G; HELWIG EB, 1963, CANCER, V16, P387, DOI 10.1002/1097-0142(196303)16:3<387::AID-CNCR2820160314>3.0.CO;2-0; Hernandez JM, 2007, AM SURGEON, V73, P307; HURT MA, 1992, J CUTAN PATHOL, V19, P134, DOI 10.1111/j.1600-0560.1992.tb01355.x; Kazakov DV, 2005, AM J SURG PATHOL, V29, P764, DOI 10.1097/01.pas.0000159104.02985.6b; LENNOX B, 1952, J PATHOL BACTERIOL, V64, P865, DOI 10.1002/path.1700640418; Martinez S, 2004, INT J ONCOL, V2, P1; Matin RN, 2011, AM J DERMATOPATH, V33, P705, DOI 10.1097/DAD.0b013e3181f9c83d; Pascual JC, 2008, CLIN EXP DERMATOL, V33, P595, DOI 10.1111/j.1365-2230.2008.02731.x; PILGRIM JP, 1985, AM J DERMATOPATH, V7, P461, DOI 10.1097/00000372-198510000-00011; Qureshi HS, 2004, AM J DERMATOPATH, V26, P353, DOI 10.1097/00000372-200410000-00001; Requena L, 1998, ACK HIST D, P217; Robson A, 2008, AM J SURG PATHOL, V32, P682, DOI 10.1097/PAS.0b013e3181590ba4; Saigal R K, 1971, Indian J Dermatol Venereol, V37, P177; Seo SH, 2011, ANN DERMATOL, V23, P519, DOI 10.5021/ad.2011.23.4.519; Taniyama K, 1988, Gan No Rinsho, V34, P379; Wako M, 2003, AM J DERMATOPATH, V25, P66, DOI 10.1097/00000372-200302000-00014; WRIGHT JD, 1979, CANCER, V44, P1757, DOI 10.1002/1097-0142(197911)44:5<1757::AID-CNCR2820440533>3.0.CO;2-8	20	0	0	0	3	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					238	242		10.4132/jptm.2017.11.21			5	Pathology	Pathology	GM8FQ	WOS:000438456900005	29366305	DOAJ Gold, Green Published			2019-10-28	
J	Joo, JW; Chung, T; Cho, YA; Kim, SK				Joo, Jin Woo; Chung, Taek; Cho, Yoon Ah; Kim, Sang Kyum			Recurrent Indeterminate Dendritic Cell Tumor of the Skin	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Indeterminate dendritic cell tumor; Skin tumor; Recurrence	CLINICOPATHOLOGICAL ENTITY; HISTIOCYTIC DISORDERS; LYMPH-NODES; LANGERIN	Indeterminate dendritic cell tumor (IDCT) is a dendritic cell tumor that displays histologic features similar to those of Langerhans cells. The origin of the indeterminate cells may represent precursors of Langerhans cells or skin dendritic cells. IDCT is extremely rare, and tumor progression and predictive factors are not well known. Here, we report a case of a 61-year-old man who presented with a papule on his back and was finally diagnosed with IDCT based on histology and immunohistochemistry. The tumor recurred three months after surgical excision.	[Joo, Jin Woo; Chung, Taek; Cho, Yoon Ah; Kim, Sang Kyum] Yonsei Univ, Dept Pathol, Severance Hosp, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea	Kim, SK (reprint author), Yonsei Univ, Dept Pathol, Severance Hosp, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.	NICEKYUMI@yuhs.ac			Ministry of Education [2016R1D1A1B03931581]	The Basic Science Research Program through the National Research Foundation of Korea (NRF) and was funded by the Ministry of Education (grant number 2016R1D1A1B03931581).	BENEZRA J, 1991, CANCER, V68, P1050, DOI 10.1002/1097-0142(19910901)68:5<1050::AID-CNCR2820680524>3.0.CO;2-K; Chikwava K, 2004, PEDIATR DEVEL PATHOL, V7, P607, DOI 10.1007/s10024-004-3027-z; CONTRERAS F, 1990, AM J DERMATOPATH, V12, P396; De La Roche HM, 2008, BRIT J DERMATOL, V158, P838, DOI 10.1111/j.1365-2133.2007.08409.x; Emile JF, 2016, BLOOD, V127, P2672, DOI [10.1182/blood-2016-01-690636, 10.1182/blood-2016-01690636]; Ibrar W, 2015, AM J CLIN PATHOL, V144, pA316, DOI 10.1093/ajcp/144.suppl2.316; Ishibashi M, 2008, CLIN EXP DERMATOL, V33, P301, DOI 10.1111/j.1365-2230.2007.02667.x; Lau SK, 2008, AM J SURG PATHOL, V32, P615, DOI 10.1097/PAS.0b013e31815b212b; LeBoit PE, 2006, PATHOLOGY GENETICS S, P220; Li Y, 2017, ANN DERMATOL, V29, P614, DOI 10.5021/ad.2017.29.5.614; Ratzinger G, 2005, J CUTAN PATHOL, V32, P552, DOI 10.1111/j.0303-6987.2005.00382.x; Rezk SA, 2008, AM J SURG PATHOL, V32, P1868, DOI 10.1097/PAS.0b013e31818593d6; Roh J, 2016, J PATHOL TRANSL MED, V50, P78, DOI 10.4132/jptm.2015.07.03; Sidoroff A, 1996, BRIT J DERMATOL, V134, P525; Vasef MA, 1995, AM J CLIN PATHOL, V104, P696; Vener C, 2007, BRIT J DERMATOL, V156, P1357, DOI 10.1111/j.1365-2133.2007.07880.x; Ventura F, 2010, DERMAT RES PRACT, DOI 10.1155/2010/569345; Wang CS, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-99; Zhao G, 2009, INT J SURG PATHOL, V17, P347, DOI 10.1177/1066896908324128	19	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					243	247		10.4132/jptm.2018.03.27			5	Pathology	Pathology	GM8FQ	WOS:000438456900006	29621879	DOAJ Gold, Green Published			2019-10-28	
J	kim, D; Han, MH; Lee, S				kim, DongJa; Han, Man-Hoon; Lee, SangHan			Sudden Child Death due to Thrombotic Giant Coronary Artery Aneurysms Complicated by Atypical Kawasaki Disease: An Autopsy Case	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article									[kim, DongJa] Shinhyunho Pathol Clin, Daegu, South Korea; [Han, Man-Hoon] Kyungpook Natl Univ Hosp, Dept Pathol, Daegu, South Korea; [Lee, SangHan] Kyungpook Natl Univ, Sch Med, Dept Forens Med, 680 Gukchaebosang Ro, Daegu 41944, South Korea	Lee, S (reprint author), Kyungpook Natl Univ, Sch Med, Dept Forens Med, 680 Gukchaebosang Ro, Daegu 41944, South Korea.	sanghan1@knu.ac.kr		Lee, SangHan/0000-0003-0390-3494			Choi YS, 2003, KOREAN J LEG MED, V27, P39; Diana MC, 2006, PEDIATR EMERG CARE, V22, P35, DOI 10.1097/01.pec.0000195757.74328.68; Kato H, 1996, CIRCULATION, V94, P1379, DOI 10.1161/01.CIR.94.6.1379; Manlhiot C, 2009, PEDIATRICS, V124, pE410, DOI 10.1542/peds.2009-0099; McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484; Pucci A, 2012, PEDIATR CARDIOL, V33, P802, DOI 10.1007/s00246-012-0186-y; Singh S, 2016, INT J RHEUM DIS, V19, P924, DOI 10.1111/1756-185X.12854; Tsuda E, 2017, PEDIATR CARDIOL, V38, P932, DOI 10.1007/s00246-017-1599-4	8	0	0	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					248	251		10.4132/jptm.2017.10.23			4	Pathology	Pathology	GM8FQ	WOS:000438456900007	29747485	DOAJ Gold, Green Published			2019-10-28	
J	Jeon, J; Kim, TJ; Park, HS; Lee, KY				Jeon, Jinyoung; Kim, Tae-Jung; Park, Hong Sik; Lee, Kyo-Young			Malignant Pleural Effusion from Metastatic Prostate Cancer: A Case Report with Unusual Cytologic Findings	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Prostatic neoplasms; Neoplasm metastasis; Pleural effusion; malignant	ADENOCARCINOMA; ASCITES	We present a case of 55-year-old man who complained of dyspnea and sputum for a month. He was an ex-smoker with a history of prostate cancer and pulmonary tuberculosis. Chest radiographs revealed bilateral pleural effusions of a small to moderate amount. Pigtail catheters were inserted for drainage. The pleural fluid consisted of large clusters and tightly cohesive groups of malignant cells, which however could not be ascribed to prostate cancer with certainty. We performed immunocytochemical panel studies to determine the origin of cancer metastasis. The immunostaining results were positive for prostate-specific antigen, alpha-methylacyl-coenzyme A racemase, and Nkx 3.1, consistent with prostate cancer. Pleural effusion associated with prostate cancer is rare. To our knowledge, this is the first case report in Korea to describe cytologic features of malignant pleural effusion associated with prostate cancer.	[Jeon, Jinyoung; Park, Hong Sik; Lee, Kyo-Young] Seoul St Marys Hosp, Dept Hosp Pathol, Seoul, South Korea; [Kim, Tae-Jung] Catholic Univ Korea, Dept Hosp Pathol, Yeouido St Marys Hosp, Coll Med, Seoul, South Korea	Lee, KY (reprint author), Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Hosp Pathol, 222 Banpo Daero, Seoul 06591, South Korea.	leekyoyo@catholic.ac.kr					Ani I, 2013, CUAJ-CAN UROL ASSOC, V7, pE248, DOI 10.5489/cuaj.547; Bajpai PA, 2014, LUNG INDIA, V31, P423, DOI 10.4103/0970-2113.142100; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; CARRASCOSA M, 1994, CHEST, V105, P1577, DOI 10.1378/chest.105.5.1577; dos Santos VM, 2011, W INDIAN MED J, V60, P690; Egan AM, 2014, QJM-INT J MED, V107, P179, DOI 10.1093/qjmed/hct245; Knight JC, 2014, RESPIR MED CASE REP, V13, P24, DOI 10.1016/j.rmcr.2014.04.001; Lim MH, 2013, NEW ZEAL MED J, V126, P42; Mai KT, 2007, DIAGN CYTOPATHOL, V35, P91, DOI 10.1002/dc.20582; MESTITZ H, 1989, RESP MED, V83, P161, DOI 10.1016/S0954-6111(89)80236-7; Renshaw AA, 1996, DIAGN CYTOPATHOL, V15, P103, DOI 10.1002/(SICI)1097-0339(199608)15:2<103::AID-DC4>3.0.CO;2-J; Saif Muhammad Wasif, 2005, J Appl Res, V5, P305; Saif MW, 1999, PROSTATE CANCER P D, V2, P290, DOI 10.1038/sj.pcan.4500385; Shimizu T, 1993, Hinyokika Kiyo, V39, P953; Thomas JM, 2013, CLIN CHEST MED, V34, P459, DOI 10.1016/j.ccm.2013.05.004; Vinjamoori AH, 2012, AM J ROENTGENOL, V199, P367, DOI 10.2214/AJR.11.7533	16	0	1	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					257	261		10.4132/jptm.2018.05.08			5	Pathology	Pathology	GM8FQ	WOS:000438456900009	29874900	DOAJ Gold, Green Published			2019-10-28	
J	Shim, B; Koh, J; Moon, JH; Park, IA; Ryu, HS				Shim, Bobae; Koh, Jiwon; Moon, Ji Hye; Park, In Ae; Ryu, Han Suk			Cytologic Diagnosis of Metastatic Alveolar Rhabdomyosarcoma in Cerebrospinal Fluid: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Rhabdomyosarcoma; Cytology; Cerebrospinal fluid	PLEURAL EFFUSION; EMBRYONAL RHABDOMYOSARCOMA	Rhabdomyosarcoma is a malignant soft tissue tumor which shows skeletal muscle differentiation. Leptomeningeal metastasis can occur as a late complication, but currently there are no reports that have documented the cytologic features in cerebrospinal fluid (CSF). We report a case of metastatic alveolar rhabdomyosarcoma diagnosed in the CSF of a 28-year-old male who was originally diagnosed with rhabdomyosarcoma on the neck, and that went through systemic therapy. The tumor was positive for anaplastic lymphoma kinase, but progressed despite additional therapy with crizotinib. The CSF specimen revealed small round cells, large atypical cells with abundant cytoplasm and eccentric nuclei, and cells with horseshoe-shaped nuclei. These cytologic findings were in agreement with previous literature and well-correlated with histopathology. This is the first report to document the cytologic feature of rhabdomyosarcoma in CSF. In many cases it is difficult to perform ancillary tests in a CSF specimen and cytopathologists should be aware of the cytomorphologic characteristics to avoid misdiagnosis.	[Shim, Bobae; Koh, Jiwon; Moon, Ji Hye; Park, In Ae; Ryu, Han Suk] Seoul Natl Univ Hosp, Dept Pathol, 101 Daehak Ro, Seoul 03080, South Korea	Ryu, HS (reprint author), Seoul Natl Univ Hosp, Dept Pathol, 101 Daehak Ro, Seoul 03080, South Korea.	karlnash@naver.com					Atahan S, 1998, CYTOPATHOLOGY, V9, P389; Bhattacharya B, 2002, DIAGN CYTOPATHOL, V26, P384, DOI 10.1002/dc.10069; Chamberlain MC, 2009, SEMIN ONCOL, V36, pS35, DOI 10.1053/j.seminoncol.2009.05.005; Dagher R, 1999, Oncologist, V4, P34; De B, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26710; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; Felkai L, 2019, PATHOL ONCOL RES, V25, P217, DOI 10.1007/s12253-017-0332-1; HAMADA T, 1989, ACTA PATHOL JAPON, V39, P803; Jaeckle KA, 2006, SEMIN ONCOL, V33, P312, DOI 10.1053/j.seminoncol.2006.04.016; Nelson AC, 2012, CYTOJOURNAL, V9, DOI 10.4103/1742-6413.94569; Parham DM, 2006, ARCH PATHOL LAB MED, V130, P1454; Rudzinski ER, 2013, AM J CLIN PATHOL, V140, P82, DOI 10.1309/AJCPA1WN7ARPCMKQ; Theunissen P, 2004, ACTA CYTOL, V48, P249, DOI 10.1159/000326326; Thiryayi SA, 2010, CYTOPATHOLOGY, V21, P273, DOI 10.1111/j.1365-2303.2009.00700.x; Thompson KS, 1997, DIAGN CYTOPATHOL, V16, P270, DOI 10.1002/(SICI)1097-0339(199703)16:3<270::AID-DC16>3.0.CO;2-I; van Gaal JC, 2012, J CLIN ONCOL, V30, P308, DOI 10.1200/JCO.2011.37.8588; WALTS AE, 1992, DIAGN CYTOPATHOL, V8, P394, DOI 10.1002/dc.2840080420	17	1	1	0	1	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JUL	2018	52	4					262	266		10.4132/jptm.2018.05.15			5	Pathology	Pathology	GM8FQ	WOS:000438456900010	29902914	DOAJ Gold, Green Published			2019-10-28	
J	Hui, Y; Wang, YH; Nam, G; Fanion, J; Sturtevant, A; Lombardo, KA; Resnick, MB				Hui, Yiang; Wang, Yihong; Nam, Gahie; Fanion, Jacqueline; Sturtevant, Ashlee; Lombardo, Kara A.; Resnick, Murray B.			Differentiating breast carcinoma with signet ring features from gastrointestinal signet ring carcinoma: assessment of immunohistochemical markers	HUMAN PATHOLOGY			English	Article						Signet ring carcinoma; Lobular carcinoma; Estrogen receptor; GATA-3; CDX2; Immunohistochemistry	INVASIVE LOBULAR CARCINOMA; CELL-CARCINOMA; E-CADHERIN; ESTROGEN-RECEPTOR; GATA3 EXPRESSION; ADENOCARCINOMA; EMPHASIS; MUTATION; STOMACH; BLADDER	Signet ring morphology is recognized throughout the gastrointestinal tract. However, this pattern may be observed in other primary sites giving rise to diagnostic challenges in the work-up of metastases. Relatively newer immunohistochemical markers have not been evaluated in this context. We assessed expression patterns of several common immunohistochemical markers in tumors with Signet ring morphology to delineate a pragmatic approach to this differential diagnosis. Primary breast and gastrointestinal carcinomas showing Signet ring features were reviewed. Non-mammary and non-gastrointestinal tumors with this morphology were included for comparison. Estrogen receptor (ER), progesterone receptor (PR), E-cadherin, CK7, CK20, GCDFP-15, mammaglobin, CDX2, GATA-3, and HepPar-1 immunohistochemistry was performed. Expression patterns were compared between breast and gastrointestinal tumors as well as lobular breast and gastric tumors. Ninety-three cases were identified: 33 breast carcinomas including 13 lobular, 50 gastrointestinal tumors including 23 gastric, and 10 from other sites. ER (sensitivity=81.8%, specificity = 100%, positive predictive value (PPV) = 100%, negative predictive value (NPV) = 89.3%) and GATA-3 (sensitivity = 100%, specificity = 98%, PPV = 96.8%, NPV = 100%) expression were associated with breast origin. CK20 (sensitivity = 66.7%, specificity=93.3%, PPV = 94.1%, NPV = 63.6%) and CDX2 (sensitivity = 72%, specificity = 100%, PPV = 100%, NPV = 68.9%) demonstrated the strongest discriminatory value for gastrointestinal origin. These markers exhibited similar discriminatory characteristics when comparing lobular and gastric signet ring carcinomas. In a limited trial on metastatic breast and gastric cases, these markers successfully discriminated between breast and gastric primary sites in 15 of 16 cases. ER and GATA-3 are most supportive of mammary origin and constitute an effective panel for distinguishing primary breast from primary gastrointestinal Signet ring tumors when combined with CK20 and CDX2 immunohistochemistry. (C) 2018 Elsevier Inc. All rights reserved.	[Hui, Yiang; Wang, Yihong; Nam, Gahie; Fanion, Jacqueline; Sturtevant, Ashlee; Lombardo, Kara A.; Resnick, Murray B.] Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Providence, RI 02903 USA	Resnick, MB (reprint author), Dept Pathol, 593 Eddy St,APC12, Providence, RI 02903 USA.	mresnick@lifespan.org	Resnick, Murray/U-2986-2019		Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Medical Center; Molecular Pathology Core of the COBRE Center for Cancer Research Development - National Institute of General Medical Sciences of the National Institutes of Health [P20GM103421]	Research funding provided by Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Medical Center and by the Molecular Pathology Core of the COBRE Center for Cancer Research Development funded by the National Institute of General Medical Sciences of the National Institutes of Health under award number P20GM103421.	Abid R, 2013, J CLIN ONCOL, V31; Chen YM, 2016, MOL CLIN ONCOL, V5, P111, DOI 10.3892/mco.2016.884; Chu PG, 2004, AM J CLIN PATHOL, V121, P884, DOI 10.1309/A09ERYMFR64NERDW; Chu PG, 2000, MODERN PATHOL, V13, P962, DOI 10.1038/modpathol.3880175; Chung DC, 2007, NEW ENGL J MED, V357, P283, DOI 10.1056/NEJMcpc079016; Clark BZ, 2014, AM J CLIN PATHOL, V142, P64, DOI 10.1309/AJCP8H2VBDSCIOBF; Da Silva L, 2008, AM J SURG PATHOL, V32, P773, DOI 10.1097/PAS.0b013e318158d6c5; Dabbs DJ, 2013, AM J SURG PATHOL, V37, pE1, DOI 10.1097/PAS.0b013e3182918a2b; El-Hage A, 2016, J SURG ONCOL, V114, P543, DOI 10.1002/jso.24362; Ellis CL, 2013, AM J SURG PATHOL, V37, P1756, DOI 10.1097/PAS.0b013e31829cdba7; Fukui Y, 2014, BIOCHEM BIOPH RES CO, V450, P1231, DOI 10.1016/j.bbrc.2014.07.025; He HY, 2014, AM J ROENTGENOL, V202, P1140, DOI 10.2214/AJR.13.11156; Ishikawa MK, 2015, ARCH PATHOL LAB MED, V139, P1253, DOI 10.5858/arpa.2015-0190-RA; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Kermanshahi TR, 2017, INT J SURG PATHOL, V25, P108, DOI 10.1177/1066896916664990; Lew M, 2015, CANCER CYTOPATHOL, V123, P576, DOI 10.1002/cncy.21574; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Ma YHR, 2017, APPL IMMUNOHISTO M M, V25, P432, DOI 10.1097/PAI.0000000000000317; Mahmud N, 2015, J CLIN ONCOL, V33, pE19, DOI 10.1200/JCO.2013.49.1159; Nash JW, 2003, ARCH PATHOL LAB MED, V127, P1591; Ricciuti B, 2016, J BREAST CANCER, V19, P324, DOI 10.4048/jbc.2016.19.3.324; Spinelli C, 2016, J CLIN DIAGN RES, V10, pPD7, DOI 10.7860/JCDR/2016/20299.8747; Tot T, 2000, APMIS, V108, P467, DOI 10.1034/j.1600-0463.2000.d01-84.x; Wendroth SM, 2015, ANN DIAGN PATHOL, V19, P6, DOI 10.1016/j.anndiagpath.2014.12.001; Yang YQ, 2017, ANN DIAGN PATHOL, V26, P1, DOI 10.1016/j.anndiagpath.2016.09.011	25	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						11	19		10.1016/j.humpath.2018.01.002			9	Pathology	Pathology	GM6ZA	WOS:000438326300002	29317235	Green Accepted			2019-10-28	
J	Agaimy, A; Michal, M; Hadravsky, L; Michal, M				Agaimy, Abbas; Michal, Michael; Hadravsky, Ladislav; Michal, Michal			Dedifferentiated liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant	HUMAN PATHOLOGY			English	Article						Dedifferentiated liposarcoma; Retroperitoneum; Rhabdoid; Epithelioid; SWI/SNF; Rhabdomyosarcoma; Melanoma	METASTATIC MALIGNANT-MELANOMA; CLINICOPATHOLOGICAL ANALYSIS; PLEOMORPHIC LIPOSARCOMA; HISTOLOGICAL PATTERN; DIFFERENTIATION; CARCINOMA; RETROPERITONEUM; EXPRESSION; MORPHOLOGY; PHENOTYPE	Dedifferentiated liposarcoma is one of the most common sarcoma types in adults with a predilection for the retroperitoneum. We have recently encountered 6 cases of DDL composed predominantly of rounded, rhabdoid or epithelioid cells mimicking rhabdoid melanoma, epithelioid rhabdomyosarcoma or undifferentiated carcinoma. Patients were 5 males and one female aged 64 to 81 years (median, 68). Tumors originated in the retroperitoneum (n = 5; 3 in the psoas muscle) and deep soft tissue of the thigh (n = 1). All 3 patients with follow-up died of metastatic disease within 4 to 8 months. Preoperative biopsy diagnoses never suggested dedifferentiated liposarcoma as a possibility; instead carcinoma, rhabdomyosarcoma and lymphoma were on top of suggestions. Five resected tumors were composed predominantly (70%-100%) of anaplastic rounded to oval rhabdoid cells with prominent central nucleoli and paranuclear rhabdoid inclusions. Bi- and multinucleation was a constant feature. The background stroma showed variable myxoid changes and minor mixed inflammatory cells. Two cases showed homologous dedifferentiation and another had sclerosing spindle cell nodule but a well-differentiated lipomatous component was not seen in any. One biopsied case showed solely monotonous small round blue cells with scattered rhabdoid cells. Immunohistochemistry showed expression of MDM2 (6/6), CDK4 (5/6), pancytokeratin AE/1 AE3 (4/6) and diffusely desmin and myogenin (2/6). All cases showed high-level co-amplification of MDM2/CDK4 by in situ hybridization. The SWI/SNF complex components (SMARCB1, SMARCA2, SMARCA4, ARID1A and PBRM1) were intact in all cases. This highly aggressive liposarcoma variant needs to be distinguished from a variety of neoplasms including undifferentiated carcinoma, melanoma, lymphoma, rhabdomyosarcoma and others. (C) 2018 Elsevier Inc. All rights reserved.	[Agaimy, Abbas] Univ Hosp, Inst Pathol, D-91054 Erlangen, Germany; [Michal, Michael; Michal, Michal] Charles Univ Prague, Fac Med Pilsen, Dept Pathol, Prague 30460, Czech Republic; [Michal, Michael] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen 30460, Czech Republic; [Hadravsky, Ladislav] Charles Univ Prague, Fac Med 1, Dept Pathol, Prague 10000, Czech Republic	Agaimy, A (reprint author), Univ Klinikum Erlangen, Pathol Inst, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	abbas.agaimy@uk-erlangen.de	Michal, Michael/I-3497-2017	Michal, Michael/0000-0003-4403-7027			Agaimy A, 2017, AM J SURG PATHOL, V41, P253, DOI 10.1097/PAS.0000000000000787; Agaimy A, 2016, VIRCHOWS ARCH, V469, P321, DOI 10.1007/s00428-016-1977-y; Agaimy A, 2016, AM J SURG PATHOL, V40, P544, DOI 10.1097/PAS.0000000000000554; Agaimy A, 2016, AM J SURG PATHOL, V40, P181, DOI 10.1097/PAS.0000000000000527; Agaimy A, 2015, MODERN PATHOL, V28, P248, DOI 10.1038/modpathol.2014.100; Binh MBN, 2007, AM J SURG PATHOL, V31, P1557, DOI 10.1097/PAS.0b013e31804b4109; BITTESINI L, 1992, HISTOPATHOLOGY, V20, P167, DOI 10.1111/j.1365-2559.1992.tb00947.x; Coindre JM, 2003, MODERN PATHOL, V16, P256, DOI 10.1097/01.MP.0000056983.78547.77; Dei Tos AP, 2013, WHO CLASSIFICATION T, P37; Dujardin F, 2011, MODERN PATHOL, V24, P624, DOI 10.1038/modpathol.2010.229; Fanburg-Smith JC, 1998, HISTOPATHOLOGY, V33, P414, DOI 10.1046/j.1365-2559.1998.00536.x; Gronchi A, 2015, AM J SURG PATHOL, V39, P383, DOI 10.1097/PAS.0000000000000366; Hasegawa T, 2000, HUM PATHOL, V31, P717, DOI 10.1053/hupa.2000.8222; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Jo VY, 2011, AM J SURG PATHOL, V35, P1523, DOI 10.1097/PAS.0b013e31822e0907; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Lucas DR, 2010, AM J SURG PATHOL, V34, P844, DOI 10.1097/PAS.0b013e3181db34d8; Makise N, 2017, AM J SURG PATHOL, V41, P1523, DOI 10.1097/PAS.0000000000000910; Marino-Enriquez A, 2010, AM J SURG PATHOL, V34, P1122, DOI 10.1097/PAS.0b013e3181e5dc49; Miettinen M, 1999, MODERN PATHOL, V12, P722; Neuville A, 2014, AM J SURG PATHOL, V38, P461, DOI 10.1097/PAS.0000000000000184; Ramalingam P, 2017, HISTOPATHOLOGY, V70, P359, DOI 10.1111/his.13091; Thway K, 2016, ADV ANAT PATHOL, V23, P30, DOI 10.1097/PAP.0000000000000101	24	3	5	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						20	27		10.1016/j.humpath.2017.12.025			8	Pathology	Pathology	GM6ZA	WOS:000438326300003	29307627				2019-10-28	
J	Folpe, AL; Graham, RP; Martinez, A; Schembri-Wismayer, D; Boland, J; Fritchie, KJ				Folpe, Andrew L.; Graham, Rondell P.; Martinez, Anthony; Schembri-Wismayer, David; Boland, Jennifer; Fritchie, Karen J.			Mesenchymal chondrosarcomas showing immunohistochemical evidence of rhabdomyoblastic differentiation: a potential diagnostic pitfall	HUMAN PATHOLOGY			English	Article						Mesenchymal chondrosarcoma; Myogenin; MyoD1; Desmin; Rhabdomyosarcoma	HEY1-NCOA2 FUSION; MYOD FAMILY; CELL TUMORS; EXPRESSION; DESMIN; RHABDOMYOSARCOMA; MYOGENIN; OSTEOSARCOMA	The diagnosis of mesenchymal chondrosarcoma, a distinctive biphasic malignant neoplasm harboring the HEY1-NCOA2 gene fusion and consisting of primitive round to spindled cells admixed with foci of relatively mature hyaline cartilage, is usually straightforward by morphologic evaluation alone. However, in the setting of a limited biopsy, specimens lacking cartilage generate a broad differential diagnosis, encompassing a variety of other primitive sarcomas, including spindle cell/sclerosing rhabdomyosarcoma. Although a small number of cases of mesenchymal chondrosarcoma with aberrant skeletal muscle marker expression have been reported, pathologists are largely unaware of this potential diagnostic pitfall. We report 6 additional cases of mesenchymal chondrosarcoma showing expression of multiple skeletal muscle markers, including one case initially misdiagnosed as "spindle cell/sclerosing rhabdomyosarcoma" on needle biopsy. Awareness of this phenomenon and judicious application of molecular diagnostic testing for the HEY1-NCOA2 fusion are critical to avoid misclassification of mesenchymal chondrosarcoma as rhabdomyosarcoma, with potentially adverse patient impact. (C) 2018 Elsevier Inc. All rights reserved.	[Folpe, Andrew L.; Graham, Rondell P.; Martinez, Anthony; Schembri-Wismayer, David; Boland, Jennifer; Fritchie, Karen J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55902 USA	Fritchie, KJ (reprint author), Mayo Clin, Dept Anat Pathol, Hilton 11,200 First St SW, Rochester, MN 55905 USA.	Fritchie.Karen@mayo.edu		Boland, Jennifer/0000-0002-2723-9586			Adhikari LA, 2012, J CUTAN PATHOL, V39, P47, DOI 10.1111/j.1600-0560.2011.01794.x; Agaram NP, 2014, GENE CHROMOSOME CANC, V53, P779, DOI 10.1002/gcc.22187; Buas MF, 2010, J BIOL CHEM, V285, P1249, DOI 10.1074/jbc.M109.046441; DEVANEY K, 1993, HUM PATHOL, V24, P1211, DOI 10.1016/0046-8177(93)90218-6; DIAS P, 1994, SEMIN DIAGN PATHOL, V11, P3; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DOBIN SM, 1995, CANCER GENET CYTOGEN, V83, P56, DOI 10.1016/0165-4608(95)00031-3; Fanburg-Smith JC, 1999, HUM PATHOL, V30, P1336, DOI 10.1016/S0046-8177(99)90065-5; Fanburg-Smith JC, 2010, ANN DIAGN PATHOL, V14, P8, DOI 10.1016/j.anndiagpath.2009.09.003; Fletcher C, 2013, WHO CLASSIFICATION T; Folpe AL, 1998, MODERN PATHOL, V11, P939; Folpe AL, 2002, AM J SURG PATHOL, V26, P1175, DOI 10.1097/01.PAS.0000024996.88486.CA; Folpe AL, 2002, ADV ANAT PATHOL, V9, P198, DOI 10.1097/00125480-200205000-00003; Folpe AL, 2005, AM J SURG PATHOL, V29, P1025; Fritchie KJ, 2013, AM J CLIN PATHOL, V140, P670, DOI 10.1309/AJCPGUNGP52ZSDNS; Gengler C, 2006, HISTOPATHOLOGY, V48, P201, DOI 10.1111/j.1365-2559.2005.02205.x; Graham RPD, 2011, AM J SURG PATHOL, V35, P1615, DOI 10.1097/PAS.0b013e3182284a3f; Hoang MP, 2000, INT J SURG PATHOL, V8, P291, DOI 10.1177/106689690000800408; HURLIMANN J, 1994, HUM PATHOL, V25, P753, DOI 10.1016/0046-8177(94)90243-7; KUROTAKI H, 1992, ACTA PATHOL JAPON, V42, P364; MARTINEZTELLO FJ, 1982, VIRCHOWS ARCH A, V396, P197, DOI 10.1007/BF00431241; Mosquera JM, 2013, GENE CHROMOSOME CANC, V52, P538, DOI 10.1002/gcc.22050; Ordonez NG, 1998, AM J SURG PATHOL, V22, P1314, DOI 10.1097/00000478-199811000-00002; PATNAIK AK, 1986, VET PATHOL, V23, P170, DOI 10.1177/030098588602300210; Povysil C, 1986, Cesk Patol, V22, P231; Romano RC, 2015, MODERN PATHOL, V28, P1033, DOI 10.1038/modpathol.2015.62; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; STEINER GC, 1973, CANCER, V32, P926, DOI 10.1002/1097-0142(197310)32:4<926::AID-CNCR2820320427>3.0.CO;2-T; SWANSON PE, 1990, ARCH PATHOL LAB MED, V114, P943; TRUONG LD, 1990, AM J CLIN PATHOL, V93, P305, DOI 10.1093/ajcp/93.3.305; VENUTI JM, 1995, J CELL BIOL, V128, P563, DOI 10.1083/jcb.128.4.563; Wang L, 2012, GENE CHROMOSOME CANC, V51, P127, DOI 10.1002/gcc.20937; Wehrli BM, 2003, HUM PATHOL, V34, P263, DOI 10.1053/hupa.2003.41; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weiss SW, 2014, ENZINGER WEISSS SOFT	35	4	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						28	34		10.1016/j.humpath.2018.03.012			7	Pathology	Pathology	GM6ZA	WOS:000438326300004	29559236				2019-10-28	
J	Wang, F; Wu, JY; Qiu, ZC; Ge, XS; Liu, XX; Zhang, C; Xu, WH; Wang, FM; Hua, D; Qi, XW; Mao, Y				Wang, Fang; Wu, Jingyi; Qiu, Zhichao; Ge, Xiaosong; Liu, Xingxiang; Zhang, Chun; Xu, Wenhuan; Wang, Fengming; Hua, Dong; Qi, Xiaowei; Mao, Yong			ACOT1 expression is associated with poor prognosis in gastric adenocarcinoma	HUMAN PATHOLOGY			English	Article						Gastric cancer; ACOT1; GLI3; Immunohistochemistry; Tissue microarray; Survival analysis	ADIPOSE-TISSUES; CANCER; HEDGEHOG; ACID; METABOLISM; ACTIVATION; INTESTINE; STOMACH; PATHWAY; PROTEIN	Acyl-CoA thioesterase 1 (ACOTI) is an important isoform of the ACOT family that catalyzes the reaction of fatty acyl-CoAs to CoA-SH and free fatty acids. Recent studies of gastrointestinal tumor metabolism suggest that there is abnormal metabolism of lipids and fatty acids during tumor progression. However, the function and contribution of ACOT1 in gastric cancer development are still poorly understood. In addition, GLI3 is a major transcription factor in the regulation of hedgehog signaling. GLI3 mutations induce glandular expansion and intestinal metaplasia in gastric cancer, which indicates a role for GLI3 in the preneoplastic process. Thus, we investigated the relationship between ACOT1 expression and GLI3 in gastric adenocarcinoma. A tissue microarray was constructed from 280 cases of gastric adenocarcinoma. The immunohistochemistry method was performed on tissue sections of 4 mu m from each tissue microarray block. We found a significant correlation between ACOT1 expression and poor histologic grade, a lower T category, TNM stage, and increased GLI3 expression. In addition, the survival analysis revealed that the ACOT1-positive group had significantly decreased overall survival rates compared with the ACOT1-negative group. Furthermore, GLI3 expression had a significant positive correlation with ACOT1 expression in gastric adenocarcinoma cells. In summary, these findings demonstrate that increased expression of ACOT1 is correlated with pivotal clinicopathological parameters and poor prognosis in gastric adenocarcinoma through increased expression of the potential tumor-promoting protein GLI3. (C) 2018 Published by Elsevier Inc.	[Wang, Fang; Wu, Jingyi; Qiu, Zhichao; Ge, Xiaosong; Xu, Wenhuan; Hua, Dong; Mao, Yong] Jiangnan Univ, Dept Oncol, Affiliated Hosp, 200 Huihe Rd, Wuxi 214062, Peoples R China; [Wang, Fang; Wu, Jingyi; Qiu, Zhichao; Zhang, Chun] Jiangnan Univ, Sch Med, Wuxi 214000, Peoples R China; [Liu, Xingxiang] Second Peoples Hosp Taizhou City, Dept Oncol, Taizhou 225300, Peoples R China; [Wang, Fengming] Blood Ctr Changzhou City, Changzhou 213000, Peoples R China; [Qi, Xiaowei] Jiangnan Univ, Affiliated Hosp, Dept Pathol, 200 Huihe Rd, Wuxi 214062, Peoples R China	Mao, Y (reprint author), Jiangnan Univ, Dept Oncol, Affiliated Hosp, 200 Huihe Rd, Wuxi 214062, Peoples R China.; Qi, XW (reprint author), Jiangnan Univ, Affiliated Hosp, Dept Pathol, 200 Huihe Rd, Wuxi 214062, Peoples R China.	qixiaowei97@163.com; mydoctorwx@aliyun.com			National Natural Science Foundation Youth Project of China [81402487, 81502042]; Natural Science Foundation Youth Project of Jiangsu Province [BK20140171]; Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural Science Foundation of Jiangsu Province [BK20151176, BK20171150]	This study was supported by grants from the National Natural Science Foundation Youth Project of China (Nos. 81402487 and 81502042), a grant from the Natural Science Foundation Youth Project of Jiangsu Province (No. BK20140171), and a grant from the Natural Science Foundation of Jiangsu Province (Nos. BK20151176 and BK20171150).	Al-Moundhri MS, 2005, J SURG ONCOL, V91, P243, DOI 10.1002/jso.20324; Biden KG, 1999, ONCOGENE, V18, P1245, DOI 10.1038/sj.onc.1202413; Demchak Barry, 2014, F1000Res, V3, P151, DOI 10.12688/f1000research.4492.1; Ellis JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116587; Franklin MP, 2017, DIABETES, V66, P2112, DOI 10.2337/db16-1519; Gomes DC, 2015, EUR J ENDOCRINOL, V172, P603, DOI 10.1530/EJE-14-0934; Hung JY, 2017, ONCOL LETT, V14, P3647, DOI 10.3892/ol.2017.6594; Jung SH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.202; Katoh Y, 2005, CANCER BIOL THER, V4, P1050, DOI 10.4161/cbt.4.10.2184; Kolterud A, 2009, GASTROENTEROLOGY, V137, P618, DOI 10.1053/j.gastro.2009.05.002; Kong DH, 2015, ANALYST, V140, P6588, DOI 10.1039/c5an01151e; Kupfer SS, 2017, GASTROENTEROLOGY, V152, P926, DOI 10.1053/j.gastro.2017.02.026; Lamont BJ, 2012, J CLIN INVEST, V122, P388, DOI 10.1172/JCI42497; Liu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0302-1; Madison BB, 2009, J BIOL CHEM, V284, P5936, DOI 10.1074/jbc.M808103200; Modi HR, 2014, BIPOLAR DISORD, V16, P875, DOI 10.1111/bdi.12220; Nagarajan RP, 2014, GENOME RES, V24, P761, DOI 10.1101/gr.164707.113; Pashaj A, 2013, PHYSIOL GENOMICS, V45, P1136, DOI 10.1152/physiolgenomics.00138.2013; Razzak Mina, 2013, Nat Rev Clin Oncol, V10, P548, DOI 10.1038/nrclinonc.2013.156; Tanaka M, 2017, GENES NUTR, V12, DOI 10.1186/s12263-017-0558-2; Tillander V, 2017, TRENDS ENDOCRIN MET, V28, P473, DOI 10.1016/j.tem.2017.03.001; van den Brink GR, 2007, PHYSIOL REV, V87, P1343, DOI 10.1152/physrev.00054.2006; Vasu S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101005; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wessler S, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0171-4; Wu K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10131; Yang SG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029652; Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011	28	1	1	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						35	44		10.1016/j.humpath.2018.03.013			10	Pathology	Pathology	GM6ZA	WOS:000438326300005	29555575				2019-10-28	
J	Garcia-Honduvilla, H; Ortega, MA; Asunsolo, A; Alvarez-Rocha, MJ; Romero, B; De Leon-Luis, J; Alvarez-Mon, M; Bujan, J				Garcia-Honduvilla, Hatalio; Ortega, Miguel A.; Asunsolo, Angel; Alvarez-Rocha, Maria J.; Romero, Beatriz; De Leon-Luis, Juan; Alvarez-Mon, Melchor; Bujan, Julia			Placentas from women with pregnancy-associated venous insufficiency show vial damage with evidence of hypoxic cellular stress	HUMAN PATHOLOGY			English	Article						Venous insufficiency; Hypoxia; Apoptosis; Placental villi; Villous space	SYNCYTIAL KNOTS; VARICOSE-VEINS; TROPHOBLAST DEPORTATION; APOPTOSIS; PREECLAMPSIA; RISK; HISTOPATHOLOGY; EXPRESSION; RECEPTOR; SYSTEM	Lower extremity venous insufficiency (VI) is a complication of pregnancy. The potential association of this venous disease with structural damage of the placenta has not been described. We analyzed the pattern of histopathologic lesions and the gene and protein expression of HIF1-alpha and apoptosis regulatory proteins. A prospective study was carried out on placenta samples from 43 women with pregnancy-associated VI and 24 age-matched pregnant healthy controls (HCs). Women with VI showed a significant increase in the number of villi (150.77 +/- 42.55 VI versus 122.13 +/- 27.74 HC) and in syncytial knots compared with those found in the placentas from HCs (67.15 +/- 31.08 VI versus 42.49 +/- 17.36 HC), and an increase in the number of bridges (32.40 +/- 2.67 VI versus 22.73 +/- 2.37 HC; P < .05). The mean number of syncytial nodes per villus is 1.37 +/- 0.90 in the VI group and 0.49 +/- 0.58 in the HC group (P < .001). Significant increases in the expression of Bax and caspase-3 and caspase-9 in the placentas from women with VI were observed compared with those found in HC. The expression of HIF-1 alpha at both the messenger RNA and protein levels was also significantly increased in the placentas from women with VI. Our study demonstrates that placentas from women with pregnancy-associated VI show structural remodeling, with an increase in the number of villi and syncytial knots and enhanced apoptotic cellular death. Interestingly, this placental damage is associated with an increased expression of hypoxia-triggered molecular pathways, such as HIF-1 alpha. (C) 2018 The Authors. Published by Elsevier Inc.	[Garcia-Honduvilla, Hatalio; Ortega, Miguel A.; Alvarez-Rocha, Maria J.; Romero, Beatriz; Alvarez-Mon, Melchor; Bujan, Julia] Univ Alcala De Henares, Fac Med & Hlth Sci, Ramon y Cajal Inst Sanitary Res IRYCIS,Dept Med &, Networking Biomed Res Ctr Bioengn Biomat & Nanome, Madrid, Spain; [Asunsolo, Angel] Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Surg Med & Social Sci, Madrid, Spain; [De Leon-Luis, Juan] Univ Hosp Gregorio Maranon, Serv Gynecol & Obstet, Sect Fetal Maternal Med, Madrid, Spain; [Alvarez-Mon, Melchor] Univ Hosp Principe de Asturias, Immune Syst Dis Rheumatol & Oncol Serv, Madrid, Spain	Bujan, J (reprint author), Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Med, Ctra Madrid Barcelona Km 33-6, Madrid 28871, Spain.; Bujan, J (reprint author), Univ Alcala De Henares, Fac Med & Hlth Sci, Dept Med Specialties, Ctra Madrid Barcelona Km 33-6, Madrid 28871, Spain.	mjulia.bujan@uah.es	Asunsolo, Angel/D-8050-2018	Asunsolo, Angel/0000-0001-7898-4685; Ortega, Miguel A/0000-0003-2588-1708; Garcia Honduvilla, Natalio/0000-0003-0904-6198; bujan, Julia/0000-0003-2419-2476	National Institute of Health Carlos III [FIS-PI13/01513];  [B2017/BMD-3804 MITIC-CM]	This work was supported by grants from the National Institute of Health Carlos III (FIS-PI13/01513) and B2017/BMD-3804 MITIC-CM.	Banhidy Ferenc, 2010, Central European Journal of Public Health, V18, P161; Benirschke K, 2012, PATHOLOGY HUMAN PLAC, DOI [10.1186/147-2105-13-134, DOI 10.1186/147-2105-13-134]; BUDD TW, 1990, J MED, V21, P181; Burton GJ, 2009, TAIWAN J OBSTET GYNE, V48, P28, DOI 10.1016/S1028-4559(09)60032-2; Calderwood CJ, 2007, CLIN RADIOL, V62, P1174, DOI 10.1016/j.crad.2007.06.003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Correa RRM, 2008, ARCH GYNECOL OBSTET, V277, P201, DOI 10.1007/s00404-007-0452-z; Costa MA, 2015, PLACENTA, V36, P69, DOI 10.1016/j.placenta.2014.10.011; Fogarty NME, 2013, AM J PATHOL, V183, P144, DOI 10.1016/j.ajpath.2013.03.016; Heazell AEP, 2007, PLACENTA, V28, pS33, DOI 10.1016/j.placenta.2006.10.007; Ismail L, 2016, J VASC SURG-VENOUS L, V4, P518, DOI 10.1016/j.jvsv.2016.06.003; Kurlak LO, 2015, PLACENTA, V36, P611, DOI 10.1016/j.placenta.2015.02.011; Laurikka JO, 2002, WORLD J SURG, V26, P648, DOI 10.1007/s00268-001-0283-1; Longtine MS, 2012, PLACENTA, V33, P352, DOI 10.1016/j.placenta.2012.01.017; Moore T, 2012, PLACENTA, V33, pS33, DOI 10.1016/j.placenta.2011.11.016; Pantham P, 2011, PLACENTA, V32, P724, DOI 10.1016/j.placenta.2011.06.019; Parks WT, 2015, SEMIN PERINATOL, V39, P1, DOI 10.1053/j.semperi.2014.10.001; Pascual G, 2008, HISTOL HISTOPATHOL, V23, P179, DOI 10.14670/HH-23.179; Prusac IK, 2011, ACTA OBSTET GYN SCAN, V90, P1157, DOI 10.1111/j.1600-0412.2011.01152.x; Rabe E, 2014, PHLEBOLOGY, V29, P338, DOI 10.1177/0268355513483280; Rabe E, 2012, PHLEBOLOGY, V27, P114, DOI [10.1258/phleb.2012.012s19, 10.1258/phleb.2012.012S19]; Robb KP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175805; Serra R, 2012, ANN VASC SURG, V26, P636, DOI 10.1016/j.avsg.2011.11.036; Summers DS, 1981, OBSTET GINECOL, V24, P742; Vallone PM, 2004, BIOTECHNIQUES, V37, P226, DOI 10.2144/04372ST03; van Kesteren F, 2016, HYPERTENS PREGNANCY, V35, P55, DOI 10.3109/10641955.2015.1100311; van Patot MCT, 2010, AM J PHYSIOL-REG I, V298, pR166, DOI 10.1152/ajpregu.00383.2009; Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134; Zamudio S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008551; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	30	5	5	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						45	53		10.1016/j.humpath.2018.03.022			9	Pathology	Pathology	GM6ZA	WOS:000438326300006	29626597	Other Gold			2019-10-28	
J	Liu, JB; Lu, FN; Gong, Y; Zhao, C; Pan, Q; Ballantyne, S; Zhao, XD; Tian, SF; Chen, HL				Liu, Jiabin; Lu, Funian; Gong, Yan; Zhao, Chen; Pan, Qi; Ballantyne, Stephanie; Zhao, Xianda; Tian, Sufang; Chen, Honglei			High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma	HUMAN PATHOLOGY			English	Article						Energy metabolism; Lung adenocarcinoma; SCO2; TIGAR; p53	TIGAR; P53; METABOLISM; CANCER; SCO2; ROS; CLASSIFICATION; CELLS	Synthesis of cytochrome c oxidase 2 (SCO2) and TP53-induced glycolysis and apoptosis regulator (TIGAR) are 2 p53-mediated proteins that can play a regulatory role in cancer energy metabolism. However, no study has examined the association of SCO2 and TIGAR with the prognosis of patients with lung adenocarcinoma (AC). In our study, the expression of SCO2 and TIGAR proteins in lung AC was detected, and the potential relation to prognosis was evaluated, aiming to take a further view of lung AC progression. Quantum dots-based immunofluorescence histochemistry staining was performed to observe the expression of p53, SCO2, and TIGAR in 75 specimens of lung AC. Of these, 51 (68.0%) showed high expression of SCO2, and 59 (78.7%) showed high expression of TIGAR. High TIGAR expression was significantly associated with a history of smoking (P = .017) and being male (P = .006). The correlation between high SCO2 expression and age also was significant (P = .042). Moreover, high TIGAR expression was positively correlated with high SCO2 expression (P = .019; r(s) = 0.271). High expression of the SCO2 and TIGAR proteins predicted poorer survival and a higher mortality rate (P = .024 and .030, respectively). High expression of SCO2 and TIGAR proteins is significantly associated with lung AC progression, suggesting their potential use as prognostic markers and therapeutic targets. (C) 2018 Elsevier Inc. All rights reserved.	[Liu, Jiabin; Lu, Funian; Gong, Yan; Zhao, Chen; Ballantyne, Stephanie; Zhao, Xianda; Chen, Honglei] Wuhan Univ, Sch Basic Med Sci, Dept Pathol, Wuhan 430071, Hubei, Peoples R China; [Pan, Qi] Tradit Chinese Med Hosp Wenling, Dept Thoracosurg, Wenling 317500, Zhejiang, Peoples R China; [Tian, Sufang; Chen, Honglei] Wuhan Univ, Zhongnan Hosp, Dept Pathol, Wuhan 430071, Hubei, Peoples R China	Chen, HL (reprint author), Wuhan Univ, Sch Basic Med Sci, Dept Pathol, Wuhan 430071, Hubei, Peoples R China.	hl-chen@whu.edu.cn		Chen, Hong-Lei/0000-0001-9832-1336	National Undergraduate Innovation Project of China [201510486090]; Public Welfare Technology Application Research of Zhejiang Province [2016C33236]	This study was funded by the National Undergraduate Innovation Project of China is founded by the Ministry of Education, which is located in Beijing (201510486090) and Public Welfare Technology Application Research of Zhejiang Province (2016C33236). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242; Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035; Dickinson EK, 2000, J BIOL CHEM, V275, P26780; Du W, 2016, STEM CELLS, V34, P960, DOI 10.1002/stem.2260; Feinberg T, 2017, J BREATH RES, V11, DOI 10.1088/1752-7163/aa51d6; Fico A, 2004, CELL DEATH DIFFER, V11, P823, DOI 10.1038/sj.cdd.4401420; Gerin I, 2014, BIOCHEM J, V458, P439, DOI 10.1042/BJ20130841; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Guppy M, 2002, BIOCHEM J, V364, P309, DOI 10.1042/bj3640309; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; KALLINOWSKI F, 1989, INT J CANCER, V44, P266, DOI 10.1002/ijc.2910440214; Kim SH, 2016, PATHOL RES PRACT, V212, P904, DOI 10.1016/j.prp.2016.07.014; Kumar B, 2015, BIOCHIMIE, V118, P26, DOI 10.1016/j.biochi.2015.07.016; Li MH, 2010, TUMORI, V96, P734; Lim HY, 2011, MITOCHONDRION, V11, P437, DOI 10.1016/j.mito.2010.12.015; Liu FB, 2015, ONCOTARGET, V6, P27199, DOI 10.18632/oncotarget.4508; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Morgada MN, 2015, P NATL ACAD SCI USA, V112, P11771, DOI 10.1073/pnas.1505056112; Ramsey MR, 2006, NAT CELL BIOL, V8, P1213, DOI 10.1038/ncb1106-1215; Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046; Sinthupibulyakit C, 2010, INT J ONCOL, V37, P1575, DOI 10.3892/ijo_00000811; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Vousden KH, 2010, P NATL ACAD SCI USA, V107, P7117, DOI 10.1073/pnas.1002656107; Wanka C, 2012, J BIOL CHEM, V287, P33436, DOI 10.1074/jbc.M112.384578; Won KY, 2012, HUM PATHOL, V43, P221, DOI 10.1016/j.humpath.2011.04.021; Zhang GJ, 2015, J NUCL MED, V56, P607, DOI 10.2967/jnumed.114.148254; Zhao XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059102; Zhou XX, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0062245, 10.1371/journal.pone.0065040]	31	3	3	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						54	62		10.1016/j.humpath.2017.12.029			9	Pathology	Pathology	GM6ZA	WOS:000438326300007	29634976				2019-10-28	
J	Isharwal, S; Huang, HY; Nanjangud, G; Audenet, F; Chen, YB; Gopalan, A; Fine, SW; Tickoo, SK; Lee, BH; Iyer, G; Chadalavada, K; Rosenberg, JE; Bajorin, DF; Herr, HW; Donat, SM; Dalbagni, G; Bochner, BH; Solit, DB; Reuter, VE; Al-Ahmadie, HA				Isharwal, Sumit; Huang, Hongying; Nanjangud, Gouri; Audenet, Francois; Chen, Ying-Bei; Gopalan, Anuradha; Fine, Samson W.; Tickoo, Satish K.; Lee, Byron H.; Iyer, Gopa; Chadalavada, Kalyani; Rosenberg, Jonathan E.; Bajorin, Dean F.; Herr, Harry W.; Donat, S. Machete; Dalbagni, Guido; Bochner, Bernard H.; Solit, David B.; Reuter, Victor E.; Al-Ahmadie, Hikmat A.			Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma	HUMAN PATHOLOGY			English	Article						Human epidermal growth factor receptor-2 (HER2, ERBB2); Micropapillary urothelial carcinoma; Fluorescence in situ hybridization; Immunohistochemistry; Intratumoral heterogeneity	TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; BLADDER-CANCER; BREAST-CANCER; VARIANT; GENE; CHEMOTHERAPY; TUMORS	Micropapillary urothelial carcinoma (MPUC) is a rare but an aggressive variant of urothelial carcinoma. MPUC has been shown to commonly exhibit ERBB2 amplification and HER2 protein overexpression, but the frequency and distribution of these findings within micropapillary (MP) and not otherwise specified (NOS) components of tumors with mixed histology have not been addressed. Therefore, we evaluated ERBB2 amplification and HER2 expression in 43 MPUC cases by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Of the 35 tumors containing both MP and NOS components, ERBB2 amplification was present in both the MP and NOS components of 12 tumors (34.3%), in only the MP component of 11 tumors (31.4%), and exclusively in the NOS component of 4 tumors (11.4%). HER2 protein overexpression was significantly more commonly present in the MP component compared to the NOS component within the same tumor (68.6% versus 34.3%, P = .012). Overall, there was a moderately positive correlation between HER2 protein expression and ERBB2 amplification in both MP (rho = 0.59, P < .001) and NOS (rho = 0.70, P < .001) components. All MP/NOS areas with IHC score 3+ and none of MP/NOS areas with IHC score 0 were associated with ERBB2 amplification. We conclude that ERBB2 amplification and HER2 overexpression are preferentially but not exclusively identified in the MP component compared to the NOS component within the same tumor. Our findings identify the presence of intratumoral heterogeneity of ERBB2 amplification and HER2 expression in MPUC and provide grounds for further investigation into the mechanisms underlying the development of MPUC. (C) 2018 Elsevier Inc. All rights reserved.	[Isharwal, Sumit; Audenet, Francois; Lee, Byron H.; Herr, Harry W.; Donat, S. Machete; Dalbagni, Guido; Bochner, Bernard H.] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10065 USA; [Huang, Hongying; Chen, Ying-Bei; Gopalan, Anuradha; Fine, Samson W.; Tickoo, Satish K.; Reuter, Victor E.; Al-Ahmadie, Hikmat A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Nanjangud, Gouri; Chadalavada, Kalyani] Mem Sloan Kettering Canc Ctr, Mol Cytogenet Core Facil, New York, NY 10065 USA; [Iyer, Gopa; Rosenberg, Jonathan E.; Bajorin, Dean F.; Solit, David B.] Mem Sloan Kettering Canc Ctr, Genitourinaiy Oncol Serv, Dept Med, New York, NY 10065 USA	Al-Ahmadie, HA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	alahmadh@mskcc.org	Solit, David B./AAC-5309-2019		Cycle for Survival; Ruth L. Kirschstein National Research Service AwardUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32CA082088]; Sloan Kettering Institute for Cancer Research Cancer Center [P30CA008748]; Marie-Josee and Henry R. Kravis Center for Molecular Oncology	This study was supported by the Cycle for Survival (HAA, DBS) and the Ruth L. Kirschstein National Research Service Award T32CA082088 (SI). This study was also funded in part by the Sloan Kettering Institute for Cancer Research Cancer Center Support Grant P30CA008748 and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology.	AMIN MB, 1994, AM J SURG PATHOL, V18, P1224, DOI 10.1097/00000478-199412000-00005; Bang YJ, 2010, LANCET, V376, P1302; Bertz S, 2016, VIRCHOWS ARCH, V469, P339, DOI 10.1007/s00428-016-1986-x; Ching CB, 2011, MODERN PATHOL, V24, P1111, DOI 10.1038/modpathol.2011.69; Choudhury NJ, 2016, J CLIN ONCOL, V34, P2165, DOI 10.1200/JCO.2015.66.3047; Fleischmann A, 2011, EUR UROL, V60, P350, DOI 10.1016/j.eururo.2011.05.035; Furrer D, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-17; Gaya JM, 2010, CAN J UROL, V17, P5370; Ghoneim IA, 2011, UROLOGY, V77, P867, DOI 10.1016/j.urology.2010.11.043; Goodman AL, 2016, HUM PATHOL, V57, P160, DOI 10.1016/j.humpath.2016.07.014; Guo CC, 2016, EUR UROL, V70, P611, DOI 10.1016/j.eururo.2016.02.056; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740; Johansson SL, 1999, J UROLOGY, V161, P1798, DOI 10.1016/S0022-5347(05)68807-6; Kamat AM, 2007, CANCER, V110, P62, DOI 10.1002/cncr.22756; Kunz PL, 2012, APPL IMMUNOHISTO M M, V20, P13, DOI 10.1097/PAI.0b013e31821c821c; Meeks JJ, 2013, BJU INT, V111, pE325, DOI 10.1111/j.1464-410X.2012.11751.x; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Ross JS, 2014, CLIN CANCER RES, V20, P68, DOI 10.1158/1078-0432.CCR-13-1992; Schneider SA, 2014, MODERN PATHOL, V27, P758, DOI 10.1038/modpathol.2013.201; Simonetti S, 2009, INT J SURG PATHOL, V17, P198, DOI 10.1177/1066896909333415; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Tafe LJ, 2011, ARCH PATHOL LAB MED, V135, P1460, DOI 10.5858/arpa.2010-0541-OA; Tschui J, 2015, VIRCHOWS ARCH, V466, P703, DOI 10.1007/s00428-015-1729-4; Vakiani E, 2015, ADV ANAT PATHOL, V22, P194, DOI 10.1097/PAP.0000000000000067; Vicario R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129876; Wang JK, 2012, WORLD J UROL, V30, P801, DOI 10.1007/s00345-012-0976-0; Watts KE, 2010, ADV ANAT PATHOL, V17, P182, DOI 10.1097/PAP.0b013e3181d97851; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	30	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						63	69		10.1016/j.humpath.2018.03.015			7	Pathology	Pathology	GM6ZA	WOS:000438326300008	29601842	Green Accepted			2019-10-28	
J	Konukiewitz, B; Jesinghaus, M; Steiger, K; Schlitter, AM; Kasajima, A; Sipos, B; Zamboni, G; Welchert, W; Pfarr, N; Kloppel, G				Konukiewitz, Bjoern; Jesinghaus, Moritz; Steiger, Katja; Schlitter, Anna Melissa; Kasajima, Atsuko; Sipos, Bence; Zamboni, Giuseppe; Welchert, Wilko; Pfarr, Nicole; Kloeppel, Gunter			Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3	HUMAN PATHOLOGY			English	Article						Pancreas; Neuroendocrine carcinoma; Neuroendocrine tumor; G3; Adenocarcinoma; Massive parallel sequencing	HIGH-GRADE; NEOPLASMS; LANDSCAPE; MUTATION; DISTINCT; CANCER; CELL	Pancreatic neuroendocrine carcinoma is a rare aggressive tumor commonly harboring TP53 and RB1 alterations and lacking neuroendocrine-related genetic changes such as mutations in MEN1 and ATRX/DAXX. Little is known about its genetic profile with regard to that of pancreatic ductal adenocarcinoma. We therefore conducted a detailed genetic study in 12 pancreatic neuroendocrine carcinomas of large cell (n = 9) and small cell type (n = 3) using massive parallel sequencing applying a 409-gene panel on an Ion Torrent system. The genetic data were compared with known data of pancreatic ductal adenocarcinoma and correlated with exocrine lineage marker expression. A similar analysis was performed in 11 pancreatic neuroendocrine tumors G3. Neuroendocrine carcinomas harbored 63 somatic mutations in 45 different genes, affecting most commonly TP53 (8/12 cases), KRAS (5/12 cases), and RBI (loss of expression with or without deletion in 4/12 cases). Five carcinomas had both TP53 and KRAS mutations. Neuroendocrine tumors G3 only shared singular mutations in 5 different genes with neuroendocrine carcinomas, including TP53, CDKN2A, ARID1A, LRP1B, and APC, affecting 5 different cases. Most KRAS-positive neuroendocrine carcinomas also expressed MIJC1 (4/5) and carcinoembryonic antigen (3/5) as markers of ductal differentiation. Our data indicate that almost half of the pancreatic neuroendocrine carcinomas are genetically and phenotypically related to pancreatic ductal adenocarcinoma, and might therefore respond to chemotherapies targeting the latter carcinomas. (C) 2018 Elsevier Inc. All rights reserved.	[Konukiewitz, Bjoern; Jesinghaus, Moritz; Steiger, Katja; Schlitter, Anna Melissa; Kasajima, Atsuko; Welchert, Wilko; Pfarr, Nicole; Kloeppel, Gunter] Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; [Sipos, Bence] Univ Hosp Tuebingen, Inst Pathol, D-72076 Tubingen, Germany; [Zamboni, Giuseppe] Sacro Cuore Don Calabria Hosp, Inst Pathol, I-37024 Verona, Italy	Konukiewitz, B (reprint author), Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany.	b.konukiewitz@tum.de	Giuseppe, Zamboni/L-6029-2019	Giuseppe, Zamboni/0000-0001-7428-4673; Kloppel, Gunter/0000-0002-6688-086X			Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Basturk O, 2014, AM J SURG PATHOL, V38, P437, DOI 10.1097/PAS.0000000000000169; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Hijioka S, 2017, CLIN CANCER RES, V23, P4625, DOI 10.1158/1078-0432.CCR-16-3135; Hosoda W, 2015, VIRCHOWS ARCH, V466, P665, DOI 10.1007/s00428-015-1751-6; Hruban RH, 2010, WHO CLASSIFICATION T; Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Lloyd RV, 2017, WHO CLASSIFICATION T; Pfarr N, 2017, GENE CHROMOSOME CANC, V56, P758, DOI 10.1002/gcc.22480; Rindi G, 2010, WHO CLASSIFICATION T; Scarpa A, 2017, NATURE, V543, P65, DOI 10.1038/nature21063; Schlitter AM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41064; Tang LH, 2016, CLIN CANCER RES, V22, P1011, DOI 10.1158/1078-0432.CCR-15-0548; Vortmeyer AO, 1997, J NATL CANCER I, V89, P1448, DOI 10.1093/jnci/89.19.1448; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Woischke C, 2017, MODERN PATHOL, V30, P95, DOI 10.1038/modpathol.2016.150; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36	22	5	5	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						70	79		10.1016/j.humpath.2018.03.018			10	Pathology	Pathology	GM6ZA	WOS:000438326300009	29596894				2019-10-28	
J	Zuo, CL; Fu, ZY; Lee, EC; Foulke, L; Young, GQ; Rego, DC; Lee, H				Zuo, Chunlai; Fu, Zhiyan; Lee, Edward C.; Foulke, Llewellyn; Young, Gloria Q.; Rego, David Cubero; Lee, Hwajeong			Microscopic ileitis in diverted and nondiverted enteric segments: an underrecognized condition with a multifactorial etiology	HUMAN PATHOLOGY			English	Article						Collagenous Ileitis; Lymphocytic Ileitis; Ileostomy; Diversion; Colostomy; High Ostomy Output	INFLAMMATORY-BOWEL-DISEASE; FECAL STREAM DIVERSION; COLLAGENOUS COLITIS; TERMINAL ILEUM; LYMPHOCYTIC COLITIS; ULCERATIVE-COLITIS; FEATURES; ASSOCIATION; INVOLVEMENT; BIOPSIES	Microscopic ileitis has been infrequently reported in the literature with the few reported cases usually associated with concurrent microscopic colitis. Having encountered a case of collagenous ileitis involving the diverted distal limb of a loop ileostomy and sparing the proximal limb, we examined additional cases of loop ileostomy, end ileostomy, colostomy, and the accompanying diverted colorectal segment for features of microscopic ileitis and colitis. A total of 101 cases of diverted and nondiverted enteric segments were examined from 37 loop ileostomies, 16 end ileostomies, and 12 colostomies status post-Hartmann's procedure. The patients' clinical histories, including demographics and risk factors for microscopic colitis, were obtained from electronic medical records. The index case and an additional case showed collagenous ileitis: the former in the diverted distal limb, and the latter in the nondiverted proximal limb of the loop ileostomy. The latter was associated with high ileostomy output with watery diarrhea. Two additional cases showed lymphocytic ileitis: one in the nondiverted proximal limb of loop ileostomy and the other in the end ileostomy. All 4 patients had one or more risk factors for microscopic colitis. The etiology of microscopic ileitis seems to be multifactorial, and microscopic ileitis may be underdiagnosed. The diverted enteric segment may be involved by microscopic enteritis, suggesting that additional factors other than fecal stasis and altered bacterial flora may be contributing to its pathogenesis. When microscopic ileitis is encountered, identifying associated risk factors, recognizing incipient clinical symptoms of microscopic colitis, and considering other associated diseases or conditions are warranted. (C) 2018 Elsevier Inc. All rights reserved.	[Zuo, Chunlai; Fu, Zhiyan; Foulke, Llewellyn; Rego, David Cubero; Lee, Hwajeong] Albany Med Coll, Pathol & Lab Med, Albany, NY 12208 USA; [Lee, Edward C.] Albany Med Coll, Gen Surg, Albany, NY 12208 USA; [Young, Gloria Q.] NYU Langone Hlth, Dept Pathol, New York, NY 10016 USA	Lee, H (reprint author), Albany Med Coll, Dept Pathol, Mail Code 81,47 New Scotland Ave, Albany, NY 12208 USA.	LeeH5@amc.edu					Ayata G, 2002, AM J SURG PATHOL, V26, P1414, DOI 10.1097/00000478-200211000-00003; Byrne MF, 2003, EUR J GASTROEN HEPAT, V15, P1051, DOI 10.1097/01.meg.0000059177.46867.19; Carrasco A, 2017, DIGEST DIS SCI, V62, P2609, DOI 10.1007/s10620-017-4692-x; Daferera N, 2015, WORLD J GASTROENTERO, V21, P6065, DOI 10.3748/wjg.v21.i19.6065; ECKSTEIN RP, 1988, AM J GASTROENTEROL, V83, P767; Erim T, 2003, DIGEST DIS SCI, V48, P1374, DOI 10.1023/A:1024127713979; Freeman HJ, 2007, CAN J GASTROENTEROL, V21, P315, DOI 10.1155/2007/950154; Fumery M, 2017, DIGEST DIS SCI, V62, P1571, DOI 10.1007/s10620-016-4306-z; Hammer STG, 2013, ARCH PATHOL LAB MED, V137, P1216, DOI 10.5858/arpa.2013-0261-RA; JARNEROT G, 1995, GASTROENTEROLOGY, V109, P449, DOI 10.1016/0016-5085(95)90332-1; Jarnerot G, 2001, SCAND J GASTROENTERO, V36, P959, DOI 10.1080/003655201750305486; Jegadeesan R, 2013, WORLD J GASTROENTERO, V19, P4252, DOI 10.3748/wjg.v19.i26.4252; Langner C, 2012, GASTROENTEROL CLIN N, V41, P561, DOI 10.1016/j.gtc.2012.06.005; Leung ST, 2009, AM J SURG PATHOL, V33, P788, DOI 10.1097/PAS.0b013e318196a67f; LEWIS FW, 1991, DIGEST DIS SCI, V36, P1161, DOI 10.1007/BF01297466; Lin JM, 2010, AM J SURG PATHOL, V34, P1672, DOI 10.1097/PAS.0b013e3181f3de93; Magro F, 2013, J CROHNS COLITIS, V7, P827, DOI 10.1016/j.crohns.2013.06.001; Maguire AA, 2009, AM J SURG PATHOL, V33, P1440, DOI 10.1097/PAS.0b013e3181ae2545; Majores M, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-114; Makinen M, 1998, DIGEST DIS SCI, V43, P1341, DOI 10.1023/A:1018836614448; MEIER PN, 1991, LEBER MAGEN DARM, V21, P231; O'Brien BH, 2011, AM J SURG PATHOL, V35, P1151, DOI 10.1097/PAS.0b013e3182206ef5; Padmanabhan V, 2003, MODERN PATHOL, V16, P115, DOI 10.1097/01.MP.0000051990.80904.AF; Phull PS, 2012, J CROHNS COLITIS, V6, P606, DOI 10.1016/j.crohns.2011.11.018; Sapp H, 2002, AM J SURG PATHOL, V26, P1484, DOI 10.1097/00000478-200211000-00011; Schaeffer DF, 2016, HUM PATHOL, V54, P31, DOI 10.1016/j.humpath.2016.03.007; Shen B, 2006, DIGEST LIVER DIS, V38, P704, DOI 10.1016/j.dld.2006.05.022; Sisman G, 2012, ACTA GASTRO-ENT BELG, V75, P458; Storr MA, 2013, ISRN GASTROENTEROL; Tagkalidis P, 2002, J GASTROEN HEPATOL, V17, P236, DOI 10.1046/j.1440-1746.2002.02640.x; Temmerman F, 2009, DIGEST DIS, V27, P137, DOI 10.1159/000268134; Verhaegh BPM, 2017, INFLAMM BOWEL DIS, V23, P1040, DOI 10.1097/MIB.0000000000001103; Williams L, 2007, GUT, V56, P796, DOI 10.1136/gut.2006.102046; YEONG ML, 1991, HISTOPATHOLOGY, V19, P55, DOI 10.1111/j.1365-2559.1991.tb00894.x; Yuan S, 2003, AM J SURG PATHOL, V27, P1375, DOI 10.1097/00000478-200310000-00010	35	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						80	87		10.1016/j.humpath.2018.03.019			8	Pathology	Pathology	GM6ZA	WOS:000438326300010	29596895				2019-10-28	
J	Kitawaki, Y; Nakamura, Y; Kubota-Nakayama, F; Yamazaki, Y; Miki, Y; Hata, S; Ise, K; Kikuchi, K; Morimoto, R; Satoh, F; Sasano, H				Kitawaki, Yuko; Nakamura, Yasuhiro; Kubota-Nakayama, Fumie; Yamazaki, Yuto; Miki, Yasuhiro; Hata, Shuko; Ise, Kazue; Kikuchi, Kumi; Morimoto, Ryo; Satoh, Fumitoshi; Sasano, Hironobu			Tumor microenvironment in functional adrenocortical adenomas: immune cell infiltration in cortisol-producing adrenocortical adenoma	HUMAN PATHOLOGY			English	Article						Tumor microenvironment; Adrenocortical adenoma; Immune cell infiltration; Steroids; Cellular senescence	SENESCENT CELLS; EXTRAMEDULLARY HEMATOPOIESIS; CANCER; EXPRESSION; RECEPTORS; BIOMARKER; HEALTH; CXCL12	The tumor microenvironment plays pivotal roles in various human neoplasms. However, that of benign tumor, particularly hormone-secreting endocrine tumors, has remained virtually unknown. There-fore, we firstly attempted to analyze the tumor microenvironment of autonomous hormone-secreting adrenocortical adenomas. We first histologically evaluated 21 cortisol-producing adrenocortical adenoma (CPA) and 13 aldosterone-producing adrenocortical adenoma (APA) cases. Quantitative histologic analysis revealed that intratumoral immune cell infiltration (ICI) was more pronounced in CPAs than in APAs. We then evaluated the cytokine and chemokine profiles using polymerase chain reaction arrays in APAs and CPAs. Angiogenic chemokines, C-X-C motif chemokine ligand (CXCL) 1 and CXCL2, were significantly more abundant in CPAs than in APAs using subsequent quantitative polymerase chain reaction and immunohistochemical analyses. We then examined the vascular density between these 2 adenomas, and the density was significantly higher in overt CPAs than in APAs. Of particular interest, CXCL12-positive vessels were detected predominantly in CPAs, and their infiltrating immune cells were C-X-C motif chemokine receptor 4 (CXCR4) positive. These results above indicated that CXCL12-CXCR4 signaling could partly account for ICI detected predominantly in CPAs. We then further explored the etiology of ICI in CPAs by evaluating the senescence of tumor cells possibly caused by excessive cortisol in CPAs. The status of senescence markers, p16 and p21, was significantly more abundant in CPAs than in APAs. In addition, all CPA cases examined were positive for senescence-associated beta-galactosidase. These results all indicated that exposure to local excessive cortisol could result in senescence of tumors cells and play essential roles in constituting the characteristic tissue microenvironment of CPAs. (C) 2018 Elsevier Inc. All rights reserved.	[Kitawaki, Yuko; Nakamura, Yasuhiro; Kubota-Nakayama, Fumie; Yamazaki, Yuto; Hata, Shuko; Ise, Kazue; Sasano, Hironobu] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 9808575, Japan; [Nakamura, Yasuhiro; Hata, Shuko; Ise, Kazue] Tohoku Med & Pharmaceut Univ, Fac Med, Div Pathol, Sendai, Miyagi 9818558, Japan; [Kubota-Nakayama, Fumie] Tohoku Rosai Hosp, Dept Diagnost Pathol, Sendai, Miyagi 9818563, Japan; [Miki, Yasuhiro] Tohoku Univ, Int Res Inst Disaster Sci IRIDes, Dept Disaster Obstet & Gynecol, Sendai, Miyagi 9808572, Japan; [Kikuchi, Kumi; Morimoto, Ryo; Satoh, Fumitoshi] Tohoku Univ Hosp, Div Nephrol Endocrinol & Vasc Med, Sendai, Miyagi 9808574, Japan; [Satoh, Fumitoshi] Tohoku Univ, Div Clin Hypertens Endocrinol & Metab, Grad Sch Med, Sendai, Miyagi 9808575, Japan	Sasano, H (reprint author), Tohoku Univ, Grad Sch Med, Dept Pathol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	hsasano@patholo2.med.tohoku.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP15H04711]; Health Labour Sciences Research GrantMinistry of Health, Labour and Welfare, Japan [H29-Nanji-Ippan-046]; Takeda Science FoundationTakeda Science Foundation (TSF)	This work was supported by JSPS KAKENHI (Grant No. JP15H04711) and Health Labour Sciences Research Grant (No. H29-Nanji-Ippan-046). Y.K. is supported by a scholarship from the Takeda Science Foundation.	Bernini GP, 2002, J CLIN ENDOCR METAB, V87, P4961, DOI 10.1210/jc.2001-011799; Besedovsky L, 2014, AM J PHYSIOL-ENDOC M, V306, pE1322, DOI 10.1152/ajpendo.00678.2013; BUDWITNOVOTNY DA, 1986, CANCER RES, V46, P5419; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cartier D, 2005, EUR J ENDOCRINOL, V153, P939, DOI 10.1530/eje.1.02051; Chew V, 2012, J ONCOL, V2012, P1; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Flint MS, 2013, STRESS, V16, P114, DOI 10.3109/10253890.2012.686075; Fumagalli M, 2009, NAT CELL BIOL, V11, P921, DOI 10.1038/ncb0809-921; Georgakopoulou EA, 2013, AGING-US, V5, P37; Herrada AA, 2011, J HYPERTENS, V29, P1684, DOI 10.1097/HJH.0b013e32834a4c75; Inra CN, 2015, NATURE, V527, P466, DOI 10.1038/nature15530; Ju ZY, 2007, ANN NY ACAD SCI, V1100, P333, DOI 10.1196/annals.1395.036; Karin N, 2010, J LEUKOCYTE BIOL, V88, P463, DOI 10.1189/jlb.0909602; Konosu-Fukaya S, 2015, MOL CELL ENDOCRINOL, V408, P205, DOI 10.1016/j.mce.2014.10.008; Kubota-Nakayama F, 2016, HUM PATHOL, V54, P165, DOI 10.1016/j.humpath.2016.03.016; Lam AKY, 2017, ENDOCR PATHOL, V28, P213, DOI 10.1007/s12022-017-9484-5; Lefebvre H, 2013, EUR J ENDOCRINOL, V169, pR115, DOI 10.1530/EJE-13-0308; Meng WF, 2018, GENE, V641, P105, DOI 10.1016/j.gene.2017.10.015; Merke DP, 1999, NEW ENGL J MED, V340, P1121, DOI 10.1056/NEJM199904083401416; Odanaka M, 2003, PATHOL INT, V53, P796, DOI 10.1046/j.1440-1827.2003.01553.x; Reeder A, 2015, BRIT J CANCER, V112, P1461, DOI 10.1038/bjc.2015.133; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Sackstein R, 2017, LAB INVEST, V97, P669, DOI 10.1038/labinvest.2017.25; Sagiv A, 2013, BIOGERONTOLOGY, V14, P617, DOI 10.1007/s10522-013-9473-0; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; White RR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7790; Willenberg HS, 1998, NEW ENGL J MED, V339, P27, DOI 10.1056/NEJM199807023390105; Yamamoto K, 2016, MOL MED REP, V13, P587, DOI 10.3892/mmr.2015.4621	32	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						88	97		10.1016/j.humpath.2018.03.016			10	Pathology	Pathology	GM6ZA	WOS:000438326300011	29596893				2019-10-28	
J	Al-Rohil, RN; Milton, DR; Nagarajan, P; Curry, JL; Feldmeyer, L; Torres-Cabala, CA; Ivan, D; Prieto, VG; Tetzlaff, MT; Aung, PP				Al-Rohil, Rami N.; Milton, Denai R.; Nagarajan, Priyadharsini; Curry, Jonathan L.; Feldmeyer, Laurence; Torres-Cabala, Carlos A.; Ivan, Doina; Prieto, Victor G.; Tetzlaff, Michael T.; Aung, Phyu P.			Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma	HUMAN PATHOLOGY			English	Article						Merkel cell carcinoma; D2-40; Lymphovascular invasion; Metastasis; Peritumoral; Intratumoral	LYMPHATIC INVASION; PROGNOSTIC-FACTORS; SINGLE INSTITUTION; NODAL METASTASIS; CLINICAL-COURSE; STAGING SYSTEM; SURVIVAL; POLYOMAVIRUS; CANCER; RECURRENCE	Primary cutaneous Merkel cell carcinoma (MCC) is an aggressive neuroendocrine malignancy in which lymphovascular invasion (LVI) correlates with more aggressive phenotype. The prognostic significance of LVI detected by D2-40 immunohistochemistry (IHC) in MCC remains controversial. We aimed to determine how LVI detected by D2-40 IHC compares with LVI detected by hematoxylin and eosin (H&E) staining in predicting MCC metastasis. Clinical and histopathologic features of MCCs diagnosed and treated in 2002 to 2015 were assembled and included 58 MCC tumors from 58 patients. H&E-stained tissue sections and D2-40-IHC studies were reviewed. When LVI was present, the location (peritumoral or intratumoral) and the size of the largest invaded vessel were recorded. LVI findings by H&E staining and D2-40 IHC were compared with each other and with histologic features and clinical outcomes. H&E staining showed LVI in 37 of 58 cases; D2-40 IHC confirmed LVI in 30 of these cases but failed to confirm LVI in 7. D2-40 IHC also detected 14 cases of LVI not identified on H&E staining. Histologically, D2-40- detected LVI was associated with infiltrative growth pattern and nonbrisk lymphoid infiltrate (P = .005 and P = .055, respectively). There was a statistically significant difference between the frequency of detection of peritumoral LVI by H&E in comparison to D2-40 NC (P = .0009). MCCs in which D2-40 IHC- detected both intratumoral and peritumoral LVI were typically larger than MCCs without (mean, 24.5 mm versus 17.3 mm; P = .03) and more frequently metastasized (87% versus 51%; P = .03). D2-40 IHC detection of both intratumoral and peritumoral LVI is associated with metastasis. (C) 2018 Elsevier Inc. All rights reserved.	[Al-Rohil, Rami N.; Nagarajan, Priyadharsini; Curry, Jonathan L.; Feldmeyer, Laurence; Torres-Cabala, Carlos A.; Ivan, Doina; Prieto, Victor G.; Tetzlaff, Michael T.; Aung, Phyu P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol Translat & Mol Pathol, Houston, TX 77030 USA; [Al-Rohil, Rami N.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Milton, Denai R.] Univ Texas MD Anderson Canc Ctr, Dept Biostat Translat & Mol Pathol, Houston, TX 77030 USA; [Curry, Jonathan L.; Torres-Cabala, Carlos A.; Ivan, Doina; Prieto, Victor G.] Univ Texas MD Anderson Canc Ctr, Dept Dermatol Translat & Mol Pathol, Houston, TX 77030 USA; [Tetzlaff, Michael T.] Univ Texas MD Anderson Canc Ctr, Translat & Mol Pathol, Houston, TX 77030 USA	Tetzlaff, MT; Aung, PP (reprint author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 85, Houston, TX 77030 USA.	mtetzlaff@mdanderson.org; PAung@mdanderson.org	Feldmeyer, Laurence/Q-2662-2018; Al-Rohil, Rami/K-3375-2019; Feldmeyer, Laurence/M-6814-2019	Feldmeyer, Laurence/0000-0002-4858-5525; Feldmeyer, Laurence/0000-0002-4858-5525			Albores-Saavedra J, 2010, J CUTAN PATHOL, V37, P20, DOI 10.1111/j.1600-0560.2009.01370.x; Andea AA, 2008, CANCER, V113, P2549, DOI 10.1002/cncr.23874; Bhatia K, 2010, INT J CANCER, V127, P1493, DOI 10.1002/ijc.25136; Braun M, 2008, BREAST CANCER RES TR, V112, P503, DOI 10.1007/s10549-007-9875-2; Engels EA, 2002, LANCET, V359, P497, DOI 10.1016/S0140-6736(02)07668-7; Feldmeyer L, 2016, CLIN CANCER RES, V22, P5553, DOI 10.1158/1078-0432.CCR-16-0392; Feldmeyer L, 2016, AM J DERMATOPATH, V38, P484, DOI 10.1097/DAD.0000000000000453; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fields RC, 2011, ANN SURG ONCOL, V18, P2529, DOI 10.1245/s10434-011-1662-y; Fields RC, 2011, ANN SURG, V254, P465, DOI 10.1097/SLA.0b013e31822c5fc1; Fitzgerald TL, 2015, AM SURGEON, V81, P802; Fleming KE, 2014, HUM PATHOL, V45, P952, DOI 10.1016/j.humpath.2013.12.008; Guler-Nizam E, 2009, BRIT J DERMATOL, V161, P90, DOI 10.1111/j.1365-2133.2009.09155.x; Harms KL, 2016, ANN SURG ONCOL, V23, P3564, DOI 10.1245/s10434-016-5266-4; Hodgson NC, 2005, J SURG ONCOL, V89, P1, DOI 10.1002/jso.20167; Kukko HM, 2010, MODERN PATHOL, V23, P1151, DOI 10.1038/modpathol.2010.100; Lemos BD, 2010, J AM ACAD DERMATOL, V63, P751, DOI 10.1016/j.jaad.2010.02.056; Niakosari F, 2005, ARCH DERMATOL, V141, P440, DOI 10.1001/archderm.141.4.440; Petersson F, 2009, J CUTAN PATHOL, V36, P1157, DOI 10.1111/j.1600-0560.2008.01242.x; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Schrama D, 2011, J INVEST DERMATOL, V131, P1631, DOI 10.1038/jid.2011.115; Sidhu G S, 1980, Am J Dermatopathol, V2, P101, DOI 10.1097/00000372-198000220-00001; Sihto H, 2009, JNCI-J NATL CANCER I, V101, P938, DOI 10.1093/jnci/djp139; Skelton HG, 1997, J AM ACAD DERMATOL, V37, P734, DOI 10.1016/S0190-9622(97)70110-5; Smith FO, 2015, CANCER-AM CANCER SOC, V121, P3252, DOI 10.1002/cncr.29452; TANG CK, 1979, MT SINAI J MED, V46, P516; Tarantola TI, 2013, J AM ACAD DERMATOL, V68, P425, DOI 10.1016/j.jaad.2012.09.036; Tomita N, 2008, PATHOL INT, V58, P282, DOI 10.1111/j.1440-1827.2008.02224.x; Vlahova L, 2012, BRIT J DERMATOL, V166, P1043, DOI 10.1111/j.1365-2133.2012.10853.x; Wada H, 2013, INT J CLIN ONCOL, V18, P1025, DOI 10.1007/s10147-012-0490-9; Weber SK, 2012, INT J GYNECOL CANCER, V22, P1442, DOI 10.1097/IGC.0b013e318269139b	31	4	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						98	107		10.1016/j.humpath.2018.03.017			10	Pathology	Pathology	GM6ZA	WOS:000438326300012	29601841				2019-10-28	
J	Zhang, M; Li, GC; Sun, XJ; Ni, SJ; Tan, C; Xu, MD; Huang, D; Ren, F; Li, DW; Wei, P; Du, X				Zhang, Meng; Li, Guichao; Sun, Xiangjie; Ni, Shujuan; Tan, Cong; Xu, Midie; Huang, Dan; Ren, Fei; Li, Dawei; Wei, Ping; Du, Xiang			MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma	HUMAN PATHOLOGY			English	Article						MET; Amplification; exon 14 mutation; Colorectal cancer; Biomarker	CELL LUNG-CANCER; TIVANTINIB ARQ 197; C-MET; GENE AMPLIFICATION; PULMONARY ADENOCARCINOMA; RANDOMIZED PHASE-2; OPEN-LABEL; COMBINATION; CHEMOTHERAPY; METAANALYSIS	MET amplification, expression, and splice mutations at exon 14 result in dysregulation of the MET signaling pathway. The aim of this study was to identify the relationship between MET amplification, protein or mRNA expression, and mutations in colorectal cancer (CRC). MET immunohistochemistry was used for MET protein expression analysis, and fluorescence in situ hybridization was used for MET amplification detection. Both analyses were performed in tissue microarrays containing 294 colorectal adenocarcinoma tissue samples and 131 samples of adjacent normal epithelial tissue. MET mRNA expression was examined by real-time quantitative polymerase chain reaction in 72 fresh colorectal adenocarcinoma tissue samples and adjacent normal colon tissue. Polymerase chain reaction sequencing was performed to screen for MET exon 14 splice mutations in 59 fresh CRC tissue samples. Our results showed that MET protein expression was higher in colorectal tumor tissue than in adjacent normal intestinal epithelium. Positive MET protein expression was associated with significantly poorer overall survival and disease-free survival. Multivariate analysis revealed that positive MET protein expression was an independent risk factor for disease-free survival but not for overall survival. MET mRNA expression was upregulated in tumor tissues compared with the adjacent normal tissues. The incidence of MET amplification was 4.4%. None of the patients was positive for MET mutation. Collectively, MET was overexpressed in colorectal adenocarcinoma, and its positive protein expression predicted a poorer outcome in CRC patients. Furthermore, according to our results, MET amplification and exon 14 mutation are extremely rare events in colorectal adenocarcinoma. (C) 2018 Elsevier Inc. All rights reserved.	[Zhang, Meng; Sun, Xiangjie; Ni, Shujuan; Tan, Cong; Xu, Midie; Huang, Dan; Ren, Fei; Wei, Ping; Du, Xiang] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China; [Zhang, Meng; Du, Xiang] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200032, Peoples R China; [Zhang, Meng; Sun, Xiangjie; Ni, Shujuan; Tan, Cong; Xu, Midie; Huang, Dan; Ren, Fei; Wei, Ping; Du, Xiang] Fudan Univ, Inst Pathol, Shanghai 200032, Peoples R China; [Li, Guichao; Sun, Xiangjie; Ni, Shujuan; Tan, Cong; Xu, Midie; Huang, Dan; Ren, Fei; Li, Dawei; Wei, Ping; Du, Xiang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Li, Guichao] Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai 200032, Peoples R China; [Li, Dawei] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai 200032, Peoples R China; [Wei, Ping; Du, Xiang] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China; [Wei, Ping] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China	Wei, P; Du, X (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Pathol, 270 Dongan Rd, Shanghai 200032, Peoples R China.	doc_zm@163.com; guichaoli11@163.com; emmasun93@163.com; nsj616@126.com; saratancong@163.com; xumd27202003@sina.com; dianehuangfdcc@gmail.com; renfei0319@163.com; davidleehero@126.com; weiping@fudan.edu.cn; dx2008cn@163.com			National Natural Science Foundation of China: Beijing, ChinaNational Natural Science Foundation of China [81572254, 81472220, 81472222, 81772583, 81602269, 81602087, 81272299]; Science and Technology Commission of the Shanghai Municipality: Shanghai, China [15495810300]; Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project: Shanghai, China [HDC12014105]; Shanghai Key Developing Disciplines: Shanghai, China [2015ZB0201]; Shanghai Science and Technology Development Fund: Shanghai, China [15ZR1407400]; Domestic Science and Technology Cooperation Project: Beijing, China [14495800300]; Hospital Foundation of the Fudan University Shanghai Cancer Center: Shanghai, China [YJ201504]	This study was supported by a grant from the National Natural Science Foundation of China: Beijing, China (81572254, 81472220, 81472222, 81772583, 81602269, 81602087, and 81272299), the Science and Technology Commission of the Shanghai Municipality: Shanghai, China (15495810300), the Shanghai Hospital Development Center Emerging Advanced Technology Joint Research Project: Shanghai, China (HDC12014105), the Shanghai Key Developing Disciplines: Shanghai, China (2015ZB0201), the Shanghai Science and Technology Development Fund: Shanghai, China (15ZR1407400), the Domestic Science and Technology Cooperation Project: Beijing, China (14495800300), and the Hospital Foundation of the Fudan University Shanghai Cancer Center: Shanghai, China (YJ201504).	Abou-Bakr A A, 2013, Gulf J Oncolog, V1, P28; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Denkert C, 2010, BREAST CARE, V5, P185; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Eng C, 2016, INT J CANCER, V139, P177, DOI 10.1002/ijc.30049; Gao HL, 2015, TUMOR BIOL, V36, P515, DOI 10.1007/s13277-014-2659-5; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Go H, 2010, J THORAC ONCOL, V5, P305, DOI 10.1097/JTO.0b013e3181ce3d1d; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3; Jardim DLF, 2014, CLIN CANCER RES, V20, P6336, DOI 10.1158/1078-0432.CCR-14-1293; Katayama R, 2013, CANCER RES, V73, P3087, DOI 10.1158/0008-5472.CAN-12-3256; Liu Y, 2015, WORLD J GASTROENTERO, V21, P3706, DOI 10.3748/wjg.v21.i12.3706; Mok TSK, 2016, J THORAC ONCOL, V11, P1736, DOI 10.1016/j.jtho.2016.05.038; Park S, 2015, LUNG CANCER, V90, P381, DOI 10.1016/j.lungcan.2015.10.022; Peng Z, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0092924, 10.1371/journal.pone.0084502]; Peng Z, 2015, MOL CANCER THER, V14, P2634, DOI 10.1158/1535-7163.MCT-15-0108; Seo AN, 2014, VIRCHOWS ARCH, V465, P547, DOI 10.1007/s00428-014-1634-2; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Specht E, 2015, HISTOPATHOLOGY, V67, P368, DOI 10.1111/his.12662; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; Welch HG, 2016, NEW ENGL J MED, V374, P1605, DOI 10.1056/NEJMp1600448; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049	28	1	1	1	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						108	115		10.1016/j.humpath.2018.03.024			8	Pathology	Pathology	GM6ZA	WOS:000438326300013	29641976				2019-10-28	
J	Tomomasa, R; Nakata, S; Nobusawa, S; Horiguchi, K; Matsumura, N; Ikota, H; Hirato, J; Yoshimoto, Y; Yokoo, H				Tomomasa, Ran; Nakata, Satoshi; Nobusawa, Sumihito; Horiguchi, Keishi; Matsumura, Nozomi; Ikota, Hayato; Hirato, Junko; Yoshimoto, Yuhei; Yokoo, Hideaki			Primary diffuse leptomeningeal atypical teratoid/rhabdoid tumor diagnosed by cerebrospinal fluid cytology: case report with molecular genetic analysis	HUMAN PATHOLOGY			English	Article						Atypical teratoid/rhabdoid tumor; Leptomeningeal; Adolescent; Cerebrospinal fluid; INI1	MALIGNANT RHABDOID TUMORS; ENTITY; AT/RT	Atypical teratoid/rhabdoid tumors (AT/RT) are rare malignant neoplasms that mainly affect infants and young children, and are typically located in the cerebellar hemispheres. These tumors are histologically characterized by varying proportions of rhabdoid cells, and nuclear INI1 immunonegativity. Here, we report a case of a 15-year-old male with primary diffuse leptomeningeal AT/RT. The patient had symptoms similar to those of meningitis. Magnetic resonance imaging revealed leptomeningeal thickening. Cytological examination using cerebrospinal fluid was repeatedly performed and revealed rhabdoid cells with loss of INI1 reactivity, and shortly after, the diagnosis of AT/RT was confirmed by tissue biopsy. Multiplex ligation-dependent probe amplification analysis revealed compound heterozygous microdeletion of the SMARCB/INI1 locus. Leptomeningeal AT/RT without primary mass is extremely rare - only four cases have been previously reported to date. To the best of our knowledge, this is the first case report of primary leptomeningeal AT/RT with detailed genetic information. (C) 2018 Elsevier Inc. All rights reserved.	[Tomomasa, Ran; Nakata, Satoshi; Nobusawa, Sumihito; Matsumura, Nozomi; Ikota, Hayato; Yokoo, Hideaki] Gunma Univ, Dept Human Pathol, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan; [Nakata, Satoshi; Horiguchi, Keishi; Yoshimoto, Yuhei] Gunma Univ, Dept Neurosurg, Grad Sch Med, Maebashi, Gumma 3718511, Japan; [Hirato, Junko] Gunma Univ Hosp, Dept Pathol, Maebashi, Gumma 3718511, Japan	Tomomasa, R (reprint author), Gunma Univ, Dept Human Pathol, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	m1620002@gunma-u.ac.jp					CHOU SM, 1991, CLIN NEUROPATHOL, V10, P1; El-Nabbout B, 2010, J NEURO-ONCOL, V98, P431, DOI 10.1007/s11060-009-0094-z; Gauvain KM, 2012, J CHILD NEUROL, V27, P1597, DOI 10.1177/0883073812436878; Huang EC, 2014, CANCER CYTOPATHOL, V122, P903, DOI 10.1002/cncy.21470; Jackson EM, 2009, CLIN CANCER RES, V15, P1923, DOI 10.1158/1078-0432.CCR-08-2091; Judkins AR, 2016, WHO CLASSIFICATION T, P209; Livermore LJ, 2013, CLIN NEUROL NEUROSUR, V115, P2170, DOI 10.1016/j.clineuro.2013.05.036; Nakata S, 2017, AM J SURG PATHOL, V41, P932, DOI 10.1097/PAS.0000000000000845; Nobusawa S, 2016, J NEUROPATH EXP NEUR, V75, P167, DOI 10.1093/jnen/nlv017; Pant I, 2016, J PEDIATR NEUROSCI, V11, P331, DOI 10.4103/1817-1745.199477; Rorke LB, 1996, J NEUROSURG, V85, P56, DOI 10.3171/jns.1996.85.1.0056; Rorke LB, 2000, PATHOLOGY GENETICS T, P145; Torchia J, 2016, CANCER CELL, V30, P891, DOI 10.1016/j.ccell.2016.11.003; Vitte J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00346-5; Yoshida A, 2015, HISTOPATHOLOGY, V66, P252, DOI 10.1111/his.12460	15	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						116	120		10.1016/j.humpath.2017.12.026			5	Pathology	Pathology	GM6ZA	WOS:000438326300014	29339179				2019-10-28	
J	Ding, QQ; Wang, Y; Zuo, Z; Gong, Y; Krishnamurthy, S; Li, CW; Lai, YJ; Wei, W; Wang, J; Manyam, GC; Diao, LX; Zhang, XN; Lin, F; Symmans, WF; Sun, L; Liu, CG; Liu, XP; Debeb, BG; Ueno, NT; Harano, K; Alvarez, RH; Wu, Y; Cristofanilli, M; Huo, L				Ding, Qingqing; Wang, Yan; Zuo, Zhuang; Gong, Yun; Krishnamurthy, Savitri; Li, Chia-Wei; Lai, Yun-Ju; Wei, Wei; Wang, Jing; Manyam, Ganiraju C.; Diao, Lixia; Zhang, Xinna; Lin, Feng; Symmans, William F.; Sun, Li; Liu, Chang-Gong; Liu, Xiuping; Debeb, Bisrat G.; Ueno, Naoto T.; Harano, Kenichi; Alvarez, Ricardo H.; Wu, Yun; Cristofanilli, Massimo; Huo, Lei			Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer	HUMAN PATHOLOGY			English	Article						MicroRNA; MiR-26b; Locally advanced breast cancer; Inflammatory breast cancer; In situ hybridization	PATHOLOGISTS GUIDELINE RECOMMENDATIONS; ZESTE HOMOLOG 2; CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; NASOPHARYNGEAL CARCINOMA; AMERICAN-SOCIETY; TARGETING EZH2; TUMOR-GROWTH; MIR-26A; INHIBIT	Advanced-stage breast cancer patients comprise a smaller proportion of breast cancer patients than do early stage patients and are more likely to experience a poor outcome. Understanding the underlying molecular mechanisms and identifying new biomarkers for treatment in this subgroup of patients is paramount. With the aim of identifying microRNAs that are regulated in advanced-stage breast cancer, we found lower expression of miR-26b, a member of the miR-26 family, in inflammatory breast cancer and noninflammatory locally advanced breast cancer tissue than in normal breast tissue, by quantitative real-time polymerase chain reaction and in situ hybridization. Quantitative real-time polymerase chain reaction (but not in situ hybridization) also revealed lower miR-26b expression in inflammatory breast cancer than in noninflammatory locally advanced breast cancer. Furthermore, lower expression of miR-26b was correlated with shorter distant metastasis-free survival and overall survival in univariate analysis, and with shorter overall survival in multivariate analysis. The expression of miRNA-26b was inversely associated with EZH2 protein expression in several breast cancer cell lines, and overexpression and knockdown of miR-26b caused corresponding changes in EZH2 expression. Our study shows that miR-26b may regulate EZH2 expression in breast cancer and may be useful as a therapeutic target for inflammatory breast cancer and noninflammatory locally advanced breast cancer. (C) 2018 Elsevier Inc. All rights reserved.	[Ding, Qingqing; Wang, Yan; Gong, Yun; Krishnamurthy, Savitri; Lin, Feng; Symmans, William F.; Sun, Li; Wu, Yun; Huo, Lei] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA; [Zuo, Zhuang] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; [Gong, Yun; Krishnamurthy, Savitri; Debeb, Bisrat G.; Ueno, Naoto T.; Alvarez, Ricardo H.; Huo, Lei] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Houston, TX 77030 USA; [Li, Chia-Wei; Lai, Yun-Ju] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Wei, Wei] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Wang, Jing; Manyam, Ganiraju C.; Diao, Lixia] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Zhang, Xinna] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Liu, Chang-Gong; Liu, Xiuping] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Debeb, Bisrat G.; Ueno, Naoto T.; Harano, Kenichi; Alvarez, Ricardo H.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Cristofanilli, Massimo] Northwestern Univ, Dept Hematol & Oncol, Chicago, IL 60611 USA	Huo, L (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	leihuo@mdanderson.org	Manyam, Ganiraju/E-9150-2012	Manyam, Ganiraju/0000-0001-6006-8961	MD Anderson institutional start-up fund; State of Texas Rare and Aggressive Breast Cancer Research Program Grant; MD Anderson departmental research fund	The authors would like to thank Kim-Anh Vu in the Department of Pathology for her assistance with the figures and Ann Sutton in the Department of Scientific Publications for editing the manuscript. This project was supported in part by the MD Anderson institutional start-up fund and departmental research fund to L.H., Morgan Welch Inflammatory Breast Cancer Research Program, and State of Texas Rare and Aggressive Breast Cancer Research Program Grant.	Acunzo Mario, 2015, Adv Biol Regul, V57, P1, DOI 10.1016/j.jbior.2014.09.013; Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64; Anderson William F, 2005, Breast Dis, V22, P9; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Borno ST, 2012, CANCER DISCOV, V2, P1024, DOI 10.1158/2159-8290.CD-12-0041; Cabello P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081298; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen J, 2017, CELL PHYSIOL BIOCHEM, V41, P583, DOI 10.1159/000457879; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Dawood S, 2011, ANN ONCOL, V22, P515, DOI 10.1093/annonc/mdq345; Dawood S, 2011, ONCOLOGY-NY, V25, P264; Deng JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076450; Frankel AE, 2016, CANCER DISCOV, V6, P949, DOI 10.1158/2159-8290.CD-16-0800; Gao J, 2011, ONCOL LETT, V2, P1019, DOI 10.3892/ol.2011.413; Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI 10.1043/1543-2165-134.6.907; Huo L, 2016, MODERN PATHOL, V29, P330, DOI 10.1038/modpathol.2016.38; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen MPHM, 2012, BREAST CANCER RES TR, V133, P937, DOI 10.1007/s10549-011-1877-4; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Koh CM, 2011, ONCOTARGET, V2, P669; Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kozubek J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072699; Kurozumi A, 2016, INT J ONCOL, V48, P1837, DOI 10.3892/ijo.2016.3440; Li HS, 2015, INT J CLIN EXP PATHO, V8, P4782; Li J, 2017, GENE, V625, P1, DOI [10.1016/j.gene.2017.0.001, 10.1016/j.gene.2017.05.001]; Li M, 2016, BIOCHEM BIOPH RES CO, V471, P361, DOI 10.1016/j.bbrc.2016.02.021; Li Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.281; Lin JX, 2015, ONCOTARGET, V6, P23793, DOI 10.18632/oncotarget.4363; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Ma DN, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-015-0229-y; Ma XL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.427; Masuda H, 2014, ANN ONCOL, V25, P384, DOI 10.1093/annonc/mdt525; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Miyamoto K, 2016, BRIT J CANCER, V115, P354, DOI 10.1038/bjc.2016.179; Palumbo T, 2013, ONCOGENE, V32, P1651, DOI 10.1038/onc.2012.190; Qian H, 2017, CELL DEATH DISCOV, V3, P1; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Shen WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086871; Shi L, 2016, FEBS OPEN BIO, V6, P1211, DOI 10.1002/2211-5463.12135; Si YR, 2017, CELL PHYSIOL BIOCHEM, V42, P1670, DOI 10.1159/000479412; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Simos D, 2014, CURR OPIN SUPPORT PA, V8, P33, DOI 10.1097/SPC.0000000000000020; Soerjomataram I, 2008, BREAST CANCER RES TR, V107, P309, DOI 10.1007/s10549-007-9556-1; Tan S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3644; Tsai MM, 2016, ONCOTARGET, V7, P39511, DOI 10.18632/oncotarget.8629; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Wang Y, 2016, ONCOTARGET, V7, P24383, DOI 10.18632/oncotarget.8328; Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2; Wu N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016264; Xie R, 2017, ONCOL REP, V37, P1682, DOI 10.3892/or.2017.5405; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Zhang B, 2011, CARCINOGENESIS, V32, P2, DOI 10.1093/carcin/bgq209; Zhang JQ, 2012, GASTROENTEROLOGY, V143, P246, DOI 10.1053/j.gastro.2012.03.045; Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278	60	3	3	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						121	129		10.1016/j.humpath.2018.04.002			9	Pathology	Pathology	GM6ZA	WOS:000438326300015	29689244				2019-10-28	
J	Kurose, N; Futatsuya, C; Mizutani, K; Kumagai, M; Shioya, A; Guo, X; Aikawa, A; Nakada, S; Fujimoto, S; Kawabata, H; Masaki, Y; Takai, K; Aoki, S; Kojima, M; Nakamura, S; Yamada, S				Kurose, Nozomu; Futatsuya, Chizuru; Mizutani, Ken-ichi; Kumagai, Motona; Shioya, Akihiro; Guo, Xin; Aikawa, Akane; Nakada, Satoko; Fujimoto, Shino; Kawabata, Hiroshi; Masaki, Yasufumi; Takai, Kazue; Aoki, Sadao; Kojima, Masaru; Nakamura, Shigeo; Yamada, Sohsuke			The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome	HUMAN PATHOLOGY			English	Article						Idiopathic multicentric Castleman disease (iMCD); TAFRO syndrome; Follicular dendritic cell (FDC); interleukin-6 (IL-6); Immunoglobulin G4 (IgG4); Creatinine (Cre)	DIAGNOSTIC-CRITERIA; SEVERITY CLASSIFICATION; APOPTOSIS; CELLS; RISK	Multicentric Castleman disease (MCD) is a systemic inflammatory disease potentially caused by an increase in the serum interleukin-6 (IL-6) level. Idiopathic MCD (iMCD) is histopathologically classified into three types: plasmacytic (PC), mixed, and hypervascular (hyperV) types. Recently, a unique clinical phenotype with a poor prognosis overlap with iMCD, thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly (TAFRO syndrome), has been reported from Japan, but its detailed clinicopathological features remain unclear. In this study, we performed a clinicopathological analysis of 70 nodal cases of iMCD with and without TAFRO syndrome (n = 37 versus n = 33). Compared with iMCD without TAFRO, iMCD with TAFRO showed more atrophic lymphoid follicles (LF), greater distances between follicles, increased glomeruloid vascular proliferation within the germinal center, and increased follicular dendritic cells. In addition, the hyperV type in particular demonstrated severe atrophic LF and interfollicular vascular proliferation. Among the mixed-type cases, the serum IL-6 levels in iMCD with TAFRO were significantly higher than those in iMCD without TAFRO. Furthermore, compared to iMCD without TAFRO, the numbers of immunoglobulin G4 (IgG4)-positive and CD38-positive plasma cells were significantly decreased in iMCD with TAFRO. (C) 2018 Elsevier Inc. All rights reserved.	[Kurose, Nozomu; Futatsuya, Chizuru; Mizutani, Ken-ichi; Kumagai, Motona; Shioya, Akihiro; Guo, Xin; Aikawa, Akane; Nakada, Satoko; Yamada, Sohsuke] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan; [Fujimoto, Shino; Kawabata, Hiroshi; Masaki, Yasufumi] Kanazawa Med Univ, Dept Hematol & Immunol, Uchinada, Ishikawa, Japan; [Takai, Kazue] Niigata City Gen Hosp, Div Hematol, Niigata, Japan; [Aoki, Sadao] Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Dept Pathophysiol, Niigata, Japan; [Kojima, Masaru] Dokkyo Univ, Sch Med, Dept Anat & Diagnost Pathol, Mibu, Tochigi, Japan; [Nakamura, Shigeo] Nagoya Univ, Grad Sch Med, Dept Pathol & Biol Response, Nagoya, Aichi, Japan	Kurose, N; Yamada, S (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Daigaku, Uchinada, Ishikawa 9200293, Japan.	sohsuke@kanazawa-med.ac.jp	Nakamura, Shigeo/I-1571-2012	/0000-0001-5709-1968	Ministry of Health, Labor, and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan [H27-Nanchi,etc.(Nan)-General-008, H29-Nanchi,etc.(Nan)-General-019, H29-Nanchi,etc.(Nan)-General-058]; Japanese Ministry of Education, Culture, Sports, Science and TechnologyMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [17591060, 15 K09510]	This work was partially supported by the Research Program of Intractable Disease provided by the Ministry of Health, Labor, and Welfare (MHLW) of Japan (H27-Nanchi,etc.(Nan)-General-008), (H29-Nanchi,etc.(Nan)-General-019), (H29-Nanchi,etc.(Nan)-General-019), (H29-Nanchi,etc.(Nan)-General-058), and by the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant No.17591060 and 15 K09510).	Bower M, 2010, BLOOD, V116, P4415, DOI 10.1182/blood-2010-07-290213; Dispenzieri A, 2017, AM J HEMATOL, V92, P814, DOI 10.1002/ajh.24802; Dossier A, 2013, CLIN INFECT DIS, V56, P833, DOI 10.1093/cid/cis1009; Fajgenbaum DC, 2017, BLOOD, V129, P1646, DOI 10.1182/blood-2016-10-746933; Fajgenbaum DC, 2014, BLOOD, V123, P2924, DOI 10.1182/blood-2013-12-545087; Fujimoto S, 2018, MOD RHEUMATOL, V28, P161, DOI 10.1080/14397595.2017.1366093; Gerard L, 2012, BLOOD, V119, P2228, DOI 10.1182/blood-2011-08-376012; Iwaki N, 2016, AM J HEMATOL, V91, P220, DOI 10.1002/ajh.24242; Kawabata H, 2013, J CLIN EXP HEMATOP, V53, P69, DOI 10.3960/jslrt.53.69; Kawatsu Y, 2014, BRIT J CANCER, V110, P2583, DOI 10.1038/bjc.2014.202; Kimura A, 2010, EUR J IMMUNOL, V40, P1830, DOI 10.1002/eji.201040391; Kojima M, 2005, PATHOL RES PRACT, V201, P325, DOI 10.1016/j.prp.2005.01.006; Kurose N., 2016, J KANAZAWA MED U, V41, P76; Masaki Y, 2016, INT J HEMATOL, V103, P686, DOI 10.1007/s12185-016-1979-1; Masaki Y, 2013, J CLIN EXP HEMATOP, V53, P79, DOI 10.3960/jslrt.53.79; Mylona EE, 2008, AIDS REV, V10, P25; Nawata A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152549; Noguchi H, 2014, AM J PATHOL, V184, P644, DOI 10.1016/j.ajpath.2013.11.030; Osborne J, 1999, HUM IMMUNOL, V60, P921, DOI 10.1016/S0198-8859(99)00083-X; Sato Y, 2010, J CLIN PATHOL, V63, P1084, DOI 10.1136/jcp.2010.082958; Soubrier M, 1997, ARTHRITIS RHEUM-US, V40, P786, DOI 10.1002/art.1780400430; Takai Kazue, 2010, Rinsho Ketsueki, V51, P320; Tasaki T, 2013, AM J PATHOL, V182, P597, DOI 10.1016/j.ajpath.2012.10.008; Wu YZ, 2009, INT IMMUNOL, V21, P745, DOI 10.1093/intimm/dxp041	24	2	2	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						130	138		10.1016/j.humpath.2018.04.001			9	Pathology	Pathology	GM6ZA	WOS:000438326300016	29684500				2019-10-28	
J	Mai, RQ; Zhou, SX; Zhou, SQ; Zhong, WX; Hong, LL; Wang, YY; Lu, SM; Pan, JK; Huang, YS; Su, MW; Crawford, R; Zhou, YW; Zhang, GH				Mai, Ruiqin; Zhou, Songxia; Zhou, Shuqin; Zhong, Weixiang; Hong, Liangli; Wang, Yuanyuan; Lu, Shanming; Pan, Jikai; Huang, Yuansheng; Su, Mingwan; Crawford, Richard; Zhou, Youwen; Zhang, Guohong			Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget's disease	HUMAN PATHOLOGY			English	Article						EMPD; FOXA1; MPD; Paget's disease; ER; AR	ANDROGEN RECEPTOR; BREAST-CANCER; GATA3 EXPRESSION; TOKER CELLS; DIFFERENTIATION; CARCINOMAS; GLAND; PROLIFERATION; HISTOGENESIS; ESTROGEN	Paget's disease (PD) is an uncommon intraepithelial adenocarcinoma with unknown pathogenesis. There are two anatomic subtypes: mammary (MPD) and extramammary (EMPD). Little is known about their molecular characteristics. Our objective was to discover novel molecular markers for PD and its subtypes. In the discovery phase, we used transcriptome analyses to uncover the most differentially expressed genes and pathways in EMPD biopsies compared with normal skin. In the validation phase, we performed immunohistochemistry analyses on the most promising marker (FOXA1) and other markers selected from a literature review (GATA3, estrogen receptor [ER], and androgen receptor [AR]) on independent biopsies of MPD (n = 86), EMPD (n = 59), and normal skin (n = 21). Transcriptome analyses revealed 210 genes differentially expressed more than 10-fold between EMPD and normal skin. These genes are involved in mammary and sweat gland development (FOXA1) and immune regulation, as well as epidermal differentiation. Immunohistochemistry staining revealed that FOXA1 was positive in 88% of both MPD and EMPD, whereas GATA3 was positive in 67% of MPD and 77% of EMPD, and ER was positive in 9% of MPD and 19% of EMPD. Finally, AR was positive in 33% of PD and 54% of EMPD. Mammary Paget's disease and EMPD share dysregulation of the glandular developmental regulator gene FOXA 1, suggesting similarity in cell-specific transcriptional regulation. Further, FOXA1 may be a useful molecular target for developing PD therapies. (C) 2018 Elsevier Inc. All rights reserved.	[Mai, Ruiqin] Shantou Univ, Dept Lab Med, Affiliated Hosp 1, Med Coll, Shantou 515031, Guangdong, Peoples R China; [Zhou, Songxia; Zhang, Guohong] Shantou Univ, Dept Pathol, Med Coll, Shantou 515041, Guangdong, Peoples R China; [Zhou, Shuqin] First Peoples Hosp Kashi, Dept Anesthesiol, Kashi 844000, Xinjiang, Peoples R China; [Zhong, Weixiang] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Pathol, Hangzhou 310006, Zhejiang, Peoples R China; [Hong, Liangli] Shantou Univ, Dept Pathol, Affiliated Hosp 1, Med Coll, Shantou 515031, Guangdong, Peoples R China; [Wang, Yuanyuan] Sun Yat Sen Univ, Dept Pathol, Shantou Cent Hosp, Shantou 515041, Guangdong, Peoples R China; [Wang, Yuanyuan] Sun Yat Sen Univ, Affiliated Shantou Hosp, Shantou 515041, Guangdong, Peoples R China; [Lu, Shanming] Meizhou Cent Hosp, Dept Pathol, Meizhou 514786, Guangdong, Peoples R China; [Pan, Jikai] Shantou Hosp Dermatol, Dept Pathol, Shantou 515031, Guangdong, Peoples R China; [Huang, Yuansheng; Su, Mingwan; Crawford, Richard; Zhou, Youwen; Zhang, Guohong] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC V5Z 1L8, Canada	Zhang, GH (reprint author), Shantou Univ, Dept Pathol, Med Coll, 22 Xinling Rd, Shantou 515031, Guangdong, Peoples R China.	g_ghzhang@stu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81402616]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [1414050001710]	This work was supported by grants from the National Natural Science Foundation of China (No. 81402616) and the Natural Science Foundation of Guangdong Province (No. 1414050001710).	Augello MA, 2011, EMBO J, V30, P3885, DOI 10.1038/emboj.2011.340; Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046; Cheng PS, 2014, BRIT J DERMATOL, V171, P191, DOI 10.1111/bjd.12851; Chung J, 2013, ANN DERMATOL, V25, P88, DOI 10.5021/ad.2013.25.1.88; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Davis DG, 2016, HUM PATHOL, V47, P26, DOI 10.1016/j.humpath.2015.09.015; de Leon ED, 2000, AM J CLIN PATHOL, V113, P572; Val-Bernal JF, 2010, AM J DERMATOPATH, V32, P787, DOI 10.1097/DAD.0b013e3181ddbec5; Giger O, 2010, PATHOL INT, V60, P726, DOI 10.1111/j.1440-1827.2010.02591.x; GUARNER J, 1989, AM J DERMATOPATH, V11, P313, DOI 10.1097/00000372-198908000-00004; Guiu S, 2015, FUTURE ONCOL, V11, P2283, DOI 10.2217/fon.15.102; Iijima M, 2006, DERMATOLOGY, V213, P144, DOI 10.1159/000093854; IMAM A, 1988, BRIT J CANCER, V58, P373, DOI 10.1038/bjc.1988.222; JONES RR, 1989, HISTOPATHOLOGY, V14, P409, DOI 10.1111/j.1365-2559.1989.tb02169.x; Kang ZH, 2015, INT J CLIN EXP PATHO, V8, P13233; Kanitakis J, 2007, J EUR ACAD DERMATOL, V21, P581, DOI 10.1111/j.1468-3083.2007.02154.x; Kasashima S, 2010, BRIT J DERMATOL, V162, P1098, DOI 10.1111/j.1365-2133.2009.09603.x; KEATINGS L, 1990, HISTOPATHOLOGY, V17, P243, DOI 10.1111/j.1365-2559.1990.tb00714.x; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kunisada M, 2009, HUM MOL GENET, V18, P1769, DOI 10.1093/hmg/ddp089; Liegl B, 2005, MODERN PATHOL, V18, P1283, DOI 10.1038/modpathol.3800437; Liu HY, 2012, AM J CLIN PATHOL, V138, P57, DOI 10.1309/AJCP5UAFMSA9ZQBZ; Liu WG, 2010, J CUTAN PATHOL, V37, P1145, DOI 10.1111/j.1600-0560.2009.01403.x; Lopes LL, 2015, AN BRAS DERMATOL, V90, P225, DOI 10.1590/abd1806-4841.20153189; Lu J, 2014, ONCOL REP, V32, P2571, DOI 10.3892/or.2014.3534; Marucci G, 2002, VIRCHOWS ARCH, V441, P117, DOI 10.1007/s00428-001-0581-x; Masse I, 2014, ARCH DERMATOL RES, V306, P201, DOI 10.1007/s00403-013-1435-5; Mertens RB, 2015, AM J DERMATOPATH, V37, P885, DOI 10.1097/DAD.0000000000000306; Ozerdem U, 2016, PATHOL RES PRACT, V212, P279, DOI 10.1016/j.prp.2016.01.004; Piris A, 2014, HUM PATHOL, V45, P320, DOI 10.1016/j.humpath.2013.09.007; Saeed D, 2014, J CLIN PATHOL, V67, P1010, DOI 10.1136/jclinpath-2014-202280; Sellheyer K, 2010, J CUTAN PATHOL, V37, P357, DOI 10.1111/j.1600-0560.2009.01416.x; Tachi K, 2016, CANCER SCI, V107, P281, DOI 10.1111/cas.12870; Tong Q, 2007, NATURE, V445, P724, DOI 10.1038/445724a; Zhang YH, 2012, J INVEST DERMATOL, V132, P1698, DOI 10.1038/jid.2012.13	35	0	0	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						152	158		10.1016/j.humpath.2017.12.030			7	Pathology	Pathology	GM6ZA	WOS:000438326300019	29630912				2019-10-28	
J	Pyo, JS; Park, MJ; Kang, DW				Pyo, Jung-Soo; Park, Mee Ja; Kang, Dong-Wook			The clinicopathological significance of micropapillary pattern in colorectal cancers	HUMAN PATHOLOGY			English	Article						Colorectal cancer; Micropapillary pattern; Mucin pools; lymphovascular invasion; Prognosis	LYMPH-NODE METASTASIS; PROGNOSTIC-SIGNIFICANCE; CARCINOMA; ADENOCARCINOMA; ASSOCIATION; COMPONENT; COLON; SURVIVAL; BEHAVIOR; VARIANT	The aim of the present study is to elucidate the clinicopathological significance and prognostic role of micropapillary pattern (MPP) in colorectal cancer (CRC). We investigated the correlation between the presence of MPP and clinicopathological characteristics and prognosis in 266 CRCs. In addition, the clinicopathological significance of MPP in mucin pools was investigated and compared to pure MPP, which is not associated with mucin pools. MPP, regardless of its proportion in the overall tumor, was found in 74 of 266 CRCs (27.8%). The rate of MPP in proportions >= 5% was 9.4% (25 of 266 cases). CRC with MPP showed higher rates of vascular and lymphatic invasion, higher metastatic lymph node ratio, and higher pT stage compared to CRC without MPP. In addition, increasing proportion of MPP in overall tumor showed more frequent vascular and lymphatic invasions (P = .002 and P = .008, respectively). Among 74 CRCs with MPP, 25 CRCs were found in mucin pools (33.8%). These cases were more right-sided and poorly differentiated with less frequent lymphatic invasion and lymph node metastasis, compared to CRCs with pure MPP. The presence of MPP significantly correlated with worse overall survival (P = .010). In 74 CRCs with MPP, overall survival significantly differed between pure MPP and MPP in mucin pools (P = .003). Taken together, our data suggest that the presence of MPP significantly correlated with aggressive tumor behavior and worse survival in CRC. In addition, the clinicopathological significance of MPP in mucin pools differed from CRC with pure MPP. (C) 2018 Elsevier Inc. All rights reserved.	[Pyo, Jung-Soo; Park, Mee Ja; Kang, Dong-Wook] Eulji Univ, Eulji Univ Hosp, Dept Pathol, Sch Med, 95 Dunsanseo Ro, Daejeon 35233, South Korea	Park, MJ (reprint author), Eulji Univ, Eulji Univ Hosp, Dept Pathol, Sch Med, 95 Dunsanseo Ro, Daejeon 35233, South Korea.	pmj@eulji.ac.kr					Amendoeira Isabel, 2003, Breast J, V9, P337, DOI 10.1046/j.1524-4741.2003.09423.x; AMIN MB, 1994, AM J SURG PATHOL, V18, P1224, DOI 10.1097/00000478-199412000-00005; Amin MB, 2002, AM J SURG PATHOL, V26, P358, DOI 10.1097/00000478-200203000-00010; Bosman FT, 2010, WHO CLASSIFICATION T; Fujita T, 2010, SURG TODAY, V40, P1197, DOI 10.1007/s00595-010-4330-0; Guzinska-Ustymowicz K, 2014, WORLD J GASTROENTERO, V20, P4597, DOI 10.3748/wjg.v20.i16.4597; Haupt B, 2007, MODERN PATHOL, V20, P729, DOI 10.1038/modpathol.3800790; Khayyata S, 2005, MODERN PATHOL, V18, P1504, DOI 10.1038/modpathol.3800460; Kim HJ, 2017, J PATHOL TRANSL MED, V51, P403, DOI 10.4132/jptm.2017.03.18; Kim MJ, 2006, HUM PATHOL, V37, P809, DOI 10.1016/j.humpath.2005.10.018; Kitagawa H, 2017, JPN J CLIN ONCOL, V47, P1129, DOI 10.1093/jjco/hyx136; Lee HJ, 2013, MODERN PATHOL, V26, P1123, DOI 10.1038/modpathol.2012.163; Lino-Silva LS, 2012, COLORECTAL DIS, V14, pe567, DOI 10.1111/j.1463-1318.2012.03013.x; Pyo JS, 2018, PATHOL ONCOL RES, V24, P547, DOI 10.1007/s12253-017-0274-7; Sakamoto K, 2005, HISTOPATHOLOGY, V47, P479, DOI 10.1111/j.1365-2559.2005.02241.x; Shet T, 2008, BREAST J, V14, P412, DOI 10.1111/j.1524-4741.2008.00616.x; Shimoda M, 2008, PATHOL INT, V58, P513, DOI 10.1111/j.1440-1827.2008.02265.x; Sonoo H, 2009, JPN J CLIN ONCOL, V39, P523, DOI 10.1093/jjco/hyp051; Ushiku T, 2011, HISTOPATHOLOGY, V59, P1081, DOI 10.1111/j.1365-2559.2011.04055.x; Verdu M, 2011, MODERN PATHOL, V24, P729, DOI 10.1038/modpathol.2011.1; Wen P, 2008, INT J CLIN EXP PATHO, V1, P457; Xu FY, 2009, AM J SURG PATHOL, V33, P1287, DOI 10.1097/PAS.0b013e3181a5387b	22	1	1	1	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						159	165		10.1016/j.humpath.2018.02.027			7	Pathology	Pathology	GM6ZA	WOS:000438326300020	29634975				2019-10-28	
J	Wen, KW; Grenert, JP; Joseph, NM; Shafizadeh, N; Huang, A; Hosseini, M; Kakar, S				Wen, Kwun Wah; Grenert, James P.; Joseph, Nancy M.; Shafizadeh, Naffs; Huang, Anne; Hosseini, Mojgan; Kakar, Sanjay			Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma	HUMAN PATHOLOGY			English	Article						Goblet cell carcinoid; Appendix; Adenocarcinoma; Mutation; Next-generation sequencing	MUCINOUS NEOPLASMS; GASTRIC-CARCINOMA; MUTATIONS; GENES; METHYLATION; MANAGEMENT; SPECTRUM; BEHAVIOR; CANCER; ILEUM	Goblet cell carcinoid (GCC) is a rare appendiceal tumor with unique morphologic features that shows glandular and neuroendocrine differentiation on immunohistochemistry. An additional component of adenocarcinoma (AC) can be present (GCC-AC). Both GCC and GCC-AC are staged and treated like AC. The histogenesis and genetic alterations underlying GCC and GCC-AC are unclear. Capture-based next-generation DNA sequencing targeting 479 cancer genes was performed on 19 appendiceal tumors: 4 GCC, 9 GCC-AC, 3 neuroendocrine tumors (NET), and 3 AC (2 conventional, 1 mucinous). Somatic coding mutations were not seen in any NET. Pathogenic (P)/likely pathogenic (LP) mutations were present in 1 GCC, 8 GCC-AC and all 3 AC cases. P/LP mutations in chromatin remodeling genes were seen in 4 (44.4%) GCC-AC cases, but not in NET, GCC or AC. In GCC-AC, P/LP mutations in ARID1A and RHOA were each present in 3 cases, and KDM6A and SOX9 mutations were each seen in 2 cases. APC and KRAS mutations were present in 1 conventional AC case, but were not observed in any GCC or GCC-AC. This limited series reveals mutations in SOX9, RHOA, and chromatin-modifier genes in goblet cell tumors, and shows that the mutational profile of GCC/GCC-AC is distinct from NET and conventional appendiceal AC. (C) 2018 Elsevier Inc. All rights reserved.	[Wen, Kwun Wah; Grenert, James P.; Joseph, Nancy M.; Kakar, Sanjay] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 91343 USA; [Shafizadeh, Naffs] Kaiser Permanente, Woodland Hills, CA 91367 USA; [Huang, Anne] Vista Pathol, Medford, OR 97504 USA; [Hosseini, Mojgan] Univ Calif San Diego, San Diego, CA 92093 USA	Kakar, S (reprint author), Univ Calif San Francisco, Dept Anat Pathol, GI Hepatobiliary Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA.	sanjay.kakar@ucsf.edu			UCSF Department of Pathology	This research was supported and funded by the Residents' Teaching and Research Endowments from the UCSF Department of Pathology.	Amin M, 2017, AM JOINT COMMITTEE C; Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Boudreaux JP, 2010, PANCREAS, V39, P753, DOI 10.1097/MPA.0b013e3181ebb2a5; Carr NJ, WHO CLASSIFICATION T; Chen SF, 2013, HUM PATHOL, V44, P2199, DOI 10.1016/j.humpath.2013.04.025; Furukawa T, 2011, SCI REP-UK, V1, DOI 10.1038/srep00161; Hara K, 2015, PATHOL RES PRACT, V211, P657, DOI 10.1016/j.prp.2015.06.004; Hristov AC, 2007, AM J SURG PATHOL, V31, P1502, DOI 10.1097/PAS.0b013e31804f7aa1; Javier BM, 2016, ONCOTARGET, V7, P50875, DOI 10.18632/oncotarget.9682; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kanthan R, 2001, ARCH PATHOL LAB MED, V125, P386; McCusker ME, 2002, CANCER, V94, P3307, DOI 10.1002/cncr.10589; McGrath J, 2015, PHARMACOL THERAPEUT, V150, P1, DOI 10.1016/j.pharmthera.2015.01.002; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Oberg K, 2013, SEMIN ONCOL, V40, P37, DOI 10.1053/j.seminoncol.2012.11.005; Pape UF, 2012, NEUROENDOCRINOLOGY, V95, P135, DOI 10.1159/000335629; Pernot S, 2015, WORLD J GASTROENTERO, V21, P11428, DOI 10.3748/wjg.v21.i40.11428; Ramnani DM, 1999, CANCER, V86, P14, DOI 10.1002/(SICI)1097-0142(19990701)86:1<14::AID-CNCR4>3.0.CO;2-X; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Reid MD, 2016, MODERN PATHOL, V29, P1243, DOI 10.1038/modpathol.2016.105; Rokutan H, 2016, J PATHOL, V240, P137, DOI 10.1002/path.4761; Sasaki M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081706; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Singhi AD, 2014, HUM PATHOL, V45, P1737, DOI 10.1016/j.humpath.2014.04.018; Stachler MD, 2015, HUM PATHOL, V46, P507, DOI 10.1016/j.humpath.2015.01.005; Stancu M, 2003, MODERN PATHOL, V16, P1189, DOI 10.1097/01.MP.0000097362.10330.B1; Tang LH, 2008, AM J SURG PATHOL, V32, P1429, DOI 10.1097/PAS.0b013e31817f1816; Turaga KK, 2012, ANN SURG ONCOL, V19, P1379, DOI 10.1245/s10434-012-2238-1; van Eeden S, 2007, HISTOPATHOLOGY, V51, P763, DOI 10.1111/j.1365-2559.2007.02883.x; Wen KW, 2017, HUM PATHOL, V65, P187, DOI 10.1016/j.humpath.2017.05.012; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246	34	6	7	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						166	174		10.1016/j.humpath.2018.03.026			9	Pathology	Pathology	GM6ZA	WOS:000438326300021	29634977				2019-10-28	
J	Lu, CY; Alex, D; Benayed, R; Rosenblum, M; Hameed, M				Lu, Chuanyong; Alex, Deepu; Benayed, Ryma; Rosenblum, Marc; Hameed, Meera			Solitary fibrous tumor with neuroendocrine and squamous dedifferentiation: a potential diagnostic pitfall	HUMAN PATHOLOGY			English	Article						Solitary fibrous tumor; Dedifferentiation; Malignant transformation; Transdifferentiation; Neuroendocrine carcinoma; Squamous differentiation	DISTINCT CLINICOPATHOLOGICAL FEATURES; NAB2-STAT6 FUSION; EXPRESSION; STAT6; VARIANTS	Solitary fibrous tumor (SFT) is a ubiquitous mesenchymal neoplasm of deep soft tissue with variable and often unpredictable biological behavior. The lineage is presumed to be fibroblastic, and histological features range from benign to overtly malignant with rare tumors showing "dedifferentiation" or transformation to undifferentiated pleomorphic sarcoma. Dedifferentiation in mesenchymal neoplasms is a phenomenon of histologic progression of a well-differentiated neoplasm to a high-grade sarcoma, which can differentiate along divergent lines. It is extremely uncommon to encounter "transdifferentiation" to non-mesenchymal lineage and still maintaining the driver genetic event of the primary tumor. Herein, we report two diagnostically challenging SFTs with transformation to neuroendocrine and squamous phenotypes. The index case is a pelvic malignant SFT, which metastasized to the liver as a high-grade neuroendocrine carcinoma. The second case is a recurrent brain tumor initially presenting as a typical SFT and evolving into a dedifferentiated SFT with foci of squamous differentiation. Positive immunohistochemical stains for CD34 and STAT6 and the detection of NAB2-STAT6 fusion supported the diagnosis of dedifferentiated SFT in both cases. In the first case, molecular study also demonstrated that both the pelvic primary and liver metastasis harbored the same NAB2-STAT6 fusion. Dedifferentiation to a non-mesenchymal lineage/lineage infidelity can be a potential diagnostic pitfall in these tumors. (C) 2018 Elsevier Inc. All rights reserved.	[Lu, Chuanyong; Alex, Deepu; Benayed, Ryma; Rosenblum, Marc; Hameed, Meera] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Lu, Chuanyong] Hosp Special Surg, Dept Pathol, 535 E 70th St, New York, NY 10021 USA	Lu, CY (reprint author), Hosp Special Surg, Dept Pathol, 535 E 70th St, New York, NY 10021 USA.	luc@hss.edu	Alex, Deepu/J-5380-2019		Department of Pathology at Memorial Sloan Kettering Cancer Center Internal Research Fund; NIH/National Cancer Institute Cancer Center [P30CA008748]	We would like to thank Dr. Leonid Li at the Department of Pathology, Saint Clare's Health System, Denville, NJ and Dr David Nochlin at the Department of Pathology, JFK Medical Center, Edison, NJ for submitting the consultation cases. We would also like to thank Peter Ntiamoah for his excellent technical support. This work was supported by the Department of Pathology at Memorial Sloan Kettering Cancer Center Internal Research Fund and in part by the NIH/National Cancer Institute Cancer Center Support grant under award P30CA008748 (Disclosures: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH).	Akaike K, 2015, HUM PATHOL, V46, P347, DOI 10.1016/j.humpath.2014.11.018; Barthelmess S, 2014, AM J PATHOL, V184, P1209, DOI 10.1016/j.ajpath.2013.12.016; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Chmielecki J, 2013, NAT GENET, V45, P131, DOI 10.1038/ng.2522; Collini P, 2012, AM J SURG PATHOL, V36, P1202, DOI 10.1097/PAS.0b013e31825748f0; Dagrada GP, 2015, MODERN PATHOL, V28, P1074, DOI 10.1038/modpathol.2015.70; Demicco EG, 2017, MODERN PATHOL, V30, P1433, DOI 10.1038/modpathol.2017.54; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Mosquera JM, 2009, AM J SURG PATHOL, V33, P1314, DOI 10.1097/PAS.0b013e3181a6cd33; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Schweizer L, 2013, ACTA NEUROPATHOL, V125, P651, DOI 10.1007/s00401-013-1117-6; Tai HC, 2015, MODERN PATHOL, V28, P1324, DOI 10.1038/modpathol.2015.90	15	4	4	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JUL	2018	77						175	180		10.1016/j.humpath.2017.12.024			6	Pathology	Pathology	GM6ZA	WOS:000438326300022	29309807	Green Accepted			2019-10-28	
J	Powers, CN; Kraft, AO				Powers, Celeste N.; Kraft, Adele O.			Cytopathologists and Ultrasound-Guided Fine-Needle Aspiration: Embracing the Black and White	AJSP-REVIEWS AND REPORTS			English	Editorial Material									[Powers, Celeste N.; Kraft, Adele O.] Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980139, Richmond, VA 23298 USA	Powers, CN (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980139, Richmond, VA 23298 USA.	celeste.powers@vcuhealh.org					Dinh VA, 2016, J ULTRAS MED, V35, P413, DOI 10.7863/ultra.15.05073; Powers CN, 2013, AJSP-REV REP, V18, P1, DOI 10.1097/PCR.0b0I3e318281c75d	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					157	158		10.1097/PCR.0000000000000250			2	Pathology	Pathology	GL9XS	WOS:000437697600001					2019-10-28	
J	Heller, HT; Cibas, ES; Kraft, AO; Jiang, XY; Foo, WC; Sanchez, MA; Powers, CN				Heller, Howard T.; Cibas, Edmund S.; Kraft, Adele O.; Jiang, Xiaoyin Sara; Foo, Wen-Chi; Sanchez, Miguel A.; Powers, Celeste N.			Ultrasound-Guided Fine-Needle Aspiration Practice Patterns	AJSP-REVIEWS AND REPORTS			English	Review						cytology; cytopathologist; cytotechnologist; fine-needle aspiration; radiologist; ultrasound		How ultrasound-guided fine-needle aspiration (USFNA) is performed in the United States varies considerably among institutions. The critical role of the cytopathologist for diagnosis is indisputable, although the degree of collaboration with other specialties and the physical setting where the procedure is performed are highly individualized, as is the degree to which the cytopathologist takes an active role in performing the biopsy. We highlight the practice patterns at 4 health centers in the United States. At 1 medical center, USFNAs are performed using a team approach: the aspiration is performed by a cytopathologist or trainee but is guided by a radiologist. In the remaining 3 medical centers, many USFNAs are performed without radiology assistance, with minor differences related to scheduling, personnel involved, and results reporting policies. All 4 medical centers report favorable patient and provider satisfaction. In conclusion, a variety of methods, all targeted to optimizing patient care and rapid diagnosis, work well and are generally well received by the physicians who refer their patients for care.	[Heller, Howard T.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA; [Cibas, Edmund S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Cibas, Edmund S.] Harvard Med Sch, Boston, MA USA; [Kraft, Adele O.; Powers, Celeste N.] Virginia Commonwealth Univ, Dept Pathol, Sch Med, Richmond, VA USA; [Jiang, Xiaoyin Sara; Foo, Wen-Chi] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA; [Sanchez, Miguel A.] Englewood Hosp & Med Ctr, Dept Pathol, Englewood, NJ USA	Powers, CN (reprint author), Virginia Commonwealth Univ Hlth, Dept Pathol, Gateway Bldg,Room 6-208,1200 East Marshall St, Richmond, VA 23298 USA.	celeste.powers@vcuhealth.org					Cibas ES, 2009, THYROID, V19, P1159, DOI 10.1089/thy.2009.0274; Yassa L, 2007, CANCER CYTOPATHOL, V111, P508, DOI 10.1002/cncr.23116	2	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					159	164		10.1097/PCR.0000000000000251			6	Pathology	Pathology	GL9XS	WOS:000437697600002					2019-10-28	
J	Jiang, XY; Foo, WC				Jiang, Xiaoyin Sara; Foo, Wen-Chi			Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: Pearls and Potential	AJSP-REVIEWS AND REPORTS			English	Review						fine-needle aspiration biopsy; thyroid; ultrasound	COST-EFFECTIVENESS; SPECIMEN ADEQUACY; BIOPSY; CYTOPATHOLOGIST; PATHOLOGIST; MASSES; FNA	Thyroid nodules are a commonplace clinical problem. Ultrasound-guided fine-needle aspiration biopsy is often the first step in the diagnosis and management of these nodules. We provide a review of technical considerations, performance, and techniques for thyroid nodule ultrasound-guided biopsy.	[Jiang, Xiaoyin Sara; Foo, Wen-Chi] Duke Hlth, Dept Pathol, Durham, NC USA	Jiang, XY (reprint author), DUMC 3712, Durham, NC 27710 USA.	jiang009@mc.duke.edu					Abele JS, 2008, CANCER CYTOPATHOL, V114, P463, DOI 10.1002/cncr.23950; Bellevicine C, 2016, CYTOPATHOLOGY, V27, P115, DOI 10.1111/cyt.12243; Can AS, 2009, BMC ENDOCR DISORD, V9, DOI 10.1186/1472-6823-9-14; Carmeci C, 1998, THYROID, V8, P283, DOI 10.1089/thy.1998.8.283; Cesur M, 2006, THYROID, V16, P555, DOI 10.1089/thy.2006.16.555; Hatada T, 1998, AM J SURG, V175, P133, DOI 10.1016/S0002-9610(97)00274-2; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Khalid AN, 2008, HEAD NECK-J SCI SPEC, V30, P1035, DOI 10.1002/hed.20829; Layfield LJ, 2010, DIAGN CYTOPATHOL, V38, P239, DOI 10.1002/dc.21172; Lieu D, 2008, DIAGN CYTOPATHOL, V36, P317, DOI 10.1002/dc.20800; Lieu D, 2009, DIAGN CYTOPATHOL, V37, P262, DOI 10.1002/dc.20984; Oertel YC, 2004, DIAGN CYTOPATHOL, V30, P295, DOI 10.1002/dc.20062; Pitman MB, 2008, DIAGN CYTOPATHOL, V36, P407, DOI 10.1002/dc.20829; Rafael OC, 2017, CANCER CYTOPATHOL, V125, P161, DOI 10.1002/cncy.21840; Redman R, 2006, THYROID, V16, P55, DOI 10.1089/thy.2006.16.55; Tessler FN, 2017, J AM COLL RADIOL, V14, P587, DOI 10.1016/j.jacr.2017.01.046; Wang N, 2006, HEAD NECK-J SCI SPEC, V28, P1077, DOI 10.1002/hed.20481; Wu MX, 2011, DIAGN CYTOPATHOL, V39, P743, DOI 10.1002/dc.21460; Zanocco K, 2013, ANN SURG ONCOL, V20, P2462, DOI 10.1245/s10434-013-2954-1	19	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					165	169		10.1097/PCR.0000000000000252			5	Pathology	Pathology	GL9XS	WOS:000437697600003					2019-10-28	
J	Wiles, AB; Kraft, AO; Powers, CN				Wiles, Austin B.; Kraft, Adele O.; Powers, Celeste N.			Ultrasound-Guided Fine-Needle Aspiration Biopsy of Salivary Glands: A Practical Review	AJSP-REVIEWS AND REPORTS			English	Review						cytopathology; fine-needle aspiration (FNA); salivary gland; ultrasound	PAROTID-GLAND; LYMPH-NODES; DIFFERENTIAL-DIAGNOSIS; PLEOMORPHIC ADENOMA; METASTATIC CANCER; TUMORS; NECK; LESIONS; HEAD; METAANALYSIS	The usage of real-time ultrasound-guided fine-needle aspiration biopsy by cytopathologists has increased the utility of biopsy in management of patients with salivary gland neoplasms. There is significant overlap between cytologic features of salivary gland neoplasms, and likewise, there is analogous overlap between ultrasound radiologic features of these lesions. However, ultrasound radiologic evaluation can provide important information for the cytopathologist when performing and interpreting a biopsy of a salivary gland neoplasm, including the specific anatomic location and structure of a target lesion. We present a practical guide for using ultrasound evaluation in the biopsy of the salivary glands for the practicing cytopathologist including common pitfalls, common lesional characteristics, and relevant lymph node morphological findings.	[Wiles, Austin B.; Kraft, Adele O.; Powers, Celeste N.] Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662,1101 E Marshal St, Richmond, VA 23298 USA	Wiles, AB (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662,1101 E Marshal St, Richmond, VA 23298 USA.	austin.wiles@vcuhealth.org					Ahuja A., 2014, DIAGNOSTIC ULTRASOUN; Ahuja AT, 2001, CLIN RADIOL, V56, P111, DOI 10.1053/crad.2000.0642; Aro K, 2018, HEAD NECK-J SCI SPEC, V40, P154, DOI 10.1002/hed.24981; BATSAKIS JG, 1983, ANN OTO RHINOL LARYN, V92, P209, DOI 10.1177/000348948309200224; BATSAKIS JG, 1990, ANN OTO RHINOL LARYN, V99, P501, DOI 10.1177/000348949009900618; Bialek EJ, 2017, J ULTRASON, V17, P59, DOI 10.15557/JoU.2017.0008; Bobin C, 2018, EUR ANN OTORHINOLARY, V135, P99, DOI 10.1016/j.anorl.2017.09.006; Bron LP, 2003, LARYNGOSCOPE, V113, P1070, DOI 10.1097/00005537-200306000-00029; CARDILLO M R, 1990, Archives d'Anatomie et de Cytologie Pathologiques, V38, P26; Catano JC, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.TNMI7-0008-2016; Clark J, 2016, ADV OTO-RHINO-LARYNG, V78, P95, DOI 10.1159/000442129; Cohen EG, 2004, ARCH OTOLARYNGOL, V130, P773, DOI 10.1001/archotol.130.6.773; Davachi Behrooz, 2014, J Dent Res Dent Clin Dent Prospects, V8, P246, DOI 10.5681/joddd.2014.044; de Oliveira FA, 2009, HEAD NECK PATHOL, V3, P271, DOI 10.1007/s12105-009-0139-9; Ellis G, 2017, WHO CLASSIFICATION H, P216; Ergun SS, 2014, J CRANIO MAXILL SURG, V42, P657, DOI 10.1016/j.jcms.2013.09.011; Forghani R, 2015, EXPERT REV ANTICANC, V15, P207, DOI 10.1586/14737140.2015.978862; FRABLE MAS, 1991, LARYNGOSCOPE, V101, P245; FRABLE MS, 1982, LARYNGOSCOPE, V92, P1414; FRABLE WJ, 1974, LARYNGOSCOPE, V84, P1069, DOI 10.1288/00005537-197407000-00001; Gong X, 2012, OR SURG OR MED OR PA, V114, P382, DOI 10.1016/j.oooo.2012.04.014; Goode RK, 2017, WHO CLASSIFICATION H, P219; GRITZMANN N, 1989, AM J ROENTGENOL, V153, P161, DOI 10.2214/ajr.153.1.161; Jousse-Joulin S, 2016, RHEUMATOLOGY, V55, P789, DOI 10.1093/rheumatology/kev385; Kaji AV, 1997, SEMIN ULTRASOUND CT, V18, P220, DOI 10.1016/S0887-2171(97)90021-4; Katz Philippe, 2009, Otolaryngol Clin North Am, V42, P973, DOI 10.1016/j.otc.2009.08.009; KLEIN K, 1989, HNO, V37, P71; Koyama T, 2004, RADIOGRAPHICS, V24, P87, DOI 10.1148/rg.241035076; Kraaij S, 2014, BRIT DENT J, V217, DOI 10.1038/sj.bdj.2014.1054; Lee YYP, 2008, EUR J RADIOL, V66, P419, DOI 10.1016/j.ejrad.2008.01.027; Liu CC, 2016, OTOLARYNG HEAD NECK, V154, P9, DOI 10.1177/0194599815607841; Loree TR, 2006, LARYNGOSCOPE, V116, P1461, DOI 10.1097/01.mlg.0000225967.93261.fc; McHugh JB, 2009, ARCH PATHOL LAB MED, V133, P1763, DOI 10.1043/1543-2165-133.11.1763; Park JH, 2014, J ULTRAS MED, V33, P1619, DOI 10.7863/ultra.33.9.1619; Pommier A, 2017, B CANCER, V104, P850, DOI 10.1016/j.bulcan.2017.09.001; Schmidt RL, 2011, AM J CLIN PATHOL, V136, P45, DOI 10.1309/AJCPOIE0CZNAT6SQ; SEIFERT G, 1986, PATHOL RES PRACT, V181, P684, DOI 10.1016/S0344-0338(86)80044-9; Sethi R, 2014, LARYNGOSCOPE, V124, P188, DOI 10.1002/lary.24254; Shkedy Y, 2018, CLIN OTOLARYNGOL, V43, P632, DOI 10.1111/coa.13038; Simpson RHW, 2017, WHO CLASSIFICATION H, P263; Skalova A, 2018, AM J SURG PATHOL, V42, pE11, DOI 10.1097/PAS.0000000000000980; Stennert E, 2001, LARYNGOSCOPE, V111, P2195, DOI 10.1097/00005537-200112000-00024; Stewart CJR, 2000, DIAGN CYTOPATHOL, V22, P139; Suh SI, 2005, J COMPUT ASSIST TOMO, V29, P121, DOI 10.1097/01.rct.0000150141.14113.ab; Trotter H., 1930, ANN OTO RHINOL LARYN, V39, P384; Witt BL, 2014, LARYNGOSCOPE, V124, P695, DOI 10.1002/lary.24339; WITTICH GR, 1985, RADIOL CLIN N AM, V23, P29; Wu MX, 2006, LARYNGOSCOPE, V116, P1212, DOI 10.1097/01.mlg.0000224507.07560.28; Wu MX, 2017, DIAGN CYTOPATHOL, V45, P878, DOI 10.1002/dc.23784; Wu MX, 2011, DIAGN CYTOPATHOL, V39, P743, DOI 10.1002/dc.21460; Zbaren P, 2007, HEAD NECK-J SCI SPEC, V29, P751, DOI 10.1002/hed.20569	51	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					170	175		10.1097/PCR.0000000000000253			6	Pathology	Pathology	GL9XS	WOS:000437697600004					2019-10-28	
J	Jug, R; Jiang, XY				Jug, Rachel; Jiang, Xiaoyin Sara			Creating Custom Phantoms for Ultrasound-Guided Fine-Needle Aspiration Biopsy Training	AJSP-REVIEWS AND REPORTS			English	Review						cytopathology; fine-needle aspiration (FNA); phantom; ultrasound	THYROID-NODULES; CYTOPATHOLOGISTS; FNA	Ultrasound-guided fine-needle aspiration (US-FNA) is superior to conventional fine-needle aspiration biopsies and when performed by cytopathologists yields higher diagnostic rates than when performed by nonpathologists. Ultrasound-guided fine-needle aspiration allows operators to perform targeted biopsies while avoiding critical nearby structures, decreasing the risk of procedural complications. Traditionally, cytopathology training programs have purchased costly commercial phantom models on which to train residents and fellows and provide opportunities for cytopathologists to practice their US-FNA technique. While phantoms are effective training tools, they are sold by several vendors at well over $1000 and have limited life spans as with continued use needle track marks obscure the ultrasound's view of practice targets. We developed and tested 2 cost-effective and easy-to-make recipes for creating your own US-FNA phantoms in-house. The first recipe features a gelatin-based phantom that can be made from ingredients available at any local grocery store. The second recipe for a silicon-based phantom is more durable but requires some ingredients that may be purchased online or at specialty costume shops. Finally, we share ideas and directions for making target lesions to be placed inside your phantoms and invite readers to harness their creativity to customize these phantom recipes to suit their practices' and trainees' needs.	[Jug, Rachel; Jiang, Xiaoyin Sara] Duke Hlth, Dept Pathol, Durham, NC USA	Jiang, XY (reprint author), DUMC 3712, Durham, NC 27710 USA.	jiang009@mc.duke.edu					Abele JS, 2008, CANCER CYTOPATHOL, V114, P463, DOI 10.1002/cncr.23950; Ayers F, 2008, FABRICATION CHARACTE; Baba M, 2017, J SURG EDUC, V74, P1039, DOI 10.1016/j.jsurg.2017.05.012; Bellevicine C, 2016, CYTOPATHOLOGY, V27, P115, DOI 10.1111/cyt.12243; BUDE RO, 1995, J CLIN ULTRASOUND, V23, P271, DOI 10.1002/jcu.1870230413; Cesur M, 2006, THYROID, V16, P555, DOI 10.1089/thy.2006.16.555; Danese D, 1998, THYROID, V8, P15, DOI 10.1089/thy.1998.8.15; Maggi LE, 2009, 2009 IE INT ULTR S 2; Nicholson RA, 1997, BRIT J RADIOL, V70, P192, DOI 10.1259/bjr.70.830.9135447; Pacioni A, 2015, INT J COMPUT ASS RAD, V10, P1065, DOI 10.1007/s11548-014-1120-y; Rafael OC, 2017, CANCER CYTOPATHOL, V125, P161, DOI 10.1002/cncy.21840; Rippey JCR, 2015, J VASC ACCESS, V16, P422, DOI 10.5301/jva.5000384; Wu MX, 2016, DIAGN CYTOPATHOL, V44, P787, DOI 10.1002/dc.23544	13	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					176	179		10.1097/PCR.0000000000000254			4	Pathology	Pathology	GL9XS	WOS:000437697600005					2019-10-28	
J	Sanchez, MA; Burga, AM; Tismenetsky, M; Goldfischer, M				Sanchez, Miguel A.; Burga, Ana M.; Tismenetsky, Mikhail; Goldfischer, Mindy			Sonographic Breast Mimickers: Examples of Cases Outside the Box	AJSP-REVIEWS AND REPORTS			English	Article						anechoic; fine-needle aspiration; immediate cytologic evaluation; sonography	FINE-NEEDLE-ASPIRATION; BIOPSY; CANCER; MASSES	Ultrasound in breast imaging has enhanced the field of radiology by using this distinct modality to evaluate breast lesions using unique features that are not available by traditional mammography. These features that are used can help characterize lesions in the breast into benign, suspicious, or malignant entities. However, not all lesions of the breast fall into these set categories, and sampling of the masses may be necessary to avoid pitfalls. In this article, we list the criteria that are classically used to favor benign versus malignant lesions and then have 2 examples that fall outside of the box and needed sampling of the masses for a definitive diagnosis.	[Sanchez, Miguel A.; Goldfischer, Mindy] Englewood Hosp & Med Ctr, Leslie Simon Breast Care & Cytodiag Ctr, Englewood, NJ 07631 USA; [Burga, Ana M.; Tismenetsky, Mikhail] Englewood Hosp & Med Ctr, Dept Pathol, 350 Engle St, Englewood, NJ 07631 USA	Burga, AM (reprint author), Englewood Hosp & Med Ctr, Dept Pathol, 350 Engle St, Englewood, NJ 07631 USA.	Ana.Burga@EHMCHealth.org					Borovicka KM, 2017, J AM OSTEOPATH COLL, V6, P5; Gagliato DD, 2014, J CLIN ONCOL, V32, P735, DOI 10.1200/JCO.2013.49.7693; Lieu D, 2009, DIAGN CYTOPATHOL, V37, P262, DOI 10.1002/dc.20984; Ly A, 2016, J NATL COMPR CANC NE, V14, P527, DOI 10.6004/jnccn.2016.0061; Masood S, 2015, DIAGN CYTOPATHOL, V43, P605, DOI 10.1002/dc.23270; Sanchez MA, 2017, CANCER CYTOPATHOL, V125, P745, DOI 10.1002/cncy.21908; Sennerstam RB, 2017, CANCER CYTOPATHOL, V125, P748, DOI 10.1002/cncy.21909; Stavros AT, 2004, BREAST ULTRASOUND	8	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					180	182		10.1097/PCR.0000000000000255			3	Pathology	Pathology	GL9XS	WOS:000437697600006					2019-10-28	
J	Kraft, A; Prasad, U				Kraft, Adele; Prasad, Uma			Extensive Intravascular Thyroid Vein Extension in Follicular Thyroid Carcinoma: Ultrasound Clues	AJSP-REVIEWS AND REPORTS			English	Article						fine-needle aspiration (FNA); follicular thyroid carcinoma; thrombi; thyroid; ultrasound	MALIGNANCY	The identification of intravascular tumor thrombi in thyroid at the time of fine-needle aspiration is important as it is, by definition, a diagnosis of malignancy. While ultrasound findings of tumor thrombi in the great veins of the neck have been well described, thrombi in the thyroid veins can be very difficult to detect and have been seldom reported. This case study, with extensive thyroid vein tumor involvement, provides clues for raising the possibility of a malignant process at the time of ultrasound-guided FNA, by correlating the pathology findings with the ultrasound images.	[Kraft, Adele] Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662, Richmond, VA 23298 USA; [Prasad, Uma] Virginia Commonwealth Univ Hlth Syst, Dept Radiol, Richmond, VA 23298 USA	Kraft, A (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662, Richmond, VA 23298 USA.	adele.kraft@vcuhealth.org					Anil G, 2011, CANCER IMAGING, V11, P209, DOI 10.1102/1470-7330.2011.0030; Cibas Edmund S, 2017, J Am Soc Cytopathol, V6, P217, DOI 10.1016/j.jasc.2017.09.002; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Kobayashi K, 2011, THYROID, V21, P527, DOI 10.1089/thy.2010.0099; Leenhardt L, 2013, EUR THYROID J, V2, P147, DOI 10.1159/000354537; Lundgren CI, 2006, CANCER, V106, P524, DOI 10.1002/cncr.21653; Marcy PYR, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-40; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Wong K T, 2005, Cancer Imaging, V5, P157, DOI 10.1102/1470-7330.2005.0110	9	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					183	185		10.1097/PCR.0000000000000256			3	Pathology	Pathology	GL9XS	WOS:000437697600007					2019-10-28	
J	Sayeed, S; Powers, CN				Sayeed, Sadia; Powers, Celeste N.			The Utility of Ultrasound in the Diagnosis of '' Cystic '' Lesions of the Salivary Gland	AJSP-REVIEWS AND REPORTS			English	Article						cysts; cytopathology; fine-needle aspiration (FNA); salivary gland; ultrasound	PLEOMORPHIC ADENOMA; DOPPLER SONOGRAPHY; PAROTID-GLAND; APPEARANCE; CARCINOMA; NODULES; BENIGN; NODES	Unlike in the thyroid, ultrasound (US) imaging of salivary gland lesions that show posterior enhancement or through transmission does not necessarily imply the presence of a cystic lesion. The 3 cases presented in this article illustrate the wide range of diagnoses that may have very similar findings by US imaging. Thus, emphasis is placed on the need for sampling of these lesions with careful evaluation of both US images and ideally US-guided fine-needle aspiration cytology to arrive at an accurate interpretation.	[Sayeed, Sadia; Powers, Celeste N.] Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662, Richmond, VA 23298 USA	Sayeed, S (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662, Richmond, VA 23298 USA.	sadia.sayeed@vcuhealth.org					Ahuja A., 2014, DIAGNOSTIC ULTRASOUN; Ahuja AT, 1999, AM J NEURORADIOL, V20, P579; Ahuja AT, 2001, CLIN RADIOL, V56, P111, DOI 10.1053/crad.2000.0642; Bialek EJ, 2016, J ULTRASON, V16, P191, DOI 10.15557/JoU.2016.0020; BRKLJACIC B, 1994, J CLIN ULTRASOUND, V22, P71, DOI 10.1002/jcu.1870220202; Frates MC, 2006, J CLIN ENDOCR METAB, V91, P3411, DOI 10.1210/jc.2006-0690; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Kessler A, 2003, J CLIN ULTRASOUND, V31, P21, DOI 10.1002/jcu.10130; Kraaij S, 2014, BRIT DENT J, V217, DOI 10.1038/sj.bdj.2014.1054; MARTINOLI C, 1995, AM J ROENTGENOL, V165, P975, DOI 10.2214/ajr.165.4.7677004; MARTINOLI C, 1994, AM J ROENTGENOL, V163, P933, DOI 10.2214/ajr.163.4.8092039; REYNOLDS JH, 1993, CLIN RADIOL, V48, P109, DOI 10.1016/S0009-9260(05)81082-7; Stennert E, 2001, LARYNGOSCOPE, V111, P2195, DOI 10.1097/00005537-200112000-00024; Stewart CJR, 2000, DIAGN CYTOPATHOL, V22, P139; Zbaren P, 2007, HEAD NECK-J SCI SPEC, V29, P751, DOI 10.1002/hed.20569	15	0	0	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					186	189		10.1097/PCR.0000000000000257			4	Pathology	Pathology	GL9XS	WOS:000437697600008					2019-10-28	
J	Jug, R; Jiang, XY				Jug, Rachel; Jiang, Xiaoyin Sara			Lymph Node Fine-Needle Aspiration: 2 Cases Demonstrating Benefits of Ultrasound Guidance	AJSP-REVIEWS AND REPORTS			English	Article						biopsy; fine-needle aspiration (FNA); lymph node; pathology; ultrasound	DIAGNOSTIC-VALUE; THYROID-NODULES; GUIDED FNA; BIOPSY; PATHOLOGISTS; METASTASIS; CARCINOMA; CYTOLOGY	Pathologist performed fine-needle aspiration (FNA) biopsies yield high adequacy rates, result in effective triage ofmaterial for additional studies, and offer a minimally invasive method for tissue procurement. Ultrasound-guided FNA (US-FNA) expands the scope of pathologists' FNA capabilities allowing for deeper, nonpalpable lesions to be biopsied while avoiding crucial structures and enabling targeted biopsies of sonographically concerning regions. To illustrate the utility of US-FNA in clinical practice, we present 2 cases in which diagnostic material was obtained by pathologist-performed US-FNA from neck lymph nodes detected on positron emission tomography scans. The first was a 71-year-old woman with a history of both invasive lung and breast adenocarcinomas, and the second was a 60-year-old woman with a history of lower gastrointestinal tract squamous cell carcinoma. The lymph node biopsy from the first patient yielded adequate material to perform molecular diagnostic studies, detecting an activating KRAS mutation, providing additional prognostic and therapy guiding information. In the second case, ultrasound guidance allowed the pathologist to perform a biopsy on a nonpalpable lymph node and obtain a diagnosis from this minimally invasive procedure. Both lymph nodes featured characteristics indicative of involvement by metastatic carcinoma. Ultrasound examination can help characterize lesions, guiding cytopathologists to select an appropriate biopsy trajectory for optimal sampling.	[Jug, Rachel; Jiang, Xiaoyin Sara] Duke Hlth, Dept Pathol, Durham, NC USA	Jiang, XY (reprint author), DUMC 3712, Durham, NC 27710 USA.	jiang009@mc.duke.edu					Al-Marzooq YM, 2004, ANN SAUDI MED, V24, P124, DOI 10.5144/0256-4947.2004.124; BASKIN HJ, 2000, THYROID ULTRASOUND U; Bialek EJ, 2017, J ULTRASON, V17, P59, DOI 10.15557/JoU.2017.0008; Cesur M, 2006, THYROID, V16, P555, DOI 10.1089/thy.2006.16.555; Cibas ES, 2008, DIAGN CYTOPATHOL, V36, P390, DOI 10.1002/dc.20827; Danese D, 1998, THYROID, V8, P15, DOI 10.1089/thy.1998.8.15; Gipponi M, 2016, BREAST, V30, P146, DOI 10.1016/j.breast.2016.09.009; Gomez-Macias GS, 2009, CYTOJOURNAL, V6, DOI 10.4103/1742-6413.52831; Gupta RK, 2003, CYTOPATHOLOGY, V14, P201, DOI 10.1046/j.1365-2303.2003.00057.x; Kupferman ME, 2004, ARCH OTOLARYNGOL, V130, P857, DOI 10.1001/archotol.130.7.857; LINDBERG R, 1972, CANCER, V29, P1446, DOI 10.1002/1097-0142(197206)29:6<1446::AID-CNCR2820290604>3.0.CO;2-C; Lopez F, 2016, HEAD NECK-J SCI SPEC, V38, pE2374, DOI 10.1002/hed.24344; Popowicz B, 2009, EUR J ENDOCRINOL, V161, P103, DOI 10.1530/EJE-09-0022; Rafael OC, 2017, CANCER CYTOPATHOL, V125, P161, DOI 10.1002/cncy.21840; Wu MX, 2016, DIAGN CYTOPATHOL, V44, P787, DOI 10.1002/dc.23544; Wu MX, 2011, DIAGN CYTOPATHOL, V39, P743, DOI 10.1002/dc.21460	16	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					190	193		10.1097/PCR.0000000000000258			4	Pathology	Pathology	GL9XS	WOS:000437697600009					2019-10-28	
J	Kloppel				Kloppel			Pancreatic Neuroendocrine Tumors: Update on the New World Health Organization Classification (vol 22, pg 233, 2017)	AJSP-REVIEWS AND REPORTS			English	Correction																Kloppel G, 2017, AJSP-REV REP, V22, P233, DOI 10.1097/PCR.0000000000000211; KLOPPEL G, 2017, REVIEWS REPORTS, V22, P233	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					193	193		10.1097/PCR.0000000000000260			1	Pathology	Pathology	GL9XS	WOS:000437697600010					2019-10-28	
J	Kraft, A; Wiles, A; Doern, C				Kraft, Adele; Wiles, Austin; Doern, Christopher			Acid-Fast Bacteria in Disguise: Mycobacterium avium Complex in Purulent Exudate; Ultrasound Correlation	AJSP-REVIEWS AND REPORTS			English	Article						fine-needle aspiration (FNA); Mycobacterium avium complex (MAC); purulent lymphadenitis; ultrasound	RECONSTITUTION INFLAMMATORY SYNDROME; LYMPH-NODES; LYMPHADENITIS; INFECTION; AIDS	In immunocompetent hosts, Mycobacterium avium complex lymphadenitis is almost exclusively a disease of children, involving cervical lymph nodes. In the setting of human immunodeficiency virus infection, it can occur as a manifestation of the immune reconstitution inflammatory syndrome. This case study reports a case of M. avium complex in the setting of immune reconstitution inflammatory syndrome, presenting as purulent lymphadenitis, correlating cytopathology and surgical pathology findings with ultrasound imaging.	[Kraft, Adele; Wiles, Austin; Doern, Christopher] Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662, Richmond, VA 23298 USA	Kraft, A (reprint author), Virginia Commonwealth Univ Hlth Syst, Dept Pathol, POB 980662, Richmond, VA 23298 USA.	adele.kraft@vcuhealth.org					Ahuja A, 2003, CLIN RADIOL, V58, P359, DOI 10.1016/S0009-9260(02)00585-8; Corti Marcelo, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P267, DOI 10.1590/S0036-46652007000400015; Lawn SD, 2004, CLIN INFECT DIS, V38, P461, DOI 10.1086/381033; Lindeboom JA, 2006, PEDIATR RADIOL, V36, P1063, DOI 10.1007/s00247-006-0271-6; Marais Suzaan, 2009, Curr HIV/AIDS Rep, V6, P162, DOI 10.1007/s11904-009-0022-z; Matusz-Fisher A, 2017, J GEN INTERN MED, V32, P712, DOI 10.1007/s11606-016-3956-z; Nayak S, 2004, DIAGN CYTOPATHOL, V31, P204, DOI 10.1002/dc.20072; Phillips P, 2005, CLIN INFECT DIS, V41, P1483, DOI 10.1086/497269; Riddell J IV, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-50; Shelburne SA, 2002, MEDICINE, V81, P213, DOI 10.1097/00005792-200205000-00005; Tarantino L, 2003, ABDOM IMAGING, V28, P602, DOI 10.1007/s00261-003-0035-9	11	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JUL-AUG	2018	23	4					194	196		10.1097/PCR.0000000000000259			3	Pathology	Pathology	GL9XS	WOS:000437697600011					2019-10-28	
J	Kuwahara, Y; Kennedy, LM; Karnezis, AN; Mora-Blanco, EL; Rogers, AB; Fletcher, CD; Huntsman, DG; Roberts, CWM; Rathmell, WK; Weissman, BE				Kuwahara, Yasumichi; Kennedy, Leslie M.; Karnezis, Anthony N.; Mora-Blanco, E. Lorena; Rogers, Arlin B.; Fletcher, Christopher D.; Huntsman, David G.; Roberts, Charles W. M.; Rathmell, W. Kimryn; Weissman, Bernard E.			High Frequency of Ovarian Cyst Development in Vhl(2B/+);Snf5(+/-) Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SMALL-CELL CARCINOMA; PROTEIN EXPRESSION; ESTROGEN-RECEPTOR; SMARCA4 MUTATIONS; SWI/SNF COMPLEX; RHABDOID TUMORS; HUMAN HOMOLOGS; ENDOMETRIAL; INACTIVATION; ARID1A	The new paradigm of mutations in chromatin-modifying genes as driver events in the development of cancers has proved challenging to resolve the complex influences over disease phenotypes. In particular, impaired activities of members of the SWI/SNF chromatin remodeling complex have appeared in an increasing variety of tumors. Mutations in SNF5, a member of this ubiquitously expressed complex, arise in almost all cases of malignant rhab doi d tumor in the absence of additional genetic alterations. Therefore, we studied how activation of additional oncogenic pathways might shift the phenotype of disease driven by SNF5 loss. With the use of a genetically engineered mouse model, we examined the effects of a hypomorphic Vhl(2B) allele on disease phenotype, with a modest up-regulation of the hypoxia response pathway. Snf5(+/-);Vhl(2B/+) mice did not demonstrate a substantial difference in overall survival or a change in malignant rhab doi d tumor development. However, a high percentage of female mice showed complex hemorrhagic ovarian cysts, a phenotype rarely found in either parental mouse strain. These lesions also showed mosaic expression of SNF5 by immunohistochemistry. Therefore, our studies implicate that modest changes in angiogenic regulation interact with perturbations of SWI/SNF complex activity to modulate disease phenotypes.	[Kuwahara, Yasumichi; Kennedy, Leslie M.; Rogers, Arlin B.; Rathmell, W. Kimryn; Weissman, Bernard E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Rogers, Arlin B.; Weissman, Bernard E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol & Oncol, Chapel Hill, NC 27599 USA; [Rathmell, W. Kimryn] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; [Karnezis, Anthony N.; Huntsman, David G.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Karnezis, Anthony N.; Huntsman, David G.] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC, Canada; [Mora-Blanco, E. Lorena; Roberts, Charles W. M.] Childrens Hosp Boston, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA USA; [Mora-Blanco, E. Lorena; Roberts, Charles W. M.] Harvard Univ, Boston, MA 02115 USA; [Fletcher, Christopher D.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA	Weissman, BE (reprint author), Univ N Carolina, Dept Pathol & Lab Med, 450 West Dr,Room 31-321, Chapel Hill, NC 27599 USA.	weissman@med.unc.edu	Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896; Karnezis, Anthony/0000-0003-2924-1126	U01 National Cancer Institute Mouse Models of Cancer Consortium Award; Garrett B. Smith Foundation; Miles for Mary; Cure ATRT Now; Avalanna Fund; Alex's Lemonade Stand; American Cancer SocietyAmerican Cancer Society; V Foundation for Cancer Research; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01CA172152, R01CA113794, R01CA91048, R01CA195670, R01CA198482, T32 HL069768]	Supported by NIH grants R01CA172152 (C.W.M.R.), R01CA113794 (C.W.M.R.), R01CA91048 (B.E.W.), R01CA195670 (D.G.H., B.E.W.), R01CA198482 (W.K.R.), and T32 HL069768 (L.M.K.); a U01 National Cancer Institute Mouse Models of Cancer Consortium Award (C.W.M.R.); the Garrett B. Smith Foundation (C.W.M.R.); Miles for Mary (C.W.M.R.); Cure ATRT Now (C.W.M.R.); the Avalanna Fund (C.W.M.R.); Alex's Lemonade Stand (C.W.M.R.); the American Cancer Society (W.K.R.); and the V Foundation for Cancer Research (W.K.R.).	Britt KL, 2000, ENDOCRINOLOGY, V141, P2614, DOI 10.1210/en.141.7.2614; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Coatham M, 2016, MODERN PATHOL, V29, P1586, DOI 10.1038/modpathol.2016.156; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; DelBove J, 2009, MOL CARCINOGEN, V48, P1139, DOI 10.1002/mc.20568; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Dupont S, 2000, DEVELOPMENT, V127, P4277; Fan HY, 2008, DEVELOPMENT, V135, P2127, DOI 10.1242/dev.020560; Han D, 2008, DEV BIOL, V315, P136, DOI 10.1016/j.ydbio.2007.12.024; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Hoang LN, 2016, HISTOPATHOLOGY, V69, P560, DOI 10.1111/his.12989; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Jelinic P, 2014, NAT GENET, V46, P424, DOI 10.1038/ng.2922; Jeyasuria P, 2004, MOL ENDOCRINOL, V18, P1610, DOI 10.1210/me.2003-0404; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Kenneth NS, 2009, J BIOL CHEM, V284, P4123, DOI 10.1074/jbc.M808491200; Kupryjanczyk J, 2013, POL J PATHOL, V64, P238, DOI 10.5114/PJP.2013.39331; Kuwahara Y, 2013, INT J CANCER, V132, P2767, DOI 10.1002/ijc.27976; Lee CM, 2009, ONCOGENE, V28, P1694, DOI 10.1038/onc.2009.12; Lee RS, 2013, BRAIN PATHOL, V23, P200, DOI 10.1111/bpa.12021; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Liu T, 2014, INT J MOL MED, V33, P1236, DOI 10.3892/ijmm.2014.1661; Ramos P, 2014, NAT GENET, V46, P427, DOI 10.1038/ng.2928; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Sena JA, 2013, MOL CELL BIOL, V33, P3849, DOI 10.1128/MCB.00731-13; Serber DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031346; Stewart CJR, 2015, PATHOLOGY, V47, P439, DOI 10.1097/PAT.0000000000000270; Strehl JD, 2015, ANN DIAGN PATHOL, V19, P198, DOI 10.1016/j.anndiagpath.2015.04.001; Tolstorukov MY, 2013, P NATL ACAD SCI USA, V110, P10165, DOI 10.1073/pnas.1302209110; Wang XF, 2014, CLIN CANCER RES, V20, P21, DOI 10.1158/1078-0432.CCR-13-0280; Weissman B, 2009, CANCER RES, V69, P8223, DOI 10.1158/0008-5472.CAN-09-2166; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Witkowski L, 2014, NAT GENET, V46, P438, DOI 10.1038/ng.2931; You JS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003459	39	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1510	1516		10.1016/j.ajpath.2018.03.010			7	Pathology	Pathology	GL7NE	WOS:000437387800001	29684361	Green Published			2019-10-28	
J	Keller, N; Andreoni, F; Reiber, C; Luethi-Schaller, H; Schuepbach, RA; Moch, H; Maggio, EM; Zinkernagel, AS				Keller, Nadia; Andreoni, Federica; Reiber, Claudine; Luethi-Schaller, Helga; Schuepbach, Reto Andreas; Moch, Holger; Maggio, Ewerton Marques; Zinkernagel, Annelies S.			Human Streptococcal Necrotizing Fasciitis Histopathology Mirrored in a Murine Model	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PYOGENES; DISEASE; CELLS	Streptococcal necrotizing fasciitis (NF) causes high morbidity and mortality despite state-of-the-art therapy. Low incidence and rapid disease progression, necessitating immediate initiation of therapy, have proven challenging aspects for setting up prospective randomized trials. This has resulted in little therapeutic progress over the past decade. The validation of reliable murine NF models to study both pathogenesis and optimized therapeutic regimens of streptococcal NF are thus essential. In this study, we characterized a murine NF model and compared the pathology with an in-depth tissue analysis of streptococcal NF in patients. We found that the streptococcal murine NF model closely reflected all histologic characteristics encountered in human streptococcal NF. This murine NE model helps understanding of human NE pathology better in a time-dependent manner and will allow studying novel therapeutic options in the future.	[Keller, Nadia; Andreoni, Federica; Reiber, Claudine; Zinkernagel, Annelies S.] Univ Hosp Zurich, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland; [Schuepbach, Reto Andreas] Univ Hosp Zurich, Inst Intens Care Med, Zurich, Switzerland; [Moch, Holger; Maggio, Ewerton Marques] Univ Hosp Zurich, Dept Pathol & Mol Pathol, Zurich, Switzerland; [Luethi-Schaller, Helga] Univ Zurich, Clin Prevent Dent Periodontol & Cariol, Div Oral Microbiol & Immunol, Ctr Dent Med, Zurich, Switzerland	Zinkernagel, AS (reprint author), Univ Zurich, Univ Hosp Zurich, Div Infect Dis & Hosp Epidemiol, Ramistr 100,U RAE, CH-8091 Zurich, Switzerland.	annelies.zinkernagel@usz.ch	Schuepbach, Reto A/J-9737-2012; Zinkernagel, Annelies/F-1780-2017	Schuepbach, Reto A/0000-0002-7058-4377; Zinkernagel, Annelies/0000-0003-4700-1118	Swiss National Science Foundation SNSFSwiss National Science Foundation (SNSF) [310030_146295/1, PZ00P3_136639]	Supported by Swiss National Science Foundation SNSF grants 310030_146295/1 (A.S.Z.) and PZ00P3_136639 (R.A.S.).	Andreoni F, 2017, J INFECT DIS, V215, P269, DOI 10.1093/infdis/jiw229; Andreoni F, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00339; BARKER FG, 1987, J CLIN PATHOL, V40, P335, DOI 10.1136/jcp.40.3.335; Chatellier S, 2000, INFECT IMMUN, V68, P3523, DOI 10.1128/IAI.68.6.3523-3534.2000; Gmur R, 2002, MICROBIOL-SGM, V148, P1379; Hietbrink F, 2016, WORLD J EMERG SURG, V11, DOI 10.1186/s13017-016-0108-z; Khamnuan P, 2015, RISK MANAG HEALTHC P, V8, P1, DOI 10.2147/RMHP.S77691; Lancerotto L, 2012, J TRAUMA ACUTE CARE, V72, P560, DOI 10.1097/TA.0b013e318232a6b3; Lepoutre A, 2011, J CLIN MICROBIOL, V49, P4094, DOI 10.1128/JCM.00070-11; Luca-Harari B, 2009, J CLIN MICROBIOL, V47, P1155, DOI 10.1128/JCM.02155-08; Medina E, 2003, J INFECT DIS, V187, P597, DOI 10.1086/373998; Ogawa T, 2011, MICROB PATHOGENESIS, V51, P58, DOI 10.1016/j.micpath.2011.03.009; Osterlund A, 1997, ACTA OTO-LARYNGOL, V117, P883, DOI 10.3109/00016489709114219; Plainvert C, 2012, CLIN MICROBIOL INFEC, V18, P702, DOI 10.1111/j.1469-0691.2011.03624.x; Siemens N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87882; Sriskandan S, 2006, J ANTIMICROB CHEMOTH, V58, P117, DOI 10.1093/jac/dkl173; STAMENKOVIC I, 1984, NEW ENGL J MED, V310, P1689, DOI 10.1056/NEJM198406283102601; Steer AC, 2012, DRUGS, V72, P1213, DOI 10.2165/11634180-000000000-00000; Stevens DL, 2014, CLIN INFECT DIS, V59, P147, DOI [10.1093/cid/ciu444, 10.1093/cid/ciu296]; Thulin P, 2006, PLOS MED, V3, P371, DOI 10.1371/journal.pmed.0030053	20	2	2	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1517	1523		10.1016/j.ajpath.2018.03.009			7	Pathology	Pathology	GL7NE	WOS:000437387800002	29684366				2019-10-28	
J	Zuiderwijk, M; Geerts, M; van Rhijn, CJ; van den Bogaerdt, A; Hamming, JF; van Dijk, RA; Lindeman, JH				Zuiderwijk, Melissa; Geerts, Marlieke; van Rhijn, Connie J.; van den Bogaerdt, Antoon; Hamming, Jaap F.; van Dijk, Rogier A.; Lindeman, Jan H.			Leukocyte Dynamics during the Evolution of Human Coronary Atherosclerosis Conclusions from a Sevenfold, Chromogen-Based, Immunohistochemical Evaluation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ARTERIES; TISSUE	Atherosclerosis is a complex process with strong inflammatory component. We developed a straightforward sevenfold staining protocol for simultaneous assessment of dominant leukocyte classes, vascularization, and expression of the putative foam cell maker CD36. The method was applied on human coronaries covering the full spectrum of atherosclerotic disease. Results confirm the progressive association of macrophages and T cells with the process and a global presence of mast cells. B cells are exclusively present in adventitial follicles that accompany the process plaque destabilization (thin cap and ruptured lesions) and are otherwise absent. Neutrophils are only present as part of the hemorrhage that accompanies plaque rupture. This study does not classify CD36 as a key factor in foam cell formation. Observed macrophage accumulation in the neointima of stabilized fibrous calcified plaques is consistent with a process of neoatherosclerosis. This study on human coronaries shows a progressive association of macrophage and T-cell abundance with plaque progression. Follicle-like structures are transiently present during the process of plaque destabilization. Plaque healing is accompanied by cessation of the inflammatory response but followed by a new cycle of atherosclerosis.	[Zuiderwijk, Melissa; Geerts, Marlieke; van Rhijn, Connie J.; Hamming, Jaap F.; van Dijk, Rogier A.; Lindeman, Jan H.] Leiden Univ, Med Ctr, Dept Surg, Einthoven Lab Cardiovasc Med,Div Vasc Surg, Leiden, Netherlands; [van den Bogaerdt, Antoon] Euro Heart Valve Bank, Beverwijk, Netherlands	Lindeman, JH (reprint author), Leiden Univ, Med Ctr, Div Vasc Surg, Einthoven Lab Cardiovasc Med, POB 9600, NL-2300 RC Leiden, Netherlands.	lindeman@lumc.nl		Zuiderwijk, Melissa/0000-0001-8532-1417	European Commission Cartardis HEALTH.2013.2.4.2-1	Supported, in part, by the European Commission Cartardis FP7 HEALTH.2013.2.4.2-1.	Chistiakov DA, 2015, EXP MOL PATHOL, V99, P663, DOI 10.1016/j.yexmp.2015.11.011; DeBakey ME, 2000, AM J CARDIOL, V85, P1045, DOI 10.1016/S0002-9149(00)00694-9; Di Angelantonio E, 2012, JAMA-J AM MED ASSOC, V307, P2499, DOI 10.1001/jama.2012.6571; Gonzalez Jose M Jr, 2016, Mol Vis, V22, P203; KITTELBERGER R, 1989, ACTA HISTOCHEM, V86, P137, DOI 10.1016/S0065-1281(89)80082-0; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Monici M, 2005, BIOTECHNOL ANN REV, V11, P227, DOI 10.1016/S1387-2656(05)11007-2; Otsuka F, 2015, EUR HEART J, V36, P2147, DOI 10.1093/eurheartj/ehv205; Park YM, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.38; Pryshchep O, 2008, CIRCULATION, V118, P1276, DOI 10.1161/CIRCULATIONAHA.108.789172; STARY HC, 1992, CIRCULATION, V85, P391, DOI 10.1161/01.CIR.85.1.391; Suvarna SK, 2013, BANCROFTS THEORY PRA; van Dijk RA, 2016, J AM HEART ASSOC, P5; van Dijk RA, 2015, J AM HEART ASSOC, P4; VANDERLOOS CM, 1993, HISTOCHEM J, V25, P1; Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538; Xu JY, 2015, INT J MOL SCI, V16, P11574, DOI 10.3390/ijms160511574; Yahagi K, 2016, NAT REV CARDIOL, V13, P79, DOI 10.1038/nrcardio.2015.164	18	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1524	1529		10.1016/j.ajpath.2018.03.011			6	Pathology	Pathology	GL7NE	WOS:000437387800003	29684365				2019-10-28	
J	Noe, M; Rezaee, N; Asrani, K; Skaro, M; Groott, VP; Wu, PH; Olson, MT; Hong, SM; Kim, SJ; Weiss, MJ; Wolfgang, CL; Makary, MA; He, J; Cameron, JL; Wirtz, D; Roberts, NJ; Offerhaus, GJA; Brosens, LAA; Wood, LD; Hruban, RH				Noe, Michael; Rezaee, Neda; Asrani, Kaushal; Skaro, Michael; Groott, Vincent P.; Wu, Pei-Hsun; Olson, Matthew T.; Hong, Seung-Mo; Kim, Sung Joo; Weiss, Matthew J.; Wolfgang, Christopher L.; Makary, Martin A.; He, Jin; Cameron, John L.; Wirtz, Denis; Roberts, Nicholas J.; Offerhaus, G. Johan A.; Brosens, Lodewijk A. A.; Wood, Laura D.; Hruban, Ralph H.			Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NUDE-MOUSE MODEL; TISSUE; ADENOCARCINOMA; CANCER; SPECIMENS; MICE; HISTOLOGY; TUMORS; DUCT	Visualizing pathologies in three dimensions can provide unique insights into the biology of human diseases. A rapid and easy-to-implement dibenzyl ether-based technique was used to clear thick sections of surgically resected human pancreatic parenchyma. Protocols were applicable to both fresh and formalin-fixed, paraffin-embedded tissue. The penetration of antibodies into dense pancreatic parenchyma was optimized using both gradually increasing antibody concentrations and centrifugal flow. Immunolabeling with antibodies against cytokeratin 19 was visualized using both light sheet and confocal laser scanning microscopy. The technique was applied successfully to 26 sections of pancreas, providing three-dimensional (3D) images of normal pancreatic tissue, pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms, and infiltrating pancreatic ductal. adenocarcinomas. 3D visualization highlighted processes that are hard to conceptualize in two dimensions, such as invasive carcinoma growing into what appeared to be pre-existing pancreatic ducts and within venules, and the tracking of long cords of neoplastic cells parallel to blood vessels. Expanding this technique to formalin-fixed, paraffin-embedded tissue opens pathology archives to 3D visualization of unique biosamples and rare diseases. The application of immunolabeling and clearing to human pancreatic parenchyma provides detailed visualization of normal pancreatic anatomy, and can be used to characterize the 3D architecture of diseases including pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and pancreatic ductal adenocarcinomas.	[Noe, Michael; Asrani, Kaushal; Skaro, Michael; Olson, Matthew T.; Wirtz, Denis; Roberts, Nicholas J.; Wood, Laura D.; Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Noe, Michael; Roberts, Nicholas J.; Wood, Laura D.; Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Rezaee, Neda; Groott, Vincent P.; Weiss, Matthew J.; Wolfgang, Christopher L.; Makary, Martin A.; He, Jin; Cameron, John L.] Johns Hopkins Univ, Sch Med, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Wu, Pei-Hsun; Wirtz, Denis] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD USA; [Hong, Seung-Mo; Kim, Sung Joo] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea; [Offerhaus, G. Johan A.; Brosens, Lodewijk A. A.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands	Hruban, RH (reprint author), Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Carnegie 415,600 N Wolfe St, Baltimore, MD 21287 USA.; Wood, LD (reprint author), Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, CRB2 Room 345,1550 Orleans St, Baltimore, MD 21287 USA.	ldwood@jhmi.edu; rhruban@jhmi.edu		Roberts, Nicholas/0000-0002-8709-0664; Noe, Michael/0000-0002-5336-4508; Groot, Vincent P./0000-0003-2102-3140; Hong, Seung-Mo/0000-0002-8888-6007	Sol Goldman Pancreatic Cancer Research Center, Specialized Programs of Research Excellence (SPORE) in Gastro-Intestinal (GI) Cancer grant [CA 62924]; Rolfe Foundation for Pancreatic Cancer Research; NIH/National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K08 DK107781]; Buffone Family Gastrointestinal Cancer Research Fund; Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention; American Gastroenterological Association (AGA)-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer; Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award; American Association for Cancer Research (AACR) Incyte Corporation Career Development Award for Pancreatic Cancer Research; Joseph C. Monastra Foundation; Gerald O. Mann Charitable Foundation; Dutch Digestive Foundation [MLDS CDG 14-020]; Nijbakker-Morra Foundation; Lisa Waller Hayes Foundation; NLH/National Cancer Institute [R00 CA190889]	Supported by the Sol Goldman Pancreatic Cancer Research Center, Specialized Programs of Research Excellence (SPORE) in Gastro-Intestinal (GI) Cancer grant CA 62924, Susan Wojcicki and Dennis Troper, Rolfe Foundation for Pancreatic Cancer Research, NIH/National Institute of Diabetes and Digestive and Kidney Diseases grant K08 DK107781, Buffone Family Gastrointestinal Cancer Research Fund, Kaya Tuncer Career Development Award in Gastrointestinal Cancer Prevention, American Gastroenterological Association (AGA)-Bernard Lee Schwartz Foundation Research Scholar Award in Pancreatic Cancer, Sidney Kimmel Foundation for Cancer Research Kimmel Scholar Award, American Association for Cancer Research (AACR) Incyte Corporation Career Development Award for Pancreatic Cancer Research, Joseph C. Monastra Foundation, and The Gerald O. Mann Charitable Foundation (Harriet and Allan Wulfstat, Trustees) (L.D.W.); The Dutch Digestive Foundation grant MLDS CDG 14-020 (L.A.A.B.); The Nijbakker-Morra Foundation and The Lisa Waller Hayes Foundation (M.N.); and NIH/National Cancer Institute grant R00 CA190889 (N.R.).	Azaripour A, 2016, PROG HISTOCHEM CYTO, V51, P9, DOI 10.1016/j.proghi.2016.04.001; Becker K, 2008, J BIOPHOTONICS, V1, P36, DOI 10.1002/jbio.200710011; Benias PC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23062-6; Boj SF, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1014757; Calve S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116662; Flessner MF, 2005, CLIN CANCER RES, V11, P3117, DOI 10.1158/1078-0432.CCR-04-2332; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hiroshima Y, 2015, J SURG ONCOL, V111, P311, DOI 10.1002/jso.23816; Hruban RH, 2014, SEMIN DIAGN PATHOL, V31, P443, DOI 10.1053/j.semdp.2014.08.004; Lee E, 2016, SCI REP-UK, V6, DOI 10.1038/srep18631; Lee H, 2014, BMC DEV BIOL, V14, DOI 10.1186/s12861-014-0048-3; Lin PY, 2016, AM J PHYSIOL-GASTR L, V311, pG412, DOI 10.1152/ajpgi.00071.2016; Qiu H, 2012, RADIOTHER ONCOL, V104, P167, DOI 10.1016/j.radonc.2012.07.004; Renier N, 2014, CELL, V159, P896, DOI 10.1016/j.cell.2014.10.010; Richardson DS, 2017, CELL, V171, P496, DOI 10.1016/j.cell.2017.09.025; Richardson DS, 2015, CELL, V162, P246, DOI 10.1016/j.cell.2015.06.067; Seo J, 2016, MOL CELLS, V39, P439, DOI 10.14348/molcells.2016.0088; Sharma S, 2004, AM J SURG PATHOL, V28, P613, DOI 10.1097/00000478-200405000-00008; Tanaka N, 2017, NAT BIOMED ENG, V1, P796, DOI 10.1038/s41551-017-0139-0; Tang SC, 2018, DIABETOLOGIA, V61, P158, DOI 10.1007/s00125-017-4408-y; Weller CV, 1921, SCI MO, V13, P33	23	4	4	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1530	1535		10.1016/j.ajpath.2018.04.002			6	Pathology	Pathology	GL7NE	WOS:000437387800004	29684363	Green Published			2019-10-28	
J	Seamons, A; Treuting, PM; Meeker, S; Hsu, C; Paik, J; Brabb, T; Escobar, SS; Alexander, JS; Ericsson, AC; Smith, JG; Maggio-Price, L				Seamons, Audrey; Treuting, Piper M.; Meeker, Stacey; Hsu, Charlie; Paik, Jisun; Brabb, Thea; Escobar, Sabine S.; Alexander, Jonathan S.; Ericsson, Aaron C.; Smith, Jason G.; Maggio-Price, Lillian			Obstructive Lymphangitis Precedes Colitis in Murine Norovirus-Infected Stat1-Deficient Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INFLAMMATORY-BOWEL-DISEASE; COLONY-STIMULATING FACTOR; CROHNS-DISEASE; LYMPHATIC VESSELS; REGIONAL ILEITIS; VIRUSES; LYMPHANGIOGENESIS; PATHOGENESIS; TISSUE; MODEL	Murine norovirus (MNV) is an RNA virus that can prove lethal. in mice with impaired innate immunity. We found that MNV-4 infection of Stat1(-/-) mice was not lethal, but produced a 100% penetrant, previously undescribed lymphatic phenotype characterized by chronic-active lymphangitis with hepatitis, splenitis, and chronic cecal and colonic inflammation. Lesion pathogenesis progressed from early ileal enteritis and regional dilated Lymphatics to Lymphangitis, granulomatous changes in the liver and spleen, and, ultimately, typhlocolitis. Lesion development was neither affected by antibiotics nor reproduced by infection with another enteric RNA virus, rotavirus. MNV-4 infection in Stat1(-/-) mice decreased expression of vascular endothelial growth factor (Vegf) receptor 3, Vegf-c, and Vegf-d and increased interferon (Ifn)-gamma, tumor necrosis factor-alpha, and inducible nitric oxide synthase. However, anti-IFN-gamma and anti-tumor necrosis factor-alpha antibody treatment did not attenuate the histologic Lesions. Studies in Ifn alpha beta gamma r(-/-) mice suggested that canonical signaling via interferon receptors did not cause MNV-4-induced disease. Infected Stat1(-/-) mice had increased STAT3 phosphorylation and expressed many STAT3-regulated genes, consistent with our findings of increased myeloid cell subsets and serum granulocyte colony-stimulating factor, which are also associated with increased STAT3 activity. In conclusion, in Stat1(-/-) mice, MNV-4 induces lymphatic lesions similar to those seen in Crohn disease as well as hepatitis, splenitis, and typhlocolitis. MNV-4-infected Stat1(-/-) mice may be a useful model to study mechanistic associations between viral infections, lymphatic dysfunction, and intestinal inflammation in a genetically susceptible host.	[Seamons, Audrey; Treuting, Piper M.; Meeker, Stacey; Hsu, Charlie; Paik, Jisun; Brabb, Thea; Escobar, Sabine S.; Maggio-Price, Lillian] Univ Washington, Dept Comparat Med, Campus Box 357340,1959 NE Pacific St, Seattle, WA 98195 USA; [Smith, Jason G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Alexander, Jonathan S.] Louisiana State Univ, Dept Mol & Cellular Physiol, Shreveport, LA 71105 USA; [Ericsson, Aaron C.] Univ Missouri, Dept Vet Pathobiol, Columbia, MO USA	Seamons, A (reprint author), Univ Washington, Dept Comparat Med, Campus Box 357340,1959 NE Pacific St, Seattle, WA 98195 USA.	auds@uw.edu	Treuting, Piper M./AAB-2721-2019	Treuting, Piper M./0000-0002-1812-1519; Smith, Jason/0000-0001-6727-5269; Seamons, Audrey/0000-0003-2609-1230	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-OD011149, K01 OD021420]; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0577]	Supported by NIH grants R01-OD011149 (L.M.-P.) and K01 OD021420 (S.M.), and Department of Defense grant W81XWH-11-1-0577 (J.S.A.).	Abe K, 2007, P NATL ACAD SCI USA, V104, P17022, DOI 10.1073/pnas.0708469104; Ai J, 2008, J LEUKOCYTE BIOL, V83, P1277, DOI 10.1189/jlb.1107751; Alexander JS, 2010, ANN NY ACAD SCI, V1207, pE75, DOI 10.1111/j.1749-6632.2010.05757.x; Algaba Alicia, 2013, J Crohns Colitis, V7, pe569, DOI 10.1016/j.crohns.2013.04.005; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Basic M, 2014, INFLAMM BOWEL DIS, V20, P431, DOI 10.1097/01.MIB.0000441346.86827.ed; Becker F, 2014, LYMPHOLOGY, V47, P3; Becker F, 2015, INFLAMM BOWEL DIS, V21, P1282, DOI 10.1097/MIB.0000000000000371; Bernstein CN, 2000, INFLAMM BOWEL DIS, V6, P34, DOI 10.1097/00054725-200002000-00005; Bosca-Watts Marta Maia, 2015, World J Gastrointest Pathophysiol, V6, P1, DOI 10.4291/wjgp.v6.i1.1; Bovolenta C, 1996, FEBS LETT, V386, P239, DOI 10.1016/0014-5793(96)00453-X; Bressenot A, 2015, INFLAMM BOWEL DIS, V21, P468, DOI 10.1097/MIB.0000000000000224; Chen YX, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12364; CHESS S, 1950, SURGERY, V27, P221; Crohn BB, 1932, J AMER MED ASSOC, V99, P1323, DOI 10.1001/jama.1932.02740680019005; Cromer W, 2015, INFLAMM BOWEL DIS, V21, P1553, DOI 10.1097/MIB.0000000000000402; Cromer WE, 2014, ANGIOGENESIS, V17, P395, DOI 10.1007/s10456-013-9393-2; D'Alessio S, 2014, J CLIN INVEST, V124, P3863, DOI 10.1172/JCI72189; Ericsson AC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116704; Ericsson AC, 2010, NEOPLASIA, V12, P1054, DOI 10.1593/neo.10940; Geleff S, 2003, VIRCHOWS ARCH, V442, P231, DOI 10.1007/s00428-002-0744-4; Gounder AP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005474; Hall KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031794; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; Holm TL, 2012, INT J INFLAMM, DOI 10.1155/2012/412178; Hsu CC, 2016, VET PATHOL, V53, P754, DOI 10.1177/0300985815618439; Hsu CC, 2005, CLIN DIAGN LAB IMMUN, V12, P1145, DOI 10.1128/CDLI.12.10.1145-1151.2005; Hsu CC, 2006, COMPARATIVE MED, V56, P247; Hsu CC, 2018, VIROLOGY, V515, P123, DOI 10.1016/j.virol.2017.12.013; Hsu CC, 2015, COMPARATIVE MED, V65, P369; Hsu CC, 2014, COMPARATIVE MED, V64, P256; Hubbard VM, 2011, VIRUSES-BASEL, V3, P1281, DOI 10.3390/v3071281; Hwang S., 2014, CURR PROTOC MICROBIO, V33, DOI DOI 10.1002/9780471729259.MC15K02S33; Jurisic G, 2010, GENES IMMUN, V11, P219, DOI 10.1038/gene.2010.4; Jurisic G, 2013, INFLAMM BOWEL DIS, V19, P1983, DOI 10.1097/MIB.0b013e31829292f7; KALIMA T V, 1970, Annales Chirurgiae et Gynaecologiae Fenniae, V59, P187; KALIMA TV, 1976, SCAND J GASTROENTERO, V11, P353; Kallal Lara E, 2013, JAKSTAT, V2, pe23504, DOI 10.4161/jkst.23504; Kamezaki K, 2005, STEM CELLS, V23, P252, DOI 10.1634/stemcells.2004-0173a; Karst SM, 2003, SCIENCE, V299, P1575, DOI 10.1126/science.1077905; Kesler CT, 2013, WIRES SYST BIOL MED, V5, P111, DOI 10.1002/wsbm.1201; Khan RR, 2009, J PEDIATR GASTR NUTR, V48, P328, DOI 10.1097/MPG.0b013e31818255cc; Lee M, 2014, NAT IMMUNOL, V15, P982, DOI 10.1038/ni.2983; Lencioni KC, 2008, COMPARATIVE MED, V58, P522; Li J, 2016, INFLAMM BOWEL DIS, V22, P1540, DOI 10.1097/MIB.0000000000000785; Li Y, 2016, INFLAMM BOWEL DIS, V22, P1483, DOI 10.1097/MIB.0000000000000791; LOCKHART.HE, 1964, GUT, V5, P493, DOI 10.1136/gut.5.6.493; Lopetuso LR, 2016, INFLAMM BOWEL DIS, V22, P1708, DOI 10.1097/MIB.0000000000000807; Lopman BA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001999; Lovato P, 2003, J BIOL CHEM, V278, P16777, DOI 10.1074/jbc.M207999200; Masclee GMC, 2013, INFLAMM BOWEL DIS, V19, P124, DOI 10.1002/ibd.22976; MCNEAL MM, 1994, VIROLOGY, V204, P642, DOI 10.1006/viro.1994.1579; Meeker S, 2014, CANCER RES, V74, P4398, DOI 10.1158/0008-5472.CAN-13-2820; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; Min Y, 2011, ONCOGENE, V30, P4901, DOI 10.1038/onc.2011.187; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Nieminen JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070738; Norman JM, 2015, CELL, V160, P447, DOI 10.1016/j.cell.2015.01.002; O'Donnell LC, 2002, J LEUKOCYTE BIOL, V72, P478; Paik J, 2015, GUT MICROBES, V6, P255, DOI 10.1080/19490976.2015.1064576; Paik J, 2015, COMPARATIVE MED, V65, P114; Paik J, 2011, COMPARATIVE MED, V61, P330; Pedica F, 2008, VIRCHOWS ARCH, V452, P57, DOI 10.1007/s00428-007-0540-2; Rahier JF, 2011, ALIMENT PHARM THER, V34, P533, DOI 10.1111/j.1365-2036.2011.04759.x; Randolph GJ, 2016, AM J PATHOL, V186, P3066, DOI 10.1016/j.ajpath.2016.07.026; Rutella S, 2005, J IMMUNOL, V175, P7085, DOI 10.4049/jimmunol.175.11.7085; Sartor RB, 2017, GASTROENTEROLOGY, V152, P327, DOI 10.1053/j.gastro.2016.10.012; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shortland A, 2014, J GEN VIROL, V95, P413, DOI 10.1099/vir.0.059188-0; Smither SJ, 2013, J VIROL METHODS, V193, P565, DOI 10.1016/j.jviromet.2013.05.015; Sura R, 2011, ALIMENT PHARM THER, V33, P930, DOI 10.1111/j.1365-2036.2011.04605.x; Tillinger W, 2009, AM J GASTROENTEROL, V104, P102, DOI 10.1038/ajg.2008.6; Tonelli F, 2012, WORLD J GASTRO SURG, V4, P228, DOI 10.4240/wjgs.v4.i10.228; Van Kruiningen HJ, 2008, GUT, V57, P1; Van Kruiningen HJ, 2016, INFLAMM BOWEL DIS, V22, P2106, DOI 10.1097/MIB.0000000000000831; Van Kruiningen HJ, 2015, CLIN GASTROENTEROL H, V13, P2381, DOI 10.1016/j.cgh.2015.07.001; VANDENBROEK MF, 1995, J VIROL, V69, P4792; von der Weid PY, 2011, CURR OPIN GASTROEN, V27, P335, DOI 10.1097/MOG.0b013e3283476e8f; Wang WW, 2015, INFLAMM BOWEL DIS, V21, P1419, DOI 10.1097/MIB.0000000000000344; Wang XL, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20154738; WARREN S, 1948, AM J PATHOL, V24, P475; Weiss G, 2011, CYTOKINE, V56, P520, DOI 10.1016/j.cyto.2011.07.024; Wen Zhonghui, 2004, Clin Dev Immunol, V11, P195, DOI 10.1080/17402520400004201; Wu TF, 2006, AM J PHYSIOL-GASTR L, V291, pG566, DOI 10.1152/ajpgi.00058.2006; Yan CG, 2015, EXP CELL RES, V337, P120, DOI 10.1016/j.yexcr.2015.07.017; Zhang Q, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2326	86	2	2	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1536	1554		10.1016/j.ajpath.2018.03.019			19	Pathology	Pathology	GL7NE	WOS:000437387800005	29753791	Green Published			2019-10-28	
J	Wang, CS; Baker, OJ				Wang, Ching-Shuen; Baker, Olga J.			The G-Protein-Coupled Receptor ALX/Fpr2 Regulates Adaptive Immune Responses in Mouse Submandibular Glands	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PRIMARY SJOGRENS-SYNDROME; RESOLVIN E1 RVE1; LIPOXIN A(4); SALIVARY-GLAND; LIPID MEDIATORS; POTENTIAL ROLE; B-LYMPHOCYTES; INFLAMMATION; RESOLUTION; EXPRESSION	Lipoxin receptor (ALX)/N-formyl peptide receptor (FPR)-2 is a G-protein-coupled receptor that has multiple binding partners, including the endogenous lipid mediators resolvin D1, lipoxin A(4), and the Ca2+-dependent phospholipid-binding protein annexin Al. Previous studies have demonstrated that resolvin DI activates ALX/Fpr2 to resolve salivary gland inflammation in the NOD/ShiLtJ mouse model of Sjogren syndrome. Moreover, mice lacking the ALX/Fpr2 display an exacerbated salivary gland inflammation in response to lipopolysaccharide. Additionally, activation of ALX/Fpr2 has been shown to be important for regulating antibody production in B cells. These previous studies indicate that ALX/Fpr2 promotes resolution of salivary gland inflammation while modulating adaptive immunity, suggesting the need for investigation of the role of ALX/Fpr2 in regulating antibody production and secretory function in mouse salivary glands. Our results indicate that aging female knockout mice lacking ALX/Fpr2 display a significant reduction in saliva flow rates and weight loss, an increased expression of autoimmune-associated genes, an up-regulation of autoantibody production, and increased CD20-positive B-cell population. Although not all effects were noted among the male knockout mice, the results nonetheless indicate that ALX/Fpr2 is clearly involved in the adaptive immunity and secretory function in salivary glands, with further investigation warranted to determine the cause(s) of these between sex differences.	[Wang, Ching-Shuen; Baker, Olga J.] Univ Utah, Sch Dent, 383 Colorow Dr, Salt Lake City, UT 84108 USA	Baker, OJ (reprint author), Univ Utah, Sch Dent, 383 Colorow Dr, Salt Lake City, UT 84108 USA.	olga.baker@hsc.utah.edu			NIH-National Institute of Dental and Craniofacial ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [R01DE021697, R01DE021697S1, R56DE02169707A1, R01 DE02297107]	Supported by NIH-National Institute of Dental and Craniofacial Research grants R01DE021697, R01DE021697S 1, R56DE02169707A1, and R01 DE02297107 (O.J.B).	ADAMSON TC, 1983, J IMMUNOL, V130, P203; Ariel A, 2003, J IMMUNOL, V170, P6266, DOI 10.4049/jimmunol.170.12.6266; Ariel A, 2007, TRENDS IMMUNOL, V28, P176, DOI 10.1016/j.it.2007.02.007; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Baker OJ, 2008, AM J PHYSIOL-CELL PH, V295, pC1191, DOI 10.1152/ajpcell.00144.2008; Bannenberg G, 2007, THESCIENTIFICWORLDJO, V7, P1440, DOI 10.1100/tsw.2007.188; Bannenberg G, 2010, BBA-MOL CELL BIOL L, V1801, P1260, DOI 10.1016/j.bbalip.2010.08.002; Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Borgeson E, 2012, FASEB J, V26, P4287, DOI 10.1096/fj.12-208249; Bombardieri M, 2012, J IMMUNOL, V189, P3767, DOI 10.4049/jimmunol.1201216; Bozinovski S, 2012, P NATL ACAD SCI USA, V109, P935, DOI 10.1073/pnas.1109382109; Brandtzaeg P, 2013, J ORAL MICROBIOL, V5, DOI 10.3402/jom.v5i0.20401; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; CHAN EKL, 1992, RHEUM DIS CLIN N AM, V18, P551; Cheema GS, 2001, ARTHRITIS RHEUM-US, V44, P1313, DOI 10.1002/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S; Cortina MS, 2011, CURR OPIN CLIN NUTR, V14, P132, DOI 10.1097/MCO.0b013e328342bb1a; Cuello C, 1998, BRIT J RHEUMATOL, V37, P779; Daridon C, 2007, ARTHRITIS RHEUM, V56, P1134, DOI 10.1002/art.22458; de Oliveira JR, 2015, BIOMED RES INT, DOI 10.1155/2015/178369; de Paiva CS, 2012, CORNEA, V31, P1299, DOI 10.1097/ICO.0b013e31823f789e; Dmitrieva N, 2014, FERTIL STERIL, V102, P1191, DOI 10.1016/j.fertnstert.2014.06.046; Dondoni L, 2014, INT ENDOD J, V47, P827, DOI 10.1111/iej.12224; Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526; Easley JT, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12990; Fredman G, 2011, ENDOD TOP, V24, P39; Gordon TP, 2001, AUTOIMMUNITY, V34, P123, DOI 10.3109/08916930109001960; GREENSPAN JS, 1974, ORAL SURG ORAL MED O, V37, P217, DOI 10.1016/0030-4220(74)90417-4; GUMPEL JM, 1970, ANN RHEUM DIS, V29, P681, DOI 10.1136/ard.29.6.681; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hasturk H, 2015, ARTERIOSCL THROM VAS, V35, P1123, DOI 10.1161/ATVBAHA.115.305324; He J, 2012, CLIN EXP RHEUMATOL, V30, P322; Hodges RR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36124; Jamin C, 2008, ARTHRITIS RHEUM-US, V58, P1900, DOI 10.1002/art.23487; Jin L, 2014, INT J CLIN EXP PATHO, V7, P1988; Lee KE, 2016, J KOREAN MED SCI, V31, P190, DOI 10.3346/jkms.2016.31.2.190; Leigh NJ, 2014, J DENT RES, V93, P300, DOI 10.1177/0022034513519108; Levy BD, 2007, FASEB J, V21, P3877, DOI 10.1096/fj.07-8653com; LEVY Y, 1994, CLIN EXP RHEUMATOL, V12, P543; Mackay F, 2002, TRENDS IMMUNOL, V23, P113, DOI 10.1016/S1471-4906(01)02159-7; Mitani Y, 2014, CLIN CANCER RES, V20, P6570, DOI 10.1158/1078-0432.CCR-14-1746; Nam K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187069; Nelson JW, 2014, AM J PHYSIOL-CELL PH, V306, pC178, DOI 10.1152/ajpcell.00284.2013; Odusanwo O, 2012, AM J PHYSIOL-CELL PH, V302, pC1331, DOI 10.1152/ajpcell.00207.2011; Ramon S, 2014, EUR J IMMUNOL, V44, P357, DOI 10.1002/eji.201343316; Robinson CP, 1998, ADV EXP MED BIOL, V438, P493; Rogerio AP, 2012, J IMMUNOL, V189, P1983, DOI 10.4049/jimmunol.1101665; Salomonsson S, 2002, SCAND J IMMUNOL, V55, P336, DOI 10.1046/j.1365-3083.2002.01058.x; Serhan Charles N, 2006, Anesthesiol Clin, V24, P341, DOI 10.1016/j.atc.2006.01.003; Shen L, 2012, CLIN IMMUNOL, V145, P251, DOI 10.1016/j.clim.2012.09.013; Sistig S, 2002, ORAL DIS, V8, P282, DOI 10.1034/j.1601-0825.2002.20844.x; Theander E, 2011, ANN RHEUM DIS, V70, P1363, DOI 10.1136/ard.2010.144782; Tsuboi H, 2012, MOD RHEUMATOL, V22, P264, DOI 10.1007/s10165-011-0514-8; Voigt A, 2015, BIOL OPEN, V4, P1410, DOI 10.1242/bio.013771; Wang CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02593-4; Wang CS, 2016, SCI REP-UK, V6, DOI 10.1038/srep24244; Xu ZZ, 2010, NAT MED, V16, P592, DOI 10.1038/nm.2123; Zhang L, 2008, INFLAMM RES, V57, P157, DOI 10.1007/s00011-007-7141-z; Zheng NY, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0064-y	58	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1555	1562		10.1016/j.ajpath.2018.04.003			8	Pathology	Pathology	GL7NE	WOS:000437387800006	29684359	Green Published			2019-10-28	
J	Paschalis, EI; Lei, FY; Zhou, CX; Kapoulea, V; Thanos, A; Dana, R; Vavvas, DG; Chodosh, J; Dohlman, CH				Paschalis, Eleftherios, I; Lei, Fengyang; Zhou, Chengxin; Kapoulea, Vassiliki; Thanos, Aristomenis; Dana, Reza; Vavvas, Demetrios G.; Chodosh, James; Dohlman, Claes H.			The Role of Microglia and Peripheral Monocytes in Retinal Damage after Corneal Chemical Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; TNF-ALPHA; GLUTAMATE RELEASE; ALKALI BURN; BRAIN; DISEASE; CELLS; MODEL; EYE; NEUROTOXICITY	Eyes that have experienced alkali burn to the surface are excessively susceptible to subsequent severe glaucoma and retinal ganglion cell loss, despite maximal efforts to prevent or slow down the disease. Recently, we have shown, in mice and rabbits, that such retinal damage is neither mediated by the alkali itself reaching the retina nor by intraocular pressure elevation. Rather, it is caused by the up-regulation of tumor necrosis factor-alpha (TNF-alpha), which rapidly diffuses posteriorly, causing retinal ganglion cell apoptosis and CD45(+) cell activation. Herein, we investigated the involvement of peripheral blood monocytes and microglia in retinal damage. Using CX3CR1(+)(/EGFP)::CCR2(+/)(RFP) reporter mice and bone marrow chimeras, we show that peripheral CX3CRI(+) CD45(hi) CD11b(+) MHC-II+ monocytes infiltrate into the retina from the optic nerve at 24 hours after the burn and release further TNF-alpha. A secondary source of peripheral monocyte response originates from a rare population of patrolling myeloid CCR2(+) cells of the retina that differentiate into CX3CR1(+) macrophages within hours after the injury. As a result, CX3CR1(+) CD45(lo)CD11b(+) microglia become reactive at 7 days, causing further TNF-alpha release. Prompt INF-alpha inhibition after corneal burn suppresses monocyte infiltration and microglia activation, and protects the retina. This study may prove relevant to other injuries of the central nervous system.	[Paschalis, Eleftherios, I; Lei, Fengyang; Zhou, Chengxin; Kapoulea, Vassiliki; Chodosh, James] Harvard Med Sch, Massachusetts Eye & Ear, Disrupt Technol Lab, Boston, MA 02114 USA; [Thanos, Aristomenis; Vavvas, Demetrios G.] Harvard Med Sch, Massachusetts Eye & Ear, Angiogenesis Lab, Boston, MA 02114 USA; [Paschalis, Eleftherios, I; Lei, Fengyang; Zhou, Chengxin; Kapoulea, Vassiliki; Dana, Reza; Chodosh, James; Dohlman, Claes H.] Harvard Med Sch, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA; [Paschalis, Eleftherios, I; Lei, Fengyang; Zhou, Chengxin; Kapoulea, Vassiliki; Dohlman, Claes H.] Harvard Med Sch, Boston Keratoprosthesis Lab, Massachusetts Eye & Ear Schepens Eye Res Inst, Boston, MA 02114 USA	Paschalis, EI (reprint author), Harvard Med Sch, Massachusetts Eye & Ear & Schepens Eye Res Inst, Boston Keratoprosthesis Lab, Dept Ophthalmol, 3rd Floor ICPro,20 Staniford St, Boston, MA 02114 USA.	eleftherios_paschalis@meei.harvard.edu		Paschalis, Eleftherios/0000-0002-4544-4452; Vavvas, Demetrios/0000-0002-8622-6478	Boston Keratoprosthesis Research Fund; Massachusetts Eye and Ear; Eleanor and Miles Shore Fund; Massachusetts Lions Eye Research Fund; Research to Prevent Blindness (New York, NY)Research to Prevent Blindness (RPB); NIH National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY003790]	Supported by Boston Keratoprosthesis Research Fund, Massachusetts Eye and Ear, the Eleanor and Miles Shore Fund, the Massachusetts Lions Eye Research Fund, Research to Prevent Blindness (New York, NY) unrestricted grant to the Department of Ophthalmology, Harvard Medical School, and NIH National Eye Institute core grant P30EY003790.	Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Arnoux I, 2015, NEURAL PLAST, DOI 10.1155/2015/689404; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boivin N, 2012, J GEN VIROL, V93, P1294, DOI 10.1099/vir.0.041046-0; Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cade F, 2014, CORNEA, V33, P382, DOI 10.1097/ICO.0000000000000071; Cade F, 2011, CORNEA, V30, P1322, DOI 10.1097/ICO.0b013e31821eead6; Chinnery HR, 2007, INVEST OPHTH VIS SCI, V48, P1568, DOI 10.1167/iovs.06-0746; Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council, 2011, GUIDE CARE USE LAB A; Crnej A, 2014, CORNEA, V33, P349, DOI 10.1097/ICO.0000000000000067; Crotti A, 2016, IMMUNITY, V44, P505, DOI 10.1016/j.immuni.2016.02.013; Dheen ST, 2007, CURR MED CHEM, V14, P1189; Dohlman CH, 2018, CORNEA, V37, P248, DOI 10.1097/ICO.0000000000001438; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Guadagno J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.59; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kezic J, 2008, J LEUKOCYTE BIOL, V84, P721, DOI 10.1189/jlb.0308166; Kierdorf K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058544; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Le YY, 2004, CELL MOL IMMUNOL, V1, P95; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Mittal R, 2010, J EXP MED, V207, P1307, DOI 10.1084/jem.20092265; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Nakazawa T, 2011, INVEST OPHTH VIS SCI, V52, P1384, DOI 10.1167/iovs.10-6509; Paschalis EI, 2017, AM J PATHOL, V187, P1327, DOI 10.1016/j.ajpath.2017.02.005; Pelus LM, 2006, EXP HEMATOL, V34, P1010, DOI 10.1016/j.exphem.2006.04.004; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Ransohoff RM, 2012, J CLIN INVEST, V122, P1164, DOI 10.1172/JCI58644; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065; Rossi D, 2009, BRAIN RES BULL, V80, P224, DOI 10.1016/j.brainresbull.2009.07.012; Sajja VSSS, 2016, FRONT INTEGR NEUROSC, V10, DOI [10.3389/fnint.2016.00007, 10.3389/fnint.7016.00007]; Salter MW, 2017, NAT MED, V23, P1018, DOI 10.1038/nm.4397; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SMITH RE, 1976, ARCH OPHTHALMOL-CHIC, V94, P81; Son JL, 2010, GLIA, V58, P780, DOI 10.1002/glia.20962; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; Vesce S, 2007, INT REV NEUROBIOL, V82, P57, DOI 10.1016/S0074-7742(07)82003-4; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Zhou CX, 2017, INVEST OPHTH VIS SCI, V58, P96, DOI 10.1167/iovs.16-20339	51	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1580	1596		10.1016/j.ajpath.2018.03.005			17	Pathology	Pathology	GL7NE	WOS:000437387800008	29630857	Green Published			2019-10-28	
J	Wang, CQ; Zhang, JT; Fok, KL; Tsang, LL; Ye, M; Liu, JN; Li, FH; Zhao, AZ; Chan, HC; Chen, H				Wang, Chaoqun; Zhang, Jieting; Fok, Kin L.; Tsang, Lai L.; Ye, Mei; Liu, Jianni; Li, Fanghong; Zhao, Allan Z.; Chan, Hsiao C.; Chen, Hao			CD147 Induces Epithelial-to-Mesenchymal Transition by Disassembling Cellular Apoptosis Susceptibility Protein/E-Cadherin/beta-Catenin Complex in Human Endometriosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SIGNALING PATHWAY; UP-REGULATION; CELLS; CANCER; EXPRESSION; MIGRATION; HAB18G/CD147; INVOLVEMENT	Epithelial-to-mesenchymal transition (EMT) is postulated to be a prerequisite for the establishment of endometriosis (EMS), a common reproductive disorder in women. Our previous studies have demonstrated the elevated expression of transmembrane glycoprotein CD147 and its prosurvival effect on abnormal cells in endometriosis. Intriguingly, CD147 is known to promote EMT in cancers. However, the involvement of CD147 in EMT during the establishment of endometriosis remains incompletely understood. We found that CD147 promotes EMT in human endometrial adenocarcinoma cell line Ishikawa. We identified a novel CD147-interacting partner, cellular apoptosis susceptibility protein (CAS), which stabilized the interaction between E-cadherin (E-cad) and beta-catenin (beta-cat) by forming the CAS/E-cad/beta-cat complex. Down-regulation of CAS led to the release and nuclear translocation of beta-cat from E-cad, resulting in the overexpression of the EMT-promoting gene SNAIL. Interestingly, overexpression of CD147 impaired the interaction between CAS and E-cad and triggered the release of beta-cat from the CAS/E-cad/beta-cat complex, which in turn led to EMT. Furthermore, CAS was down-regulated in EMS, with elevated levels of CD147 and nuclear beta-cat. These findings suggest a previously undefined role of CAS in regulating EMT and reveal the involvement of a CD147-induced EMT signaling pathway in pathogenic progression of EMS.	[Wang, Chaoqun; Zhang, Jieting; Fok, Kin L.; Tsang, Lai L.; Chan, Hsiao C.; Chen, Hao] Chinese Univ Hong Kong, Fac Med, Epithelial Cell Biol Res Ctr, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China; [Ye, Mei; Liu, Jianni; Li, Fanghong; Zhao, Allan Z.; Chen, Hao] Guangdong Univ Technol, Inst Biomed & Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China; [Ye, Mei; Liu, Jianni; Li, Fanghong; Zhao, Allan Z.; Chen, Hao] Sichuan Univ, Chinese Univ Hong Kong Joint Lab Reprod Med, Chengdu, Sichuan, Peoples R China; [Chan, Hsiao C.] Sichuan Univ, West China Univ Hosp 2, Chengdu, Sichuan, Peoples R China	Chen, H (reprint author), Chinese Univ Hong Kong, Fac Med, Epithelial Cell Biol Res Ctr, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.; Chen, H (reprint author), Guangdong Univ Technol, Guangzhou Higher Educ Mega Ctr, Inst Biomed & Pharmaceut Sci, 100 Waihuan Xi Rd, Guangzhou 510006, Guangdong, Peoples R China.	chenhao@gdut.edu	Fok, Kin Lam/G-2757-2017; Fok, Ellis/M-2784-2019; Chen, Hao/V-4299-2019	Fok, Kin Lam/0000-0003-3038-1337; Fok, Ellis/0000-0003-3038-1337; Chen, Hao/0000-0002-8400-3780	National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81671432, 81370709]; Science and Technology Planning Project of Guangdong Province [2016A020218005]; Hong Kong PhD Fellowship Scheme by Research Grants Council of Hong Kong.	Supported in part by National Nature Science Foundation of China grants 81671432 (H.C.) and 81370709 (H.C.C.) and Science and Technology Planning Project of Guangdong Province grant 2016A020218005 (H.C.). C.W. was supported by the Hong Kong PhD Fellowship Scheme issued by Research Grants Council of Hong Kong.	Chen H, 2012, SPERMATOGENESIS, V2, P264, DOI DOI 10.4161/SPMG.2201423248767; Chen H, 2011, MOL HUM REPROD, V17, P405, DOI 10.1093/molehr/gar013; Dai CS, 2009, J AM SOC NEPHROL, V20, P1997, DOI 10.1681/ASN.2009010019; Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8; Gaetje R, 1997, AM J PATHOL, V150, P461; Gaetje R, 2007, FERTIL STERIL, V88, P1534, DOI 10.1016/j.fertnstert.2007.01.128; Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021; Gilles C, 2003, CANCER RES, V63, P2658; Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274; GOLDSTEIN DP, 1980, J REPROD MED, V24, P251; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Huang WQ, 2017, ONCOTARGET, V8, P66951, DOI 10.18632/oncotarget.16441; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Jiang MC, 2002, BIOCHEM BIOPH RES CO, V294, P900, DOI 10.1016/S0006-291X(02)00551-X; Jin AH, 2014, FERTIL STERIL, V101, P1681, DOI 10.1016/j.fertnstert.2014.02.007; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Matsuzaki Sachiko, 2014, Mol Cell Ther, V2, P36, DOI 10.1186/s40591-014-0036-9; Matsuzaki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061690; Matsuzaki S, 2012, HUM REPROD, V27, P712, DOI 10.1093/humrep/der442; Sidhu SS, 2010, ONCOGENE, V29, P4145, DOI 10.1038/onc.2010.166; Sun JX, 2001, CANCER RES, V61, P2276; Wang CQ, 2017, ONCOTARGET, V8, P3132, DOI 10.18632/oncotarget.13624; Wang CQ, 2015, J CLIN ENDOCR METAB, V100, pE955, DOI 10.1210/jc.2015-1431; Weidle Ulrich H., 2010, Cancer Genomics & Proteomics, V7, P157; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Wu J, 2011, ONCOGENE, V30, P4410, DOI 10.1038/onc.2011.149; Xu T, 2014, INT J CLIN EXP PATHO, V7, P7432; Yan L, 2005, THROMB HAEMOSTASIS, V93, P199, DOI 10.1160/TH04-08-0536; Zeitvogel A, 2001, AM J PATHOL, V159, P1839, DOI 10.1016/S0002-9440(10)63030-1	30	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1597	1607		10.1016/j.ajpath.2018.03.004			11	Pathology	Pathology	GL7NE	WOS:000437387800009	29630856	Bronze			2019-10-28	
J	Tsai, HC; Li, TH; Huang, CC; Huang, SF; Liu, RS; Yang, YY; Hsieh, YC; Lee, KC; Huang, YH; Hou, MC; Lin, HC				Tsai, Hung-Cheng; Li, Tzu-Hao; Huang, Chia-Chang; Huang, Shiang-Fen; Liu, Ren-Shyan; Yang, Ying-Ying; Hsieh, Yun-Cheng; Lee, Kuei-Chuan; Huang, Yi-Hsiang; Hou, Ming-Chih; Lin, Han-Chieh			Beneficial Effects of the Peroxisome Proliferator-Activated Receptor alpha/gamma Agonist Aleglitazar on Progressive Hepatic and Splanchnic Abnormalities in Cirrhotic Rats with Portal Hypertension	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NECROSIS-FACTOR-ALPHA; TNF-ALPHA; INTRAHEPATIC ANGIOGENESIS; BACTERIAL TRANSLOCATION; LABORATORY TESTS; GLYCEMIC CONTROL; LIVER-CIRRHOSIS; UP-REGULATION; NITRIC-OXIDE; FENOFIBRATE	Recent studies have reported that peroxisome proliferator-activated receptor alpha (PPAR alpha) agonist decreases intrahepatic resistance, whereas PPAR gamma agonist reduces portosystemic shunts (PSSs) and splanchnic angiogenesis in cirrhotic rats. The present study investigated the effects of a 21-day treatment with the dual PPAR alpha/gamma agonist aleglitazar (Ale) on progressive abnormalities in bile-duct-ligated and thioacetamide-induced cirrhotic rats with portal hypertension (PH). In vivo and in vitro effects were evaluated. Chronic Ale treatment significantly up-regulated PPAR alpha/PPAR gamma receptors and down-regulated tumor necrosis factor-alpha (TNF-alpha) and NF-kappa B expression in the liver, splanchnic tissues, collateral vessels, and intestines of cirrhotic rats with PH. Notably, Ale improved PH by the suppression of systemic/tissue inflammation, hepatic fibrosis, hepatic Rho-kinase-mediated endothelin-1 hyperresponsiveness, intrahepatic/mesenteric angiogenesis, vascular endothelial growth factor expression, PSS, intestinal mucosal injury, and hyperpermeability in cirrhotic rats. Acute Ale treatment-inhibited TNF-alpha-enhanced endothelin-1-induced contraction of primary hepatic stellate cells, vascular endothelial growth factor-induced migration/angiogenesis of liver sinusoidal endothelial cells, and TNF-alpha-induced disruption of Caco-2 cell monolayer-epithelial barrier. The present study suggested that Ale can potentially treat relevant abnormalities through the inhibition of inflammatory, vasoconstrictive, angiogenic, and mucosal-disrupted pathogenic markers in cirrhosis. Overall, chronic Ale treatment ameliorated PH syndrome by the suppression of hepatic fibrogenesis, neoangiogenesis, vasoconstrictor hyperresponsiveness, splanchnic vasodilatation, and PSS; and decreased intestinal mucosal injury and hyperpermeability in cirrhotic rats.	[Tsai, Hung-Cheng; Hou, Ming-Chih] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan; [Liu, Ren-Shyan] Taipei Vet Gen Hosp, Dept Nucl Med, Taipei, Taiwan; [Li, Tzu-Hao] Taipei Vet Gen Hosp, Div Allergy & Immunol, Taipei, Taiwan; [Huang, Shiang-Fen] Taipei Vet Gen Hosp, Div Infect, Taipei, Taiwan; [Yang, Ying-Ying; Hsieh, Yun-Cheng; Lee, Kuei-Chuan; Huang, Yi-Hsiang; Lin, Han-Chieh] Taipei Vet Gen Hosp, Div Gastroenterol & Hepatol, Taipei, Taiwan; [Yang, Ying-Ying] Taipei Vet Gen Hosp, Div Gen Med, Taipei, Taiwan; [Tsai, Hung-Cheng; Huang, Chia-Chang; Huang, Shiang-Fen; Liu, Ren-Shyan; Yang, Ying-Ying; Hsieh, Yun-Cheng; Lee, Kuei-Chuan; Huang, Yi-Hsiang; Hou, Ming-Chih; Lin, Han-Chieh] Natl Yang Ming Univ, Sch Med, Dept Med, Taipei, Taiwan; [Li, Tzu-Hao] Taichung Vet Gen Hosp, Chia Yi Branch, Chiayi, Taiwan; [Huang, Chia-Chang] Inst Clin Med, Taipei, Taiwan	Yang, YY (reprint author), Taipei Vet Gen Hosp, Div Clin Skills Training, 201,Sect 2,Shipai Rd, Taipei 11217, Taiwan.	yangyy@vghtpe.gov.tw		Huang, Yi-Hsiang/0000-0001-5241-5425; Huang, Shiang-Fen/0000-0002-6685-8259	Molecular and Genetic Imaging Core/National Research Program for Genomic Medicine at National Yang-Ming University; National Science CouncilNational Science Council of Taiwan [MOST-105-2314-B-010-024-MY3]; Taipei Veterans General HospitalTaipei Veterans General Hospital [V105C-010, V106C-007]	Supported, in part, by the Molecular and Genetic Imaging Core/National Research Program for Genomic Medicine at National Yang-Ming University, by National Science Council grant MOST-105-2314-B-010-024-MY3 (Y.-Y.Y. and H.-C.L.), and Taipei Veterans General Hospital grants V105C-010 (Y.-Y.Y. and H.-C.L.) and V106C-007 (Y.-Y.Y. and H.-C.L.).	Aljada A, 2008, ANGIOGENESIS, V11, P361, DOI 10.1007/s10456-008-9118-0; Aller MA, 2007, THEOR BIOL MED MODEL, V4, DOI 10.1186/1742-4682-4-44; Amacher DE, 2013, MOL DIAGN THER, V17, P343, DOI 10.1007/s40291-013-0049-0; BAUDRY N, 1993, J APPL PHYSIOL, V75, P2392; Beguin P, 2013, FOOD FUNCT, V4, P923, DOI 10.1039/c3fo60036j; Benardeau A, 2013, DIABETES OBES METAB, V15, P164, DOI 10.1111/dom.12006; Bosch J, 2000, J HEPATOL, V32, P141, DOI 10.1016/S0168-8278(00)80422-5; Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010; Bril F, 2017, CLIN GASTROENTEROL H; Chen Y, 2017, DIABETES VASC DIS RE, V14, P152, DOI 10.1177/1479164116679081; Chrostek L, 2014, CLIN EXP MED, V14, P417, DOI 10.1007/s10238-013-0262-5; Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, NAT RES COUNC GUID C; Corpechot C, 2002, HEPATOLOGY, V35, P1010, DOI 10.1053/jhep.2002.32524; Cusi K, 2016, ANN INTERN MED, V165, P305, DOI 10.7326/M15-1774; de la Flor R, 2013, INVEST OPHTH VIS SCI, V54; Dufour DR, 2000, CLIN CHEM, V46, P2050; Dzyakanchuk A, CIRCULATION, V122; Eldor R, 2013, DIABETES CARE, V36, pS162, DOI 10.2337/dcS13-2003; Fievet C, 2006, CURR OPIN PHARMACOL, V6, P606, DOI 10.1016/j.coph.2006.06.009; Gabele E, 2009, BIOCHEM BIOPH RES CO, V378, P348, DOI 10.1016/j.bbrc.2008.10.155; Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282; Grigorian AY, 2015, CLIN RES HEPATOL GAS, V39, P296, DOI 10.1016/j.clinre.2015.02.011; Hansen BC, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-7; Henry RR, 2009, LANCET, V374, P126, DOI 10.1016/S0140-6736(09)60870-9; Hickman IJ, 2007, AM J MED, V120, P829, DOI 10.1016/j.amjmed.2007.03.025; Hottelart C, 1999, NEPHROLOGIE, V20, P41; Iizuka M, 2011, AM J PHYSIOL-GASTR L, V300, pG1010, DOI 10.1152/ajpgi.00350.2010; Keech A, 2005, LANCET, V366, P1849, DOI 10.1016/S0140-6736(05)67667-2; Kostapanos MS, 2013, WORLD J HEPATOL, V5, P470, DOI 10.4254/wjh.v5.i9.470; Leppkes M, 2014, INT IMMUNOL, V26, P509, DOI 10.1093/intimm/dxu051; Li TH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147212; Lok ASF, 2005, HEPATOLOGY, V42, P282, DOI 10.1002/hep.20772; LOPEZTALAVERA JC, 1995, GASTROENTEROLOGY, V108, P761, DOI 10.1016/0016-5085(95)90449-2; Ma TY, 2004, AM J PHYSIOL-GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003; Massaro M, 2016, PHARMACOL RES, V107, P125, DOI 10.1016/j.phrs.2016.02.027; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; Mejias M, 2009, HEPATOLOGY, V49, P1245, DOI 10.1002/hep.22758; Moraes LA, 2006, PHARMACOL THERAPEUT, V110, P371, DOI 10.1016/j.pharmthera.2005.08.007; Nan YM, 2009, SCAND J GASTROENTERO, V44, P358, DOI 10.1080/00365520802530861; Natarajan SK, 2006, HEPATOLOGY, V43, P837, DOI 10.1002/hep.21097; Natarajan SK, 2007, J HEPATOL, V46, P797; Oh-oka K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098016; Osawa Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065251; Panes J, 1996, GASTROENTEROLOGY, V110, P866, DOI 10.1053/gast.1996.v110.pm8608897; Pannen BHJ, 1996, AM J PHYSIOL-HEART C, V270, pH7; Paukkeri EL, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4211; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rodriguez-Vilarrupla A, 2012, J HEPATOL, V56, P1033, DOI 10.1016/j.jhep.2011.12.008; ROTHSCHILD MA, 1969, J CLIN INVEST, V48, P344, DOI 10.1172/JCI105990; Ruilope L, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-180; Schwabl P, 2014, J HEPATOL, V60, P1135, DOI 10.1016/j.jhep.2014.01.025; Serste T, 2010, HEPATOLOGY, V52, P1017, DOI 10.1002/hep.23775; Thabut D, 2010, J HEPATOL, V53, P976, DOI 10.1016/j.jhep.2010.07.004; Theodorakis NG, 2010, INT J PHYSL PATH PHA, V2, P104; Trebicka J, 2008, HEPATOLOGY, V47, P1264, DOI 10.1002/hep.22170; Trebicka J, 2011, EUR J GASTROEN HEPAT, V23, P1218, DOI 10.1097/MEG.0b013e32834a75dc; Unno N, 1996, AM J PHYSIOL-GASTR L, V270, pG1010; Wang L, 2017, HEPATOL RES, V47, pE94, DOI 10.1111/hepr.12732; Wiest R, 1999, J CLIN INVEST, V104, P1223, DOI 10.1172/JCI7458; Yakubu MA, 2007, J PHARMACOL EXP THER, V320, P774, DOI 10.1124/jpet.106.104992; Yang YY, 2014, J HEPATOL, V61, P1004, DOI 10.1016/j.jhep.2014.05.049; Yang YY, 2012, HEPATOLOGY, V55, P1540, DOI 10.1002/hep.25534; Ye Ping, 2004, Chinese Medical Sciences Journal, V19, P243; Zadelaar ASM, 2006, ARTERIOSCL THROM VAS, V26, P2560, DOI 10.1161/01.ATV.0000242904.34700.66; Zhao Ruo-Zhi, 2005, Biochem Biophys Res Commun, V327, P985, DOI 10.1016/j.bbrc.2004.12.109; Zhou Q, 2006, GUT, V55, P1296, DOI 10.1136/gut.2005.081059	66	1	1	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1608	1624		10.1016/j.ajpath.2018.03.018			17	Pathology	Pathology	GL7NE	WOS:000437387800010	29929914				2019-10-28	
J	Zhang, LQ; Nsumu, M; Huang, P; Heruth, DP; Riordan, SM; Shortt, K; Zhang, NN; Grigoryev, DN; Li, DY; Friesen, CA; Van Haandel, L; Leeder, JS; Olson, J; Ye, SQ				Zhang, Li Q.; Nsumu, Marianne; Huang, Peixin; Heruth, Daniel P.; Riordan, Sean M.; Shortt, Katherine; Zhang, Nini; Grigoryev, Dmitry N.; Li, Ding-You; Friesen, Craig A.; Van Haandel, Leon; Leeder, J. Steven; Olson, Jody; Ye, Shui Q.			Novel Protective Role of Nicotinamide Phosphoribosyltransferase in Acetaminophen-Induced Acute Liver Injury in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							COLONY-ENHANCING FACTOR; OXIDATIVE STRESS; PROTEIN; NAD; HEPATOTOXICITY; METABOLISM; FAILURE; MITOCHONDRIA; DISPOSITION; MECHANISMS	Acetaminophen overdose is the most common cause of acute liver injury (ALI) or acute liver failure in the United States. Its pathogenetic mechanisms are incompletely understood. Additional studies are warranted to identify new genetic risk factors for more mechanistic insights and new therapeutic target discoveries. The objective of this study was to explore the role and mechanisms of nicotinamide phosphoribosyltransferase (NAMPT) in acetaminophen-induced ALI. C57BL/6 Nampt gene wild-type (Nampt(+/+)), heterozygous knockout (Nampt(+/-)), and overexpression (Nampt(0E)) mice were treated with overdose of acetaminophen, followed by histologic, biochemical, and transcriptomic evaluation of liver injury. The mechanism of Nampt in acetaminophen-induced hepatocytic toxicity was also explored in cultured primary hepatocytes. Three lines of evidence have convergently demonstrated that acetaminophen overdose triggers the most severe oxidative stress and necrosis, and the highest expression of key necrosis driving genes in Nampt(+/-) mice, whereas the effects in Nampt(0E) mice were least severe relative to Nampt(+/+) mice. Treatment of P7C3-A20, a small chemical molecule up-regulator of Nampt, ameliorated acetaminophen-induced mouse ALI over the reagent control. These findings support the fact that NAMPT protects against acetaminophen-induced ALI.	[Zhang, Li Q.; Nsumu, Marianne; Huang, Peixin; Heruth, Daniel P.; Riordan, Sean M.; Shortt, Katherine; Zhang, Nini; Grigoryev, Dmitry N.; Ye, Shui Q.] Univ Missouri Kansas City, Sch Med, Childrens Mercy Hosp, Div Expt & Translat Genet,Dept Pediat, Kansas City, MO 64108 USA; [Zhang, Nini; Li, Ding-You; Friesen, Craig A.] Univ Missouri Kansas City, Sch Med, Childrens Mercy Hosp, Div Gastroenterol Hepatol & Nutr,Dept Pediat, Kansas City, MO 64108 USA; [Van Haandel, Leon; Leeder, J. Steven] Univ Missouri Kansas City, Sch Med, Childrens Mercy Hosp, Div Clin Pharmacol & Therapeut Innovat,Dept Pedia, Kansas City, MO 64108 USA; [Zhang, Li Q.] Univ Missouri Kansas City, Sch Med, Dept Biomed Sci, 2411 Holmes,M5-128, Kansas City, MO 64108 USA; [Shortt, Katherine; Zhang, Nini; Grigoryev, Dmitry N.; Ye, Shui Q.] Univ Missouri Kansas City, Sch Med, Dept Biomed & Hlth Informat, 2411 Holmes,M5-128, Kansas City, MO 64108 USA; [Shortt, Katherine; Ye, Shui Q.] Univ Missouri Kansas City, Sch Biol Sci, Div Cell Biol & Biophys, Kansas City, MO 64108 USA; [Olson, Jody] Univ Missouri Kansas City, Sch Med, Univ Kansas Liver Ctr, Kansas City, MO 64108 USA	Zhang, LQ (reprint author), Univ Missouri Kansas City, Sch Med, Dept Biomed Sci, 2411 Holmes,M5-128, Kansas City, MO 64108 USA.; Ye, SQ (reprint author), Univ Missouri Kansas City, Sch Med, Dept Biomed & Hlth Informat, 2411 Holmes,M5-128, Kansas City, MO 64108 USA.	zhanglq@umkc.edu; yes@umkc.edu		Shortt, Katherine/0000-0002-6207-1862	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R0IHL080042, HL080042S1]; Children's Mercy Hospital, University of Missouri Kansas City School of Medicine and Missouri State	Supported by NIH grants R0IHL080042 and HL080042S1 (S.Q.Y.) and the start-up fund and William R. Brown/Missouri State endowments of The Children's Mercy Hospital, University of Missouri Kansas City School of Medicine and Missouri State (S.Q.Y.).	Antoine DJ, 2009, TOXICOL SCI, V112, P521, DOI 10.1093/toxsci/kfp235; Carbone F, 2017, COMPR PHYSIOL, V7, P603, DOI 10.1002/cphy.c160029; Chen Y, 2013, FOOD CHEM TOXICOL, V60, P38, DOI 10.1016/j.fct.2013.07.008; Cheranova D, 2013, JOVE-J VIS EXP, V72, P4393; Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003; Chung Raymond T, 2012, Gastroenterology, V143, pe1, DOI 10.1053/j.gastro.2012.07.011; Cichoz-Lach H, 2014, WORLD J GASTROENTERO, V20, P8082, DOI 10.3748/wjg.v20.i25.8082; Du K, 2016, REDOX BIOL, V10, P148, DOI 10.1016/j.redox.2016.10.001; Eguchi A, 2014, J HEPATOL, V60, P1063, DOI 10.1016/j.jhep.2013.12.026; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; Guarente L, 2011, NEW ENGL J MED, V364, P2235, DOI 10.1056/NEJMra1100831; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Heller F, 2013, ACTA CLIN BELG, V68, P77, DOI 10.2143/ACB.3270; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Hong SB, 2008, AM J RESP CRIT CARE, V178, P605, DOI 10.1164/rccm.200712-1822OC; Iorga A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051018; Jaeschke H, 2012, DRUG METAB REV, V44, P88, DOI 10.3109/03602532.2011.602688; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Khaidizar FD, 2017, GENES CELLS, V22, P982, DOI 10.1111/gtc.12542; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Lee WM, 2003, SEMIN LIVER DIS, V23, P217; Mazaleuskaya LL, 2015, PHARMACOGENET GENOM, V25, P416, DOI 10.1097/FPC.0000000000000150; McGill MR, 2014, EXPERT OPIN DRUG MET, V10, P1005, DOI 10.1517/17425255.2014.920823; McGill MR, 2013, PHARM RES-DORDR, V30, P2174, DOI 10.1007/s11095-013-1007-6; Mohar I, 2009, CUR PROTOC TOXICOL; Newton K, 2014, SCIENCE, V343, P1357, DOI 10.1126/science.1249361; Ni HM, 2012, HEPATOLOGY, V55, P222, DOI 10.1002/hep.24690; Nicholls P, 2012, ARCH BIOCHEM BIOPHYS, V525, P95, DOI 10.1016/j.abb.2012.01.015; Nikiforov A, 2015, CRIT REV BIOCHEM MOL, V50, P284, DOI 10.3109/10409238.2015.1028612; Ostapowicz G, 2002, ANN INTERN MED, V137, P947, DOI 10.7326/0003-4819-137-12-200212170-00007; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; PRESCOTT LF, 1983, DRUGS, V25, P290, DOI 10.2165/00003495-198325030-00002; Ramachandran A, 2013, HEPATOLOGY, V58, P2099, DOI 10.1002/hep.26547; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Xu RH, 2017, ONCOL REP, V38, P1767, DOI 10.3892/or.2017.5793; Ye SQ, 2005, AM J RESP CRIT CARE, V171, P361, DOI 10.1164/rccm.200404-563OC; Yuan LY, 2013, CLIN LIVER DIS, V17, P507, DOI 10.1016/j.cld.2013.07.002; Zhang Li Qin, 2011, J Bioanal Biomed, V3, P13; Zhang LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031229; Zhang MC, 2019, ANTIOXID REDOX SIGN, V30, P890, DOI 10.1089/ars.2017.7445; Zhang WP, 2010, J CEREBR BLOOD F MET, V30, P1962, DOI 10.1038/jcbfm.2010.71; Zhang WS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037103; Zhao P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080991; Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x	47	3	3	2	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1640	1652		10.1016/j.ajpath.2018.04.004			13	Pathology	Pathology	GL7NE	WOS:000437387800012	29684358	Green Published			2019-10-28	
J	Kaufman-Francis, K; Djordjevic, JT; Juillard, PG; Lev, S; Desmarini, D; Grau, GER; Sorrell, TC				Kaufman-Francis, Keren; Djordjevic, Julianne T.; Juillard, Pierre-Georges; Lev, Sophie; Desmarini, Desmarini; Grau, Georges E. R.; Sorrell, Tania C.			The Early Innate Immune Response to, and Phagocyte-Dependent Entry of, Cryptococcus neoformans Map to the Perivascular Space of Cortical Post-Capillary Venules in Neurocryptococcosis	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; BLOOD-BRAIN-BARRIER; TRANSENDOTHELIAL MIGRATION; MURINE MODEL; MACROPHAGES; CHEMOKINES; CELLS; MENINGOENCEPHALITIS; TRANSMIGRATION; DISSEMINATION	The innate immune system is the primary defense against cryptococcal infection, but paradoxically it promotes infection of the central nervous system. We performed a detailed longitudinal study of neurocryptococcosis in normal, chimeric, green fluorescent protein phagocyte-positive mice and phagocyte-depleted mice and interrogated the central nervous system innate immune response to Cryptococcus neoformans H99 using confocal microscopy, histology, flow cytometry, and quantification of brain cytokine/chemokines and fungal burdens. C. neoformans was present in the perivascular space (PVS) of post-capillary venules. This was associated with a massive influx of blood-derived monocytes, neutrophils, and T lymphocytes into the PVS and a predominantly proinflammatory cytokine/chemokine response. Phagocytes containing cryptococci were present only in the lumen and corresponding PVS of post-capillary venules. Free cryptococci were observed breaching the glia limitans, the protective barrier between the PVS and the cerebral parenchyma. Parenchymal cryptococcomas were typically in direct contact with post-capillary venules and lacked surrounding immune cell infiltrates. Phagocyte depletion abrogated cryptococcoma formation and PVS infiltrates. Together, these observations suggest that cryptococcomas can originate via phagocyte-dependent transport across post-capillary venular endothelium into the PVS and thence via passage of free cryptococci into the brain. In conclusion, we demonstrate for the first time that the PVS of cortical post-capillary venules is the major site of the early innate immune response to, and phagocyte-dependent entry of, C. neoformans.	[Kaufman-Francis, Keren; Djordjevic, Julianne T.; Juillard, Pierre-Georges; Lev, Sophie; Desmarini, Desmarini; Grau, Georges E. R.; Sorrell, Tania C.] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW, Australia; [Kaufman-Francis, Keren; Djordjevic, Julianne T.; Juillard, Pierre-Georges; Lev, Sophie; Desmarini, Desmarini; Sorrell, Tania C.] Westmead Inst Med Res, Fungal Pathogenesis Lab, Ctr Infect Dis & Microbiol, Westmead, NSW, Australia; [Djordjevic, Julianne T.; Lev, Sophie; Sorrell, Tania C.] Univ Sydney, Westmead Clin Sch, Sydney, NSW, Australia; [Juillard, Pierre-Georges; Grau, Georges E. R.] Univ Sydney, Sydney Med Sch, Vasc Immunol Unit, Sydney, NSW, Australia; [Grau, Georges E. R.] Univ Sydney, Dept Pathol, Sch Med Sci, Sydney, NSW, Australia; [Grau, Georges E. R.] Univ Sydney, Univ Sydney Nano Inst Sydney Nano, Sydney, NSW, Australia	Sorrell, TC (reprint author), Westmead Inst Med Res, Ctr Infect Dis & Microbiol, 176 Hawkesbury Rd,POB 412, Westmead, NSW 2145, Australia.	tania.sorrell@sydney.edu.au		Lev, Sophie/0000-0003-3511-457X; Sorrell, Tania/0000-0001-9460-0960	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [APP 1050106]; Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney; Sydney Medical School Foundation, University of Sydney	Supported by the National Health and Medical Research Council of Australia grant APP 1050106 (T.C.S., J.T.D., and G.E.R.G.) and a seed grant from the Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney. T.C.S. is a Sydney Medical Foundation Fellow, whose work is also supported by the Sydney Medical School Foundation, University of Sydney.	Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Bryan AM, 2015, MEDIAT INFLAMM, DOI 10.1155/2015/640540; Casadevall A, 1998, CRYPTOCOCCUS NEOFORM; Charlier C, 2009, INFECT IMMUN, V77, P120, DOI 10.1128/IAI.01065-08; Chretien F, 2002, J INFECT DIS, V186, P522, DOI 10.1086/341564; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Davis JM, 2016, INFECT IMMUN, V84, P3047, DOI 10.1128/IAI.00506-16; Goldmann T, 2016, NAT IMMUNOL, V17, P797, DOI 10.1038/ni.3423; Harrison-Brown M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122030; Holman DW, 2011, BBA-MOL BASIS DIS, V1812, P220, DOI 10.1016/j.bbadis.2010.07.019; Huang SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048570; Johnston SA, 2013, CELL MICROBIOL, V15, P403, DOI 10.1111/cmi.12067; Kinnecom K, 2005, BRAIN RES PROTOC, V16, P1, DOI 10.1016/j.brainresprot.2005.08.002; Klein RS, 2017, NAT IMMUNOL, V18, P132, DOI 10.1038/ni.3656; Krueger M, 2010, GLIA, V58, P1, DOI 10.1002/glia.20898; Laschinger M, 2000, J NEUROIMMUNOL, V102, P32, DOI 10.1016/S0165-5728(99)00156-3; Maffei CML, 2004, INFECT IMMUN, V72, P2338, DOI 10.1128/IAI.72.4.2338-2349.2004; Monaco S, 2007, BIOCHEM J, V402, P503, DOI 10.1042/BJ20061064; Nichols CB, 2015, EUKARYOT CELL, V14, P626, DOI 10.1128/EC.00010-15; Olszewski MA, 2004, AM J PATHOL, V164, P1761, DOI 10.1016/S0002-9440(10)63734-0; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; Pollock H, 1997, J ANAT, V191, P337, DOI 10.1046/j.1469-7580.1997.19130337.x; Prinz M, 2017, NAT IMMUNOL, V18, P385, DOI 10.1038/ni.3703; Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]; Rodrigues ML, 2008, EUKARYOT CELL, V7, P58, DOI 10.1128/EC.00370-07; Santangelo R, 2004, INFECT IMMUN, V72, P2229, DOI 10.1128/IAI.72.4.2229-2239.2004; Santiago-Tirado FH, 2017, MBIO, V8, DOI 10.1128/mBio.02183-16; Shi MQ, 2010, J CLIN INVEST, V120, P1683, DOI 10.1172/JCI41963; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sorrell TC, 2016, MICROBES INFECT, V18, P57, DOI 10.1016/j.micinf.2015.08.017; Stukes SA, 2014, INFECT IMMUN, V82, P2059, DOI 10.1128/IAI.01503-14; Thompson GR, 2012, J ANTIMICROB CHEMOTH, V67, P1432, DOI 10.1093/jac/dks060; van Buul JD, 2007, J CELL BIOL, V178, P1279, DOI 10.1083/jcb.200612053; Van den Steen PE, 2008, EUR J IMMUNOL, V38, P1082, DOI 10.1002/eji.200737906; Vu K, 2014, MBIO, V5, DOI 10.1128/mBio.01101-14; ZHANG ET, 1990, J ANAT, V170, P111; Zhang MS, 2016, J LEUKOCYTE BIOL, V99, P467, DOI 10.1189/jlb.4AB0715-281R	38	7	7	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1653	1665		10.1016/j.ajpath.2018.03.015			13	Pathology	Pathology	GL7NE	WOS:000437387800013	29929915				2019-10-28	
J	Ihms, EA; Urbanowski, ME; Bishai, WR				Ihms, Elizabeth A.; Urbanowski, Michael E.; Bishai, William R.			Diverse Cavity Types and Evidence that Mechanical Action on the Necrotic Granuloma Drives Tuberculous Cavitation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							PULMONARY TUBERCULOSIS; DISEASE; PATHOLOGY; LESIONS; LUNG; METALLOPROTEINASES; PATHOGENESIS; COLLAGEN; RABBITS; ROLES	Effacement of normal lung parenchyma by cavities is an important sequela of pulmonary tuberculosis. Despite its clinical significance, the pathogenesis of tuberculous cavitation is poorly understood, with controversy as to whether the fundamental mechanism involves matrix depletion, lipid pneumonia, or mechanical factors. In this study, a repetitive aerosol infection model using Mycobacterium tuberculosis was used to generate cavities in 20 New Zealand white rabbits. Serial computed tomography was performed to monitor cavity progression over 14 weeks. Three-dimensional reconstructions were compiled for each time point, allowing comprehensive four-dimensional cavity mapping. Terminally, cavities were processed for histopathology. Cavities progressed rapidly from areas of consolidation, and often showed a pattern of explosive growth followed by gradual contraction. Cavities formed preferentially in the caudodorsal lung fields, and frequently were subpleural. Cavitation was associated invariably with necrosis. Histomorphology showed four distinct cavity types that provide mechanistic clues and insight on early cavity development. Our study shows that cavitation is a highly dynamic process with preferential formation at sites of high mechanical stress. These findings suggest a model for the pathogenesis of tuberculous cavitation in which mechanical stress acts on the necrotic granuloma to produce acute tears in structurally weakened tissue, with subsequent air trapping and cavity expansion.	[Ihms, Elizabeth A.] Johns Hopkins Univ, Sch Med, Dept Mol & Comparat Pathobiol, Baltimore, MD USA; [Ihms, Elizabeth A.; Urbanowski, Michael E.; Bishai, William R.] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res,Div Infect Dis, Baltimore, MD 21205 USA	Bishai, WR (reprint author), Johns Hopkins Sch Med, Ctr TB Res, Dept Med, Div Infect Dis, CRB2,Room 108,1550 Orleans St, Baltimore, MD 21287 USA.	wbishai1@jhmi.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI36973, AI37856, HL133190]; Howard Hughes Medical InstituteHoward Hughes Medical Institute	Supported by NIH grants AI36973, AI37856, and HL133190 (W.R.B.); and by the Howard Hughes Medical Institute (W.R.B.).	AGOSTONI E, 1972, PHYSIOL REV, V52, P57; Belton M, 2016, THORAX, V71, P1145, DOI 10.1136/thoraxjnl-2015-207402; Benator D, 2002, LANCET, V360, P528; Canetti G, 1955, TUBERCLE BACILLUS PU; Cardona PJ, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/868246; Casha AR, 2015, CLIN ANAT, V28, P614, DOI 10.1002/ca.22544; Converse PJ, 1998, CLIN DIAGN LAB IMMUN, V5, P871; Coryllos PN, 1939, J FRANKLIN I, V227, P287; Coryllos PN, 1938, J THORACIC SURG, V8, P10; Coryllos PN, 1936, AM REV TUBERC, V33, P639; DANGELO E, 1970, RESP PHYSIOL, V8, P204, DOI 10.1016/0034-5687(70)90016-2; Dannenberg AM, 2009, TUBERCULOSIS, V89, P243, DOI 10.1016/j.tube.2009.05.006; Elkington P, 2011, J CLIN INVEST, V121, P1827, DOI 10.1172/JCI45666; Elkington PT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001847; Eloesser L, 1937, J THORACIC SURG, V7, P1; Gadkowski LB, 2008, CLIN MICROBIOL REV, V21, P305, DOI 10.1128/CMR.00060-07; Gekler WA, 1924, J AMER MED ASSOC, V82, P457, DOI 10.1001/jama.1924.02650320027009; Gill SE, 2008, INT J BIOCHEM CELL B, V40, P1334, DOI 10.1016/j.biocel.2007.10.024; Gillespie SH, 2002, ANTIMICROB AGENTS CH, V46, P267, DOI 10.1128/AAC.46.2.267-274.2002; HAAPANEN JH, 1959, AM REV RESPIR DIS, V80, P1; Helke KL, 2006, TUBERCULOSIS, V86, P337, DOI 10.1016/j.tube.2005.09.001; HULNICK DH, 1983, RADIOLOGY, V149, P759, DOI 10.1148/radiology.149.3.6647852; Hunter RL, 2006, ANN CLIN LAB SCI, V36, P371; Hunter RL, 2011, TUBERCULOSIS, V91, pS6, DOI 10.1016/j.tube.2011.10.003; Jepson PD, 2003, NATURE, V425, P575, DOI 10.1038/425575a; Kubler A, 2013, DEV INVESTIGATION RA; Kubler A, 2016, J INFECT DIS, V213, P618, DOI 10.1093/infdis/jiv458; Kubler A, 2015, J PATHOL, V235, P431, DOI 10.1002/path.4432; Leong FJ, 2010, COLOR ATLAS COMP PAT; Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877; Medlar E. M., 1936, AM REV TUBERC, V34, P456; MEDLAR EM, 1955, AM REV TUBERC PULM, V71, pR3; Ordonez AA, 2016, DIS MODEL MECH, V9, P779, DOI 10.1242/dmm.025643; Perrin FMR, 2010, INT J TUBERC LUNG D, V14, P1596; SPEARE DJ, 1990, J COMP PATHOL, V103, P421, DOI 10.1016/S0021-9975(08)80030-8; Suki B, 2005, J APPL PHYSIOL, V98, P1892, DOI 10.1152/japplphysiol.01087.2004; SWEANY HC, 1956, DIS CHEST, V29, P119, DOI 10.1378/chest.29.2.119; Tsokos M, 2008, INT J LEGAL MED, V122, P35, DOI 10.1007/s00414-007-0163-9; Urbanowski ME, 2018, J INFECT DIS, V218, P53, DOI 10.1093/infdis/jiy127; WAGNER PD, 1974, J CLIN INVEST, V54, P54, DOI 10.1172/JCI107750; Walker NF, 2012, AM J RESP CRIT CARE, V185, P989, DOI 10.1164/rccm.201110-1769OC; Walker NF, 2017, CLIN INFECT DIS, V86, P913; Wells RG, 2013, BBA-MOL BASIS DIS, V1832, P884, DOI 10.1016/j.bbadis.2013.02.007; WEST JB, 1971, LANCET, V1, P839; YOKOYAMA T, 1967, RESP PHYSIOL, V3, P166, DOI 10.1016/0034-5687(67)90007-2	45	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1666	1675		10.1016/j.ajpath.2018.04.006			10	Pathology	Pathology	GL7NE	WOS:000437387800014	29753789	Green Published			2019-10-28	
J	Mota, R; Parry, TL; Yates, CC; Qiang, Z; Eaton, SC; Mwiza, JM; Tulasi, D; Schisler, JC; Patterson, C; Zaglia, T; Sandri, M; Willis, MS				Mota, Roberto; Parry, Traci L.; Yates, Cecelia C.; Qiang, Zhaoyan; Eaton, Samuel C.; Mwiza, Jean Marie; Tulasi, Deepthi; Schisler, Jonathan C.; Patterson, Cam; Zaglia, Tania; Sandri, Marco; Willis, Monte S.			Increasing Cardiomyocyte Atrogin-1 Reduces Aging-Associated Fibrosis and Regulates Remodeling in Vivo	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DEPENDENT CARDIAC-HYPERTROPHY; SKELETAL-MUSCLE ATROPHY; FOXO TRANSCRIPTION; UBIQUITIN LIGASES; LIFE-SPAN; TRANSGENIC OVEREXPRESSION; MATRIX METALLOPROTEINASES; PROMOTES TUMORIGENESIS; EXPRESSION; HEART	The muscle-specific ubiquitin Ligase atrogin-1 (MAFbx) has been identified as a critical regulator of pathologic and physiological cardiac hypertrophy; it regulates these processes by ubiquitinating transcription factors [nuclear factor of activated T-cells and forkhead box O (FoxO) 1/3]. However, the role of atrogin-1 in regulating transcription factors in aging has not previously been described. Atrogin-1 cardiomyocyte-specific transgenic (Tg(+)) adult mice (alpha-major histocompatibility complex promoter driven) have normal cardiac function and size. Herein, we demonstrate that 18-month-old atrogin-1 Tg(+) hearts exhibit significantly increased anterior wall thickness without functional impairment versus wild-type mice. Histologic analysis at 18 months revealed atrogin-1 Tg(+) mice had significantly less fibrosis and significantly greater nuclei and cardiomyocyte cross-sectional analysis. Furthermore, by real-time quantitative PCR, atrogin-1 Tg(+) had increased Col 6a4, 6a5, 6a6, matrix metalloproteinase 8 (Mmp8), and Mmp9 mRNA, suggesting a role for atrogin-1 in regulating collagen deposits and MMP-8 and MMP-9. Because atrogin-1 Tg(+) mice exhibited significantly Less collagen deposition and protein Levels, enhanced Mmp8 and Mmp9 mRNA may offer one mechanism by which collagen levels are kept in check in the aged atrogin-1 Tg(+) heart. In addition, atrogin-1 Tg(+) hearts showed enhanced FoxO1/3 activity. The present study shows a novel link between atrogin-1-mediated regulation of FoxO1/3 activity and reduced collagen deposition and fibrosis in the aged heart. Therefore, targeting FoxO1/3 activity via the muscle-specific atrogin-1 ubiquitin Ligase may offer a muscle-specific method to modulate aging-related cardiac fibrosis.	[Mota, Roberto; Parry, Traci L.; Schisler, Jonathan C.; Willis, Monte S.] Univ N Carolina, McAllister Heart Inst, Chapel Hill, NC USA; [Parry, Traci L.; Qiang, Zhaoyan; Mwiza, Jean Marie; Willis, Monte S.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Eaton, Samuel C.; Schisler, Jonathan C.; Willis, Monte S.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA; [Tulasi, Deepthi] Univ N Carolina, Dept Biol, Chapel Hill, NC USA; [Yates, Cecelia C.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Qiang, Zhaoyan] Tianjin Med Univ, Dept Pharmacol, Tianjin, Peoples R China; [Patterson, Cam] Weill Cornell Med Ctr, Presbyterian Hosp, New York, NY USA; [Zaglia, Tania; Sandri, Marco] Univ Padua, Dept Biomed Sci, Padua, Italy; [Zaglia, Tania] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy; [Sandri, Marco] Dulbecco Telethon Inst, Padua, Italy; [Zaglia, Tania] Venetian Inst Mol Med, Padua, Italy; [Willis, Monte S.] Univ Indiana Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA; [Willis, Monte S.] Univ Indiana Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA	Willis, MS (reprint author), Indiana Ctr Musculoskeletal Hlth, Van Nuys Med Sci Bldg,Suite 5067, Indianapolis, IN 46202 USA.	willisms@iu.edu	Willis, Monte/J-9994-2015; Mota, Roberto/D-3501-2018	Willis, Monte/0000-0002-0769-5816; Mota, Roberto/0000-0002-4911-0687	Jefferson-Pilot Corporation Fellowship in Academic Medicine; NIH National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL104129]; Leducq FoundationLeducq Foundation [11CVD04]; China Scholarship Council State Scholarship FundChina Scholarship Council	Supported by the Jefferson-Pilot Corporation Fellowship in Academic Medicine (M.S.W.), the NIH National Heart, Lung, and Blood Institute grant R01HL104129 (M.S.W.), the Leducq Foundation grant 11CVD04 (M.S.W. and C.P.), and the China Scholarship Council State Scholarship Fund (Z.Q.).	Abel ED, 2011, CARDIOVASC RES, V90, P234, DOI 10.1093/cvr/cvr015; Adamo ML, 2006, AGEING RES REV, V5, P310, DOI 10.1016/j.arr.2006.05.001; Al Darazi F, 2014, J CARDIOVASC PHARM, V64, P237, DOI 10.1097/FJC.0000000000000111; Al-Yacoub N, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0861-4; Altun M, 2010, J BIOL CHEM, V285, P39597, DOI 10.1074/jbc.M110.129718; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Barns M, 2014, INT J BIOCHEM CELL B, V53, P174, DOI 10.1016/j.biocel.2014.04.025; Bertaggia E, 2012, AM J PHYSIOL-CELL PH, V302, pC587, DOI 10.1152/ajpcell.00142.2011; Blice-Baum AC, 2017, AGING CELL, V16, P93, DOI 10.1111/acel.12543; Bodine SC, 2014, AM J PHYSIOL-ENDOC M, V307, pE469, DOI 10.1152/ajpendo.00204.2014; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Chen JL, 2017, J CELL MOL MED, V21, P3679, DOI 10.1111/jcmm.13278; Collier P, 2012, J MOL CELL CARDIOL, V52, P148, DOI 10.1016/j.yjmcc.2011.10.002; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; Evans-Anderson HJ, 2008, CIRC RES, V102, P686, DOI 10.1161/CIRCRESAHA.107.163428; Feist P, 2015, INT J MOL SCI, V16, P3537, DOI 10.3390/ijms16023537; Fitzgerald J, 2008, J BIOL CHEM, V283, P20170, DOI 10.1074/jbc.M710139200; Goodman CA, 2013, EXERC SPORT SCI REV, V41, P107, DOI 10.1097/JES.0b013e3182798a95; Harty MW, 2005, SURGERY, V138, P313, DOI 10.1016/j.surg.2005.04.009; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Jazbutyte V, 2013, AGE, V35, P747, DOI 10.1007/s11357-012-9407-9; Kang SH, 2017, AM J PHYSIOL-ENDOC M, V312, pE495, DOI 10.1152/ajpendo.00389.2016; Kato S, 2008, J BIOL CHEM, V283, P35464, DOI 10.1074/jbc.M801011200; Kavazis AN, 2014, J APPL PHYSIOL, V117, P223, DOI 10.1152/japplphysiol.00210.2014; Lagirand-Cantaloube J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004973; Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410; Lee WS, 2017, BIOCHIM BIOPHYS ACTA, V1864, P1931; Li F, 2009, J BIOL CHEM, V284, P20090, DOI 10.1074/jbc.M109.017046; Li HH, 2004, J CLIN INVEST, V114, P1058, DOI 10.1172/JCl200422220; Li HH, 2007, J CLIN INVEST, V117, P3211, DOI 10.1172/JCI31757; Li YH, 2016, ONCOTARGET, V7, P19185, DOI 10.18632/oncotarget.8313; Mattox TA, 2014, J BIOENERG BIOMEMBR, V46, P173, DOI 10.1007/s10863-014-9549-9; McElwee J, 2003, AGING CELL, V2, P111, DOI 10.1046/j.1474-9728.2003.00043.x; Mearini G, 2010, CARDIOVASC RES, V85, P357, DOI 10.1093/cvr/cvp348; Meschiari CA, 2017, GEROSCIENCE, V39, P7, DOI 10.1007/s11357-017-9959-9; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Naugle JE, 2006, AM J PHYSIOL-HEART C, V290, pH323, DOI 10.1152/ajpheart.00321.2005; Oakley RH, 2013, P NATL ACAD SCI USA, V110, P17035, DOI 10.1073/pnas.1302546110; Ock S, 2016, ENDOCRINOLOGY, V157, P336, DOI 10.1210/en.2015-1709; Paula-Gomes S, 2013, HORM METAB RES, V45, P849, DOI 10.1055/s-0033-1347209; Pomies P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160092; Quintana MT, 2016, AM J PATHOL, V186, P1989, DOI 10.1016/j.ajpath.2016.03.017; Reiter E, 2007, MOL ASPECTS MED, V28, P668, DOI 10.1016/j.mam.2007.01.003; Ren RQ, 2012, ENDOCRINOLOGY, V153, P5346, DOI 10.1210/en.2012-1563; Reynolds TH, 2012, AM J PHYSIOL-REG I, V303, pR1186, DOI 10.1152/ajpregu.00358.2012; Risling TE, 2012, CAN VET J, V53, P299; Rivas DA, 2014, FASEB J, V28, P4133, DOI 10.1096/fj.14-254490; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Schuster E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.54; Shimizu T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93187; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Steenman Marja, 2017, Biophys Rev, V9, P131, DOI 10.1007/s12551-017-0255-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Sun XJ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00548; Takahashi Y, 2011, CELL METAB, V13, P505, DOI 10.1016/j.cmet.2011.03.017; Thakur S, 2017, BIOCHEM BIOPH RES CO, V486, P937, DOI 10.1016/j.bbrc.2017.03.129; Tintignac LA, 2005, J BIOL CHEM, V280, P2847, DOI 10.1074/jbc.M411346200; Toba H, 2017, AM J PHYSIOL-HEART C, V312, pH375, DOI 10.1152/ajpheart.00633.2016; Wadosky KM, 2014, AM J PHYSIOL-ENDOC M, V306, pE723, DOI 10.1152/ajpendo.00326.2013; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Weiss A, 1996, ANNU REV CELL DEV BI, V12, P417, DOI 10.1146/annurev.cellbio.12.1.417; Willis MS, 2008, FUTUR CARDIOL, V4, P65, DOI 10.2217/14796678.4.1.65; Willis MS, 2014, CELL BIOCHEM FUNCT, V32, P39, DOI 10.1002/cbf.2969; Willis MS, 2009, CIRC RES, V105, P80, DOI 10.1161/CIRCRESAHA.109.194928; Xu BQ, 2016, J ECHOCARDIOGR, V14, P139, DOI 10.1007/s12574-016-0292-6; Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Zaglia T, 2014, J CLIN INVEST, V124, P2410, DOI [10.1172/JCI6339, 10.1172/JCI66339]; Zamilpa R, 2012, J MOL CELL CARDIOL, V53, P599, DOI 10.1016/j.yjmcc.2012.07.017; Zheng B, 2010, FASEB J, V24, P2660, DOI 10.1096/fj.09-151480	75	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1676	1692		10.1016/j.ajpath.2018.04.007			17	Pathology	Pathology	GL7NE	WOS:000437387800015	29758183	Green Published			2019-10-28	
J	Zhang, JL; Qiao, Q; Liu, MD; He, T; Shi, JH; Bai, XZ; Zhang, YJ; Li, Y; Cai, WX; Han, SC; Guan, H; Hu, DH				Zhang, Julei; Qiao, Qiao; Liu, Mengdong; He, Ting; Shi, Jihong; Bai, Xiaozhi; Zhang, Yijie; Li, Yan; Cai, Weixia; Han, Shichao; Guan, Hao; Hu, Dahai			IL-17 Promotes Scar Formation by Inducing Macrophage Infiltration	AMERICAN JOURNAL OF PATHOLOGY			English	Article								Trauma or burn injuries that affect the deep dermis often produce a hypertrophic scar, which limits patients' joint movement and generates an aesthetic problem. Inflammation is believed to be one of the main pathogenic mechanisms. We found that IL-17 was increased in scar tissues from patients with hypertrophic scar compared with normal skin. Recombinant mouse IL-17 was subcutaneously injected into mice that underwent full-thickness excision surgery to investigate the role of IL-17 in scar formation. Mice stimulated with IL-17 showed aggravated fibrogenesis, delayed wound healing, and increased inflammation. In addition, macrophage infiltration was also increased. According to the results of the Transwell assay, IL-17 promoted macrophage infiltration through an indirect mechanism. After depleting macrophages with clodronate liposomes, the effect of IL-17 disappeared. Levels of monocyte chemotactic protein (MCP) 1, MCP2, and MCP3 (together referred to as MCPs) were increased by IL-17 stimulation. Bindarit (an inhibitor of MCPs) was used to verify the role of MCPs. In addition, the Ly6C-low macrophages were responsible for wound fibrogenesis in mice. In this study, we detected the increased levels of IL-17 for the first time and revealed that IL-17 induced the infiltration of a specific subtype of macrophages to aggravate fibrosis through an MCP-dependent mechanism. Thus, our results provide a better understanding of scar formation and new strategies for scar prevention.	[Zhang, Julei; Liu, Mengdong; He, Ting; Shi, Jihong; Bai, Xiaozhi; Zhang, Yijie; Li, Yan; Cai, Weixia; Han, Shichao; Guan, Hao; Hu, Dahai] Fourth Mil Med Univ, Dept Burns & Cutaneous Surg, Xijing Hosp, 127 Changle W Rd, Xian 710032, Shaanxi, Peoples R China; [Qiao, Qiao] Fourth Mil Med Univ, Sch Stomatol, Dept Implant Dent, Xian 710032, Shaanxi, Peoples R China	Guan, H; Hu, DH (reprint author), Fourth Mil Med Univ, Dept Burns & Cutaneous Surg, Xijing Hosp, 127 Changle W Rd, Xian 710032, Shaanxi, Peoples R China.	zh-jl@qq.com; xjbumlab@163.com		Hu, Dahai/0000-0001-5543-092X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81571914, 81601689, 81772017]; Bum Center of PLA, Department of Bums and Cutaneous Surgery, Xijing Hospital	Supported by the National Natural Science Foundation of China grants 81571914 (J.S.), 81601689 (T.H.), and 81772017 (D.H.), and The Bum Center of PLA, Department of Bums and Cutaneous Surgery, Xijing Hospital.	Amini-Nik S, 2014, J CLIN INVEST, V124, P2599, DOI 10.1172/JCI62059; Block L, 2015, ADV WOUND CARE, V4, P607, DOI 10.1089/wound.2015.0646; Borthwick LA, 2016, MUCOSAL IMMUNOL, V9, P38, DOI 10.1038/mi.2015.34; Butzelaar L, 2016, EXP DERMATOL, V25, P797, DOI 10.1111/exd.13100; Chiang RS, 2016, WOUND REPAIR REGEN, V24, P466, DOI 10.1111/wrr.12432; Clements M, 2016, J AM SOC NEPHROL, V27, P159, DOI 10.1681/ASN.2014111138; Cremers NAJ, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00086; Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001; Epelman S, 2014, IMMUNITY, V40, P91, DOI 10.1016/j.immuni.2013.11.019; Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kwon SH, 2017, EXP DERMATOL, V26, P133, DOI 10.1111/exd.13167; Lech M, 2013, BBA-MOL BASIS DIS, V1832, P989, DOI 10.1016/j.bbadis.2012.12.001; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Meng FL, 2012, GASTROENTEROLOGY, V143, P765, DOI 10.1053/j.gastro.2012.05.049; Miossec P, 2012, NAT REV DRUG DISCOV, V11, P763, DOI 10.1038/nrd3794; Motwani MP, 2015, SEMIN IMMUNOL, V27, P257, DOI 10.1016/j.smim.2015.07.002; Okamoto Y, 2012, ARTHRITIS RHEUM-US, V64, P3726, DOI 10.1002/art.34643; Penn JW, 2012, INT J BURNS TRAUMA, V2, P18; Qian LW, 2016, WOUND REPAIR REGEN, V24, P26, DOI 10.1111/wrr.12381; Ramachandran P, 2012, P NATL ACAD SCI USA, V109, pE3186, DOI 10.1073/pnas.1119964109; Sasaki JR, 2011, BURNS, V37, P646, DOI 10.1016/j.burns.2011.01.028; Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.44; Shi J, 2014, PLOS ONE, V5; Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y; Ud-Din S, 2014, EXP DERMATOL, V23, P615, DOI 10.1111/exd.12457; van den Broek LJ, 2015, EXP DERMATOL, V24, P623, DOI 10.1111/exd.12739; Wang H, 2015, EUR J PHARMACOL, V751, P42, DOI 10.1016/j.ejphar.2015.01.040; Wilson MS, 2010, J EXP MED, V207, P535, DOI 10.1084/jem.20092121; Wong VW, 2012, NAT MED, V18, P148, DOI 10.1038/nm.2574; Zhang JL, 2018, HISTOL HISTOPATHOL, V33, P27, DOI 10.14670/HH-11-908; Zhu ZS, 2016, WOUND REPAIR REGEN, V24, P644, DOI 10.1111/wrr.12442	32	3	3	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1693	1702		10.1016/j.ajpath.2018.04.005			10	Pathology	Pathology	GL7NE	WOS:000437387800016	29753790	Bronze			2019-10-28	
J	Theriault, M; Gendron, SP; Brunette, I; Rochette, PJ; Proulx, S				Theriault, Mathieu; Gendron, Sebastien P.; Brunette, Isabelle; Rochette, Patrick J.; Proulx, Stephanie			Function-Related Protein Expression in Fuchs Endothelial Corneal Dystrophy Cells and Tissue Models	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FACTOR-BETA SWITCH; PUMP SITE DENSITY; AQUEOUS-HUMOR; BULLOUS KERATOPATHY; OXIDATIVE STRESS; IN-VIVO; MITOCHONDRIAL DYSFUNCTION; CONFOCAL MICROSCOPY; ALTERED EXPRESSION; MISSENSE MUTATIONS	Fuchs endothelial corneal dystrophy (FECD) is a corneal pathology that affects the endothelial cell's ability to maintain deturgescence, resulting in a progressive loss of corneal transparency. In this study, we investigated the expression of function-related proteins in corneal endothelial cells using FECD or healthy corneal endothelial cells, either in a cell culture two-dimensional model or in an engineered corneal endothelium three-dimensional tissue model. No statistically significant difference in gene regulation was observed for the function-related families ATP1, SLC4, SLC16, AQP, TJP, and CDH between the FECD and the healthy cell models. Similarly, no difference in barrier integrity (transendothelial electrical resistance measurements and permeability assays) was observed in vitro between FECD and healthy cultured cells. Protein expression of the key function-related families was decreased for Na+/K+-ATPase alpha 1 subunit, monocarboxylate transporters 1 and 4 in native ex vivo end-stage FECD specimens, whereas it returned to levels comparable to that of healthy tissues in the engineered FECD model. These results indicate that cell expansion and tissue engineering culture conditions can generate a corneal endothelium from pathologic FECD cells, with levels of function-related proteins similar to that of healthy tissues. Overall, these results explain why it is possible to reform a functional endothelium using corneal endothelial cells isolated from nonfunctional FECD pathologic specimens.	[Theriault, Mathieu; Gendron, Sebastien P.; Rochette, Patrick J.; Proulx, Stephanie] Univ Laval, CHU Quebec, Ctr Rech, Hop St Sacrement, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada; [Theriault, Mathieu; Gendron, Sebastien P.; Rochette, Patrick J.; Proulx, Stephanie] Univ Laval, Ctr Rech Organogenese Expt, Lab Organogenese Expt, Quebec City, PQ, Canada; [Rochette, Patrick J.; Proulx, Stephanie] Univ Laval, Dept Ophtalmol & ORL Chirurg Cervicofaciale, Quebec City, PQ, Canada; [Brunette, Isabelle] Maisonneuve Rosemont Hosp Res Ctr, Montreal, PQ, Canada; [Brunette, Isabelle] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada	Proulx, S (reprint author), Univ Laval, CHU Quebec, Ctr Rech, Hop St Sacrement, 1050 Chemin Ste Foy, Quebec City, PQ G1S 4L8, Canada.	stephanie.proulx@fmed.ulaval.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP-106517]; Reseau de Therapie Cellulaire et Tissulaire (TheCell); Charles-Albert Poissant Research Chair in Corneal Transplantation, University of Montreal (Canada); Vision Health Research Network of the Fond de Recherche du Quebec en Sante	Supported by Canadian Institutes of Health Research grant MOP-106517 (I.B., P.J.R., and S.P.) and the Reseau de Therapie Cellulaire et Tissulaire (TheCell). M.T. held a studentship Bourse d'Excellence au Doctorat du Center Laboratoire d'Organogenese Experimental/Universite Laval pour la Recherche en Vision, and S.G. from the Fond de Recherche du Quebec en Sante. I.B. is the recipient of the Charles-Albert Poissant Research Chair in Corneal Transplantation, University of Montreal (Canada). P.J.R. is a research scholar from the Fond de Recherche du Quebec en Sante, and S.P. is a research scholar from the Fond de Recherche du Quebec en Sante in partnership with the Fondation Antoine Turmel. Procurement of eyes and corneas for research from the Centre Universitaire d'Opthalmologie Eye Bank was supported by the Vision Health Research Network of the Fond de Recherche du Quebec en Sante (S.P. and P.J.R.).	Alomar TS, 2011, INVEST OPHTH VIS SCI, V52, P8193, DOI 10.1167/iovs.11-8047; BAHN CF, 1986, INVEST OPHTH VIS SCI, V27, P44; Baratz KH, 2010, NEW ENGL J MED, V363, P1016, DOI 10.1056/NEJMoa1007064; Bergmanson JPG, 1999, OPHTHAL PHYSL OPT, V19, P210, DOI 10.1046/j.1475-1313.1999.00408.x; Bitar MS, 2012, INVEST OPHTH VIS SCI, V53, P5806, DOI 10.1167/iovs.12-10119; Bonanno JA, 2003, PROG RETIN EYE RES, V22, P69, DOI 10.1016/S1350-9462(02)00059-9; Bonanno JA, 2012, EXP EYE RES, V95, P2, DOI 10.1016/j.exer.2011.06.004; Borderie VM, 2000, INVEST OPHTH VIS SCI, V41, P2501; Boudjadi S, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-16; BOURNE WM, 1982, ARCH OPHTHALMOL-CHIC, V100, P1952, DOI 10.1001/archopht.1982.01030040932013; Bourne WM, 1997, INVEST OPHTH VIS SCI, V38, P779; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; BROWN STUART I., 1965, INVEST OPHTHALMOL, V4, P216; CROSS HE, 1971, ARCH OPHTHALMOL-CHIC, V85, P268; De Roo AK, 2016, INVEST OPHTH VIS SCI, V57, P771, DOI 10.1167/iovs.15-18768; Duval C, 2015, EXP EYE RES, V135, P146, DOI 10.1016/j.exer.2015.03.001; Edelhauser HF, 2006, INVEST OPHTH VIS SCI, V47, P1755, DOI 10.1167/iovs.05-1139; Fischbarg J, 2006, J MEMBRANE BIOL, V210, P117, DOI 10.1007/s00232-005-0850-8; Gottsch JD, 2005, INVEST OPHTH VIS SCI, V46, P4504, DOI 10.1167/iovs.05-0497; Gottsch JD, 2005, INVEST OPHTH VIS SCI, V46, P1934, DOI 10.1167/iovs.04-0937; Goyer B, 2018, TISSUE ENG PT A, V24, P607, DOI [10.1089/ten.TEA.2017.0128, 10.1089/ten.tea.2017.0128]; Halestrap AP, 2013, MOL ASPECTS MED, V34, P337, DOI 10.1016/j.mam.2012.05.003; Halilovic A, 2016, ANTIOXID REDOX SIGN, V24, P1072, DOI 10.1089/ars.2015.6532; Haydari MN, 2012, INVEST OPHTH VIS SCI, V53, P6343, DOI 10.1167/iovs.12-9708; IWAMOTO T, 1971, INVEST OPHTH VISUAL, V10, P9; Jalimarada SS, 2014, MOL VIS, V20, P1668; Jalimarada SS, 2013, INVEST OPHTH VIS SCI, V54, P4330, DOI 10.1167/iovs.13-11929; Jun AS, 2012, HUM MOL GENET, V21, P384, DOI 10.1093/hmg/ddr473; Jurkunas UV, 2008, INVEST OPHTH VIS SCI, V49, P2956, DOI 10.1167/iovs.07-1529; Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279; Kenney MC, 2004, J HISTOCHEM CYTOCHEM, V52, P1341, DOI 10.1369/jhc.4A6385.2004; KIM JH, 1971, EXP EYE RES, V12, P231, DOI 10.1016/0014-4835(71)90143-6; KRACHMER JH, 1978, ARCH OPHTHALMOL-CHIC, V96, P2036, DOI 10.1001/archopht.1978.03910060424004; Landreville S, 2011, PIGM CELL MELANOMA R, V24, P643, DOI 10.1111/j.1755-148X.2011.00869.x; Leclerc VB, 2015, INVEST OPHTH VIS SCI, V56; Li QJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1597; Ljubimov AV, 2002, CORNEA, V21, P74, DOI 10.1097/00003226-200201000-00016; Ma L, 2007, EXP EYE RES, V84, P790, DOI 10.1016/j.exer.2006.12.018; Matthaei M, 2016, INVEST OPHTH VIS SCI, V57, P773, DOI 10.1167/iovs.15-19049; Matthaei M, 2015, INVEST OPHTH VIS SCI, V56, P2749, DOI 10.1167/iovs.15-16395; MCCARTNEY MD, 1987, CURR EYE RES, V6, P1479, DOI 10.3109/02713688709044512; MCCARTNEY MD, 1987, INVEST OPHTH VIS SCI, V28, P1955; MCCARTNEY MD, 1987, CURR EYE RES, V6, P589, DOI 10.3109/02713688709025218; MCCARTNEY MD, 1989, INVEST OPHTH VIS SCI, V30, P1560; Meng H, 2013, INVEST OPHTH VIS SCI, V54, P1887, DOI 10.1167/iovs.12-11021; MISHIMA S, 1982, AM J OPHTHALMOL, V93, P1; Molloy-Simard V, 2012, INVEST OPHTH VIS SCI, V53, P6219, DOI [10.1167/ivos.11-8853, 10.1167/iovs.11-8853]; Murphy KT, 2004, J PHYSIOL-LONDON, V556, P507, DOI 10.1113/jphysiol.2003.054981; Mustonen RK, 1998, CORNEA, V17, P493, DOI 10.1097/00003226-199809000-00006; Noske W, 1994, Ger J Ophthalmol, V3, P253; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; POLACK F M, 1976, Survey of Ophthalmology, V20, P375, DOI 10.1016/0039-6257(76)90066-7; Price FW, 2005, J REFRACT SURG, V21, P339; Proulx S, 2009, TISSUE ENG PT A, V15, P1709, DOI 10.1089/ten.tea.2008.0208; Reinhard T, 2006, CORNEA EXTERNAL EYE; Riazuddin SA, 2012, AM J HUM GENET, V90, P533, DOI 10.1016/j.ajhg.2012.01.013; Riazuddin SA, 2010, HUM MUTAT, V31, P1261, DOI 10.1002/humu.21356; Riazuddin SA, 2010, AM J HUM GENET, V86, P45, DOI 10.1016/j.ajhg.2009.12.001; Riazuddin SA, 2009, INVEST OPHTH VIS SCI, V50, P5667, DOI 10.1167/iovs.09-3764; Richardson MR, 2010, MOL VIS, V16, P2376; Soumittra N, 2014, J HUM GENET, V59, P444, DOI 10.1038/jhg.2014.55; Srinivas SP, 2012, EXP EYE RES, V95, P8, DOI 10.1016/j.exer.2011.09.009; Srinivas SP, 2004, EXP EYE RES, V79, P543, DOI 10.1016/j.exer.2004.06.027; Szentmary N, 2005, EUR J OPHTHALMOL, V15, P17; Thiagarajah JR, 2002, J BIOL CHEM, V277, P19139, DOI 10.1074/jbc.M202071200; TUBERVILLE AW, 1986, CURR EYE RES, V5, P939, DOI 10.3109/02713688608995175; Vallabh NA, 2017, MITOCHONDRION, V36, P103, DOI 10.1016/j.mito.2017.05.009; Vithana EN, 2008, HUM MOL GENET, V17, P656, DOI 10.1093/hmg/ddm337; WILSON SE, 1989, INVEST OPHTH VIS SCI, V30, P449; Wojcik KA, 2013, INT J MOL SCI, V14, P19294, DOI 10.3390/ijms140919294; Yuen HKL, 2005, CORNEA, V24, P319, DOI 10.1097/01.ico.0000148288.53323.b2; Zaniolo K, 2012, EXP EYE RES, V94, P22, DOI 10.1016/j.exer.2011.10.018; Zhu C, 2004, INVEST OPHTH VIS SCI, V45, P1743, DOI 10.1167/iovs.03-0814; Zhu YT, 2008, INVEST OPHTH VIS SCI, V49, P3879, DOI 10.1167/iovs.08-1693	74	2	2	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1703	1712		10.1016/j.ajpath.2018.03.014			10	Pathology	Pathology	GL7NE	WOS:000437387800017	29698634	Other Gold			2019-10-28	
J	She, XJ; Lu, XM; Li, T; Sun, JR; Liang, J; Zhai, YQ; Yang, SQ; Gu, Q; Wei, F; Zhu, H; Wang, FH; Luo, XT; Sun, XD				She, Xiangjun; Lu, Xinmin; Li, Tong; Sun, Junran; Liang, Jian; Zhai, Yuanqi; Yang, Shiqi; Gu, Qing; Wei, Fang; Zhu, Hong; Wang, Fenghua; Luo, Xueting; Sun, Xiaodong			Inhibition of Mitochondrial Fission Preserves Photoreceptors after Retinal Detachment	AMERICAN JOURNAL OF PATHOLOGY			English	Article							CELL-DEATH; APOPTOSIS; RECEPTOR; DRP1; DEGENERATION; DYNAMICS; GLUCOSE; FUSION; MICE	Photoreceptor degeneration is a Leading cause of visual impairment worldwide. Separation of neurosensory retina from the underlying retinal pigment epithelium is a prominent feature preceding photoreceptor degeneration in a variety of retinal diseases. Although ophthalmic surgical procedures have been well developed to restore retinal structures, postoperative patients usually experience progressive photoreceptor degeneration and irreversible vision loss that is incurable at present. Previous studies point to a critical role of mitochondria-mediated apoptotic pathway in photoreceptor degeneration, but the upstream triggers remain largely unexplored. In this study, we show that after experimental retinal detachment induction, photoreceptors activate dynamin-related protein 1 (Drp1)-dependent mitochondrial fission pathway and subsequent apoptotic cascades. Mechanistically, endogenous reactive oxygen species (ROS) are necessary for Drp1 activation in vivo, and exogenous ROS insult is sufficient to activate Drp1-dependent mitochondrial fission in cultured photoreceptors. Accordingly, inhibition of Drp1 activity effectively preserves mitochondrial integrity and rescues photoreceptors. Collectively, our data delineate an ROS-Drp1-mitochondria axis that promotes photoreceptor degeneration in retinal diseased models.	[She, Xiangjun; Lu, Xinmin; Li, Tong; Sun, Junran; Liang, Jian; Zhai, Yuanqi; Yang, Shiqi; Zhu, Hong; Wang, Fenghua; Luo, Xueting; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Gen Hosp,Shanghai Peoples Hosp 1, Shanghai, Peoples R China; [Liang, Jian; Zhai, Yuanqi; Zhu, Hong; Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China; [Gu, Qing; Wei, Fang; Luo, Xueting; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China	Luo, XT; Sun, XD (reprint author), Shanghai Jiao Tong Univ, Sch Med, Dept Ophthalmol, Shanghai Peoples Hosp 1, 100 Hai Ning Rd, Shanghai 200080, Peoples R China.	xtluo@sjtu.edu.cn; xdsun@sjtu.edu.cn			National Science Fund for Distinguished Young Scholars grantNational Natural Science Foundation of ChinaNational Science Fund for Distinguished Young Scholars [81425006]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81470640]; Science and Technology Commission of Shanghai Municipality grants [16dz2251500, 16140900800]; Shanghai Pujiang ProgramShanghai Pujiang Program [16PJ1408500]; Program for Eastern Young Scholar at Shanghai Institutions of Higher Learning grant [QD2016003]; Translational Medicine Innovation Fund of Shanghai Jiao Tong University School of Medicine [15ZH4005, 15ZH2009]	Supported by National Science Fund for Distinguished Young Scholars grant 81425006 (X.Su.), National Natural Science Foundation of China grant 81470640 (F.Wa.), Science and Technology Commission of Shanghai Municipality grants 16dz2251500 (F.Wa.) and 16140900800 (X.Luo), Shanghai Pujiang Program grant 16PJ1408500 (H.Z.), Program for Eastern Young Scholar at Shanghai Institutions of Higher Learning grant QD2016003 (X.Luo), Translational Medicine Innovation Fund of Shanghai Jiao Tong University School of Medicine grant 15ZH4005 (X.Su.), and Translational Medicine Innovation Fund of Shanghai Jiao Tong University School of Medicine grant 15ZH2009 (X.Su. and X.Lu).	AHMED J, 1993, INVEST OPHTH VIS SCI, V34, P516; Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; Arroyo JG, 2005, AM J OPHTHALMOL, V139, P605, DOI 10.1016/j.ajo.2004.11.046; Ballweg K, 2014, AM J PHYSIOL-LUNG C, V307, pL895, DOI 10.1152/ajplung.00180.2014; BARBER VC, 1969, J ULTRA MOL STRUCT R, V26, P515, DOI 10.1016/S0022-5320(69)90055-0; Besirli CG, 2010, INVEST OPHTH VIS SCI, V51, P2177, DOI 10.1167/iovs.09-4439; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chertov AO, 2011, J BIOL CHEM, V286, P34700, DOI 10.1074/jbc.M111.279752; Cherubini M, 2017, BIOCHEM BIOPH RES CO, V483, P1063, DOI 10.1016/j.bbrc.2016.08.042; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Dong K, 2012, AM J PATHOL, V181, P1634, DOI 10.1016/j.ajpath.2012.07.029; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Grosse L, 2016, EMBO J, V35, P402, DOI 10.15252/embj.201592789; Huang QC, 2014, J HEPATOL, V61, P859, DOI 10.1016/j.jhep.2014.04.035; Ishihara N, 2009, NAT CELL BIOL, V11, P958, DOI 10.1038/ncb1907; Kam JH, 2015, ONCOTARGET, V6, P26690, DOI 10.18632/oncotarget.5614; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7; Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117; Liu H, 2010, EYE, V24, P137, DOI 10.1038/eye.2009.20; Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324; Murakami Y, 2013, PROG RETIN EYE RES, V37, P114, DOI 10.1016/j.preteyeres.2013.08.001; NAKANISHI S, 1995, TRENDS NEUROSCI, V18, P359, DOI 10.1016/0166-2236(95)93929-R; Okawa H, 2008, CURR BIOL, V18, P1917, DOI 10.1016/j.cub.2008.10.029; Picard M, 2013, AM J PHYSIOL-REG I, V304, pR393, DOI 10.1152/ajpregu.00584.2012; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Roh MI, 2011, INVEST OPHTH VIS SCI, V52, P3825, DOI 10.1167/iovs.10-6797; Sies H, 2014, J BIOL CHEM, V289, P8735, DOI 10.1074/jbc.R113.544635; Tanaka A, 2008, MOL CELL, V29, P409, DOI 10.1016/j.molcel.2008.02.005; Trichonas G, 2010, P NATL ACAD SCI USA, V107, P21695, DOI 10.1073/pnas.1009179107; Vakifahmetoglu-Norberg H, 2017, BIOCHEM BIOPH RES CO, V482, P426, DOI 10.1016/j.bbrc.2016.11.088; Wang L, 2015, CARDIOVASC RES, V106, P272, DOI 10.1093/cvr/cvv005; Wei JX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005382; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Wubben TJ, 2016, OPHTHALMOLOGY, V123, P1553, DOI 10.1016/j.ophtha.2016.02.040; Yang L, 2004, INVEST OPHTH VIS SCI, V45, P648, DOI 10.1167/iovs.03-0827; Yu TZ, 2014, J BIOL CHEM, V289, P34074, DOI 10.1074/jbc.M114.588616	37	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUL	2018	188	7					1713	1722		10.1016/j.ajpath.2018.03.013			10	Pathology	Pathology	GL7NE	WOS:000437387800018	29684364				2019-10-28	
J	Dahl, E; Schirmacher, P; Knuchel-Clarke, R				Dahl, E.; Schirmacher, P.; Knuechel-Clarke, R.			Biobanks A central Task in Pathology	PATHOLOGE			German	Editorial Material									[Dahl, E.; Knuechel-Clarke, R.] Uniklin RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Schirmacher, P.] Univ Klinikum Heidelberg, Pathol Inst, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany	Dahl, E; Knuchel-Clarke, R (reprint author), Uniklin RWTH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.; Schirmacher, P (reprint author), Univ Klinikum Heidelberg, Pathol Inst, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	edahl@ukaachen.de; Peter.Schirmacher@med.uni-heidelberg.de; rknuechel-clarke@ukaachen.de					Bundesarztekammer, 2017, MED ETH UNDR BIOB	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					288	288		10.1007/s00292-018-0448-4			1	Pathology	Pathology	GL7ZV	WOS:000437430200002	29846764	Bronze			2019-10-28	
J	Schuttler, C; Buschhuter, N; Dollinger, C; Ebert, L; Hummel, M; Linde, J; Prokosch, HU; Proynova, R; Lablans, M				Schuettler, C.; Buschhueter, N.; Doellinger, C.; Ebert, L.; Hummel, M.; Linde, J.; Prokosch, H. -U.; Proynova, R.; Lablans, M.			Requirements for a cross-location biobank IT infrastructure Survey of stakeholder input on the establishment of a biobank network of the German Biobank Alliance (GBA)	PATHOLOGE			German	Article						Biological specimen banks; Needs assessment; Request management; Medical nformatics; Stakeholder participation		The large number of biobanks within Germany results in a high degree of heterogeneity with regard to the IT components used at the respective locations. Within the German Biobank Alliance (GBA), 13 biobanks implement harmonized processes for the provision of biomaterial and accompanying data. The networking of the individual biobanks and the associated harmonisation of the IT infrastructure should facilitate access to biomaterial and related clinical data. For this purpose, the relevant target groups were first identified in order to determine their requirements for IT solutions to be developed in a workshop. Of the seven identified interest groups, three were initially invited to a first round of discussions. The stakeholder input expressed resulted in a catalogue of requirements with regard to IT support for (i) a sample and data request, (ii) the handling of patient consent and inclusion, and (iii) the subsequent evaluation of the sample and data request. The next step is to design the IT solutions as prototypes based on these requirements. In parallel, further user groups are being surveyed in order to be able to further concretise the specifications for development.	[Schuettler, C.; Prokosch, H. -U.] Friedrich Alexander Univ Erlangen Nurnberg, Lehrstuhl Med Informat, Wetterkreuz 13, D-91058 Erlangen, Germany; [Buschhueter, N.] Rhein Westfal TH Aachen, Med Fak, Zent Biomat Bank, Aachen, Germany; [Doellinger, C.] Univ Klinikum Heidelberg, BioMat Bank Heidelberg, Heidelberg, Germany; [Ebert, L.; Proynova, R.; Lablans, M.] Deutsch Krebsforschungszentrum, Med Informat Translat Onkol, Heidelberg, Germany; [Hummel, M.] Charite Univ Med Berlin, Zent Biomat Bank ZeBanC, Berlin, Germany; [Hummel, M.] Charite Univ Med Berlin, GBN, Berlin, Germany; [Linde, J.] Univ Med Gottingen, UMG Biobank, Gottingen, Germany	Schuttler, C (reprint author), Friedrich Alexander Univ Erlangen Nurnberg, Lehrstuhl Med Informat, Wetterkreuz 13, D-91058 Erlangen, Germany.	christina.schuettler@fau.de		Ebert, Lars Christian/0000-0002-8215-7006			[Anonymous], 2010, 92412102010 ISO; Arbeitskreis Medizinischer Ethik-Kommissionen, 2016, MUST INF EINW LIG VE; Das Mosaic-Projekt, 2017, EINW MAN GLCS; Deutsches Biobanken Register, 2017, BIOB; German Biobank Node. bbmri. de, 2017, NUTZ ZUFR; Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (GEKID), 2014, ADT GEKID BAS; Heinze O, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-58; Lablans M, 2015, METHOD INFORM MED, V54, P346, DOI 10.3414/ME14-01-0137; Lablans M, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00062; Lablans M, 2016, BUNDESGESUNDHEITSBLA, V59, P373, DOI 10.1007/s00103-015-2299-y; Lesch W, 2016, ISBER 2016; Maguire M, 2001, INT J HUM-COMPUT ST, V55, P453, DOI 10.1006/ijhc.2001.0486; Mate S, 2017, STUD HEALTH TECHNOL, V243, P100, DOI 10.3233/978-1-61499-808-2-100; Mayrhofer MT, 2016, BUNDESGESUNDHEITSBLA, V59, P379, DOI 10.1007/s00103-015-2301-8; Prokosch HU, 2010, APPL CLIN INFORM, V1, P419, DOI 10.4338/ACI-2010-05-RA-0034; Proynova R, 2017, STUD HEALTH TECHNOL, V243, P75, DOI 10.3233/978-1-61499-808-2-75; Richter G, 2016, ETHIK MED, V28, P311, DOI 10.1007/s00481-016-0398-4	17	1	1	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					289	296		10.1007/s00292-018-0435-9			8	Pathology	Pathology	GL7ZV	WOS:000437430200003	29691676	Other Gold			2019-10-28	
J	Becker, KF; Wipperfurth, J; Herpel, E				Becker, K. -F.; Wipperfuerth, J.; Herpel, E.			Preanalytics and biobanking. Influence of preanalytical factors on tissue sample quality	PATHOLOGE			German	Article						Tissue banks; Tissue preservation; Preanalytical phase; Reference standards	PARAFFIN-EMBEDDED TISSUE; C-REACTIVE PROTEIN; BIOLOGICAL-FLUIDS; MENSTRUAL-CYCLE; BIOSPECIMENS; VARIABLES; BIOMARKERS; EXTRACTION; BLOCKS; CANCER	Access to well-characterized human biosamples is one of the most important prerequisites for modern biomedical research. Biobanks play a decisive role here, as they provide corresponding biosamples for planned analyses. Many interfering factors influencing the quality of biosamples have to be taken into account. In addition to logistical, ethical, and data protection aspects, preanalytical variables in the context of sample acquisition, storage, and processing should be mentioned in particular. In this paper, therefore, the most important preanalytical influencing factors are presented systematically and an overview of current national and international activities for the standardized recording of these factors is provided with the goal of being able to better understand their influence on results and to minimize them in the near future.	[Becker, K. -F.] Tech Univ Munich, Klinikums Rechts Isar, Gewebebank, Munich, Germany; [Becker, K. -F.] Tech Univ Munich, Fak Med, Munich, Germany; [Wipperfuerth, J.] Rhein Westfal TH Aachen, Med Fak, Zentr Biomat Bank, Aachen, Germany; [Herpel, E.] Univ Klinikum Heidelberg, Gewebebank NCT, Inst Pathol, Heidelberg, Germany; [Herpel, E.] Univ Klinikum Heidelberg, Inst Pathol, Abt Allgemeine Pathol & Pathol Anat, Neuenheimer Feld 224, D-69120 Heidelberg, Germany	Herpel, E (reprint author), Univ Klinikum Heidelberg, Inst Pathol, Abt Allgemeine Pathol & Pathol Anat, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	esther.herpel@med.uni-heidelberg.de					Asslaber M, 2007, PATHOBIOLOGY, V74, P251, DOI 10.1159/000104453; Betsou F, 2010, CANCER EPIDEM BIOMAR, V19, P1004, DOI 10.1158/1055-9965.EPI-09-1268; Bevilacqua G, 2010, VIRCHOWS ARCH, V456, P449, DOI 10.1007/s00428-010-0887-7; Boellner S, 2015, EXPERT REV MOL DIAGN, V15, P1277, DOI 10.1586/14737159.2015.1070098; Caixeiro NJ, 2016, J CLIN PATHOL, V69, P260, DOI 10.1136/jclinpath-2015-203384; Carraro P, 2007, CLIN CHEM, V53, P1338, DOI 10.1373/clinchem.2007.088344; Ellervik C, 2015, CLIN CHEM, V61, P914, DOI 10.1373/clinchem.2014.228783; Espina V, 2008, MOL CELL PROTEOMICS, V7, P1998, DOI 10.1074/mcp.M700596-MCP200; Ferguson RE, 2007, PROTEOM CLIN APPL, V1, P739, DOI 10.1002/prca.200700380; Gaskins AJ, 2012, AM J EPIDEMIOL, V175, P423, DOI 10.1093/aje/kwr343; Gnanapragasam VJ, 2010, BJU INT, V105, P274, DOI 10.1111/j.1464-410X.2009.08665.x; Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023; Guendisch S, 2012, J PROTEOME RES, V11, P5748, DOI 10.1021/pr300560y; Herpel E, 2008, Pathologe, V29 Suppl 2, P204, DOI 10.1007/s00292-008-1067-2; Herpel E, 2016, BUNDESGESUNDHEITSBLA, V59, P325, DOI 10.1007/s00103-015-2294-3; Kiehntopf M, 2011, HUM GENET, V130, P369, DOI 10.1007/s00439-011-1068-8; Kokkat TJ, 2013, BIOPRESERV BIOBANK, V11, P101, DOI 10.1089/bio.2012.0052; Kokkat TJ, 2013, CYTOJOURNAL, V10, DOI 10.4103/1742-6413.122299; Livesey JH, 2008, CLIN BIOCHEM REV, V29, P11; Lydia Kynast K, 2017, EXP CLIN ENDOCR DIAB, V125, P603, DOI 10.1055/s-0042-123039; Meric-Bernstam F, 2014, CLIN CANCER RES, V20, P3870, DOI 10.1158/1078-0432.CCR-13-1507; Morrin Helen, 2005, N Z Med J, V118, pU1735; Nanni U, 2012, INT J BIOL MARKER, V27, P272, DOI 10.5301/JBM.2012.9718; Ollier W, 2005, PHARMACOGENOMICS, V6, P639, DOI 10.2217/14622416.6.6.639; Plebani M, 1997, CLIN CHEM, V43, P1348; Riegman PHJ, 2008, MOL ONCOL, V2, P213, DOI 10.1016/j.molonc.2008.07.004; Riegman PH, 2015, SCI TRANSL MED, V7, p297fs231; Schrohl AS, 2008, MOL CELL PROTEOMICS, V7, P2061, DOI 10.1074/mcp.R800010-MCP200; Wander K, 2008, AM J PHYS ANTHROPOL, V136, P138, DOI 10.1002/ajpa.20785	29	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					297	302		10.1007/s00292-018-0437-7			6	Pathology	Pathology	GL7ZV	WOS:000437430200004	29619508				2019-10-28	
J	Koschmieder, S; Brummendorf, TH				Koschmieder, S.; Bruemmendorf, T. H.			Biobanking requirements from the perspective of the clinician. Experiences in hematology and oncology	PATHOLOGE			German	Article						Biological specimen banks; Biomedical research; Clinical medicine; Clinical trial; Clinical registries	MYELOPROLIFERATIVE NEOPLASMS MPN; MYELOFIBROSIS; RUXOLITINIB; INHIBITOR; MUTATIONS; KINASE; CELLS; JAK2	The requirements for optimal biobanking from the point of view of the clinical partner can be highly variable. Depending on the material, processing, storage conditions, clinical data, and involvement of external partners, there will be special requirements for the participating clinician and specialist areas. What they all have in common is that the goal of any biobanking must be to improve clinical, translational, and basic research. While in the past biomaterials often had to be individually stored for each research project, modern biobanking offers decisive advantages: a comprehensive ethics vote fulfilling state-of-the-art data safety requirements, standardized processing and storage protocols, specialized biobank software for pseudonymization and localization, protection against power failures and defects of the equipment, centralized and sustainable storage, easy localization and return of samples, and their destruction or anonymization after completion of an individual project. In addition to this important pure storage function, central biobanking can provide a link to clinical data as well as the anonymous use of samples for project-independent research. Both biobank functions serve different purposes, are associated with specific requirements, and should be pursued in parallel. If successful, central biomaterial management can achieve a sustainable improvement of academic and non-academic biomedical research and the optimal use of resources. The close collaboration between clinicians and non-clinicians is a crucial prerequisite for this.	[Koschmieder, S.; Bruemmendorf, T. H.] RWTH Uniklin Aachen, Med Fak, Klin Hamatol Onkol Hamostaseol & Stammzelltranspl, Pauwelsstr 30, D-52074 Aachen, Germany	Koschmieder, S (reprint author), RWTH Uniklin Aachen, Med Fak, Klin Hamatol Onkol Hamostaseol & Stammzelltranspl, Pauwelsstr 30, D-52074 Aachen, Germany.	skoschmieder@ukaachen.de					Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Hajdu SI, 2003, ANN CLIN LAB SCI, V33, P237; Harrison C, 2012, THER ADV HEMATOL, V3, P341, DOI 10.1177/2040620712459746; Hehlmann R, 2017, LEUKEMIA, V31, P2398, DOI 10.1038/leu.2017.253; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Kaifie A, 2016, ANN HEMATOL, V95, P1399, DOI 10.1007/s00277-016-2730-y; Kaifie A, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0242-9; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Verstovsek S, 2012, NEW ENGL J MED, V366, P799, DOI 10.1056/NEJMoa1110557	11	1	1	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					303	307		10.1007/s00292-018-0434-x			5	Pathology	Pathology	GL7ZV	WOS:000437430200005	29623404				2019-10-28	
J	Dahl, E				Dahl, E.			Biobanking and the further development of precision medicine	PATHOLOGE			German	Article						Biological specimen banks; Lung neoplasms; Precision medicine; Proto-oncogenes; Translationalmedical research	LUNG-CANCER; FUSIONS; RET; ALK	Over the last 15 years, an estimated 3000 large centralized biobanks have been established worldwide, making important contributions to the further development of precision medicine. In many cases, these biobanks are affiliated with pathological institutes or work closely with them. In which translational research projects, and during which phases in the development of new drugs are human bioprobes being used and can their use be easily traced in the literature? PubMed, Internet research, and information from the German Biobank Alliance and the European initiative BBMRI-ERIC. High-quality biosamples from centralized biobanks are increasingly used in clinical research and development projects. Success stories, where bioprobes have contributed to the further development of precision medicine, are shown in this paper using among others the example of RET gene fusion discovery in lung cancer. Interestingly enough, many key publications in the field of precision medicine do not contain exact references to the biobanks involved. The importance of centralized biobanks in translational research and clinical development is constantly increasing. However, in order to ensure the acceptance and visibility of biobanks, their participation in success stories of biomedical progress must be systematically documented and published.	[Dahl, E.] Uniklin RWTH Aachen, Inst Pathol, Lehr & Forsch Gebiet Tumorpathol, Arbeitsgrp Mol Onkol, Pauwelsstr 30, D-52074 Aachen, Germany; [Dahl, E.] Uniklin RWTH Aachen, Med Fak, RWTH Zent Biomat Bank RWTH cBMB, Aachen, Germany	Dahl, E (reprint author), Uniklin RWTH Aachen, Inst Pathol, Lehr & Forsch Gebiet Tumorpathol, Arbeitsgrp Mol Onkol, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de					Ferrara R, 2018, J THORAC ONCOL, V13, P27, DOI 10.1016/j.jtho.2017.10.021; Kohno T, 2013, CANCER SCI, V104, P1396, DOI 10.1111/cas.12275; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Weeden CE, 2017, MOL CANCER THER, V16, P1610, DOI 10.1158/1535-7163.MCT-17-0174; Zatloukal K, 2010, BIOMARK MED, V4, P895, DOI 10.2217/BMM.10.104; Zhou JH, 2015, ARCH PATHOL LAB MED, V139, P812, DOI 10.5858/arpa.2014-0261-RA	8	2	2	2	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					308	312		10.1007/s00292-018-0449-3			5	Pathology	Pathology	GL7ZV	WOS:000437430200006	29876651				2019-10-28	
J	Hummel, M; Stege, A				Hummel, M.; Stege, A.			The construction and operation of a central biomaterial bankThe ZeBanC of the Charite Berlin	PATHOLOGE			German	Article						Biobanks; Biomedical research; Database; Cryopreservation; Specimen handling		The use of high-quality, well-characterized biomaterials and their clinical and demographic information for biomedical research has steadily increased in importance over the last 10 years. There are several reasons for this. On the one hand, several studies have shown that even in high-profile scientific papers the description of the origin and characteristics of the biomaterials used is missing or insufficient. On the other hand, it has become generally accepted that small collections of biomaterials are often created under ethically and legally unclear conditions without quality measures and without sufficient sustainability. The establishment of a centralized biomaterial bank (ZeBanC) was initiated in order to steer the biomaterial collections at the Charit, under well defined conditions. This activity is carried out in close cooperation between the Charit, and the Berlin Institute of Health (BIH).	[Hummel, M.] Charite Univ Med Berlin, Zent Biomat Bank Charite ZeBanC, Charitepl 1, D-10117 Berlin, Germany; [Hummel, M.] Charite Univ Med Berlin, BIH, Charitepl 1, D-10117 Berlin, Germany	Hummel, M (reprint author), Charite Univ Med Berlin, Zent Biomat Bank Charite ZeBanC, Charitepl 1, D-10117 Berlin, Germany.; Hummel, M (reprint author), Charite Univ Med Berlin, BIH, Charitepl 1, D-10117 Berlin, Germany.	michael.hummel@charite.de					Domhardt M, 2015, NATL BIOBANKEN S 201	1	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					313	319		10.1007/s00292-018-0451-9			7	Pathology	Pathology	GL7ZV	WOS:000437430200007	29922857				2019-10-28	
J	Schmitt, S; Dollinger, C; Maier, A; Herpel, E; Schirmacher, P; Kirsten, R				Schmitt, S.; Doellinger, C.; Maier, A.; Herpel, E.; Schirmacher, P.; Kirsten, R.			Merging different biobanks under one roof. Benefits and constraints on the way to a centralized biobank using the example of the BMBH	PATHOLOGE			German	Article						Biological specimen banks; Biomedical research; Tissue banks; Health care quality assurance		Founded in 1386, Heidelberg University is Germany's oldest and one of Europe's most reputable universities. As a scientific hub in Germany, Heidelberg is home to several internationally renowned medical research facilities that have an enormous demand for biomaterial samples and data-especially in the field of translational and cancer research. The main objective of the BMBF-funded project "BioMaterialBank Heidelberg" (BMBH) was the harmonization of local biobanking under the same administrative roof through the implementation of common and standardized project, data, and quality management procedures. In the very beginning, existing structures and processes of the participating biobanks in Heidelberg were identified and a common administrative structure with central representatives for IT and quality management (QM) was established to coordinate all BMBH activities. Over time, implementation of consented structures and processes took place, also revealing organizational challenges that had to be solved concerning, for example, differences in sample handling and the definition of consistent access regulations. We will discuss below these challenges as well as the opportunities of building a centralized biobank and show how issues can be resolved using the example of the BMBH.	[Schmitt, S.; Doellinger, C.; Maier, A.; Herpel, E.; Schirmacher, P.; Kirsten, R.] Univ Klinikum Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany	Schmitt, S (reprint author), Univ Klinikum Heidelberg, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.	sabrina.schmitt@med.uni-heidelberg.de					AMEidBD V., 2016, MUSTERTEXT INFORM EI; Herpel E, 2013, DEUT MED WOCHENSCHR, V138, P1069, DOI 10.1055/s-0033-1343143; Herpel E, 2008, Pathologe, V29 Suppl 2, P204, DOI 10.1007/s00292-008-1067-2; Herpel E, 2012, FORUM, V27, P47; Herpel E, 2010, VIRCHOWS ARCH, V457, P741, DOI 10.1007/s00428-010-0998-1; Kirsten R, 2016, BUNDESGESUNDHEITSBLA, V59, P390, DOI 10.1007/s00103-015-2302-7; (Marsilius-Kolleg) E-P, 2013, ETH RECHTL ASP GANZG, V2; Schmitt S, 2015, PATHOLOGE, V36, P205, DOI 10.1007/s00292-015-0083-2; Schmitt S, 2016, VIRCHOWS ARCH, V468, P93, DOI 10.1007/s00428-015-1825-5	9	0	0	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					320	327		10.1007/s00292-018-0444-8			8	Pathology	Pathology	GL7ZV	WOS:000437430200008	29796710				2019-10-28	
J	Jurmeister, P				Jurmeister, P.			Early Diagnosis and Localization of Cancer by Liquid Biopsy	PATHOLOGE			German	Editorial Material									[Jurmeister, P.] Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany	Jurmeister, P (reprint author), Charite Univ Med Berlin, Inst Pathol, Charitepl 1, D-10117 Berlin, Germany.	Philipp.Jurmeister@charite.de					Heitzer E, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0039-5; Mishra Alok, 2010, Cancers (Basel), V2, P190, DOI 10.3390/cancers2010190	2	0	0	1	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					328	329		10.1007/s00292-018-0454-6			2	Pathology	Pathology	GL7ZV	WOS:000437430200009	29951738				2019-10-28	
J	Meister, P; Kelker, W; Gossler, U; Hammerstingl, R; Vogl, TJ; Winkelmann, R				Meister, P.; Kelker, W.; Goessler, U.; Hammerstingl, R.; Vogl, T. J.; Winkelmann, R.			Vascularized tumor of the retroauricular skin	PATHOLOGE			German	Article						Glomus tumor; Glomus jugulare tumor; Skin neoplasm; Mastoid process; Paraganglioma		An 84-year-old female patient with loss of hearing and otorrhoea went to an otolaryngologist. On examination, a polypoid mass in the auditory canal and a retroauricular skin lesion, possibly seborrheic keratosis, were found. Only the skin was submitted for histological examination and showed a cutaneous highly vascular lesion with an associated "zellballen" of clear cells without atypia. The initial diagnosis was that of a cutaneous glomangioma. Immunohistochemical findings favored diagnosis of a paraganglioma. Additional clinical information revealed a large mastoid tumor mass. Therefore, the findings were compatible with an jugulotympanic paraganglioma with infiltration of the overlying skin. This possibility was initially not considered in differential diagnosis, as cutaneous glomangiomas are relatively common (typically located on the hands). Cutaneous paragangliomas, however, are not reported.	[Meister, P.; Winkelmann, R.] Univ Klinikum Frankfurt, Dr Senckenberg Inst Pathol, Theodor Stern Kai 6, D-60590 Frankfurt, Germany; [Kelker, W.; Goessler, U.] St Marien Hosp, Frankfurt, Germany; [Hammerstingl, R.; Vogl, T. J.] Univ Klinikum Frankfurt, Inst Diagnost & Intervent Radiol, Frankfurt, Germany	Winkelmann, R (reprint author), Univ Klinikum Frankfurt, Dr Senckenberg Inst Pathol, Theodor Stern Kai 6, D-60590 Frankfurt, Germany.	winkelmann@em.uni-frankfurt.de					DeLellis RA, 2004, WHO CLASSIFICATION T; Fishbein L, 2017, CANCER CELL, V31, P181, DOI 10.1016/j.ccell.2017.01.001; LACK EE, 1997, TUMORS ADRENAL GLAND; Moore MG, 2016, OTOLARYNG HEAD NECK, V154, P597, DOI 10.1177/0194599815627667; Tischler AS, 2015, ENDOCR-RELAT CANCER, V22, pT123, DOI 10.1530/ERC-15-0261	5	0	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					330	332		10.1007/s00292-018-0445-7			3	Pathology	Pathology	GL7ZV	WOS:000437430200010	29789864				2019-10-28	
J	Tritschler, S; Erdelkamp, R; Stief, C; Hentrich, M				Tritschler, S.; Erdelkamp, R.; Stief, C.; Hentrich, M.			Neuroendocrine prostate cancer	PATHOLOGE			German	Article						Prostate; Neuroendocrine carcinoma; Androgen deprivation therapy; Chromogranin A; Chemotherapy	SMALL-CELL CARCINOMA; PROGNOSTIC-SIGNIFICANCE; CONTEMPORARY INCIDENCE; PHASE-II; DIFFERENTIATION; SURVIVAL; ADENOCARCINOMA; PERSPECTIVES; CHEMOTHERAPY; EXPRESSION	Neuroendocrine prostate cancer (NEPC) mostly occurs as a treatment-emergent adaptive response under the pressure of intensive androgen deprivation treatment (t-NEPC). Approximately 30-40% of patients with metastatic castration-resistant prostate cancer (mCRPC) also have neuroendocrine involvement. In contrast primary small cell prostate cancer is very rare (< 1%). A taEuroNEPC should be clinically suspected in patients who have particularly aggressive mCRPC but a disproportionately low prostate-specific antigen (PSA) level and elevated neuroendocrine tumor markers, such as chromogranin A and neuron-specific enolase. The initial Gleason score was shown to be an independent factor correlated to the risk of development of taEuroNEPC. Treatment is oriented to that of small cell lung cancer. In patients with negative PSA levels, chemotherapy with cisplatin and etoposide is the first line treatment, for which response rates in the range of 30-60% with a median survival time of usually less than 1 year can be achieved. In patients with much higher serum PSA levels, chemotherapy with carboplatin plus docetaxel should be considered.	[Tritschler, S.; Stief, C.] LMU Munchen, Klinikum Grosshadern, Urol Klin & Poliklin, Marchioninistr 15, D-81377 Munich, Germany; [Erdelkamp, R.] LMU Munchen, Pathol Inst, Munich, Germany; [Hentrich, M.] Rotkreuzklinikum Munchen, Med Klin 3, Munich, Germany	Tritschler, S (reprint author), LMU Munchen, Klinikum Grosshadern, Urol Klin & Poliklin, Marchioninistr 15, D-81377 Munich, Germany.	Stefan.Tritschler@med.uni-muenchen.de					Aggarwal RR, 2017, ONCOLOGY-NY, V31, P467; Alanee S, 2015, ANTICANCER RES, V35, P4145; Alonso O, 2011, CLIN NUCL MED, V36, P1063, DOI 10.1097/RLU.0b013e31822920c9; AMATO RJ, 1992, J UROLOGY, V147, P935, DOI 10.1016/S0022-5347(17)37427-X; Aparicio A, 2014, ONCOLOGY-NY, V28, P831; Aparicio AM, 2013, CLIN CANCER RES, V19, P3621, DOI 10.1158/1078-0432.CCR-12-3791; Asmis TR, 2006, BJU INT, V97, P711, DOI 10.1111/j.1464-410X.2006.06041.x; Beltran H, 2016, CLIN ADV HEMATOL ONC, V14, P513; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Berruti A, 2007, J UROLOGY, V178, P838, DOI 10.1016/j.juro.2007.05.018; Culine S, 2007, J UROLOGY, V178, P844, DOI 10.1016/j.juro.2007.05.044; Epstein JI, 2014, AM J SURG PATHOL, V38, P756, DOI 10.1097/PAS.0000000000000208; Evans AJ, 2006, AM J SURG PATHOL, V30, P684, DOI 10.1097/00000478-200606000-00003; Flechon A, 2011, ANN ONCOL, V22, P2476, DOI 10.1093/annonc/mdr004; Gofrit ON, 2017, CLIN NUCL MED, V42, P1, DOI 10.1097/RLU.0000000000001424; Hirano D, 2004, EUR UROL, V45, P586, DOI 10.1016/j.eururo.2003.11.032; Lotan TL, 2011, MODERN PATHOL, V24, P820, DOI 10.1038/modpathol.2011.7; Luboldt W, 2010, MOL IMAGING BIOL, V12, P78, DOI 10.1007/s11307-009-0230-3; Marcus DM, 2012, PROSTATE CANCER P D, V15, P283, DOI 10.1038/pcan.2012.4; Nadal R, 2014, NAT REV UROL, V11, P213, DOI 10.1038/nrurol.2014.21; OESTERLING JE, 1992, J UROLOGY, V147, P804, DOI 10.1016/S0022-5347(17)37390-1; Papandreou CN, 2002, J CLIN ONCOL, V20, P3072, DOI 10.1200/JCO.2002.12.065; Parimi V, 2014, AM J CLIN EXP UROL, V2, P273; Santoni M, 2014, BBA-REV CANCER, V1846, P630, DOI 10.1016/j.bbcan.2014.10.008; Small EJ, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.5003; Stephens PJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.5027; Tagawa ST, 2014, J CLIN ONCOL, V32, P3360, DOI 10.1200/JCO.2014.57.5100; Tamas EF, 2006, AM J SURG PATHOL, V30, P980, DOI 10.1097/00000478-200608000-00008; Taplin ME, 2005, UROLOGY, V66, P386, DOI 10.1016/j.urology.2005.03.040; Vlachostergios PJ, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00006; Wang HT, 2014, J CLIN ONCOL, V32, P3383, DOI 10.1200/JCO.2013.54.3553; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Zaffuto E, 2017, CLIN GENITOURIN CANC, V15, pE793, DOI 10.1016/j.clgc.2017.04.006	33	0	0	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8113	1432-1963		PATHOLOGE	Pathologe	JUL	2018	39	4					333	341		10.1007/s00292-018-0453-7			9	Pathology	Pathology	GL7ZV	WOS:000437430200011	29946852				2019-10-28	
J	Miyamoto, A; Sharma, A; Nishino, M; Mino-Kenudson, M; Matsubara, O; Mark, EJ				Miyamoto, Atsushi; Sharma, Amita; Nishino, Michiya; Mino-Kenudson, Mari; Matsubara, Osamu; Mark, Eugene Jerome			Expanded acceptance of acute exacerbation of nonspecific interstitial pneumonia, including 7 additional cases with detailed clinical pathologic correlation	PATHOLOGY INTERNATIONAL			English	Article						acute exacerbation; fibroblastic foci; idiopathic interstitial pneumonia; nonspecific interstitial pneumonia; pathology; surgical lung biopsy	IDIOPATHIC PULMONARY-FIBROSIS; FIBROTIC LUNG-DISEASE; ORGANIZING PNEUMONIA; HISTOLOGIC FEATURES; CLASSIFICATION; PROGRESSION; DIAGNOSIS	Acute exacerbation is uncommonly diagnosed in patients with nonspecific interstitial pneumonia (NSIP) and its pathologic features have received relatively little attention compared to idiopathic pulmonary fibrosis. We retrospectively studied 14 consecutive cases of histopathologically proven NSIP by surgical lung biopsy. The diagnosis of acute exacerbation was confirmed clinically. We analyzed whether four reported pathologic features, including organizing pneumonia lesion, alveolar hemorrhage, many fibroblastic foci, and focal hyaline membranes were present and suggestive of acute exacerbation of NSIP or not. Acute exacerbation in patients with NSIP was diagnosed in 8 cases, while the remaining 6 cases were diagnosed as clinically stable. Seven cases of organizing pneumonia lesion, 7 of alveolar hemorrhage, 6 of many fibroblastic foci, and 3 of focal hyaline membranes were identified as the main pathologic components in patients with acute exacerbation. Organizing pneumonia lesion and many fibroblastic foci were identified in 2 and 3 stable cases, respectively. Having more than two components was significantly associated with acute exacerbation. Evaluation of lung biopsies with NSIP for organizing pneumonia lesions, alveolar hemorrhage, many fibroblastic foci, and focal hyaline membranes may be useful to predict the possibility of acute exacerbation.	[Miyamoto, Atsushi; Nishino, Michiya; Mino-Kenudson, Mari; Mark, Eugene Jerome] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA; [Sharma, Amita] Massachusetts Gen Hosp, Div Thorac Imaging & Intervent, Boston, MA 02114 USA; [Matsubara, Osamu] Hiratsuka Kyosai Hosp, Dept Pathol, Hiratsuka, Kanagawa, Japan; [Miyamoto, Atsushi] Toranomon Gen Hosp, Dept Resp Med, Resp Ctr, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan; [Nishino, Michiya] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA	Miyamoto, A (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.; Miyamoto, A (reprint author), Toranomon Gen Hosp, Dept Resp Med, Resp Ctr, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan.	atsushimotty@gmail.com					American Thoracic Society, 2002, AM J RESP CRIT CARE, V165, P277; Aubry MCBA, 2017, PRACTICAL THORACIC P, P82; Churg A, 2007, AM J SURG PATHOL, V31, P277, DOI 10.1097/01.pas.0000213341.70852.9d; Churg A, 2016, HISTOPATHOLOGY, V69, P128, DOI 10.1111/his.12950; Churg A, 2011, HISTOPATHOLOGY, V58, P525, DOI 10.1111/j.1365-2559.2010.03650.x; Collard HR, 2007, AM J RESP CRIT CARE, V176, P636, DOI 10.1164/rccm.200703-463PP; Collard HR, 2016, AM J RESP CRIT CARE, V194, P265, DOI 10.1164/rccm.201604-0801CI; Collard HR, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-73; Huie TJ, 2010, RESPIROLOGY, V15, P909, DOI 10.1111/j.1440-1843.2010.01774.x; KATZENSTEIN ALA, 1994, AM J SURG PATHOL, V18, P136, DOI 10.1097/00000478-199402000-00003; Katzenstein ALA, 2008, HUM PATHOL, V39, P1275, DOI 10.1016/j.humpath.2008.05.009; KONDOH Y, 1993, CHEST, V103, P1808, DOI 10.1378/chest.103.6.1808; Lee JW, 2010, AM J ROENTGENOL, V195, P916, DOI 10.2214/AJR.09.3940; Marie I, 2002, ARTHRIT RHEUM-ARTHR, V47, P614, DOI 10.1002/art.10794; Mukhopadhyay S, 2012, SEMIN RESP CRIT CARE, V33, P476, DOI 10.1055/s-0032-1325158; Myers JL, 2009, HISTOPATHOLOGY, V54, P90, DOI 10.1111/j.1365-2559.2008.03173.x; Nicholson AG, 2002, AM J RESP CRIT CARE, V166, P173, DOI 10.1164/rccm.2109039; Oda K, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0109-y; Park IN, 2007, CHEST, V132, P214, DOI 10.1378/chest.07-0323; Roberton BJ, 2011, EUR RADIOL, V21, P2244, DOI 10.1007/s00330-011-2191-6; Schmidt SL, 2009, RESPIROLOGY, V14, P934, DOI 10.1111/j.1440-1843.2009.01626.x; Song JW, 2011, EUR RESPIR J, V37, P356, DOI 10.1183/09031936.00159709; Suda T, 2009, RESP MED, V103, P846, DOI 10.1016/j.rmed.2008.12.019; Taniguchi H, 2016, RESPIROLOGY, V21, P810, DOI 10.1111/resp.12786; Todd NW, 2015, RESP MED, V109, P1460, DOI 10.1016/j.rmed.2015.09.015; Travis WD, 2008, AM J RESP CRIT CARE, V177, P1338, DOI 10.1164/rccm.200611-1685OC; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Wells AU, 2016, CURR OPIN PULM MED, V22, P450, DOI 10.1097/MCP.0000000000000302	28	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					401	408		10.1111/pin.12676			8	Pathology	Pathology	GL2IH	WOS:000436942800001	29726062				2019-10-28	
J	Fujii, M; Mizutani, Y; Sakuma, T; Tagami, K; Okamoto, K; Kuno, Y; Harada, M; Kubouchi, K; Tsutsumi, Y				Fujii, Mari; Mizutani, Yasuyoshi; Sakuma, Takahiko; Tagami, Kouichiro; Okamoto, Kiichiro; Kuno, Yasushi; Harada, Michihiko; Kubouchi, Koichi; Tsutsumi, Yutaka			Corynebacterium kroppenstedtii in granulomatous mastitis: Analysis of formalin-fixed, paraffin-embedded biopsy specimens by immunostaining using low-specificity bacterial antisera and real-time polymerase chain reaction	PATHOLOGY INTERNATIONAL			English	Article						Corynebacterium kroppenstedtii; formalin-fixed paraffin-embedded tissue; granulomatous mastitis; immunohistochemistry; low-specificity antiserum; real-time PCR	PROPIONIBACTERIUM-ACNES; BREAST ABSCESS; INFECTION; DIAGNOSIS; IDENTIFICATION; ASSOCIATION; RHODOCOCCUS	Granulomatous mastitis (GM) is a rare inflammatory disease of the post-lactation breast, clinically mimicking breast cancer. GM is microscopically characterized by formation of epithelioid granulomas and abscess (suppurative granulomas) with lipid droplet-centered inflammation. Corynebacterium kroppenstedtii (Ck) is known as a causative bacterium of GM, and identification of Ck infection within the lesion should thus be essential for confirming the diagnosis. In the present study, we analyzed formalin-fixed, paraffin-embedded (FFPE) biopsy specimens of a total of 18 GM lesions with immunostaining and real-time PCR for Ck genome. Widely cross-reactive rabbit antisera against Bacillus Calmette-Guerin (BCG), Bacillus cereus, Treponema pallidum and Escherichia coli were chosen. With real-time PCR, Ck genome was demonstrated in 7 of 18 GM lesions. Immunohistochemically, the low-specificity antisera reacted with the cytoplasm of phagocytes and/or granuloma-engulfed lipid droplets in 12 of 18 GM lesions. Antigenic positivity was observed in the following order: BCG > B. cereus > T. pallidum > E. coli. Real-time PCR using DNA extracted from FFPE sections was useful but not consistent for identifying the Ck genome in GM, while immunostaining using cross-reactive antisera against four kinds of bacteria was not Ck-specific but was applicable to visualizing bacterial infection within the GM lesions.	[Fujii, Mari] Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan; [Mizutani, Yasuyoshi; Tsutsumi, Yutaka] Fujita Hlth Univ, Sch Med, Dept Pathol, Toyoake, Aichi, Japan; [Sakuma, Takahiko] Atsumi Hosp, Dept Lab Med, Tahara, Japan; [Tagami, Kouichiro] Atsumi Hosp, Surg, Tahara, Japan; [Okamoto, Kiichiro] Toyohashi Med Ctr, Dept Surg, Toyohashi, Aichi, Japan; [Kuno, Yasushi] Hinaga Gastrointestinal & Breast Clin, Yokaichi, Mie, Japan; [Harada, Michihiko] Minami Nagano Koen Clin, Nagano, Japan; [Kubouchi, Koichi] Yokohama Breast & GI Clin, Kohoku Ku, Yokohama, Kanagawa, Japan; [Tsutsumi, Yutaka] Pathos Tsutsumi, 412 Palnes Zengo,1735 Zene,Zengo Cho, Toyoake, Aichi 4701151, Japan; [Mizutani, Yasuyoshi] Fujita Hlth Univ, Sch Med, Dept Mol Oncol, Toyoake, Aichi 4701192, Japan	Tsutsumi, Y (reprint author), Pathos Tsutsumi, 412 Palnes Zengo,1735 Zene,Zengo Cho, Toyoake, Aichi 4701151, Japan.	pathos223@kind.ocn.ne.jp		Sakuma, Takahiko/0000-0002-9477-2196			Altintoprak Fatih, 2014, World J Clin Cases, V2, P852, DOI 10.12998/wjcc.v2.i12.852; Ang LMN, 2007, J CLIN MICROBIOL, V45, P1666, DOI 10.1128/JCM.02160-06; Bani-Hani Kamal E, 2004, Breast J, V10, P318, DOI 10.1111/j.1075-122X.2004.21336.x; D'Alfonso TM, 2015, J PATHOL TRANSL MED, V49, P279, DOI 10.4132/jptm.2015.06.11; Dobinson HC, 2015, J CLIN MICROBIOL, V53, P2895, DOI 10.1128/JCM.00760-15; EALES JEAN D., 1964, AUSTRALIAN VETERINARY J, V40, P321, DOI 10.1111/j.1751-0813.1964.tb04528.x; Fernandez-Natal I., 2016, New Microbes and New Infections, V14, P93, DOI 10.1016/j.nmni.2016.09.006; Gneiding K, 2008, J CLIN MICROBIOL, V46, P3646, DOI 10.1128/JCM.01202-08; Hoyles L, 2013, VET MICROBIOL, V165, P469, DOI 10.1016/j.vetmic.2013.03.025; Johnson JA, 2011, J CLIN MICROBIOL, V49, P1662, DOI 10.1128/JCM.02121-10; Kanazawa Shigeo, 2000, International Journal of Clinical Oncology, V5, P57, DOI 10.1007/s101470050011; KESSLER E, 1972, AM J CLIN PATHOL, V58, P642; Koerner RJ, 2009, FEMS IMMUNOL MED MIC, V55, P296, DOI 10.1111/j.1574-695X.2008.00513.x; Kritikos A., 2015, New Microbes and New Infections, V4, P9, DOI 10.1016/j.nmni.2014.12.001; Kutsuna S, 2015, INTERNAL MED, V54, P1815, DOI 10.2169/internalmedicine.54.4254; Le Fleche-Mateos A, 2012, CASE REP INFECT DIS, DOI 10.1155/2012/120968; Negi M, 2012, MODERN PATHOL, V25, P1284, DOI 10.1038/modpathol.2012.80; Nishiuchi Y, 2000, J MICROBIOL METH, V40, P1, DOI 10.1016/S0167-7012(99)00116-5; Paviour S, 2002, CLIN INFECT DIS, V35, P1434, DOI 10.1086/344463; Perry A, 2011, EXPERT REV ANTI-INFE, V9, P1149, DOI [10.1586/ERI.11.137, 10.1586/eri.11.137]; PRESCOTT JF, 1991, CLIN MICROBIOL REV, V4, P20; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; Ratcliff RM, 2007, CURR ISSUES MOL BIOL, V9, P87; Riegel P, 2004, INT J MED MICROBIOL, V294, P413, DOI 10.1016/j.ijmm.2004.07.013; Shang XZ, 2002, AM J PATHOL, V161, P257, DOI 10.1016/S0002-9440(10)64177-6; Stary Creed Michael, 2011, Hawaii Med J, V70, P99; Tamakuma K, 2012, CLIN MICROBIOL INFEC, V18, P260, DOI 10.1111/j.1469-0691.2011.03569.x; Tauch A, 2016, INT J INFECT DIS, V48, P33, DOI 10.1016/j.ijid.2016.04.023; Taylor GB, 2003, PATHOLOGY, V35, P109, DOI [10.1080/0031302031000082197, 10.1080/00313020307574]; Tokunaga Eriko, 2004, Breast J, V10, P261, DOI 10.1111/j.1075-122X.2004.21319.x; Tse GMK, 2004, PATHOLOGY, V36, P254, DOI 10.1080/00313020410001692602; Tsutsumi Y., 2018, ANTIBIOT CHEMOTHER, V34, P4; Wang YS, 2017, CASE REP INFECT DIS, P1, DOI 10.1155/2017/7052908; Watts JL, 2000, J DAIRY SCI, V83, P2373, DOI 10.3168/jds.S0022-0302(00)75126-5; Wong SCY, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx096	35	2	2	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					409	418		10.1111/pin.12683			10	Pathology	Pathology	GL2IH	WOS:000436942800002	29862601				2019-10-28	
J	Kato, S; Yanazaki, M; Hayashi, K; Satoh, F; Isobe, I; Tsutsumi, Y				Kato, Shu; Yanazaki, Motoi; Hayashi, Kino; Satoh, Fumiko; Isobe, Ichiro; Tsutsumi, Yutaka			Fulminant group A streptococcal infection without gangrene in the extremities: Analysis of five autopsy cases	PATHOLOGY INTERNATIONAL			English	Article						autopsy; fulminant streptococcal infection; hemophagocytosis; immunohistochemistry; streptococcal toxic shock syndrome	PYOGENES INFECTION; EVASION; DISEASE; INTERLEUKIN-8; PATHOGENESIS; NEUTROPHILS	Five autopsy cases of fulminant group A streptococcal infection without gangrene in the extremities are presented. Clinical course of the fulminant illness was short (2-4 days). One pathological autopsy case was aged (86-years-old), and hemorrhagic cystitis was observed. The other four forensic autopsy cases were young (24-38 years-old) with the mean age of 32, and the primary infective lesions were located in the postpartum endometrium, tonsil and bronchus (2 cases). Systemic coccal dissemination with poor neutrophilic reaction was seen in two of five cases. Bilateral renal cortical necrosis was noted in three cases (including two with bacterial embolism). Hemophagocytosis, probably resulting from hypercytokinemia, was characteristic in three cases without bacterial embolism. Gram-positive cocci colonizing the hemorrhagic and necrotizing lesions were consistently immunoreactive for streptococcal antigens and Strep A (a carbohydrate antigen on group A streptococci). Neutrophilic reaction was mild in the primary infected foci. Clinicians should note that fulminant streptococcal infection (streptococcal toxic shock syndrome) in young and immunocompetent patients may not be associated with gangrene in the extremities. Autopsy prosecutors (diagnostic and forensic pathologists) must recognize the difficulty in making an appropriate autopsy diagnosis, particularly when bacterial embolism is not associated.	[Kato, Shu; Yanazaki, Motoi] Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan; [Kato, Shu; Yanazaki, Motoi; Tsutsumi, Yutaka] Fujita Hlth Univ, Sch Med, Dept Pathol, Toyoake, Aichi, Japan; [Hayashi, Kino] Tokyo Med Examiners Off, Tokyo, Japan; [Satoh, Fumiko] Kitasato Univ, Sch Med, Dept Legal Med, Sagamihara, Kanagawa, Japan; [Isobe, Ichiro] Fujita Hlth Univ, Sch Med, Dept Legal Med, Toyoake, Aichi, Japan; [Tsutsumi, Yutaka] Pathos Tsutsumi, 412 Palnes Zengo,1735 Zene,Zengo Cho, Toyoake, Aichi 4701151, Japan	Tsutsumi, Y (reprint author), Pathos Tsutsumi, 412 Palnes Zengo,1735 Zene,Zengo Cho, Toyoake, Aichi 4701151, Japan.	pathos223@kind.ocn.ne.jp					Bakleh M, 2005, CLIN INFECT DIS, V40, P410, DOI 10.1086/427286; Bryant AE, 2005, J INFECT DIS, V192, P1014, DOI 10.1086/432729; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; FUJIWARA F, 1993, AM J PEDIAT HEMATOL, V15, P92; Fukusato T, 1984, Nihon Jinzo Gakkai Shi, V26, P1461; Kuo CF, 2008, INFECT IMMUN, V76, P1163, DOI 10.1128/IAI.01116-07; Lamagni TL, 2008, J CLIN MICROBIOL, V46, P2359, DOI 10.1128/JCM.00422-08; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Onouchi T, 2015, MICROBIOL IMMUNOL, V59, P13, DOI 10.1111/1348-0421.12213; Ooe K, 1997, HUM PATHOL, V28, P509, DOI 10.1016/S0046-8177(97)90043-5; Sitkiewicz I, 2010, POL J MICROBIOL, V59, P219; STEVENS DL, 1995, EMERG INFECT DIS, V1, P69, DOI 10.3201/eid0103.950301; Tajiri T, 2008, INTERNAL MED, V47, P1499, DOI 10.2169/internalmedicine.47.1160; Terao Y, 2008, J BIOL CHEM, V283, P6253, DOI 10.1074/jbc.M704821200; Terao Y, 2006, J BIOL CHEM, V281, P14215, DOI 10.1074/jbc.M513408200; Tormos LM, 2013, J FORENSIC SCI, V58, P1071, DOI 10.1111/1556-4029.12099; Tsutsumi Y., 2018, ANTIBIOT CHEMOTHER, V34, P4; Turner CE, 2009, J INFECT DIS, V200, P555, DOI 10.1086/603541; Voyich JM, 2004, MICROBES INFECT, V6, P1117, DOI 10.1016/j.micinf.2004.05.022; Wu XJ, 2014, ANALYST, V139, P4056, DOI 10.1039/c4an00541d	20	0	0	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					419	424		10.1111/pin.12678			6	Pathology	Pathology	GL2IH	WOS:000436942800003	29722472				2019-10-28	
J	Kitawaki, Y; Fujishima, F; Taniuchi, S; Saito, R; Nakamura, Y; Sato, R; Aoyama, Y; Onodera, Y; Inoshita, N; Matsuda, Y; Watanabe, M; Sasano, H				Kitawaki, Yuko; Fujishima, Fumiyoshi; Taniuchi, Shinji; Saito, Ryoko; Nakamura, Yasuhiro; Sato, Ryoko; Aoyama, Yayoi; Onodera, Yoshiaki; Inoshita, Naoko; Matsuda, Yasushi; Watanabe, Mika; Sasano, Hironobu			Coexistence of glandular papilloma and sclerosing pneumocytoma in the bronchiole	PATHOLOGY INTERNATIONAL			English	Article						AKT1; BRAF; glandular papilloma; lung; p16; sclerosing pneumocytoma	LUNG; P16(INK4A); SENESCENCE; MUTATIONS; TUMORS; BRAF; AKT1	Both glandular papilloma (GP) and sclerosing pneumocytoma (SP) are rare tumors in the lung. We herein report an extremely rare case of coexistence of these two uncommon tumors. The patient was a 40-year-old Japanese woman with no chief complaint. A solitary nodule of the lung was detected using chest computed tomography. The transbronchial biopsy revealed that the tumor histologically corresponded to GP. The patient subsequently underwent partial resection of the right upper lobe. Histological examination of the resected specimens further revealed that the mass contained two different and independent elements and displayed typically histological features of GP and SP. Molecular analysis further revealed the presence of BRAF V600E and AKT1 E17K mutations in GP, whereas only AKT1 mutation was detected in SP. To our knowledge, this is the first case of coexistence of GP and SP in the bronchiole harboring common AKT1 mutation and different BRAF V600E mutational status.	[Kitawaki, Yuko; Saito, Ryoko; Sasano, Hironobu] Tohoku Univ, Grad Sch Med, Dept Anat Pathol, Sendai, Miyagi, Japan; [Fujishima, Fumiyoshi; Taniuchi, Shinji; Sato, Ryoko; Aoyama, Yayoi; Onodera, Yoshiaki] Tohoku Univ Hosp, Div Pathol, Sendai, Miyagi, Japan; [Nakamura, Yasuhiro] Tohoku Med & Pharmaceut Univ, Fac Med, Div Pathol, Sendai, Miyagi, Japan; [Inoshita, Naoko] Toranomon Gen Hosp, Dept Pathol, Tokyo, Japan; [Matsuda, Yasushi] Tohoku Univ Hosp, Dept Thorac Surg, Sendai, Miyagi, Japan; [Watanabe, Mika] Tohoku Univ, Inst Dev Aging & Canc, Res Div Dev Antiinfect Agents, Sendai, Miyagi, Japan	Kitawaki, Y (reprint author), Tohoku Univ, Dept Pathol, Aoba Ku, Seiryo Machi 2-1, Sendai, Miyagi, Japan.	yuko.ktwk@patholo2.med.tohoku.ac.jp					Chandeck C, 2010, ADV ANAT PATHOL, V17, P42, DOI 10.1097/PAP.0b013e3181c66f4e; Devouassoux-Shisheboran M, 2004, MODERN PATHOL, V17, P252, DOI 10.1038/modpathol.3800045; Emerson LL, 2012, PATHOL RES PRACT, V208, P726, DOI 10.1016/j.prp.2012.09.007; Flieder DB, 1998, AM J SURG PATHOL, V22, P1328, DOI 10.1097/00000478-199811000-00003; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Jung SH, 2016, P NATL ACAD SCI USA, V113, P10672, DOI 10.1073/pnas.1606946113; Kamata T, 2015, AM J SURG PATHOL, V39, P753, DOI 10.1097/PAS.0000000000000414; Kaseda K, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-149; Kim BH, 2013, APMIS, V121, P105, DOI 10.1111/j.1600-0463.2012.02945.x; Kim L, 2017, J THORAC DIS, V9, pE1039, DOI 10.21037/jtd.2017.11.120; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Miyoshi R, 2017, PATHOL INT, V67, P306, DOI 10.1111/pin.12531; Niemiec J, 2015, AM J CLIN PATHOL, V143, P419, DOI 10.1309/AJCPHAEK82QWQORJ; Travis WD, 2004, WHO CLASSIFICATION T; Tryfon S, 2012, J THORAC ONCOL, V7, P643, DOI 10.1097/JTO.0b013e3182468d06; Udo E, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0651-2; Wang JM, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3493-6; Wohlschlager J, 2013, PATHOLOGE, V34, P338, DOI 10.1007/s00292-012-1725-2	19	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					425	430		10.1111/pin.12677			6	Pathology	Pathology	GL2IH	WOS:000436942800004	29696743				2019-10-28	
J	Yamada, R; Tonooka, A; Horiguchi, S; Motoi, T; Horio, H; Hishima, T				Yamada, Rin; Tonooka, Akiko; Horiguchi, Shin-ichiro; Motoi, Toru; Horio, Hirotoshi; Hishima, Tsunekazu			An unusual case of pulmonary hamartoma with predominant bronchial mucous glands in the peripheral lung	PATHOLOGY INTERNATIONAL			English	Article						adenomatoid hyperplasia; bronchial gland; minor salivary gland; mucous gland; pulmonary hamartoma	SALIVARY-GLAND; ADENOMATOID HYPERPLASIA; TUMORS; BENIGN; INTRAPULMONARY; REARRANGEMENT	Pulmonary hamartoma (PH) is the most common benign lung tumor, comprising various amounts of mescenchymal components with entrapped epithelial components. We describe an unusual case of PH in the left lower lung lobe of a 60-year-old female. The tumor was 9x9mm in size, light brown, weakly glistening, and microscopically found to be composed of well-developed epithelial and mesenchymal components without atypia. Both components were intermingled but without apparent transition. Epithelial components were occupied by predominant bronchial mucous glands. Serous glands, entrapped bronchioles, and clefts lined by respiratory epithelium were also apparent. Mesenchymal components including cartilage and fat were scattered, and swirling smooth muscle fascicles were interlaced with epithelial components. Collision tumor or other biphasic tumors were unlikely, and hyperplastic change in bronchial glands as in the rare conditions of intraoral minor salivary glands and epithelial entrapments by PH may explain these interesting histological findings. It is important to be aware of the possibility that a large number of bronchial mucous glands may be noted in the peripheral lung, and not to mistake this for other malignancies.	[Yamada, Rin; Tonooka, Akiko; Horiguchi, Shin-ichiro; Motoi, Toru; Hishima, Tsunekazu] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Tokyo, Japan; [Horio, Hirotoshi] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Chest Surg, Tokyo, Japan	Yamada, R (reprint author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	r.yamada82@gmail.com	Yamada, Rin/L-2928-2019	Yamada, Rin/0000-0001-9161-1429			Asano S, 2000, VIRCHOWS ARCH, V436, P384, DOI 10.1007/s004280050463; BARRETT AW, 1995, ORAL SURG ORAL MED O, V79, P482, DOI 10.1016/S1079-2104(05)80132-5; BATESON EM, 1965, THORAX, V20, P447, DOI 10.1136/thx.20.5.447; BUCHNER A, 1991, ORAL SURG ORAL MED O, V71, P583, DOI 10.1016/0030-4220(91)90367-L; ENGLAND DM, 1995, AM J SURG PATHOL, V19, P887, DOI 10.1097/00000478-199508000-00003; FLETCHER JA, 1992, CANCER RES, V52, P6224; Gjevre JA, 1996, MAYO CLIN PROC, V71, P14, DOI 10.4065/71.1.14; Jin MS, 2008, ACTA CYTOL, V52, P357, DOI 10.1159/000325523; Karpathiou G, 2013, CASE REP PATHOL, DOI 10.1155/2013/239173; Kazmierczak B, 1999, GENE CHROMOSOME CANC, V26, P125; Lee Boram, 2014, Korean J Pathol, V48, P167, DOI 10.4132/KoreanJPathol.2014.48.2.167; MORAN CA, 1994, CANCER-AM CANCER SOC, V73, P2481, DOI 10.1002/1097-0142(19940515)73:10<2481::AID-CNCR2820731006>3.0.CO;2-A; Okudela K, 2014, PATHOL INT, V64, P618, DOI 10.1111/pin.12222; Pelosi G, 2006, AM J SURG PATHOL, V30, P375; PEREZATAYDE AR, 1984, CANCER, V53, P485, DOI 10.1002/1097-0142(19840201)53:3<485::AID-CNCR2820530319>3.0.CO;2-S; Saini ML, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-38; Sengul AT, 2012, ANN THORAC SURG, V94, pE73, DOI 10.1016/j.athoracsur.2012.02.076; Takemura T, 1999, PATHOL INT, V49, P938, DOI 10.1046/j.1440-1827.1999.00969.x; Tallini G, 2000, LAB INVEST, V80, P359, DOI 10.1038/labinvest.3780040; VANDENBOSCH JMM, 1987, THORAX, V42, P790, DOI 10.1136/thx.42.10.790	20	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					431	435		10.1111/pin.12682			5	Pathology	Pathology	GL2IH	WOS:000436942800005	29770587				2019-10-28	
J	Yagi, H; Takahashi, S; Shinmura, K; Iwashita, T; Ogawa, H				Yagi, Haruna; Takahashi, Seishiro; Shinmura, Kazuya; Iwashita, Toshihide; Ogawa, Hiroshi			Mesothelial/monocytic incidental cardiac excrescence with bone marrow	PATHOLOGY INTERNATIONAL			English	Letter							SURGERY		[Yagi, Haruna; Takahashi, Seishiro; Ogawa, Hiroshi] Seirei Mikatahara Hosp, Dept Diagnost Pathol, 3453 Mikataharacho, Hamamatsu, Shizuoka 4338558, Japan; [Yagi, Haruna; Iwashita, Toshihide] Hamamatsu Univ Sch Med, Dept Regenerat & Infect Pathol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan; [Shinmura, Kazuya] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan	Yagi, H (reprint author), Seirei Mikatahara Hosp, Dept Diagnost Pathol, 3453 Mikataharacho, Hamamatsu, Shizuoka 4338558, Japan.		Shinmura, Kazuya/K-8940-2012	Shinmura, Kazuya/0000-0003-4963-746X			Bando Y, 2000, VIRCHOWS ARCH, V437, P331, DOI 10.1007/s004280000232; COURTICE RW, 1994, AM J SURG PATHOL, V18, P167, DOI 10.1097/00000478-199402000-00006; Ikeda Y, 1998, PATHOL INT, V48, P641, DOI 10.1111/j.1440-1827.1998.tb03963.x; Jiao NL, 2014, INT J CLIN EXP PATHO, V7, P6219; LUTHRINGER DJ, 1990, AM J SURG PATHOL, V14, P993, DOI 10.1097/00000478-199011000-00001	5	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					436	438		10.1111/pin.12661			3	Pathology	Pathology	GL2IH	WOS:000436942800006	29570908	Other Gold			2019-10-28	
J	Hashimoto, H; Negishi, R; Ohata, K; Horiuchi, H				Hashimoto, Hirotsugu; Negishi, Ryoju; Ohata, Ken; Horiuchi, Hajime			Hamartomatous inverted polyp of the sigmoid colon: A case demonstrating its immunohistochemical characteristics	PATHOLOGY INTERNATIONAL			English	Letter									[Hashimoto, Hirotsugu; Horiuchi, Hajime] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan; [Negishi, Ryoju; Ohata, Ken] NTT Med Ctr Tokyo, Dept Gastroenterol, Tokyo, Japan	Hashimoto, H (reprint author), NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan.						ALLEN MS, 1966, CANCER, V19, P257, DOI 10.1002/1097-0142(196602)19:2<257::AID-CNCR2820190218>3.0.CO;2-H; Burkart AL, 2007, AM J SURG PATHOL, V31, P1209, DOI 10.1097/PAS.0b013e3180339944; Gibson JA, 2011, AM J SURG PATHOL, V35, P742, DOI 10.1097/PAS.0b013e31821537a2; Tanaka S, 2007, DIGEST ENDOSC, V19, P40, DOI 10.1111/j.1443-1661.2007.00674.x; Yantiss RK, 2001, MODERN PATHOL, V14, P869, DOI 10.1038/modpathol.3880403	5	0	0	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JUL	2018	68	7					439	441		10.1111/pin.12658			3	Pathology	Pathology	GL2IH	WOS:000436942800007	29570906				2019-10-28	
J	Craig, L; Fox, R; Langohr, I				Craig, Linden; Fox, Richard; Langohr, Ingeborg			Image Challenge: An Engaging New Feature in Veterinary Pathology	VETERINARY PATHOLOGY			English	Editorial Material									[Craig, Linden] Univ Tennessee, Knoxville, TN 37996 USA; [Fox, Richard] Finn Pathologists, Norfolk, England; [Langohr, Ingeborg] Louisiana State Univ, Baton Rouge, LA 70803 USA	Craig, L (reprint author), Univ Tennessee, Knoxville, TN 37996 USA.		Langohr, Ingeborg/H-5570-2019	Langohr, Ingeborg/0000-0001-7366-4391				0	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					485	485		10.1177/0300985818771148			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800001	29890928				2019-10-28	
J	[Anonymous]				[Anonymous]			Image Challenge in Veterinary Pathology	VETERINARY PATHOLOGY			English	Editorial Material																	0	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					486	+		10.1177/0300985818771140			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800002	30043710	Bronze			2019-10-28	
J	Aeffner, F; Blanchard, TW; Keel, MK; Williams, BH				Aeffner, Famke; Blanchard, Terrell W.; Keel, M. Kevin; Williams, Bruce H.			Whole-Slide Imaging: The Future Is Here	VETERINARY PATHOLOGY			English	Editorial Material									[Aeffner, Famke] Amgen Inc, Comparat Biol & Safety Sci, San Francisco, CA USA; [Blanchard, Terrell W.] IDEXX Labs Inc, Westbrook, ME USA; [Keel, M. Kevin] Univ Calif Davis, Sch Vet Med, Davis, CA USA; [Williams, Bruce H.] Joint Pathol Ctr, Vet Pathol Serv, Silver Spring, MD USA	Williams, BH (reprint author), Joint Pathol Ctr, Vet Pathol Serv, 606 Stephen Sitter Ave, Rockville, MD 20852 USA.	bruce.h.williams@hotmail.com					Abels Esther, 2017, J Pathol Inform, V8, P23, DOI 10.4103/jpi.jpi_11_17; Aeffner F, 2017, ARCH PATHOL LAB MED, V141, P1267, DOI 10.5858/arpa.2016-0386-RA; Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585; Bertram CA, VET PATHOL; Granter SR, 2017, ARCH PATHOL LAB MED, V141, P619, DOI 10.5858/arpa.2016-0471-ED	5	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					488	489		10.1177/0300985818771146			2	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800003	29890924				2019-10-28	
J	Bertram, CA; Gurtner, C; Dettwiler, M; Kershaw, O; Dietert, K; Pieper, L; Pischon, H; Gruber, AD; Klopfleisch, R				Bertram, Christof A.; Gurtner, Corinne; Dettwiler, Martina; Kershaw, Olivia; Dietert, Kristina; Pieper, Laura; Pischon, Hannah; Gruber, Achim D.; Klopfleisch, Robert			Validation of Digital Microscopy Compared With Light Microscopy for the Diagnosis of Canine Cutaneous Tumors	VETERINARY PATHOLOGY			English	Article						digital pathology; virtual microscopy; diagnostic concordance; technical quality; scanning magnification; whole-slide images; validation study; laboratory proficiency testing	WHOLE SLIDE IMAGES; AMERICAN-PATHOLOGISTS PATHOLOGY; LABORATORY QUALITY CENTER; SURGICAL PATHOLOGY; VIRTUAL SLIDES; DERMATOPATHOLOGY; FEASIBILITY; ROUTINE; PERFORMANCE; UNIVERSITY	Integration of new technologies, such as digital microscopy, into a highly standardized laboratory routine requires the validation of its performance in terms of reliability, specificity, and sensitivity. However, a validation study of digital microscopy is currently lacking in veterinary pathology. The aim of the current study was to validate the usability of digital microscopy in terms of diagnostic accuracy, speed, and confidence for diagnosing and differentiating common canine cutaneous tumor types and to compare it to classical light microscopy. Therefore, 80 histologic sections including 17 different skin tumor types were examined twice as glass slides and twice as digital whole-slide images by 6 pathologists with different levels of experience at 4 time points. Comparison of both methods found digital microscopy to be noninferior for differentiating individual tumor types within the category epithelial and mesenchymal tumors, but diagnostic concordance was slightly lower for differentiating individual round cell tumor types by digital microscopy. In addition, digital microscopy was associated with significantly shorter diagnostic time, but diagnostic confidence was lower and technical quality was considered inferior for whole-slide images compared with glass slides. Of note, diagnostic performance for whole-slide images scanned at 200x magnification was noninferior in diagnostic performance for slides scanned at 400x. In conclusion, digital microscopy differs only minimally from light microscopy in few aspects of diagnostic performance and overall appears adequate for the diagnosis of individual canine cutaneous tumors with minor limitations for differentiating individual round cell tumor types and grading of mast cell tumors.	[Bertram, Christof A.; Gurtner, Corinne; Kershaw, Olivia; Dietert, Kristina; Pischon, Hannah; Gruber, Achim D.; Klopfleisch, Robert] Free Univ Berlin, Inst Vet Pathol, D-14163 Berlin, Germany; [Gurtner, Corinne; Dettwiler, Martina] Univ Bern, Vetsuisse Fac, Inst Anim Pathol, Dept Infect Dis & Pathobiol, Bern, Switzerland; [Pieper, Laura] Free Univ Berlin, Inst Vet Epidemiol & Biostat, Berlin, Germany	Klopfleisch, R (reprint author), Free Univ Berlin, Inst Vet Pathol, D-14163 Berlin, Germany.	robert.klopfleisch@fu-berlin.de		Dietert, Kristina/0000-0002-5667-6750; Pieper, Laura/0000-0002-3765-5401			Al Habeeb Ayman, 2012, J Pathol Inform, V3, P2, DOI 10.4103/2153-3539.93399; Al-Janabi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082576; Al-Janabi S, 2012, J CLIN PATHOL, V65, P1107, DOI 10.1136/jclinpath-2012-200878; Al-Janabi S, 2012, J CLIN PATHOL, V65, P152, DOI 10.1136/jclinpath-2011-200277; Bauer TW, 2013, ARCH PATHOL LAB MED, V137, P518, DOI 10.5858/arpa.2011-0678-OA; Bertram CA, 2017, VET PATHOL, V54, P756, DOI 10.1177/0300985817709888; Brunelli M, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-S1-S12; Buck Thomas P, 2014, J Pathol Inform, V5, P43, DOI 10.4103/2153-3539.145731; Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; Clarke EL, COLOR RES APPL; Clarke EL, 2017, HISTOPATHOLOGY, V70, P153, DOI 10.1111/his.13079; Garcia-Rojo M, 2016, PATHOBIOLOGY, V83, P99, DOI 10.1159/000441192; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; Gui Dorina, 2012, J Pathol Inform, V3, P27; Jen KY, 2013, HUM PATHOL, V44, P888, DOI 10.1016/j.humpath.2012.08.015; Kiupel M, 2011, VET PATHOL, V48, P147, DOI 10.1177/0300985810386469; Krupinski EA, 2012, J DIGIT IMAGING, V25, P738, DOI 10.1007/s10278-012-9479-1; Lee JJ, 2018, AM J DERMATOPATH, V40, P17, DOI 10.1097/DAD.0000000000000888; Li XX, 2007, HUM PATHOL, V38, P1842, DOI 10.1016/j.humpath.2007.04.019; Massone C, 2007, HUM PATHOL, V38, P546, DOI 10.1016/j.humpath.2006.10.006; Meuten DJ, 2016, VET PATHOL, V53, P7, DOI 10.1177/0300985815593349; Nielsen PS, 2010, HUM PATHOL, V41, P1770, DOI 10.1016/j.humpath.2010.05.015; Ordi J, 2015, J CLIN PATHOL, V68, P33, DOI 10.1136/jclinpath-2014-202524; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; PATNAIK AK, 1984, VET PATHOL, V21, P469, DOI 10.1177/030098588402100503; Randell R, 2014, HUM PATHOL, V45, P2101, DOI 10.1016/j.humpath.2014.06.017; Saco A, 2016, PATHOBIOLOGY, V83, P89, DOI 10.1159/000442823; Snead DRJ, 2016, HISTOPATHOLOGY, V68, P1063, DOI 10.1111/his.12879; Stathonikos Nikolas, 2013, J Pathol Inform, V4, P15, DOI 10.4103/2153-3539.114206; Thorstenson Sten, 2014, J Pathol Inform, V5, P14, DOI 10.4103/2153-3539.129452; Velez N, 2008, HUM PATHOL, V39, P1341, DOI 10.1016/j.humpath.2008.01.006; Vodovnik Aleksandar, 2016, J Pathol Inform, V7, P4, DOI 10.4103/2153-3539.175377; Vyas Nikki S, 2016, J Pathol Inform, V7, P30, DOI 10.4103/2153-3539.186909; Wright AM, 2013, ARCH PATHOL LAB MED, V137, P618, DOI 10.5858/arpa.2012-0430-OA	34	6	6	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					490	500		10.1177/0300985818755254			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800004	29402206				2019-10-28	
J	Verin, R; Cian, F; Stewart, J; Binanti, D; MacNeill, AL; Piviani, M; Monti, P; Baroni, G; Le Calvez, S; Scase, TJ; Finotello, R				Verin, Ranieri; Cian, Francesco; Stewart, Jennifer; Binanti, Diana; MacNeill, Amy L.; Piviani, Martina; Monti, Paola; Baroni, Gianna; Le Calvez, Sophie; Scase, Timothy J.; Finotello, Riccardo			Canine Clitoral Carcinoma: A Clinical, Cytologic, Histopathologic, Immunohistochemical, and Ultrastructural Study	VETERINARY PATHOLOGY			English	Article						clitoris; dog; carcinoma; neuroendocrine; vulva; ultrastructure; immunohistochemistry; surgical pathology; external genitalia	DOG; TUMORS; HYPERCALCEMIA; DIFFERENTIATION; ADENOCARCINOMAS; GLANDS	Vaginal and vulvar tumors are uncommon in dogs. Knowledge of canine primary clitoral neoplasia is restricted to a few case reports, and only carcinomas have been reported. Cytologic and histologic features reported in the literature seem to overlap with those of canine apocrine gland anal sac adenocarcinoma (AGASA). Clinical features also recall those of canine AGASA, such as locoregional metastases and hypercalcemia of malignancy (HM). In this study, 6 cases of primary canine clitoral carcinomas (CCCs), with and without HM, were investigated by means of cytology, histopathology, electron microscopy, and immunohistochemistry for neuroendocrine markers including chromogranin A (CGA), synaptophysin (SYN), neuron-specific enolase (NSE), and S-100. In all 6 tumors, cytologic findings were consistent with malignant epithelial neoplasia of apocrine gland origin. The tumors examined were classified into 3 different histological patterns representing different degrees of differentiation: tubular, solid, and rosette type. Both CGA and SYN were mildly expressed in 2 of 6 tumors, while NSE was consistently expressed in all 6 cases. None of the tumors were S-100 positive. Transmission electron microscopy revealed electron-dense cytoplasmic granules compatible with neuroendocrine granules in all 6 cases. CCCs presented clinicopathologic features resembling AGASAs with neuroendocrine characteristics, and 2 of 6 neoplasms were considered as carcinomas with neuroendocrine differentiation and were positive for 3 neuroendocrine markers. CCCs can often present with HM, and long-term outcome is likely poor. Our study concludes that CCC seems to be a rare tumor, but it might be underestimated because of the overlapping features with AGASA. Further studies should aim to define the true incidence of this disease.	[Verin, Ranieri] Univ Liverpool, Inst Vet Sci, Dept Vet Pathol & Publ Hlth, Liverpool, Merseyside, England; [Cian, Francesco] Batt Labs Ltd, Coventry, W Midlands, England; [Stewart, Jennifer] Anim Hlth Trust, Ctr Preventat Med, Newmarket, Suffolk, England; [Binanti, Diana] AbLab, Vet Diagnost Lab, Sarzana, La Spezia, Italy; [MacNeill, Amy L.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol, Ft Collins, CO 80523 USA; [MacNeill, Amy L.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Immunol, Ft Collins, CO 80523 USA; [MacNeill, Amy L.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Pathol, Ft Collins, CO 80523 USA; [Piviani, Martina; Finotello, Riccardo] Univ Liverpool, Inst Vet Sci, Dept Small Anim Clin Sci, Chester High Rd, Liverpool CH64 7TE, Merseyside, England; [Monti, Paola] Dick White Referrals, DWR Diagnost, Newmarket, Suffolk, England; [Baroni, Gianna] Univ Florence, Dept Surg & Translat Med, Div Anat Pathol, Florence, Italy; [Le Calvez, Sophie] IDEXX Labs, Wetherby, W Yorkshire, England; [Scase, Timothy J.] Bridge Pathol Ltd, Bristol, Avon, England	Finotello, R (reprint author), Univ Liverpool, Inst Vet Sci, Dept Small Anim Clin Sci, Chester High Rd, Liverpool CH64 7TE, Merseyside, England.	rfinot@liv.ac.uk	Monti, Paola/J-6818-2019				Al-Shebaily MM, 2008, INT J CANC RES, V4, P110; Barone R, 2003, TRATTATO ANATOMIA CO, V4, P223; Bergman P., 2013, WITHROW MACEWENS SMA, P83; BRODEY RS, 1967, J AM VET MED ASSOC, V151, P1294; CAPEN CC, 1971, AM J MED, V50, P598, DOI 10.1016/0002-9343(71)90115-X; Goldschmidt M. H., 2017, Tumors in domestic animals, P88; HERRON MA, 1983, J AM ANIM HOSP ASSOC, V19, P981; Khanna C, 2006, NAT BIOTECHNOL, V24, P1065, DOI 10.1038/nbt0906-1065b; KYDD DM, 1986, J SMALL ANIM PRACT, V27, P255, DOI 10.1111/j.1748-5827.1986.tb02136.x; Mahapokai W, 2000, PROSTATE, V44, P40; MEUTEN DJ, 1982, AM J PATHOL, V107, P167; Mitchell KE, 2012, AUST VET PRACT, V42, P279; Neihaus SA, 2010, J AM ANIM HOSP ASSOC, V46, P193, DOI 10.5326/0460193; Patnaik AK, 2002, VET PATHOL, V39, P496, DOI 10.1354/vp.39-4-496; Patnaik AK, 2001, VET PATHOL, V38, P553, DOI 10.1354/vp.38-5-553; Potanas CP, 2015, JAVMA-J AM VET MED A, V246, P877, DOI 10.2460/javma.246.8.877; Rout ED, 2016, VET CLIN PATH, V45, P197, DOI 10.1111/vcp.12322; Samuelson DA, 2006, TXB VET HISTOLOGY; Suzuki K, 2013, J COMP PATHOL, V149, P199, DOI 10.1016/j.jcpa.2013.01.013; Teske E, 2002, MOL CELL ENDOCRINOL, V197, P251, DOI 10.1016/S0303-7207(02)00261-7; THACHER C, 1983, J AM VET MED ASSOC, V183, P690	21	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					501	509		10.1177/0300985818759772			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800005	29444629				2019-10-28	
J	Brandao, YD; Toledo, MB; Chequin, A; Cristo, TG; Sousa, RS; Ramos, EAS; Klassen, G				Brandao, Yara de Oliveira; Toledo, Mariana Busato; Chequin, Andressa; Cristo, Thierry Grima; Sousa, Renato Silva; Souza Ramos, Edneia Amancio; Klassen, Giseli			DNA Methylation Status of the Estrogen Receptor alpha Gene in Canine Mammary Tumors	VETERINARY PATHOLOGY			English	Article						canine mammary tumor; breast cancer; estrogen receptor gene (ESR1); DNA methylation; epigenetics	MESSENGER-RNA EXPRESSION; BREAST-CANCER; SUPPRESSOR GENE; CPG ISLANDS; HYPERMETHYLATION; PROMOTER; FEATURES; TISSUES; GENOME; DOG	Estrogen receptor (ER) has an important role in mammary carcinogenesis, prognosis, and treatment. In human and canine mammary cancer, the most aggressive tumors show loss of ER expression, which in human breast cancer has been attributed to methylation of the cytosine followed by guanine (CpG) island within the estrogen receptor gene (ESR1) promoter. This study aimed to investigate the role of ESR1 CpG island (CGI) methylation in ER expression in canine mammary tumors. Twenty-one canine mammary samples were sorted into three groups: malignant tumor (n = 9), benign tumor (n = 8), and normal gland (n = 4). Immunohistochemical analysis and reverse-transcription quantitative real-time PCR were performed to assess ER expression and ESR1 mRNA levels. The methylation status was determined using sodium-bisulfite-treated DNA sequencing. All normal mammary glands and benign tumors showed high ER expression (score range, 5-8). Six of the nine malignant tumors did not show ER expression (score 0), two had score 2, and one had score 4. Lower ER (P < .005) and ESR1 mRNA levels (P < .005) were found in malignant mammary tumors than in the other two groups. Canine ESR1 has an intragenic and non-promoter-associated CGI, different from humans. No significant variation in methylation percentage was observed among the groups, suggesting that ESR1 is not regulated by DNA methylation, unlike that in humans. This difference should be considered in further research using ER as a biomarker for mammary tumors in canine studies on ER-targeting therapy.	[Brandao, Yara de Oliveira; Toledo, Mariana Busato; Chequin, Andressa; Souza Ramos, Edneia Amancio; Klassen, Giseli] Univ Fed Parana, Dept Basic Pathol, Epigenet Lab, Curitiba, Parana, Brazil; [Cristo, Thierry Grima; Sousa, Renato Silva] Univ Fed Parana, Vet Hosp, Lab Vet Pathol, Curitiba, Parana, Brazil	Klassen, G (reprint author), Univ Fed Parana, Setor Ciencias Biol, Dept Patol Basica, Campus Politecn,Av Cel Francisco H dos Santos, BR-81531970 Curitiba, Parana, Brazil.	giseli.ufpr@gmail.com	Cavalieri, Edneia ASR/Q-9636-2019; Klassen, Giseli/F-8753-2012	Cavalieri, Edneia ASR/0000-0002-8855-5988; Klassen, Giseli/0000-0001-5336-6178; Grima de Cristo, Thierry/0000-0003-4650-0687			Aporntewan C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017934; Auton A, PLOS GENETICS, V9, P1; Barazandeh A, 2016, CZECH J ANIM SCI, V61, P487, DOI 10.17221/78/2015-CJAS; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Blackburn J, 2016, MOL CARCINOGEN, V55, P1940, DOI 10.1002/mc.22441; Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524; Bronzini I, 2017, VET COMP ONCOL, V15, P910, DOI 10.1111/vco.12231; de las Mulas JM, 2005, VET PATHOL, V42, P200, DOI 10.1354/vp.42-2-200; Dong YY, 2014, BIOMED REP, V2, P326, DOI 10.3892/br.2014.237; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fujiwara-Igarashi A, 2014, RES VET SCI, V97, P60, DOI 10.1016/j.rvsc.2014.04.008; Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258; Han L, 2009, GENOMICS, V94, P117, DOI 10.1016/j.ygeno.2009.04.007; Harman RM, 2016, J MAMMARY GLAND BIOL, V21, P51, DOI 10.1007/s10911-016-9350-y; Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2; Karayannopoulou M, 2016, REV MED VET-TOULOUSE, V167, P192; Kim NH, 2014, J COMP PATHOL, V151, P42, DOI 10.1016/j.jcpa.2014.04.001; Klopfleisch R, 2010, VET PATHOL, V47, P446, DOI 10.1177/0300985810363904; Kosti I, 2016, SCI REP-UK, V6, DOI 10.1038/srep24799; Lamp O, 2013, VET COMP ONCOL, V11, P70, DOI 10.1111/j.1476-5829.2011.00303.x; Lee SM, 2014, P NATL ACAD SCI USA, V111, P9555, DOI 10.1073/pnas.1400604111; Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011; Mainenti M, 2014, VET J, V202, P62, DOI 10.1016/j.tvjl.2014.06.003; Martinez-Galan J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-59; Millanta F, 2005, RES VET SCI, V79, P225, DOI 10.1016/j.rvsc.2005.02.002; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mohr A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163311; Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Pena L, 2014, VET PATHOL, V51, P127, DOI 10.1177/0300985813509388; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1; Riccardo F, 2015, CANCER IMMUNOL IMMUN, V64, P137, DOI 10.1007/s00262-014-1645-5; Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004; Sakamoto A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145630; Schuler SL, 2008, JPEN-PARENTER ENTER, V32, P184, DOI 10.1177/0148607108314387; Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107; Shimizu R, 2016, LEUKEMIA RES, V50, P85, DOI 10.1016/j.leukres.2016.09.018; Sleeckx N, 2011, REPROD DOMEST ANIM, V46, P1112, DOI 10.1111/j.1439-0531.2011.01816.x; Sorenmo KU, 2011, VET PATHOL, V48, P85, DOI 10.1177/0300985810389480; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spoerri M, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0546-y; Stuart-Harris R, 2010, WOMENS HEALTH, V6, P383, DOI [10.2217/whe.10.25, 10.2217/WHE.10.25]; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wurm Y, 2009, BMC GENOMICS, V10, DOI [10.1186/1471-2164-10-5, 10.1186/1471-2164-10-135]; Yue W, 2013, STEROIDS, V78, P161, DOI 10.1016/j.steroids.2012.11.001	46	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					510	516		10.1177/0300985818763711			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800006	29566609				2019-10-28	
J	Stilwell, JM; Rissi, DR				Stilwell, Justin M.; Rissi, Daniel R.			Immunohistochemical Labeling of Multiple Myeloma Oncogene I/Interferon Regulatory Factor 4 (MUMI/IRF-4) in Canine Cutaneous Histiocytoma	VETERINARY PATHOLOGY			English	Article						histiocytoma; plasma cell tumor; dogs; immunohistochemistry; MUMI/IRF-4	SEQUENCE BINDING-PROTEIN; ROUND-CELL TUMORS; DIFFERENTIAL EXPRESSION; MACROPHAGES; GENE; DOGS	Multiple myeloma oncogene I/interferon regulatory factor 4 (MUMI/IRF-4) immunohistochemistry (IHC) is mainly used for diagnostic confirmation of plasma cell tumors (PCTs) in dogs and cats. This article describes MUMI/IRF-4 IHC expression in 20 cases of canine cutaneous histiocytoma (CH) and compares it with 10 cutaneous or mucocutaneous PCTs and 5 cutaneous histiocytic sarcomas (HSs) submitted to the same IHC protocol. All histiocytomas had strong nuclear and variable cytoplasmic immunolabeling for MUMI/IRF-4, whereas all PCTs had strong nuclear and moderate cytoplasmic immunolabeling for MUMI/IRF-4. No MUMI/IRF-4 immunolabeling was detected in the HSs. Although not typically a diagnostic challenge, MUMI/IRF-4 expression may have to be used with caution or in conjunction with additional immunomarkers to differentiate among poorly differentiated round cell tumors, especially when a histiocytic or plasma cell origin is suspected.	[Stilwell, Justin M.; Rissi, Daniel R.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA; [Rissi, Daniel R.] Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA	Rissi, DR (reprint author), Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA.; Rissi, DR (reprint author), Univ Georgia, Coll Vet Med, Athens Vet Diagnost Lab, Athens, GA 30602 USA.	rissi@uga.edu					Fernandez NJ, 2005, VET PATHOL, V42, P437, DOI 10.1354/vp.42-4-437; Grennan AK, 2006, PLANT PHYSIOL, V141, P1164, DOI 10.1104/pp.104.900198; Lehtonen A, 2005, J IMMUNOL, V175, P6570, DOI 10.4049/jimmunol.175.10.6570; Marecki S, 1999, J IMMUNOL, V163, P2713; Moore PF, 2014, VET PATHOL, V51, P167, DOI 10.1177/0300985813510413; Natkunam Y, 2001, MODERN PATHOL, V14, P686, DOI 10.1038/modpathol.3880373; RAKICH PM, 1989, J AM VET MED ASSOC, V194, P803; Ramos-Vara JA, 2007, VET PATHOL, V44, P875, DOI 10.1354/vp.44-6-875; Ramos-Vara J. A., 2017, Tumors in domestic animals, P44; Ramos-Vara JA, 2011, VET PATHOL, V48, P758, DOI 10.1177/0300985811398251; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; SANDUSKY GE, 1987, VET PATHOL, V24, P495, DOI 10.1177/030098588702400604; Suzuki S, 2004, P NATL ACAD SCI USA, V101, P8981, DOI 10.1073/pnas.0402139101; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990	14	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					517	520		10.1177/0300985818759770			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800007	29444632				2019-10-28	
J	Novakovic, P; Detmer, SE; Suleman, M; Malgarin, CM; MacPhee, DJ; Harding, JCS				Novakovic, Predrag; Detmer, Susan E.; Suleman, Muhammad; Malgarin, Carol M.; MacPhee, Daniel J.; Harding, John C. S.			Histologic Changes Associated With Placental Separation in Gilts Infected with Porcine Reproductive and Respiratory Syndrome Virus	VETERINARY PATHOLOGY			English	Article						endometritis; detachment; fetal death; placenta; porcine reproductive and respiratory syndrome; pigs; placental separation; vasculitis	MYSTERY SWINE DISEASE; MICROSCOPIC LESIONS; LELYSTAD VIRUS; PREGNANT GILTS; VIRAL LOAD; FETUSES; APOPTOSIS; ABORTION	The placenta is a vital organ providing the developing fetus with nutrient and gas exchange, thermoregulation, and waste elimination necessary for fetal development, as well as producing hormones to maintain pregnancy. It is hypothesized that fetal pig death in porcine reproductive and respiratory syndrome may be attributed to pathology of the maternal-fetal interface leading to premature placental separation. This study was designed to evaluate the chronologic progression of porcine reproductive and respiratory syndrome virus (PRRSV)-induced lesions at the maternal-fetal interface, with particular focus on placental separation in experimentally challenged third-trimester gilts. Fifteen gilts were inoculated with a virulent strain of PRRSV-2 on gestation day 86 +/- 0.4. On multiple days postinoculation, 3 gilts along with 1 sham-inoculated control per time point were euthanized, and uterine and fetal placental tissues corresponding to each fetus were collected for histopathologic evaluation. The presence of any fetal lesion was 23 times more likely in compromised (meconium-stained and decomposed) compared with viable fetuses (P < .001). In PRRSV-infected gilts, endometritis was more severe than placentitis, and the severity of endometrial inflammation and vasculitis increased progressively from 2 to 14 days postinoculation. Neither placental vasculitis nor a chronologic progression in the severity of placental detachment was observed. Severe placental detachment was more frequently present in PRRSV-infected compared with noninfected samples and was most significantly associated with placental inflammation, compared with other uterine lesions, viral load, or termination day. The results of this study suggest that placental separation by itself is not sufficient to significantly compromise fetal viability in reproductive porcine reproductive and respiratory syndrome.	[Novakovic, Predrag; Suleman, Muhammad; Malgarin, Carol M.; Harding, John C. S.] Univ Saskatchewan, Western Coll Vet Med, Dept Large Anim Clin Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada; [Detmer, Susan E.] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Pathol, Saskatoon, SK, Canada; [MacPhee, Daniel J.] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Biomed Sci, Saskatoon, SK, Canada	Harding, JCS (reprint author), Univ Saskatchewan, Western Coll Vet Med, Dept Large Anim Clin Sci, 52 Campus Dr, Saskatoon, SK S7N 5B4, Canada.	john.harding@usask.ca			Genome CanadaGenome Canada; Genome Prairie (Saskatchewan Ministry of Agriculture); Genome Alberta	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by Genome Canada, Genome Prairie (Saskatchewan Ministry of Agriculture) and Genome Alberta.	Del Piero F, 2000, VET PATHOL, V37, P287, DOI 10.1354/vp.37-4-287; Dong MY, 2005, ACTA OBSTET GYN SCAN, V84, P788, DOI 10.1111/j.0001-6349.2005.00714.x; Feng LL, 2013, VIRUS RES, V171, P209, DOI 10.1016/j.virusres.2012.11.015; Harding JCS, 2017, VET MICROBIOL, V209, P114, DOI 10.1016/j.vetmic.2017.02.019; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Karniychuk UU, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-95; Karniychuk UU, 2011, MICROB PATHOGENESIS, V51, P194, DOI 10.1016/j.micpath.2011.04.001; Kleiboeker SB, 2005, J VET DIAGN INVEST, V17, P165, DOI 10.1177/104063870501700211; Ladinig A, 2015, VET RES, V46, DOI 10.1186/s13567-015-0251-7; Ladinig A, 2014, VET RES, V45, DOI 10.1186/s13567-014-0113-8; Ladinig A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096104; Lager KM, 1996, J VET DIAGN INVEST, V8, P275, DOI 10.1177/104063879600800301; LAGER KM, 1995, CAN J VET RES, V59, P187; Lopez-Fuertes L, 2000, VIRUS RES, V69, P41, DOI 10.1016/S0168-1702(00)00172-6; MEIS PJ, 1978, AM J OBSTET GYNECOL, V131, P509, DOI 10.1016/0002-9378(78)90111-4; MENGELING WL, 1994, AM J VET RES, V55, P1391; Mota-Rojas D, 2006, LIVEST SCI, V102, P155, DOI 10.1016/j.livsci.2006.01.002; Novakovic P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173360; Novakovic P, 2016, VET RES, V47, DOI 10.1186/s13567-016-0364-7; Novakovic P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151198; Rossow KD, 1996, VET PATHOL, V33, P95, DOI 10.1177/030098589603300115; Rossow KD, 1998, VET PATHOL, V35, P1, DOI 10.1177/030098589803500101; Rowland RRR, 2010, VIRUS RES, V154, P114, DOI 10.1016/j.virusres.2010.09.001; Schlafer D, 2016, JUBB KENNEDY PALMERS, P393; Sinkora M, 2009, DEV COMP IMMUNOL, V33, P273, DOI 10.1016/j.dci.2008.07.011; STOCKHOFFZURWIEDEN N, 1993, J VET MED B, V40, P261, DOI 10.1111/j.1439-0450.1993.tb00137.x; TERPSTRA C, 1991, VET QUART, V13, P131, DOI 10.1080/01652176.1991.9694297; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Wilkinson JM, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2720-4; Williams N, 2012, KIRKBRIDES DIAGNOSIS; Yue X, 1997, NEUROPATH APPL NEURO, V23, P16	31	2	2	0	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					521	530		10.1177/0300985818765067			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800008	29566610				2019-10-28	
J	Hofmeister, EK; Lund, M; Bochsler, VS				Hofmeister, Erik K.; Lund, Melissa; Bochsler, Valerie Shearn			West Nile Virus Infection in American Singer Canaries: An Experimental Model in a Highly Susceptible Avian Species	VETERINARY PATHOLOGY			English	Article						American singer canary; animal model; West Nile virus; American crow	LINKED-IMMUNOSORBENT-ASSAY; NEW-YORK; BIRDS; MOSQUITOS; OUTBREAK; STRESS; CROWS	This study investigated the susceptibility of American singer canaries (Serinus canaria) to West Nile virus (WNV) infection. Adult canaries were inoculated with 10(5), 10(2), and 10(1) plaque forming units (PFU) of WNV. All birds became infected and mortality occurred by 5 days postinoculation. The load of viral RNA as determined by RT-qPCR was dose dependent, and was higher at all doses than the level of viral RNA detected in American crows (Corvus brachyrhynchos) challenged with 10(5) PFU of WNV. In a subset of birds, viremia was detected by virus isolation; canaries inoculated with 10(1) PFU of WNV developed viremia exceeding 10(10) PFU/mL serum, a log higher than American crows inoculated with 10(5) PFU of virus. In canaries euthanized at 3 days postinoculation, WNV was isolated at >10(7) PFU of virus/100 mg of lung, liver, heart, spleen, and kidney tissues. Pallor of the liver and splenomegaly were the most common macroscopic observations and histologic lesions were most severe in liver, spleen, and kidney, particularly in canaries challenged with 10(2) and 10(1) PFU. Immunoreactivity to WNV was pronounced in the liver and spleen. IgG antibodies to WNV were detected in serum by enzyme immunoassay in 11 of 21 (52%) challenged canaries and, in 4 of 5 (20%) of these sera, neutralization antibodies were detected at a titer >= 1:20. American singer canaries provide a useful model as this bird species is highly susceptible to WNV infection.	[Hofmeister, Erik K.; Lund, Melissa; Bochsler, Valerie Shearn] Natl Wildlife Hlth Ctr, US Geol Survey, 6006 Schroeder Rd, Madison, WI 53711 USA	Hofmeister, EK (reprint author), Natl Wildlife Hlth Ctr, US Geol Survey, 6006 Schroeder Rd, Madison, WI 53711 USA.	ehofmeister@usgs.gov			USGS Ecosystems Mission Area funds	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was conducted with USGS Ecosystems Mission Area funds.	Anderson JF, 1999, SCIENCE, V286, P2331, DOI 10.1126/science.286.5448.2331; Balakrishnan CN, 2009, GENETICS, V181, P645, DOI 10.1534/genetics.108.094250; Beaty B. J., 1989, DIAGNOSTIC PROCEDURE, P797; Boenisch T, 2001, DAKO HDB IMMUNOCHEMI; Dabbs D. J., 2013, DIAGNOSTIC IMMUNOHIS; Dhabhar FS, 2009, NEUROIMMUNOMODULAT, V16, P300, DOI 10.1159/000216188; Dickens MJ, 2009, GEN COMP ENDOCR, V160, P76, DOI 10.1016/j.ygcen.2008.10.023; Ebel GD, 2002, EMERG INFECT DIS, V8, P979, DOI 10.3201/eid0809.020152; Fine F, 1999, CDC MORBIDITY MORTAL, V48, P944; Hofmeister EK, 2016, J WILDLIFE DIS, V52, P345, DOI 10.7589/2015-06-148; Komar N, 2003, EMERG INFECT DIS, V9, P311, DOI 10.3201/eid0903.020628; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Nemeth NM, 2011, VET PATHOL, V48, P1061, DOI 10.1177/0300985811398249; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Steele KE, 2000, VET PATHOL, V37, P208, DOI 10.1354/vp.37-3-208; Vorndam V, 2002, AM J TROP MED HYG, V66, P208, DOI 10.4269/ajtmh.2002.66.208; Weingartl HM, 2004, VET PATHOL, V41, P362, DOI 10.1354/vp.41-4-362; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	19	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					531	538		10.1177/0300985818760377			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800009	29506438				2019-10-28	
J	De Biase, D; Costagliola, A; Del Piero, F; Di Palo, R; Coronati, D; Galiero, G; Uberti, BD; Lucibelli, MG; Fabbiano, A; Davoust, B; Raoult, D; Paciello, O				De Biase, Davide; Costagliola, Alessandro; Del Piero, Fabio; Di Palo, Rossella; Coronati, Domenico; Galiero, Giorgio; Degli Uberti, Barbara; Lucibelli, Maria Gabriella; Fabbiano, Annalisa; Davoust, Bernard; Raoult, Didier; Paciello, Orlando			Coxiella burnetii in Infertile Dairy Cattle With Chronic Endometritis	VETERINARY PATHOLOGY			English	Article						cattle; Coxiella burnetii; endometritis; dairy cows; double label immunofluorescence; immunohistochemistry; PCR	Q-FEVER; BIOPSY; COWS	Coxiella burnetii is an obligate intracellular pathogen and the cause of Q fever in many animal species and humans. Several studies have reported the association between C. burnetii and abortion, premature delivery, stillbirth, and weak offspring. However, no solid evidence indicates that C. burnetii causes endometritis, subfertility, and retained fetal membranes. For this study, histopathological and PCR evaluation were performed on 40 uterine biopsies from dairy cattle with poor fertility. Uterine swabs were concurrently tested with microbiology assays. The endometrial biopsies of 30 cows did not have any significant lesions, and no pathogens were identified by aerobic bacterial culture and PCR. Ten cows were PCR-positive for C. burnetii and negative for other pathogens by aerobic bacterial culture and PCR. These 10 cases revealed a mild to severe chronic endometritis admixed with perivascular and periglandular fibrosis. Immunohistochemical evaluation of C. burnetii PCR-positive biopsies identified, for the first time, the presence of intralesional and intracytoplasmic C. burnetii in macrophages in the endometrium of cattle.	[De Biase, Davide; Costagliola, Alessandro; Di Palo, Rossella; Fabbiano, Annalisa; Paciello, Orlando] Univ Naples Federico II, Dept Vet Med & Anim Prod, Via Delpino 1, I-80137 Naples, Italy; [Del Piero, Fabio] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA; [Galiero, Giorgio; Degli Uberti, Barbara; Lucibelli, Maria Gabriella] Ist Zooprofilatt Sperimentale Mezzogiorno, Naples, Italy; [Davoust, Bernard; Raoult, Didier] Aix Marseille Univ, Fac Med, Unite Rech Malad Infect & Trop Emergentes URMITE, Marseille, France	Paciello, O (reprint author), Univ Naples Federico II, Dept Vet Med & Anim Prod, Via Delpino 1, I-80137 Naples, Italy.	paciello@unina.it		De Biase, Davide/0000-0002-8118-9807; di palo, rossella/0000-0003-4468-0928	Progetto di Ricerca Corrente IZSM Portici [06/2013]	This work was in part funded by "Progetto di Ricerca Corrente 06/2013 IZSM Portici."	Agerholm JS, 2013, ACTA VET SCAND, V55, DOI 10.1186/1751-0147-55-13; AKPORIAYE ET, 1983, INFECT IMMUN, V40, P1155; BONNETT BN, 1991, CAN J VET RES, V55, P155; Chapwanya A, 2010, THERIOGENOLOGY, V73, P988, DOI 10.1016/j.theriogenology.2009.11.015; Kazar J, 2005, ANN NY ACAD SCI, V1063, P105, DOI 10.1196/annals.1355.018; Lepidi H, 2003, J INFECT DIS, V187, P1097, DOI 10.1086/368219; Luhrmann A, 2007, INFECT IMMUN, V75, P5282, DOI 10.1128/IAI.00863-07; Magnino S, 2000, LARGE ANIM REV, V3, P25; MERIEN F, 1992, J CLIN MICROBIOL, V30, P2219; Muskens J, 2011, VET MICROBIOL, V147, P186, DOI 10.1016/j.vetmic.2010.05.041; Paciello O, 2010, MUSCLE NERVE, V41, P355, DOI 10.1002/mus.21502; Pagano TB, 2015, VET J, V206, P54, DOI 10.1016/j.tvjl.2015.07.005; Perugini AG, 2009, RES VET SCI, V87, P189, DOI 10.1016/j.rvsc.2009.01.005; Quinn PJ, 1994, CLIN VET MICROBIOLOG, P20; Raoult D, 2005, LANCET INFECT DIS, V5, P219, DOI 10.1016/S1473-3099(05)70052-9; RAOULT D, 1990, J CLIN MICROBIOL, V28, P2482; Sambook J, 1989, MOL CLONING LAB MANU, P61; Schleifer DH, 2007, JUBB KENNEDY PALMERS, V3, P505; VIDIC B, 1990, ACTA VET-BEOGRAD, V40, P27; Voth DE, 2007, CELL MICROBIOL, V9, P829, DOI 10.1111/j.1462-5822.2007.00901.x	20	5	5	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					539	542		10.1177/0300985818760376			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800010	29566608				2019-10-28	
J	Chambers, JK; Thongtharb, A; Shiga, T; Azakami, D; Saito, M; Sato, M; Morozumi, M; Nakayama, H; Uchida, K				Chambers, James K.; Thongtharb, Atigan; Shiga, Takanori; Azakami, Daigo; Saito, Miyoko; Sato, Masumi; Morozumi, Motoji; Nakayama, Hiroyuki; Uchida, Kazuyuki			Accumulation of Laforin and Other Related Proteins in Canine Lafora Disease With EPM2B Repeat Expansion	VETERINARY PATHOLOGY			English	Article						animal model of human disease; autophagy; brain; dog; EPM2B; Lafora disease; laforin; muscle fiber type; neuropathology; ubiquitin	PROGRESSIVE MYOCLONUS EPILEPSY; E3 UBIQUITIN LIGASE; DEFICIENT MICE; MALIN; AUTOPHAGY; BODIES; DEGRADATION; NEURODEGENERATION; PROTEASOME; PROMOTES	Canine Lafora disease (LD) is an autosomal recessive genetic disorder causing nonfatal structural epilepsy, mainly affecting miniature wirehaired dachshunds. Repeat expansion in the EPM2B gene causes a functional impairment of the ubiquitin ligase malin which regulates glycogen metabolism. Abnormally structured glycogen accumulates and develop polyglucosan bodies predominantly in the central nervous system. The authors performed a comprehensive clinical, genetic, and pathological study of 4 LD cases affecting miniature wirehaired dachshund dogs with EPM2B repeat expansions, with systemic distribution of polyglucosan bodies and accumulation of laforin and other functionally associated proteins in the polyglucosan bodies. Myoclonic seizures first appeared at 7-9 years of age, and the dogs died at 14-16 years of age. Immunohistochemistry for calbindin revealed that the polyglucosan bodies were located in the cell bodies and dendritic processes of Purkinje cells. Polyglucosan bodies were also positive for laforin, hsp70, alpha/beta-synuclein, ubiquitin, LC3, and p62. Laforin-positive polyglucosan bodies were located in neurofilament-positive neurons but not in GFAP-positive astrocytes. In nonneural tissues, periodic acid-Schiff (PAS)-positive polyglucosan bodies were observed in the heart, skeletal muscle, liver, apocrine sweat gland, and smooth muscle layer of the urinary bladder. In the skeletal muscle, polyglucosan bodies were observed only in type 1 fibers and not in type 2 fibers. The results indicate that although the repeat expansion of the EPM2B gene is specific to dogs, the immunohistochemical properties of polyglucosan body in canine LD are comparable to human LD. However, important phenotypic variations exist between the 2 species including the affected skeletal muscle fiber type.	[Chambers, James K.; Thongtharb, Atigan; Shiga, Takanori; Nakayama, Hiroyuki; Uchida, Kazuyuki] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan; [Azakami, Daigo] Nippon Vet & Life Sci Univ, Lab Vet Nursing, Musashino, Tokyo, Japan; [Saito, Miyoko] Azabu Univ, Lab Vet Surg 2, Chuo Ward, Sagamihara, Kanagawa, Japan; [Sato, Masumi] Natl Inst Anim Hlth, Tsukuba, Ibaraki, Japan; [Morozumi, Motoji] Togasaki Anim Hosp, Saitama, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp	Azakami, Daigo/M-8873-2019				Aguado C, 2010, HUM MOL GENET, V19, P2867, DOI 10.1093/hmg/ddq190; BAUMANN RJ, 1983, ANN NEUROL, V14, P86, DOI 10.1002/ana.410140116; Berendt M, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0461-2; Chan EM, 2004, HUM MOL GENET, V13, P1117, DOI 10.1093/hmg/ddh130; Criado O, 2012, HUM MOL GENET, V21, P1521, DOI 10.1093/hmg/ddr590; Delgado-Escueta AV, 2007, CURR NEUROL NEUROSCI, V7, P428, DOI 10.1007/s11910-007-0066-7; DePaoli-Roach AA, 2010, J BIOL CHEM, V285, P25372, DOI 10.1074/jbc.M110.148668; Ebrahimi-Fakhari D, 2014, PEDIATR RES, V75, P217, DOI 10.1038/pr.2013.185; Frake RA, 2015, J CLIN INVEST, V125, P65, DOI 10.1172/JCI73944; Garyali P, 2009, HUM MOL GENET, V18, P688, DOI 10.1093/hmg/ddn398; Gentry MS, 2005, P NATL ACAD SCI USA, V102, P8501, DOI 10.1073/pnas.0503285102; Gomez-Garre P, 2007, NEUROLOGY, V68, P1369, DOI 10.1212/01.wnl.0000260061.37559.67; Hajek I, 2016, J SMALL ANIM PRACT, V57, P650, DOI 10.1111/jsap.12593; Hall DG, 1998, VET PATHOL, V35, P218, DOI 10.1177/030098589803500307; Honnold SP, 2010, J ZOO WILDLIFE MED, V41, P530, DOI 10.1638/2009-0090.1; IANNACCONE S, 1991, J NEUROL, V238, P217, DOI 10.1007/BF00314784; Lohi H, 2005, SCIENCE, V307, P81, DOI 10.1126/science.1102832; Mittal S, 2007, HUM MOL GENET, V16, P753, DOI 10.1093/hmg/ddm006; Mochel F, 2012, ANN NEUROL, V72, P433, DOI 10.1002/ana.23598; NEWTON GA, 1987, ARCH DERMATOL, V123, P1667, DOI 10.1001/archderm.123.12.1667; Puri R, 2009, J BIOL CHEM, V284, P22657, DOI 10.1074/jbc.M109.009688; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Rao SNR, 2010, HUM MOL GENET, V19, P4726, DOI 10.1093/hmg/ddq407; Sainsbury R, 2014, VET REC, V175, P568, DOI 10.1136/vr.g7417; Shahwan A, 2005, LANCET NEUROL, V4, P239, DOI 10.1016/S1474-4422(05)70043-0; Sharma J, 2011, NEUROBIOL DIS, V44, P133, DOI 10.1016/j.nbd.2011.06.013; Shiga T, 2017, J VET DIAGN INVEST, V29, P805, DOI 10.1177/1040638717715287; SIMMONS MM, 1994, J COMP PATHOL, V110, P389, DOI 10.1016/S0021-9975(08)80316-7; Swain L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182024; Tiberia E, 2012, J BIOL CHEM, V287, P25650, DOI 10.1074/jbc.M111.331611; Turnbull J, 2011, NEUROLOGY, V76, P1674, DOI 10.1212/WNL.0b013e318219faf6; Uchida K, 2017, VET PATHOL, V54, P881, DOI 10.1177/0300985817720984; Uchiyama Y, 2008, HISTOCHEM CELL BIOL, V129, P407, DOI 10.1007/s00418-008-0406-y; Valles-Ortega J, 2011, EMBO MOL MED, V3, P667, DOI 10.1002/emmm.201100174; Worby CA, 2008, J BIOL CHEM, V283, P4069, DOI 10.1074/jbc.M708712200; Youssef SA, 2016, VET PATHOL, V53, P327, DOI 10.1177/0300985815623997	36	1	1	1	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					543	551		10.1177/0300985818758471			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800011	29444631				2019-10-28	
J	Alex, CE; Kubiski, SV; Li, LL; Sadeghi, M; Wack, RF; McCarthy, MA; Pesavento, JB; Delwart, E; Pesavento, PA				Alex, Charles E.; Kubiski, Steven V.; Li, Linlin; Sadeghi, Mohammadreza; Wack, Raymund F.; McCarthy, Megan A.; Pesavento, Joseph B.; Delwart, Eric; Pesavento, Patricia A.			Amdoparvovirus Infection in Red Pandas (Ailurus fulgens)	VETERINARY PATHOLOGY			English	Article						Ailurus fulgens; amdoparvovirus; metagenomics; red panda; endangered species; in situ hybridization; electron microscopy	SKUNKS MEPHITIS-MEPHITIS; MINK-DISEASE PARVOVIRUS; ALEUTIAN-DISEASE; STRIPED SKUNK; B19 DNA; VIRUS; TRANSMISSION; PERSISTENCE; SEQUENCE; PLATFORM	Aleutian mink disease virus is the type species in the genus Amdoparvovirus, and in mink and other Mustelidae can cause either subclinical disease or fatal chronic immune stimulation and immune complex disease. The authors describe a novel amdoparvovirus in the endangered red panda (Ailurus fulgens), discovered using viral metagenomics. The authors analyzed the prevalence, tissue distribution, and disease association by PCR, in situ hybridization, electron microscopy, and histology in a group of 6 red pandas from a single zoological collection. The study incorporates a fecal shedding survey and analysis of tissues from 4 necropsied animals over a 12-year span. The tentatively named red panda amdoparvovirus (RpAPV) was detected in the feces and/or tissues of all animals tested. At necropsy of 1 geriatric animal, infection was associated with pyogranulomatous peritonitis, pancreatitis, and myocarditis. Other animals had detectable low-level viral nucleic acid in lymph nodes and both oral and intestinal epithelium at the time of necropsy. Full-length genome sequences of RpAPV strains from 2 animals had 12% sequence divergence, demonstrating genetic diversity even among in-contact animals. RpAPV is a persistent infection in this cohort of red pandas, and has variable clinical expression.	[Alex, Charles E.; Kubiski, Steven V.; Wack, Raymund F.; McCarthy, Megan A.; Pesavento, Patricia A.] Univ Calif Davis, Davis, CA 95616 USA; [Alex, Charles E.; Kubiski, Steven V.] San Diego Zoo Global, Inst Conservat Res, San Diego, CA USA; [Li, Linlin; Sadeghi, Mohammadreza; Delwart, Eric] Blood Syst Res Inst, San Francisco, CA USA; [Li, Linlin] Calif Dept Publ Hlth, Microbial Dis Lab, Richmond, CA USA; [Pesavento, Joseph B.] Calif Anim Hlth & Food Safety Labs, Davis, CA USA	Pesavento, PA (reprint author), Univ Calif Davis, Sch Vet Med, Pathol Microbiol & Immunol, 4206 VM3A,1 Shields Ave, Davis, CA 95616 USA.	papesavento@ucdavis.edu			Pesavento laboratory by Boehringer Ingelheim Vetmedica; Bernice Barbour Foundation; Blood Systems Research Institute; Sigrid Juselius FoundationSigrid Juselius Foundation [WBS 4703764]	We thank Ken Jackson for technical assistance and mentorship. Drs Sebastian Carrasco and Sarah Stevens generously provided retrospective cases. We thank the keeper and curatorial staff of the Sacramento Zoo for making animals, samples, and records available. This study was supported in the Pesavento laboratory by Boehringer Ingelheim Vetmedica (for viral discovery) and the Bernice Barbour Foundation (research in naturally occurring infectious disease). Linlin Li, Mohammadreza Sadeghi, and Eric Delwart are supported by funds from Blood Systems Research Institute. Mohammadreza Sadeghi also supported by The Sigrid Juselius Foundation (grant WBS 4703764).	ALEXANDERSEN S, 1985, ACTA PATH MICRO IM B, V93, P195; Allender MC, 2008, JAVMA-J AM VET MED A, V232, P742, DOI 10.2460/javma.232.5.742; Allison AB, 2013, J VIROL, V87, P2342, DOI 10.1128/JVI.02428-12; Best SM, 2005, J VET MED B, V52, P331, DOI 10.1111/j.1439-0450.2005.00864.x; Bodewes R, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-89; Calvignac-Spencer S, 2016, ARCH VIROL, V161, P1739, DOI 10.1007/s00705-016-2794-y; Canuti M, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.13; Canuti M, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew004; Canuti M, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01119; CHESEBRO B, 1975, NATURE, V254, P456, DOI 10.1038/254456a0; Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1; Delaski KM, 2015, J ZOO WILDLIFE MED, V46, P779, DOI 10.1638/2014-0166.1; Deng XT, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv002; Fournier-Chambrillon C, 2004, J WILDLIFE DIS, V40, P394, DOI 10.7589/0090-3558-40.3.394; Glatston A, AILURUS FULGENS IUCN, DOI [10. 2305/IUCN. UK. 2015-4. RLTS. T714A45195924. en, DOI 10.2305/IUCN.UK.2015-4.RLTS.T714A45195924]; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Hartsough GR, 1956, NAT FUR NEWS, P10; Jepsen JR, 2009, EMERG INFECT DIS, V15, P2040, DOI 10.3201/eid1512.090514; KAADEN OR, 1990, DEUT TIERARZTL WOCH, V97, P96; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; LaDouceur EEB, 2015, VET PATHOL, V52, P1250, DOI 10.1177/0300985814560234; Li L, 2015, J VIROL METHODS, V213, P139, DOI 10.1016/j.jviromet.2014.12.002; Li LL, 2011, EMERG INFECT DIS, V17, P1876, DOI 10.3201/eid1710.110233; Manas S, 2001, J WILDLIFE DIS, V37, P138, DOI 10.7589/0090-3558-37.1.138; Molenaar-de Backer MWA, 2016, J CLIN VIROL, V84, P19, DOI 10.1016/j.jcv.2016.09.004; Nituch LA, 2015, J WILDLIFE DIS, V51, P389, DOI 10.7589/2014-05-141; Nowalany-Kozielska E, 2015, INTERVIROLOGY, V58, P350, DOI 10.1159/000443375; Oie KL, 1996, J VIROL, V70, P852; Parrish CR, 2010, CURR TOP MICROBIOL, V343, P149, DOI 10.1007/82_2010_33; Pennick KE, 2007, VET PATHOL, V44, P687, DOI 10.1354/vp.44-5-687; Phan TG, 2016, VIROLOGY, V496, P299, DOI 10.1016/j.virol.2016.06.013; PORTER HG, 1982, INFECT IMMUN, V36, P379; Pyoria L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14930; Santonja C, 2017, BRIT J DERMATOL, V177, P1060, DOI 10.1111/bjd.15382; Shackelton LA, 2005, P NATL ACAD SCI USA, V102, P379, DOI 10.1073/pnas.0406765102; Shackelton LA, 2007, J GEN VIROL, V88, P3294, DOI 10.1099/vir.0.83255-0; Shao XQ, 2014, EMERG INFECT DIS, V20, P2085, DOI 10.3201/eid2012.140289; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Victoria JG, 2009, J VIROL, V83, P4642, DOI 10.1128/JVI.02301-08; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002	40	1	3	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					552	561		10.1177/0300985818758470			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800012	29433401				2019-10-28	
J	Chambers, JK; Shiga, T; Takimoto, H; Dohata, A; Miwa, Y; Nakayama, H; Uchida, K				Chambers, James K.; Shiga, Takanori; Takimoto, Haruka; Dohata, Atsushi; Miwa, Yasutsugu; Nakayama, Hiroyuki; Uchida, Kazuyuki			Proliferative Lesions of the Endometrium of 50 Four-Toed Hedgehogs (Atelerix albiventris)	VETERINARY PATHOLOGY			English	Article						Atelerix albiventris; endometrial stromal tumor; four-toed hedgehog; immunohistochemistry; neoplasia; reproductive; uterus	MIXED MULLERIAN TUMOR; RABBIT ORYCTOLAGUS-CUNICULUS; SMOOTH-MUSCLE TUMORS; STROMAL CELLS; PROGESTERONE-RECEPTORS; FELINE UTERUS; EXPRESSION; CD10; NEOPLASMS; POLYPS	Uteri from 50 four-toed hedgehogs (Atelerix albiventris) with clinical signs of uterine disease were histopathologically examined. Sixteen animals (32%) were diagnosed with endometrial hyperplasia, 7 animals (14%) were diagnosed with endometrial polyp, and 27 animals (54%) were diagnosed with endometrial neoplasia. The mean ages of the animals with endometrial hyperplasia, polyp, and neoplasia were 28.7 months, 29.4 months, and 25.2 months, respectively. The neoplasms were classified into 7 endometrial mixed tumors, 12 endometrial stromal nodules, and 8 endometrial stromal sarcomas. However, the endometrial stromal nodules and endometrial stromal sarcomas often developed within or were contiguous with an endometrial polyp or mixed tumor. Interestingly, the stromal tumors and the stromal components of the endometrial polyp and mixed tumor displayed extraendometrial differentiation (eg, into adipocytes, granular cells, smooth muscle cells, and osteoid tissue). The endometrial stromal sarcomas exhibited severe cellular atypia and invaded subendometrial tissue. Immunohistochemical examinations demonstrated that the stromal cells of the hyperplastic lesions as well as the neoplastic lesions were positive for CD10, the progesterone receptor, and Wilms tumor 1. The four-toed hedgehog develops unique uterine neoplasms that are mainly composed of endometrial stromal cells and probably arise from endometrial polyps and/or mixed tumors.	[Chambers, James K.; Shiga, Takanori; Dohata, Atsushi; Nakayama, Hiroyuki; Uchida, Kazuyuki] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Tokyo, Japan; [Takimoto, Haruka; Miwa, Yasutsugu] Miwa Exot Anim Hosp, Tokyo, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Pathol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp					Adegboyega PA, 2008, HUM PATHOL, V39, P1459, DOI 10.1016/j.humpath.2008.02.008; Agnew DW, 2004, VET PATHOL, V41, P179, DOI 10.1354/vp.41-2-179; Anthony FW, 2003, J SOC GYNECOL INVEST, V10, P509, DOI 10.1016/S1071-5576(03)00147-3; Arnold JT, 2001, HUM REPROD, V16, P836, DOI 10.1093/humrep/16.5.836; Asakawa MG, 2008, VET PATHOL, V45, P217, DOI 10.1354/vp.45-2-217; Atkins HM, 2016, VET PATHOL, V53, P1252, DOI 10.1177/0300985816646433; Bedenice D, 2000, J VET DIAGN INVEST, V12, P275, DOI 10.1177/104063870001200316; Bhargava R, 2005, MODERN PATHOL, V18, P40, DOI 10.1038/modpathol.3800248; Carpenter JW, 2005, EXOTIC ANIMAL FORMUL, P361; Chaffee BK, 2016, VET PATHOL, V53, P425, DOI 10.1177/0300985815620654; Chambers JK, 2014, J VET MED SCI, V76, P909, DOI 10.1292/jvms.14-0053; Cho HS, 2006, J VET MED A, V53, P464, DOI 10.1111/j.1439-0442.2006.00873.x; Chu PG, 2001, MODERN PATHOL, V14, P465, DOI 10.1038/modpathol.3880335; Conklin CMJ, 2014, ADV ANAT PATHOL, V21, P383, DOI 10.1097/PAP.0000000000000046; CZERNOBILSKY B, 1982, LAB ANIM, V16, P285, DOI 10.1258/002367782780891804; Deligdisch L, 2000, MODERN PATHOL, V13, P285, DOI 10.1038/modpathol.3880050; Gargett CE, 2016, HUM REPROD UPDATE, V22, P137, DOI 10.1093/humupd/dmv051; GELBERG HB, 1984, VET PATHOL, V21, P570, DOI 10.1177/030098588402100604; Gonzalez D, 2012, J CLIN ENDOCR METAB, V97, P957, DOI 10.1210/jc.2011-2366; Goto M, 2006, VET PATHOL, V43, P560, DOI 10.1354/vp.43-4-560; Greaves E, 2014, AM J PATHOL, V184, P1930, DOI 10.1016/j.ajpath.2014.03.011; HAMIR AN, 1989, VET PATHOL, V26, P185, DOI 10.1177/030098588902600216; Holman HJ, 2016, J ZOO WILDLIFE MED, V47, P1114, DOI 10.1638/2016-0095.1; IMAI K, 1992, BIOL REPROD, V46, P328, DOI 10.1095/biolreprod46.3.328; KASPAREITRITTINGHAUSEN J, 1990, TOXICOL PATHOL, V18, P417, DOI 10.1177/019262339001800309; Kennedy PC, 2008, WHO INT HISTOLOGICAL, VIV, P32; Klattig J, 2007, SEX DEV, V1, P238, DOI 10.1159/000104774; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kurman RJ, 2014, WHO CLASSIFICATION T; Laik-Schandelmaier C, 2017, J COMP PATHOL, V156, P339, DOI 10.1016/j.jcpa.2017.03.002; Makrigiannakis A, 2001, J CLIN ENDOCR METAB, V86, P5964, DOI 10.1210/jc.86.12.5964; Marino G, 2013, J COMP PATHOL, V149, P410, DOI 10.1016/j.jcpa.2013.03.004; McCluggage WG, 2001, HISTOPATHOLOGY, V39, P273, DOI 10.1046/j.1365-2559.2001.01215.x; Mikaelian I, 2004, J ZOO WILDLIFE MED, V35, P216, DOI 10.1638/01-077; Mikami Y, 2002, MODERN PATHOL, V15, P923, DOI 10.1097/01.MP.0000026058.33869.DB; Miller MA, 2003, J VET DIAGN INVEST, V15, P515, DOI 10.1177/104063870301500602; Nicotina PA, 2002, VET PATHOL, V39, P158, DOI 10.1354/vp.39-1-158; Oliva E, 2000, ADV ANAT PATHOL, V7, P257, DOI 10.1097/00125480-200007050-00001; Oliva E, 2002, AM J SURG PATHOL, V26, P403, DOI 10.1097/00000478-200204000-00001; PAPPARELLA S, 1984, VET PATHOL, V21, P257, DOI 10.1177/030098588402100222; Phillips ID, 2005, CAN VET J, V46, P524; Poteracki J, 1998, TOXICOL SCI, V45, P1; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Reich O, 2000, BRIT J CANCER, V82, P1030; REUBER MD, 1981, J GERONTOL, V36, P663, DOI 10.1093/geronj/36.6.663; Sato T, 2007, VET PATHOL, V44, P379, DOI 10.1354/vp.44-3-379; Schlafer DH, 2008, THERIOGENOLOGY, V70, P349, DOI 10.1016/j.theriogenology.2008.04.041; Schlafer DH, 2016, PATHOLOGY DOMESTIC A, V3, P447; Schwab KE, 2007, HUM REPROD, V22, P2903, DOI 10.1093/humrep/dem265; Spencer TE, 2005, CURR TOP DEV BIOL, V68, P85, DOI 10.1016/S0070-2153(05)68004-0; Sumathi VP, 2004, INT J GYNECOL PATHOL, V23, P241, DOI 10.1097/01.pgp.0000130051.04396.13; TOFT JD, 1975, VET PATHOL, V12, P32, DOI 10.1177/030098587501200105; Toki T, 2002, INT J GYNECOL PATHOL, V21, P41, DOI 10.1097/00004347-200201000-00008; van den Brink-Knol H, 2010, VET PATHOL, V47, P1105, DOI 10.1177/0300985810374840; Veiga-Parga T, 2016, J VET DIAGN INVEST, V28, P656, DOI 10.1177/1040638716665429; Walter B, 2010, VET REC, V166, P230, DOI 10.1136/vr.b4749; Zadravec M, 2012, J VET DIAGN INVEST, V24, P418, DOI 10.1177/1040638711433324	57	2	2	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					562	571		10.1177/0300985818758467			10	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800013	29448904				2019-10-28	
J	Clarke, LL; Niedringhaus, KD; Carmichael, KP; Keel, MK; Fenton, H				Clarke, Lorelei L.; Niedringhaus, Kevin D.; Carmichael, K. Paige; Keel, M. Kevin; Fenton, Heather			Congenital Ocular Abnormalities in Free-Ranging White-Tailed Deer	VETERINARY PATHOLOGY			English	Article						deer; anophthalmia; microphthalmia; coloboma; cataract; congenital; eye abnormalities; wild animals; Odocoileus virginianus	CERVUS-ELAPHUS; CATTLE; MICROPHTHALMIA; ANOPHTHALMIA; DEFECTS; COLOBOMATA; PATHOLOGY; ANOMALIES; CALVES	Congenital ocular abnormalities in cervids have been previously reported as individual cases from various regions of the United States and include microphthalmia, anophthalmia, congenital cataracts, dermoids, and colobomata. A common underlying cause for these abnormalities, such as nutritional deficiencies, environmental toxin exposures, or genetic mutations, has not been established. This retrospective study summarized and compared cases of suspected congenital ocular abnormalities in free-ranging white-tailed deer (Odocoileus virginianus) submitted to the Southeastern Cooperative Wildlife Disease Study (SCWDS) in Athens, Georgia, to the preexisting literature. Of 3645 accessions of white-tailed deer submitted to SCWDS, 15 qualifying case records were found. An additional 15 cases were reported previously in the literature. Conditions described in SCWDS cases included microphthalmia (8/15), congenital cataracts (3/15), anophthalmia (2/15), colobomata (1/15), anterior segment dysgenesis (1/15), ectopic lacrimal gland tissue (1/15), and congenital blindness with corneal opacity (1/15). Most (11/15; 73%) of the SCWDS cases were male fawns with an average age of 4 months at presentation, consistent with previously described cases. Most animals had bilateral abnormalities with few extraocular congenital abnormalities, also consistent with existing reports. Cases were variably tested for various infectious agents at the time of submission; 2 cases were seropositive for bluetongue virus. Spatiotemporal clustering of cases was not evident. This study provided a concise and systematic summary of known existing cases of congenital ocular defects in fawns but did not identify a cause.	[Clarke, Lorelei L.; Carmichael, K. Paige] Univ Georgia, Coll Vet Med, Dept Pathol, 501 DW Brooks Dr, Athens, GA 30602 USA; [Niedringhaus, Kevin D.] Univ Georgia, Coll Vet Med, Southeastern Cooperat Wildlife Dis Study, Athens, GA USA; [Keel, M. Kevin] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA USA; [Fenton, Heather] Govt Northwest Terr, Yellowknife, NT, Canada	Clarke, LL (reprint author), Univ Georgia, Coll Vet Med, Dept Pathol, 501 DW Brooks Dr, Athens, GA 30602 USA.	lclarke@uga.edu			Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Alabama; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Arkansas; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Florida; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Georgia; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Kentucky; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Kansas; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Louisiana; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Maryland; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Mississippi; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Missouri; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Nebraska; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of North Carolina; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Ohio; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Oklahoma; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Pennsylvania; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of South Carolina; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Tennessee; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of Virginia; Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agency of West Virginia, United States; Federal Aid to Wildlife Restoration Act [50 Stat. 917]	The authors received the following financial support for the research, authorship, and/or publication of this article: Funding was provided by the sponsorship of the Southeastern Cooperative Wildlife Disease Study by the fish and wildlife agencies of Alabama, Arkansas, Florida, Georgia, Kentucky, Kansas, Louisiana, Maryland, Mississippi, Missouri, Nebraska, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Virginia, and West Virginia, United States. Support from the states to SCWDS was provided in part by the Federal Aid to Wildlife Restoration Act (50 Stat. 917).	Abbasi AR, 2009, GENOMICS, V94, P55, DOI 10.1016/j.ygeno.2009.04.001; Agerholm JS, 2015, ACTA VET SCAND, V57, DOI 10.1186/s13028-015-0145-8; Barnett KC, 2002, VET OPHTHALMOL, V5, P197, DOI 10.1046/j.1463-5224.2002.00219.x; BARRETT M W, 1975, Journal of Wildlife Diseases, V11, P497; Becker D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008689; Bildfell R, 2003, EQUINE VET J, V35, P325, DOI 10.2746/042516403776148237; Dubielzig RR, 2010, VET OCULAR PATHOLOGY; FALCO M, 1978, VET REC, V102, P102, DOI 10.1136/vr.102.5.102; FULTON AB, 1977, J COMP PATHOL, V87, P557, DOI 10.1016/0021-9975(77)90062-7; Gelmetti D, 2010, J WILDLIFE DIS, V46, P961, DOI 10.7589/0090-3558-46.3.961; Hassig M, 2009, SCHWEIZ ARCH TIERH, V151, P471, DOI 10.1024/0036-7281.151.10.471; HOWARD D R, 1976, Journal of Wildlife Diseases, V12, P143; Krump L, 2014, IRISH VET J, V67, DOI 10.1186/2046-0481-67-2; Kuiken T, 1997, J WILDLIFE DIS, V33, P87, DOI 10.7589/0090-3558-33.1.87; LaDouceur EEB, 2012, J WILDLIFE DIS, V48, P826, DOI 10.7589/0090-3558-48.3.826; LEIPOLD HW, 1968, PATHOL VET, V5, P407, DOI 10.1177/030098586800500503; Moore CP, 1999, J ZOO WILDLIFE MED, V30, P423; Mosier DA, 1983, EQUINE VET J S, V15, P18; Mutinelli F, 2012, J VET MED SCI, V74, P527, DOI 10.1292/jvms.11-0385; Onwochei BC, 2000, SURV OPHTHALMOL, V45, P175, DOI 10.1016/S0039-6257(00)00151-X; RENDER JA, 1983, J WILDLIFE DIS, V19, P234, DOI 10.7589/0090-3558-19.3.234; Ryel L. A., 1963, Journal of Mammalogy, V44, P79, DOI 10.2307/1377171; See AWM, 2009, DEV BIOL, V325, P94, DOI 10.1016/j.ydbio.2008.09.030; Skalicky SE, 2013, JAMA OPHTHALMOL, V131, P1517, DOI 10.1001/jamaophthalmol.2013.5305; Stone W. B, 1970, N.Y. Fish Game J., V17, P133; Uchida K, 2006, VET PATHOL, V43, P1017, DOI 10.1354/vp.43-6-1017; VANDERLUGT JJ, 1989, ONDERSTEPOORT J VET, V56, P99; Wheeler C A, 1990, Equine Vet J Suppl, P39; Wilcoc BP, 2016, JUBB KENNEDY PALMERS; WOBESER G, 1973, Journal of Wildlife Diseases, V9, P356; WYAND DS, 1972, J COMP PATHOL, V82, P219, DOI 10.1016/0021-9975(72)90066-7; Zeiss CJ, 2008, VET OPHTHALMOL, V11, P30, DOI 10.1111/j.1463-5224.2007.00597.x	32	1	1	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					584	590		10.1177/0300985818759771			7	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800015	29444630				2019-10-28	
J	Iverson, WO; Karanth, S; Wilcox, A; Pham, CD; Lockhart, SR; Nicholson, SM				Iverson, William O.; Karanth, Subramanya; Wilcox, Angela; Pham, Cau D.; Lockhart, Shawn R.; Nicholson, Simone M.			Talaromycosis (Penicilliosis) in a Cynomolgus Macaque	VETERINARY PATHOLOGY			English	Article						Talaromyces (Penicillium) marneffei; Macaca fascicularis; immunosuppression; fungus	MARNEFFEI INFECTION; PRIMATES	A sexually mature Chinese-origin female Macaca fascicularis assigned to the high-dose group in a 26-week toxicology study with an experimental immunomodulatory therapeutic antibody (a CD40 L antagonist fusion protein) was euthanized at the scheduled terminal sacrifice on study day 192. The animal was healthy at study initiation and remained clinically normal throughout the study. On study day 141, abnormal clinical pathology changes were found during a scheduled evaluation; splenomegaly was detected on study day 149 and supported by ultrasound examination. At the scheduled necropsy, there was marked splenomegaly with a nodular and discolored appearance. Cytologic examination of a splenic impression smear revealed yeast-like organisms within macrophages. Histologically, there was disseminated systemic granulomatous inflammation with 2- to 3-m oval, intracytoplasmic yeast-like organisms in multiple organs identified as Talaromyces (Penicillium) marneffei. This organism, not previously reported as a pathogen in macaques, causes an important opportunistic infection in immunosuppressed humans in specific global geographic locations.	[Iverson, William O.; Karanth, Subramanya; Nicholson, Simone M.] MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 USA; [Wilcox, Angela] Charles River Labs, Preclin Serv, Reno, NV USA; [Pham, Cau D.; Lockhart, Shawn R.] Natl Ctr Emerging & Zoonot Infect Dis, Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Fungal Reference Unit,Mycot Dis Branch, Atlanta, GA USA	Iverson, WO (reprint author), MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878 USA.	iversonw@medimmune.com					Bailey C, 2010, VET PATHOL, V47, P462, DOI 10.1177/0300985810363719; CAPPONI M., 1956, BULL SOC PATHOL EXOT, V49, P418; Chan JFW, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.18; Chan JFW, 2015, EMERG INFECT DIS, V21, P1101, DOI 10.3201/eid2107.150138; Fedullo JDL, 2013, J MED PRIMATOL, V42, P293, DOI 10.1111/jmp.12056; Munoz-Cadavid C, 2010, J CLIN MICROBIOL, V48, P2147, DOI 10.1128/JCM.00459-10; Samson RA, 2011, STUD MYCOL, P159, DOI 10.3114/sim.2011.70.04; Sapmak A, 2016, VIRULENCE, V7, P702, DOI 10.1080/21505594.2016.1193275; Sasseville VG, 2010, J IMMUNOTOXICOL, V7, P79, DOI 10.3109/15476910903213521; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; SUPPARATPINYO K, 1994, LANCET, V344, P110, DOI 10.1016/S0140-6736(94)91287-4; Sze KH, 2017, CELL CHEM BIOL, V24, P182, DOI 10.1016/j.chembiol.2016.12.014; Vanittanakom N, 2006, CLIN MICROBIOL REV, V19, P95, DOI 10.1128/CMR.19.1.95-110.2006	13	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					591	594		10.1177/0300985818758468			4	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800016	29444633				2019-10-28	
J	Belluco, S				Belluco, Sara			Citation Index Is Not Critically Important to Veterinary Pathology, Medicine, and Research	VETERINARY PATHOLOGY			English	Letter						M2 macrophages		The article "CD204-Expressing Tumor-Associated Macrophages Are Associated With Malignant, High-Grade, and Hormone Receptor-Negative Canine Mammary Gland Tumors" does not provide evidence that CD204 is a marker for M2 macrophages.	[Belluco, Sara] VetAgro Sup, Serv Anat Pathol, Campus Vet 1,Ave Bourgelat, F-69280 Marcy Letoile, France	Belluco, S (reprint author), VetAgro Sup, Serv Anat Pathol, Campus Vet 1,Ave Bourgelat, F-69280 Marcy Letoile, France.	sara.belluco@vetagro-sup.fr					Heinrich F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183572; Kato Y, 2013, J COMP PATHOL, V148, P188, DOI 10.1016/j.jcpa.2012.06.009; Seung BJ, 2018, VET PATHOL, V55, P417, DOI 10.1177/0300985817750457	3	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					597	597		10.1177/0300985818763717			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800018	29890926	Bronze			2019-10-28	
J	Sur, JH				Sur, Jung-Hyang			Citation Index Is Not Critically Important to Veterinary Pathology, Medicine, and Research Response	VETERINARY PATHOLOGY			English	Letter									[Sur, Jung-Hyang] Konkuk Univ, Coll Vet Med, Small Anim Tumor Diagnost Ctr, Dept Vet Pathol, 120 Neugdong Ro, Seoul 05029, South Korea	Sur, JH (reprint author), Konkuk Univ, Coll Vet Med, Small Anim Tumor Diagnost Ctr, Dept Vet Pathol, 120 Neugdong Ro, Seoul 05029, South Korea.			Sur, Jung-Hyang/0000-0003-4496-7582			Gelberman RH, 2017, CLIN ORTHOP RELAT R, V475, P2318, DOI 10.1007/s11999-017-5369-7; Heinrich F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183572	2	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JUL	2018	55	4					598	598		10.1177/0300985818763718			1	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	GK3VC	WOS:000436075800019	29890925				2019-10-28	
J	Sempoux, C; Bioulac-Sage, P				Sempoux, Christine; Bioulac-Sage, Paulette			Vascular liver lesions: contemporary views on long-recognized entities	VIRCHOWS ARCHIV			English	Editorial Material									[Sempoux, Christine] Lausanne Univ Hosp, Serv Clin Pathol, Inst Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland; [Bioulac-Sage, Paulette] INSERM, UMR1053, Bordeaux Res Translat Oncol, BaRITOn, F-33000 Bordeaux, France; [Bioulac-Sage, Paulette] Univ Bordeaux, F-33076 Bordeaux, France	Sempoux, C (reprint author), Lausanne Univ Hosp, Serv Clin Pathol, Inst Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland.	christine.sempoux@chuv.ch					Cazals-Hatem D, 2011, J HEPATOL, V54, P455, DOI 10.1016/j.jhep.2010.07.038; Guido M, 2016, LIVER INT, V36, P454, DOI 10.1111/liv.12936; Hytiroglou P, 2012, AM J CLIN PATHOL, V137, P5, DOI 10.1309/AJCP2T2OHTAPBTMP; Sempoux C, 2015, J HEPATOL, V63, P1173, DOI 10.1016/j.jhep.2015.06.017	4	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					1	2		10.1007/s00428-018-2328-y			2	Pathology	Pathology	GK9JO	WOS:000436563100001	29536168	Bronze			2019-10-28	
J	Valla, DC; Cazals-Hatem, D				Valla, Dominique-Charles; Cazals-Hatem, Dominique			Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts	VIRCHOWS ARCHIV			English	Review						Budd-Chiari syndrome; Hepatic vein thrombosis; Portal vein thrombosis; Portal cavernoma; Idiopathic portal hypertension; Idiopathic noncirrhotic intrahepatic portal hypertension; Obliterative portal venopathy; Nodular regenerative hyperplasia; Incomplete septal cirrhosis; Hepatoportal sclerosis; Sinusoidal obstruction syndrome; Venoocclusive disease; Nonobstructive sinusoidal dilatation; Peliosis; Congenital portosystemic shunt; Abernethy malformation	PORTAL-VEIN THROMBOSIS; BUDD-CHIARI-SYNDROME; CONGENITAL PORTOSYSTEMIC SHUNTS; SINUSOIDAL OBSTRUCTION SYNDROME; RISK-FACTORS; ADVANCED CIRRHOSIS; NATURAL-HISTORY; HYPERTENSION; MANAGEMENT; TRANSPLANTATION	The components of the hepatic vascular system (hepatic arteries, portal and hepatic veins, sinusoids, and lymphatics) can be damaged by various types of injury. Each of the resulting conditions is rare, which has limited knowledge and awareness. In the last two decades, international collaborations have allowed to reach critical masses of data, which has driven significant progresses in understanding and management of vascular disorders of the liver. The present paper discusses definitions, denominations, and diagnosis of such vascular disorders with the exception of those affecting hepatic arteries. Evolving pathogenic or pathophysiologic views relevant to the clinical aspects are also overviewed.	[Valla, Dominique-Charles] Hop Beaujon, Serv Hepatol, 100 Blvd Gen Leclerc, F-92118 Clichy, France; [Valla, Dominique-Charles; Cazals-Hatem, Dominique] Hop Beaujon, APHP, DHU UNITY, Clichy La Garenne, France; [Valla, Dominique-Charles; Cazals-Hatem, Dominique] Univ Paris Diderot, UMR 1149, CRI, Paris, France; [Valla, Dominique-Charles; Cazals-Hatem, Dominique] INSERM, Paris, France; [Cazals-Hatem, Dominique] Serv Cent Anat & Cytol Pathol, Paris, France	Valla, DC (reprint author), Hop Beaujon, Serv Hepatol, 100 Blvd Gen Leclerc, F-92118 Clichy, France.; Valla, DC (reprint author), Hop Beaujon, APHP, DHU UNITY, Clichy La Garenne, France.; Valla, DC (reprint author), Univ Paris Diderot, UMR 1149, CRI, Paris, France.; Valla, DC (reprint author), INSERM, Paris, France.	dominique.valla@aphp.fr					Bernard O, 2012, SEMIN LIVER DIS, V32, P273, DOI 10.1055/s-0032-1329896; Berry K, 2015, CLIN GASTROENTEROL H, V13, P585, DOI 10.1016/j.cgh.2014.10.010; Berzigotti A, 2014, NAT REV GASTRO HEPAT, V11, P308, DOI 10.1038/nrgastro.2013.258; Blanc T, 2014, ANN SURG, V260, P188, DOI 10.1097/SLA.0000000000000266; Cazals-Hatem D, 2003, HEPATOLOGY, V37, P510, DOI 10.1053/jhep.2003.50076; Cazals-Hatem D, 2011, J HEPATOL, V54, P455, DOI 10.1016/j.jhep.2010.07.038; Chait Y, 2005, BRIT J HAEMATOL, V129, P553, DOI 10.1111/j.1365-2141.2005.05490.x; Condat B, 2001, GASTROENTEROLOGY, V120, P490, DOI 10.1053/gast.2001.21209; de Franchis R, 2015, J HEPATOL, V63, P743, DOI 10.1016/j.jhep.2015.05.022; DeLeve LD, 2009, HEPATOLOGY, V49, P1729, DOI 10.1002/hep.22772; Dhiman RK, 2014, J CLIN EXP HEPATOL, V4, pS2, DOI 10.1016/j.jceh.2014.02.003; Doenecke A, 2010, CLIN TRANSPLANT, V24, P48, DOI 10.1111/j.1399-0012.2009.00977.x; Elkrief L, 2014, LIVER INT, V34, P1314, DOI 10.1111/liv.12386; Englesbe MJ, 2010, LIVER TRANSPLANT, V16, P999, DOI 10.1002/lt.22105; Faraoun SA, 2016, CLIN IMAG, V40, P637, DOI [10.1016/J.clinimag.2016.01.006, 10.1016/j.clinimag.2016.01.006]; Francoz C, 2012, J HEPATOL, V57, P203, DOI 10.1016/j.jhep.2011.12.034; Garcia-Pagan JC, 2016, J HEPATOL, V64, P179, DOI 10.1016/j.jhep.2015.07.040; Ghabril M, 2016, TRANSPLANTATION, V100, P126, DOI 10.1097/TP.0000000000000785; Guido M, 2016, LIVER INT, V36, P454, DOI 10.1111/liv.12936; HADENGUE A, 1994, GASTROENTEROLOGY, V106, P1042, DOI 10.1016/0016-5085(94)90765-X; Harb R, 2009, GASTROENTEROLOGY, V137, P704, DOI 10.1053/j.gastro.2009.05.009; Hibi T, 2014, ANN SURG, V259, P760, DOI 10.1097/SLA.0000000000000252; Hillaire S, 2002, GUT, V51, P275, DOI 10.1136/gut.51.2.275; Khanna R, 2014, J HEPATOL, V60, P421, DOI 10.1016/j.jhep.2013.08.013; Ki M, 2016, LIVER INT, V36, P1067, DOI 10.1111/liv.13008; Klinger C, 2017, DIGEST LIVER DIS, V49, P1345, DOI 10.1016/j.dld.2017.05.020; Lautz TB, 2013, J AM COLL SURGEONS, V216, P83, DOI 10.1016/j.jamcollsurg.2012.09.013; Loffredo L, 2017, GASTROENTEROLOGY, V153, P480, DOI 10.1053/j.gastro.2017.04.042; Luca A, 2012, RADIOLOGY, V265, P124, DOI 10.1148/radiol.12112236; Luca A, 2011, GUT, V60, P846, DOI 10.1136/gut.2010.228023; Luo XF, 2015, RADIOLOGY, V276, P286, DOI 10.1148/radiol.15141252; Maruyama H, 2013, AM J GASTROENTEROL, V108, P568, DOI 10.1038/ajg.2012.452; Marzano C, 2015, HEPATOLOGY, V62, P956, DOI 10.1002/hep.27747; Matsutani S, 2005, LIVER INT, V25, P978, DOI 10.1111/j.1478-3231.2005.01151.x; MIKKELSEN WILLIAM P., 1965, ANN SURG, V162, P602; Moucari R, 2008, GUT, V57, P828, DOI 10.1136/gut.2007.139477; Nery F, 2015, HEPATOLOGY, V61, P660, DOI 10.1002/hep.27546; Plessier A, 2010, HEPATOLOGY, V51, P210, DOI 10.1002/hep.23259; Poisson J, 2017, J HEPATOL, V67, P501, DOI 10.1016/j.jhep.2017.04.021; Qi XS, 2015, GASTROENT RES PRACT, DOI 10.1155/2015/480842; Qi XS, 2013, THROMB HAEMOSTASIS, V109, P878, DOI 10.1160/TH12-10-0784; Ronot M, 2016, EUR RADIOL, V26, P3094, DOI 10.1007/s00330-015-4124-2; Rosenqvist K, 2016, ACTA RADIOL, V57, P572, DOI 10.1177/0284185115595060; Rubbia-Brandt L, 2010, HISTOPATHOLOGY, V56, P430, DOI 10.1111/j.1365-2559.2010.03511.x; Saadoun D, 2004, GUT, V53, P1516, DOI 10.1136/gut.2003.037135; Schouten JNL, 2012, ALIMENT PHARM THER, V35, P1424, DOI 10.1111/j.1365-2036.2012.05112.x; Schouten JNL, 2011, HEPATOLOGY, V54, P1071, DOI 10.1002/hep.24422; Seijo S, 2013, HEPATOLOGY, V57, P1962, DOI 10.1002/hep.26306; Seijo S, 2012, DIGEST LIVER DIS, V44, P855, DOI 10.1016/j.dld.2012.05.005; Sempoux C, 2015, J HEPATOL, V63, P1173, DOI 10.1016/j.jhep.2015.06.017; Sharma P, 2009, AM J GASTROENTEROL, V104, P885, DOI 10.1038/ajg.2009.84; Shrestha SM, 1996, J GASTROEN HEPATOL, V11, P170, DOI 10.1111/j.1440-1746.1996.tb00056.x; Simonetto DA, 2015, HEPATOLOGY, V61, P648, DOI 10.1002/hep.27387; Siramolpiwat S, 2014, HEPATOLOGY, V59, P2276, DOI 10.1002/hep.26904; Smalberg JH, 2008, THROMB HAEMOSTASIS, V100, P1084, DOI 10.1160/TH08-01-0015; Stine JG, 2015, WORLD J HEPATOL, V7, P2774, DOI 10.4254/wjh.v7.i27.2774; Tripodi A, 2011, J THROMB HAEMOST, V9, P1713, DOI 10.1111/j.1538-7836.2011.04429.x; Turnes J, 2008, CLIN GASTROENTEROL H, V6, P1412, DOI 10.1016/j.cgh.2008.07.031; Valla DC, 2000, J HEPATOL, V32, P865, DOI 10.1016/S0168-8278(00)80259-7; Valla DC, 2016, CLIN RES HEPATOL GAS, V40, P378, DOI 10.1016/j.clinre.2016.01.006; Valla DC, 2009, J HEPATOL, V50, P195, DOI 10.1016/j.jhep.2008.10.007; Verheij J, 2013, HISTOPATHOLOGY, V62, P1083, DOI 10.1111/his.12114; Vilgrain V, 2006, RADIOLOGY, V241, P149, DOI 10.1148/radiol.2411051102; Villa E, 2012, GASTROENTEROLOGY, V143, P1253, DOI 10.1053/j.gastro.2012.07.018; WANLESS IR, 1995, HEPATOLOGY, V21, P1238, DOI 10.1002/hep.1840210505; Zocco MA, 2009, J HEPATOL, V51, P682, DOI 10.1016/j.jhep.2009.03.013	66	4	4	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					3	13		10.1007/s00428-018-2331-3			11	Pathology	Pathology	GK9JO	WOS:000436563100002	29572606				2019-10-28	
J	Hytiroglou, P; Theise, ND				Hytiroglou, Prodromos; Theise, Neil D.			Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.	VIRCHOWS ARCHIV			English	Review						Regression; Cirrhosis; Incomplete septal cirrhosis; Vascular lesions	CHRONIC HEPATITIS-B; INCOMPLETE SEPTAL CIRRHOSIS; HISTOLOGICAL IMPROVEMENT; VIROLOGICAL RESPONSE; AUTOIMMUNE HEPATITIS; PORTAL-HYPERTENSION; FIBROSIS; THERAPY; LIVER; CLASSIFICATION	Cirrhosis has been traditionally viewed as an irreversible, end-stage condition. Eighteen years ago, Wanless, Nakashima, and Sherman published a study that was based on the concept that hepatic architecture is under constant remodeling in the course of chronic liver diseases, even during their most advanced stages; depending on the balance between injury and repair, the histologic changes might be progressing or regressing. These authors described in detail the morphologic features of regressing cirrhosis, identified a set of histologic features of regression that they called the "hepatic repair complex," and provided convincing morphologic evidence that incomplete septal cirrhosis represents regressed cirrhosis. In the years that followed publication of this pioneering article, a number of clinical studies with performance of pre- and post-treatment liver biopsies provided abundant evidence that cirrhosis can regress after successful therapy of chronic hepatitis B, chronic hepatitis C, autoimmune hepatitis, and genetic hemochromatosis. Evidence for other chronic liver diseases may also be provided in the future, pending ongoing studies. Successful therapy allows resorption of fibrous septa, which can be followed by loss of nodularity and architectural improvement; however, many vascular lesions of cirrhotic livers are not thought to regress. Cases of cirrhosis that are considered more likely to improve than others include those of recent onset, with relatively thin fibrous septa and mild vascular changes. Histologic examination of liver biopsy specimens from patients with chronic liver diseases provides the opportunity to appreciate the features of the hepatic repair complex on a routine diagnostic basis; however, interpretation is often difficult, and can be aided by immunohistochemical stains. Clinicopathologic correlation is essential for a meaningful assessment of such cases. For many patients, cirrhosis is not an end-stage condition anymore; therefore, use of the term "cirrhosis" has been challenged, almost 200 years after its invention. However, regression of cirrhosis does not imply regression of molecular changes involved in hepatocarcinogenesis; therefore, surveillance for hepatocellular carcinoma should be continued in these patients.	[Hytiroglou, Prodromos] Aristotle Univ Thessaloniki, Sch Med, Dept Pathol, Thessaloniki 54006, Greece; [Theise, Neil D.] NYU, Sch Med, Dept Pathol, 550 First Ave,TH415, New York, NY 10016 USA	Hytiroglou, P (reprint author), Aristotle Univ Thessaloniki, Sch Med, Dept Pathol, Thessaloniki 54006, Greece.	phitir@med.auth.gr; Neil.Theise@nyumc.com					ANTHONY PP, 1977, B WORLD HEALTH ORGAN, V55, P521; Bedossa P, 2018, MACSWEENS PATHOLOGY, P636; Beuers U, 2015, HEPATOLOGY, V62, P1620, DOI 10.1002/hep.28140; Caldwell Stephen, 2012, Hepatology, V55, P1634, DOI 10.1002/hep.25623; Chang TT, 2010, HEPATOLOGY, V52, P886, DOI 10.1002/hep.23785; Chedid A, 2000, ARCH PATHOL LAB MED, V124, P1591; Chejfec G, 2000, ARCH PATHOL LAB MED, V124, P1585; Crawford JM, 2018, MACSWEENS PATHOLOGY, P1; Czaja AJ, 2004, J HEPATOL, V40, P646, DOI 10.1016/j.jhep.2004.01.009; D'Ambrosio R, 2012, HEPATOLOGY, V56, P532, DOI 10.1002/hep.25606; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; Dienstag JL, 2003, GASTROENTEROLOGY, V124, P105, DOI 10.1053/gast.2003.50013; Dufour JF, 1997, ANN INTERN MED, V127, P981, DOI 10.7326/0003-4819-127-11-199712010-00006; Everson GT, 2008, ALIMENT PHARM THERAP, V27, P542, DOI 10.1111/j.1365-2036.2008.03620.x; Falize L, 2006, HEPATOLOGY, V44, P472, DOI 10.1002/hep.21260; Falkowski O, 2003, J HEPATOL, V39, P357, DOI 10.1016/S0168-8278(03)00309-X; FAUERHOLDT L, 1983, HEPATOLOGY, V3, P928; Friedman SL, 2017, HEPATOLOGY; Friedman SL., 1999, SCHIFFS DIS LIVER, P371; Garcia-Tsao G, 2010, HEPATOLOGY, V51, P1445, DOI 10.1002/hep.23478; Geller SA, 2000, ARCH PATHOL LAB MED, V124, P1587; GRAND RJ, 1975, J PEDIATR-US, V87, P1161, DOI 10.1016/S0022-3476(75)80131-4; Hadziyannis SJ, 2006, GASTROENTEROLOGY, V131, P1743, DOI 10.1053/j.gastro.2006.09.020; Hydroglou P, 2007, GASTROENTEROL CLIN N, V36, P867, DOI 10.1016/j.gtc.2007.08.010; Hytiroglou P, 2012, AM J CLIN PATHOL, V137, P5, DOI 10.1309/AJCP2T2OHTAPBTMP; Intagliata NM, 2015, SEMIN THROMB HEMOST, V41, P514, DOI 10.1055/s-0035-1550436; Kaplan MM, 1997, ANN INTERN MED, V126, P682, DOI 10.7326/0003-4819-126-9-199705010-00002; Kim MY, 2011, J HEPATOL, V55, P1004, DOI 10.1016/j.jhep.2011.02.012; Kim SU, 2012, J HEPATOL, V57, P556, DOI 10.1016/j.jhep.2012.04.029; Kutami R, 2000, HEPATOLOGY, V32, p407A; Laennec RTH, 1819, AUSCULTATION MEDIATE, V1, P368; Lee YA, 2015, GUT, V64, P1337, DOI 10.1136/gutjnl-2014-306842corr1; Marcellin P, 2013, LANCET, V381, P468, DOI 10.1016/S0140-6736(12)61425-1; Papachrysos N, 2015, ANN GASTROENTEROL, V28, P374; Papatheodoridis GV, 2015, J HEPATOL, V62, P956, DOI 10.1016/j.jhep.2015.01.002; Perez-Tamayo R, 1979, Pathol Annu, V14 Pt 2, P183; Poynard T, 2002, GASTROENTEROLOGY, V122, P1303, DOI 10.1053/gast.2002.33023; Quaglia A, 2016, HISTOPATHOLOGY, V68, P953, DOI 10.1111/his.12957; Ray MB, 2000, ARCH PATHOL LAB MED, V124, P1589; SCIOT R, 1988, HISTOPATHOLOGY, V13, P593; Serpaggi J, 2006, HUM PATHOL, V37, P1519, DOI 10.1016/j.humpath.2006.07.007; Sun YM, 2017, HEPATOLOGY, V65, P1438, DOI 10.1002/hep.29009; Theise ND, 1996, GASTROENTEROLOGY, V111, P526, DOI 10.1053/gast.1996.v111.agast961110526; Theise Neil D, 2002, Clin Liver Dis, V6, P497, DOI 10.1016/S1089-3261(02)00006-5; van der Meer AJ, 2016, J HEPATOL, V65, pS95, DOI 10.1016/j.jhep.2016.07.039; Vilar-Gomez E, 2015, GASTROENTEROLOGY, V149, P367, DOI 10.1053/j.gastro.2015.04.005; Wanless IR, 2000, ARCH PATHOL LAB MED, V124, P1592; Wanless IR, 2000, ARCH PATHOL LAB MED, V124, P1599; WANLESS IR, 1995, HEPATOLOGY, V21, P1232, DOI 10.1002/hep.1840210504; WANLESS IR, 1995, HEPATOLOGY, V21, P1238, DOI 10.1002/hep.1840210505	50	3	4	2	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					15	22		10.1007/s00428-018-2340-2			8	Pathology	Pathology	GK9JO	WOS:000436563100003	29589101				2019-10-28	
J	Guido, M; Sarcognato, S; Sacchi, D; Colloredo, G				Guido, Maria; Sarcognato, Samantha; Sacchi, Diana; Colloredo, Guido			Pathology of idiopathic non-cirrhotic portal hypertension	VIRCHOWS ARCHIV			English	Review						Idiopathic non-cirrhotic portal hypertension; Vascular lesions; Obliterative portal venopathy; Incomplete septal cirrhosis; Nodular regenerative hyperplasia	NODULAR REGENERATIVE HYPERPLASIA; INCOMPLETE SEPTAL CIRRHOSIS; HEPATOPORTAL SCLEROSIS; SINUSOIDAL DILATATION; LIVER BIOPSIES; VENOPATHY; FIBROSIS; DISEASES; PATHOGENESIS; FEATURES	Idiopathic non-cirrhotic portal hypertension is an under-recognized vascular liver disease of unknown etiology, characterized by clinical signs of portal hypertension in the absence of cirrhosis. By definition, any disorder known to cause portal hypertension in the absence of cirrhosis and any cause of chronic liver disease must be excluded to make a diagnosis of idiopathic non-cirrhotic portal hypertension. However, the diagnosis is often difficult because the disease resembles cirrhosis and there is no gold standard test. Liver biopsy is an essential tool: it is able to exclude cirrhosis and other causes of portal hypertension and it allows the identification of the characteristic lesions. Nonetheless, the histological diagnosis of idiopathic non-cirrhotic portal hypertension is not always straightforward, in particular by needle biopsy samples, because there is no pathognomonic lesion, but rather a variety of vascular changes which are unevenly distributed, very subtle, and not all necessarily identified in a single specimen. Pathologists should be able to recognize several patterns of injury, involving portal/periportal areas as well as parenchymal structures.The histological features of idiopathic non-cirrhotic portal hypertension are described in this review, focusing on their interpretation in needle biopsy specimens.	[Guido, Maria; Sarcognato, Samantha; Sacchi, Diana] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy; [Colloredo, Guido] San Pietro Hosp, Dept Internal Med, Ponte San Pietro, Italy	Guido, M (reprint author), Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy.	mguido@unipd.it					Aggarwal S, 2013, DIGEST DIS SCI, V58, P2767, DOI 10.1007/s10620-013-2736-4; Albuquerque A, 2013, AM J GASTROENTEROL, V108, P150, DOI 10.1038/ajg.2012.370; Barge S, 2016, LIVER INT, V36, P1059, DOI 10.1111/liv.12974; Berzigotti A, 2006, WORLD J GASTROENTERO, V12, P3612, DOI 10.3748/wjg.v12.i22.3612; BIOULACSAGE P, 1995, SEMIN LIVER DIS, V15, P329, DOI 10.1055/s-2007-1007285; Brunt EM, 2014, HISTOPATHOLOGY, V64, P907, DOI 10.1111/his.12364; Cazals-Hatem D, 2011, J HEPATOL, V54, P455, DOI 10.1016/j.jhep.2010.07.038; Chawla Y, 2008, SEMIN LIVER DIS, V28, P270, DOI 10.1055/s-0028-1085095; Crawford AR, 1998, HEPATOLOGY, V28, P323, DOI 10.1002/hep.510280206; Delladetsima I, 2016, HISTOL HISTOPATHOL, V31, P1089, DOI 10.14670/HH-11-738; Dhiman RK, 2002, J GASTROEN HEPATOL, V17, P6, DOI 10.1046/j.1440-1746.2002.02596.x; Eapen CE, 2011, DIGEST DIS SCI, V56, P227, DOI 10.1007/s10620-010-1278-2; Elkrief L, 2016, LIVER INT, V36, P325, DOI 10.1111/liv.13048; Fiel MI, 2007, AM J SURG PATHOL, V31, P607; Franchi-Abella S, 2014, J PEDIATR-US, V165, P190, DOI 10.1016/j.jpeds.2014.03.025; FUKUDA K, 1985, ACTA PATHOL JAPON, V35, P885; Garcia-Pagan JC, 2016, J HEPATOL, V64, P179, DOI 10.1016/j.jhep.2015.07.040; Girard M, 2005, AM J MED GENET A, V135A, P186, DOI 10.1002/ajmg.a.30724; Goel A, 2014, J CLIN EXP HEPATOL, V4, P247, DOI 10.1016/j.jceh.2014.07.005; Guido M, 2016, LIVER INT, V36, P454, DOI 10.1111/liv.12936; Hartleb M, 2011, WORLD J GASTROENTERO, V17, P1400, DOI 10.3748/wjg.v17.i11.1400; Hillaire S, 2002, GUT, V51, P275, DOI 10.1136/gut.51.2.275; IBER FL, 1969, ANN INTERN MED, V71, P660, DOI 10.7326/0003-4819-71-3-660; Jharap B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120299; Kakar S, 2004, ARCH PATHOL LAB MED, V128, P901; Krasinskas AM, 2005, LIVER TRANSPLANT, V11, P627, DOI 10.1002/lt.20431; Krasinskas AM, 2005, AM J SURG PATHOL, V29, P1382, DOI 10.1097/01.pas.0000168508.70114.fd; Lee H, 2016, J PATHOL TRANSL MED, V50, P17, DOI 10.4132/jptm.2015.09.23; LUDWIG J, 1993, HISTOPATHOLOGY, V22, P227, DOI 10.1111/j.1365-2559.1993.tb00112.x; Marzano C, 2015, HEPATOLOGY, V62, P956, DOI 10.1002/hep.27747; MIKKELSEN WILLIAM P., 1965, ANN SURG, V162, P602; Millward-Sadler G. H., 1994, P397; Mukta V, 2017, TROP DOCT, V47, P26, DOI 10.1177/0049475516636982; Nakanuma Y, 1996, HISTOPATHOLOGY, V28, P195, DOI 10.1046/j.1365-2559.1996.d01-412.x; Nakanuma Y, 2001, PATHOL RES PRACT, V197, P759, DOI 10.1078/0344-0338-00155; Nakanuma Y, 2001, PATHOL RES PRACT, V197, P65, DOI 10.1078/0344-0338-5710012; Nayak NC, 2011, J CLIN PATHOL, V64, P592, DOI 10.1136/jcp.2010.087395; NAYAK NC, 1969, ARCH PATHOL, V87, P359; OHBU M, 1994, HEPATOLOGY, V20, P302, DOI 10.1016/0270-9139(94)90178-3; OKUDA K, 1982, Liver, V2, P176; Okudaira M, 2002, SEMIN LIVER DIS, V22, P59, DOI 10.1055/s-2002-23207; Popper H, 1966, CONTROVERSY INTERNAL, P233; Reshamwala PA, 2006, HEPATOLOGY, V44, P7, DOI 10.1002/hep.21258; Riggio O, 2016, HEPATIC MED-EVID RES, V8, P81, DOI 10.2147/HMER.S85544; Roulot D, 2013, LIVER INT, V33, P24, DOI 10.1111/liv.12007; SAITO K, 1993, HEPATO-GASTROENTEROL, V40, P163; Sarin SK, 2014, CLIN LIVER DIS, V18, P451, DOI 10.1016/j.cld.2014.01.009; Sarin SK, 2007, HEPATOL INT, V1, P398, DOI 10.1007/s12072-007-9010-9; Sarin SK, 1998, DIGESTION, V59, P420, DOI 10.1159/000007502; Sarin SK, 2002, J GASTROEN HEPATOL, V17, P526, DOI 10.1046/j.1440-1746.2002.02764.x; Sawada S, 2007, J GASTROEN HEPATOL, V22, P204, DOI 10.1111/j.1440-1746.2006.04492.x; Schinoni MI, 2004, LIVER INT, V24, P452, DOI 10.1111/j.1478-3231.2004.0989.x; Schouten JNL, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0288-8; Schouten JNL, 2011, HEPATOLOGY, V54, P1071, DOI 10.1002/hep.24422; Sharma P, 2017, J CLIN EXP HEPATOL, V7, P230, DOI 10.1016/j.jceh.2017.03.002; STEINER PE, 1959, AM J PATHOL, V35, P943; TERADA T, 1989, VIRCHOWS ARCH A, V415, P61, DOI 10.1007/BF00718605; VAKILI C, 1992, WORLD J SURG, V16, P118, DOI 10.1007/BF02067126; Verheij J, 2013, HISTOPATHOLOGY, V62, P1083, DOI 10.1111/his.12114; Wanless IR, 2000, ARCH PATHOL LAB MED, V124, P1599; WANLESS IR, 1980, MEDICINE, V59, P367, DOI 10.1097/00005792-198009000-00004; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; Yilmaz G, 2012, PEDIATR DEVEL PATHOL, V15, P107, DOI 10.2350/11-04-1017-OA.1; Zuo CL, 2017, HEPATOL INT, V11, P452, DOI 10.1007/s12072-017-9801-6	64	3	4	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					23	31		10.1007/s00428-018-2355-8			9	Pathology	Pathology	GK9JO	WOS:000436563100004	29644430				2019-10-28	
J	Sempoux, C; Balabaud, C; Paradis, V; Bioulac-Sage, P				Sempoux, Christine; Balabaud, Charles; Paradis, Valerie; Bioulac-Sage, Paulette			Hepatocellular nodules in vascular liver diseases	VIRCHOWS ARCHIV			English	Review						Liver; Vascular diseases; Hepatocellular nodules; Hepatocellular adenoma; Focal nodular hyperplasia; Hepatocellular carcinoma	BUDD-CHIARI-SYNDROME; CONGENITAL PORTOSYSTEMIC SHUNTS; HEREDITARY HEMORRHAGIC TELANGIECTASIA; LARGE REGENERATIVE NODULES; OBLITERATIVE PORTAL VENOPATHY; OF-THE-LITERATURE; FONTAN PROCEDURE; ABERNETHY MALFORMATION; RISK-FACTORS; MALIGNANT-TRANSFORMATION	Hepatocellular nodules have been recognized in vascular liver diseases for a long time and mostly described and studied in the imaging literature. Some confusions in their identification and overlap in their definitions exist, especially in this specific clinical context. Pathology descriptions report the development of nodular regenerative hyperplasia, large regenerative nodule, and focal nodular hyperplasia, as adaptive responses of the liver parenchyma to the modified blood flow. True neoplastic hepatocellular nodules such as hepatocellular adenoma and hepatocellular carcinoma can also appear, mainly in Budd-Chiari syndrome, and have to be correctly diagnosed. This is more difficult for the radiologist in these diseased livers, leading more frequently to perform liver biopsies. We describe the histology of each type of well-differentiated hepatocellular nodules and provide some clues for their differential diagnosis. A review of the literature gives an historical perspective of the problem and enlightens the frequency and the subtypes of hepatocellular nodules found in the most common vascular liver diseases.	[Sempoux, Christine] Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland; [Balabaud, Charles; Bioulac-Sage, Paulette] INSERM, UMR1053, Bordeaux Res Translat Oncol, BaRITOn, F-33000 Bordeaux, France; [Balabaud, Charles; Bioulac-Sage, Paulette] Univ Bordeaux, F-33076 Bordeaux, France; [Paradis, Valerie] Univ Paris Diderot, INSERM, UMR 1149, Pathol Dept,Beaujon Hosp, 101 Bd Gen Leclerc, F-92110 Clichy, France	Sempoux, C (reprint author), Lausanne Univ Hosp, Inst Pathol, Serv Clin Pathol, 25 Rue Bugnon, CH-1011 Lausanne, Switzerland.	christine.sempoux@chuv.ch	Paradis, Valerie/X-9097-2019				Agni RM, 2017, SEMIN DIAGN PATHOL, V34, P126, DOI 10.1053/j.semdp.2016.12.008; Ames JT, 2009, CLIN RADIOL, V64, P1190, DOI 10.1016/j.crad.2009.07.015; Arrive L, 2016, HEPATOLOGY, V64, P675, DOI 10.1002/hep.28590; Asrani SK, 2012, HEPATOLOGY, V56, P1160, DOI 10.1002/hep.25692; Babaoglu K, 2010, PEDIATR CARDIOL, V31, P861, DOI 10.1007/s00246-010-9685-x; Bedossa P, 2018, MACSWEENS PATHOLOGY, P636; Benedict M, 2017, PEDIATR DEVEL PATHOL, V20, P354, DOI 10.1177/1093526616686458; Bernard O, 2012, SEMIN LIVER DIS, V32, P273, DOI 10.1055/s-0032-1329896; Bioulac-Sage P, 2017, SEMIN DIAGN PATHOL, V34, P112, DOI 10.1053/j.semdp.2016.12.007; Bioulac-Sage P, 2009, LIVER INT, V29, P459, DOI 10.1111/j.1478-3231.2008.01849.x; Blanc T, 2014, ANN SURG, V260, P188, DOI 10.1097/SLA.0000000000000266; Brancatelli G, 2002, AM J ROENTGENOL, V178, P877, DOI 10.2214/ajr.178.4.1780877; Brasoveanu V, 2015, AM J CASE REP, V16, P637, DOI 10.12659/AJCR.895235; Brenard R, 2010, EUR J GASTROEN HEPAT, V22, P1253, DOI 10.1097/MEG.0b013e32833ac4a1; Bryant T, 2011, INT J CARDIOL, V151, P268, DOI 10.1016/j.ijcard.2010.05.047; Calderaro J, 2016, MODERN PATHOL, V29, P43, DOI 10.1038/modpathol.2015.119; Cazals-Hatem D, 2003, HEPATOLOGY, V37, P510, DOI 10.1053/jhep.2003.50076; Cazals-Hatem D, 2011, J HEPATOL, V54, P455, DOI 10.1016/j.jhep.2010.07.038; Chiche L, 2018, CLIN RES HEPATOL GAS; Choi WT, 2017, HUM PATHOL, V63, P1, DOI 10.1016/j.humpath.2016.12.025; Conroy MR, 2017, CARDIOL YOUNG, V27, P407, DOI 10.1017/S1047951116001360; Di Tommaso L, 2007, HEPATOLOGY, V45, P725, DOI 10.1002/hep.21531; Dissanayake R, 2017, BMC Res Notes, V10, P58, DOI 10.1186/s13104-017-2397-z; Elder RW, 2013, NEW ENGL J MED, V369, P490, DOI 10.1056/NEJMc1306854; FERRELL LD, 1993, AM J SURG PATHOL, V17, P1113, DOI 10.1097/00000478-199311000-00004; Franchi-Abella S, 2014, J PEDIATR-US, V165, P190, DOI 10.1016/j.jpeds.2014.03.025; Franchi-Abella S, 2010, J PEDIATR GASTR NUTR, V51, P322, DOI 10.1097/MPG.0b013e3181d9cb92; Garcia-Tsao G, 2000, NEW ENGL J MED, V343, P931, DOI 10.1056/NEJM200009283431305; Ghaferi AA, 2005, J THORAC CARDIOV SUR, V129, P1348, DOI 10.1016/j.jtcvs.2004.10.005; Glatard AS, 2012, RADIOLOGY, V263, P741, DOI 10.1148/radiol.12111785; Gordic S, 2017, EUR J RADIOL OPEN, V4, P115, DOI 10.1016/j.ejro.2017.08.001; Gordon-Burroughs S, 2014, TRANSPL P, V46, P2418, DOI 10.1016/j.transproceed.2014.04.012; Guido M, 2016, LIVER INT, V36, P454, DOI 10.1111/liv.12936; Gulsen Z, 2016, SURG RADIOL ANAT, V38, P373, DOI 10.1007/s00276-015-1460-5; Gwon DI, 2010, RADIOLOGY, V254, P617, DOI 10.1148/radiol.09090738; Handra-Luca A, 2006, HISTOPATHOLOGY, V48, P309, DOI 10.1111/j.1365-2559.2005.02250.x; Hao YB, 2015, ONCOL LETT, V9, P695, DOI 10.3892/ol.2014.2767; Henriet E, 2017, HEPATOLOGY, V66, P2016, DOI 10.1002/hep.29336; Hilscher MB, 2017, CONGENIT HEART DIS, V12, P124, DOI 10.1111/chd.12446; Hubert C, 2007, LIVER INT, V27, P938, DOI 10.1111/j.1478-3231.2007.01511.x; Hytiroglou P, 1998, SEMIN DIAGN PATHOL, V15, P285; Hytiroglou P, 2017, SEMIN DIAGN PATHOL, V34, P138, DOI 10.1053/j.semdp.2016.12.009; Ibarrola C, 2004, HISTOPATHOLOGY, V44, P172, DOI 10.1111/j.1365-2559.2004.01795.x; Jitta DJ, 2016, INT J CARDIOL, V206, P21, DOI 10.1016/j.ijcard.2015.12.033; Kanazawa H, 2015, J PEDIATR SURG, V50, P688, DOI 10.1016/j.jpedsurg.2015.01.009; Kim H, 2015, CLIN MOL HEPATOL, V21, P89, DOI 10.3350/cmh.2015.21.1.89; Kobayashi S, 2009, JPN J RADIOL, V27, P53, DOI 10.1007/s11604-008-0299-7; Kwon S, 2015, J GASTROINTEST ONCOL, V6, pE55, DOI 10.3978/j.issn.2078-6891.2015.009; Lammert F, 2016, J HEPATOL, V65, P146, DOI 10.1016/j.jhep.2016.03.005; Lautz TB, 2016, J PEDIATR GASTR NUTR, V62, P542, DOI 10.1097/MPG.0000000000001012; Lee H, 2016, J PATHOL TRANSL MED, V50, P17, DOI 10.4132/jptm.2015.09.23; Lisovsky M, 2011, AM J SURG PATHOL, V35, P1381, DOI 10.1097/PAS.0b013e3182230ce4; Liu FY, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-105; Moucari R, 2008, GUT, V57, P828, DOI 10.1136/gut.2007.139477; Nandwana SB, 2018, CURR PROBL DIAGN RAD, V47, P19, DOI 10.1067/j.cpradiol.2017.04.002; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Nault JC, 2017, GASTROENTEROLOGY, V152, P880, DOI 10.1053/j.gastro.2016.11.042; Nault JC, 2013, GASTROENTEROLOGY, V144, P888, DOI 10.1053/j.gastro.2013.02.032; Oh C, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004823; Osorio MJ, 2011, PEDIATR TRANSPLANT, V15, pE149, DOI 10.1111/j.1399-3046.2010.01337.x; Paradis V, 2003, GASTROENTEROLOGY, V124, P651, DOI 10.1053/gast.2003.50104; Paradis V, 1997, HEPATOLOGY, V26, P891; Paradis V, 2014, CLIN RES HEPATOL GAS, V38, pE114, DOI 10.1016/j.clinre.2014.03.011; Park YN, 2007, CANCER, V109, P915, DOI 10.1002/cncr.22460; Pittman ME, 2015, CLIN LIVER DIS, V19, P239, DOI 10.1016/j.cld.2015.01.003; Poterucha JT, 2015, MAYO CLIN PROC, V90, P882, DOI 10.1016/j.mayocp.2015.04.020; Pupulim LF, 2013, CLIN RADIOL, V68, pE362, DOI 10.1016/j.crad.2013.01.024; Putra J, 2015, ANN HEPATOL, V14, P547, DOI 10.1016/S1665-2681(19)31177-9; Quaglia A, 2005, WORLD J GASTROENTERO, V11, P6262, DOI 10.3748/wjg.v11.i40.6262; Rebouissou S, 2008, J HEPATOL, V49, P61, DOI 10.1016/j.jhep.2008.03.013; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Ren WR, 2013, EUR J GASTROEN HEPAT, V25, P830, DOI 10.1097/MEG.0b013e32835eb8d4; Roncalli M, 1999, ITAL J GASTROENTEROL, V31, P301; Ronot M, 2014, CLIN RES HEPATOL GAS, V38, P681, DOI 10.1016/j.clinre.2014.01.014; Rubbia-Brandt L, 2010, HISTOPATHOLOGY, V56, P430, DOI 10.1111/j.1365-2559.2010.03511.x; Saldarriaga J, 2017, HISTOPATHOLOGY, V71, P989, DOI 10.1111/his.13283; Sanada Y, 2015, J HEPATO-BIL-PAN SCI, V22, P746, DOI 10.1002/jhbp.277; Sannier A, 2016, LIVER INT, V36, P1668, DOI 10.1111/liv.13113; Sasaki M, 2013, HISTOL HISTOPATHOL, V28, P1499, DOI 10.14670/HH-28.1499; Sasaki M, 2012, MODERN PATHOL, V25, P1584, DOI 10.1038/modpathol.2012.114; Scardapane A, 2013, RADIOL MED, V118, P1, DOI 10.1007/s11547-012-0789-3; Sempoux C, 2015, J HEPATOL, V63, P1173, DOI 10.1016/j.jhep.2015.06.017; Shafizadeh N, 2008, MODERN PATHOL, V21, P1011, DOI 10.1038/modpathol.2008.85; Sharma R, 2015, HEPATOB PANCREAT DIS, V14, P552, DOI 10.1016/s1499-3872(15)60418-0; Shimoyama Y, 2009, CLIN J GASTROENTEROL, V2, P131, DOI 10.1007/s12328-008-0054-8; Sinakos E, 2015, DIGEST LIVER DIS, V47, P1089, DOI 10.1016/j.dld.2015.07.046; Sorkin T, 2016, HUM PATHOL, V53, P153, DOI 10.1016/j.humpath.2016.02.025; Sugimoto K, 2014, HEPATOL RES, V44, pE309, DOI 10.1111/hepr.12273; Takuma Y, 2016, INTERNAL MED, V55, P3265, DOI 10.2169/internalmedicine.55.6869; Tanaka M, 1998, HEPATOLOGY, V27, P488, DOI 10.1002/hep.510270224; Tateishi Y, 2013, PATHOL INT, V63, P358, DOI 10.1111/pin.12072; Ueda T, 2011, J HEPATO-BIL-PAN SCI, V18, P386, DOI 10.1007/s00534-010-0342-9; Vigano L, 2015, ANN SURG ONCOL, V22, P4149, DOI 10.1245/s10434-015-4533-0; Vilgrain V, 1999, RADIOLOGY, V210, P443, DOI 10.1148/radiology.210.2.r99fe13443; Vilgrain V, 2018, ABDOM RADIOL, V43, P1968, DOI 10.1007/s00261-018-1502-7; Wang YX, 2015, ANN SAUDI MED, V35, P72, DOI 10.5144/0256-4947.2015.72; WANLESS IR, 1985, HEPATOLOGY, V5, P1194, DOI 10.1002/hep.1840050622; WANLESS IR, 1986, ARCH PATHOL LAB MED, V110, P331; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341; WEBSTER MW, 1979, DIGESTION, V19, P328, DOI 10.1159/000198381; Zhou H, 2000, HEPATO-GASTROENTEROL, V47, P522	101	1	1	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					33	44		10.1007/s00428-018-2373-6			12	Pathology	Pathology	GK9JO	WOS:000436563100005	29804132				2019-10-28	
J	Raspollini, MR; Lax, SF; McCluggage, WG				Raspollini, Maria Rosaria; Lax, Sigurd F.; McCluggage, W. Glenn			The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines	VIRCHOWS ARCHIV			English	Review						Cervical cancer; Guidelines; Management; Pathology report; Multidisciplinary team	INVASIVE ENDOCERVICAL ADENOCARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; CLASSIFICATION-SYSTEM; CLINICAL-IMPLICATIONS; SQUAMOUS CARCINOMA; UTERINE CERVIX; PROGNOSIS; SENTINEL; NEOPLASMS; CRITERIA	The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) nominated an international multidisciplinary development group consisting of practicing clinicians who have demonstrated leadership and expertise in cervical cancer to produce evidence-based guidelines regarding all aspects of the management of patients with this disease. Herein, we provide a detailed analysis of the pathological reporting of cervical carcinoma specimens, focusing on practical aspects of specimen sampling and on the core pathological data which are critical for patient management.	[Raspollini, Maria Rosaria] Univ Hosp Careggi, Histopathol & Mol Diagnost, Largo Brambilla 3, I-50134 Florence, Italy; [Lax, Sigurd F.] Hosp Graz Sued West, Dept Pathol, Graz, Austria; [Lax, Sigurd F.] Med Univ Graz, Graz, Austria; [McCluggage, W. Glenn] Belfast Hlth & Social Care Trust, Dept Pathol, Belfast, Antrim, North Ireland	Raspollini, MR (reprint author), Univ Hosp Careggi, Histopathol & Mol Diagnost, Largo Brambilla 3, I-50134 Florence, Italy.	mariarosaria.raspollini@unifi.it					Amin M, 2017, AM JOINT COMMITTEE C; Benda J A, 1996, J Natl Cancer Inst Monogr, P27; Boyle DP, 2015, HISTOPATHOLOGY, V66, P658, DOI 10.1111/his.12498; Brierley JD, 2017, TNM CLASSIFICATION M; Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578; Cibula D, 2018, RADIOTHER ONCOL, V127, P404, DOI 10.1016/j.radonc.2018.03.003; Cibula D, 2018, VIRCHOWS ARCH, V472, P919, DOI 10.1007/s00428-018-2362-9; Cibula D, 2018, INT J GYNECOL CANCER, V28, P641, DOI 10.1097/IGC.0000000000001216; Day E, 2016, INT J GYNECOL PATHOL, V35, P467, DOI 10.1097/PGP.0000000000000269; de Boer M, 2010, J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008; De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; DELGADO G, 1989, GYNECOL ONCOL, V35, P314, DOI 10.1016/0090-8258(89)90070-X; Freneaux P, 2002, MODERN PATHOL, V15, P641, DOI 10.1038/modpathol.3880580; Howitt BE, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0617-2; Howitt BE, 2015, AM J SURG PATHOL, V39, P1411, DOI 10.1097/PAS.0000000000000471; Kadkhodayan S, 2015, EJSO-EUR J SURG ONC, V41, P1, DOI 10.1016/j.ejso.2014.09.010; Kalof AN, 2006, ADV ANAT PATHOL, V13, P190, DOI 10.1097/00125480-200607000-00006; Karamurzin YS, 2015, AM J SURG PATHOL, V39, P1449, DOI 10.1097/PAS.0000000000000532; Kenny SL, 2012, AM J SURG PATHOL, V36, P799, DOI 10.1097/PAS.0b013e31824a72c6; Kurman RJ, 2014, TUMOURS FEMALE REPRO; McCluggage WG, 2018, INT J GYNECOL PATHOL, V37, P205, DOI 10.1097/PGP.0000000000000412; McCluggage WG, 2010, AM J SURG PATHOL, V34, P525, DOI 10.1097/PAS.0b013e3181d1d457; McIlwaine P, 2014, INT J GYNECOL PATHOL, V33, P213, DOI 10.1097/PGP.0b013e31829040ce; Pol FJM, 2015, GYNECOL ONCOL, V138, P579, DOI 10.1016/j.ygyno.2015.06.035; Roma AA, 2017, AM J SURG PATHOL, V41, P1205, DOI 10.1097/PAS.0000000000000822; Roma AA, 2016, GYNECOL ONCOL, V141, P36, DOI 10.1016/j.ygyno.2016.02.028; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Rutgers JKL, 2016, MODERN PATHOL, V29, P1083, DOI 10.1038/modpathol.2016.94; Talia KL, 2017, AM J SURG PATHOL, V41, P1023, DOI 10.1097/PAS.0000000000000855; Tiltman AJ, 2005, BEST PRACT RES CL OB, V19, P485, DOI 10.1016/j.bpobgyn.2005.02.003; Weaver DL, 2000, CANCER, V88, P1099, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1099::AID-CNCR22>3.0.CO;2-7; ZAINO RJ, 1992, CANCER, V69, P1750, DOI 10.1002/1097-0142(19920401)69:7<1750::AID-CNCR2820690717>3.0.CO;2-S	32	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					45	54		10.1007/s00428-018-2372-7			10	Pathology	Pathology	GK9JO	WOS:000436563100006	29799071				2019-10-28	
J	Park, JY; Baek, MH; Park, Y; Kim, YT; Nam, JH				Park, Jeong-Yeol; Baek, Min-Hyun; Park, Yangsoon; Kim, Young-Tak; Nam, Joo-Hyun			Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma	VIRCHOWS ARCHIV			English	Article						Endometrial stromal sarcoma; Estrogen receptor; Progesterone receptor; Androgen receptor; Gonadotropin-releasing hormone receptor; CYP19A1	UTERINE SARCOMA; LETROZOLE; NEOPLASMS; THERAPY; PCR	To evaluate the immunohistochemical (IHC) expression of hormone receptors and analyze the prognostic implication of these receptors in patients with endometrial stromal sarcoma (ESS). Fifty-one patients with ESS whose paraffin blocks and pathologic slides, which were obtained after hysterectomy, were available and included in this study. Clinicopathologic data were gathered from patients' medical records, and IHC staining of hormone receptors was performed using tissue microarrays. Estrogen receptor (ER)-alpha was expressed in 37 patients (72.5%), and strong immunoreactivity was observed in 27 patients (52.9%). However, ER-beta expression was observed in only two patients (3.9%). Progesterone receptor (PR) expression was identified in 36 patients (70.6%), and strong immunoreactivity was found in 26 patients (51%). Androgen receptor (AR) expression was observed in 30 patients (58.8%), and strong immunoreactivity was noted in 14 patients (27.5%). Gonadotropin-releasing hormone receptor (GnRH-R) expression was observed in 49 patients (96.1%), but no patient exhibited strong immunoreactivity. All patients expressed CYP19A1, and 43 patients (84.3%) had strong immunoreactivity. ER-alpha, PR, and AR positivity was associated with significantly better overall survival (OS). No patient with AR positivity died of ESS. When the patients were categorized according to ER-alpha, PR, and AR immunoreactivity, triple-positive ESS had the best OS, and triple-negative ESS was linked to the worst OS. Expression of hormone receptors was associated with favorable survival outcome in ESS. Hormone receptors that showed strong expression deserve further evaluation to clarify their importance as a therapeutic target and predictor of treatment response.	[Park, Jeong-Yeol; Kim, Young-Tak; Nam, Joo-Hyun] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea; [Baek, Min-Hyun] Hallym Univ, Sacred Heart Hosp, Dept Obstet & Gynecol, Anyang, South Korea; [Park, Yangsoon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea	Park, JY (reprint author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Obstet & Gynecol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.	catgut1-0@hanmail.net		Baek, Min-Hyun/0000-0003-0423-9038			Abeler VM, 2009, HISTOPATHOLOGY, V54, P355, DOI 10.1111/j.1365-2559.2009.03231.x; Altman AD, 2012, INT J GYNECOL CANCER, V22, P1006, DOI 10.1097/IGC.0b013e31825b7de8; Amant F, 2014, INT J GYNECOL CANCER, V24, pS67, DOI 10.1097/IGC.0000000000000205; Balleine RL, 2004, INT J GYNECOL PATHOL, V23, P138, DOI 10.1097/01.pgp.0000117099.98872.94; Brooks BE, 2004, GYNECOL ONCOL, V93, P204, DOI 10.1016/j.ygyno.2003.12.029; Brys M, 2002, ANTICANCER RES, V22, P1025; Burke C, 2004, OBSTET GYNECOL, V104, P1182, DOI 10.1097/01.AOG.0000133533.05148.aa; Cade TJ, 2014, AUST NZ J OBSTET GYN, V54, P453, DOI 10.1111/ajo.12245; Castoria G, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.497; Castoria G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076899; CHANG KL, 1990, AM J SURG PATHOL, V14, P415, DOI 10.1097/00000478-199005000-00002; duPont Nefertiti Chianti, 2010, Sarcoma, P353679, DOI 10.1155/2010/353679; Ingram DR, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-42; Koivisto-Korander R, 2011, TUMOR BIOL, V32, P451, DOI 10.1007/s13277-010-0138-1; Leunen M, 2004, GYNECOL ONCOL, V95, P769, DOI 10.1016/j.ygyno.2004.07.063; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maluf FC, 2001, GYNECOL ONCOL, V82, P384, DOI 10.1006/gyno.2001.6238; Mesia AF, 2000, AM J OBSTET GYNECOL, V182, P1140, DOI 10.1067/mob.2000.103939; Moinfar F, 2004, VIRCHOWS ARCH, V444, P410, DOI 10.1007/s00428-004-0981-9; Nam JH, 2011, BEST PRACT RES CL OB, V25, P751, DOI 10.1016/j.bpobgyn.2011.05.009; Nam JH, 2010, CURR OPIN OBSTET GYN, V22, P36, DOI 10.1097/GCO.0b013e328334d90f; Rauh-Hain JA, 2013, OBSTET GYNECOL, V122, P676, DOI 10.1097/AOG.0b013e3182a189ac; Reich O, 2005, MODERN PATHOL, V18, P573, DOI 10.1038/modpathol.3800325; Reich O, 2004, MODERN PATHOL, V17, P104, DOI 10.1038/modpathol.3800031; Reich O, 2000, BRIT J CANCER, V82, P1030; Ryu H, 2015, ONCOL LETT, V10, P3310, DOI 10.3892/ol.2015.3674; Scribner DR, 1998, GYNECOL ONCOL, V71, P458, DOI 10.1006/gyno.1998.5174; Shah JP, 2008, OBSTET GYNECOL, V112, P1102, DOI 10.1097/AOG.0b013e31818aa89a; Shoji K, 2011, MED ONCOL, V28, P771, DOI 10.1007/s12032-010-9511-6; Sommeijer DW, 2013, CURR ONCOL REP, V15, P541, DOI 10.1007/s11912-013-0343-3; Thanopoulou E, 2015, CLIN SARCOMA RES, V5, DOI 10.1186/s13569-015-0024-0; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; WADE K, 1990, GYNECOL ONCOL, V39, P364, DOI 10.1016/0090-8258(90)90267-O; Wagle S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13144; Yamaguchi M, 2015, INT J GYNECOL CANCER, V25, P1645, DOI 10.1097/IGC.0000000000000557	35	2	3	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					61	69		10.1007/s00428-018-2358-5			9	Pathology	Pathology	GK9JO	WOS:000436563100008	29869299				2019-10-28	
J	Jeon, MK; Kaemmerer, E; Schneider, U; Schiffer, M; Klaus, C; Hennings, J; Clahsen, T; Ackerstaff, T; Niggemann, M; Schippers, A; Longerich, T; Sellge, G; Trautwein, C; Wagner, N; Liedtke, C; Gassler, N				Jeon, M. K.; Kaemmerer, E.; Schneider, U.; Schiffer, M.; Klaus, C.; Hennings, J.; Clahsen, T.; Ackerstaff, T.; Niggemann, M.; Schippers, A.; Longerich, T.; Sellge, G.; Trautwein, C.; Wagner, N.; Liedtke, C.; Gassler, N.			Notch inhibition counteracts Paneth cell death in absence of caspase-8	VIRCHOWS ARCHIV			English	Article						Caspase 8; Crohn's disease; Notch; Paneth cell	INTESTINAL STEM-CELLS; WNT; EXPRESSION; DIFFERENTIATION; PROLIFERATION; INFLAMMATION; NECROPTOSIS; HOMEOSTASIS; LIGANDS; CANCER	Opposing activities of Notch and Wnt signaling regulate mucosal barrier homeostasis and differentiation of intestinal epithelial cells. Specifically, Wnt activity is essential for differentiation of secretory cells including Wnt3-producing Paneth cells, whereas Notch signaling strongly promotes generation of absorptive cells. Loss of caspase-8 in intestinal epithelium (casp8(a dagger int)) is associated with fulminant epithelial necroptosis, severe Paneth cell death, secondary intestinal inflammation, and an increase in Notch activity. Here, we found that pharmacological Notch inhibition with dibenzazepine (DBZ) is able to essentially rescue the loss of Paneth cells, deescalate the inflammatory phenotype, and reduce intestinal permeability in casp8(a dagger int) mice. The secretory cell metaplasia in DBZ-treated casp8(a dagger int) animals is proliferative, indicating for Notch activities partially insensitive to gamma-secretase inhibition in a casp8(a dagger int) background. Our data suggest that casp8 acts in the intestinal Notch network.	[Jeon, M. K.; Kaemmerer, E.; Schneider, U.; Schiffer, M.; Klaus, C.; Ackerstaff, T.; Longerich, T.; Gassler, N.] Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany; [Kaemmerer, E.; Clahsen, T.; Schippers, A.; Wagner, N.] Rhein Westfal TH Aachen, Dept Pediat, Pauwelsstr 30, D-52074 Aachen, Germany; [Hennings, J.; Sellge, G.; Trautwein, C.; Liedtke, C.] Rhein Westfal TH Aachen, Dept Med 3, Pauwelsstr 30, D-52074 Aachen, Germany; [Niggemann, M.] Rhein Westfal TH Aachen, Inst Organ Chem, Landoltweg 1, D-52056 Aachen, Germany; [Gassler, N.] Klinikum Braunschweig, Inst Pathol, Celler Str 28, D-38114 Braunschweig, Germany	Gassler, N (reprint author), Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.; Gassler, N (reprint author), Klinikum Braunschweig, Inst Pathol, Celler Str 28, D-38114 Braunschweig, Germany.	ngassler@ukaachen.de		Liedtke, Christian/0000-0003-4681-7887	Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [GA 785/5-1]; Deutsche KrebshilfeDeutsche Krebshilfe [GA 109313]	The work was partially supported by Deutsche Forschungsgemeinschaft (DFG GA 785/5-1) and Deutsche Krebshilfe (GA 109313).	Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599; Andersen P, 2012, TRENDS CELL BIOL, V22, P257, DOI 10.1016/j.tcb.2012.02.003; Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Barker N, 2008, GENE DEV, V22, P1856, DOI 10.1101/gad.1674008; Bolos V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006-0046; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070-2153(10)92003-6; Demitrack ES, 2016, J PHYSIOL-LONDON, V594, P4791, DOI 10.1113/JP271667; Farin HF, 2012, GASTROENTEROLOGY, V143, P1518, DOI 10.1053/j.gastro.2012.08.031; Farin HF, 2016, NATURE, V530, P340, DOI 10.1038/nature16937; Fiuza UM, 2007, J ENDOCRINOL, V194, P459, DOI 10.1677/JOE-07-0242; Gunther C, 2013, GUT, V62, P1062, DOI 10.1136/gutjnl-2011-301364; Gunther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400; Heuberger J, 2014, P NATL ACAD SCI USA, V111, P3472, DOI 10.1073/pnas.1309342111; Hodin CM, 2011, AM J PATHOL, V179, P2885, DOI 10.1016/j.ajpath.2011.08.030; Horvay K, 2013, ADV EXP MED BIOL, V786, P175, DOI 10.1007/978-94-007-6621-1_10; Kaemmerer E, 2015, WORLD J GASTROENTERO, V21, P4499, DOI 10.3748/wjg.v21.i15.4499; Kim TH, 2012, P NATL ACAD SCI USA, V109, P3932, DOI 10.1073/pnas.1113890109; Kim TH, 2011, J BIOL CHEM, V286, P11427, DOI 10.1074/jbc.M110.188797; Li YM, 2013, CURR CANCER DRUG TAR, V13, P957, DOI 10.2174/15680096113136660101; Liedtke C, 2011, GASTROENTEROLOGY, V141, P2176, DOI 10.1053/j.gastro.2011.08.037; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Ostaff MJ, 2013, EMBO MOL MED, V5, P1465, DOI 10.1002/emmm.201201773; Pellegrinet L, 2011, GASTROENTEROLOGY, V140, P1230, DOI 10.1053/j.gastro.2011.01.005; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Sancho R, 2015, EMBO REP, V16, P571, DOI 10.15252/embr.201540188; Sander GR, 2004, J HISTOCHEM CYTOCHEM, V52, P509, DOI 10.1177/002215540405200409; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Tian H, 2015, CELL REP, V11, P33, DOI 10.1016/j.celrep.2015.03.007; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; VanDussen KL, 2012, DEVELOPMENT, V139, P488, DOI 10.1242/dev.070763	34	1	1	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					71	83		10.1007/s00428-018-2368-3			13	Pathology	Pathology	GK9JO	WOS:000436563100009	29770852				2019-10-28	
J	Tretiakova, M; Mehta, V; Kocherginsky, M; Minor, A; Shen, SS; Sirintrapun, SJ; Yao, JL; Alvarado-Cabrero, I; Antic, T; Eggener, SE; Picken, MM; Paner, GP				Tretiakova, Maria; Mehta, Vikas; Kocherginsky, Masha; Minor, Agata; Shen, Steven S.; Sirintrapun, Sahussapont Joseph; Yao, Jorge L.; Alvarado-Cabrero, Isabel; Antic, Tatjana; Eggener, Scott E.; Picken, Maria M.; Paner, Gladell P.			Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum	VIRCHOWS ARCHIV			English	Article						Renal; Cystic; Clear cell; Neoplasm; Multilocular; Carcinoma	PATHOBIOLOGICAL ASPECTS; CHROMOSOME 3P; KIDNEY; TUMORS; ENTITIES; SERIES; ADULTS; FOCUS; VHL	Multilocular cystic renal cell carcinoma has been recently excluded from clear cell renal cell carcinoma (CCRCC) category and re-designated as multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) due to its uniformly good outcomes. While strict distinction between MCRNLMP from predominantly cystic CCRCC (pc-CCRCC) is being emphasized, the significance of extensive true cystic component in CCRCC has not been investigated. Herein, we analyzed 57 MCRNLMP, 69 pc-CCRCC, and 46 non-cystic CCRCC. There were no statistically significant differences between the three subtypes in age, gender, and laterality. ISUP grades were 1 (73%) or 2 (27%) for MCRNLMP; for pc-CCRCC were 1 (31%), 2 (60%), and 3 (9%); and for non-cystic CCRCC were 1 (9%), 2 (52%), 3 (26%), and 4 (13%). MCRNLMP were either pT stage 1 (91%) or 2 (9%), pT stages for pc-CCRCC were 1 (92.5%), 2 (1.5%), and 3 (6%) and for non-cystic CCRCC were 1 (58.7%), 2 (6.5%), and 3 (34.8%). None of MCRNLMP patients developed recurrences or metastases, and only 1 contralateral kidney tumor and 1 metastasis developed in pc-CCRCC. In contrast, 19 patients with non-cystic CCRCC developed metastases (5-year PFS 58%, CI 38.3-73.5%), and 1 patient died of disease. Monosomy 3 was common in both MCRNLMP (3/3) and pc-CCRCC (6/7). This large series of MCRNLMP confirms its indolent behavior, shows that pc-CCRCC has significantly better prognosis than non-cystic CCRCC and may define the lower grade spectrum of CCRCC. We recommend that the presence and extent of CCRCC cystic component should be documented in the pathology report.	[Tretiakova, Maria] Univ Washington, Sch Med, Dept Pathol, 325 9th Ave,Box 359791, Seattle, WA 98104 USA; [Mehta, Vikas; Picken, Maria M.] Loyola Univ Med Ctr, Dept Pathol & Lab Med, Maywood, IL 60153 USA; [Kocherginsky, Masha] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Minor, Agata; Antic, Tatjana; Paner, Gladell P.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Shen, Steven S.] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA; [Sirintrapun, Sahussapont Joseph] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA; [Yao, Jorge L.] Pathline Emerge Labs, Ramsey, NJ USA; [Alvarado-Cabrero, Isabel] Mexican Oncol Hosp, Dept Pathol, IMSS, Mexico City, DF, Mexico; [Eggener, Scott E.; Paner, Gladell P.] Univ Chicago, Dept Surg, Urol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA	Tretiakova, M (reprint author), Univ Washington, Sch Med, Dept Pathol, 325 9th Ave,Box 359791, Seattle, WA 98104 USA.	mariast@uw.edu	Mehta, Vikas/J-4279-2019				Agarwal S, 2011, ARCH PATHOL LAB MED, V135, P290, DOI 10.1043/2010-0243-LE.1; Aubert S, 2005, J UROLOGY, V174, P2115, DOI 10.1097/01.ju.0000181210.72528.ab; Bhatt JR, 2016, J UROLOGY, V196, P1350, DOI 10.1016/j.juro.2016.05.118; Brunelli M, 2011, HISTOL HISTOPATHOL, V26, P1207, DOI 10.14670/HH-26.1207; Chen YB, 2012, ARCH PATHOL LAB MED, V136, P400, DOI 10.5858/arpa.2011-0485-RA; Corica FA, 1999, J UROLOGY, V161, P408, DOI 10.1016/S0022-5347(01)61903-7; Eble JN, 1998, SEMIN DIAGN PATHOL, V15, P2; Eble JN, 2004, PATHOLOGY GENETICS T; Edge SB, 2010, AJCC CANC STAGING HD; Favazza L, 2017, MODERN PATHOL, V30, P1603, DOI 10.1038/modpathol.2017.72; Gong K, 2008, J CANCER RES CLIN, V134, P433, DOI 10.1007/s00432-007-0302-1; Halat S, 2010, MODERN PATHOL, V23, P931, DOI 10.1038/modpathol.2010.78; Han KR, 2004, UROL ONCOL-SEMIN ORI, V22, P410, DOI 10.1016/S1078-1439(03)00173-X; Hindman NM, 2012, AM J ROENTGENOL, V198, pW20, DOI 10.2214/AJR.11.6762; Jhaveri K, 2013, AM J ROENTGENOL, V201, pW292, DOI 10.2214/AJR.12.9414; Katabathina VS, 2012, J COMPUT ASSIST TOMO, V36, P659, DOI 10.1097/RCT.0b013e31826dba18; Klatte T, 2009, J CLIN ONCOL, V27, P746, DOI 10.1200/JCO.2007.15.8345; Kuroda N, 2012, HISTOL HISTOPATHOL, V27, P969, DOI 10.14670/HH-27.969; LEWIS RH, 1982, J UROLOGY, V127, P314, DOI 10.1016/S0022-5347(17)53758-1; Li T, 2016, CLIN GENITOURIN CANC, V14, pE553, DOI 10.1016/j.clgc.2016.03.017; Mazzucchelli R, 2012, ANAL QUANT CYTOL, V34, P235; Moch H, 2016, WHO CLASSIFICATION T; Moch H, 2010, ADV ANAT PATHOL, V17, P209, DOI 10.1097/PAP.0b013e3181d98c9d; Montironi R, 2013, HISTOL HISTOPATHOL; Montironi R, 2013, EUR UROL, V63, P400, DOI 10.1016/j.eururo.2012.11.017; MURAD T, 1991, AM J CLIN PATHOL, V95, P633, DOI 10.1093/ajcp/95.5.633; Nassir A, 2002, UROLOGY, V60, P421, DOI 10.1016/S0090-4295(02)01742-9; Raspollini MR, 2017, PATHOL RES PRACT, V213, P804, DOI 10.1016/j.prp.2017.03.007; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Suzigan S, 2006, AM J CLIN PATHOL, V125, P217, DOI 10.1039/AH6FC77PYR2V6YAY; von Teichman A, 2011, MODERN PATHOL, V24, P571, DOI 10.1038/modpathol.2010.222; Williamson SR, 2013, HISTOPATHOLOGY, V63, P767, DOI 10.1111/his.12239; Williamson SR, 2012, AM J SURG PATHOL, V36, P1425, DOI 10.1097/PAS.0b013e31825b37f0; Wolff DJ, 2007, J MOL DIAGN, V9, P134, DOI 10.2353/jmoldx.2007.060128; You D, 2011, BJU INT, V108, P1444, DOI 10.1111/j.1464-410X.2011.10247.x; Zhang JX, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-158	36	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					85	93		10.1007/s00428-018-2371-8			9	Pathology	Pathology	GK9JO	WOS:000436563100010	29770853				2019-10-28	
J	Zhang, J; Sun, J; Feng, J; Luo, YF; Ling, Q; Wu, SF; Zeng, X; Liang, ZY				Zhang, Jing; Sun, Jian; Feng, Jun; Luo, Yufeng; Ling, Qing; Wu, Shafei; Zeng, Xuan; Liang, Zhiyong			Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China	VIRCHOWS ARCHIV			English	Article						Adrenal lymphoma; Diffuse large B cell lymphoma; Clinicopathological; Fluorescence in situ hybridization	NON-HODGKINS-LYMPHOMA; EPSTEIN-BARR-VIRUS; OF-THE-LITERATURE; POOR-PROGNOSIS; EXPRESSION; IMMUNOHISTOCHEMISTRY; CLASSIFICATION; CHEMOTHERAPY; INVOLVEMENT; PHENOTYPE	Primary adrenal lymphoma is a rare entity that, in most cases, is derived from B cells. The most commonly seen primary adrenal lymphoma is diffuse large B cell lymphoma (DLBCL). To better understand the clinicopathological and molecular features of these tumors, we studied 14 Chinese patients with DLBCL who initially presented with an adrenal tumor. The clinicopathological features of the 14 primary adrenal DLBCL cases were retrospectively reviewed using immunohistochemistry, immunoglobulin gene rearrangement analysis, evaluation of Epstein-Barr virus status, and fluorescence in situ hybridization. Patient age ranged from 43 to 69 years, with a mean age of 58 years. The patients most commonly presented with abdominal pain and adrenal mass. Ten patients exhibited bilateral adrenal masses, and four had unilateral adrenal masses (three left, one right). Thirteen of 14 DLBCLs were DLBCL not otherwise specified, and one was an intravascular large B cell lymphoma. According to the algorithm of Hans et al. (Blood 103:275-282, 2004), 13 and 1 cases were classified as the non-germinal center B-cell-like subtype and the germinal center B-cell-like subtype, respectively. The Ki-67 index ranged from 35 to 80%. Epstein-Barr virus-encoded RNA was detected by in situ hybridization in 6 of the 12 available cases. Two patients showed BCL-6 rearrangements. The follow-up period ranged from 1 to 87 months. During the follow-up period, four patients died of the disease, five were alive with the disease, four were alive without disease, and one was lost during the follow-up period. In summary, most primary adrenal lymphomas are non-germinal-center B-cell-like subtype DLBCLs, which have high proliferative activity and a poor prognosis.	[Zhang, Jing; Sun, Jian; Luo, Yufeng; Ling, Qing; Wu, Shafei; Zeng, Xuan; Liang, Zhiyong] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China; [Feng, Jun] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China	Liang, ZY (reprint author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, 1 Shuai Fu Yuan Hu Tong, Beijing 100730, Peoples R China.	jingzhangsmile@163.com; sunjian_126@126.com; fjbluerain@hotmail.com; 963328725@qq.com; lq07@yahoo.com; Suphie@sina.com; zengxuan88@yahoo.com; liangzhiyong1220@yahoo.com		Sun, Jian/0000-0003-4997-2604	Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine [2017-I2M-2-001]	This work was supported by grants from Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (2017-I2M-2-001).	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; CEDERMARK BJ, 1981, SURG GYNECOL OBSTET, V152, P461; CEDERMARK BJ, 1981, SURG GYNECOL OBSTET, V152, P607; Sanchez CD, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.634; Fujiwara T, 2001, ANN HEMATOL, V80, P561, DOI 10.1007/s002770100335; Grigg AP, 2003, CLIN LYMPHOMA, V4, P154, DOI 10.3816/CLM.2003.n.024; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Ichikawa S, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-19; Ide M, 2007, LEUKEMIA LYMPHOMA, V48, P2244, DOI 10.1080/10428190701636450; Kawamoto K, 2016, CANCER SCI, V107, P853, DOI 10.1111/cas.12942; Kim KM, 2009, J KOREAN MED SCI, V24, P525, DOI 10.3346/jkms.2009.24.3.525; Kim YR, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-49; Laurent C, 2017, QJM-INT J MED, V110, P103, DOI 10.1093/qjmed/hcw174; Li W, 2016, HELL J NUCL MED, V19, P57, DOI 10.1967/s002449910342; Lomte N, 2016, ENDOCR CONNECT, V5, P92, DOI 10.1530/EC-16-0015; Lu TX, 2015, SCI REP-UK, V5, DOI 10.1038/srep12168; Moonim MT, 2017, INT J SURG PATHOL, V25, P326, DOI 10.1177/1066896916681843; Mozos A, 2009, MODERN PATHOL, V22, P1210, DOI 10.1038/modpathol.2009.87; Niitsu N, 2010, ANN ONCOL, V21, P2069, DOI 10.1093/annonc/mdq057; Ohkura Y, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001270; Ohsawa M, 1996, MODERN PATHOL, V9, P534; Ozimek A, 2008, EUR J MED RES, V13, P221; PALING MR, 1983, AM J ROENTGENOL, V141, P303, DOI 10.2214/ajr.141.2.303; Petrella T, 2017, ANN ONCOL, V28, P1042, DOI 10.1093/annonc/mdx022; Pfreundschuh M, 2012, J CLIN ONCOL, V30, P3433, DOI 10.1200/JCO.2012.44.4729; Rashidi A, 2013, ANN HEMATOL, V92, P1583, DOI 10.1007/s00277-013-1812-3; Rashidi A, 2013, ANN HEMATOL, V92, P1281, DOI 10.1007/s00277-013-1690-8; Singh D, 2004, LEUKEMIA LYMPHOMA, V45, P789, DOI 10.1080/10428190310001615756; Srivatsa Sumathi, 2008, Endocr Pract, V14, P884; Staiger AM, 2017, J CLIN ONCOL, V35, P2515, DOI 10.1200/JCO.2016.70.3660; Sun J, 2011, MODERN PATHOL, V24, P983, DOI 10.1038/modpathol.2011.45; Swerdlow SH, 2008, WHO CLASSIFICATION T; Takahashi Y, 2012, CASE REP MED, DOI 10.1155/2012/849285; Taniguchi M, 1998, BLOOD, V91, P1145, DOI 10.1182/blood.V91.4.1145; Thompson MA, 2007, AM J HEMATOL, V82, P299, DOI 10.1002/ajh.20811; Visco C, 2012, LEUKEMIA, V26, P2103, DOI 10.1038/leu.2012.83; Yamaguchi M, 2002, BLOOD, V99, P815, DOI 10.1182/blood.V99.3.815; Yamaguchi M, 2008, HAEMATOL-HEMATOL J, V93, P1195, DOI 10.3324/haematol.12810; Yan LX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104068	39	1	1	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					95	103		10.1007/s00428-018-2378-1			9	Pathology	Pathology	GK9JO	WOS:000436563100011	29802470				2019-10-28	
J	Metovic, J; Bertero, L; Musuraca, C; Veneziano, F; Annaratone, L; Mariani, S; Cassoni, P; Bussolati, G; Papotti, M				Metovic, J.; Bertero, L.; Musuraca, C.; Veneziano, F.; Annaratone, L.; Mariani, S.; Cassoni, P.; Bussolati, G.; Papotti, Mauro			Safe transportation of formalin-fixed liquid-free pathology specimens	VIRCHOWS ARCHIV			English	Article						Pathology; Formalin; Specimen; Transportation; Safety; Vacuum storage	BREAST-CANCER; FORMALDEHYDE; FIXATION; TISSUE; TOXICITY; VACUUM	Diagnostic pathology activities are largely based on fixation of tissues in 4% formaldehyde, which has recently been re-classified as a carcinogenic compound and banned in several countries. Hospitals that do not have in-house pathology services need to send surgical and biopsy specimens to referral centers. These are generally transferred in liquid containers, under suboptimal safety conditions, as accidental spillage of potentially dangerous substances may occur. A safe, innovative, two-step procedure for pathology sample transportation is presented. Formalin-fixed material from ten surgical cases was dissected (including surrogate biopsies) and preserved in liquid-free plastic bags under vacuum for up to 30 days and subsequently processed for conventional histology, several immunohistochemical markers, and molecular tests (e.g., RAS mutation). The data were compared with the corresponding routine analyses. Formalin-fixed specimens after up to 30 days under vacuum storage gave equivalent results compared to standard histopathological slides and molecular tests, regarding both hematoxylin-eosin, immuno-stained slides and also nucleic acid extracted for molecular tests. The proposal of under-vacuum sealing pathology specimens that were previously formalin fixed can be adopted to transfer liquid-free biopsy and surgical specimens to referral pathology services. In fact, it is easy to perform, less expensive (both plastic bags and domestic-type vacuum chamber machines are at affordable costs), and above all is fully safe and adequate in the pre-analytical processing of pathology specimens.	[Metovic, J.; Musuraca, C.; Papotti, Mauro] Univ Turin, Dept Oncol, Pathol Unit, Via Santena 7, I-10126 Turin, Italy; [Metovic, J.; Bertero, L.; Musuraca, C.; Veneziano, F.; Annaratone, L.; Mariani, S.; Cassoni, P.; Bussolati, G.; Papotti, Mauro] Citta Salute & Sci Hosp, Via Santena 7, I-10126 Turin, Italy; [Bertero, L.; Veneziano, F.; Annaratone, L.; Mariani, S.; Cassoni, P.; Bussolati, G.] Univ Turin, Dept Med Sci, Pathol Unit, Via Santena 7, I-10126 Turin, Italy; [Papotti, Mauro] Univ Torino, Anat Patol, Via Santena 7, I-10126 Turin, Italy	Papotti, M (reprint author), Univ Turin, Dept Oncol, Pathol Unit, Via Santena 7, I-10126 Turin, Italy.; Papotti, M (reprint author), Citta Salute & Sci Hosp, Via Santena 7, I-10126 Turin, Italy.; Papotti, M (reprint author), Univ Torino, Anat Patol, Via Santena 7, I-10126 Turin, Italy.	mauro.papotti@unito.it	Annaratone, Laura/J-9261-2016; Bertero, Luca/N-5357-2017	Annaratone, Laura/0000-0001-5750-1445; PAPOTTI, Mauro Giulio/0000-0002-2713-1700; Bertero, Luca/0000-0001-9887-7668; Metovic, Jasna/0000-0002-9146-1747			Adesina A, 2013, LANCET ONCOL, V14, pE152, DOI 10.1016/S1470-2045(12)70598-3; Adeyi OA, 2011, ARCH PATHOL LAB MED, V135, P183, DOI 10.1043/2008-0432-CCR.1; Berg D, 2011, METHODS MOL BIOL, V785, P109, DOI 10.1007/978-1-61779-286-1_8; Bussolati G, 2008, VIRCHOWS ARCH, V452, P229, DOI 10.1007/s00428-007-0529-x; Bussolati G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182965; Cheng JY, 2016, IMMUNOPHARM IMMUNOT, V38, P495, DOI 10.1080/08923973.2016.1248844; Denoux Y, 2002, B CANCER, V89, P401; Di Novi C, 2010, SCI TOTAL ENVIRON, V408, P3092, DOI 10.1016/j.scitotenv.2010.04.022; Duong A, 2011, MUTAT RES-REV MUTAT, V728, P118, DOI 10.1016/j.mrrev.2011.07.003; FOX CH, 1985, J HISTOCHEM CYTOCHEM, V33, P845, DOI 10.1177/33.8.3894502; Gopal S, 2013, LANCET ONCOL, V14, P291, DOI 10.1016/S1470-2045(13)70109-8; Han RT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168466; Hewitt SM, 2008, ARCH PATHOL LAB MED, V132, P1929, DOI 10.1043/1543-2165-132.12.1929; IARC, 2012, CHEM AGENTS RELATE F, V100, P401; Khoury T, 2009, MODERN PATHOL, V22, P1457, DOI 10.1038/modpathol.2009.117; Marchio C, 2009, J PATHOL, V219, P16, DOI 10.1002/path.2574; Mariani S, 2017, BRIT J CANCER, V117, P358, DOI 10.1038/bjc.2017.170; Sapino A, 2006, VIRCHOWS ARCH, V449, P288, DOI 10.1007/s00428-006-0233-2; van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889; van der Loos CM, 2007, BIOTECH HISTOCHEM, V82, P141, DOI 10.1080/10520290701375302; Zarbo Richard J, 2015, Recent Results Cancer Res, V199, P15, DOI 10.1007/978-3-319-13957-9_2; Zhang LP, 2010, CANCER EPIDEM BIOMAR, V19, P80, DOI 10.1158/1055-9965.EPI-09-0762	22	3	3	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					105	113		10.1007/s00428-018-2383-4			9	Pathology	Pathology	GK9JO	WOS:000436563100012	29860620				2019-10-28	
J	Franceschi, T; Allias, F; Mauduit, C; Bolze, PA; Devouassoux-Shisheboran, M				Franceschi, Tatiana; Allias, Fabienne; Mauduit, Claire; Bolze, Pierre-Adrien; Devouassoux-Shisheboran, Mojgan			Chondroid nodule in the female peritoneum arises from normal tissue and not from teratoma or conception product	VIRCHOWS ARCHIV			English	Article						Teratoma; Cartilaginous metaplasia; Heterotopic cartilage; Peritoneum; Peritoneal chondroid metaplasia	HETEROTOPIC CARTILAGE; METAPLASIA	The pathogenesis of benign-looking cartilaginous tissue within the peritoneum is unknown. Chondroid metaplasia of subcoelomic mesenchyme has been suggested, as has been the case for other gynecological diseases such as endometriosis, peritoneal leiomyomatosis, or gliomatosis peritonei, but has never been proven. Chondroid nodules in the peritoneum may represent either teratomatous tissue, fetal rests from a conception product, or metaplasia of pluripotent mesenchymal cells. Herein, the unique genetic characteristics of ovarian teratomas (homozygous at many polymorphic microsatellite loci) versus normal tissues (heterozygous at the same loci) were used to investigate the origin of chondroid nodules in the peritoneum. DNA samples extracted from paraffin-embedded normal peritoneal tissue and chondroid peritoneal nodules from two patients were studied. In both cases, chondroid and normal tissue showed heterozygosity at each informative microsatellite locus on different chromosomes, with a profile similar to the mother. These results indicate that peritoneal chondroid nodules arise within the peritoneum, presumably from pluripotent mesodermal stem cells, and are not related to teratomatous proliferation, or previous pregnancy. This finding shows once again the plasticity and metaplastic potential of stem cells within the peritoneal cavity.	[Franceschi, Tatiana; Allias, Fabienne; Mauduit, Claire; Devouassoux-Shisheboran, Mojgan] Hosp Civils Lyon, Dept Pathol, Ctr Biol & Pathol Sud, Chemin Grand Revoyet, F-69495 Pierre Benite, France; [Bolze, Pierre-Adrien] Dept Gynecol Surg & Oncol, Obstet, 165 Chemin Grand Revoyet, F-69495 Pierre Benite, France	Devouassoux-Shisheboran, M (reprint author), Hosp Civils Lyon, Dept Pathol, Ctr Biol & Pathol Sud, Chemin Grand Revoyet, F-69495 Pierre Benite, France.	mojgan.devouassoux@chu-lyon.fr					BEDROSIAN SA, 1983, UROLOGY, V21, P536, DOI 10.1016/0090-4295(83)90064-X; Boukas A, 2013, PEDIATR NEUROSURG, V49, P93, DOI 10.1159/000356931; DONNA A, 1991, HISTOPATHOLOGY, V19, P239, DOI 10.1111/j.1365-2559.1991.tb00028.x; Fadare O, 2002, MODERN PATHOL, V15, P777, DOI 10.1097/01.MP.0000017565.19341.63; Ferguson AW, 2001, AM J PATHOL, V159, P51, DOI 10.1016/S0002-9440(10)61672-0; Giardino Luciano, 2006, Oral Surg Oral Med Oral Pathol Oral Radiol Endod, V102, pe42, DOI 10.1016/j.tripleo.2005.10.059; Hegde P, 2014, J OBSTET GYNAECOL RE, V40, P618, DOI 10.1111/jog.12198; Houang M, 2010, PATHOLOGY, V42, P585, DOI 10.3109/00313025.2010.508737; Jakubowitz O, 1925, THESIS; Kohl Shane K, 2009, Ear Nose Throat J, V88, pE4; Mutsaers SE, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00113; Patel RM, 2006, AM J SURG PATHOL, V30, P119, DOI 10.1097/01.pas.0000184820.71752.20; Qasem SA, 2014, SEMIN DIAGN PATHOL, V31, P10, DOI 10.1053/j.semdp.2014.01.006; ROTH E, 1966, OBSTET GYNECOL, V27, P838; Scully RE, 1998, ATLAS TUMOR PATHOL, P81; Vortmeyer AO, 1999, AM J PATHOL, V154, P987, DOI 10.1016/S0002-9440(10)65350-3	16	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					115	119		10.1007/s00428-018-2295-3			5	Pathology	Pathology	GK9JO	WOS:000436563100013	29368082				2019-10-28	
J	Slavik, T; Potgieter, FM; Brittain, D				Slavik, Tomas; Potgieter, Fritz M.; Brittain, David			Thymoma-associated multiorgan autoimmunity with exclusive gastrointestinal tract involvement: case report and review of the literature	VIRCHOWS ARCHIV			English	Review						Thymoma-associated multiorgan autoimmunity; Graft-versus-host disease-like gastroenterocolitis; Paraneoplastic syndrome; Secondary autoimmune enteropathy	DISEASE-LIKE ERYTHRODERMA; HOST-LIKE DISEASE; MALIGNANT THYMOMA; COLITIS; LESIONS	Thymoma-associated multiorgan autoimmunity (TAMA) is a recently delineated and rare paraneoplastic syndrome reported in patients with thymoma. The disorder is characterized by graft-versus-host disease-like pathology affecting the skin, gastrointestinal tract (GIT), and liver, and is usually associated with a poor outcome. We document a case of TAMA with exclusive GIT involvement which included the stomach, small and large bowel, presenting in a 66-year-old male patient 5 years after complete resection of a type B2 thymoma. A brief review is provided of this scarce syndrome, the GIT pathology described in the 21 TAMA cases reported to date, and the unique characteristics of patients with exclusive GIT involvement by this acquired autoimmune disorder.	[Slavik, Tomas] Ampath Pathol Labs, Dept Anat Pathol, Pretoria, South Africa; [Slavik, Tomas] Univ Pretoria, Pretoria, South Africa; [Potgieter, Fritz M.] Midstream Mediclin Hosp, Pretoria, South Africa; [Brittain, David] Pretoria East Netcare Hosp, Pretoria, South Africa	Slavik, T (reprint author), Ampath Pathol Labs, Dept Anat Pathol, Pretoria, South Africa.; Slavik, T (reprint author), Univ Pretoria, Pretoria, South Africa.	slavikt@ampath.co.za					Fukushima A, 2017, J DERMATOL, V44, P830, DOI 10.1111/1346-8138.13777; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P223, DOI 10.1111/his.13068; Hanafusa T, 2011, CLIN EXP IMMUNOL, V166, P164, DOI 10.1111/j.1365-2249.2011.04472.x; Holder J, 1997, CLIN EXP DERMATOL, V22, P287, DOI 10.1046/j.1365-2230.1997.2750703.x; KORNACKI S, 1995, AM J SURG PATHOL, V19, P224, DOI 10.1097/00000478-199502000-00011; LEE FD, 1993, J CLIN PATHOL, V46, P118, DOI 10.1136/jcp.46.2.118; Maverakis E, 2012, CLIN REV ALLERG IMMU, V42, P135, DOI 10.1007/s12016-010-8248-5; Offerhaus GJ, 2007, IMMUNOL LETT, V114, P31, DOI 10.1016/j.imlet.2007.09.010; Sader C, 2002, ANN THORAC SURG, V73, P1947, DOI 10.1016/S0003-4975(01)03505-6; Slavik T, 2012, ARCH PATHOL LAB MED, V136, P316, DOI 10.5858/arpa.2011-0336-RA; Umetsu SE, 2018, VIRCHOWS ARCH, V472, P55, DOI 10.1007/s00428-017-2243-7; Wadhera A, 2007, J AM ACAD DERMATOL, V57, P683, DOI 10.1016/j.jaad.2007.02.027; Wang MH, 2000, SCAND J GASTROENTERO, V35, P667; Warren S, 2015, J CUTAN PATHOL, V42, P663, DOI 10.1111/cup.12642; Weber A, 2013, PATHOBIOLOGY, V80, P282, DOI 10.1159/000350758	15	1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					121	125		10.1007/s00428-018-2304-6			5	Pathology	Pathology	GK9JO	WOS:000436563100014	29374317				2019-10-28	
J	Pau, M; Brcic, L; Seethala, RR; Klein-Theyer, AK; Magyar, M; Reinbacher, KE; Schweiger, M; Wallner, J; Jakse, N				Pau, Mauro; Brcic, Luka; Seethala, Raja R.; Klein-Theyer, Angelika K.; Magyar, Marton; Reinbacher, Knut E.; Schweiger, Michael; Wallner, Juergen; Jakse, Norbert			Non-sebaceous lymphadenoma of the lacrimal gland: first report of a new localization	VIRCHOWS ARCHIV			English	Article							SALIVARY-GLAND; LESIONS; TUMORS; DENMARK		[Pau, Mauro; Reinbacher, Knut E.; Schweiger, Michael; Wallner, Juergen; Jakse, Norbert] Med Univ Graz, Dept Oral & Maxillofacial Surg, Graz, Austria; [Brcic, Luka] Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria; [Seethala, Raja R.] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA USA; [Klein-Theyer, Angelika K.] Med Univ Graz, Dept Ophthalmol, Graz, Austria; [Magyar, Marton] Med Univ Graz, Dept Radiol, Graz, Austria	Brcic, L (reprint author), Med Univ Graz, Inst Pathol, Neue Stiftingtalstr 6, A-8010 Graz, Austria.	luka.brcic@medunigraz.at		Brcic, Luka/0000-0002-9098-8416			El-Naggar AK, 2017, WHO CLASSIFICATION H, P159; El-Naggar AK, 2017, WHO CLASSIFICATION H, P190; Font RL, 2006, TUMORS EYE OCULAR AD, P223; Gallego L, 2009, ORAL SURG ORAL MED O, V107, P555, DOI 10.1016/j.tripleo.2008.11.018; Johansen S, 2000, ACTA OPHTHALMOL SCAN, V78, P547, DOI 10.1034/j.1600-0420.2000.078005547.x; Kennedy R E, 1984, Trans Am Ophthalmol Soc, V82, P134; Liu GL, 2014, ONCOL LETT, V7, P1097, DOI 10.3892/ol.2014.1827; Musthyala NB, 2004, J CLIN PATHOL, V57, P1007, DOI 10.1136/jcp.2004.018028; Seethala RR, 2012, MODERN PATHOL, V25, P26, DOI 10.1038/modpathol.2011.135; SHIELDS CL, 1989, OPHTHALMOLOGY, V96, P431; von Holstein SL, 2013, ACTA OPHTHALMOL, V91, P349, DOI 10.1111/j.1755-3768.2012.02403.x; von Holstein SL, 2013, ACTA OPHTHALMOL, V91, P195, DOI 10.1111/j.1755-3768.2012.02402.x; Weiler C, 2012, VIRCHOWS ARCH, V460, P467, DOI 10.1007/s00428-012-1225-z; Weis E, 2009, ARCH OPHTHALMOL-CHIC, V127, P1016, DOI 10.1001/archophthalmol.2009.209; Yang SD, 2007, VIRCHOWS ARCH, V450, P595, DOI 10.1007/s00428-007-0393-8	15	0	0	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					127	130		10.1007/s00428-018-2322-4			4	Pathology	Pathology	GK9JO	WOS:000436563100015	29460186				2019-10-28	
J	Ware, AD; Birkness, J; Duffield, AS; Gocke, CD				Ware, Alisha D.; Birkness, Jacqueline; Duffield, Amy S.; Gocke, Christopher D.			Molecular evidence of JAK2 p.V617F mutated pure erythroid leukemia arising from polycythemia vera	VIRCHOWS ARCHIV			English	Article							DI GUGLIELMOS SYNDROME; ACUTE ERYTHROLEUKEMIA; MYELOID NEOPLASMS		[Ware, Alisha D.; Birkness, Jacqueline; Duffield, Amy S.; Gocke, Christopher D.] Johns Hopkins Univ, Sch Med, Dept Pathol, 600 N Wolfe St,Pathol Bldg,Room 401, Baltimore, MD 21287 USA	Ware, AD (reprint author), Johns Hopkins Univ, Sch Med, Dept Pathol, 600 N Wolfe St,Pathol Bldg,Room 401, Baltimore, MD 21287 USA.	agordy2@jhmi.edu					BANK A, 1966, NEW ENGL J MED, V275, P489, DOI 10.1056/NEJM196609012750908; Blum S, 2012, BLOOD, V120, P1974, DOI 10.1182/blood-2011-11-390047; Brada SJL, 1998, NETH J MED, V52, P142, DOI 10.1016/S0300-2977(98)00011-4; EASTMAN P, 1968, J AMER MED ASSOC, V204, P1141, DOI 10.1001/jama.204.12.1141; Li HM, 2016, AM J CLIN PATHOL, V145, P538, DOI 10.1093/ajcp/aqw033; PEZZIMENTI JF, 1976, CANCER, V38, P2242, DOI 10.1002/1097-0142(197612)38:6<2242::AID-CNCR2820380608>3.0.CO;2-G; Santos FPS, 2009, LEUKEMIA, V23, P2275, DOI 10.1038/leu.2009.181; Santos FPS, 2010, EXPERT REV HEMATOL, V3, P705, DOI [10.1586/ehm.10.62, 10.1586/EHM.10.62]; SCOTT RB, 1964, AM J MED, V37, P162, DOI 10.1016/0002-9343(64)90002-6; Stein BL, 2014, ANN HEMATOL, V93, P1965, DOI 10.1007/s00277-014-2205-y; Tallarico M, 2015, CURR HEMATOL MALIG R, V10, P112, DOI 10.1007/s11899-015-0259-0; Tefferi A, 2015, AM J HEMATOL, V90, P163, DOI 10.1002/ajh.23895; Wang SA, 2015, AM J CLIN PATHOL, V144, P44, DOI 10.1309/AJCPRKYAT6EZQHC7; Wang SA, 2012, HUM PATHOL, V43, P153, DOI 10.1016/j.humpath.2011.08.008; Zuo ZA, 2010, ARCH PATHOL LAB MED, V134, P1261, DOI 10.1043/2009-0350-RA.1	15	0	0	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JUL	2018	473	1					131	135		10.1007/s00428-018-2347-8			5	Pathology	Pathology	GK9JO	WOS:000436563100016	29611054				2019-10-28	
